<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="0" size="13" family="Times" color="#ffffff"/>
	<fontspec id="1" size="26" family="Times" color="#15549a"/>
	<fontspec id="2" size="14" family="Times" color="#231f20"/>
	<fontspec id="3" size="11" family="Times" color="#005d59"/>
	<fontspec id="4" size="13" family="Times" color="#231f20"/>
	<fontspec id="5" size="13" family="Times" color="#231f20"/>
	<fontspec id="6" size="8" family="Times" color="#231f20"/>
	<fontspec id="7" size="8" family="Times" color="#3b456e"/>
	<fontspec id="8" size="8" family="Times" color="#231f20"/>
	<fontspec id="9" size="8" family="Times" color="#ffffff"/>
<text top="113" left="69" width="153" height="13" font="0">PRACTICE GUIDELINE</text>
<text top="163" left="86" width="615" height="25" font="1">2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline</text>
<text top="199" left="86" width="604" height="25" font="1">for the Diagnosis and Management of Patients With</text>
<text top="235" left="86" width="352" height="25" font="1">Stable Ischemic Heart Disease</text>
<text top="277" left="89" width="697" height="17" font="2">A Report of the American College of Cardiology Foundation/American Heart Association Task Force</text>
<text top="295" left="89" width="682" height="17" font="2">on Practice Guidelines, and the American College of Physicians, American Association for Thoracic</text>
<text top="313" left="89" width="676" height="17" font="2">Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and</text>
<text top="331" left="89" width="326" height="17" font="2">Interventions, and Society of Thoracic Surgeons</text>
<text top="387" left="86" width="47" height="11" font="3">Writing</text>
<text top="403" left="86" width="71" height="11" font="3">Committee</text>
<text top="420" left="86" width="68" height="11" font="3">Members*</text>
<text top="386" left="185" width="236" height="16" font="4">Stephan D. Fihn, MD, MPH, <i>Chair</i>†</text>
<text top="406" left="185" width="224" height="16" font="4">Julius M. Gardin, MD, <i>Vice Chair</i>*‡</text>
<text top="446" left="185" width="150" height="16" font="4">Jonathan Abrams, MD‡</text>
<text top="466" left="185" width="190" height="16" font="4">Kathleen Berra, MSN, ANP*§</text>
<text top="485" left="185" width="176" height="16" font="4">James C. Blankenship, MD*</text>
<text top="482" left="360" width="5" height="20" font="4">储</text>
<text top="505" left="185" width="170" height="16" font="4">Apostolos P. Dallas, MD*†</text>
<text top="524" left="185" width="165" height="16" font="4">Pamela S. Douglas, MD*‡</text>
<text top="544" left="185" width="161" height="16" font="4">JoAnne M. Foody, MD*‡</text>
<text top="563" left="185" width="171" height="16" font="4">Thomas C. Gerber, MD, P</text>
<text top="567" left="356" width="9" height="11" font="6">H</text>
<text top="563" left="365" width="20" height="16" font="4">D‡</text>
<text top="583" left="185" width="165" height="16" font="4">Alan L. Hinderliter, MD‡</text>
<text top="602" left="185" width="171" height="16" font="4">Spencer B. King III, MD*‡</text>
<text top="622" left="185" width="148" height="16" font="4">Paul D. Kligfield, MD‡</text>
<text top="641" left="185" width="176" height="16" font="4">Harlan M. Krumholz, MD‡</text>
<text top="661" left="185" width="189" height="16" font="4">Raymond Y. K. Kwong, MD‡</text>
<text top="680" left="185" width="135" height="16" font="4">Michael J. Lim, MD*</text>
<text top="677" left="320" width="5" height="20" font="4">储</text>
<text top="700" left="185" width="234" height="16" font="4">Jane A. Linderbaum, MS, CNP-BC¶</text>
<text top="386" left="504" width="151" height="16" font="4">Michael J. Mack, MD*#</text>
<text top="407" left="504" width="126" height="16" font="4">Mark A. Munger, P</text>
<text top="410" left="630" width="34" height="11" font="6">HARM</text>
<text top="407" left="664" width="25" height="16" font="4">D*‡</text>
<text top="427" left="504" width="154" height="16" font="4">Richard L. Prager, MD#</text>
<text top="447" left="504" width="148" height="16" font="4">Joseph F. Sabik, MD***</text>
<text top="467" left="504" width="108" height="16" font="4">Leslee J. Shaw, P</text>
<text top="470" left="612" width="9" height="11" font="6">H</text>
<text top="467" left="621" width="25" height="16" font="4">D*‡</text>
<text top="487" left="504" width="244" height="16" font="4">Joanna D. Sikkema, MSN, ANP-BC*§</text>
<text top="507" left="504" width="109" height="16" font="4">Craig R. Smith, J</text>
<text top="511" left="613" width="7" height="11" font="6">R</text>
<text top="507" left="621" width="46" height="16" font="4">, MD**</text>
<text top="528" left="504" width="117" height="16" font="4">Sidney C. Smith, J</text>
<text top="531" left="621" width="7" height="11" font="6">R</text>
<text top="528" left="628" width="56" height="16" font="4">, MD*††</text>
<text top="548" left="504" width="200" height="16" font="4">John A. Spertus, MD, MPH*‡‡</text>
<text top="568" left="504" width="171" height="16" font="4">Sankey V. Williams, MD*†</text>
<text top="618" left="504" width="302" height="11" font="6">*Writing committee members are required to recuse themselves from</text>
<text top="633" left="504" width="302" height="11" font="6">voting on sections to which their specific relationship could apply; see</text>
<text top="647" left="504" width="50" height="11" font="7"><a href="e44.full.html#116">Appendix 1</a></text>
<text top="647" left="558" width="247" height="11" font="6">for detailed information. †ACP Representative. ‡ACCF/</text>
<text top="661" left="504" width="201" height="11" font="6">AHA Representative. §PCNA Representative.</text>
<text top="659" left="708" width="97" height="14" font="6">储SCAI Representative.</text>
<text top="675" left="504" width="302" height="11" font="6">¶Critical care nursing expertise. #STS Representative. **AATS Repre-</text>
<text top="689" left="504" width="302" height="11" font="6">sentative. ††ACCF/AHA Task Force on Practice Guidelines Liaison.</text>
<text top="703" left="504" width="273" height="11" font="6">‡‡ACCF/AHA Task Force on Performance Measures Liaison.</text>
<text top="909" left="59" width="360" height="11" font="6">The writing committee gratefully acknowledges the memory of James T. Dove, MD,</text>
<text top="922" left="59" width="360" height="11" font="6">who died during the development of this document but contributed immensely to our</text>
<text top="936" left="59" width="200" height="11" font="6">understanding of stable ischemic heart disease.</text>
<text top="949" left="69" width="350" height="11" font="6">This document was approved by the American College of Cardiology Foun-</text>
<text top="963" left="59" width="360" height="11" font="6">dation Board of Trustees, American Heart Association Science Advisory and</text>
<text top="976" left="59" width="360" height="11" font="6">Coordinating Committee, American College of Physicians, American Association</text>
<text top="990" left="59" width="360" height="11" font="6">for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for</text>
<text top="1003" left="59" width="360" height="11" font="6">Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</text>
<text top="1017" left="59" width="58" height="11" font="6">in July 2012.</text>
<text top="1030" left="69" width="350" height="11" font="6">The American College of Cardiology Foundation requests that this document be</text>
<text top="1044" left="59" width="360" height="11" font="6">cited as follows: Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas</text>
<text top="1057" left="59" width="360" height="11" font="6">AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB III, Kligfield PD,</text>
<text top="1071" left="59" width="360" height="11" font="6">Krumholz HM, Kwong RYK, Lim MJ, Linderbaum JA, Mack MJ, Munger MA,</text>
<text top="1084" left="59" width="360" height="11" font="6">Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA,</text>
<text top="1098" left="59" width="360" height="11" font="6">Williams SV. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the</text>
<text top="909" left="445" width="360" height="11" font="6">diagnosis and management of patients with stable ischemic heart disease: a report of</text>
<text top="923" left="445" width="360" height="11" font="6">the American College of Cardiology Foundation/American Heart Association Task</text>
<text top="937" left="445" width="360" height="11" font="6">Force on, American Association for Thoracic Surgery, Preventive Cardiovascular</text>
<text top="951" left="445" width="360" height="11" font="6">Nurses Association, Society for Cardiovascular Angiography and Interventions, and</text>
<text top="966" left="445" width="293" height="11" font="6">Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44 –164.</text>
<text top="981" left="456" width="176" height="11" font="6">This article is copublished in <i>Circulation</i>.</text>
<text top="997" left="456" width="350" height="11" font="6">Copies: This document is available on the World Wide Web sites of the American</text>
<text top="1011" left="445" width="109" height="11" font="6">College of Cardiology <a href="http://www.cardiosource.org">(</a></text>
<text top="1011" left="554" width="93" height="11" font="7"><a href="http://www.cardiosource.org">www.cardiosource.org</a></text>
<text top="1011" left="648" width="158" height="11" font="6"><a href="http://www.cardiosource.org">) </a>and American Heart Association</text>
<text top="1025" left="445" width="3" height="11" font="6"><a href="http://my.americanheart.org">(</a></text>
<text top="1025" left="449" width="92" height="11" font="7"><a href="http://my.americanheart.org">my.americanheart.org</a></text>
<text top="1025" left="541" width="265" height="11" font="6"><a href="http://my.americanheart.org">). </a>For copies of this document, please contact Elsevier Inc.</text>
<text top="1040" left="445" width="210" height="11" font="6">Reprint Department, fax (212) 633-3820, e-mail</text>
<text top="1040" left="659" width="92" height="11" font="7"><a href="mailto:reprints@elsevier.com">reprints@elsevier.com</a></text>
<text top="1040" left="751" width="3" height="11" font="6"><a href="mailto:reprints@elsevier.com">.</a></text>
<text top="1055" left="456" width="350" height="11" font="6">Permissions: Modification, alteration, enhancement and/or distribution of this</text>
<text top="1069" left="445" width="360" height="11" font="6">document are not permitted without the express permission of the American College</text>
<text top="1084" left="445" width="360" height="11" font="6">of Cardiology Foundation. Please contact Elsevier’s permission department:</text>
<text top="1098" left="445" width="139" height="11" font="7"><a href="mailto:healthpermissions@elsevier.com/">healthpermissions@elsevier.com/</a></text>
<text top="1098" left="585" width="3" height="11" font="6"><a href="mailto:healthpermissions@elsevier.com/">.</a></text>
<text top="52" left="58" width="203" height="11" font="9">Journal of the American College of Cardiology</text>
<text top="52" left="710" width="96" height="11" font="9">Vol. 60, No. 24, 2012</text>
<text top="64" left="58" width="444" height="11" font="9">© 2012 by the American College of Cardiology Foundation and the American Heart Association, Inc.</text>
<text top="64" left="700" width="106" height="11" font="9">ISSN 0735-1097/$36.00</text>
<text top="76" left="58" width="112" height="11" font="9">Published by Elsevier Inc.</text>
<text top="76" left="617" width="188" height="11" font="9">http://dx.doi.org/10.1016/j.jacc.2012.07.013</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="10" size="11" family="Times" color="#a70c2f"/>
	<fontspec id="11" size="7" family="Times" color="#231f20"/>
	<fontspec id="12" size="10" family="Times" color="#231f20"/>
	<fontspec id="13" size="10" family="Times" color="#005d59"/>
	<fontspec id="14" size="11" family="Times" color="#231f20"/>
<text top="154" left="86" width="69" height="11" font="3">ACCF/AHA</text>
<text top="171" left="86" width="70" height="11" font="3">Task Force</text>
<text top="187" left="86" width="60" height="11" font="3">Members</text>
<text top="154" left="185" width="264" height="16" font="4">Jeffrey L. Anderson, MD, FACC, FAHA,</text>
<text top="173" left="200" width="33" height="16" font="5"><i>Chair</i></text>
<text top="193" left="185" width="276" height="16" font="4">Jonathan L. Halperin, MD, FACC, FAHA,</text>
<text top="212" left="200" width="68" height="16" font="5"><i>Chair-Elect</i></text>
<text top="232" left="185" width="238" height="16" font="4">Alice K. Jacobs, MD, FACC, FAHA,</text>
<text top="251" left="200" width="219" height="16" font="5"><i>Immediate Past Chair 2009 –2011</i>§§</text>
<text top="271" left="185" width="117" height="16" font="4">Sidney C. Smith, J</text>
<text top="274" left="301" width="7" height="11" font="6">R</text>
<text top="271" left="309" width="144" height="16" font="4">, MD, FACC, FAHA,</text>
<text top="290" left="199" width="155" height="16" font="5"><i>Past Chair 2006 –2008</i>§§</text>
<text top="331" left="185" width="244" height="16" font="4">Cynthia D. Adams, MSN, APRN-BC,</text>
<text top="350" left="200" width="60" height="16" font="4">FAHA§§</text>
<text top="370" left="185" width="124" height="16" font="4">Nancy M. Albert, P</text>
<text top="373" left="309" width="9" height="11" font="6">H</text>
<text top="370" left="318" width="121" height="16" font="4">D, CCNS, CCRN,</text>
<text top="389" left="200" width="44" height="16" font="4">FAHA</text>
<text top="409" left="185" width="245" height="16" font="4">Ralph G. Brindis, MD, MPH, MACC</text>
<text top="428" left="185" width="237" height="16" font="4">Christopher E. Buller, MD, FACC§§</text>
<text top="448" left="185" width="246" height="16" font="4">Mark A. Creager, MD, FACC, FAHA</text>
<text top="467" left="185" width="110" height="16" font="4">David DeMets, P</text>
<text top="471" left="294" width="9" height="11" font="6">H</text>
<text top="467" left="303" width="12" height="16" font="4">D</text>
<text top="154" left="504" width="223" height="16" font="4">Steven M. Ettinger, MD, FACC§§</text>
<text top="173" left="504" width="200" height="16" font="4">Robert A. Guyton, MD, FACC</text>
<text top="193" left="504" width="260" height="16" font="4">Judith S. Hochman, MD, FACC, FAHA</text>
<text top="212" left="504" width="270" height="16" font="4">Sharon Ann Hunt, MD, FACC, FAHA§§</text>
<text top="232" left="504" width="249" height="16" font="4">Richard J. Kovacs, MD, FACC, FAHA</text>
<text top="251" left="504" width="291" height="16" font="4">Frederick G. Kushner, MD, FACC, FAHA§§</text>
<text top="271" left="504" width="252" height="16" font="4">Bruce W. Lytle, MD, FACC, FAHA§§</text>
<text top="290" left="504" width="274" height="16" font="4">Rick A. Nishimura, MD, FACC, FAHA§§</text>
<text top="310" left="504" width="207" height="16" font="4">E. Magnus Ohman, MD, FACC</text>
<text top="329" left="504" width="257" height="16" font="4">Richard L. Page, MD, FACC, FAHA§§</text>
<text top="349" left="504" width="131" height="16" font="4">Barbara Riegel, DNS</text>
<text top="352" left="635" width="8" height="11" font="6">C</text>
<text top="349" left="643" width="100" height="16" font="4">, RN, FAHA§§</text>
<text top="368" left="504" width="277" height="16" font="4">William G. Stevenson, MD, FACC, FAHA</text>
<text top="388" left="504" width="175" height="16" font="4">Lynn G. Tarkington, RN§§</text>
<text top="407" left="504" width="242" height="16" font="4">Clyde W. Yancy, MD, FACC, FAHA</text>
<text top="445" left="504" width="246" height="11" font="6">§§Former Task Force member during this writing effort.</text>
<text top="542" left="69" width="153" height="13" font="0">TABLE OF CONTENTS</text>
<text top="572" left="59" width="62" height="11" font="10">Preamble</text>
<text top="575" left="121" width="281" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="573" left="402" width="17" height="12" font="12">e47</text>
<text top="608" left="59" width="99" height="11" font="10">1. Introduction</text>
<text top="611" left="158" width="244" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="608" left="402" width="17" height="12" font="12">e49</text>
<text top="642" left="82" width="257" height="11" font="13">1.1. Methodology and Evidence Overview</text>
<text top="644" left="341" width="60" height="9" font="11">. . . . . . . . . . . .</text>
<text top="642" left="401" width="17" height="12" font="12">e49</text>
<text top="662" left="82" width="269" height="11" font="13">1.2. Organization of the Writing Committee</text>
<text top="664" left="352" width="50" height="9" font="11">. . . . . . . . . .</text>
<text top="661" left="401" width="17" height="12" font="12">e50</text>
<text top="681" left="82" width="226" height="11" font="13">1.3. Document Review and Approval</text>
<text top="683" left="310" width="92" height="9" font="11">. . . . . . . . . . . . . . . . . .</text>
<text top="681" left="401" width="17" height="12" font="12">e50</text>
<text top="701" left="82" width="172" height="11" font="13">1.4. Scope of the Guideline</text>
<text top="703" left="257" width="144" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="701" left="401" width="17" height="12" font="12">e50</text>
<text top="721" left="82" width="249" height="11" font="13">1.5. General Approach and Overlap With</text>
<text top="736" left="112" width="196" height="11" font="13">Other Guidelines or Statements</text>
<text top="738" left="310" width="92" height="9" font="11">. . . . . . . . . . . . . . . . . .</text>
<text top="736" left="401" width="17" height="12" font="12">e52</text>
<text top="755" left="82" width="192" height="11" font="13">1.6. Magnitude of the Problem</text>
<text top="757" left="278" width="123" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="755" left="401" width="17" height="12" font="12">e53</text>
<text top="775" left="82" width="211" height="11" font="13">1.7. Organization of the Guideline</text>
<text top="777" left="294" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="775" left="401" width="17" height="12" font="12">e54</text>
<text top="795" left="82" width="267" height="11" font="13">1.8. Vital Importance of Involvement by an</text>
<text top="810" left="112" width="219" height="11" font="13">Informed Patient: Recommendation</text>
<text top="812" left="336" width="65" height="9" font="11">. . . . . . . . . . . . .</text>
<text top="810" left="401" width="17" height="12" font="12">e56</text>
<text top="838" left="59" width="137" height="11" font="10">2. Diagnosis of SIHD</text>
<text top="841" left="200" width="202" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="838" left="401" width="17" height="12" font="12">e58</text>
<text top="872" left="82" width="250" height="11" font="13">2.1. Clinical Evaluation of Patients With</text>
<text top="887" left="112" width="67" height="11" font="13">Chest Pain</text>
<text top="889" left="184" width="218" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="887" left="401" width="17" height="12" font="12">e58</text>
<text top="901" left="116" width="285" height="14" font="14">2.1.1. Clinical Evaluation in the Initial Diagnosis of</text>
<text top="916" left="153" width="196" height="14" font="14">SIHD in Patients With Chest Pain:</text>
<text top="931" left="153" width="99" height="14" font="14">Recommendations</text>
<text top="934" left="252" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="932" left="401" width="17" height="12" font="12">e58</text>
<text top="947" left="116" width="77" height="14" font="14">2.1.2. History</text>
<text top="950" left="194" width="207" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="947" left="401" width="17" height="12" font="12">e58</text>
<text top="962" left="116" width="153" height="14" font="14">2.1.3. Physical Examination</text>
<text top="965" left="273" width="128" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="963" left="401" width="17" height="12" font="12">e60</text>
<text top="977" left="116" width="144" height="14" font="14">2.1.4. Electrocardiography</text>
<text top="980" left="263" width="139" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="978" left="401" width="17" height="12" font="12">e60</text>
<text top="992" left="151" width="180" height="8" font="11">2.1.4.1. RESTING ELECTROCARDIOGRAPHY</text>
<text top="1007" left="189" width="152" height="8" font="11">TO ASSESS RISK: RECOMMENDATION</text>
<text top="1007" left="347" width="55" height="9" font="11">. . . . . . . . . . .</text>
<text top="1005" left="401" width="17" height="12" font="12">e60</text>
<text top="1019" left="116" width="154" height="14" font="14">2.1.5. Differential Diagnosis</text>
<text top="1022" left="273" width="128" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1019" left="401" width="17" height="12" font="12">e60</text>
<text top="1034" left="116" width="234" height="14" font="14">2.1.6. Developing the Probability Estimate</text>
<text top="1037" left="352" width="50" height="9" font="11">. . . . . . . . . .</text>
<text top="1035" left="401" width="17" height="12" font="12">e61</text>
<text top="1054" left="82" width="283" height="11" font="13">2.2. Noninvasive Testing for Diagnosis of IHD</text>
<text top="1056" left="368" width="34" height="9" font="11">. . . . . . .</text>
<text top="1054" left="401" width="17" height="12" font="12">e62</text>
<text top="1069" left="116" width="255" height="14" font="14">2.2.1. Approach to the Selection of Diagnostic</text>
<text top="1084" left="153" width="136" height="14" font="14">Tests to Diagnose SIHD</text>
<text top="1087" left="289" width="113" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1085" left="401" width="17" height="12" font="12">e62</text>
<text top="1099" left="151" width="224" height="8" font="11">2.2.1.1. ASSESSING DIAGNOSTIC TEST CHARACTERISTICS</text>
<text top="1099" left="375" width="29" height="9" font="11">. . . . . .</text>
<text top="1097" left="403" width="16" height="12" font="12">e63</text>
<text top="532" left="538" width="196" height="8" font="11">2.2.1.2. SAFETY AND OTHER CONSIDERATIONS</text>
<text top="547" left="576" width="171" height="8" font="11">POTENTIALLY AFFECTING TEST SELECTION</text>
<text top="547" left="749" width="39" height="9" font="11">. . . . . . . .</text>
<text top="545" left="788" width="17" height="12" font="12">e64</text>
<text top="562" left="538" width="222" height="8" font="11">2.2.1.3. EXERCISE VERSUS PHARMACOLOGICAL TESTING</text>
<text top="562" left="762" width="29" height="9" font="11">. . . . . .</text>
<text top="560" left="790" width="16" height="12" font="12">e65</text>
<text top="577" left="538" width="204" height="8" font="11">2.2.1.4. CONCOMITANT DIAGNOSIS OF SIHD AND</text>
<text top="592" left="576" width="91" height="8" font="11">ASSESSMENT OF RISK</text>
<text top="592" left="671" width="118" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="590" left="788" width="17" height="12" font="12">e65</text>
<text top="607" left="538" width="126" height="8" font="11">2.2.1.5. COST-EFFECTIVENESS</text>
<text top="607" left="665" width="123" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="605" left="788" width="17" height="12" font="12">e65</text>
<text top="618" left="503" width="262" height="14" font="14">2.2.2. Stress Testing and Advanced Imaging for</text>
<text top="633" left="540" width="241" height="14" font="14">Initial Diagnosis in Patients With Suspected</text>
<text top="648" left="540" width="229" height="14" font="14">SIHD Who Require Noninvasive Testing:</text>
<text top="663" left="540" width="99" height="14" font="14">Recommendations</text>
<text top="666" left="639" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="664" left="788" width="17" height="12" font="12">e66</text>
<text top="678" left="538" width="116" height="8" font="11">2.2.2.1. ABLE TO EXERCISE</text>
<text top="678" left="655" width="134" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="676" left="788" width="17" height="12" font="12">e66</text>
<text top="693" left="538" width="127" height="8" font="11">2.2.2.2. UNABLE TO EXERCISE</text>
<text top="693" left="665" width="123" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="691" left="788" width="17" height="12" font="12">e66</text>
<text top="708" left="538" width="66" height="8" font="11">2.2.2.3. OTHER</text>
<text top="708" left="608" width="181" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="706" left="788" width="17" height="12" font="12">e67</text>
<text top="719" left="503" width="257" height="14" font="14">2.2.3. Diagnostic Accuracy of Nonimaging and</text>
<text top="734" left="540" width="201" height="14" font="14">Imaging Stress Testing for the Initial</text>
<text top="749" left="540" width="163" height="14" font="14">Diagnosis of Suspected SIHD</text>
<text top="752" left="707" width="81" height="9" font="11">. . . . . . . . . . . . . . . .</text>
<text top="750" left="788" width="17" height="12" font="12">e68</text>
<text top="765" left="538" width="98" height="8" font="11">2.2.3.1. EXERCISE ECG</text>
<text top="764" left="639" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="762" left="788" width="17" height="12" font="12">e68</text>
<text top="780" left="538" width="219" height="8" font="11">2.2.3.2. EXERCISE AND PHARMACOLOGICAL STRESS</text>
<text top="795" left="576" width="89" height="8" font="11">ECHOCARDIOGRAPHY</text>
<text top="794" left="665" width="123" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="792" left="788" width="17" height="12" font="12">e68</text>
<text top="810" left="538" width="219" height="8" font="11">2.2.3.3. EXERCISE AND PHARMACOLOGICAL STRESS</text>
<text top="825" left="576" width="195" height="8" font="11">NUCLEAR MYOCARDIAL PERFUSION SPECT AND</text>
<text top="840" left="576" width="122" height="8" font="11">MYOCARDIAL PERFUSION PET</text>
<text top="839" left="702" width="86" height="9" font="11">. . . . . . . . . . . . . . . . .</text>
<text top="837" left="788" width="17" height="12" font="12">e68</text>
<text top="855" left="538" width="204" height="8" font="11">2.2.3.4. PHARMACOLOGICAL STRESS CMR WALL</text>
<text top="870" left="576" width="84" height="8" font="11">MOTION/PERFUSION</text>
<text top="869" left="665" width="123" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="867" left="788" width="17" height="12" font="12">e69</text>
<text top="885" left="538" width="109" height="8" font="11">2.2.3.5. HYBRID IMAGING</text>
<text top="884" left="650" width="139" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="882" left="788" width="17" height="12" font="12">e69</text>
<text top="896" left="503" width="264" height="14" font="14">2.2.4. Diagnostic Accuracy of Anatomic Testing</text>
<text top="911" left="540" width="183" height="14" font="14">for the Initial Diagnosis of SIHD</text>
<text top="914" left="723" width="65" height="9" font="11">. . . . . . . . . . . . .</text>
<text top="911" left="788" width="17" height="12" font="12">e69</text>
<text top="926" left="538" width="161" height="8" font="11">2.2.4.1. CORONARY CT ANGIOGRAPHY</text>
<text top="926" left="702" width="86" height="9" font="11">. . . . . . . . . . . . . . . . .</text>
<text top="923" left="788" width="17" height="12" font="12">e69</text>
<text top="941" left="538" width="95" height="8" font="11">2.2.4.2. CAC SCORING</text>
<text top="941" left="634" width="155" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="938" left="788" width="17" height="12" font="12">e70</text>
<text top="956" left="538" width="121" height="8" font="11">2.2.4.3. CMR ANGIOGRAPHY</text>
<text top="956" left="660" width="128" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="953" left="788" width="17" height="12" font="12">e70</text>
<text top="984" left="446" width="132" height="11" font="10">3. Risk Assessment</text>
<text top="986" left="581" width="207" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="984" left="788" width="17" height="12" font="12">e70</text>
<text top="1017" left="469" width="155" height="11" font="13">3.1. Clinical Assessment</text>
<text top="1019" left="629" width="160" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1017" left="788" width="17" height="12" font="12">e70</text>
<text top="1031" left="503" width="284" height="14" font="14">3.1.1. Prognosis of IHD for Death or Nonfatal MI:</text>
<text top="1046" left="540" width="127" height="14" font="14">General Considerations</text>
<text top="1049" left="671" width="118" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1047" left="788" width="17" height="12" font="12">e70</text>
<text top="1061" left="503" width="261" height="14" font="14">3.1.2. Risk Assessment Using Clinical Parameters</text>
<text top="1064" left="766" width="23" height="9" font="11">. . . . .</text>
<text top="1062" left="789" width="17" height="12" font="12">e71</text>
<text top="1082" left="469" width="220" height="11" font="13">3.2. Advanced Testing: Resting and</text>
<text top="1097" left="499" width="168" height="11" font="13">Stress Noninvasive Testing</text>
<text top="1099" left="671" width="118" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1097" left="788" width="17" height="12" font="12">e72</text>
<text top="52" left="787" width="18" height="10" font="12">e45</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="116" width="279" height="14" font="14">3.2.1. Resting Imaging to Assess Cardiac Structure</text>
<text top="119" left="153" width="178" height="14" font="14">and Function: Recommendations</text>
<text top="122" left="336" width="65" height="9" font="11">. . . . . . . . . . . . .</text>
<text top="120" left="401" width="17" height="12" font="12">e72</text>
<text top="134" left="116" width="257" height="14" font="14">3.2.2. Stress Testing and Advanced Imaging in</text>
<text top="149" left="153" width="235" height="14" font="14">Patients With Known SIHD Who Require</text>
<text top="164" left="153" width="227" height="14" font="14">Noninvasive Testing for Risk Assessment:</text>
<text top="179" left="153" width="99" height="14" font="14">Recommendations</text>
<text top="182" left="252" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="180" left="401" width="17" height="12" font="12">e74</text>
<text top="195" left="151" width="207" height="8" font="11">3.2.2.1. RISK ASSESSMENT IN PATIENTS ABLE TO</text>
<text top="210" left="189" width="40" height="8" font="11">EXERCISE</text>
<text top="209" left="231" width="170" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="207" left="401" width="17" height="12" font="12">e74</text>
<text top="225" left="151" width="218" height="8" font="11">3.2.2.2. RISK ASSESSMENT IN PATIENTS UNABLE TO</text>
<text top="240" left="189" width="40" height="8" font="11">EXERCISE</text>
<text top="239" left="231" width="170" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="237" left="401" width="17" height="12" font="12">e74</text>
<text top="255" left="151" width="188" height="8" font="11">3.2.2.3. RISK ASSESSMENT REGARDLESS OF</text>
<text top="270" left="189" width="131" height="8" font="11">PATIENTS’ ABILITY TO EXERCISE</text>
<text top="269" left="320" width="81" height="9" font="11">. . . . . . . . . . . . . . . .</text>
<text top="267" left="401" width="17" height="12" font="12">e74</text>
<text top="285" left="151" width="98" height="8" font="11">3.2.2.4. EXERCISE ECG</text>
<text top="284" left="252" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="282" left="401" width="17" height="12" font="12">e75</text>
<text top="300" left="151" width="233" height="8" font="11">3.2.2.5. EXERCISE ECHOCARDIOGRAPHY AND EXERCISE</text>
<text top="315" left="189" width="57" height="8" font="11">NUCLEAR MPI</text>
<text top="314" left="247" width="155" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="312" left="401" width="17" height="12" font="12">e76</text>
<text top="330" left="151" width="240" height="8" font="11">3.2.2.6. DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND</text>
<text top="345" left="189" width="177" height="8" font="11">PHARMACOLOGICAL STRESS NUCLEAR MPI</text>
<text top="344" left="368" width="34" height="9" font="11">. . . . . . .</text>
<text top="342" left="401" width="17" height="12" font="12">e77</text>
<text top="360" left="151" width="217" height="8" font="11">3.2.2.7. PHARMACOLOGICAL STRESS CMR IMAGING</text>
<text top="359" left="368" width="34" height="9" font="11">. . . . . . .</text>
<text top="357" left="401" width="17" height="12" font="12">e77</text>
<text top="375" left="151" width="236" height="8" font="11">3.2.2.8. SPECIAL PATIENT GROUP: RISK ASSESSMENT IN</text>
<text top="390" left="189" width="201" height="8" font="11">PATIENTS WHO HAVE AN UNINTERPRETABLE ECG</text>
<text top="405" left="189" width="184" height="8" font="11">BECAUSE OF LBBB OR VENTRICULAR PACING</text>
<text top="404" left="378" width="23" height="9" font="11">. . . . .</text>
<text top="402" left="401" width="17" height="12" font="12">e77</text>
<text top="416" left="116" width="257" height="14" font="14">3.2.3. Prognostic Accuracy of Anatomic Testing to</text>
<text top="431" left="153" width="216" height="14" font="14">Assess Risk in Patients With Known CAD</text>
<text top="434" left="369" width="34" height="9" font="11">. . . . . . .</text>
<text top="431" left="402" width="16" height="12" font="12">e78</text>
<text top="446" left="151" width="161" height="8" font="11">3.2.3.1. CORONARY CT ANGIOGRAPHY</text>
<text top="446" left="315" width="86" height="9" font="11">. . . . . . . . . . . . . . . . .</text>
<text top="443" left="401" width="17" height="12" font="12">e78</text>
<text top="466" left="82" width="166" height="11" font="13">3.3. Coronary Angiography</text>
<text top="468" left="252" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="466" left="401" width="17" height="12" font="12">e78</text>
<text top="480" left="116" width="274" height="14" font="14">3.3.1. Coronary Angiography as an Initial Testing</text>
<text top="495" left="153" width="221" height="14" font="14">Strategy to Assess Risk: Recommendations</text>
<text top="498" left="379" width="23" height="9" font="11">. . . . .</text>
<text top="496" left="402" width="17" height="12" font="12">e78</text>
<text top="510" left="116" width="275" height="14" font="14">3.3.2. Coronary Angiography to Assess Risk After</text>
<text top="525" left="153" width="232" height="14" font="14">Initial Workup With Noninvasive Testing:</text>
<text top="540" left="153" width="99" height="14" font="14">Recommendations</text>
<text top="543" left="252" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="541" left="401" width="17" height="12" font="12">e78</text>
<text top="569" left="59" width="86" height="11" font="10">4. Treatment</text>
<text top="572" left="147" width="254" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="569" left="402" width="17" height="12" font="12">e80</text>
<text top="603" left="82" width="246" height="11" font="13">4.1. Definition of Successful Treatment</text>
<text top="605" left="331" width="71" height="9" font="11">. . . . . . . . . . . . . .</text>
<text top="602" left="401" width="17" height="12" font="12">e80</text>
<text top="622" left="82" width="209" height="11" font="13">4.2. General Approach to Therapy</text>
<text top="624" left="294" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="622" left="401" width="17" height="12" font="12">e82</text>
<text top="636" left="116" width="227" height="14" font="14">4.2.1. Factors That Should Not Influence</text>
<text top="651" left="153" width="112" height="14" font="14">Treatment Decisions</text>
<text top="654" left="268" width="134" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="652" left="401" width="17" height="12" font="12">e83</text>
<text top="666" left="116" width="223" height="14" font="14">4.2.2. Assessing Patients’ Quality of Life</text>
<text top="669" left="341" width="60" height="9" font="11">. . . . . . . . . . . .</text>
<text top="667" left="401" width="17" height="12" font="12">e84</text>
<text top="687" left="82" width="262" height="11" font="13">4.3. Patient Education: Recommendations</text>
<text top="689" left="347" width="55" height="9" font="11">. . . . . . . . . . .</text>
<text top="686" left="401" width="17" height="12" font="12">e84</text>
<text top="706" left="82" width="248" height="11" font="13">4.4. Guideline-Directed Medical Therapy</text>
<text top="708" left="331" width="71" height="9" font="11">. . . . . . . . . . . . . .</text>
<text top="706" left="401" width="17" height="12" font="12">e86</text>
<text top="720" left="116" width="176" height="14" font="14">4.4.1. Risk Factor Modification:</text>
<text top="735" left="153" width="99" height="14" font="14">Recommendations</text>
<text top="738" left="252" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="736" left="401" width="17" height="12" font="12">e86</text>
<text top="750" left="151" width="122" height="8" font="11">4.4.1.1. LIPID MANAGEMENT</text>
<text top="750" left="273" width="128" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="748" left="401" width="17" height="12" font="12">e86</text>
<text top="765" left="151" width="176" height="8" font="11">4.4.1.2. BLOOD PRESSURE MANAGEMENT</text>
<text top="765" left="331" width="71" height="9" font="11">. . . . . . . . . . . . . .</text>
<text top="763" left="401" width="17" height="12" font="12">e88</text>
<text top="780" left="151" width="141" height="8" font="11">4.4.1.3. DIABETES MANAGEMENT</text>
<text top="780" left="294" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="778" left="401" width="17" height="12" font="12">e89</text>
<text top="795" left="151" width="117" height="8" font="11">4.4.1.4. PHYSICAL ACTIVITY</text>
<text top="795" left="268" width="134" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="793" left="401" width="17" height="12" font="12">e91</text>
<text top="810" left="151" width="133" height="8" font="11">4.4.1.5. WEIGHT MANAGEMENT</text>
<text top="810" left="284" width="118" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="808" left="401" width="17" height="12" font="12">e92</text>
<text top="825" left="151" width="182" height="8" font="11">4.4.1.6. SMOKING CESSATION COUNSELING</text>
<text top="825" left="336" width="65" height="9" font="11">. . . . . . . . . . . . .</text>
<text top="823" left="401" width="17" height="12" font="12">e92</text>
<text top="840" left="151" width="223" height="8" font="11">4.4.1.7. MANAGEMENT OF PSYCHOLOGICAL FACTORS</text>
<text top="840" left="378" width="23" height="9" font="11">. . . . .</text>
<text top="838" left="401" width="17" height="12" font="12">e93</text>
<text top="855" left="151" width="141" height="8" font="11">4.4.1.8. ALCOHOL CONSUMPTION</text>
<text top="855" left="294" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="853" left="401" width="17" height="12" font="12">e94</text>
<text top="870" left="151" width="204" height="8" font="11">4.4.1.9. AVOIDING EXPOSURE TO AIR POLLUTION</text>
<text top="870" left="357" width="44" height="9" font="11">. . . . . . . . .</text>
<text top="868" left="401" width="17" height="12" font="12">e94</text>
<text top="881" left="116" width="296" height="14" font="14">4.4.2. Additional Medical Therapy to Prevent MI and</text>
<text top="896" left="153" width="140" height="14" font="14">Death: Recommendations</text>
<text top="899" left="294" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="897" left="401" width="17" height="12" font="12">e95</text>
<text top="912" left="151" width="138" height="8" font="11">4.4.2.1. ANTIPLATELET THERAPY</text>
<text top="911" left="289" width="113" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="909" left="401" width="17" height="12" font="12">e95</text>
<text top="927" left="151" width="141" height="8" font="11">4.4.2.2. BETA-BLOCKER THERAPY</text>
<text top="926" left="294" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="924" left="401" width="17" height="12" font="12">e96</text>
<text top="942" left="151" width="227" height="8" font="11">4.4.2.3. RENIN-ANGIOTENSIN-ALDOSTERONE BLOCKER</text>
<text top="957" left="189" width="38" height="8" font="11">THERAPY</text>
<text top="956" left="231" width="170" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="954" left="401" width="17" height="12" font="12">e97</text>
<text top="972" left="151" width="142" height="8" font="11">4.4.2.4. INFLUENZA VACCINATION</text>
<text top="971" left="294" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="969" left="401" width="17" height="12" font="12">e98</text>
<text top="987" left="151" width="248" height="8" font="11">4.4.2.5. ADDITIONAL THERAPY TO REDUCE RISK OF MI AND</text>
<text top="1002" left="189" width="27" height="8" font="11">DEATH</text>
<text top="1001" left="221" width="181" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="999" left="401" width="17" height="12" font="12">e99</text>
<text top="1013" left="116" width="260" height="14" font="14">4.4.3. Medical Therapy for Relief of Symptoms</text>
<text top="1016" left="377" width="18" height="9" font="11">. . . .</text>
<text top="1013" left="395" width="23" height="12" font="12">e100</text>
<text top="1028" left="151" width="194" height="8" font="11">4.4.3.1. USE OF ANTI-ISCHEMIC MEDICATIONS:</text>
<text top="1043" left="189" width="85" height="8" font="11">RECOMMENDATIONS</text>
<text top="1043" left="278" width="118" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1040" left="395" width="23" height="12" font="12">e100</text>
<text top="1054" left="116" width="284" height="14" font="14">4.4.4. Alternative Therapies for Relief of Symptoms</text>
<text top="1069" left="153" width="197" height="14" font="14">in Patients With Refractory Angina:</text>
<text top="1084" left="153" width="99" height="14" font="14">Recommendations</text>
<text top="1087" left="257" width="139" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1085" left="395" width="23" height="12" font="12">e104</text>
<text top="1099" left="151" width="217" height="8" font="11">4.4.4.1. ENHANCED EXTERNAL COUNTERPULSATION</text>
<text top="1099" left="372" width="23" height="9" font="11">. . . . .</text>
<text top="1097" left="395" width="23" height="12" font="12">e104</text>
<text top="105" left="538" width="153" height="8" font="11">4.4.4.2. SPINAL CORD STIMULATION</text>
<text top="104" left="691" width="92" height="9" font="11">. . . . . . . . . . . . . . . . . .</text>
<text top="102" left="782" width="23" height="12" font="12">e105</text>
<text top="120" left="538" width="99" height="8" font="11">4.4.4.3. ACUPUNCTURE</text>
<text top="120" left="638" width="144" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="117" left="782" width="23" height="12" font="12">e105</text>
<text top="149" left="446" width="167" height="11" font="10">5. CAD Revascularization</text>
<text top="151" left="617" width="165" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="149" left="782" width="23" height="12" font="12">e106</text>
<text top="183" left="469" width="293" height="11" font="13">5.1. Heart Team Approach to Revascularization</text>
<text top="198" left="499" width="181" height="11" font="13">Decisions: Recommendations</text>
<text top="200" left="686" width="97" height="9" font="11">. . . . . . . . . . . . . . . . . . .</text>
<text top="198" left="782" width="23" height="12" font="12">e106</text>
<text top="218" left="469" width="269" height="11" font="13">5.2. Revascularization to Improve Survival:</text>
<text top="233" left="499" width="113" height="11" font="13">Recommendations</text>
<text top="236" left="617" width="165" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="233" left="782" width="23" height="12" font="12">e108</text>
<text top="253" left="469" width="283" height="11" font="13">5.3. Revascularization to Improve Symptoms:</text>
<text top="269" left="499" width="113" height="11" font="13">Recommendations</text>
<text top="271" left="617" width="165" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="268" left="782" width="23" height="12" font="12">e109</text>
<text top="288" left="469" width="279" height="11" font="13">5.4. CABG Versus Contemporaneous Medical</text>
<text top="304" left="499" width="48" height="11" font="13">Therapy</text>
<text top="306" left="549" width="233" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="304" left="782" width="23" height="12" font="12">e109</text>
<text top="323" left="469" width="202" height="11" font="13">5.5. PCI Versus Medical Therapy</text>
<text top="326" left="675" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="323" left="782" width="23" height="12" font="12">e110</text>
<text top="343" left="469" width="136" height="11" font="13">5.6. CABG Versus PCI</text>
<text top="345" left="607" width="176" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="343" left="782" width="23" height="12" font="12">e110</text>
<text top="358" left="503" width="258" height="14" font="14">5.6.1. CABG Versus Balloon Angioplasty or BMS</text>
<text top="361" left="761" width="23" height="9" font="11">. . . . .</text>
<text top="358" left="784" width="22" height="12" font="12">e110</text>
<text top="373" left="503" width="147" height="14" font="14">5.6.2. CABG Versus DES</text>
<text top="376" left="654" width="128" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="374" left="782" width="23" height="12" font="12">e111</text>
<text top="394" left="469" width="119" height="11" font="13">5.7. Left Main CAD</text>
<text top="396" left="591" width="191" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="394" left="782" width="23" height="12" font="12">e111</text>
<text top="408" left="503" width="255" height="14" font="14">5.7.1. CABG or PCI Versus Medical Therapy</text>
<text top="423" left="540" width="110" height="14" font="14">for Left Main CAD</text>
<text top="426" left="654" width="128" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="424" left="782" width="23" height="12" font="12">e111</text>
<text top="439" left="503" width="251" height="14" font="14">5.7.2. Studies Comparing PCI Versus CABG</text>
<text top="454" left="540" width="110" height="14" font="14">for Left Main CAD</text>
<text top="457" left="654" width="128" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="455" left="782" width="23" height="12" font="12">e111</text>
<text top="469" left="503" width="233" height="14" font="14">5.7.3. Revascularization Considerations for</text>
<text top="485" left="540" width="90" height="14" font="14">Left Main CAD</text>
<text top="488" left="633" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="485" left="782" width="23" height="12" font="12">e112</text>
<text top="505" left="469" width="208" height="11" font="13">5.8. Proximal LAD Artery Disease</text>
<text top="507" left="680" width="102" height="9" font="11">. . . . . . . . . . . . . . . . . . . .</text>
<text top="505" left="782" width="23" height="12" font="12">e112</text>
<text top="525" left="469" width="271" height="11" font="13">5.9. Clinical Factors That May Influence the</text>
<text top="540" left="499" width="173" height="11" font="13">Choice of Revascularization</text>
<text top="543" left="675" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="540" left="782" width="23" height="12" font="12">e113</text>
<text top="555" left="503" width="223" height="14" font="14">5.9.1. Completeness of Revascularization</text>
<text top="558" left="728" width="55" height="9" font="11">. . . . . . . . . . .</text>
<text top="556" left="782" width="23" height="12" font="12">e113</text>
<text top="570" left="503" width="170" height="14" font="14">5.9.2. LV Systolic Dysfunction</text>
<text top="573" left="675" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="571" left="782" width="23" height="12" font="12">e113</text>
<text top="585" left="503" width="126" height="14" font="14">5.9.3. Previous CABG</text>
<text top="588" left="633" width="149" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="586" left="782" width="23" height="12" font="12">e113</text>
<text top="601" left="503" width="235" height="14" font="14">5.9.4. Unstable Angina/Non–ST-Elevation</text>
<text top="616" left="540" width="117" height="14" font="14">Myocardial Infarction</text>
<text top="619" left="659" width="123" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="617" left="782" width="23" height="12" font="12">e113</text>
<text top="631" left="503" width="271" height="14" font="14">5.9.5. DAPT Compliance and Stent Thrombosis:</text>
<text top="647" left="540" width="94" height="14" font="14">Recommendation</text>
<text top="650" left="638" width="144" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="647" left="782" width="23" height="12" font="12">e113</text>
<text top="667" left="461" width="252" height="11" font="13">5.10. Transmyocardial Revascularization</text>
<text top="669" left="717" width="65" height="9" font="11">. . . . . . . . . . . . .</text>
<text top="667" left="782" width="23" height="12" font="12">e114</text>
<text top="687" left="461" width="254" height="11" font="13">5.11. Hybrid Coronary Revascularization:</text>
<text top="702" left="499" width="113" height="11" font="13">Recommendations</text>
<text top="705" left="617" width="165" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="702" left="782" width="23" height="12" font="12">e114</text>
<text top="722" left="461" width="180" height="11" font="13">5.12. Special Considerations</text>
<text top="724" left="644" width="139" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="722" left="782" width="23" height="12" font="12">e114</text>
<text top="737" left="496" width="87" height="14" font="14">5.12.1. Women</text>
<text top="740" left="586" width="197" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="737" left="782" width="23" height="12" font="12">e115</text>
<text top="752" left="496" width="115" height="14" font="14">5.12.2. Older Adults</text>
<text top="755" left="612" width="170" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="753" left="782" width="23" height="12" font="12">e115</text>
<text top="767" left="496" width="139" height="14" font="14">5.12.3. Diabetes Mellitus</text>
<text top="770" left="638" width="144" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="768" left="782" width="23" height="12" font="12">e116</text>
<text top="783" left="496" width="85" height="14" font="14">5.12.4. Obesity</text>
<text top="786" left="586" width="197" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="783" left="782" width="23" height="12" font="12">e117</text>
<text top="798" left="496" width="175" height="14" font="14">5.12.5. Chronic Kidney Disease</text>
<text top="801" left="675" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="799" left="782" width="23" height="12" font="12">e118</text>
<text top="813" left="496" width="184" height="14" font="14">5.12.6. HIV Infection and SIHD</text>
<text top="816" left="680" width="102" height="9" font="11">. . . . . . . . . . . . . . . . . . . .</text>
<text top="814" left="782" width="23" height="12" font="12">e118</text>
<text top="828" left="496" width="171" height="14" font="14">5.12.7. Autoimmune Disorders</text>
<text top="831" left="670" width="113" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="829" left="782" width="23" height="12" font="12">e119</text>
<text top="844" left="496" width="167" height="14" font="14">5.12.8. Socioeconomic Factors</text>
<text top="847" left="665" width="118" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="845" left="782" width="23" height="12" font="12">e119</text>
<text top="859" left="496" width="152" height="14" font="14">5.12.9. Special Occupations</text>
<text top="862" left="649" width="134" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="860" left="782" width="23" height="12" font="12">e119</text>
<text top="888" left="446" width="303" height="11" font="10">6. Patient Follow-Up: Monitoring of Symptoms</text>
<text top="905" left="465" width="157" height="11" font="10">and Antianginal Therapy</text>
<text top="908" left="623" width="160" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="905" left="782" width="23" height="12" font="12">e119</text>
<text top="939" left="469" width="306" height="11" font="13">6.1. Clinical Evaluation, Echocardiography During</text>
<text top="954" left="499" width="173" height="11" font="13">Routine, Periodic Follow-Up:</text>
<text top="970" left="499" width="113" height="11" font="13">Recommendations</text>
<text top="972" left="617" width="165" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="970" left="782" width="23" height="12" font="12">e120</text>
<text top="989" left="469" width="229" height="11" font="13">6.2. Follow-Up of Patients With SIHD</text>
<text top="992" left="701" width="81" height="9" font="11">. . . . . . . . . . . . . . . .</text>
<text top="989" left="782" width="23" height="12" font="12">e121</text>
<text top="1004" left="503" width="236" height="14" font="14">6.2.1. Focused Follow-Up Visit: Frequency</text>
<text top="1007" left="743" width="39" height="9" font="11">. . . . . . . .</text>
<text top="1005" left="782" width="23" height="12" font="12">e121</text>
<text top="1019" left="503" width="266" height="14" font="14">6.2.2. Focused Follow-Up Visit: Interval History</text>
<text top="1034" left="540" width="145" height="14" font="14">and Coexisting Conditions</text>
<text top="1037" left="686" width="97" height="9" font="11">. . . . . . . . . . . . . . . . . . .</text>
<text top="1035" left="782" width="23" height="12" font="12">e121</text>
<text top="1050" left="503" width="224" height="14" font="14">6.2.3. Focused Follow-Up Visit: Physical</text>
<text top="1065" left="540" width="68" height="14" font="14">Examination</text>
<text top="1068" left="612" width="170" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1066" left="782" width="23" height="12" font="12">e122</text>
<text top="1080" left="503" width="271" height="14" font="14">6.2.4. Focused Follow-Up Visit: Resting 12-Lead</text>
<text top="1096" left="540" width="30" height="14" font="14">ECG</text>
<text top="1099" left="570" width="212" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1096" left="782" width="23" height="12" font="12">e122</text>
<text top="52" left="58" width="18" height="10" font="12">e46</text>
<text top="52" left="112" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="15" size="14" family="Times" color="#a70c2f"/>
	<fontspec id="16" size="13" family="Times" color="#3b456e"/>
<text top="104" left="116" width="239" height="14" font="14">6.2.5. Focused Follow-Up Visit: Laboratory</text>
<text top="119" left="153" width="68" height="14" font="14">Examination</text>
<text top="122" left="225" width="170" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="120" left="395" width="23" height="12" font="12">e122</text>
<text top="140" left="82" width="249" height="11" font="13">6.3. Noninvasive Testing in Known SIHD</text>
<text top="142" left="335" width="60" height="9" font="11">. . . . . . . . . . . .</text>
<text top="140" left="395" width="23" height="12" font="12">e122</text>
<text top="154" left="116" width="272" height="14" font="14">6.3.1. Follow-Up Noninvasive Testing in Patients</text>
<text top="169" left="153" width="222" height="14" font="14">With Known SIHD: New, Recurrent, or</text>
<text top="184" left="153" width="239" height="14" font="14">Worsening Symptoms Not Consistent With</text>
<text top="199" left="153" width="197" height="14" font="14">Unstable Angina: Recommendations</text>
<text top="202" left="351" width="44" height="9" font="11">. . . . . . . . .</text>
<text top="200" left="395" width="23" height="12" font="12">e122</text>
<text top="214" left="151" width="158" height="8" font="11">6.3.1.1. PATIENTS ABLE TO EXERCISE</text>
<text top="214" left="309" width="86" height="9" font="11">. . . . . . . . . . . . . . . . .</text>
<text top="212" left="395" width="23" height="12" font="12">e122</text>
<text top="229" left="151" width="169" height="8" font="11">6.3.1.2. PATIENTS UNABLE TO EXERCISE</text>
<text top="229" left="325" width="71" height="9" font="11">. . . . . . . . . . . . . .</text>
<text top="227" left="395" width="23" height="12" font="12">e123</text>
<text top="244" left="151" width="200" height="8" font="11">6.3.1.3. IRRESPECTIVE OF ABILITY TO EXERCISE</text>
<text top="244" left="351" width="44" height="9" font="11">. . . . . . . . .</text>
<text top="242" left="395" width="23" height="12" font="12">e124</text>
<text top="255" left="116" width="205" height="14" font="14">6.3.2. Noninvasive Testing in Known</text>
<text top="270" left="153" width="249" height="14" font="14">SIHD—Asymptomatic (or Stable Symptoms):</text>
<text top="285" left="153" width="99" height="14" font="14">Recommendations</text>
<text top="288" left="257" width="139" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="286" left="395" width="23" height="12" font="12">e124</text>
<text top="300" left="116" width="264" height="14" font="14">6.3.3. Factors Influencing the Use of Follow-Up</text>
<text top="315" left="153" width="41" height="14" font="14">Testing</text>
<text top="318" left="194" width="202" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="316" left="395" width="23" height="12" font="12">e124</text>
<text top="330" left="116" width="172" height="14" font="14">6.3.4. Patient Risk and Testing</text>
<text top="333" left="288" width="107" height="9" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="331" left="395" width="23" height="12" font="12">e125</text>
<text top="345" left="116" width="216" height="14" font="14">6.3.5. Stability of Results After Normal</text>
<text top="360" left="153" width="214" height="14" font="14">Stress Testing in Patients With Known</text>
<text top="375" left="153" width="34" height="14" font="14">SIHD</text>
<text top="378" left="188" width="207" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="376" left="395" width="23" height="12" font="12">e126</text>
<text top="390" left="116" width="270" height="14" font="14">6.3.6. Utility of Repeat Stress Testing in Patients</text>
<text top="405" left="153" width="106" height="14" font="14">With Known CAD</text>
<text top="408" left="262" width="134" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="406" left="395" width="23" height="12" font="12">e127</text>
<text top="420" left="116" width="153" height="14" font="14">6.3.7. Future Developments</text>
<text top="423" left="272" width="123" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="421" left="395" width="23" height="12" font="12">e127</text>
<text top="444" left="59" width="310" height="11" font="10">Appendix 1. Author Relationships With Industry</text>
<text top="461" left="59" width="191" height="11" font="10">and Other Entities (Relevant)</text>
<text top="464" left="251" width="144" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="461" left="395" width="23" height="12" font="12">e159</text>
<text top="498" left="59" width="327" height="11" font="10">Appendix 2. Reviewer Relationships With Industry</text>
<text top="515" left="59" width="191" height="11" font="10">and Other Entities (Relevant)</text>
<text top="518" left="251" width="144" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="515" left="395" width="23" height="12" font="12">e161</text>
<text top="552" left="59" width="200" height="11" font="10">Appendix 3. Abbreviations List</text>
<text top="555" left="262" width="134" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="553" left="395" width="23" height="12" font="12">e163</text>
<text top="590" left="59" width="316" height="11" font="10">Appendix 4. Nomogram for Estimating–Year CAD</text>
<text top="606" left="59" width="126" height="11" font="10">Event-Free Survival</text>
<text top="609" left="188" width="207" height="9" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="607" left="396" width="23" height="12" font="12">e164</text>
<text top="656" left="59" width="75" height="14" font="15">Preamble</text>
<text top="698" left="59" width="360" height="16" font="4">The medical profession should play a central role in evalu-</text>
<text top="716" left="59" width="360" height="16" font="4">ating the evidence related to drugs, devices, and procedures</text>
<text top="734" left="59" width="360" height="16" font="4">for the detection, management, and prevention of disease.</text>
<text top="752" left="59" width="360" height="16" font="4">When properly applied, expert analysis of available data on</text>
<text top="770" left="59" width="360" height="16" font="4">the benefits and risks of these therapies and procedures can</text>
<text top="788" left="59" width="360" height="16" font="4">improve the quality of care, optimize patient outcomes, and</text>
<text top="806" left="59" width="360" height="16" font="4">favorably affect costs by focusing resources on the most</text>
<text top="824" left="59" width="360" height="16" font="4">effective strategies. An organized and directed approach to a</text>
<text top="842" left="59" width="360" height="16" font="4">thorough review of evidence has resulted in the production</text>
<text top="860" left="59" width="360" height="16" font="4">of clinical practice guidelines that assist physicians in select-</text>
<text top="878" left="59" width="360" height="16" font="4">ing the best management strategy for an individual patient.</text>
<text top="896" left="59" width="360" height="16" font="4">Moreover, clinical practice guidelines can provide a foun-</text>
<text top="914" left="59" width="360" height="16" font="4">dation for other applications, such as performance measures,</text>
<text top="932" left="59" width="360" height="16" font="4">appropriate use criteria, and both quality improvement and</text>
<text top="950" left="59" width="185" height="16" font="4">clinical decision support tools.</text>
<text top="968" left="74" width="345" height="16" font="4">The American College of Cardiology Foundation</text>
<text top="986" left="59" width="360" height="16" font="4">(ACCF) and the American Heart Association (AHA) have</text>
<text top="1004" left="59" width="360" height="16" font="4">jointly produced guidelines in the area of cardiovascular</text>
<text top="1022" left="59" width="360" height="16" font="4">disease since 1980. The ACCF/AHA Task Force on</text>
<text top="1040" left="59" width="360" height="16" font="4">Practice Guidelines (Task Force), charged with developing,</text>
<text top="1058" left="59" width="360" height="16" font="4">updating, and revising practice guidelines for cardiovascular</text>
<text top="1076" left="59" width="360" height="16" font="4">diseases and procedures, directs and oversees this effort.</text>
<text top="1094" left="59" width="360" height="16" font="4">Writing committees are charged with regularly reviewing</text>
<text top="104" left="446" width="360" height="16" font="4">and evaluating all available evidence to develop balanced,</text>
<text top="122" left="446" width="326" height="16" font="4">patient-centric recommendations for clinical practice.</text>
<text top="140" left="461" width="345" height="16" font="4">Experts in the subject under consideration are selected by</text>
<text top="158" left="446" width="360" height="16" font="4">the ACCF and AHA to examine subject-specific data and</text>
<text top="176" left="446" width="360" height="16" font="4">write guidelines in partnership with representatives from</text>
<text top="194" left="446" width="360" height="16" font="4">other medical organizations and specialty groups. Writing</text>
<text top="212" left="446" width="360" height="16" font="4">committees are asked to perform a literature review; weigh</text>
<text top="230" left="446" width="360" height="16" font="4">the strength of evidence for or against particular tests,</text>
<text top="248" left="446" width="360" height="16" font="4">treatments, or procedures; and include estimates of expected</text>
<text top="266" left="446" width="360" height="16" font="4">outcomes where such data exist. Patient-specific modifiers,</text>
<text top="284" left="446" width="360" height="16" font="4">comorbidities, and issues of patient preference that may</text>
<text top="302" left="446" width="360" height="16" font="4">influence the choice of tests or therapies are considered.</text>
<text top="320" left="446" width="360" height="16" font="4">When available, information from studies on cost is con-</text>
<text top="338" left="446" width="360" height="16" font="4">sidered, but data on efficacy and outcomes constitute the</text>
<text top="356" left="446" width="350" height="16" font="4">primary basis for the recommendations contained herein.</text>
<text top="374" left="461" width="345" height="16" font="4">In analyzing the data and developing recommendations</text>
<text top="392" left="446" width="360" height="16" font="4">and supporting text, the writing committee uses evidence-</text>
<text top="410" left="446" width="315" height="16" font="4">based methodologies developed by the Task Force <a href="e44.full.html#85">(</a></text>
<text top="410" left="760" width="8" height="16" font="16"><a href="e44.full.html#85">1</a></text>
<text top="410" left="768" width="38" height="16" font="4"><a href="e44.full.html#85">). </a>The</text>
<text top="428" left="446" width="360" height="16" font="4">Class of Recommendation (COR) is an estimate of the size</text>
<text top="446" left="446" width="360" height="16" font="4">of the treatment effect, with consideration given to risks</text>
<text top="464" left="446" width="360" height="16" font="4">versus benefits as well as evidence and/or agreement that a</text>
<text top="482" left="446" width="360" height="16" font="4">given treatment or procedure is or is not useful/effective or</text>
<text top="500" left="446" width="360" height="16" font="4">in some situations may cause harm. The Level of Evidence</text>
<text top="518" left="446" width="360" height="16" font="4">(LOE) is an estimate of the certainty or precision of the</text>
<text top="536" left="446" width="360" height="16" font="4">treatment effect. The writing committee reviews and ranks</text>
<text top="554" left="446" width="360" height="16" font="4">evidence supporting each recommendation, with the weight</text>
<text top="572" left="446" width="360" height="16" font="4">of evidence ranked as LOE A, B, or C according to specific</text>
<text top="590" left="446" width="188" height="16" font="4">definitions that are included in</text>
<text top="590" left="638" width="47" height="16" font="16"><a href="e44.full.html#5">Table 1</a></text>
<text top="590" left="685" width="121" height="16" font="4"><a href="e44.full.html#5">. </a>Studies are identi-</text>
<text top="608" left="446" width="360" height="16" font="4">fied as observational, retrospective, prospective, or random-</text>
<text top="626" left="446" width="360" height="16" font="4">ized as appropriate. For certain conditions for which inad-</text>
<text top="644" left="446" width="360" height="16" font="4">equate data are available, recommendations are based on</text>
<text top="662" left="446" width="360" height="16" font="4">expert consensus and clinical experience and are ranked as</text>
<text top="680" left="446" width="360" height="16" font="4">LOE C. When recommendations at LOE C are supported</text>
<text top="698" left="446" width="360" height="16" font="4">by historical clinical data, appropriate references (including</text>
<text top="716" left="446" width="360" height="16" font="4">clinical reviews) are cited if available. For issues for which</text>
<text top="734" left="446" width="360" height="16" font="4">sparse data are available, a survey of current practice among</text>
<text top="752" left="446" width="361" height="16" font="4">the clinicians on the writing committee is the basis for LOE C</text>
<text top="770" left="446" width="360" height="16" font="4">recommendations, and no references are cited. The schema</text>
<text top="788" left="446" width="233" height="16" font="4">for COR and LOE is summarized in</text>
<text top="788" left="684" width="48" height="16" font="16"><a href="e44.full.html#5">Table 1</a></text>
<text top="788" left="731" width="74" height="16" font="4"><a href="e44.full.html#5">, </a>which also</text>
<text top="806" left="446" width="360" height="16" font="4">provides suggested phrases for writing recommendations</text>
<text top="824" left="446" width="360" height="16" font="4">within each COR. A new addition to this methodology is</text>
<text top="842" left="446" width="360" height="16" font="4">separation of the Class III recommendations to delineate</text>
<text top="860" left="446" width="360" height="16" font="4">whether the recommendation is determined to be of “no</text>
<text top="878" left="446" width="360" height="16" font="4">benefit” or is associated with “harm” to the patient. In</text>
<text top="896" left="446" width="360" height="16" font="4">addition, in view of the increasing number of comparative</text>
<text top="914" left="446" width="360" height="16" font="4">effectiveness studies, comparator verbs and suggested</text>
<text top="932" left="446" width="360" height="16" font="4">phrases for writing recommendations for the comparative</text>
<text top="950" left="446" width="360" height="16" font="4">effectiveness of one treatment or strategy versus another</text>
<text top="968" left="446" width="348" height="16" font="4">have been added for COR I and IIa, LOE A or B only.</text>
<text top="986" left="461" width="345" height="16" font="4">In view of the advances in medical therapy across the</text>
<text top="1004" left="446" width="360" height="16" font="4">spectrum of cardiovascular diseases, the Task Force has</text>
<text top="1022" left="446" width="360" height="16" font="4">designated the term <i>guideline-directed medical therapy</i></text>
<text top="1040" left="446" width="360" height="16" font="5"><i>(GDMT) </i>to represent optimal medical therapy as defined by</text>
<text top="1058" left="446" width="360" height="16" font="4">ACCF/AHA guideline (primarily Class I)–recommended</text>
<text top="1076" left="446" width="360" height="16" font="4">therapies. This new term, <i>GDMT</i>, will be used herein and</text>
<text top="1094" left="446" width="198" height="16" font="4">throughout all future guidelines.</text>
<text top="52" left="787" width="18" height="10" font="12">e47</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="17" size="6" family="Times" color="#231f20"/>
<text top="874" left="74" width="345" height="16" font="4">Because the ACCF/AHA practice guidelines address</text>
<text top="892" left="59" width="360" height="16" font="4">patient populations (and healthcare providers) residing in</text>
<text top="911" left="59" width="360" height="16" font="4">North America, drugs that are not currently available in</text>
<text top="929" left="59" width="360" height="16" font="4">North America are discussed in the text without a specific</text>
<text top="948" left="59" width="360" height="16" font="4">COR. For studies performed in large numbers of subjects</text>
<text top="966" left="59" width="360" height="16" font="4">outside North America, each writing committee reviews the</text>
<text top="984" left="59" width="360" height="16" font="4">potential influence of different practice patterns and patient</text>
<text top="1003" left="59" width="360" height="16" font="4">populations on the treatment effect and relevance to the</text>
<text top="1021" left="59" width="360" height="16" font="4">ACCF/AHA target population to determine whether the</text>
<text top="1039" left="59" width="311" height="16" font="4">findings should inform a specific recommendation.</text>
<text top="1058" left="74" width="345" height="16" font="4">The ACCF/AHA practice guidelines are intended to</text>
<text top="1076" left="59" width="360" height="16" font="4">assist healthcare providers in clinical decision making by</text>
<text top="1094" left="59" width="360" height="16" font="4">describing a range of generally acceptable approaches to the</text>
<text top="874" left="446" width="360" height="16" font="4">diagnosis, management, and prevention of specific diseases</text>
<text top="893" left="446" width="360" height="16" font="4">or conditions. The guidelines attempt to define practices</text>
<text top="911" left="446" width="360" height="16" font="4">that meet the needs of most patients in most circumstances.</text>
<text top="929" left="446" width="360" height="16" font="4">The ultimate judgment about care of a particular patient</text>
<text top="948" left="446" width="360" height="16" font="4">must be made by the healthcare provider and patient in light</text>
<text top="966" left="446" width="360" height="16" font="4">of all the circumstances presented by that patient. As a</text>
<text top="984" left="446" width="360" height="16" font="4">result, situations may arise in which deviations from these</text>
<text top="1003" left="446" width="360" height="16" font="4">guidelines might be appropriate. Clinical decision making</text>
<text top="1021" left="446" width="360" height="16" font="4">should involve consideration of the quality and availability</text>
<text top="1039" left="446" width="360" height="16" font="4">of expertise in the area where care is provided. When these</text>
<text top="1058" left="446" width="360" height="16" font="4">guidelines are used as the basis for regulatory or payer</text>
<text top="1076" left="446" width="360" height="16" font="4">decisions, the goal should be improvement in quality of care.</text>
<text top="1094" left="446" width="360" height="16" font="4">The Task Force recognizes that situations arise in which</text>
<text top="105" left="59" width="438" height="11" font="13">Table 1. Applying Classification of Recommendations and Level of Evidence</text>
<text top="782" left="59" width="747" height="7" font="17">A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.</text>
<text top="794" left="59" width="539" height="7" font="17">Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.</text>
<text top="803" left="67" width="739" height="11" font="17">ⴱData available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart</text>
<text top="818" left="59" width="110" height="7" font="17">failure, and prior aspirin use.</text>
<text top="830" left="67" width="738" height="7" font="17">†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the</text>
<text top="842" left="59" width="157" height="7" font="17">treatments or strategies being evaluated.</text>
<text top="52" left="59" width="18" height="10" font="12">e48</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="18" size="12" family="Times" color="#005d59"/>
<text top="104" left="59" width="360" height="16" font="4">additional data are needed to inform patient care more</text>
<text top="122" left="59" width="360" height="16" font="4">effectively; these areas will be identified within each respec-</text>
<text top="140" left="59" width="197" height="16" font="4">tive guideline when appropriate.</text>
<text top="158" left="74" width="345" height="16" font="4">Prescribed courses of treatment in accordance with these</text>
<text top="176" left="59" width="360" height="16" font="4">recommendations are effective only if followed. Because lack of</text>
<text top="194" left="59" width="360" height="16" font="4">patient understanding and adherence may adversely affect</text>
<text top="212" left="59" width="360" height="16" font="4">outcomes, physicians and other healthcare providers should</text>
<text top="230" left="59" width="360" height="16" font="4">make every effort to engage the patient’s active participation in</text>
<text top="248" left="59" width="360" height="16" font="4">prescribed medical regimens and lifestyles. In addition, patients</text>
<text top="266" left="59" width="360" height="16" font="4">should be informed of the risks, benefits, and alternatives to a</text>
<text top="284" left="59" width="360" height="16" font="4">particular treatment and should be involved in shared decision</text>
<text top="302" left="59" width="360" height="16" font="4">making whenever feasible, particularly for COR IIa and IIb,</text>
<text top="320" left="59" width="285" height="16" font="4">for which the benefit-to-risk ratio may be lower.</text>
<text top="338" left="74" width="345" height="16" font="4">The Task Force makes every effort to avoid actual,</text>
<text top="356" left="59" width="360" height="16" font="4">potential, or perceived conflicts of interest that may arise as</text>
<text top="374" left="59" width="360" height="16" font="4">a result of industry relationships or personal interests among</text>
<text top="392" left="59" width="360" height="16" font="4">the members of the writing committee. All writing com-</text>
<text top="410" left="59" width="360" height="16" font="4">mittee members and peer reviewers of this guideline were</text>
<text top="428" left="59" width="360" height="16" font="4">required to disclose all such current health care-related</text>
<text top="446" left="59" width="360" height="16" font="4">relationships, including those existing 24 months (from</text>
<text top="464" left="59" width="360" height="16" font="4">2005) before initiation of the writing effort. The writing</text>
<text top="482" left="59" width="360" height="16" font="4">committee chair may not have any relevant relationships</text>
<text top="500" left="59" width="360" height="16" font="4">with industry or other entities (RWI); however, RWI are</text>
<text top="518" left="59" width="360" height="16" font="4">permitted for the vice chair position. In December 2009, the</text>
<text top="536" left="59" width="360" height="16" font="4">ACCF and AHA implemented a new policy that requires a</text>
<text top="554" left="59" width="360" height="16" font="4">minimum of 50% of the writing committee to have no</text>
<text top="572" left="59" width="360" height="16" font="5"><i>relevant </i>RWI; in addition, the disclosure term was changed</text>
<text top="590" left="59" width="360" height="16" font="4">to 12 months before writing committee initiation. The</text>
<text top="608" left="59" width="360" height="16" font="4">present guideline was developed during the transition in</text>
<text top="626" left="59" width="360" height="16" font="4">RWI policy and occurred over an extended period of time.</text>
<text top="644" left="59" width="360" height="16" font="4">In the interest of transparency, we provide full information</text>
<text top="662" left="59" width="360" height="16" font="4">on RWI existing over the entire period of guideline devel-</text>
<text top="680" left="59" width="360" height="16" font="4">opment, including delineation of relationships that expired</text>
<text top="698" left="59" width="360" height="16" font="4">more than 24 months before the guideline was finalized.</text>
<text top="716" left="59" width="196" height="16" font="4">This information is included in</text>
<text top="716" left="260" width="73" height="16" font="16"><a href="e44.full.html#116">Appendix 1</a></text>
<text top="716" left="333" width="86" height="16" font="4"><a href="e44.full.html#116">. </a>These state-</text>
<text top="734" left="59" width="360" height="16" font="4">ments are reviewed by the Task Force and all members</text>
<text top="752" left="59" width="360" height="16" font="4">during each conference call and meeting of the writing</text>
<text top="770" left="59" width="360" height="16" font="4">committee and are updated as changes occur. All guideline</text>
<text top="788" left="59" width="360" height="16" font="4">recommendations require a confidential vote by the writing</text>
<text top="806" left="59" width="360" height="16" font="4">committee and must be approved by a consensus of the</text>
<text top="824" left="59" width="360" height="16" font="4">voting members. Members who recused themselves from</text>
<text top="842" left="59" width="360" height="16" font="4">voting are indicated in the list of writing committee mem-</text>
<text top="860" left="59" width="280" height="16" font="4">bers, and specific section recusals are noted in</text>
<text top="860" left="343" width="72" height="16" font="16"><a href="e44.full.html#116">Appendix 1</a></text>
<text top="860" left="415" width="4" height="16" font="4"><a href="e44.full.html#116">.</a></text>
<text top="878" left="59" width="360" height="16" font="4">Authors’ and peer reviewers’ RWI pertinent to this guide-</text>
<text top="896" left="59" width="132" height="16" font="4">line are disclosed in</text>
<text top="896" left="199" width="87" height="16" font="16"><a href="e44.full.html#116">Appendixes 1</a></text>
<text top="896" left="295" width="22" height="16" font="4">and</text>
<text top="896" left="326" width="8" height="16" font="16"><a href="e44.full.html#118">2</a></text>
<text top="896" left="333" width="85" height="16" font="4"><a href="e44.full.html#118">, </a>respectively.</text>
<text top="914" left="58" width="360" height="16" font="4">Comprehensive disclosure information for the Task Force is</text>
<text top="932" left="58" width="138" height="16" font="4">also available online at</text>
<text top="932" left="201" width="217" height="16" font="16"><a href="http://www.cardiosource.org/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">http://www.cardiosource.org/ACC/</a></text>
<text top="950" left="58" width="360" height="16" font="16"><a href="http://www.cardiosource.org/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">About-ACC/Who-We-Are/Leadership/Guidelines-and-</a></text>
<text top="968" left="58" width="181" height="16" font="16"><a href="http://www.cardiosource.org/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">Documents-Task-Forces.aspx</a></text>
<text top="968" left="240" width="179" height="16" font="4"><a href="http://www.cardiosource.org/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">. </a>The work of the writing com-</text>
<text top="986" left="58" width="360" height="16" font="4">mittee is supported exclusively by the ACCF, AHA, American</text>
<text top="1004" left="58" width="360" height="16" font="4">College of Physicians (ACP), American Association for Tho-</text>
<text top="1022" left="58" width="360" height="16" font="4">racic Surgery (AATS), Preventive Cardiovascular Nurses As-</text>
<text top="1040" left="58" width="360" height="16" font="4">sociation (PCNA), Society for Cardiovascular Angiography</text>
<text top="1058" left="58" width="360" height="16" font="4">and Interventions (SCAI), and Society of Thoracic Surgeons</text>
<text top="1076" left="58" width="360" height="16" font="4">(STS), without commercial support. Writing committee</text>
<text top="1094" left="58" width="283" height="16" font="4">members volunteered their time for this activity.</text>
<text top="104" left="461" width="345" height="16" font="4">The recommendations in this guideline are considered</text>
<text top="123" left="446" width="360" height="16" font="4">current until they are superseded by a focused update or the</text>
<text top="141" left="446" width="360" height="16" font="4">full-text guideline is revised. Guidelines are official policy of</text>
<text top="159" left="446" width="171" height="16" font="4">both the ACCF and AHA.</text>
<text top="186" left="565" width="240" height="16" font="5"><i>Jeffrey L. Anderson, MD, FACC, FAHA</i></text>
<text top="204" left="488" width="317" height="16" font="5"><i>Chair, ACCF/AHA Task Force on Practice Guidelines</i></text>
<text top="241" left="446" width="120" height="14" font="15">1. Introduction</text>
<text top="291" left="446" width="286" height="12" font="18">1.1. Methodology and Evidence Overview</text>
<text top="314" left="446" width="360" height="16" font="4">The recommendations listed in this document are, when-</text>
<text top="332" left="446" width="360" height="16" font="4">ever possible, evidence based. An extensive evidence review</text>
<text top="350" left="446" width="360" height="16" font="4">was conducted as the document was compiled through</text>
<text top="368" left="446" width="360" height="16" font="4">December 2008. Repeated literature searches were per-</text>
<text top="386" left="446" width="360" height="16" font="4">formed by the guideline development staff and writing</text>
<text top="405" left="446" width="360" height="16" font="4">committee members as new issues were considered. New</text>
<text top="423" left="446" width="360" height="16" font="4">clinical trials published in peer-reviewed journals and arti-</text>
<text top="441" left="446" width="360" height="16" font="4">cles through December 2011 were also reviewed and incor-</text>
<text top="459" left="446" width="360" height="16" font="4">porated when relevant. Furthermore, because of the ex-</text>
<text top="477" left="446" width="360" height="16" font="4">tended development time period for this guideline, peer</text>
<text top="495" left="446" width="360" height="16" font="4">review comments indicated that the sections focused on</text>
<text top="513" left="446" width="360" height="16" font="4">imaging technologies required additional updating, which</text>
<text top="532" left="446" width="360" height="16" font="4">occurred during 2011. Therefore, the evidence review for</text>
<text top="550" left="446" width="360" height="16" font="4">the imaging sections includes published literature through</text>
<text top="568" left="446" width="101" height="16" font="4">December 2011.</text>
<text top="586" left="461" width="345" height="16" font="4">Searches were limited to studies, reviews, and other</text>
<text top="604" left="446" width="360" height="16" font="4">evidence in human subjects and that were published in</text>
<text top="622" left="446" width="360" height="16" font="4">English. Key search words included but were not limited to</text>
<text top="641" left="446" width="360" height="16" font="4">the following: <i>accuracy, angina, asymptomatic patients, cardiac</i></text>
<text top="659" left="446" width="360" height="16" font="5"><i>magnetic resonance (CMR), cardiac rehabilitation, chest pain,</i></text>
<text top="677" left="446" width="360" height="16" font="5"><i>chronic angina, chronic coronary occlusions, chronic ischemic</i></text>
<text top="695" left="446" width="360" height="16" font="5"><i>heart disease (IHD), chronic total occlusion, connective tissue</i></text>
<text top="713" left="446" width="360" height="16" font="5"><i>disease, coronary artery bypass graft (CABG) versus medical</i></text>
<text top="731" left="446" width="360" height="16" font="5"><i>therapy, coronary artery disease (CAD) and exercise, coronary</i></text>
<text top="749" left="446" width="360" height="16" font="5"><i>calcium scanning, cardiac/coronary computed tomography angiog-</i></text>
<text top="768" left="446" width="360" height="16" font="5"><i>raphy (CCTA), CMR angiography, CMR imaging, coronary</i></text>
<text top="786" left="446" width="360" height="16" font="5"><i>stenosis, death, depression, detection of CAD in symptomatic</i></text>
<text top="804" left="446" width="360" height="16" font="5"><i>patients, diabetes, diagnosis, dobutamine stress echocardiography,</i></text>
<text top="822" left="446" width="360" height="16" font="5"><i>echocardiography, elderly, electrocardiogram (ECG) and chronic</i></text>
<text top="840" left="446" width="360" height="16" font="5"><i>stable angina, emergency department, ethnic, exercise, exercise stress</i></text>
<text top="858" left="446" width="360" height="16" font="5"><i>testing, follow-up testing, gender, glycemic control, hypertension,</i></text>
<text top="876" left="446" width="360" height="16" font="5"><i>intravascular ultrasound, fractional flow reserve (FFR), invasive</i></text>
<text top="895" left="446" width="360" height="16" font="5"><i>coronary angiography, kidney disease, low-density lipoprotein</i></text>
<text top="913" left="446" width="360" height="16" font="5"><i>(LDL) lowering, magnetic resonance imaging (MRI), medication</i></text>
<text top="931" left="446" width="360" height="16" font="5"><i>adherence, minority groups, mortality, myocardial infarction (MI),</i></text>
<text top="949" left="446" width="360" height="16" font="5"><i>noninvasive testing and mortality, nuclear myocardial perfusion,</i></text>
<text top="967" left="446" width="360" height="16" font="5"><i>nutrition, obesity, outcomes, patient follow-up, patient education,</i></text>
<text top="985" left="446" width="360" height="16" font="5"><i>prognosis, proximal left anterior descending (LAD) disease, physical</i></text>
<text top="1004" left="446" width="360" height="16" font="5"><i>activity, reoperation, risk stratification, smoking, stable ischemic</i></text>
<text top="1022" left="446" width="360" height="16" font="5"><i>heart disease (SIHD), stable angina and reoperation, stable angina</i></text>
<text top="1040" left="446" width="360" height="16" font="5"><i>and revascularization, stress echocardiography, radionuclide stress</i></text>
<text top="1058" left="446" width="360" height="16" font="5"><i>testing, stenting versus CABG, unprotected left main, weight</i></text>
<text top="1076" left="446" width="126" height="16" font="5"><i>reduction, and women.</i></text>
<text top="1076" left="576" width="69" height="16" font="16"><a href="e44.full.html#120">Appendix 3</a></text>
<text top="1076" left="650" width="156" height="16" font="4">contains an list of abbrevi-</text>
<text top="1094" left="445" width="173" height="16" font="4">ations used in this document.</text>
<text top="52" left="787" width="18" height="10" font="12">e49</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="19" size="5" family="Times" color="#231f20"/>
	<fontspec id="20" size="5" family="Times" color="#231f20"/>
	<fontspec id="21" size="4" family="Times" color="#231f20"/>
<text top="104" left="74" width="345" height="16" font="4">To provide clinicians with a comprehensive set of data,</text>
<text top="122" left="59" width="360" height="16" font="4">the absolute risk difference and number needed to treat or</text>
<text top="140" left="59" width="360" height="16" font="4">harm, if they were published and their inclusion was deemed</text>
<text top="158" left="59" width="360" height="16" font="4">appropriate, are provided in the guideline, along with</text>
<text top="176" left="59" width="360" height="16" font="4">confidence intervals (CIs) and data related to the relative</text>
<text top="194" left="59" width="360" height="16" font="4">treatment effects, such as odds ratio (OR), relative risk</text>
<text top="212" left="59" width="260" height="16" font="4">(RR), hazard ratio, or incidence rate ratio.</text>
<text top="240" left="59" width="300" height="12" font="18">1.2. Organization of the Writing Committee</text>
<text top="263" left="59" width="360" height="16" font="4">The writing committee was composed of physicians, car-</text>
<text top="281" left="59" width="360" height="16" font="4">diovascular interventionalists, surgeons, general internists,</text>
<text top="299" left="59" width="360" height="16" font="4">imagers, nurses, and pharmacists. The writing committee</text>
<text top="317" left="59" width="360" height="16" font="4">included representatives from the ACP, AATS, PCNA,</text>
<text top="335" left="59" width="103" height="16" font="4">SCAI, and STS.</text>
<text top="362" left="59" width="251" height="12" font="18">1.3. Document Review and Approval</text>
<text top="385" left="59" width="360" height="16" font="4">This document was reviewed by 2 external reviewers nom-</text>
<text top="403" left="59" width="360" height="16" font="4">inated by both the ACCF and the AHA; 2 reviewers</text>
<text top="421" left="59" width="360" height="16" font="4">nominated by the ACP, AATS, PCNA, SCAI, and STS;</text>
<text top="439" left="59" width="360" height="16" font="4">and 19 content reviewers, including members of the ACCF</text>
<text top="457" left="59" width="360" height="16" font="4">Imaging Council, ACCF Interventional Scientific Council,</text>
<text top="475" left="59" width="360" height="16" font="4">and the AHA Council on Clinical Cardiology. Reviewers’</text>
<text top="493" left="59" width="360" height="16" font="4">RWI information was collected and distributed to the</text>
<text top="511" left="59" width="360" height="16" font="4">writing committee and is published in this document</text>
<text top="529" left="59" width="5" height="16" font="4"><a href="e44.full.html#118">(</a></text>
<text top="529" left="63" width="75" height="16" font="16"><a href="e44.full.html#118">Appendix 2</a></text>
<text top="529" left="139" width="280" height="16" font="4"><a href="e44.full.html#118">). </a>Because extensive peer review comments</text>
<text top="547" left="59" width="360" height="16" font="4">resulted in substantial revision, the guideline was subjected</text>
<text top="565" left="59" width="360" height="16" font="4">to a second peer review by all official and organizational</text>
<text top="583" left="59" width="360" height="16" font="4">reviewers. Lastly, the imaging sections were peer reviewed</text>
<text top="601" left="59" width="298" height="16" font="4">separately, after an update to that evidence base.</text>
<text top="619" left="74" width="345" height="16" font="4">This document was approved for publication by the</text>
<text top="637" left="59" width="360" height="16" font="4">governing bodies of the ACCF, AHA, ACP, AATS,</text>
<text top="655" left="59" width="155" height="16" font="4">PCNA, SCAI, and STS.</text>
<text top="682" left="59" width="191" height="12" font="18">1.4. Scope of the Guideline</text>
<text top="705" left="59" width="360" height="16" font="4">These guidelines are intended to apply to adult patients with</text>
<text top="723" left="59" width="360" height="16" font="4">stable known or suspected IHD, including new-onset chest</text>
<text top="741" left="59" width="360" height="16" font="4">pain (i.e., low-risk unstable angina [UA]), or to adult</text>
<text top="759" left="59" width="241" height="16" font="4">patients with stable pain syndromes <a href="e44.full.html#7">(</a></text>
<text top="759" left="299" width="54" height="16" font="16"><a href="e44.full.html#7">Figure 1</a></text>
<text top="759" left="354" width="65" height="16" font="4"><a href="e44.full.html#7">). </a>Patients</text>
<text top="104" left="446" width="360" height="16" font="4">who have “ischemic equivalents,” such as dyspnea or arm</text>
<text top="123" left="446" width="360" height="16" font="4">pain with exertion, are included in the latter group. Many</text>
<text top="141" left="446" width="360" height="16" font="4">patients with IHD can become asymptomatic with appro-</text>
<text top="159" left="446" width="360" height="16" font="4">priate therapy. Accordingly, the follow-up sections of this</text>
<text top="177" left="446" width="360" height="16" font="4">guideline pertain to patients who were previously symptom-</text>
<text top="195" left="446" width="360" height="16" font="4">atic, including those who have undergone percutaneous</text>
<text top="214" left="446" width="242" height="16" font="4">coronary intervention (PCI) or CABG.</text>
<text top="232" left="461" width="345" height="16" font="4">This guideline also addresses the initial diagnostic ap-</text>
<text top="250" left="446" width="360" height="16" font="4">proach to patients who present with symptoms that suggest</text>
<text top="268" left="446" width="360" height="16" font="4">IHD, such as anginal-type chest pain, but who are not known</text>
<text top="286" left="446" width="360" height="16" font="4">to have IHD. In this circumstance, it is essential that the</text>
<text top="304" left="446" width="360" height="16" font="4">practitioner ascertain whether such symptoms represent the</text>
<text top="323" left="446" width="360" height="16" font="4">initial clinical recognition of chronic stable angina, reflecting</text>
<text top="341" left="446" width="360" height="16" font="4">gradual progression of obstructive CAD or an increase in</text>
<text top="359" left="446" width="360" height="16" font="4">supply/demand mismatch precipitated by a change in activ-</text>
<text top="377" left="446" width="360" height="16" font="4">ity or concurrent illness (e.g., anemia or infection), or</text>
<text top="395" left="446" width="360" height="16" font="4">whether they represent an acute coronary syndrome (ACS),</text>
<text top="414" left="446" width="360" height="16" font="4">most likely due to an unstable plaque causing acute throm-</text>
<text top="432" left="446" width="360" height="16" font="4">bosis. For patients with newly diagnosed stable angina, this</text>
<text top="450" left="446" width="360" height="16" font="4">guideline should be used. Patients with ACS have either</text>
<text top="468" left="446" width="360" height="16" font="4">acute myocardial infarction (AMI) or UA. For patients with</text>
<text top="486" left="446" width="360" height="16" font="4">AMI, the reader is referred to the “ACCF/AHA Guidelines</text>
<text top="504" left="446" width="360" height="16" font="4">for the Management of Patients With ST-Elevation Myo-</text>
<text top="523" left="446" width="190" height="16" font="4">cardial Infarction” (STEMI) <a href="e44.full.html#85">(</a></text>
<text top="523" left="635" width="19" height="16" font="16"><a href="e44.full.html#85">2,3</a></text>
<text top="523" left="654" width="152" height="16" font="4"><a href="e44.full.html#85">). </a>Similarly, for patients</text>
<text top="541" left="446" width="360" height="16" font="4">with UA that is believed to be due to an acute change in</text>
<text top="559" left="446" width="360" height="16" font="4">clinical status attributable to an unstable plaque or an abrupt</text>
<text top="577" left="446" width="360" height="16" font="4">change in supply (e.g., coronary occlusion with myocardial</text>
<text top="595" left="446" width="360" height="16" font="4">supply through collaterals), the reader is referred to the</text>
<text top="613" left="446" width="360" height="16" font="4">“ACCF/AHA Guidelines for the Management of Patients</text>
<text top="632" left="446" width="360" height="16" font="4">With Unstable Angina/non–ST-Elevation Myocardial Infarc-</text>
<text top="650" left="446" width="144" height="16" font="4">tion” (UA/NSTEMI) <a href="e44.full.html#85">(</a></text>
<text top="650" left="590" width="24" height="16" font="16"><a href="e44.full.html#85">4,4a</a></text>
<text top="650" left="614" width="192" height="16" font="4"><a href="e44.full.html#85">). </a>There are, however, patients</text>
<text top="668" left="446" width="360" height="16" font="4">with UA who can be categorized as low risk and are addressed</text>
<text top="686" left="446" width="104" height="16" font="4">in this guideline <a href="e44.full.html#8">(</a></text>
<text top="686" left="549" width="45" height="16" font="16"><a href="e44.full.html#8">Table 2</a></text>
<text top="686" left="594" width="8" height="16" font="4"><a href="e44.full.html#8">).</a></text>
<text top="704" left="461" width="345" height="16" font="4">A key premise of this guideline is that once a diagnosis of</text>
<text top="723" left="446" width="360" height="16" font="4">IHD is established, it is necessary in most patients to assess</text>
<text top="741" left="446" width="360" height="16" font="4">their risk of subsequent complications, such as AMI or</text>
<text top="759" left="446" width="360" height="16" font="4">death. Because the approach to diagnosis of suspected IHD</text>
<text top="797" left="500" width="68" height="10" font="6">Asymptomatic</text>
<text top="809" left="522" width="24" height="7" font="19"><b>(SIHD)</b></text>
<text top="872" left="202" width="91" height="13" font="14">Asymptomatic </text>
<text top="889" left="220" width="54" height="13" font="14">Persons </text>
<text top="905" left="222" width="51" height="13" font="14">Without </text>
<text top="922" left="210" width="70" height="13" font="14">Known IHD</text>
<text top="937" left="229" width="33" height="7" font="20">(CV Risk)</text>
<text top="867" left="500" width="70" height="10" font="6">Stable Angina </text>
<text top="879" left="505" width="60" height="10" font="6">or Low-Risk </text>
<text top="892" left="524" width="19" height="10" font="6">UA*</text>
<text top="905" left="502" width="64" height="7" font="20">(<b>SIHD</b>; PCI/CABG)</text>
<text top="949" left="496" width="78" height="10" font="6">Acute Coronary </text>
<text top="962" left="507" width="55" height="10" font="6">Syndromes</text>
<text top="975" left="497" width="74" height="7" font="20">(UA/NSTEMI; STEMI;</text>
<text top="984" left="514" width="39" height="7" font="20">PCI/CABG)</text>
<text top="885" left="602" width="54" height="13" font="14">Patients </text>
<text top="902" left="615" width="28" height="13" font="14">with </text>
<text top="918" left="592" width="70" height="13" font="14">Known IHD</text>
<text top="948" left="348" width="57" height="10" font="6">Noncardiac </text>
<text top="961" left="348" width="53" height="10" font="6">Chest Pain</text>
<text top="873" left="348" width="56" height="10" font="6">New Onset </text>
<text top="886" left="348" width="53" height="10" font="6">Chest Pain</text>
<text top="898" left="326" width="97" height="7" font="20">(<b>SIHD</b>; UA/NSTEMI; STEMI)</text>
<text top="997" left="367" width="109" height="10" font="6">Sudden Cardiac Death</text>
<text top="1009" left="404" width="34" height="7" font="20">(VA-SCD)</text>
<text top="800" left="377" width="33" height="6" font="21">Noninvasive</text>
<text top="807" left="384" width="20" height="6" font="21">Testing</text>
<text top="816" left="369" width="102" height="6" font="21">*Features of low risk unstable angina:</text>
<text top="822" left="373" width="29" height="8" font="21">•Age, 70 y</text>
<text top="830" left="373" width="91" height="8" font="21">•Exertional pain lasting &lt;20 min. </text>
<text top="837" left="373" width="81" height="8" font="21">•Pain not rapidly accelerating</text>
<text top="845" left="373" width="78" height="8" font="21">•Normal or unchanged ECG</text>
<text top="852" left="373" width="90" height="8" font="21">•No elevation of cardiac markers</text>
<text top="1040" left="59" width="147" height="11" font="13">Figure 1. Spectrum of IHD</text>
<text top="1072" left="59" width="745" height="8" font="11">Guidelines relevant to the spectrum of IHD are in parentheses. CABG indicates coronary artery bypass graft; CV, cardiovascular; ECG, electrocardiogram; IHD, ischemic heart</text>
<text top="1085" left="59" width="741" height="8" font="11">disease; PCI, percutaneous coronary intervention; SCD, sudden cardiac death; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; UA, unstable</text>
<text top="1099" left="59" width="465" height="8" font="11">angina; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; and VA, ventricular arrhythmia.</text>
<text top="52" left="59" width="18" height="10" font="12">e50</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="22" size="6" family="Times" color="#3b456e"/>
<text top="716" left="59" width="360" height="16" font="4">and the assessment of risk in a patient with known IHD are</text>
<text top="734" left="59" width="360" height="16" font="4">conceptually different and are based on different literature,</text>
<text top="752" left="59" width="360" height="16" font="4">the writing committee constructed this guideline to address</text>
<text top="770" left="59" width="360" height="16" font="4">these issues separately. It is recognized, however, that a</text>
<text top="788" left="59" width="360" height="16" font="4">clinician might select a procedure for a patient with a</text>
<text top="806" left="59" width="360" height="16" font="4">moderate to high pretest likelihood of IHD to provide</text>
<text top="824" left="59" width="360" height="16" font="4">information for both diagnosis and risk assessment, whereas</text>
<text top="842" left="59" width="360" height="16" font="4">in a patient with a low likelihood of IHD, it could be</text>
<text top="860" left="59" width="360" height="16" font="4">sensible to select a test simply for diagnostic purposes</text>
<text top="878" left="59" width="360" height="16" font="4">without regard to risk assessment. By separating the con-</text>
<text top="896" left="59" width="360" height="16" font="4">ceptual approaches to ascertaining diagnosis and prognosis,</text>
<text top="914" left="59" width="360" height="16" font="4">the goal of the writing committee is to promote the sensible</text>
<text top="932" left="59" width="360" height="16" font="4">application of appropriate testing rather than routine use of</text>
<text top="950" left="59" width="360" height="16" font="4">the most expensive or complex tests whether warranted or</text>
<text top="968" left="59" width="360" height="16" font="4">not. It is not the intent of the writing committee to promote</text>
<text top="986" left="59" width="360" height="16" font="4">unnecessary or duplicate testing, although in some patients</text>
<text top="1004" left="59" width="160" height="16" font="4">this could be unavoidable.</text>
<text top="1022" left="74" width="345" height="16" font="4">Additionally, this guideline addresses the approach to</text>
<text top="1040" left="59" width="360" height="16" font="4">asymptomatic patients with SIHD that has been diagnosed</text>
<text top="1058" left="59" width="360" height="16" font="4">solely on the basis of an abnormal screening study, rather</text>
<text top="1076" left="59" width="360" height="16" font="4">than on the basis of clinical symptoms or events such as</text>
<text top="1094" left="59" width="360" height="16" font="4">anginal symptoms or ACS. The inclusion of such asymp-</text>
<text top="716" left="446" width="360" height="16" font="4">tomatic patients does not constitute an endorsement of such</text>
<text top="734" left="446" width="360" height="16" font="4">tests for the purposes of screening but is simply an acknowl-</text>
<text top="752" left="446" width="360" height="16" font="4">edgment of the clinical reality that asymptomatic patients</text>
<text top="770" left="446" width="360" height="16" font="4">often present for evaluation after such tests have been</text>
<text top="788" left="446" width="360" height="16" font="4">performed. Multiple ACCF/AHA guidelines and scientific</text>
<text top="806" left="446" width="360" height="16" font="4">statements have discouraged the use of ambulatory moni-</text>
<text top="824" left="446" width="360" height="16" font="4">toring, treadmill testing, stress echocardiography, stress</text>
<text top="842" left="446" width="360" height="16" font="4">myocardial perfusion imaging (MPI), and computed to-</text>
<text top="860" left="446" width="360" height="16" font="4">mography (CT) scoring of coronary calcium or coronary</text>
<text top="878" left="446" width="360" height="16" font="4">angiography as routine screening tests in asymptomatic</text>
<text top="896" left="446" width="360" height="16" font="4">individuals. The reader is referred to these documents for a</text>
<text top="914" left="446" width="360" height="16" font="4">detailed discussion of screening, which is beyond the scope</text>
<text top="932" left="446" width="110" height="16" font="4">of this guideline <a href="e44.full.html#9">(</a></text>
<text top="932" left="555" width="47" height="16" font="16"><a href="e44.full.html#9">Table 3</a></text>
<text top="932" left="602" width="9" height="16" font="4"><a href="e44.full.html#9">).</a></text>
<text top="950" left="461" width="345" height="16" font="4">Patients with known IHD who were previously asymptom-</text>
<text top="968" left="446" width="360" height="16" font="4">atic or whose symptoms were stable can develop new or</text>
<text top="986" left="446" width="360" height="16" font="4">recurrent chest pain or other symptoms suggesting ACS. Just</text>
<text top="1004" left="446" width="360" height="16" font="4">as in the case of patients with new-onset chest pain, the</text>
<text top="1022" left="446" width="360" height="16" font="4">clinician must determine whether such recurrent or worsening</text>
<text top="1040" left="446" width="360" height="16" font="4">pain is consistent with ACS or simply represents symptoms</text>
<text top="1058" left="446" width="360" height="16" font="4">more consistent with chronic stable angina that do not require</text>
<text top="1076" left="446" width="360" height="16" font="4">emergent attention. As indicated previously, patients with</text>
<text top="1094" left="446" width="360" height="16" font="4">AMI or moderate- to high-risk UA fall outside of the scope of</text>
<text top="105" left="59" width="456" height="11" font="13">Table 2. Short-Term Risk of Death or Nonfatal MI in Patients With UA/NSTEMI</text>
<text top="173" left="79" width="36" height="9" font="6">Feature</text>
<text top="130" left="241" width="45" height="9" font="6">High Risk</text>
<text top="130" left="444" width="84" height="9" font="6">Intermediate Risk</text>
<text top="130" left="695" width="43" height="9" font="6">Low Risk</text>
<text top="160" left="202" width="124" height="9" font="8"><i>At least 1 of the following</i></text>
<text top="173" left="202" width="123" height="9" font="8"><i>features must be present:</i></text>
<text top="160" left="397" width="178" height="9" font="8"><i>No high-risk features are present, but</i></text>
<text top="173" left="398" width="176" height="9" font="8"><i>patient must have 1 of the following:</i></text>
<text top="148" left="628" width="177" height="9" font="8"><i>No high- or intermediate-risk features</i></text>
<text top="160" left="636" width="161" height="9" font="8"><i>are present, but patient may have</i></text>
<text top="173" left="668" width="96" height="9" font="8"><i>any of the following:</i></text>
<text top="190" left="58" width="31" height="9" font="6">History</text>
<text top="190" left="183" width="143" height="9" font="6">Accelerating tempo of ischemic</text>
<text top="205" left="195" width="130" height="9" font="6">symptoms in preceding 48 h</text>
<text top="190" left="393" width="174" height="9" font="6">Prior MI, peripheral or cerebrovascular</text>
<text top="205" left="405" width="78" height="9" font="6">disease, or CABG</text>
<text top="219" left="393" width="74" height="9" font="6">Prior aspirin use</text>
<text top="190" left="707" width="18" height="9" font="6">N/A</text>
<text top="236" left="58" width="67" height="9" font="6">Characteristics</text>
<text top="250" left="70" width="31" height="9" font="6">of pain</text>
<text top="236" left="183" width="91" height="9" font="6">Prolonged ongoing (</text>
<text top="233" left="274" width="45" height="14" font="6">⬎20 min)</text>
<text top="250" left="195" width="40" height="9" font="6">rest pain</text>
<text top="236" left="393" width="52" height="9" font="6">Prolonged (</text>
<text top="233" left="445" width="123" height="14" font="6">⬎20 min) rest angina, now</text>
<text top="250" left="405" width="144" height="9" font="6">resolved, with moderate or high</text>
<text top="265" left="405" width="78" height="9" font="6">likelihood of CAD</text>
<text top="279" left="393" width="60" height="9" font="6">Rest angina (</text>
<text top="276" left="453" width="117" height="14" font="6">⬎20 min) or relieved with</text>
<text top="293" left="405" width="100" height="9" font="6">rest or sublingual NTG</text>
<text top="307" left="393" width="77" height="9" font="6">Nocturnal angina</text>
<text top="322" left="393" width="185" height="9" font="6">New-onset or progressive CCS Class III or</text>
<text top="336" left="405" width="156" height="9" font="6">IV angina in previous 2 wk without</text>
<text top="350" left="405" width="51" height="9" font="6">prolonged (</text>
<text top="347" left="456" width="105" height="14" font="6">⬎20 min) rest pain but</text>
<text top="364" left="405" width="161" height="9" font="6">with intermediate or high likelihood</text>
<text top="379" left="405" width="31" height="9" font="6">of CAD</text>
<text top="236" left="628" width="168" height="9" font="6">Increased angina frequency, severity,</text>
<text top="250" left="640" width="50" height="9" font="6">or duration</text>
<text top="265" left="628" width="170" height="9" font="6">Angina provoked at a lower threshold</text>
<text top="279" left="628" width="168" height="9" font="6">New-onset angina with onset 2 wk to</text>
<text top="293" left="640" width="116" height="9" font="6">2 mo before presentation</text>
<text top="396" left="59" width="71" height="9" font="6">Clinical findings</text>
<text top="396" left="183" width="138" height="9" font="6">Pulmonary edema, most likely</text>
<text top="410" left="195" width="73" height="9" font="6">due to ischemia</text>
<text top="424" left="183" width="111" height="9" font="6">New or worsening mitral</text>
<text top="439" left="195" width="97" height="9" font="6">regurgitation murmur</text>
<text top="453" left="183" width="6" height="9" font="6">S</text>
<text top="458" left="189" width="5" height="6" font="21">3</text>
<text top="453" left="197" width="107" height="9" font="6">or new/worsening rales</text>
<text top="467" left="183" width="129" height="9" font="6">Hypotension, bradycardia, or</text>
<text top="481" left="195" width="52" height="9" font="6">tachycardia</text>
<text top="496" left="183" width="17" height="9" font="6">Age</text>
<text top="493" left="203" width="29" height="14" font="6">⬎75 y</text>
<text top="396" left="393" width="17" height="9" font="6">Age</text>
<text top="393" left="413" width="29" height="14" font="6">⬎70 y</text>
<text top="396" left="707" width="18" height="9" font="6">N/A</text>
<text top="513" left="59" width="18" height="9" font="6">ECG</text>
<text top="513" left="183" width="129" height="9" font="6">Angina at rest with transient</text>
<text top="527" left="195" width="94" height="9" font="6">ST-segment changes</text>
<text top="524" left="292" width="45" height="14" font="6">⬎0.5 mm</text>
<text top="541" left="183" width="129" height="9" font="6">Bundle-branch block, new or</text>
<text top="556" left="195" width="67" height="9" font="6">presumed new</text>
<text top="570" left="183" width="151" height="9" font="6">Sustained ventricular tachycardia</text>
<text top="513" left="393" width="71" height="9" font="6">T-wave changes</text>
<text top="527" left="393" width="143" height="9" font="6">Pathological Q waves or resting</text>
<text top="541" left="405" width="63" height="9" font="6">ST-depression</text>
<text top="539" left="471" width="88" height="14" font="6">⬍1 mm in multiple</text>
<text top="556" left="405" width="170" height="9" font="6">lead groups (anterior, inferior, lateral)</text>
<text top="513" left="657" width="120" height="9" font="6">Normal or unchanged ECG</text>
<text top="587" left="59" width="75" height="9" font="6">Cardiac markers</text>
<text top="587" left="183" width="160" height="9" font="6">Elevated cardiac TnT, TnI, or CK-MB</text>
<text top="601" left="195" width="67" height="9" font="6">(i.e., TnT or TnI</text>
<text top="599" left="265" width="60" height="14" font="6">⬎0.1 ng/mL)</text>
<text top="587" left="393" width="181" height="9" font="6">Slightly elevated cardiac TnT, TnI, or CK-</text>
<text top="601" left="405" width="56" height="9" font="6">MB (i.e., TnT</text>
<text top="599" left="464" width="111" height="14" font="6">⬎0.01 but ⬍0.1 ng/mL)</text>
<text top="587" left="700" width="33" height="9" font="6">Normal</text>
<text top="639" left="59" width="747" height="7" font="17">Estimation of the short-term risks of death and nonfatal cardiac ischemic events in UA or NSTEMI is a complex multivariable problem that cannot be fully specified in a table such as this. Therefore,</text>
<text top="651" left="59" width="335" height="7" font="17">the table is meant to offer general guidance and illustration rather than rigid algorithms.</text>
<text top="663" left="67" width="739" height="7" font="17">CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CK-MB, creatine kinase-MB fraction; ECG, electrocardiogram; MI, myocardial</text>
<text top="675" left="59" width="586" height="7" font="17">infarction; NTG, nitroglycerin; N/A, not available; TnI, troponin I; TnT, troponin T; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.</text>
<text top="687" left="67" width="122" height="7" font="17">Modified from Braunwald et al. <a href="e44.full.html#85">(</a></text>
<text top="687" left="189" width="5" height="7" font="22"><a href="e44.full.html#85">6</a></text>
<text top="687" left="194" width="5" height="7" font="17"><a href="e44.full.html#85">).</a></text>
<text top="52" left="787" width="18" height="10" font="12">e51</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1161" width="864">
<text top="482" left="59" width="360" height="16" font="4">this guideline, whereas those with chronic stable angina or</text>
<text top="500" left="59" width="303" height="16" font="4">low-risk UA are addressed in the present guideline.</text>
<text top="518" left="74" width="345" height="16" font="4">When patients with documented IHD develop recurrent</text>
<text top="536" left="59" width="360" height="16" font="4">chest pain, the symptoms still could be attributable to another</text>
<text top="554" left="59" width="360" height="16" font="4">condition. Such patients are included in this guideline if there</text>
<text top="572" left="59" width="360" height="16" font="4">is sufficient suspicion that their heart disease is a likely source</text>
<text top="590" left="59" width="360" height="16" font="4">of symptoms to warrant cardiac evaluation. If the evaluation</text>
<text top="608" left="59" width="360" height="16" font="4">demonstrates that IHD is unlikely to cause the symptoms, the</text>
<text top="626" left="59" width="360" height="16" font="4">evaluation of noncardiac causes is beyond the scope of this</text>
<text top="644" left="59" width="360" height="16" font="4">guideline. If the evaluation demonstrates that IHD is the likely</text>
<text top="662" left="59" width="360" height="16" font="4">cause of their recurrent symptoms, subsequent management of</text>
<text top="680" left="59" width="257" height="16" font="4">such patients does fall within this guideline.</text>
<text top="698" left="74" width="345" height="16" font="4">The approach to screening and management of asymp-</text>
<text top="716" left="59" width="360" height="16" font="4">tomatic patients who are at risk for IHD but who are not</text>
<text top="734" left="59" width="360" height="16" font="4">known to have IHD is also beyond the scope of this</text>
<text top="752" left="59" width="360" height="16" font="4">guideline, but it is addressed in the “ACCF/AHA Guide-</text>
<text top="770" left="59" width="360" height="16" font="4">line for Assessment of Cardiovascular Risk in Asymptom-</text>
<text top="788" left="59" width="84" height="16" font="4">atic Adults” <a href="e44.full.html#85">(</a></text>
<text top="788" left="143" width="8" height="16" font="16"><a href="e44.full.html#85">5</a></text>
<text top="788" left="150" width="268" height="16" font="4"><a href="e44.full.html#85">). </a>Similarly, the present guideline does not</text>
<text top="806" left="59" width="360" height="16" font="4">apply to patients with chest pain symptoms early after</text>
<text top="824" left="59" width="360" height="16" font="4">revascularization by either percutaneous techniques or</text>
<text top="842" left="59" width="360" height="16" font="4">CABG. Although the division between “early” and “late”</text>
<text top="860" left="59" width="360" height="16" font="4">symptoms is arbitrary, the writing committee believed that</text>
<text top="878" left="59" width="360" height="16" font="4">this guideline should not be applied to patients who develop</text>
<text top="896" left="59" width="360" height="16" font="4">recurrent symptoms within 6 months of revascularization.</text>
<text top="914" left="59" width="360" height="16" font="4">Pediatric patients are beyond the scope of this guideline,</text>
<text top="932" left="59" width="360" height="16" font="4">because IHD is very unusual in such patients and is related</text>
<text top="950" left="59" width="360" height="16" font="4">primarily to the presence of coronary artery anomalies.</text>
<text top="968" left="59" width="360" height="16" font="4">Patients with chest pain syndromes after cardiac transplan-</text>
<text top="986" left="59" width="276" height="16" font="4">tation also are not included in this guideline.</text>
<text top="1018" left="59" width="277" height="12" font="18">1.5. General Approach and Overlap With</text>
<text top="1036" left="59" width="219" height="12" font="18">Other Guidelines or Statements</text>
<text top="1058" left="59" width="360" height="16" font="4">This guideline overlaps with numerous clinical practice</text>
<text top="1076" left="59" width="360" height="16" font="4">guidelines published by the ACCF/AHA Task Force on</text>
<text top="1094" left="59" width="360" height="16" font="4">Practice Guidelines; the National Heart, Lung, and Blood</text>
<text top="482" left="446" width="149" height="16" font="4">Institute; and the ACP <a href="e44.full.html#9">(</a></text>
<text top="482" left="595" width="46" height="16" font="16"><a href="e44.full.html#9">Table 3</a></text>
<text top="482" left="641" width="165" height="16" font="4"><a href="e44.full.html#9">). </a>To maintain consistency,</text>
<text top="500" left="446" width="360" height="16" font="4">the writing committee worked with members of other</text>
<text top="518" left="446" width="360" height="16" font="4">committees to harmonize recommendations and eliminate</text>
<text top="536" left="446" width="360" height="16" font="4">discrepancies. Some recommendations from earlier guide-</text>
<text top="554" left="446" width="360" height="16" font="4">lines have been updated as warranted by new evidence or a</text>
<text top="572" left="446" width="360" height="16" font="4">better understanding of earlier evidence, whereas others that</text>
<text top="590" left="446" width="360" height="16" font="4">were no longer accurate or relevant or were overlapping were</text>
<text top="608" left="446" width="360" height="16" font="4">modified; recommendations from previous guidelines that</text>
<text top="626" left="446" width="360" height="16" font="4">were similar or redundant were eliminated or consolidated</text>
<text top="644" left="446" width="89" height="16" font="4">when possible.</text>
<text top="662" left="461" width="345" height="16" font="4">Most of the topics mentioned in the present guideline</text>
<text top="680" left="446" width="360" height="16" font="4">were addressed in the “ACC/AHA 2002 Guideline Update</text>
<text top="698" left="446" width="360" height="16" font="4">for the Management of Patients With Chronic Stable</text>
<text top="716" left="446" width="182" height="16" font="4">Angina—Summary Article” <a href="e44.full.html#85">(</a></text>
<text top="716" left="628" width="8" height="16" font="16"><a href="e44.full.html#85">7</a></text>
<text top="716" left="635" width="170" height="16" font="4"><a href="e44.full.html#85">), </a>and many of the recom-</text>
<text top="734" left="446" width="360" height="16" font="4">mendations in the present guideline are consistent with</text>
<text top="752" left="446" width="360" height="16" font="4">those in the 2002 document. Whereas the 2002 update dealt</text>
<text top="770" left="446" width="360" height="16" font="4">individually with specific drugs and interventions for reduc-</text>
<text top="788" left="446" width="360" height="16" font="4">ing cardiovascular risk and medical therapy of angina</text>
<text top="806" left="446" width="360" height="16" font="4">pectoris, the present document recommends a combination</text>
<text top="824" left="446" width="360" height="16" font="4">of lifestyle modifications and medications that constitute</text>
<text top="842" left="446" width="360" height="16" font="4">GDMT. In addition, recommendations for risk reduction</text>
<text top="860" left="446" width="360" height="16" font="4">have been revised to reflect new evidence and are now</text>
<text top="878" left="446" width="360" height="16" font="4">consistent with the “AHA/ACCF Secondary Prevention</text>
<text top="896" left="446" width="360" height="16" font="4">and Risk Reduction Therapy for Patients With Coronary</text>
<text top="914" left="446" width="360" height="16" font="4">and Other Atherosclerotic Vascular Disease: 2011 Update”</text>
<text top="932" left="446" width="5" height="16" font="4"><a href="e44.full.html#85">(</a></text>
<text top="932" left="450" width="8" height="16" font="16"><a href="e44.full.html#85">8</a></text>
<text top="932" left="458" width="348" height="16" font="4"><a href="e44.full.html#85">). </a>Also in the present guideline, recommendations and</text>
<text top="950" left="446" width="360" height="16" font="4">text related to revascularization are the result of extensive</text>
<text top="968" left="446" width="360" height="16" font="4">collaborative discussions between the PCI and CABG</text>
<text top="986" left="446" width="360" height="16" font="4">writing committees, as well as key members of the SIHD</text>
<text top="1004" left="446" width="360" height="16" font="4">and UA/NSTEMI writing committees. In a major under-</text>
<text top="1022" left="446" width="360" height="16" font="4">taking, the PCI and CABG guidelines were written con-</text>
<text top="1040" left="446" width="360" height="16" font="4">currently with input from the STEMI guideline writing</text>
<text top="1058" left="446" width="360" height="16" font="4">committee and additional collaboration with the SIHD</text>
<text top="1076" left="446" width="360" height="16" font="4">guideline writing committee, allowing greater collaboration</text>
<text top="1094" left="446" width="360" height="16" font="4">between these writing committees on revascularization</text>
<text top="105" left="59" width="276" height="11" font="13">Table 3. Associated Guidelines and Statements</text>
<text top="130" left="256" width="48" height="9" font="6">Document</text>
<text top="130" left="531" width="61" height="9" font="6">Reference(s)</text>
<text top="130" left="630" width="59" height="9" font="6">Organization</text>
<text top="130" left="727" width="77" height="9" font="6">Publication Year</text>
<text top="148" left="58" width="47" height="9" font="6">Guidelines</text>
<text top="165" left="69" width="206" height="9" font="6">Chronic Stable Angina: 2007 Focused Update</text>
<text top="165" left="543" width="3" height="9" font="6"><a href="e44.full.html#86">(</a></text>
<text top="165" left="546" width="12" height="9" font="7"><a href="e44.full.html#86">19</a></text>
<text top="165" left="558" width="3" height="9" font="6"><a href="e44.full.html#86">)</a></text>
<text top="165" left="621" width="48" height="9" font="6">ACCF/AHA</text>
<text top="165" left="754" width="25" height="9" font="6">2007</text>
<text top="182" left="69" width="102" height="9" font="6">Valvular Heart Disease</text>
<text top="182" left="543" width="3" height="9" font="6"><a href="e44.full.html#86">(</a></text>
<text top="182" left="546" width="12" height="9" font="7"><a href="e44.full.html#86">20</a></text>
<text top="182" left="558" width="3" height="9" font="6"><a href="e44.full.html#86">)</a></text>
<text top="182" left="621" width="48" height="9" font="6">ACCF/AHA</text>
<text top="182" left="754" width="25" height="9" font="6">2008</text>
<text top="199" left="69" width="124" height="9" font="6">Heart Failure: 2009 Update</text>
<text top="199" left="543" width="3" height="9" font="6"><a href="e44.full.html#86">(</a></text>
<text top="199" left="546" width="12" height="9" font="7"><a href="e44.full.html#86">21</a></text>
<text top="199" left="558" width="3" height="9" font="6"><a href="e44.full.html#86">)</a></text>
<text top="199" left="621" width="48" height="9" font="6">ACCF/AHA</text>
<text top="199" left="754" width="25" height="9" font="6">2009</text>
<text top="217" left="69" width="28" height="9" font="6">STEMI</text>
<text top="217" left="543" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="217" left="546" width="30" height="9" font="7"><a href="e44.full.html#85">2,3,22</a></text>
<text top="217" left="576" width="3" height="9" font="6"><a href="e44.full.html#85">)</a></text>
<text top="217" left="621" width="48" height="9" font="6">ACCF/AHA</text>
<text top="217" left="754" width="25" height="9" font="6">2009</text>
<text top="234" left="69" width="270" height="9" font="6">Assessment of Cardiovascular Risk in Asymptomatic Adults</text>
<text top="234" left="543" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="234" left="546" width="6" height="9" font="7"><a href="e44.full.html#85">5</a></text>
<text top="234" left="552" width="3" height="9" font="6"><a href="e44.full.html#85">)</a></text>
<text top="234" left="621" width="48" height="9" font="6">ACCF/AHA</text>
<text top="234" left="754" width="25" height="9" font="6">2010</text>
<text top="251" left="69" width="168" height="9" font="6">Coronary Artery Bypass Graft Surgery</text>
<text top="251" left="543" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="251" left="546" width="6" height="9" font="7"><a href="e44.full.html#85">9</a></text>
<text top="251" left="552" width="3" height="9" font="6"><a href="e44.full.html#85">)</a></text>
<text top="251" left="621" width="48" height="9" font="6">ACCF/AHA</text>
<text top="251" left="754" width="25" height="9" font="6">2011</text>
<text top="268" left="69" width="162" height="9" font="6">Percutaneous Coronary Intervention</text>
<text top="268" left="543" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="268" left="546" width="12" height="9" font="7"><a href="e44.full.html#85">10</a></text>
<text top="268" left="558" width="3" height="9" font="6"><a href="e44.full.html#85">)</a></text>
<text top="268" left="621" width="74" height="9" font="6">ACCF/AHA/SCAI</text>
<text top="268" left="754" width="25" height="9" font="6">2011</text>
<text top="286" left="69" width="371" height="9" font="6">Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and</text>
<text top="300" left="83" width="176" height="9" font="6">Other Atherosclerotic Vascular Disease</text>
<text top="286" left="543" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="286" left="546" width="6" height="9" font="7"><a href="e44.full.html#85">8</a></text>
<text top="286" left="552" width="3" height="9" font="6"><a href="e44.full.html#85">)</a></text>
<text top="286" left="621" width="48" height="9" font="6">AHA/ACCF</text>
<text top="286" left="754" width="25" height="9" font="6">2011</text>
<text top="317" left="69" width="170" height="9" font="6">UA/NSTEMI: 2007 and 2012 Updates</text>
<text top="317" left="543" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="317" left="546" width="21" height="9" font="7"><a href="e44.full.html#85">4,4a</a></text>
<text top="317" left="567" width="3" height="9" font="6"><a href="e44.full.html#85">)</a></text>
<text top="317" left="621" width="48" height="9" font="6">ACCF/AHA</text>
<text top="317" left="754" width="25" height="9" font="6">2012</text>
<text top="334" left="58" width="52" height="9" font="6">Statements</text>
<text top="352" left="69" width="225" height="9" font="6">NCEP ATP III Implications of Recent Clinical Trials</text>
<text top="352" left="543" width="3" height="9" font="6"><a href="e44.full.html#86">(</a></text>
<text top="352" left="546" width="27" height="9" font="7"><a href="e44.full.html#86">18,24</a></text>
<text top="352" left="573" width="3" height="9" font="6"><a href="e44.full.html#86">)</a></text>
<text top="352" left="621" width="28" height="9" font="6">NHLBI</text>
<text top="352" left="754" width="25" height="9" font="6">2004</text>
<text top="369" left="69" width="231" height="9" font="6">National Hypertension Education Program (JNC VII)</text>
<text top="369" left="543" width="3" height="9" font="6"><a href="e44.full.html#86">(</a></text>
<text top="369" left="546" width="12" height="9" font="7"><a href="e44.full.html#86">17</a></text>
<text top="369" left="558" width="3" height="9" font="6"><a href="e44.full.html#86">)</a></text>
<text top="369" left="621" width="28" height="9" font="6">NHLBI</text>
<text top="369" left="754" width="25" height="9" font="6">2004</text>
<text top="386" left="69" width="430" height="9" font="6">Referral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Prevention Programs at</text>
<text top="400" left="83" width="302" height="9" font="6">Clinical Centers and Beyond: A Presidential Advisory From the AHA</text>
<text top="386" left="543" width="4" height="9" font="6"><a href="e44.full.html#86">(</a></text>
<text top="386" left="547" width="12" height="9" font="7"><a href="e44.full.html#86">25</a></text>
<text top="386" left="559" width="4" height="9" font="6"><a href="e44.full.html#86">)</a></text>
<text top="386" left="621" width="19" height="9" font="6">AHA</text>
<text top="386" left="754" width="25" height="9" font="6">2011</text>
<text top="438" left="59" width="747" height="7" font="17">ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; ATP III, Adult Treatment Panel 3;JNC VII, The Seventh Report of the Joint National Committee on Prevention,</text>
<text top="450" left="59" width="681" height="7" font="17">Detection, Evaluation, and Treatment of High Blood Pressure; NHLBI, National Heart, Lung and Blood Institute; and SCAI, Society for Cardiovascular Angiography and Interventions.</text>
<text top="52" left="59" width="18" height="10" font="12">e52</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">strategies in patients with CAD (including unprotected left</text>
<text top="123" left="59" width="360" height="16" font="4">main PCI, multivessel disease revascularization, and hybrid</text>
<text top="142" left="59" width="82" height="16" font="4">procedures) <a href="e44.full.html#85">(</a></text>
<text top="142" left="140" width="26" height="16" font="16"><a href="e44.full.html#85">9,10</a></text>
<text top="142" left="167" width="9" height="16" font="4"><a href="e44.full.html#85">).</a></text>
<text top="142" left="182" width="59" height="16" font="16"><a href="e44.full.html#63">Section 5</a></text>
<text top="142" left="248" width="170" height="16" font="4">is included as published in</text>
<text top="160" left="58" width="316" height="16" font="4">both the PCI and CABG guidelines in its entirety.</text>
<text top="179" left="73" width="345" height="16" font="4">In addition to cosponsoring practice guidelines, the</text>
<text top="198" left="58" width="360" height="16" font="4">ACCF has sponsored appropriate use criteria (AUC) doc-</text>
<text top="216" left="58" width="360" height="16" font="4">uments for imaging testing, diagnostic catheterization, and</text>
<text top="235" left="58" width="256" height="16" font="4">coronary revascularization since 2005 <a href="e44.full.html#85">(</a></text>
<text top="235" left="314" width="38" height="16" font="16"><a href="e44.full.html#85">11–16</a></text>
<text top="235" left="352" width="67" height="16" font="4"><a href="e44.full.html#85">). </a>Practice</text>
<text top="254" left="58" width="360" height="16" font="4">guideline recommendations are based on evidence from</text>
<text top="273" left="58" width="360" height="16" font="4">clinical and observational trials and expert consensus; AUCs</text>
<text top="291" left="58" width="360" height="16" font="4">are complementary to practice guidelines and make every</text>
<text top="310" left="58" width="360" height="16" font="4">effort to be concordant with their recommendations. In</text>
<text top="329" left="58" width="360" height="16" font="4">general, the recommendations in this guideline and current</text>
<text top="347" left="58" width="360" height="16" font="4">AUCs are consistent. Apparent discrepancies usually reflect</text>
<text top="366" left="58" width="360" height="16" font="4">differing frameworks or imaging methodologies. Moreover,</text>
<text top="385" left="58" width="360" height="16" font="4">where guidelines leave “gaps” (i.e., unaddressed applica-</text>
<text top="403" left="58" width="360" height="16" font="4">tions), AUCs can provide additional clinical guidance based</text>
<text top="422" left="58" width="360" height="16" font="4">on the best available clinical evidence and use a prospective,</text>
<text top="441" left="58" width="208" height="16" font="4">expert consensus methodology <a href="e44.full.html#86">(</a></text>
<text top="441" left="267" width="15" height="16" font="16"><a href="e44.full.html#86">16</a></text>
<text top="441" left="282" width="137" height="16" font="4"><a href="e44.full.html#86">). </a>Specifically, AUCs</text>
<text top="459" left="58" width="360" height="16" font="4">provide detailed indications for testing and procedures to</text>
<text top="478" left="58" width="360" height="16" font="4">aid clinical decision making, categorizing each indication as</text>
<text top="497" left="58" width="360" height="16" font="4">appropriate, uncertain, or inappropriate. Thus, ACCF</text>
<text top="515" left="58" width="360" height="16" font="4">AUCs provide an additional means to identify candidates</text>
<text top="534" left="58" width="360" height="16" font="4">for testing or procedures as well as those for whom they</text>
<text top="553" left="58" width="360" height="16" font="4">would be inappropriate or for whom the optimal approach</text>
<text top="571" left="58" width="360" height="16" font="4">is uncertain. Inappropriate candidates are those for whom</text>
<text top="590" left="58" width="360" height="16" font="4">compelling evidence indicates that testing is not indicated</text>
<text top="609" left="58" width="360" height="16" font="4">or, in some cases, results in reduced accuracy. Uncertain</text>
<text top="627" left="58" width="360" height="16" font="4">indications are those with either published evidence or lack</text>
<text top="646" left="58" width="213" height="16" font="4">of expert consensus on testing use.</text>
<text top="665" left="73" width="345" height="16" font="4">AUCs also include relevant clinical scenarios not ad-</text>
<text top="683" left="58" width="172" height="16" font="4">dressed by these guidelines <a href="e44.full.html#85">(</a></text>
<text top="683" left="230" width="15" height="16" font="16"><a href="e44.full.html#85">11</a></text>
<text top="683" left="245" width="173" height="16" font="4"><a href="e44.full.html#85">), </a>such as the issue of testing</text>
<text top="702" left="58" width="360" height="16" font="4">during follow-up of patients with SIHD with stress echo-</text>
<text top="721" left="58" width="91" height="16" font="4">cardiography <a href="e44.full.html#86">(</a></text>
<text top="721" left="149" width="15" height="16" font="16"><a href="e44.full.html#86">15</a></text>
<text top="721" left="164" width="254" height="16" font="4"><a href="e44.full.html#86">), </a>single-photon emission computed to-</text>
<text top="739" left="58" width="166" height="16" font="4">mography (SPECT) MPI <a href="e44.full.html#85">(</a></text>
<text top="739" left="225" width="15" height="16" font="16"><a href="e44.full.html#85">12</a></text>
<text top="739" left="240" width="136" height="16" font="4"><a href="e44.full.html#85">), </a>CMR, and CCTA <a href="e44.full.html#85">(</a></text>
<text top="739" left="376" width="34" height="16" font="16"><a href="e44.full.html#85">13,14</a></text>
<text top="739" left="410" width="9" height="16" font="4"><a href="e44.full.html#85">).</a></text>
<text top="758" left="58" width="360" height="16" font="4">These AUC documents address the intervals between test-</text>
<text top="777" left="58" width="360" height="16" font="4">ing for various stress imaging indications. As with all</text>
<text top="795" left="58" width="360" height="16" font="4">standards documents, ongoing evaluation is required to</text>
<text top="814" left="58" width="360" height="16" font="4">update the recommendations on the value, limitations,</text>
<text top="833" left="58" width="360" height="16" font="4">timing, costs, and risks of imaging as an adjunct to clinical</text>
<text top="851" left="58" width="360" height="16" font="4">assessment during follow-up of patients with established</text>
<text top="870" left="58" width="360" height="16" font="4">SIHD. Review of these AUCs is beyond the scope of the</text>
<text top="889" left="58" width="360" height="16" font="4">present document, and the reader is referred to the most recent</text>
<text top="907" left="58" width="360" height="16" font="4">AUC documents to complement the guidelines provided here.</text>
<text top="926" left="73" width="345" height="16" font="4">As the scientific basis of the approach to management of</text>
<text top="945" left="58" width="360" height="16" font="4">cardiovascular disease has rapidly expanded, the size and</text>
<text top="963" left="58" width="360" height="16" font="4">scope of clinical practice guidelines have grown commen-</text>
<text top="982" left="58" width="360" height="16" font="4">surately to a point where they have become too unwieldy for</text>
<text top="1001" left="58" width="360" height="16" font="4">routine use by practicing clinicians. The most current</text>
<text top="1019" left="58" width="360" height="16" font="4">national guidelines for management of hypertension (Joint</text>
<text top="1038" left="58" width="171" height="16" font="4">National Committee VII) <a href="e44.full.html#86">(</a></text>
<text top="1038" left="229" width="15" height="16" font="16"><a href="e44.full.html#86">17</a></text>
<text top="1038" left="244" width="174" height="16" font="4"><a href="e44.full.html#86">) </a>and hyperlipidemia (Adult</text>
<text top="1057" left="58" width="143" height="16" font="4">Treatment Panel III) <a href="e44.full.html#86">(</a></text>
<text top="1057" left="202" width="15" height="16" font="16"><a href="e44.full.html#86">18</a></text>
<text top="1057" left="217" width="202" height="16" font="4"><a href="e44.full.html#86">) </a>combined comprise nearly 400</text>
<text top="1075" left="58" width="360" height="16" font="4">pages. Thus, the writing committee recognized that it</text>
<text top="1094" left="58" width="360" height="16" font="4">would be unfeasible to produce a document that would be</text>
<text top="104" left="446" width="360" height="16" font="4">simultaneously practical and exhaustive and, therefore, has</text>
<text top="122" left="446" width="360" height="16" font="4">tried to create a resource that provides a comprehensive</text>
<text top="140" left="446" width="360" height="16" font="4">approach to management of SIHD for which the relevant</text>
<text top="158" left="446" width="360" height="16" font="4">evidence is succinctly summarized and referenced. The</text>
<text top="176" left="446" width="360" height="16" font="4">writing committee used current and credible meta-analyses,</text>
<text top="194" left="446" width="360" height="16" font="4">when available, instead of conducting a systematic review of</text>
<text top="212" left="446" width="129" height="16" font="4">all primary literature.</text>
<text top="244" left="446" width="213" height="12" font="18">1.6. Magnitude of the Problem</text>
<text top="266" left="446" width="360" height="16" font="4">IHD remains a major public health problem nationally and</text>
<text top="284" left="446" width="360" height="16" font="4">internationally. It is estimated that 1 in 3 adults in the</text>
<text top="302" left="446" width="360" height="16" font="4">United States (about 81 million) has some form of cardio-</text>
<text top="320" left="446" width="158" height="16" font="4">vascular disease, including</text>
<text top="317" left="608" width="198" height="20" font="4">⬎17 million with coronary heart</text>
<text top="338" left="446" width="317" height="16" font="4">disease and nearly 10 million with angina pectoris <a href="e44.full.html#86">(</a></text>
<text top="338" left="763" width="34" height="16" font="16"><a href="e44.full.html#86">26,27</a></text>
<text top="338" left="797" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="356" left="446" width="360" height="16" font="4">Among persons 60 to 79 years of age, approximately 25% of</text>
<text top="374" left="446" width="360" height="16" font="4">men and 16% of women have coronary heart disease, and</text>
<text top="392" left="446" width="360" height="16" font="4">these figures rise to 37% and 23% among men and women</text>
<text top="407" left="446" width="192" height="20" font="4">ⱖ80 years of age, respectively <a href="e44.full.html#86">(</a></text>
<text top="410" left="638" width="15" height="16" font="16"><a href="e44.full.html#86">27</a></text>
<text top="410" left="653" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="428" left="461" width="345" height="16" font="4">Although the survival rate of patients with IHD has been</text>
<text top="446" left="446" width="125" height="16" font="4">steadily improving <a href="e44.full.html#86">(</a></text>
<text top="446" left="570" width="15" height="16" font="16"><a href="e44.full.html#86">28</a></text>
<text top="446" left="585" width="220" height="16" font="4"><a href="e44.full.html#86">), </a>it was still responsible for nearly</text>
<text top="464" left="446" width="360" height="16" font="4">380,000 deaths in the United States during 2010, with an</text>
<text top="482" left="446" width="360" height="16" font="4">age-adjusted mortality rate of 113 per 100,000 population</text>
<text top="500" left="446" width="5" height="16" font="4"><a href="e44.full.html#86">(</a></text>
<text top="500" left="450" width="15" height="16" font="16"><a href="e44.full.html#86">29</a></text>
<text top="500" left="465" width="340" height="16" font="4"><a href="e44.full.html#86">). </a>Although IHD is widely known to be the number 1</text>
<text top="518" left="446" width="360" height="16" font="4">cause of death in men, this is also the case for women,</text>
<text top="536" left="446" width="360" height="16" font="4">among whom this condition accounts for 27% of deaths</text>
<text top="554" left="446" width="220" height="16" font="4">(compared with 22% due to cancer) <a href="e44.full.html#86">(</a></text>
<text top="554" left="666" width="15" height="16" font="16"><a href="e44.full.html#86">30</a></text>
<text top="554" left="681" width="125" height="16" font="4"><a href="e44.full.html#86">). </a>IHD also accounts</text>
<text top="572" left="446" width="360" height="16" font="4">for the vast majority of the mortality and morbidity of</text>
<text top="590" left="446" width="165" height="16" font="4">cardiac disease. Each year,</text>
<text top="587" left="617" width="188" height="20" font="4">⬎1.5 million patients have an</text>
<text top="608" left="445" width="360" height="16" font="4">MI. Many more are hospitalized for UA and for evaluation</text>
<text top="626" left="445" width="360" height="16" font="4">and treatment of stable chest pain syndromes. Beyond the</text>
<text top="644" left="445" width="360" height="16" font="4">need for hospitalization, many patients with chronic chest</text>
<text top="662" left="445" width="360" height="16" font="4">pain syndromes are temporarily unable to perform normal</text>
<text top="680" left="445" width="360" height="16" font="4">activities for hours or days and thus experience a reduced</text>
<text top="698" left="445" width="360" height="16" font="4">quality of life. Among patients enrolled in the BARI</text>
<text top="716" left="445" width="360" height="16" font="4">(Bypass Angioplasty Revascularization Investigation) study</text>
<text top="734" left="445" width="5" height="16" font="4"><a href="e44.full.html#86">(</a></text>
<text top="734" left="450" width="15" height="16" font="16"><a href="e44.full.html#86">31</a></text>
<text top="734" left="465" width="340" height="16" font="4"><a href="e44.full.html#86">), </a>about 30% never returned to work after coronary</text>
<text top="752" left="445" width="360" height="16" font="4">revascularization, and 15% to 20% of patients rated their</text>
<text top="770" left="445" width="360" height="16" font="4">own health as “fair” or “poor” despite revascularization.</text>
<text top="788" left="445" width="360" height="16" font="4">Similarly, observational studies of patients recovering from</text>
<text top="806" left="445" width="360" height="16" font="4">an AMI demonstrated that 1 in 5 patients, even after</text>
<text top="824" left="445" width="360" height="16" font="4">intensive treatment at the time of their AMI, still suffered</text>
<text top="842" left="445" width="120" height="16" font="4">angina 1 year later <a href="e44.full.html#86">(</a></text>
<text top="842" left="565" width="15" height="16" font="16"><a href="e44.full.html#86">32</a></text>
<text top="842" left="580" width="225" height="16" font="4"><a href="e44.full.html#86">). </a>These data confirm the widespread</text>
<text top="860" left="445" width="360" height="16" font="4">clinical impression that IHD continues to be associated with</text>
<text top="878" left="445" width="360" height="16" font="4">considerable patient morbidity despite the decline in car-</text>
<text top="896" left="445" width="360" height="16" font="4">diovascular mortality rate. Patients who have had ACS,</text>
<text top="914" left="445" width="360" height="16" font="4">such as AMI, remain at risk for recurrent events even if they</text>
<text top="932" left="445" width="360" height="16" font="4">have no, or limited, symptoms and should be considered to</text>
<text top="950" left="445" width="75" height="16" font="4">have SIHD.</text>
<text top="968" left="460" width="345" height="16" font="4">In approximately 50% of patients, angina pectoris is the</text>
<text top="986" left="445" width="184" height="16" font="4">initial manifestation of IHD <a href="e44.full.html#86">(</a></text>
<text top="986" left="629" width="15" height="16" font="16"><a href="e44.full.html#86">27</a></text>
<text top="986" left="644" width="161" height="16" font="4"><a href="e44.full.html#86">). </a>The incidence of angina</text>
<text top="1004" left="445" width="360" height="16" font="4">rises continuously with age in women, whereas the inci-</text>
<text top="1022" left="445" width="360" height="16" font="4">dence of angina in men peaks between 55 and 65 years of</text>
<text top="1040" left="445" width="134" height="16" font="4">age before declining <a href="e44.full.html#86">(</a></text>
<text top="1040" left="580" width="15" height="16" font="16"><a href="e44.full.html#86">27</a></text>
<text top="1040" left="595" width="211" height="16" font="4"><a href="e44.full.html#86">). </a>Despite angina’s clinical impor-</text>
<text top="1058" left="445" width="360" height="16" font="4">tance and high frequency, modern, population-based data</text>
<text top="1076" left="445" width="360" height="16" font="4">are quite limited, and these figures likely underestimate the</text>
<text top="1094" left="445" width="164" height="16" font="4">true prevalence of angina <a href="e44.full.html#86">(</a></text>
<text top="1094" left="609" width="15" height="16" font="16"><a href="e44.full.html#86">33</a></text>
<text top="1094" left="624" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="52" left="787" width="18" height="10" font="12">e53</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="74" width="345" height="16" font="4">The annual rates per 1,000 population of new episodes of</text>
<text top="123" left="59" width="360" height="16" font="4">angina for nonblack men are 28.3 for ages 65 to 74 years,</text>
<text top="141" left="59" width="267" height="16" font="4">36.3 for ages 75 to 84 years, and 33.0 for age</text>
<text top="138" left="329" width="90" height="20" font="4">ⱖ85 years. For</text>
<text top="159" left="59" width="360" height="16" font="4">nonblack women in the same age groups, the rates are 14.1,</text>
<text top="178" left="59" width="360" height="16" font="4">20.0, and 22.9, respectively. For black men, the rates are</text>
<text top="196" left="59" width="360" height="16" font="4">22.4, 33.8, and 39.5, and for black women, the rates are</text>
<text top="215" left="59" width="206" height="16" font="4">15.3, 23.6, and 35.9, respectively <a href="e44.full.html#86">(</a></text>
<text top="215" left="265" width="15" height="16" font="16"><a href="e44.full.html#86">30</a></text>
<text top="215" left="280" width="139" height="16" font="4"><a href="e44.full.html#86">). </a>In a study conducted</text>
<text top="233" left="59" width="360" height="16" font="4">in Finland, the age-standardized, annual incidence of an-</text>
<text top="251" left="59" width="360" height="16" font="4">gina was 2.03 in men and 1.89 in women per 100 popula-</text>
<text top="270" left="59" width="40" height="16" font="4">tions <a href="e44.full.html#86">(</a></text>
<text top="270" left="98" width="15" height="16" font="16"><a href="e44.full.html#86">33</a></text>
<text top="270" left="113" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="288" left="74" width="345" height="16" font="4">Further estimates of the prevalence of chronic, symp-</text>
<text top="306" left="59" width="360" height="16" font="4">tomatic IHD can be obtained by extrapolating from data</text>
<text top="325" left="59" width="360" height="16" font="4">on ACS and, more specifically, AMI. About one half of</text>
<text top="343" left="59" width="360" height="16" font="4">patients presenting to the hospital with ACS have</text>
<text top="361" left="59" width="116" height="16" font="4">preceding angina <a href="e44.full.html#86">(</a></text>
<text top="361" left="175" width="15" height="16" font="16"><a href="e44.full.html#86">27</a></text>
<text top="361" left="190" width="228" height="16" font="4"><a href="e44.full.html#86">). </a>One current estimate is that about</text>
<text top="380" left="59" width="360" height="16" font="4">50% of patients who suffer an AMI each year in the</text>
<text top="398" left="59" width="297" height="16" font="4">United States survive until hospitalization <a href="e44.full.html#86">(</a></text>
<text top="398" left="356" width="15" height="16" font="16"><a href="e44.full.html#86">27</a></text>
<text top="398" left="372" width="47" height="16" font="4"><a href="e44.full.html#86">). </a>Two</text>
<text top="416" left="59" width="360" height="16" font="4">older population-based studies from Olmsted County,</text>
<text top="435" left="59" width="360" height="16" font="4">MN, and Framingham, MA, examined the annual rates</text>
<text top="453" left="59" width="360" height="16" font="4">of MI in patients with symptoms of angina and reported</text>
<text top="471" left="59" width="257" height="16" font="4">similar rates of 3% to 3.5% per year <a href="e44.full.html#86">(</a></text>
<text top="471" left="316" width="35" height="16" font="16"><a href="e44.full.html#86">34,35</a></text>
<text top="471" left="351" width="68" height="16" font="4"><a href="e44.full.html#86">). </a>On this</text>
<text top="490" left="59" width="360" height="16" font="4">basis, it can be estimated that there were 30 patients with</text>
<text top="508" left="59" width="360" height="16" font="4">stable angina for every patient with infarction who was</text>
<text top="526" left="59" width="360" height="16" font="4">hospitalized, which represents 16.5 million persons with</text>
<text top="545" left="59" width="360" height="16" font="4">angina in the United States. However, since the data</text>
<text top="563" left="59" width="360" height="16" font="4">reported in these studies were collected, it is likely that</text>
<text top="581" left="59" width="360" height="16" font="4">the much greater use of effective medical therapies,</text>
<text top="600" left="59" width="360" height="16" font="4">including antianginal medications and revascularization</text>
<text top="618" left="59" width="360" height="16" font="4">procedures, has reduced the proportion of patients with</text>
<text top="636" left="59" width="360" height="16" font="4">symptomatic angina—although there are still many pa-</text>
<text top="655" left="59" width="297" height="16" font="4">tients whose symptoms are poorly controlled <a href="e44.full.html#86">(</a></text>
<text top="655" left="356" width="40" height="16" font="16"><a href="e44.full.html#86">36 –38</a></text>
<text top="655" left="397" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="673" left="74" width="345" height="16" font="4">The costs of caring for patients with IHD are enormous,</text>
<text top="691" left="59" width="360" height="16" font="4">estimated at $156 billion in the United States for both direct</text>
<text top="710" left="59" width="360" height="16" font="4">and indirect costs in 2008. More than one half of direct</text>
<text top="728" left="59" width="360" height="16" font="4">costs are related to hospitalization. In 2003, the Medicare</text>
<text top="746" left="59" width="360" height="16" font="4">program alone paid $12.2 billion for hospitalizations for</text>
<text top="765" left="59" width="360" height="16" font="4">IHD, including $12,321 per discharge for AMI and</text>
<text top="783" left="59" width="360" height="16" font="4">$11,783 per discharge for admissions for coronary athero-</text>
<text top="801" left="59" width="59" height="16" font="4">sclerosis <a href="e44.full.html#86">(</a></text>
<text top="801" left="117" width="15" height="16" font="16"><a href="e44.full.html#86">39</a></text>
<text top="801" left="132" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="820" left="74" width="345" height="16" font="4">Another major expense is for invasive procedures and</text>
<text top="838" left="59" width="360" height="16" font="4">related costs. In 2006 in the United States, there were</text>
<text top="856" left="59" width="360" height="16" font="4">1,313,000 inpatient PCI procedures, 448,000 inpatient</text>
<text top="875" left="59" width="360" height="16" font="4">coronary artery bypass procedures, and 1,115,000 inpa-</text>
<text top="893" left="59" width="267" height="16" font="4">tient diagnostic cardiac catheterizations <a href="e44.full.html#86">(</a></text>
<text top="893" left="326" width="35" height="16" font="16"><a href="e44.full.html#86">27,40</a></text>
<text top="893" left="362" width="57" height="16" font="4"><a href="e44.full.html#86">). </a>In ad-</text>
<text top="911" left="59" width="42" height="16" font="4">dition,</text>
<text top="908" left="104" width="315" height="20" font="4">ⱖ13 million outpatient visits for IHD occur in the</text>
<text top="930" left="59" width="160" height="16" font="4">United States annually <a href="e44.full.html#86">(</a></text>
<text top="930" left="219" width="15" height="16" font="16"><a href="e44.full.html#86">41</a></text>
<text top="930" left="235" width="184" height="16" font="4"><a href="e44.full.html#86">). </a>It was estimated that the</text>
<text top="948" left="59" width="360" height="16" font="4">costs of outpatient and emergency department visits in</text>
<text top="966" left="59" width="360" height="16" font="4">2000 by patients with chronic angina were $922 million</text>
<text top="985" left="59" width="360" height="16" font="4">and $286 million, respectively, and prescriptions ac-</text>
<text top="1003" left="59" width="360" height="16" font="4">counted for $291 million. Long-term care costs—</text>
<text top="1021" left="59" width="360" height="16" font="4">including skilled nursing, home health, and hospice</text>
<text top="1040" left="59" width="360" height="16" font="4">care—were $2.6 billion, which represented 30% of the</text>
<text top="1058" left="59" width="241" height="16" font="4">total cost of care for chronic angina <a href="e44.full.html#86">(</a></text>
<text top="1058" left="300" width="15" height="16" font="16"><a href="e44.full.html#86">42</a></text>
<text top="1058" left="315" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="1076" left="74" width="345" height="16" font="4">Although the direct costs associated with SIHD are</text>
<text top="1095" left="59" width="360" height="16" font="4">substantial, they do not account for the significant</text>
<text top="105" left="446" width="360" height="16" font="4">indirect costs of lost workdays, reduced productivity,</text>
<text top="123" left="446" width="360" height="16" font="4">long-term medication, and associated effects. The indi-</text>
<text top="142" left="446" width="360" height="16" font="4">rect costs have been estimated to be almost as great as the</text>
<text top="161" left="446" width="87" height="16" font="4">direct costs (</text>
<text top="161" left="533" width="35" height="16" font="16"><a href="e44.full.html#86">27,43</a></text>
<text top="161" left="569" width="18" height="16" font="4"><a href="e44.full.html#86">) </a><a href="e44.full.html#11">(</a></text>
<text top="161" left="587" width="52" height="16" font="16"><a href="e44.full.html#11">Table 4</a></text>
<text top="161" left="639" width="167" height="16" font="4"><a href="e44.full.html#11">). </a>The magnitude of the</text>
<text top="180" left="446" width="360" height="16" font="4">problem can be summarized succinctly: SIHD affects</text>
<text top="198" left="446" width="360" height="16" font="4">many millions of Americans, with associated annual costs</text>
<text top="217" left="446" width="302" height="16" font="4">that are measured in tens of billions of dollars.</text>
<text top="254" left="446" width="235" height="12" font="18">1.7. Organization of the Guideline</text>
<text top="278" left="446" width="360" height="16" font="4">The overarching framework adopted in constructing this</text>
<text top="296" left="446" width="360" height="16" font="4">guideline reflects the complementary goals of treating pa-</text>
<text top="315" left="446" width="360" height="16" font="4">tients with known SIHD, alleviating or improving symp-</text>
<text top="334" left="446" width="360" height="16" font="4">toms, and prolonging life. This guideline is divided into 4</text>
<text top="353" left="446" width="360" height="16" font="4">basic sections summarizing the approaches to diagnosis, risk</text>
<text top="371" left="446" width="360" height="16" font="4">assessment, treatment, and follow-up. Five algorithms sum-</text>
<text top="390" left="446" width="303" height="16" font="4">marize the management of stable angina: diagnosis <a href="e44.full.html#12">(</a></text>
<text top="390" left="748" width="49" height="16" font="16"><a href="e44.full.html#12">Figure 2</a></text>
<text top="390" left="797" width="8" height="16" font="4"><a href="e44.full.html#12">),</a></text>
<text top="409" left="446" width="99" height="16" font="4">risk assessment <a href="e44.full.html#13">(</a></text>
<text top="409" left="544" width="51" height="16" font="16"><a href="e44.full.html#13">Figure 3</a></text>
<text top="409" left="595" width="73" height="16" font="4"><a href="e44.full.html#13">), </a>GDMT <a href="e44.full.html#14">(</a></text>
<text top="409" left="667" width="51" height="16" font="16"><a href="e44.full.html#14">Figure 4</a></text>
<text top="409" left="717" width="88" height="16" font="4"><a href="e44.full.html#14">), </a>and revascu-</text>
<text top="428" left="446" width="64" height="16" font="4">larization <a href="e44.full.html#15">(</a></text>
<text top="428" left="509" width="55" height="16" font="16"><a href="e44.full.html#15">Figures 5</a></text>
<text top="428" left="569" width="22" height="16" font="4">and</text>
<text top="428" left="595" width="8" height="16" font="16"><a href="e44.full.html#16">6</a></text>
<text top="428" left="602" width="203" height="16" font="4"><a href="e44.full.html#16">)</a>. We readily acknowledge, how-</text>
<text top="446" left="446" width="360" height="16" font="4">ever, that in actual clinical practice, the elements comprising</text>
<text top="465" left="446" width="360" height="16" font="4">the 4 sections and the steps delineated in the algorithms</text>
<text top="484" left="446" width="360" height="16" font="4">often overlap and are not always separable. Some low-risk</text>
<text top="503" left="446" width="360" height="16" font="4">patients, for example, might require only clinical assessment</text>
<text top="521" left="446" width="360" height="16" font="4">to determine that they do not need any further evaluation or</text>
<text top="540" left="446" width="360" height="16" font="4">treatment. Other patients might require only clinical assess-</text>
<text top="559" left="446" width="360" height="16" font="4">ment and further adjustment of medical therapy if their</text>
<text top="578" left="446" width="360" height="16" font="4">preferences and comorbidities preclude revascularization,</text>
<text top="596" left="446" width="360" height="16" font="4">thus obviating the necessity for risk stratification. The stress</text>
<text top="615" left="446" width="360" height="16" font="4">testing/angiography algorithm might be applicable for di-</text>
<text top="634" left="446" width="360" height="16" font="4">agnostic purposes in patients with symptoms that suggest</text>
<text top="653" left="446" width="360" height="16" font="4">SIHD or to perform risk assessment in patients with</text>
<text top="671" left="446" width="114" height="16" font="4">established SIHD.</text>
<text top="762" left="446" width="340" height="11" font="13">Table 4. Estimated Direct and Indirect Costs (in Billions of</text>
<text top="778" left="446" width="313" height="11" font="13">Dollars) of Heart Disease and Coronary Heart Disease:</text>
<text top="793" left="446" width="118" height="11" font="13">United States: 2010</text>
<text top="819" left="615" width="66" height="9" font="6">Heart Disease</text>
<text top="831" left="617" width="63" height="9" font="6">($ in billions)</text>
<text top="819" left="717" width="71" height="9" font="6">Coronary Heart</text>
<text top="831" left="701" width="104" height="9" font="6">Disease ($ in billions)</text>
<text top="849" left="446" width="53" height="9" font="6">Direct costs</text>
<text top="866" left="456" width="37" height="9" font="6">Hospital</text>
<text top="866" left="635" width="27" height="9" font="6">110.2</text>
<text top="866" left="746" width="21" height="9" font="6">56.6</text>
<text top="883" left="456" width="63" height="9" font="6">Nursing home</text>
<text top="883" left="641" width="21" height="9" font="6">24.7</text>
<text top="883" left="746" width="21" height="9" font="6">13.0</text>
<text top="900" left="456" width="139" height="9" font="6">Physicians/other professionals</text>
<text top="900" left="641" width="21" height="9" font="6">24.7</text>
<text top="900" left="746" width="21" height="9" font="6">13.9</text>
<text top="918" left="456" width="55" height="9" font="6">Drugs/other</text>
<text top="935" left="467" width="77" height="9" font="6">Medical durables</text>
<text top="935" left="641" width="21" height="9" font="6">22.5</text>
<text top="935" left="746" width="21" height="9" font="6">10.0</text>
<text top="952" left="467" width="81" height="9" font="6">Home health care</text>
<text top="952" left="647" width="15" height="9" font="6">8.3</text>
<text top="952" left="752" width="15" height="9" font="6">2.5</text>
<text top="969" left="456" width="83" height="9" font="6">Total expenditures</text>
<text top="969" left="635" width="27" height="9" font="6">189.4</text>
<text top="969" left="746" width="21" height="9" font="6">96.0</text>
<text top="987" left="446" width="60" height="9" font="6">Indirect costs</text>
<text top="1004" left="456" width="122" height="9" font="6">Lost productivity/morbidity</text>
<text top="1004" left="641" width="21" height="9" font="6">25.6</text>
<text top="1004" left="746" width="21" height="9" font="6">11.3</text>
<text top="1021" left="456" width="125" height="9" font="6">Lost productivity/mortality*</text>
<text top="1021" left="635" width="27" height="9" font="6">101.4</text>
<text top="1021" left="746" width="21" height="9" font="6">69.8</text>
<text top="1038" left="446" width="56" height="9" font="6">Grand totals</text>
<text top="1038" left="635" width="27" height="9" font="6">316.4</text>
<text top="1038" left="739" width="27" height="9" font="6">177.1</text>
<text top="1076" left="446" width="317" height="7" font="17">All estimates prepared by Thomas Thom, National Heart, Lung, and Blood Institute.</text>
<text top="1088" left="446" width="279" height="7" font="17">*Lost future earnings of persons who will die in 2010, discounted at 3%.</text>
<text top="1100" left="454" width="139" height="7" font="17">Reproduced from Lloyd-Jones et al. <a href="e44.full.html#86">(</a></text>
<text top="1100" left="593" width="10" height="7" font="22"><a href="e44.full.html#86">27</a></text>
<text top="1100" left="603" width="5" height="7" font="17"><a href="e44.full.html#86">).</a></text>
<text top="52" left="59" width="18" height="10" font="12">e54</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="23" size="7" family="Times" color="#3b456e"/>
<text top="976" left="59" width="400" height="11" font="13">Figure 2. Diagnosis of Patients with Suspected Ischemic Heart Disease*</text>
<text top="1008" left="59" width="305" height="8" font="11">*Colors correspond to the class of recommendations in the ACCF/AHA</text>
<text top="1008" left="366" width="32" height="8" font="23"><a href="e44.full.html#5">Table 1</a></text>
<text top="1008" left="399" width="396" height="8" font="11"><a href="e44.full.html#5">. </a>The algorithms do not represent a comprehensive list of recommendations (see text for all</text>
<text top="1021" left="59" width="108" height="8" font="11">recommendations). †See</text>
<text top="1021" left="170" width="32" height="8" font="23"><a href="e44.full.html#8">Table 2</a></text>
<text top="1021" left="205" width="304" height="8" font="11">for short-term risk of death or nonfatal MI in patients with UA/NSTEMI.</text>
<text top="1021" left="513" width="286" height="9" font="11">‡CCTA is reasonable only for patients with intermediate probability</text>
<text top="1035" left="59" width="744" height="8" font="11">of IHD. CCTA indicates computed coronary tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; IHD, ischemic heart dis-</text>
<text top="1048" left="59" width="730" height="8" font="11">ease; MI, myocardial infarction; MPI, myocardial perfusion imaging; Pharm, pharmacological; UA, unstable angina; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial</text>
<text top="1062" left="59" width="41" height="8" font="11">infarction.</text>
<text top="52" left="787" width="18" height="10" font="12">e55</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="24" size="7" family="Times" color="#a70c2f"/>
	<fontspec id="25" size="10" family="Times" color="#005d59"/>
<text top="692" left="59" width="297" height="12" font="18">1.8. Vital Importance of Involvement by an</text>
<text top="710" left="59" width="245" height="12" font="18">Informed Patient: Recommendation</text>
<text top="740" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="752" left="59" width="360" height="10" font="13">1. Choices about diagnostic and therapeutic options should be made</text>
<text top="769" left="74" width="344" height="10" font="13">through a process of shared decision making involving the patient</text>
<text top="786" left="74" width="344" height="10" font="13">and provider, with the provider explaining information about risks,</text>
<text top="803" left="74" width="288" height="10" font="13">benefits, and costs to the patient. <i>(Level of Evidence: C)</i></text>
<text top="824" left="59" width="360" height="16" font="4">In accordance with the principle of autonomy, the health-</text>
<text top="842" left="59" width="360" height="16" font="4">care provider is obliged to solicit and respect the patient’s</text>
<text top="860" left="59" width="360" height="16" font="4">preferences about choice of therapy. Although this princi-</text>
<text top="878" left="59" width="360" height="16" font="4">ple, in the setting of cardiovascular disease, has received only</text>
<text top="896" left="59" width="360" height="16" font="4">limited study, the concept of shared decision making in-</text>
<text top="914" left="59" width="360" height="16" font="4">creasingly is viewed as an approach that ensures that</text>
<text top="932" left="59" width="360" height="16" font="4">patients remain involved in key decisions. This approach</text>
<text top="950" left="59" width="193" height="16" font="4">leads to higher quality of care <a href="e44.full.html#86">(</a></text>
<text top="950" left="251" width="34" height="16" font="16"><a href="e44.full.html#86">44,45</a></text>
<text top="950" left="285" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="968" left="74" width="345" height="16" font="4">To ensure that the patient is able to make the most</text>
<text top="986" left="59" width="360" height="16" font="4">informed decisions possible, the provider must give suffi-</text>
<text top="1004" left="59" width="360" height="16" font="4">cient information about the underlying disease process,</text>
<text top="1022" left="59" width="360" height="16" font="4">along with all relevant diagnostic and therapeutic options—</text>
<text top="1040" left="59" width="360" height="16" font="4">including anticipated outcomes, risks, and costs to the</text>
<text top="1058" left="59" width="55" height="16" font="4">patient <a href="e44.full.html#86">(</a></text>
<text top="1058" left="114" width="15" height="16" font="16"><a href="e44.full.html#86">46</a></text>
<text top="1058" left="129" width="290" height="16" font="4"><a href="e44.full.html#86">). </a>This information should be provided in a</text>
<text top="1076" left="59" width="360" height="16" font="4">manner that is readily comprehensible and permits the</text>
<text top="1094" left="59" width="228" height="16" font="4">opportunity for dialog and questions.</text>
<text top="692" left="461" width="345" height="16" font="4">Patients should be encouraged to seek additional infor-</text>
<text top="710" left="446" width="360" height="16" font="4">mation from other sources, including those on the Internet,</text>
<text top="728" left="446" width="360" height="16" font="4">such as those maintained by the National Institutes of</text>
<text top="747" left="446" width="360" height="16" font="4">Health, the Centers for Disease Control and Prevention,</text>
<text top="765" left="446" width="360" height="16" font="4">and the ACCF/AHA. Substantial research indicates that</text>
<text top="783" left="446" width="360" height="16" font="4">when informed about absolute or marginal benefit, patients</text>
<text top="802" left="446" width="360" height="16" font="4">often elect to postpone or forego invasive procedures. Two</text>
<text top="820" left="446" width="360" height="16" font="4">patients with similar pretest probabilities of IHD could</text>
<text top="838" left="446" width="360" height="16" font="4">prefer different approaches because of variations in personal</text>
<text top="857" left="446" width="360" height="16" font="4">beliefs, economic situation, or stage of life. Because of the</text>
<text top="875" left="446" width="360" height="16" font="4">variation in symptoms and clinical characteristics among pa-</text>
<text top="893" left="446" width="360" height="16" font="4">tients, as well as their unique perceptions, expectations, and</text>
<text top="911" left="446" width="360" height="16" font="4">preferences, there is often no single correct approach to any</text>
<text top="930" left="446" width="360" height="16" font="4">given set of clinical circumstances. In assisting patients to reach</text>
<text top="948" left="446" width="360" height="16" font="4">an informed decision, it is essential to elicit the breadth of their</text>
<text top="966" left="446" width="266" height="16" font="4">knowledge, values, preferences, and concerns.</text>
<text top="985" left="461" width="345" height="16" font="4">The healthcare provider has a responsibility to ensure that</text>
<text top="1003" left="446" width="360" height="16" font="4">patients understand and consider both the upside and</text>
<text top="1021" left="446" width="360" height="16" font="4">downside of available options, in both the near and long</text>
<text top="1039" left="446" width="360" height="16" font="4">terms. All previous guidelines reviewed by the writing</text>
<text top="1058" left="446" width="360" height="16" font="4">committee have recognized the crucial role that patient</text>
<text top="1076" left="446" width="360" height="16" font="4">preferences play in the selection of a treatment strategy</text>
<text top="1094" left="446" width="5" height="16" font="4"><a href="e44.full.html#85">(</a></text>
<text top="1094" left="450" width="69" height="16" font="16"><a href="e44.full.html#85">9,10,47– 49</a></text>
<text top="1094" left="520" width="286" height="16" font="4"><a href="e44.full.html#85">). </a>It is essential that these discussions be con-</text>
<text top="604" left="59" width="355" height="11" font="13">Figure 3. Algorithm for Risk Assessment of Patients With SIHD*</text>
<text top="636" left="59" width="305" height="8" font="11">*Colors correspond to the class of recommendations in the ACCF/AHA</text>
<text top="636" left="366" width="32" height="8" font="23"><a href="e44.full.html#5">Table 1</a></text>
<text top="636" left="399" width="396" height="8" font="11"><a href="e44.full.html#5">. </a>The algorithms do not represent a comprehensive list of recommendations (see text for all</text>
<text top="650" left="59" width="740" height="8" font="11">recommendations). CCTA indicates coronary computed tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; LBBB,</text>
<text top="663" left="59" width="386" height="8" font="11">left bundle-branch block; MPI, myocardial perfusion imaging; and Pharm, pharmacological.</text>
<text top="52" left="59" width="18" height="10" font="12">e56</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1161" width="864">
<text top="769" left="59" width="360" height="16" font="4">ducted in a location and atmosphere that permits adequate</text>
<text top="787" left="59" width="360" height="16" font="4">time for discussion and contemplation. Initiating a discus-</text>
<text top="805" left="59" width="360" height="16" font="4">sion about the relative merits of PCI or CABG while a</text>
<text top="823" left="59" width="360" height="16" font="4">patient is in the midst of a procedure, for example, is not</text>
<text top="841" left="59" width="242" height="16" font="4">usually consistent with these principles.</text>
<text top="859" left="74" width="345" height="16" font="4">In crafting a diagnostic strategy, the objective is to ascertain,</text>
<text top="877" left="59" width="360" height="16" font="4">as accurately as possible, whether the patient has IHD while</text>
<text top="895" left="59" width="360" height="16" font="4">minimizing the expense, discomfort, and potential harms of</text>
<text top="913" left="59" width="360" height="16" font="4">any tests or procedures. This includes avoiding procedures that</text>
<text top="932" left="59" width="360" height="16" font="4">are likely to yield false positive or false negative results or that</text>
<text top="950" left="59" width="360" height="16" font="4">are unnecessary or inappropriate. The objective for procedures</text>
<text top="968" left="59" width="225" height="16" font="4">intended to assess prognosis is similar.</text>
<text top="986" left="74" width="345" height="16" font="4">Treatment options should be emphasized, especially in</text>
<text top="1004" left="59" width="360" height="16" font="4">cases where there is no substantial advantage of one strategy</text>
<text top="1022" left="59" width="360" height="16" font="4">over others. For most patients, the goal of treatment should</text>
<text top="1040" left="59" width="360" height="16" font="4">be to simultaneously maximize survival and to achieve</text>
<text top="1058" left="59" width="360" height="16" font="4">prompt and complete (or nearly complete) elimination of</text>
<text top="1076" left="59" width="360" height="16" font="4">anginal chest pain with return to normal activities—in other</text>
<text top="1094" left="59" width="360" height="16" font="4">words, a functional capacity of Canadian Cardiovascular</text>
<text top="769" left="446" width="202" height="16" font="4">Society (CCS) Class I angina <a href="e44.full.html#86">(</a></text>
<text top="769" left="647" width="15" height="16" font="16"><a href="e44.full.html#86">50</a></text>
<text top="769" left="662" width="143" height="16" font="4"><a href="e44.full.html#86">). </a>For example, for an</text>
<text top="787" left="446" width="360" height="16" font="4">otherwise healthy, active patient, the treatment goal is</text>
<text top="805" left="446" width="360" height="16" font="4">usually the complete elimination of chest pain and a return</text>
<text top="823" left="446" width="360" height="16" font="4">to vigorous physical activity. Conversely, an elderly patient</text>
<text top="841" left="446" width="360" height="16" font="4">with more severe angina and several serious coexisting</text>
<text top="859" left="446" width="360" height="16" font="4">medical problems might be satisfied with a reduction in</text>
<text top="877" left="446" width="360" height="16" font="4">symptoms that permits limited activities of daily living.</text>
<text top="895" left="446" width="360" height="16" font="4">Patients with anatomy that would ordinarily favor the</text>
<text top="913" left="446" width="360" height="16" font="4">choice of CABG could have comorbidities that make the</text>
<text top="932" left="446" width="360" height="16" font="4">risk of surgery unacceptable, in which case PCI or medical</text>
<text top="950" left="446" width="215" height="16" font="4">therapy is a more attractive option.</text>
<text top="968" left="461" width="345" height="16" font="4">In counseling patients, the healthcare provider should be</text>
<text top="986" left="446" width="360" height="16" font="4">aware of, and help to rectify, common misperceptions.</text>
<text top="1004" left="446" width="360" height="16" font="4">Many patients assume, for example, that opening a partially</text>
<text top="1022" left="446" width="360" height="16" font="4">blocked artery will naturally prevent a heart attack and</text>
<text top="1040" left="446" width="360" height="16" font="4">prolong life irrespective of other anatomic and clinical</text>
<text top="1058" left="446" width="360" height="16" font="4">factors. When there is little expectation of an improvement</text>
<text top="1076" left="446" width="360" height="16" font="4">in survival from revascularization, patients should be so</text>
<text top="1095" left="446" width="360" height="16" font="4">informed. When evidence points to probable benefit from</text>
<text top="622" left="59" width="457" height="11" font="13">Figure 4. Algorithm for Guideline-Directed Medical Therapy for Patients With SIHD*</text>
<text top="654" left="59" width="305" height="8" font="11">*Colors correspond to the class of recommendations in the ACCF/AHA</text>
<text top="654" left="366" width="32" height="8" font="23"><a href="e44.full.html#5">Table 1</a></text>
<text top="654" left="399" width="396" height="8" font="11"><a href="e44.full.html#5">. </a>The algorithms do not represent a comprehensive list of recommendations (see text for all</text>
<text top="668" left="59" width="447" height="8" font="11">recommendations). †The use of bile acid sequestrant is relatively contraindicated when triglycerides are</text>
<text top="665" left="509" width="281" height="13" font="11">ⱖ200 mg/dL and is contraindicated when triglycerides are ⱖ500</text>
<text top="681" left="59" width="31" height="8" font="11">mg/dL.</text>
<text top="681" left="93" width="645" height="9" font="11">‡Dietary supplement niacin must not be used as a substitute for prescription niacin. ACCF indicates American College of Cardiology Foundation; ACEI,</text>
<text top="695" left="59" width="738" height="8" font="11">angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin-receptor blocker; ASA, aspirin, ATP III, Adult Treatment Panel 3; BP, blood pres-</text>
<text top="708" left="59" width="730" height="8" font="11">sure; CCB, calcium channel blocker; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol, JNC VII, Seventh Report of the Joint National Committee on</text>
<text top="722" left="59" width="724" height="8" font="11">Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; MI, myocardial infarction; NHLBI,</text>
<text top="735" left="59" width="279" height="8" font="11">National Heart, Lung, and Blood Institute; and NTG, nitroglycerin.</text>
<text top="52" left="787" width="18" height="10" font="12">e57</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="26" size="13" family="Times" color="#231f20"/>
	<fontspec id="27" size="9" family="Times" color="#000000"/>
	<fontspec id="28" size="6" family="Times" color="#000000"/>
	<fontspec id="29" size="9" family="Times" color="#000000"/>
	<fontspec id="30" size="9" family="Times" color="#000000"/>
	<fontspec id="31" size="9" family="Times" color="#000000"/>
<text top="788" left="59" width="360" height="16" font="4">either revascularization or medical therapy, it should be</text>
<text top="806" left="59" width="360" height="16" font="4">quantified to the extent possible, with explicit acknowledg-</text>
<text top="824" left="59" width="360" height="16" font="4">ment of uncertainties, and should be discussed in the</text>
<text top="842" left="59" width="360" height="16" font="4">context of what treatment option is best for that particular</text>
<text top="860" left="59" width="360" height="16" font="4">patient. When possible, the relative time course of response</text>
<text top="878" left="59" width="360" height="16" font="4">to therapy should be described for therapeutic choices.</text>
<text top="896" left="59" width="360" height="16" font="4">Some patients might, for example, initially opt for PCI over</text>
<text top="914" left="59" width="360" height="16" font="4">medical therapy because relief of symptoms is typically more</text>
<text top="932" left="59" width="360" height="16" font="4">rapid. However, when informed of the immediate risk of</text>
<text top="950" left="59" width="360" height="16" font="4">complications of PCI, some patients could prefer conserva-</text>
<text top="968" left="59" width="360" height="16" font="4">tive therapy. Similarly, many patients choose PCI over</text>
<text top="986" left="59" width="360" height="16" font="4">CABG because it is less invasive and provides for quicker</text>
<text top="1004" left="59" width="360" height="16" font="4">recovery, despite the fact that repeat revascularization pro-</text>
<text top="1022" left="59" width="360" height="16" font="4">cedures are performed more frequently after PCI. Patients’</text>
<text top="1040" left="59" width="360" height="16" font="4">preferences in these circumstances often are influenced by</text>
<text top="1058" left="59" width="360" height="16" font="4">their attitudes toward risk and by the tendency to let</text>
<text top="1076" left="59" width="360" height="16" font="4">immediate smaller benefits outweigh larger future risks, a</text>
<text top="1094" left="59" width="282" height="16" font="4">phenomenon termed “temporal discounting” <a href="e44.full.html#87">(</a></text>
<text top="1094" left="341" width="15" height="16" font="16"><a href="e44.full.html#87">51</a></text>
<text top="1094" left="356" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="789" left="446" width="167" height="14" font="15">2. Diagnosis of SIHD</text>
<text top="829" left="446" width="358" height="12" font="18">2.1. Clinical Evaluation of Patients With Chest Pain</text>
<text top="856" left="446" width="342" height="16" font="26"><b>2.1.1. Clinical Evaluation in the Initial Diagnosis of</b></text>
<text top="874" left="446" width="358" height="16" font="26"><b>SIHD in Patients With Chest Pain: Recommendations</b></text>
<text top="904" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="917" left="446" width="360" height="10" font="13">1. Patients with chest pain should receive a thorough history and</text>
<text top="933" left="461" width="344" height="10" font="13">physical examination to assess the probability of IHD before addi-</text>
<text top="950" left="461" width="209" height="10" font="13">tional testing <a href="e44.full.html#87">(52). </a>(<i>Level of Evidence: C)</i></text>
<text top="967" left="446" width="360" height="10" font="13">2. Patients who present with acute angina should be categorized as</text>
<text top="984" left="461" width="344" height="10" font="13">stable or unstable; patients with UA should be further categorized as</text>
<text top="1001" left="461" width="336" height="10" font="13">being at high, moderate, or low risk <a href="e44.full.html#85">(4,4a). </a>(<i>Level of Evidence: C)</i></text>
<text top="1033" left="446" width="91" height="16" font="26"><b>2.1.2. History</b></text>
<text top="1058" left="446" width="360" height="16" font="4">The clinical examination is the key first step in evaluating a</text>
<text top="1076" left="446" width="360" height="16" font="4">patient with chest pain and should include a detailed</text>
<text top="1094" left="446" width="360" height="16" font="4">assessment of symptoms, including quality, location, sever-</text>
<text top="251" left="280" width="185" height="10" font="27">Potential revascularization procedure </text>
<text top="264" left="285" width="175" height="10" font="27">warranted based on assessment of </text>
<text top="278" left="269" width="205" height="10" font="27">coexisting cardiac and noncardiac factors </text>
<text top="291" left="310" width="122" height="10" font="27">and patient preferences?</text>
<text top="361" left="351" width="42" height="10" font="27">Perform </text>
<text top="374" left="349" width="46" height="10" font="27">coronary </text>
<text top="387" left="340" width="61" height="10" font="27">angiography</text>
<text top="327" left="363" width="15" height="8" font="28">Yes</text>
<text top="440" left="305" width="135" height="10" font="27">Heart Team concludes that </text>
<text top="453" left="303" width="139" height="10" font="27">anatomy and clinical factors </text>
<text top="466" left="297" width="151" height="10" font="27">indicate revascularization may </text>
<text top="479" left="304" width="133" height="10" font="27">improve survival (Table 18)</text>
<text top="545" left="300" width="145" height="10" font="27">Determine optimal method of </text>
<text top="558" left="299" width="147" height="10" font="27">revascularization based upon </text>
<text top="571" left="284" width="177" height="10" font="27">patient preferences, anatomy, other </text>
<text top="584" left="285" width="174" height="10" font="27">clinical factors, and local resources </text>
<text top="598" left="311" width="120" height="10" font="27">and expertise (Table 18)</text>
<text top="510" left="363" width="15" height="8" font="28">Yes</text>
<text top="272" left="510" width="11" height="8" font="28">No</text>
<text top="460" left="590" width="11" height="8" font="28">No</text>
<text top="123" left="319" width="107" height="10" font="29"><b>Noninvasive testing </b></text>
<text top="137" left="322" width="101" height="10" font="29"><b>suggests high-risk </b></text>
<text top="150" left="323" width="96" height="10" font="29"><b>coronary lesion(s)</b></text>
<text top="161" left="338" width="66" height="13" font="30"><i>from Figure 2</i></text>
<text top="223" left="549" width="112" height="10" font="29"><b>Continued Guideline-</b></text>
<text top="236" left="561" width="91" height="10" font="29"><b>Directed Medical </b></text>
<text top="250" left="571" width="71" height="10" font="29"><b>Therapy with </b></text>
<text top="263" left="564" width="86" height="10" font="29"><b>ongoing patient </b></text>
<text top="276" left="579" width="52" height="10" font="29"><b>education</b></text>
<text top="287" left="570" width="71" height="13" font="30"><i>Go to Figure 4</i></text>
<text top="666" left="277" width="191" height="12" font="31"><i><b>Guideline-Directed Medical Therapy </b></i></text>
<text top="679" left="308" width="126" height="12" font="31"><i><b>continued in all patients</b></i></text>
<text top="710" left="59" width="464" height="11" font="13">Figure 5. Algorithm for Revascularization to Improve Survival of Patients With SIHD*</text>
<text top="742" left="59" width="305" height="8" font="11">*Colors correspond to the class of recommendations in the ACCF/AHA</text>
<text top="742" left="366" width="32" height="8" font="23"><a href="e44.full.html#5">Table 1</a></text>
<text top="742" left="399" width="396" height="8" font="11"><a href="e44.full.html#5">. </a>The algorithms do not represent a comprehensive list of recommendations (see text for all</text>
<text top="755" left="59" width="82" height="8" font="11">recommendations).</text>
<text top="52" left="59" width="18" height="10" font="12">e58</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1161" width="864">
<text top="872" left="59" width="360" height="16" font="4">ity, and duration of pain; radiation; associated symptoms;</text>
<text top="891" left="59" width="360" height="16" font="4">provocative factors; and alleviating factors. Adjectives often</text>
<text top="909" left="59" width="360" height="16" font="4">used to describe anginal pain include “squeezing,” “grip-</text>
<text top="928" left="59" width="360" height="16" font="4">like,” “suffocating,” and “heavy,” but it is rarely sharp or</text>
<text top="946" left="59" width="360" height="16" font="4">stabbing and typically does not vary with position or</text>
<text top="965" left="59" width="360" height="16" font="4">respiration. On occasion the patient might demonstrate the</text>
<text top="983" left="59" width="360" height="16" font="4">classic Levine’s sign by placing a clenched fist over the</text>
<text top="1002" left="59" width="360" height="16" font="4">precordium to describe the pain. Many patients do not,</text>
<text top="1020" left="59" width="360" height="16" font="4">however, describe angina as frank pain but as tightness,</text>
<text top="1039" left="59" width="360" height="16" font="4">pressure, or discomfort. Other patients, in particular women</text>
<text top="1057" left="59" width="360" height="16" font="4">and the elderly, can present with atypical symptoms such as</text>
<text top="1076" left="59" width="360" height="16" font="4">nausea, vomiting, midepigastric discomfort, or sharp (atyp-</text>
<text top="1094" left="59" width="360" height="16" font="4">ical) chest pain. In the WISE (Women’s Ischemic Syn-</text>
<text top="872" left="446" width="360" height="16" font="4">drome Evaluation) study, 65% of women with ischemia</text>
<text top="891" left="446" width="217" height="16" font="4">presented with atypical symptoms <a href="e44.full.html#87">(</a></text>
<text top="891" left="663" width="15" height="16" font="16"><a href="e44.full.html#87">54</a></text>
<text top="891" left="678" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="909" left="461" width="345" height="16" font="4">Anginal pain caused by cardiac ischemia typically lasts</text>
<text top="928" left="446" width="360" height="16" font="4">minutes. The location is usually substernal, and pain can</text>
<text top="946" left="446" width="360" height="16" font="4">radiate to the neck, jaw, epigastrium, or arms. Pain above</text>
<text top="965" left="446" width="360" height="16" font="4">the mandible, below the epigastrium, or localized to a small</text>
<text top="983" left="446" width="360" height="16" font="4">area over the left lateral chest wall is rarely angina. Angina</text>
<text top="1002" left="446" width="360" height="16" font="4">is often precipitated by exertion or emotional stress and</text>
<text top="1020" left="446" width="360" height="16" font="4">relieved by rest. Sublingual nitroglycerin also usually relieves</text>
<text top="1039" left="446" width="360" height="16" font="4">angina, within 30 seconds to several minutes. The history</text>
<text top="1057" left="446" width="360" height="16" font="4">can be used to classify symptoms as typical, atypical, or</text>
<text top="1076" left="446" width="140" height="16" font="4">noncardiac chest pain <a href="e44.full.html#85">(</a></text>
<text top="1076" left="586" width="8" height="16" font="16"><a href="e44.full.html#85">6</a></text>
<text top="1076" left="593" width="14" height="16" font="4"><a href="e44.full.html#85">) </a><a href="e44.full.html#17">(</a></text>
<text top="1076" left="607" width="47" height="16" font="16"><a href="e44.full.html#17">Table 5</a></text>
<text top="1076" left="654" width="152" height="16" font="4"><a href="e44.full.html#17">). </a>The patient presenting</text>
<text top="1094" left="446" width="360" height="16" font="4">with angina must be categorized as having stable angina or</text>
<text top="794" left="59" width="478" height="11" font="13">Figure 6. Algorithm for Revascularization to Improve Symptoms of Patients With SIHD*</text>
<text top="826" left="59" width="305" height="8" font="11">*Colors correspond to the class of recommendations in the ACCF/AHA</text>
<text top="826" left="366" width="32" height="8" font="23"><a href="e44.full.html#5">Table 1</a></text>
<text top="826" left="399" width="396" height="8" font="11"><a href="e44.full.html#5">. </a>The algorithms do not represent a comprehensive list of recommendations (see text for all</text>
<text top="839" left="59" width="454" height="8" font="11">recommendations). CABG indicates coronary artery bypass graft; PCI, percutaneous coronary intervention.</text>
<text top="52" left="787" width="18" height="10" font="12">e59</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1161" width="864">
<text top="277" left="59" width="35" height="16" font="4">UA <a href="e44.full.html#85">(</a></text>
<text top="277" left="94" width="25" height="16" font="16"><a href="e44.full.html#85">4,4a</a></text>
<text top="277" left="119" width="299" height="16" font="4"><a href="e44.full.html#85">). </a>UA is defined as new onset, increasing (in</text>
<text top="295" left="59" width="340" height="16" font="4">frequency, intensity, or duration), or occurring at rest <a href="e44.full.html#86">(</a></text>
<text top="295" left="399" width="15" height="16" font="16"><a href="e44.full.html#86">50</a></text>
<text top="295" left="414" width="5" height="16" font="4"><a href="e44.full.html#86">)</a></text>
<text top="313" left="59" width="5" height="16" font="4"><a href="e44.full.html#17">(</a></text>
<text top="313" left="63" width="52" height="16" font="16"><a href="e44.full.html#17">Table 6</a></text>
<text top="313" left="115" width="303" height="16" font="4"><a href="e44.full.html#17">). </a>However, patients presenting with UA are</text>
<text top="331" left="59" width="230" height="16" font="4">subdivided by their short-term risk <a href="e44.full.html#8">(</a></text>
<text top="331" left="289" width="48" height="16" font="16"><a href="e44.full.html#8">Table 2</a></text>
<text top="331" left="337" width="81" height="16" font="4"><a href="e44.full.html#8">). </a>Patients at</text>
<text top="349" left="59" width="360" height="16" font="4">high or moderate risk often have experienced rupture of</text>
<text top="367" left="59" width="360" height="16" font="4">coronary artery plaque and have a risk of death higher than</text>
<text top="385" left="59" width="360" height="16" font="4">that of patients with stable angina but not as great as that of</text>
<text top="403" left="59" width="360" height="16" font="4">patients with AMI. These patients should be transferred</text>
<text top="421" left="59" width="360" height="16" font="4">promptly to an emergency department for evaluation and</text>
<text top="439" left="59" width="360" height="16" font="4">treatment. The short-term prognosis of patients with low-</text>
<text top="457" left="59" width="360" height="16" font="4">risk UA, however, is comparable to those with stable angina,</text>
<text top="475" left="59" width="360" height="16" font="4">and their evaluation can be conducted safely and expedi-</text>
<text top="493" left="59" width="192" height="16" font="4">tiously in an outpatient setting.</text>
<text top="511" left="74" width="345" height="16" font="4">After thorough characterization of chest pain, the pres-</text>
<text top="529" left="59" width="193" height="16" font="4">ence of risk factors for IHD <a href="e44.full.html#87">(</a></text>
<text top="529" left="252" width="15" height="16" font="16"><a href="e44.full.html#87">55</a></text>
<text top="529" left="267" width="152" height="16" font="4"><a href="e44.full.html#87">) </a>should be determined.</text>
<text top="547" left="59" width="360" height="16" font="4">These include smoking, hyperlipidemia, diabetes mellitus,</text>
<text top="565" left="59" width="360" height="16" font="4">hypertension, obesity or metabolic syndrome, physical in-</text>
<text top="583" left="59" width="360" height="16" font="4">activity, and a family history of premature IHD (i.e., onset</text>
<text top="601" left="59" width="360" height="16" font="4">in a father, brother, or son before age 55 years or a mother,</text>
<text top="619" left="59" width="360" height="16" font="4">sister, or daughter before age 65 years). A history of</text>
<text top="637" left="59" width="360" height="16" font="4">cerebrovascular or peripheral artery disease (PAD) also</text>
<text top="655" left="59" width="199" height="16" font="4">increases the likelihood of IHD.</text>
<text top="682" left="59" width="182" height="16" font="26"><b>2.1.3. Physical Examination</b></text>
<text top="708" left="59" width="360" height="16" font="4">The examination is often normal or nonspecific in patients</text>
<text top="726" left="59" width="122" height="16" font="4">with stable angina <a href="e44.full.html#87">(</a></text>
<text top="726" left="181" width="15" height="16" font="16"><a href="e44.full.html#87">56</a></text>
<text top="726" left="196" width="223" height="16" font="4"><a href="e44.full.html#87">) </a>but could reveal related conditions</text>
<text top="744" left="59" width="360" height="16" font="4">such as heart failure, valvular heart disease, or hypertrophic</text>
<text top="762" left="59" width="360" height="16" font="4">cardiomyopathy. An audible rub suggests pericardial or</text>
<text top="780" left="59" width="360" height="16" font="4">pleural disease. Evidence of vascular disease includes carotid</text>
<text top="798" left="59" width="360" height="16" font="4">or renal artery bruits, a diminished pedal pulse, or a palpable</text>
<text top="816" left="59" width="360" height="16" font="4">abdominal aneurysm. Elevated blood pressure (BP), xan-</text>
<text top="834" left="59" width="360" height="16" font="4">thomas, and retinal exudates point to the presence of IHD</text>
<text top="852" left="59" width="360" height="16" font="4">risk factors. Pain reproduced by pressure on the chest wall</text>
<text top="870" left="59" width="360" height="16" font="4">suggests a musculoskeletal etiology but does not eliminate</text>
<text top="888" left="59" width="230" height="16" font="4">the possibility of angina due to IHD.</text>
<text top="915" left="59" width="171" height="16" font="26"><b>2.1.4. Electrocardiography</b></text>
<text top="946" left="59" width="280" height="9" font="6">2.1.4.1. RESTING ELECTROCARDIOGRAPHY TO ASSESS RISK:</text>
<text top="964" left="59" width="89" height="9" font="6">RECOMMENDATION</text>
<text top="986" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="999" left="59" width="360" height="10" font="13">1. A resting ECG is recommended in patients without an obvious,</text>
<text top="1016" left="74" width="323" height="10" font="13">noncardiac cause of chest pain <a href="e44.full.html#87">(57–59). </a><i>(Level of Evidence: B)</i></text>
<text top="1040" left="59" width="360" height="16" font="4">Patients with SIHD who have the following abnormalities</text>
<text top="1058" left="59" width="360" height="16" font="4">on a resting ECG have a worse prognosis than those with</text>
<text top="1076" left="59" width="97" height="16" font="4">normal ECGs <a href="e44.full.html#87">(</a></text>
<text top="1076" left="156" width="38" height="16" font="16"><a href="e44.full.html#87">57–59</a></text>
<text top="1076" left="193" width="225" height="16" font="4"><a href="e44.full.html#87">): </a>evidence of prior MI, especially Q</text>
<text top="1094" left="59" width="360" height="16" font="4">waves in multiple leads or an R wave in V1 indicating a</text>
<text top="104" left="446" width="128" height="16" font="4">posterior infarction <a href="e44.full.html#87">(</a></text>
<text top="104" left="573" width="15" height="16" font="16"><a href="e44.full.html#87">60</a></text>
<text top="104" left="588" width="217" height="16" font="4"><a href="e44.full.html#87">); </a>persistent ST-T-wave inversions,</text>
<text top="122" left="446" width="194" height="16" font="4">particularly in leads V1 to V3 <a href="e44.full.html#87">(</a></text>
<text top="122" left="639" width="39" height="16" font="16"><a href="e44.full.html#87">61– 64</a></text>
<text top="122" left="678" width="127" height="16" font="4"><a href="e44.full.html#87">); </a>left bundle-branch</text>
<text top="140" left="446" width="360" height="16" font="4">block (LBBB), bifascicular block, second- or third-degree</text>
<text top="158" left="446" width="360" height="16" font="4">atrioventricular (AV) block, or ventricular tachyarrhythmia</text>
<text top="176" left="446" width="5" height="16" font="4"><a href="e44.full.html#87">(</a></text>
<text top="176" left="450" width="15" height="16" font="16"><a href="e44.full.html#87">65</a></text>
<text top="176" left="465" width="244" height="16" font="4"><a href="e44.full.html#87">); </a>or left ventricular (LV) hypertrophy <a href="e44.full.html#87">(</a></text>
<text top="176" left="709" width="34" height="16" font="16"><a href="e44.full.html#87">62,66</a></text>
<text top="176" left="743" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="203" left="446" width="185" height="16" font="26"><b>2.1.5. Differential Diagnosis</b></text>
<text top="229" left="446" width="360" height="16" font="4">Although the symptoms of some patients might be consis-</text>
<text top="247" left="446" width="360" height="16" font="4">tent with a very high probability of IHD, in others, the</text>
<text top="265" left="446" width="360" height="16" font="4">etiology might be less certain, and alternative diagnoses</text>
<text top="283" left="446" width="134" height="16" font="4">should be considered <a href="e44.full.html#18">(</a></text>
<text top="283" left="579" width="46" height="16" font="16"><a href="e44.full.html#18">Table 7</a></text>
<text top="283" left="625" width="181" height="16" font="4"><a href="e44.full.html#18">). </a>However, even when angina</text>
<text top="301" left="446" width="360" height="16" font="4">seems likely to be related to IHD, other coexisting condi-</text>
<text top="319" left="446" width="360" height="16" font="4">tions can precipitate symptoms by inducing or exacerbating</text>
<text top="337" left="446" width="360" height="16" font="4">myocardial ischemia, by either increased myocardial oxygen</text>
<text top="355" left="446" width="304" height="16" font="4">demand or decreased myocardial oxygen supply <a href="e44.full.html#18">(</a></text>
<text top="355" left="749" width="48" height="16" font="16"><a href="e44.full.html#18">Table 8</a></text>
<text top="355" left="797" width="9" height="16" font="4"><a href="e44.full.html#18">).</a></text>
<text top="373" left="446" width="360" height="16" font="4">When severe, these conditions can cause angina in the</text>
<text top="391" left="446" width="360" height="16" font="4">absence of significant anatomic coronary obstruction. Chest</text>
<text top="409" left="446" width="360" height="16" font="4">pain in women is less often due to IHD than in men, even</text>
<text top="427" left="446" width="360" height="16" font="4">when the pain is typical. Nevertheless, pain in women can</text>
<text top="445" left="446" width="360" height="16" font="4">be related to vascular dysfunction in the absence of epicar-</text>
<text top="463" left="446" width="360" height="16" font="4">dial CAD. Entities that cause increased oxygen demand</text>
<text top="481" left="446" width="360" height="16" font="4">include hyperthermia (particularly if accompanied by vol-</text>
<text top="499" left="446" width="121" height="16" font="4">ume contraction) <a href="e44.full.html#87">(</a></text>
<text top="499" left="566" width="15" height="16" font="16"><a href="e44.full.html#87">67</a></text>
<text top="499" left="581" width="224" height="16" font="4"><a href="e44.full.html#87">), </a>hyperthyroidism, and cocaine or</text>
<text top="517" left="446" width="360" height="16" font="4">methamphetamine abuse. Sympathomimetic toxicity, due,</text>
<text top="535" left="446" width="360" height="16" font="4">for example, to cocaine intoxication, not only increases</text>
<text top="553" left="446" width="360" height="16" font="4">myocardial oxygen demand but also induces coronary vaso-</text>
<text top="571" left="446" width="360" height="16" font="4">spasm and can cause infarction in young patients. Long-</text>
<text top="589" left="446" width="360" height="16" font="4">term cocaine use can cause premature development of IHD</text>
<text top="607" left="446" width="5" height="16" font="4"><a href="e44.full.html#87">(</a></text>
<text top="607" left="450" width="34" height="16" font="16"><a href="e44.full.html#87">68,69</a></text>
<text top="607" left="484" width="321" height="16" font="4"><a href="e44.full.html#87">). </a>Severe uncontrolled hypertension increases LV wall</text>
<text top="625" left="446" width="360" height="16" font="4">tension, leading to increased myocardial oxygen demand</text>
<text top="643" left="446" width="360" height="16" font="4">and decreased subendocardial perfusion. Hypertrophic car-</text>
<text top="661" left="446" width="360" height="16" font="4">diomyopathy and aortic stenosis can induce even more</text>
<text top="679" left="446" width="360" height="16" font="4">severe LV hypertrophy and resultant wall tension. Ventric-</text>
<text top="697" left="446" width="360" height="16" font="4">ular or supraventricular tachycardias are another cause of</text>
<text top="715" left="446" width="360" height="16" font="4">increased myocardial oxygen demand, but when paroxysmal</text>
<text top="733" left="446" width="183" height="16" font="4">these are difficult to diagnose.</text>
<text top="751" left="461" width="345" height="16" font="4">Anemia is the prototype for conditions that limit myo-</text>
<text top="769" left="446" width="360" height="16" font="4">cardial oxygen supply. Cardiac output rises when the hemo-</text>
<text top="787" left="446" width="92" height="16" font="4">globin drops to</text>
<text top="784" left="541" width="264" height="20" font="4">⬍9 g/dL, and ST-T-wave changes (depres-</text>
<text top="805" left="446" width="224" height="16" font="4">sion or inversion) can occur at levels</text>
<text top="802" left="674" width="59" height="20" font="4">⬍7 g/dL.</text>
<text top="823" left="461" width="345" height="16" font="4">Hypoxemia resulting from pulmonary disease (e.g., pneu-</text>
<text top="841" left="446" width="360" height="16" font="4">monia, asthma, chronic obstructive pulmonary disease, pul-</text>
<text top="859" left="446" width="360" height="16" font="4">monary hypertension, interstitial fibrosis, or obstructive</text>
<text top="877" left="446" width="360" height="16" font="4">sleep apnea) can also precipitate angina. Polycythemia,</text>
<text top="895" left="446" width="360" height="16" font="4">leukemia, thrombocytosis, and hypergammaglobulinemia</text>
<text top="105" left="59" width="259" height="11" font="13">Table 5. Clinical Classification of Chest Pain</text>
<text top="128" left="59" width="65" height="9" font="8"><i>Typical </i>angina</text>
<text top="142" left="71" width="40" height="9" font="6">(definite)</text>
<text top="127" left="150" width="267" height="9" font="6">1) Substernal chest discomfort with a characteristic quality</text>
<text top="142" left="162" width="211" height="9" font="6">and duration that is 2) provoked by exertion or</text>
<text top="156" left="162" width="250" height="9" font="6">emotional stress and 3) relieved by rest or nitroglycerin</text>
<text top="173" left="59" width="70" height="9" font="8"><i>Atypical </i>angina</text>
<text top="187" left="71" width="46" height="9" font="6">(probable)</text>
<text top="173" left="150" width="165" height="9" font="6">Meets 2 of the above characteristics</text>
<text top="205" left="59" width="51" height="9" font="8"><i>Noncardiac</i></text>
<text top="219" left="71" width="47" height="9" font="6">chest pain</text>
<text top="205" left="150" width="241" height="9" font="6">Meets 1 or none of the typical anginal characteristics</text>
<text top="256" left="59" width="121" height="7" font="17">Adapted from Braunwald et al. <a href="e44.full.html#85">(</a></text>
<text top="256" left="179" width="5" height="7" font="22"><a href="e44.full.html#85">6</a></text>
<text top="256" left="184" width="5" height="7" font="17"><a href="e44.full.html#85">).</a></text>
<text top="922" left="446" width="258" height="11" font="13">Table 6. Three Principal Presentations of UA</text>
<text top="944" left="446" width="264" height="9" font="6">Rest angina Angina occurring at rest and usually prolonged</text>
<text top="942" left="712" width="85" height="14" font="6">⬎20 min, occurring</text>
<text top="959" left="520" width="119" height="9" font="6">within 1 wk of presentation</text>
<text top="976" left="445" width="47" height="9" font="6">New-onset</text>
<text top="990" left="457" width="31" height="9" font="6">angina</text>
<text top="976" left="508" width="296" height="9" font="6">Angina of at least CCS Class III severity with onset within 2 mo of</text>
<text top="990" left="520" width="85" height="9" font="6">initial presentation</text>
<text top="1007" left="445" width="46" height="9" font="6">Increasing</text>
<text top="1022" left="457" width="31" height="9" font="6">angina</text>
<text top="1007" left="508" width="274" height="9" font="6">Previously diagnosed angina that is distinctly more frequent,</text>
<text top="1022" left="520" width="261" height="9" font="6">longer in duration, or lower in threshold (i.e., increased by</text>
<text top="1033" left="520" width="268" height="14" font="6">ⱖ1 CCS class within 2 mo of initial presentation to at least</text>
<text top="1050" left="520" width="97" height="9" font="6">CCS Class III severity)</text>
<text top="1088" left="446" width="182" height="7" font="17">CCS indicates Canadian Cardiovascular Society.</text>
<text top="1100" left="454" width="112" height="7" font="17">Reproduced from Braunwald <a href="e44.full.html#86">(</a></text>
<text top="1100" left="566" width="10" height="7" font="22"><a href="e44.full.html#86">50</a></text>
<text top="1100" left="577" width="5" height="7" font="17"><a href="e44.full.html#86">).</a></text>
<text top="52" left="59" width="18" height="10" font="12">e60</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1161" width="864">
<text top="369" left="59" width="360" height="16" font="4">are associated with increased blood viscosity that can de-</text>
<text top="387" left="59" width="360" height="16" font="4">crease coronary artery blood flow and precipitate angina,</text>
<text top="405" left="59" width="331" height="16" font="4">even in patients without significant coronary stenoses.</text>
<text top="432" left="59" width="279" height="16" font="26"><b>2.1.6. Developing the Probability Estimate</b></text>
<text top="457" left="59" width="360" height="16" font="4">When the clinical evaluation is complete, the practitioner</text>
<text top="475" left="59" width="360" height="16" font="4">must determine whether the probability of IHD is sufficient</text>
<text top="493" left="59" width="360" height="16" font="4">to recommend further testing, which is often a standard</text>
<text top="511" left="59" width="317" height="16" font="4">exercise test. When the probability of disease is</text>
<text top="508" left="384" width="35" height="20" font="4">⬍5%,</text>
<text top="529" left="59" width="360" height="16" font="4">further testing is usually not warranted because the likeli-</text>
<text top="547" left="59" width="360" height="16" font="4">hood of a false-positive test (i.e., positive test in the absence</text>
<text top="565" left="59" width="360" height="16" font="4">of obstructive CAD) is actually higher than that of a true</text>
<text top="583" left="59" width="360" height="16" font="4">positive. On the other hand, when the exercise test is</text>
<text top="601" left="59" width="360" height="16" font="4">negative in a patient who has a very high likelihood of IHD</text>
<text top="619" left="59" width="360" height="16" font="4">on the basis of the history, there is a substantial chance that</text>
<text top="637" left="59" width="360" height="16" font="4">in reality the result is falsely negative. Thus, further testing</text>
<text top="369" left="446" width="360" height="16" font="4">is most useful in patients in whom the cause of chest pain is</text>
<text top="387" left="446" width="360" height="16" font="4">truly uncertain (i.e., the probability of IHD is between 20%</text>
<text top="405" left="446" width="360" height="16" font="4">and 70%). It is necessary to note, however, that these</text>
<text top="423" left="446" width="360" height="16" font="4">probabilities relate solely to the presence of obstructive</text>
<text top="441" left="446" width="360" height="16" font="4">CAD and do not pertain to ischemia due to microvascular</text>
<text top="460" left="446" width="360" height="16" font="4">disease or other causes. They also do not reflect the</text>
<text top="478" left="446" width="360" height="16" font="4">likelihood that a nonobstructing plaque could become</text>
<text top="496" left="446" width="175" height="16" font="4">unstable and cause ischemia.</text>
<text top="514" left="461" width="124" height="16" font="4">A landmark study <a href="e44.full.html#87">(</a></text>
<text top="514" left="584" width="15" height="16" font="16"><a href="e44.full.html#87">52</a></text>
<text top="514" left="599" width="206" height="16" font="4"><a href="e44.full.html#87">) </a>showed how information about</text>
<text top="532" left="446" width="360" height="16" font="4">the type of pain and age and sex of the patient can provide</text>
<text top="550" left="446" width="360" height="16" font="4">a reasonable estimate of the likelihood of IHD. For in-</text>
<text top="568" left="446" width="360" height="16" font="4">stance, a 64-year-old man with typical angina has a 94%</text>
<text top="587" left="446" width="360" height="16" font="4">likelihood of having significant coronary stenosis. A 32-</text>
<text top="605" left="446" width="360" height="16" font="4">year-old woman with nonanginal chest pain has a 1%</text>
<text top="623" left="446" width="175" height="16" font="4">chance of coronary stenosis <a href="e44.full.html#87">(</a></text>
<text top="623" left="621" width="39" height="16" font="16"><a href="e44.full.html#87">70 –72</a></text>
<text top="623" left="660" width="146" height="16" font="4"><a href="e44.full.html#87">). </a>Other clinical charac-</text>
<text top="641" left="446" width="360" height="16" font="4">teristics that improved the accuracy of prediction include</text>
<text top="659" left="446" width="360" height="16" font="4">active or recent smoking, Q-wave or ST-T-wave changes on</text>
<text top="677" left="446" width="360" height="16" font="4">the ECG, hyperlipidemia (defined at the time of study as a</text>
<text top="695" left="446" width="128" height="16" font="4">total cholesterol level</text>
<text top="692" left="580" width="225" height="20" font="4">⬎250 mg/dL), and diabetes mellitus</text>
<text top="714" left="445" width="268" height="16" font="4">(defined at that time as a fasting glucose level</text>
<text top="710" left="718" width="88" height="20" font="4">⬎140 mg/dL).</text>
<text top="732" left="445" width="360" height="16" font="4">Of these characteristics, diabetes mellitus had the greatest</text>
<text top="750" left="445" width="360" height="16" font="4">influence on increasing the probability of IHD. The pres-</text>
<text top="768" left="445" width="360" height="16" font="4">ence of hypertension or a family history of premature IHD</text>
<text top="786" left="445" width="360" height="16" font="4">did not provide additional predictive accuracy. The results</text>
<text top="804" left="445" width="360" height="16" font="4">of the aforementioned landmark study subsequently were</text>
<text top="822" left="445" width="360" height="16" font="4">replicated with data from CASS (Coronary Artery Surgery</text>
<text top="840" left="445" width="49" height="16" font="4">Study) <a href="e44.full.html#87">(</a></text>
<text top="840" left="494" width="15" height="16" font="16"><a href="e44.full.html#87">73</a></text>
<text top="840" left="509" width="297" height="16" font="4"><a href="e44.full.html#87">) </a>and were within 5% of the original estimates for</text>
<text top="859" left="445" width="360" height="16" font="4">23 of 24 patient groupings. The single major exception was</text>
<text top="877" left="445" width="207" height="16" font="4">the category of adults who were</text>
<text top="874" left="660" width="145" height="20" font="4">ⱕ50 years of age with</text>
<text top="895" left="445" width="360" height="16" font="4">atypical angina, for whom the CASS estimate was 17%</text>
<text top="913" left="445" width="360" height="16" font="4">higher. On the basis of this high degree of concordance, the</text>
<text top="931" left="445" width="360" height="16" font="4">data from these studies were merged in the 2002 Chronic</text>
<text top="949" left="445" width="157" height="16" font="4">Stable Angina guideline <a href="e44.full.html#85">(</a></text>
<text top="949" left="603" width="45" height="16" font="16"><a href="e44.full.html#85">7,52,73</a></text>
<text top="949" left="648" width="15" height="16" font="4"><a href="e44.full.html#85">) </a><a href="e44.full.html#19">(</a></text>
<text top="949" left="663" width="47" height="16" font="16"><a href="e44.full.html#19">Table 9</a></text>
<text top="949" left="710" width="9" height="16" font="4"><a href="e44.full.html#19">).</a></text>
<text top="967" left="460" width="345" height="16" font="4">Additional validation studies were conducted with data</text>
<text top="986" left="445" width="360" height="16" font="4">from the Duke Databank for Cardiovascular Disease, which</text>
<text top="1004" left="445" width="360" height="16" font="4">also incorporated electrocardiographic findings (Q waves or</text>
<text top="1022" left="445" width="360" height="16" font="4">ST-T changes) and information about risk factors (smok-</text>
<text top="1040" left="445" width="242" height="16" font="4">ing, diabetes mellitus, hyperlipidemia) <a href="e44.full.html#87">(</a></text>
<text top="1040" left="688" width="15" height="16" font="16"><a href="e44.full.html#87">71</a></text>
<text top="1040" left="703" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="1040" left="716" width="54" height="16" font="16"><a href="e44.full.html#19">Table 10</a></text>
<text top="1040" left="775" width="31" height="16" font="4">pres-</text>
<text top="1058" left="445" width="360" height="16" font="4">ents the Duke data for mid-decade patients (35, 45, 55, and</text>
<text top="1076" left="445" width="360" height="16" font="4">65 years of age). Two probabilities are given. The first is for</text>
<text top="1094" left="445" width="360" height="16" font="4">a low-risk patient with no risk factors and a normal ECG.</text>
<text top="105" left="59" width="407" height="11" font="13">Table 7. Alternative Diagnoses to Angina for Patients With Chest Pain</text>
<text top="130" left="66" width="60" height="9" font="6">Nonischemic</text>
<text top="143" left="62" width="70" height="9" font="6">Cardiovascular</text>
<text top="143" left="183" width="49" height="9" font="6">Pulmonary</text>
<text top="143" left="322" width="75" height="9" font="6">Gastrointestinal</text>
<text top="143" left="507" width="52" height="9" font="6">Chest Wall</text>
<text top="143" left="690" width="52" height="9" font="6">Psychiatric</text>
<text top="160" left="59" width="75" height="9" font="6">Aortic dissection</text>
<text top="160" left="158" width="97" height="9" font="6">Pulmonary embolism</text>
<text top="160" left="280" width="52" height="9" font="6">Esophageal</text>
<text top="175" left="280" width="52" height="9" font="6">Esophagitis</text>
<text top="189" left="280" width="31" height="9" font="6">Spasm</text>
<text top="203" left="280" width="28" height="9" font="6">Reflux</text>
<text top="160" left="462" width="70" height="9" font="6">Costochondritis</text>
<text top="175" left="462" width="41" height="9" font="6">Fibrositis</text>
<text top="189" left="462" width="53" height="9" font="6">Rib fracture</text>
<text top="203" left="462" width="110" height="9" font="6">Sternoclavicular arthritis</text>
<text top="217" left="462" width="140" height="9" font="6">Herpes zoster (before the rash)</text>
<text top="160" left="628" width="77" height="9" font="6">Anxiety disorders</text>
<text top="175" left="628" width="73" height="9" font="6">Hyperventilation</text>
<text top="189" left="628" width="65" height="9" font="6">Panic disorder</text>
<text top="203" left="628" width="70" height="9" font="6">Primary anxiety</text>
<text top="235" left="59" width="51" height="9" font="6">Pericarditis</text>
<text top="235" left="158" width="66" height="9" font="6">Pneumothorax</text>
<text top="249" left="158" width="52" height="9" font="6">Pneumonia</text>
<text top="263" left="158" width="37" height="9" font="6">Pleuritis</text>
<text top="235" left="280" width="28" height="9" font="6">Biliary</text>
<text top="249" left="280" width="22" height="9" font="6">Colic</text>
<text top="263" left="290" width="147" height="9" font="6">Cholecystitis Choledocholithiasis</text>
<text top="277" left="290" width="50" height="9" font="6">Cholangitis</text>
<text top="292" left="280" width="53" height="9" font="6">Peptic ulcer</text>
<text top="306" left="280" width="54" height="9" font="6">Pancreatitis</text>
<text top="235" left="628" width="161" height="9" font="6">Affective disorders (i.e., depression)</text>
<text top="249" left="628" width="98" height="9" font="6">Somatiform disorders</text>
<text top="263" left="628" width="177" height="9" font="6">Thought disorders (i.e., fixed delusions)</text>
<text top="343" left="59" width="126" height="7" font="17">Reproduced from Gibbons et al. <a href="e44.full.html#85">(</a></text>
<text top="343" left="185" width="5" height="7" font="22"><a href="e44.full.html#85">7</a></text>
<text top="343" left="190" width="5" height="7" font="17"><a href="e44.full.html#85">).</a></text>
<text top="669" left="59" width="325" height="11" font="13">Table 8. Conditions Provoking or Exacerbating Ischemia</text>
<text top="694" left="71" width="126" height="9" font="6">Increased Oxygen Demand</text>
<text top="694" left="262" width="123" height="9" font="6">Decreased Oxygen Supply</text>
<text top="711" left="59" width="51" height="9" font="8"><i>Noncardiac</i></text>
<text top="711" left="229" width="51" height="9" font="8"><i>Noncardiac</i></text>
<text top="728" left="69" width="61" height="9" font="6">Hyperthermia</text>
<text top="743" left="69" width="73" height="9" font="6">Hyperthyroidism</text>
<text top="757" left="69" width="118" height="9" font="6">Sympathomimetic toxicity</text>
<text top="771" left="83" width="79" height="9" font="6">(i.e., cocaine use)</text>
<text top="785" left="69" width="59" height="9" font="6">Hypertension</text>
<text top="800" left="69" width="33" height="9" font="6">Anxiety</text>
<text top="814" left="69" width="98" height="9" font="6">Arteriovenous fistulae</text>
<text top="728" left="240" width="35" height="9" font="6">Anemia</text>
<text top="743" left="240" width="50" height="9" font="6">Hypoxemia</text>
<text top="757" left="250" width="52" height="9" font="6">Pneumonia</text>
<text top="771" left="250" width="35" height="9" font="6">Asthma</text>
<text top="785" left="250" width="138" height="9" font="6">Chronic obstructive pulmonary</text>
<text top="800" left="277" width="34" height="9" font="6">disease</text>
<text top="814" left="250" width="110" height="9" font="6">Pulmonary hypertension</text>
<text top="828" left="250" width="132" height="9" font="6">Interstitial pulmonary fibrosis</text>
<text top="842" left="250" width="109" height="9" font="6">Obstructive sleep apnea</text>
<text top="857" left="240" width="83" height="9" font="6">Sickle cell disease</text>
<text top="871" left="240" width="178" height="9" font="6">Sympathomimetic toxicity (i.e., cocaine</text>
<text top="885" left="265" width="115" height="9" font="6">use, pheochromocytoma)</text>
<text top="899" left="240" width="64" height="9" font="6">Hyperviscosity</text>
<text top="914" left="240" width="61" height="9" font="6">Polycythemia</text>
<text top="928" left="250" width="45" height="9" font="6">Leukemia</text>
<text top="942" left="250" width="71" height="9" font="6">Thrombocytosis</text>
<text top="956" left="250" width="120" height="9" font="6">Hypergammaglobulinemia</text>
<text top="974" left="59" width="34" height="9" font="8"><i>Cardiac</i></text>
<text top="974" left="229" width="34" height="9" font="8"><i>Cardiac</i></text>
<text top="991" left="69" width="132" height="9" font="6">Hypertrophic cardiomyopathy</text>
<text top="1005" left="69" width="66" height="9" font="6">Aortic stenosis</text>
<text top="1019" left="69" width="107" height="9" font="6">Dilated cardiomyopathy</text>
<text top="1034" left="69" width="54" height="9" font="6">Tachycardia</text>
<text top="1048" left="80" width="49" height="9" font="6">Ventricular</text>
<text top="1062" left="80" width="74" height="9" font="6">Supraventricular</text>
<text top="991" left="240" width="66" height="9" font="6">Aortic stenosis</text>
<text top="1005" left="240" width="132" height="9" font="6">Hypertrophic cardiomyopathy</text>
<text top="1019" left="240" width="143" height="9" font="6">Significant coronary obstruction</text>
<text top="1034" left="240" width="100" height="9" font="6">Microvascular disease</text>
<text top="1100" left="59" width="114" height="7" font="17">Modified from Gibbons et al. <a href="e44.full.html#85">(</a></text>
<text top="1100" left="172" width="5" height="7" font="22"><a href="e44.full.html#85">7</a></text>
<text top="1100" left="177" width="5" height="7" font="17"><a href="e44.full.html#85">).</a></text>
<text top="52" left="787" width="18" height="10" font="12">e61</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1161" width="864">
<text top="350" left="59" width="360" height="16" font="4">The second is for a high-risk patient who smokes and has</text>
<text top="368" left="59" width="360" height="16" font="4">diabetes mellitus and hyperlipidemia but has a normal</text>
<text top="386" left="59" width="360" height="16" font="4">ECG. A key contribution of the Duke Databank is the</text>
<text top="404" left="59" width="360" height="16" font="4">value of incorporating data about risk factors into the</text>
<text top="422" left="59" width="124" height="16" font="4">probability estimate.</text>
<text top="440" left="74" width="345" height="16" font="4">A limitation of these predictive models, however, is that</text>
<text top="458" left="59" width="360" height="16" font="4">because they were developed with data from patients re-</text>
<text top="476" left="59" width="360" height="16" font="4">ferred to university medical centers, they tended to overes-</text>
<text top="494" left="59" width="360" height="16" font="4">timate the likelihood of IHD in patients at lower risk. It is</text>
<text top="512" left="59" width="360" height="16" font="4">possible to correct this referral (or ascertainment) bias by</text>
<text top="530" left="59" width="360" height="16" font="4">using the overall prevalence of IHD in the primary-care</text>
<text top="548" left="59" width="74" height="16" font="4">population <a href="e44.full.html#87">(</a></text>
<text top="548" left="133" width="15" height="16" font="16"><a href="e44.full.html#87">72</a></text>
<text top="548" left="148" width="271" height="16" font="4"><a href="e44.full.html#87">), </a>although these adjustments are themselves</text>
<text top="566" left="59" width="330" height="16" font="4">subject to error if the prevalence estimates are flawed.</text>
<text top="584" left="74" width="345" height="16" font="4">An additional limitation of these models is that they were</text>
<text top="602" left="59" width="222" height="16" font="4">derived from populations of patients</text>
<text top="599" left="285" width="133" height="20" font="4">ⱕ70 years of age. Yet</text>
<text top="620" left="59" width="360" height="16" font="4">another drawback is that they perform less well in women,</text>
<text top="638" left="59" width="360" height="16" font="4">in part because the prevalence of obstructive CAD is lower</text>
<text top="656" left="59" width="217" height="16" font="4">in women than in men. As shown in</text>
<text top="656" left="279" width="46" height="16" font="16"><a href="e44.full.html#19">Table 9</a></text>
<text top="656" left="325" width="94" height="16" font="4"><a href="e44.full.html#19">, </a>the Diamond-</text>
<text top="674" left="59" width="360" height="16" font="4">Forrester model substantially overestimates the likelihood of</text>
<text top="692" left="59" width="360" height="16" font="4">CAD compared with the prevalence observed in the WISE</text>
<text top="710" left="59" width="42" height="16" font="4">study <a href="e44.full.html#87">(</a></text>
<text top="710" left="101" width="34" height="16" font="16"><a href="e44.full.html#87">52,74</a></text>
<text top="710" left="134" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="728" left="74" width="345" height="16" font="4">After integrating data from the clinical evaluation, model</text>
<text top="746" left="59" width="360" height="16" font="4">predictions, and other relevant factors to develop a proba-</text>
<text top="764" left="59" width="360" height="16" font="4">bility estimate, the clinician must then engage the patient in</text>
<text top="782" left="59" width="286" height="16" font="4">a process of shared decision making, as noted in</text>
<text top="782" left="347" width="67" height="16" font="16"><a href="e44.full.html#13">Section 1.8</a></text>
<text top="782" left="415" width="4" height="16" font="4"><a href="e44.full.html#13">,</a></text>
<text top="800" left="59" width="308" height="16" font="4">to determine whether further testing is warranted.</text>
<text top="394" left="446" width="315" height="12" font="18">2.2. Noninvasive Testing for Diagnosis of IHD</text>
<text top="421" left="446" width="344" height="16" font="26"><b>2.2.1. Approach to the Selection of Diagnostic Tests</b></text>
<text top="439" left="446" width="124" height="16" font="26"><b>to Diagnose SIHD</b></text>
<text top="464" left="446" width="360" height="16" font="4">Functional or stress testing to detect inducible ischemia has</text>
<text top="482" left="446" width="360" height="16" font="4">been the “gold standard” and is the most common nonin-</text>
<text top="500" left="446" width="360" height="16" font="4">vasive test used to diagnose SIHD. All functional tests are</text>
<text top="518" left="446" width="360" height="16" font="4">designed to provoke cardiac ischemia by using exercise or</text>
<text top="536" left="446" width="360" height="16" font="4">pharmacological stress agents either to increase myocardial</text>
<text top="554" left="446" width="360" height="16" font="4">work and oxygen demand or to induce vasodilation-elicited</text>
<text top="572" left="446" width="360" height="16" font="4">heterogeneity in induced coronary flow. These techniques</text>
<text top="590" left="446" width="360" height="16" font="4">rely on the principles embodied within the ischemic cascade</text>
<text top="608" left="446" width="5" height="16" font="4"><a href="e44.full.html#19">(</a></text>
<text top="608" left="450" width="52" height="16" font="16"><a href="e44.full.html#19">Figure 7</a></text>
<text top="608" left="502" width="303" height="16" font="4"><a href="e44.full.html#19">), </a>in which graded ischemia of increasing severity</text>
<text top="626" left="446" width="360" height="16" font="4">and duration produces sequential changes in perfusion,</text>
<text top="644" left="446" width="360" height="16" font="4">relaxation and contraction, wall motion, repolarization, and,</text>
<text top="662" left="446" width="360" height="16" font="4">ultimately, symptoms, all of which can be detected by an</text>
<text top="680" left="446" width="255" height="16" font="4">array of cardiovascular testing modalities <a href="e44.full.html#87">(</a></text>
<text top="680" left="700" width="15" height="16" font="16"><a href="e44.full.html#87">75</a></text>
<text top="680" left="715" width="90" height="16" font="4"><a href="e44.full.html#87">). </a>The produc-</text>
<text top="698" left="446" width="360" height="16" font="4">tion of ischemia, however, depends on the severity of stress</text>
<text top="716" left="446" width="360" height="16" font="4">imposed (i.e., submaximal exercise can fail to produce</text>
<text top="734" left="446" width="360" height="16" font="4">ischemia) and the severity of the flow disturbance. Coronary</text>
<text top="752" left="446" width="49" height="16" font="4">stenoses</text>
<text top="749" left="500" width="303" height="20" font="4">⬍70% are often undetected by functional testing.</text>
<text top="770" left="461" width="345" height="16" font="4">Because abnormalities of regional or global ventricular</text>
<text top="788" left="446" width="360" height="16" font="4">function occur later in the ischemic cascade, they are more</text>
<text top="806" left="446" width="360" height="16" font="4">likely to indicate severe stenosis and, thus, demonstrate a</text>
<text top="824" left="446" width="360" height="16" font="4">higher diagnostic specificity for SIHD than do perfusion</text>
<text top="842" left="446" width="360" height="16" font="4">defects, such as those seen on nuclear MPI. Isolated</text>
<text top="860" left="446" width="360" height="16" font="4">perfusion defects, on the other hand, can result from</text>
<text top="878" left="446" width="360" height="16" font="4">stenoses of borderline significance, raising the sensitivity of</text>
<text top="896" left="446" width="360" height="16" font="4">nuclear MPI for underlying CAD but lowering the speci-</text>
<text top="914" left="446" width="185" height="16" font="4">ficity for more severe stenosis.</text>
<text top="932" left="461" width="345" height="16" font="4">The recent availability of multislice CCTA allows for the</text>
<text top="950" left="446" width="360" height="16" font="4">noninvasive visualization of anatomic CAD with high-</text>
<text top="968" left="446" width="360" height="16" font="4">resolution images similar to invasive coronary angiography.</text>
<text top="986" left="446" width="360" height="16" font="4">As would be expected, CCTA and invasive angiography</text>
<text top="1004" left="446" width="360" height="16" font="4">exhibit a high degree of concordance, as they are both</text>
<text top="1022" left="446" width="360" height="16" font="4">anatomic tests, and CCTA is more sensitive in detecting</text>
<text top="1040" left="446" width="310" height="16" font="4">obstructive CAD, especially at diameter stenosis</text>
<text top="1037" left="763" width="43" height="20" font="4">ⱕ70%,</text>
<text top="1058" left="446" width="134" height="16" font="4">than is nuclear MPI <a href="e44.full.html#87">(</a></text>
<text top="1058" left="580" width="15" height="16" font="16"><a href="e44.full.html#87">76</a></text>
<text top="1058" left="595" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="1076" left="461" width="345" height="16" font="4">The accuracy of a CCTA reader in estimating coronary</text>
<text top="1094" left="446" width="360" height="16" font="4">stenosis within a vessel is hindered by the presence of dense</text>
<text top="105" left="59" width="347" height="11" font="13">Table 9. Pretest Likelihood of CAD in Symptomatic Patients</text>
<text top="121" left="59" width="337" height="11" font="13">According to Age and Sex* (Combined Diamond/Forrester</text>
<text top="137" left="59" width="93" height="11" font="13">and CASS Data)</text>
<text top="162" left="131" width="52" height="9" font="6">Nonanginal</text>
<text top="175" left="132" width="52" height="9" font="6">Chest Pain</text>
<text top="175" left="230" width="74" height="9" font="6">Atypical Angina</text>
<text top="175" left="342" width="69" height="9" font="6">Typical Angina</text>
<text top="198" left="59" width="30" height="9" font="6">Age, y</text>
<text top="198" left="116" width="21" height="9" font="6">Men</text>
<text top="198" left="164" width="35" height="9" font="6">Women</text>
<text top="198" left="226" width="21" height="9" font="6">Men</text>
<text top="198" left="273" width="35" height="9" font="6">Women</text>
<text top="198" left="335" width="21" height="9" font="6">Men</text>
<text top="198" left="383" width="35" height="9" font="6">Women</text>
<text top="215" left="59" width="30" height="9" font="6">30–39</text>
<text top="215" left="126" width="6" height="9" font="6">4</text>
<text top="215" left="181" width="6" height="9" font="6">2</text>
<text top="215" left="230" width="12" height="9" font="6">34</text>
<text top="215" left="285" width="12" height="9" font="6">12</text>
<text top="215" left="339" width="12" height="9" font="6">76</text>
<text top="215" left="394" width="12" height="9" font="6">26</text>
<text top="232" left="59" width="30" height="9" font="6">40–49</text>
<text top="232" left="120" width="12" height="9" font="6">13</text>
<text top="232" left="181" width="6" height="9" font="6">3</text>
<text top="232" left="230" width="12" height="9" font="6">51</text>
<text top="232" left="285" width="12" height="9" font="6">22</text>
<text top="232" left="339" width="12" height="9" font="6">87</text>
<text top="232" left="394" width="12" height="9" font="6">55</text>
<text top="249" left="59" width="30" height="9" font="6">50–59</text>
<text top="249" left="120" width="12" height="9" font="6">20</text>
<text top="249" left="181" width="6" height="9" font="6">7</text>
<text top="249" left="230" width="12" height="9" font="6">65</text>
<text top="249" left="285" width="12" height="9" font="6">31</text>
<text top="249" left="339" width="12" height="9" font="6">93</text>
<text top="249" left="394" width="12" height="9" font="6">73</text>
<text top="267" left="59" width="30" height="9" font="6">60–69</text>
<text top="267" left="120" width="12" height="9" font="6">27</text>
<text top="267" left="175" width="12" height="9" font="6">14</text>
<text top="267" left="230" width="12" height="9" font="6">72</text>
<text top="267" left="285" width="12" height="9" font="6">51</text>
<text top="267" left="339" width="12" height="9" font="6">94</text>
<text top="267" left="394" width="12" height="9" font="6">86</text>
<text top="304" left="59" width="308" height="7" font="17">CAD indicates coronary artery disease; and CASS, Coronary Artery Surgery Study.</text>
<text top="316" left="67" width="287" height="7" font="17">*Each value represents the percent with significant CAD on catheterization.</text>
<text top="328" left="67" width="146" height="7" font="17">Adapted from Forrester and Diamond <a href="e44.full.html#87">(</a></text>
<text top="328" left="213" width="23" height="7" font="22"><a href="e44.full.html#87">52,73</a></text>
<text top="328" left="236" width="5" height="7" font="17"><a href="e44.full.html#87">).</a></text>
<text top="829" left="59" width="344" height="11" font="13">Table 10. Comparing Pretest Likelihood of CAD in Low-Risk</text>
<text top="845" left="59" width="348" height="11" font="13">Symptomatic Patients With High-Risk Symptomatic Patients</text>
<text top="860" left="59" width="97" height="11" font="13">(Duke Database)</text>
<text top="886" left="129" width="52" height="9" font="6">Nonanginal</text>
<text top="898" left="129" width="52" height="9" font="6">Chest Pain</text>
<text top="898" left="228" width="74" height="9" font="6">Atypical Angina</text>
<text top="898" left="340" width="69" height="9" font="6">Typical Angina</text>
<text top="921" left="59" width="30" height="9" font="6">Age, y</text>
<text top="921" left="116" width="21" height="9" font="6">Men</text>
<text top="921" left="164" width="35" height="9" font="6">Women</text>
<text top="921" left="226" width="21" height="9" font="6">Men</text>
<text top="921" left="273" width="35" height="9" font="6">Women</text>
<text top="921" left="335" width="21" height="9" font="6">Men</text>
<text top="921" left="383" width="35" height="9" font="6">Women</text>
<text top="939" left="68" width="12" height="9" font="6">35</text>
<text top="939" left="118" width="24" height="9" font="6">3–35</text>
<text top="939" left="169" width="24" height="9" font="6">1–19</text>
<text top="939" left="227" width="24" height="9" font="6">8–59</text>
<text top="939" left="282" width="24" height="9" font="6">2–39</text>
<text top="939" left="331" width="30" height="9" font="6">30–88</text>
<text top="939" left="385" width="30" height="9" font="6">10–78</text>
<text top="956" left="68" width="12" height="9" font="6">45</text>
<text top="956" left="118" width="24" height="9" font="6">9–47</text>
<text top="956" left="169" width="24" height="9" font="6">2–22</text>
<text top="956" left="221" width="30" height="9" font="6">21–70</text>
<text top="956" left="282" width="24" height="9" font="6">5–43</text>
<text top="956" left="331" width="30" height="9" font="6">51–92</text>
<text top="956" left="385" width="30" height="9" font="6">20–79</text>
<text top="973" left="68" width="12" height="9" font="6">55</text>
<text top="973" left="111" width="30" height="9" font="6">23–59</text>
<text top="973" left="169" width="24" height="9" font="6">4–21</text>
<text top="973" left="221" width="30" height="9" font="6">45–79</text>
<text top="973" left="276" width="30" height="9" font="6">10–47</text>
<text top="973" left="331" width="30" height="9" font="6">80–95</text>
<text top="973" left="385" width="30" height="9" font="6">38–82</text>
<text top="990" left="68" width="12" height="9" font="6">65</text>
<text top="990" left="111" width="30" height="9" font="6">49–69</text>
<text top="990" left="169" width="24" height="9" font="6">9–29</text>
<text top="990" left="221" width="30" height="9" font="6">71–86</text>
<text top="990" left="276" width="30" height="9" font="6">20–51</text>
<text top="990" left="331" width="30" height="9" font="6">93–97</text>
<text top="990" left="385" width="30" height="9" font="6">56–84</text>
<text top="1028" left="59" width="360" height="7" font="17">Each value represents the percentage with significant CAD. The first is the percentage for a</text>
<text top="1040" left="59" width="360" height="7" font="17">low-risk, mid-decade patient without diabetes mellitus, smoking, or hyperlipidemia. The second</text>
<text top="1052" left="59" width="360" height="7" font="17">is that of a patient of the same age with diabetes mellitus, smoking, and hyperlipidemia. Both</text>
<text top="1064" left="59" width="360" height="7" font="17">high- and low-risk patients have normal resting ECGs. If ST-T-wave changes or Q waves had been</text>
<text top="1076" left="59" width="278" height="7" font="17">present, the likelihood of CAD would be higher in each entry of the table.</text>
<text top="1088" left="67" width="258" height="7" font="17">CAD indicates coronary artery disease; and ECG, electrocardiogram.</text>
<text top="1100" left="67" width="106" height="7" font="17">Reprinted from Pryor et al. <a href="e44.full.html#87">(</a></text>
<text top="1100" left="173" width="10" height="7" font="22"><a href="e44.full.html#87">71</a></text>
<text top="1100" left="183" width="5" height="7" font="17"><a href="e44.full.html#87">).</a></text>
<text top="329" left="446" width="180" height="11" font="13">Figure 7. The Ischemic Cascade</text>
<text top="361" left="446" width="202" height="8" font="11">Reproduced with permission from Shaw et al. <a href="e44.full.html#87">(</a></text>
<text top="361" left="647" width="12" height="8" font="23"><a href="e44.full.html#87">75</a></text>
<text top="361" left="659" width="6" height="8" font="11"><a href="e44.full.html#87">).</a></text>
<text top="52" left="59" width="18" height="10" font="12">e62</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">coronary calcification and a tendency to overestimate the</text>
<text top="123" left="59" width="312" height="16" font="4">severity of lesions relative to invasive angiography <a href="e44.full.html#87">(</a></text>
<text top="123" left="371" width="15" height="16" font="16"><a href="e44.full.html#87">77</a></text>
<text top="123" left="386" width="33" height="16" font="4"><a href="e44.full.html#87">). </a>No</text>
<text top="141" left="59" width="360" height="16" font="4">direct comparisons of the effectiveness of a functional</text>
<text top="159" left="59" width="360" height="16" font="4">approach with inducible ischemia or an anatomic approach</text>
<text top="177" left="59" width="360" height="16" font="4">assessing coronary stenosis have been completed in the</text>
<text top="195" left="59" width="360" height="16" font="4">noninvasive setting, although several randomized controlled</text>
<text top="213" left="59" width="360" height="16" font="4">trials (RCTs) are under way, which will directly or indirectly</text>
<text top="232" left="59" width="360" height="16" font="4">compare test modalities: PROMISE (Prospective Multi-</text>
<text top="250" left="59" width="322" height="16" font="4">center Imaging Study for Evaluation of Chest Pain;</text>
<text top="250" left="386" width="32" height="16" font="16"><a href="http://www.clinicaltrials.gov">clini-</a></text>
<text top="268" left="59" width="71" height="16" font="16"><a href="http://www.clinicaltrials.gov">caltrials.gov</a></text>
<text top="268" left="138" width="55" height="16" font="4">identifier</text>
<text top="268" left="201" width="94" height="16" font="16"><a href="http://www.clinicaltrials.gov/ct2/show/NCT01174550?term=NCT01174550&amp;rank=1">NCT01174550</a></text>
<text top="268" left="295" width="124" height="16" font="4"><a href="http://www.clinicaltrials.gov/ct2/show/NCT01174550?term=NCT01174550&amp;rank=1">), </a>RESCUE (Ran-</text>
<text top="286" left="58" width="360" height="16" font="4">domized Evaluation of Patients With Stable Angina</text>
<text top="304" left="58" width="249" height="16" font="4">Comparing Diagnostic Examinations;</text>
<text top="304" left="318" width="101" height="16" font="16"><a href="http://www.clinicaltrials.gov">clinicaltrials.gov</a></text>
<text top="322" left="58" width="55" height="16" font="4">identifier</text>
<text top="322" left="118" width="94" height="16" font="16"><a href="http://www.clinicaltrials.gov/ct2/show/NCT01262625?term=NCT01262625&amp;rank=1">NCT01262625</a></text>
<text top="322" left="211" width="207" height="16" font="4"><a href="http://www.clinicaltrials.gov/ct2/show/NCT01262625?term=NCT01262625&amp;rank=1">), </a>and ISCHEMIA (International</text>
<text top="341" left="58" width="360" height="16" font="4">Study of Comparative Health Effectiveness with Medical</text>
<text top="359" left="58" width="176" height="16" font="4">and Invasive Approaches;</text>
<text top="359" left="245" width="104" height="16" font="16"><a href="http://www.clinicaltrials.gov">clinicaltrials.gov</a></text>
<text top="359" left="360" width="58" height="16" font="4">identifier</text>
<text top="377" left="58" width="94" height="16" font="16"><a href="http://www.clinicaltrials.gov/ct2/show/NCT01471522?term=NCT01471522&amp;rank=1">NCT01471522</a></text>
<text top="377" left="152" width="9" height="16" font="4"><a href="http://www.clinicaltrials.gov/ct2/show/NCT01471522?term=NCT01471522&amp;rank=1">).</a></text>
<text top="395" left="73" width="345" height="16" font="4">In 2010, the United Kingdom’s National Institute for</text>
<text top="413" left="58" width="360" height="16" font="4">Clinical Excellence Guidance for “Chest pain of recent</text>
<text top="431" left="58" width="360" height="16" font="4">onset: Assessment and diagnosis of recent onset chest pain</text>
<text top="450" left="58" width="360" height="16" font="4">or discomfort of suspected cardiac origin” provide, for a</text>
<text top="468" left="58" width="360" height="16" font="4">healthcare system that allocates resources differently from</text>
<text top="486" left="58" width="360" height="16" font="4">that of the United States, recommendations for an initial</text>
<text top="504" left="58" width="360" height="16" font="4">assessment of CAD. This Guidance recommends beginning</text>
<text top="522" left="58" width="360" height="16" font="4">in people without confirmed CAD with a detailed clinical</text>
<text top="540" left="58" width="360" height="16" font="4">assessment and performing a 12-lead ECG in those in</text>
<text top="559" left="58" width="360" height="16" font="4">whom stable angina cannot be diagnosed or excluded on the</text>
<text top="577" left="58" width="360" height="16" font="4">basis of clinical assessment alone. The Guidance suggests</text>
<text top="595" left="58" width="360" height="16" font="4">that there is no need for further testing in those with an</text>
<text top="613" left="58" width="126" height="16" font="4">estimated likelihood</text>
<text top="610" left="192" width="226" height="20" font="4">⬍10%. In those with an estimated</text>
<text top="631" left="58" width="360" height="16" font="4">likelihood of CAD of 10% to 29%, the National Institute</text>
<text top="649" left="58" width="360" height="16" font="4">for Clinical Excellence document recommends beginning</text>
<text top="668" left="58" width="360" height="16" font="4">with CT coronary artery calcium (CAC) scoring as the</text>
<text top="686" left="58" width="360" height="16" font="4">first-line diagnostic investigation, whereas the present</text>
<text top="704" left="58" width="360" height="16" font="4">SIHD guideline provides a Class IIb recommendation for</text>
<text top="722" left="58" width="181" height="16" font="4">several reasons, as outlined in</text>
<text top="722" left="245" width="91" height="16" font="16"><a href="e44.full.html#27">Section 2.2.4.2</a></text>
<text top="722" left="336" width="4" height="16" font="4"><a href="e44.full.html#27">.</a></text>
<text top="753" left="59" width="264" height="9" font="6">2.2.1.1. ASSESSING DIAGNOSTIC TEST CHARACTERISTICS</text>
<text top="768" left="59" width="360" height="16" font="4">A hierarchy of diagnostic test evidence has been proposed</text>
<text top="786" left="59" width="177" height="16" font="4">by Fryback and Thornbury <a href="e44.full.html#87">(</a></text>
<text top="786" left="235" width="15" height="16" font="16"><a href="e44.full.html#87">78</a></text>
<text top="786" left="250" width="168" height="16" font="4"><a href="e44.full.html#87">) </a>and ranges from evidence</text>
<text top="804" left="59" width="360" height="16" font="4">on technical quality (level 1) through test accuracy (sensi-</text>
<text top="822" left="59" width="360" height="16" font="4">tivity and specificity associated with test interpretation), to</text>
<text top="840" left="59" width="360" height="16" font="4">changes in diagnostic thinking, effect on patient manage-</text>
<text top="858" left="59" width="360" height="16" font="4">ment, and patient outcomes, to societal costs and benefits</text>
<text top="877" left="59" width="360" height="16" font="4">(level 6). A similar framework has been proposed for</text>
<text top="895" left="59" width="194" height="16" font="4">biomarkers by Hlatky et al. <a href="e44.full.html#87">(</a></text>
<text top="895" left="253" width="15" height="16" font="16"><a href="e44.full.html#87">79</a></text>
<text top="895" left="268" width="151" height="16" font="4"><a href="e44.full.html#87">). </a>In practice, although</text>
<text top="913" left="59" width="360" height="16" font="4">knowledge of the effect of diagnostic testing on outcomes</text>
<text top="931" left="59" width="360" height="16" font="4">would be highly desirable, the vast majority of available</text>
<text top="949" left="59" width="360" height="16" font="4">evidence is on diagnostic or prognostic accuracy. Therefore,</text>
<text top="967" left="59" width="360" height="16" font="4">this information most commonly is used to compare test</text>
<text top="985" left="59" width="79" height="16" font="4">performance.</text>
<text top="1004" left="74" width="345" height="16" font="4">Diagnostic accuracy is commonly represented by the</text>
<text top="1022" left="59" width="360" height="16" font="4">terms <i>sensitivity </i>and <i>specificity</i>, which are calculated by</text>
<text top="1040" left="59" width="360" height="16" font="4">comparing test results to the “gold standard” of the results of</text>
<text top="1058" left="59" width="360" height="16" font="4">invasive coronary angiography. The sensitivity of any non-</text>
<text top="1076" left="59" width="360" height="16" font="4">invasive test to diagnose SIHD expresses the frequency that</text>
<text top="1094" left="59" width="360" height="16" font="4">a patient with angiographic IHD will have a positive test</text>
<text top="104" left="446" width="360" height="16" font="4">result, whereas the specificity measures the frequency that a</text>
<text top="122" left="446" width="360" height="16" font="4">patient without IHD will have a negative result. In addition,</text>
<text top="140" left="446" width="360" height="16" font="4">predictive accuracy represents the frequency that a patient</text>
<text top="158" left="446" width="360" height="16" font="4">with a positive test does have IHD (positive predictive</text>
<text top="176" left="446" width="360" height="16" font="4">value) or that a patient with a negative test truly does not</text>
<text top="194" left="446" width="360" height="16" font="4">have IHD (negative predictive value). The predictive accu-</text>
<text top="212" left="446" width="360" height="16" font="4">racy may be used for both diagnostic and prognostic</text>
<text top="230" left="446" width="360" height="16" font="4">accuracy analyses; in the latter case, the comparison is to</text>
<text top="248" left="446" width="360" height="16" font="4">subsequent cardiovascular events. It is important to note</text>
<text top="266" left="446" width="360" height="16" font="4">that apparent test performance can be altered substantially</text>
<text top="284" left="446" width="222" height="16" font="4">by the pretest probability of IHD <a href="e44.full.html#87">(</a></text>
<text top="284" left="668" width="53" height="16" font="16"><a href="e44.full.html#87">52,80,81</a></text>
<text top="284" left="720" width="85" height="16" font="4"><a href="e44.full.html#87">), </a>making the</text>
<text top="302" left="446" width="360" height="16" font="4">accurate assessment of pretest probability and proper patient</text>
<text top="320" left="446" width="360" height="16" font="4">selection essential for diagnostic interpretation statements</text>
<text top="338" left="446" width="360" height="16" font="4">on IHD prevalence by test results. The positive predictive</text>
<text top="356" left="446" width="360" height="16" font="4">value of a test declines as the disease prevalence decreases in</text>
<text top="374" left="446" width="360" height="16" font="4">the population under study, whereas the negative predictive</text>
<text top="392" left="446" width="118" height="16" font="4">accuracy increases <a href="e44.full.html#87">(</a></text>
<text top="392" left="564" width="15" height="16" font="16"><a href="e44.full.html#87">82</a></text>
<text top="392" left="579" width="227" height="16" font="4"><a href="e44.full.html#87">). </a>Finally, the performance of nonin-</text>
<text top="410" left="446" width="360" height="16" font="4">vasive tests also varies in certain patient populations, such as</text>
<text top="428" left="446" width="245" height="16" font="4">obese patients, the elderly, and women <a href="e44.full.html#71">(</a></text>
<text top="428" left="691" width="76" height="16" font="16"><a href="e44.full.html#71">Section 5.12</a></text>
<text top="428" left="767" width="39" height="16" font="4"><a href="e44.full.html#71">), </a>who</text>
<text top="446" left="446" width="278" height="16" font="4">often are underrepresented in clinical studies.</text>
<text top="464" left="461" width="345" height="16" font="4">Estimates of all test characteristics are subject to workup</text>
<text top="482" left="446" width="360" height="16" font="4">bias, also known as verification or posttest referral bias</text>
<text top="500" left="446" width="5" height="16" font="4"><a href="e44.full.html#87">(</a></text>
<text top="500" left="450" width="53" height="16" font="16"><a href="e44.full.html#87">81,83,84</a></text>
<text top="500" left="503" width="302" height="16" font="4"><a href="e44.full.html#87">). </a>This bias occurs when the results of stress</text>
<text top="518" left="446" width="360" height="16" font="4">testing are used to decide which patients undergo the</text>
<text top="536" left="446" width="360" height="16" font="4">standard reference procedure (invasive coronary angiogra-</text>
<text top="554" left="446" width="360" height="16" font="4">phy) to establish a definitive diagnosis of IHD (i.e., patients</text>
<text top="572" left="446" width="360" height="16" font="4">with positive results on stress testing are referred for</text>
<text top="590" left="446" width="360" height="16" font="4">coronary angiography, whereas those with negative results</text>
<text top="608" left="446" width="360" height="16" font="4">are not). This bias has the effect of raising the measured</text>
<text top="626" left="446" width="360" height="16" font="4">sensitivity and lowering the measured specificity in relation</text>
<text top="644" left="446" width="360" height="16" font="4">to their true values. Mathematical corrections can be applied</text>
<text top="662" left="446" width="179" height="16" font="4">to estimate corrected values <a href="e44.full.html#87">(</a></text>
<text top="662" left="624" width="41" height="16" font="16"><a href="e44.full.html#87">84 – 86</a></text>
<text top="662" left="665" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="680" left="461" width="345" height="16" font="4">Diagnostic testing is most valuable when the pretest</text>
<text top="698" left="446" width="360" height="16" font="4">probability of IHD is intermediate—for example, when a</text>
<text top="716" left="446" width="360" height="16" font="4">50-year-old man has atypical angina, and the probability of</text>
<text top="734" left="446" width="170" height="16" font="4">IHD is approximately 50% <a href="e44.full.html#19">(</a></text>
<text top="734" left="616" width="46" height="16" font="16"><a href="e44.full.html#19">Table 9</a></text>
<text top="734" left="662" width="144" height="16" font="4"><a href="e44.full.html#19">). </a>The precise definition</text>
<text top="752" left="446" width="360" height="16" font="4">of intermediate probability (i.e., between 10% and 90%,</text>
<text top="770" left="446" width="360" height="16" font="4">20% and 80%, or 30% and 70%) is somewhat arbitrary. In</text>
<text top="788" left="446" width="360" height="16" font="4">addition to these boundaries, other factors are important in</text>
<text top="806" left="446" width="360" height="16" font="4">the decision to refer a patient to testing, including the</text>
<text top="824" left="446" width="360" height="16" font="4">degree of uncertainty acceptable to the physician and</text>
<text top="842" left="446" width="360" height="16" font="4">patient; the likelihood of an alternative diagnosis; the</text>
<text top="860" left="446" width="360" height="16" font="4">accuracy of the diagnostic test selected (i.e., sensitivity and</text>
<text top="878" left="446" width="360" height="16" font="4">specificity), test reliability, procedural cost, and the potential</text>
<text top="896" left="446" width="360" height="16" font="4">risks of further testing; and the benefits and risks of</text>
<text top="914" left="446" width="360" height="16" font="4">treatment in the absence of additional testing. A definition</text>
<text top="932" left="446" width="275" height="16" font="4">of 10% and 90%, first advocated in 1980 <a href="e44.full.html#87">(</a></text>
<text top="932" left="720" width="15" height="16" font="16"><a href="e44.full.html#87">87</a></text>
<text top="932" left="735" width="70" height="16" font="4"><a href="e44.full.html#87">), </a>has been</text>
<text top="950" left="446" width="175" height="16" font="4">applied in several studies <a href="e44.full.html#87">(</a></text>
<text top="950" left="620" width="34" height="16" font="16"><a href="e44.full.html#87">88,89</a></text>
<text top="950" left="654" width="152" height="16" font="4"><a href="e44.full.html#87">). </a>Although broad, this</text>
<text top="968" left="446" width="360" height="16" font="4">range still excludes several sizable patient groups (e.g., older</text>
<text top="986" left="446" width="360" height="16" font="4">men with typical angina and younger women with nonangi-</text>
<text top="1004" left="446" width="360" height="16" font="4">nal pain). When the probability of IHD is high, a positive</text>
<text top="1022" left="446" width="360" height="16" font="4">test result is merely confirmatory, whereas a negative test</text>
<text top="1040" left="446" width="360" height="16" font="4">result might not diminish the probability of disease suffi-</text>
<text top="1058" left="446" width="360" height="16" font="4">ciently to be clinically useful and could even be misleading</text>
<text top="1076" left="446" width="360" height="16" font="4">because of the possibility that it is a false negative result.</text>
<text top="1094" left="446" width="360" height="16" font="4">When the probability of IHD is very low, however, a</text>
<text top="52" left="787" width="18" height="10" font="12">e63</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="32" size="11" family="Times" color="#3b456e"/>
<text top="104" left="59" width="360" height="16" font="4">negative test result is simply confirmatory, whereas a posi-</text>
<text top="123" left="59" width="360" height="16" font="4">tive test result might not be clinically useful and could be</text>
<text top="141" left="59" width="360" height="16" font="4">misleading if falsely positive. The importance of relying on</text>
<text top="159" left="59" width="360" height="16" font="4">clinical judgment and refraining from testing in very low-</text>
<text top="177" left="59" width="360" height="16" font="4">risk populations is well illustrated by a thought experiment</text>
<text top="195" left="59" width="360" height="16" font="4">proposed by Diamond and Kaul in a letter to the editor of</text>
<text top="213" left="59" width="233" height="16" font="5"><i>The New England Journal of Medicine</i>:</text>
<text top="242" left="77" width="324" height="14" font="14">“As an example, suppose we have a test marker with 80%</text>
<text top="258" left="77" width="324" height="14" font="14">sensitivity and 80% specificity (typical of cardiac stress tests).</text>
<text top="275" left="77" width="324" height="14" font="14">Given 100 individuals with a10% disease prevalence, there</text>
<text top="292" left="77" width="163" height="14" font="14">will be 8 true positives (100</text>
<text top="289" left="245" width="155" height="18" font="14">⫻ 0.1 ⫻ 0.8) and 18 false</text>
<text top="308" left="77" width="78" height="14" font="14">positives (100</text>
<text top="305" left="161" width="239" height="18" font="14">⫻ 0.9 ⫻ 0.2). If we refer only these 26</text>
<text top="325" left="77" width="324" height="14" font="14">positive responders for angiography, the observed “diagnos-</text>
<text top="341" left="77" width="324" height="14" font="14">tic yield” is only 31% (8/26). Moreover, the test’s sensitivity</text>
<text top="358" left="77" width="324" height="14" font="14">will appear to be 100% (all diseased subjects having a</text>
<text top="375" left="77" width="324" height="14" font="14">positive test), and its specificity will appear to be 0% (all</text>
<text top="391" left="77" width="324" height="14" font="14">non-diseased subjects also having a positive test). Hence,</text>
<text top="408" left="77" width="324" height="14" font="14">the more we rely on a test, the less well it appears to</text>
<text top="425" left="77" width="61" height="14" font="14">perform.” <a href="e44.full.html#87">(</a></text>
<text top="425" left="137" width="14" height="14" font="32"><a href="e44.full.html#87">90</a></text>
<text top="425" left="151" width="41" height="14" font="14"><a href="e44.full.html#87">, </a>p. 93)</text>
<text top="451" left="59" width="360" height="16" font="4">The likelihood of CAD proposed above differs substantially</text>
<text top="469" left="59" width="360" height="16" font="4">from that in the populations from which the estimates of</text>
<text top="487" left="59" width="360" height="16" font="4">noninvasive test performance were derived; the overall</text>
<text top="505" left="59" width="336" height="16" font="4">prevalence of CAD from a meta-analysis was 60% <a href="e44.full.html#87">(</a></text>
<text top="505" left="395" width="15" height="16" font="16"><a href="e44.full.html#87">91</a></text>
<text top="505" left="410" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="523" left="59" width="360" height="16" font="4">Instead, contemporary age-, sex-, and symptom-based IHD</text>
<text top="541" left="59" width="360" height="16" font="4">probability estimates can be gleaned from a multicenter</text>
<text top="559" left="59" width="360" height="16" font="4">cohort of 14,048 patients with suspected IHD undergoing</text>
<text top="578" left="59" width="54" height="16" font="4">CCTA <a href="e44.full.html#87">(</a></text>
<text top="578" left="113" width="15" height="16" font="16"><a href="e44.full.html#87">92</a></text>
<text top="578" left="128" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="609" left="59" width="280" height="9" font="6">2.2.1.2. SAFETY AND OTHER CONSIDERATIONS POTENTIALLY</text>
<text top="627" left="59" width="128" height="9" font="6">AFFECTING TEST SELECTION</text>
<text top="641" left="59" width="360" height="16" font="4">All forms of noninvasive stress testing carry some risk.</text>
<text top="659" left="59" width="360" height="16" font="4">Maximal exercise testing is associated with a low but finite</text>
<text top="677" left="59" width="360" height="16" font="4">incidence of cardiac arrest, AMI, and even death. Pharma-</text>
<text top="695" left="59" width="360" height="16" font="4">cological stress agents fall into 2 broad categories: beta-</text>
<text top="714" left="59" width="360" height="16" font="4">agonists such as dobutamine, which increase heart rate and</text>
<text top="732" left="59" width="360" height="16" font="4">inotropy, and vasodilators such as adenosine, dipyridamole,</text>
<text top="750" left="59" width="360" height="16" font="4">or regadenoson, which act to increase blood flow to normal</text>
<text top="768" left="59" width="360" height="16" font="4">arteries while decreasing perfusion to stenotic vessels. Each</text>
<text top="786" left="59" width="360" height="16" font="4">of these pharmacological stress agents also carries a very</text>
<text top="804" left="59" width="360" height="16" font="4">small risk of drug-specific adverse events (dobutamine:</text>
<text top="822" left="59" width="360" height="16" font="4">ventricular arrhythmias; dipyridamole/adenosine: broncho-</text>
<text top="841" left="59" width="300" height="16" font="4">spasm in chronic obstructive pulmonary disease).</text>
<text top="859" left="74" width="345" height="16" font="4">Nuclear perfusion imaging and CCTA use ionizing</text>
<text top="877" left="59" width="360" height="16" font="4">radiation techniques for visualizing myocardial perfusion</text>
<text top="895" left="59" width="360" height="16" font="4">and anatomic CAD, respectively. Risk projections are based</text>
<text top="913" left="59" width="360" height="16" font="4">largely on observations from atomic bomb survivors exposed</text>
<text top="931" left="59" width="360" height="16" font="4">to higher levels of ionizing radiation. The Linear-No-</text>
<text top="949" left="59" width="360" height="16" font="4">Threshold hypothesis states that any exposure could result</text>
<text top="967" left="59" width="360" height="16" font="4">in an increased projected cancer risk and that there is a</text>
<text top="986" left="59" width="360" height="16" font="4">dose–response relationship to elevated cancer risk with</text>
<text top="1004" left="59" width="360" height="16" font="4">higher exposures. Considerable controversy exists surround-</text>
<text top="1022" left="59" width="360" height="16" font="4">ing the extrapolation of projected cancer risk to low-level</text>
<text top="1040" left="59" width="360" height="16" font="4">exposure in medical testing, and no reported evidence links</text>
<text top="1058" left="59" width="360" height="16" font="4">low-level exposure to observed cancer risk. Even when the</text>
<text top="1076" left="59" width="360" height="16" font="4">Linear-No-Threshold hypothesis is used, the projected</text>
<text top="1094" left="59" width="360" height="16" font="4">incident cancer is estimated to be very low for nuclear MPI</text>
<text top="104" left="446" width="79" height="16" font="4">and CCTA <a href="e44.full.html#87">(</a></text>
<text top="104" left="525" width="38" height="16" font="16"><a href="e44.full.html#87">93–95</a></text>
<text top="104" left="562" width="243" height="16" font="4"><a href="e44.full.html#87">). </a>Nevertheless, general agreement exists</text>
<text top="122" left="446" width="360" height="16" font="4">that the overriding principle of caution and safety should</text>
<text top="140" left="446" width="353" height="16" font="4">apply by projecting the Linear-No-Threshold hypothesis.</text>
<text top="158" left="461" width="345" height="16" font="4">The principle of As Low as Reasonably Achievable</text>
<text top="176" left="446" width="360" height="16" font="4">(ALARA) should be applied in all patient populations. For</text>
<text top="194" left="446" width="360" height="16" font="4">CCTA performed with contemporary equipment in accor-</text>
<text top="212" left="446" width="360" height="16" font="4">dance with the Society of Cardiovascular Computed To-</text>
<text top="230" left="446" width="360" height="16" font="4">mography recommendations, average estimated radiation</text>
<text top="248" left="446" width="190" height="16" font="4">dose ranges from 5 to 10 mSv <a href="e44.full.html#88">(</a></text>
<text top="248" left="635" width="15" height="16" font="16"><a href="e44.full.html#88">96</a></text>
<text top="248" left="650" width="155" height="16" font="4"><a href="e44.full.html#88">). </a>For stress nuclear MPI,</text>
<text top="266" left="446" width="360" height="16" font="4">when the American Society of Nuclear Cardiology–</text>
<text top="284" left="446" width="360" height="16" font="4">recommended rest-stress Tc-99m SPECT or Rb-82 posi-</text>
<text top="302" left="446" width="268" height="16" font="4">tron emission tomography (PET) protocol <a href="e44.full.html#88">(</a></text>
<text top="302" left="713" width="15" height="16" font="16"><a href="e44.full.html#88">97</a></text>
<text top="302" left="728" width="78" height="16" font="4"><a href="e44.full.html#88">) </a>is used, the</text>
<text top="320" left="446" width="360" height="16" font="4">estimated radiation dose is approximately 11 or 3 mSV,</text>
<text top="338" left="446" width="80" height="16" font="4">respectively <a href="e44.full.html#88">(</a></text>
<text top="338" left="526" width="34" height="16" font="16"><a href="e44.full.html#88">97,98</a></text>
<text top="338" left="559" width="246" height="16" font="4"><a href="e44.full.html#88">). </a>On the basis of American Society of</text>
<text top="356" left="446" width="360" height="16" font="4">Nuclear Cardiology guidelines, dual-isotope or rest-stress</text>
<text top="374" left="446" width="360" height="16" font="4">Tl-201 imaging is discouraged for diagnostic procedures</text>
<text top="392" left="446" width="360" height="16" font="4">because of its high radiation exposure. The use of new</text>
<text top="410" left="446" width="360" height="16" font="4">high-efficiency nuclear MPI cameras results in a similar or</text>
<text top="428" left="446" width="360" height="16" font="4">lower effective dose for both dual-isotope and rest-stress</text>
<text top="446" left="446" width="122" height="16" font="4">Tc-99m imaging <a href="e44.full.html#88">(</a></text>
<text top="446" left="568" width="47" height="16" font="16"><a href="e44.full.html#88">99 –101</a></text>
<text top="446" left="614" width="191" height="16" font="4"><a href="e44.full.html#88">). </a>For both CT and nuclear</text>
<text top="464" left="446" width="360" height="16" font="4">imaging, the AHA, Society of Cardiovascular Computed</text>
<text top="482" left="446" width="360" height="16" font="4">Tomography, and American Society of Nuclear Cardiology</text>
<text top="500" left="446" width="360" height="16" font="4">recommend widespread application of dose-reduction tech-</text>
<text top="518" left="446" width="164" height="16" font="4">niques whenever possible <a href="e44.full.html#88">(</a></text>
<text top="518" left="609" width="39" height="16" font="16"><a href="e44.full.html#88">96 –98</a></text>
<text top="518" left="648" width="157" height="16" font="4"><a href="e44.full.html#88">). </a>Clinicians should apply</text>
<text top="536" left="446" width="360" height="16" font="4">the concept of benefit-to-risk ratio when considering test-</text>
<text top="554" left="446" width="360" height="16" font="4">ing. When testing is used appropriately, the clinical benefit</text>
<text top="572" left="446" width="360" height="16" font="4">in terms of supportive diagnostic or prognostic accuracy</text>
<text top="590" left="446" width="360" height="16" font="4">exceeds the projected risk such that there is an advantage to</text>
<text top="608" left="446" width="49" height="16" font="4">testing <a href="e44.full.html#85">(</a></text>
<text top="608" left="495" width="34" height="16" font="16"><a href="e44.full.html#85">13,14</a></text>
<text top="608" left="528" width="277" height="16" font="4"><a href="e44.full.html#85">). </a>When it is used inappropriately or overused,</text>
<text top="626" left="446" width="360" height="16" font="4">the benefit of testing is low, and the risk of exposure is</text>
<text top="644" left="446" width="360" height="16" font="4">unacceptably high. Of note, care should be taken when</text>
<text top="662" left="446" width="360" height="16" font="4">exposing low-risk patients to ionizing radiation. This is</text>
<text top="680" left="446" width="360" height="16" font="4">particularly of concern in younger patients for whom the</text>
<text top="698" left="446" width="203" height="16" font="4">projected cancer risk is elevated <a href="e44.full.html#88">(</a></text>
<text top="698" left="649" width="23" height="16" font="16"><a href="e44.full.html#88">102</a></text>
<text top="698" left="671" width="9" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="716" left="461" width="345" height="16" font="4">Use of contrast agents with CCTA can cause allergic</text>
<text top="734" left="446" width="360" height="16" font="4">reactions. Contrast agents also can affect renal function and</text>
<text top="752" left="446" width="360" height="16" font="4">therefore should be avoided in patients with chronic kidney</text>
<text top="770" left="446" width="360" height="16" font="4">disease. CMR might be contraindicated in patients with</text>
<text top="788" left="446" width="360" height="16" font="4">claustrophobia or implanted devices, and use of gadolinium</text>
<text top="806" left="446" width="360" height="16" font="4">contrast agents is associated rarely with nephrogenic sys-</text>
<text top="824" left="446" width="360" height="16" font="4">temic fibrosis. For this reason, gadolinium is contraindi-</text>
<text top="842" left="446" width="360" height="16" font="4">cated in patients with severe renal dysfunction (estimated</text>
<text top="860" left="446" width="156" height="16" font="4">glomerular filtration rates</text>
<text top="857" left="607" width="157" height="20" font="4">⬍30 mL/min per 1.73 m</text>
<text top="858" left="764" width="6" height="10" font="11">2</text>
<text top="860" left="769" width="36" height="16" font="4">), and</text>
<text top="878" left="445" width="360" height="16" font="4">the dose should be adjusted for patients with mild to</text>
<text top="896" left="445" width="360" height="16" font="4">moderate dysfunction (estimated glomerular filtration rates</text>
<text top="914" left="445" width="183" height="16" font="4">30 to 60 mL/min per 1.73 m</text>
<text top="912" left="628" width="6" height="10" font="11">2</text>
<text top="914" left="634" width="172" height="16" font="4">). As with all safety consid-</text>
<text top="932" left="445" width="360" height="16" font="4">erations, the potential risks need to be considered carefully</text>
<text top="950" left="445" width="360" height="16" font="4">in concert with the potential benefits from the added</text>
<text top="968" left="445" width="218" height="16" font="4">information obtained to guide care.</text>
<text top="986" left="460" width="345" height="16" font="4">In addition to pretest likelihood, a variety of clinical</text>
<text top="1004" left="445" width="261" height="16" font="4">factors influence noninvasive test selection <a href="e44.full.html#88">(</a></text>
<text top="1004" left="707" width="53" height="16" font="16"><a href="e44.full.html#88">103–105</a></text>
<text top="1004" left="759" width="47" height="16" font="4"><a href="e44.full.html#88">). </a>Chief</text>
<text top="1022" left="445" width="360" height="16" font="4">among these are the patient’s ability to exercise, body</text>
<text top="1040" left="445" width="360" height="16" font="4">habitus, cardiac medication use, and ECG interpretability.</text>
<text top="1058" left="445" width="360" height="16" font="4">The decision to add imaging in patients who have an</text>
<text top="1076" left="445" width="360" height="16" font="4">interpretable ECG and are capable of vigorous exercise is</text>
<text top="1094" left="445" width="360" height="16" font="4">important because imaging and nonimaging testing have</text>
<text top="52" left="59" width="18" height="10" font="12">e64</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">different diagnostic accuracies, predictive values, and costs.</text>
<text top="123" left="59" width="360" height="16" font="4">Most, but not all, studies evaluating cohorts of patients</text>
<text top="141" left="59" width="360" height="16" font="4">undergoing both exercise ECG and stress imaging have</text>
<text top="159" left="59" width="360" height="16" font="4">shown that the addition of imaging information provides</text>
<text top="177" left="59" width="360" height="16" font="4">incremental benefit in terms of both diagnostic and prog-</text>
<text top="195" left="59" width="360" height="16" font="4">nostic information with an acceptable increase in cost</text>
<text top="213" left="59" width="5" height="16" font="4"><a href="e44.full.html#22">(</a></text>
<text top="213" left="63" width="91" height="16" font="16"><a href="e44.full.html#22">Section 2.2.1.5</a></text>
<text top="213" left="155" width="15" height="16" font="4"><a href="e44.full.html#22">) </a><a href="e44.full.html#88">(</a></text>
<text top="213" left="170" width="54" height="16" font="16"><a href="e44.full.html#88">106 –117</a></text>
<text top="213" left="224" width="9" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="232" left="74" width="345" height="16" font="4">Other factors affecting test choice include local availabil-</text>
<text top="250" left="59" width="360" height="16" font="4">ity of specific tests, local expertise in test performance and</text>
<text top="268" left="59" width="360" height="16" font="4">interpretation, the presence of multiple diagnostic or prog-</text>
<text top="286" left="59" width="360" height="16" font="4">nostic questions better addressed by one form of testing over</text>
<text top="304" left="59" width="360" height="16" font="4">another, and the existence of prior test results (especially</text>
<text top="322" left="59" width="360" height="16" font="4">when prior images are available for comparison). Finally,</text>
<text top="341" left="59" width="360" height="16" font="4">although echocardiographic, radionuclide, and CMR stress</text>
<text top="359" left="59" width="360" height="16" font="4">imaging can have complementary roles for estimating pa-</text>
<text top="377" left="59" width="360" height="16" font="4">tient prognosis, there is rarely a reason to perform multiple</text>
<text top="395" left="59" width="360" height="16" font="4">tests in the same patient, unless the results of the initial</text>
<text top="413" left="59" width="360" height="16" font="4">imaging test are unsatisfactory for technical reasons or the</text>
<text top="431" left="59" width="284" height="16" font="4">findings are equivocal or require confirmation.</text>
<text top="463" left="59" width="261" height="9" font="6">2.2.1.3. EXERCISE VERSUS PHARMACOLOGICAL TESTING</text>
<text top="477" left="59" width="360" height="16" font="4">When a patient is able to perform routine activities of</text>
<text top="495" left="59" width="360" height="16" font="4">daily living without difficulty, exercise testing to provoke</text>
<text top="513" left="59" width="360" height="16" font="4">ischemia is preferred because it often can provide a higher</text>
<text top="531" left="59" width="360" height="16" font="4">physiological stress than would be achieved by pharma-</text>
<text top="550" left="59" width="360" height="16" font="4">cological testing. This can translate into a superior ability</text>
<text top="568" left="59" width="360" height="16" font="4">to detect ischemia as well as providing a correlation to a</text>
<text top="586" left="59" width="360" height="16" font="4">patient’s daily symptom burden and physical work capac-</text>
<text top="604" left="59" width="360" height="16" font="4">ity not offered by pharmacological stress testing. In</text>
<text top="622" left="59" width="360" height="16" font="4">addition, exercise capacity alone is a very strong prognos-</text>
<text top="640" left="59" width="88" height="16" font="4">tic indicator <a href="e44.full.html#88">(</a></text>
<text top="640" left="147" width="51" height="16" font="16"><a href="e44.full.html#88">118,119</a></text>
<text top="640" left="198" width="9" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="659" left="74" width="345" height="16" font="4">The goal of exercise testing for suspected SIHD patients</text>
<text top="677" left="59" width="360" height="16" font="4">is 1) to achieve high levels of exercise (i.e., maximal</text>
<text top="695" left="59" width="360" height="16" font="4">exertion), which in the setting of a negative ECG generally</text>
<text top="713" left="59" width="360" height="16" font="4">and reliably excludes obstructive CAD, or 2) to document</text>
<text top="731" left="59" width="360" height="16" font="4">the extent and severity of ECG changes and angina at a</text>
<text top="749" left="59" width="360" height="16" font="4">given workload (i.e., demand ischemia) so as to predict the</text>
<text top="767" left="59" width="360" height="16" font="4">likelihood of underlying significant or severe CAD. Thus,</text>
<text top="786" left="59" width="360" height="16" font="4">candidates for exercise testing must possess sufficient func-</text>
<text top="804" left="59" width="360" height="16" font="4">tional capacity to attain maximal, volitional stress levels.</text>
<text top="822" left="59" width="360" height="16" font="4">Because there is high variability in age-predicted maximal</text>
<text top="840" left="59" width="267" height="16" font="4">heart rate among subjects of identical age <a href="e44.full.html#88">(</a></text>
<text top="840" left="325" width="23" height="16" font="16"><a href="e44.full.html#88">120</a></text>
<text top="840" left="348" width="71" height="16" font="4"><a href="e44.full.html#88">), </a>achieving</text>
<text top="858" left="59" width="360" height="16" font="4">85% of age-predicted maximal heart rate might not indicate</text>
<text top="876" left="59" width="360" height="16" font="4">sufficient effort during exercise testing and should not be used</text>
<text top="895" left="59" width="233" height="16" font="4">as a criterion to terminate a stress test <a href="e44.full.html#88">(</a></text>
<text top="895" left="291" width="22" height="16" font="16"><a href="e44.full.html#88">121</a></text>
<text top="895" left="313" width="106" height="16" font="4"><a href="e44.full.html#88">). </a>Failure to reach</text>
<text top="913" left="58" width="360" height="16" font="4">peak heart rate (if beta blockers have been held as recom-</text>
<text top="931" left="58" width="360" height="16" font="4">mended) or to achieve adequate levels of exercise in the setting</text>
<text top="949" left="58" width="360" height="16" font="4">of a negative ECG is consistent with functional disability and</text>
<text top="967" left="58" width="360" height="16" font="4">results in an indeterminate estimation of CAD. Female-</text>
<text top="985" left="58" width="360" height="16" font="4">specific age-predicted maximal heart rate and functional ca-</text>
<text top="1004" left="58" width="206" height="16" font="4">pacity measurements are available <a href="e44.full.html#88">(</a></text>
<text top="1004" left="264" width="47" height="16" font="16"><a href="e44.full.html#88">118,122</a></text>
<text top="1004" left="311" width="8" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="1022" left="73" width="345" height="16" font="4">Standard treadmill protocols initiate exercise at 3.2 to 4.7</text>
<text top="1040" left="58" width="360" height="16" font="4">metabolic equivalents (METs) of work and increase by</text>
<text top="1058" left="58" width="360" height="16" font="4">several METs every 2 to 3 minutes of exercise (e.g.,</text>
<text top="1076" left="58" width="360" height="16" font="4">modified or standard Bruce protocol). Most activities of</text>
<text top="1094" left="58" width="360" height="16" font="4">daily living require approximately 4 to 5 METs of physical</text>
<text top="104" left="445" width="360" height="16" font="4">work to perform. Thus, reported limitations in activities of</text>
<text top="122" left="445" width="360" height="16" font="4">daily living identify a patient who might be unable to</text>
<text top="140" left="445" width="360" height="16" font="4">perform maximal exercise. Gentler treadmill protocols, with</text>
<text top="158" left="445" width="360" height="16" font="4">incremental stages of 1 MET, or bicycle stress can help</text>
<text top="176" left="445" width="297" height="16" font="4">some patients achieve maximal exercise capacity.</text>
<text top="194" left="460" width="345" height="16" font="4">Optimal candidates with sufficient physical functioning</text>
<text top="212" left="445" width="360" height="16" font="4">may be identified as those capable of performing at least</text>
<text top="230" left="445" width="360" height="16" font="4">moderate physical functioning (i.e., performing at least</text>
<text top="248" left="445" width="360" height="16" font="4">moderate household, yard, or recreational work <i>and </i>most</text>
<text top="266" left="445" width="360" height="16" font="4">activities of daily living) and with no disabling comorbidity</text>
<text top="284" left="445" width="360" height="16" font="4">(including frailty, advanced age, marked obesity, PAD,</text>
<text top="302" left="445" width="360" height="16" font="4">chronic obstructive pulmonary disease, or orthopedic limi-</text>
<text top="320" left="445" width="360" height="16" font="4">tations). Patients incapable of at least moderate physical</text>
<text top="338" left="445" width="360" height="16" font="4">functioning or with disabling comorbidity should be re-</text>
<text top="356" left="445" width="360" height="16" font="4">ferred for pharmacological stress imaging. In the setting of</text>
<text top="374" left="445" width="360" height="16" font="4">submaximal exercise and a negative stress ECG, consider-</text>
<text top="392" left="445" width="360" height="16" font="4">ation should be given to performing additional testing with</text>
<text top="410" left="445" width="360" height="16" font="4">pharmacological stress imaging to evaluate for inducible</text>
<text top="428" left="445" width="56" height="16" font="4">ischemia.</text>
<text top="459" left="446" width="330" height="9" font="6">2.2.1.4. CONCOMITANT DIAGNOSIS OF SIHD AND ASSESSMENT OF RISK</text>
<text top="473" left="446" width="360" height="16" font="4">Although the primary goal of testing among patients with</text>
<text top="491" left="446" width="360" height="16" font="4">new onset of symptoms suggesting SIHD is to diagnose or</text>
<text top="509" left="446" width="360" height="16" font="4">exclude obstructive CAD, the various modalities also can</text>
<text top="527" left="446" width="360" height="16" font="4">provide additional information about long-term risk</text>
<text top="545" left="446" width="5" height="16" font="4"><a href="e44.full.html#35">(</a></text>
<text top="545" left="451" width="84" height="16" font="16"><a href="e44.full.html#35">Section 3.3.2</a></text>
<text top="545" left="535" width="270" height="16" font="4"><a href="e44.full.html#35">)</a>, and this prognostic ability may influence</text>
<text top="563" left="446" width="360" height="16" font="4">the selection of an initial test. Exercise capacity remains one</text>
<text top="581" left="446" width="360" height="16" font="4">of the strongest indicators of long-term risk (including</text>
<text top="599" left="446" width="360" height="16" font="4">death) for men and women with suspected and known</text>
<text top="617" left="446" width="43" height="16" font="4">CAD <a href="e44.full.html#88">(</a></text>
<text top="617" left="488" width="79" height="16" font="16"><a href="e44.full.html#88">118,123–125</a></text>
<text top="617" left="567" width="238" height="16" font="4"><a href="e44.full.html#88">). </a>In addition, information derived from</text>
<text top="635" left="446" width="280" height="16" font="4">treadmill exercise (e.g., Duke treadmill score <a href="e44.full.html#88">(</a></text>
<text top="635" left="725" width="49" height="16" font="16"><a href="e44.full.html#88">126,127</a></text>
<text top="635" left="774" width="31" height="16" font="4"><a href="e44.full.html#88">) </a>and</text>
<text top="653" left="446" width="360" height="16" font="4">heart rate recovery) provides incremental diagnostic and</text>
<text top="671" left="446" width="360" height="16" font="4">prognostic information. For this reason, it is preferable to</text>
<text top="689" left="446" width="360" height="16" font="4">perform exercise stress if the patient is able to achieve a</text>
<text top="707" left="446" width="360" height="16" font="4">maximal workload. For the exercise-capable patient with a</text>
<text top="725" left="446" width="360" height="16" font="4">normal baseline ECG, the decision to perform imaging</text>
<text top="743" left="446" width="360" height="16" font="4">with nuclear or echocardiographic techniques along with</text>
<text top="761" left="446" width="360" height="16" font="4">stress ECG should be based on many factors, including the</text>
<text top="779" left="446" width="360" height="16" font="4">likelihood of garnering substantial incremental prognostic</text>
<text top="797" left="446" width="360" height="16" font="4">information that is likely to alter clinical and therapeutic</text>
<text top="815" left="446" width="82" height="16" font="4">management.</text>
<text top="846" left="446" width="138" height="9" font="6">2.2.1.5. COST-EFFECTIVENESS</text>
<text top="860" left="446" width="360" height="16" font="4">Estimates of cost-effectiveness of various testing strate-</text>
<text top="878" left="446" width="360" height="16" font="4">gies in symptomatic patients have been used to inform</text>
<text top="896" left="446" width="360" height="16" font="4">responses to rising healthcare costs. However, to be of</text>
<text top="914" left="446" width="360" height="16" font="4">value, estimates of cost-effectiveness must use contempo-</text>
<text top="932" left="446" width="360" height="16" font="4">rary estimates of effectiveness that incorporate consider-</text>
<text top="950" left="446" width="360" height="16" font="4">ations of disease prevalence and test accuracy. Further-</text>
<text top="968" left="446" width="360" height="16" font="4">more, costs must reflect not only the index test but also</text>
<text top="986" left="446" width="360" height="16" font="4">the episode of care and the longer-term induced costs and</text>
<text top="1004" left="446" width="360" height="16" font="4">outcomes of diagnosed and undiagnosed SIHD. Ideally,</text>
<text top="1022" left="446" width="360" height="16" font="4">these data would be derived from RCTs or registries</text>
<text top="1040" left="446" width="360" height="16" font="4">designed to compare the effectiveness of testing strategies</text>
<text top="1058" left="446" width="360" height="16" font="4">and observed associated costs. However, in the interim</text>
<text top="1076" left="446" width="360" height="16" font="4">until such evidence is available, mixed methods and</text>
<text top="1094" left="446" width="360" height="16" font="4">decision analytic models provide general estimates of the</text>
<text top="52" left="787" width="18" height="10" font="12">e65</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">cost-effectiveness of various forms of testing. Mixed</text>
<text top="123" left="59" width="360" height="16" font="4">methods use observational evidence of index and down-</text>
<text top="142" left="59" width="360" height="16" font="4">stream procedures, hospitalization, and drug costs and</text>
<text top="160" left="59" width="327" height="16" font="4">apply cost weights to estimate cumulative costs <a href="e44.full.html#88">(</a></text>
<text top="160" left="386" width="33" height="16" font="16"><a href="e44.full.html#88">128 –</a></text>
<text top="179" left="59" width="23" height="16" font="16"><a href="e44.full.html#88">130</a></text>
<text top="179" left="82" width="337" height="16" font="4"><a href="e44.full.html#88">)</a>, whereas decision analytic models simulate clinical and</text>
<text top="198" left="59" width="89" height="16" font="4">financial data <a href="e44.full.html#88">(</a></text>
<text top="198" left="147" width="52" height="16" font="16"><a href="e44.full.html#88">131–137</a></text>
<text top="198" left="200" width="219" height="16" font="4"><a href="e44.full.html#88">). </a>Regardless of the approach, inher-</text>
<text top="216" left="59" width="360" height="16" font="4">ent assumptions and uncertainties with regard to the data</text>
<text top="235" left="59" width="360" height="16" font="4">and incomplete consideration of risks and benefits require</text>
<text top="254" left="59" width="329" height="16" font="4">that such calculations be considered as estimates only <a href="e44.full.html#89">(</a></text>
<text top="254" left="387" width="23" height="16" font="16"><a href="e44.full.html#89">138</a></text>
<text top="254" left="410" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="273" left="74" width="345" height="16" font="4">In most studies, stress imaging is estimated to provide a</text>
<text top="291" left="59" width="360" height="16" font="4">benefit over exercise ECG at a reasonable cost, commensu-</text>
<text top="310" left="59" width="360" height="16" font="4">rate with accepted values for cost effectiveness (i.e., at the</text>
<text top="329" left="59" width="224" height="16" font="4">threshold for economic efficiency of</text>
<text top="325" left="289" width="129" height="20" font="4">⬍$50,000 per added</text>
<text top="347" left="59" width="360" height="16" font="4">year of life), a result driven primarily by more frequent</text>
<text top="366" left="59" width="360" height="16" font="4">angiography and adverse cardiovascular events for those</text>
<text top="385" left="59" width="360" height="16" font="4">with a negative exercise ECG. Results of decision analytic</text>
<text top="403" left="59" width="360" height="16" font="4">and mixed modeling approaches comparing stress echocar-</text>
<text top="422" left="59" width="360" height="16" font="4">diography with myocardial perfusion SPECT vary, with</text>
<text top="441" left="59" width="360" height="16" font="4">some favoring exercise echocardiography and others favor-</text>
<text top="459" left="59" width="163" height="16" font="4">ing exercise nuclear MPI <a href="e44.full.html#88">(</a></text>
<text top="459" left="222" width="49" height="16" font="16"><a href="e44.full.html#88">128,133</a></text>
<text top="459" left="271" width="9" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="478" left="74" width="345" height="16" font="4">The patient’s pretest likelihood of CAD also influences</text>
<text top="497" left="59" width="360" height="16" font="4">cost-effectiveness such that exercise echocardiography is</text>
<text top="515" left="59" width="360" height="16" font="4">more cost-effective in lower-risk patients (with annual risk</text>
<text top="534" left="59" width="90" height="16" font="4">of death or MI</text>
<text top="531" left="152" width="266" height="20" font="4">⬍2%) than in higher-risk patients, in whom</text>
<text top="553" left="59" width="360" height="16" font="4">nuclear MPI is more cost-effective. Use of invasive coronary</text>
<text top="571" left="59" width="360" height="16" font="4">angiography as a first test is not cost-effective in patients</text>
<text top="590" left="59" width="160" height="16" font="4">with a pretest probability</text>
<text top="587" left="226" width="51" height="20" font="4">⬍75% <a href="e44.full.html#89">(</a></text>
<text top="590" left="276" width="49" height="16" font="16"><a href="e44.full.html#89">139,140</a></text>
<text top="590" left="325" width="93" height="16" font="4"><a href="e44.full.html#89">). </a>Finally, it is</text>
<text top="609" left="59" width="360" height="16" font="4">important to note that as the reimbursement for stress</text>
<text top="627" left="59" width="360" height="16" font="4">imaging decreases (it is now less than half the value used in</text>
<text top="646" left="59" width="360" height="16" font="4">older studies), the relative cost-effectiveness (dollars/</text>
<text top="665" left="59" width="360" height="16" font="4">quality-adjusted life-year saved) of stress imaging is more</text>
<text top="683" left="59" width="360" height="16" font="4">favorable than that of exercise ECG, and the comparative</text>
<text top="702" left="59" width="360" height="16" font="4">advantage of lower- to higher-cost imaging procedures is</text>
<text top="721" left="59" width="69" height="16" font="4">minimized.</text>
<text top="739" left="74" width="345" height="16" font="4">The cost-efficiency of CCTA is less well studied but</text>
<text top="758" left="59" width="258" height="16" font="4">also depends on disease prevalence <a href="e44.full.html#89">(</a></text>
<text top="758" left="317" width="51" height="16" font="16"><a href="e44.full.html#89">139,140</a></text>
<text top="758" left="368" width="50" height="16" font="4"><a href="e44.full.html#89">). </a>Data</text>
<text top="777" left="59" width="360" height="16" font="4">conflict as to whether patients undergoing CCTA as</text>
<text top="795" left="59" width="360" height="16" font="4">initial imaging modality are less or more likely to undergo</text>
<text top="814" left="59" width="360" height="16" font="4">invasive coronary angiography or revascularization, al-</text>
<text top="833" left="59" width="360" height="16" font="4">though it appears that they have similar or lower rates of</text>
<text top="851" left="59" width="204" height="16" font="4">adverse cardiovascular events <a href="e44.full.html#88">(</a></text>
<text top="851" left="263" width="106" height="16" font="16"><a href="e44.full.html#88">128,130,141,142</a></text>
<text top="851" left="369" width="50" height="16" font="4"><a href="e44.full.html#88">). </a>As a</text>
<text top="870" left="59" width="360" height="16" font="4">result, CCTA performed alone or in combination with</text>
<text top="889" left="59" width="360" height="16" font="4">functional testing minimizes adverse cardiac events, max-</text>
<text top="907" left="59" width="221" height="16" font="4">imizes quality-adjusted life-years <a href="e44.full.html#89">(</a></text>
<text top="907" left="280" width="51" height="16" font="16"><a href="e44.full.html#89">140,143</a></text>
<text top="907" left="331" width="87" height="16" font="4"><a href="e44.full.html#89">), </a>and is esti-</text>
<text top="926" left="59" width="169" height="16" font="4">mated to be cost-effective.</text>
<text top="945" left="74" width="345" height="16" font="4">Although data on cost-effectiveness and patient satisfac-</text>
<text top="963" left="59" width="360" height="16" font="4">tion for CMR are limited, evidence suggests that CMR can</text>
<text top="982" left="59" width="360" height="16" font="4">improve patient management. The German Pilot/European</text>
<text top="1001" left="59" width="360" height="16" font="4">Cardiovascular Magnetic Resonance (EuroCMR) registry</text>
<text top="1019" left="59" width="360" height="16" font="4">of 11,040 consecutive patients evaluated for cardiomyopa-</text>
<text top="1038" left="59" width="360" height="16" font="4">thy, ischemia, and myocardial viability found that CMR</text>
<text top="1057" left="59" width="360" height="16" font="4">satisfied all requested imaging needs in 86% of patients so</text>
<text top="1075" left="59" width="244" height="16" font="4">that no further imaging was required <a href="e44.full.html#89">(</a></text>
<text top="1075" left="302" width="23" height="16" font="16"><a href="e44.full.html#89">144</a></text>
<text top="1075" left="325" width="94" height="16" font="4"><a href="e44.full.html#89">). </a>In the 3,351</text>
<text top="1094" left="59" width="360" height="16" font="4">stress CMR cases, invasive angiography was avoided in</text>
<text top="104" left="446" width="360" height="16" font="4">45%, compared with 18% in patients who underwent</text>
<text top="122" left="446" width="101" height="16" font="4">nuclear imaging.</text>
<text top="149" left="446" width="312" height="16" font="26"><b>2.2.2. Stress Testing and Advanced Imaging for</b></text>
<text top="167" left="446" width="336" height="16" font="26"><b>Initial Diagnosis in Patients With Suspected SIHD</b></text>
<text top="185" left="446" width="354" height="16" font="26"><b>Who Require Noninvasive Testing: Recommendations</b></text>
<text top="211" left="446" width="21" height="16" font="4">See</text>
<text top="211" left="471" width="54" height="16" font="16"><a href="e44.full.html#24">Table 11</a></text>
<text top="211" left="529" width="276" height="16" font="4">for a summary of recommendations from this</text>
<text top="229" left="446" width="46" height="16" font="4">section.</text>
<text top="260" left="446" width="126" height="9" font="6">2.2.2.1. ABLE TO EXERCISE</text>
<text top="286" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="299" left="446" width="360" height="10" font="13">1. Standard exercise ECG testing is recommended for patients with an</text>
<text top="316" left="461" width="344" height="10" font="13">intermediate pretest probability of IHD who have an interpretable</text>
<text top="332" left="461" width="344" height="10" font="13">ECG and at least moderate physical functioning or no disabling</text>
<text top="349" left="461" width="261" height="10" font="13">comorbidity <a href="e44.full.html#88">(114,145–147). </a><i>(Level of Evidence: A)</i></text>
<text top="366" left="445" width="360" height="10" font="13">2. Exercise stress with nuclear MPI or echocardiography is recom-</text>
<text top="383" left="461" width="344" height="10" font="13">mended for patients with an intermediate to high pretest probability</text>
<text top="400" left="461" width="344" height="10" font="13">of IHD who have an <i>un</i>interpretable ECG and at least moderate</text>
<text top="417" left="461" width="344" height="10" font="13">physical functioning or no disabling comorbidity <a href="e44.full.html#87">(91,132,148–156).</a></text>
<text top="434" left="461" width="111" height="10" font="25"><i>(Level of Evidence: B)</i></text>
<text top="462" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="475" left="446" width="360" height="10" font="13">1. For patients with a low pretest probability of obstructive IHD who do</text>
<text top="492" left="461" width="344" height="10" font="13">require testing, standard exercise ECG testing can be useful, provided</text>
<text top="508" left="461" width="344" height="10" font="13">the patient has an interpretable ECG and at least moderate physical</text>
<text top="525" left="461" width="304" height="10" font="13">functioning or no disabling comorbidity. <i>(Level of Evidence: C)</i></text>
<text top="542" left="446" width="360" height="10" font="13">2. Exercise stress with nuclear MPI or echocardiography is reasonable for</text>
<text top="559" left="461" width="344" height="10" font="13">patients with an intermediate to high pretest probability of obstructive</text>
<text top="576" left="461" width="344" height="10" font="13">IHD who have an interpretable ECG and at least moderate physical</text>
<text top="593" left="461" width="344" height="10" font="13">functioning or no disabling comorbidity <a href="e44.full.html#87">(91,132,148–156). </a>(<i>Level of</i></text>
<text top="610" left="461" width="61" height="10" font="25"><i>Evidence: B)</i></text>
<text top="627" left="446" width="360" height="10" font="13">3. Pharmacological stress with CMR can be useful for patients with an</text>
<text top="643" left="461" width="344" height="10" font="13">intermediate to high pretest probability of obstructive IHD who have</text>
<text top="660" left="461" width="344" height="10" font="13">an <i>un</i>interpretable ECG and at least moderate physical functioning</text>
<text top="677" left="461" width="338" height="10" font="13">or no disabling comorbidity <a href="e44.full.html#89">(153,157,158). </a><i>(Level of Evidence: B)</i></text>
<text top="706" left="446" width="46" height="8" font="24">CLASS IIb</text>
<text top="718" left="446" width="360" height="10" font="13">1. CCTA might be reasonable for patients with an intermediate pretest</text>
<text top="735" left="461" width="344" height="10" font="13">probability of IHD who have at least moderate physical functioning</text>
<text top="752" left="461" width="317" height="10" font="13">or no disabling comorbidity <a href="e44.full.html#89">(158–166). </a><i>(Level of Evidence: B)</i></text>
<text top="769" left="446" width="360" height="10" font="13">2. For patients with a low pretest probability of obstructive IHD who do</text>
<text top="786" left="461" width="344" height="10" font="13">require testing, standard exercise stress echocardiography might be</text>
<text top="803" left="461" width="344" height="10" font="13">reasonable, provided the patient has an interpretable ECG and at</text>
<text top="819" left="461" width="344" height="10" font="13">least moderate physical functioning or no disabling comorbidity.</text>
<text top="837" left="461" width="110" height="10" font="25"><i>(Level of Evidence: C)</i></text>
<text top="865" left="446" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="877" left="446" width="360" height="10" font="13">1. Pharmacological stress with nuclear MPI, echocardiography, or</text>
<text top="894" left="461" width="344" height="10" font="13">CMR is not recommended for patients who have an interpretable</text>
<text top="911" left="461" width="344" height="10" font="13">ECG and at least moderate physical functioning or no disabling</text>
<text top="928" left="461" width="258" height="10" font="13">comorbidity <a href="e44.full.html#89">(155,167,168). </a><i>(Level of Evidence: C)</i></text>
<text top="945" left="445" width="360" height="10" font="13">2. Exercise stress with nuclear MPI is not recommended as an initial</text>
<text top="962" left="461" width="344" height="10" font="13">test in low-risk patients who have an interpretable ECG and at least</text>
<text top="979" left="461" width="344" height="10" font="13">moderate physical functioning or no disabling comorbidity. <i>(Level of</i></text>
<text top="996" left="461" width="63" height="10" font="25"><i>Evidence: C)</i></text>
<text top="1025" left="446" width="139" height="9" font="6">2.2.2.2. UNABLE TO EXERCISE</text>
<text top="1051" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="1064" left="446" width="360" height="10" font="13">1. Pharmacological stress with nuclear MPI or echocardiography is</text>
<text top="1080" left="461" width="344" height="10" font="13">recommended for patients with an intermediate to high pretest</text>
<text top="1097" left="461" width="344" height="10" font="13">probability of IHD who are incapable of at least moderate physical</text>
<text top="52" left="58" width="18" height="10" font="12">e66</text>
<text top="52" left="112" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="33" size="13" family="Times" color="#3b456e"/>
	<fontspec id="34" size="6" family="Times" color="#231f20"/>
<text top="797" left="75" width="344" height="10" font="13">functioning or have disabling comorbidity <a href="e44.full.html#89">(148–150,152–156).</a></text>
<text top="814" left="75" width="111" height="10" font="25"><i>(Level of Evidence: B)</i></text>
<text top="841" left="59" width="46" height="8" font="24">CLASS IIa</text>
<text top="854" left="59" width="360" height="10" font="13">1. Pharmacological stress echocardiography is reasonable for patients</text>
<text top="871" left="74" width="344" height="10" font="13">with a low pretest probability of IHD who require testing and are</text>
<text top="888" left="74" width="344" height="10" font="13">incapable of at least moderate physical functioning or have dis-</text>
<text top="905" left="74" width="213" height="10" font="13">abling comorbidity. <i>(Level of Evidence: C)</i></text>
<text top="922" left="58" width="360" height="10" font="13">2. CCTA is reasonable for patients with a low to intermediate pretest</text>
<text top="939" left="74" width="344" height="10" font="13">probability of IHD who are incapable of at least moderate physical</text>
<text top="955" left="74" width="344" height="10" font="13">functioning or have disabling comorbidity <a href="e44.full.html#89">(158–166). </a><i>(Level of</i></text>
<text top="973" left="74" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="989" left="58" width="360" height="10" font="13">3. Pharmacological stress CMR is reasonable for patients with an</text>
<text top="1006" left="74" width="344" height="10" font="13">intermediate to high pretest probability of IHD who are incapable of</text>
<text top="1023" left="74" width="344" height="10" font="13">at least moderate physical functioning or have disabling comorbid-</text>
<text top="1040" left="74" width="261" height="10" font="13">ity <a href="e44.full.html#89">(153,157,158,169–172). </a><i>(Level of Evidence: B)</i></text>
<text top="1068" left="59" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="1080" left="59" width="360" height="10" font="13">1. Standard exercise ECG testing is not recommended for patients who</text>
<text top="1097" left="74" width="344" height="10" font="13">have an <i>un</i>interpretable ECG or are incapable of at least moderate</text>
<text top="797" left="461" width="344" height="10" font="13">physical functioning or have disabling comorbidity <a href="e44.full.html#87">(91,132,148–</a></text>
<text top="814" left="461" width="166" height="10" font="13"><a href="e44.full.html#87">156,161). </a><i>(Level of Evidence: C)</i></text>
<text top="843" left="446" width="71" height="9" font="6">2.2.2.3. OTHER</text>
<text top="872" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="884" left="446" width="360" height="10" font="13">1. CCTA is reasonable for patients with an intermediate pretest prob-</text>
<text top="902" left="461" width="344" height="10" font="13">ability of IHD who a) have continued symptoms with prior normal</text>
<text top="919" left="461" width="344" height="10" font="13">test findings, or b) have inconclusive results from prior exercise or</text>
<text top="936" left="461" width="344" height="10" font="13">pharmacological stress testing, or c) are unable to undergo stress</text>
<text top="953" left="461" width="344" height="10" font="13">with nuclear MPI or echocardiography <a href="e44.full.html#89">(173). </a>(<i>Level of Evidence: C</i>)</text>
<text top="983" left="446" width="46" height="8" font="24">CLASS IIb</text>
<text top="998" left="446" width="360" height="10" font="13">1. For patients with a low to intermediate pretest probability of ob-</text>
<text top="1015" left="461" width="344" height="10" font="13">structive IHD, noncontrast cardiac CT to determine the CAC score</text>
<text top="1032" left="461" width="247" height="10" font="13">may be considered <a href="e44.full.html#89">(174). </a><i>(Level of Evidence: C)</i></text>
<text top="1057" left="446" width="18" height="16" font="5"><i>See</i></text>
<text top="1057" left="468" width="156" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplement 1</i></a></text>
<text top="1057" left="627" width="178" height="16" font="5"><i>for additional data on diagnos-</i></text>
<text top="1076" left="446" width="360" height="16" font="5"><i>tic accuracy of stress testing and advanced imaging for the</i></text>
<text top="1094" left="446" width="167" height="16" font="5"><i>diagnosis of suspected SIHD.</i></text>
<text top="105" left="59" width="588" height="11" font="13">Table 11. Stress Testing and Advanced Imaging for Initial Diagnosis in Patients With Suspected SIHD</text>
<text top="121" left="59" width="192" height="11" font="13">Who Require Noninvasive Testing</text>
<text top="182" left="132" width="21" height="9" font="6">Test</text>
<text top="147" left="247" width="40" height="9" font="6">Exercise</text>
<text top="159" left="252" width="31" height="9" font="6">Status</text>
<text top="147" left="349" width="20" height="9" font="6">ECG</text>
<text top="159" left="329" width="61" height="9" font="6">Interpretable</text>
<text top="159" left="423" width="121" height="9" font="6">Pretest Probability of IHD</text>
<text top="182" left="589" width="21" height="9" font="6">COR</text>
<text top="182" left="647" width="18" height="9" font="6">LOE</text>
<text top="182" left="713" width="53" height="9" font="6">References</text>
<text top="182" left="232" width="21" height="9" font="6">Able</text>
<text top="182" left="271" width="32" height="9" font="6">Unable</text>
<text top="182" left="327" width="17" height="9" font="6">Yes</text>
<text top="182" left="377" width="13" height="9" font="6">No</text>
<text top="182" left="416" width="19" height="9" font="6">Low</text>
<text top="182" left="452" width="60" height="9" font="6">Intermediate</text>
<text top="182" left="529" width="21" height="9" font="6">High</text>
<text top="199" left="68" width="117" height="9" font="6">Patients able to exercise*</text>
<text top="217" left="79" width="58" height="9" font="6">Exercise ECG</text>
<text top="217" left="240" width="6" height="9" font="6">X</text>
<text top="217" left="333" width="6" height="9" font="6">X</text>
<text top="217" left="479" width="6" height="9" font="6">X</text>
<text top="217" left="567" width="3" height="9" font="6">I</text>
<text top="217" left="653" width="6" height="9" font="6">A</text>
<text top="217" left="682" width="3" height="9" font="6"><a href="e44.full.html#88">(</a></text>
<text top="217" left="686" width="63" height="9" font="7"><a href="e44.full.html#88">114,145–147</a></text>
<text top="217" left="749" width="3" height="9" font="6"><a href="e44.full.html#88">)</a></text>
<text top="234" left="79" width="116" height="9" font="6">Exercise with nuclear MPI</text>
<text top="248" left="92" width="34" height="9" font="6">or Echo</text>
<text top="234" left="240" width="6" height="9" font="6">X</text>
<text top="234" left="381" width="6" height="9" font="6">X</text>
<text top="234" left="479" width="6" height="9" font="6">X</text>
<text top="234" left="537" width="6" height="9" font="6">X</text>
<text top="234" left="567" width="3" height="9" font="6">I</text>
<text top="234" left="653" width="6" height="9" font="6">B</text>
<text top="234" left="682" width="3" height="9" font="6"><a href="e44.full.html#87">(</a></text>
<text top="234" left="686" width="78" height="9" font="7"><a href="e44.full.html#87">91,132,148–156</a></text>
<text top="234" left="764" width="3" height="9" font="6"><a href="e44.full.html#87">)</a></text>
<text top="265" left="79" width="58" height="9" font="6">Exercise ECG</text>
<text top="265" left="240" width="6" height="9" font="6">X</text>
<text top="265" left="333" width="6" height="9" font="6">X</text>
<text top="265" left="422" width="6" height="9" font="6">X</text>
<text top="265" left="567" width="11" height="9" font="6">IIa</text>
<text top="265" left="653" width="6" height="9" font="6">C</text>
<text top="265" left="682" width="18" height="9" font="6">N/A</text>
<text top="283" left="79" width="116" height="9" font="6">Exercise with nuclear MPI</text>
<text top="297" left="92" width="34" height="9" font="6">or Echo</text>
<text top="283" left="240" width="6" height="9" font="6">X</text>
<text top="283" left="333" width="6" height="9" font="6">X</text>
<text top="283" left="479" width="6" height="9" font="6">X</text>
<text top="283" left="537" width="6" height="9" font="6">X</text>
<text top="283" left="567" width="11" height="9" font="6">IIa</text>
<text top="283" left="653" width="6" height="9" font="6">B</text>
<text top="283" left="682" width="3" height="9" font="6"><a href="e44.full.html#87">(</a></text>
<text top="283" left="686" width="78" height="9" font="7"><a href="e44.full.html#87">91,132,148–156</a></text>
<text top="283" left="764" width="3" height="9" font="6"><a href="e44.full.html#87">)</a></text>
<text top="314" left="79" width="130" height="9" font="6">Pharmacological stress CMR</text>
<text top="314" left="240" width="6" height="9" font="6">X</text>
<text top="314" left="381" width="6" height="9" font="6">X</text>
<text top="314" left="479" width="6" height="9" font="6">X</text>
<text top="314" left="537" width="6" height="9" font="6">X</text>
<text top="314" left="567" width="11" height="9" font="6">IIa</text>
<text top="314" left="653" width="6" height="9" font="6">B</text>
<text top="314" left="682" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="314" left="686" width="61" height="9" font="7"><a href="e44.full.html#89">153,157,158</a></text>
<text top="314" left="746" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="331" left="79" width="24" height="9" font="6">CCTA</text>
<text top="331" left="240" width="6" height="9" font="6">X</text>
<text top="331" left="351" width="17" height="9" font="6">Any</text>
<text top="331" left="479" width="6" height="9" font="6">X</text>
<text top="331" left="567" width="11" height="9" font="6">IIb</text>
<text top="331" left="653" width="6" height="9" font="6">B</text>
<text top="331" left="682" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="331" left="686" width="42" height="9" font="7"><a href="e44.full.html#89">158–166</a></text>
<text top="331" left="728" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="349" left="79" width="62" height="9" font="6">Exercise Echo</text>
<text top="349" left="240" width="6" height="9" font="6">X</text>
<text top="349" left="333" width="6" height="9" font="6">X</text>
<text top="349" left="479" width="6" height="9" font="6">X</text>
<text top="349" left="567" width="11" height="9" font="6">IIb</text>
<text top="349" left="653" width="6" height="9" font="6">C</text>
<text top="349" left="682" width="18" height="9" font="6">N/A</text>
<text top="366" left="79" width="127" height="9" font="6">Pharmacological stress with</text>
<text top="380" left="92" width="120" height="9" font="6">nuclear MPI, Echo, or CMR</text>
<text top="366" left="240" width="6" height="9" font="6">X</text>
<text top="366" left="333" width="6" height="9" font="6">X</text>
<text top="366" left="475" width="17" height="9" font="6">Any</text>
<text top="366" left="567" width="62" height="9" font="6">III: No Benefit</text>
<text top="366" left="653" width="6" height="9" font="6">C</text>
<text top="366" left="682" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="366" left="686" width="61" height="9" font="7"><a href="e44.full.html#89">155,167,168</a></text>
<text top="366" left="746" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="397" left="79" width="125" height="9" font="6">Exercise stress with nuclear</text>
<text top="412" left="92" width="18" height="9" font="6">MPI</text>
<text top="397" left="240" width="6" height="9" font="6">X</text>
<text top="397" left="333" width="6" height="9" font="6">X</text>
<text top="397" left="422" width="6" height="9" font="6">X</text>
<text top="397" left="567" width="62" height="9" font="6">III: No Benefit</text>
<text top="397" left="653" width="6" height="9" font="6">C</text>
<text top="397" left="682" width="18" height="9" font="6">N/A</text>
<text top="429" left="68" width="123" height="9" font="6">Patients unable to exercise</text>
<text top="446" left="79" width="127" height="9" font="6">Pharmacological stress with</text>
<text top="460" left="92" width="91" height="9" font="6">nuclear MPI or Echo</text>
<text top="446" left="284" width="6" height="9" font="6">X</text>
<text top="446" left="351" width="17" height="9" font="6">Any</text>
<text top="446" left="479" width="6" height="9" font="6">X</text>
<text top="446" left="537" width="6" height="9" font="6">X</text>
<text top="446" left="567" width="3" height="9" font="6">I</text>
<text top="446" left="653" width="6" height="9" font="6">B</text>
<text top="446" left="682" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="446" left="686" width="87" height="9" font="7"><a href="e44.full.html#89">148–150,152–156</a></text>
<text top="446" left="773" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="478" left="79" width="130" height="9" font="6">Pharmacological stress Echo</text>
<text top="478" left="284" width="6" height="9" font="6">X</text>
<text top="478" left="351" width="17" height="9" font="6">Any</text>
<text top="478" left="422" width="6" height="9" font="6">X</text>
<text top="478" left="567" width="11" height="9" font="6">IIa</text>
<text top="478" left="653" width="6" height="9" font="6">C</text>
<text top="478" left="682" width="18" height="9" font="6">N/A</text>
<text top="495" left="79" width="24" height="9" font="6">CCTA</text>
<text top="495" left="284" width="6" height="9" font="6">X</text>
<text top="495" left="351" width="17" height="9" font="6">Any</text>
<text top="495" left="422" width="6" height="9" font="6">X</text>
<text top="495" left="479" width="6" height="9" font="6">X</text>
<text top="495" left="567" width="11" height="9" font="6">IIa</text>
<text top="495" left="653" width="6" height="9" font="6">B</text>
<text top="495" left="682" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="495" left="686" width="42" height="9" font="7"><a href="e44.full.html#89">158–166</a></text>
<text top="495" left="728" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="512" left="79" width="130" height="9" font="6">Pharmacological stress CMR</text>
<text top="512" left="284" width="6" height="9" font="6">X</text>
<text top="512" left="351" width="17" height="9" font="6">Any</text>
<text top="512" left="479" width="6" height="9" font="6">X</text>
<text top="512" left="537" width="6" height="9" font="6">X</text>
<text top="512" left="567" width="11" height="9" font="6">IIa</text>
<text top="512" left="653" width="6" height="9" font="6">B</text>
<text top="512" left="682" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="512" left="686" width="105" height="9" font="7"><a href="e44.full.html#89">153,157,158,169–172</a></text>
<text top="512" left="791" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="529" left="79" width="58" height="9" font="6">Exercise ECG</text>
<text top="529" left="284" width="6" height="9" font="6">X</text>
<text top="529" left="381" width="6" height="9" font="6">X</text>
<text top="529" left="475" width="17" height="9" font="6">Any</text>
<text top="529" left="567" width="62" height="9" font="6">III: No Benefit</text>
<text top="529" left="653" width="6" height="9" font="6">C</text>
<text top="529" left="682" width="3" height="9" font="6"><a href="e44.full.html#87">(</a></text>
<text top="529" left="686" width="99" height="9" font="7"><a href="e44.full.html#87">91,132,148–156,161</a></text>
<text top="529" left="785" width="3" height="9" font="6"><a href="e44.full.html#87">)</a></text>
<text top="547" left="79" width="25" height="9" font="6">Other</text>
<text top="564" left="79" width="24" height="9" font="6">CCTA</text>
<text top="578" left="79" width="109" height="9" font="6">If patient has any of the</text>
<text top="592" left="92" width="43" height="9" font="6">following:</text>
<text top="607" left="79" width="130" height="9" font="6">a) Continued symptoms with</text>
<text top="621" left="92" width="91" height="9" font="6">prior normal test, or</text>
<text top="635" left="79" width="119" height="9" font="6">b) Inconclusive exercise or</text>
<text top="649" left="92" width="119" height="9" font="6">pharmacological stress, or</text>
<text top="664" left="79" width="124" height="9" font="6">c) Unable to undergo stress</text>
<text top="678" left="92" width="76" height="9" font="6">with MPI or Echo</text>
<text top="564" left="259" width="17" height="9" font="6">Any</text>
<text top="564" left="351" width="17" height="9" font="6">Any</text>
<text top="564" left="479" width="6" height="9" font="6">X</text>
<text top="564" left="567" width="11" height="9" font="6">IIa</text>
<text top="564" left="653" width="6" height="9" font="6">C</text>
<text top="564" left="682" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="564" left="686" width="18" height="9" font="7"><a href="e44.full.html#89">173</a></text>
<text top="564" left="704" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="695" left="79" width="46" height="9" font="6">CAC score</text>
<text top="695" left="259" width="17" height="9" font="6">Any</text>
<text top="695" left="351" width="17" height="9" font="6">Any</text>
<text top="695" left="422" width="6" height="9" font="6">X</text>
<text top="695" left="567" width="11" height="9" font="6">IIb</text>
<text top="695" left="653" width="6" height="9" font="6">C</text>
<text top="695" left="682" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="695" left="686" width="18" height="9" font="7"><a href="e44.full.html#89">174</a></text>
<text top="695" left="704" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="733" left="59" width="747" height="7" font="17">CAC indicates coronary artery calcium; CCTA, cardiac computed tomography angiography; CMR, cardiac magnetic resonance imaging; COR, class of recommendation; ECG, electrocardiogram; Echo,</text>
<text top="745" left="59" width="641" height="7" font="17">echocardiography; IHD, ischemic heart disease; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not available; and SIHD, stable ischemic heart disease.</text>
<text top="757" left="67" width="739" height="7" font="17">*Patients are candidates for exercise testing if they are capable of performing at least moderate physical functioning (i.e., moderate household, yard, or recreational work <i>and </i>most activities of daily</text>
<text top="769" left="59" width="456" height="7" font="17">living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicted maximum heart rate.</text>
<text top="52" left="787" width="18" height="10" font="12">e67</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="306" height="16" font="26"><b>2.2.3. Diagnostic Accuracy of Nonimaging and</b></text>
<text top="123" left="59" width="330" height="16" font="26"><b>Imaging Stress Testing for the Initial Diagnosis of</b></text>
<text top="141" left="59" width="109" height="16" font="26"><b>Suspected SIHD</b></text>
<text top="173" left="59" width="106" height="9" font="6">2.2.3.1. EXERCISE ECG</text>
<text top="187" left="59" width="360" height="16" font="4">The exercise ECG has been the cornerstone of diagnostic</text>
<text top="206" left="59" width="360" height="16" font="4">testing of SIHD patients for several decades. The diagnostic</text>
<text top="225" left="59" width="215" height="16" font="4">endpoint for an ischemic ECG is</text>
<text top="221" left="280" width="139" height="20" font="4">ⱖ1 mm horizontal or</text>
<text top="243" left="58" width="360" height="16" font="4">down-sloping (at 80 ms after the J point) ST-segment</text>
<text top="262" left="58" width="360" height="16" font="4">depression at peak exercise. ST-segment elevation (in a</text>
<text top="280" left="58" width="360" height="16" font="4">non–Q-wave lead and excluding aortic valve replacement)</text>
<text top="299" left="58" width="360" height="16" font="4">during or after exercise occurs infrequently but represents a</text>
<text top="317" left="58" width="360" height="16" font="4">high-risk ECG finding consistent with an ACS. The</text>
<text top="336" left="58" width="360" height="16" font="4">diagnostic accuracy of exertional ST-segment depression</text>
<text top="354" left="58" width="360" height="16" font="4">has been studied extensively in several meta-analyses, sys-</text>
<text top="373" left="58" width="360" height="16" font="4">tematic reviews, large observational registries, and RCTs</text>
<text top="391" left="58" width="5" height="16" font="4"><a href="e44.full.html#88">(</a></text>
<text top="391" left="63" width="105" height="16" font="16"><a href="e44.full.html#88">114,145–147,175</a></text>
<text top="391" left="169" width="250" height="16" font="4"><a href="e44.full.html#88">). </a>The composite diagnostic sensitivity</text>
<text top="410" left="58" width="360" height="16" font="4">and specificity, unadjusted for referral bias, is 61% and</text>
<text top="428" left="58" width="360" height="16" font="4">ranges from 70% to 77%, but it is lower in women</text>
<text top="447" left="58" width="5" height="16" font="4"><a href="e44.full.html#89">(</a></text>
<text top="447" left="63" width="75" height="16" font="16"><a href="e44.full.html#89">146,147,175</a></text>
<text top="447" left="139" width="280" height="16" font="4"><a href="e44.full.html#89">) </a>and lower than that for stress imaging mo-</text>
<text top="465" left="58" width="360" height="16" font="4">dalities. A similar accuracy has been reported for correlation</text>
<text top="484" left="58" width="329" height="16" font="4">of ECG ischemia with anatomic CAD by CCTA <a href="e44.full.html#90">(</a></text>
<text top="484" left="387" width="23" height="16" font="16"><a href="e44.full.html#90">176</a></text>
<text top="484" left="410" width="9" height="16" font="4"><a href="e44.full.html#90">).</a></text>
<text top="502" left="58" width="360" height="16" font="4">Diagnostic accuracy is improved when consideration is</text>
<text top="521" left="58" width="360" height="16" font="4">given to additional non-ECG factors, such as exercise</text>
<text top="539" left="58" width="360" height="16" font="4">duration, chronotropic incompetence, angina, ventricular</text>
<text top="558" left="58" width="360" height="16" font="4">arrhythmias, heart rate recovery, and hemodynamic re-</text>
<text top="576" left="58" width="360" height="16" font="4">sponse to exercise (i.e., drop in systolic BP), or when</text>
<text top="595" left="58" width="360" height="16" font="4">combination scores such as the Duke treadmill or Lauer</text>
<text top="613" left="58" width="118" height="16" font="4">scores are applied <a href="e44.full.html#88">(</a></text>
<text top="613" left="176" width="79" height="16" font="16"><a href="e44.full.html#88">118,177–180</a></text>
<text top="613" left="255" width="9" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="632" left="73" width="345" height="16" font="4">Multiple factors in addition to the patient’s inability to</text>
<text top="650" left="58" width="360" height="16" font="4">achieve maximal exercise levels influence the accuracy of the</text>
<text top="669" left="58" width="360" height="16" font="4">ECG during exercise testing to diagnose obstructive CAD.</text>
<text top="687" left="58" width="360" height="16" font="4">Resting ECG abnormalities preclude accurate interpreta-</text>
<text top="706" left="58" width="360" height="16" font="4">tion of exercise-induced changes and reduce test accuracy;</text>
<text top="724" left="58" width="360" height="16" font="4">these include abnormalities affecting the ST segment, such</text>
<text top="743" left="58" width="360" height="16" font="4">as LV hypertrophy, LBBB, ventricular-paced rhythm, or</text>
<text top="761" left="58" width="221" height="16" font="4">any resting ST-segment depression</text>
<text top="758" left="287" width="132" height="20" font="4">ⱖ0.5 mm. Although</text>
<text top="780" left="58" width="360" height="16" font="4">some have proposed calculating the difference from rest to</text>
<text top="798" left="58" width="120" height="16" font="4">exercise of changes</text>
<text top="795" left="186" width="233" height="20" font="4">ⱖ1 mm for patients with significant</text>
<text top="817" left="58" width="360" height="16" font="4">resting ST-segment changes, the accuracy of this approach</text>
<text top="835" left="58" width="360" height="16" font="4">has been less extensively studied and validated. The inter-</text>
<text top="854" left="58" width="360" height="16" font="4">pretation of ST-segment changes in patients with right</text>
<text top="872" left="58" width="360" height="16" font="4">bundle-branch block can be limited, especially in the pre-</text>
<text top="891" left="58" width="360" height="16" font="4">cordial leads. Certain medications, including digitalis, also</text>
<text top="909" left="58" width="360" height="16" font="4">influence ST-segment changes and can produce ischemic</text>
<text top="928" left="58" width="360" height="16" font="4">ECG changes that are frequently false positive findings. In</text>
<text top="946" left="58" width="360" height="16" font="4">addition, anti-ischemic therapies can reduce heart rate and</text>
<text top="965" left="58" width="360" height="16" font="4">myocardial workload, and therefore, a lack of ischemic</text>
<text top="983" left="58" width="360" height="16" font="4">ECG changes can reflect false negative findings when the</text>
<text top="1002" left="58" width="360" height="16" font="4">test is used to diagnose SIHD. It is routine practice to</text>
<text top="1020" left="58" width="360" height="16" font="4">withhold beta-blocker therapy for 24 to 48 hours before</text>
<text top="1039" left="58" width="360" height="16" font="4">testing. Patients who are candidates for an exercise ECG</text>
<text top="1057" left="58" width="360" height="16" font="4">must be able to exercise and must have an interpretable</text>
<text top="1076" left="58" width="360" height="16" font="4">ECG, which is defined as a normal 12-lead ECG or one</text>
<text top="1094" left="58" width="293" height="16" font="4">with minimal resting ST-T-wave abnormalities (</text>
<text top="1091" left="351" width="68" height="20" font="4">⬍0.5 mm).</text>
<text top="108" left="446" width="345" height="9" font="6">2.2.3.2. EXERCISE AND PHARMACOLOGICAL STRESS ECHOCARDIOGRAPHY</text>
<text top="123" left="446" width="360" height="16" font="4">The diagnostic endpoint of exercise and pharmacological</text>
<text top="141" left="446" width="360" height="16" font="4">stress echocardiography is new or worsening wall motion</text>
<text top="159" left="446" width="360" height="16" font="4">abnormalities and changes in global LV function during or</text>
<text top="177" left="446" width="360" height="16" font="4">immediately after stress. In addition to the detection of</text>
<text top="195" left="446" width="360" height="16" font="4">inducible wall motion abnormalities, most stress echocardi-</text>
<text top="213" left="446" width="360" height="16" font="4">ography includes screening images to evaluate resting ven-</text>
<text top="232" left="446" width="360" height="16" font="4">tricular function and valvular abnormalities. This informa-</text>
<text top="250" left="446" width="360" height="16" font="4">tion can be helpful in a symptomatic patient without a</text>
<text top="268" left="446" width="106" height="16" font="4">proven diagnosis.</text>
<text top="286" left="461" width="345" height="16" font="4">Pharmacological stress echocardiography in the United</text>
<text top="304" left="446" width="360" height="16" font="4">States is performed largely by using dobutamine with an</text>
<text top="322" left="446" width="298" height="16" font="4">endpoint of inducible wall motion abnormalities <a href="e44.full.html#24">(</a></text>
<text top="322" left="743" width="53" height="16" font="16"><a href="e44.full.html#24">Table 11</a></text>
<text top="322" left="797" width="9" height="16" font="4"><a href="e44.full.html#24">).</a></text>
<text top="341" left="446" width="360" height="16" font="4">Vasodilator agents such as adenosine are used rarely in the</text>
<text top="359" left="446" width="360" height="16" font="4">United States but are used more commonly in Europe. The</text>
<text top="377" left="446" width="360" height="16" font="4">diagnostic accuracy of exercise and pharmacological stress</text>
<text top="395" left="446" width="360" height="16" font="4">echocardiography has been studied extensively in multiple</text>
<text top="413" left="446" width="360" height="16" font="4">meta-analyses, systematic reviews, and large, multicenter,</text>
<text top="431" left="446" width="155" height="16" font="4">observational registries <a href="e44.full.html#87">(</a></text>
<text top="431" left="601" width="126" height="16" font="16"><a href="e44.full.html#87">91,148 –152,154,175</a></text>
<text top="431" left="726" width="79" height="16" font="4"><a href="e44.full.html#87">). </a>In several</text>
<text top="450" left="446" width="360" height="16" font="4">contemporary meta-analyses, the diagnostic sensitivity (un-</text>
<text top="468" left="446" width="360" height="16" font="4">corrected for referral bias) ranged from 70% to 85% for</text>
<text top="486" left="446" width="360" height="16" font="4">exercise and 85% to 90% for pharmacological stress echo-</text>
<text top="504" left="446" width="87" height="16" font="4">cardiography <a href="e44.full.html#87">(</a></text>
<text top="504" left="533" width="94" height="16" font="16"><a href="e44.full.html#87">91,150,152,154</a></text>
<text top="504" left="627" width="179" height="16" font="4"><a href="e44.full.html#87">). </a>The uncorrected diagnostic</text>
<text top="522" left="446" width="360" height="16" font="4">specificity ranges from 77% to 89% and 79% to 90% for</text>
<text top="540" left="446" width="360" height="16" font="4">exercise and pharmacological stress echocardiography, re-</text>
<text top="559" left="446" width="360" height="16" font="4">spectively. The use of intravenous ultrasound contrast</text>
<text top="577" left="446" width="360" height="16" font="4">agents can improve endocardial border delineation and can</text>
<text top="595" left="446" width="253" height="16" font="4">result in improved diagnostic accuracy <a href="e44.full.html#90">(</a></text>
<text top="595" left="699" width="23" height="16" font="16"><a href="e44.full.html#90">181</a></text>
<text top="595" left="721" width="84" height="16" font="4"><a href="e44.full.html#90">). </a>Myocardial</text>
<text top="613" left="446" width="360" height="16" font="4">contrast echocardiography also has been examined for de-</text>
<text top="631" left="446" width="360" height="16" font="4">termination of rest and stress myocardial perfusion, with the</text>
<text top="649" left="446" width="360" height="16" font="4">results showing comparability to myocardial perfusion</text>
<text top="668" left="446" width="243" height="16" font="4">SPECT findings in small patient series <a href="e44.full.html#90">(</a></text>
<text top="668" left="689" width="23" height="16" font="16"><a href="e44.full.html#90">182</a></text>
<text top="668" left="711" width="94" height="16" font="4"><a href="e44.full.html#90">). </a>However, the</text>
<text top="686" left="446" width="354" height="16" font="4">technique is currently in limited use in the United States.</text>
<text top="704" left="461" width="345" height="16" font="4">The diagnostic accuracy of all imaging modalities is</text>
<text top="722" left="446" width="360" height="16" font="4">influenced by technical factors that could be inherent in the</text>
<text top="740" left="446" width="360" height="16" font="4">technique (i.e., variable correlation between perfusion and</text>
<text top="758" left="446" width="360" height="16" font="4">wall motion abnormalities and CAD extent and severity) or</text>
<text top="777" left="446" width="360" height="16" font="4">that result from physical characteristics of the patient that</text>
<text top="795" left="446" width="360" height="16" font="4">reduce image quality. For echocardiography, reduced image</text>
<text top="813" left="446" width="360" height="16" font="4">quality, defined as reduced LV endocardial visualization, has</text>
<text top="831" left="446" width="360" height="16" font="4">been reported for obese individuals and those with chronic</text>
<text top="849" left="446" width="360" height="16" font="4">lung disease, although the use of intravenous contrast</text>
<text top="867" left="446" width="360" height="16" font="4">enhancement results in sizeable improvement in endocardial</text>
<text top="886" left="446" width="115" height="16" font="4">border delineation.</text>
<text top="917" left="446" width="288" height="9" font="6">2.2.3.3. EXERCISE AND PHARMACOLOGICAL STRESS NUCLEAR</text>
<text top="935" left="446" width="312" height="9" font="6">MYOCARDIAL PERFUSION SPECT AND MYOCARDIAL PERFUSION PET</text>
<text top="949" left="446" width="360" height="16" font="4">Myocardial perfusion SPECT generally is performed with</text>
<text top="967" left="446" width="360" height="16" font="4">rest and (for exercise or pharmacological stress) with stress</text>
<text top="986" left="446" width="360" height="16" font="4">Tc-99m agents, with Tl-201 having limited applications</text>
<text top="1004" left="446" width="336" height="16" font="4">(e.g., viability) because of its higher radiation exposure <a href="e44.full.html#88">(</a></text>
<text top="1004" left="782" width="15" height="16" font="16"><a href="e44.full.html#88">97</a></text>
<text top="1004" left="797" width="9" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="1022" left="446" width="360" height="16" font="4">Pharmacological stress generally is used with vasodilator</text>
<text top="1040" left="446" width="360" height="16" font="4">agents administered as a continuous infusion (adenosine,</text>
<text top="1058" left="446" width="360" height="16" font="4">dipyridamole) or bolus (regadenoson) injection. The diag-</text>
<text top="1076" left="446" width="360" height="16" font="4">nostic endpoint of nuclear MPI is reduction in myocardial</text>
<text top="1094" left="446" width="360" height="16" font="4">perfusion after stress. Nonperfusion high-risk markers in-</text>
<text top="52" left="59" width="18" height="10" font="12">e68</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">clude a markedly abnormal ECG, extensive stress-induced</text>
<text top="123" left="59" width="360" height="16" font="4">wall motion abnormalities, reduced post-stress left ventric-</text>
<text top="141" left="59" width="178" height="16" font="4">ular ejection fraction (LVEF)</text>
<text top="138" left="240" width="179" height="20" font="4">ⱖ5% or global LVEF (rest or</text>
<text top="159" left="59" width="69" height="16" font="4">post-stress)</text>
<text top="156" left="136" width="282" height="20" font="4">⬍45%, transient ischemic LV dilation, in-</text>
<text top="177" left="59" width="360" height="16" font="4">creased lung or right ventricular uptake, or abnormal coro-</text>
<text top="195" left="59" width="360" height="16" font="4">nary flow reserve with myocardial perfusion PET</text>
<text top="213" left="59" width="5" height="16" font="4"><a href="e44.full.html#90">(</a></text>
<text top="213" left="63" width="53" height="16" font="16"><a href="e44.full.html#90">183–186</a></text>
<text top="213" left="116" width="9" height="16" font="4"><a href="e44.full.html#90">).</a></text>
<text top="232" left="74" width="345" height="16" font="4">The diagnostic accuracy for detection of obstructive</text>
<text top="250" left="59" width="360" height="16" font="4">CAD of exercise and pharmacological stress nuclear MPI</text>
<text top="268" left="59" width="360" height="16" font="4">has been studied extensively in multiple meta-analyses,</text>
<text top="286" left="59" width="360" height="16" font="4">systematic reviews, RCTs, and large, multicenter, observa-</text>
<text top="304" left="59" width="117" height="16" font="4">tional registries <a href="e44.full.html#87">(</a></text>
<text top="304" left="176" width="233" height="16" font="16"><a href="e44.full.html#87">91,114,132,147,148,152,155,156,175</a></text>
<text top="304" left="409" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="322" left="59" width="360" height="16" font="4">From these reports, the uncorrected diagnostic sensitivity</text>
<text top="341" left="59" width="360" height="16" font="4">ranged from 82% to 88% for exercise and 88% to 91% for</text>
<text top="359" left="59" width="360" height="16" font="4">pharmacological stress nuclear MPI. The uncorrected diag-</text>
<text top="377" left="59" width="360" height="16" font="4">nostic specificity ranged from 70% to 88% and 75% to 90%</text>
<text top="395" left="59" width="360" height="16" font="4">for exercise and pharmacological stress nuclear MPI,</text>
<text top="413" left="59" width="73" height="16" font="4">respectively.</text>
<text top="431" left="74" width="345" height="16" font="4">Diagnostic image quality is affected in obese patients, as well</text>
<text top="450" left="59" width="360" height="16" font="4">as in women and men with large breasts. Reductions in breast</text>
<text top="468" left="59" width="360" height="16" font="4">tissue artifact have been reported with the use of the Tc-99m</text>
<text top="486" left="59" width="360" height="16" font="4">agents as well as with attenuation-correction algorithms or</text>
<text top="504" left="59" width="94" height="16" font="4">prone imaging <a href="e44.full.html#90">(</a></text>
<text top="504" left="153" width="51" height="16" font="16"><a href="e44.full.html#90">187–190</a></text>
<text top="504" left="203" width="216" height="16" font="4"><a href="e44.full.html#90">). </a>For myocardial perfusion SPECT,</text>
<text top="522" left="59" width="360" height="16" font="4">global reductions in myocardial perfusion, such as in the setting</text>
<text top="540" left="59" width="360" height="16" font="4">of left main or 3-vessel CAD, can result in balanced reduction</text>
<text top="559" left="59" width="258" height="16" font="4">and an underestimation of ischemic burden.</text>
<text top="577" left="74" width="345" height="16" font="4">Myocardial perfusion PET is characterized by high spa-</text>
<text top="595" left="59" width="360" height="16" font="4">tial resolution of the photon attenuation– corrected images</text>
<text top="613" left="59" width="27" height="16" font="4">with</text>
<text top="611" left="89" width="11" height="10" font="11">82</text>
<text top="613" left="100" width="77" height="16" font="4">Rubidium or</text>
<text top="611" left="181" width="11" height="10" font="11">13</text>
<text top="613" left="192" width="227" height="16" font="4">N-ammonia used as myocardial blood</text>
<text top="631" left="59" width="360" height="16" font="4">flow tracers. Although less well studied than myocardial</text>
<text top="650" left="59" width="360" height="16" font="4">perfusion SPECT, a meta-analysis of 19 studies suggests</text>
<text top="668" left="59" width="360" height="16" font="4">that PET has a slightly higher (uncorrected) sensitivity for</text>
<text top="686" left="59" width="117" height="16" font="4">detection of CAD <a href="e44.full.html#90">(</a></text>
<text top="686" left="176" width="49" height="16" font="16"><a href="e44.full.html#90">191,192</a></text>
<text top="686" left="225" width="194" height="16" font="4"><a href="e44.full.html#90">), </a>including in women and obese</text>
<text top="704" left="59" width="57" height="16" font="4">patients <a href="e44.full.html#90">(</a></text>
<text top="704" left="116" width="23" height="16" font="16"><a href="e44.full.html#90">193</a></text>
<text top="704" left="138" width="9" height="16" font="4"><a href="e44.full.html#90">).</a></text>
<text top="735" left="59" width="322" height="9" font="6">2.2.3.4. PHARMACOLOGICAL STRESS CMR WALL MOTION/PERFUSION</text>
<text top="749" left="59" width="360" height="16" font="4">In recent years, more centers have used pharmacological</text>
<text top="768" left="59" width="360" height="16" font="4">stress CMR in the diagnostic evaluation of SIHD patients.</text>
<text top="786" left="59" width="360" height="16" font="4">The imaging endpoint depends on the stress agent: devel-</text>
<text top="804" left="59" width="360" height="16" font="4">opment of a new wall motion abnormality for cine CMR</text>
<text top="822" left="59" width="360" height="16" font="4">with dobutamine stress or a new perfusion abnormality with</text>
<text top="840" left="59" width="360" height="16" font="4">vasodilator stress. From a contemporary meta-analysis of 37</text>
<text top="858" left="59" width="360" height="16" font="4">studies, the uncorrected diagnostic sensitivity and specificity</text>
<text top="877" left="59" width="360" height="16" font="4">of dobutamine-induced CMR wall motion imaging were</text>
<text top="895" left="59" width="360" height="16" font="4">83% and 86%, whereas the uncorrected diagnostic sensitiv-</text>
<text top="913" left="59" width="360" height="16" font="4">ity and specificity of vasodilator stress–induced CMR MPI</text>
<text top="931" left="59" width="128" height="16" font="4">were 91% and 81% <a href="e44.full.html#89">(</a></text>
<text top="931" left="187" width="23" height="16" font="16"><a href="e44.full.html#89">153</a></text>
<text top="931" left="209" width="209" height="16" font="4"><a href="e44.full.html#89">). </a>Several small comparative series</text>
<text top="949" left="59" width="360" height="16" font="4">have reported accuracy data in relation to stress echocardi-</text>
<text top="967" left="59" width="360" height="16" font="4">ography and nuclear imaging. Importantly, normal CMR</text>
<text top="985" left="59" width="360" height="16" font="4">perfusion has a high negative predictive value for obstructive</text>
<text top="1004" left="59" width="49" height="16" font="4">CAD <a href="e44.full.html#90">(</a></text>
<text top="1004" left="107" width="23" height="16" font="16"><a href="e44.full.html#90">194</a></text>
<text top="1004" left="130" width="289" height="16" font="4"><a href="e44.full.html#90">). </a>One multicenter study that enrolled 234</text>
<text top="1022" left="59" width="360" height="16" font="4">patients demonstrated similar diagnostic accuracy between</text>
<text top="1040" left="59" width="360" height="16" font="4">CMR perfusion and SPECT MPI in detecting obstructive</text>
<text top="1058" left="59" width="47" height="16" font="4">CAD <a href="e44.full.html#89">(</a></text>
<text top="1058" left="105" width="23" height="16" font="16"><a href="e44.full.html#89">172</a></text>
<text top="1058" left="128" width="291" height="16" font="4"><a href="e44.full.html#89">). </a>More recently, a randomized study of 752</text>
<text top="1076" left="59" width="360" height="16" font="4">patients directly compared pharmacological stress CMR</text>
<text top="1094" left="59" width="360" height="16" font="4">with SPECT MPI and reported higher sensitivity by</text>
<text top="104" left="446" width="360" height="16" font="4">pharmacological stress CMR than SPECT MPI in the</text>
<text top="123" left="446" width="360" height="16" font="4">detection of angiographically significant coronary stenosis</text>
<text top="141" left="446" width="133" height="16" font="4">(87% versus 67%; p</text>
<text top="138" left="578" width="73" height="20" font="4">⬍0.0001) <a href="e44.full.html#89">(</a></text>
<text top="141" left="651" width="23" height="16" font="16"><a href="e44.full.html#89">169</a></text>
<text top="141" left="674" width="132" height="16" font="4"><a href="e44.full.html#89">). </a>With dobutamine</text>
<text top="159" left="446" width="360" height="16" font="4">stress, CMR wall motion had high accuracy for detection of</text>
<text top="177" left="446" width="360" height="16" font="4">obstructive CAD in patients with suboptimal echocardio-</text>
<text top="195" left="446" width="171" height="16" font="4">graphic acoustic window <a href="e44.full.html#89">(</a></text>
<text top="195" left="616" width="23" height="16" font="16"><a href="e44.full.html#89">170</a></text>
<text top="195" left="639" width="167" height="16" font="4"><a href="e44.full.html#89">). </a>CMR dobutamine wall</text>
<text top="213" left="446" width="360" height="16" font="4">motion imaging demonstrated higher accuracy than dobut-</text>
<text top="232" left="446" width="236" height="16" font="4">amine echocardiography wall motion <a href="e44.full.html#89">(</a></text>
<text top="232" left="682" width="23" height="16" font="16"><a href="e44.full.html#89">171</a></text>
<text top="232" left="704" width="101" height="16" font="4"><a href="e44.full.html#89">). </a>Although wall</text>
<text top="250" left="446" width="360" height="16" font="4">motion and perfusion imaging are used to assess the</text>
<text top="268" left="446" width="360" height="16" font="4">presence and extent of ischemia, most experienced centers</text>
<text top="286" left="446" width="360" height="16" font="4">also acquire late gadolinium enhancement (LGE) imaging</text>
<text top="304" left="446" width="360" height="16" font="4">in the same session to delineate the extent and severity of</text>
<text top="322" left="446" width="126" height="16" font="4">scarred myocardium.</text>
<text top="354" left="446" width="119" height="9" font="6">2.2.3.5. HYBRID IMAGING</text>
<text top="368" left="446" width="360" height="16" font="4">Current imaging is based largely on the use of a single</text>
<text top="386" left="446" width="360" height="16" font="4">modality, but combined or hybrid applications increasingly</text>
<text top="404" left="446" width="360" height="16" font="4">are available, which include both PET and CT or SPECT</text>
<text top="422" left="446" width="360" height="16" font="4">and CT, thus allowing for combined anatomic and func-</text>
<text top="440" left="446" width="360" height="16" font="4">tional testing. In addition, newer scanning techniques have</text>
<text top="459" left="446" width="360" height="16" font="4">allowed assessment of perfusion and FFR by CCTA alone,</text>
<text top="477" left="446" width="206" height="16" font="4">in addition to coronary anatomy <a href="e44.full.html#90">(</a></text>
<text top="477" left="652" width="53" height="16" font="16"><a href="e44.full.html#90">195–201</a></text>
<text top="477" left="704" width="101" height="16" font="4"><a href="e44.full.html#90">). </a>Notably, these</text>
<text top="495" left="446" width="360" height="16" font="4">combined assessments allow for a fused image in which the</text>
<text top="513" left="446" width="360" height="16" font="4">physiological assessment of flow is coupled with the ana-</text>
<text top="531" left="446" width="360" height="16" font="4">tomic extent and severity of CAD and also provides infor-</text>
<text top="549" left="446" width="360" height="16" font="4">mation on plaque composition and arterial remodeling.</text>
<text top="568" left="446" width="360" height="16" font="4">Limited evidence is available on hybrid imaging, although</text>
<text top="586" left="446" width="360" height="16" font="4">several reports have reported prognostic accuracy for cardiac</text>
<text top="604" left="446" width="299" height="16" font="4">events with both ischemic and anatomic markers <a href="e44.full.html#90">(</a></text>
<text top="604" left="744" width="53" height="16" font="16"><a href="e44.full.html#90">202–206</a></text>
<text top="604" left="797" width="9" height="16" font="4"><a href="e44.full.html#90">).</a></text>
<text top="622" left="446" width="360" height="16" font="4">Other combinations of imaging modalities also are being</text>
<text top="640" left="446" width="360" height="16" font="4">developed, including PET/CMR, which is currently a</text>
<text top="658" left="446" width="360" height="16" font="4">research application. The strength of combined imaging is</text>
<text top="677" left="446" width="360" height="16" font="4">the added value of anatomy guiding interpretation of</text>
<text top="695" left="446" width="360" height="16" font="4">ischemic and scarred myocardium as well as providing</text>
<text top="713" left="446" width="360" height="16" font="4">information to guide therapeutic decision making. Hybrid</text>
<text top="731" left="446" width="360" height="16" font="4">imaging also can overcome technical limitations of myocar-</text>
<text top="749" left="446" width="360" height="16" font="4">dial perfusion SPECT or myocardial perfusion PET by</text>
<text top="767" left="446" width="360" height="16" font="4">providing anatomic correlates to guide interpretative accu-</text>
<text top="786" left="446" width="34" height="16" font="4">racy <a href="e44.full.html#90">(</a></text>
<text top="786" left="480" width="23" height="16" font="16"><a href="e44.full.html#90">207</a></text>
<text top="786" left="502" width="303" height="16" font="4"><a href="e44.full.html#90">) </a>and can provide the functional information that</text>
<text top="804" left="446" width="360" height="16" font="4">an anatomic technique like CCTA or magnetic resonance</text>
<text top="822" left="446" width="341" height="16" font="4">angiography lacks; however, radiation dose is increased.</text>
<text top="849" left="446" width="337" height="16" font="26"><b>2.2.4. Diagnostic Accuracy of Anatomic Testing for</b></text>
<text top="867" left="446" width="197" height="16" font="26"><b>the Initial Diagnosis of SIHD</b></text>
<text top="898" left="446" width="177" height="9" font="6">2.2.4.1. CORONARY CT ANGIOGRAPHY</text>
<text top="913" left="446" width="360" height="16" font="4">With improvements in temporal and spatial resolution as</text>
<text top="931" left="446" width="360" height="16" font="4">well as volume coverage, evaluation of coronary arteries with</text>
<text top="949" left="446" width="360" height="16" font="4">CCTA is now possible with a high degree of image quality</text>
<text top="967" left="446" width="5" height="16" font="4"><a href="e44.full.html#90">(</a></text>
<text top="967" left="450" width="23" height="16" font="16"><a href="e44.full.html#90">208</a></text>
<text top="967" left="473" width="333" height="16" font="4"><a href="e44.full.html#90">). </a>The extent and severity of angiographic CAD are 2</text>
<text top="985" left="446" width="360" height="16" font="4">of the most important prognostic factors and remain essen-</text>
<text top="1004" left="446" width="258" height="16" font="4">tial for revascularization decision making <a href="e44.full.html#90">(</a></text>
<text top="1004" left="704" width="23" height="16" font="16"><a href="e44.full.html#90">209</a></text>
<text top="1004" left="726" width="79" height="16" font="4"><a href="e44.full.html#90">). </a>Five meta-</text>
<text top="1022" left="446" width="360" height="16" font="4">analyses and 3 controlled clinical trials have reported the</text>
<text top="1040" left="446" width="360" height="16" font="4">diagnostic accuracy of CCTA with 64-slice CT, yielding</text>
<text top="1058" left="446" width="360" height="16" font="4">sensitivity values ranging from 93% to 97% and specificity</text>
<text top="1076" left="446" width="216" height="16" font="4">values ranging from 80% to 90% <a href="e44.full.html#89">(</a></text>
<text top="1076" left="662" width="54" height="16" font="16"><a href="e44.full.html#89">159 –166</a></text>
<text top="1076" left="716" width="89" height="16" font="4"><a href="e44.full.html#89">) </a>for detecting</text>
<text top="1094" left="446" width="360" height="16" font="4">obstructive CAD on invasive coronary angiography, unad-</text>
<text top="52" left="787" width="18" height="10" font="12">e69</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">justed for referral bias. In a small series of women, the</text>
<text top="123" left="59" width="329" height="16" font="4">diagnostic accuracy of CCTA was similarly high <a href="e44.full.html#90">(</a></text>
<text top="123" left="387" width="23" height="16" font="16"><a href="e44.full.html#90">210</a></text>
<text top="123" left="410" width="9" height="16" font="4"><a href="e44.full.html#90">).</a></text>
<text top="141" left="59" width="360" height="16" font="4">Prior reports included subsets of patients who already had</text>
<text top="159" left="59" width="360" height="16" font="4">been referred for invasive angiography, and as such, test</text>
<text top="177" left="59" width="360" height="16" font="4">performance would be altered by the biases inherent in a</text>
<text top="195" left="59" width="360" height="16" font="4">preselected population. Factors related to diminished accu-</text>
<text top="213" left="59" width="360" height="16" font="4">racy include image quality, the extent of coronary calcifica-</text>
<text top="232" left="59" width="217" height="16" font="4">tion, and body mass index (BMI) <a href="e44.full.html#90">(</a></text>
<text top="232" left="275" width="23" height="16" font="16"><a href="e44.full.html#90">208</a></text>
<text top="232" left="298" width="9" height="16" font="4"><a href="e44.full.html#90">).</a></text>
<text top="250" left="74" width="345" height="16" font="4">A potential advantage of CCTA over standard functional</text>
<text top="268" left="59" width="360" height="16" font="4">testing is its very high negative predictive value for obstruc-</text>
<text top="286" left="59" width="360" height="16" font="4">tive CAD, which can reassure caregivers that providing</text>
<text top="304" left="59" width="360" height="16" font="4">GDMT and deferring consideration of revascularization</text>
<text top="322" left="59" width="360" height="16" font="4">constitute a sensible strategy. In addition to documentation</text>
<text top="341" left="59" width="360" height="16" font="4">of stenotic lesions, CCTA can qualitatively visualize arterial</text>
<text top="359" left="59" width="360" height="16" font="4">remodeling and nonobstructive plaque, including calcified,</text>
<text top="377" left="59" width="193" height="16" font="4">noncalcified, or mixed plaque <a href="e44.full.html#90">(</a></text>
<text top="377" left="252" width="53" height="16" font="16"><a href="e44.full.html#90">211–216</a></text>
<text top="377" left="304" width="115" height="16" font="4"><a href="e44.full.html#90">). </a>The presence of</text>
<text top="395" left="59" width="360" height="16" font="4">nonobstructive plaque has been shown to be helpful to</text>
<text top="413" left="59" width="360" height="16" font="4">guiding risk assessment and can aid in discerning the</text>
<text top="431" left="59" width="190" height="16" font="4">etiology of patient symptoms <a href="e44.full.html#90">(</a></text>
<text top="431" left="248" width="75" height="16" font="16"><a href="e44.full.html#90">211,215,216</a></text>
<text top="431" left="323" width="95" height="16" font="4"><a href="e44.full.html#90">). </a>CT informa-</text>
<text top="450" left="59" width="360" height="16" font="4">tion has been correlated with functional stress testing</text>
<text top="468" left="59" width="5" height="16" font="4"><a href="e44.full.html#90">(</a></text>
<text top="468" left="63" width="75" height="16" font="16"><a href="e44.full.html#90">203,204,215</a></text>
<text top="468" left="139" width="280" height="16" font="4"><a href="e44.full.html#90">). </a>Not every obstructive lesion produces isch-</text>
<text top="486" left="59" width="360" height="16" font="4">emia, and ischemia can be present in the absence of a</text>
<text top="504" left="59" width="360" height="16" font="4">significant stenosis in epicardial vessels, which results in</text>
<text top="522" left="59" width="360" height="16" font="4">discordance between anatomic imaging with CCTA and</text>
<text top="540" left="59" width="360" height="16" font="4">functional stress testing. Several series have reported the</text>
<text top="559" left="59" width="360" height="16" font="4">positive predictive value of an anatomic lesion detected on</text>
<text top="577" left="59" width="360" height="16" font="4">CCTA to range from 29% to 44% when ischemia on a stress</text>
<text top="595" left="59" width="242" height="16" font="4">study is used as a reference standard <a href="e44.full.html#90">(</a></text>
<text top="595" left="300" width="49" height="16" font="16"><a href="e44.full.html#90">203,204</a></text>
<text top="595" left="349" width="69" height="16" font="4"><a href="e44.full.html#90">). </a>The evi-</text>
<text top="613" left="59" width="360" height="16" font="4">dence on concordance, however, remains incomplete, with</text>
<text top="631" left="59" width="360" height="16" font="4">current research showing the highest degree of concordance</text>
<text top="649" left="59" width="360" height="16" font="4">between ischemia and mixed plaque. Because the presence</text>
<text top="668" left="59" width="360" height="16" font="4">of significant calcification often can preclude the accurate</text>
<text top="686" left="59" width="360" height="16" font="4">assessment of lesion severity or cause a false positive study,</text>
<text top="704" left="59" width="360" height="16" font="4">CCTA should not be performed in patients who have</text>
<text top="722" left="59" width="326" height="16" font="4">known extensive calcification or a high risk of CAD.</text>
<text top="753" left="59" width="104" height="9" font="6">2.2.4.2. CAC SCORING</text>
<text top="768" left="59" width="360" height="16" font="4">CT also provides measurement of a CAC score, calculated</text>
<text top="786" left="59" width="360" height="16" font="4">as the product of the CAC area by maximal plaque density</text>
<text top="804" left="59" width="137" height="16" font="4">(in Hounsfield units) <a href="e44.full.html#91">(</a></text>
<text top="804" left="196" width="23" height="16" font="16"><a href="e44.full.html#91">217</a></text>
<text top="804" left="218" width="200" height="16" font="4"><a href="e44.full.html#91">). </a>The CAC score frequently has</text>
<text top="822" left="59" width="360" height="16" font="4">been applied for risk assessment in asymptomatic individu-</text>
<text top="840" left="59" width="25" height="16" font="4">als <a href="e44.full.html#85">(</a></text>
<text top="840" left="84" width="8" height="16" font="16"><a href="e44.full.html#85">5</a></text>
<text top="840" left="91" width="327" height="16" font="4"><a href="e44.full.html#85">), </a>and it also has been used to predict the presence of</text>
<text top="858" left="59" width="360" height="16" font="4">high-grade coronary stenosis as the cause of chest pain in</text>
<text top="877" left="59" width="360" height="16" font="4">symptomatic patients. When the data from 2 large multi-</text>
<text top="895" left="59" width="360" height="16" font="4">center registries, including a total of 3,615 symptomatic</text>
<text top="913" left="59" width="360" height="16" font="4">patients, were combined, the estimated diagnostic sensitiv-</text>
<text top="931" left="59" width="360" height="16" font="4">ity for the CAC score to predict obstructive CAD on</text>
<text top="949" left="59" width="360" height="16" font="4">invasive angiography was 85%, with a specificity of 75%</text>
<text top="967" left="59" width="5" height="16" font="4"><a href="e44.full.html#91">(</a></text>
<text top="967" left="63" width="23" height="16" font="16"><a href="e44.full.html#91">218</a></text>
<text top="967" left="86" width="333" height="16" font="4"><a href="e44.full.html#91">). </a>In a recent meta-analysis of 18 studies, which</text>
<text top="985" left="59" width="360" height="16" font="4">included 10,355 symptomatic patients, the presence of</text>
<text top="1004" left="59" width="360" height="16" font="4">nonzero CAC score had a pooled sensitivity and specificity</text>
<text top="1022" left="59" width="360" height="16" font="4">of 98% and 40%, respectively, for detection of significant</text>
<text top="1040" left="59" width="254" height="16" font="4">CAD on invasive coronary angiography <a href="e44.full.html#89">(</a></text>
<text top="1040" left="312" width="23" height="16" font="16"><a href="e44.full.html#89">174</a></text>
<text top="1040" left="335" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="1058" left="74" width="345" height="16" font="4">Although the diagnostic sensitivity of CAC to detect</text>
<text top="1076" left="59" width="360" height="16" font="4">obstructive CAD is fairly high, the frequency of false</text>
<text top="1094" left="59" width="360" height="16" font="4">negative exams (i.e., significant CAD in the absence of</text>
<text top="104" left="446" width="360" height="16" font="4">CAC) is not well established. In small single-center studies,</text>
<text top="122" left="446" width="360" height="16" font="4">perfusion defects on nuclear MPI or high-grade coronary</text>
<text top="140" left="446" width="360" height="16" font="4">stenosis on coronary angiography can be present in 0% to 39%</text>
<text top="158" left="446" width="329" height="16" font="4">of symptomatic patients with a calcium score of zero <a href="e44.full.html#91">(</a></text>
<text top="158" left="775" width="31" height="16" font="16"><a href="e44.full.html#91">219–</a></text>
<text top="176" left="446" width="22" height="16" font="16"><a href="e44.full.html#91">223</a></text>
<text top="176" left="467" width="338" height="16" font="4"><a href="e44.full.html#91">). </a>In the recent large, multicenter, CONFIRM (Coronary</text>
<text top="194" left="446" width="360" height="16" font="4">CT Angiography Evaluation For Clinical Outcomes: An</text>
<text top="212" left="446" width="360" height="16" font="4">International Multicenter Registry) registry, CCTA showed</text>
<text top="230" left="446" width="262" height="16" font="4">mild, nonobstructive CAD in 13%, stenosis</text>
<text top="227" left="713" width="93" height="20" font="4">ⱖ50% in 3.5%,</text>
<text top="248" left="445" width="75" height="16" font="4">and stenosis</text>
<text top="245" left="529" width="276" height="20" font="4">ⱖ70% in 1.4% of the 10,037 symptomatic</text>
<text top="266" left="445" width="360" height="16" font="4">patients without known CAD who had a CAC score of zero</text>
<text top="284" left="445" width="5" height="16" font="4"><a href="e44.full.html#91">(</a></text>
<text top="284" left="450" width="22" height="16" font="16"><a href="e44.full.html#91">214</a></text>
<text top="284" left="472" width="334" height="16" font="4"><a href="e44.full.html#91">). </a>Documentation of obstructive CAD without CAC</text>
<text top="302" left="445" width="360" height="16" font="4">occurs more often in younger patients in whom atherosclerotic</text>
<text top="320" left="445" width="309" height="16" font="4">plaque has not advanced to the stage of calcification.</text>
<text top="338" left="460" width="345" height="16" font="4">Previous official documents from the AHA and ACCF</text>
<text top="356" left="445" width="5" height="16" font="4"><a href="e44.full.html#91">(</a></text>
<text top="356" left="450" width="22" height="16" font="16"><a href="e44.full.html#91">218</a></text>
<text top="356" left="472" width="334" height="16" font="4"><a href="e44.full.html#91">) </a>concluded that “patients considered to be at low risk of</text>
<text top="374" left="445" width="360" height="16" font="4">coronary disease by virtue of atypical cardiac symptoms may</text>
<text top="392" left="445" width="360" height="16" font="4">benefit from CAC testing to help in ruling out the presence of</text>
<text top="410" left="445" width="178" height="16" font="4">obstructive coronary disease” <a href="e44.full.html#91">(</a></text>
<text top="410" left="623" width="22" height="16" font="16"><a href="e44.full.html#91">218</a></text>
<text top="410" left="645" width="161" height="16" font="4"><a href="e44.full.html#91">) </a>or that “coronary calcium</text>
<text top="428" left="445" width="360" height="16" font="4">assessment may be reasonable for the assessment of symptom-</text>
<text top="446" left="445" width="360" height="16" font="4">atic patients, especially in the setting of equivocal treadmill or</text>
<text top="464" left="445" width="360" height="16" font="4">functional testing (Class IIb, LOE: B).” The present writing</text>
<text top="482" left="445" width="360" height="16" font="4">committee believed that additional evidence in sufficiently large</text>
<text top="500" left="445" width="360" height="16" font="4">cohorts of patients establishing the uncorrected diagnostic</text>
<text top="518" left="445" width="360" height="16" font="4">accuracy of CAC to rule in or rule out high-grade coronary</text>
<text top="536" left="445" width="302" height="16" font="4">artery stenosis in symptomatic patients was needed.</text>
<text top="567" left="446" width="133" height="9" font="6">2.2.4.3. CMR ANGIOGRAPHY</text>
<text top="581" left="446" width="360" height="16" font="4">Although not widely applied, CMR angiography has been</text>
<text top="599" left="446" width="360" height="16" font="4">performed for the detection of the extent and severity of</text>
<text top="617" left="446" width="360" height="16" font="4">obstructive CAD. As a result of small coronary artery size,</text>
<text top="635" left="446" width="360" height="16" font="4">tortuosity, and motion, the diagnostic accuracy of CMR</text>
<text top="653" left="446" width="313" height="16" font="4">angiography is reduced as compared with CCTA <a href="e44.full.html#91">(</a></text>
<text top="653" left="758" width="23" height="16" font="16"><a href="e44.full.html#91">224</a></text>
<text top="653" left="781" width="25" height="16" font="4"><a href="e44.full.html#91">). </a>A</text>
<text top="671" left="446" width="360" height="16" font="4">multicenter, controlled clinical trial of patients referred to</text>
<text top="689" left="446" width="360" height="16" font="4">invasive angiography revealed that magnetic resonance an-</text>
<text top="707" left="446" width="360" height="16" font="4">giography had an 81% negative predictive value for exclud-</text>
<text top="725" left="446" width="67" height="16" font="4">ing CAD <a href="e44.full.html#91">(</a></text>
<text top="725" left="513" width="23" height="16" font="16"><a href="e44.full.html#91">225</a></text>
<text top="725" left="535" width="270" height="16" font="4"><a href="e44.full.html#91">). </a>Several meta-analyses that included a total</text>
<text top="743" left="446" width="360" height="16" font="4">of 59 studies have reported diagnostic sensitivity and spec-</text>
<text top="761" left="446" width="360" height="16" font="4">ificity ranging from 87% to 88% and 56% to 70%, respec-</text>
<text top="779" left="446" width="42" height="16" font="4">tively <a href="e44.full.html#89">(</a></text>
<text top="779" left="487" width="49" height="16" font="16"><a href="e44.full.html#89">158,226</a></text>
<text top="779" left="536" width="270" height="16" font="4"><a href="e44.full.html#89">), </a>with reports of a lower accuracy than that</text>
<text top="797" left="446" width="76" height="16" font="4">of CCTA <a href="e44.full.html#89">(</a></text>
<text top="797" left="522" width="23" height="16" font="16"><a href="e44.full.html#89">164</a></text>
<text top="797" left="544" width="261" height="16" font="4"><a href="e44.full.html#89">). </a>Variability in diagnostic accuracy with</text>
<text top="815" left="446" width="360" height="16" font="4">CMR angiography has been attributed to a lack of unifor-</text>
<text top="833" left="446" width="360" height="16" font="4">mity in pulse sequences and the application of varying</text>
<text top="851" left="446" width="122" height="16" font="4">analytic methods <a href="e44.full.html#91">(</a></text>
<text top="851" left="567" width="23" height="16" font="16"><a href="e44.full.html#91">227</a></text>
<text top="851" left="590" width="216" height="16" font="4"><a href="e44.full.html#91">). </a>Recent improvements applying</text>
<text top="869" left="446" width="360" height="16" font="4">32-channel 3.0-T CMR have shown comparable abilities to</text>
<text top="887" left="446" width="254" height="16" font="4">detect CAD as compared with CCTA <a href="e44.full.html#91">(</a></text>
<text top="887" left="700" width="23" height="16" font="16"><a href="e44.full.html#91">228</a></text>
<text top="887" left="722" width="83" height="16" font="4"><a href="e44.full.html#91">). </a>No recom-</text>
<text top="905" left="446" width="360" height="16" font="4">mendations for the use of CMR angiography are included in</text>
<text top="923" left="446" width="86" height="16" font="4">this guideline.</text>
<text top="960" left="446" width="160" height="14" font="15">3. Risk Assessment</text>
<text top="1006" left="446" width="172" height="12" font="18">3.1. Clinical Assessment</text>
<text top="1033" left="446" width="338" height="16" font="26"><b>3.1.1. Prognosis of IHD for Death or Nonfatal MI:</b></text>
<text top="1051" left="446" width="153" height="16" font="26"><b>General Considerations</b></text>
<text top="1076" left="446" width="360" height="16" font="4">IHD is a chronic disorder with a natural history that spans</text>
<text top="1094" left="446" width="360" height="16" font="4">multiple decades. The disease typically cycles through clin-</text>
<text top="52" left="59" width="18" height="10" font="12">e70</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">ically defined phases: asymptomatic, stable angina, acceler-</text>
<text top="123" left="59" width="360" height="16" font="4">ating angina, and ACS (UA or AMI), although the pro-</text>
<text top="141" left="59" width="360" height="16" font="4">gression from one state to another is not necessarily linear.</text>
<text top="159" left="59" width="360" height="16" font="4">The specific approach to assessing risk of subsequent ad-</text>
<text top="177" left="59" width="360" height="16" font="4">verse outcomes varies according to the patient’s clinical</text>
<text top="195" left="59" width="360" height="16" font="4">phase, even though for those with SIHD, there is no</text>
<text top="213" left="59" width="360" height="16" font="4">universally accepted approach. This represents a key area for</text>
<text top="231" left="59" width="360" height="16" font="4">future research. The approach recommended in the present</text>
<text top="249" left="59" width="360" height="16" font="4">guideline is informed by the treatment goals of prolonging</text>
<text top="268" left="59" width="360" height="16" font="4">survival and optimizing health status and by the concept</text>
<text top="286" left="59" width="360" height="16" font="4">that the benefits of treatment are often proportional to the</text>
<text top="304" left="59" width="360" height="16" font="4">patient’s underlying risk. From this perspective, it is essen-</text>
<text top="322" left="59" width="360" height="16" font="4">tial to quantify the patient’s prognosis as accurately as</text>
<text top="340" left="59" width="360" height="16" font="4">possible. Several approaches to estimating the risk of car-</text>
<text top="358" left="59" width="360" height="16" font="4">diovascular mortality or events are provided later in this</text>
<text top="376" left="59" width="360" height="16" font="4">guideline. In the absence of an established prognostic</text>
<text top="394" left="59" width="320" height="16" font="4">model, the following considerations are highlighted:</text>
<text top="426" left="59" width="360" height="16" font="4">1. <i>Sociodemographic characteristics: </i>Age is the single stron-</text>
<text top="444" left="77" width="341" height="16" font="4">gest determinant of survival, whereas ethnicity and sex</text>
<text top="462" left="77" width="341" height="16" font="4">have conflicting and less important effects on risk. Lower</text>
<text top="480" left="77" width="341" height="16" font="4">socioeconomic status also is associated with worse out-</text>
<text top="498" left="77" width="47" height="16" font="4">comes <a href="e44.full.html#91">(</a></text>
<text top="498" left="125" width="23" height="16" font="16"><a href="e44.full.html#91">229</a></text>
<text top="498" left="147" width="9" height="16" font="4"><a href="e44.full.html#91">).</a></text>
<text top="517" left="58" width="360" height="16" font="4">2. <i>Cardiovascular risk factors: </i>Smoking, hypertension, dyslipi-</text>
<text top="535" left="77" width="341" height="16" font="4">demia, family history of premature CAD, obesity, and</text>
<text top="553" left="77" width="327" height="16" font="4">sedentary lifestyle confer a greater risk of complications.</text>
<text top="571" left="58" width="329" height="16" font="4">3. <i>Coexisting medical conditions: </i>Diabetes mellitus <a href="e44.full.html#91">(</a></text>
<text top="571" left="387" width="23" height="16" font="16"><a href="e44.full.html#91">230</a></text>
<text top="571" left="410" width="9" height="16" font="4"><a href="e44.full.html#91">),</a></text>
<text top="589" left="77" width="192" height="16" font="4">chronic kidney disease (CKD) <a href="e44.full.html#91">(</a></text>
<text top="589" left="269" width="23" height="16" font="16"><a href="e44.full.html#91">231</a></text>
<text top="589" left="292" width="127" height="16" font="4"><a href="e44.full.html#91">), </a>chronic pulmonary</text>
<text top="607" left="77" width="341" height="16" font="4">disease, and malignancy are the most important noncar-</text>
<text top="625" left="77" width="242" height="16" font="4">diac conditions to influence prognosis <a href="e44.full.html#91">(</a></text>
<text top="625" left="319" width="53" height="16" font="16"><a href="e44.full.html#91">232–234</a></text>
<text top="625" left="372" width="9" height="16" font="4"><a href="e44.full.html#91">).</a></text>
<text top="643" left="58" width="360" height="16" font="4">4. <i>Cardiovascular comorbidities: </i>Heart failure, PAD, and</text>
<text top="662" left="77" width="341" height="16" font="4">cerebrovascular diseases are strong prognostic risk factors</text>
<text top="680" left="77" width="81" height="16" font="4">for mortality.</text>
<text top="698" left="58" width="360" height="16" font="4">5. <i>Psychosocial characteristics: </i>Depression repeatedly has been</text>
<text top="716" left="77" width="341" height="16" font="4">demonstrated to be strongly and independently associated</text>
<text top="734" left="77" width="341" height="16" font="4">with worse survival, and anxiety has also been implicated</text>
<text top="752" left="77" width="5" height="16" font="4"><a href="e44.full.html#91">(</a></text>
<text top="752" left="82" width="51" height="16" font="16"><a href="e44.full.html#91">235–242</a></text>
<text top="752" left="132" width="286" height="16" font="4"><a href="e44.full.html#91">). </a>Poor social support, poverty, and stress also are</text>
<text top="770" left="77" width="204" height="16" font="4">associated with adverse prognosis <a href="e44.full.html#91">(</a></text>
<text top="770" left="281" width="76" height="16" font="16"><a href="e44.full.html#91">236,243–245</a></text>
<text top="770" left="356" width="8" height="16" font="4"><a href="e44.full.html#91">).</a></text>
<text top="788" left="58" width="360" height="16" font="4">6. <i>Health status: </i>Patients’ symptoms, functional capacity, and</text>
<text top="806" left="77" width="341" height="16" font="4">quality of life are associated significantly with survival and</text>
<text top="825" left="77" width="216" height="16" font="4">the incidence of subsequent ACS <a href="e44.full.html#91">(</a></text>
<text top="825" left="293" width="47" height="16" font="16"><a href="e44.full.html#91">246,247</a></text>
<text top="825" left="340" width="79" height="16" font="4"><a href="e44.full.html#91">). </a>In a large,</text>
<text top="843" left="77" width="341" height="16" font="4">prospective cohort of patients in the Veterans Affairs</text>
<text top="861" left="77" width="341" height="16" font="4">healthcare system, physical limitations due to angina were</text>
<text top="879" left="77" width="255" height="16" font="4">second only to age in predicting mortality <a href="e44.full.html#91">(</a></text>
<text top="879" left="332" width="22" height="16" font="16"><a href="e44.full.html#91">246</a></text>
<text top="879" left="353" width="8" height="16" font="4"><a href="e44.full.html#91">).</a></text>
<text top="897" left="58" width="360" height="16" font="4">7. <i>Anginal frequency: </i>Frequency of angina is a very strong</text>
<text top="915" left="77" width="288" height="16" font="4">predictor of subsequent ACS hospitalizations <a href="e44.full.html#91">(</a></text>
<text top="915" left="365" width="23" height="16" font="16"><a href="e44.full.html#91">246</a></text>
<text top="915" left="388" width="9" height="16" font="4"><a href="e44.full.html#91">).</a></text>
<text top="933" left="59" width="360" height="16" font="4">8. <i>Cardiac disease severity: </i>The degree and distribution of</text>
<text top="951" left="77" width="341" height="16" font="4">stenoses measured by coronary angiography, findings on</text>
<text top="969" left="77" width="341" height="16" font="4">exercise testing and stress imaging, and LV function</text>
<text top="987" left="77" width="341" height="16" font="4">measured with a variety of technologies all provide</text>
<text top="1006" left="77" width="341" height="16" font="4">meaningful prognostic information that supplements</text>
<text top="1024" left="77" width="159" height="16" font="4">more clinical information.</text>
<text top="1051" left="58" width="324" height="16" font="26"><b>3.1.2. Risk Assessment Using Clinical Parameters</b></text>
<text top="1076" left="58" width="360" height="16" font="4">Although there are several models to predict the likelihood</text>
<text top="1095" left="58" width="360" height="16" font="4">of complications and survival in asymptomatic, general</text>
<text top="105" left="446" width="360" height="16" font="4">populations and in patients with ACS, there is a relative</text>
<text top="123" left="446" width="360" height="16" font="4">paucity of information about models for assessing the risk of</text>
<text top="141" left="446" width="360" height="16" font="4">patients with known SIHD that incorporate a broad range</text>
<text top="160" left="446" width="360" height="16" font="4">of relevant data. Accurate risk assessment according to</text>
<text top="178" left="446" width="360" height="16" font="4">clinical variables is essential to determining optimal treat-</text>
<text top="196" left="446" width="360" height="16" font="4">ment strategies. Lauer and colleagues developed a risk index</text>
<text top="215" left="446" width="360" height="16" font="4">that incorporates variables from the history and exercise test</text>
<text top="233" left="446" width="154" height="16" font="4">on the basis of data from</text>
<text top="230" left="604" width="134" height="20" font="4">⬎32,000 individuals <a href="e44.full.html#91">(</a></text>
<text top="233" left="738" width="23" height="16" font="16"><a href="e44.full.html#91">248</a></text>
<text top="233" left="760" width="45" height="16" font="4"><a href="e44.full.html#91">). </a>They</text>
<text top="251" left="446" width="360" height="16" font="4">found that their index, which can be calculated by using a</text>
<text top="270" left="446" width="75" height="16" font="4">nomogram <a href="e44.full.html#29">(</a></text>
<text top="270" left="520" width="51" height="16" font="16"><a href="e44.full.html#29">Figure 8</a></text>
<text top="270" left="571" width="234" height="16" font="4"><a href="e44.full.html#29">), </a>was better able to predict individuals</text>
<text top="288" left="446" width="71" height="16" font="4">with a low (</text>
<text top="285" left="516" width="289" height="20" font="4">⬍3%) risk of death than was the Duke treadmill</text>
<text top="306" left="446" width="360" height="16" font="4">score. Daly and colleagues reported an index to estimate risk</text>
<text top="325" left="446" width="360" height="16" font="4">of death or nonfatal AMI derived from data on an interna-</text>
<text top="343" left="446" width="360" height="16" font="4">tional sample of approximately 3,000 patients who pre-</text>
<text top="361" left="446" width="360" height="16" font="4">sented with angina and were followed up for 18 months</text>
<text top="380" left="446" width="5" height="16" font="4"><a href="e44.full.html#30">(</a></text>
<text top="380" left="450" width="58" height="16" font="16"><a href="e44.full.html#30">Figures 9</a></text>
<text top="380" left="513" width="22" height="16" font="4">and</text>
<text top="380" left="541" width="15" height="16" font="16"><a href="e44.full.html#30">10</a></text>
<text top="380" left="556" width="249" height="16" font="4"><a href="e44.full.html#30">). </a>Obstructive CAD was documented in</text>
<text top="398" left="446" width="360" height="16" font="4">one third, whereas another third had negative evaluations.</text>
<text top="416" left="446" width="360" height="16" font="4">The <i>c </i>statistic for the model was 0.74, which indicates a</text>
<text top="435" left="446" width="201" height="16" font="4">relatively high level of accuracy <a href="e44.full.html#87">(</a></text>
<text top="435" left="646" width="15" height="16" font="16"><a href="e44.full.html#87">57</a></text>
<text top="435" left="661" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="453" left="461" width="345" height="16" font="4">Several risk-assessment schemes have been developed to</text>
<text top="471" left="446" width="360" height="16" font="4">assist in identifying patients with severe CAD, including</text>
<text top="490" left="446" width="360" height="16" font="4">left main disease, although several of these studies are up to</text>
<text top="508" left="446" width="167" height="16" font="4">2 decades old. One study <a href="e44.full.html#87">(</a></text>
<text top="508" left="613" width="15" height="16" font="16"><a href="e44.full.html#87">70</a></text>
<text top="508" left="628" width="178" height="16" font="4"><a href="e44.full.html#87">) </a>identified 8 clinical charac-</text>
<text top="526" left="446" width="360" height="16" font="4">teristics that are important in estimating the likelihood of</text>
<text top="545" left="446" width="360" height="16" font="4">severe IHD: typical angina, previous MI, age, sex, duration</text>
<text top="563" left="446" width="360" height="16" font="4">of chest pain symptoms, risk factors (hypertension, diabetes</text>
<text top="581" left="446" width="360" height="16" font="4">mellitus, hyperlipidemia, and smoking), carotid bruit, and</text>
<text top="600" left="446" width="280" height="16" font="4">chest pain frequency. A subsequent study <a href="e44.full.html#87">(</a></text>
<text top="600" left="725" width="15" height="16" font="16"><a href="e44.full.html#87">71</a></text>
<text top="600" left="740" width="65" height="16" font="4"><a href="e44.full.html#87">) </a>provided</text>
<text top="618" left="446" width="360" height="16" font="4">detailed equations to predict both severe IHD and survival</text>
<text top="637" left="446" width="291" height="16" font="4">on the basis of clinical parameters. One study <a href="e44.full.html#91">(</a></text>
<text top="637" left="736" width="23" height="16" font="16"><a href="e44.full.html#91">249</a></text>
<text top="637" left="759" width="47" height="16" font="4"><a href="e44.full.html#91">) </a>devel-</text>
<text top="655" left="446" width="360" height="16" font="4">oped a simple risk score for predicting severe (left main or</text>
<text top="673" left="446" width="360" height="16" font="4">3-vessel) CAD that was based on 5 clinical variables: age,</text>
<text top="692" left="446" width="360" height="16" font="4">sex, history of MI, presence of typical angina, and diabetes</text>
<text top="710" left="446" width="360" height="16" font="4">mellitus with or without insulin use. This same score was</text>
<text top="728" left="446" width="303" height="16" font="4">validated subsequently for prognostic purposes <a href="e44.full.html#91">(</a></text>
<text top="728" left="748" width="49" height="16" font="16"><a href="e44.full.html#91">250,251</a></text>
<text top="728" left="797" width="9" height="16" font="4"><a href="e44.full.html#91">).</a></text>
<text top="747" left="446" width="299" height="16" font="4">This score can be easily memorized and calculated <a href="e44.full.html#31">(</a></text>
<text top="747" left="745" width="56" height="16" font="16"><a href="e44.full.html#31">Figure 11</a></text>
<text top="747" left="801" width="5" height="16" font="4"><a href="e44.full.html#31">)</a></text>
<text top="765" left="446" width="271" height="16" font="4">and yields an integer ranging from 0 to 10 <a href="e44.full.html#87">(</a></text>
<text top="765" left="717" width="15" height="16" font="16"><a href="e44.full.html#87">57</a></text>
<text top="765" left="732" width="74" height="16" font="4"><a href="e44.full.html#87">). </a>The score</text>
<text top="783" left="446" width="360" height="16" font="4">can be applied to determine if a patient is more suitable for</text>
<text top="802" left="446" width="360" height="16" font="4">stress testing or possibly (in appropriate patients who are at</text>
<text top="820" left="446" width="360" height="16" font="4">highest risk) for proceeding directly to coronary angiogra-</text>
<text top="838" left="446" width="360" height="16" font="4">phy. Each curve shows the probability of severe IHD as a</text>
<text top="856" left="446" width="360" height="16" font="4">function of age for a given cardiac risk score. As shown on</text>
<text top="875" left="446" width="19" height="16" font="4">the</text>
<text top="875" left="470" width="60" height="16" font="16"><a href="e44.full.html#31">Figure 11</a></text>
<text top="875" left="535" width="271" height="16" font="4">graph, some patients have a high likelihood</text>
<text top="893" left="446" width="5" height="16" font="4">(</text>
<text top="890" left="450" width="355" height="20" font="4">⬎50%) of having severe disease for which revascularization</text>
<text top="911" left="446" width="360" height="16" font="4">might improve survival on the basis of clinical parameters</text>
<text top="930" left="446" width="360" height="16" font="4">alone. For example, a 50-year-old male patient who has</text>
<text top="948" left="446" width="360" height="16" font="4">diabetes mellitus, is taking insulin, and has typical angina</text>
<text top="966" left="446" width="360" height="16" font="4">and a history of previous MI has a likelihood of severe</text>
<text top="985" left="446" width="103" height="16" font="4">coronary stenosis</text>
<text top="982" left="553" width="253" height="20" font="4">⬎60% and thus might proceed directly to</text>
<text top="1003" left="446" width="360" height="16" font="4">angiography if warranted by his preferences and other</text>
<text top="1021" left="446" width="360" height="16" font="4">clinical factors, although in most circumstances stress test-</text>
<text top="1040" left="446" width="360" height="16" font="4">ing will assist in planning further tests and treatments</text>
<text top="1058" left="446" width="5" height="16" font="4"><a href="e44.full.html#87">(</a></text>
<text top="1058" left="450" width="41" height="16" font="16"><a href="e44.full.html#87">87,252</a></text>
<text top="1058" left="492" width="314" height="16" font="4"><a href="e44.full.html#87">). </a>Creation of valid, quantitative models on the basis</text>
<text top="1076" left="446" width="360" height="16" font="4">of data from current registries and trials to accurately</text>
<text top="1095" left="446" width="360" height="16" font="4">identify patients with anatomic distributions of CAD for</text>
<text top="52" left="787" width="18" height="10" font="12">e71</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1161" width="864">
<text top="872" left="59" width="360" height="16" font="4">which revascularization has been shown to improve survival,</text>
<text top="891" left="59" width="338" height="16" font="4">such as left main disease, should be a research priority.</text>
<text top="909" left="74" width="345" height="16" font="4">Studies have suggested that addition of levels of novel</text>
<text top="928" left="59" width="360" height="16" font="4">biomarkers such as C-reactive protein and brain natriuretic</text>
<text top="946" left="59" width="360" height="16" font="4">peptide can improve prediction of mortality and cardiovas-</text>
<text top="965" left="59" width="79" height="16" font="4">cular events <a href="e44.full.html#85">(</a></text>
<text top="965" left="137" width="26" height="16" font="16"><a href="e44.full.html#85">5,57</a></text>
<text top="965" left="164" width="255" height="16" font="4"><a href="e44.full.html#85">). </a>Considerable controversy remains; how-</text>
<text top="983" left="59" width="360" height="16" font="4">ever, as to whether these tests truly provide incremental</text>
<text top="1002" left="59" width="360" height="16" font="4">information beyond more well-accepted risk factors, and</text>
<text top="1020" left="59" width="360" height="16" font="4">few of the studies have focused on patients with SIHD</text>
<text top="1039" left="59" width="5" height="16" font="4"><a href="e44.full.html#91">(</a></text>
<text top="1039" left="63" width="53" height="16" font="16"><a href="e44.full.html#91">253–255</a></text>
<text top="1039" left="116" width="303" height="16" font="4"><a href="e44.full.html#91">). </a>Inflammatory biomarkers, such as myeloperox-</text>
<text top="1057" left="59" width="42" height="16" font="4">idase <a href="e44.full.html#92">(</a></text>
<text top="1057" left="101" width="23" height="16" font="16"><a href="e44.full.html#92">256</a></text>
<text top="1057" left="123" width="295" height="16" font="4"><a href="e44.full.html#92">), </a>biochemical markers of lipid-related athero-</text>
<text top="1076" left="59" width="360" height="16" font="4">genic processes [lipoprotein(a), apolipoprotein B, small</text>
<text top="1094" left="59" width="360" height="16" font="4">dense LDL, and lipoprotein-associated phospholipase A2]</text>
<text top="872" left="446" width="5" height="16" font="4"><a href="e44.full.html#92">(</a></text>
<text top="872" left="450" width="49" height="16" font="16"><a href="e44.full.html#92">257,258</a></text>
<text top="872" left="499" width="306" height="16" font="4"><a href="e44.full.html#92">), </a>and low levels of circulating troponin detected by</text>
<text top="890" left="446" width="143" height="16" font="4">high-sensitivity assays <a href="e44.full.html#92">(</a></text>
<text top="890" left="589" width="23" height="16" font="16"><a href="e44.full.html#92">259</a></text>
<text top="890" left="611" width="194" height="16" font="4"><a href="e44.full.html#92">) </a>also are under investigation as</text>
<text top="908" left="446" width="235" height="16" font="4">indices of risk in patients with SIHD.</text>
<text top="935" left="446" width="158" height="12" font="18">3.2. Advanced Testing:</text>
<text top="953" left="446" width="274" height="12" font="18">Resting and Stress Noninvasive Testing</text>
<text top="984" left="446" width="333" height="16" font="26"><b>3.2.1. Resting Imaging to Assess Cardiac Structure</b></text>
<text top="1002" left="446" width="215" height="16" font="26"><b>and Function: Recommendations</b></text>
<text top="1034" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="1047" left="446" width="360" height="10" font="13">1. Assessment of resting LV systolic and diastolic ventricular function</text>
<text top="1064" left="461" width="344" height="10" font="13">and evaluation for abnormalities of myocardium, heart valves, or</text>
<text top="1080" left="461" width="344" height="10" font="13">pericardium are recommended with the use of Doppler echocardi-</text>
<text top="1097" left="461" width="344" height="10" font="13">ography in patients with known or suspected IHD and a prior MI,</text>
<text top="780" left="59" width="554" height="11" font="13">Figure 8. Nomogram to Predict Risk of Death Based on Clinical Data and Results of Exercise Testing</text>
<text top="812" left="59" width="738" height="8" font="11">To determine risk, draw a vertical line from each risk marker to the top line, labeled “POINTS,” to calculate points for each risk marker. The sum of all these points is then</text>
<text top="826" left="59" width="733" height="8" font="11">marked on the line labeled “TOTAL POINTS.” Drop vertical lines from there to yield the 3- and 5-year survival probabilities. For binary variables, 1 means yes and 0 means</text>
<text top="839" left="59" width="307" height="8" font="11">no. MET indicates metabolic equivalent. Reproduced from Lauer et al. <a href="e44.full.html#91">(</a></text>
<text top="839" left="365" width="18" height="8" font="23"><a href="e44.full.html#91">248</a></text>
<text top="839" left="383" width="6" height="8" font="11"><a href="e44.full.html#91">).</a></text>
<text top="52" left="59" width="18" height="10" font="12">e72</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1161" width="864">
<text top="630" left="75" width="344" height="10" font="13">pathological Q waves, symptoms or signs suggestive of heart fail-</text>
<text top="647" left="75" width="344" height="10" font="13">ure, complex ventricular arrhythmias, or an undiagnosed heart</text>
<text top="664" left="75" width="266" height="10" font="13">murmur <a href="e44.full.html#86">(21,57,58,260,261). </a><i>(Level of Evidence: B)</i></text>
<text top="690" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="703" left="59" width="360" height="10" font="13">1. Assessment of cardiac structure and function with resting echocar-</text>
<text top="720" left="74" width="344" height="10" font="13">diography may be considered in patients with hypertension or</text>
<text top="737" left="74" width="323" height="10" font="13">diabetes mellitus and an abnormal ECG. <i>(Level of Evidence: C)</i></text>
<text top="754" left="58" width="360" height="10" font="13">2. Measurement of LV function with radionuclide imaging may be</text>
<text top="770" left="74" width="344" height="10" font="13">considered in patients with a prior MI or pathological Q waves,</text>
<text top="787" left="74" width="344" height="10" font="13">provided there is no need to evaluate symptoms or signs suggestive</text>
<text top="630" left="461" width="344" height="10" font="13">of heart failure, complex ventricular arrhythmias, or an undiagnosed</text>
<text top="647" left="461" width="189" height="10" font="13">heart murmur. <i>(Level of Evidence: C)</i></text>
<text top="679" left="446" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="692" left="446" width="360" height="10" font="13">1. Echocardiography, radionuclide imaging, CMR, and cardiac CT are not</text>
<text top="710" left="461" width="344" height="10" font="13">recommended for routine assessment of LV function in patients with a</text>
<text top="727" left="461" width="344" height="10" font="13">normal ECG, no history of MI, no symptoms or signs suggestive of heart</text>
<text top="745" left="461" width="329" height="10" font="13">failure, and no complex ventricular arrhythmias. <i>(Level of Evidence: C)</i></text>
<text top="763" left="445" width="140" height="10" font="13">2. Routine reassessment (</text>
<text top="759" left="586" width="220" height="16" font="13">⬍1 year) of LV function with technologies</text>
<text top="780" left="461" width="344" height="10" font="13">such as echocardiography radionuclide imaging, CMR, or cardiac CT</text>
<text top="798" left="461" width="344" height="10" font="13">is not recommended in patients with no change in clinical status</text>
<text top="815" left="461" width="344" height="10" font="13">and for whom no change in therapy is contemplated. <i>(Level of</i></text>
<text top="833" left="461" width="63" height="10" font="25"><i>Evidence: C)</i></text>
<text top="858" left="446" width="18" height="16" font="5"><i>See</i></text>
<text top="858" left="470" width="162" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplement 2</i></a></text>
<text top="858" left="638" width="168" height="16" font="5"><i>for additional data on using</i></text>
<text top="876" left="446" width="321" height="16" font="5"><i>resting imaging to assess cardiac structure and function.</i></text>
<text top="907" left="461" width="345" height="16" font="4">In the presence of signs or symptoms suggestive of heart</text>
<text top="926" left="446" width="360" height="16" font="4">failure, it is imperative to obtain an objective measure of LV</text>
<text top="945" left="446" width="360" height="16" font="4">function if a prognosis-altering change in therapy could be</text>
<text top="963" left="446" width="360" height="16" font="4">based on the findings. For example, a rest ejection fraction</text>
<text top="982" left="446" width="29" height="16" font="4">(EF)</text>
<text top="979" left="478" width="327" height="20" font="4">⬍35% is associated with an annual mortality rate ⬎3%</text>
<text top="1001" left="445" width="65" height="16" font="4">per year <a href="e44.full.html#92">(</a></text>
<text top="1001" left="510" width="23" height="16" font="16"><a href="e44.full.html#92">260</a></text>
<text top="1001" left="533" width="273" height="16" font="4"><a href="e44.full.html#92">). </a>Resting 2-dimensional echocardiography</text>
<text top="1020" left="445" width="360" height="16" font="4">with Doppler echocardiography is the preferred approach</text>
<text top="1038" left="445" width="360" height="16" font="4">because it provides a thorough assessment of all aspects of</text>
<text top="1057" left="445" width="360" height="16" font="4">cardiac structure and function, including identifying the</text>
<text top="1076" left="445" width="360" height="16" font="4">mechanism of heart failure and differentiating systolic LV</text>
<text top="1094" left="445" width="163" height="16" font="4">from diastolic dysfunction.</text>
<text top="462" left="59" width="720" height="11" font="13">Figure 9. Euro Heart Score Sheet to Calculate Risk Score for Patients Presenting With Stable Angina (Derived From 3,779 Patients</text>
<text top="478" left="58" width="156" height="10" font="13">With Newly Diagnosed SIHD)</text>
<text top="509" left="59" width="6" height="8" font="11">*</text>
<text top="507" left="64" width="720" height="13" font="11">ⱖ1 of previous cerebrovascular event; hepatic disease defined as chronic hepatitis or cirrhosis, or other hepatic disease causing elevation of transaminases ⱖ3 times</text>
<text top="523" left="59" width="734" height="8" font="11">upper limit of normal; PVD defined as claudication either at rest or on exertion, amputation for arterial vascular insufficiency, vascular surgery (reconstruction or bypass) or</text>
<text top="536" left="59" width="742" height="8" font="11">angioplasty to the extremities, documented aortic aneurysm, or noninvasive evidence of impaired arterial flow; chronic renal failure defined as chronic dialysis or renal trans-</text>
<text top="550" left="59" width="129" height="8" font="11">plantation or serum creatinine</text>
<text top="547" left="191" width="598" height="13" font="11">⬎200 mmol/L; chronic respiratory disease defined as a diagnosis previously made by physician or patient receiving bronchodilators or FEV</text>
<text top="554" left="789" width="5" height="6" font="21">1</text>
<text top="561" left="59" width="77" height="13" font="11">⬍75%, arterial p0</text>
<text top="568" left="136" width="5" height="6" font="21">2</text>
<text top="561" left="143" width="95" height="13" font="11">⬍60%, or arterial pCO</text>
<text top="568" left="239" width="5" height="6" font="21">2</text>
<text top="561" left="246" width="539" height="13" font="11">⬎50% predicted in previous studies; chronic inflammatory conditions defined as a diagnosis of rheumatoid arthritis, systemic</text>
<text top="577" left="58" width="738" height="8" font="11">lupus erythematosus or other connective tissue disease, polymyalgia rheumatica, and so on; malignancy defined as a diagnosis of malignancy within a year of active malig-</text>
<text top="590" left="58" width="46" height="8" font="11">nancy. FEV</text>
<text top="595" left="105" width="5" height="6" font="21">1</text>
<text top="590" left="113" width="158" height="8" font="11">indicates forced expiratory volume; p</text>
<text top="592" left="270" width="11" height="8" font="21">O2,</text>
<text top="590" left="285" width="123" height="8" font="11">partial pressure of oxygen; P</text>
<text top="592" left="408" width="15" height="8" font="21">CO2,</text>
<text top="590" left="426" width="368" height="8" font="11">partial pressure of carbon dioxide; and PVD, peripheral vascular disease. Reproduced</text>
<text top="604" left="58" width="72" height="8" font="11">from Daly et al. <a href="e44.full.html#87">(</a></text>
<text top="604" left="131" width="12" height="8" font="23"><a href="e44.full.html#87">57</a></text>
<text top="604" left="142" width="6" height="8" font="11"><a href="e44.full.html#87">).</a></text>
<text top="1024" left="59" width="339" height="11" font="13">Figure 10. Risk of Death or MI Over 1-Year After Diagnosis of</text>
<text top="1040" left="59" width="196" height="10" font="13">SIHD According to Euro Heart Score</text>
<text top="1072" left="59" width="350" height="8" font="11">Plot to assign estimated probability of death or nonfatal MI within 1 year of presenta-</text>
<text top="1085" left="59" width="356" height="8" font="11">tion according to combination of clinical and investigative features in patients with sta-</text>
<text top="1099" left="59" width="312" height="8" font="11">ble angina. MI indicates myocardial infarction. Reproduced from Daly et al. <a href="e44.full.html#87">(</a></text>
<text top="1099" left="371" width="12" height="8" font="23"><a href="e44.full.html#87">57</a></text>
<text top="1099" left="382" width="6" height="8" font="11"><a href="e44.full.html#87">).</a></text>
<text top="52" left="787" width="18" height="10" font="12">e73</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1161" width="864">
<text top="466" left="74" width="345" height="16" font="4">Rest imaging also can provide valuable therapeutic guid-</text>
<text top="484" left="59" width="360" height="16" font="4">ance and prognostic information in patients without symp-</text>
<text top="502" left="59" width="360" height="16" font="4">toms or signs of ventricular dysfunction or changing clinical</text>
<text top="520" left="59" width="360" height="16" font="4">status, especially in those with evidence of other forms of</text>
<text top="538" left="59" width="360" height="16" font="4">heart disease (e.g., hypertensive, valvular). For example,</text>
<text top="556" left="59" width="360" height="16" font="4">echocardiography can identify LV or left atrial dilation;</text>
<text top="574" left="59" width="360" height="16" font="4">identify aortic stenosis (a potential non-CAD mechanism</text>
<text top="592" left="59" width="360" height="16" font="4">for angina-like chest pain); measure pulmonary artery pres-</text>
<text top="610" left="59" width="360" height="16" font="4">sure; quantify mitral regurgitation; identify a LV aneurysm;</text>
<text top="628" left="59" width="360" height="16" font="4">identify a LV thrombus, which increases the risk of death</text>
<text top="646" left="59" width="5" height="16" font="4"><a href="e44.full.html#92">(</a></text>
<text top="646" left="63" width="23" height="16" font="16"><a href="e44.full.html#92">262</a></text>
<text top="646" left="86" width="333" height="16" font="4"><a href="e44.full.html#92">); </a>and measure LV mass and the ratio of wall thickness</text>
<text top="664" left="59" width="360" height="16" font="4">to chamber radius—all of which predict cardiac events and</text>
<text top="682" left="59" width="65" height="16" font="4">mortality <a href="e44.full.html#86">(</a></text>
<text top="682" left="123" width="98" height="16" font="16"><a href="e44.full.html#86">20,117,263–267</a></text>
<text top="682" left="221" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="700" left="74" width="345" height="16" font="4">Although nuclear imaging accurately measures EF, it</text>
<text top="718" left="59" width="360" height="16" font="4">does not provide additional information on valvular or</text>
<text top="736" left="59" width="360" height="16" font="4">pericardial disease and requires exposure to ionizing radia-</text>
<text top="754" left="59" width="33" height="16" font="4">tion <a href="e44.full.html#86">(</a></text>
<text top="754" left="92" width="41" height="16" font="16"><a href="e44.full.html#86">21,268</a></text>
<text top="754" left="133" width="285" height="16" font="4"><a href="e44.full.html#86">). </a>Although CMR is applied less widely, it also</text>
<text top="772" left="59" width="360" height="16" font="4">accurately measures LV performance and provides insight</text>
<text top="790" left="59" width="238" height="16" font="4">into myocardial and valvular structures <a href="e44.full.html#92">(</a></text>
<text top="790" left="297" width="23" height="16" font="16"><a href="e44.full.html#92">269</a></text>
<text top="790" left="319" width="99" height="16" font="4"><a href="e44.full.html#92">). </a>Use of delayed</text>
<text top="808" left="59" width="360" height="16" font="4">hyperenhancement techniques can identify otherwise unde-</text>
<text top="826" left="59" width="360" height="16" font="4">tected scarred as well as viable myocardium. Cardiac CT</text>
<text top="844" left="59" width="360" height="16" font="4">also provides high-resolution detection of cardiac structures</text>
<text top="862" left="59" width="360" height="16" font="4">and EF. Nevertheless, all 3 tests generally are more expen-</text>
<text top="880" left="59" width="360" height="16" font="4">sive than a resting echocardiogram. Although the amount of</text>
<text top="898" left="59" width="360" height="16" font="4">ionizing radiation required in cardiac CT and nuclear MPI</text>
<text top="916" left="59" width="360" height="16" font="4">has been lowered over the years and will continue to reduce,</text>
<text top="934" left="59" width="360" height="16" font="4">the use of these tests for risk assessment is discouraged in</text>
<text top="952" left="59" width="360" height="16" font="4">patients with low pretest probability of CAD and in young</text>
<text top="970" left="59" width="51" height="16" font="4">patients.</text>
<text top="997" left="59" width="307" height="16" font="26"><b>3.2.2. Stress Testing and Advanced Imaging in</b></text>
<text top="1015" left="59" width="280" height="16" font="26"><b>Patients With Known SIHD Who Require</b></text>
<text top="1033" left="59" width="274" height="16" font="26"><b>Noninvasive Testing for Risk Assessment:</b></text>
<text top="1051" left="59" width="119" height="16" font="26"><b>Recommendations</b></text>
<text top="1076" left="59" width="21" height="16" font="4">See</text>
<text top="1076" left="84" width="54" height="16" font="16"><a href="e44.full.html#32">Table 12</a></text>
<text top="1076" left="142" width="276" height="16" font="4">for a summary of recommendations from this</text>
<text top="1094" left="59" width="46" height="16" font="4">section.</text>
<text top="108" left="446" width="276" height="9" font="6">3.2.2.1. RISK ASSESSMENT IN PATIENTS ABLE TO EXERCISE</text>
<text top="137" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="150" left="446" width="360" height="10" font="13">1. Standard exercise ECG testing is recommended for risk assessment</text>
<text top="167" left="461" width="344" height="10" font="13">in patients with SIHD who are able to exercise to an adequate</text>
<text top="184" left="461" width="344" height="10" font="13">workload and have an interpretable ECG <a href="e44.full.html#88">(106–110,112–114,132–</a></text>
<text top="201" left="461" width="142" height="10" font="13"><a href="e44.full.html#88">134). </a>(<i>Level of Evidence: B</i>)</text>
<text top="218" left="446" width="360" height="10" font="13">2. The addition of either nuclear MPI or echocardiography to standard</text>
<text top="235" left="461" width="344" height="10" font="13">exercise ECG testing is recommended for risk assessment in patients</text>
<text top="252" left="461" width="344" height="10" font="13">with SIHD who are able to exercise to an adequate workload but have</text>
<text top="269" left="461" width="344" height="10" font="13">an <i>un</i>interpretable ECG not due to LBBB or ventricular pacing</text>
<text top="286" left="461" width="267" height="10" font="13"><a href="e44.full.html#85">(7,111,264–266,270,299,300). </a><i>(Level of Evidence: B)</i></text>
<text top="317" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="330" left="446" width="360" height="10" font="13">1. The addition of either nuclear MPI or echocardiography to standard</text>
<text top="347" left="461" width="344" height="10" font="13">exercise ECG testing is reasonable for risk assessment in patients with</text>
<text top="364" left="461" width="344" height="10" font="13">SIHD who are able to exercise to an adequate workload and have an</text>
<text top="381" left="461" width="255" height="10" font="13">interpretable ECG <a href="e44.full.html#92">(271–279). </a>(<i>Level of Evidence: B</i>)</text>
<text top="398" left="446" width="360" height="10" font="13">2. CMR with pharmacological stress is reasonable for risk assessment</text>
<text top="415" left="461" width="344" height="10" font="13">in patients with SIHD who are able to exercise to an adequate</text>
<text top="432" left="461" width="344" height="10" font="13">workload but have an <i>un</i>interpretable ECG <a href="e44.full.html#92">(279–284). </a><i>(Level of</i></text>
<text top="450" left="461" width="63" height="10" font="25"><i>Evidence: B</i>)</text>
<text top="480" left="446" width="46" height="8" font="24">CLASS IIb</text>
<text top="493" left="446" width="360" height="10" font="13">1. CCTA may be reasonable for risk assessment in patients with SIHD</text>
<text top="510" left="461" width="344" height="10" font="13">who are able to exercise to an adequate workload but have an</text>
<text top="527" left="461" width="277" height="10" font="25"><i>un</i>interpretable ECG <a href="e44.full.html#92">(285,286). </a><i>(Level of Evidence: B)</i></text>
<text top="558" left="446" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="571" left="446" width="360" height="10" font="13">1. Pharmacological stress imaging (nuclear MPI, echocardiography, or</text>
<text top="588" left="461" width="344" height="10" font="13">CMR) or CCTA is not recommended for risk assessment in patients</text>
<text top="605" left="461" width="344" height="10" font="13">with SIHD who are able to exercise to an adequate workload and</text>
<text top="622" left="461" width="252" height="10" font="13">have an interpretable ECG. <i>(Level of Evidence: C)</i></text>
<text top="651" left="446" width="289" height="9" font="6">3.2.2.2. RISK ASSESSMENT IN PATIENTS UNABLE TO EXERCISE</text>
<text top="680" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="693" left="446" width="360" height="10" font="13">1. Pharmacological stress with either nuclear MPI or echocardiography is</text>
<text top="710" left="461" width="344" height="10" font="13">recommended for risk assessment in patients with SIHD who are</text>
<text top="727" left="461" width="344" height="10" font="13">unable to exercise to an adequate workload regardless of interpretabil-</text>
<text top="744" left="461" width="275" height="10" font="13">ity of ECG <a href="e44.full.html#85">(7,264–266,287–290). </a>(<i>Level of Evidence: B)</i></text>
<text top="775" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="787" left="446" width="360" height="10" font="13">1. Pharmacological stress CMR is reasonable for risk assessment in</text>
<text top="804" left="461" width="344" height="10" font="13">patients with SIHD who are unable to exercise to an adequate</text>
<text top="822" left="461" width="344" height="10" font="13">workload regardless of interpretability of ECG <a href="e44.full.html#92">(280–284,291).</a></text>
<text top="839" left="461" width="111" height="10" font="13">(<i>Level of Evidence: B)</i></text>
<text top="856" left="446" width="360" height="10" font="13">2. CCTA can be useful as a first-line test for risk assessment in patients</text>
<text top="873" left="461" width="344" height="10" font="13">with SIHD who are unable to exercise to an adequate workload</text>
<text top="890" left="461" width="334" height="10" font="13">regardless of interpretability of ECG <a href="e44.full.html#92">(286). </a><i>(Level of Evidence: C)</i></text>
<text top="919" left="446" width="357" height="9" font="6">3.2.2.3. RISK ASSESSMENT REGARDLESS OF PATIENTS’ ABILITY TO EXERCISE</text>
<text top="948" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="961" left="446" width="360" height="10" font="13">1. Pharmacological stress with either nuclear MPI or echocardiogra-</text>
<text top="978" left="461" width="344" height="10" font="13">phy is recommended for risk assessment in patients with SIHD who</text>
<text top="995" left="461" width="344" height="10" font="13">have LBBB on ECG, regardless of ability to exercise to an adequate</text>
<text top="1012" left="461" width="248" height="10" font="13">workload <a href="e44.full.html#92">(287–290,292). </a><i>(Level of Evidence: B</i>)</text>
<text top="1029" left="445" width="360" height="10" font="13">2. Either exercise or pharmacological stress with imaging (nuclear</text>
<text top="1046" left="461" width="344" height="10" font="13">MPI, echocardiography, or CMR) is recommended for risk assess-</text>
<text top="1063" left="461" width="344" height="10" font="13">ment in patients with SIHD who are being considered for revascu-</text>
<text top="1080" left="461" width="344" height="10" font="13">larization of known coronary stenosis of unclear physiological sig-</text>
<text top="1097" left="461" width="268" height="10" font="13">nificance <a href="e44.full.html#92">(266,278,293,294). </a><i>(Level of Evidence: B)</i></text>
<text top="331" left="59" width="325" height="11" font="13">Figure 11. Nomogram Showing the Probability of Severe</text>
<text top="346" left="59" width="335" height="11" font="13">(3-Vessel or Left Main) Coronary Disease Based on a 5-Point</text>
<text top="362" left="59" width="32" height="11" font="13">Score</text>
<text top="394" left="59" width="352" height="8" font="11">One point is awarded for each of the following variables: male sex, typical angina,</text>
<text top="408" left="59" width="351" height="8" font="11">history and electrocardiographic evidence of MI, and diabetes mellitus and use of</text>
<text top="421" left="59" width="353" height="8" font="11">insulin. Each curve shows the probability of severe coronary disease as a function</text>
<text top="435" left="59" width="177" height="8" font="11">of age. Reproduced from Hubbard et al. <a href="e44.full.html#91">(</a></text>
<text top="435" left="235" width="18" height="8" font="23"><a href="e44.full.html#91">249</a></text>
<text top="435" left="253" width="6" height="8" font="11"><a href="e44.full.html#91">).</a></text>
<text top="52" left="59" width="18" height="10" font="12">e74</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1161" width="864">
<text top="838" left="59" width="46" height="8" font="24">CLASS IIa</text>
<text top="850" left="59" width="360" height="10" font="13">1. CCTA can be useful for risk assessment in patients with SIHD who</text>
<text top="867" left="74" width="344" height="10" font="13">have an indeterminate result from functional testing <a href="e44.full.html#92">(286). </a><i>(Level of</i></text>
<text top="884" left="74" width="63" height="10" font="25"><i>Evidence: C)</i></text>
<text top="919" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="932" left="59" width="360" height="10" font="13">1. CCTA might be considered for risk assessment in patients with</text>
<text top="949" left="74" width="344" height="10" font="13">SIHD unable to undergo stress imaging or as an alternative to</text>
<text top="966" left="74" width="344" height="10" font="13">invasive coronary angiography when functional testing indicates a</text>
<text top="983" left="74" width="344" height="10" font="13">moderate- to high-risk result and knowledge of angiographic coro-</text>
<text top="999" left="74" width="250" height="10" font="13">nary anatomy is unknown. <i>(Level of Evidence: C)</i></text>
<text top="1034" left="59" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="1047" left="59" width="360" height="10" font="13">1. A request to perform either a) more than 1 stress imaging study or</text>
<text top="1064" left="74" width="344" height="10" font="13">b) a stress imaging study and a CCTA at the same time is not</text>
<text top="1080" left="74" width="344" height="10" font="13">recommended for risk assessment in patients with SIHD. <i>(Level of</i></text>
<text top="1097" left="74" width="63" height="10" font="25"><i>Evidence: C)</i></text>
<text top="837" left="446" width="18" height="16" font="5"><i>See</i></text>
<text top="837" left="471" width="165" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplement </i>2</a></text>
<text top="837" left="643" width="163" height="16" font="5"><i>for additional data on risk</i></text>
<text top="856" left="446" width="62" height="16" font="5"><i>assessment.</i></text>
<text top="893" left="446" width="106" height="9" font="6">3.2.2.4. EXERCISE ECG</text>
<text top="907" left="446" width="360" height="16" font="4">To assess the risk of cardiovascular events in patients who</text>
<text top="926" left="446" width="360" height="16" font="4">are able to exercise to an adequate workload and have an</text>
<text top="945" left="446" width="360" height="16" font="4">interpretable resting ECG, exercise is the preferred stressor</text>
<text top="964" left="446" width="360" height="16" font="4">because it provides an objective assessment of functional</text>
<text top="982" left="446" width="360" height="16" font="4">capacity and correlative information with activities of daily</text>
<text top="1001" left="446" width="360" height="16" font="4">living. The occurrence of ST-segment depression at a</text>
<text top="1020" left="446" width="360" height="16" font="4">reduced workload or persisting into recovery coupled with</text>
<text top="1038" left="446" width="360" height="16" font="4">exertional symptoms is associated with a high risk of</text>
<text top="1057" left="446" width="153" height="16" font="4">cardiovascular mortality <a href="e44.full.html#93">(</a></text>
<text top="1057" left="598" width="23" height="16" font="16"><a href="e44.full.html#93">302</a></text>
<text top="1057" left="621" width="185" height="16" font="4"><a href="e44.full.html#93">). </a>Other risk markers for mor-</text>
<text top="1076" left="446" width="360" height="16" font="4">tality include low exercise capacity (generally defined as less</text>
<text top="1095" left="446" width="250" height="16" font="4">than stage II of the Bruce protocol or</text>
<text top="1091" left="703" width="102" height="20" font="4">ⱕ20% age- and</text>
<text top="105" left="59" width="688" height="11" font="13">Table 12. Using Stress Testing and Advanced Imaging for Patients With Known SIHD Who Require Noninvasive Testing</text>
<text top="121" left="59" width="118" height="11" font="13">for Risk Assessment</text>
<text top="182" left="135" width="21" height="9" font="6">Test</text>
<text top="147" left="245" width="40" height="9" font="6">Exercise</text>
<text top="159" left="250" width="31" height="9" font="6">Status</text>
<text top="147" left="334" width="20" height="9" font="6">ECG</text>
<text top="159" left="314" width="61" height="9" font="6">Interpretable</text>
<text top="182" left="411" width="21" height="9" font="6">COR</text>
<text top="182" left="464" width="18" height="9" font="6">LOE</text>
<text top="182" left="536" width="53" height="9" font="6">References</text>
<text top="182" left="658" width="121" height="9" font="6">Additional Considerations</text>
<text top="182" left="233" width="21" height="9" font="6">Able</text>
<text top="182" left="265" width="32" height="9" font="6">Unable</text>
<text top="182" left="315" width="17" height="9" font="6">Yes</text>
<text top="182" left="359" width="13" height="9" font="6">No</text>
<text top="199" left="68" width="117" height="9" font="6">Patients able to exercise*</text>
<text top="217" left="79" width="58" height="9" font="6">Exercise ECG</text>
<text top="217" left="240" width="6" height="9" font="6">X</text>
<text top="217" left="321" width="6" height="9" font="6">X</text>
<text top="217" left="390" width="3" height="9" font="6">I</text>
<text top="217" left="470" width="6" height="9" font="6">B</text>
<text top="217" left="492" width="3" height="9" font="6"><a href="e44.full.html#88">(</a></text>
<text top="217" left="496" width="132" height="9" font="7"><a href="e44.full.html#88">106–110,112–114,132–134</a></text>
<text top="217" left="628" width="3" height="9" font="6"><a href="e44.full.html#88">)</a></text>
<text top="234" left="79" width="128" height="9" font="6">Exercise with nuclear MPI or</text>
<text top="248" left="92" width="22" height="9" font="6">Echo</text>
<text top="234" left="240" width="6" height="9" font="6">X</text>
<text top="234" left="362" width="6" height="9" font="6">X</text>
<text top="234" left="390" width="3" height="9" font="6">I</text>
<text top="234" left="470" width="6" height="9" font="6">B</text>
<text top="234" left="492" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="234" left="496" width="135" height="9" font="7"><a href="e44.full.html#85">7,111,264–266,270,299,300</a></text>
<text top="234" left="631" width="163" height="9" font="6"><a href="e44.full.html#85">) </a>Abnormalities other than LBBB or</text>
<text top="248" left="654" width="80" height="9" font="6">ventricular pacing</text>
<text top="265" left="79" width="128" height="9" font="6">Exercise with nuclear MPI or</text>
<text top="280" left="92" width="22" height="9" font="6">Echo</text>
<text top="265" left="240" width="6" height="9" font="6">X</text>
<text top="265" left="321" width="6" height="9" font="6">X</text>
<text top="265" left="390" width="11" height="9" font="6">IIa</text>
<text top="265" left="470" width="6" height="9" font="6">B</text>
<text top="265" left="492" width="3" height="9" font="6"><a href="e44.full.html#92">(</a></text>
<text top="265" left="496" width="42" height="9" font="7"><a href="e44.full.html#92">271–279</a></text>
<text top="265" left="538" width="3" height="9" font="6"><a href="e44.full.html#92">)</a></text>
<text top="297" left="79" width="130" height="9" font="6">Pharmacological stress CMR</text>
<text top="297" left="240" width="6" height="9" font="6">X</text>
<text top="297" left="362" width="6" height="9" font="6">X</text>
<text top="297" left="390" width="11" height="9" font="6">IIa</text>
<text top="297" left="470" width="6" height="9" font="6">B</text>
<text top="297" left="492" width="3" height="9" font="6"><a href="e44.full.html#92">(</a></text>
<text top="297" left="496" width="42" height="9" font="7"><a href="e44.full.html#92">279–284</a></text>
<text top="297" left="538" width="3" height="9" font="6"><a href="e44.full.html#92">)</a></text>
<text top="314" left="79" width="24" height="9" font="6">CCTA</text>
<text top="314" left="240" width="6" height="9" font="6">X</text>
<text top="314" left="362" width="6" height="9" font="6">X</text>
<text top="314" left="390" width="11" height="9" font="6">IIb</text>
<text top="314" left="470" width="6" height="9" font="6">B</text>
<text top="314" left="492" width="3" height="9" font="6"><a href="e44.full.html#92">(</a></text>
<text top="314" left="496" width="40" height="9" font="7"><a href="e44.full.html#92">285,286</a></text>
<text top="314" left="535" width="3" height="9" font="6"><a href="e44.full.html#92">)</a></text>
<text top="331" left="79" width="105" height="9" font="6">Pharmacological stress</text>
<text top="346" left="92" width="127" height="9" font="6">imaging (nuclear MPI, Echo,</text>
<text top="360" left="92" width="63" height="9" font="6">CMR) or CCTA</text>
<text top="331" left="240" width="6" height="9" font="6">X</text>
<text top="331" left="321" width="6" height="9" font="6">X</text>
<text top="331" left="390" width="62" height="9" font="6">III: No Benefit</text>
<text top="331" left="470" width="6" height="9" font="6">C</text>
<text top="331" left="492" width="18" height="9" font="6">N/A</text>
<text top="377" left="68" width="123" height="9" font="6">Patients unable to exercise</text>
<text top="394" left="79" width="127" height="9" font="6">Pharmacological stress with</text>
<text top="409" left="92" width="91" height="9" font="6">nuclear MPI or Echo</text>
<text top="394" left="278" width="6" height="9" font="6">X</text>
<text top="394" left="336" width="17" height="9" font="6">Any</text>
<text top="394" left="390" width="3" height="9" font="6">I</text>
<text top="394" left="470" width="6" height="9" font="6">B</text>
<text top="394" left="492" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="394" left="496" width="96" height="9" font="7"><a href="e44.full.html#85">7,264–266,287–290</a></text>
<text top="394" left="591" width="3" height="9" font="6"><a href="e44.full.html#85">)</a></text>
<text top="426" left="79" width="130" height="9" font="6">Pharmacological stress CMR</text>
<text top="426" left="278" width="6" height="9" font="6">X</text>
<text top="426" left="336" width="17" height="9" font="6">Any</text>
<text top="426" left="390" width="11" height="9" font="6">IIa</text>
<text top="426" left="470" width="6" height="9" font="6">B</text>
<text top="426" left="492" width="3" height="9" font="6"><a href="e44.full.html#92">(</a></text>
<text top="426" left="496" width="63" height="9" font="7"><a href="e44.full.html#92">280–284,291</a></text>
<text top="426" left="559" width="3" height="9" font="6"><a href="e44.full.html#92">)</a></text>
<text top="443" left="79" width="24" height="9" font="6">CCTA</text>
<text top="443" left="278" width="6" height="9" font="6">X</text>
<text top="443" left="336" width="17" height="9" font="6">Any</text>
<text top="443" left="390" width="11" height="9" font="6">IIa</text>
<text top="443" left="470" width="6" height="9" font="6">C</text>
<text top="443" left="492" width="3" height="9" font="6"><a href="e44.full.html#92">(</a></text>
<text top="443" left="496" width="18" height="9" font="7"><a href="e44.full.html#92">286</a></text>
<text top="443" left="514" width="3" height="9" font="6"><a href="e44.full.html#92">)</a></text>
<text top="443" left="642" width="109" height="9" font="6">Without prior stress test</text>
<text top="460" left="68" width="186" height="9" font="6">Regardless of patient’s ability to exercise</text>
<text top="478" left="79" width="127" height="9" font="6">Pharmacological stress with</text>
<text top="492" left="92" width="91" height="9" font="6">nuclear MPI or Echo</text>
<text top="478" left="257" width="17" height="9" font="6">Any</text>
<text top="478" left="362" width="6" height="9" font="6">X</text>
<text top="478" left="390" width="3" height="9" font="6">I</text>
<text top="478" left="470" width="6" height="9" font="6">B</text>
<text top="478" left="492" width="3" height="9" font="6"><a href="e44.full.html#92">(</a></text>
<text top="478" left="496" width="63" height="9" font="7"><a href="e44.full.html#92">287–290,292</a></text>
<text top="478" left="559" width="3" height="9" font="6"><a href="e44.full.html#92">)</a></text>
<text top="478" left="642" width="61" height="9" font="6">LBBB present</text>
<text top="509" left="79" width="117" height="9" font="6">Exercise/pharmacological</text>
<text top="523" left="92" width="108" height="9" font="6">stress with nuclear MPI,</text>
<text top="538" left="92" width="61" height="9" font="6">Echo, or CMR</text>
<text top="509" left="257" width="17" height="9" font="6">Any</text>
<text top="509" left="336" width="17" height="9" font="6">Any</text>
<text top="509" left="390" width="3" height="9" font="6">I</text>
<text top="509" left="470" width="6" height="9" font="6">B</text>
<text top="509" left="493" width="3" height="9" font="6"><a href="e44.full.html#92">(</a></text>
<text top="509" left="496" width="82" height="9" font="7"><a href="e44.full.html#92">266,278,293,294</a></text>
<text top="509" left="577" width="3" height="9" font="6"><a href="e44.full.html#92">)</a></text>
<text top="509" left="642" width="125" height="9" font="6">Known coronary stenosis of</text>
<text top="523" left="654" width="95" height="9" font="6">unclear physiological</text>
<text top="538" left="654" width="134" height="9" font="6">significance being considered</text>
<text top="552" left="654" width="92" height="9" font="6">for revascularization</text>
<text top="569" left="79" width="24" height="9" font="6">CCTA</text>
<text top="569" left="257" width="17" height="9" font="6">Any</text>
<text top="569" left="336" width="17" height="9" font="6">Any</text>
<text top="569" left="390" width="11" height="9" font="6">IIa</text>
<text top="569" left="470" width="6" height="9" font="6">C</text>
<text top="569" left="493" width="18" height="9" font="6">N/A</text>
<text top="569" left="642" width="117" height="9" font="6">Indeterminate result from</text>
<text top="583" left="654" width="79" height="9" font="6">functional testing</text>
<text top="601" left="79" width="24" height="9" font="6">CCTA</text>
<text top="601" left="257" width="17" height="9" font="6">Any</text>
<text top="601" left="336" width="17" height="9" font="6">Any</text>
<text top="601" left="390" width="11" height="9" font="6">IIb</text>
<text top="601" left="470" width="6" height="9" font="6">C</text>
<text top="601" left="493" width="18" height="9" font="6">N/A</text>
<text top="601" left="642" width="153" height="9" font="6">Unable to undergo stress imaging</text>
<text top="615" left="654" width="128" height="9" font="6">or as alternative to coronary</text>
<text top="629" left="654" width="95" height="9" font="6">catheterization when</text>
<text top="643" left="654" width="122" height="9" font="6">functional testing indicates</text>
<text top="658" left="654" width="118" height="9" font="6">moderate to high risk and</text>
<text top="672" left="654" width="100" height="9" font="6">angiographic coronary</text>
<text top="686" left="654" width="94" height="9" font="6">anatomy is unknown</text>
<text top="703" left="79" width="133" height="9" font="6">Requests to perform multiple</text>
<text top="718" left="92" width="114" height="9" font="6">cardiac imaging or stress</text>
<text top="732" left="92" width="114" height="9" font="6">studies at the same time</text>
<text top="703" left="257" width="17" height="9" font="6">Any</text>
<text top="703" left="336" width="17" height="9" font="6">Any</text>
<text top="703" left="390" width="62" height="9" font="6">III: No Benefit</text>
<text top="703" left="470" width="6" height="9" font="6">C</text>
<text top="703" left="493" width="18" height="9" font="6">N/A</text>
<text top="770" left="59" width="747" height="7" font="17">*Patients are candidates for exercise testing if they are capable of performing at least moderate physical functioning (i.e., moderate household, yard, or recreational work <i>and </i>most activities of daily</text>
<text top="782" left="59" width="456" height="7" font="17">living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicted maximum heart rate.</text>
<text top="794" left="67" width="739" height="7" font="17">CCTA indicates cardiac computed tomography angiography; CMR, cardiac magnetic resonance imaging; COR, class of recommendation; ECG, electrocardiogram; Echo, echocardiography; LBBB, left</text>
<text top="806" left="59" width="394" height="7" font="17">bundle-branch block; LOE, level of evidence; MPI, myocardial perfusion imaging; and N/A, not available.</text>
<text top="52" left="787" width="18" height="10" font="12">e75</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="134" height="16" font="4">sex-predicted values) <a href="e44.full.html#88">(</a></text>
<text top="104" left="192" width="23" height="16" font="16"><a href="e44.full.html#88">118</a></text>
<text top="104" left="215" width="204" height="16" font="4"><a href="e44.full.html#88">), </a>failure to increase systolic BP to</text>
<text top="119" left="59" width="360" height="20" font="4">⬎120 mm Hg or a sustained ⬎10–mm Hg decrease from</text>
<text top="141" left="58" width="360" height="16" font="4">resting values during exercise, complex ventricular ectopy or</text>
<text top="159" left="58" width="360" height="16" font="4">arrhythmias during stress or recovery, and delayed heart rate</text>
<text top="177" left="58" width="86" height="16" font="4">recovery (e.g.,</text>
<text top="174" left="151" width="267" height="20" font="4">⬍10- or 12-beats-per-minute reduction in</text>
<text top="195" left="58" width="112" height="16" font="4">the first minute) <a href="e44.full.html#93">(</a></text>
<text top="195" left="170" width="22" height="16" font="16"><a href="e44.full.html#93">303</a></text>
<text top="195" left="193" width="226" height="16" font="4"><a href="e44.full.html#93">). </a>The Duke treadmill score and the</text>
<text top="213" left="58" width="360" height="16" font="4">Lauer nomogram score are validated predictive instruments</text>
<text top="232" left="58" width="360" height="16" font="4">that incorporate parameters from an exercise ECG test. The</text>
<text top="250" left="58" width="360" height="16" font="4">Duke treadmill score includes duration of exercise, severity</text>
<text top="268" left="58" width="360" height="16" font="4">of ST-depression or elevation, and angina (limiting and</text>
<text top="286" left="58" width="360" height="16" font="4">nonlimiting); has been demonstrated to be highly predictive</text>
<text top="304" left="58" width="360" height="16" font="4">across an array of patient populations, including women and</text>
<text top="322" left="58" width="360" height="16" font="4">men with suspected and known SIHD; and has been shown</text>
<text top="341" left="58" width="360" height="16" font="4">to provide independent risk information beyond clinical</text>
<text top="359" left="58" width="231" height="16" font="4">data, coronary anatomy, and LVEF <a href="e44.full.html#88">(</a></text>
<text top="359" left="289" width="49" height="16" font="16"><a href="e44.full.html#88">126,177</a></text>
<text top="359" left="338" width="80" height="16" font="4"><a href="e44.full.html#88">). </a>It stratifies</text>
<text top="377" left="58" width="360" height="16" font="4">patients into risk groups that could prove useful for patient</text>
<text top="395" left="58" width="360" height="16" font="4">management, as follows: no further testing for low-risk</text>
<text top="413" left="58" width="360" height="16" font="4">patients, consideration for invasive testing for high-risk</text>
<text top="431" left="58" width="360" height="16" font="4">patients, and stress imaging for the intermediate-risk pa-</text>
<text top="450" left="58" width="360" height="16" font="4">tients. By comparison, the Lauer score incorporates clinical</text>
<text top="468" left="58" width="360" height="16" font="4">variables, which results in more effective classification of</text>
<text top="486" left="58" width="60" height="16" font="4">low-risk (</text>
<text top="483" left="118" width="231" height="20" font="4">⬍1% annual mortality rate) patients <a href="e44.full.html#91">(</a></text>
<text top="486" left="349" width="23" height="16" font="16"><a href="e44.full.html#91">248</a></text>
<text top="486" left="372" width="9" height="16" font="4"><a href="e44.full.html#91">).</a></text>
<text top="517" left="59" width="324" height="9" font="6">3.2.2.5. EXERCISE ECHOCARDIOGRAPHY AND EXERCISE NUCLEAR MPI</text>
<text top="531" left="59" width="360" height="16" font="4">Evidence from thousands of patients evaluated in multiple</text>
<text top="550" left="59" width="360" height="16" font="4">large registries and clinical trials and meta-analyses confirm</text>
<text top="568" left="59" width="360" height="16" font="4">that a normal exercise echocardiogram or exercise nuclear</text>
<text top="586" left="59" width="360" height="16" font="4">MPI is associated with a very low risk of death due to</text>
<text top="604" left="59" width="200" height="16" font="4">cardiovascular causes or AMI <a href="e44.full.html#88">(</a></text>
<text top="604" left="258" width="75" height="16" font="16"><a href="e44.full.html#88">111,265,304</a></text>
<text top="604" left="333" width="85" height="16" font="4"><a href="e44.full.html#88">). </a>The extent</text>
<text top="622" left="59" width="360" height="16" font="4">and severity of inducible abnormalities in wall motion or</text>
<text top="640" left="59" width="360" height="16" font="4">perfusion are directly correlated with the degree of risk. For</text>
<text top="659" left="59" width="360" height="16" font="4">nuclear MPI, reversible perfusion defects encompassing</text>
<text top="677" left="59" width="360" height="16" font="4">10% of the myocardium (determined either semiquantita-</text>
<text top="695" left="59" width="360" height="16" font="4">tively with summed scores or quantitatively) to assess defect</text>
<text top="713" left="59" width="360" height="16" font="4">extent and severity are considered moderately abnormal, and</text>
<text top="731" left="59" width="264" height="16" font="4">reversible perfusion defects encompassing</text>
<text top="728" left="331" width="87" height="20" font="4">ⱖ15% of the</text>
<text top="749" left="58" width="332" height="16" font="4">myocardium are considered severely abnormal <a href="e44.full.html#92">(</a></text>
<text top="749" left="391" width="27" height="16" font="16"><a href="e44.full.html#92">277,</a></text>
<text top="768" left="58" width="49" height="16" font="16"><a href="e44.full.html#92">305,306</a></text>
<text top="768" left="107" width="311" height="16" font="4"><a href="e44.full.html#92">). </a>Other findings also indicative of elevated risk</text>
<text top="786" left="58" width="297" height="16" font="4">include a reduction in reduced post-stress LVEF</text>
<text top="782" left="360" width="59" height="20" font="4">ⱖ5% or a</text>
<text top="804" left="58" width="83" height="16" font="4">global LVEF</text>
<text top="801" left="148" width="270" height="20" font="4">⬍45%, transient ischemic LV dilation, in-</text>
<text top="822" left="58" width="360" height="16" font="4">creased lung or right ventricular uptake, or abnormal coro-</text>
<text top="840" left="58" width="360" height="16" font="4">nary reserve (detected on myocardial perfusion PET). For</text>
<text top="858" left="58" width="360" height="16" font="4">echocardiography, a wall motion abnormality extending</text>
<text top="877" left="58" width="360" height="16" font="4">beyond 2 to 3 segments as well as the presence of change in</text>
<text top="891" left="58" width="360" height="20" font="4">⬎1 coronary territory are suggestive of higher risk. For both</text>
<text top="913" left="58" width="360" height="16" font="4">tests, multiple defects in different coronary territories with</text>
<text top="931" left="58" width="261" height="16" font="4">either moderately reduced perfusion (or</text>
<text top="928" left="329" width="89" height="20" font="4">ⱖ10% of the</text>
<text top="949" left="58" width="360" height="16" font="4">myocardium) or inducible wall motion abnormalities with</text>
<text top="967" left="58" width="360" height="16" font="4">transient ischemic dilatation are suggestive of severe CAD.</text>
<text top="985" left="58" width="360" height="16" font="4">Currently, the National Institutes of Health–National</text>
<text top="1004" left="58" width="360" height="16" font="4">Heart, Lung, and Blood Institute–sponsored ISCHEMIA</text>
<text top="1022" left="58" width="360" height="16" font="4">trial is under way and is comparing the effectiveness of a</text>
<text top="1040" left="58" width="360" height="16" font="4">conservative versus catheterization-based initial manage-</text>
<text top="1058" left="58" width="356" height="16" font="4">ment strategy for patients with moderate–severe ischemia.</text>
<text top="1076" left="73" width="345" height="16" font="4">Several large single-center and multicenter registries have</text>
<text top="1094" left="58" width="360" height="16" font="4">demonstrated consistently that both stress nuclear MPI and</text>
<text top="104" left="445" width="360" height="16" font="4">stress echocardiography provide incremental prognostic</text>
<text top="122" left="445" width="360" height="16" font="4">value beyond that provided by a standard ECG</text>
<text top="140" left="445" width="5" height="16" font="4"><a href="e44.full.html#88">(</a></text>
<text top="140" left="450" width="158" height="16" font="16"><a href="e44.full.html#88">115,272,299,305,307–315</a></text>
<text top="140" left="608" width="197" height="16" font="4"><a href="e44.full.html#88">). </a>The addition of imaging is</text>
<text top="159" left="445" width="360" height="16" font="4">mandatory for patients who have an uninterpretable baseline</text>
<text top="177" left="445" width="360" height="16" font="4">ECG (including the presence of LBBB or ventricular</text>
<text top="195" left="445" width="360" height="16" font="4">pacing, LV hypertrophy, use of digitalis or electrolyte</text>
<text top="213" left="445" width="360" height="16" font="4">abnormalities, coexisting resting ST-segment abnormality,</text>
<text top="231" left="445" width="360" height="16" font="4">or preexcitation syndromes) and might be of value in</text>
<text top="249" left="445" width="261" height="16" font="4">patients with equivocal stress-induced <a href="e44.full.html#93">(</a></text>
<text top="249" left="706" width="23" height="16" font="16"><a href="e44.full.html#93">316</a></text>
<text top="249" left="729" width="77" height="16" font="4"><a href="e44.full.html#93">) </a>ECG ST</text>
<text top="267" left="445" width="61" height="16" font="4">changes <a href="e44.full.html#93">(</a></text>
<text top="267" left="506" width="23" height="16" font="16"><a href="e44.full.html#93">317</a></text>
<text top="267" left="529" width="277" height="16" font="4"><a href="e44.full.html#93">) </a>or an intermediate Duke treadmill score</text>
<text top="285" left="445" width="5" height="16" font="4"><a href="e44.full.html#93">(</a></text>
<text top="285" left="450" width="23" height="16" font="16"><a href="e44.full.html#93">316</a></text>
<text top="285" left="473" width="333" height="16" font="4"><a href="e44.full.html#93">). </a>Poornima et al., demonstrated that nuclear MPI has</text>
<text top="303" left="445" width="360" height="16" font="4">independent prognostic value even in patients with low-risk</text>
<text top="321" left="445" width="360" height="16" font="4">Duke treadmill scores, but only if there is increased clinical</text>
<text top="339" left="445" width="360" height="16" font="4">risk, such as a history of typical angina, MI, diabetes</text>
<text top="358" left="445" width="179" height="16" font="4">mellitus, and advanced age <a href="e44.full.html#93">(</a></text>
<text top="358" left="624" width="49" height="16" font="16"><a href="e44.full.html#93">318,319</a></text>
<text top="358" left="673" width="133" height="16" font="4"><a href="e44.full.html#93">). </a>Similarly, informa-</text>
<text top="376" left="445" width="360" height="16" font="4">tion from exercise echocardiography appears to provide</text>
<text top="394" left="445" width="360" height="16" font="4">improved prediction of mortality among patients with</text>
<text top="412" left="445" width="210" height="16" font="4">low-risk Duke treadmill scores <a href="e44.full.html#93">(</a></text>
<text top="412" left="655" width="49" height="16" font="16"><a href="e44.full.html#93">311,318</a></text>
<text top="412" left="704" width="102" height="16" font="4"><a href="e44.full.html#93">). </a>From a large</text>
<text top="430" left="445" width="360" height="16" font="4">registry, the extent of ischemic myocardium as quantified by</text>
<text top="448" left="445" width="360" height="16" font="4">summed difference score by nuclear MPI has been shown to</text>
<text top="466" left="445" width="360" height="16" font="4">form an effective prognostic score for the prediction of</text>
<text top="484" left="445" width="112" height="16" font="4">cardiac mortality <a href="e44.full.html#93">(</a></text>
<text top="484" left="557" width="23" height="16" font="16"><a href="e44.full.html#93">320</a></text>
<text top="484" left="580" width="226" height="16" font="4"><a href="e44.full.html#93">). </a>Results from exercise nuclear MPI</text>
<text top="502" left="445" width="360" height="16" font="4">and exercise stress echocardiography appear to provide</text>
<text top="520" left="445" width="360" height="16" font="4">accurate estimates of the likelihood of death among men</text>
<text top="538" left="445" width="360" height="16" font="4">and women with suspected and known SIHD and for</text>
<text top="557" left="445" width="235" height="16" font="4">patients from different ethnic groups <a href="e44.full.html#93">(</a></text>
<text top="557" left="680" width="75" height="16" font="16"><a href="e44.full.html#93">314,321,322</a></text>
<text top="557" left="756" width="9" height="16" font="4"><a href="e44.full.html#93">).</a></text>
<text top="575" left="460" width="345" height="16" font="4">From a review of large single- and multicenter registries</text>
<text top="593" left="445" width="119" height="16" font="4">and meta-analyses <a href="e44.full.html#88">(</a></text>
<text top="593" left="564" width="75" height="16" font="16"><a href="e44.full.html#88">111,115,272</a></text>
<text top="593" left="640" width="166" height="16" font="4"><a href="e44.full.html#88">), </a>the following conclusions</text>
<text top="611" left="445" width="81" height="16" font="4">can be made:</text>
<text top="642" left="445" width="360" height="16" font="4">1. A normal exercise nuclear MPI study or a normal</text>
<text top="661" left="464" width="341" height="16" font="4">exercise stress echocardiogram during which the age-</text>
<text top="679" left="464" width="341" height="16" font="4">predicted target heart rate is achieved is associated with</text>
<text top="697" left="464" width="341" height="16" font="4">a very low annual risk of cardiac death and AMI</text>
<text top="715" left="464" width="59" height="16" font="4">(generally</text>
<text top="712" left="528" width="198" height="20" font="4">⬍1%) in both men and women.</text>
<text top="733" left="445" width="360" height="16" font="4">2. Normal and mildly abnormal nuclear MPI or exercise</text>
<text top="751" left="464" width="341" height="16" font="4">stress echocardiography is associated with a low fre-</text>
<text top="769" left="464" width="341" height="16" font="4">quency of referral for coronary revascularization or wors-</text>
<text top="787" left="464" width="341" height="16" font="4">ening clinical status and UA admission (1.3% and 1%</text>
<text top="805" left="464" width="143" height="16" font="4">annually, respectively) <a href="e44.full.html#89">(</a></text>
<text top="805" left="608" width="23" height="16" font="16"><a href="e44.full.html#89">141</a></text>
<text top="805" left="630" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="823" left="445" width="360" height="16" font="4">3. Rates of cardiac ischemic events increase in proportion to</text>
<text top="841" left="464" width="341" height="16" font="4">the degree of abnormalities on stress nuclear MPI or</text>
<text top="859" left="464" width="341" height="16" font="4">echocardiography, with moderate to severe abnormalities</text>
<text top="878" left="464" width="341" height="16" font="4">associated with an annual risk of cardiovascular death or</text>
<text top="896" left="464" width="20" height="16" font="4">MI</text>
<text top="892" left="494" width="45" height="20" font="4">ⱖ5% <a href="e44.full.html#88">(</a></text>
<text top="896" left="539" width="267" height="16" font="16"><a href="e44.full.html#88">115,278,279,284,305,306,310,313,314,323–</a></text>
<text top="914" left="464" width="23" height="16" font="16"><a href="e44.full.html#88">330</a></text>
<text top="914" left="487" width="9" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="932" left="445" width="360" height="16" font="4">4. For patients with mild abnormalities, coronary angiog-</text>
<text top="950" left="464" width="341" height="16" font="4">raphy might be considered if the patient exhibits other</text>
<text top="968" left="464" width="341" height="16" font="4">features that might indicate the likelihood of “high-risk”</text>
<text top="986" left="464" width="341" height="16" font="4">CAD, including low EF on gated nuclear MPI or</text>
<text top="1004" left="464" width="177" height="16" font="4">echocardiographic imaging <a href="e44.full.html#94">(</a></text>
<text top="1004" left="641" width="23" height="16" font="16"><a href="e44.full.html#94">331</a></text>
<text top="1004" left="664" width="142" height="16" font="4"><a href="e44.full.html#94">) </a>or transient ischemic</text>
<text top="1022" left="464" width="190" height="16" font="4">dilatation of the left ventricle <a href="e44.full.html#94">(</a></text>
<text top="1022" left="654" width="23" height="16" font="16"><a href="e44.full.html#94">332</a></text>
<text top="1022" left="676" width="9" height="16" font="4"><a href="e44.full.html#94">).</a></text>
<text top="1040" left="445" width="360" height="16" font="4">5. Moderate to severe abnormalities, such as abnormal wall</text>
<text top="1058" left="464" width="63" height="16" font="4">motion in</text>
<text top="1055" left="535" width="270" height="20" font="4">ⱖ4 segments or multivessel abnormalities,</text>
<text top="1076" left="464" width="341" height="16" font="4">indicate an increased risk (range: 6- to 10-fold) over that</text>
<text top="1094" left="464" width="294" height="16" font="4">of patients with a normal stress imaging study <a href="e44.full.html#92">(</a></text>
<text top="1094" left="759" width="23" height="16" font="16"><a href="e44.full.html#92">271</a></text>
<text top="1094" left="781" width="9" height="16" font="4"><a href="e44.full.html#92">).</a></text>
<text top="52" left="59" width="18" height="10" font="12">e76</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="74" width="345" height="16" font="4">Nonetheless, the current literature with regard to exercise</text>
<text top="123" left="59" width="360" height="16" font="4">nuclear MPI or exercise echocardiography should be clari-</text>
<text top="141" left="59" width="360" height="16" font="4">fied in several ways. Although a normal exercise nuclear</text>
<text top="159" left="59" width="360" height="16" font="4">MPI or exercise echocardiogram usually is associated with a</text>
<text top="177" left="59" width="360" height="16" font="4">low annual risk of cardiac death or AMI, the negative</text>
<text top="195" left="59" width="360" height="16" font="4">predictive value is reduced among patients with a higher</text>
<text top="213" left="59" width="176" height="16" font="4">pretest likelihood of CAD <a href="e44.full.html#88">(</a></text>
<text top="213" left="234" width="184" height="16" font="16"><a href="e44.full.html#88">111,115,279,284,305,306,310,</a></text>
<text top="232" left="59" width="131" height="16" font="16"><a href="e44.full.html#88">313,314,323–328,330</a></text>
<text top="232" left="190" width="229" height="16" font="4"><a href="e44.full.html#88">). </a>Furthermore, although trials have</text>
<text top="250" left="59" width="360" height="16" font="4">shown that imaging is useful to detect ischemia and guide</text>
<text top="268" left="59" width="360" height="16" font="4">intervention in patients with SIHD and that a reduction in</text>
<text top="286" left="59" width="360" height="16" font="4">ischemia by stress nuclear MPI is associated with an</text>
<text top="304" left="59" width="255" height="16" font="4">observed (unadjusted) event-free survival <a href="e44.full.html#93">(</a></text>
<text top="304" left="313" width="49" height="16" font="16"><a href="e44.full.html#93">306,333</a></text>
<text top="304" left="362" width="57" height="16" font="4"><a href="e44.full.html#93">), </a>there is</text>
<text top="322" left="59" width="360" height="16" font="4">no trial evidence comparing the effectiveness of a strategy of</text>
<text top="341" left="59" width="360" height="16" font="4">imaging testing for risk stratification versus a strategy of</text>
<text top="359" left="59" width="213" height="16" font="4">nontesting in patients with SIHD.</text>
<text top="390" left="59" width="266" height="9" font="6">3.2.2.6. DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND</text>
<text top="408" left="59" width="198" height="9" font="6">PHARMACOLOGICAL STRESS NUCLEAR MPI</text>
<text top="422" left="59" width="360" height="16" font="4">In one third to one half of patients who undergo risk</text>
<text top="441" left="59" width="360" height="16" font="4">assessment, exercise stress is not recommended because of</text>
<text top="459" left="59" width="360" height="16" font="4">an inability to exercise or an abnormal ECG. Similar to</text>
<text top="477" left="59" width="360" height="16" font="4">exercise echocardiography, multiple large single-center re-</text>
<text top="495" left="59" width="360" height="16" font="4">ports have shown that dobutamine stress echocardiography</text>
<text top="513" left="59" width="360" height="16" font="4">accurately classifies patients into high-risk and very-low-risk</text>
<text top="531" left="59" width="360" height="16" font="4">groups. A normal dobutamine echocardiogram is associated</text>
<text top="549" left="59" width="360" height="16" font="4">with a risk of an adverse cardiac event of 1% to 2%</text>
<text top="568" left="59" width="5" height="16" font="4"><a href="e44.full.html#93">(</a></text>
<text top="568" left="63" width="49" height="16" font="16"><a href="e44.full.html#93">312,334</a></text>
<text top="568" left="112" width="306" height="16" font="4"><a href="e44.full.html#93">). </a>Classification as high risk by dobutamine stress</text>
<text top="586" left="59" width="360" height="16" font="4">echocardiography is most reliable when ischemia is detected</text>
<text top="604" left="59" width="360" height="16" font="4">in the territory of the LAD and is somewhat less reliable in</text>
<text top="622" left="59" width="192" height="16" font="4">patients with diabetes mellitus <a href="e44.full.html#94">(</a></text>
<text top="622" left="251" width="23" height="16" font="16"><a href="e44.full.html#94">335</a></text>
<text top="622" left="273" width="145" height="16" font="4"><a href="e44.full.html#94">). </a>In specialized centers,</text>
<text top="640" left="59" width="360" height="16" font="4">either quantification of strain rate or myocardial contrast</text>
<text top="658" left="59" width="360" height="16" font="4">enhancement on dobutamine echocardiography has been</text>
<text top="677" left="59" width="360" height="16" font="4">shown to provide information that supplements the wall</text>
<text top="695" left="59" width="329" height="16" font="4">motion score alone in predicting cardiac mortality <a href="e44.full.html#94">(</a></text>
<text top="695" left="387" width="23" height="16" font="16"><a href="e44.full.html#94">336</a></text>
<text top="695" left="410" width="9" height="16" font="4"><a href="e44.full.html#94">).</a></text>
<text top="713" left="59" width="360" height="16" font="4">Dobutamine echocardiography also has been used exten-</text>
<text top="731" left="59" width="360" height="16" font="4">sively in risk-stratifying patients with SIHD undergoing</text>
<text top="749" left="59" width="360" height="16" font="4">noncardiac vascular surgery. Because the risk of a cardiac</text>
<text top="767" left="59" width="360" height="16" font="4">event in the perioperative period is quite low, the positive</text>
<text top="786" left="59" width="360" height="16" font="4">predictive value of dobutamine echocardiography is also</text>
<text top="804" left="59" width="360" height="16" font="4">low, although the negative predictive value of a normal</text>
<text top="822" left="59" width="360" height="16" font="4">result is very high and is associated with a very low</text>
<text top="840" left="59" width="219" height="16" font="4">likelihood of a perioperative event <a href="e44.full.html#94">(</a></text>
<text top="840" left="277" width="49" height="16" font="16"><a href="e44.full.html#94">337,338</a></text>
<text top="840" left="326" width="9" height="16" font="4"><a href="e44.full.html#94">).</a></text>
<text top="858" left="74" width="345" height="16" font="4">Similar to exercise SPECT, vasodilator stress nuclear</text>
<text top="876" left="59" width="360" height="16" font="4">MPI has been shown to effectively assess risk of subsequent</text>
<text top="895" left="59" width="360" height="16" font="4">events in patients with SIHD, with a low annualized event</text>
<text top="913" left="59" width="360" height="16" font="4">rate of 1.6% observed in patients with a normal adenosine</text>
<text top="931" left="59" width="360" height="16" font="4">SPECT versus 10.6% in patients with a severely abnormal</text>
<text top="949" left="59" width="163" height="16" font="4">study (summed stress score</text>
<text top="946" left="225" width="41" height="20" font="4">⬎13) <a href="e44.full.html#94">(</a></text>
<text top="949" left="266" width="23" height="16" font="16"><a href="e44.full.html#94">339</a></text>
<text top="949" left="289" width="130" height="16" font="4"><a href="e44.full.html#94">). </a>This event rate also</text>
<text top="967" left="59" width="360" height="16" font="4">was observed in elderly patients with normal pharmacolog-</text>
<text top="985" left="59" width="86" height="16" font="4">ical SPECT <a href="e44.full.html#94">(</a></text>
<text top="985" left="145" width="49" height="16" font="16"><a href="e44.full.html#94">340,341</a></text>
<text top="985" left="194" width="225" height="16" font="4"><a href="e44.full.html#94">). </a>Because of greater comorbidity in</text>
<text top="1004" left="59" width="360" height="16" font="4">patients who cannot exercise, the annualized event rate of</text>
<text top="1022" left="59" width="360" height="16" font="4">patients who had a normal pharmacological stress nuclear</text>
<text top="1040" left="59" width="360" height="16" font="4">MPI increase the event rate nearly 2-fold higher than that</text>
<text top="1058" left="59" width="360" height="16" font="4">of exercising patients who had a normal nuclear MPI, after</text>
<text top="1076" left="59" width="254" height="16" font="4">adjustment for age and comorbidity <a href="e44.full.html#94">(</a></text>
<text top="1076" left="312" width="23" height="16" font="16"><a href="e44.full.html#94">342</a></text>
<text top="1076" left="335" width="84" height="16" font="4"><a href="e44.full.html#94">). </a>Additional</text>
<text top="1094" left="59" width="360" height="16" font="4">nonperfusion risk markers can be derived from pharmaco-</text>
<text top="104" left="446" width="360" height="16" font="4">logical stress, including an abnormal ECG, high resting</text>
<text top="122" left="446" width="280" height="16" font="4">heart rate, and low peak/rest heart rate ratio <a href="e44.full.html#92">(</a></text>
<text top="122" left="725" width="49" height="16" font="16"><a href="e44.full.html#92">276,332</a></text>
<text top="122" left="774" width="31" height="16" font="4"><a href="e44.full.html#92">). </a>To</text>
<text top="140" left="446" width="360" height="16" font="4">facilitate clinical risk assessment, a nomogram based on</text>
<text top="158" left="446" width="360" height="16" font="4">robust risk markers, including LV function and extent of</text>
<text top="176" left="446" width="360" height="16" font="4">myocardial ischemia by SPECT, has been developed and</text>
<text top="194" left="446" width="64" height="16" font="4">validated <a href="e44.full.html#121">(</a></text>
<text top="194" left="509" width="72" height="16" font="16"><a href="e44.full.html#121">Appendix 4</a></text>
<text top="194" left="581" width="15" height="16" font="4"><a href="e44.full.html#121">) </a><a href="e44.full.html#92">(</a></text>
<text top="194" left="596" width="23" height="16" font="16"><a href="e44.full.html#92">276</a></text>
<text top="194" left="619" width="9" height="16" font="4"><a href="e44.full.html#92">).</a></text>
<text top="225" left="446" width="240" height="9" font="6">3.2.2.7. PHARMACOLOGICAL STRESS CMR IMAGING</text>
<text top="239" left="446" width="360" height="16" font="4">Although clinical experience with using stress CMR for risk</text>
<text top="257" left="446" width="360" height="16" font="4">assessment is substantially less than with stress echocardi-</text>
<text top="275" left="446" width="360" height="16" font="4">ography and nuclear MPI, available evidence indicates that</text>
<text top="293" left="446" width="360" height="16" font="4">stress CMR can provide highly accurate prognostic infor-</text>
<text top="311" left="446" width="360" height="16" font="4">mation. On the basis of 16 single-site studies providing data</text>
<text top="329" left="446" width="132" height="16" font="4">from 7,200 patients <a href="e44.full.html#92">(</a></text>
<text top="329" left="578" width="23" height="16" font="16"><a href="e44.full.html#92">283</a></text>
<text top="329" left="600" width="206" height="16" font="4"><a href="e44.full.html#92">) </a>(8 of these studies used vasodi-</text>
<text top="347" left="446" width="360" height="16" font="4">lator stress perfusion imaging, 6 dobutamine stress CMR</text>
<text top="365" left="446" width="360" height="16" font="4">cine imaging, and 2 combined stress perfusion and cine</text>
<text top="383" left="446" width="357" height="16" font="4">imaging), the following general conclusions can be drawn:</text>
<text top="410" left="446" width="360" height="16" font="4">1. A normal stress CMR study with either vasodilator</text>
<text top="428" left="464" width="341" height="16" font="4">myocardial perfusion or inotropic stress cine imaging is</text>
<text top="446" left="464" width="341" height="16" font="4">associated with a low annual rate of cardiac death or MI,</text>
<text top="464" left="464" width="199" height="16" font="4">ranging from 0.01% to 0.6% <a href="e44.full.html#92">(</a></text>
<text top="464" left="663" width="47" height="16" font="16"><a href="e44.full.html#92">280,283</a></text>
<text top="464" left="710" width="96" height="16" font="4"><a href="e44.full.html#92">), </a>and provides</text>
<text top="482" left="464" width="287" height="16" font="4">accurate risk assessment in patients of either sex <a href="e44.full.html#92">(</a></text>
<text top="482" left="751" width="47" height="16" font="16"><a href="e44.full.html#92">281,343</a></text>
<text top="482" left="797" width="8" height="16" font="4"><a href="e44.full.html#92">).</a></text>
<text top="500" left="446" width="360" height="16" font="4">2. Detection of myocardial ischemia (by either perfusion or</text>
<text top="518" left="464" width="341" height="16" font="4">cine imaging) and LGE imaging of infarction appear to</text>
<text top="536" left="464" width="224" height="16" font="4">provide complementary information.</text>
<text top="554" left="446" width="360" height="16" font="4">3. An abnormal stress CMR with evidence of ischemia is</text>
<text top="572" left="464" width="341" height="16" font="4">associated with elevated likelihood of cardiac death or MI,</text>
<text top="590" left="464" width="255" height="16" font="4">with hazard ratios ranging from 2.2 to 12 <a href="e44.full.html#92">(</a></text>
<text top="590" left="719" width="47" height="16" font="16"><a href="e44.full.html#92">279,282</a></text>
<text top="590" left="765" width="8" height="16" font="4"><a href="e44.full.html#92">).</a></text>
<text top="617" left="461" width="345" height="16" font="4">The current evidence related to CMR for risk assessment</text>
<text top="635" left="446" width="360" height="16" font="4">of patients is limited by the predominance of data collection</text>
<text top="653" left="446" width="360" height="16" font="4">from tertiary care centers with high experience in CMR,</text>
<text top="671" left="446" width="360" height="16" font="4">heterogeneity of imaging techniques and equipment, and</text>
<text top="689" left="446" width="224" height="16" font="4">evolution of interpretative standards.</text>
<text top="720" left="446" width="261" height="9" font="6">3.2.2.8. SPECIAL PATIENT GROUP: RISK ASSESSMENT IN</text>
<text top="738" left="446" width="286" height="9" font="6">PATIENTS WHO HAVE AN UNINTERPRETABLE ECG BECAUSE OF</text>
<text top="756" left="446" width="145" height="9" font="6">LBBB OR VENTRICULAR PACING</text>
<text top="770" left="446" width="360" height="16" font="4">Isolated “false-positive” reversible perfusion defects of the</text>
<text top="788" left="446" width="360" height="16" font="4">septum on nuclear MPI due to abnormal septal motion</text>
<text top="806" left="446" width="360" height="16" font="4">causing a reduction in diastolic filling time have been</text>
<text top="824" left="446" width="360" height="16" font="4">reported in patients with LBBB without significant coro-</text>
<text top="842" left="446" width="360" height="16" font="4">nary stenosis. Compared to patients without LBBB, use of</text>
<text top="860" left="446" width="360" height="16" font="4">exercise stress in patients with LBBB or ventricular pacing</text>
<text top="878" left="446" width="275" height="16" font="4">substantially reduced diagnostic specificity <a href="e44.full.html#92">(</a></text>
<text top="878" left="720" width="49" height="16" font="16"><a href="e44.full.html#92">289,292</a></text>
<text top="878" left="769" width="37" height="16" font="4"><a href="e44.full.html#92">). </a>Al-</text>
<text top="896" left="446" width="360" height="16" font="4">though a normal nuclear perfusion scan in this clinical</text>
<text top="914" left="446" width="360" height="16" font="4">setting is highly accurate in indicating the absence of a</text>
<text top="932" left="446" width="360" height="16" font="4">significant coronary stenosis and a low risk of subsequent</text>
<text top="950" left="446" width="92" height="16" font="4">cardiac events <a href="e44.full.html#92">(</a></text>
<text top="950" left="538" width="23" height="16" font="16"><a href="e44.full.html#92">288</a></text>
<text top="950" left="560" width="245" height="16" font="4"><a href="e44.full.html#92">), </a>an abnormal study can be nondiagnos-</text>
<text top="968" left="446" width="28" height="16" font="4">tic <a href="e44.full.html#89">(</a></text>
<text top="968" left="474" width="49" height="16" font="16"><a href="e44.full.html#89">148,287</a></text>
<text top="968" left="522" width="283" height="16" font="4"><a href="e44.full.html#89">). </a>In patients with LBBB on a rest ECG,</text>
<text top="986" left="446" width="360" height="16" font="4">dobutamine stress echocardiography is less sensitive but</text>
<text top="1004" left="446" width="360" height="16" font="4">more specific than nuclear MPI in detecting coronary</text>
<text top="1022" left="446" width="360" height="16" font="4">stenosis and provides prognostic information that is incre-</text>
<text top="1040" left="446" width="172" height="16" font="4">mental to clinical findings <a href="e44.full.html#94">(</a></text>
<text top="1040" left="617" width="23" height="16" font="16"><a href="e44.full.html#94">344</a></text>
<text top="1040" left="640" width="166" height="16" font="4"><a href="e44.full.html#94">). </a>One meta-analysis dem-</text>
<text top="1058" left="446" width="360" height="16" font="4">onstrated that abnormal stress nuclear MPI and stress</text>
<text top="1076" left="446" width="360" height="16" font="4">echocardiography each confer an up to 7-fold increased risk</text>
<text top="1094" left="446" width="203" height="16" font="4">of adverse cardiovascular events <a href="e44.full.html#89">(</a></text>
<text top="1094" left="648" width="23" height="16" font="16"><a href="e44.full.html#89">148</a></text>
<text top="1094" left="671" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="52" left="787" width="18" height="10" font="12">e77</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="331" height="16" font="26"><b>3.2.3. Prognostic Accuracy of Anatomic Testing to</b></text>
<text top="123" left="59" width="279" height="16" font="26"><b>Assess Risk in Patients With Known CAD</b></text>
<text top="154" left="59" width="177" height="9" font="6">3.2.3.1. CORONARY CT ANGIOGRAPHY</text>
<text top="168" left="59" width="360" height="16" font="4">Given the high accuracy in detecting angiographically sig-</text>
<text top="186" left="59" width="360" height="16" font="4">nificant coronary stenosis, estimates of cardiovascular risk</text>
<text top="204" left="59" width="360" height="16" font="4">according to the Duke CAD index with data obtained via</text>
<text top="222" left="59" width="360" height="16" font="4">CCTA appear to be as accurate as those obtained from</text>
<text top="241" left="59" width="360" height="16" font="4">cardiac catheterization. However, the actual event rates in</text>
<text top="259" left="59" width="360" height="16" font="4">patients undergoing CCTA have been substantially lower</text>
<text top="277" left="59" width="360" height="16" font="4">because of differences in the underlying risk profiles of</text>
<text top="295" left="59" width="360" height="16" font="4">patient groups that have been referred for these 2 procedures</text>
<text top="313" left="59" width="5" height="16" font="4"><a href="e44.full.html#94">(</a></text>
<text top="313" left="63" width="23" height="16" font="16"><a href="e44.full.html#94">345</a></text>
<text top="313" left="86" width="333" height="16" font="4"><a href="e44.full.html#94">). </a>Furthermore, data from CONFIRM suggest that the</text>
<text top="331" left="59" width="360" height="16" font="4">finding of nonobstructive CAD on CCTA supplements</text>
<text top="350" left="59" width="329" height="16" font="4">clinical information in predicting risk of mortality <a href="e44.full.html#92">(</a></text>
<text top="350" left="387" width="23" height="16" font="16"><a href="e44.full.html#92">286</a></text>
<text top="350" left="410" width="9" height="16" font="4"><a href="e44.full.html#92">).</a></text>
<text top="368" left="59" width="360" height="16" font="4">For example, 20% to 25% of patients with an intermediate</text>
<text top="386" left="59" width="360" height="16" font="4">pretest likelihood of risk (1% to 3% annual mortality rate)</text>
<text top="404" left="59" width="360" height="16" font="4">based on clinical information (without EF) were reassigned</text>
<text top="422" left="59" width="360" height="16" font="4">to a different risk category according to information from</text>
<text top="440" left="59" width="360" height="16" font="4">CCTA. Given that failed bypass grafts can result in unpro-</text>
<text top="459" left="59" width="360" height="16" font="4">tected CAD, which confers a higher risk, the assessment of</text>
<text top="477" left="59" width="360" height="16" font="4">the extent of graft patency by CCTA is also of prognostic</text>
<text top="495" left="59" width="41" height="16" font="4">value <a href="e44.full.html#94">(</a></text>
<text top="495" left="99" width="49" height="16" font="16"><a href="e44.full.html#94">346,347</a></text>
<text top="495" left="148" width="271" height="16" font="4"><a href="e44.full.html#94">). </a>Although exercise stress testing in general</text>
<text top="513" left="59" width="360" height="16" font="4">is preferred in risk assessment, for patients unlikely to</text>
<text top="531" left="59" width="360" height="16" font="4">achi<b>e</b>ve conclusive results, consensus opinion suggests that it</text>
<text top="549" left="59" width="360" height="16" font="4">is reasonable to proceed with a CCTA for risk-assessment</text>
<text top="567" left="59" width="56" height="16" font="4">purposes.</text>
<text top="586" left="74" width="345" height="16" font="4">Several ongoing trials are comparing the prognostic</text>
<text top="604" left="59" width="360" height="16" font="4">values of CCTA and functional imaging modalities such as</text>
<text top="622" left="59" width="258" height="16" font="4">nuclear MPI and stress echocardiography <a href="e44.full.html#94">(</a></text>
<text top="622" left="316" width="23" height="16" font="16"><a href="e44.full.html#94">348</a></text>
<text top="622" left="339" width="80" height="16" font="4"><a href="e44.full.html#94">). </a>At present,</text>
<text top="640" left="59" width="360" height="16" font="4">there are no prospectively gathered trial data demonstrating</text>
<text top="658" left="59" width="360" height="16" font="4">that CCTA leads to better patient selection for medical or</text>
<text top="676" left="59" width="314" height="16" font="4">invasive intervention or to better clinical outcomes.</text>
<text top="713" left="59" width="184" height="12" font="18">3.3. Coronary Angiography</text>
<text top="740" left="59" width="326" height="16" font="26"><b>3.3.1. Coronary Angiography as an Initial Testing</b></text>
<text top="758" left="59" width="278" height="16" font="26"><b>Strategy to Assess Risk: Recommendations</b></text>
<text top="790" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="803" left="59" width="360" height="10" font="13">1. Patients with SIHD who have survived sudden cardiac death or</text>
<text top="820" left="74" width="344" height="10" font="13">potentially life-threatening ventricular arrhythmia should undergo</text>
<text top="837" left="74" width="344" height="10" font="13">coronary angiography to assess cardiac risk <a href="e44.full.html#94">(349–351). </a><i>(Level of</i></text>
<text top="854" left="74" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="871" left="58" width="360" height="10" font="13">2. Patients with SIHD who develop symptoms and signs of heart failure</text>
<text top="888" left="74" width="344" height="10" font="13">should be evaluated to determine whether coronary angiography</text>
<text top="905" left="74" width="344" height="10" font="13">should be performed for risk assessment <a href="e44.full.html#94">(352–355). </a><i>(Level of</i></text>
<text top="922" left="74" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="948" left="59" width="326" height="16" font="26"><b>3.3.2. Coronary Angiography to Assess Risk After</b></text>
<text top="966" left="59" width="279" height="16" font="26"><b>Initial Workup With Noninvasive Testing:</b></text>
<text top="984" left="59" width="119" height="16" font="26"><b>Recommendations</b></text>
<text top="1016" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="1029" left="59" width="360" height="10" font="13">1. Coronary arteriography is recommended for patients with SIHD</text>
<text top="1046" left="74" width="344" height="10" font="13">whose clinical characteristics and results of noninvasive testing</text>
<text top="1063" left="74" width="344" height="10" font="13">indicate a high likelihood of severe IHD and when the benefits are</text>
<text top="1080" left="74" width="344" height="10" font="13">deemed to exceed risk <a href="e44.full.html#87">(59,126,260,310,356–362). </a><i>(Level of Evi-</i></text>
<text top="1097" left="74" width="48" height="10" font="25"><i>dence: C)</i></text>
<text top="105" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="118" left="446" width="360" height="10" font="13">1. Coronary angiography is reasonable to further assess risk in pa-</text>
<text top="135" left="461" width="279" height="10" font="13">tients with SIHD who have depressed LV function (EF</text>
<text top="132" left="745" width="61" height="16" font="13">⬍50%) and</text>
<text top="152" left="461" width="344" height="10" font="13">moderate risk criteria on noninvasive testing with demonstrable</text>
<text top="169" left="461" width="223" height="10" font="13">ischemia <a href="e44.full.html#94">(363–365). </a><i>(Level of Evidence: C)</i></text>
<text top="185" left="445" width="360" height="10" font="13">2. Coronary angiography is reasonable to further assess risk in pa-</text>
<text top="202" left="461" width="344" height="10" font="13">tients with SIHD and inconclusive prognostic information after</text>
<text top="219" left="461" width="344" height="10" font="13">noninvasive testing or in patients for whom noninvasive testing is</text>
<text top="236" left="461" width="273" height="10" font="13">contraindicated or inadequate. <i>(Level of Evidence: C)</i></text>
<text top="253" left="445" width="360" height="10" font="13">3. Coronary angiography for risk assessment is reasonable for patients</text>
<text top="270" left="461" width="344" height="10" font="13">with SIHD who have unsatisfactory quality of life due to angina, have</text>
<text top="287" left="461" width="141" height="10" font="13">preserved LV function (EF</text>
<text top="284" left="610" width="196" height="16" font="13">⬎50%), and have intermediate risk</text>
<text top="304" left="461" width="328" height="10" font="13">criteria on noninvasive testing <a href="e44.full.html#93">(306,366). </a><i>(Level of Evidence: C)</i></text>
<text top="334" left="446" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="347" left="446" width="360" height="10" font="13">1. Coronary angiography for risk assessment is not recommended</text>
<text top="364" left="461" width="344" height="10" font="13">in patients with SIHD who elect not to undergo revascularization</text>
<text top="381" left="461" width="344" height="10" font="13">or who are not candidates for revascularization because of</text>
<text top="398" left="461" width="344" height="10" font="13">comorbidities or individual preferences <a href="e44.full.html#93">(306,366). </a><i>(Level of Evi-</i></text>
<text top="415" left="461" width="50" height="10" font="25"><i>dence: B)</i></text>
<text top="432" left="446" width="360" height="10" font="13">2. Coronary angiography is not recommended to further assess risk in</text>
<text top="448" left="461" width="281" height="10" font="13">patients with SIHD who have preserved LV function (EF</text>
<text top="445" left="746" width="60" height="16" font="13">⬎50%) and</text>
<text top="465" left="461" width="344" height="10" font="13">low-risk criteria on noninvasive testing <a href="e44.full.html#93">(306,366). </a><i>(Level of Evi-</i></text>
<text top="482" left="461" width="48" height="10" font="25"><i>dence: B)</i></text>
<text top="499" left="446" width="360" height="10" font="13">3. Coronary angiography is not recommended to assess risk in pa-</text>
<text top="516" left="461" width="344" height="10" font="13">tients who are at low risk according to clinical criteria and who have</text>
<text top="533" left="461" width="317" height="10" font="13">not undergone noninvasive risk testing. <i>(Level of Evidence: C)</i></text>
<text top="550" left="446" width="360" height="10" font="13">4. Coronary angiography is not recommended to assess risk in asymp-</text>
<text top="567" left="461" width="344" height="10" font="13">tomatic patients with no evidence of ischemia on noninvasive</text>
<text top="584" left="461" width="152" height="10" font="13">testing. <i>(Level of Evidence: C)</i></text>
<text top="608" left="446" width="360" height="16" font="4">Coronary angiography defines coronary anatomy, includ-</text>
<text top="626" left="446" width="360" height="16" font="4">ing the location, length, diameter, and contour of the</text>
<text top="644" left="446" width="360" height="16" font="4">epicardial coronary arteries; the presence and severity of</text>
<text top="662" left="446" width="360" height="16" font="4">coronary luminal obstruction(s); the nature of the ob-</text>
<text top="680" left="446" width="360" height="16" font="4">struction; the presence and extent of angiographically</text>
<text top="698" left="446" width="360" height="16" font="4">visible collateral flow; and coronary blood flow. Despite</text>
<text top="716" left="446" width="360" height="16" font="4">the ability of newer noninvasive imaging modalities such</text>
<text top="734" left="446" width="360" height="16" font="4">as CT angiography to visualize and characterize the</text>
<text top="752" left="446" width="360" height="16" font="4">coronary tree, invasive coronary angiography currently</text>
<text top="770" left="446" width="360" height="16" font="4">remains the “gold standard.” Coronary angiography has 2</text>
<text top="788" left="446" width="360" height="16" font="4">clinical goals: 1) to assess a patient’s risk of death and</text>
<text top="806" left="446" width="360" height="16" font="4">future cardiovascular events through characterization of</text>
<text top="824" left="446" width="360" height="16" font="4">the presence and extent of obstructive CAD and 2) to</text>
<text top="842" left="446" width="360" height="16" font="4">ascertain the feasibility of percutaneous or surgical revas-</text>
<text top="860" left="446" width="360" height="16" font="4">cularization. The likelihood that revascularization might</text>
<text top="878" left="446" width="360" height="16" font="4">decrease angina and improve a patient’s quality of life</text>
<text top="896" left="446" width="360" height="16" font="4">should be considered when a patient deems his or her</text>
<text top="914" left="446" width="360" height="16" font="4">quality of life unsatisfactory despite a conscientious</text>
<text top="932" left="446" width="282" height="16" font="4">program of evidence-based medical therapy.</text>
<text top="950" left="461" width="345" height="16" font="4">The most commonly used nomenclature for defining</text>
<text top="968" left="446" width="360" height="16" font="4">coronary anatomy is that which was developed for CASS</text>
<text top="986" left="446" width="5" height="16" font="4"><a href="e44.full.html#95">(</a></text>
<text top="986" left="451" width="23" height="16" font="16"><a href="e44.full.html#95">367</a></text>
<text top="986" left="474" width="331" height="16" font="4"><a href="e44.full.html#95">) </a>and further modified by the BARI study group</text>
<text top="1004" left="446" width="5" height="16" font="4"><a href="e44.full.html#95">(</a></text>
<text top="1004" left="451" width="23" height="16" font="16"><a href="e44.full.html#95">368</a></text>
<text top="1004" left="474" width="331" height="16" font="4"><a href="e44.full.html#95">). </a>This scheme is based on the assumption that there</text>
<text top="1022" left="446" width="360" height="16" font="4">are 3 major coronary arteries: the LAD, the circumflex,</text>
<text top="1040" left="446" width="360" height="16" font="4">and the right coronary artery, with a right-dominant,</text>
<text top="1058" left="446" width="360" height="16" font="4">left-dominant, or codominant circulation. The extent of</text>
<text top="1076" left="446" width="360" height="16" font="4">disease is defined as 1-vessel, 2-vessel, 3-vessel, or left</text>
<text top="1094" left="446" width="254" height="16" font="4">main disease, with a significant stenosis</text>
<text top="1091" left="705" width="100" height="20" font="4">ⱖ70% diameter</text>
<text top="52" left="59" width="18" height="10" font="12">e78</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">reduction. Left main disease, however, also has been</text>
<text top="122" left="59" width="130" height="16" font="4">defined as a stenosis</text>
<text top="119" left="194" width="44" height="20" font="4">ⱖ50%.</text>
<text top="140" left="73" width="345" height="16" font="4">Despite being recognized as the traditional “gold stan-</text>
<text top="158" left="58" width="360" height="16" font="4">dard” for clinical assessment of coronary atherosclerosis,</text>
<text top="176" left="58" width="360" height="16" font="4">coronary angiography is not without limitations. First, the</text>
<text top="194" left="58" width="360" height="16" font="4">technical quality of angiograms in many settings can make</text>
<text top="212" left="58" width="360" height="16" font="4">accurate interpretation difficult or impossible. In a random</text>
<text top="230" left="58" width="60" height="16" font="4">sample of</text>
<text top="227" left="126" width="293" height="20" font="4">⬎300 coronary angiograms performed in New</text>
<text top="248" left="58" width="360" height="16" font="4">York State during the 1990s, 4% were of unacceptable</text>
<text top="266" left="58" width="360" height="16" font="4">quality, and 48% exhibited technical deficiencies that could</text>
<text top="284" left="58" width="231" height="16" font="4">interfere with accurate interpretation <a href="e44.full.html#95">(</a></text>
<text top="284" left="290" width="23" height="16" font="16"><a href="e44.full.html#95">369</a></text>
<text top="284" left="312" width="106" height="16" font="4"><a href="e44.full.html#95">). </a>Although more</text>
<text top="302" left="58" width="360" height="16" font="4">modern techniques and equipment likely have eliminated</text>
<text top="320" left="58" width="360" height="16" font="4">some of these deficiencies, few studies have addressed this</text>
<text top="338" left="58" width="360" height="16" font="4">issue, particularly in patients who present technical chal-</text>
<text top="356" left="58" width="360" height="16" font="4">lenges, such as those who are obese. Second, problems also</text>
<text top="374" left="58" width="360" height="16" font="4">exist with interobserver reliability. These investigators also</text>
<text top="392" left="58" width="360" height="16" font="4">found only 70% overall agreement among readers with</text>
<text top="410" left="58" width="360" height="16" font="4">regard to the severity of stenosis, and this was reduced to</text>
<text top="428" left="58" width="360" height="16" font="4">51% when restricted to coronary vessels rated as having</text>
<text top="446" left="58" width="360" height="16" font="4">some stenosis by any reader. Third, angiography in isolation</text>
<text top="464" left="58" width="360" height="16" font="4">provides only anatomic data and is not a reliable indicator of</text>
<text top="482" left="58" width="360" height="16" font="4">the functional significance of a given coronary stenosis</text>
<text top="500" left="58" width="360" height="16" font="4">unless a technique such as FFR (discussed below) is used to</text>
<text top="518" left="58" width="360" height="16" font="4">provide information about the physiological significance of</text>
<text top="536" left="58" width="360" height="16" font="4">an anatomic stenosis. Lastly, coronary angiography does not</text>
<text top="554" left="58" width="360" height="16" font="4">distinguish between a vulnerable plaque, with a large lipid</text>
<text top="572" left="58" width="360" height="16" font="4">core, thin fibrous cap, and increased macrophages, and a</text>
<text top="590" left="58" width="360" height="16" font="4">stable plaque that does not exhibit these features. Serial</text>
<text top="608" left="58" width="360" height="16" font="4">angiographic studies performed before and after acute</text>
<text top="626" left="58" width="360" height="16" font="4">events and early after MI suggest that plaques resulting in</text>
<text top="644" left="58" width="247" height="16" font="4">UA and MI commonly were found to be</text>
<text top="641" left="310" width="109" height="20" font="4">⬍50% obstructive</text>
<text top="662" left="58" width="360" height="16" font="4">before the acute event and were therefore angiographically</text>
<text top="680" left="58" width="53" height="16" font="4">“silent” <a href="e44.full.html#95">(</a></text>
<text top="680" left="112" width="49" height="16" font="16"><a href="e44.full.html#95">370,371</a></text>
<text top="680" left="161" width="258" height="16" font="4"><a href="e44.full.html#95">). </a>Diagnostic testing to determine vulner-</text>
<text top="698" left="58" width="360" height="16" font="4">able plaque, and therefore the subsequent risk for MI,</text>
<text top="716" left="58" width="360" height="16" font="4">remains intensely studied, but no “gold standard” yet has</text>
<text top="734" left="58" width="61" height="16" font="4">emerged <a href="e44.full.html#95">(</a></text>
<text top="734" left="119" width="23" height="16" font="16"><a href="e44.full.html#95">372</a></text>
<text top="734" left="142" width="277" height="16" font="4"><a href="e44.full.html#95">)</a>. Despite these limitations of coronary angiog-</text>
<text top="752" left="58" width="360" height="16" font="4">raphy, the extent and severity of CAD remain very significant</text>
<text top="770" left="58" width="294" height="16" font="4">predictors of long-term patient outcomes <a href="e44.full.html#36">(</a></text>
<text top="770" left="353" width="61" height="16" font="16"><a href="e44.full.html#36">Table 13</a></text>
<text top="770" left="414" width="5" height="16" font="4"><a href="e44.full.html#36">)</a></text>
<text top="788" left="58" width="5" height="16" font="4"><a href="e44.full.html#87">(</a></text>
<text top="788" left="63" width="101" height="16" font="16"><a href="e44.full.html#87">55,70,71,373,374</a></text>
<text top="788" left="164" width="8" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="806" left="73" width="345" height="16" font="4">For patients who are found to be at high risk of coronary</text>
<text top="824" left="58" width="360" height="16" font="4">events or death on the basis of clinical data and noninvasive</text>
<text top="842" left="58" width="360" height="16" font="4">testing, coronary angiography is often warranted to provide</text>
<text top="860" left="58" width="360" height="16" font="4">a more complete risk assessment even though cardiac</text>
<text top="878" left="58" width="360" height="16" font="4">symptoms might not be severe. Certain clinical character-</text>
<text top="896" left="58" width="360" height="16" font="4">istics, though relatively infrequent in patients with IHD,</text>
<text top="914" left="58" width="360" height="16" font="4">have been associated with a high likelihood of severe</text>
<text top="932" left="58" width="360" height="16" font="4">disease, including the following: chest pain leading to</text>
<text top="950" left="58" width="360" height="16" font="4">pulmonary edema, chest pain associated with lightheaded-</text>
<text top="968" left="58" width="360" height="16" font="4">ness, syncope or hypotension, exertional syncope, and an</text>
<text top="986" left="58" width="360" height="16" font="4">exercise-induced gallop sound on cardiac auscultation. In</text>
<text top="1004" left="58" width="360" height="16" font="4">addition to clinical signs and symptoms, findings on</text>
<text top="1022" left="58" width="360" height="16" font="4">noninvasive studies could also suggest that certain pa-</text>
<text top="1040" left="58" width="360" height="16" font="4">tients are at high risk of serious cardiac events. These</text>
<text top="1058" left="58" width="360" height="16" font="4">findings include abnormal physiological response to ex-</text>
<text top="1076" left="58" width="360" height="16" font="4">ercise or imaging studies that suggest extensive myocar-</text>
<text top="1094" left="58" width="96" height="16" font="4">dial ischemia <a href="e44.full.html#37">(</a></text>
<text top="1094" left="154" width="56" height="16" font="16"><a href="e44.full.html#37">Table 14</a></text>
<text top="1094" left="210" width="146" height="16" font="4"><a href="e44.full.html#37">). </a>Some examples from</text>
<text top="1094" left="363" width="56" height="16" font="16"><a href="e44.full.html#37">Table 14</a></text>
<text top="446" left="446" width="360" height="16" font="4">(high-risk category) which may suggest somewhat less</text>
<text top="464" left="446" width="360" height="16" font="4">extensive myocardial ischemia: CCTA 2-vessel disease,</text>
<text top="482" left="446" width="70" height="16" font="4">CAC score</text>
<text top="479" left="522" width="284" height="20" font="4">⬎400 Agatston units, severe resting LV dys-</text>
<text top="500" left="446" width="100" height="16" font="4">function (LVEF</text>
<text top="497" left="551" width="255" height="20" font="4">⬍35%) not readily explained by noncoro-</text>
<text top="518" left="446" width="360" height="16" font="4">nary causes, stress defects at 10% level, 2 coronary beds wall</text>
<text top="536" left="446" width="360" height="16" font="4">motion abnormality on stress echocardiography but only 2</text>
<text top="554" left="446" width="59" height="16" font="4">segments.</text>
<text top="572" left="461" width="345" height="16" font="4">Coronary angiography helps to quantify risk on the basis</text>
<text top="590" left="446" width="360" height="16" font="4">of an anatomic prognostic index; the simplest and most</text>
<text top="608" left="446" width="360" height="16" font="4">widely used is the classification of disease into 1-, 2-, or</text>
<text top="626" left="446" width="182" height="16" font="4">3-vessel or left main CAD <a href="e44.full.html#94">(</a></text>
<text top="626" left="627" width="79" height="16" font="16"><a href="e44.full.html#94">358,375–377</a></text>
<text top="626" left="706" width="100" height="16" font="4"><a href="e44.full.html#94">). </a>In the CASS</text>
<text top="644" left="446" width="58" height="16" font="4">registry <a href="e44.full.html#94">(</a></text>
<text top="644" left="503" width="23" height="16" font="16"><a href="e44.full.html#94">364</a></text>
<text top="644" left="526" width="280" height="16" font="4"><a href="e44.full.html#94">) </a>of medically treated patients, the 12-year</text>
<text top="662" left="446" width="360" height="16" font="4">survival rate of patients with normal coronary arteries was</text>
<text top="680" left="446" width="360" height="16" font="4">91%, compared with 74% for those with 1-vessel disease,</text>
<text top="698" left="446" width="360" height="16" font="4">59% for those with 2-vessel disease, and 40% for those with</text>
<text top="716" left="446" width="360" height="16" font="4">3-vessel disease. The probability of survival declines progres-</text>
<text top="734" left="446" width="360" height="16" font="4">sively with the number of coronary arteries that are occluded.</text>
<text top="752" left="446" width="360" height="16" font="4">The presence of severe proximal LAD artery disease signifi-</text>
<text top="770" left="446" width="360" height="16" font="4">cantly reduces the survival rate. The 5-year survival rate with</text>
<text top="788" left="446" width="120" height="16" font="4">3-vessel disease plus</text>
<text top="785" left="572" width="234" height="20" font="4">⬎95% proximal LAD stenosis was re-</text>
<text top="806" left="446" width="360" height="16" font="4">ported to be 59%, as compared with a rate of 79% for 3-vessel</text>
<text top="824" left="446" width="185" height="16" font="4">disease without LAD stenosis <a href="e44.full.html#36">(</a></text>
<text top="824" left="630" width="53" height="16" font="16"><a href="e44.full.html#36">Table 13</a></text>
<text top="824" left="683" width="8" height="16" font="4"><a href="e44.full.html#36">).</a></text>
<text top="842" left="461" width="345" height="16" font="4">With the use of data accumulated in the 1980s, a</text>
<text top="860" left="446" width="360" height="16" font="4">nomogram was developed to predict 5-year survival rate on</text>
<text top="878" left="446" width="360" height="16" font="4">the basis of clinical history, physical examination, coronary</text>
<text top="896" left="446" width="165" height="16" font="4">angiography, and LVEF <a href="e44.full.html#38">(</a></text>
<text top="896" left="611" width="61" height="16" font="16"><a href="e44.full.html#38">Figure 12</a></text>
<text top="896" left="672" width="134" height="16" font="4"><a href="e44.full.html#38">). </a>The importance of</text>
<text top="914" left="446" width="360" height="16" font="4">considering clinical factors and especially LV function in</text>
<text top="932" left="446" width="360" height="16" font="4">estimating the risk of a given coronary angiographic finding</text>
<text top="950" left="446" width="360" height="16" font="4">is illustrated by comparing the predicted 5-year survival rate</text>
<text top="968" left="446" width="360" height="16" font="4">of a 65-year-old man with stable angina, 3-vessel disease,</text>
<text top="986" left="446" width="360" height="16" font="4">and normal ventricular function with that of a 65-year-old</text>
<text top="1004" left="446" width="360" height="16" font="4">man with stable angina, 3-vessel disease, heart failure, and</text>
<text top="1022" left="446" width="360" height="16" font="4">an EF of 30%. The 5-year survival rate for the former was</text>
<text top="1040" left="446" width="360" height="16" font="4">estimated to be 93%, whereas patients with the same</text>
<text top="1058" left="446" width="360" height="16" font="4">characteristics but with heart failure and reduced EF had a</text>
<text top="1076" left="446" width="360" height="16" font="4">predicted survival rate of only 58%. Because of advances in</text>
<text top="1094" left="446" width="360" height="16" font="4">treatment, it is almost certain that the survival rate has</text>
<text top="105" left="446" width="187" height="11" font="13">Table 13. CAD Prognostic Index</text>
<text top="156" left="513" width="67" height="9" font="6">Extent of CAD</text>
<text top="130" left="677" width="51" height="9" font="6">Prognostic</text>
<text top="143" left="686" width="33" height="9" font="6">Weight</text>
<text top="156" left="683" width="38" height="9" font="6">(0–100)</text>
<text top="130" left="766" width="30" height="9" font="6">5-Year</text>
<text top="143" left="763" width="37" height="9" font="6">Survival</text>
<text top="156" left="758" width="47" height="9" font="6">Rate (%)*</text>
<text top="173" left="446" width="100" height="9" font="6">1-vessel disease, 75%</text>
<text top="173" left="696" width="12" height="9" font="6">23</text>
<text top="173" left="775" width="12" height="9" font="6">93</text>
<text top="190" left="446" width="135" height="9" font="6">1-vessel disease, 50% to 74%</text>
<text top="190" left="696" width="12" height="9" font="6">23</text>
<text top="190" left="775" width="12" height="9" font="6">93</text>
<text top="208" left="446" width="77" height="9" font="6">1-vessel disease,</text>
<text top="205" left="525" width="29" height="14" font="6">ⱖ95%</text>
<text top="208" left="696" width="12" height="9" font="6">32</text>
<text top="208" left="775" width="12" height="9" font="6">91</text>
<text top="225" left="446" width="74" height="9" font="6">2-vessel disease</text>
<text top="225" left="696" width="12" height="9" font="6">37</text>
<text top="225" left="775" width="12" height="9" font="6">88</text>
<text top="242" left="446" width="100" height="9" font="6">2-vessel disease, both</text>
<text top="239" left="548" width="29" height="14" font="6">ⱖ95%</text>
<text top="242" left="696" width="12" height="9" font="6">42</text>
<text top="242" left="775" width="12" height="9" font="6">86</text>
<text top="259" left="446" width="77" height="9" font="6">1-vessel disease,</text>
<text top="257" left="525" width="122" height="14" font="6">ⱖ95% proximal LAD artery</text>
<text top="259" left="697" width="12" height="9" font="6">48</text>
<text top="259" left="775" width="12" height="9" font="6">83</text>
<text top="277" left="446" width="77" height="9" font="6">2-vessel disease,</text>
<text top="274" left="525" width="80" height="14" font="6">ⱖ95% LAD artery</text>
<text top="277" left="696" width="12" height="9" font="6">48</text>
<text top="277" left="775" width="12" height="9" font="6">83</text>
<text top="294" left="446" width="77" height="9" font="6">2-vessel disease,</text>
<text top="291" left="525" width="122" height="14" font="6">ⱖ95% proximal LAD artery</text>
<text top="294" left="697" width="12" height="9" font="6">56</text>
<text top="294" left="775" width="12" height="9" font="6">79</text>
<text top="311" left="446" width="74" height="9" font="6">3-vessel disease</text>
<text top="311" left="696" width="12" height="9" font="6">56</text>
<text top="311" left="775" width="12" height="9" font="6">79</text>
<text top="328" left="446" width="77" height="9" font="6">3-vessel disease,</text>
<text top="326" left="525" width="89" height="14" font="6">ⱖ95% in ⱖ1 vessel</text>
<text top="328" left="697" width="12" height="9" font="6">63</text>
<text top="328" left="775" width="12" height="9" font="6">73</text>
<text top="346" left="446" width="193" height="9" font="6">3-vessel disease, 75% proximal LAD artery</text>
<text top="346" left="697" width="12" height="9" font="6">67</text>
<text top="346" left="775" width="12" height="9" font="6">67</text>
<text top="363" left="446" width="77" height="9" font="6">3-vessel disease,</text>
<text top="360" left="525" width="122" height="14" font="6">ⱖ95% proximal LAD artery</text>
<text top="363" left="697" width="12" height="9" font="6">74</text>
<text top="363" left="775" width="12" height="9" font="6">59</text>
<text top="400" left="446" width="360" height="7" font="17">*Assuming medical treatment only. CAD indicates coronary artery disease; LAD, left anterior</text>
<text top="412" left="446" width="46" height="7" font="17">descending.</text>
<text top="424" left="454" width="114" height="7" font="17">Reproduced from Califf et al. <a href="e44.full.html#87">(</a></text>
<text top="424" left="568" width="10" height="7" font="22"><a href="e44.full.html#87">55</a></text>
<text top="424" left="579" width="5" height="7" font="17"><a href="e44.full.html#87">).</a></text>
<text top="52" left="787" width="18" height="10" font="12">e79</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1161" width="864">
<text top="968" left="59" width="360" height="16" font="4">improved since these studies were conducted, but the</text>
<text top="986" left="59" width="264" height="16" font="4">relative differences in survival likely persist.</text>
<text top="1004" left="74" width="345" height="16" font="4">The development of symptomatic LV failure in a patient</text>
<text top="1022" left="59" width="360" height="16" font="4">with SIHD is often an indication of severe, obstructive</text>
<text top="1040" left="59" width="360" height="16" font="4">CAD and demands expeditious evaluation for the presence</text>
<text top="1058" left="59" width="360" height="16" font="4">of active ischemia. Depending on the acuity and severity of</text>
<text top="1076" left="59" width="360" height="16" font="4">symptoms, angiography or evaluation for ischemia with</text>
<text top="1094" left="59" width="200" height="16" font="4">noninvasive testing is warranted.</text>
<text top="104" left="461" width="345" height="16" font="4">An additional, but less quantifiable, benefit of coronary</text>
<text top="123" left="446" width="360" height="16" font="4">angiography and LV function assessment derives from the</text>
<text top="141" left="446" width="360" height="16" font="4">ability of experienced angiographers to integrate the find-</text>
<text top="159" left="446" width="360" height="16" font="4">ings on coronary angiography and left ventriculography to</text>
<text top="177" left="446" width="360" height="16" font="4">estimate the potential benefit of revascularization strategies</text>
<text top="195" left="446" width="360" height="16" font="4">discussed below. The characteristics of coronary lesions</text>
<text top="213" left="446" width="360" height="16" font="4">(e.g., stenosis severity, length, complexity, and presence of</text>
<text top="231" left="446" width="360" height="16" font="4">thrombus), the number of lesions posing jeopardy to regions</text>
<text top="249" left="446" width="360" height="16" font="4">of contracting myocardium, the possible role of collaterals,</text>
<text top="267" left="446" width="360" height="16" font="4">and the mass of jeopardized viable myocardium also can</text>
<text top="285" left="446" width="360" height="16" font="4">afford some insight into the consequences of subsequent</text>
<text top="303" left="446" width="360" height="16" font="4">vessel occlusion. For example, a patient with a noncontract-</text>
<text top="322" left="446" width="360" height="16" font="4">ing inferior or lateral wall and severe proximal stenosis of a</text>
<text top="340" left="446" width="360" height="16" font="4">very large LAD artery is presumably at substantial risk of</text>
<text top="358" left="446" width="360" height="16" font="4">developing cardiogenic shock if the LAD artery were to</text>
<text top="376" left="446" width="108" height="16" font="4">become occluded.</text>
<text top="394" left="461" width="345" height="16" font="4">In view of the importance of proximal versus distal</text>
<text top="412" left="446" width="360" height="16" font="4">coronary stenoses, a “jeopardy score” has been developed,</text>
<text top="430" left="446" width="360" height="16" font="4">which takes the prognostic significance of a lesion’s location</text>
<text top="448" left="446" width="118" height="16" font="4">into consideration <a href="e44.full.html#95">(</a></text>
<text top="448" left="563" width="23" height="16" font="16"><a href="e44.full.html#95">378</a></text>
<text top="448" left="586" width="220" height="16" font="4"><a href="e44.full.html#95">). </a>Angiographic studies indicate that</text>
<text top="466" left="446" width="360" height="16" font="4">a direct correlation also exists between the angiographic</text>
<text top="484" left="446" width="360" height="16" font="4">severity of CAD and the amount of angiographically insig-</text>
<text top="502" left="446" width="360" height="16" font="4">nificant plaque buildup elsewhere in the coronary tree.</text>
<text top="520" left="446" width="360" height="16" font="4">These studies suggest that the higher mortality rate of</text>
<text top="538" left="446" width="360" height="16" font="4">patients with multivessel disease could occur because they</text>
<text top="556" left="446" width="360" height="16" font="4">have more mildly stenotic or nonstenotic plaques that are</text>
<text top="574" left="446" width="360" height="16" font="4">potential sites for acute coronary events than do patients</text>
<text top="592" left="446" width="136" height="16" font="4">with 1-vessel disease <a href="e44.full.html#95">(</a></text>
<text top="592" left="582" width="23" height="16" font="16"><a href="e44.full.html#95">379</a></text>
<text top="592" left="604" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="610" left="461" width="345" height="16" font="4">For many years, it has been known that patients with</text>
<text top="629" left="446" width="360" height="16" font="4">severe stenosis of the left main coronary artery have a poor</text>
<text top="647" left="446" width="360" height="16" font="4">prognosis when treated medically. A gradation of worsening</text>
<text top="665" left="446" width="360" height="16" font="4">risk also has been found with increasing degrees of stenosis</text>
<text top="683" left="446" width="297" height="16" font="4">of the left main in medically managed patients <a href="e44.full.html#95">(</a></text>
<text top="683" left="743" width="54" height="16" font="16"><a href="e44.full.html#95">380 –382</a></text>
<text top="683" left="797" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="701" left="446" width="360" height="16" font="4">Angiographic determination of the significance of left main</text>
<text top="719" left="446" width="360" height="16" font="4">disease can be difficult, with suboptimal intraobserver agree-</text>
<text top="737" left="446" width="360" height="16" font="4">ment with regard to the degree of severity of any given</text>
<text top="755" left="446" width="56" height="16" font="4">stenosis <a href="e44.full.html#95">(</a></text>
<text top="755" left="501" width="75" height="16" font="16"><a href="e44.full.html#95">381,383,384</a></text>
<text top="755" left="577" width="229" height="16" font="4"><a href="e44.full.html#95">). </a>However, multiple other modalities</text>
<text top="773" left="446" width="360" height="16" font="4">are available to the angiographer to assist in accurately</text>
<text top="791" left="446" width="360" height="16" font="4">determining the significance of a left main lesion (i.e., FFR</text>
<text top="809" left="446" width="360" height="16" font="4">and intravascular ultrasound). Despite the challenges posed</text>
<text top="827" left="446" width="360" height="16" font="4">by angiographic determination of left main disease, it</text>
<text top="845" left="446" width="360" height="16" font="4">remains the best option for the diagnosis and reevaluation of</text>
<text top="863" left="446" width="360" height="16" font="4">left main disease if concern exists about progression of</text>
<text top="881" left="446" width="360" height="16" font="4">previously diagnosed disease because of the inability to</text>
<text top="899" left="446" width="360" height="16" font="4">consistently detect and evaluate this condition with nonin-</text>
<text top="918" left="446" width="226" height="16" font="4">vasive testing or clinical assessment <a href="e44.full.html#95">(</a></text>
<text top="918" left="672" width="53" height="16" font="16"><a href="e44.full.html#95">385–390</a></text>
<text top="918" left="724" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="954" left="446" width="104" height="14" font="15">4. Treatment</text>
<text top="1004" left="446" width="273" height="12" font="18">4.1. Definition of Successful Treatment</text>
<text top="1027" left="446" width="360" height="16" font="4">The paramount goals of treating patients with SIHD are to</text>
<text top="1045" left="446" width="360" height="16" font="4">minimize the likelihood of death while maximizing health</text>
<text top="1063" left="446" width="304" height="16" font="4">and function. The more specific objectives are to:</text>
<text top="1091" left="461" width="260" height="20" font="4">• Reduce premature cardiovascular death;</text>
<text top="105" left="59" width="237" height="11" font="13">Table 14. Noninvasive Risk Stratification</text>
<text top="127" left="59" width="46" height="9" font="6">High risk (</text>
<text top="125" left="105" width="115" height="14" font="6">⬎3% annual death or MI)</text>
<text top="145" left="76" width="173" height="9" font="6">1. Severe resting LV dysfunction (LVEF</text>
<text top="142" left="252" width="143" height="14" font="6">⬍35%) not readily explained by</text>
<text top="159" left="89" width="90" height="9" font="6">noncoronary causes</text>
<text top="176" left="76" width="156" height="9" font="6">2. Resting perfusion abnormalities</text>
<text top="173" left="235" width="169" height="14" font="6">ⱖ10% of the myocardium in patients</text>
<text top="190" left="89" width="172" height="9" font="6">without prior history or evidence of MI</text>
<text top="208" left="76" width="143" height="9" font="6">3. Stress ECG findings including</text>
<text top="205" left="222" width="168" height="14" font="6">ⱖ2 mm of ST-segment depression at</text>
<text top="222" left="89" width="317" height="9" font="6">low workload or persisting into recovery, exercise-induced ST-segment</text>
<text top="236" left="89" width="164" height="9" font="6">elevation, or exercise-induced VT/VF</text>
<text top="253" left="76" width="273" height="9" font="6">4. Severe stress-induced LV dysfunction (peak exercise LVEF</text>
<text top="251" left="352" width="41" height="14" font="6">⬍45% or</text>
<text top="268" left="89" width="108" height="9" font="6">drop in LVEF with stress</text>
<text top="265" left="201" width="32" height="14" font="6">ⱖ10%)</text>
<text top="285" left="76" width="251" height="9" font="6">5. Stress-induced perfusion abnormalities encumbering</text>
<text top="282" left="330" width="29" height="14" font="6">ⱖ10%</text>
<text top="299" left="89" width="309" height="9" font="6">myocardium or stress segmental scores indicating multiple vascular</text>
<text top="313" left="89" width="131" height="9" font="6">territories with abnormalities</text>
<text top="331" left="76" width="129" height="9" font="6">6. Stress-induced LV dilation</text>
<text top="348" left="76" width="212" height="9" font="6">7. Inducible wall motion abnormality (involving</text>
<text top="345" left="291" width="74" height="14" font="6">⬎2 segments or</text>
<text top="362" left="89" width="76" height="9" font="6">2 coronary beds)</text>
<text top="379" left="76" width="300" height="9" font="6">8. Wall motion abnormality developing at low dose of dobutamine</text>
<text top="394" left="89" width="3" height="9" font="6">(</text>
<text top="391" left="92" width="267" height="14" font="6">ⱕ10 mg/kg/min) or at a low heart rate (⬍120 beats/min)</text>
<text top="411" left="76" width="58" height="9" font="6">9. CAC score</text>
<text top="408" left="136" width="96" height="14" font="6">⬎400 Agatston units</text>
<text top="428" left="70" width="149" height="9" font="6">10. Multivessel obstructive CAD (</text>
<text top="425" left="219" width="168" height="14" font="6">ⱖ70% stenosis) or left main stenosis</text>
<text top="442" left="89" width="3" height="9" font="6">(</text>
<text top="440" left="92" width="113" height="14" font="6">ⱖ50% stenosis) on CCTA</text>
<text top="460" left="59" width="220" height="9" font="6">Intermediate risk (1% to 3% annual death or MI)</text>
<text top="477" left="70" width="324" height="9" font="6">1. Mild/moderate resting LV dysfunction (LVEF 35% to 49%) not readily</text>
<text top="491" left="83" width="150" height="9" font="6">explained by noncoronary causes</text>
<text top="508" left="70" width="323" height="9" font="6">2. Resting perfusion abnormalities in 5% to 9.9% of the myocardium in</text>
<text top="523" left="83" width="220" height="9" font="6">patients without a history or prior evidence of MI</text>
<text top="540" left="70" width="9" height="9" font="6">3.</text>
<text top="537" left="82" width="321" height="14" font="6">ⱖ1 mm of ST-segment depression occurring with exertional symptoms</text>
<text top="557" left="70" width="332" height="9" font="6">4. Stress-induced perfusion abnormalities encumbering 5% to 9.9% of</text>
<text top="571" left="83" width="317" height="9" font="6">the myocardium or stress segmental scores (in multiple segments)</text>
<text top="586" left="83" width="301" height="9" font="6">indicating 1 vascular territory with abnormalities but without LV</text>
<text top="600" left="83" width="35" height="9" font="6">dilation</text>
<text top="617" left="70" width="312" height="9" font="6">5. Small wall motion abnormality involving 1 to 2 segments and only</text>
<text top="631" left="83" width="68" height="9" font="6">1 coronary bed</text>
<text top="649" left="70" width="181" height="9" font="6">6. CAC score 100 to 399 Agatston units</text>
<text top="666" left="70" width="105" height="9" font="6">7. One vessel CAD with</text>
<text top="663" left="178" width="191" height="14" font="6">ⱖ70% stenosis or moderate CAD stenosis</text>
<text top="680" left="83" width="114" height="9" font="6">(50% to 69% stenosis) in</text>
<text top="677" left="200" width="93" height="14" font="6">ⱖ2 arteries on CCTA</text>
<text top="697" left="59" width="44" height="9" font="6">Low risk (</text>
<text top="695" left="103" width="115" height="14" font="6">⬍1% annual death or MI)</text>
<text top="715" left="70" width="150" height="9" font="6">1. Low-risk treadmill score (score</text>
<text top="712" left="223" width="175" height="14" font="6">ⱖ5) or no new ST segment changes or</text>
<text top="729" left="83" width="334" height="9" font="6">exercise-induced chest pain symptoms; when achieving maximal levels of</text>
<text top="743" left="83" width="37" height="9" font="6">exercise</text>
<text top="760" left="70" width="310" height="9" font="6">2. Normal or small myocardial perfusion defect at rest or with stress</text>
<text top="775" left="83" width="59" height="9" font="6">encumbering</text>
<text top="772" left="145" width="118" height="14" font="6">⬍5% of the myocardium*</text>
<text top="792" left="70" width="339" height="9" font="6">3. Normal stress or no change of limited resting wall motion abnormalities</text>
<text top="806" left="83" width="58" height="9" font="6">during stress</text>
<text top="823" left="70" width="58" height="9" font="6">4. CAC score</text>
<text top="821" left="130" width="92" height="14" font="6">⬍100 Agaston units</text>
<text top="841" left="70" width="106" height="9" font="6">5. No coronary stenosis</text>
<text top="838" left="179" width="70" height="14" font="6">⬎50% on CCTA</text>
<text top="878" left="59" width="360" height="7" font="17">*Although the published data are limited; patients with these findings will probably not be at low risk in the</text>
<text top="890" left="59" width="290" height="7" font="17">presence of either a high-risk treadmill score or severe resting LV dysfunction (LVEF</text>
<text top="888" left="350" width="27" height="11" font="17">⬍35%).</text>
<text top="902" left="67" width="351" height="7" font="17">CAC indicates coronary artery calcium; CAD, coronary artery disease; CCTA, coronary computed</text>
<text top="914" left="58" width="360" height="7" font="17">tomography angiography; LV, left ventricular; LVEF, left ventricular ejection fraction; and MI,</text>
<text top="926" left="58" width="81" height="7" font="17">myocardial infarction.</text>
<text top="938" left="67" width="113" height="7" font="17">Adapted from Gibbons et al. <a href="e44.full.html#85">(</a></text>
<text top="938" left="180" width="5" height="7" font="22"><a href="e44.full.html#85">7</a></text>
<text top="938" left="185" width="5" height="7" font="17"><a href="e44.full.html#85">).</a></text>
<text top="52" left="59" width="18" height="10" font="12">e80</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1161" width="864">
<text top="598" left="74" width="345" height="20" font="4">• Prevent complications of SIHD that directly or indi-</text>
<text top="620" left="90" width="328" height="16" font="4">rectly impair patients’ functional well-being, including</text>
<text top="638" left="90" width="196" height="16" font="4">nonfatal AMI and heart failure;</text>
<text top="652" left="74" width="345" height="20" font="4">• Maintain or restore a level of activity, functional capacity,</text>
<text top="674" left="90" width="301" height="16" font="4">and quality of life that is satisfactory to the patient;</text>
<text top="688" left="74" width="345" height="20" font="4">• Completely, or nearly completely, eliminate ischemic</text>
<text top="710" left="90" width="92" height="16" font="4">symptoms; and</text>
<text top="724" left="74" width="345" height="20" font="4">• Minimize costs of health care, in particular by elimi-</text>
<text top="746" left="90" width="328" height="16" font="4">nating avoidable adverse effects of tests and treatments,</text>
<text top="602" left="477" width="328" height="16" font="4">by preventing hospital admissions, and by eliminating</text>
<text top="620" left="477" width="203" height="16" font="4">unnecessary tests and treatments.</text>
<text top="647" left="461" width="345" height="16" font="4">These goals are pursued with 5 fundamental, comple-</text>
<text top="665" left="446" width="220" height="16" font="4">mentary, and overlapping strategies:</text>
<text top="692" left="446" width="360" height="16" font="4">1. Educate patients about the etiology, clinical manifesta-</text>
<text top="710" left="464" width="341" height="16" font="4">tions, treatment options, and prognosis of IHD, to</text>
<text top="728" left="464" width="341" height="16" font="4">support active participation of patients in their treatment</text>
<text top="746" left="464" width="58" height="16" font="4">decisions.</text>
<text top="541" left="59" width="743" height="11" font="13">Figure 12. Nomogram for Prediction of 5-Year Survival From Clinical, Physical Examination, and Cardiac Catheterization Findings</text>
<text top="573" left="59" width="618" height="8" font="11">Asymp indicates asymptomatic; CAD, coronary artery disease; MI, myocardial infarction; and Symp, symptomatic. Reproduced from Califf et al. <a href="e44.full.html#87">(</a></text>
<text top="573" left="677" width="12" height="8" font="23"><a href="e44.full.html#87">55</a></text>
<text top="573" left="689" width="6" height="8" font="11"><a href="e44.full.html#87">).</a></text>
<text top="1038" left="59" width="730" height="11" font="13">Figure 13. Cumulative Incidence of MACE in Patients With 3-Vessel CAD Based on SYNTAX Score at 3-Year Follow-Up in the SYNTAX Trial</text>
<text top="1054" left="58" width="243" height="10" font="13">Treated With Either CABG (Blue) or PCI (Gold)</text>
<text top="1085" left="59" width="746" height="8" font="11">CABG indicates coronary artery bypass graft; CAD, coronary artery disease; MACE, major adverse cardiovascular event; PCI, percutaneous coronary intervention; and SYNTAX,</text>
<text top="1099" left="59" width="484" height="8" font="11">Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery. Adapted from Kappetein <a href="e44.full.html#109">(</a></text>
<text top="1099" left="543" width="18" height="8" font="23"><a href="e44.full.html#109">980</a></text>
<text top="1099" left="560" width="6" height="8" font="11"><a href="e44.full.html#109">).</a></text>
<text top="52" left="787" width="18" height="10" font="12">e81</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">2. Identify and treat conditions that contribute to, worsen,</text>
<text top="123" left="77" width="122" height="16" font="4">or complicate IHD.</text>
<text top="142" left="59" width="360" height="16" font="4">3. Effectively modify risk factors for IHD by both pharma-</text>
<text top="160" left="77" width="267" height="16" font="4">cological and nonpharmacological methods.</text>
<text top="179" left="59" width="360" height="16" font="4">4. Use evidence-based pharmacological treatments to im-</text>
<text top="197" left="77" width="341" height="16" font="4">prove patients’ health status and survival, with attention</text>
<text top="216" left="77" width="278" height="16" font="4">to avoiding drug interactions and side effects.</text>
<text top="235" left="59" width="360" height="16" font="4">5. Use revascularization by percutaneous catheter-based</text>
<text top="253" left="77" width="341" height="16" font="4">techniques or CABG when there is clear evidence of</text>
<text top="272" left="77" width="341" height="16" font="4">the potential to improve patients’ health status and</text>
<text top="290" left="77" width="51" height="16" font="4">survival.</text>
<text top="327" left="59" width="232" height="12" font="18">4.2. General Approach to Therapy</text>
<text top="351" left="59" width="360" height="16" font="4">The writing committee has constructed these guidelines</text>
<text top="369" left="59" width="360" height="16" font="4">from the perspective that when making decisions about</text>
<text top="388" left="59" width="360" height="16" font="4">diagnostic tests and therapeutic interventions, their poten-</text>
<text top="406" left="59" width="360" height="16" font="4">tial effects on improving survival and health status should be</text>
<text top="425" left="59" width="360" height="16" font="4">considered independently. Although treatment choices of-</text>
<text top="444" left="59" width="360" height="16" font="4">ten are intended to achieve both goals simultaneously,</text>
<text top="462" left="59" width="360" height="16" font="4">circumstances exist in which a treatment is administered in</text>
<text top="481" left="59" width="360" height="16" font="4">pursuit of only one of these goals. For example, when</text>
<text top="499" left="59" width="360" height="16" font="4">pharmacotherapy such as aspirin or angiotensin-converting</text>
<text top="518" left="59" width="360" height="16" font="4">enzyme (ACE) inhibitors is prescribed, the goal is to</text>
<text top="537" left="59" width="360" height="16" font="4">improve survival but not necessarily quality of life. Similarly,</text>
<text top="555" left="59" width="360" height="16" font="4">revascularization can be performed to improve symptoms,</text>
<text top="574" left="59" width="360" height="16" font="4">even when there is no expectation of improved survival.</text>
<text top="592" left="59" width="360" height="16" font="4">Occasionally, treatment recommendations related to achiev-</text>
<text top="611" left="59" width="360" height="16" font="4">ing these goals can be at odds, such as when a patient is</text>
<text top="629" left="59" width="360" height="16" font="4">encouraged to take a medication that significantly reduces</text>
<text top="648" left="59" width="360" height="16" font="4">the risk of death even though it causes mild or moderate</text>
<text top="667" left="59" width="118" height="16" font="4">adverse side effects.</text>
<text top="685" left="74" width="345" height="16" font="4">It might also be the case that a patient expresses a</text>
<text top="704" left="59" width="360" height="16" font="4">preference for a treatment approach (e.g., PCI) when the</text>
<text top="722" left="59" width="360" height="16" font="4">practitioner believes another approach (e.g., GDMT) would</text>
<text top="741" left="59" width="360" height="16" font="4">be preferable. Although practitioners always should engage</text>
<text top="760" left="59" width="360" height="16" font="4">patients in a detailed discussion about their individual goals</text>
<text top="778" left="59" width="360" height="16" font="4">and values in order to tailor therapy, this is particularly</text>
<text top="797" left="59" width="360" height="16" font="4">important when therapeutic goals or the patient’s or pro-</text>
<text top="815" left="59" width="360" height="16" font="4">vider’s preferences are not aligned. It is essential that these</text>
<text top="834" left="59" width="360" height="16" font="4">discussions be conducted in a location and atmosphere that</text>
<text top="852" left="59" width="360" height="16" font="4">permits adequate time for discussion and contemplation.</text>
<text top="871" left="59" width="360" height="16" font="4">Initiating a discussion about the relative merits of medical</text>
<text top="890" left="59" width="360" height="16" font="4">therapy versus revascularization while a patient is in the</text>
<text top="908" left="59" width="360" height="16" font="4">midst of procedure, for example, is not usually consistent</text>
<text top="927" left="59" width="130" height="16" font="4">with these principles.</text>
<text top="945" left="74" width="345" height="16" font="4">Reducing the risk of mortality should be pursued as</text>
<text top="964" left="59" width="360" height="16" font="4">intensively as is sensible for all patients with SIHD. It has</text>
<text top="983" left="59" width="360" height="16" font="4">been estimated that nearly half of the dramatic decline in</text>
<text top="1001" left="59" width="360" height="16" font="4">cardiovascular mortality observed during the past 40 years is</text>
<text top="1020" left="59" width="360" height="16" font="4">attributable to interventions directed at modifying risk</text>
<text top="1038" left="59" width="360" height="16" font="4">factors. Of this change, 47% can be attributed to treatments,</text>
<text top="1057" left="59" width="360" height="16" font="4">including risk factor reduction after AMI, other guideline-</text>
<text top="1075" left="59" width="360" height="16" font="4">based treatments for UA and heart failure, and revascular-</text>
<text top="1094" left="59" width="166" height="16" font="4">ization for chronic angina <a href="e44.full.html#95">(</a></text>
<text top="1094" left="225" width="23" height="16" font="16"><a href="e44.full.html#95">391</a></text>
<text top="1094" left="247" width="171" height="16" font="4"><a href="e44.full.html#95">). </a>An additional 44% reduc-</text>
<text top="105" left="446" width="360" height="16" font="4">tion in age-adjusted death is attributed to population-based</text>
<text top="123" left="446" width="147" height="16" font="4">changes in risk factors <a href="e44.full.html#95">(</a></text>
<text top="123" left="592" width="23" height="16" font="16"><a href="e44.full.html#95">391</a></text>
<text top="123" left="615" width="191" height="16" font="4"><a href="e44.full.html#95">). </a>Unfortunately, these changes</text>
<text top="141" left="446" width="360" height="16" font="4">have been offset somewhat by increases in BMI and type 2</text>
<text top="160" left="446" width="360" height="16" font="4">diabetes mellitus, which result in an increased number of</text>
<text top="178" left="446" width="49" height="16" font="4">deaths <a href="e44.full.html#95">(</a></text>
<text top="178" left="494" width="23" height="16" font="16"><a href="e44.full.html#95">391</a></text>
<text top="178" left="517" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="196" left="461" width="345" height="16" font="4">The 2011 secondary prevention and risk reduction ther-</text>
<text top="215" left="446" width="94" height="16" font="4">apy statement <a href="e44.full.html#85">(</a></text>
<text top="215" left="539" width="8" height="16" font="16"><a href="e44.full.html#85">8</a></text>
<text top="215" left="547" width="259" height="16" font="4"><a href="e44.full.html#85">) </a>summarizes the key interventions known</text>
<text top="233" left="446" width="360" height="16" font="4">to improve survival and prevent subsequent cardiac events.</text>
<text top="251" left="446" width="360" height="16" font="4">Worldwide, it has been estimated that 90% of the risk of MI</text>
<text top="270" left="446" width="360" height="16" font="4">is attributable to 9 measureable risk factors, including</text>
<text top="288" left="446" width="360" height="16" font="4">smoking, diabetes mellitus, hypertension, obesity, impaired</text>
<text top="306" left="446" width="360" height="16" font="4">psychological well-being, poor diet, lack of exercise, alcohol</text>
<text top="325" left="446" width="200" height="16" font="4">consumption, and dyslipidemia <a href="e44.full.html#95">(</a></text>
<text top="325" left="645" width="23" height="16" font="16"><a href="e44.full.html#95">392</a></text>
<text top="325" left="668" width="138" height="16" font="4"><a href="e44.full.html#95">). </a>The initial approach</text>
<text top="343" left="446" width="360" height="16" font="4">to all patients should be focused on eliminating unhealthy</text>
<text top="361" left="446" width="360" height="16" font="4">behaviors such as smoking and effectively promoting life-</text>
<text top="380" left="446" width="360" height="16" font="4">style changes (e.g., maintaining a healthy weight, engaging</text>
<text top="398" left="446" width="275" height="16" font="4">in physical activity, adopting a healthy diet <a href="e44.full.html#14">[</a></text>
<text top="398" left="721" width="52" height="16" font="16"><a href="e44.full.html#14">Figure 4</a></text>
<text top="398" left="773" width="33" height="16" font="4"><a href="e44.full.html#14">]). </a>In</text>
<text top="417" left="446" width="360" height="16" font="4">addition, for most patients, an evidence-based set of phar-</text>
<text top="435" left="446" width="360" height="16" font="4">macological interventions is indicated to reduce the risk of</text>
<text top="453" left="446" width="360" height="16" font="4">future events. The presumed mechanism by which these</text>
<text top="472" left="446" width="360" height="16" font="4">interventions work is stabilization of the coronary plaque to</text>
<text top="490" left="446" width="212" height="16" font="4">prevent rupture and thrombosis <a href="e44.full.html#85">(</a></text>
<text top="490" left="658" width="8" height="16" font="16"><a href="e44.full.html#85">8</a></text>
<text top="490" left="665" width="140" height="16" font="4"><a href="e44.full.html#85">). </a>These include anti-</text>
<text top="508" left="446" width="97" height="16" font="4">platelet agents <a href="e44.full.html#95">(</a></text>
<text top="508" left="542" width="23" height="16" font="16"><a href="e44.full.html#95">393</a></text>
<text top="508" left="565" width="62" height="16" font="4"><a href="e44.full.html#95">), </a>statins <a href="e44.full.html#95">(</a></text>
<text top="508" left="626" width="56" height="16" font="16"><a href="e44.full.html#95">394 – 401</a></text>
<text top="508" left="682" width="123" height="16" font="4"><a href="e44.full.html#95">), </a>and beta blockers,</text>
<text top="527" left="446" width="360" height="16" font="4">along with other agents if indicated, to control hypertension</text>
<text top="545" left="446" width="5" height="16" font="4"><a href="e44.full.html#95">(</a></text>
<text top="545" left="450" width="49" height="16" font="16"><a href="e44.full.html#95">402,403</a></text>
<text top="545" left="499" width="306" height="16" font="4"><a href="e44.full.html#95">). </a>ACE inhibitors are indicated in many patients</text>
<text top="563" left="446" width="360" height="16" font="4">with SIHD, especially those with diabetes mellitus or LV</text>
<text top="582" left="446" width="79" height="16" font="4">dysfunction <a href="e44.full.html#93">(</a></text>
<text top="582" left="525" width="75" height="16" font="16"><a href="e44.full.html#93">296,301,404</a></text>
<text top="582" left="600" width="206" height="16" font="4"><a href="e44.full.html#93">). </a>Similarly, tight glycemic control</text>
<text top="600" left="446" width="360" height="16" font="4">not only has not been shown to reduce the risk of macro-</text>
<text top="618" left="446" width="360" height="16" font="4">vascular complications in patients with type 2 diabetes</text>
<text top="637" left="446" width="360" height="16" font="4">mellitus, it also appears to increase the risk of cardiovascular</text>
<text top="655" left="446" width="360" height="16" font="4">death and complications. Nonetheless, weight loss, aerobic</text>
<text top="673" left="446" width="360" height="16" font="4">exercise, an AHA Step II diet, and ACE inhibitors in</text>
<text top="692" left="446" width="360" height="16" font="4">patients with diabetes mellitus with proteinuria all can</text>
<text top="710" left="446" width="360" height="16" font="4">improve patients’ risks of microvascular complications and,</text>
<text top="728" left="446" width="161" height="16" font="4">potentially, cardiac events.</text>
<text top="747" left="461" width="345" height="16" font="4">For the purposes of this guideline, the writing committee</text>
<text top="765" left="446" width="360" height="16" font="4">elected to retain the classification for risk of cardiovascular</text>
<text top="783" left="446" width="360" height="16" font="4">events that has been accepted by consensus over the past 2</text>
<text top="802" left="446" width="360" height="16" font="4">decades. Patients with a predicted annual cardiac mortality</text>
<text top="820" left="446" width="39" height="16" font="4">rate of</text>
<text top="817" left="489" width="317" height="20" font="4">⬍1% per year are considered to be at low risk, those</text>
<text top="838" left="446" width="360" height="16" font="4">with a predicted rate of 1% to 3% per year are considered to</text>
<text top="857" left="446" width="360" height="16" font="4">be at intermediate risk, and those with a predicted average</text>
<text top="872" left="446" width="293" height="20" font="4">⬎3% per year are considered to be at high risk.</text>
<text top="893" left="461" width="345" height="16" font="4">For patients at high risk of mortality, the prevalence of</text>
<text top="912" left="446" width="360" height="16" font="4">severe CAD (e.g., left main coronary occlusion) is higher,</text>
<text top="930" left="446" width="360" height="16" font="4">and coronary angiography can define the coronary anatomy</text>
<text top="948" left="446" width="360" height="16" font="4">and help to plan further therapy beyond standard GDMT</text>
<text top="967" left="446" width="5" height="16" font="4"><a href="e44.full.html#15">(</a></text>
<text top="967" left="450" width="52" height="16" font="16"><a href="e44.full.html#15">Figure 5</a></text>
<text top="967" left="503" width="303" height="16" font="4"><a href="e44.full.html#15">). </a>If the patient is at low or intermediate risk for</text>
<text top="985" left="446" width="360" height="16" font="4">mortality, therapeutic decisions should be directed toward</text>
<text top="1003" left="446" width="360" height="16" font="4">improving symptoms and function, and catheterization may</text>
<text top="1022" left="446" width="360" height="16" font="4">be deferred if symptoms can be controlled with medical</text>
<text top="1040" left="446" width="360" height="16" font="4">therapy alone. For patients in whom angiography is per-</text>
<text top="1058" left="446" width="360" height="16" font="4">formed and who are determined to be at low or intermediate</text>
<text top="1077" left="446" width="360" height="16" font="4">risk, evidence reaffirms that it is safe to defer revasculariza-</text>
<text top="1095" left="446" width="360" height="16" font="4">tion and institute a program of evidence-based medical</text>
<text top="52" left="59" width="18" height="10" font="12">e82</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">therapy, because neither survival nor adverse cardiac events</text>
<text top="123" left="59" width="360" height="16" font="4">are averted by proceeding immediately to revascularization</text>
<text top="141" left="59" width="5" height="16" font="4"><a href="e44.full.html#94">(</a></text>
<text top="141" left="63" width="107" height="16" font="16"><a href="e44.full.html#94">366,397,405– 409</a></text>
<text top="141" left="170" width="248" height="16" font="4"><a href="e44.full.html#94">). </a>If a patient in this category has symp-</text>
<text top="159" left="59" width="360" height="16" font="4">toms that are completely or almost completely relieved with</text>
<text top="178" left="59" width="360" height="16" font="4">medical therapy, it is usually prudent to continue with</text>
<text top="196" left="59" width="360" height="16" font="4">medical therapy without proceeding to revascularization. If</text>
<text top="215" left="59" width="360" height="16" font="4">symptoms persist, however, then a discussion with the</text>
<text top="233" left="59" width="360" height="16" font="4">patient to elicit his or her preferences and goals is necessary,</text>
<text top="251" left="59" width="360" height="16" font="4">along with a frank discussion of the benefits and risks of</text>
<text top="270" left="59" width="360" height="16" font="4">PCI and CABG, to ascertain whether the symptoms have</text>
<text top="288" left="59" width="360" height="16" font="4">been ameliorated sufficiently to warrant simply continuing</text>
<text top="306" left="59" width="176" height="16" font="4">with medical therapy alone <a href="e44.full.html#14">(</a></text>
<text top="306" left="234" width="57" height="16" font="16"><a href="e44.full.html#14">Figures 4</a></text>
<text top="306" left="297" width="22" height="16" font="4">and</text>
<text top="306" left="324" width="8" height="16" font="16"><a href="e44.full.html#15">5</a></text>
<text top="306" left="331" width="9" height="16" font="4"><a href="e44.full.html#15">).</a></text>
<text top="325" left="74" width="345" height="16" font="4">Coronary revascularization generally improves survival</text>
<text top="343" left="59" width="360" height="16" font="4">among certain subgroups of patients, particularly those with</text>
<text top="361" left="59" width="360" height="16" font="4">severe left main coronary stenosis. When revascularization is</text>
<text top="380" left="59" width="360" height="16" font="4">being considered on an elective basis solely for reducing the</text>
<text top="398" left="59" width="360" height="16" font="4">risk of death, the healthcare provider should engage the</text>
<text top="416" left="59" width="360" height="16" font="4">patient in an explicit consideration of the estimated im-</text>
<text top="435" left="59" width="360" height="16" font="4">provement in survival relative to the potential risks and costs</text>
<text top="453" left="59" width="360" height="16" font="4">of the procedure and related interventions. Because reliable</text>
<text top="471" left="59" width="360" height="16" font="4">estimates of benefit, such as absolute risk reduction, are</text>
<text top="490" left="59" width="360" height="16" font="4">frequently unavailable for many specific subgroups, the risk</text>
<text top="508" left="59" width="360" height="16" font="4">for death can be estimated before treatment and the</text>
<text top="526" left="59" width="360" height="16" font="4">anticipated absolute risk reduction calculated (obtained by</text>
<text top="545" left="59" width="360" height="16" font="4">multiplying the RR reduction by the pretreatment risk). In</text>
<text top="563" left="59" width="360" height="16" font="4">the STICH (Surgical Treatment for Ischemic Heart Fail-</text>
<text top="581" left="59" width="292" height="16" font="4">ure) trial, in which 1,212 patients with an LVEF</text>
<text top="578" left="354" width="65" height="20" font="4">ⱕ35% and</text>
<text top="600" left="59" width="360" height="16" font="4">CAD amenable to revascularization were randomized to</text>
<text top="618" left="59" width="360" height="16" font="4">CABG or medical therapy, there was no significant differ-</text>
<text top="636" left="59" width="360" height="16" font="4">ence in overall mortality rate, but during a median follow-up</text>
<text top="655" left="59" width="360" height="16" font="4">of 56 months, 28% of those assigned to CABG died of a</text>
<text top="673" left="59" width="360" height="16" font="4">cardiovascular cause, compared with 33% of those receiving</text>
<text top="691" left="59" width="103" height="16" font="4">medical therapy <a href="e44.full.html#95">(</a></text>
<text top="691" left="162" width="23" height="16" font="16"><a href="e44.full.html#95">410</a></text>
<text top="691" left="184" width="234" height="16" font="4"><a href="e44.full.html#95">). </a>This information can be converted to</text>
<text top="710" left="59" width="360" height="16" font="4">a more interpretable framework, such as the average reduc-</text>
<text top="728" left="59" width="360" height="16" font="4">tion in risk of events or number needed to treat. In this</text>
<text top="746" left="59" width="360" height="16" font="4">example, the average reduction in cardiovascular events was</text>
<text top="765" left="59" width="360" height="16" font="4">19%, and it would be necessary to perform bypass surgery on</text>
<text top="783" left="59" width="360" height="16" font="4">about 5 patients with LV dysfunction to prevent 1 cardio-</text>
<text top="801" left="59" width="327" height="16" font="4">vascular death at 5 years (i.e., number needed to treat</text>
<text top="798" left="390" width="28" height="20" font="4">⫽ 5,</text>
<text top="820" left="59" width="93" height="16" font="4">calculated as 1</text>
<text top="817" left="158" width="260" height="20" font="4">⫼ absolute risk reduction, or 1/0.19 [al-</text>
<text top="838" left="59" width="360" height="16" font="4">though there would be no effect on overall mortality rate]).</text>
<text top="856" left="59" width="360" height="16" font="4">This process complies with the Institute of Medicine’s goals</text>
<text top="875" left="59" width="360" height="16" font="4">for transparently sharing evidence with patients so that they</text>
<text top="893" left="59" width="360" height="16" font="4">can control (or more actively participate in) their own</text>
<text top="911" left="59" width="64" height="16" font="4">decisions <a href="e44.full.html#95">(</a></text>
<text top="911" left="123" width="23" height="16" font="16"><a href="e44.full.html#95">411</a></text>
<text top="911" left="145" width="274" height="16" font="4"><a href="e44.full.html#95">). </a>In general, a beneficial effect of revascular-</text>
<text top="930" left="59" width="360" height="16" font="4">ization on survival has been demonstrated most clearly</text>
<text top="948" left="59" width="329" height="16" font="4">among patients with the highest cardiovascular risk <a href="e44.full.html#95">(</a></text>
<text top="948" left="387" width="23" height="16" font="16"><a href="e44.full.html#95">412</a></text>
<text top="948" left="410" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="966" left="59" width="360" height="16" font="4">Although traditional methods of risk stratification have</text>
<text top="985" left="59" width="360" height="16" font="4">relied on coronary anatomy and LV function, other strate-</text>
<text top="1003" left="59" width="276" height="16" font="4">gies described in this guideline can be used <a href="e44.full.html#15">(</a></text>
<text top="1003" left="334" width="52" height="16" font="16"><a href="e44.full.html#15">Figure 5</a></text>
<text top="1003" left="386" width="9" height="16" font="4"><a href="e44.full.html#15">).</a></text>
<text top="1021" left="74" width="345" height="16" font="4">The specific anatomic features of the patient and the</text>
<text top="1040" left="59" width="360" height="16" font="4">likelihood of procedural success often influence the ap-</text>
<text top="1058" left="59" width="360" height="16" font="4">proach to a patient for whom revascularization is being</text>
<text top="1076" left="59" width="360" height="16" font="4">considered. For example, a given patient with 1-vessel</text>
<text top="1095" left="59" width="360" height="16" font="4">disease might have coronary anatomic features that would</text>
<text top="105" left="446" width="360" height="16" font="4">make the risk of PCI high enough and the likelihood of</text>
<text top="123" left="446" width="360" height="16" font="4">success low enough that CABG or medical therapy would</text>
<text top="141" left="446" width="360" height="16" font="4">be preferred. In general, complete revascularization leads to</text>
<text top="160" left="446" width="285" height="16" font="4">better outcomes than incomplete revascularization <a href="e44.full.html#96">(</a></text>
<text top="160" left="730" width="51" height="16" font="16"><a href="e44.full.html#96">413–418</a></text>
<text top="160" left="780" width="25" height="16" font="4"><a href="e44.full.html#96">). </a>In</text>
<text top="178" left="446" width="360" height="16" font="4">patients with chronic total occlusion, CABG could be</text>
<text top="197" left="446" width="130" height="16" font="4">preferable to PCI <a href="e44.full.html#96">(</a></text>
<text top="197" left="575" width="23" height="16" font="16"><a href="e44.full.html#96">419</a></text>
<text top="197" left="598" width="208" height="16" font="4"><a href="e44.full.html#96">), </a>but this is still controversial.</text>
<text top="215" left="446" width="360" height="16" font="4">Although the technology and techniques for PCI of chronic</text>
<text top="233" left="446" width="360" height="16" font="4">total occlusions are improving, there remains no current</text>
<text top="252" left="446" width="360" height="16" font="4">evidence that survival is improved after successful PCI of a</text>
<text top="270" left="446" width="360" height="16" font="4">chronic total occlusion. Some patients with diabetes melli-</text>
<text top="288" left="446" width="360" height="16" font="4">tus can have such diffuse disease that neither CABG nor</text>
<text top="307" left="446" width="360" height="16" font="4">PCI is likely to produce sustained benefits. Other patients</text>
<text top="325" left="446" width="360" height="16" font="4">can have small-caliber arteries or diffuse disease that is likely</text>
<text top="344" left="446" width="360" height="16" font="4">to lead to early graft failure. Still others can have long,</text>
<text top="362" left="446" width="360" height="16" font="4">complex lesions that are very likely to undergo restenosis</text>
<text top="380" left="446" width="360" height="16" font="4">after PCI, although use of drug-eluting stents (DES) can</text>
<text top="399" left="446" width="97" height="16" font="4">reduce this risk.</text>
<text top="417" left="461" width="345" height="16" font="4">The majority of patients with SIHD have clinical features</text>
<text top="435" left="446" width="360" height="16" font="4">indicating that revascularization is unlikely to improve life</text>
<text top="454" left="446" width="360" height="16" font="4">expectancy or the risk of subsequent MI. For such patients,</text>
<text top="472" left="446" width="360" height="16" font="4">antianginal therapy and intensive treatment for risk factors</text>
<text top="491" left="446" width="360" height="16" font="4">are recommended before consideration of PCI or CABG to</text>
<text top="509" left="446" width="360" height="16" font="4">relieve symptoms. A broad range of highly effective drugs is</text>
<text top="527" left="446" width="360" height="16" font="4">available, including beta blockers, calcium channel blockers,</text>
<text top="546" left="446" width="360" height="16" font="4">long-acting nitrates, and newer agents such as ranolazine.</text>
<text top="564" left="446" width="360" height="16" font="4">Comparative trials among these medications are relatively</text>
<text top="582" left="446" width="205" height="16" font="4">few and for the most part small <a href="e44.full.html#96">(</a></text>
<text top="582" left="650" width="23" height="16" font="16"><a href="e44.full.html#96">420</a></text>
<text top="582" left="673" width="133" height="16" font="4"><a href="e44.full.html#96">). </a>On the basis of the</text>
<text top="601" left="446" width="360" height="16" font="4">available data, however, all of the classes of agents appear to</text>
<text top="619" left="446" width="360" height="16" font="4">be relatively similar in antianginal efficacy, and all have very</text>
<text top="638" left="446" width="360" height="16" font="4">acceptable profiles of safety and tolerability. Beta blockers</text>
<text top="656" left="446" width="360" height="16" font="4">have been shown to improve survival in patients after AMI</text>
<text top="674" left="446" width="360" height="16" font="4">and in patients with hypertension; they provide 24-hour</text>
<text top="693" left="446" width="360" height="16" font="4">coverage and have a long history of clinical use. For these</text>
<text top="711" left="446" width="360" height="16" font="4">reasons, the writing committee recommends these agents as</text>
<text top="729" left="446" width="360" height="16" font="4">first-line drugs for treating angina. In patients who do not</text>
<text top="748" left="446" width="360" height="16" font="4">tolerate or adequately respond to beta blockers, calcium</text>
<text top="766" left="446" width="360" height="16" font="4">channel blockers and/or long-acting nitrates may be substi-</text>
<text top="784" left="446" width="360" height="16" font="4">tuted or added. Ranolazine has been shown to inhibit the</text>
<text top="803" left="446" width="360" height="16" font="4">late sodium current in humans and has demonstrated</text>
<text top="821" left="446" width="132" height="16" font="4">lusitropic properties <a href="e44.full.html#96">(</a></text>
<text top="821" left="578" width="23" height="16" font="16"><a href="e44.full.html#96">421</a></text>
<text top="821" left="601" width="205" height="16" font="4"><a href="e44.full.html#96">). </a>Clinical trials have shown that</text>
<text top="840" left="446" width="360" height="16" font="4">this agent is comparable to other agents in alleviating</text>
<text top="858" left="446" width="360" height="16" font="4">angina. Although this agent has been approved by the U.S.</text>
<text top="876" left="446" width="360" height="16" font="4">Food and Drug Administration (FDA) for first-line use in</text>
<text top="895" left="446" width="360" height="16" font="4">patients with chronic angina, the writing committee recom-</text>
<text top="913" left="446" width="360" height="16" font="4">mends that ranolazine be considered in circumstances in</text>
<text top="931" left="446" width="360" height="16" font="4">which beta blockers, calcium channel blockers, and nitrates</text>
<text top="950" left="446" width="293" height="16" font="4">are not adequately effective or are not tolerated.</text>
<text top="977" left="446" width="272" height="16" font="26"><b>4.2.1. Factors That Should Not Influence</b></text>
<text top="995" left="446" width="136" height="16" font="26"><b>Treatment Decisions</b></text>
<text top="1021" left="446" width="360" height="16" font="4">The 2 medical indications for revascularization are to</text>
<text top="1040" left="446" width="360" height="16" font="4">prevent death and cardiovascular complications and to</text>
<text top="1058" left="446" width="360" height="16" font="4">improve symptoms and quality of life. Nonetheless, the use</text>
<text top="1076" left="446" width="360" height="16" font="4">of revascularization has risen dramatically in the past 3</text>
<text top="1095" left="446" width="360" height="16" font="4">decades. Much of this increase appears to be for indications</text>
<text top="52" left="787" width="18" height="10" font="12">e83</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="35" size="5" family="Times" color="#005d59"/>
<text top="104" left="59" width="360" height="16" font="4">for which benefits in survival or symptoms in comparison</text>
<text top="123" left="59" width="243" height="16" font="4">with noninvasive therapies are unlikely <a href="e44.full.html#96">(</a></text>
<text top="123" left="301" width="23" height="16" font="16"><a href="e44.full.html#96">422</a></text>
<text top="123" left="324" width="95" height="16" font="4"><a href="e44.full.html#96">). </a>National data</text>
<text top="141" left="59" width="360" height="16" font="4">suggest that about 12% of PCIs could be inappropriate</text>
<text top="160" left="59" width="360" height="16" font="4">because they lack evident potential to improve either sur-</text>
<text top="178" left="59" width="121" height="16" font="4">vival or symptoms <a href="e44.full.html#96">(</a></text>
<text top="178" left="179" width="23" height="16" font="16"><a href="e44.full.html#96">423</a></text>
<text top="178" left="202" width="217" height="16" font="4"><a href="e44.full.html#96">). </a>Several reasons influence patients</text>
<text top="196" left="59" width="360" height="16" font="4">and physicians to prefer revascularization when the likeli-</text>
<text top="215" left="59" width="360" height="16" font="4">hood of benefit is less than the potential risk of the</text>
<text top="233" left="59" width="360" height="16" font="4">procedure. An ingrained preference for action (i.e., revas-</text>
<text top="251" left="59" width="360" height="16" font="4">cularization) over perceived inaction (i.e., medical therapy</text>
<text top="270" left="59" width="360" height="16" font="4">alone) likely often influences the decision making of both</text>
<text top="288" left="59" width="154" height="16" font="4">patients and physicians <a href="e44.full.html#91">(</a></text>
<text top="288" left="213" width="23" height="16" font="16"><a href="e44.full.html#91">252</a></text>
<text top="288" left="235" width="183" height="16" font="4"><a href="e44.full.html#91">). </a>Moreover, some healthcare</text>
<text top="307" left="59" width="360" height="16" font="4">professionals are unduly pessimistic about survival with</text>
<text top="325" left="59" width="360" height="16" font="4">conservative medical therapy and inaccurately optimistic</text>
<text top="343" left="59" width="360" height="16" font="4">about the survival benefits of revascularization procedures</text>
<text top="362" left="59" width="5" height="16" font="4"><a href="e44.full.html#96">(</a></text>
<text top="362" left="63" width="23" height="16" font="16"><a href="e44.full.html#96">424</a></text>
<text top="362" left="86" width="333" height="16" font="4"><a href="e44.full.html#96">). </a>As indicated earlier, patients often believe mistakenly</text>
<text top="380" left="59" width="360" height="16" font="4">that PCI has the potential to prevent AMI and prolong</text>
<text top="398" left="59" width="56" height="16" font="4">survival <a href="e44.full.html#96">(</a></text>
<text top="398" left="114" width="49" height="16" font="16"><a href="e44.full.html#96">423,425</a></text>
<text top="398" left="163" width="255" height="16" font="4"><a href="e44.full.html#96">). </a>In addition, the attendant expense and</text>
<text top="417" left="59" width="360" height="16" font="4">risk of combined antiplatelet therapy for an uncertain period</text>
<text top="435" left="59" width="360" height="16" font="4">of time might not be fully considered. Physicians are</text>
<text top="454" left="59" width="360" height="16" font="4">professionally obligated to provide accurate estimates of the</text>
<text top="472" left="59" width="360" height="16" font="4">risks, benefits, and costs of various therapeutic options that</text>
<text top="490" left="59" width="360" height="16" font="4">are based on the best available scientific data. Other factors</text>
<text top="509" left="59" width="360" height="16" font="4">can induce physicians to recommend revascularization.</text>
<text top="527" left="59" width="360" height="16" font="4">These include medicolegal concerns (often exaggerated) and</text>
<text top="545" left="59" width="360" height="16" font="4">feeling compelled to satisfy the expectations of patients and</text>
<text top="564" left="59" width="360" height="16" font="4">referring physicians (which are sometimes misinformed or</text>
<text top="582" left="59" width="76" height="16" font="4">unrealistic) <a href="e44.full.html#96">(</a></text>
<text top="582" left="135" width="23" height="16" font="16"><a href="e44.full.html#96">426</a></text>
<text top="582" left="157" width="261" height="16" font="4"><a href="e44.full.html#96">). </a>Additionally, there are well-documented</text>
<text top="601" left="59" width="360" height="16" font="4">regional variations in the use and appropriateness of cardiac</text>
<text top="619" left="59" width="329" height="16" font="4">procedures that appear to reflect local practice styles <a href="e44.full.html#96">(</a></text>
<text top="619" left="387" width="23" height="16" font="16"><a href="e44.full.html#96">427</a></text>
<text top="619" left="410" width="9" height="16" font="4"><a href="e44.full.html#96">).</a></text>
<text top="637" left="59" width="360" height="16" font="4">This might partly reflect a mistaken belief by some physi-</text>
<text top="656" left="59" width="261" height="16" font="4">cians that “more care is better care” <a href="e44.full.html#96">(</a></text>
<text top="656" left="319" width="23" height="16" font="16"><a href="e44.full.html#96">428</a></text>
<text top="656" left="342" width="77" height="16" font="4"><a href="e44.full.html#96">). </a>Although</text>
<text top="674" left="59" width="360" height="16" font="4">successful procedures can be psychologically satisfying to the</text>
<text top="692" left="59" width="360" height="16" font="4">physician and the patient, this does not justify the attendant</text>
<text top="711" left="59" width="360" height="16" font="4">economic costs and risk of complications of procedures that</text>
<text top="729" left="59" width="238" height="16" font="4">offer minimal, if any, genuine benefit <a href="e44.full.html#96">(</a></text>
<text top="729" left="297" width="56" height="16" font="16"><a href="e44.full.html#96">429 – 431</a></text>
<text top="729" left="353" width="9" height="16" font="4"><a href="e44.full.html#96">).</a></text>
<text top="748" left="74" width="345" height="16" font="4">Although rarely discussed explicitly, financial incentives</text>
<text top="766" left="59" width="360" height="16" font="4">seem to affect the willingness of a minority of physicians and</text>
<text top="784" left="59" width="360" height="16" font="4">institutions to recommend certain procedures or drug ther-</text>
<text top="803" left="59" width="360" height="16" font="4">apies. Strong incentives created by the payment system</text>
<text top="821" left="59" width="360" height="16" font="4">encourage overutilization. Also, a small number of physi-</text>
<text top="839" left="59" width="360" height="16" font="4">cians might have financial relationships with the manufac-</text>
<text top="858" left="59" width="360" height="16" font="4">turers of devices or drugs that might represent apparent</text>
<text top="876" left="59" width="360" height="16" font="4">conflicts that ought to be disclosed to patients. At a higher</text>
<text top="894" left="59" width="360" height="16" font="4">level, those responsible for the payment system, the manu-</text>
<text top="913" left="59" width="360" height="16" font="4">facturers of devices and drugs, and physicians making</text>
<text top="931" left="59" width="360" height="16" font="4">clinical decisions must commit to supporting guideline-</text>
<text top="949" left="59" width="360" height="16" font="4">based interventions. Any and all conflicts of interest must be</text>
<text top="968" left="59" width="360" height="16" font="4">revealed to patients in the process of informed consent</text>
<text top="986" left="59" width="277" height="16" font="4">before any invasive or noninvasive procedure.</text>
<text top="1014" left="59" width="266" height="16" font="26"><b>4.2.2. Assessing Patients’ Quality of Life</b></text>
<text top="1039" left="59" width="360" height="16" font="4">In addition to interventions undertaken to improve survival</text>
<text top="1058" left="59" width="360" height="16" font="4">and prevent cardiovascular complications, therapy also is</text>
<text top="1076" left="59" width="360" height="16" font="4">prescribed to improve patients’ <i>health status, </i>a general term</text>
<text top="1094" left="59" width="360" height="16" font="4">that incorporates many facets, including severity of symp-</text>
<text top="104" left="446" width="360" height="16" font="4">toms, functional limitations, and quality of life. Assessment</text>
<text top="122" left="446" width="360" height="16" font="4">of health status is often unstructured and exclusively quali-</text>
<text top="140" left="446" width="360" height="16" font="4">tative, but efforts to standardize this assessment are recom-</text>
<text top="158" left="446" width="360" height="16" font="4">mended, beginning with a structured inventory of activity,</text>
<text top="176" left="446" width="360" height="16" font="4">symptoms, and quality of life, supplemented by the use of</text>
<text top="194" left="446" width="360" height="16" font="4">simple, semiquantitative scales such as the CCS and New</text>
<text top="212" left="446" width="242" height="16" font="4">York Heart Association classifications <a href="e44.full.html#96">(</a></text>
<text top="212" left="687" width="49" height="16" font="16"><a href="e44.full.html#96">432,433</a></text>
<text top="212" left="736" width="9" height="16" font="4"><a href="e44.full.html#96">).</a></text>
<text top="230" left="461" width="345" height="16" font="4">The CCS and New York Heart Association classifica-</text>
<text top="248" left="446" width="360" height="16" font="4">tions are limited, however, because they quantify health</text>
<text top="266" left="446" width="360" height="16" font="4">status from the physicians’ perspective, rather than directly</text>
<text top="284" left="446" width="360" height="16" font="4">reporting patients’ experiences, and they are known to have</text>
<text top="302" left="446" width="360" height="16" font="4">limited reproducibility and sensitivity to important clinical</text>
<text top="320" left="446" width="360" height="16" font="4">changes. Furthermore, even these simple classifications of</text>
<text top="338" left="446" width="360" height="16" font="4">health status are recorded infrequently in health records</text>
<text top="356" left="446" width="5" height="16" font="4"><a href="e44.full.html#96">(</a></text>
<text top="356" left="450" width="49" height="16" font="16"><a href="e44.full.html#96">432,434</a></text>
<text top="356" left="499" width="306" height="16" font="4"><a href="e44.full.html#96">). </a>One approach to directly eliciting perceptions of</text>
<text top="374" left="446" width="360" height="16" font="4">health status from patients with IHD is to use the self-</text>
<text top="392" left="446" width="360" height="16" font="4">administered Seattle Angina Questionnaire (SAQ), a valid,</text>
<text top="410" left="446" width="360" height="16" font="4">sensitive, and prognostically important questionnaire, to</text>
<text top="428" left="446" width="360" height="16" font="4">quantify the symptoms, functional limitations, and quality</text>
<text top="446" left="446" width="183" height="16" font="4">of life of patients with SIHD <a href="e44.full.html#91">(</a></text>
<text top="446" left="629" width="75" height="16" font="16"><a href="e44.full.html#91">246,247,435</a></text>
<text top="446" left="704" width="102" height="16" font="4"><a href="e44.full.html#91">). </a>Although such</text>
<text top="464" left="446" width="360" height="16" font="4">instruments typically are used in research trials, they are</text>
<text top="482" left="446" width="360" height="16" font="4">readily applicable to clinical practice and can be used serially</text>
<text top="500" left="446" width="360" height="16" font="4">to assess and monitor the effectiveness of therapy, including</text>
<text top="518" left="446" width="296" height="16" font="4">antianginal medications and revascularization <a href="e44.full.html#96">(</a></text>
<text top="518" left="742" width="23" height="16" font="16"><a href="e44.full.html#96">434</a></text>
<text top="518" left="764" width="41" height="16" font="4"><a href="e44.full.html#96">). </a>The</text>
<text top="536" left="446" width="360" height="16" font="4">formal assessment of a patient’s disease-specific health</text>
<text top="554" left="446" width="360" height="16" font="4">status, through either the CCS or the SAQ, has been</text>
<text top="572" left="446" width="360" height="16" font="4">endorsed as a performance measure of healthcare quality</text>
<text top="590" left="446" width="5" height="16" font="4"><a href="e44.full.html#96">(</a></text>
<text top="590" left="450" width="23" height="16" font="16"><a href="e44.full.html#96">436</a></text>
<text top="590" left="473" width="9" height="16" font="4"><a href="e44.full.html#96">).</a></text>
<text top="623" left="446" width="292" height="12" font="18">4.3. Patient Education: Recommendations</text>
<text top="654" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="667" left="446" width="360" height="10" font="13">1. Patients with SIHD should have an individualized education plan to</text>
<text top="684" left="462" width="244" height="10" font="13">optimize care and promote wellness, including:</text>
<text top="701" left="461" width="345" height="10" font="13">a. education on the importance of medication adherence for man-</text>
<text top="718" left="477" width="328" height="10" font="13">aging symptoms and retarding disease progression <a href="e44.full.html#96">(437–439)</a></text>
<text top="735" left="477" width="113" height="10" font="25"><i>(Level of Evidence: C);</i></text>
<text top="751" left="461" width="345" height="10" font="13">b. an explanation of medication management and cardiovascular</text>
<text top="768" left="477" width="328" height="10" font="13">risk reduction strategies in a manner that respects the patient’s</text>
<text top="785" left="477" width="328" height="10" font="13">level of understanding, reading comprehension, and ethnicity</text>
<text top="802" left="477" width="183" height="10" font="13"><a href="e44.full.html#85">(8,440–444) </a><i>(Level of Evidence: B);</i></text>
<text top="819" left="461" width="344" height="10" font="13">c. a comprehensive review of all therapeutic options <a href="e44.full.html#85">(8,441–444)</a></text>
<text top="836" left="477" width="114" height="10" font="25"><i>(Level of Evidence: B)</i>;</text>
<text top="853" left="461" width="345" height="10" font="13">d. a description of appropriate levels of exercise, with encourage-</text>
<text top="869" left="477" width="328" height="10" font="13">ment to maintain recommended levels of daily physical activity</text>
<text top="886" left="477" width="182" height="10" font="13"><a href="e44.full.html#85">(8,445–448) </a><i>(Level of Evidence: C);</i></text>
<text top="903" left="461" width="345" height="10" font="13">e. introduction to self-monitoring skills <a href="e44.full.html#96">(445,447,448) </a><i>(Level of</i></text>
<text top="920" left="477" width="89" height="10" font="25"><i>Evidence: C); </i>and</text>
<text top="937" left="463" width="342" height="10" font="13">f. information on how to recognize worsening cardiovascular symp-</text>
<text top="954" left="477" width="291" height="10" font="13">toms and take appropriate action. <i>(Level of Evidence: C)</i></text>
<text top="979" left="446" width="360" height="10" font="13">2. Patients with SIHD should be educated about the following lifestyle</text>
<text top="996" left="462" width="344" height="10" font="13">elements that could influence prognosis: weight control, mainte-</text>
<text top="1013" left="462" width="189" height="10" font="13">nance of a BMI of 18.5 to 24.9 kg/m</text>
<text top="1011" left="651" width="5" height="6" font="35">2</text>
<text top="1013" left="657" width="149" height="10" font="13">, and maintenance of a waist</text>
<text top="1030" left="462" width="344" height="10" font="13">circumference less than 102 cm (40 inches) in men and less than</text>
<text top="1047" left="462" width="344" height="10" font="13">88 cm (35 inches) in women (less for certain racial groups)</text>
<text top="1064" left="462" width="344" height="10" font="13"><a href="e44.full.html#85">(8,440,449–452); </a>lipid management <a href="e44.full.html#86">(18); </a>BP control <a href="e44.full.html#86">(17,453);</a></text>
<text top="1080" left="462" width="344" height="10" font="13">smoking cessation and avoidance of exposure to secondhand</text>
<text top="1097" left="462" width="344" height="10" font="13">smoke <a href="e44.full.html#85">(8,454,455); </a>and individualized medical, nutrition, and life-</text>
<text top="52" left="58" width="18" height="10" font="12">e84</text>
<text top="52" left="112" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1161" width="864">
<text top="105" left="75" width="344" height="10" font="13">style changes for patients with diabetes mellitus to supplement</text>
<text top="122" left="75" width="342" height="10" font="13">diabetes treatment goals and education <a href="e44.full.html#97">(456). </a><i>(Level of Evidence: C)</i></text>
<text top="152" left="59" width="46" height="8" font="24">CLASS IIa</text>
<text top="165" left="59" width="290" height="10" font="13">1. It is reasonable to educate patients with SIHD about:</text>
<text top="182" left="74" width="345" height="10" font="13">a. adherence to a diet that is low in saturated fat, cholesterol, and</text>
<text top="199" left="91" width="328" height="10" font="25"><i>trans </i>fat; high in fresh fruits, whole grains, and vegetables; and</text>
<text top="216" left="91" width="328" height="10" font="13">reduced in sodium intake, with cultural and ethnic preferences</text>
<text top="233" left="91" width="282" height="10" font="13">incorporated <a href="e44.full.html#85">(8,17,18,457,458) </a><i>(Level of Evidence: B);</i></text>
<text top="250" left="74" width="345" height="10" font="13">b. common symptoms of stress and depression to minimize stress-</text>
<text top="267" left="91" width="282" height="10" font="13">related angina symptoms <a href="e44.full.html#97">(459) </a><i>(Level of Evidence: C)</i>;</text>
<text top="284" left="75" width="344" height="10" font="13">c. comprehensive behavioral approaches for the management of</text>
<text top="301" left="91" width="328" height="10" font="13">stress and depression <a href="e44.full.html#91">(237,460–462) </a><i>(Level of Evidence: C)</i>; and</text>
<text top="318" left="74" width="345" height="10" font="13">d. evaluation and treatment of major depressive disorder when</text>
<text top="334" left="91" width="328" height="10" font="13">indicated <a href="e44.full.html#91">(237,238,437,461,463,464,467,468). </a><i>(Level of Evi-</i></text>
<text top="352" left="91" width="48" height="10" font="25"><i>dence: B)</i></text>
<text top="373" left="71" width="348" height="16" font="4">Multiple risk factors for heart disease, vascular disease,</text>
<text top="391" left="59" width="360" height="16" font="4">and stroke are typically present in persons with SIHD,</text>
<text top="409" left="59" width="360" height="16" font="4">including hypertension, smoking, dyslipidemia, diabetes</text>
<text top="427" left="59" width="277" height="16" font="4">mellitus, overweight, and physical inactivity <a href="e44.full.html#86">(</a></text>
<text top="427" left="336" width="41" height="16" font="16"><a href="e44.full.html#86">27,392</a></text>
<text top="427" left="377" width="41" height="16" font="4"><a href="e44.full.html#86">). </a>At a</text>
<text top="445" left="59" width="360" height="16" font="4">national level, in 2000, only 5% of individuals without IHD</text>
<text top="463" left="59" width="360" height="16" font="4">and 7% of those with IHD were fully adherent to recom-</text>
<text top="481" left="59" width="360" height="16" font="4">mendations for physical activity, fruit and vegetable con-</text>
<text top="499" left="59" width="172" height="16" font="4">sumption, and nonsmoking.</text>
<text top="517" left="74" width="345" height="16" font="4">The approach to managing risk factors usually requires</text>
<text top="535" left="59" width="360" height="16" font="4">partnerships among the healthcare team, the patient, their</text>
<text top="553" left="59" width="360" height="16" font="4">family, and their community. The goal of this partnership is</text>
<text top="571" left="59" width="360" height="16" font="4">to assure an effective exchange of information, sharing of</text>
<text top="589" left="59" width="360" height="16" font="4">concerns, and an improved understanding of treatments,</text>
<text top="607" left="59" width="360" height="16" font="4">with the aim of improving quality of life and health</text>
<text top="625" left="59" width="360" height="16" font="4">outcomes. The American Academy of Family Physicians</text>
<text top="644" left="59" width="360" height="16" font="4">defines patient education as “the process of influencing</text>
<text top="662" left="59" width="360" height="16" font="4">patient behavior through the provision of information and</text>
<text top="680" left="59" width="360" height="16" font="4">counseling that is designed to produce changes in knowl-</text>
<text top="698" left="59" width="360" height="16" font="4">edge, attitudes, and skills necessary to maintain or improve</text>
<text top="716" left="59" width="56" height="16" font="4">health” <a href="e44.full.html#97">(</a></text>
<text top="716" left="115" width="23" height="16" font="16"><a href="e44.full.html#97">469</a></text>
<text top="716" left="137" width="281" height="16" font="4"><a href="e44.full.html#97">). </a>The Joint Commission mandates patient</text>
<text top="734" left="59" width="360" height="16" font="4">education as a principal guiding policy to improve health</text>
<text top="752" left="59" width="360" height="16" font="4">outcomes. Effective patient education and counseling are</text>
<text top="770" left="59" width="360" height="16" font="4">based on a collaborative approach that acknowledges indi-</text>
<text top="788" left="59" width="360" height="16" font="4">vidual patient needs through an understanding of cognitive,</text>
<text top="806" left="59" width="360" height="16" font="4">behavioral, and sociodemographic factors. Patients actively</text>
<text top="824" left="59" width="360" height="16" font="4">involved in care decisions are more likely to follow a</text>
<text top="842" left="59" width="360" height="16" font="4">treatment plan and engage in behaviors that can improve</text>
<text top="860" left="59" width="75" height="16" font="4">their health.</text>
<text top="878" left="74" width="345" height="16" font="4">When educating patients, it is important to communicate</text>
<text top="896" left="59" width="360" height="16" font="4">an understanding of a specific disease process, the need for</text>
<text top="914" left="59" width="360" height="16" font="4">laboratory testing, medication management and adherence,</text>
<text top="932" left="59" width="360" height="16" font="4">reporting of efficacy and side effects, and behavioral lifestyle</text>
<text top="950" left="59" width="54" height="16" font="4">change <a href="e44.full.html#85">(</a></text>
<text top="950" left="113" width="8" height="16" font="16"><a href="e44.full.html#85">8</a></text>
<text top="950" left="120" width="298" height="16" font="4"><a href="e44.full.html#85">). </a>Unfortunately, the type, intensity, frequency,</text>
<text top="968" left="59" width="360" height="16" font="4">and duration of educational programs are not well estab-</text>
<text top="986" left="59" width="360" height="16" font="4">lished for individual risk factors. For example, the Ask,</text>
<text top="1004" left="59" width="360" height="16" font="4">Advise, Assess, Assist, and Arrange algorithm for smoking</text>
<text top="1022" left="59" width="360" height="16" font="4">cessation often is used, although supporting data from</text>
<text top="1040" left="59" width="123" height="16" font="4">RCTs are lacking <a href="e44.full.html#97">(</a></text>
<text top="1040" left="181" width="23" height="16" font="16"><a href="e44.full.html#97">470</a></text>
<text top="1040" left="204" width="215" height="16" font="4"><a href="e44.full.html#97">). </a>In addition, who should deliver</text>
<text top="1058" left="59" width="360" height="16" font="4">education programs and how to evaluate efficacy are not well</text>
<text top="1076" left="59" width="360" height="16" font="4">studied. In smoking cessation, the most effective interven-</text>
<text top="1094" left="59" width="360" height="16" font="4">tion continues to be a physician’s recommendation for the</text>
<text top="104" left="446" width="360" height="16" font="4">patient “to quit.” However, quit rates for smoking are also</text>
<text top="122" left="446" width="360" height="16" font="4">dependent on the appropriate use of medical therapies and</text>
<text top="140" left="446" width="154" height="16" font="4">group support programs <a href="e44.full.html#96">(</a></text>
<text top="140" left="600" width="49" height="16" font="16"><a href="e44.full.html#96">442,471</a></text>
<text top="140" left="649" width="157" height="16" font="4"><a href="e44.full.html#96">). </a>In diabetes care, patient</text>
<text top="158" left="446" width="360" height="16" font="4">education has the potential to be as effective as or more</text>
<text top="176" left="446" width="200" height="16" font="4">effective than medical therapies <a href="e44.full.html#97">(</a></text>
<text top="176" left="646" width="23" height="16" font="16"><a href="e44.full.html#97">472</a></text>
<text top="176" left="668" width="137" height="16" font="4"><a href="e44.full.html#97">). </a>The management of</text>
<text top="194" left="446" width="360" height="16" font="4">hypertension, heart failure, dyslipidemia, type 2 diabetes</text>
<text top="212" left="446" width="360" height="16" font="4">mellitus, weight loss, and physical activity is enhanced by</text>
<text top="230" left="446" width="360" height="16" font="4">ongoing health education and support in addition to phy-</text>
<text top="248" left="446" width="109" height="16" font="4">sician office visits.</text>
<text top="266" left="461" width="345" height="16" font="4">Factors that complicate effective patient education in-</text>
<text top="284" left="446" width="360" height="16" font="4">clude low literacy, adverse sociodemographic factors (e.g.,</text>
<text top="302" left="446" width="360" height="16" font="4">poverty, social isolation, and emotional disorders such as</text>
<text top="320" left="446" width="360" height="16" font="4">depression), cultural beliefs and language barriers, environ-</text>
<text top="338" left="446" width="360" height="16" font="4">mental factors, advanced age, and the presence of complex</text>
<text top="356" left="446" width="360" height="16" font="4">comorbidities. These factors and others play an important</text>
<text top="374" left="446" width="360" height="16" font="4">role in the adoption of healthy lifestyles and adherence to</text>
<text top="392" left="446" width="360" height="16" font="4">recommended medical therapies. In addition, how to best</text>
<text top="410" left="446" width="360" height="16" font="4">provide cost-effective educational strategies remains a chal-</text>
<text top="428" left="446" width="253" height="16" font="4">lenge in today’s healthcare environment <a href="e44.full.html#97">(</a></text>
<text top="428" left="699" width="23" height="16" font="16"><a href="e44.full.html#97">473</a></text>
<text top="428" left="721" width="85" height="16" font="4"><a href="e44.full.html#97">). </a>The lack of</text>
<text top="446" left="446" width="360" height="16" font="4">payment for these activities remains an important barrier.</text>
<text top="464" left="446" width="358" height="16" font="4">Clinic-based education generally consists of the following:</text>
<text top="491" left="446" width="360" height="16" font="4">1. <i>Individual counseling. </i>This educational format commonly</text>
<text top="509" left="464" width="341" height="16" font="4">is used in the context of a routine clinic visit. It tends to</text>
<text top="527" left="464" width="341" height="16" font="4">be directive and didactic, generally not interactive or</text>
<text top="545" left="464" width="341" height="16" font="4">behaviorally oriented, relatively brief, and sometimes</text>
<text top="563" left="464" width="341" height="16" font="4">supported with written materials. Follow-up to ascertain</text>
<text top="581" left="464" width="245" height="16" font="4">effectiveness is not commonly practiced.</text>
<text top="599" left="446" width="360" height="16" font="4">2. <i>Group education. </i>Group care or shared office visits have</text>
<text top="617" left="464" width="341" height="16" font="4">been tested in multispecialty group practices. They offer</text>
<text top="635" left="464" width="341" height="16" font="4">the benefit of providing education to larger numbers of</text>
<text top="653" left="464" width="341" height="16" font="4">patients with similar diagnoses (e.g., type 2 diabetes</text>
<text top="671" left="464" width="341" height="16" font="4">mellitus), combined with an individualized physician</text>
<text top="689" left="464" width="341" height="16" font="4">visit. They tend to be behaviorally oriented with planned</text>
<text top="707" left="464" width="253" height="16" font="4">follow-up for effectiveness and outcomes.</text>
<text top="725" left="446" width="360" height="16" font="4">3. <i>Self-monitoring. </i>Self-monitoring skills enhance patient</text>
<text top="743" left="464" width="341" height="16" font="4">education and behavior change. Examples such as home</text>
<text top="761" left="464" width="341" height="16" font="4">BP and blood glucose monitoring and tracking daily</text>
<text top="779" left="464" width="341" height="16" font="4">calories and physical activity minutes can support impor-</text>
<text top="797" left="464" width="341" height="16" font="4">tant lifestyle change. Review of self-monitoring logs by</text>
<text top="815" left="464" width="341" height="16" font="4">patient and provider at subsequent clinic visits supports</text>
<text top="833" left="464" width="341" height="16" font="4">the continued importance of and attention to behavior</text>
<text top="851" left="464" width="341" height="16" font="4">change. In some healthcare plans, these data can be</text>
<text top="869" left="464" width="226" height="16" font="4">entered via web portals for patients <a href="e44.full.html#97">(</a></text>
<text top="869" left="691" width="23" height="16" font="16"><a href="e44.full.html#97">474</a></text>
<text top="869" left="713" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="887" left="446" width="360" height="16" font="4">4. <i>Internet- and computer-based education. </i>A growing num-</text>
<text top="905" left="464" width="341" height="16" font="4">ber of health plans provide health information via web-</text>
<text top="923" left="464" width="341" height="16" font="4">sites and special programs. This approach is often low in</text>
<text top="941" left="464" width="341" height="16" font="4">cost to the patient but requires adequate computer access</text>
<text top="959" left="464" width="341" height="16" font="4">and skills, higher reading levels, and self-motivation to</text>
<text top="977" left="464" width="297" height="16" font="4">change behavior (e.g., AHA Choose to Move) <a href="e44.full.html#97">(</a></text>
<text top="977" left="761" width="23" height="16" font="16"><a href="e44.full.html#97">475</a></text>
<text top="977" left="784" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="995" left="446" width="360" height="16" font="4">5. <i>Hand-held computer devices, smartphones, and other porta-</i></text>
<text top="1013" left="464" width="341" height="16" font="5"><i>ble devices. </i>Portable devices have the potential to provide</text>
<text top="1031" left="464" width="341" height="16" font="4">motivational reminders and prompts for lifestyle change</text>
<text top="1049" left="464" width="249" height="16" font="4">but have not yet been thoroughly tested.</text>
<text top="1076" left="460" width="345" height="16" font="4">Present efforts to improve the effectiveness of patient</text>
<text top="1094" left="446" width="360" height="16" font="4">education and lifestyle interventions integrate key constructs</text>
<text top="52" left="787" width="18" height="10" font="12">e85</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">related to behavior change theory. A summary of the most</text>
<text top="122" left="59" width="218" height="16" font="4">common models is provided below:</text>
<text top="149" left="59" width="360" height="16" font="4">1. <i>Motivational interviewing, </i>a social learning theory, pro-</text>
<text top="167" left="77" width="341" height="16" font="4">motes behavioral change through empathetic and reflec-</text>
<text top="185" left="77" width="341" height="16" font="4">tive listening, encouraging patients to determine their</text>
<text top="203" left="77" width="341" height="16" font="4">reasons for change, helping healthcare professionals deal</text>
<text top="221" left="77" width="275" height="16" font="4">with resistance, and supporting self-efficacy <a href="e44.full.html#97">(</a></text>
<text top="221" left="353" width="23" height="16" font="16"><a href="e44.full.html#97">476</a></text>
<text top="221" left="375" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="239" left="58" width="360" height="16" font="4">2. <i>Self-efficacy theory </i>posits that the ability to change behav-</text>
<text top="257" left="77" width="341" height="16" font="4">ior depends upon one’s self-confidence to perform a</text>
<text top="275" left="77" width="341" height="16" font="4">specific action (such as walking 30 minutes daily) and the</text>
<text top="293" left="77" width="341" height="16" font="4">belief that one can persist with this action. Low self-</text>
<text top="311" left="77" width="341" height="16" font="4">efficacy predicts poor ability to achieve a specified life-</text>
<text top="329" left="77" width="341" height="16" font="4">style change. Improving one’s self-efficacy will improve</text>
<text top="347" left="77" width="260" height="16" font="4">the ability to change a particular lifestyle <a href="e44.full.html#97">(</a></text>
<text top="347" left="338" width="23" height="16" font="16"><a href="e44.full.html#97">477</a></text>
<text top="347" left="360" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="365" left="58" width="360" height="16" font="4">3. The <i>Transtheoretical Model </i>of behavior change is based</text>
<text top="383" left="77" width="341" height="16" font="4">on “stages of change.” The theory relies on the observa-</text>
<text top="401" left="77" width="341" height="16" font="4">tion that many individuals traverse 5 distinct temporal</text>
<text top="419" left="77" width="341" height="16" font="4">processes in achieving permanent change. These include</text>
<text top="437" left="77" width="341" height="16" font="4">precontemplation, contemplation, preparation, action,</text>
<text top="455" left="77" width="341" height="16" font="4">and maintenance. Application of this model of change</text>
<text top="473" left="77" width="341" height="16" font="4">entails categorizing an individual’s progress in the pro-</text>
<text top="491" left="77" width="341" height="16" font="4">cess of change and recognizing that cycling through</text>
<text top="509" left="77" width="341" height="16" font="4">phases is common in the process of achieving permanent</text>
<text top="527" left="77" width="52" height="16" font="4">change <a href="e44.full.html#97">(</a></text>
<text top="527" left="130" width="23" height="16" font="16"><a href="e44.full.html#97">478</a></text>
<text top="527" left="152" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="554" left="73" width="345" height="16" font="4">The interventions described above should be provided</text>
<text top="572" left="58" width="360" height="16" font="4">within a medical environment that provides coordinated,</text>
<text top="590" left="58" width="360" height="16" font="4">team-based care. Data accumulating from interventions that</text>
<text top="608" left="58" width="298" height="16" font="4">incorporate principles of the chronic care model <a href="e44.full.html#97">(</a></text>
<text top="608" left="356" width="23" height="16" font="16"><a href="e44.full.html#97">479</a></text>
<text top="608" left="379" width="40" height="16" font="4"><a href="e44.full.html#97">), </a>such</text>
<text top="626" left="58" width="360" height="16" font="4">as the patient-centered medical home, have demonstrated</text>
<text top="644" left="58" width="360" height="16" font="4">beneficial effects not only on intermediate outcomes such as</text>
<text top="662" left="58" width="360" height="16" font="4">glycemic and BP but also on cost, utilization, and mortality</text>
<text top="680" left="58" width="32" height="16" font="4">rate <a href="e44.full.html#97">(</a></text>
<text top="680" left="90" width="49" height="16" font="16"><a href="e44.full.html#97">480,481</a></text>
<text top="680" left="139" width="280" height="16" font="4"><a href="e44.full.html#97">). </a>This approach depends on the active partic-</text>
<text top="698" left="58" width="360" height="16" font="4">ipation of an engaged, informed patient, which in turn relies</text>
<text top="716" left="58" width="360" height="16" font="4">on the patient’s understanding of his or her condition,</text>
<text top="734" left="58" width="360" height="16" font="4">ability to adhere safely to complex medical therapies, and</text>
<text top="752" left="58" width="360" height="16" font="4">willingness to communicate on a regular basis with the</text>
<text top="770" left="58" width="360" height="16" font="4">healthcare team. In addition to counseling about the ap-</text>
<text top="788" left="58" width="360" height="16" font="4">proach to management of SIHD and risk reduction, pa-</text>
<text top="806" left="58" width="360" height="16" font="4">tients often seek information about other aspects of their</text>
<text top="824" left="58" width="360" height="16" font="4">health, particularly issues that are often not directly ad-</text>
<text top="842" left="58" width="194" height="16" font="4">dressed by healthcare providers.</text>
<text top="860" left="73" width="345" height="16" font="4">One such topic that commonly arises is possible restric-</text>
<text top="878" left="58" width="360" height="16" font="4">tions on sexual activity. Regrettably, there are relatively</text>
<text top="896" left="58" width="360" height="16" font="4">limited scientific data on the cardiovascular demands and</text>
<text top="914" left="58" width="360" height="16" font="4">potential risks of sexual activity in patients with heart</text>
<text top="932" left="58" width="360" height="16" font="4">disease, some of it dating back 3 or 4 decades and nearly all</text>
<text top="950" left="58" width="360" height="16" font="4">of it dealing with men. In general, sexual activity is</text>
<text top="968" left="58" width="360" height="16" font="4">equivalent to mild to moderate physical activity requiring 3</text>
<text top="986" left="58" width="360" height="16" font="4">to 5 METs (i.e., the equivalent of climbing 2 flights of stairs</text>
<text top="1004" left="58" width="123" height="16" font="4">or walking briskly) <a href="e44.full.html#97">(</a></text>
<text top="1004" left="182" width="23" height="16" font="16"><a href="e44.full.html#97">482</a></text>
<text top="1004" left="204" width="214" height="16" font="4"><a href="e44.full.html#97">). </a>The few available studies suggest</text>
<text top="1022" left="58" width="360" height="16" font="4">that AMI within 1 to 2 hours of sexual activity is associated</text>
<text top="1040" left="58" width="360" height="16" font="4">with an average RR of 2.7 among middle-aged men, with</text>
<text top="1058" left="58" width="297" height="16" font="4">the greatest risk among those who are sedentary <a href="e44.full.html#97">(</a></text>
<text top="1058" left="356" width="54" height="16" font="16"><a href="e44.full.html#97">483– 486</a></text>
<text top="1058" left="410" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="1076" left="58" width="360" height="16" font="4">Because the overall incidence of AMI is low in the popu-</text>
<text top="1094" left="58" width="360" height="16" font="4">lation and periods of exposure relatively infrequent, it has</text>
<text top="104" left="446" width="360" height="16" font="4">been postulated that the absolute risk is exceedingly low for</text>
<text top="122" left="446" width="100" height="16" font="4">any individual <a href="e44.full.html#97">(</a></text>
<text top="122" left="545" width="23" height="16" font="16"><a href="e44.full.html#97">487</a></text>
<text top="122" left="568" width="238" height="16" font="4"><a href="e44.full.html#97">). </a>However, ECG monitoring during</text>
<text top="140" left="446" width="360" height="16" font="4">sexual activity in 1 study of men with IHD revealed that</text>
<text top="158" left="446" width="360" height="16" font="4">nearly a third developed ST depression and nearly half</text>
<text top="176" left="446" width="360" height="16" font="4">developed arrhythmias. It appeared, however, that these</text>
<text top="194" left="446" width="360" height="16" font="4">findings also were found during similarly stressful activities</text>
<text top="212" left="446" width="360" height="16" font="4">that did not involve sex, and the arrhythmias were largely</text>
<text top="230" left="446" width="360" height="16" font="4">benign. Moreover, these patients were not initially on</text>
<text top="248" left="446" width="360" height="16" font="4">anti-ischemic medications, and it was reported that the</text>
<text top="266" left="446" width="360" height="16" font="4">ischemic changes on ECG resolved when subjects took beta</text>
<text top="284" left="446" width="360" height="16" font="4">blockers. Thus, it seems that sexual activity should not</text>
<text top="302" left="446" width="360" height="16" font="4">necessarily be regarded as appreciably different from other</text>
<text top="320" left="446" width="360" height="16" font="4">types of physical activity that impose equivalent metabolic</text>
<text top="338" left="446" width="360" height="16" font="4">demands. Needless to say, patients should be treated to</text>
<text top="356" left="446" width="360" height="16" font="4">maximize their capacity for physical activity, as described</text>
<text top="374" left="446" width="185" height="16" font="4">subsequently in this guideline.</text>
<text top="392" left="461" width="345" height="16" font="4">Patients often express concerns that medications given to</text>
<text top="410" left="446" width="360" height="16" font="4">treat symptoms or reduce cardiovascular risk could cause</text>
<text top="428" left="446" width="360" height="16" font="4">erectile dysfunction. Although these perceptions are often</text>
<text top="446" left="446" width="360" height="16" font="4">firmly and widely held, studies and reviews have not</text>
<text top="464" left="446" width="360" height="16" font="4">delineated a clear association between these drugs, including</text>
<text top="482" left="446" width="237" height="16" font="4">beta blockers, and sexual dysfunction <a href="e44.full.html#97">(</a></text>
<text top="482" left="682" width="56" height="16" font="16"><a href="e44.full.html#97">488 – 492</a></text>
<text top="482" left="738" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="500" left="461" width="345" height="16" font="4">A related issue that could arise is use of phosphodiesterase</text>
<text top="518" left="446" width="360" height="16" font="4">5 inhibitors, such as sildenafil, vardenafil, or tadalafil, to</text>
<text top="536" left="446" width="360" height="16" font="4">improve erectile function. Although, as discussed in the</text>
<text top="554" left="446" width="360" height="16" font="4">section on treatment of SIHD, current evidence has shown</text>
<text top="572" left="446" width="360" height="16" font="4">that these drugs do not raise the risk of adverse cardiovas-</text>
<text top="590" left="446" width="207" height="16" font="4">cular events in men with SIHD <a href="e44.full.html#97">(</a></text>
<text top="590" left="653" width="49" height="16" font="16"><a href="e44.full.html#97">493,494</a></text>
<text top="590" left="701" width="104" height="16" font="4"><a href="e44.full.html#97">), </a>there is a clear</text>
<text top="608" left="446" width="360" height="16" font="4">risk of serious hypotension when they are taken in conjunc-</text>
<text top="626" left="446" width="360" height="16" font="4">tion with nitrates, and the combination is absolutely con-</text>
<text top="644" left="446" width="360" height="16" font="4">traindicated. There are also potential drug– drug interac-</text>
<text top="662" left="446" width="360" height="16" font="4">tions with alpha-blockers that are sometimes used to treat</text>
<text top="680" left="446" width="88" height="16" font="4">hypertension <a href="e44.full.html#97">(</a></text>
<text top="680" left="533" width="23" height="16" font="16"><a href="e44.full.html#97">495</a></text>
<text top="680" left="556" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="708" left="446" width="276" height="12" font="18">4.4. Guideline-Directed Medical Therapy</text>
<text top="734" left="446" width="334" height="16" font="26"><b>4.4.1. Risk Factor Modification: Recommendations</b></text>
<text top="765" left="446" width="134" height="9" font="6">4.4.1.1. LIPID MANAGEMENT</text>
<text top="788" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="801" left="446" width="360" height="10" font="13">1. Lifestyle modifications, including daily physical activity and weight</text>
<text top="818" left="461" width="344" height="10" font="13">management, are strongly recommended for all patients with SIHD</text>
<text top="835" left="461" width="163" height="10" font="13"><a href="e44.full.html#86">(18,496). </a><i>(Level of Evidence: B)</i></text>
<text top="852" left="446" width="360" height="10" font="13">2. Dietary therapy for all patients should include reduced intake of</text>
<text top="869" left="461" width="90" height="10" font="13">saturated fats (to</text>
<text top="866" left="555" width="251" height="16" font="13">⬍7% of total calories), <i>trans </i>fatty acids (to ⬍1%</text>
<text top="886" left="461" width="192" height="10" font="13">of total calories), and cholesterol (to</text>
<text top="882" left="658" width="148" height="16" font="13">⬍200 mg/d) <a href="e44.full.html#86">(18,497–500).</a></text>
<text top="903" left="461" width="111" height="10" font="25"><i>(Level of Evidence: B)</i></text>
<text top="919" left="446" width="360" height="10" font="13">3. In addition to therapeutic lifestyle changes, a moderate or high dose</text>
<text top="936" left="461" width="344" height="10" font="13">of a statin therapy should be prescribed, in the absence of contra-</text>
<text top="953" left="461" width="344" height="10" font="13">indications or documented adverse effects. <a href="e44.full.html#86">(18,398,400,458,501).</a></text>
<text top="970" left="461" width="111" height="10" font="25"><i>(Level of Evidence: A)</i></text>
<text top="995" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="1008" left="446" width="360" height="10" font="13">1. For patients who do not tolerate statins, LDL cholesterol–lowering</text>
<text top="1025" left="461" width="344" height="10" font="13">therapy with bile acid sequestrants,* niacin,† or both is reasonable</text>
<text top="1042" left="461" width="194" height="10" font="13"><a href="e44.full.html#98">(502,504,505). </a><i>(Level of Evidence: B)</i></text>
<text top="1071" left="446" width="360" height="11" font="6">*The use of bile acid sequestrant is relatively contraindicated when triglycerides are</text>
<text top="1082" left="446" width="316" height="14" font="6">ⱖ200 mg/dL and is contraindicated when triglycerides are ⱖ500 mg/dL.</text>
<text top="1098" left="446" width="360" height="11" font="6">†Dietary supplement niacin must not be used as a substitute for prescription niacin.</text>
<text top="52" left="59" width="18" height="10" font="12">e86</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">Epidemiological studies have established serum cholesterol</text>
<text top="122" left="59" width="360" height="16" font="4">as an important coronary heart disease risk factor. The</text>
<text top="140" left="59" width="360" height="16" font="4">Framingham Heart Study, Multiple Risk Factor Interven-</text>
<text top="158" left="59" width="360" height="16" font="4">tion trial, and the Lipid Research Clinics trials all found a</text>
<text top="176" left="59" width="360" height="16" font="4">continuous, graded increase in coronary events with increas-</text>
<text top="194" left="59" width="360" height="16" font="4">ing LDL cholesterol in men and women who were initially</text>
<text top="212" left="59" width="81" height="16" font="4">free of IHD <a href="e44.full.html#98">(</a></text>
<text top="212" left="140" width="81" height="16" font="16"><a href="e44.full.html#98">502,506 –508</a></text>
<text top="212" left="220" width="198" height="16" font="4"><a href="e44.full.html#98">). </a>A similar relationship has been</text>
<text top="230" left="59" width="233" height="16" font="4">observed among patients with SIHD <a href="e44.full.html#98">(</a></text>
<text top="230" left="292" width="54" height="16" font="16"><a href="e44.full.html#98">509 –511</a></text>
<text top="230" left="346" width="73" height="16" font="4"><a href="e44.full.html#98">). </a>The asso-</text>
<text top="248" left="59" width="360" height="16" font="4">ciation between LDL cholesterol and cardiovascular risk is</text>
<text top="266" left="59" width="360" height="16" font="4">curvilinear, or log-linear, meaning that the decrease in RR</text>
<text top="284" left="59" width="360" height="16" font="4">for a given 1-mg/dL decrease in LDL cholesterol seems to</text>
<text top="302" left="59" width="360" height="16" font="4">be the same at any level of baseline LDL cholesterol. The</text>
<text top="320" left="59" width="360" height="16" font="4">principal lipid modification strategy recommended by the</text>
<text top="338" left="59" width="360" height="16" font="4">NCEP ATP-III (National Cholesterol Education Program</text>
<text top="356" left="59" width="360" height="16" font="4">Adult Treatment Panel III) in patients with SIHD is the</text>
<text top="374" left="59" width="201" height="16" font="4">reduction of LDL cholesterol <a href="e44.full.html#86">(</a></text>
<text top="374" left="259" width="34" height="16" font="16"><a href="e44.full.html#86">18,24</a></text>
<text top="374" left="293" width="125" height="16" font="4"><a href="e44.full.html#86">). </a>This should start</text>
<text top="392" left="59" width="360" height="16" font="4">with therapeutic lifestyle changes, including dietary therapy,</text>
<text top="410" left="59" width="360" height="16" font="4">daily physical activity, and weight management. Most pa-</text>
<text top="428" left="59" width="360" height="16" font="4">tients also will benefit from cholesterol-lowering drug ther-</text>
<text top="446" left="59" width="175" height="16" font="4">apy, preferably with a statin.</text>
<text top="464" left="74" width="345" height="16" font="4">Effective dietary approaches to lowering LDL cholesterol</text>
<text top="482" left="59" width="360" height="16" font="4">include replacing saturated and <i>trans </i>fatty acids with dietary</text>
<text top="500" left="59" width="360" height="16" font="4">carbohydrates or unsaturated fatty acids and reducing di-</text>
<text top="518" left="59" width="360" height="16" font="4">etary cholesterol. Although the response to dietary inter-</text>
<text top="536" left="59" width="360" height="16" font="4">ventions is variable, a diet low in saturated fat and choles-</text>
<text top="554" left="59" width="360" height="16" font="4">terol typically lowers LDL cholesterol by 10% to 15%</text>
<text top="572" left="59" width="5" height="16" font="4"><a href="e44.full.html#97">(</a></text>
<text top="572" left="63" width="53" height="16" font="16"><a href="e44.full.html#97">497–500</a></text>
<text top="572" left="116" width="303" height="16" font="4"><a href="e44.full.html#97">). </a>Other beneficial dietary interventions can in-</text>
<text top="590" left="59" width="360" height="16" font="4">clude addition of plant stanols/sterols (2 g/d), which trials</text>
<text top="608" left="59" width="360" height="16" font="4">suggest lower LDL cholesterol by 5% to 15%, and addition</text>
<text top="626" left="59" width="101" height="16" font="4">of viscous fiber (</text>
<text top="623" left="160" width="259" height="20" font="4">⬎10 g/d), which reduces LDL cholesterol</text>
<text top="644" left="59" width="87" height="16" font="4">by 3% to 5% <a href="e44.full.html#98">(</a></text>
<text top="644" left="146" width="53" height="16" font="16"><a href="e44.full.html#98">512–515</a></text>
<text top="644" left="198" width="220" height="16" font="4"><a href="e44.full.html#98">). </a>A 10-lb weight loss reduces LDL</text>
<text top="662" left="59" width="160" height="16" font="4">cholesterol by 5% to 8% <a href="e44.full.html#97">(</a></text>
<text top="662" left="219" width="23" height="16" font="16"><a href="e44.full.html#97">496</a></text>
<text top="662" left="241" width="178" height="16" font="4"><a href="e44.full.html#97">). </a>Regular physical activity is</text>
<text top="680" left="59" width="360" height="16" font="4">also a key component of therapeutic lifestyle modification.</text>
<text top="698" left="59" width="360" height="16" font="4">Although exercise does not reliably lower LDL cholesterol,</text>
<text top="716" left="59" width="360" height="16" font="4">it facilitates weight loss and has other beneficial effects on</text>
<text top="734" left="59" width="105" height="16" font="4">the lipid profile <a href="e44.full.html#98">(</a></text>
<text top="734" left="164" width="54" height="16" font="16"><a href="e44.full.html#98">516 –518</a></text>
<text top="734" left="218" width="9" height="16" font="4"><a href="e44.full.html#98">).</a></text>
<text top="752" left="74" width="345" height="16" font="4">Controlled clinical trials of lipid-lowering drug therapy</text>
<text top="770" left="59" width="360" height="16" font="4">have demonstrated that lowering of LDL cholesterol is</text>
<text top="788" left="59" width="360" height="16" font="4">associated with a reduced risk of adverse cardiovascular</text>
<text top="806" left="59" width="360" height="16" font="4">events. Earlier trials used bile acid sequestrants (cholesty-</text>
<text top="824" left="59" width="360" height="16" font="4">ramine), fibric acid derivatives (gemfibrozil and clofibrate),</text>
<text top="842" left="59" width="360" height="16" font="4">or niacin. More contemporary studies have convincingly</text>
<text top="860" left="59" width="360" height="16" font="4">established the efficacy of statins in the primary and sec-</text>
<text top="878" left="59" width="249" height="16" font="4">ondary prevention of coronary events <a href="e44.full.html#95">(</a></text>
<text top="878" left="308" width="111" height="16" font="16"><a href="e44.full.html#95">394 –396,398,400,</a></text>
<text top="896" left="59" width="81" height="16" font="16"><a href="e44.full.html#95">501,519 –522</a></text>
<text top="896" left="139" width="279" height="16" font="4"><a href="e44.full.html#95">). </a>In a prospective meta-analysis published by</text>
<text top="914" left="59" width="360" height="16" font="4">the Cholesterol Treatment Trialist Collaborators in 2010</text>
<text top="932" left="59" width="360" height="16" font="4">that examined data from 26 randomized trials of statin</text>
<text top="950" left="59" width="360" height="16" font="4">therapy (comparing higher- to lower-dose statin therapy or</text>
<text top="968" left="59" width="360" height="16" font="4">statin therapy to a control regimen), the mean difference in</text>
<text top="986" left="59" width="360" height="16" font="4">LDL cholesterol was 31 mg/dL, ranging from 12 to 68</text>
<text top="1004" left="59" width="360" height="16" font="4">mg/dL. Each 40-mg/dL reduction in LDL cholesterol was</text>
<text top="1022" left="59" width="360" height="16" font="4">associated with a 10% reduction in all-cause mortality and a</text>
<text top="1040" left="59" width="360" height="16" font="4">20% reduction in coronary mortality, with corresponding</text>
<text top="1058" left="59" width="360" height="16" font="4">reductions in nonfatal MI, need for coronary revasculariza-</text>
<text top="1076" left="59" width="245" height="16" font="4">tion, and first nonfatal ischemic stroke <a href="e44.full.html#97">(</a></text>
<text top="1076" left="304" width="23" height="16" font="16"><a href="e44.full.html#97">458</a></text>
<text top="1076" left="326" width="93" height="16" font="4"><a href="e44.full.html#97">). </a>The absolute</text>
<text top="1094" left="59" width="360" height="16" font="4">benefit of therapy was a function of an individual’s absolute</text>
<text top="104" left="446" width="120" height="16" font="4">risk of fatal MI <a href="e44.full.html#97">(</a></text>
<text top="104" left="566" width="23" height="16" font="16"><a href="e44.full.html#97">458</a></text>
<text top="104" left="588" width="217" height="16" font="4"><a href="e44.full.html#97">). </a>In trials comparing higher- to</text>
<text top="122" left="446" width="360" height="16" font="4">lower-dose statin therapy, the average, weighted reduction</text>
<text top="140" left="446" width="360" height="16" font="4">in LDL cholesterol at 1 year was 20 mg/dL among those</text>
<text top="158" left="446" width="360" height="16" font="4">receiving higher-dose regimens. Among patients assigned</text>
<text top="176" left="446" width="360" height="16" font="4">to more intensive regimens, there was a 15% lower inci-</text>
<text top="194" left="446" width="360" height="16" font="4">dence of major vascular events (95% CI: 11 to 18;</text>
<text top="212" left="446" width="8" height="16" font="4">p</text>
<text top="209" left="453" width="352" height="20" font="4">⬍0.0001), which reflected a 13% lower risk of coronary</text>
<text top="230" left="446" width="255" height="16" font="4">death or nonfatal MI (95% CI: 7 to 19; p</text>
<text top="227" left="701" width="104" height="20" font="4">⬍0.0001), a 19%</text>
<text top="248" left="446" width="360" height="16" font="4">lower risk of undergoing coronary revascularization (95%</text>
<text top="266" left="446" width="92" height="16" font="4">CI: 15 to 24; p</text>
<text top="263" left="538" width="268" height="20" font="4">⬍0.0001), and a 16% lower risk of ischemic</text>
<text top="284" left="446" width="155" height="16" font="4">stroke (95% CI: 5 to 26; p</text>
<text top="281" left="601" width="205" height="20" font="4">⫽0.005). The reductions in serum</text>
<text top="302" left="446" width="360" height="16" font="4">LDL cholesterol and in cardiovascular risk were similar in</text>
<text top="320" left="446" width="360" height="16" font="4">magnitude to those observed in trials comparing statin</text>
<text top="338" left="446" width="360" height="16" font="4">therapy to a control regimen. The absolute benefit of</text>
<text top="356" left="446" width="360" height="16" font="4">therapy was defined chiefly by an individual’s absolute risk</text>
<text top="374" left="446" width="246" height="16" font="4">of death due to coronary occlusion <a href="e44.full.html#97">(</a></text>
<text top="374" left="692" width="23" height="16" font="16"><a href="e44.full.html#97">458</a></text>
<text top="374" left="714" width="91" height="16" font="4"><a href="e44.full.html#97">). </a>Appropriate</text>
<text top="392" left="446" width="360" height="16" font="4">treatment goals for patients with SIHD have been informed</text>
<text top="410" left="446" width="360" height="16" font="4">by several trials of intensive lipid-lowering therapy. The</text>
<text top="428" left="446" width="360" height="16" font="4">HPS (Heart Protection Study) compared simvastatin 40 mg</text>
<text top="446" left="446" width="360" height="16" font="4">daily to placebo in patients with IHD, other occlusive</text>
<text top="464" left="446" width="360" height="16" font="4">vascular disease, or diabetes mellitus. On-treatment LDL</text>
<text top="482" left="446" width="360" height="16" font="4">cholesterol levels averaged 88 mg/dL in those allocated to</text>
<text top="500" left="446" width="360" height="16" font="4">simvastatin and 127 mg/dL in those randomized to placebo.</text>
<text top="518" left="446" width="360" height="16" font="4">A consistent and early benefit of therapy was demonstrated,</text>
<text top="536" left="446" width="360" height="16" font="4">with a 13% reduction in mortality rate and an 18% reduction</text>
<text top="554" left="446" width="141" height="16" font="4">in coronary death rate <a href="e44.full.html#95">(</a></text>
<text top="554" left="587" width="23" height="16" font="16"><a href="e44.full.html#95">398</a></text>
<text top="554" left="609" width="196" height="16" font="4"><a href="e44.full.html#95">). </a>Similar reductions in RR were</text>
<text top="572" left="446" width="360" height="16" font="4">observed regardless of baseline levels of LDL cholesterol,</text>
<text top="590" left="446" width="222" height="16" font="4">including in those with initial levels</text>
<text top="587" left="672" width="133" height="20" font="4">⬍116 mg/dL or ⬍97</text>
<text top="608" left="446" width="360" height="16" font="4">mg/dL. (Of note, LDL cholesterol levels in the HPS were</text>
<text top="626" left="446" width="360" height="16" font="4">not drawn with patients in the fasting state and were</text>
<text top="644" left="446" width="360" height="16" font="4">measured values rather than the calculated values used in</text>
<text top="662" left="446" width="360" height="16" font="4">clinical practice and in most trials; measured LDL choles-</text>
<text top="680" left="446" width="360" height="16" font="4">terol is generally about 15% higher than calculated LDL</text>
<text top="698" left="446" width="80" height="16" font="4">cholesterol) <a href="e44.full.html#95">(</a></text>
<text top="698" left="525" width="23" height="16" font="16"><a href="e44.full.html#95">398</a></text>
<text top="698" left="548" width="258" height="16" font="4"><a href="e44.full.html#95">). </a>In the TNT (Treating to New Targets)</text>
<text top="716" left="446" width="360" height="16" font="4">trial, patients with clinically apparent IHD and LDL</text>
<text top="734" left="446" width="65" height="16" font="4">cholesterol</text>
<text top="731" left="515" width="290" height="20" font="4">⬎130 mg/dL were randomly assigned to either</text>
<text top="752" left="446" width="360" height="16" font="4">10 mg or 80 mg of atorvastatin per day. The mean LDL</text>
<text top="770" left="446" width="360" height="16" font="4">cholesterols were 77 mg/dL during treatment with 80 mg of</text>
<text top="788" left="446" width="360" height="16" font="4">atorvastatin and 101 mg/dL during treatment with 10 mg of</text>
<text top="806" left="446" width="360" height="16" font="4">atorvastatin. There was a 22% reduction in a composite</text>
<text top="824" left="446" width="360" height="16" font="4">cardiovascular endpoint and a 20% reduction in cardiac</text>
<text top="842" left="446" width="360" height="16" font="4">deaths with more intensive therapy but no reduction in</text>
<text top="860" left="446" width="131" height="16" font="4">all-cause mortality <a href="e44.full.html#95">(</a></text>
<text top="860" left="577" width="23" height="16" font="16"><a href="e44.full.html#95">400</a></text>
<text top="860" left="599" width="207" height="16" font="4"><a href="e44.full.html#95">). </a>In the IDEAL (Incremental</text>
<text top="878" left="446" width="360" height="16" font="4">Decrease in End Points Through Aggressive Lipid Lower-</text>
<text top="896" left="446" width="360" height="16" font="4">ing) study patients with a past history of MI were randomly</text>
<text top="914" left="446" width="360" height="16" font="4">assigned to intensive lipid-lowering therapy with atorvasta-</text>
<text top="932" left="446" width="360" height="16" font="4">tin 80 mg daily or simvastatin 20 mg daily. During treat-</text>
<text top="950" left="446" width="360" height="16" font="4">ment, mean LDL cholesterol levels were 104 mg/dL in the</text>
<text top="968" left="446" width="360" height="16" font="4">simvastatin group and 80 mg/dL in the atorvastatin group.</text>
<text top="986" left="446" width="360" height="16" font="4">The results showed a nonsignificant trend toward reduction</text>
<text top="1004" left="446" width="360" height="16" font="4">of the primary composite endpoint of coronary death,</text>
<text top="1022" left="446" width="360" height="16" font="4">nonfatal MI, or cardiac arrest (hazard ratio: 0.89; 95% CI:</text>
<text top="1040" left="446" width="360" height="16" font="4">0.78 to 1.01); significant reductions in some secondary</text>
<text top="1058" left="446" width="360" height="16" font="4">endpoints such as nonfatal MI and coronary revascular-</text>
<text top="1076" left="446" width="308" height="16" font="4">ization; and no effect on all-cause mortality <a href="e44.full.html#98">(</a></text>
<text top="1076" left="754" width="23" height="16" font="16"><a href="e44.full.html#98">501</a></text>
<text top="1076" left="778" width="28" height="16" font="4"><a href="e44.full.html#98">). </a>It</text>
<text top="1094" left="446" width="360" height="16" font="4">should be noted that both these trials compared 2 drug</text>
<text top="52" left="787" width="18" height="10" font="12">e87</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">regimens and did not directly test the benefit of achieving</text>
<text top="123" left="59" width="360" height="16" font="4">a given level of LDL cholesterol and that, to date, there</text>
<text top="141" left="59" width="360" height="16" font="4">is no clear evidence that treating to a specific target, as</text>
<text top="159" left="59" width="360" height="16" font="4">opposed to treating with a higher dose of a higher-</text>
<text top="178" left="59" width="360" height="16" font="4">potency statin, is beneficial. The mean achieved LDL</text>
<text top="196" left="59" width="360" height="16" font="4">cholesterol levels among patients treated in the high-dose</text>
<text top="215" left="59" width="360" height="16" font="4">atorvastatin arms of the TNT and IDEAL studies were</text>
<text top="233" left="59" width="200" height="16" font="4">77 and 81 mg/dL, respectively.</text>
<text top="251" left="74" width="345" height="16" font="4">These data support intensive LDL cholesterol lowering</text>
<text top="270" left="59" width="360" height="16" font="4">with statins in patients with SIHD. An update of the</text>
<text top="288" left="59" width="104" height="16" font="4">ATP-III report <a href="e44.full.html#86">(</a></text>
<text top="288" left="163" width="34" height="16" font="16"><a href="e44.full.html#86">18,24</a></text>
<text top="288" left="197" width="222" height="16" font="4"><a href="e44.full.html#86">) </a>recommends treatment to an LDL</text>
<text top="306" left="59" width="97" height="16" font="4">cholesterol level</text>
<text top="303" left="161" width="257" height="20" font="4">⬍100 mg/dL in patients with established</text>
<text top="325" left="59" width="360" height="16" font="4">CAD or other high-risk features, with an LDL cholesterol</text>
<text top="343" left="59" width="43" height="16" font="4">goal of</text>
<text top="340" left="107" width="311" height="20" font="4">⬍70 mg/dL as a therapeutic option in patients at</text>
<text top="361" left="59" width="360" height="16" font="4">very high risk. However, as discussed above, although the</text>
<text top="380" left="59" width="360" height="16" font="4">presence of data confirming the use of a specific, numeric</text>
<text top="398" left="59" width="360" height="16" font="4">target LDL cholesterol level for all patients with SIHD has</text>
<text top="416" left="59" width="360" height="16" font="4">been challenged, the benefit of therapy with moderate- to</text>
<text top="435" left="59" width="275" height="16" font="4">high-dose statin therapy is well established <a href="e44.full.html#97">(</a></text>
<text top="435" left="333" width="23" height="16" font="16"><a href="e44.full.html#97">458</a></text>
<text top="435" left="356" width="63" height="16" font="4"><a href="e44.full.html#97">). </a>For this</text>
<text top="453" left="59" width="360" height="16" font="4">reason, the recommendations in this guideline stress the</text>
<text top="471" left="59" width="360" height="16" font="4">importance of prescribing a statin in at least a moderate</text>
<text top="490" left="59" width="360" height="16" font="4">dose. The ATP-IV report is anticipated later in 2012 and is</text>
<text top="508" left="59" width="360" height="16" font="4">expected to provide guidance for the treatment of LDL</text>
<text top="526" left="59" width="360" height="16" font="4">cholesterol levels on the basis of the results of an extensive</text>
<text top="545" left="59" width="360" height="16" font="4">systematic review. Factors that identify patients at very high</text>
<text top="563" left="59" width="360" height="16" font="4">risk in the ATP-III update include the presence of estab-</text>
<text top="581" left="59" width="360" height="16" font="4">lished coronary vascular disease, plus 1) multiple major risk</text>
<text top="600" left="59" width="360" height="16" font="4">factors, especially diabetes mellitus; 2) severe and poorly</text>
<text top="618" left="59" width="360" height="16" font="4">controlled risk factors, especially continued tobacco use; and</text>
<text top="636" left="59" width="360" height="16" font="4">3) multiple risk factors for the metabolic syndrome. Again,</text>
<text top="655" left="59" width="360" height="16" font="4">it should be acknowledged that no studies have assessed the</text>
<text top="673" left="59" width="360" height="16" font="4">benefits of titrating lipid-lowering drugs to achieve a specific</text>
<text top="691" left="59" width="360" height="16" font="4">LDL cholesterol target. In addition, trials of intensive lipid</text>
<text top="710" left="59" width="360" height="16" font="4">lowering for secondary prevention have used statins alone.</text>
<text top="728" left="59" width="360" height="16" font="4">Although the addition of other agents could lower LDL</text>
<text top="746" left="59" width="360" height="16" font="4">cholesterol in patients in whom a target level cannot be</text>
<text top="765" left="59" width="360" height="16" font="4">achieved with a statin, the utility of this approach in</text>
<text top="783" left="59" width="360" height="16" font="4">reducing risk of cardiovascular morbidity and mortality has</text>
<text top="801" left="59" width="169" height="16" font="4">not been firmly established.</text>
<text top="820" left="74" width="345" height="16" font="4">A secondary target of therapy introduced by ATP-III is</text>
<text top="838" left="59" width="360" height="16" font="4">non–HDL cholesterol in patients with elevated triglycerides</text>
<text top="856" left="59" width="5" height="16" font="4"><a href="e44.full.html#86">(</a></text>
<text top="856" left="63" width="34" height="16" font="16"><a href="e44.full.html#86">18,24</a></text>
<text top="856" left="97" width="321" height="16" font="4"><a href="e44.full.html#86">). </a>Non–HDL cholesterol is defined as the difference</text>
<text top="875" left="59" width="360" height="16" font="4">between total cholesterol and HDL cholesterol. It includes</text>
<text top="893" left="59" width="360" height="16" font="4">all cholesterol and lipoprotein particles that are considered</text>
<text top="911" left="59" width="360" height="16" font="4">atherogenic, including LDL cholesterol, lipoprotein,</text>
<text top="930" left="59" width="360" height="16" font="4">intermediate-density lipoprotein, and very-low-density li-</text>
<text top="948" left="59" width="329" height="16" font="4">poprotein, and is a predictor of cardiovascular death <a href="e44.full.html#98">(</a></text>
<text top="948" left="387" width="23" height="16" font="16"><a href="e44.full.html#98">523</a></text>
<text top="948" left="410" width="9" height="16" font="4"><a href="e44.full.html#98">).</a></text>
<text top="966" left="59" width="360" height="16" font="4">Because statins lower LDL cholesterol and non–HDL</text>
<text top="985" left="59" width="360" height="16" font="4">cholesterol to a similar extent, the relative benefits of</text>
<text top="1003" left="59" width="360" height="16" font="4">lowering these 2 lipid measures cannot be distinguished</text>
<text top="1021" left="59" width="360" height="16" font="4">from recent clinical trials. Fibrates could reduce the risk of</text>
<text top="1040" left="59" width="360" height="16" font="4">coronary events in patients with high triglycerides and low</text>
<text top="1058" left="59" width="360" height="16" font="4">HDL cholesterol levels and could have an adjunctive role in</text>
<text top="1076" left="59" width="269" height="16" font="4">these patients in combination with statins <a href="e44.full.html#98">(</a></text>
<text top="1076" left="328" width="49" height="16" font="16"><a href="e44.full.html#98">503,524</a></text>
<text top="1076" left="376" width="42" height="16" font="4"><a href="e44.full.html#98">). </a>Nic-</text>
<text top="1095" left="59" width="360" height="16" font="4">otinic acid raises HDL cholesterol, and several trials support</text>
<text top="105" left="446" width="360" height="16" font="4">the efficacy of niacin when used alone or in combination</text>
<text top="123" left="446" width="81" height="16" font="4">with statins <a href="e44.full.html#98">(</a></text>
<text top="123" left="526" width="75" height="16" font="16"><a href="e44.full.html#98">504,505,525</a></text>
<text top="123" left="601" width="9" height="16" font="4"><a href="e44.full.html#98">).</a></text>
<text top="141" left="461" width="345" height="16" font="4">Observational studies and treatment trials suggest that</text>
<text top="159" left="446" width="360" height="16" font="4">consumption of omega-3 fatty acids reduces cardiovascular</text>
<text top="177" left="446" width="360" height="16" font="4">risk. Cohort and case– control studies have found an RR</text>
<text top="195" left="446" width="360" height="16" font="4">reduction of about 15% for fish consumption versus little or</text>
<text top="214" left="446" width="134" height="16" font="4">no fish consumption <a href="e44.full.html#98">(</a></text>
<text top="214" left="580" width="23" height="16" font="16"><a href="e44.full.html#98">526</a></text>
<text top="214" left="602" width="203" height="16" font="4"><a href="e44.full.html#98">). </a>In the GISSI (Gruppo Italiano</text>
<text top="232" left="446" width="360" height="16" font="4">per lo Studio della Sopravvivenza nell’Infarto Miocardico)</text>
<text top="250" left="446" width="360" height="16" font="4">Prevention study in patients with prior MI, 1 g daily of fish</text>
<text top="268" left="446" width="360" height="16" font="4">oil supplement resulted in a 20% reduction in mortality at</text>
<text top="286" left="446" width="73" height="16" font="4">42 months <a href="e44.full.html#98">(</a></text>
<text top="286" left="518" width="23" height="16" font="16"><a href="e44.full.html#98">527</a></text>
<text top="286" left="541" width="264" height="16" font="4"><a href="e44.full.html#98">). </a>Pharmacological treatment with fish oil at</text>
<text top="304" left="446" width="360" height="16" font="4">higher doses (2 to 4 g daily) is effective in reducing</text>
<text top="323" left="446" width="115" height="16" font="4">triglyceride levels <a href="e44.full.html#98">(</a></text>
<text top="323" left="560" width="23" height="16" font="16"><a href="e44.full.html#98">528</a></text>
<text top="323" left="583" width="9" height="16" font="4"><a href="e44.full.html#98">).</a></text>
<text top="353" left="446" width="194" height="9" font="6">4.4.1.2. BLOOD PRESSURE MANAGEMENT</text>
<text top="382" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="395" left="446" width="360" height="10" font="13">1. All patients should be counseled about the need for lifestyle modi-</text>
<text top="412" left="461" width="344" height="10" font="13">fication: weight control; increased physical activity; alcohol moder-</text>
<text top="429" left="461" width="344" height="10" font="13">ation; sodium reduction; and emphasis on increased consumption</text>
<text top="446" left="461" width="344" height="10" font="13">of fresh fruits, vegetables, and low-fat dairy products <a href="e44.full.html#86">(17,529–537).</a></text>
<text top="463" left="461" width="111" height="10" font="25"><i>(Level of Evidence: B)</i></text>
<text top="480" left="446" width="360" height="10" font="13">2. In patients with SIHD with BP 140/90 mm Hg or higher, antihyper-</text>
<text top="497" left="461" width="344" height="10" font="13">tensive drug therapy should be instituted in addition to or after a</text>
<text top="514" left="461" width="326" height="10" font="13">trial of lifestyle modifications <a href="e44.full.html#98">(538–543). </a><i>(Level of Evidence: A)</i></text>
<text top="531" left="446" width="360" height="10" font="13">3. The specific medications used for treatment of high BP should be</text>
<text top="548" left="461" width="344" height="10" font="13">based on specific patient characteristics and may include ACE</text>
<text top="565" left="461" width="344" height="10" font="13">inhibitors and/or beta blockers, with addition of other drugs, such as</text>
<text top="582" left="461" width="344" height="10" font="13">thiazide diuretics or calcium channel blockers, if needed to achieve</text>
<text top="599" left="461" width="344" height="10" font="13">a goal BP of less than 140/90 mm Hg <a href="e44.full.html#99">(544,545). </a><i>(Level of Evi-</i></text>
<text top="616" left="461" width="48" height="10" font="25"><i>dence: B)</i></text>
<text top="641" left="446" width="360" height="16" font="4">Hypertension is an important independent risk factor for</text>
<text top="659" left="446" width="360" height="16" font="4">ischemic cardiovascular events. Observational studies have</text>
<text top="677" left="446" width="360" height="16" font="4">demonstrated a continuous and graded relationship between</text>
<text top="695" left="446" width="360" height="16" font="4">BP and cardiovascular risk. In a collaborative meta-analysis</text>
<text top="713" left="446" width="360" height="16" font="4">of prospective studies of nearly 1 million adults without</text>
<text top="732" left="446" width="360" height="16" font="4">preexisting vascular disease, the risk of a vascular death</text>
<text top="750" left="446" width="360" height="16" font="4">increased linearly over the BP range of 115/75 mm Hg to</text>
<text top="768" left="446" width="360" height="16" font="4">185/115 mm Hg, without a threshold effect. Each incre-</text>
<text top="786" left="446" width="360" height="16" font="4">ment of 20 mm Hg in systolic BP or 10 mm Hg in diastolic</text>
<text top="804" left="446" width="284" height="16" font="4">BP was associated with a doubling of risk <a href="e44.full.html#99">(</a></text>
<text top="804" left="730" width="23" height="16" font="16"><a href="e44.full.html#99">546</a></text>
<text top="804" left="752" width="53" height="16" font="4"><a href="e44.full.html#99">). </a>RCTs</text>
<text top="822" left="446" width="360" height="16" font="4">indicate that treatment results in a reduction of cardiovas-</text>
<text top="840" left="446" width="360" height="16" font="4">cular risk consistent with predictions from epidemiological</text>
<text top="859" left="446" width="51" height="16" font="4">studies <a href="e44.full.html#98">(</a></text>
<text top="859" left="497" width="81" height="16" font="16"><a href="e44.full.html#98">538 –543,547</a></text>
<text top="859" left="577" width="9" height="16" font="4"><a href="e44.full.html#98">).</a></text>
<text top="877" left="461" width="345" height="16" font="4">Treatment of high BP should begin with lifestyle mea-</text>
<text top="895" left="446" width="360" height="16" font="4">sures. Maintenance of an appropriate body weight (BMI</text>
<text top="910" left="446" width="66" height="20" font="4">⬍25 kg/m</text>
<text top="911" left="512" width="6" height="10" font="11">2</text>
<text top="913" left="517" width="288" height="16" font="4">) is a key element of the nonpharmacological</text>
<text top="931" left="446" width="360" height="16" font="4">strategies recommended to improve BP control; weight loss</text>
<text top="949" left="446" width="360" height="16" font="4">of 10 kg typically results in a decrease in BP of 5 to 20 mm Hg</text>
<text top="967" left="446" width="5" height="16" font="4"><a href="e44.full.html#98">(</a></text>
<text top="967" left="450" width="107" height="16" font="16"><a href="e44.full.html#98">529 –531,548,549</a></text>
<text top="967" left="557" width="248" height="16" font="4"><a href="e44.full.html#98">). </a>Consumption of a diet rich in fruits,</text>
<text top="986" left="446" width="241" height="16" font="4">vegetables, and low-fat dairy products <a href="e44.full.html#98">(</a></text>
<text top="986" left="686" width="49" height="16" font="16"><a href="e44.full.html#98">532,533</a></text>
<text top="986" left="735" width="71" height="16" font="4"><a href="e44.full.html#98">); </a>reduction</text>
<text top="1004" left="446" width="173" height="16" font="4">of dietary sodium intake <a href="e44.full.html#98">(</a></text>
<text top="1004" left="619" width="128" height="16" font="16"><a href="e44.full.html#98">529,531,533,534,550</a></text>
<text top="1004" left="747" width="59" height="16" font="4"><a href="e44.full.html#98">); </a>regular</text>
<text top="1022" left="446" width="103" height="16" font="4">physical activity <a href="e44.full.html#98">(</a></text>
<text top="1022" left="549" width="23" height="16" font="16"><a href="e44.full.html#98">535</a></text>
<text top="1022" left="571" width="234" height="16" font="4"><a href="e44.full.html#98">); </a>and moderation of alcohol consump-</text>
<text top="1040" left="446" width="34" height="16" font="4">tion <a href="e44.full.html#98">(</a></text>
<text top="1040" left="480" width="23" height="16" font="16"><a href="e44.full.html#98">536</a></text>
<text top="1040" left="502" width="257" height="16" font="4"><a href="e44.full.html#98">) </a>also result in significant lowering of BP.</text>
<text top="1058" left="461" width="345" height="16" font="4">In many patients with SIHD, therapy with medications</text>
<text top="1076" left="446" width="360" height="16" font="4">will be required to lower BP to the desired level. Treatment</text>
<text top="1094" left="446" width="360" height="16" font="4">trials have definitively demonstrated a beneficial effect of</text>
<text top="52" left="59" width="18" height="10" font="12">e88</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">antihypertensive drug therapy on cardiovascular disease risk.</text>
<text top="122" left="59" width="360" height="16" font="4">An overview of 17 placebo-controlled trials, most of which</text>
<text top="140" left="59" width="360" height="16" font="4">focused on lowering diastolic BP, showed that reducing</text>
<text top="158" left="59" width="360" height="16" font="4">diastolic BP 5 to 6 mm Hg (or an estimated 10 to 20 mm Hg</text>
<text top="176" left="59" width="360" height="16" font="4">in systolic BP) within a population was associated with a</text>
<text top="194" left="59" width="360" height="16" font="4">significant reduction in vascular mortality, with approxi-</text>
<text top="212" left="59" width="360" height="16" font="4">mately 40% reduction in stroke and 20% reduction in</text>
<text top="230" left="59" width="107" height="16" font="4">coronary events <a href="e44.full.html#99">(</a></text>
<text top="230" left="166" width="23" height="16" font="16"><a href="e44.full.html#99">547</a></text>
<text top="230" left="188" width="230" height="16" font="4"><a href="e44.full.html#99">). </a>This benefit of treatment also has</text>
<text top="248" left="59" width="360" height="16" font="4">been observed in studies of older adult patients with isolated</text>
<text top="266" left="59" width="136" height="16" font="4">systolic hypertension <a href="e44.full.html#98">(</a></text>
<text top="266" left="195" width="75" height="16" font="16"><a href="e44.full.html#98">539,551,552</a></text>
<text top="266" left="270" width="9" height="16" font="4"><a href="e44.full.html#98">).</a></text>
<text top="284" left="74" width="345" height="16" font="4">Despite the plethora of clinical studies, the appropriate</text>
<text top="302" left="59" width="360" height="16" font="4">BP threshold for initiating medical therapy and specific</text>
<text top="320" left="59" width="360" height="16" font="4">treatment goals for patients with chronic IHD remain</text>
<text top="338" left="59" width="360" height="16" font="4">controversial. RCTs have demonstrated a benefit from</text>
<text top="356" left="59" width="329" height="16" font="4">antihypertensive therapy in patients with a diastolic BP</text>
<text top="353" left="391" width="27" height="20" font="4">⬎90</text>
<text top="374" left="59" width="63" height="16" font="4">mm Hg <a href="e44.full.html#99">(</a></text>
<text top="374" left="121" width="23" height="16" font="16"><a href="e44.full.html#99">547</a></text>
<text top="374" left="144" width="275" height="16" font="4"><a href="e44.full.html#99">) </a>and also in patients with isolated systolic</text>
<text top="392" left="59" width="196" height="16" font="4">hypertension and a systolic BP</text>
<text top="389" left="261" width="105" height="20" font="4">⬎160 mm Hg <a href="e44.full.html#98">(</a></text>
<text top="392" left="366" width="53" height="16" font="16"><a href="e44.full.html#98">539,551,</a></text>
<text top="410" left="59" width="23" height="16" font="16"><a href="e44.full.html#98">552</a></text>
<text top="410" left="81" width="337" height="16" font="4"><a href="e44.full.html#98">). </a>The Seventh Report of the Joint National Committee</text>
<text top="428" left="59" width="360" height="16" font="4">on Prevention, Detection, Evaluation, and Treatment of</text>
<text top="446" left="59" width="300" height="16" font="4">High Blood Pressure recommends a target BP of</text>
<text top="443" left="363" width="55" height="20" font="4">⬍140/90</text>
<text top="464" left="59" width="360" height="16" font="4">mm Hg in patients with uncomplicated hypertension and of</text>
<text top="479" left="59" width="360" height="20" font="4">⬍130/80 mm Hg in patients with diabetes mellitus or CKD</text>
<text top="500" left="59" width="5" height="16" font="4"><a href="e44.full.html#86">(</a></text>
<text top="500" left="63" width="15" height="16" font="16"><a href="e44.full.html#86">17</a></text>
<text top="500" left="78" width="340" height="16" font="4"><a href="e44.full.html#86">). </a>Observations from epidemiological studies and the</text>
<text top="518" left="59" width="360" height="16" font="4">relatively high absolute risk of cardiovascular events in</text>
<text top="536" left="59" width="360" height="16" font="4">patients with vascular disease have led some to suggest that</text>
<text top="554" left="59" width="360" height="16" font="4">a lower BP target might also be appropriate in individuals</text>
<text top="572" left="59" width="81" height="16" font="4">with SIHD <a href="e44.full.html#99">(</a></text>
<text top="572" left="139" width="23" height="16" font="16"><a href="e44.full.html#99">553</a></text>
<text top="572" left="162" width="9" height="16" font="4"><a href="e44.full.html#99">).</a></text>
<text top="590" left="74" width="345" height="16" font="4">On the other hand, excessive reduction in diastolic BP</text>
<text top="608" left="59" width="360" height="16" font="4">could compromise coronary perfusion in SIHD patients,</text>
<text top="626" left="59" width="360" height="16" font="4">and some studies have demonstrated a J-shaped relationship</text>
<text top="644" left="59" width="294" height="16" font="4">between diastolic BP and coronary events <a href="e44.full.html#99">(</a></text>
<text top="644" left="353" width="23" height="16" font="16"><a href="e44.full.html#99">554</a></text>
<text top="644" left="375" width="44" height="16" font="4"><a href="e44.full.html#99">). </a>The</text>
<text top="662" left="59" width="360" height="16" font="4">ACCORD (Action to Control Cardiovascular Risk in</text>
<text top="680" left="59" width="120" height="16" font="4">Diabetes) BP trial <a href="e44.full.html#99">(</a></text>
<text top="680" left="179" width="23" height="16" font="16"><a href="e44.full.html#99">555</a></text>
<text top="680" left="201" width="217" height="16" font="4"><a href="e44.full.html#99">), </a>which enrolled patients with type</text>
<text top="698" left="59" width="360" height="16" font="4">2 diabetes mellitus at high risk of cardiovascular events,</text>
<text top="716" left="59" width="360" height="16" font="4">found no benefit of targeting a systolic BP of 120 mm Hg</text>
<text top="734" left="59" width="360" height="16" font="4">compared with a systolic BP of 140 mm Hg in reducing a</text>
<text top="752" left="59" width="360" height="16" font="4">composite endpoint of MI, stroke, or death from cardiovas-</text>
<text top="770" left="59" width="360" height="16" font="4">cular causes. In a related vein, in AASK (African-American</text>
<text top="788" left="59" width="290" height="16" font="4">Study of Kidney Diseases and Hypertension) <a href="e44.full.html#99">(</a></text>
<text top="788" left="348" width="23" height="16" font="16"><a href="e44.full.html#99">556</a></text>
<text top="788" left="371" width="48" height="16" font="4"><a href="e44.full.html#99">), </a>1,094</text>
<text top="806" left="59" width="360" height="16" font="4">black patients with hypertensive kidney disease (diastolic</text>
<text top="824" left="59" width="49" height="16" font="4">pressure</text>
<text top="821" left="111" width="307" height="20" font="4">⬎95 mm Hg and glomerular filtration rate of 20 to</text>
<text top="842" left="59" width="360" height="16" font="4">60 mL/min) and no diabetes mellitus were randomly</text>
<text top="104" left="446" width="281" height="16" font="4">assigned to achieve a mean arterial pressure target</text>
<text top="101" left="730" width="76" height="20" font="4">ⱕ92 mm Hg</text>
<text top="123" left="446" width="360" height="16" font="4">(corresponding to 130/80 mm Hg) or to a target of 102 to</text>
<text top="141" left="446" width="360" height="16" font="4">107 mm Hg (corresponding to 140/90 mm Hg). Overall,</text>
<text top="159" left="446" width="360" height="16" font="4">there was no advantage to more intensive BP control with</text>
<text top="177" left="446" width="360" height="16" font="4">regard to progression to end-stage kidney disease or death</text>
<text top="196" left="446" width="5" height="16" font="4"><a href="e44.full.html#99">(</a></text>
<text top="196" left="450" width="23" height="16" font="16"><a href="e44.full.html#99">556</a></text>
<text top="196" left="473" width="9" height="16" font="4"><a href="e44.full.html#99">).</a></text>
<text top="214" left="461" width="345" height="16" font="4">Although in patients with uncomplicated hypertension</text>
<text top="232" left="446" width="360" height="16" font="4">there are a variety of considerations in selecting a medica-</text>
<text top="250" left="446" width="360" height="16" font="4">tion, effective BP lowering is the most important factor in</text>
<text top="268" left="446" width="360" height="16" font="4">preventing stroke and MI. Clinical trials have failed to</text>
<text top="287" left="446" width="360" height="16" font="4">convincingly demonstrate superiority of any single antihy-</text>
<text top="305" left="446" width="360" height="16" font="4">pertensive drug class in preventing cardiovascular events</text>
<text top="323" left="446" width="5" height="16" font="4"><a href="e44.full.html#99">(</a></text>
<text top="323" left="450" width="49" height="16" font="16"><a href="e44.full.html#99">544,545</a></text>
<text top="323" left="499" width="306" height="16" font="4"><a href="e44.full.html#99">). </a>In many patients with SIHD, the choice of</text>
<text top="341" left="446" width="360" height="16" font="4">medications is guided by compelling indications for specific</text>
<text top="360" left="446" width="360" height="16" font="4">classes of drugs, as discussed elsewhere in this guideline</text>
<text top="378" left="446" width="5" height="16" font="4"><a href="e44.full.html#46">(</a></text>
<text top="378" left="450" width="58" height="16" font="16"><a href="e44.full.html#46">Table 15</a></text>
<text top="378" left="508" width="18" height="16" font="4"><a href="e44.full.html#46">) </a><a href="e44.full.html#99">(</a></text>
<text top="378" left="526" width="23" height="16" font="16"><a href="e44.full.html#99">557</a></text>
<text top="378" left="548" width="257" height="16" font="4"><a href="e44.full.html#99">). </a>ACE inhibitors improve outcomes in</text>
<text top="396" left="446" width="360" height="16" font="4">most patients with CAD, especially those with a history of</text>
<text top="414" left="446" width="360" height="16" font="4">MI, LV dysfunction and heart failure, or CKD or diabetes</text>
<text top="432" left="446" width="66" height="16" font="4">mellitus <a href="e44.full.html#93">(</a></text>
<text top="432" left="511" width="139" height="16" font="16"><a href="e44.full.html#93">295,296,301,558 –562</a></text>
<text top="432" left="650" width="155" height="16" font="4"><a href="e44.full.html#93">). </a>Angiotensin-receptor</text>
<text top="451" left="446" width="360" height="16" font="4">blockers (ARBs) are beneficial in the same spectrum of</text>
<text top="469" left="446" width="61" height="16" font="4">patients <a href="e44.full.html#99">(</a></text>
<text top="469" left="507" width="53" height="16" font="16"><a href="e44.full.html#99">563–566</a></text>
<text top="469" left="559" width="246" height="16" font="4"><a href="e44.full.html#99">). </a>Beta blockers are recommended in</text>
<text top="487" left="446" width="360" height="16" font="4">patients with angina pectoris, a history of MI, or LV</text>
<text top="505" left="446" width="83" height="16" font="4">dysfunction <a href="e44.full.html#99">(</a></text>
<text top="505" left="529" width="53" height="16" font="16"><a href="e44.full.html#99">567–571</a></text>
<text top="505" left="581" width="224" height="16" font="4"><a href="e44.full.html#99">). </a>Aldosterone antagonists improve</text>
<text top="524" left="446" width="360" height="16" font="4">prognosis in patients with LV dysfunction and heart failure</text>
<text top="542" left="446" width="5" height="16" font="4"><a href="e44.full.html#99">(</a></text>
<text top="542" left="450" width="49" height="16" font="16"><a href="e44.full.html#99">572,573</a></text>
<text top="542" left="499" width="306" height="16" font="4"><a href="e44.full.html#99">). </a>Calcium antagonists are useful in the treatment</text>
<text top="560" left="446" width="360" height="16" font="4">of angina. Many patients with SIHD will require a combi-</text>
<text top="578" left="446" width="360" height="16" font="4">nation of drugs, including a diuretic, to achieve optimal BP</text>
<text top="597" left="446" width="47" height="16" font="4">control.</text>
<text top="615" left="461" width="345" height="16" font="4">The role of emotional stress in relationship to hyperten-</text>
<text top="633" left="446" width="360" height="16" font="4">sion has yet to be fully elucidated. It might be important to</text>
<text top="651" left="446" width="360" height="16" font="4">acknowledge the potential relationship of stress to many of</text>
<text top="669" left="446" width="360" height="16" font="4">the cardiovascular risk factors, particularly hypertension,</text>
<text top="688" left="446" width="158" height="16" font="4">when counseling patients.</text>
<text top="718" left="446" width="154" height="9" font="6">4.4.1.3. DIABETES MANAGEMENT</text>
<text top="747" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="760" left="446" width="360" height="10" font="13">1. For selected individual patients, such as those with a short duration</text>
<text top="777" left="461" width="344" height="10" font="13">of diabetes mellitus and a long life expectancy, a goal hemoglobin</text>
<text top="794" left="461" width="344" height="10" font="13">A1c (HbA1c) of 7% or less is reasonable <a href="e44.full.html#99">(574–576). </a><i>(Level of</i></text>
<text top="811" left="461" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="828" left="446" width="360" height="10" font="13">2. A goal HbA1c between 7% and 9% is reasonable for certain patients</text>
<text top="845" left="461" width="344" height="10" font="13">according to age, history of hypoglycemia, presence of microvascu-</text>
<text top="874" left="59" width="613" height="11" font="13">Table 15. Indications for Individual Drug Classes in the Treatment of Hypertension in Patients With SIHD*</text>
<text top="935" left="96" width="47" height="9" font="6">Indication</text>
<text top="899" left="467" width="100" height="9" font="6">Recommended Drugs</text>
<text top="935" left="230" width="37" height="9" font="6">Diuretic</text>
<text top="935" left="318" width="62" height="9" font="6">Beta Blocker</text>
<text top="935" left="430" width="62" height="9" font="6">ACE Inhibitor</text>
<text top="935" left="542" width="21" height="9" font="6">ARB</text>
<text top="922" left="613" width="79" height="9" font="6">Calcium-Channel</text>
<text top="935" left="634" width="36" height="9" font="6">Blocker</text>
<text top="922" left="745" width="56" height="9" font="6">Aldosterone</text>
<text top="935" left="748" width="51" height="9" font="6">Antagonist</text>
<text top="952" left="59" width="57" height="9" font="6">Heart failure</text>
<text top="954" left="247" width="3" height="8" font="21">●</text>
<text top="954" left="347" width="3" height="8" font="21">●</text>
<text top="954" left="459" width="3" height="8" font="21">●</text>
<text top="954" left="551" width="3" height="8" font="21">●</text>
<text top="954" left="772" width="3" height="8" font="21">●</text>
<text top="969" left="59" width="66" height="9" font="6">LV dysfunction</text>
<text top="971" left="459" width="3" height="8" font="21">●</text>
<text top="971" left="551" width="3" height="8" font="21">●</text>
<text top="987" left="59" width="121" height="9" font="6">After myocardial infarction</text>
<text top="988" left="347" width="3" height="8" font="21">●</text>
<text top="988" left="459" width="3" height="8" font="21">●</text>
<text top="988" left="551" width="3" height="8" font="21">●</text>
<text top="988" left="772" width="3" height="8" font="21">●</text>
<text top="1004" left="59" width="31" height="9" font="6">Angina</text>
<text top="1005" left="347" width="3" height="8" font="21">●</text>
<text top="1005" left="651" width="3" height="8" font="21">●</text>
<text top="1021" left="59" width="79" height="9" font="6">Diabetes mellitus</text>
<text top="1023" left="347" width="3" height="8" font="21">●</text>
<text top="1023" left="459" width="3" height="8" font="21">●</text>
<text top="1023" left="551" width="3" height="8" font="21">●</text>
<text top="1038" left="59" width="104" height="9" font="6">Chronic kidney disease</text>
<text top="1040" left="459" width="3" height="8" font="21">●</text>
<text top="1040" left="551" width="3" height="8" font="21">●</text>
<text top="1076" left="59" width="747" height="7" font="17">*Table indicates drugs that should be considered and does not indicate that all drugs should necessarily be prescribed in an individual patient (e.g., ACE inhibitors and ARB typically are not prescribed</text>
<text top="1088" left="59" width="36" height="7" font="17">together).</text>
<text top="1100" left="67" width="397" height="7" font="17">ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; and LV, left ventricular.</text>
<text top="52" left="787" width="18" height="10" font="12">e89</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1161" width="864">
<text top="105" left="75" width="344" height="10" font="13">lar or macrovascular complications, or presence of coexisting med-</text>
<text top="122" left="75" width="247" height="10" font="13">ical conditions <a href="e44.full.html#99">(577,578). </a><i>(Level of Evidence: C)</i></text>
<text top="152" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="165" left="59" width="360" height="10" font="13">1. Initiation of pharmacotherapy interventions to achieve target HbA1c</text>
<text top="182" left="74" width="307" height="10" font="13">might be reasonable <a href="e44.full.html#97">(456,579–588). </a><i>(Level of Evidence: A)</i></text>
<text top="212" left="59" width="74" height="8" font="24">CLASS III: Harm</text>
<text top="225" left="59" width="360" height="10" font="13">1. Therapy with rosiglitazone should not be initiated in patients with</text>
<text top="242" left="74" width="199" height="10" font="13">SIHD <a href="e44.full.html#100">(589,590). </a><i>(Level of Evidence: C)</i></text>
<text top="266" left="59" width="360" height="16" font="4">Diabetes mellitus is an important independent risk factor</text>
<text top="284" left="59" width="360" height="16" font="4">for cardiovascular disease. Type 1 diabetes mellitus is</text>
<text top="302" left="59" width="360" height="16" font="4">associated with at least a 10-fold increase in cardiovascular</text>
<text top="320" left="59" width="47" height="16" font="4">events <a href="e44.full.html#100">(</a></text>
<text top="320" left="105" width="49" height="16" font="16"><a href="e44.full.html#100">591,592</a></text>
<text top="320" left="154" width="265" height="16" font="4"><a href="e44.full.html#100">), </a>and patients with type 2 diabetes mellitus</text>
<text top="338" left="59" width="360" height="16" font="4">have a risk of death from cardiovascular causes that is 2 to</text>
<text top="356" left="59" width="299" height="16" font="4">6 times that of persons without diabetes mellitus <a href="e44.full.html#100">(</a></text>
<text top="356" left="357" width="53" height="16" font="16"><a href="e44.full.html#100">593–595</a></text>
<text top="356" left="410" width="9" height="16" font="4"><a href="e44.full.html#100">).</a></text>
<text top="374" left="59" width="360" height="16" font="4">The complications of atherosclerosis account for 80% of</text>
<text top="392" left="59" width="360" height="16" font="4">deaths among patients with diabetes mellitus, and IHD is</text>
<text top="410" left="59" width="244" height="16" font="4">responsible for the majority of deaths <a href="e44.full.html#99">(</a></text>
<text top="410" left="302" width="49" height="16" font="16"><a href="e44.full.html#99">574,596</a></text>
<text top="410" left="351" width="68" height="16" font="4"><a href="e44.full.html#99">). </a>Diabetes</text>
<text top="428" left="59" width="360" height="16" font="4">mellitus is associated with a poor outcome in patients with</text>
<text top="446" left="59" width="360" height="16" font="4">SIHD, even after the extent of disease and other clinical</text>
<text top="464" left="59" width="360" height="16" font="4">characteristics are taken into account. In the CASS registry,</text>
<text top="482" left="59" width="360" height="16" font="4">for example, patients with diabetes mellitus had a 57% greater</text>
<text top="500" left="59" width="307" height="16" font="4">risk of death after adjustment for other risk factors <a href="e44.full.html#100">(</a></text>
<text top="500" left="365" width="22" height="16" font="16"><a href="e44.full.html#100">597</a></text>
<text top="500" left="386" width="8" height="16" font="4"><a href="e44.full.html#100">).</a></text>
<text top="518" left="74" width="345" height="16" font="4">Clinical trials have demonstrated a salutary effect of</text>
<text top="536" left="59" width="360" height="16" font="4">intensive glycemic control on the development of microvas-</text>
<text top="554" left="59" width="360" height="16" font="4">cular complications of diabetes mellitus, such as retinopa-</text>
<text top="572" left="59" width="360" height="16" font="4">thy, nephropathy, and peripheral and autonomic neuropa-</text>
<text top="590" left="59" width="32" height="16" font="4">thy <a href="e44.full.html#99">(</a></text>
<text top="590" left="91" width="75" height="16" font="16"><a href="e44.full.html#99">574,575,598</a></text>
<text top="590" left="166" width="253" height="16" font="4"><a href="e44.full.html#99">), </a>with secondary analyses suggesting a</text>
<text top="608" left="59" width="360" height="16" font="4">benefit extending into the normal range of HbA1c. How-</text>
<text top="626" left="59" width="360" height="16" font="4">ever, the efficacy of intensive diabetes therapy in reducing</text>
<text top="644" left="59" width="360" height="16" font="4">cardiovascular disease is less well established. In the DCCT</text>
<text top="662" left="59" width="360" height="16" font="4">(Diabetes Control and Complications Trial), patients with</text>
<text top="680" left="59" width="360" height="16" font="4">type 1 diabetes mellitus were randomized to intensive (mean</text>
<text top="698" left="59" width="360" height="16" font="4">achieved HbA1c 7.4%) or conventional (mean achieved</text>
<text top="716" left="59" width="360" height="16" font="4">HbA1c 9.1%) therapy. During the mean 6.5 years of</text>
<text top="734" left="59" width="360" height="16" font="4">observation, fewer cardiovascular events occurred in the</text>
<text top="752" left="59" width="360" height="16" font="4">intensive-treatment group, but the number of events was</text>
<text top="770" left="59" width="360" height="16" font="4">small, and the difference between groups did not reach</text>
<text top="788" left="59" width="138" height="16" font="4">statistical significance <a href="e44.full.html#99">(</a></text>
<text top="788" left="197" width="23" height="16" font="16"><a href="e44.full.html#99">574</a></text>
<text top="788" left="219" width="199" height="16" font="4"><a href="e44.full.html#99">). </a>In a long-term follow-up study</text>
<text top="806" left="59" width="360" height="16" font="4">of this population, however, intensive therapy reduced the</text>
<text top="824" left="59" width="228" height="16" font="4">risk of cardiovascular events by 42% <a href="e44.full.html#99">(</a></text>
<text top="824" left="287" width="23" height="16" font="16"><a href="e44.full.html#99">579</a></text>
<text top="824" left="309" width="109" height="16" font="4"><a href="e44.full.html#99">). </a>Intensive glyce-</text>
<text top="842" left="59" width="360" height="16" font="4">mic controlled to a reduction in microvascular complications</text>
<text top="860" left="59" width="360" height="16" font="4">(primarily the need for retinal laser photocoagulation) but</text>
<text top="878" left="59" width="360" height="16" font="4">not cardiovascular events in the patients with type 2 diabetes</text>
<text top="896" left="59" width="360" height="16" font="4">mellitus who participated in the UKPDS (UK Prospective</text>
<text top="914" left="59" width="110" height="16" font="4">Diabetes Study) <a href="e44.full.html#99">(</a></text>
<text top="914" left="169" width="23" height="16" font="16"><a href="e44.full.html#99">575</a></text>
<text top="914" left="191" width="227" height="16" font="4"><a href="e44.full.html#99">). </a>In a secondary analysis, treatment</text>
<text top="932" left="59" width="360" height="16" font="4">with metformin seemed to confer most of the benefit,</text>
<text top="950" left="59" width="360" height="16" font="4">whereas treatment with a sulfonylurea was not associated</text>
<text top="968" left="59" width="329" height="16" font="4">with a significant improvement in any endpoint <a href="e44.full.html#100">(</a></text>
<text top="968" left="387" width="23" height="16" font="16"><a href="e44.full.html#100">599</a></text>
<text top="968" left="410" width="9" height="16" font="4"><a href="e44.full.html#100">).</a></text>
<text top="986" left="59" width="360" height="16" font="4">Patients in UKPDS treated with metformin had a lower</text>
<text top="1004" left="59" width="360" height="16" font="4">median HbA1c (7.4% versus 8.0%) and a 37% reduction in</text>
<text top="1019" left="59" width="360" height="20" font="4">ⱖ1 diabetes endpoints compared with those in the conven-</text>
<text top="1040" left="59" width="213" height="16" font="4">tional therapy (diet alone) group <a href="e44.full.html#99">(</a></text>
<text top="1040" left="271" width="23" height="16" font="16"><a href="e44.full.html#99">580</a></text>
<text top="1040" left="294" width="125" height="16" font="4"><a href="e44.full.html#99">). </a>In the PROactive</text>
<text top="1058" left="59" width="360" height="16" font="4">(Prospective Pioglitazone Clinical Trial in Macrovascular</text>
<text top="1076" left="59" width="360" height="16" font="4">Events) study, patients with type 2 diabetes mellitus and</text>
<text top="1094" left="59" width="360" height="16" font="4">evidence of vascular disease were randomized to pioglita-</text>
<text top="104" left="446" width="360" height="16" font="4">zone or placebo. HbA1c averaged 7.8% at baseline and</text>
<text top="123" left="446" width="360" height="16" font="4">decreased by 0.3% in the placebo group and by 0.8% in</text>
<text top="141" left="446" width="360" height="16" font="4">those on active therapy. There was no significant difference</text>
<text top="159" left="446" width="360" height="16" font="4">between treatment groups in the primary study endpoint,</text>
<text top="178" left="446" width="360" height="16" font="4">although pioglitazone resulted in a statistically significant</text>
<text top="196" left="446" width="360" height="16" font="4">16% relative reduction in a secondary endpoint of mortality,</text>
<text top="215" left="446" width="157" height="16" font="4">nonfatal MI, and stroke <a href="e44.full.html#99">(</a></text>
<text top="215" left="603" width="23" height="16" font="16"><a href="e44.full.html#99">581</a></text>
<text top="215" left="625" width="9" height="16" font="4"><a href="e44.full.html#99">).</a></text>
<text top="233" left="461" width="345" height="16" font="4">Three studies in patients with type 2 diabetes mellitus</text>
<text top="251" left="446" width="360" height="16" font="4">suggest that even more intensive glucose lowering fails to</text>
<text top="270" left="446" width="360" height="16" font="4">reduce the incidence of cardiovascular events and could</text>
<text top="288" left="446" width="84" height="16" font="4">cause harm <a href="e44.full.html#99">(</a></text>
<text top="288" left="529" width="75" height="16" font="16"><a href="e44.full.html#99">576,578,600</a></text>
<text top="288" left="604" width="201" height="16" font="4"><a href="e44.full.html#99">). </a>The ADVANCE (Action in</text>
<text top="306" left="446" width="360" height="16" font="4">Diabetes and Vascular Disease: Preterax and Diamicron</text>
<text top="325" left="446" width="360" height="16" font="4">Modified Release Controlled Evaluation) trial tested a</text>
<text top="343" left="446" width="360" height="16" font="4">strategy of intensive glucose control with a target HbA1c of</text>
<text top="361" left="446" width="360" height="16" font="4">6.5%, with the sulfonylurea gliclazide (modified release) and</text>
<text top="380" left="446" width="184" height="16" font="4">other drugs used as required <a href="e44.full.html#99">(</a></text>
<text top="380" left="629" width="23" height="16" font="16"><a href="e44.full.html#99">576</a></text>
<text top="380" left="652" width="154" height="16" font="4"><a href="e44.full.html#99">). </a>After a median 5 years</text>
<text top="398" left="446" width="360" height="16" font="4">of follow-up, HbA1c averaged 6.5% in the intensive-control</text>
<text top="416" left="446" width="360" height="16" font="4">group and 7.3% in the standard-control group. Intensive</text>
<text top="435" left="446" width="360" height="16" font="4">control reduced the incidence of microvascular events but</text>
<text top="453" left="446" width="360" height="16" font="4">had no effect on a composite of macrovascular events that</text>
<text top="471" left="446" width="360" height="16" font="4">included nonfatal MI, nonfatal stroke, or death from car-</text>
<text top="490" left="446" width="119" height="16" font="4">diovascular causes <a href="e44.full.html#99">(</a></text>
<text top="490" left="564" width="23" height="16" font="16"><a href="e44.full.html#99">576</a></text>
<text top="490" left="587" width="219" height="16" font="4"><a href="e44.full.html#99">). </a>In the ACCORD study, patients</text>
<text top="508" left="446" width="360" height="16" font="4">were assigned to receive intensive therapy with a goal of</text>
<text top="526" left="446" width="180" height="16" font="4">normalizing the HbA1c (to</text>
<text top="523" left="634" width="171" height="20" font="4">⬍6%) or standard therapy</text>
<text top="545" left="446" width="218" height="16" font="4">targeting a level of 7.0% to 7.9% <a href="e44.full.html#100">(</a></text>
<text top="545" left="663" width="23" height="16" font="16"><a href="e44.full.html#100">600</a></text>
<text top="545" left="686" width="120" height="16" font="4"><a href="e44.full.html#100">). </a>Median achieved</text>
<text top="563" left="446" width="360" height="16" font="4">HbA1c levels at 1 year were 6.4% and 7.5% in the 2 groups,</text>
<text top="581" left="446" width="360" height="16" font="4">respectively. Over 3.5 years, the use of intensive therapy did</text>
<text top="600" left="446" width="360" height="16" font="4">not significantly reduce major cardiovascular events (nonfa-</text>
<text top="618" left="446" width="360" height="16" font="4">tal MI, nonfatal stroke, and death from cardiovascular</text>
<text top="636" left="446" width="360" height="16" font="4">causes) but was associated with a 22% greater all-cause</text>
<text top="655" left="446" width="64" height="16" font="4">mortality <a href="e44.full.html#99">(</a></text>
<text top="655" left="509" width="49" height="16" font="16"><a href="e44.full.html#99">578,600</a></text>
<text top="655" left="558" width="248" height="16" font="4"><a href="e44.full.html#99">). </a>The VADT (Veterans Affairs Diabetes</text>
<text top="673" left="446" width="360" height="16" font="4">Trial) examined macrovascular complications in patients</text>
<text top="691" left="446" width="360" height="16" font="4">randomized to standard glycemic control or to intensive</text>
<text top="710" left="446" width="155" height="16" font="4">therapy (goal HbA1c of</text>
<text top="707" left="608" width="197" height="20" font="4">⬍6%), with a planned HbA1c</text>
<text top="728" left="446" width="82" height="16" font="4">separation of</text>
<text top="725" left="535" width="55" height="20" font="4">ⱖ1.5% <a href="e44.full.html#99">(</a></text>
<text top="728" left="590" width="23" height="16" font="16"><a href="e44.full.html#99">578</a></text>
<text top="728" left="613" width="193" height="16" font="4"><a href="e44.full.html#99">). </a>Median HbA1c levels were</text>
<text top="746" left="445" width="360" height="16" font="4">8.4% and 6.9% in the standard- and intensive-therapy</text>
<text top="765" left="445" width="360" height="16" font="4">groups, respectively. There were no differences in the</text>
<text top="783" left="445" width="360" height="16" font="4">primary endpoint of time to occurrence of a cardiovascular</text>
<text top="801" left="445" width="360" height="16" font="4">event or all-cause mortality in the 2 groups over a median</text>
<text top="820" left="445" width="138" height="16" font="4">follow-up of 5.6 years.</text>
<text top="838" left="460" width="345" height="16" font="4">In summary, the most appropriate goal level for HbA1c</text>
<text top="856" left="445" width="360" height="16" font="4">in patients with diabetes mellitus has not been established</text>
<text top="875" left="445" width="270" height="16" font="4">definitively by clinical trials. A goal HbA1c</text>
<text top="872" left="721" width="85" height="20" font="4">⬍7%—a level</text>
<text top="893" left="445" width="360" height="16" font="4">approximating that achieved in the intensive-therapy arms</text>
<text top="911" left="445" width="360" height="16" font="4">of the DCCT, UKPDS, and PROactive studies—is reason-</text>
<text top="930" left="445" width="360" height="16" font="4">able for many younger patients, depending on their duration</text>
<text top="948" left="445" width="360" height="16" font="4">of diabetes mellitus, comorbidities, adherence, and personal</text>
<text top="966" left="445" width="360" height="16" font="4">preferences. Secondary analyses of the DCCT and UKPDS</text>
<text top="985" left="445" width="360" height="16" font="4">and microvascular data from the ADVANCE trial suggest</text>
<text top="1003" left="445" width="360" height="16" font="4">that even lower HbA1c levels could be beneficial in selected</text>
<text top="1021" left="445" width="360" height="16" font="4">individuals. On the other hand, treatment to achieve a</text>
<text top="1040" left="445" width="45" height="16" font="4">HbA1c</text>
<text top="1037" left="499" width="306" height="20" font="4">⬍7% might not be safe or practical for some</text>
<text top="1058" left="445" width="360" height="16" font="4">patients, and factors such as life expectancy, advanced</text>
<text top="1076" left="445" width="360" height="16" font="4">microvascular or macrovascular complications, cognitive</text>
<text top="1095" left="445" width="360" height="16" font="4">function, comorbidities, and risk of hypoglycemia should be</text>
<text top="52" left="59" width="18" height="10" font="12">e90</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">considered in every patient before intensifying the therapeu-</text>
<text top="123" left="59" width="73" height="16" font="4">tic regimen.</text>
<text top="141" left="74" width="345" height="16" font="4">Regardless of the degree of glycemic control, treatment of</text>
<text top="159" left="59" width="360" height="16" font="4">other modifiable risk factors that often accompany diabetes</text>
<text top="177" left="59" width="360" height="16" font="4">mellitus, such as hypertension and dyslipidemia, results in a</text>
<text top="196" left="59" width="360" height="16" font="4">substantial reduction in cardiovascular risk. The benefits of</text>
<text top="214" left="59" width="360" height="16" font="4">a target-driven, multifactorial intervention in patients with</text>
<text top="232" left="59" width="360" height="16" font="4">type 2 diabetes mellitus were demonstrated in the Steno-2</text>
<text top="250" left="59" width="43" height="16" font="4">study <a href="e44.full.html#100">(</a></text>
<text top="250" left="102" width="23" height="16" font="16"><a href="e44.full.html#100">601</a></text>
<text top="250" left="124" width="294" height="16" font="4"><a href="e44.full.html#100">). </a>Behavioral modification and pharmacological</text>
<text top="268" left="59" width="360" height="16" font="4">therapy targeting hyperglycemia, hypertension, dyslipide-</text>
<text top="287" left="59" width="360" height="16" font="4">mia, and microalbuminuria lowered the risk of cardiovascu-</text>
<text top="305" left="59" width="81" height="16" font="4">lar disease by</text>
<text top="302" left="145" width="49" height="20" font="4">⬎50% <a href="e44.full.html#100">(</a></text>
<text top="305" left="193" width="23" height="16" font="16"><a href="e44.full.html#100">601</a></text>
<text top="305" left="216" width="9" height="16" font="4"><a href="e44.full.html#100">).</a></text>
<text top="323" left="74" width="345" height="16" font="4">When the patient and provider elect to use pharmaco-</text>
<text top="341" left="59" width="360" height="16" font="4">logical therapy to improve glycemic control, several factors</text>
<text top="360" left="59" width="360" height="16" font="4">should be considered in selecting an agent, including ac-</text>
<text top="378" left="59" width="360" height="16" font="4">ceptability and safety. Although head-to-head comparisons</text>
<text top="396" left="59" width="360" height="16" font="4">of different pharmacological regimens are largely lacking,</text>
<text top="414" left="59" width="360" height="16" font="4">limited evidence suggests that all agents are not equivalent.</text>
<text top="432" left="59" width="360" height="16" font="4">For example, long-term follow-up from the UKPDS indi-</text>
<text top="451" left="59" width="360" height="16" font="4">cates that patients receiving metformin, particularly those</text>
<text top="469" left="59" width="360" height="16" font="4">who were overweight, had a lower incidence of diabetic</text>
<text top="487" left="59" width="360" height="16" font="4">complications, MI, and death than those who received</text>
<text top="505" left="59" width="184" height="16" font="4">insulin plus a sulfonylurea <a href="e44.full.html#100">(</a></text>
<text top="505" left="242" width="23" height="16" font="16"><a href="e44.full.html#100">588</a></text>
<text top="505" left="265" width="154" height="16" font="4"><a href="e44.full.html#100">). </a>In addition, available</text>
<text top="524" left="59" width="360" height="16" font="4">information suggests that certain agents lack an acceptable</text>
<text top="542" left="59" width="360" height="16" font="4">safety profile. The FDA, for example, has imposed restric-</text>
<text top="560" left="59" width="360" height="16" font="4">tions on use of rosiglitazone, a thiazolidinedione, because of</text>
<text top="578" left="59" width="360" height="16" font="4">data that suggest an increased risk of cardiovascular com-</text>
<text top="597" left="59" width="360" height="16" font="4">plications. Prescriptions for rosiglitazone should not be</text>
<text top="615" left="59" width="360" height="16" font="4">initiated for patients with SIHD. Patients who are already</text>
<text top="633" left="59" width="360" height="16" font="4">receiving this agent and whose blood glucose is well con-</text>
<text top="651" left="59" width="360" height="16" font="4">trolled should be counseled about the potential hazards, and</text>
<text top="669" left="59" width="360" height="16" font="4">switching to a different agent should be strongly considered.</text>
<text top="688" left="59" width="360" height="16" font="4">In this light, when deciding whether to prescribe newer</text>
<text top="706" left="59" width="360" height="16" font="4">hypoglycemic agents, providers should bear in mind the</text>
<text top="724" left="59" width="360" height="16" font="4">potential for safety concerns that could emerge when these</text>
<text top="742" left="59" width="205" height="16" font="4">drugs are adopted into wider use.</text>
<text top="773" left="59" width="128" height="9" font="6">4.4.1.4. PHYSICAL ACTIVITY</text>
<text top="802" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="815" left="59" width="360" height="10" font="13">1. For all patients, the clinician should encourage 30 to 60 minutes of</text>
<text top="832" left="74" width="344" height="10" font="13">moderate-intensity aerobic activity, such as brisk walking, at least 5</text>
<text top="849" left="74" width="344" height="10" font="13">days and preferably 7 days per week, supplemented by an increase</text>
<text top="866" left="74" width="344" height="10" font="13">in daily lifestyle activities (e.g., walking breaks at work, gardening,</text>
<text top="883" left="74" width="344" height="10" font="13">household work) to improve cardiorespiratory fitness and move</text>
<text top="900" left="74" width="344" height="10" font="13">patients out of the least-fit, least-active, high-risk cohort (bottom</text>
<text top="917" left="74" width="203" height="10" font="13">20%) <a href="e44.full.html#100">(602–604). </a><i>(Level of Evidence: B)</i></text>
<text top="934" left="58" width="360" height="10" font="13">2. For all patients, risk assessment with a physical activity history</text>
<text top="951" left="74" width="344" height="10" font="13">and/or an exercise test is recommended to guide prognosis and</text>
<text top="968" left="74" width="237" height="10" font="13">prescription <a href="e44.full.html#100">(605–608). </a><i>(Level of Evidence: B)</i></text>
<text top="985" left="58" width="65" height="10" font="13">3. Medically</text>
<text top="985" left="135" width="55" height="10" font="13">supervised</text>
<text top="985" left="201" width="49" height="10" font="13">programs</text>
<text top="985" left="262" width="41" height="10" font="13">(cardiac</text>
<text top="985" left="315" width="72" height="10" font="13">rehabilitation)</text>
<text top="985" left="399" width="19" height="10" font="13">and</text>
<text top="1002" left="74" width="344" height="10" font="13">physician-directed, home-based programs are recommended for at-</text>
<text top="1020" left="74" width="335" height="10" font="13">risk patients at first diagnosis <a href="e44.full.html#100">(602,609,610). </a><i>(Level of Evidence: A)</i></text>
<text top="1050" left="59" width="46" height="8" font="24">CLASS IIa</text>
<text top="1063" left="59" width="360" height="10" font="13">1. It is reasonable for the clinician to recommend complementary</text>
<text top="1080" left="74" width="344" height="10" font="13">resistance training at least 2 days per week <a href="e44.full.html#100">(611,612). </a><i>(Level of</i></text>
<text top="1097" left="74" width="63" height="10" font="25"><i>Evidence: C)</i></text>
<text top="104" left="446" width="360" height="16" font="4">Physical activity counseling is an integral component of a</text>
<text top="122" left="446" width="360" height="16" font="4">comprehensive coronary risk factor modification strategy in</text>
<text top="140" left="446" width="360" height="16" font="4">patients with SIHD. Consistent with the American College</text>
<text top="158" left="446" width="360" height="16" font="4">of Sports Medicine and AHA recommendations for healthy</text>
<text top="176" left="446" width="44" height="16" font="4">adults <a href="e44.full.html#100">(</a></text>
<text top="176" left="490" width="23" height="16" font="16"><a href="e44.full.html#100">603</a></text>
<text top="176" left="512" width="294" height="16" font="4"><a href="e44.full.html#100">), </a>most patients with CAD should be encouraged</text>
<text top="194" left="446" width="360" height="16" font="4">to engage in 30 to 60 minutes of moderate-intensity aerobic</text>
<text top="212" left="446" width="360" height="16" font="4">activity, such as brisk walking, on most, and preferably all,</text>
<text top="230" left="446" width="360" height="16" font="4">days of the week. Similar recommendations (2 hours and 30</text>
<text top="248" left="446" width="360" height="16" font="4">minutes of moderate-intensity aerobic activity and muscle-</text>
<text top="266" left="446" width="168" height="16" font="4">strengthening activities on</text>
<text top="263" left="621" width="184" height="20" font="4">ⱖ2 days a week) have been</text>
<text top="284" left="446" width="360" height="16" font="4">advanced by the Centers for Disease Control and Preven-</text>
<text top="302" left="446" width="33" height="16" font="4">tion <a href="e44.full.html#86">(</a></text>
<text top="302" left="479" width="41" height="16" font="16"><a href="e44.full.html#86">18,613</a></text>
<text top="302" left="520" width="286" height="16" font="4"><a href="e44.full.html#86">). </a>Many patients benefit from participation in a</text>
<text top="320" left="446" width="360" height="16" font="4">cardiac rehabilitation program that incorporates supervised</text>
<text top="338" left="446" width="360" height="16" font="4">exercise into a comprehensive secondary prevention pro-</text>
<text top="356" left="446" width="41" height="16" font="4">gram <a href="e44.full.html#100">(</a></text>
<text top="356" left="486" width="23" height="16" font="16"><a href="e44.full.html#100">614</a></text>
<text top="356" left="509" width="9" height="16" font="4"><a href="e44.full.html#100">).</a></text>
<text top="374" left="461" width="345" height="16" font="4">Multiple controlled clinical trials have examined the</text>
<text top="392" left="446" width="360" height="16" font="4">benefits of exercise training and cardiac rehabilitation in</text>
<text top="410" left="446" width="360" height="16" font="4">patients with IHD. Most of these studies have been</text>
<text top="428" left="446" width="360" height="16" font="4">relatively small, but in aggregate they demonstrate that</text>
<text top="446" left="446" width="360" height="16" font="4">regular exercise reduces mortality in patients with IHD. A</text>
<text top="464" left="446" width="360" height="16" font="4">systematic review and meta-analysis published in 2004</text>
<text top="482" left="446" width="360" height="16" font="4">examined 48 RCTs of exercise interventions in a total of</text>
<text top="500" left="446" width="168" height="16" font="4">8,940 patients with IHD <a href="e44.full.html#100">(</a></text>
<text top="500" left="613" width="23" height="16" font="16"><a href="e44.full.html#100">602</a></text>
<text top="500" left="636" width="170" height="16" font="4"><a href="e44.full.html#100">). </a>The median intervention</text>
<text top="518" left="446" width="360" height="16" font="4">duration was 3 months (range, 0.25 to 30 months), and the</text>
<text top="536" left="446" width="360" height="16" font="4">median duration of follow-up was 15 months (range, 6 to 72</text>
<text top="554" left="446" width="360" height="16" font="4">months). Exercise training resulted in a 20% reduction in</text>
<text top="572" left="446" width="360" height="16" font="4">all-cause mortality and a 26% reduction in total cardiac</text>
<text top="590" left="446" width="360" height="16" font="4">mortality; favorable but nonsignificant trends were noted in</text>
<text top="608" left="446" width="360" height="16" font="4">nonfatal MI, CABG, and percutaneous coronary revascu-</text>
<text top="626" left="446" width="360" height="16" font="4">larization procedures. There was no difference between the</text>
<text top="644" left="446" width="360" height="16" font="4">mortality rate effects of exercise-only and more comprehen-</text>
<text top="662" left="446" width="360" height="16" font="4">sive cardiac rehabilitation interventions, and the benefits</text>
<text top="680" left="446" width="360" height="16" font="4">were independent of actual amount and intensity of exercise.</text>
<text top="698" left="461" width="345" height="16" font="4">Many of the studies demonstrating the efficacy of</text>
<text top="716" left="446" width="360" height="16" font="4">exercise-based cardiac rehabilitation enrolled patients after</text>
<text top="734" left="446" width="360" height="16" font="4">an AMI or coronary revascularization procedure. Clear</text>
<text top="752" left="446" width="360" height="16" font="4">benefits of exercise training also have been shown in patients</text>
<text top="770" left="446" width="360" height="16" font="4">with stable angina. Controlled trials consistently have dem-</text>
<text top="788" left="446" width="360" height="16" font="4">onstrated an improvement in functional capacity and a delay</text>
<text top="806" left="446" width="360" height="16" font="4">in the onset of ischemia in anginal patients who complete an</text>
<text top="824" left="446" width="157" height="16" font="4">exercise training program <a href="e44.full.html#96">(</a></text>
<text top="824" left="602" width="78" height="16" font="16"><a href="e44.full.html#96">444,615–620</a></text>
<text top="824" left="680" width="126" height="16" font="4"><a href="e44.full.html#96">). </a>Exercise-based car-</text>
<text top="842" left="446" width="360" height="16" font="4">diac rehabilitation could also reduce subjective evidence of</text>
<text top="860" left="446" width="250" height="16" font="4">ischemia and could ameliorate symptoms <a href="e44.full.html#100">(</a></text>
<text top="860" left="695" width="97" height="16" font="16"><a href="e44.full.html#100">615,619,621,622</a></text>
<text top="860" left="792" width="8" height="16" font="4"><a href="e44.full.html#100">).</a></text>
<text top="878" left="461" width="345" height="16" font="4">The reduction in mortality rate associated with exercise</text>
<text top="896" left="446" width="360" height="16" font="4">interventions might be explained partially by modification</text>
<text top="914" left="446" width="360" height="16" font="4">of traditional cardiovascular risk factors. Controlled trials</text>
<text top="932" left="446" width="360" height="16" font="4">have demonstrated reductions in total cholesterol, triglyc-</text>
<text top="950" left="446" width="360" height="16" font="4">erides, and BP, although these findings have not been</text>
<text top="968" left="446" width="360" height="16" font="4">uniform. Exercise also can enhance smoking quit rates.</text>
<text top="986" left="446" width="360" height="16" font="4">Other potential mechanisms include decreased fibrinogen</text>
<text top="1004" left="446" width="112" height="16" font="4">and coagulability <a href="e44.full.html#100">(</a></text>
<text top="1004" left="557" width="23" height="16" font="16"><a href="e44.full.html#100">623</a></text>
<text top="1004" left="580" width="194" height="16" font="4"><a href="e44.full.html#100">), </a>moderation of inflammation <a href="e44.full.html#100">(</a></text>
<text top="1004" left="774" width="23" height="16" font="16"><a href="e44.full.html#100">624</a></text>
<text top="1004" left="797" width="9" height="16" font="4"><a href="e44.full.html#100">),</a></text>
<text top="1022" left="446" width="202" height="16" font="4">improved endothelial function <a href="e44.full.html#100">(</a></text>
<text top="1022" left="648" width="54" height="16" font="16"><a href="e44.full.html#100">625– 627</a></text>
<text top="1022" left="702" width="103" height="16" font="4"><a href="e44.full.html#100">), </a>and improved</text>
<text top="1040" left="446" width="140" height="16" font="4">autonomic regulation <a href="e44.full.html#101">(</a></text>
<text top="1040" left="585" width="49" height="16" font="16"><a href="e44.full.html#101">628,629</a></text>
<text top="1040" left="634" width="9" height="16" font="4"><a href="e44.full.html#101">).</a></text>
<text top="1058" left="461" width="345" height="16" font="4">Several studies have documented the safety of exercise-</text>
<text top="1076" left="446" width="360" height="16" font="4">based cardiac rehabilitation in patients with documented</text>
<text top="1094" left="446" width="48" height="16" font="4">SIHD <a href="e44.full.html#101">(</a></text>
<text top="1094" left="493" width="56" height="16" font="16"><a href="e44.full.html#101">630 – 633</a></text>
<text top="1094" left="549" width="256" height="16" font="4"><a href="e44.full.html#101">). </a>The 2007 AHA Scientific Statement on</text>
<text top="52" left="787" width="18" height="10" font="12">e91</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">Exercise and Acute Cardiovascular Events estimates the risk</text>
<text top="123" left="59" width="360" height="16" font="4">of a major adverse cardiac event (MACE) at 1 in 80,000</text>
<text top="141" left="59" width="90" height="16" font="4">patient-hours <a href="e44.full.html#96">(</a></text>
<text top="141" left="149" width="23" height="16" font="16"><a href="e44.full.html#96">447</a></text>
<text top="141" left="171" width="248" height="16" font="4"><a href="e44.full.html#96">). </a>This low event rate applies to medically</text>
<text top="159" left="59" width="360" height="16" font="4">supervised programs that evaluate patients before participa-</text>
<text top="177" left="59" width="360" height="16" font="4">tion, provide serial surveillance, and are equipped to handle</text>
<text top="195" left="59" width="360" height="16" font="4">emergencies. Specific strategies for reducing exercise-related</text>
<text top="213" left="59" width="360" height="16" font="4">cardiovascular events have not been evaluated. It seems</text>
<text top="231" left="59" width="360" height="16" font="4">prudent, however, that patients at high risk of cardiac</text>
<text top="249" left="59" width="360" height="16" font="4">complications (i.e., those with a history of multiple MIs or</text>
<text top="268" left="59" width="360" height="16" font="4">cardiac arrest, New York Heart Association functional class</text>
<text top="286" left="59" width="190" height="16" font="4">III or IV or exercise capacity</text>
<text top="282" left="256" width="162" height="20" font="4">⬍6 METs, or significant</text>
<text top="304" left="59" width="360" height="16" font="4">exercise-induced ischemia on treadmill testing) participate</text>
<text top="322" left="59" width="360" height="16" font="4">in a medically supervised program for at least 8 to 12 weeks</text>
<text top="340" left="59" width="350" height="16" font="4">to establish the safety of the prescribed exercise regimen.</text>
<text top="358" left="74" width="345" height="16" font="4">The value of resistance exercise increasingly is recognized</text>
<text top="376" left="59" width="360" height="16" font="4">for improving functional capacity, independence, and qual-</text>
<text top="394" left="59" width="360" height="16" font="4">ity of life in patients with and without cardiovascular</text>
<text top="412" left="59" width="360" height="16" font="4">disease. Although the risks and benefits of resistance ther-</text>
<text top="431" left="59" width="360" height="16" font="4">apy have not been evaluated extensively in patients with</text>
<text top="449" left="59" width="360" height="16" font="4">SIHD, several small studies have indicated that resistance</text>
<text top="467" left="59" width="360" height="16" font="4">therapy is well tolerated and is associated with improve-</text>
<text top="485" left="59" width="360" height="16" font="4">ments in quality of life, strength, and endurance when</text>
<text top="503" left="59" width="294" height="16" font="4">added to a program of regular aerobic exercise <a href="e44.full.html#100">(</a></text>
<text top="503" left="353" width="49" height="16" font="16"><a href="e44.full.html#100">611,612</a></text>
<text top="503" left="402" width="9" height="16" font="4"><a href="e44.full.html#100">).</a></text>
<text top="521" left="74" width="345" height="16" font="4">Although previous guidelines have recommended that all</text>
<text top="539" left="59" width="360" height="16" font="4">patients undergo an exercise test before participating in a</text>
<text top="557" left="59" width="360" height="16" font="4">cardiac rehabilitation program, according to the World</text>
<text top="575" left="59" width="139" height="16" font="4">Health Organization <a href="e44.full.html#101">(</a></text>
<text top="575" left="197" width="23" height="16" font="16"><a href="e44.full.html#101">634</a></text>
<text top="575" left="220" width="199" height="16" font="4"><a href="e44.full.html#101">), </a>an exercise test is not consid-</text>
<text top="594" left="59" width="360" height="16" font="4">ered necessary for medical and economic reasons if the</text>
<text top="612" left="59" width="360" height="16" font="4">patient enters a low- or moderate-intensity-level training</text>
<text top="630" left="59" width="55" height="16" font="4">program.</text>
<text top="661" left="59" width="146" height="9" font="6">4.4.1.5. WEIGHT MANAGEMENT</text>
<text top="689" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="702" left="59" width="360" height="10" font="13">1. BMI and/or waist circumference should be assessed at every visit,</text>
<text top="719" left="74" width="344" height="10" font="13">and the clinician should consistently encourage weight mainte-</text>
<text top="736" left="74" width="344" height="10" font="13">nance or reduction through an appropriate balance of lifestyle</text>
<text top="753" left="74" width="344" height="10" font="13">physical activity, structured exercise, caloric intake, and formal</text>
<text top="770" left="74" width="344" height="10" font="13">behavioral programs when indicated to maintain or achieve a BMI</text>
<text top="787" left="74" width="152" height="10" font="13">between 18.5 and 24.9 kg/m</text>
<text top="785" left="226" width="5" height="6" font="35">2</text>
<text top="787" left="234" width="184" height="10" font="13">and a waist circumference less than</text>
<text top="804" left="74" width="344" height="10" font="13">102 cm (40 inches) in men and less than 88 cm (35 inches) in</text>
<text top="821" left="74" width="344" height="10" font="13">women (less for certain racial groups) <a href="e44.full.html#92">(257,449,635–642). </a><i>(Level of</i></text>
<text top="838" left="74" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="855" left="59" width="360" height="10" font="13">2. The initial goal of weight loss therapy should be to reduce body weight</text>
<text top="872" left="74" width="344" height="10" font="13">by approximately 5% to 10% from baseline. With success, further</text>
<text top="889" left="74" width="317" height="10" font="13">weight loss can be attempted if indicated. (<i>Level of Evidence: C)</i></text>
<text top="913" left="59" width="360" height="16" font="4">Population studies consistently have demonstrated an asso-</text>
<text top="932" left="59" width="360" height="16" font="4">ciation of increased BMI with ischemic cardiac events. In a</text>
<text top="950" left="59" width="290" height="16" font="4">meta-analysis of 21 cohort studies including</text>
<text top="946" left="357" width="61" height="20" font="4">⬎300,000</text>
<text top="968" left="59" width="360" height="16" font="4">persons, the risks for cardiovascular events in patients who</text>
<text top="986" left="59" width="248" height="16" font="4">were overweight (BMI 25.0 to 29.9 kg/m</text>
<text top="983" left="307" width="6" height="10" font="11">2</text>
<text top="986" left="312" width="106" height="16" font="4">) and obese (BMI</text>
<text top="1001" left="59" width="65" height="20" font="4">⬎30 kg/m</text>
<text top="1001" left="124" width="6" height="10" font="11">2</text>
<text top="1004" left="130" width="289" height="16" font="4">) compared with those of normal weight were</text>
<text top="1022" left="58" width="360" height="16" font="4">32% and 81% higher, respectively, after adjustment for age,</text>
<text top="1040" left="58" width="215" height="16" font="4">sex, physical activity, and smoking <a href="e44.full.html#101">(</a></text>
<text top="1040" left="273" width="23" height="16" font="16"><a href="e44.full.html#101">635</a></text>
<text top="1040" left="296" width="123" height="16" font="4"><a href="e44.full.html#101">)</a>. Cardiovascular risk</text>
<text top="1058" left="58" width="360" height="16" font="4">is increased particularly in patients with central obesity, which</text>
<text top="1076" left="58" width="236" height="16" font="4">can be identified by a waist circumference</text>
<text top="1073" left="298" width="121" height="20" font="4">⬎102 cm (40 inches)</text>
<text top="1094" left="58" width="60" height="16" font="4">in men or</text>
<text top="1091" left="124" width="196" height="20" font="4">⬎88 cm (35 inches) in women <a href="e44.full.html#101">(</a></text>
<text top="1094" left="320" width="47" height="16" font="16"><a href="e44.full.html#101">643,644</a></text>
<text top="1094" left="366" width="52" height="16" font="4"><a href="e44.full.html#101">), </a>and in</text>
<text top="104" left="445" width="283" height="16" font="4">those with extreme obesity, defined as a BMI</text>
<text top="101" left="736" width="65" height="20" font="4">⬎40 kg/m</text>
<text top="102" left="800" width="6" height="10" font="11">2</text>
<text top="122" left="446" width="5" height="16" font="4"><a href="e44.full.html#101">(</a></text>
<text top="122" left="450" width="22" height="16" font="16"><a href="e44.full.html#101">645</a></text>
<text top="122" left="472" width="8" height="16" font="4"><a href="e44.full.html#101">).</a></text>
<text top="140" left="461" width="345" height="16" font="4">Obesity likely contributes to increased cardiovascular risk</text>
<text top="158" left="446" width="360" height="16" font="4">through multiple pathophysiological pathways. Obesity is</text>
<text top="176" left="446" width="360" height="16" font="4">associated with traditional cardiovascular risk factors, such</text>
<text top="194" left="446" width="360" height="16" font="4">as diabetes mellitus, dyslipidemia, and hypertension, but in</text>
<text top="212" left="446" width="360" height="16" font="4">and of itself obesity increases sympathetic tone, induces a</text>
<text top="230" left="446" width="360" height="16" font="4">hypercoagulable state, and is associated with markers of</text>
<text top="248" left="446" width="92" height="16" font="4">inflammation <a href="e44.full.html#101">(</a></text>
<text top="248" left="537" width="23" height="16" font="16"><a href="e44.full.html#101">646</a></text>
<text top="248" left="560" width="246" height="16" font="4"><a href="e44.full.html#101">). </a>Curiously, despite the strong associa-</text>
<text top="266" left="446" width="360" height="16" font="4">tion of BMI with cardiovascular risk in population studies,</text>
<text top="284" left="446" width="360" height="16" font="4">a similar relationship between BMI and death is not</text>
<text top="302" left="446" width="360" height="16" font="4">observed consistently in cohorts with established IHD</text>
<text top="320" left="446" width="5" height="16" font="4"><a href="e44.full.html#101">(</a></text>
<text top="320" left="450" width="23" height="16" font="16"><a href="e44.full.html#101">647</a></text>
<text top="320" left="473" width="333" height="16" font="4"><a href="e44.full.html#101">). </a>This could be due to weaknesses of BMI as a measure</text>
<text top="338" left="446" width="360" height="16" font="4">of adiposity; confounding factors such as age, smoking, or</text>
<text top="356" left="446" width="360" height="16" font="4">medications; or weight loss in association with advanced</text>
<text top="374" left="446" width="91" height="16" font="4">chronic illness.</text>
<text top="392" left="461" width="345" height="16" font="4">No clinical trials have examined specifically the effects of</text>
<text top="410" left="446" width="360" height="16" font="4">weight loss on cardiovascular event rates in patients with</text>
<text top="428" left="446" width="360" height="16" font="4">SIHD. In the SOS (Swedish Obese Subjects) study, how-</text>
<text top="446" left="446" width="360" height="16" font="4">ever, weight losses of 20% to 32% at 1 year achieved with</text>
<text top="464" left="446" width="360" height="16" font="4">bariatric surgery were associated with a 24% reduction in</text>
<text top="482" left="446" width="90" height="16" font="4">mortality rate <a href="e44.full.html#101">(</a></text>
<text top="482" left="536" width="23" height="16" font="16"><a href="e44.full.html#101">648</a></text>
<text top="482" left="558" width="247" height="16" font="4"><a href="e44.full.html#101">). </a>The association of adiposity with other</text>
<text top="500" left="446" width="360" height="16" font="4">cardiovascular risk factors suggests that weight reduction is</text>
<text top="518" left="446" width="360" height="16" font="4">indicated in all overweight or obese patients. Reducing</text>
<text top="536" left="446" width="360" height="16" font="4">caloric intake is a cornerstone of weight management</text>
<text top="554" left="446" width="360" height="16" font="4">therapy. Referral to an experienced dietitian or to a reputa-</text>
<text top="572" left="446" width="360" height="16" font="4">ble weight loss program for nutritional counseling and</text>
<text top="590" left="446" width="360" height="16" font="4">behavioral modification therapy can be helpful. The effects</text>
<text top="608" left="446" width="360" height="16" font="4">of caloric restriction are potentiated by regular aerobic</text>
<text top="626" left="446" width="360" height="16" font="4">physical activity. Therapy with medications or bariatric</text>
<text top="644" left="446" width="360" height="16" font="4">surgery may be considered in selected patients who are</text>
<text top="662" left="446" width="360" height="16" font="4">unable to achieve adequate weight loss by conventional</text>
<text top="680" left="446" width="142" height="16" font="4">lifestyle modifications <a href="e44.full.html#101">(</a></text>
<text top="680" left="588" width="23" height="16" font="16"><a href="e44.full.html#101">649</a></text>
<text top="680" left="610" width="9" height="16" font="4"><a href="e44.full.html#101">).</a></text>
<text top="711" left="446" width="201" height="9" font="6">4.4.1.6. SMOKING CESSATION COUNSELING</text>
<text top="739" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="751" left="446" width="360" height="10" font="13">1. Smoking cessation and avoidance of exposure to environmental</text>
<text top="768" left="461" width="344" height="10" font="13">tobacco smoke at work and home should be encouraged for all</text>
<text top="785" left="461" width="344" height="10" font="13">patients with SIHD. Follow-up, referral to special programs, and</text>
<text top="802" left="461" width="344" height="10" font="13">pharmacotherapy are recommended, as is a stepwise strategy for</text>
<text top="819" left="461" width="344" height="10" font="13">smoking cessation (Ask, Advise, Assess, Assist, Arrange, Avoid)</text>
<text top="836" left="461" width="173" height="10" font="13"><a href="e44.full.html#101">(650–652). </a><i>(Level of Evidence: B)</i></text>
<text top="860" left="446" width="360" height="16" font="4">Observational studies over the past 4 decades have furnished</text>
<text top="878" left="446" width="360" height="16" font="4">incontrovertible evidence that smoking increases the risk of</text>
<text top="896" left="446" width="190" height="16" font="4">cardiovascular disease events <a href="e44.full.html#101">(</a></text>
<text top="896" left="636" width="49" height="16" font="16"><a href="e44.full.html#101">653,654</a></text>
<text top="896" left="685" width="121" height="16" font="4"><a href="e44.full.html#101">). </a>A dose–response</text>
<text top="914" left="446" width="360" height="16" font="4">relationship exists between cigarettes smoked and cardio-</text>
<text top="932" left="446" width="360" height="16" font="4">vascular risk, with an RR approaching 5.5 for cardiovascular</text>
<text top="950" left="446" width="360" height="16" font="4">events among heavy smokers compared with nonsmokers</text>
<text top="968" left="446" width="5" height="16" font="4"><a href="e44.full.html#101">(</a></text>
<text top="968" left="450" width="23" height="16" font="16"><a href="e44.full.html#101">654</a></text>
<text top="968" left="473" width="333" height="16" font="4"><a href="e44.full.html#101">). </a>Potential mechanisms by which smoking predisposes</text>
<text top="986" left="446" width="360" height="16" font="4">to cardiovascular events include adverse effects on fibrinogen</text>
<text top="1004" left="446" width="42" height="16" font="4">levels <a href="e44.full.html#101">(</a></text>
<text top="1004" left="488" width="23" height="16" font="16"><a href="e44.full.html#101">655</a></text>
<text top="1004" left="510" width="127" height="16" font="4"><a href="e44.full.html#101">), </a>platelet adhesion <a href="e44.full.html#101">(</a></text>
<text top="1004" left="637" width="23" height="16" font="16"><a href="e44.full.html#101">656</a></text>
<text top="1004" left="660" width="146" height="16" font="4"><a href="e44.full.html#101">), </a>and endothelial func-</text>
<text top="1022" left="446" width="38" height="16" font="4">tion <a href="e44.full.html#101">(</a></text>
<text top="1022" left="484" width="23" height="16" font="16"><a href="e44.full.html#101">657</a></text>
<text top="1022" left="506" width="237" height="16" font="4"><a href="e44.full.html#101">); </a>reduced HDL cholesterol levels <a href="e44.full.html#101">(</a></text>
<text top="1022" left="743" width="23" height="16" font="16"><a href="e44.full.html#101">658</a></text>
<text top="1022" left="766" width="40" height="16" font="4"><a href="e44.full.html#101">); </a>and</text>
<text top="1040" left="446" width="204" height="16" font="4">coronary artery vasoconstriction <a href="e44.full.html#101">(</a></text>
<text top="1040" left="649" width="23" height="16" font="16"><a href="e44.full.html#101">659</a></text>
<text top="1040" left="672" width="9" height="16" font="4"><a href="e44.full.html#101">).</a></text>
<text top="1058" left="461" width="345" height="16" font="4">Although RCTs have not been performed in patients</text>
<text top="1076" left="446" width="360" height="16" font="4">with SIHD, results of observational studies strongly suggest</text>
<text top="1094" left="446" width="360" height="16" font="4">that smoking cessation is an effective strategy for secondary</text>
<text top="52" left="59" width="18" height="10" font="12">e92</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">prevention of coronary events. A meta-analysis of 20 pro-</text>
<text top="122" left="59" width="360" height="16" font="4">spective cohort studies found a 30% reduction in RR of</text>
<text top="140" left="59" width="360" height="16" font="4">mortality for those who quit compared with those who</text>
<text top="158" left="59" width="360" height="16" font="4">continued smoking, and a similar reduction was noted in</text>
<text top="176" left="59" width="90" height="16" font="4">nonfatal MIs <a href="e44.full.html#101">(</a></text>
<text top="176" left="148" width="22" height="16" font="16"><a href="e44.full.html#101">650</a></text>
<text top="176" left="170" width="249" height="16" font="4"><a href="e44.full.html#101">). </a>Some studies suggest that most of the</text>
<text top="194" left="59" width="360" height="16" font="4">reduction in risk occurs within 2 or 3 years of quitting</text>
<text top="212" left="59" width="5" height="16" font="4"><a href="e44.full.html#101">(</a></text>
<text top="212" left="63" width="47" height="16" font="16"><a href="e44.full.html#101">660,661</a></text>
<text top="212" left="110" width="8" height="16" font="4"><a href="e44.full.html#101">).</a></text>
<text top="230" left="74" width="345" height="16" font="4">The most effective smoking-cessation therapies include</text>
<text top="248" left="59" width="360" height="16" font="4">both nonpharmacological and medical interventions. Phy-</text>
<text top="266" left="59" width="329" height="16" font="4">sician advice has a significant effect on quit rates <a href="e44.full.html#101">(</a></text>
<text top="266" left="387" width="23" height="16" font="16"><a href="e44.full.html#101">662</a></text>
<text top="266" left="410" width="9" height="16" font="4"><a href="e44.full.html#101">).</a></text>
<text top="284" left="59" width="360" height="16" font="4">Self-help programs, telephone counseling, behavioral ther-</text>
<text top="302" left="59" width="360" height="16" font="4">apy, and perhaps exercise programs also have modest effi-</text>
<text top="320" left="59" width="229" height="16" font="4">cacy in increasing cessation rates <a href="e44.full.html#101">(</a></text>
<text top="320" left="288" width="54" height="16" font="16"><a href="e44.full.html#101">663– 667</a></text>
<text top="320" left="342" width="76" height="16" font="4"><a href="e44.full.html#101">). </a>Nicotine-</text>
<text top="338" left="59" width="360" height="16" font="4">replacement therapy (gum, patch, tablet, lozenge, or nasal</text>
<text top="356" left="59" width="360" height="16" font="4">spray) approximately doubles the chances of success of a quit</text>
<text top="374" left="59" width="57" height="16" font="4">attempt <a href="e44.full.html#101">(</a></text>
<text top="374" left="115" width="23" height="16" font="16"><a href="e44.full.html#101">668</a></text>
<text top="374" left="138" width="281" height="16" font="4"><a href="e44.full.html#101">). </a>Similar efficacy has been demonstrated with</text>
<text top="392" left="59" width="186" height="16" font="4">bupropion sustained-release <a href="e44.full.html#101">(</a></text>
<text top="392" left="245" width="23" height="16" font="16"><a href="e44.full.html#101">669</a></text>
<text top="392" left="267" width="151" height="16" font="4"><a href="e44.full.html#101">). </a>Varenicline, a partial</text>
<text top="410" left="59" width="86" height="16" font="4">agonist of the</text>
<text top="407" left="150" width="268" height="20" font="4">␣4␤2 nicotinic receptor, is the most recent</text>
<text top="428" left="58" width="360" height="16" font="4">FDA-approved agent for smoking cessation and compares</text>
<text top="446" left="58" width="360" height="16" font="4">favorably with placebo and with bupropion in clinical trials</text>
<text top="464" left="58" width="5" height="16" font="4"><a href="e44.full.html#101">(</a></text>
<text top="464" left="63" width="49" height="16" font="16"><a href="e44.full.html#101">670,671</a></text>
<text top="464" left="112" width="306" height="16" font="4"><a href="e44.full.html#101">). </a>There have, however, been concerns about pos-</text>
<text top="482" left="58" width="360" height="16" font="4">sible worsening of preexisting depression and the risk of</text>
<text top="500" left="58" width="360" height="16" font="4">suicide due to varenicline, and the FDA has issued an alert</text>
<text top="518" left="58" width="360" height="16" font="4">warning that serious neuropsychiatric symptoms can occur</text>
<text top="536" left="58" width="177" height="16" font="4">in patients taking this drug <a href="e44.full.html#101">(</a></text>
<text top="536" left="236" width="49" height="16" font="16"><a href="e44.full.html#101">672,673</a></text>
<text top="536" left="285" width="9" height="16" font="4"><a href="e44.full.html#101">).</a></text>
<text top="554" left="73" width="345" height="16" font="4">Physicians should approach smoking cessation by using</text>
<text top="572" left="58" width="130" height="16" font="4">the 6 A’s framework:</text>
<text top="596" left="73" width="316" height="20" font="4">• <i>Ask </i>each patient about tobacco use at every visit;</text>
<text top="614" left="73" width="186" height="20" font="4">• <i>Advise </i>each smoker to quit;</text>
<text top="632" left="73" width="304" height="20" font="4">• <i>Assess </i>each smoker’s willingness to make a quit</text>
<text top="653" left="90" width="51" height="16" font="4">attempt;</text>
<text top="668" left="73" width="345" height="20" font="4">• <i>Assist </i>each smoker in making a quit attempt by offering</text>
<text top="689" left="90" width="237" height="16" font="4">medication and referral for counseling;</text>
<text top="704" left="73" width="180" height="20" font="4">• <i>Arrange </i>for follow-up; and</text>
<text top="722" left="73" width="317" height="20" font="4">• <i>Avoid </i>exposure to environmental tobacco smoke.</text>
<text top="756" left="59" width="247" height="9" font="6">4.4.1.7. MANAGEMENT OF PSYCHOLOGICAL FACTORS</text>
<text top="784" left="59" width="46" height="8" font="24">CLASS IIa</text>
<text top="797" left="59" width="360" height="10" font="13">1. It is reasonable to consider screening SIHD patients for depression</text>
<text top="814" left="74" width="344" height="10" font="13">and to refer or treat when indicated <a href="e44.full.html#91">(237,239,323,457,463,674,</a></text>
<text top="831" left="74" width="142" height="10" font="13"><a href="e44.full.html#91">675). </a><i>(Level of Evidence: B)</i></text>
<text top="861" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="874" left="59" width="360" height="10" font="13">1. Treatment of depression has not been shown to improve cardiovas-</text>
<text top="891" left="74" width="344" height="10" font="13">cular disease outcomes but might be reasonable for its other</text>
<text top="908" left="74" width="278" height="10" font="13">clinical benefits <a href="e44.full.html#91">(237,238,676). </a><i>(Level of Evidence: C)</i></text>
<text top="932" left="59" width="360" height="16" font="4">Depression is a major cause of disability in developed</text>
<text top="950" left="59" width="258" height="16" font="4">countries and often coexists with SIHD <a href="e44.full.html#102">(</a></text>
<text top="950" left="317" width="49" height="16" font="16"><a href="e44.full.html#102">677,678</a></text>
<text top="950" left="366" width="53" height="16" font="4"><a href="e44.full.html#102">). </a>About</text>
<text top="968" left="59" width="360" height="16" font="4">20% of patients with angiographic evidence of CAD and a</text>
<text top="986" left="59" width="360" height="16" font="4">similar percentage of those recovering from AMI have</text>
<text top="1004" left="59" width="136" height="16" font="4">comorbid depression <a href="e44.full.html#102">(</a></text>
<text top="1004" left="195" width="56" height="16" font="16"><a href="e44.full.html#102">679 – 682</a></text>
<text top="1004" left="251" width="9" height="16" font="4"><a href="e44.full.html#102">).</a></text>
<text top="1022" left="74" width="345" height="16" font="4">Multiple observational studies have demonstrated an</text>
<text top="1040" left="59" width="360" height="16" font="4">association between depression and cardiovascular events. In</text>
<text top="1058" left="59" width="150" height="16" font="4">several studies involving</text>
<text top="1055" left="215" width="203" height="20" font="4">ⱖ1,000 outpatients with SIHD,</text>
<text top="1076" left="59" width="360" height="16" font="4">those with symptoms of depression had more physical</text>
<text top="1094" left="59" width="360" height="16" font="4">limitation, more frequent angina, and lower perceived qual-</text>
<text top="104" left="446" width="360" height="16" font="4">ity of life than patients without depressive symptoms</text>
<text top="122" left="446" width="5" height="16" font="4"><a href="e44.full.html#91">(</a></text>
<text top="122" left="450" width="49" height="16" font="16"><a href="e44.full.html#91">239,683</a></text>
<text top="122" left="499" width="306" height="16" font="4"><a href="e44.full.html#91">). </a>One meta-analysis examined 21 prospective</text>
<text top="140" left="446" width="360" height="16" font="4">studies in healthy populations and 34 studies in patients</text>
<text top="158" left="446" width="129" height="16" font="4">with existing IHD <a href="e44.full.html#102">(</a></text>
<text top="158" left="574" width="23" height="16" font="16"><a href="e44.full.html#102">684</a></text>
<text top="158" left="597" width="209" height="16" font="4"><a href="e44.full.html#102">). </a>The studies in healthy cohorts</text>
<text top="176" left="446" width="360" height="16" font="4">demonstrated an 81% greater incidence of ischemic events</text>
<text top="194" left="446" width="360" height="16" font="4">(MI or fatal IHD) among patients with symptoms of</text>
<text top="212" left="446" width="360" height="16" font="4">depression over an average follow-up period of 10.8 years. A</text>
<text top="230" left="446" width="360" height="16" font="4">similarly increased risk was observed in patients with estab-</text>
<text top="248" left="446" width="360" height="16" font="4">lished IHD who had symptoms of depression. Relatively</text>
<text top="266" left="446" width="360" height="16" font="4">few studies, however, have reported estimates of risk that</text>
<text top="284" left="446" width="360" height="16" font="4">have been adjusted for traditional risk factors or severity of</text>
<text top="302" left="446" width="360" height="16" font="4">CAD. Although in aggregate the observational cohort</text>
<text top="320" left="446" width="360" height="16" font="4">studies suggest that depression confers a significant risk for</text>
<text top="338" left="446" width="360" height="16" font="4">adverse cardiovascular outcomes, confounding by other risk</text>
<text top="356" left="446" width="360" height="16" font="4">factors or by disease severity is difficult to exclude. More-</text>
<text top="374" left="446" width="360" height="16" font="4">over, most studies in patients with CAD have enrolled</text>
<text top="392" left="446" width="360" height="16" font="4">patients after recent MI or CABG, and the relevance to</text>
<text top="410" left="446" width="203" height="16" font="4">patients with SIHD is uncertain.</text>
<text top="428" left="461" width="345" height="16" font="4">Putative mechanisms for a contribution of depression to</text>
<text top="446" left="446" width="360" height="16" font="4">atherogenesis and adverse cardiovascular events include</text>
<text top="464" left="446" width="360" height="16" font="4">both behavioral and biological effects. Depression is associ-</text>
<text top="482" left="446" width="360" height="16" font="4">ated with poor compliance with risk factor–modification</text>
<text top="500" left="446" width="360" height="16" font="4">strategies and with poor adherence to prescribed medication</text>
<text top="518" left="446" width="65" height="16" font="4">regimens <a href="e44.full.html#97">(</a></text>
<text top="518" left="511" width="49" height="16" font="16"><a href="e44.full.html#97">460,462</a></text>
<text top="518" left="560" width="246" height="16" font="4"><a href="e44.full.html#97">). </a>Patients diagnosed with this disorder</text>
<text top="536" left="446" width="360" height="16" font="4">are 2- to 4-fold less likely to adhere to medications and</text>
<text top="554" left="446" width="360" height="16" font="4">lifestyle recommendations, engage in self-management</text>
<text top="572" left="446" width="360" height="16" font="4">practices, or comply with recommendations for testing and</text>
<text top="590" left="446" width="70" height="16" font="4">follow-up <a href="e44.full.html#97">(</a></text>
<text top="590" left="516" width="107" height="16" font="16"><a href="e44.full.html#97">462,675,685– 691</a></text>
<text top="590" left="623" width="183" height="16" font="4"><a href="e44.full.html#97">). </a>Alternatively, some studies</text>
<text top="608" left="446" width="360" height="16" font="4">suggest the possibility of more direct pathophysiological</text>
<text top="626" left="446" width="223" height="16" font="4">links, including platelet activation <a href="e44.full.html#102">(</a></text>
<text top="626" left="669" width="54" height="16" font="16"><a href="e44.full.html#102">692– 695</a></text>
<text top="626" left="723" width="82" height="16" font="4"><a href="e44.full.html#102">), </a>endothelial</text>
<text top="644" left="446" width="80" height="16" font="4">dysfunction <a href="e44.full.html#102">(</a></text>
<text top="644" left="525" width="23" height="16" font="16"><a href="e44.full.html#102">696</a></text>
<text top="644" left="548" width="195" height="16" font="4"><a href="e44.full.html#102">), </a>reduced heart rate variability <a href="e44.full.html#102">(</a></text>
<text top="644" left="743" width="54" height="16" font="16"><a href="e44.full.html#102">697– 699</a></text>
<text top="644" left="797" width="9" height="16" font="4"><a href="e44.full.html#102">),</a></text>
<text top="662" left="446" width="119" height="16" font="4">and inflammation <a href="e44.full.html#102">(</a></text>
<text top="662" left="564" width="23" height="16" font="16"><a href="e44.full.html#102">700</a></text>
<text top="662" left="587" width="9" height="16" font="4"><a href="e44.full.html#102">).</a></text>
<text top="680" left="461" width="345" height="16" font="4">Despite the association of depression with adverse car-</text>
<text top="698" left="446" width="360" height="16" font="4">diovascular outcomes, no clinical trials have established a</text>
<text top="716" left="446" width="360" height="16" font="4">reduction in cardiovascular risk with either counseling or</text>
<text top="734" left="446" width="360" height="16" font="4">antidepressant therapy. In the ENRICHD (Enhancing</text>
<text top="752" left="446" width="360" height="16" font="4">Recovery in Coronary Heart Disease) trial, 2,481 patients</text>
<text top="770" left="446" width="360" height="16" font="4">with depression or low social support after MI were ran-</text>
<text top="788" left="446" width="360" height="16" font="4">domized to usual care or cognitive behavioral therapy,</text>
<text top="806" left="446" width="360" height="16" font="4">supplemented by a selective serotonin reuptake inhibitor</text>
<text top="824" left="446" width="360" height="16" font="4">when indicated. Active therapy was associated with im-</text>
<text top="842" left="446" width="360" height="16" font="4">provements in depression and low social support but with</text>
<text top="860" left="446" width="360" height="16" font="4">no improvement in event-free survival after a mean 24</text>
<text top="878" left="446" width="136" height="16" font="4">months of follow-up <a href="e44.full.html#91">(</a></text>
<text top="878" left="581" width="23" height="16" font="16"><a href="e44.full.html#91">237</a></text>
<text top="878" left="604" width="202" height="16" font="4"><a href="e44.full.html#91">). </a>A secondary analysis, however,</text>
<text top="896" left="446" width="360" height="16" font="4">demonstrated a significantly lower risk of death or MI in</text>
<text top="914" left="446" width="360" height="16" font="4">patients treated with a selective serotonin reuptake inhibitor</text>
<text top="932" left="446" width="5" height="16" font="4"><a href="e44.full.html#102">(</a></text>
<text top="932" left="450" width="23" height="16" font="16"><a href="e44.full.html#102">676</a></text>
<text top="932" left="473" width="333" height="16" font="4"><a href="e44.full.html#102">). </a>The safety and efficacy of sertraline in patients with a</text>
<text top="950" left="446" width="360" height="16" font="4">recent ACS were demonstrated in SADHART (Sertraline</text>
<text top="968" left="446" width="360" height="16" font="4">Antidepressant Heart Attack Randomized Trial). Patients</text>
<text top="986" left="446" width="360" height="16" font="4">were randomized to sertraline or placebo for 24 weeks.</text>
<text top="1004" left="446" width="360" height="16" font="4">Sertraline resulted in improved depressive symptoms and no</text>
<text top="1022" left="446" width="360" height="16" font="4">change in LVEF, ventricular ectopy, or QT interval. The</text>
<text top="1040" left="446" width="360" height="16" font="4">study was not powered to detect a difference in cardiovas-</text>
<text top="1058" left="446" width="110" height="16" font="4">cular outcomes <a href="e44.full.html#91">(</a></text>
<text top="1058" left="555" width="23" height="16" font="16"><a href="e44.full.html#91">238</a></text>
<text top="1058" left="578" width="228" height="16" font="4"><a href="e44.full.html#91">). </a>Similarly, citalopram, a selective</text>
<text top="1076" left="446" width="360" height="16" font="4">serotonin reuptake inhibitor, and mirtazapine, a dual-acting</text>
<text top="1094" left="446" width="360" height="16" font="4">antidepressant, improved depression in postinfarction pa-</text>
<text top="52" left="787" width="18" height="10" font="12">e93</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1161" width="864">
<text top="246" left="59" width="43" height="16" font="4">tients <a href="e44.full.html#97">(</a></text>
<text top="246" left="102" width="49" height="16" font="16"><a href="e44.full.html#97">463,674</a></text>
<text top="246" left="151" width="268" height="16" font="4"><a href="e44.full.html#97">). </a>Thus, treatment of depression in patients</text>
<text top="264" left="59" width="360" height="16" font="4">with SIHD by cognitive therapy or medication is safe and</text>
<text top="282" left="59" width="360" height="16" font="4">contributes to relief of depressive symptoms but does not</text>
<text top="300" left="59" width="360" height="16" font="4">have proven efficacy in reducing cardiovascular morbidity</text>
<text top="318" left="59" width="119" height="16" font="4">and mortality rates.</text>
<text top="336" left="74" width="345" height="16" font="4">Either the 2-item Patient Health Questionnaire</text>
<text top="354" left="59" width="360" height="16" font="4">(PHQ)-2 or the 9-item PHQ-9 can be used as a screening</text>
<text top="372" left="59" width="125" height="16" font="4">tool for depression <a href="e44.full.html#102">(</a></text>
<text top="372" left="184" width="49" height="16" font="16"><a href="e44.full.html#102">701,702</a></text>
<text top="372" left="232" width="15" height="16" font="4"><a href="e44.full.html#102">) </a><a href="e44.full.html#51">(</a></text>
<text top="372" left="248" width="60" height="16" font="16"><a href="e44.full.html#51">Tables 16</a></text>
<text top="372" left="313" width="22" height="16" font="4">and</text>
<text top="372" left="341" width="15" height="16" font="16"><a href="e44.full.html#51">17</a></text>
<text top="372" left="356" width="63" height="16" font="4"><a href="e44.full.html#51">). </a>Patients</text>
<text top="390" left="58" width="360" height="16" font="4">who respond affirmatively to either item on the PHQ-2 or</text>
<text top="408" left="58" width="283" height="16" font="4">to item 9 on the PHQ-9 or who have a score</text>
<text top="405" left="346" width="72" height="20" font="4">ⱖ10 on the</text>
<text top="426" left="58" width="360" height="16" font="4">PHQ-9 should be referred for a more comprehensive</text>
<text top="444" left="58" width="119" height="16" font="4">clinical evaluation <a href="e44.full.html#102">(</a></text>
<text top="444" left="177" width="49" height="16" font="16"><a href="e44.full.html#102">701,702</a></text>
<text top="444" left="226" width="15" height="16" font="4"><a href="e44.full.html#102">) </a><a href="e44.full.html#51">(</a></text>
<text top="444" left="241" width="55" height="16" font="16"><a href="e44.full.html#51">Table 17</a></text>
<text top="444" left="296" width="9" height="16" font="4"><a href="e44.full.html#51">).</a></text>
<text top="462" left="73" width="345" height="16" font="4">Patients with SIHD report high levels of psychosocial</text>
<text top="480" left="58" width="360" height="16" font="4">stress, and indices of stress are associated with an increased</text>
<text top="498" left="58" width="188" height="16" font="4">risk of cardiovascular events <a href="e44.full.html#91">(</a></text>
<text top="498" left="246" width="23" height="16" font="16"><a href="e44.full.html#91">245</a></text>
<text top="498" left="269" width="150" height="16" font="4"><a href="e44.full.html#91">). </a>Counseling to reduce</text>
<text top="516" left="58" width="360" height="16" font="4">psychological stress is recommended as a core component of</text>
<text top="534" left="58" width="360" height="16" font="4">comprehensive cardiac rehabilitation programs. Stress-</text>
<text top="552" left="58" width="360" height="16" font="4">management interventions use relaxation techniques and</text>
<text top="570" left="58" width="360" height="16" font="4">provide instruction in specific skills to reduce cognitive,</text>
<text top="588" left="58" width="360" height="16" font="4">behavioral, and psychological stress levels. Although stress-</text>
<text top="607" left="58" width="360" height="16" font="4">management programs are not of proven value in reducing</text>
<text top="625" left="58" width="360" height="16" font="4">the risk of cardiovascular events, they are effective in</text>
<text top="643" left="58" width="326" height="16" font="4">relieving anxiety and reducing depressive symptoms <a href="e44.full.html#97">(</a></text>
<text top="643" left="384" width="23" height="16" font="16"><a href="e44.full.html#97">461</a></text>
<text top="643" left="407" width="9" height="16" font="4"><a href="e44.full.html#97">).</a></text>
<text top="674" left="59" width="154" height="9" font="6">4.4.1.8. ALCOHOL CONSUMPTION</text>
<text top="702" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="715" left="59" width="360" height="10" font="13">1. In patients with SIHD who use alcohol, it might be reasonable for</text>
<text top="732" left="74" width="344" height="10" font="13">nonpregnant women to have 1 drink (4 ounces of wine, 12 ounces</text>
<text top="748" left="74" width="344" height="10" font="13">of beer, or 1 ounce of spirits) a day and for men to have 1 or 2 drinks</text>
<text top="765" left="74" width="344" height="10" font="13">a day, unless alcohol is contraindicated (such as in patients with a</text>
<text top="782" left="74" width="344" height="10" font="13">history of alcohol abuse or dependence or with liver disease)</text>
<text top="799" left="74" width="172" height="10" font="13"><a href="e44.full.html#102">(703–705). </a><i>(Level of Evidence: C)</i></text>
<text top="824" left="59" width="360" height="16" font="4">Observational studies suggest that light to moderate alcohol</text>
<text top="842" left="59" width="360" height="16" font="4">consumption is associated with a lower risk of IHD and</text>
<text top="860" left="59" width="360" height="16" font="4">all-cause mortality. Most studies report a J-shaped relation-</text>
<text top="878" left="59" width="360" height="16" font="4">ship between alcohol consumed and cardiovascular event</text>
<text top="896" left="59" width="360" height="16" font="4">rate or mortality; light to moderate drinkers have less risk</text>
<text top="914" left="59" width="360" height="16" font="4">than abstainers, but heavy drinkers are at greatest risk. A</text>
<text top="932" left="59" width="360" height="16" font="4">meta-analysis of 34 prospective studies found mortality rate</text>
<text top="950" left="59" width="360" height="16" font="4">reductions of 17% in men and 18% in women with low</text>
<text top="968" left="59" width="360" height="16" font="4">levels of alcohol intake, with the lowest mortality rate at 6 g</text>
<text top="986" left="59" width="329" height="16" font="4">of alcohol (approximately one half drink) per day <a href="e44.full.html#102">(</a></text>
<text top="986" left="387" width="23" height="16" font="16"><a href="e44.full.html#102">703</a></text>
<text top="986" left="410" width="9" height="16" font="4"><a href="e44.full.html#102">).</a></text>
<text top="1004" left="59" width="360" height="16" font="4">Most of these studies were performed in healthy cohorts,</text>
<text top="1022" left="59" width="333" height="16" font="4">and data in patients with IHD are limited. One study <a href="e44.full.html#102">(</a></text>
<text top="1022" left="391" width="23" height="16" font="16"><a href="e44.full.html#102">704</a></text>
<text top="1022" left="414" width="5" height="16" font="4"><a href="e44.full.html#102">)</a></text>
<text top="1040" left="59" width="360" height="16" font="4">examined survival rate among early survivors of MI and</text>
<text top="1058" left="59" width="360" height="16" font="4">found that moderate alcohol consumption in the year before</text>
<text top="1076" left="59" width="360" height="16" font="4">presentation was predictive of lower all-cause mortality.</text>
<text top="1094" left="59" width="360" height="16" font="4">Similarly, among participants in the Physician’s Health</text>
<text top="104" left="446" width="360" height="16" font="4">Study who experienced a self-reported MI, moderate drink-</text>
<text top="122" left="446" width="314" height="16" font="4">ers had a 30% lower risk of death than abstainers <a href="e44.full.html#102">(</a></text>
<text top="122" left="759" width="23" height="16" font="16"><a href="e44.full.html#102">705</a></text>
<text top="122" left="782" width="9" height="16" font="4"><a href="e44.full.html#102">).</a></text>
<text top="140" left="461" width="345" height="16" font="4">Light to moderate alcohol consumption might confer</text>
<text top="158" left="446" width="360" height="16" font="4">protection against cardiovascular disease through beneficial</text>
<text top="176" left="446" width="360" height="16" font="4">effects on the lipid profile and on insulin sensitivity. Alcohol</text>
<text top="194" left="446" width="360" height="16" font="4">intake modestly increases HDL cholesterol in a dose-</text>
<text top="212" left="446" width="121" height="16" font="4">dependent fashion <a href="e44.full.html#102">(</a></text>
<text top="212" left="566" width="49" height="16" font="16"><a href="e44.full.html#102">706,707</a></text>
<text top="212" left="615" width="191" height="16" font="4"><a href="e44.full.html#102">). </a>Consumption of 2 drinks per</text>
<text top="230" left="446" width="360" height="16" font="4">day lowers fasting and postprandial insulin levels and</text>
<text top="248" left="446" width="290" height="16" font="4">increases insulin sensitivity in healthy subjects <a href="e44.full.html#102">(</a></text>
<text top="248" left="735" width="23" height="16" font="16"><a href="e44.full.html#102">708</a></text>
<text top="248" left="758" width="48" height="16" font="4"><a href="e44.full.html#102">). </a>Light</text>
<text top="266" left="446" width="360" height="16" font="4">to moderate alcohol consumption might also have antiin-</text>
<text top="284" left="446" width="360" height="16" font="4">flammatory effects, as reflected by a reduction in C-reactive</text>
<text top="302" left="446" width="52" height="16" font="4">protein <a href="e44.full.html#102">(</a></text>
<text top="302" left="498" width="49" height="16" font="16"><a href="e44.full.html#102">709,710</a></text>
<text top="302" left="547" width="259" height="16" font="4"><a href="e44.full.html#102">). </a>Alternatively, the apparent cardioprotec-</text>
<text top="320" left="446" width="360" height="16" font="4">tive effects of modest alcohol consumption reported in</text>
<text top="338" left="446" width="360" height="16" font="4">observational studies could represent uncontrolled con-</text>
<text top="356" left="446" width="360" height="16" font="4">founding, as many coronary risk factors are more prevalent</text>
<text top="374" left="446" width="315" height="16" font="4">in nondrinkers than in light to moderate drinkers <a href="e44.full.html#102">(</a></text>
<text top="374" left="760" width="23" height="16" font="16"><a href="e44.full.html#102">711</a></text>
<text top="374" left="783" width="9" height="16" font="4"><a href="e44.full.html#102">).</a></text>
<text top="392" left="461" width="345" height="16" font="4">There are no RCTs in either healthy individuals or in</text>
<text top="410" left="446" width="360" height="16" font="4">patients with SIHD demonstrating improved clinical out-</text>
<text top="428" left="446" width="360" height="16" font="4">comes with alcohol consumption. Because of the many</text>
<text top="446" left="446" width="360" height="16" font="4">health and societal consequences of alcohol abuse, patients</text>
<text top="464" left="446" width="360" height="16" font="4">who do not already drink alcohol should not be encouraged</text>
<text top="482" left="446" width="360" height="16" font="4">to start. Patients who do consume alcoholic beverages</text>
<text top="500" left="446" width="360" height="16" font="4">should be counseled to do so in moderation: no more than</text>
<text top="518" left="446" width="360" height="16" font="4">1 drink (4 ounces of wine or 1 ounce of spirits) per day for</text>
<text top="536" left="446" width="323" height="16" font="4">women and no more than 2 drinks per day for men.</text>
<text top="567" left="446" width="225" height="9" font="6">4.4.1.9. AVOIDING EXPOSURE TO AIR POLLUTION</text>
<text top="592" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="604" left="446" width="360" height="10" font="13">1. It is reasonable for patients with SIHD to avoid exposure to in-</text>
<text top="621" left="461" width="344" height="10" font="13">creased air pollution to reduce the risk of cardiovascular events</text>
<text top="638" left="461" width="172" height="10" font="13"><a href="e44.full.html#102">(712–715). </a><i>(Level of Evidence: C)</i></text>
<text top="663" left="446" width="360" height="16" font="4">Although they are seldom an explicit focus in provision of</text>
<text top="681" left="446" width="360" height="16" font="4">care to individual patients, environmental influences such as</text>
<text top="699" left="446" width="360" height="16" font="4">exposure to air pollution can increase the risk of cardiovas-</text>
<text top="717" left="446" width="360" height="16" font="4">cular events, possibly because of progression of atheroscle-</text>
<text top="735" left="446" width="308" height="16" font="4">rosis due to oxidative stress and inflammation <a href="e44.full.html#102">(</a></text>
<text top="735" left="753" width="22" height="16" font="16"><a href="e44.full.html#102">715</a></text>
<text top="735" left="776" width="30" height="16" font="4"><a href="e44.full.html#102">). </a>In</text>
<text top="753" left="446" width="360" height="16" font="4">particular, fine particulate matter, defined as particulate</text>
<text top="105" left="59" width="237" height="11" font="13">Table 16. Patient Health Questionnaire-2</text>
<text top="127" left="59" width="326" height="9" font="6">Over the past 2 weeks, how often have you been bothered by any of the</text>
<text top="142" left="83" width="91" height="9" font="6">following problems?</text>
<text top="159" left="70" width="196" height="9" font="6">1) Little interest or pleasure in doing things</text>
<text top="176" left="70" width="182" height="9" font="6">2) Feeling down, depressed, or hopeless</text>
<text top="213" left="59" width="127" height="7" font="17">Reproduced from Kroenke et al. <a href="e44.full.html#102">(</a></text>
<text top="213" left="185" width="16" height="7" font="22"><a href="e44.full.html#102">702</a></text>
<text top="213" left="201" width="5" height="7" font="17"><a href="e44.full.html#102">).</a></text>
<text top="784" left="446" width="234" height="11" font="13">Table 17. Patient Health Questionaire-9:</text>
<text top="799" left="446" width="167" height="11" font="13">Depression Screening Scales</text>
<text top="821" left="446" width="326" height="9" font="6">Over the past 2 weeks, how often have you been bothered by any of the</text>
<text top="836" left="470" width="91" height="9" font="6">following problems?</text>
<text top="853" left="457" width="196" height="9" font="6">1) Little interest or pleasure in doing things</text>
<text top="870" left="457" width="182" height="9" font="6">2) Feeling down, depressed, or hopeless</text>
<text top="887" left="457" width="281" height="9" font="6">3) Trouble falling asleep, staying asleep, or sleeping too much</text>
<text top="905" left="457" width="170" height="9" font="6">4) Feeling tired or having little energy</text>
<text top="922" left="457" width="136" height="9" font="6">5) Poor appetite or overeating</text>
<text top="939" left="457" width="337" height="9" font="6">6) Feeling bad about yourself, feeling that you are a failure, or feeling that</text>
<text top="953" left="470" width="186" height="9" font="6">you have let yourself or your family down</text>
<text top="971" left="457" width="312" height="9" font="6">7) Trouble concentrating on things such as reading the newspaper or</text>
<text top="985" left="470" width="86" height="9" font="6">watching television</text>
<text top="1002" left="457" width="330" height="9" font="6">8) Moving or speaking so slowly that other people could have noticed. Or</text>
<text top="1016" left="470" width="332" height="9" font="6">being so fidgety or restless that you have been moving around a lot more</text>
<text top="1031" left="470" width="48" height="9" font="6">than usual</text>
<text top="1048" left="457" width="316" height="9" font="6">9) Thinking that you would be better off dead or that you want to hurt</text>
<text top="1062" left="470" width="95" height="9" font="6">yourself in some way</text>
<text top="1100" left="446" width="127" height="7" font="17">Reproduced from Kroenke et al. <a href="e44.full.html#102">(</a></text>
<text top="1100" left="572" width="16" height="7" font="22"><a href="e44.full.html#102">702</a></text>
<text top="1100" left="588" width="5" height="7" font="17"><a href="e44.full.html#102">).</a></text>
<text top="52" left="59" width="18" height="10" font="12">e94</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="36" size="9" family="Times" color="#231f20"/>
<text top="104" left="59" width="40" height="16" font="4">matter</text>
<text top="101" left="105" width="313" height="20" font="4">⬍2.5 microns in diameter (PM2.5), is associated</text>
<text top="122" left="59" width="360" height="16" font="4">with a heightened risk of death due to cardiovascular causes</text>
<text top="140" left="59" width="5" height="16" font="4"><a href="e44.full.html#102">(</a></text>
<text top="140" left="63" width="23" height="16" font="16"><a href="e44.full.html#102">714</a></text>
<text top="140" left="86" width="333" height="16" font="4"><a href="e44.full.html#102">). </a>In nonsmokers, the relative odds of AMI death rise</text>
<text top="158" left="59" width="256" height="16" font="4">22% for each 10 mcg increase in PM2.5 <a href="e44.full.html#102">(</a></text>
<text top="158" left="314" width="23" height="16" font="16"><a href="e44.full.html#102">712</a></text>
<text top="158" left="337" width="82" height="16" font="4"><a href="e44.full.html#102">). </a>Short-term</text>
<text top="176" left="59" width="360" height="16" font="4">exposure to higher concentrations of pollution, for example</text>
<text top="194" left="59" width="360" height="16" font="4">after a forest fire, also is associated with the risk for ACS</text>
<text top="212" left="59" width="69" height="16" font="4">and death <a href="e44.full.html#102">(</a></text>
<text top="212" left="127" width="23" height="16" font="16"><a href="e44.full.html#102">713</a></text>
<text top="212" left="150" width="269" height="16" font="4"><a href="e44.full.html#102">). </a>Thus, patients with SIHD may be advised</text>
<text top="230" left="59" width="360" height="16" font="4">to avoid exposure to increased air pollution (i.e., by remain-</text>
<text top="248" left="59" width="360" height="16" font="4">ing indoors during transient elevations of air pollution).</text>
<text top="266" left="59" width="360" height="16" font="4">Public policy efforts to minimize small particulate matter</text>
<text top="284" left="59" width="360" height="16" font="4">(i.e., through tighter regulations on the emissions from</text>
<text top="302" left="59" width="360" height="16" font="4">coal-fired power plants) have the potential to reduce cardiac</text>
<text top="320" left="59" width="262" height="16" font="4">complications among patients with SIHD.</text>
<text top="347" left="59" width="324" height="16" font="26"><b>4.4.2. Additional Medical Therapy to Prevent MI</b></text>
<text top="365" left="59" width="196" height="16" font="26"><b>and Death: Recommendations</b></text>
<text top="396" left="59" width="151" height="9" font="6">4.4.2.1. ANTIPLATELET THERAPY</text>
<text top="423" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="436" left="59" width="360" height="10" font="13">1. Treatment with aspirin 75 to 162 mg daily should be continued</text>
<text top="453" left="74" width="344" height="10" font="13">indefinitely in the absence of contraindications in patients with SIHD</text>
<text top="470" left="74" width="171" height="10" font="13"><a href="e44.full.html#102">(716,717). </a>(<i>Level of Evidence: A</i>)</text>
<text top="487" left="59" width="360" height="10" font="13">2. Treatment with clopidogrel is reasonable when aspirin is contrain-</text>
<text top="503" left="74" width="300" height="10" font="13">dicated in patients with SIHD <a href="e44.full.html#102">(718). </a>(<i>Level of Evidence: B</i>)</text>
<text top="533" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="545" left="59" width="360" height="10" font="13">1. Treatment with aspirin 75 to 162 mg daily and clopidogrel 75 mg</text>
<text top="562" left="74" width="344" height="10" font="13">daily might be reasonable in certain high-risk patients with SIHD</text>
<text top="579" left="74" width="146" height="10" font="13"><a href="e44.full.html#102">(719). </a><i>(Level of Evidence: B)</i></text>
<text top="608" left="59" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="621" left="59" width="360" height="10" font="13">1. Dipyridamole is not recommended as antiplatelet therapy for pa-</text>
<text top="638" left="74" width="260" height="10" font="13">tients with SIHD <a href="e44.full.html#103">(720–722). </a>(<i>Level of Evidence: B</i>)</text>
<text top="666" left="59" width="44" height="9" font="6">4.4.2.1.1.</text>
<text top="665" left="108" width="148" height="12" font="36">ANTIPLATELET AGENTS.</text>
<text top="662" left="263" width="156" height="16" font="4">Because platelet aggrega-</text>
<text top="680" left="58" width="360" height="16" font="4">tion is a key element of the thrombotic response to plaque</text>
<text top="698" left="58" width="360" height="16" font="4">disruption, platelet inhibition is recommended in patients</text>
<text top="716" left="58" width="360" height="16" font="4">with SIHD unless contraindicated. Aspirin is a cyclooxy-</text>
<text top="734" left="58" width="360" height="16" font="4">genase inhibitor that produces irreversible blockade of</text>
<text top="752" left="58" width="360" height="16" font="4">prostaglandin endoperoxide formation. Among 2,920 pa-</text>
<text top="770" left="58" width="360" height="16" font="4">tients with SIHD, a comprehensive meta-analysis of source</text>
<text top="788" left="58" width="360" height="16" font="4">data revealed an association of aspirin use with a 37%</text>
<text top="806" left="58" width="360" height="16" font="4">reduction in the risk of serious vascular events, including a</text>
<text top="824" left="58" width="360" height="16" font="4">46% decrease in the risk for UA and a 53% decrease in the</text>
<text top="842" left="58" width="248" height="16" font="4">risk of requiring coronary angioplasty <a href="e44.full.html#102">(</a></text>
<text top="842" left="306" width="23" height="16" font="16"><a href="e44.full.html#102">716</a></text>
<text top="842" left="329" width="90" height="16" font="4"><a href="e44.full.html#102">). </a>Almost two</text>
<text top="860" left="58" width="360" height="16" font="4">thirds of the patients included in this meta-analysis were</text>
<text top="878" left="58" width="360" height="16" font="4">participants in SAPAT (Swedish Angina Pectoris Aspirin</text>
<text top="896" left="58" width="360" height="16" font="4">Trial), in which patients with SIHD were assigned ran-</text>
<text top="914" left="58" width="360" height="16" font="4">domly to aspirin 75 mg per day or placebo for a median of</text>
<text top="932" left="58" width="74" height="16" font="4">15 months <a href="e44.full.html#102">(</a></text>
<text top="932" left="132" width="23" height="16" font="16"><a href="e44.full.html#102">717</a></text>
<text top="932" left="155" width="264" height="16" font="4"><a href="e44.full.html#102">). </a>Aspirin in a dose of 75 to 162 mg daily is</text>
<text top="950" left="58" width="360" height="16" font="4">equally as effective as 325 mg in secondary prevention and is</text>
<text top="968" left="58" width="276" height="16" font="4">associated with a lower risk of bleeding. Doses</text>
<text top="965" left="338" width="81" height="20" font="4">⬍75 mg have</text>
<text top="986" left="58" width="121" height="16" font="4">less proven benefit <a href="e44.full.html#102">(</a></text>
<text top="986" left="180" width="49" height="16" font="16"><a href="e44.full.html#102">716,723</a></text>
<text top="986" left="228" width="190" height="16" font="4"><a href="e44.full.html#102">). </a>Aspirin is relatively contrain-</text>
<text top="1004" left="58" width="360" height="16" font="4">dicated in patients with known allergies to nonsteroidal</text>
<text top="1022" left="58" width="360" height="16" font="4">antiinflammatory drugs and in patients with the syndrome</text>
<text top="1040" left="58" width="226" height="16" font="4">of asthma, rhinitis, and nasal polyps.</text>
<text top="1058" left="73" width="345" height="16" font="4">Clopidogrel, a thienopyridine derivative, inhibits platelet</text>
<text top="1076" left="58" width="360" height="16" font="4">aggregation via selective and irreversible inhibition of the</text>
<text top="1094" left="58" width="360" height="16" font="4">adenosine diphosphate P2Y12 receptor. Clopidogrel 75 mg</text>
<text top="104" left="445" width="360" height="16" font="4">has been compared with aspirin 325 mg in patients with</text>
<text top="122" left="445" width="360" height="16" font="4">previous MI, stroke, or symptomatic PAD in the prospec-</text>
<text top="140" left="445" width="360" height="16" font="4">tive, randomized CAPRIE (Clopidogrel versus Aspirin in</text>
<text top="158" left="445" width="267" height="16" font="4">Patients at Risk of Ischaemic Events) study <a href="e44.full.html#102">(</a></text>
<text top="158" left="713" width="23" height="16" font="16"><a href="e44.full.html#102">718</a></text>
<text top="158" left="735" width="70" height="16" font="4"><a href="e44.full.html#102">). </a>Although</text>
<text top="176" left="445" width="360" height="16" font="4">clopidogrel demonstrated superiority over aspirin in the</text>
<text top="194" left="445" width="360" height="16" font="4">secondary prevention of MI and death in this group of</text>
<text top="212" left="445" width="360" height="16" font="4">patients, the magnitude of difference was small. Because no</text>
<text top="230" left="445" width="360" height="16" font="4">additional trials comparing aspirin and clopidogrel in pa-</text>
<text top="248" left="445" width="360" height="16" font="4">tients with SIHD have been conducted, clopidogrel remains</text>
<text top="266" left="445" width="253" height="16" font="4">an acceptable alternative agent to aspirin.</text>
<text top="284" left="460" width="345" height="16" font="4">In certain high-risk patients, combined treatment with</text>
<text top="302" left="445" width="360" height="16" font="4">aspirin and clopidogrel has been shown to be beneficial. In</text>
<text top="320" left="445" width="360" height="16" font="4">the CURE (Clopidogrel in Unstable Angina to Prevent</text>
<text top="338" left="445" width="360" height="16" font="4">Recurrent Events) study, patients with a recent NSTEMI</text>
<text top="356" left="445" width="360" height="16" font="4">were randomized to clopidogrel plus aspirin (300 mg/d and</text>
<text top="374" left="445" width="360" height="16" font="4">75 mg/d) for an average of 9 months. These patients</text>
<text top="392" left="445" width="360" height="16" font="4">experienced fewer deaths from cardiovascular causes, non-</text>
<text top="410" left="445" width="360" height="16" font="4">fatal MIs, and strokes than did patients receiving placebo</text>
<text top="428" left="445" width="200" height="16" font="4">plus aspirin (75 to 325 mg/d) <a href="e44.full.html#103">(</a></text>
<text top="428" left="645" width="23" height="16" font="16"><a href="e44.full.html#103">724</a></text>
<text top="428" left="668" width="138" height="16" font="4"><a href="e44.full.html#103">). </a>Similar results were</text>
<text top="446" left="445" width="360" height="16" font="4">found in the CREDO (Clopidogrel for Reduction of Events</text>
<text top="464" left="445" width="360" height="16" font="4">During Observation) study. Combined therapy for an aver-</text>
<text top="482" left="445" width="360" height="16" font="4">age of 1 year significantly reduced the risk of death, MI, or</text>
<text top="500" left="445" width="48" height="16" font="4">stroke <a href="e44.full.html#103">(</a></text>
<text top="500" left="493" width="22" height="16" font="16"><a href="e44.full.html#103">725</a></text>
<text top="500" left="515" width="291" height="16" font="4"><a href="e44.full.html#103">). </a>In contradistinction to these positive results</text>
<text top="518" left="445" width="360" height="16" font="4">among high-risk patients, a comparison of aspirin alone versus</text>
<text top="536" left="445" width="360" height="16" font="4">aspirin combined with clopidogrel in 15,603 patients with</text>
<text top="554" left="445" width="360" height="16" font="4">multiple cardiovascular risk factors (most of whom were</text>
<text top="572" left="445" width="360" height="16" font="4">without a prior cardiovascular event) in the CHARISMA</text>
<text top="590" left="445" width="360" height="16" font="4">(Clopidogrel for High Atherothrombotic Risk Ischemic</text>
<text top="608" left="445" width="360" height="16" font="4">Stabilization, Management, and Avoidance) trial demon-</text>
<text top="626" left="445" width="360" height="16" font="4">strated no differences in the rates of MI, stroke, or death</text>
<text top="644" left="445" width="5" height="16" font="4"><a href="e44.full.html#95">(</a></text>
<text top="644" left="450" width="23" height="16" font="16"><a href="e44.full.html#95">393</a></text>
<text top="644" left="473" width="333" height="16" font="4"><a href="e44.full.html#95">). </a>A post hoc analysis of this study suggested that a</text>
<text top="662" left="445" width="360" height="16" font="4">subgroup of patients with documented prior MI, ischemic</text>
<text top="680" left="445" width="360" height="16" font="4">stroke, or symptomatic PAD might have had better out-</text>
<text top="698" left="445" width="360" height="16" font="4">comes from dual antiplatelet therapy (DAPT) with clopi-</text>
<text top="716" left="445" width="129" height="16" font="4">dogrel plus aspirin <a href="e44.full.html#102">(</a></text>
<text top="716" left="574" width="23" height="16" font="16"><a href="e44.full.html#102">719</a></text>
<text top="716" left="597" width="209" height="16" font="4"><a href="e44.full.html#102">). </a>In a meta-analysis of 5 RCTs</text>
<text top="734" left="445" width="360" height="16" font="4">comparing clopidogrel plus aspirin to aspirin alone in</text>
<text top="752" left="445" width="360" height="16" font="4">patients with IHD, the incidence of all-cause mortality, MI,</text>
<text top="770" left="445" width="360" height="16" font="4">and stroke was found to be reduced in the clopidogrel-plus-</text>
<text top="788" left="445" width="360" height="16" font="4">aspirin group, whereas the risk of major bleeding increased</text>
<text top="806" left="445" width="83" height="16" font="4">significantly <a href="e44.full.html#103">(</a></text>
<text top="806" left="528" width="23" height="16" font="16"><a href="e44.full.html#103">726</a></text>
<text top="806" left="551" width="255" height="16" font="4"><a href="e44.full.html#103">). </a>Overall, it appears that the addition of</text>
<text top="824" left="445" width="360" height="16" font="4">clopidogrel to aspirin could be beneficial in certain high-risk</text>
<text top="842" left="445" width="360" height="16" font="4">groups of patients with SIHD, but data on specific sub-</text>
<text top="860" left="445" width="134" height="16" font="4">groups are lacking <a href="e44.full.html#103">(</a></text>
<text top="860" left="580" width="23" height="16" font="16"><a href="e44.full.html#103">727</a></text>
<text top="860" left="602" width="204" height="16" font="4"><a href="e44.full.html#103">), </a>and further research will be</text>
<text top="878" left="445" width="290" height="16" font="4">required to identify the ideal target population.</text>
<text top="896" left="460" width="345" height="16" font="4">The effectiveness of clopidogrel depends on generation of</text>
<text top="914" left="445" width="360" height="16" font="4">the active metabolite in 2 steps that are catalyzed by</text>
<text top="932" left="445" width="360" height="16" font="4">enzymes of the cytochrome P450 system, principally</text>
<text top="950" left="445" width="360" height="16" font="5"><i>CYP2C19</i>. Variants of the <i>CYP2C19 </i>gene have been iden-</text>
<text top="968" left="445" width="360" height="16" font="4">tified that are associated with impaired antiplatelet effects,</text>
<text top="986" left="445" width="360" height="16" font="4">as measured by ex vivo platelet aggregation assays, and with</text>
<text top="1004" left="445" width="360" height="16" font="4">higher cardiovascular event rates after ACS and percutane-</text>
<text top="1022" left="445" width="206" height="16" font="4">ous revascularization procedures <a href="e44.full.html#103">(</a></text>
<text top="1022" left="652" width="54" height="16" font="16"><a href="e44.full.html#103">728 –731</a></text>
<text top="1022" left="706" width="99" height="16" font="4"><a href="e44.full.html#103">). </a>Poor metabo-</text>
<text top="1040" left="445" width="360" height="16" font="4">lizers of clopidogrel can be identified by clinically available</text>
<text top="1058" left="445" width="360" height="16" font="4">tests, but optimal dosing strategies for these individuals have</text>
<text top="1076" left="445" width="302" height="16" font="4">not been established in clinical outcome trials <a href="e44.full.html#103">(</a></text>
<text top="1076" left="748" width="49" height="16" font="16"><a href="e44.full.html#103">732,733</a></text>
<text top="1076" left="797" width="9" height="16" font="4"><a href="e44.full.html#103">).</a></text>
<text top="1094" left="445" width="360" height="16" font="4">Other drugs that are metabolized by <i>CYP2C19 </i>could</text>
<text top="52" left="787" width="18" height="10" font="12">e95</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">competitively inhibit the enzyme and impair metabolism of</text>
<text top="123" left="59" width="360" height="16" font="4">clopidogrel. Several studies have demonstrated a pharmaco-</text>
<text top="141" left="59" width="360" height="16" font="4">dynamic interaction between proton pump inhibitors and</text>
<text top="159" left="59" width="76" height="16" font="4">clopidogrel <a href="e44.full.html#103">(</a></text>
<text top="159" left="134" width="47" height="16" font="16"><a href="e44.full.html#103">734,735</a></text>
<text top="159" left="181" width="238" height="16" font="4"><a href="e44.full.html#103">). </a>Observational studies have suggested</text>
<text top="178" left="59" width="360" height="16" font="4">that use of a proton pump inhibitor in combination with</text>
<text top="196" left="59" width="360" height="16" font="4">clopidogrel is associated with an approximately 25% in-</text>
<text top="215" left="59" width="303" height="16" font="4">creased RR of adverse cardiovascular events <a href="e44.full.html#103">(</a></text>
<text top="215" left="361" width="49" height="16" font="16"><a href="e44.full.html#103">736,737</a></text>
<text top="215" left="410" width="9" height="16" font="4"><a href="e44.full.html#103">),</a></text>
<text top="233" left="59" width="360" height="16" font="4">although post hoc analyses of several clinical trials and a</text>
<text top="251" left="59" width="360" height="16" font="4">recent observational study have failed to demonstrate a</text>
<text top="270" left="59" width="202" height="16" font="4">clinically significant interaction <a href="e44.full.html#103">(</a></text>
<text top="270" left="261" width="49" height="16" font="16"><a href="e44.full.html#103">738,739</a></text>
<text top="270" left="310" width="109" height="16" font="4"><a href="e44.full.html#103">). </a>Pantoprazole is</text>
<text top="288" left="59" width="360" height="16" font="4">less likely than other proton pump inhibitors to inhibit</text>
<text top="306" left="59" width="360" height="16" font="5"><i>CYP2C19 </i>and does not impair the pharmacodynamic re-</text>
<text top="325" left="59" width="147" height="16" font="4">sponse to clopidogrel <a href="e44.full.html#103">(</a></text>
<text top="325" left="205" width="54" height="16" font="16"><a href="e44.full.html#103">740 –742</a></text>
<text top="325" left="260" width="159" height="16" font="4"><a href="e44.full.html#103">); </a>alternatively, treatment</text>
<text top="343" left="59" width="360" height="16" font="4">with an H2 antagonist or antacid could be sufficient in some</text>
<text top="361" left="59" width="360" height="16" font="4">patients. The combination of clopidogrel with a statin can</text>
<text top="380" left="59" width="360" height="16" font="4">be prescribed safely on the basis of a secondary analysis of</text>
<text top="398" left="59" width="360" height="16" font="4">the CHARISMA trial in 10,078 patients with cardiovascu-</text>
<text top="416" left="59" width="329" height="16" font="4">lar disease or multiple high-risk coronary risk factors <a href="e44.full.html#103">(</a></text>
<text top="416" left="387" width="23" height="16" font="16"><a href="e44.full.html#103">743</a></text>
<text top="416" left="410" width="9" height="16" font="4"><a href="e44.full.html#103">).</a></text>
<text top="435" left="59" width="360" height="16" font="4">There was no difference in the composite endpoint of MI,</text>
<text top="453" left="59" width="360" height="16" font="4">stroke, or cardiovascular death between the agents, inde-</text>
<text top="471" left="59" width="360" height="16" font="4">pendent of the metabolism pathway of the statin. Clopi-</text>
<text top="490" left="59" width="360" height="16" font="4">dogrel requires a loading dose to accelerate the onset,</text>
<text top="508" left="59" width="248" height="16" font="4">intensity, and consistency of inhibition <a href="e44.full.html#103">(</a></text>
<text top="508" left="306" width="49" height="16" font="16"><a href="e44.full.html#103">744,745</a></text>
<text top="508" left="355" width="9" height="16" font="4"><a href="e44.full.html#103">).</a></text>
<text top="526" left="74" width="345" height="16" font="4">Prasugrel is a third-generation thienopyridine that has</text>
<text top="545" left="59" width="360" height="16" font="4">more potent antiplatelet effects and is associated with less</text>
<text top="563" left="59" width="360" height="16" font="4">interpatient variability in response than clopidogrel. In</text>
<text top="581" left="59" width="360" height="16" font="4">TRITON-TIMI (Trial to Assess Improvement in Thera-</text>
<text top="600" left="59" width="360" height="16" font="4">peutic Outcomes by Optimizing Platelet Inhibition with</text>
<text top="618" left="59" width="360" height="16" font="4">Prasugrel–Thrombolysis In Myocardial Infarction) 38,</text>
<text top="636" left="59" width="360" height="16" font="4">there was a 19% reduction in RR of the primary efficacy</text>
<text top="655" left="59" width="360" height="16" font="4">endpoint (cardiovascular death, nonfatal MI, or nonfatal</text>
<text top="673" left="59" width="360" height="16" font="4">stroke) but an increased risk of bleeding with prasugrel</text>
<text top="691" left="59" width="360" height="16" font="4">compared with clopidogrel in ACS patients scheduled for</text>
<text top="710" left="59" width="192" height="16" font="4">percutaneous revascularization <a href="e44.full.html#103">(</a></text>
<text top="710" left="250" width="23" height="16" font="16"><a href="e44.full.html#103">746</a></text>
<text top="710" left="273" width="146" height="16" font="4"><a href="e44.full.html#103">). </a>Clinical trials evaluat-</text>
<text top="728" left="59" width="360" height="16" font="4">ing prasugrel in patients with SIHD have not been con-</text>
<text top="746" left="59" width="360" height="16" font="4">ducted. It has not been tested or approved for use in patients</text>
<text top="765" left="59" width="360" height="16" font="4">with SIHD. Ticagrelor is a newly approved agent that has</text>
<text top="783" left="59" width="360" height="16" font="4">been shown to be beneficial in patients with ACS but has</text>
<text top="801" left="59" width="249" height="16" font="4">not been tested in patients with SIHD <a href="e44.full.html#103">(</a></text>
<text top="801" left="308" width="23" height="16" font="16"><a href="e44.full.html#103">747</a></text>
<text top="801" left="330" width="9" height="16" font="4"><a href="e44.full.html#103">).</a></text>
<text top="820" left="74" width="345" height="16" font="4">Ticlopidine is a thienopyridine derivative that also inhib-</text>
<text top="838" left="59" width="360" height="16" font="4">its platelet aggregation but compares less favorably to</text>
<text top="856" left="59" width="360" height="16" font="4">clopidogrel as an alternative to aspirin, because it has limited</text>
<text top="875" left="59" width="360" height="16" font="4">evidence for cardiovascular event reduction among patients</text>
<text top="893" left="59" width="360" height="16" font="4">with SIHD and an associated risk of blood dyscrasias</text>
<text top="911" left="59" width="5" height="16" font="4"><a href="e44.full.html#103">(</a></text>
<text top="911" left="63" width="49" height="16" font="16"><a href="e44.full.html#103">720,721</a></text>
<text top="911" left="112" width="306" height="16" font="4"><a href="e44.full.html#103">). </a>For these reasons, its use is quite limited for</text>
<text top="930" left="59" width="307" height="16" font="4">secondary prevention among patients with SIHD.</text>
<text top="948" left="74" width="345" height="16" font="4">The pyrimido-pyrimidine derivative, dipyridamole, pos-</text>
<text top="966" left="59" width="360" height="16" font="4">sesses antiplatelet effects but does not have a proven role in</text>
<text top="985" left="59" width="360" height="16" font="4">patients with SIHD. The combination of aspirin and</text>
<text top="1003" left="59" width="360" height="16" font="4">dipyridamole was not clearly superior to aspirin alone in</text>
<text top="1021" left="59" width="360" height="16" font="4">preventing reinfarction in the PARIS (Persantine-Aspirin</text>
<text top="1040" left="59" width="127" height="16" font="4">Reinfarction Study) <a href="e44.full.html#103">(</a></text>
<text top="1040" left="186" width="23" height="16" font="16"><a href="e44.full.html#103">722</a></text>
<text top="1040" left="208" width="211" height="16" font="4"><a href="e44.full.html#103">). </a>Because dipyridamole vasodilates</text>
<text top="1058" left="59" width="360" height="16" font="4">coronary resistance vessels and can provoke exercise-induced</text>
<text top="1076" left="59" width="360" height="16" font="4">myocardial ischemia, it is not recommended for secondary</text>
<text top="1095" left="59" width="220" height="16" font="4">prevention in patients with SIHD <a href="e44.full.html#103">(</a></text>
<text top="1095" left="278" width="49" height="16" font="16"><a href="e44.full.html#103">748,749</a></text>
<text top="1095" left="327" width="9" height="16" font="4"><a href="e44.full.html#103">).</a></text>
<text top="108" left="446" width="48" height="9" font="6">4.4.2.1.2.</text>
<text top="107" left="499" width="223" height="12" font="36">ORAL ANTICOAGULANT THERAPY.</text>
<text top="104" left="730" width="75" height="16" font="4">Fibrinolytic</text>
<text top="123" left="445" width="360" height="16" font="4">function can be disturbed in patients with IHD, particularly</text>
<text top="141" left="445" width="360" height="16" font="4">related to activation of the extrinsic coagulation pathway</text>
<text top="159" left="445" width="360" height="16" font="4">leading to formation of thrombin. Thrombin, in turn,</text>
<text top="177" left="445" width="360" height="16" font="4">generates fibrin and promotes platelet activation and aggre-</text>
<text top="196" left="445" width="360" height="16" font="4">gation, thereby amplifying the activity of both the coagula-</text>
<text top="214" left="445" width="174" height="16" font="4">tion and platelet pathways <a href="e44.full.html#103">(</a></text>
<text top="214" left="620" width="54" height="16" font="16"><a href="e44.full.html#103">750 –752</a></text>
<text top="214" left="674" width="131" height="16" font="4"><a href="e44.full.html#103">). </a>These observations</text>
<text top="232" left="445" width="360" height="16" font="4">have provided a potential rationale for antithrombotic ther-</text>
<text top="250" left="445" width="360" height="16" font="4">apy in patients with SIHD. A systematic review of random-</text>
<text top="269" left="445" width="360" height="16" font="4">ized trials of oral anticoagulants with and without antiplate-</text>
<text top="287" left="445" width="360" height="16" font="4">let therapy among 20,000 patients with IHD, however,</text>
<text top="305" left="445" width="360" height="16" font="4">failed to provide evidence of benefit from anticoagulation,</text>
<text top="324" left="445" width="187" height="16" font="4">and it is not recommended <a href="e44.full.html#103">(</a></text>
<text top="324" left="632" width="23" height="16" font="16"><a href="e44.full.html#103">753</a></text>
<text top="324" left="655" width="151" height="16" font="4"><a href="e44.full.html#103">). </a>Similarly, there is no</text>
<text top="342" left="445" width="360" height="16" font="4">evidence that individuals with defects in the coagulation</text>
<text top="360" left="445" width="360" height="16" font="4">system, such as G1691A factor V Leiden, G20201A pro-</text>
<text top="378" left="445" width="360" height="16" font="4">thrombin, G455A fibrinogen chain, G10976A factor VII,</text>
<text top="397" left="445" width="360" height="16" font="4">or the plasminogen activator inhibitor-1 4G/5G polymor-</text>
<text top="415" left="445" width="360" height="16" font="4">phisms, are at higher risk of cardiac events, and they should</text>
<text top="433" left="445" width="360" height="16" font="4">not receive anticoagulation therapy solely to prevent such</text>
<text top="451" left="445" width="47" height="16" font="4">events <a href="e44.full.html#103">(</a></text>
<text top="451" left="493" width="54" height="16" font="16"><a href="e44.full.html#103">754 –756</a></text>
<text top="451" left="547" width="9" height="16" font="4"><a href="e44.full.html#103">).</a></text>
<text top="482" left="446" width="155" height="9" font="6">4.4.2.2. BETA-BLOCKER THERAPY</text>
<text top="511" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="524" left="446" width="360" height="10" font="13">1. Beta-blocker therapy should be started and continued for 3 years in</text>
<text top="541" left="461" width="344" height="10" font="13">all patients with normal LV function after MI or ACS <a href="e44.full.html#103">(757–759).</a></text>
<text top="558" left="461" width="111" height="10" font="25"><i>(Level of Evidence: B)</i></text>
<text top="575" left="446" width="360" height="10" font="13">2. Beta-blocker therapy should be used in all patients with LV systolic</text>
<text top="592" left="461" width="79" height="10" font="13">dysfunction (EF</text>
<text top="589" left="543" width="262" height="16" font="13">ⱕ40%) with heart failure or prior MI, unless contra-</text>
<text top="610" left="461" width="344" height="10" font="13">indicated. (Use should be limited to carvedilol, metoprolol succi-</text>
<text top="627" left="461" width="344" height="10" font="13">nate, or bisoprolol, which have been shown to reduce risk of death.)</text>
<text top="644" left="461" width="194" height="10" font="13"><a href="e44.full.html#99">(571,760–763) </a><i>(Level of Evidence: A)</i></text>
<text top="674" left="446" width="46" height="8" font="24">CLASS IIb</text>
<text top="687" left="446" width="360" height="10" font="13">1. Beta blockers may be considered as chronic therapy for all other</text>
<text top="705" left="461" width="344" height="10" font="13">patients with coronary or other vascular disease. <i>(Level of Evidence: C)</i></text>
<text top="730" left="446" width="360" height="16" font="4">Beta-receptor activation is associated with increases in heart</text>
<text top="748" left="446" width="360" height="16" font="4">rate, accelerated AV nodal conduction, and increased con-</text>
<text top="766" left="446" width="360" height="16" font="4">tractility, which contribute to increased myocardial oxygen</text>
<text top="784" left="446" width="360" height="16" font="4">demand. Decreases in the rate–BP product, AV nodal</text>
<text top="803" left="446" width="360" height="16" font="4">conduction, and myocardial contractility from beta blockers</text>
<text top="821" left="446" width="360" height="16" font="4">reduce myocardial oxygen demand, counteracting beta-</text>
<text top="839" left="446" width="360" height="16" font="4">receptor activity and contributing to a reduction in angina</text>
<text top="857" left="446" width="360" height="16" font="4">onset, with improvement in the ischemic threshold during</text>
<text top="876" left="446" width="167" height="16" font="4">exercise and in symptoms <a href="e44.full.html#104">(</a></text>
<text top="876" left="613" width="54" height="16" font="16"><a href="e44.full.html#104">764 –769</a></text>
<text top="876" left="667" width="138" height="16" font="4"><a href="e44.full.html#104">). </a>These agents signif-</text>
<text top="894" left="446" width="360" height="16" font="4">icantly reduce deaths and recurrent MIs in patients who</text>
<text top="912" left="446" width="360" height="16" font="4">have suffered a MI and are especially effective when a</text>
<text top="930" left="446" width="360" height="16" font="4">STEMI is complicated by persistent or recurrent ischemia</text>
<text top="949" left="446" width="329" height="16" font="4">or tachyarrhythmias early after the onset of infarction <a href="e44.full.html#103">(</a></text>
<text top="949" left="774" width="23" height="16" font="16"><a href="e44.full.html#103">757</a></text>
<text top="949" left="797" width="9" height="16" font="4"><a href="e44.full.html#103">).</a></text>
<text top="967" left="446" width="360" height="16" font="4">However, no large trials have assessed effects of beta</text>
<text top="985" left="446" width="360" height="16" font="4">blockers on survival or coronary event rates in patients with</text>
<text top="1003" left="446" width="43" height="16" font="4">SIHD.</text>
<text top="1021" left="461" width="345" height="16" font="4">Many clinically important differences exist between beta</text>
<text top="1040" left="446" width="360" height="16" font="4">blockers. These differences relate to cardioselectivity, pres-</text>
<text top="1058" left="446" width="360" height="16" font="4">ence of intrinsic sympathomimetic activity or vasodilating</text>
<text top="1076" left="446" width="360" height="16" font="4">properties, and relative lipid solubility in the presence of</text>
<text top="1094" left="446" width="360" height="16" font="4">renal or hepatic impairment. Despite these differences, all</text>
<text top="52" left="59" width="18" height="10" font="12">e96</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="37" size="10" family="Times" color="#3b456e"/>
<text top="104" left="59" width="360" height="16" font="4">beta blockers seem to be equally efficacious in SIHD</text>
<text top="122" left="59" width="5" height="16" font="4"><a href="e44.full.html#104">(</a></text>
<text top="122" left="63" width="105" height="16" font="16"><a href="e44.full.html#104">765–767,770,771</a></text>
<text top="122" left="169" width="9" height="16" font="4"><a href="e44.full.html#104">).</a></text>
<text top="140" left="74" width="345" height="16" font="4">Two large long-term follow-up studies investigating the</text>
<text top="158" left="59" width="360" height="16" font="4">prognostic importance of heart rate showed that all-cause</text>
<text top="176" left="59" width="360" height="16" font="4">mortality rate progressively increases with higher resting</text>
<text top="194" left="59" width="360" height="16" font="4">heart rate after adjustment for exercise capacity, age, diabe-</text>
<text top="212" left="59" width="360" height="16" font="4">tes mellitus, systolic arterial pressure, BMI, and level of</text>
<text top="230" left="59" width="109" height="16" font="4">physical activity <a href="e44.full.html#104">(</a></text>
<text top="230" left="168" width="49" height="16" font="16"><a href="e44.full.html#104">772,773</a></text>
<text top="230" left="216" width="202" height="16" font="4"><a href="e44.full.html#104">). </a>Therefore, it is recommended</text>
<text top="248" left="59" width="360" height="16" font="4">that beta-blocker dosing be adjusted to limit the heart rate</text>
<text top="266" left="59" width="224" height="16" font="4">to 55 to 60 beats per minute at rest.</text>
<text top="284" left="74" width="345" height="16" font="4">In large prospective studies, bisoprolol, carvedilol, and</text>
<text top="302" left="59" width="360" height="16" font="4">metoprolol, when administered on a background of ACE</text>
<text top="320" left="59" width="360" height="16" font="4">inhibitors and diuretics with or without digoxin, have been</text>
<text top="338" left="59" width="360" height="16" font="4">shown to reduce the risk of death and to improve symptoms,</text>
<text top="356" left="59" width="360" height="16" font="4">clinical status, and quality of life in patients with chronic</text>
<text top="374" left="59" width="360" height="16" font="4">systolic heart failure. Importantly, these benefits were seen</text>
<text top="392" left="59" width="221" height="16" font="4">in patients with and without IHD <a href="e44.full.html#99">(</a></text>
<text top="392" left="280" width="75" height="16" font="16"><a href="e44.full.html#99">571,760,761</a></text>
<text top="392" left="355" width="9" height="16" font="4"><a href="e44.full.html#99">).</a></text>
<text top="410" left="74" width="345" height="16" font="4">Studies on multiple polymorphisms in the gene encoding</text>
<text top="428" left="59" width="360" height="16" font="4">for the beta-adrenergic receptor have variously shown asso-</text>
<text top="446" left="59" width="297" height="16" font="4">ciations with physiological responses to exercise <a href="e44.full.html#104">(</a></text>
<text top="446" left="356" width="54" height="16" font="16"><a href="e44.full.html#104">774 –781</a></text>
<text top="446" left="410" width="9" height="16" font="4"><a href="e44.full.html#104">).</a></text>
<text top="464" left="59" width="360" height="16" font="4">Clinical studies with a variety of beta blockers in different</text>
<text top="482" left="59" width="360" height="16" font="4">patient populations with hypertension have, however,</text>
<text top="500" left="59" width="360" height="16" font="4">yielded divergent results in terms of associations with BP</text>
<text top="518" left="59" width="105" height="16" font="4">and heart rate <a href="e44.full.html#104">(</a></text>
<text top="518" left="163" width="52" height="16" font="16"><a href="e44.full.html#104">782–785</a></text>
<text top="518" left="216" width="203" height="16" font="4"><a href="e44.full.html#104">), </a>but it remains to be studied</text>
<text top="536" left="59" width="360" height="16" font="4">whether this variation is mainly a function of beta-</text>
<text top="554" left="59" width="360" height="16" font="4">adrenergic receptor genotype and whether genotype influ-</text>
<text top="572" left="59" width="360" height="16" font="4">ences the clinical outcome of beta-blocker use in patients</text>
<text top="590" left="59" width="75" height="16" font="4">with SIHD.</text>
<text top="608" left="74" width="345" height="16" font="4">Beta blockers have been compared with and combined</text>
<text top="626" left="59" width="360" height="16" font="4">with dihydropyridine calcium channel blockers in controlled</text>
<text top="644" left="59" width="360" height="16" font="4">clinical trials. The results of the APSIS (Angina Prognosis</text>
<text top="662" left="59" width="360" height="16" font="4">Study in Stockholm), TIBBS (Total Ischemic Burden</text>
<text top="680" left="59" width="360" height="16" font="4">Bisoprolol Study), and IMAGE (International Multicenter</text>
<text top="698" left="59" width="360" height="16" font="4">Angina Exercise) studies showed that a beta blocker was</text>
<text top="716" left="59" width="360" height="16" font="4">more effective than a calcium channel blocker in control of</text>
<text top="734" left="59" width="360" height="16" font="4">angina, reduction of cardiovascular events, and need for</text>
<text top="752" left="59" width="114" height="16" font="4">revascularization <a href="e44.full.html#104">(</a></text>
<text top="752" left="173" width="54" height="16" font="16"><a href="e44.full.html#104">786 –788</a></text>
<text top="752" left="227" width="191" height="16" font="4"><a href="e44.full.html#104">). </a>A rationale for combining</text>
<text top="770" left="59" width="360" height="16" font="4">these agents is a reduction of dihydropyridine-induced</text>
<text top="788" left="59" width="360" height="16" font="4">tachycardia by beta-blockade. When combined, beta block-</text>
<text top="806" left="59" width="360" height="16" font="4">ers and dihydropyridine calcium channel blockers have</text>
<text top="824" left="59" width="360" height="16" font="4">increased exercise time and shown a trend toward a lower</text>
<text top="842" left="59" width="201" height="16" font="4">rate of cardiovascular outcomes <a href="e44.full.html#104">(</a></text>
<text top="842" left="260" width="49" height="16" font="16"><a href="e44.full.html#104">788,789</a></text>
<text top="842" left="308" width="110" height="16" font="4"><a href="e44.full.html#104">). </a>Caution is war-</text>
<text top="860" left="59" width="360" height="16" font="4">ranted when a beta blocker is combined with verapamil or</text>
<text top="878" left="59" width="360" height="16" font="4">diltiazem because of the potential for development of</text>
<text top="896" left="59" width="267" height="16" font="4">bradycardia, AV block, or excessive fatigue.</text>
<text top="914" left="74" width="345" height="16" font="4">The combination of a beta blocker with a nitrate could be an</text>
<text top="932" left="59" width="360" height="16" font="4">additive combination in patients with SIHD. Nitrates increase</text>
<text top="950" left="59" width="360" height="16" font="4">sympathetic tone, which can lead to reflex tachycardia, which</text>
<text top="968" left="59" width="360" height="16" font="4">is attenuated by the beta blocker. Beta blockers can increase LV</text>
<text top="986" left="59" width="360" height="16" font="4">wall tension associated with decreased heart rate, which is</text>
<text top="1004" left="59" width="360" height="16" font="4">counteracted by the concomitant use of nitroglycerin. Clinical</text>
<text top="1022" left="59" width="360" height="16" font="4">trials have validated this rationale, showing that the combina-</text>
<text top="1040" left="59" width="360" height="16" font="4">tion is more effective in controlling angina than is either</text>
<text top="1058" left="59" width="122" height="16" font="4">monotherapy alone <a href="e44.full.html#104">(</a></text>
<text top="1058" left="180" width="47" height="16" font="16"><a href="e44.full.html#104">790,791</a></text>
<text top="1058" left="227" width="8" height="16" font="4"><a href="e44.full.html#104">).</a></text>
<text top="1076" left="74" width="345" height="16" font="4">Absolute contraindications to beta blockers are severe</text>
<text top="1094" left="59" width="360" height="16" font="4">bradycardia, preexisting high-degree AV block, sick sinus</text>
<text top="104" left="446" width="360" height="16" font="4">syndrome (without a pacemaker in place), and refractory</text>
<text top="122" left="446" width="360" height="16" font="4">heart failure. Relative contraindications include bronchos-</text>
<text top="140" left="446" width="360" height="16" font="4">pastic disease or active PAD (beta blockers without vasodi-</text>
<text top="158" left="446" width="360" height="16" font="4">lating properties or selective agents at low doses may be</text>
<text top="176" left="446" width="360" height="16" font="4">used). Because they can mask symptoms of hypoglycemia,</text>
<text top="194" left="446" width="360" height="16" font="4">beta blockers should be used with caution in patients with</text>
<text top="212" left="446" width="360" height="16" font="4">insulin-dependent diabetes mellitus. Abrupt beta-blocker</text>
<text top="230" left="446" width="360" height="16" font="4">withdrawal should be avoided because heightened beta-</text>
<text top="248" left="446" width="360" height="16" font="4">receptor density and sensitivity can result in a rebound</text>
<text top="266" left="446" width="360" height="16" font="4">phenomenon associated with an increased risk for AMI and</text>
<text top="284" left="446" width="360" height="16" font="4">sudden death. If withdrawal is necessary, beta blockers</text>
<text top="302" left="446" width="360" height="16" font="4">should be tapered over a 1- to 3-week period, with consid-</text>
<text top="320" left="446" width="360" height="16" font="4">eration given to use of sublingual nitroglycerin or substitu-</text>
<text top="338" left="446" width="360" height="16" font="4">tion with a nondihydropyridine calcium channel blocker</text>
<text top="356" left="446" width="183" height="16" font="4">during the withdrawal period.</text>
<text top="374" left="461" width="345" height="16" font="4">The principle adverse effects of beta blockers are fatigue,</text>
<text top="392" left="446" width="360" height="16" font="4">exercise intolerance, lethargy, insomnia, nightmares, and</text>
<text top="410" left="446" width="67" height="16" font="4">impotence.</text>
<text top="441" left="446" width="297" height="9" font="6">4.4.2.3. RENIN-ANGIOTENSIN-ALDOSTERONE BLOCKER THERAPY</text>
<text top="468" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="480" left="446" width="360" height="10" font="13">1. ACE inhibitors should be prescribed in all patients with SIHD who</text>
<text top="497" left="461" width="344" height="10" font="13">also have hypertension, diabetes mellitus, LVEF 40% or less, or CKD,</text>
<text top="514" left="461" width="317" height="10" font="13">unless contraindicated <a href="e44.full.html#93">(295–298,301). </a>(<i>Level of Evidence: A</i>)</text>
<text top="531" left="446" width="360" height="10" font="13">2. ARBs are recommended for patients with SIHD who have hyperten-</text>
<text top="548" left="461" width="344" height="10" font="13">sion, diabetes mellitus, LV systolic dysfunction, or CKD and have</text>
<text top="565" left="461" width="344" height="10" font="13">indications for, but are intolerant of, ACE inhibitors <a href="e44.full.html#104">(792–794).</a></text>
<text top="582" left="461" width="111" height="10" font="25"><i>(Level of Evidence: A)</i></text>
<text top="610" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="623" left="446" width="360" height="10" font="13">1. Treatment with an ACE inhibitor is reasonable in patients with both</text>
<text top="640" left="461" width="341" height="10" font="13">SIHD and other vascular disease <a href="e44.full.html#104">(795,796). </a><i>(Level of Evidence: B)</i></text>
<text top="657" left="445" width="360" height="10" font="13">2. It is reasonable to use ARBs in other patients who are ACE inhibitor</text>
<text top="674" left="461" width="206" height="10" font="13">intolerant <a href="e44.full.html#104">(797). </a><i>(Level of Evidence: C) </i><a href="e44.full.html#46">(</a></text>
<text top="674" left="667" width="46" height="10" font="37"><a href="e44.full.html#46">Table 15</a></text>
<text top="674" left="713" width="4" height="10" font="13"><a href="e44.full.html#46">)</a></text>
<text top="698" left="446" width="360" height="16" font="4">A substantial body of evidence supports the concept that</text>
<text top="716" left="446" width="360" height="16" font="4">ACE inhibitors have cardiovascular protective effects, re-</text>
<text top="734" left="446" width="360" height="16" font="4">ducing the risks of future ischemic events. ACE inhibitors</text>
<text top="752" left="446" width="360" height="16" font="4">result in a reduction in angiotensin II with an increase in</text>
<text top="770" left="446" width="360" height="16" font="4">bradykinin. These changes in the physiological balance</text>
<text top="788" left="446" width="360" height="16" font="4">between angiotensin II and bradykinin could contribute to</text>
<text top="806" left="446" width="360" height="16" font="4">the reductions in LV and vascular hypertrophy, atheroscle-</text>
<text top="824" left="446" width="360" height="16" font="4">rosis progression, plaque rupture, and thrombosis; the fa-</text>
<text top="842" left="446" width="360" height="16" font="4">vorable changes in cardiac hemodynamics; and the im-</text>
<text top="860" left="446" width="360" height="16" font="4">proved myocardial oxygen supply/demand that result from</text>
<text top="878" left="446" width="295" height="16" font="4">treatment with ACE inhibitors and ARBs <a href="e44.full.html#104">(</a></text>
<text top="878" left="741" width="56" height="16" font="16"><a href="e44.full.html#104">798 – 801</a></text>
<text top="878" left="797" width="9" height="16" font="4"><a href="e44.full.html#104">).</a></text>
<text top="896" left="446" width="360" height="16" font="4">Clinical studies have demonstrated significant reductions in</text>
<text top="914" left="446" width="360" height="16" font="4">the incidence of AMI, UA, and the need for coronary</text>
<text top="932" left="446" width="360" height="16" font="4">revascularization in patients after MI with LV dysfunction,</text>
<text top="950" left="446" width="155" height="16" font="4">independent of etiology <a href="e44.full.html#99">(</a></text>
<text top="950" left="601" width="75" height="16" font="16"><a href="e44.full.html#99">559,561,801</a></text>
<text top="950" left="676" width="9" height="16" font="4"><a href="e44.full.html#99">).</a></text>
<text top="968" left="461" width="345" height="16" font="4">The benefits of ACE inhibitors extend to patients with</text>
<text top="986" left="446" width="360" height="16" font="4">IHD in the absence of LV dysfunction. In patients with</text>
<text top="1004" left="446" width="360" height="16" font="4">atherosclerotic vascular disease or diabetes mellitus and at</text>
<text top="1022" left="446" width="360" height="16" font="4">least 1 other IHD risk factor, the HOPE (Heart Outcomes</text>
<text top="1040" left="446" width="188" height="16" font="4">Prevention Evaluation) study <a href="e44.full.html#93">(</a></text>
<text top="1040" left="634" width="23" height="16" font="16"><a href="e44.full.html#93">301</a></text>
<text top="1040" left="656" width="149" height="16" font="4"><a href="e44.full.html#93">) </a>showed that compared</text>
<text top="1058" left="446" width="360" height="16" font="4">with placebo, ramipril significantly decreased the primary</text>
<text top="1076" left="446" width="360" height="16" font="4">composite endpoint of cardiovascular death, AMI, and</text>
<text top="1094" left="446" width="96" height="16" font="4">stroke by 22% <a href="e44.full.html#93">(</a></text>
<text top="1094" left="541" width="23" height="16" font="16"><a href="e44.full.html#93">301</a></text>
<text top="1094" left="564" width="242" height="16" font="4"><a href="e44.full.html#93">). </a>MICRO-HOPE (Microalbuminuria,</text>
<text top="52" left="787" width="18" height="10" font="12">e97</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">Cardiovascular, and Renal Outcomes), a substudy of</text>
<text top="122" left="59" width="360" height="16" font="4">HOPE, additionally showed, in middle-aged patients with</text>
<text top="140" left="59" width="360" height="16" font="4">diabetes mellitus who were at high risk for cardiovascular</text>
<text top="158" left="59" width="360" height="16" font="4">events, significant reductions in MI by 22%, stroke by 33%,</text>
<text top="176" left="59" width="360" height="16" font="4">cardiovascular death by 37%, and the combined primary</text>
<text top="194" left="59" width="156" height="16" font="4">event outcome by 25% <a href="e44.full.html#105">(</a></text>
<text top="194" left="215" width="23" height="16" font="16"><a href="e44.full.html#105">802</a></text>
<text top="194" left="237" width="182" height="16" font="4"><a href="e44.full.html#105">). </a>Furthermore, the need for</text>
<text top="212" left="59" width="360" height="16" font="4">revascularization and incidence of worsening angina also</text>
<text top="230" left="59" width="360" height="16" font="4">were significantly reduced. The EUROPA (European trial</text>
<text top="248" left="59" width="360" height="16" font="4">on Reduction Of cardiac events with Perindopril in stable</text>
<text top="266" left="59" width="360" height="16" font="4">coronary Artery disease) trial provided added support to the</text>
<text top="284" left="59" width="360" height="16" font="4">HOPE trial results in patients with SIHD without clinical</text>
<text top="302" left="59" width="156" height="16" font="4">evidence of heart failure <a href="e44.full.html#93">(</a></text>
<text top="302" left="215" width="23" height="16" font="16"><a href="e44.full.html#93">296</a></text>
<text top="302" left="237" width="181" height="16" font="4"><a href="e44.full.html#93">). </a>In 12,218 patients followed</text>
<text top="320" left="59" width="360" height="16" font="4">up for a mean of 4.2 years, there was a 20% relative increase</text>
<text top="338" left="59" width="360" height="16" font="4">in the time to the primary composite endpoint of cardio-</text>
<text top="356" left="59" width="360" height="16" font="4">vascular death, nonfatal MI, or cardiac arrest with perindo-</text>
<text top="374" left="59" width="180" height="16" font="4">pril compared with placebo <a href="e44.full.html#93">(</a></text>
<text top="374" left="238" width="23" height="16" font="16"><a href="e44.full.html#93">296</a></text>
<text top="374" left="261" width="158" height="16" font="4"><a href="e44.full.html#93">). </a>Perindopril was further</text>
<text top="392" left="59" width="360" height="16" font="4">tested in the PEACE (Prevention of Events with</text>
<text top="410" left="59" width="360" height="16" font="4">Angiotensin-Converting Enzyme Inhibitor) trial, which</text>
<text top="428" left="59" width="360" height="16" font="4">enrolled 4,158 patients with SIHD and normal or slightly</text>
<text top="446" left="59" width="360" height="16" font="4">reduced LV function (i.e., absence of LV wall-motion</text>
<text top="464" left="59" width="95" height="16" font="4">abnormalities) <a href="e44.full.html#93">(</a></text>
<text top="464" left="153" width="23" height="16" font="16"><a href="e44.full.html#93">295</a></text>
<text top="464" left="176" width="243" height="16" font="4"><a href="e44.full.html#93">). </a>The incidence of the primary endpoint</text>
<text top="482" left="59" width="360" height="16" font="4">of death from cardiovascular causes, MI, or coronary revas-</text>
<text top="500" left="59" width="360" height="16" font="4">cularization was equivalent between perindopril and pla-</text>
<text top="518" left="59" width="360" height="16" font="4">cebo, but the overall rate of cardiovascular events was lower</text>
<text top="536" left="59" width="360" height="16" font="4">than in the HOPE and EUROPA trials. Equivalent results</text>
<text top="554" left="59" width="360" height="16" font="4">were seen in HOPE and EUROPA when examined by age,</text>
<text top="572" left="59" width="360" height="16" font="4">sex, known IHD, LV function, previous MI, hypertension,</text>
<text top="590" left="59" width="360" height="16" font="4">or diabetes mellitus. In QUIET (Quinapril Ischemic Event</text>
<text top="608" left="59" width="360" height="16" font="4">Trial), there was also no significant reduction with quinapril</text>
<text top="626" left="59" width="360" height="16" font="4">in ischemic events and progression of CAD in coronary</text>
<text top="644" left="59" width="360" height="16" font="4">angioplasty patients without systolic LV dysfunction (RR:</text>
<text top="662" left="59" width="42" height="16" font="4">13%; p</text>
<text top="659" left="101" width="318" height="20" font="4">⫽0.49), although this finding has been attributed to</text>
<text top="680" left="59" width="160" height="16" font="4">study design limitations <a href="e44.full.html#104">(</a></text>
<text top="680" left="219" width="23" height="16" font="16"><a href="e44.full.html#104">797</a></text>
<text top="680" left="241" width="177" height="16" font="4"><a href="e44.full.html#104">). </a>Similarly, the IMAGINE</text>
<text top="698" left="59" width="360" height="16" font="4">(Ischemia Management With Accupril Post-Bypass Graft</text>
<text top="716" left="59" width="360" height="16" font="4">via Inhibition of the Converting Enzyme) study demon-</text>
<text top="734" left="59" width="360" height="16" font="4">strated no reduction in clinical outcomes in low-risk pa-</text>
<text top="752" left="59" width="83" height="16" font="4">tients (LVEF</text>
<text top="749" left="146" width="272" height="20" font="4">⬎40%) with quinapril after surgical revascu-</text>
<text top="770" left="59" width="72" height="16" font="4">larization <a href="e44.full.html#105">(</a></text>
<text top="770" left="130" width="23" height="16" font="16"><a href="e44.full.html#105">803</a></text>
<text top="770" left="153" width="265" height="16" font="4"><a href="e44.full.html#105">). </a>In a meta-analysis of ACE-inhibitor</text>
<text top="788" left="59" width="360" height="16" font="4">therapy versus placebo in 31,555 patients from HOPE,</text>
<text top="806" left="59" width="360" height="16" font="4">EUROPA, PEACE, and QUIET, ACE-inhibitor therapy</text>
<text top="824" left="59" width="360" height="16" font="4">produced 14% reductions in all-cause mortality and MI</text>
<text top="842" left="59" width="47" height="16" font="4">(both p</text>
<text top="839" left="105" width="313" height="20" font="4">⫽0.0004), a 23% reduction in stroke (p⫽0.0004),</text>
<text top="860" left="59" width="360" height="16" font="4">and a 7% reduction in revascularization procedures</text>
<text top="878" left="59" width="13" height="16" font="4">(p</text>
<text top="875" left="71" width="208" height="20" font="4">⫽0.025) compared with placebo <a href="e44.full.html#104">(</a></text>
<text top="878" left="279" width="23" height="16" font="16"><a href="e44.full.html#104">796</a></text>
<text top="878" left="302" width="9" height="16" font="4"><a href="e44.full.html#104">).</a></text>
<text top="896" left="74" width="345" height="16" font="4">Although the cited studies involved a variety of ACE</text>
<text top="914" left="59" width="360" height="16" font="4">inhibitors that differ with regard to structure, bioavailability,</text>
<text top="932" left="59" width="360" height="16" font="4">potency, receptor-binding characteristics, tissue distribu-</text>
<text top="950" left="59" width="360" height="16" font="4">tion, metabolism, and excretion properties, there is little</text>
<text top="968" left="59" width="360" height="16" font="4">evidence that these differences are associated with therapeu-</text>
<text top="986" left="59" width="360" height="16" font="4">tic advantages. Because the benefits of ACE inhibitors seem</text>
<text top="1004" left="59" width="360" height="16" font="4">to reflect a class effect, the selection of a particular agent can</text>
<text top="1022" left="59" width="360" height="16" font="4">be based on such factors as availability in local formularies,</text>
<text top="1040" left="59" width="128" height="16" font="4">cost, and tolerability.</text>
<text top="1058" left="74" width="345" height="16" font="4">ACE inhibitors are recommended for all patients with</text>
<text top="1076" left="59" width="360" height="16" font="4">SIHD and hypertension, diabetes mellitus, LV dysfunction</text>
<text top="1094" left="59" width="24" height="16" font="4">(EF</text>
<text top="1091" left="87" width="288" height="20" font="4">ⱕ40%), or CKD. Also included in the HOPE <a href="e44.full.html#93">(</a></text>
<text top="1094" left="375" width="23" height="16" font="16"><a href="e44.full.html#93">301</a></text>
<text top="1094" left="397" width="21" height="16" font="4"><a href="e44.full.html#93">) </a>or</text>
<text top="104" left="446" width="75" height="16" font="4">EUROPA <a href="e44.full.html#93">(</a></text>
<text top="104" left="520" width="23" height="16" font="16"><a href="e44.full.html#93">296</a></text>
<text top="104" left="543" width="263" height="16" font="4"><a href="e44.full.html#93">) </a>trials were participants who did not have</text>
<text top="122" left="446" width="360" height="16" font="4">one of these conditions but did have multiple cardiac risk</text>
<text top="140" left="446" width="360" height="16" font="4">factors, and it seems that they also benefited from use of</text>
<text top="158" left="446" width="106" height="16" font="4">ACE inhibitors <a href="e44.full.html#104">(</a></text>
<text top="158" left="551" width="23" height="16" font="16"><a href="e44.full.html#104">797</a></text>
<text top="158" left="574" width="9" height="16" font="4"><a href="e44.full.html#104">).</a></text>
<text top="176" left="461" width="345" height="16" font="4">ARBs also play an important role in vascular protection.</text>
<text top="194" left="446" width="360" height="16" font="4">They bind in a competitive or insurmountable manner to</text>
<text top="212" left="446" width="360" height="16" font="4">the type 1 angiotensin II receptor, increasing plasma renin</text>
<text top="230" left="446" width="360" height="16" font="4">activity, plasma renin, and angiotensin I and II concentra-</text>
<text top="248" left="446" width="360" height="16" font="4">tions. In patients with hypertension or cardiovascular dis-</text>
<text top="266" left="446" width="360" height="16" font="4">ease, ARBs produce reductions in BP equivalent to those</text>
<text top="284" left="446" width="196" height="16" font="4">achieved with ACE inhibitors <a href="e44.full.html#105">(</a></text>
<text top="284" left="641" width="23" height="16" font="16"><a href="e44.full.html#105">804</a></text>
<text top="284" left="664" width="142" height="16" font="4"><a href="e44.full.html#105">). </a>These agents signifi-</text>
<text top="302" left="446" width="360" height="16" font="4">cantly reduce LV mass and stroke incidences compared with</text>
<text top="320" left="446" width="360" height="16" font="4">beta blockers and improve outcomes in diabetic nephropa-</text>
<text top="338" left="446" width="134" height="16" font="4">thy and heart failure <a href="e44.full.html#99">(</a></text>
<text top="338" left="579" width="101" height="16" font="16"><a href="e44.full.html#99">563,565,792,805</a></text>
<text top="338" left="680" width="125" height="16" font="4"><a href="e44.full.html#99">). </a>A meta-regression</text>
<text top="356" left="446" width="360" height="16" font="4">analysis of 26 trials compared the effects of ACE inhibitors</text>
<text top="374" left="446" width="329" height="16" font="4">and ARBs on major vascular events by BP effects <a href="e44.full.html#105">(</a></text>
<text top="374" left="774" width="23" height="16" font="16"><a href="e44.full.html#105">804</a></text>
<text top="374" left="797" width="9" height="16" font="4"><a href="e44.full.html#105">).</a></text>
<text top="392" left="446" width="360" height="16" font="4">Treatment with ACE inhibitor– based regimens was asso-</text>
<text top="410" left="446" width="360" height="16" font="4">ciated with a reduction in the risk for stroke (by 19%), IHD</text>
<text top="428" left="446" width="360" height="16" font="4">(by 16%), and heart failure (by 27%) for each 5–mm Hg</text>
<text top="446" left="446" width="360" height="16" font="4">reduction in BP; corresponding figures for the reduction in</text>
<text top="464" left="446" width="360" height="16" font="4">risk for ARBs were 26%, 17%, and 12%, respectively. There</text>
<text top="482" left="446" width="360" height="16" font="4">were no significant differences between ARB- and ACE</text>
<text top="500" left="446" width="360" height="16" font="4">inhibitor– based regimens in the risk of stroke, IHD, and</text>
<text top="518" left="446" width="360" height="16" font="4">heart failure for each 5–mm Hg reduction in BP. When</text>
<text top="536" left="446" width="360" height="16" font="4">these outcomes were assessed at zero BP reduction, the risk</text>
<text top="554" left="446" width="360" height="16" font="4">reduction for IHD was significantly greater for ACE</text>
<text top="572" left="446" width="175" height="16" font="4">inhibitors than for ARBs (p</text>
<text top="569" left="621" width="185" height="20" font="4">⫽0.002). Furthermore, unlike</text>
<text top="590" left="446" width="360" height="16" font="4">ARBs, ACE inhibitors were associated with a significant</text>
<text top="608" left="446" width="255" height="16" font="4">additional risk reduction for IHD of 9% (p</text>
<text top="605" left="700" width="105" height="20" font="4">⫽0<i>.</i>004), without</text>
<text top="626" left="446" width="360" height="16" font="4">differences seen for stroke or heart failure versus ARBs. It is</text>
<text top="644" left="446" width="360" height="16" font="4">therefore recommended that ARBs be substituted for ACE</text>
<text top="662" left="446" width="360" height="16" font="4">inhibitors in patients with SIHD and hypertension who are</text>
<text top="680" left="446" width="187" height="16" font="4">intolerant of ACE inhibitors <a href="e44.full.html#99">(</a></text>
<text top="680" left="632" width="128" height="16" font="16"><a href="e44.full.html#99">563,565,792,804,805</a></text>
<text top="680" left="760" width="9" height="16" font="4"><a href="e44.full.html#99">).</a></text>
<text top="711" left="446" width="156" height="9" font="6">4.4.2.4. INFLUENZA VACCINATION</text>
<text top="734" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="747" left="446" width="360" height="10" font="13">1. An annual influenza vaccine is recommended for patients with SIHD</text>
<text top="764" left="461" width="173" height="10" font="13"><a href="e44.full.html#105">(806–810). </a><i>(Level of Evidence: B)</i></text>
<text top="788" left="446" width="360" height="16" font="4">In patients with chronic medical conditions such as cardio-</text>
<text top="806" left="446" width="360" height="16" font="4">vascular disease, influenza contributes to a higher risk for</text>
<text top="824" left="446" width="360" height="16" font="4">mortality and hospitalization and exacerbates underlying</text>
<text top="842" left="446" width="360" height="16" font="4">medical conditions. The World Health Organization and</text>
<text top="860" left="446" width="360" height="16" font="4">the AHA/ACCF recommend annual vaccination with in-</text>
<text top="878" left="446" width="360" height="16" font="4">activated vaccine (administered intramuscularly) against</text>
<text top="896" left="446" width="360" height="16" font="4">seasonal influenza to prevent all-cause mortality and mor-</text>
<text top="914" left="446" width="360" height="16" font="4">bidity in patients with underlying cardiovascular conditions</text>
<text top="932" left="446" width="5" height="16" font="4"><a href="e44.full.html#105">(</a></text>
<text top="932" left="450" width="49" height="16" font="16"><a href="e44.full.html#105">806,807</a></text>
<text top="932" left="499" width="227" height="16" font="4"><a href="e44.full.html#105">). </a>A cohort study in 1,340 elderly (i.e.,</text>
<text top="929" left="729" width="76" height="20" font="4">ⱖ65 years of</text>
<text top="950" left="446" width="360" height="16" font="4">age) patients with heart failure or IHD showed that annual</text>
<text top="968" left="446" width="360" height="16" font="4">influenza vaccinations reduced the risk of mortality by 37%</text>
<text top="986" left="446" width="360" height="16" font="4">during the winter period (January through April), but not</text>
<text top="1004" left="446" width="360" height="16" font="4">the summer period (June through September), resulting in a</text>
<text top="1022" left="446" width="360" height="16" font="4">number needed to treat to prevent 1 death during 1</text>
<text top="1040" left="446" width="278" height="16" font="4">influenza period of 122 annual vaccinations <a href="e44.full.html#105">(</a></text>
<text top="1040" left="723" width="23" height="16" font="16"><a href="e44.full.html#105">808</a></text>
<text top="1040" left="746" width="60" height="16" font="4"><a href="e44.full.html#105">). </a>Further</text>
<text top="1058" left="446" width="360" height="16" font="4">mechanistic and confirmatory studies in heart failure and</text>
<text top="1076" left="446" width="360" height="16" font="4">other cardiovascular disease are needed to confirm these</text>
<text top="1094" left="446" width="360" height="16" font="4">findings. Evidence from 2 prospective randomized clinical</text>
<text top="52" left="59" width="18" height="10" font="12">e98</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="114" height="16" font="4">studies in patients</text>
<text top="101" left="179" width="240" height="20" font="4">ⱖ65 years of age who were medically</text>
<text top="122" left="59" width="360" height="16" font="4">stable supports increasing influenza vaccine doses to achieve</text>
<text top="140" left="59" width="360" height="16" font="4">higher serum antibody titers and potentially improved</text>
<text top="158" left="59" width="225" height="16" font="4">protection from influenza infection <a href="e44.full.html#105">(</a></text>
<text top="158" left="283" width="49" height="16" font="16"><a href="e44.full.html#105">809,810</a></text>
<text top="158" left="332" width="87" height="16" font="4"><a href="e44.full.html#105">). </a>This dosing</text>
<text top="176" left="59" width="360" height="16" font="4">scheme was associated with higher injection site reactions,</text>
<text top="194" left="59" width="360" height="16" font="4">including pain and myalgias. Currently, it is recommended</text>
<text top="212" left="59" width="360" height="16" font="4">that patients with SIHD receive an annual influenza vacci-</text>
<text top="230" left="59" width="172" height="16" font="4">nation in the standard dose.</text>
<text top="261" left="59" width="308" height="9" font="6">4.4.2.5. ADDITIONAL THERAPY TO REDUCE RISK OF MI AND DEATH</text>
<text top="284" left="59" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="297" left="59" width="360" height="10" font="13">1. Estrogen therapy is not recommended in postmenopausal women</text>
<text top="314" left="74" width="344" height="10" font="13">with SIHD with the intent of reducing cardiovascular risk or improv-</text>
<text top="331" left="74" width="285" height="10" font="13">ing clinical outcomes <a href="e44.full.html#105">(811–814). </a><i>(Level of Evidence: A)</i></text>
<text top="347" left="59" width="360" height="10" font="13">2. Vitamin C, vitamin E, and beta-carotene supplementation are not</text>
<text top="364" left="74" width="344" height="10" font="13">recommended with the intent of reducing cardiovascular risk or</text>
<text top="381" left="74" width="344" height="10" font="13">improving clinical outcomes in patients with SIHD <a href="e44.full.html#95">(398,527,815–</a></text>
<text top="398" left="74" width="166" height="10" font="13"><a href="e44.full.html#95">818,818). </a><i>(Level of Evidence: A)</i></text>
<text top="415" left="58" width="360" height="10" font="13">3. Treatment of elevated homocysteine with folate or vitamins B6 and</text>
<text top="432" left="74" width="344" height="10" font="13">B12 is not recommended with the intent of reducing cardiovascular</text>
<text top="449" left="74" width="344" height="10" font="13">risk or improving clinical outcomes in patients with SIHD <a href="e44.full.html#105">(819–</a></text>
<text top="466" left="74" width="142" height="10" font="13"><a href="e44.full.html#105">822). </a><i>(Level of Evidence: A)</i></text>
<text top="482" left="59" width="360" height="10" font="13">4. Chelation therapy is not recommended with the intent of improving</text>
<text top="499" left="74" width="344" height="10" font="13">symptoms or reducing cardiovascular risk in patients with SIHD</text>
<text top="516" left="74" width="172" height="10" font="13"><a href="e44.full.html#105">(823–826). </a><i>(Level of Evidence: C)</i></text>
<text top="533" left="59" width="360" height="10" font="13">5. Treatment with garlic, coenzyme Q10, selenium, or chromium is not</text>
<text top="550" left="74" width="344" height="10" font="13">recommended with the intent of reducing cardiovascular risk or</text>
<text top="567" left="74" width="344" height="10" font="13">improving clinical outcomes in patients with SIHD. <i>(Level of Evi-</i></text>
<text top="584" left="74" width="48" height="10" font="25"><i>dence: C)</i></text>
<text top="612" left="59" width="46" height="9" font="6">4.4.2.5.1.</text>
<text top="611" left="111" width="235" height="12" font="36">HORMONE REPLACEMENT THERAPY.</text>
<text top="608" left="353" width="65" height="16" font="4">Numerous</text>
<text top="626" left="58" width="360" height="16" font="4">observational studies have suggested that estrogen therapy</text>
<text top="644" left="58" width="360" height="16" font="4">might provide protection against the development of IHD</text>
<text top="662" left="58" width="173" height="16" font="4">in postmenopausal women <a href="e44.full.html#105">(</a></text>
<text top="662" left="232" width="54" height="16" font="16"><a href="e44.full.html#105">827– 829</a></text>
<text top="662" left="286" width="133" height="16" font="4"><a href="e44.full.html#105">). </a>Beneficial effects of</text>
<text top="680" left="58" width="360" height="16" font="4">exogenous estrogen include an increase in HDL cholesterol,</text>
<text top="698" left="58" width="360" height="16" font="4">a decrease in LDL cholesterol, and enhanced endothelial</text>
<text top="716" left="58" width="62" height="16" font="4">function <a href="e44.full.html#105">(</a></text>
<text top="716" left="121" width="56" height="16" font="16"><a href="e44.full.html#105">830 – 833</a></text>
<text top="716" left="177" width="242" height="16" font="4"><a href="e44.full.html#105">). </a>In light of the epidemiological data</text>
<text top="734" left="58" width="360" height="16" font="4">and evidence of salutary physiological effects, postmeno-</text>
<text top="752" left="58" width="360" height="16" font="4">pausal estrogen replacement previously was advocated for</text>
<text top="770" left="58" width="360" height="16" font="4">the primary and secondary prevention of CAD in women.</text>
<text top="788" left="58" width="360" height="16" font="4">Clinical trials in women with and without established</text>
<text top="806" left="58" width="360" height="16" font="4">CAD, however, have failed to confirm a decrease in cardio-</text>
<text top="824" left="58" width="360" height="16" font="4">vascular events with hormone therapy. In HERS (Heart and</text>
<text top="842" left="58" width="360" height="16" font="4">Estrogen/progesterone Replacement Study), 2,763 post-</text>
<text top="860" left="58" width="360" height="16" font="4">menopausal women with CAD were randomized to therapy</text>
<text top="878" left="58" width="360" height="16" font="4">with 0.625 mg of conjugated estrogen plus 2.5 mg of</text>
<text top="896" left="58" width="360" height="16" font="4">medroxy progesterone acetate or placebo and were followed</text>
<text top="914" left="58" width="360" height="16" font="4">up for an average of 4.4 years. Despite an 11% lower level of</text>
<text top="932" left="58" width="360" height="16" font="4">LDL cholesterol and a 10% higher level of HDL cholesterol</text>
<text top="950" left="58" width="360" height="16" font="4">in the hormone therapy group, there was no difference in</text>
<text top="968" left="58" width="360" height="16" font="4">the composite primary endpoint of MI or IHD death, and</text>
<text top="986" left="58" width="360" height="16" font="4">an early increase in cardiovascular events was observed</text>
<text top="1004" left="58" width="5" height="16" font="4"><a href="e44.full.html#105">(</a></text>
<text top="1004" left="63" width="23" height="16" font="16"><a href="e44.full.html#105">811</a></text>
<text top="1004" left="86" width="333" height="16" font="4"><a href="e44.full.html#105">). </a>In HERS-II, an unblinded follow-up study of</text>
<text top="1022" left="58" width="360" height="16" font="4">HERS, the lack of benefit with estrogen/progestin therapy</text>
<text top="1040" left="58" width="237" height="16" font="4">persisted at an average of 6.8 years <a href="e44.full.html#105">(</a></text>
<text top="1040" left="296" width="23" height="16" font="16"><a href="e44.full.html#105">834</a></text>
<text top="1040" left="318" width="100" height="16" font="4"><a href="e44.full.html#105">). </a>A subsequent</text>
<text top="1058" left="58" width="360" height="16" font="4">angiographic study demonstrated a nonsignificant worsen-</text>
<text top="1076" left="58" width="360" height="16" font="4">ing of coronary stenoses in patients prescribed estrogen</text>
<text top="1094" left="58" width="55" height="16" font="4">therapy <a href="e44.full.html#105">(</a></text>
<text top="1094" left="114" width="22" height="16" font="16"><a href="e44.full.html#105">835</a></text>
<text top="1094" left="136" width="282" height="16" font="4"><a href="e44.full.html#105">). </a>The Women’s Health Initiative, a random-</text>
<text top="104" left="445" width="360" height="16" font="4">ized controlled primary prevention trial, also found no</text>
<text top="123" left="445" width="297" height="16" font="4">evidence that estrogen protects against IHD <a href="e44.full.html#105">(</a></text>
<text top="123" left="742" width="54" height="16" font="16"><a href="e44.full.html#105">812– 814</a></text>
<text top="123" left="797" width="9" height="16" font="4"><a href="e44.full.html#105">).</a></text>
<text top="141" left="445" width="360" height="16" font="4">Thus, the weight of current scientific evidence suggests that</text>
<text top="159" left="445" width="360" height="16" font="4">estrogen/progestin therapy in postmenopausal women does</text>
<text top="178" left="445" width="360" height="16" font="4">not reduce the risk of vascular events or coronary deaths in</text>
<text top="196" left="445" width="360" height="16" font="4">secondary prevention. Women who are taking estrogen</text>
<text top="215" left="445" width="360" height="16" font="4">therapy and who have vascular disease can continue this</text>
<text top="233" left="445" width="360" height="16" font="4">therapy if it is prescribed for other well-established indica-</text>
<text top="251" left="445" width="360" height="16" font="4">tions and if no better alternative therapies are appropriate,</text>
<text top="270" left="445" width="360" height="16" font="4">although the FDA recommends use in the lowest dose and</text>
<text top="288" left="445" width="360" height="16" font="4">shortest duration acceptable. There is, however, no basis for</text>
<text top="306" left="445" width="360" height="16" font="4">adding or continuing estrogens in postmenopausal women</text>
<text top="325" left="445" width="360" height="16" font="4">with clinically evident SIHD in an effort to prevent or retard</text>
<text top="343" left="445" width="263" height="16" font="4">progression of their atherosclerotic disease.</text>
<text top="365" left="446" width="50" height="9" font="6">4.4.2.5.2.</text>
<text top="364" left="502" width="303" height="12" font="36">VITAMIN C, VITAMIN E, AND BETA-CAROTENE.</text>
<text top="380" left="446" width="360" height="16" font="4">Epidemiological and population studies have suggested that</text>
<text top="398" left="446" width="360" height="16" font="4">antioxidant vitamins, such as vitamin E, vitamin C, and</text>
<text top="416" left="446" width="302" height="16" font="4">beta-carotene, could lower cardiovascular risk <a href="e44.full.html#105">(</a></text>
<text top="416" left="748" width="49" height="16" font="16"><a href="e44.full.html#105">836,837</a></text>
<text top="416" left="797" width="9" height="16" font="4"><a href="e44.full.html#105">).</a></text>
<text top="435" left="446" width="360" height="16" font="4">Controlled clinical trials, however, have failed to demon-</text>
<text top="453" left="446" width="360" height="16" font="4">strate a beneficial effect of antioxidant supplements on risk</text>
<text top="471" left="446" width="277" height="16" font="4">of cardiovascular morbidity and mortality <a href="e44.full.html#95">(</a></text>
<text top="471" left="723" width="83" height="16" font="16"><a href="e44.full.html#95">398,527,815–</a></text>
<text top="490" left="446" width="23" height="16" font="16"><a href="e44.full.html#95">817</a></text>
<text top="490" left="468" width="338" height="16" font="4"><a href="e44.full.html#95">). </a>A meta-analysis of antioxidant vitamin studies exam-</text>
<text top="508" left="446" width="360" height="16" font="4">ined 7 trials of vitamin E treatment and 8 trials of</text>
<text top="526" left="446" width="175" height="16" font="4">beta-carotene treatment with</text>
<text top="523" left="624" width="182" height="20" font="4">⬎1,000 subjects in each. Most</text>
<text top="545" left="446" width="360" height="16" font="4">of these studies were performed in patients with CAD or at</text>
<text top="563" left="446" width="360" height="16" font="4">risk of CAD. Vitamin E had no effect on all-cause mortality</text>
<text top="581" left="446" width="151" height="16" font="4">or cardiovascular death <a href="e44.full.html#105">(</a></text>
<text top="581" left="596" width="23" height="16" font="16"><a href="e44.full.html#105">838</a></text>
<text top="581" left="619" width="187" height="16" font="4"><a href="e44.full.html#105">). </a>Beta-carotene led to a small</text>
<text top="600" left="446" width="360" height="16" font="4">but statistically significant increase in all-cause mortality</text>
<text top="618" left="446" width="360" height="16" font="4">and cardiovascular death. Thus, existing scientific evidence</text>
<text top="636" left="446" width="360" height="16" font="4">does not justify routine use of antioxidant supplements for</text>
<text top="655" left="446" width="327" height="16" font="4">the prevention or treatment of cardiovascular disease.</text>
<text top="677" left="446" width="44" height="9" font="6">4.4.2.5.3.</text>
<text top="676" left="495" width="210" height="12" font="36">FOLATE AND VITAMINS B6 AND B12.</text>
<text top="673" left="712" width="93" height="16" font="4">Prospective ob-</text>
<text top="691" left="445" width="360" height="16" font="4">servational studies have demonstrated that the serum ho-</text>
<text top="710" left="445" width="360" height="16" font="4">mocysteine level is a strong, independent risk factor for</text>
<text top="728" left="445" width="110" height="16" font="4">ischemic events <a href="e44.full.html#105">(</a></text>
<text top="728" left="556" width="56" height="16" font="16"><a href="e44.full.html#105">839 – 841</a></text>
<text top="728" left="612" width="194" height="16" font="4"><a href="e44.full.html#105">). </a>Homocysteine levels can be</text>
<text top="746" left="445" width="360" height="16" font="4">lowered with folic acid or B-vitamins. Trials of folate and</text>
<text top="765" left="445" width="360" height="16" font="4">vitamin B supplementation, however, consistently have</text>
<text top="783" left="445" width="360" height="16" font="4">failed to demonstrate a decrease in cardiovascular morbidity</text>
<text top="801" left="445" width="360" height="16" font="4">or mortality rates. The VISP (Vitamin Intervention for</text>
<text top="820" left="445" width="360" height="16" font="4">Stroke Prevention) trial randomized patients with prior</text>
<text top="838" left="445" width="360" height="16" font="4">nondisabling stroke to varying doses of folic acid, B6, and</text>
<text top="856" left="445" width="360" height="16" font="4">B12. Despite a reduction in homocysteine that was 2</text>
<text top="875" left="445" width="360" height="16" font="4">mmol/L greater in the group allocated to the high dose of</text>
<text top="893" left="445" width="360" height="16" font="4">supplementation, there were no differences in the incidence</text>
<text top="911" left="445" width="237" height="16" font="4">of recurrent stroke, IHD, or death <a href="e44.full.html#105">(</a></text>
<text top="911" left="682" width="23" height="16" font="16"><a href="e44.full.html#105">822</a></text>
<text top="911" left="705" width="101" height="16" font="4"><a href="e44.full.html#105">). </a>Similarly, the</text>
<text top="930" left="445" width="360" height="16" font="4">HOPE 2 (Heart Outcome in Prevention) trial found no</text>
<text top="948" left="445" width="360" height="16" font="4">benefit of folate and vitamins B6 and B12 in patients with</text>
<text top="966" left="445" width="231" height="16" font="4">vascular disease or diabetes mellitus <a href="e44.full.html#105">(</a></text>
<text top="966" left="677" width="23" height="16" font="16"><a href="e44.full.html#105">821</a></text>
<text top="966" left="699" width="106" height="16" font="4"><a href="e44.full.html#105">). </a>The NORVIT</text>
<text top="985" left="445" width="360" height="16" font="4">(Norwegian Vitamin Trial) examined 3 combinations of</text>
<text top="1003" left="445" width="360" height="16" font="4">folate and B vitamins in patients who had an AMI and</text>
<text top="1021" left="445" width="360" height="16" font="4">observed no decrease in the risk of cardiovascular events</text>
<text top="1040" left="445" width="5" height="16" font="4"><a href="e44.full.html#105">(</a></text>
<text top="1040" left="450" width="23" height="16" font="16"><a href="e44.full.html#105">820</a></text>
<text top="1040" left="473" width="333" height="16" font="4"><a href="e44.full.html#105">). </a>A meta-analysis of these and 9 other smaller trials</text>
<text top="1058" left="445" width="360" height="16" font="4">also found no reduction in cardiovascular events or mortality</text>
<text top="1076" left="445" width="185" height="16" font="4">with folate supplementation <a href="e44.full.html#105">(</a></text>
<text top="1076" left="630" width="23" height="16" font="16"><a href="e44.full.html#105">819</a></text>
<text top="1076" left="653" width="153" height="16" font="4"><a href="e44.full.html#105">). </a>These studies indicate</text>
<text top="1095" left="445" width="360" height="16" font="4">that routine use of folate and B vitamins for the prevention</text>
<text top="52" left="787" width="18" height="10" font="12">e99</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">or treatment of cardiovascular disease should not be</text>
<text top="122" left="59" width="90" height="16" font="4">recommended.</text>
<text top="144" left="59" width="44" height="9" font="6">4.4.2.5.4.</text>
<text top="143" left="108" width="140" height="12" font="36">CHELATION THERAPY.</text>
<text top="140" left="255" width="164" height="16" font="4">Chelation therapy, which</text>
<text top="158" left="58" width="360" height="16" font="4">consists of a series of intravenous infusions of disodium</text>
<text top="176" left="58" width="360" height="16" font="4">ethylene diamine tetraacetic acid (EDTA) in combina-</text>
<text top="194" left="58" width="360" height="16" font="4">tion with other substances, has been promoted as a</text>
<text top="212" left="58" width="360" height="16" font="4">noninvasive means of improving blood flow in athero-</text>
<text top="230" left="58" width="360" height="16" font="4">sclerotic vessels. EDTA combines with polyvalent cat-</text>
<text top="248" left="58" width="360" height="16" font="4">ions, such as calcium ions, to form soluble complexes that</text>
<text top="266" left="58" width="360" height="16" font="4">can be excreted. Advocates maintain that this process can</text>
<text top="284" left="58" width="360" height="16" font="4">result in regression of atherosclerotic plaques and relief of</text>
<text top="302" left="58" width="360" height="16" font="4">angina and that EDTA reduces oxidative stress in the</text>
<text top="320" left="58" width="84" height="16" font="4">vascular wall.</text>
<text top="338" left="73" width="345" height="16" font="4">Anecdotal reports have suggested that EDTA chelation</text>
<text top="356" left="58" width="360" height="16" font="4">therapy can result in relief of angina in patients with SIHD.</text>
<text top="374" left="58" width="360" height="16" font="4">In general, however, the efficacy of chelation therapy in</text>
<text top="392" left="58" width="360" height="16" font="4">atherosclerotic disease is not supported by clinical trials.</text>
<text top="410" left="58" width="360" height="16" font="4">Studies in patients with intermittent claudication have failed</text>
<text top="428" left="58" width="360" height="16" font="4">to demonstrate improvements in exercise measures</text>
<text top="446" left="58" width="5" height="16" font="4"><a href="e44.full.html#105">(</a></text>
<text top="446" left="63" width="49" height="16" font="16"><a href="e44.full.html#105">823,824</a></text>
<text top="446" left="112" width="152" height="16" font="4"><a href="e44.full.html#105">), </a>ankle-brachial index <a href="e44.full.html#105">(</a></text>
<text top="446" left="264" width="49" height="16" font="16"><a href="e44.full.html#105">823,824</a></text>
<text top="446" left="313" width="106" height="16" font="4"><a href="e44.full.html#105">), </a>or digital sub-</text>
<text top="464" left="58" width="228" height="16" font="4">traction angiograms with chelation <a href="e44.full.html#105">(</a></text>
<text top="464" left="286" width="23" height="16" font="16"><a href="e44.full.html#105">825</a></text>
<text top="464" left="309" width="110" height="16" font="4"><a href="e44.full.html#105">). </a>The only RCT</text>
<text top="482" left="58" width="360" height="16" font="4">examining the effectiveness of chelation therapy on SIHD</text>
<text top="500" left="58" width="5" height="16" font="4"><a href="e44.full.html#105">(</a></text>
<text top="500" left="63" width="23" height="16" font="16"><a href="e44.full.html#105">826</a></text>
<text top="500" left="86" width="333" height="16" font="4"><a href="e44.full.html#105">) </a>studied 84 patients with stable angina and a positive</text>
<text top="518" left="58" width="360" height="16" font="4">treadmill test for ischemia. Those randomized to active</text>
<text top="536" left="58" width="360" height="16" font="4">therapy received weight-adjusted disodium EDTA chela-</text>
<text top="554" left="58" width="360" height="16" font="4">tion therapy for 3 hours per treatment, twice weekly for 15</text>
<text top="572" left="58" width="360" height="16" font="4">weeks and then once monthly for an additional 3 months.</text>
<text top="590" left="58" width="360" height="16" font="4">There were no differences between groups in changes in</text>
<text top="608" left="58" width="360" height="16" font="4">exercise time to ischemia, exercise capacity, or quality-of-</text>
<text top="626" left="58" width="360" height="16" font="4">life scores. The National Center of Complementary and</text>
<text top="644" left="58" width="360" height="16" font="4">Alternative Medicine and the National Heart, Lung, and</text>
<text top="662" left="58" width="360" height="16" font="4">Blood Institute have sponsored TACT (Trial to Assess</text>
<text top="680" left="58" width="129" height="16" font="4">Chelation Therapy) <a href="e44.full.html#105">(</a></text>
<text top="680" left="188" width="23" height="16" font="16"><a href="e44.full.html#105">842</a></text>
<text top="680" left="210" width="208" height="16" font="4"><a href="e44.full.html#105">), </a>an RCT comparing chelation to</text>
<text top="698" left="58" width="360" height="16" font="4">placebo in patients who had experienced an MI. There is</text>
<text top="716" left="58" width="360" height="16" font="4">insufficient evidence to support chelation therapy for im-</text>
<text top="734" left="58" width="360" height="16" font="4">proving symptoms or preventing adverse outcomes in pa-</text>
<text top="752" left="58" width="360" height="16" font="4">tients with SIHD. Moreover, this therapy is costly and time</text>
<text top="770" left="58" width="360" height="16" font="4">consuming, can result in harm, and could result in patients</text>
<text top="788" left="58" width="275" height="16" font="4">failing to pursue proven treatment strategies.</text>
<text top="810" left="59" width="44" height="9" font="6">4.4.2.5.5.</text>
<text top="809" left="108" width="311" height="12" font="36">GARLIC, COENZYME Q10, SELENIUM, AND CHROMIUM.</text>
<text top="824" left="59" width="360" height="16" font="4">Nutritional supplements for the prevention and treatment of</text>
<text top="842" left="59" width="360" height="16" font="4">cardiovascular disease have grown increasingly popular in</text>
<text top="860" left="59" width="360" height="16" font="4">the United States. These alternative therapies often are</text>
<text top="878" left="59" width="360" height="16" font="4">promoted with anecdotal claims of efficacy but have not</text>
<text top="896" left="59" width="360" height="16" font="4">been studied rigorously. When data are available, they often</text>
<text top="914" left="59" width="360" height="16" font="4">conflict and consist of results of small, open-label trials. At</text>
<text top="932" left="59" width="360" height="16" font="4">present, there is no definitive evidence to recommend</text>
<text top="950" left="59" width="360" height="16" font="4">treatment with garlic, coenzyme Q10, selenium, or chro-</text>
<text top="968" left="59" width="360" height="16" font="4">mium for improving cardiovascular outcomes in patients</text>
<text top="986" left="59" width="75" height="16" font="4">with SIHD.</text>
<text top="1013" left="59" width="309" height="16" font="26"><b>4.4.3. Medical Therapy for Relief of Symptoms</b></text>
<text top="1044" left="59" width="312" height="9" font="6">4.4.3.1. USE OF ANTI-ISCHEMIC MEDICATIONS: RECOMMENDATIONS</text>
<text top="1068" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="1080" left="59" width="360" height="10" font="13">1. Beta blockers should be prescribed as initial therapy for relief of</text>
<text top="1097" left="74" width="344" height="10" font="13">symptoms in patients with SIHD <a href="e44.full.html#103">(757,765,766). </a><i>(Level of Evidence: B)</i></text>
<text top="105" left="445" width="360" height="10" font="13">2. Calcium channel blockers or long-acting nitrates should be pre-</text>
<text top="122" left="461" width="344" height="10" font="13">scribed for relief of symptoms when beta blockers are contraindi-</text>
<text top="139" left="461" width="344" height="10" font="13">cated or cause unacceptable side effects in patients with SIHD</text>
<text top="156" left="461" width="194" height="10" font="13"><a href="e44.full.html#96">(420,768,769). </a><i>(Level of Evidence: B)</i></text>
<text top="173" left="445" width="360" height="10" font="13">3. Calcium channel blockers or long-acting nitrates, in combination</text>
<text top="190" left="461" width="344" height="10" font="13">with beta blockers, should be prescribed for relief of symptoms</text>
<text top="207" left="461" width="344" height="10" font="13">when initial treatment with beta blockers is unsuccessful in patients</text>
<text top="224" left="461" width="200" height="10" font="13">with SIHD <a href="e44.full.html#96">(420). </a><i>(Level of Evidence: B)</i></text>
<text top="242" left="445" width="360" height="10" font="13">4. Sublingual nitroglycerin or nitroglycerin spray is recommended for</text>
<text top="259" left="461" width="344" height="10" font="13">immediate relief of angina in patients with SIHD <a href="e44.full.html#105">(843–845). </a><i>(Level</i></text>
<text top="276" left="461" width="77" height="10" font="25"><i>of Evidence: B)</i></text>
<text top="306" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="319" left="446" width="360" height="10" font="13">1. Treatment with a long-acting nondihydropyridine calcium channel</text>
<text top="336" left="461" width="344" height="10" font="13">blocker (verapamil or diltiazem) instead of a beta blocker as initial</text>
<text top="353" left="461" width="344" height="10" font="13">therapy for relief of symptoms is reasonable in patients with SIHD</text>
<text top="370" left="461" width="146" height="10" font="13"><a href="e44.full.html#96">(420). </a><i>(Level of Evidence: B)</i></text>
<text top="387" left="446" width="360" height="10" font="13">2. Ranolazine can be useful when prescribed as a substitute for beta</text>
<text top="404" left="461" width="344" height="10" font="13">blockers for relief of symptoms in patients with SIHD if initial</text>
<text top="422" left="461" width="344" height="10" font="13">treatment with beta blockers leads to unacceptable side effects or</text>
<text top="439" left="461" width="344" height="10" font="13">is ineffective or if initial treatment with beta blockers is contraindi-</text>
<text top="456" left="461" width="178" height="10" font="13">cated <a href="e44.full.html#105">(846). </a><i>(Level of Evidence: B)</i></text>
<text top="473" left="445" width="360" height="10" font="13">3. Ranolazine in combination with beta blockers can be useful when</text>
<text top="490" left="461" width="344" height="10" font="13">prescribed for relief of symptoms when initial treatment with beta</text>
<text top="507" left="461" width="344" height="10" font="13">blockers is not successful in patients with SIHD <a href="e44.full.html#106">(847,848). </a><i>(Level of</i></text>
<text top="524" left="461" width="63" height="10" font="25"><i>Evidence: A)</i></text>
<text top="553" left="446" width="44" height="9" font="6">4.4.3.1.1.</text>
<text top="552" left="495" width="103" height="12" font="36">BETA BLOCKERS.</text>
<text top="549" left="605" width="200" height="16" font="4">Beta blockers are recommended</text>
<text top="567" left="446" width="360" height="16" font="4">as the initial agents to relieve symptoms in most patients</text>
<text top="585" left="446" width="360" height="16" font="4">with SIHD. Beta blockers reduce myocardial oxygen con-</text>
<text top="603" left="446" width="360" height="16" font="4">sumption by reducing heart rate, myocardial contractility,</text>
<text top="622" left="446" width="360" height="16" font="4">and afterload, with attenuation of cardiovascular remodeling</text>
<text top="640" left="446" width="360" height="16" font="4">by decreasing LV wall tension with long-term use. The</text>
<text top="658" left="446" width="360" height="16" font="4">reduction in myocardial oxygen demand is directly propor-</text>
<text top="676" left="446" width="360" height="16" font="4">tional to the level of adrenergic tonic stimulation. Further-</text>
<text top="694" left="446" width="360" height="16" font="4">more, the reduction in heart rate also shifts the cardiac cycle,</text>
<text top="712" left="446" width="360" height="16" font="4">permitting more diastolic time and greater coronary perfu-</text>
<text top="731" left="446" width="311" height="16" font="4">sion, thereby improving myocardial oxygen supply.</text>
<text top="749" left="461" width="345" height="16" font="4">Long-term beta-blocker treatment is well tolerated, has</text>
<text top="767" left="446" width="360" height="16" font="4">proven benefit in SIHD by reducing ischemic burden and</text>
<text top="785" left="446" width="360" height="16" font="4">threshold, and improves survival in patients with LV dysfunc-</text>
<text top="803" left="446" width="150" height="16" font="4">tion or history of MI <a href="e44.full.html#103">(</a></text>
<text top="803" left="595" width="72" height="16" font="16"><a href="e44.full.html#103">757,765,766</a></text>
<text top="803" left="667" width="139" height="16" font="4"><a href="e44.full.html#103">). </a>When prescribed in</text>
<text top="822" left="446" width="360" height="16" font="4">combination with agents that block the renin-angiotensin-</text>
<text top="840" left="446" width="360" height="16" font="4">aldosterone system, beta blockers are the preferred agents</text>
<text top="858" left="446" width="360" height="16" font="4">for the treatment of angina in patients with LV dysfunction</text>
<text top="876" left="446" width="360" height="16" font="4">after MI and in patients with heart failure, on the basis of</text>
<text top="894" left="446" width="360" height="16" font="4">documented improvements in survival and ventricular per-</text>
<text top="912" left="446" width="66" height="16" font="4">formance <a href="e44.full.html#95">(</a></text>
<text top="912" left="512" width="128" height="16" font="16"><a href="e44.full.html#95">402,571,760,792,801</a></text>
<text top="912" left="639" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="931" left="461" width="345" height="16" font="4">A meta-analysis of comparison trials between beta block-</text>
<text top="949" left="446" width="360" height="16" font="4">ers and calcium channel blockers (dihydropyridine and</text>
<text top="967" left="446" width="360" height="16" font="4">nondihydropyridine agents) showed negligible differences in</text>
<text top="985" left="446" width="360" height="16" font="4">the rate of death or MI over relatively brief durations of</text>
<text top="1003" left="446" width="360" height="16" font="4">administration (i.e., 6 wk to 6 mo), although patients with</text>
<text top="1021" left="446" width="360" height="16" font="4">heart failure, heart block, or significant pulmonary disease</text>
<text top="1040" left="446" width="242" height="16" font="4">were excluded from the meta-analysis <a href="e44.full.html#96">(</a></text>
<text top="1040" left="687" width="23" height="16" font="16"><a href="e44.full.html#96">420</a></text>
<text top="1040" left="710" width="96" height="16" font="4"><a href="e44.full.html#96">). </a>Beta blockers</text>
<text top="1058" left="446" width="360" height="16" font="4">were found to exhibit an advantage with regard to control of</text>
<text top="1076" left="446" width="360" height="16" font="4">angina and withdrawals from therapy due to adverse events,</text>
<text top="1094" left="446" width="329" height="16" font="4">a problem that was most pronounced with nifedipine <a href="e44.full.html#96">(</a></text>
<text top="1094" left="774" width="23" height="16" font="16"><a href="e44.full.html#96">420</a></text>
<text top="1094" left="797" width="9" height="16" font="4"><a href="e44.full.html#96">).</a></text>
<text top="52" left="59" width="25" height="10" font="12">e100</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">Calcium channel blockers, however, have not been shown to</text>
<text top="122" left="59" width="360" height="16" font="4">improve survival after MI, as beta blockers have, but have</text>
<text top="140" left="59" width="360" height="16" font="4">been shown to offer protection against severe angina and to</text>
<text top="158" left="59" width="250" height="16" font="4">reduce the risk of reinfarction after MI <a href="e44.full.html#106">(</a></text>
<text top="158" left="309" width="56" height="16" font="16"><a href="e44.full.html#106">849 – 851</a></text>
<text top="158" left="365" width="9" height="16" font="4"><a href="e44.full.html#106">).</a></text>
<text top="176" left="74" width="345" height="16" font="4">Adherence to beta-blocker therapy can be influenced by</text>
<text top="194" left="59" width="360" height="16" font="4">the occurrence of adverse effects such as fatigue, lethargy,</text>
<text top="212" left="59" width="360" height="16" font="4">sexual dysfunction, or sleep disturbances. Although beta</text>
<text top="230" left="59" width="360" height="16" font="4">blockers have the potential to worsen symptoms in patients</text>
<text top="248" left="59" width="360" height="16" font="4">with significant depressive illness or PAD, these effects are</text>
<text top="266" left="59" width="360" height="16" font="4">observed rarely in clinical practice. For patients with severe</text>
<text top="284" left="59" width="360" height="16" font="4">PAD or those with vasospastic (Prinzmetal’s) angina, wors-</text>
<text top="302" left="59" width="360" height="16" font="4">ening symptoms due to vasoconstriction from unopposed</text>
<text top="320" left="59" width="360" height="16" font="4">alpha-adrenergic activity can be avoided by using beta</text>
<text top="338" left="59" width="360" height="16" font="4">blockers with alpha-adrenergic blocking (e.g., labetalol or</text>
<text top="356" left="59" width="358" height="16" font="4">carvedilol) or direct vasodilator (e.g., nebivolol) properties.</text>
<text top="378" left="59" width="44" height="9" font="6">4.4.3.1.2.</text>
<text top="377" left="108" width="188" height="12" font="36">CALCIUM CHANNEL BLOCKERS.</text>
<text top="374" left="303" width="115" height="16" font="4">If adverse effects or</text>
<text top="392" left="58" width="360" height="16" font="4">contraindications limit the use of beta blockers, calcium</text>
<text top="410" left="58" width="360" height="16" font="4">channel blockers are recommended for relief of anginal</text>
<text top="428" left="58" width="360" height="16" font="4">symptoms. These agents noncompetitively limit calcium ion</text>
<text top="446" left="58" width="360" height="16" font="4">influx through voltage-dependent L-type calcium channels,</text>
<text top="464" left="58" width="360" height="16" font="4">resulting in negative inotropic effects, cardiac pacemaker</text>
<text top="482" left="58" width="360" height="16" font="4">depression, slowing conduction, and smooth muscle relax-</text>
<text top="500" left="58" width="360" height="16" font="4">ation. There are 3 classes of calcium channel blockers: the</text>
<text top="518" left="58" width="360" height="16" font="4">dihydropyridines (e.g., nifedipine) and 2 types of nondihy-</text>
<text top="536" left="58" width="360" height="16" font="4">dropyridines, the phenylalkylamines (e.g., verapamil) and</text>
<text top="554" left="58" width="360" height="16" font="4">the benzothiazepines (e.g., diltiazem). All classes improve</text>
<text top="572" left="58" width="360" height="16" font="4">myocardial oxygen supply by decreasing coronary vascular</text>
<text top="590" left="58" width="360" height="16" font="4">resistance and augmenting epicardial conduit vessel and</text>
<text top="608" left="58" width="360" height="16" font="4">systemic arterial blood flow. Myocardial demand is de-</text>
<text top="626" left="58" width="360" height="16" font="4">creased by a reduction in myocardial contractility, systemic</text>
<text top="644" left="58" width="360" height="16" font="4">vascular resistance, and arterial pressure. However, the</text>
<text top="662" left="58" width="360" height="16" font="4">phenylalkylamines and, to a lesser extent, the benzothiaz-</text>
<text top="680" left="58" width="360" height="16" font="4">epines also depress cardiac pacemaker rate and slow con-</text>
<text top="698" left="58" width="360" height="16" font="4">duction. This depressant effect can cause sinus bradycardia</text>
<text top="716" left="58" width="360" height="16" font="4">or can worsen preexisting conduction defects, leading to</text>
<text top="734" left="58" width="360" height="16" font="4">heart block. Myocardial contractile depression also is a</text>
<text top="752" left="58" width="360" height="16" font="4">common feature, although the degree is variable according</text>
<text top="770" left="58" width="360" height="16" font="4">to drug class. As a result of these pharmacological proper-</text>
<text top="788" left="58" width="360" height="16" font="4">ties, the calcium channel blockers are effective anti-ischemic</text>
<text top="806" left="58" width="273" height="16" font="4">drugs, but their use must be individualized <a href="e44.full.html#106">(</a></text>
<text top="806" left="331" width="49" height="16" font="16"><a href="e44.full.html#106">852,853</a></text>
<text top="806" left="380" width="9" height="16" font="4"><a href="e44.full.html#106">).</a></text>
<text top="824" left="73" width="345" height="16" font="4">All classes of calcium channel blockers reduce anginal</text>
<text top="842" left="58" width="360" height="16" font="4">episodes, increase exercise duration, and reduce use of</text>
<text top="860" left="58" width="360" height="16" font="4">sublingual nitroglycerin in patients with effort-induced an-</text>
<text top="878" left="58" width="40" height="16" font="4">gina <a href="e44.full.html#106">(</a></text>
<text top="878" left="98" width="56" height="16" font="16"><a href="e44.full.html#106">854 – 856</a></text>
<text top="878" left="154" width="264" height="16" font="4"><a href="e44.full.html#106">). </a>Because all 3 classes also reduce the</text>
<text top="896" left="58" width="360" height="16" font="4">frequency of Prinzmetal’s variant angina, they are the drugs</text>
<text top="914" left="58" width="360" height="16" font="4">of choice, along with nitrates, used alone or in combination</text>
<text top="932" left="58" width="5" height="16" font="4"><a href="e44.full.html#106">(</a></text>
<text top="932" left="63" width="54" height="16" font="16"><a href="e44.full.html#106">857– 859</a></text>
<text top="932" left="118" width="9" height="16" font="4"><a href="e44.full.html#106">).</a></text>
<text top="950" left="73" width="345" height="16" font="4">Because the 3 classes seem to be equally efficacious in</text>
<text top="968" left="58" width="360" height="16" font="4">treating angina, the choice of a particular agent should be</text>
<text top="986" left="58" width="360" height="16" font="4">based on potential drug interactions and adverse events. The</text>
<text top="1004" left="58" width="360" height="16" font="4">dihydropyridine class is preferred over other calcium chan-</text>
<text top="1022" left="58" width="360" height="16" font="4">nel blockers in patients with cardiac conduction defects such</text>
<text top="1040" left="58" width="360" height="16" font="4">as sick sinus syndrome, sinus bradycardia, or significant AV</text>
<text top="1058" left="58" width="360" height="16" font="4">conduction disturbances. Dihydropyridines should be used</text>
<text top="1076" left="58" width="360" height="16" font="4">with caution in patients with severe aortic valve stenosis.</text>
<text top="1094" left="58" width="360" height="16" font="4">Short-acting dihydropyridines in patients with fixed lesions</text>
<text top="104" left="445" width="360" height="16" font="4">can exacerbate angina, possibly by excessive lowering of</text>
<text top="122" left="445" width="360" height="16" font="4">arterial pressure with reflex tachycardia, and therefore</text>
<text top="140" left="445" width="360" height="16" font="4">should be avoided. Short-acting nifedipine seems to in-</text>
<text top="158" left="445" width="302" height="16" font="4">crease mortality in patients with hypertension <a href="e44.full.html#106">(</a></text>
<text top="158" left="747" width="23" height="16" font="16"><a href="e44.full.html#106">860</a></text>
<text top="158" left="770" width="36" height="16" font="4"><a href="e44.full.html#106">), </a>but</text>
<text top="176" left="445" width="360" height="16" font="4">there is currently no evidence that these concerns apply to</text>
<text top="194" left="445" width="193" height="16" font="4">extended-release preparations <a href="e44.full.html#106">(</a></text>
<text top="194" left="639" width="49" height="16" font="16"><a href="e44.full.html#106">861,862</a></text>
<text top="194" left="687" width="118" height="16" font="4"><a href="e44.full.html#106">). </a>Because of their</text>
<text top="212" left="445" width="360" height="16" font="4">effects on contractility, none of the calcium channel blockers</text>
<text top="230" left="445" width="360" height="16" font="4">are recommended for routine treatment of patients with</text>
<text top="248" left="445" width="360" height="16" font="4">current or prior symptoms of heart failure and a reduced</text>
<text top="266" left="445" width="50" height="16" font="4">LVEF <a href="e44.full.html#86">(</a></text>
<text top="266" left="495" width="15" height="16" font="16"><a href="e44.full.html#86">21</a></text>
<text top="266" left="510" width="9" height="16" font="4"><a href="e44.full.html#86">).</a></text>
<text top="284" left="460" width="345" height="16" font="4">Many drug interactions associated with calcium channel</text>
<text top="302" left="445" width="360" height="16" font="4">blockers occur because of rapid absorption or low bioavail-</text>
<text top="320" left="445" width="360" height="16" font="4">ability due to high first-pass metabolism by the cytochrome</text>
<text top="338" left="445" width="360" height="16" font="4">P450 (i.e., <i>CYP3A4</i>) system. These pharmacokinetic prop-</text>
<text top="356" left="445" width="360" height="16" font="4">erties result in high intraindividual and interindividual</text>
<text top="374" left="445" width="360" height="16" font="4">variability, necessitating dosage adjustment. These drugs</text>
<text top="392" left="445" width="360" height="16" font="4">should be used with caution when combined with cyclo-</text>
<text top="410" left="445" width="360" height="16" font="4">sporine, carbamazepine, lithium carbonate, amiodarone, or</text>
<text top="428" left="445" width="360" height="16" font="4">digoxin (i.e., 50% to 70% increase in digoxin concentrations</text>
<text top="446" left="445" width="360" height="16" font="4">in first week of therapy). Combining verapamil or diltiazem</text>
<text top="464" left="445" width="360" height="16" font="4">with beta blockers generally should be avoided because of</text>
<text top="482" left="445" width="360" height="16" font="4">potentially profound adverse effects on AV nodal conduc-</text>
<text top="500" left="445" width="241" height="16" font="4">tion, heart rate, or cardiac contractility.</text>
<text top="518" left="460" width="345" height="16" font="4">Overall, calcium channel blockers, particularly diltiazem,</text>
<text top="536" left="445" width="360" height="16" font="4">are well tolerated. The major adverse effects of dihydropyri-</text>
<text top="554" left="445" width="360" height="16" font="4">dines are related to vasodilation and systemic hypotension,</text>
<text top="572" left="445" width="360" height="16" font="4">including headache, dizziness, palpitations, and flushing.</text>
<text top="590" left="445" width="360" height="16" font="4">Many patients experience peripheral edema because of</text>
<text top="608" left="445" width="360" height="16" font="4">excessive arterial vasodilation unmatched to venous dilation.</text>
<text top="626" left="445" width="360" height="16" font="4">Verapamil can cause constipation that can be severe, par-</text>
<text top="644" left="445" width="138" height="16" font="4">ticularly in the elderly.</text>
<text top="666" left="446" width="44" height="9" font="6">4.4.3.1.3.</text>
<text top="665" left="495" width="62" height="12" font="36">NITRATES.</text>
<text top="662" left="564" width="242" height="16" font="4">Nitrates are effective in the treatment of</text>
<text top="680" left="446" width="360" height="16" font="4">all forms of angina. They relax vascular smooth muscle in</text>
<text top="698" left="446" width="360" height="16" font="4">the systemic arteries, inclusive of the coronary arteries, and</text>
<text top="716" left="446" width="360" height="16" font="4">veins (predominant effect at lower doses) in patients with</text>
<text top="734" left="446" width="360" height="16" font="4">SIHD. Short-term continuous nitroglycerin delivery by the</text>
<text top="752" left="446" width="360" height="16" font="4">intravenous or transdermal route for only 2 to 4 hours</text>
<text top="770" left="446" width="360" height="16" font="4">protects the endothelium from experimental ischemia in</text>
<text top="788" left="446" width="360" height="16" font="4">healthy volunteers and reduces ischemia during coronary</text>
<text top="806" left="446" width="330" height="16" font="4">angioplasty and physical exercise in IHD patients <a href="e44.full.html#106">(</a></text>
<text top="806" left="776" width="30" height="16" font="16"><a href="e44.full.html#106">863–</a></text>
<text top="824" left="446" width="23" height="16" font="16"><a href="e44.full.html#106">865</a></text>
<text top="824" left="468" width="338" height="16" font="4"><a href="e44.full.html#106">). </a>Oxygen free radical release seems to be associated with</text>
<text top="842" left="446" width="360" height="16" font="4">these protective outcomes. Nitroglycerin causes dilation of</text>
<text top="860" left="446" width="360" height="16" font="4">the artery wall not affected by plaque, but independent of an</text>
<text top="878" left="446" width="360" height="16" font="4">intact endothelium, leading to reduced resistance across the</text>
<text top="896" left="446" width="121" height="16" font="4">obstructed lumen <a href="e44.full.html#106">(</a></text>
<text top="896" left="566" width="23" height="16" font="16"><a href="e44.full.html#106">866</a></text>
<text top="896" left="589" width="217" height="16" font="4"><a href="e44.full.html#106">). </a>Furthermore, nitroglycerin con-</text>
<text top="914" left="446" width="360" height="16" font="4">tributes to coronary blood flow redistribution, by augment-</text>
<text top="932" left="446" width="360" height="16" font="4">ing collateral flow and lowering ventricular diastolic pres-</text>
<text top="950" left="446" width="360" height="16" font="4">sure, from areas of normal perfusion to ischemic zones</text>
<text top="968" left="446" width="5" height="16" font="4"><a href="e44.full.html#106">(</a></text>
<text top="968" left="450" width="23" height="16" font="16"><a href="e44.full.html#106">867</a></text>
<text top="968" left="473" width="333" height="16" font="4"><a href="e44.full.html#106">). </a>Preload is reduced, leading to reductions in myocar-</text>
<text top="986" left="446" width="360" height="16" font="4">dial wall tension and myocardial oxygen demand, although</text>
<text top="1004" left="446" width="360" height="16" font="4">this effect is offset by increased heart rate and myocardial</text>
<text top="1022" left="446" width="360" height="16" font="4">contractile state due to reflex sympathetic activity. Nitro-</text>
<text top="1040" left="446" width="360" height="16" font="4">glycerin also has demonstrated antithrombotic and anti-</text>
<text top="1058" left="446" width="96" height="16" font="4">platelet effects <a href="e44.full.html#106">(</a></text>
<text top="1058" left="542" width="49" height="16" font="16"><a href="e44.full.html#106">868,869</a></text>
<text top="1058" left="590" width="9" height="16" font="4"><a href="e44.full.html#106">).</a></text>
<text top="1076" left="461" width="345" height="16" font="4">Long-term nitrate therapy, however, could offset the</text>
<text top="1094" left="446" width="360" height="16" font="4">beneficial short-term ischemic preconditioning effects.</text>
<text top="52" left="781" width="25" height="10" font="12">e101</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">Long-term nitroglycerin therapy is associated with endo-</text>
<text top="122" left="59" width="360" height="16" font="4">thelial dysfunction via accumulation of the same oxygen free</text>
<text top="140" left="59" width="360" height="16" font="4">radicals that seem to be beneficial in short-term administration</text>
<text top="158" left="59" width="5" height="16" font="4"><a href="e44.full.html#106">(</a></text>
<text top="158" left="63" width="47" height="16" font="16"><a href="e44.full.html#106">870,871</a></text>
<text top="158" left="110" width="309" height="16" font="4"><a href="e44.full.html#106">). </a>The oxygen free radical accumulation increases</text>
<text top="176" left="59" width="360" height="16" font="4">arterial sensitivity to vasoconstrictors such as angiotensin II,</text>
<text top="194" left="59" width="360" height="16" font="4">which can be counteracted by concomitant treatment with</text>
<text top="212" left="59" width="215" height="16" font="4">an ACE inhibitor or hydralazine <a href="e44.full.html#106">(</a></text>
<text top="212" left="274" width="54" height="16" font="16"><a href="e44.full.html#106">872– 875</a></text>
<text top="212" left="328" width="91" height="16" font="4"><a href="e44.full.html#106">). </a>Importantly,</text>
<text top="230" left="59" width="360" height="16" font="4">these physiological changes are independent of dose or the</text>
<text top="248" left="59" width="360" height="16" font="4">presence or absence of a nitrate-free interval and can result</text>
<text top="266" left="59" width="360" height="16" font="4">in a decrease in the anginal threshold during the nitrate-free</text>
<text top="284" left="59" width="57" height="16" font="4">interval <a href="e44.full.html#106">(</a></text>
<text top="284" left="116" width="23" height="16" font="16"><a href="e44.full.html#106">876</a></text>
<text top="284" left="138" width="280" height="16" font="4"><a href="e44.full.html#106">). </a>Further research to better understand the</text>
<text top="302" left="59" width="360" height="16" font="4">balance between the long-term benefits and safety concerns</text>
<text top="320" left="59" width="351" height="16" font="4">of these compounds is warranted in patients with SIHD.</text>
<text top="338" left="74" width="345" height="16" font="4">Despite these physiological observations, nitrates improve</text>
<text top="356" left="59" width="360" height="16" font="4">exercise tolerance, time to ST-segment depression, and time</text>
<text top="374" left="59" width="360" height="16" font="4">to onset of angina in patients with SIHD, albeit in small</text>
<text top="392" left="59" width="328" height="16" font="4">patient studies conducted for relatively short periods <a href="e44.full.html#106">(</a></text>
<text top="392" left="387" width="32" height="16" font="16"><a href="e44.full.html#106">876 –</a></text>
<text top="410" left="59" width="23" height="16" font="16"><a href="e44.full.html#106">878</a></text>
<text top="410" left="81" width="338" height="16" font="4"><a href="e44.full.html#106">). </a>Comparisons of nitrates to beta blockers or calcium</text>
<text top="428" left="59" width="360" height="16" font="4">channel blockers have not shown significant differences with</text>
<text top="446" left="59" width="360" height="16" font="4">regard to weekly anginal episodes, time to ST-segment</text>
<text top="464" left="59" width="360" height="16" font="4">depression, total exercise time, or sublingual nitroglycerin</text>
<text top="482" left="59" width="33" height="16" font="4">use <a href="e44.full.html#96">(</a></text>
<text top="482" left="91" width="23" height="16" font="16"><a href="e44.full.html#96">420</a></text>
<text top="482" left="114" width="305" height="16" font="4"><a href="e44.full.html#96">). </a>Withdrawal for adverse effects was also not</text>
<text top="500" left="59" width="281" height="16" font="4">statistically different between the drug classes.</text>
<text top="518" left="74" width="345" height="16" font="4">All patients with SIHD should be prescribed sublingual</text>
<text top="536" left="59" width="360" height="16" font="4">nitroglycerin tablets or nitroglycerin spray for immediate</text>
<text top="554" left="59" width="360" height="16" font="4">relief of angina. Most patients respond within 5 minutes of</text>
<text top="572" left="59" width="360" height="16" font="4">taking 1 to 2 sublingual dose(s) of 0.3 to 0.6 mg. Nitro-</text>
<text top="590" left="59" width="360" height="16" font="4">glycerin spray is available in a 0.4-mg metered-dose canister</text>
<text top="608" left="59" width="360" height="16" font="4">that dispenses 200 doses. The tablets should be placed under</text>
<text top="626" left="59" width="360" height="16" font="4">the tongue and not swallowed. If the spray is used, it should</text>
<text top="644" left="59" width="360" height="16" font="4">be applied to the tongue and not swallowed or inhaled. If</text>
<text top="662" left="59" width="360" height="16" font="4">additional doses are necessary, they should be taken at</text>
<text top="680" left="59" width="258" height="16" font="4">5-minute intervals, for a maximum dose of</text>
<text top="677" left="321" width="98" height="20" font="4">ⱕ1.2 mg within</text>
<text top="698" left="59" width="360" height="16" font="4">15 minutes. During this timeframe, if relief does not occur,</text>
<text top="716" left="59" width="360" height="16" font="4">the patient should seek immediate medical attention. These</text>
<text top="734" left="59" width="360" height="16" font="4">products are also effective for prevention of effort-induced</text>
<text top="752" left="59" width="360" height="16" font="4">angina when administered 5 to 10 minutes before activity,</text>
<text top="770" left="59" width="360" height="16" font="4">with relief lasting approximately 30 to 40 minutes. The</text>
<text top="788" left="59" width="360" height="16" font="4">tablets must be kept in the manufacturer’s bottle (loss of</text>
<text top="806" left="59" width="360" height="16" font="4">potency can occur in a few hours if out of the bottle) and</text>
<text top="824" left="59" width="360" height="16" font="4">should be stored in a cool, dry place but should not be</text>
<text top="842" left="59" width="360" height="16" font="4">refrigerated. The tablets should not be used 6 to 12 months</text>
<text top="860" left="59" width="360" height="16" font="4">after opening the bottle. Patients usually are able to detect</text>
<text top="878" left="59" width="360" height="16" font="4">when tablets have lost potency by the absence of a burning</text>
<text top="896" left="59" width="360" height="16" font="4">sensation beneath the tongue. Nitroglycerin ointment also</text>
<text top="914" left="59" width="360" height="16" font="4">may be used for short-term relief of angina. Applied to the</text>
<text top="932" left="59" width="360" height="16" font="4">chest in doses of 0.5 to 2.0 inches, with a delay in relief of</text>
<text top="950" left="59" width="360" height="16" font="4">30 minutes, this preparation can be effective for 4 to 6 hours.</text>
<text top="968" left="59" width="360" height="16" font="4">Absorption can be increased by rotating the application</text>
<text top="986" left="59" width="360" height="16" font="4">sites, covering the paste with plastic, or not applying the</text>
<text top="1004" left="59" width="360" height="16" font="4">ointment continuously (i.e., maintenance of a nitrate-free</text>
<text top="1022" left="59" width="62" height="16" font="4">interval) <a href="e44.full.html#106">(</a></text>
<text top="1022" left="120" width="56" height="16" font="16"><a href="e44.full.html#106">879 – 881</a></text>
<text top="1022" left="176" width="242" height="16" font="4"><a href="e44.full.html#106">). </a>All short-acting nitrate preparations</text>
<text top="1040" left="59" width="360" height="16" font="4">can cause hypotension, sometimes severe, and headaches</text>
<text top="1058" left="59" width="360" height="16" font="4">that limit adherence to these agents. Patients should be</text>
<text top="1076" left="59" width="360" height="16" font="4">counseled about these adverse effects and advised to seek</text>
<text top="1094" left="59" width="360" height="16" font="4">medical treatment if syncope or resistant chest pain occurs.</text>
<text top="104" left="446" width="360" height="16" font="4">The ointment can cause permanent discoloration of</text>
<text top="122" left="446" width="53" height="16" font="4">clothing.</text>
<text top="140" left="461" width="345" height="16" font="4">Long-acting nitrate preparations (e.g., nitroglycerin,</text>
<text top="158" left="446" width="360" height="16" font="4">isosorbide dinitrate, isosorbide-5-mononitrate) are recom-</text>
<text top="176" left="446" width="360" height="16" font="4">mended for treatment of angina when initial therapy with a</text>
<text top="194" left="446" width="360" height="16" font="4">beta blocker or nondihydropyridine calcium channel blocker</text>
<text top="212" left="446" width="360" height="16" font="4">is contraindicated or poorly tolerated or when additional</text>
<text top="230" left="446" width="360" height="16" font="4">therapy to control angina is necessary. Isosorbide dinitrate</text>
<text top="248" left="446" width="360" height="16" font="4">undergoes rapid high first-pass metabolism, resulting in low</text>
<text top="266" left="446" width="360" height="16" font="4">bioavailability. However, substantial interpatient variability</text>
<text top="284" left="446" width="360" height="16" font="4">exists in the metabolic enzyme systems responsible for</text>
<text top="302" left="446" width="360" height="16" font="4">isosorbide dinitrate conversion. Isosorbide mononitrate, the</text>
<text top="320" left="446" width="360" height="16" font="4">active metabolite of the dinitrate formulation, is 100%</text>
<text top="338" left="446" width="360" height="16" font="4">bioavailable. Nitroglycerin also can be delivered through</text>
<text top="356" left="446" width="360" height="16" font="4">silicone gel or polymer matrix release patch systems. The</text>
<text top="374" left="446" width="360" height="16" font="4">rate of release varies between these systems, necessitating</text>
<text top="392" left="446" width="360" height="16" font="4">individualization of dosing. With all formulations, titration</text>
<text top="410" left="446" width="360" height="16" font="4">of dose is important to gain adequate anginal control with</text>
<text top="428" left="446" width="360" height="16" font="4">the lowest possible dose to limit the occurrence of head-</text>
<text top="446" left="446" width="360" height="16" font="4">aches, avoid nitrate tolerance, and facilitate long-term</text>
<text top="464" left="446" width="360" height="16" font="4">adherence. The effectiveness of all of these formulations</text>
<text top="482" left="446" width="360" height="16" font="4">seems to be roughly equivalent despite differences in the</text>
<text top="500" left="446" width="222" height="16" font="4">preparation and dosing schedules <a href="e44.full.html#105">(</a></text>
<text top="500" left="667" width="49" height="16" font="16"><a href="e44.full.html#105">843,882</a></text>
<text top="500" left="716" width="89" height="16" font="4"><a href="e44.full.html#105">). </a>With all of</text>
<text top="518" left="446" width="360" height="16" font="4">them, it is necessary to maintain a daily nitrate-free interval</text>
<text top="536" left="446" width="360" height="16" font="4">of 10 to 14 hours to avoid development of nitrate tolerance</text>
<text top="554" left="446" width="5" height="16" font="4"><a href="e44.full.html#105">(</a></text>
<text top="554" left="450" width="23" height="16" font="16"><a href="e44.full.html#105">843</a></text>
<text top="554" left="473" width="333" height="16" font="4"><a href="e44.full.html#105">). </a>Nitrate tolerance does not develop with the sublin-</text>
<text top="572" left="446" width="360" height="16" font="4">gual route of administration. Use of long-acting nitrates also</text>
<text top="590" left="446" width="360" height="16" font="4">does not result in tolerance to the use of sublingual products.</text>
<text top="608" left="461" width="345" height="16" font="4">Nitrates are relatively well tolerated if a titration schedule</text>
<text top="626" left="446" width="360" height="16" font="4">is used at initiation and with discontinuation. The most</text>
<text top="644" left="446" width="360" height="16" font="4">common side effects are headache, flushing, and hypoten-</text>
<text top="662" left="446" width="360" height="16" font="4">sion. Patients should be instructed to remain seated when</text>
<text top="680" left="446" width="360" height="16" font="4">taking rapid-acting nitrate products as a safety precaution to</text>
<text top="698" left="446" width="360" height="16" font="4">avoid syncope from vasodilation. Tolerance to the head-</text>
<text top="716" left="446" width="360" height="16" font="4">aches could develop after a few weeks of continuing the</text>
<text top="734" left="446" width="360" height="16" font="4">medication. Prophylactic analgesics can be helpful until</text>
<text top="752" left="446" width="360" height="16" font="4">headache tolerance develops. Methemoglobinemia is a rare</text>
<text top="770" left="446" width="360" height="16" font="4">adverse effect, usually seen only with large doses. Nitrates</text>
<text top="788" left="446" width="360" height="16" font="4">are relatively contraindicated in hypertrophic obstructive</text>
<text top="806" left="446" width="360" height="16" font="4">cardiomyopathy because of the potential to increase the</text>
<text top="824" left="446" width="360" height="16" font="4">outflow tract obstruction and mitral regurgitant flow. They</text>
<text top="842" left="446" width="360" height="16" font="4">should be avoided in patients with severe aortic valvular</text>
<text top="860" left="446" width="360" height="16" font="4">stenosis. Coadministration of the phosphodiesterase inhib-</text>
<text top="878" left="446" width="360" height="16" font="4">itors sildenafil, tadalafil, or vardenafil with long-acting</text>
<text top="896" left="446" width="360" height="16" font="4">nitrates should be strictly avoided within 24 hours of nitrate</text>
<text top="914" left="446" width="360" height="16" font="4">administration because of the risk of profound hypotension</text>
<text top="932" left="446" width="360" height="16" font="4">(e.g., 25–mm Hg drop in systolic BP). Patients should be</text>
<text top="950" left="446" width="360" height="16" font="4">advised not to take phosphodiesterase inhibitors within 24</text>
<text top="968" left="446" width="360" height="16" font="4">hours of long-acting nitrates, and nitrates should not be</text>
<text top="986" left="446" width="360" height="16" font="4">taken for 24 hours after use of sildenafil or 48 hours after</text>
<text top="1004" left="446" width="360" height="16" font="4">tadalafil; a suitable time interval after vardenafil has not</text>
<text top="1022" left="446" width="360" height="16" font="4">been determined. Patients should be made aware of the</text>
<text top="1040" left="446" width="360" height="16" font="4">possibility of intensification of their angina if nitrates are</text>
<text top="1058" left="446" width="360" height="16" font="4">discontinued abruptly. This effect could be reduced by</text>
<text top="1076" left="446" width="360" height="16" font="4">concomitant administration of other antianginals or by</text>
<text top="1094" left="446" width="259" height="16" font="4">tapering of the long-acting nitrate dosage.</text>
<text top="52" left="59" width="25" height="10" font="12">e102</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1161" width="864">
<text top="108" left="59" width="44" height="9" font="6">4.4.3.1.4.</text>
<text top="107" left="108" width="82" height="12" font="36">RANOLAZINE.</text>
<text top="104" left="197" width="222" height="16" font="4">Ranolazine inhibits the late inward</text>
<text top="122" left="58" width="360" height="16" font="4">sodium current, indirectly reducing the sodium-dependent</text>
<text top="140" left="58" width="360" height="16" font="4">calcium current during ischemic conditions and leading to</text>
<text top="158" left="58" width="360" height="16" font="4">improvement in ventricular diastolic tension and oxygen</text>
<text top="176" left="58" width="340" height="16" font="4">consumption. Minimal changes in mean heart rate (</text>
<text top="173" left="399" width="20" height="20" font="4">⬍2</text>
<text top="194" left="58" width="223" height="16" font="4">beats per minute) and systolic BP (</text>
<text top="191" left="281" width="137" height="20" font="4">⬍3 mm Hg) occur in</text>
<text top="212" left="58" width="360" height="16" font="4">controlled studies. At maximal exercise, the rate–pressure</text>
<text top="230" left="58" width="360" height="16" font="4">product is not increased, independent of age, or in the</text>
<text top="248" left="58" width="360" height="16" font="4">presence of diabetes mellitus, reactive airway disease, or</text>
<text top="266" left="58" width="82" height="16" font="4">heart failure <a href="e44.full.html#106">(</a></text>
<text top="266" left="140" width="23" height="16" font="16"><a href="e44.full.html#106">883</a></text>
<text top="266" left="163" width="256" height="16" font="4"><a href="e44.full.html#106">). </a>Ranolazine is currently indicated for the</text>
<text top="284" left="58" width="360" height="16" font="4">treatment of chronic angina and may be used in combina-</text>
<text top="302" left="58" width="360" height="16" font="4">tion with beta blockers, nitrates, dihydropyridine calcium</text>
<text top="320" left="58" width="360" height="16" font="4">channel blockers, ACE inhibitors, ARBs, and antiplatelet</text>
<text top="338" left="58" width="360" height="16" font="4">and lipid-lowering therapy. It should be prescribed only in</text>
<text top="356" left="58" width="360" height="16" font="4">low doses in combination with verapamil or diltiazem, as</text>
<text top="374" left="58" width="360" height="16" font="4">described later. The lack of an effect on BP and heart rate</text>
<text top="392" left="58" width="360" height="16" font="4">makes ranolazine an attractive alternative in patients with</text>
<text top="410" left="58" width="360" height="16" font="4">bradycardia or low BP. Although ranolazine has been well</text>
<text top="428" left="58" width="360" height="16" font="4">studied in SIHD, the agent was not administered in the</text>
<text top="446" left="58" width="360" height="16" font="4">COURAGE (Clinical Outcomes Utilizing Revasculariza-</text>
<text top="464" left="58" width="299" height="16" font="4">tion and Aggressive Drug Evaluation) study <a href="e44.full.html#94">(</a></text>
<text top="464" left="357" width="22" height="16" font="16"><a href="e44.full.html#94">366</a></text>
<text top="464" left="380" width="39" height="16" font="4"><a href="e44.full.html#94">), </a>and</text>
<text top="482" left="58" width="360" height="16" font="4">further clinical evaluation is needed, especially of ranolazine</text>
<text top="500" left="58" width="360" height="16" font="4">as an element of intensive interventions for multiple risk</text>
<text top="518" left="58" width="44" height="16" font="4">factors.</text>
<text top="536" left="73" width="345" height="16" font="4">The ranolazine extended-release preparation reduces the</text>
<text top="554" left="58" width="360" height="16" font="4">frequency of angina, improves exercise performance, and</text>
<text top="572" left="58" width="360" height="16" font="4">delays the development of exercise-induced angina and</text>
<text top="590" left="58" width="152" height="16" font="4">ST-segment depression <a href="e44.full.html#106">(</a></text>
<text top="590" left="211" width="49" height="16" font="16"><a href="e44.full.html#106">847,884</a></text>
<text top="590" left="259" width="159" height="16" font="4"><a href="e44.full.html#106">). </a>In one study, ranolazine</text>
<text top="608" left="58" width="360" height="16" font="4">reduced weekly anginal frequency by 36% and nitroglycerin</text>
<text top="626" left="58" width="246" height="16" font="4">use by 43% in comparison with placebo <a href="e44.full.html#106">(</a></text>
<text top="626" left="305" width="23" height="16" font="16"><a href="e44.full.html#106">848</a></text>
<text top="626" left="327" width="91" height="16" font="4"><a href="e44.full.html#106">)</a>. Other studies</text>
<text top="644" left="58" width="360" height="16" font="4">indicated that among patients with ACS, ranolazine did not</text>
<text top="662" left="58" width="238" height="16" font="4">reduce the incidence of MI or death <a href="e44.full.html#106">(</a></text>
<text top="662" left="296" width="22" height="16" font="16"><a href="e44.full.html#106">885</a></text>
<text top="662" left="318" width="101" height="16" font="4"><a href="e44.full.html#106">) </a>but did reduce</text>
<text top="680" left="58" width="308" height="16" font="4">recurrent ischemia in the postinfarction period <a href="e44.full.html#106">(</a></text>
<text top="680" left="366" width="22" height="16" font="16"><a href="e44.full.html#106">886</a></text>
<text top="680" left="388" width="31" height="16" font="4"><a href="e44.full.html#106">). </a>In</text>
<text top="698" left="58" width="360" height="16" font="4">patients with preexisting angina, it was superior to placebo in</text>
<text top="716" left="58" width="263" height="16" font="4">improving patients’ angina and quality of life <a href="e44.full.html#106">(</a></text>
<text top="716" left="321" width="22" height="16" font="16"><a href="e44.full.html#106">887</a></text>
<text top="716" left="342" width="76" height="16" font="4"><a href="e44.full.html#106">). </a>Ranolazine</text>
<text top="734" left="58" width="360" height="16" font="4">could exert a beneficial effect on glycemic control and has</text>
<text top="752" left="58" width="360" height="16" font="4">demonstrated consistent reductions in HbA1c in patients with</text>
<text top="770" left="58" width="178" height="16" font="4">diabetes mellitus in 2 studies <a href="e44.full.html#106">(</a></text>
<text top="770" left="236" width="72" height="16" font="16"><a href="e44.full.html#106">883,888,889</a></text>
<text top="770" left="308" width="8" height="16" font="4"><a href="e44.full.html#106">).</a></text>
<text top="788" left="73" width="345" height="16" font="4">Ranolazine blocks the delayed rectifier potassium current</text>
<text top="806" left="58" width="360" height="16" font="4">and prolongs the QTc interval in a dose-related manner,</text>
<text top="824" left="58" width="360" height="16" font="4">resulting in a mean increase in QTc of approximately 6 msec</text>
<text top="842" left="58" width="360" height="16" font="4">at maximal recommended dosing. Currently, there is limited</text>
<text top="860" left="58" width="360" height="16" font="4">experience with concomitant administration of ranolazine and</text>
<text top="878" left="58" width="360" height="16" font="4">other drugs that prolong the QT interval, including Class IA</text>
<text top="896" left="58" width="360" height="16" font="4">and III antiarrhythmics and certain antipsychotics (thiorid-</text>
<text top="914" left="58" width="360" height="16" font="4">azine and ziprasidone). In 3,162 patients with ACS, there</text>
<text top="932" left="58" width="360" height="16" font="4">was no increased risk of proarrhythmia or sudden death. In</text>
<text top="950" left="58" width="360" height="16" font="4">this study, there was a significantly lower incidence of</text>
<text top="968" left="58" width="360" height="16" font="4">arrhythmias, including ventricular tachycardia, bradycardia,</text>
<text top="986" left="58" width="360" height="16" font="4">supraventricular tachycardia, and new atrial fibrillation, in</text>
<text top="1004" left="58" width="360" height="16" font="4">patients treated with ranolazine (80%) versus placebo (87%)</text>
<text top="1022" left="58" width="5" height="16" font="4"><a href="e44.full.html#106">(</a></text>
<text top="1022" left="63" width="101" height="16" font="16"><a href="e44.full.html#106">883,885,890,891</a></text>
<text top="1022" left="165" width="9" height="16" font="4"><a href="e44.full.html#106">).</a></text>
<text top="1040" left="73" width="345" height="16" font="4">Ranolazine does not require dose adjustment for age, sex,</text>
<text top="1058" left="58" width="360" height="16" font="4">New York Heart Association class I–IV heart failure, or</text>
<text top="1076" left="58" width="360" height="16" font="4">diabetes mellitus. Plasma concentrations of ranolazine are</text>
<text top="1094" left="58" width="360" height="16" font="4">increased by up to 50% in patients with Stage 4 CKD</text>
<text top="104" left="445" width="127" height="16" font="4">(creatinine clearance</text>
<text top="101" left="581" width="106" height="20" font="4">⬍30 mL/min) <a href="e44.full.html#107">(</a></text>
<text top="104" left="687" width="23" height="16" font="16"><a href="e44.full.html#107">892</a></text>
<text top="104" left="709" width="96" height="16" font="4"><a href="e44.full.html#107">). </a>The drug is</text>
<text top="123" left="445" width="360" height="16" font="4">contraindicated in patients with clinically significant hepatic</text>
<text top="141" left="445" width="360" height="16" font="4">impairment because of increased plasma concentrations and</text>
<text top="159" left="445" width="360" height="16" font="4">QT prolongation. In general, dosing in the elderly should</text>
<text top="178" left="445" width="255" height="16" font="4">start at the low end of the dosing range <a href="e44.full.html#106">(</a></text>
<text top="178" left="700" width="23" height="16" font="16"><a href="e44.full.html#106">883</a></text>
<text top="178" left="723" width="9" height="16" font="4"><a href="e44.full.html#106">).</a></text>
<text top="196" left="460" width="345" height="16" font="4">Ranolazine is contraindicated in combination with potent</text>
<text top="215" left="445" width="360" height="16" font="4">inhibitors of the <i>CYP3A4 </i>pathway, including ketoconazole</text>
<text top="233" left="445" width="360" height="16" font="4">(3.2-fold increase in ranolazine plasma levels) and other</text>
<text top="251" left="445" width="360" height="16" font="4">azole antifungals, macrolide antibiotics, HIV (human im-</text>
<text top="270" left="445" width="360" height="16" font="4">munodeficiency virus) protease inhibitors, grapefruit prod-</text>
<text top="288" left="445" width="360" height="16" font="4">ucts or juice, diltiazem (1.8- to 2.3-fold increase in ranola-</text>
<text top="306" left="445" width="360" height="16" font="4">zine plasma levels), itraconazole, clarithromycin, and certain</text>
<text top="325" left="445" width="360" height="16" font="4">HIV protease inhibitors. When administered with moder-</text>
<text top="343" left="445" width="360" height="16" font="4">ate inhibitors of <i>CYP3A </i>such as diltiazem, verapamil,</text>
<text top="361" left="445" width="360" height="16" font="4">aprepitant, erythromycin, fluconazole, or grapefruit juice,</text>
<text top="380" left="445" width="360" height="16" font="4">the dose of ranolazine should be limited to 500 mg twice</text>
<text top="398" left="445" width="360" height="16" font="4">daily because of an approximately 2-fold increase in rano-</text>
<text top="416" left="445" width="360" height="16" font="4">lazine plasma levels. No dose adjustment is required in</text>
<text top="435" left="445" width="360" height="16" font="4">patients treated with cimetidine or paroxetine. Coadminis-</text>
<text top="453" left="445" width="360" height="16" font="4">tration of ranolazine (1,000 mg twice daily) with simvastatin</text>
<text top="471" left="445" width="360" height="16" font="4">increases the plasma concentration of simvastatin and its</text>
<text top="490" left="445" width="360" height="16" font="4">active metabolite 2-fold. Digoxin plasma concentrations are</text>
<text top="508" left="445" width="360" height="16" font="4">increased 1.5-fold, but this interaction might not be</text>
<text top="526" left="445" width="360" height="16" font="4">clinically relevant with lower digoxin dosing (0.125 mg</text>
<text top="545" left="445" width="360" height="16" font="4">daily). Coadministration of ranolazine with drugs that</text>
<text top="563" left="445" width="360" height="16" font="4">inhibit <i>CYP2D6</i>, with the exceptions of tricyclic antide-</text>
<text top="581" left="445" width="360" height="16" font="4">pressants and some antipsychotics, does not require</text>
<text top="600" left="445" width="121" height="16" font="4">dosage adjustment.</text>
<text top="618" left="460" width="345" height="16" font="4">Ranolazine is well tolerated; the major adverse effects are</text>
<text top="636" left="445" width="360" height="16" font="4">constipation, nausea, dizziness, and headache. The inci-</text>
<text top="655" left="445" width="119" height="16" font="4">dence of syncope is</text>
<text top="652" left="569" width="35" height="20" font="4">⬍1%.</text>
<text top="677" left="446" width="44" height="9" font="6">4.4.3.1.5.</text>
<text top="676" left="495" width="311" height="12" font="36">ANTIANGINAL AGENTS NOT CURRENTLY AVAILABLE</text>
<text top="694" left="445" width="140" height="12" font="36">IN THE UNITED STATES</text>
<text top="714" left="446" width="53" height="9" font="8"><i>4.4.3.1.5.1.</i></text>
<text top="710" left="504" width="302" height="16" font="5"><i>Nicorandil. </i>Nicorandil is a nicotinamide ester</text>
<text top="728" left="446" width="360" height="16" font="4">with a dual mechanism of action. It activates adenosine</text>
<text top="746" left="446" width="360" height="16" font="4">triphosphate–sensitive potassium channels and promotes</text>
<text top="765" left="446" width="360" height="16" font="4">systemic venous and coronary vasodilation through a nitrate</text>
<text top="783" left="446" width="54" height="16" font="4">moiety <a href="e44.full.html#107">(</a></text>
<text top="783" left="499" width="23" height="16" font="16"><a href="e44.full.html#107">893</a></text>
<text top="783" left="522" width="284" height="16" font="4"><a href="e44.full.html#107">). </a>This dual action increases coronary blood</text>
<text top="801" left="446" width="360" height="16" font="4">flow, with reductions in afterload, preload, and oxidative</text>
<text top="820" left="446" width="44" height="16" font="4">injury <a href="e44.full.html#107">(</a></text>
<text top="820" left="490" width="22" height="16" font="16"><a href="e44.full.html#107">893</a></text>
<text top="820" left="512" width="293" height="16" font="4"><a href="e44.full.html#107">). </a>The agent does not exhibit effects on contrac-</text>
<text top="838" left="446" width="127" height="16" font="4">tility or conduction <a href="e44.full.html#107">(</a></text>
<text top="838" left="572" width="49" height="16" font="16"><a href="e44.full.html#107">894,895</a></text>
<text top="838" left="621" width="185" height="16" font="4"><a href="e44.full.html#107">). </a>The antianginal efficacy and</text>
<text top="856" left="446" width="360" height="16" font="4">safety of nicorandil are similar to those of oral nitrates, beta</text>
<text top="875" left="446" width="247" height="16" font="4">blockers, and calcium channel blockers <a href="e44.full.html#107">(</a></text>
<text top="875" left="692" width="75" height="16" font="16"><a href="e44.full.html#107">893,896,897</a></text>
<text top="875" left="767" width="38" height="16" font="4"><a href="e44.full.html#107">). </a>In a</text>
<text top="893" left="446" width="360" height="16" font="4">prospective, randomized, study of 5,126 patients with</text>
<text top="911" left="446" width="360" height="16" font="4">chronic stable angina, the addition of nicorandil to standard</text>
<text top="930" left="446" width="360" height="16" font="4">therapy was found to produce a 17% RR reduction in the</text>
<text top="948" left="446" width="360" height="16" font="4">composite endpoint of IHD death, nonfatal MI, or un-</text>
<text top="966" left="446" width="329" height="16" font="4">planned hospital admission for cardiac chest pain <a href="e44.full.html#107">(</a></text>
<text top="966" left="774" width="23" height="16" font="16"><a href="e44.full.html#107">898</a></text>
<text top="966" left="797" width="9" height="16" font="4"><a href="e44.full.html#107">).</a></text>
<text top="985" left="446" width="360" height="16" font="4">There was, however, no difference between nicorandil and</text>
<text top="1003" left="446" width="360" height="16" font="4">placebo with regard to death from IHD or nonfatal MI</text>
<text top="1021" left="446" width="5" height="16" font="4"><a href="e44.full.html#107">(</a></text>
<text top="1021" left="450" width="23" height="16" font="16"><a href="e44.full.html#107">894</a></text>
<text top="1021" left="473" width="301" height="16" font="4"><a href="e44.full.html#107">). </a>Tolerance can develop with long-term dosing <a href="e44.full.html#107">(</a></text>
<text top="1021" left="774" width="23" height="16" font="16"><a href="e44.full.html#107">899</a></text>
<text top="1021" left="797" width="9" height="16" font="4"><a href="e44.full.html#107">).</a></text>
<text top="1040" left="446" width="360" height="16" font="4">Common side effects include flushing; palpitation; weak-</text>
<text top="1058" left="446" width="360" height="16" font="4">ness; headache; ulceration of the mouth, perianal, ileal, and</text>
<text top="1076" left="446" width="360" height="16" font="4">peristomal areas; nausea; and vomiting. The agent is not</text>
<text top="1095" left="446" width="243" height="16" font="4">currently available in the United States.</text>
<text top="52" left="781" width="25" height="10" font="12">e103</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1161" width="864">
<text top="108" left="59" width="52" height="9" font="8"><i>4.4.3.1.5.2.</i></text>
<text top="104" left="116" width="303" height="16" font="5"><i>Ivabradine. </i>Ivabradine is a specific inhibitor of</text>
<text top="123" left="59" width="360" height="16" font="4">the <i>If </i>current of pacemaker cells in the sinoatrial node at</text>
<text top="142" left="59" width="360" height="16" font="4">concentrations that do not inhibit other cardiac currents</text>
<text top="161" left="59" width="5" height="16" font="4"><a href="e44.full.html#107">(</a></text>
<text top="161" left="64" width="23" height="16" font="16"><a href="e44.full.html#107">900</a></text>
<text top="161" left="87" width="331" height="16" font="4"><a href="e44.full.html#107">). </a>This action results in heart rate reduction, pro-</text>
<text top="179" left="59" width="360" height="16" font="4">longing diastole and thereby improving myocardial oxy-</text>
<text top="198" left="59" width="360" height="16" font="4">gen balance. Ivabradine has no effect on BP, myocardial</text>
<text top="217" left="59" width="329" height="16" font="4">contractility, or intracardiac conduction parameters <a href="e44.full.html#107">(</a></text>
<text top="217" left="388" width="31" height="16" font="16"><a href="e44.full.html#107">901–</a></text>
<text top="236" left="59" width="23" height="16" font="16"><a href="e44.full.html#107">903</a></text>
<text top="236" left="82" width="337" height="16" font="4"><a href="e44.full.html#107">). </a>Ivabradine improves exercise capacity and reduces</text>
<text top="254" left="59" width="360" height="16" font="4">anginal frequency in comparison to atenolol among</text>
<text top="273" left="59" width="238" height="16" font="4">patients with chronic stable angina <a href="e44.full.html#107">(</a></text>
<text top="273" left="297" width="51" height="16" font="16"><a href="e44.full.html#107">904,905</a></text>
<text top="273" left="348" width="71" height="16" font="4"><a href="e44.full.html#107">). </a>In 5,479</text>
<text top="292" left="59" width="360" height="16" font="4">patients with IHD and LV systolic dysfunction, however,</text>
<text top="311" left="59" width="360" height="16" font="4">ivabradine added to standard treatment had no effect,</text>
<text top="329" left="59" width="360" height="16" font="4">when compared with placebo, on the composite endpoint</text>
<text top="348" left="59" width="360" height="16" font="4">of cardiovascular death, admission to the hospital for</text>
<text top="367" left="59" width="360" height="16" font="4">AMI, and admission to the hospital for new-onset or</text>
<text top="385" left="59" width="154" height="16" font="4">worsening heart failure <a href="e44.full.html#107">(</a></text>
<text top="385" left="212" width="23" height="16" font="16"><a href="e44.full.html#107">906</a></text>
<text top="385" left="236" width="183" height="16" font="4"><a href="e44.full.html#107">). </a>The most common adverse</text>
<text top="404" left="59" width="360" height="16" font="4">event, reported in 14.5% of patients, is phosphenes,</text>
<text top="423" left="59" width="360" height="16" font="4">described as a transient enhanced brightness in a limited</text>
<text top="442" left="59" width="360" height="16" font="4">area of the visual field that typically occurs within the first</text>
<text top="460" left="59" width="360" height="16" font="4">2 months of treatment. Most of these luminous visual-</text>
<text top="479" left="59" width="360" height="16" font="4">field disturbances (77%) resolve without discontinuing</text>
<text top="498" left="59" width="360" height="16" font="4">treatment. The drug is approved in Europe (not currently</text>
<text top="517" left="59" width="360" height="16" font="4">available in the United States) for the symptomatic</text>
<text top="535" left="59" width="360" height="16" font="4">treatment of chronic stable angina in patients with</text>
<text top="554" left="59" width="360" height="16" font="4">normal sinus rhythm with a contraindication or intoler-</text>
<text top="573" left="59" width="139" height="16" font="4">ance to beta blockers.</text>
<text top="596" left="59" width="52" height="9" font="8"><i>4.4.3.1.5.3.</i></text>
<text top="592" left="116" width="303" height="16" font="5"><i>Trimetazidine. </i>Trimetazidine seems to improve</text>
<text top="610" left="59" width="360" height="16" font="4">cellular tolerance to ischemia by inhibiting fatty acid me-</text>
<text top="629" left="59" width="360" height="16" font="4">tabolism and secondarily by stimulating glucose metabo-</text>
<text top="648" left="59" width="360" height="16" font="4">lism, although the exact anti-ischemic mechanisms are</text>
<text top="666" left="59" width="66" height="16" font="4">unknown <a href="e44.full.html#107">(</a></text>
<text top="666" left="124" width="23" height="16" font="16"><a href="e44.full.html#107">907</a></text>
<text top="666" left="147" width="272" height="16" font="4"><a href="e44.full.html#107">). </a>In patients with chronic stable angina, this</text>
<text top="685" left="59" width="360" height="16" font="4">agent increases coronary flow reserve, delaying the onset of</text>
<text top="704" left="59" width="360" height="16" font="4">ischemia associated with exercise and reducing the number</text>
<text top="723" left="59" width="360" height="16" font="4">of weekly angina episodes and weekly nitroglycerin con-</text>
<text top="741" left="59" width="72" height="16" font="4">sumption <a href="e44.full.html#107">(</a></text>
<text top="741" left="130" width="49" height="16" font="16"><a href="e44.full.html#107">908,909</a></text>
<text top="741" left="179" width="240" height="16" font="4"><a href="e44.full.html#107">). </a>The anti-ischemic effects are not</text>
<text top="760" left="59" width="360" height="16" font="4">associated with changes in heart rate or systolic BP. Few</text>
<text top="779" left="59" width="360" height="16" font="4">data exist on the effect of trimetazidine on cardiovascular</text>
<text top="798" left="59" width="360" height="16" font="4">endpoints, mortality, or quality of life. The most frequently</text>
<text top="816" left="59" width="360" height="16" font="4">reported adverse events are gastrointestinal disorders, but</text>
<text top="835" left="59" width="360" height="16" font="4">the incidence is low. The agent is not available in the United</text>
<text top="854" left="59" width="325" height="16" font="4">States but is available in Europe and reportedly in</text>
<text top="851" left="391" width="27" height="20" font="4">⬎80</text>
<text top="872" left="58" width="127" height="16" font="4">countries worldwide.</text>
<text top="903" left="58" width="356" height="16" font="26"><b>4.4.4. Alternative Therapies for Relief of Symptoms in</b></text>
<text top="922" left="58" width="342" height="16" font="26"><b>Patients With Refractory Angina: Recommendations</b></text>
<text top="961" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="974" left="59" width="360" height="10" font="13">1. Enhanced external counterpulsation (EECP) may be considered for</text>
<text top="992" left="74" width="344" height="10" font="13">relief of refractory angina in patients with SIHD <a href="e44.full.html#107">(910). </a><i>(Level of</i></text>
<text top="1010" left="74" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="1027" left="58" width="360" height="10" font="13">2. Spinal cord stimulation may be considered for relief of refractory</text>
<text top="1044" left="74" width="320" height="10" font="13">angina in patients with SIHD <a href="e44.full.html#107">(911,912). </a><i>(Level of Evidence: C)</i></text>
<text top="1062" left="58" width="360" height="10" font="13">3. Transmyocardial revascularization (TMR) may be considered for</text>
<text top="1080" left="74" width="344" height="10" font="13">relief of refractory angina in patients with SIHD <a href="e44.full.html#107">(913–915). </a><i>(Level of</i></text>
<text top="1098" left="74" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="105" left="446" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="118" left="446" width="360" height="10" font="13">1. Acupuncture should not be used for the purpose of improving</text>
<text top="135" left="461" width="344" height="10" font="13">symptoms or reducing cardiovascular risk in patients with SIHD</text>
<text top="152" left="461" width="169" height="10" font="13"><a href="e44.full.html#107">(916,917). </a><i>(Level of Evidence: C)</i></text>
<text top="176" left="446" width="360" height="16" font="4">TMR has been used as either a percutaneous or a surgical</text>
<text top="194" left="446" width="360" height="16" font="4">procedure concomitant with CABG or as sole therapy in patients</text>
<text top="212" left="446" width="257" height="16" font="4">with angina refractory to medical therapy <a href="e44.full.html#107">(</a></text>
<text top="212" left="702" width="73" height="16" font="16"><a href="e44.full.html#107">913–915,918</a></text>
<text top="212" left="774" width="31" height="16" font="4"><a href="e44.full.html#107">)</a>, al-</text>
<text top="231" left="446" width="360" height="16" font="4">though the mechanism by which it might be efficacious is</text>
<text top="249" left="446" width="71" height="16" font="4">unknown <a href="e44.full.html#107">(</a></text>
<text top="249" left="517" width="49" height="16" font="16"><a href="e44.full.html#107">919,920</a></text>
<text top="249" left="565" width="240" height="16" font="4"><a href="e44.full.html#107">). </a>Early studies of the percutaneous</text>
<text top="267" left="446" width="360" height="16" font="4">approach demonstrated no therapeutic benefit, and it was</text>
<text top="285" left="446" width="134" height="16" font="4">promptly abandoned <a href="e44.full.html#107">(</a></text>
<text top="285" left="580" width="23" height="16" font="16"><a href="e44.full.html#107">921</a></text>
<text top="285" left="602" width="203" height="16" font="4"><a href="e44.full.html#107">). </a>When used as sole therapy by a</text>
<text top="303" left="446" width="360" height="16" font="4">surgical approach, TMR is reserved for the patient with</text>
<text top="322" left="446" width="360" height="16" font="4">incapacitating, medically refractory angina and no other</text>
<text top="340" left="446" width="360" height="16" font="4">feasible therapeutic options. Proposed mechanisms of action</text>
<text top="358" left="446" width="360" height="16" font="4">include stimulation of microcirculation, creation of myocar-</text>
<text top="376" left="446" width="360" height="16" font="4">dial scarring, and denervation of ischemic myocardium</text>
<text top="394" left="446" width="5" height="16" font="4"><a href="e44.full.html#107">(</a></text>
<text top="394" left="450" width="23" height="16" font="16"><a href="e44.full.html#107">922</a></text>
<text top="394" left="473" width="333" height="16" font="4"><a href="e44.full.html#107">). </a>Various energy sources have been used, including</text>
<text top="412" left="446" width="360" height="16" font="4">carbon dioxide XeCl excimer and holmium:YAG lasers</text>
<text top="431" left="446" width="5" height="16" font="4"><a href="e44.full.html#107">(</a></text>
<text top="431" left="450" width="53" height="16" font="16"><a href="e44.full.html#107">923–925</a></text>
<text top="431" left="503" width="303" height="16" font="4"><a href="e44.full.html#107">). </a>There is no convincing evidence that one energy</text>
<text top="449" left="446" width="360" height="16" font="4">source is superior to the others. TMR also has been</text>
<text top="467" left="446" width="360" height="16" font="4">combined with cardiac denervation by thoracic sympathec-</text>
<text top="485" left="446" width="41" height="16" font="4">tomy <a href="e44.full.html#107">(</a></text>
<text top="485" left="486" width="23" height="16" font="16"><a href="e44.full.html#107">926</a></text>
<text top="485" left="509" width="9" height="16" font="4"><a href="e44.full.html#107">).</a></text>
<text top="503" left="461" width="345" height="16" font="4">Numerous single-center and a few multicenter random-</text>
<text top="521" left="446" width="360" height="16" font="4">ized trials have been published that compare TMR with</text>
<text top="540" left="446" width="299" height="16" font="4">medical therapy for relief of refractory angina <a href="e44.full.html#107">(</a></text>
<text top="540" left="744" width="53" height="16" font="16"><a href="e44.full.html#107">927–930</a></text>
<text top="540" left="797" width="9" height="16" font="4"><a href="e44.full.html#107">).</a></text>
<text top="558" left="446" width="360" height="16" font="4">Most have shown better angina relief with TMR but no</text>
<text top="576" left="446" width="360" height="16" font="4">survival benefit. The exception is a single multicenter trial</text>
<text top="594" left="446" width="360" height="16" font="4">that shows a survival benefit as well as better relief of angina</text>
<text top="612" left="446" width="79" height="16" font="4">at 5 years <a href="e44.full.html#107">(</a></text>
<text top="612" left="524" width="23" height="16" font="16"><a href="e44.full.html#107">931</a></text>
<text top="612" left="547" width="259" height="16" font="4"><a href="e44.full.html#107">). </a>A 5-year follow-up of a multicenter,</text>
<text top="631" left="446" width="360" height="16" font="4">prospectively randomized trial reported not only sustained</text>
<text top="649" left="446" width="360" height="16" font="4">angina relief but also improved survival in CCS Class IV</text>
<text top="667" left="446" width="360" height="16" font="4">angina, and patients with no additional options for therapy</text>
<text top="685" left="446" width="308" height="16" font="4">who were randomized to sole-therapy TMR <a href="e44.full.html#107">(</a></text>
<text top="685" left="754" width="23" height="16" font="16"><a href="e44.full.html#107">931</a></text>
<text top="685" left="776" width="29" height="16" font="4"><a href="e44.full.html#107">). </a>A</text>
<text top="703" left="446" width="360" height="16" font="4">meta-analysis of 7 RCTs involving 1,053 patients evaluated</text>
<text top="721" left="446" width="299" height="16" font="4">the effect of TMR on survival and angina relief <a href="e44.full.html#107">(</a></text>
<text top="721" left="745" width="23" height="16" font="16"><a href="e44.full.html#107">932</a></text>
<text top="721" left="767" width="38" height="16" font="4"><a href="e44.full.html#107">). </a>The</text>
<text top="740" left="446" width="360" height="16" font="4">conclusion was that at 1 year, TMR improved angina class</text>
<text top="758" left="446" width="360" height="16" font="4">but not survival when used as the sole procedural interven-</text>
<text top="776" left="446" width="360" height="16" font="4">tion compared with medical therapy alone. A number of</text>
<text top="794" left="446" width="360" height="16" font="4">other series also have reported sustained angina relief and</text>
<text top="812" left="446" width="360" height="16" font="4">improved quality of life in randomized patients receiving</text>
<text top="831" left="446" width="256" height="16" font="4">TMR at 3 to 5 years after treatment <a href="e44.full.html#71">(</a></text>
<text top="831" left="702" width="79" height="16" font="16"><a href="e44.full.html#71">Section 5.10</a></text>
<text top="831" left="788" width="17" height="16" font="4">for</text>
<text top="849" left="446" width="329" height="16" font="4">additional information on TMR in revascularization).</text>
<text top="867" left="461" width="345" height="16" font="4">A growing number of patients with SIHD have refractory</text>
<text top="885" left="446" width="360" height="16" font="4">angina, defined as multivessel CAD with ischemia and</text>
<text top="903" left="446" width="360" height="16" font="4">symptoms that cannot be controlled with medical therapy or</text>
<text top="921" left="446" width="360" height="16" font="4">surgical or percutaneous revascularization. The prevalence</text>
<text top="940" left="446" width="360" height="16" font="4">of this syndrome is not well established, but data from</text>
<text top="958" left="446" width="360" height="16" font="4">registries suggest that about 10% of patients referred for</text>
<text top="976" left="446" width="360" height="16" font="4">angiography for symptomatic SIHD have coronary anatomy</text>
<text top="994" left="446" width="257" height="16" font="4">that is not amenable to revascularization <a href="e44.full.html#107">(</a></text>
<text top="994" left="703" width="53" height="16" font="16"><a href="e44.full.html#107">933–935</a></text>
<text top="994" left="755" width="50" height="16" font="4"><a href="e44.full.html#107">). </a>Other</text>
<text top="1012" left="446" width="360" height="16" font="4">nonpharmacological therapies may be considered in these</text>
<text top="1031" left="446" width="283" height="16" font="4">patients in an effort to improve quality of life.</text>
<text top="1062" left="446" width="240" height="9" font="6">4.4.4.1. ENHANCED EXTERNAL COUNTERPULSATION</text>
<text top="1076" left="446" width="360" height="16" font="4">EECP is a technique that uses inflatable cuffs wrapped</text>
<text top="1094" left="446" width="360" height="16" font="4">around the lower extremities to increase venous return and</text>
<text top="52" left="59" width="25" height="10" font="12">e104</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">augment diastolic BP. The cuffs are inflated sequentially</text>
<text top="123" left="59" width="360" height="16" font="4">from the calves to the thigh muscles during diastole and are</text>
<text top="141" left="59" width="360" height="16" font="4">deflated instantaneously during systole. The resultant dia-</text>
<text top="159" left="59" width="360" height="16" font="4">stolic augmentation increases coronary perfusion pressure,</text>
<text top="177" left="59" width="360" height="16" font="4">and the systolic cuff depression decreases peripheral resis-</text>
<text top="195" left="59" width="360" height="16" font="4">tance. Treatment is associated with improved LV diastolic</text>
<text top="213" left="59" width="260" height="16" font="4">filling and improved endothelial function <a href="e44.full.html#108">(</a></text>
<text top="213" left="319" width="54" height="16" font="16"><a href="e44.full.html#108">936 –938</a></text>
<text top="213" left="373" width="45" height="16" font="4"><a href="e44.full.html#108">); </a>other</text>
<text top="232" left="59" width="360" height="16" font="4">putative mechanisms for improvement in symptoms include</text>
<text top="250" left="59" width="360" height="16" font="4">recruitment of collaterals, release of proangiogenic cyto-</text>
<text top="268" left="59" width="360" height="16" font="4">kines, and a peripheral training effect. A treatment course</text>
<text top="286" left="59" width="360" height="16" font="4">typically consists of 35 hour-long treatment sessions, given</text>
<text top="304" left="59" width="360" height="16" font="4">5 days a week. Contraindications include decompensated</text>
<text top="322" left="59" width="354" height="16" font="4">heart failure, severe PAD, and severe aortic regurgitation.</text>
<text top="341" left="74" width="345" height="16" font="4">The efficacy of EECP in treating stable angina pectoris</text>
<text top="359" left="59" width="360" height="16" font="4">has been evaluated in a single RCT and several observa-</text>
<text top="377" left="59" width="360" height="16" font="4">tional registry studies. In MUST-EECP (Multicenter</text>
<text top="395" left="59" width="360" height="16" font="4">Study of Enhanced External Counterpulsation), 139 pa-</text>
<text top="413" left="59" width="360" height="16" font="4">tients with angina, documented CAD, and evidence of</text>
<text top="431" left="59" width="360" height="16" font="4">ischemia on exercise testing were randomized to 35 hours of</text>
<text top="450" left="59" width="360" height="16" font="4">active counterpulsation or to inactive counterpulsation</text>
<text top="468" left="59" width="5" height="16" font="4"><a href="e44.full.html#107">(</a></text>
<text top="468" left="63" width="23" height="16" font="16"><a href="e44.full.html#107">910</a></text>
<text top="468" left="86" width="65" height="16" font="4"><a href="e44.full.html#107">). </a>Time to</text>
<text top="465" left="157" width="262" height="20" font="4">ⱖ1-mm ST-segment depression increased</text>
<text top="486" left="59" width="360" height="16" font="4">significantly in patients treated with active counterpulsation</text>
<text top="504" left="59" width="60" height="16" font="4">(from 337</text>
<text top="501" left="119" width="300" height="20" font="4">⫾18 s to 379⫾18 s) compared with placebo (from</text>
<text top="522" left="59" width="23" height="16" font="4">326</text>
<text top="519" left="81" width="337" height="20" font="4">⫾21 s to 330⫾20 s; p⫽0.01), although there was no</text>
<text top="540" left="58" width="360" height="16" font="4">difference between the groups in exercise duration. More</text>
<text top="559" left="58" width="360" height="16" font="4">active counterpulsation patients experienced a decrease in</text>
<text top="577" left="58" width="360" height="16" font="4">anginal episodes. Of patients receiving EECP, 55% re-</text>
<text top="595" left="58" width="360" height="16" font="4">ported adverse events, including leg and back pain and skin</text>
<text top="613" left="58" width="360" height="16" font="4">abrasions, compared with 26% in the control group, with</text>
<text top="631" left="58" width="360" height="16" font="4">approximately half of these events categorized as device</text>
<text top="649" left="58" width="45" height="16" font="4">related.</text>
<text top="668" left="73" width="345" height="16" font="4">In a meta-analysis of 13 observational studies that tracked</text>
<text top="686" left="58" width="360" height="16" font="4">949 patients, anginal class as categorized by the CCS</text>
<text top="704" left="58" width="187" height="16" font="4">classification was improved by</text>
<text top="701" left="252" width="167" height="20" font="4">ⱖ1 class in 86% (95% CI:</text>
<text top="722" left="58" width="102" height="16" font="4">82% to 90%) <a href="e44.full.html#108">(</a></text>
<text top="722" left="161" width="23" height="16" font="16"><a href="e44.full.html#108">939</a></text>
<text top="722" left="183" width="235" height="16" font="4"><a href="e44.full.html#108">). </a>The EECP Consortium reported</text>
<text top="740" left="58" width="360" height="16" font="4">results in 2,289 consecutive patients undergoing EECP</text>
<text top="758" left="58" width="360" height="16" font="4">therapy at 84 participating centers, including a subgroup of</text>
<text top="777" left="58" width="360" height="16" font="4">175 patients from 7 centers who underwent radionuclide</text>
<text top="795" left="58" width="285" height="16" font="4">perfusion stress tests before and after therapy <a href="e44.full.html#108">(</a></text>
<text top="795" left="343" width="23" height="16" font="16"><a href="e44.full.html#108">940</a></text>
<text top="795" left="366" width="53" height="16" font="4"><a href="e44.full.html#108">). </a>Treat-</text>
<text top="813" left="58" width="360" height="16" font="4">ment was associated with improved perfusion images and</text>
<text top="831" left="58" width="360" height="16" font="4">increased exercise duration. Similarly, the International</text>
<text top="849" left="58" width="248" height="16" font="4">EECP Registry reported improvement of</text>
<text top="846" left="309" width="109" height="20" font="4">ⱖ1 angina class in</text>
<text top="867" left="58" width="329" height="16" font="4">81% of patients immediately after the last treatment <a href="e44.full.html#108">(</a></text>
<text top="867" left="387" width="23" height="16" font="16"><a href="e44.full.html#108">941</a></text>
<text top="867" left="410" width="9" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="886" left="73" width="345" height="16" font="4">In general, existing data, largely from uncontrolled stud-</text>
<text top="904" left="58" width="360" height="16" font="4">ies, suggest a benefit from EECP in patients with angina</text>
<text top="922" left="58" width="360" height="16" font="4">refractory to other therapy. Additional data from well-</text>
<text top="940" left="58" width="360" height="16" font="4">designed RCTs are needed to better define the role of this</text>
<text top="958" left="58" width="274" height="16" font="4">therapeutic strategy in patients with SIHD <a href="e44.full.html#108">(</a></text>
<text top="958" left="333" width="23" height="16" font="16"><a href="e44.full.html#108">942</a></text>
<text top="958" left="355" width="9" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="989" left="59" width="168" height="9" font="6">4.4.4.2. SPINAL CORD STIMULATION</text>
<text top="1004" left="59" width="360" height="16" font="4">Spinal cord stimulation at the T1 to T2 level has been</text>
<text top="1022" left="59" width="360" height="16" font="4">advocated as a therapeutic option for patients with angina</text>
<text top="1040" left="59" width="360" height="16" font="4">pectoris that is refractory to medical therapy and coronary</text>
<text top="1058" left="59" width="360" height="16" font="4">revascularization. The stimulation lead is inserted into the</text>
<text top="1076" left="59" width="360" height="16" font="4">epidural space and is connected to a pulse generator im-</text>
<text top="1094" left="59" width="360" height="16" font="4">planted subcutaneously. A paresthetic stimulus is delivered</text>
<text top="104" left="446" width="360" height="16" font="4">in a continuous, cyclic, or intermittent manner. The mech-</text>
<text top="123" left="446" width="360" height="16" font="4">anisms by which spinal cord stimulation leads to reduced</text>
<text top="141" left="446" width="360" height="16" font="4">angina are not well established. Although inhibition of pain</text>
<text top="159" left="446" width="360" height="16" font="4">transmission plays a role, some studies suggest that spinal</text>
<text top="177" left="446" width="360" height="16" font="4">cord stimulation also might reduce myocardial ischemia</text>
<text top="195" left="446" width="5" height="16" font="4"><a href="e44.full.html#108">(</a></text>
<text top="195" left="450" width="53" height="16" font="16"><a href="e44.full.html#108">943–945</a></text>
<text top="195" left="503" width="9" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="213" left="461" width="345" height="16" font="4">The efficacy of spinal cord stimulation has been evaluated</text>
<text top="232" left="446" width="360" height="16" font="4">in several observational and cohort studies. The Prospective</text>
<text top="250" left="446" width="360" height="16" font="4">Italian Registry described outcomes in 104 patients with</text>
<text top="268" left="446" width="360" height="16" font="4">severe angina refractory to medical therapy over an average</text>
<text top="286" left="446" width="360" height="16" font="4">of 13 months after initiation of spinal cord stimulation</text>
<text top="304" left="446" width="5" height="16" font="4"><a href="e44.full.html#108">(</a></text>
<text top="304" left="450" width="23" height="16" font="16"><a href="e44.full.html#108">946</a></text>
<text top="304" left="473" width="27" height="16" font="4"><a href="e44.full.html#108">). </a>A</text>
<text top="301" left="507" width="299" height="20" font="4">⬎50% reduction in anginal symptoms was ob-</text>
<text top="322" left="446" width="304" height="16" font="4">served in 73% of patients. CCS class improved by</text>
<text top="319" left="754" width="52" height="20" font="4">ⱖ1 class</text>
<text top="341" left="446" width="87" height="16" font="4">in 80% and by</text>
<text top="337" left="536" width="269" height="20" font="4">ⱖ2 classes in 42% of patients. Similarly, in a</text>
<text top="359" left="446" width="360" height="16" font="4">cohort of 51 patients with refractory CCS Class III or IV</text>
<text top="377" left="446" width="360" height="16" font="4">angina, spinal cord stimulation was associated with a sig-</text>
<text top="395" left="446" width="360" height="16" font="4">nificant reduction in anginal episodes in 88% of subjects at</text>
<text top="413" left="446" width="162" height="16" font="4">24 months of follow-up <a href="e44.full.html#108">(</a></text>
<text top="413" left="607" width="23" height="16" font="16"><a href="e44.full.html#108">947</a></text>
<text top="413" left="630" width="176" height="16" font="4"><a href="e44.full.html#108">). </a>There were no significant</text>
<text top="431" left="446" width="249" height="16" font="4">complications of therapy in either series.</text>
<text top="450" left="461" width="345" height="16" font="4">The published RCTs of spinal cord stimulation were</text>
<text top="468" left="446" width="360" height="16" font="4">small. One study tested the efficacy of spinal cord stimula-</text>
<text top="486" left="446" width="360" height="16" font="4">tion in 13 patients with chronic, intractable angina com-</text>
<text top="504" left="446" width="241" height="16" font="4">pared with 12 controls over 6 weeks <a href="e44.full.html#107">(</a></text>
<text top="504" left="686" width="23" height="16" font="16"><a href="e44.full.html#107">912</a></text>
<text top="504" left="709" width="97" height="16" font="4"><a href="e44.full.html#107">). </a>Patients with</text>
<text top="522" left="446" width="360" height="16" font="4">spinal cord stimulation demonstrated greater exercise dura-</text>
<text top="540" left="446" width="360" height="16" font="4">tion and time to angina during treadmill testing and fewer</text>
<text top="559" left="446" width="360" height="16" font="4">bouts of angina and fewer episodes of ST depression on</text>
<text top="577" left="446" width="360" height="16" font="4">ambulatory echocardiographic monitoring. A subsequent</text>
<text top="595" left="446" width="329" height="16" font="4">trial compared spinal cord stimulation to CABG <a href="e44.full.html#107">(</a></text>
<text top="595" left="774" width="23" height="16" font="16"><a href="e44.full.html#107">911</a></text>
<text top="595" left="797" width="9" height="16" font="4"><a href="e44.full.html#107">).</a></text>
<text top="613" left="446" width="360" height="16" font="4">Subjects included 104 patients with severe angina who</text>
<text top="631" left="446" width="360" height="16" font="4">would not be expected to derive survival benefit from</text>
<text top="649" left="446" width="360" height="16" font="4">revascularization, were at increased risk of surgical compli-</text>
<text top="668" left="446" width="360" height="16" font="4">cations, and were unsuitable for PCI. Patients in both</text>
<text top="686" left="446" width="360" height="16" font="4">groups had significant symptom relief. Those assigned to</text>
<text top="704" left="446" width="360" height="16" font="4">bypass surgery had greater increases in exercise capacity and</text>
<text top="722" left="446" width="360" height="16" font="4">less ST depression on treadmill testing than did those</text>
<text top="740" left="446" width="360" height="16" font="4">treated with spinal cord stimulation. Mortality and cardio-</text>
<text top="758" left="446" width="360" height="16" font="4">vascular morbidity rates were lower in the spinal cord</text>
<text top="777" left="446" width="112" height="16" font="4">stimulation group.</text>
<text top="795" left="461" width="345" height="16" font="4">In summary, studies of spinal cord stimulation suggest</text>
<text top="813" left="446" width="360" height="16" font="4">that this technique might have some use as a method to</text>
<text top="831" left="446" width="360" height="16" font="4">relieve angina in patients with symptoms that are refractory</text>
<text top="849" left="446" width="360" height="16" font="4">to standard medical therapy and revascularization. There is</text>
<text top="867" left="446" width="360" height="16" font="4">a paucity of data on the mechanisms and long-term risks</text>
<text top="886" left="446" width="313" height="16" font="4">and benefits of this therapeutic approach, however.</text>
<text top="917" left="446" width="108" height="9" font="6">4.4.4.3. ACUPUNCTURE</text>
<text top="931" left="446" width="360" height="16" font="4">Acupuncture is used by some practitioners for the relief of</text>
<text top="949" left="446" width="360" height="16" font="4">acute and chronic pain. The efficacy of acupuncture in the</text>
<text top="967" left="446" width="360" height="16" font="4">treatment of angina pectoris has not been studied rigorously,</text>
<text top="986" left="446" width="360" height="16" font="4">however. In part this is due to the difficulty of blinding both</text>
<text top="1004" left="446" width="360" height="16" font="4">patients and healthcare providers. Twenty-six patients with</text>
<text top="1022" left="446" width="360" height="16" font="4">severe angina resistant to standard medical therapy were</text>
<text top="1040" left="446" width="360" height="16" font="4">studied in one of the first randomized trials comparing</text>
<text top="1058" left="446" width="234" height="16" font="4">acupuncture and sham acupuncture <a href="e44.full.html#107">(</a></text>
<text top="1058" left="679" width="23" height="16" font="16"><a href="e44.full.html#107">917</a></text>
<text top="1058" left="702" width="104" height="16" font="4"><a href="e44.full.html#107">). </a>There was no</text>
<text top="1076" left="446" width="360" height="16" font="4">difference between groups in the frequency of angina or use</text>
<text top="1094" left="446" width="360" height="16" font="4">of nitroglycerin, although patients treated with acupuncture</text>
<text top="52" left="781" width="25" height="10" font="12">e105</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">achieved a higher pressure–rate product on exercise testing.</text>
<text top="123" left="59" width="360" height="16" font="4">A subsequent study by the same investigators in patients</text>
<text top="141" left="59" width="360" height="16" font="4">with less severe ischemia failed to show a difference in either</text>
<text top="159" left="59" width="360" height="16" font="4">exercise variables or subjective measures between acupunc-</text>
<text top="177" left="59" width="167" height="16" font="4">ture and placebo patients <a href="e44.full.html#107">(</a></text>
<text top="177" left="225" width="23" height="16" font="16"><a href="e44.full.html#107">916</a></text>
<text top="177" left="248" width="171" height="16" font="4"><a href="e44.full.html#107">). </a>In contrast, a decrease in</text>
<text top="196" left="59" width="360" height="16" font="4">anginal episodes and an increase in the workload required to</text>
<text top="214" left="59" width="360" height="16" font="4">induce ischemia were observed with acupuncture in a</text>
<text top="232" left="59" width="360" height="16" font="4">crossover study of 21 patients with stable angina. The</text>
<text top="250" left="59" width="360" height="16" font="4">control condition in this trial was a pill placebo, however, so</text>
<text top="268" left="59" width="294" height="16" font="4">neither subjects nor investigators were blinded <a href="e44.full.html#108">(</a></text>
<text top="268" left="353" width="23" height="16" font="16"><a href="e44.full.html#108">948</a></text>
<text top="268" left="375" width="9" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="287" left="74" width="345" height="16" font="4">In summary, acupuncture has not been studied suffi-</text>
<text top="305" left="59" width="360" height="16" font="4">ciently to warrant recommendation as a treatment option</text>
<text top="323" left="59" width="285" height="16" font="4">for relief of symptoms in patients with SIHD.</text>
<text top="360" left="59" width="203" height="14" font="15">5. CAD Revascularization</text>
<text top="403" left="59" width="360" height="16" font="4">Recommendations and text in this section are the result of</text>
<text top="421" left="59" width="360" height="16" font="4">extensive collaborative discussions between the PCI and</text>
<text top="439" left="59" width="360" height="16" font="4">CABG writing committees, as well as key members of the</text>
<text top="457" left="59" width="360" height="16" font="4">SIHD and UA/NSTEMI writing committees. Certain</text>
<text top="475" left="59" width="360" height="16" font="4">issues, such as older versus more contemporary studies,</text>
<text top="494" left="59" width="360" height="16" font="4">primary analyses versus subgroup analyses, and prospective</text>
<text top="512" left="59" width="360" height="16" font="4">versus post hoc analyses, have been carefully weighed in</text>
<text top="530" left="59" width="360" height="16" font="4">designating COR and LOE; they are addressed in the</text>
<text top="548" left="59" width="360" height="16" font="4">appropriate corresponding text. The goals of revasculariza-</text>
<text top="567" left="59" width="360" height="16" font="4">tion for patients with CAD are to 1) improve survival and</text>
<text top="585" left="59" width="126" height="16" font="4">2) relieve symptoms.</text>
<text top="603" left="74" width="345" height="16" font="4">Revascularization recommendations in this section are</text>
<text top="621" left="59" width="360" height="16" font="4">based predominantly on studies of patients with symptom-</text>
<text top="639" left="59" width="360" height="16" font="4">atic SIHD and should be interpreted in this context. As</text>
<text top="658" left="59" width="360" height="16" font="4">discussed later in this section, recommendations on the type</text>
<text top="676" left="59" width="360" height="16" font="4">of revascularization are, in general, applicable to patients</text>
<text top="694" left="59" width="360" height="16" font="4">with UA/NSTEMI. In some cases (e.g., unprotected left</text>
<text top="712" left="59" width="360" height="16" font="4">main CAD), specific recommendations are made for pa-</text>
<text top="730" left="59" width="235" height="16" font="4">tients with UA/NSTEMI or STEMI.</text>
<text top="749" left="74" width="345" height="16" font="4">Historically, most studies of revascularization have been</text>
<text top="767" left="59" width="360" height="16" font="4">based on and reported according to angiographic criteria.</text>
<text top="785" left="59" width="317" height="16" font="4">Most studies have defined a “significant” stenosis as</text>
<text top="782" left="380" width="39" height="20" font="4">ⱖ70%</text>
<text top="803" left="59" width="360" height="16" font="4">diameter narrowing; therefore, for revascularization deci-</text>
<text top="821" left="59" width="360" height="16" font="4">sions and recommendations in this section, a “significant”</text>
<text top="840" left="59" width="183" height="16" font="4">stenosis has been defined as</text>
<text top="836" left="249" width="169" height="20" font="4">ⱖ70% diameter narrowing</text>
<text top="858" left="59" width="5" height="16" font="4">(</text>
<text top="855" left="63" width="355" height="20" font="4">ⱖ50% for left main CAD). Physiological criteria, such as</text>
<text top="876" left="59" width="360" height="16" font="4">an assessment of FFR, have been used in deciding when</text>
<text top="894" left="59" width="360" height="16" font="4">revascularization is indicated. Thus, for recommendations</text>
<text top="913" left="59" width="360" height="16" font="4">about revascularization in this section, coronary stenoses</text>
<text top="931" left="59" width="60" height="16" font="4">with FFR</text>
<text top="928" left="123" width="295" height="20" font="4">ⱕ0.80 can also be considered to be “significant.”</text>
<text top="949" left="74" width="345" height="16" font="4">As noted, the revascularization recommendations have</text>
<text top="967" left="58" width="360" height="16" font="4">been formulated to address issues related to 1) improved</text>
<text top="985" left="58" width="360" height="16" font="4">survival and/or 2) improved symptoms. When one method</text>
<text top="1004" left="58" width="360" height="16" font="4">of revascularization is preferred over the other for improved</text>
<text top="1022" left="58" width="360" height="16" font="4">survival, this consideration, in general, takes precedence</text>
<text top="1040" left="58" width="360" height="16" font="4">over improved symptoms. When options for revasculariza-</text>
<text top="1058" left="58" width="360" height="16" font="4">tion are discussed with the patient, he or she should</text>
<text top="1076" left="58" width="360" height="16" font="4">understand when the procedure is being performed in an</text>
<text top="1095" left="58" width="297" height="16" font="4">attempt to improve symptoms, survival, or both.</text>
<text top="105" left="461" width="345" height="16" font="4">Although some results from the SYNTAX (Synergy</text>
<text top="123" left="446" width="360" height="16" font="4">between Percutaneous Coronary Intervention with TAXUS</text>
<text top="141" left="446" width="360" height="16" font="4">and Cardiac Surgery) study are best characterized as sub-</text>
<text top="159" left="446" width="360" height="16" font="4">group analyses and “hypothesis generating,” SYNTAX</text>
<text top="177" left="446" width="360" height="16" font="4">nonetheless represents the latest and most comprehensive</text>
<text top="195" left="446" width="208" height="16" font="4">comparison of PCI and CABG <a href="e44.full.html#108">(</a></text>
<text top="195" left="653" width="49" height="16" font="16"><a href="e44.full.html#108">949,950</a></text>
<text top="195" left="702" width="103" height="16" font="4"><a href="e44.full.html#108">). </a>Therefore, the</text>
<text top="213" left="446" width="360" height="16" font="4">results of SYNTAX have been considered appropriately</text>
<text top="231" left="446" width="360" height="16" font="4">when formulating our revascularization recommendations.</text>
<text top="249" left="446" width="360" height="16" font="4">Although the limitations of using the SYNTAX score for</text>
<text top="267" left="446" width="360" height="16" font="4">certain revascularization recommendations are recognized,</text>
<text top="285" left="446" width="360" height="16" font="4">the SYNTAX score is a reasonable surrogate for the extent</text>
<text top="303" left="446" width="360" height="16" font="4">of CAD and its complexity and serves as important infor-</text>
<text top="321" left="446" width="360" height="16" font="4">mation that should be considered when making revascular-</text>
<text top="339" left="446" width="360" height="16" font="4">ization decisions. Recommendations that refer to SYNTAX</text>
<text top="357" left="446" width="360" height="16" font="4">scores use them as surrogates for the extent and complexity</text>
<text top="375" left="446" width="55" height="16" font="4">of CAD.</text>
<text top="393" left="461" width="345" height="16" font="4">Revascularization recommendations to improve survival</text>
<text top="411" left="446" width="360" height="16" font="4">and symptoms are provided in the following text and are</text>
<text top="429" left="446" width="93" height="16" font="4">summarized in</text>
<text top="429" left="546" width="63" height="16" font="16"><a href="e44.full.html#64">Tables 18</a></text>
<text top="429" left="616" width="22" height="16" font="4">and</text>
<text top="429" left="646" width="15" height="16" font="16"><a href="e44.full.html#65">19</a></text>
<text top="429" left="661" width="145" height="16" font="4"><a href="e44.full.html#65">. </a>References to studies</text>
<text top="447" left="445" width="360" height="16" font="4">comparing revascularization with medical therapy are pre-</text>
<text top="465" left="445" width="360" height="16" font="4">sented when available for each anatomic subgroup. When</text>
<text top="483" left="445" width="360" height="16" font="4">such studies have been completed only for CABG, RCTs or</text>
<text top="501" left="445" width="360" height="16" font="4">cohort studies comparing CABG with PCI are presented,</text>
<text top="519" left="445" width="232" height="16" font="4">but the LOE for PCI is downgraded.</text>
<text top="546" left="445" width="18" height="16" font="5"><i>See</i></text>
<text top="546" left="471" width="213" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplements 3 and 4</i></a></text>
<text top="546" left="691" width="114" height="16" font="5"><i>for additional data</i></text>
<text top="564" left="445" width="360" height="16" font="5"><i>regarding the survival and symptomatic benefits with CABG or</i></text>
<text top="582" left="445" width="199" height="16" font="5"><i>PCI for different anatomic subsets.</i></text>
<text top="612" left="446" width="326" height="12" font="18">5.1. Heart Team Approach to Revascularization</text>
<text top="630" left="446" width="203" height="12" font="18">Decisions: Recommendations</text>
<text top="662" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="674" left="446" width="360" height="10" font="13">1. A Heart Team approach to revascularization is recommended in</text>
<text top="691" left="461" width="344" height="10" font="13">patients with unprotected left main or complex CAD <a href="e44.full.html#108">(950–952).</a></text>
<text top="708" left="461" width="110" height="10" font="25"><i>(Level of Evidence: C)</i></text>
<text top="738" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="751" left="446" width="360" height="10" font="13">1. Calculation of the STS and SYNTAX scores is reasonable in patients</text>
<text top="768" left="461" width="344" height="10" font="13">with unprotected left main and complex CAD <a href="e44.full.html#108">(949,950,953–957).</a></text>
<text top="785" left="461" width="111" height="10" font="25"><i>(Level of Evidence: B)</i></text>
<text top="806" left="446" width="177" height="16" font="4">One protocol used in RCTs <a href="e44.full.html#108">(</a></text>
<text top="806" left="623" width="81" height="16" font="16"><a href="e44.full.html#108">950 –952,958</a></text>
<text top="806" left="703" width="102" height="16" font="4"><a href="e44.full.html#108">) </a>often involves a</text>
<text top="824" left="446" width="360" height="16" font="4">multidisciplinary approach referred to as the Heart Team.</text>
<text top="842" left="446" width="360" height="16" font="4">Composed of an interventional cardiologist and a cardiac</text>
<text top="860" left="446" width="360" height="16" font="4">surgeon, the Heart Team 1) reviews the patient’s medical</text>
<text top="878" left="446" width="360" height="16" font="4">condition and coronary anatomy, 2) determines that PCI</text>
<text top="896" left="446" width="360" height="16" font="4">and/or CABG are technically feasible and reasonable, and</text>
<text top="914" left="446" width="360" height="16" font="4">3) discusses revascularization options with the patient before</text>
<text top="932" left="446" width="360" height="16" font="4">a treatment strategy is selected. Support for using a Heart</text>
<text top="950" left="446" width="360" height="16" font="4">Team approach comes from reports that patients with</text>
<text top="968" left="446" width="360" height="16" font="4">complex CAD referred specifically for PCI or CABG in</text>
<text top="986" left="446" width="360" height="16" font="4">concurrent trial registries have lower mortality rates than</text>
<text top="1004" left="446" width="360" height="16" font="4">those randomly assigned to PCI or CABG in controlled</text>
<text top="1022" left="446" width="39" height="16" font="4">trials <a href="e44.full.html#108">(</a></text>
<text top="1022" left="485" width="49" height="16" font="16"><a href="e44.full.html#108">951,952</a></text>
<text top="1022" left="534" width="9" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="1040" left="461" width="345" height="16" font="4">The SIHD, PCI, and CABG guideline writing commit-</text>
<text top="1058" left="446" width="360" height="16" font="4">tees endorse a Heart Team approach in patients with</text>
<text top="1076" left="446" width="360" height="16" font="4">unprotected left main CAD and/or complex CAD in whom</text>
<text top="1094" left="446" width="360" height="16" font="4">the optimal revascularization strategy is not straightforward.</text>
<text top="52" left="59" width="25" height="10" font="12">e106</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1161" width="864">
<text top="105" left="59" width="467" height="11" font="13">Table 18. Revascularization to Improve Survival Compared With Medical Therapy</text>
<text top="131" left="69" width="82" height="9" font="6">Anatomic Setting</text>
<text top="131" left="357" width="21" height="9" font="6">COR</text>
<text top="131" left="583" width="18" height="9" font="6">LOE</text>
<text top="131" left="684" width="53" height="9" font="6">References</text>
<text top="148" left="68" width="108" height="9" font="6">UPLM or complex CAD</text>
<text top="165" left="79" width="68" height="9" font="6">CABG and PCI</text>
<text top="165" left="175" width="181" height="9" font="6">I—Heart Team approach recommended</text>
<text top="165" left="589" width="6" height="9" font="6">C</text>
<text top="165" left="625" width="3" height="9" font="6"><a href="e44.full.html#108">(</a></text>
<text top="165" left="629" width="42" height="9" font="7"><a href="e44.full.html#108">950–952</a></text>
<text top="165" left="671" width="3" height="9" font="6"><a href="e44.full.html#108">)</a></text>
<text top="183" left="79" width="68" height="9" font="6">CABG and PCI</text>
<text top="183" left="175" width="195" height="9" font="6">IIa—Calculation of STS and SYNTAX scores</text>
<text top="183" left="589" width="6" height="9" font="6">B</text>
<text top="183" left="625" width="3" height="9" font="6"><a href="e44.full.html#108">(</a></text>
<text top="183" left="629" width="84" height="9" font="7"><a href="e44.full.html#108">949,950,953–957</a></text>
<text top="183" left="713" width="3" height="9" font="6"><a href="e44.full.html#108">)</a></text>
<text top="200" left="68" width="34" height="9" font="6">UPLM*</text>
<text top="217" left="79" width="28" height="9" font="6">CABG</text>
<text top="217" left="175" width="3" height="9" font="6">I</text>
<text top="217" left="589" width="6" height="9" font="6">B</text>
<text top="217" left="625" width="3" height="9" font="6"><a href="e44.full.html#87">(</a></text>
<text top="217" left="629" width="99" height="9" font="7"><a href="e44.full.html#87">73,381,412,959–962</a></text>
<text top="217" left="728" width="3" height="9" font="6"><a href="e44.full.html#87">)</a></text>
<text top="234" left="79" width="17" height="9" font="6">PCI</text>
<text top="234" left="175" width="242" height="9" font="6">IIa—For SIHD when <i>both </i>of the following are present:</text>
<text top="250" left="186" width="3" height="8" font="21">●</text>
<text top="249" left="192" width="360" height="9" font="6">Anatomic conditions associated with a low risk of PCI procedural complications</text>
<text top="263" left="193" width="352" height="9" font="6">and a high likelihood of good long-term outcome (e.g., a low SYNTAX score of</text>
<text top="274" left="193" width="160" height="14" font="6">ⱕ22, ostial or trunk left main CAD)</text>
<text top="293" left="186" width="3" height="8" font="21">●</text>
<text top="291" left="192" width="338" height="9" font="6">Clinical characteristics that predict a significantly increased risk of adverse</text>
<text top="306" left="193" width="292" height="9" font="6">surgical outcomes (e.g., STS-predicted risk of operative mortality</text>
<text top="303" left="488" width="26" height="14" font="6">ⱖ5%)</text>
<text top="234" left="589" width="6" height="9" font="6">B</text>
<text top="234" left="625" width="3" height="9" font="6"><a href="e44.full.html#108">(</a></text>
<text top="234" left="629" width="127" height="9" font="7"><a href="e44.full.html#108">949,953,955,958,963–980</a></text>
<text top="234" left="755" width="3" height="9" font="6"><a href="e44.full.html#108">)</a></text>
<text top="323" left="175" width="203" height="9" font="6">IIa—For UA/NSTEMI if not a CABG candidate</text>
<text top="323" left="589" width="6" height="9" font="6">B</text>
<text top="323" left="625" width="3" height="9" font="6"><a href="e44.full.html#108">(</a></text>
<text top="323" left="629" width="129" height="9" font="7"><a href="e44.full.html#108">949,968–971,976–979,981</a></text>
<text top="323" left="758" width="3" height="9" font="6"><a href="e44.full.html#108">)</a></text>
<text top="340" left="175" width="268" height="9" font="6">IIa—For STEMI when distal coronary flow is TIMI flow grade</text>
<text top="337" left="447" width="87" height="14" font="6">⬍3 and PCI can be</text>
<text top="354" left="199" width="209" height="9" font="6">performed more rapidly and safely than CABG</text>
<text top="340" left="589" width="6" height="9" font="6">C</text>
<text top="340" left="625" width="3" height="9" font="6"><a href="e44.full.html#108">(</a></text>
<text top="340" left="629" width="61" height="9" font="7"><a href="e44.full.html#108">965,982,983</a></text>
<text top="340" left="689" width="3" height="9" font="6"><a href="e44.full.html#108">)</a></text>
<text top="372" left="175" width="242" height="9" font="6">IIb—For SIHD when <i>both </i>of the following are present:</text>
<text top="387" left="186" width="3" height="8" font="21">●</text>
<text top="386" left="192" width="367" height="9" font="6">Anatomic conditions associated with a low to intermediate risk of PCI procedural</text>
<text top="400" left="193" width="366" height="9" font="6">complications and an intermediate to high likelihood of good long-term outcome</text>
<text top="414" left="193" width="179" height="9" font="6">(e.g., low-intermediate SYNTAX score of</text>
<text top="412" left="375" width="145" height="14" font="6">⬍33, bifurcation left main CAD)</text>
<text top="430" left="186" width="3" height="8" font="21">●</text>
<text top="429" left="192" width="325" height="9" font="6">Clinical characteristics that predict an increased risk of adverse surgical</text>
<text top="443" left="193" width="349" height="9" font="6">outcomes (e.g., moderate—severe COPD, disability from prior stroke, or prior</text>
<text top="457" left="193" width="225" height="9" font="6">cardiac surgery; STS-predicted operative mortality</text>
<text top="454" left="421" width="26" height="14" font="6">⬎2%)</text>
<text top="372" left="589" width="6" height="9" font="6">B</text>
<text top="372" left="625" width="3" height="9" font="6"><a href="e44.full.html#108">(</a></text>
<text top="372" left="629" width="148" height="9" font="7"><a href="e44.full.html#108">949,953,955,958,963–980,984</a></text>
<text top="372" left="776" width="3" height="9" font="6"><a href="e44.full.html#108">)</a></text>
<text top="474" left="175" width="381" height="9" font="6">III: Harm—For SIHD in patients (versus performing CABG) with unfavorable anatomy</text>
<text top="489" left="199" width="212" height="9" font="6">for PCI and who are good candidates for CABG</text>
<text top="474" left="589" width="6" height="9" font="6">B</text>
<text top="474" left="625" width="3" height="9" font="6"><a href="e44.full.html#87">(</a></text>
<text top="474" left="629" width="163" height="9" font="7"><a href="e44.full.html#87">73,381,412,949,953,955,959–964</a></text>
<text top="474" left="791" width="3" height="9" font="6"><a href="e44.full.html#87">)</a></text>
<text top="506" left="68" width="296" height="9" font="6">3-vessel disease with or without proximal LAD artery disease*</text>
<text top="523" left="79" width="28" height="9" font="6">CABG</text>
<text top="523" left="175" width="3" height="9" font="6">I</text>
<text top="523" left="589" width="6" height="9" font="6">B</text>
<text top="523" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="523" left="629" width="105" height="9" font="7"><a href="e44.full.html#94">353,412,959,985–987</a></text>
<text top="523" left="734" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="540" left="175" width="383" height="9" font="6">IIa—It is reasonable to choose CABG over PCI in patients with complex 3-vessel CAD</text>
<text top="555" left="199" width="88" height="9" font="6">(e.g., SYNTAX score</text>
<text top="552" left="290" width="188" height="14" font="6">⬎22) who are good candidates for CABG.</text>
<text top="540" left="589" width="6" height="9" font="6">B</text>
<text top="540" left="625" width="3" height="9" font="6"><a href="e44.full.html#108">(</a></text>
<text top="540" left="629" width="84" height="9" font="7"><a href="e44.full.html#108">964,980,987–989</a></text>
<text top="540" left="713" width="3" height="9" font="6"><a href="e44.full.html#108">)</a></text>
<text top="572" left="79" width="17" height="9" font="6">PCI</text>
<text top="572" left="175" width="112" height="9" font="6">IIb—Of uncertain benefit</text>
<text top="572" left="589" width="6" height="9" font="6">B</text>
<text top="572" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="572" left="629" width="103" height="9" font="7"><a href="e44.full.html#94">366,959,980,985,987</a></text>
<text top="572" left="731" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="589" left="68" width="244" height="9" font="6">2-vessel disease with proximal LAD artery disease*</text>
<text top="606" left="79" width="28" height="9" font="6">CABG</text>
<text top="606" left="175" width="3" height="9" font="6">I</text>
<text top="606" left="589" width="6" height="9" font="6">B</text>
<text top="606" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="606" left="629" width="105" height="9" font="7"><a href="e44.full.html#94">353,412,959,985–987</a></text>
<text top="606" left="734" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="624" left="79" width="17" height="9" font="6">PCI</text>
<text top="624" left="175" width="112" height="9" font="6">IIb—Of uncertain benefit</text>
<text top="624" left="589" width="6" height="9" font="6">B</text>
<text top="624" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="624" left="629" width="82" height="9" font="7"><a href="e44.full.html#94">366,959,985,987</a></text>
<text top="624" left="710" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="641" left="68" width="259" height="9" font="6">2-vessel disease without proximal LAD artery disease*</text>
<text top="658" left="79" width="28" height="9" font="6">CABG</text>
<text top="658" left="175" width="132" height="9" font="6">IIa—With extensive ischemia</text>
<text top="658" left="589" width="6" height="9" font="6">B</text>
<text top="658" left="625" width="3" height="9" font="6"><a href="e44.full.html#93">(</a></text>
<text top="658" left="629" width="63" height="9" font="7"><a href="e44.full.html#93">327,990–992</a></text>
<text top="658" left="692" width="3" height="9" font="6"><a href="e44.full.html#93">)</a></text>
<text top="675" left="175" width="238" height="9" font="6">IIb—Of uncertain benefit without extensive ischemia</text>
<text top="675" left="589" width="6" height="9" font="6">C</text>
<text top="675" left="625" width="3" height="9" font="6"><a href="e44.full.html#109">(</a></text>
<text top="675" left="629" width="18" height="9" font="7"><a href="e44.full.html#109">987</a></text>
<text top="675" left="647" width="3" height="9" font="6"><a href="e44.full.html#109">)</a></text>
<text top="693" left="79" width="17" height="9" font="6">PCI</text>
<text top="693" left="175" width="112" height="9" font="6">IIb—Of uncertain benefit</text>
<text top="693" left="589" width="6" height="9" font="6">B</text>
<text top="693" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="693" left="629" width="82" height="9" font="7"><a href="e44.full.html#94">366,959,985,987</a></text>
<text top="693" left="710" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="710" left="68" width="175" height="9" font="6">1-vessel proximal LAD artery disease</text>
<text top="727" left="79" width="28" height="9" font="6">CABG</text>
<text top="727" left="175" width="165" height="9" font="6">IIa—With LIMA for long-term benefit</text>
<text top="727" left="589" width="6" height="9" font="6">B</text>
<text top="727" left="625" width="3" height="9" font="6"><a href="e44.full.html#95">(</a></text>
<text top="727" left="629" width="82" height="9" font="7"><a href="e44.full.html#95">412 987,993,994</a></text>
<text top="727" left="711" width="3" height="9" font="6"><a href="e44.full.html#95">)</a></text>
<text top="744" left="79" width="17" height="9" font="6">PCI</text>
<text top="744" left="175" width="112" height="9" font="6">IIb—Of uncertain benefit</text>
<text top="744" left="589" width="6" height="9" font="6">B</text>
<text top="744" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="744" left="629" width="82" height="9" font="7"><a href="e44.full.html#94">366,959,985,987</a></text>
<text top="744" left="710" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="762" left="68" width="274" height="9" font="6">1-vessel disease without proximal LAD artery involvement</text>
<text top="779" left="79" width="28" height="9" font="6">CABG</text>
<text top="779" left="175" width="39" height="9" font="6">III: Harm</text>
<text top="779" left="589" width="6" height="9" font="6">B</text>
<text top="779" left="625" width="3" height="9" font="6"><a href="e44.full.html#93">(</a></text>
<text top="779" left="629" width="148" height="9" font="7"><a href="e44.full.html#93">306,327,412,985,990,995–998</a></text>
<text top="779" left="776" width="3" height="9" font="6"><a href="e44.full.html#93">)</a></text>
<text top="796" left="79" width="17" height="9" font="6">PCI</text>
<text top="796" left="175" width="39" height="9" font="6">III: Harm</text>
<text top="796" left="589" width="6" height="9" font="6">B</text>
<text top="796" left="625" width="3" height="9" font="6"><a href="e44.full.html#93">(</a></text>
<text top="796" left="629" width="148" height="9" font="7"><a href="e44.full.html#93">306,327,412,985,990,995–998</a></text>
<text top="796" left="776" width="3" height="9" font="6"><a href="e44.full.html#93">)</a></text>
<text top="813" left="68" width="69" height="9" font="6">LV dysfunction</text>
<text top="831" left="79" width="28" height="9" font="6">CABG</text>
<text top="831" left="175" width="92" height="9" font="6">IIa—EF 35% to 50%</text>
<text top="831" left="589" width="6" height="9" font="6">B</text>
<text top="831" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="831" left="629" width="91" height="9" font="7"><a href="e44.full.html#94">365,412,999–1002</a></text>
<text top="831" left="719" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="848" left="79" width="28" height="9" font="6">CABG</text>
<text top="848" left="175" width="33" height="9" font="6">IIb—EF</text>
<text top="845" left="211" width="181" height="14" font="6">⬍35% without significant left main CAD</text>
<text top="848" left="589" width="6" height="9" font="6">B</text>
<text top="848" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="848" left="629" width="133" height="9" font="7"><a href="e44.full.html#94">355,365,410,412,999–1002</a></text>
<text top="848" left="761" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="865" left="79" width="17" height="9" font="6">PCI</text>
<text top="865" left="175" width="73" height="9" font="6">Insufficient data</text>
<text top="865" left="625" width="18" height="9" font="6">N/A</text>
<text top="882" left="68" width="341" height="9" font="6">Survivors of sudden cardiac death with presumed ischemia-mediated VT</text>
<text top="900" left="79" width="28" height="9" font="6">CABG</text>
<text top="900" left="175" width="3" height="9" font="6">I</text>
<text top="900" left="589" width="6" height="9" font="6">B</text>
<text top="900" left="625" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="900" left="628" width="73" height="9" font="7"><a href="e44.full.html#94">350,1003,1004</a></text>
<text top="900" left="701" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="917" left="79" width="17" height="9" font="6">PCI</text>
<text top="917" left="175" width="3" height="9" font="6">I</text>
<text top="917" left="589" width="6" height="9" font="6">C</text>
<text top="917" left="625" width="3" height="9" font="6"><a href="e44.full.html#109">(</a></text>
<text top="917" left="628" width="25" height="9" font="7"><a href="e44.full.html#109">1003</a></text>
<text top="917" left="653" width="3" height="9" font="6"><a href="e44.full.html#109">)</a></text>
<text top="934" left="68" width="273" height="9" font="6">No anatomic or physiological criteria for revascularization</text>
<text top="951" left="79" width="28" height="9" font="6">CABG</text>
<text top="951" left="175" width="39" height="9" font="6">III: Harm</text>
<text top="951" left="589" width="6" height="9" font="6">B</text>
<text top="951" left="625" width="3" height="9" font="6"><a href="e44.full.html#93">(</a></text>
<text top="951" left="628" width="148" height="9" font="7"><a href="e44.full.html#93">306,327,412,985,990,995–998</a></text>
<text top="951" left="776" width="3" height="9" font="6"><a href="e44.full.html#93">)</a></text>
<text top="969" left="79" width="17" height="9" font="6">PCI</text>
<text top="969" left="175" width="39" height="9" font="6">III: Harm</text>
<text top="969" left="589" width="6" height="9" font="6">B</text>
<text top="969" left="625" width="3" height="9" font="6"><a href="e44.full.html#93">(</a></text>
<text top="969" left="628" width="148" height="9" font="7"><a href="e44.full.html#93">306,327,412,985,990,995–998</a></text>
<text top="969" left="776" width="3" height="9" font="6"><a href="e44.full.html#93">)</a></text>
<text top="1006" left="59" width="445" height="7" font="17">*In patients with multivessel disease who also have diabetes mellitus, it is reasonable to choose CABG (with LIMA) over PCI <a href="e44.full.html#86">(</a></text>
<text top="1006" left="503" width="77" height="7" font="22"><a href="e44.full.html#86">30,991,1005–1011</a></text>
<text top="1006" left="580" width="77" height="7" font="17"><a href="e44.full.html#86">) </a>(<i>Class IIa; LOE: B</i>).</text>
<text top="1018" left="76" width="730" height="7" font="17">CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF, ejection fraction; LAD, left anterior</text>
<text top="1030" left="59" width="747" height="7" font="17">descending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not available; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; STEMI,</text>
<text top="1042" left="59" width="747" height="7" font="17">ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial</text>
<text top="1054" left="59" width="571" height="7" font="17">Infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; UPLM, unprotected left main disease; and VT, ventricular tachycardia.</text>
<text top="52" left="781" width="25" height="10" font="12">e107</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="38" size="8" family="Times" color="#231f20"/>
<text top="423" left="59" width="360" height="16" font="4">A collaborative assessment of revascularization options, or</text>
<text top="441" left="59" width="360" height="16" font="4">the decision to treat with GDMT without revascularization,</text>
<text top="459" left="59" width="360" height="16" font="4">involving an interventional cardiologist, a cardiac surgeon,</text>
<text top="477" left="59" width="360" height="16" font="4">and (often) the patient’s general cardiologist, followed by</text>
<text top="495" left="59" width="360" height="16" font="4">discussion with the patient about treatment options, is</text>
<text top="513" left="59" width="360" height="16" font="4">optimal. Particularly in patients with SIHD and unpro-</text>
<text top="531" left="59" width="360" height="16" font="4">tected left main and/or complex CAD for whom a revas-</text>
<text top="549" left="59" width="360" height="16" font="4">cularization strategy is not straightforward, an approach has</text>
<text top="567" left="59" width="360" height="16" font="4">been endorsed that involves terminating the procedure after</text>
<text top="585" left="59" width="360" height="16" font="4">diagnostic coronary angiography is completed; this allows a</text>
<text top="603" left="59" width="360" height="16" font="4">thorough discussion and affords both the interventional</text>
<text top="621" left="59" width="360" height="16" font="4">cardiologist and cardiac surgeon the opportunity to discuss</text>
<text top="639" left="59" width="360" height="16" font="4">revascularization options with the patient. Because the STS</text>
<text top="657" left="59" width="360" height="16" font="4">score and the SYNTAX score have been shown to predict</text>
<text top="675" left="59" width="360" height="16" font="4">adverse outcomes in patients undergoing CABG and PCI,</text>
<text top="693" left="59" width="360" height="16" font="4">respectively, calculation of these scores is often useful in</text>
<text top="711" left="59" width="220" height="16" font="4">making revascularization decisions <a href="e44.full.html#108">(</a></text>
<text top="711" left="278" width="105" height="16" font="16"><a href="e44.full.html#108">949,950,953–957</a></text>
<text top="711" left="383" width="9" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="739" left="59" width="299" height="12" font="18">5.2. Revascularization to Improve Survival:</text>
<text top="757" left="59" width="127" height="12" font="18">Recommendations</text>
<text top="779" left="59" width="224" height="16" font="26"><b>Left Main CAD Revascularization</b></text>
<text top="808" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="821" left="59" width="360" height="10" font="13">1. CABG to improve survival is recommended for patients with signif-</text>
<text top="838" left="74" width="33" height="10" font="13">icant (</text>
<text top="835" left="107" width="311" height="16" font="13">ⱖ50% diameter stenosis) left main coronary artery stenosis</text>
<text top="855" left="74" width="238" height="10" font="13"><a href="e44.full.html#87">(73,381,412,959–962). </a><i>(Level of Evidence: B)</i></text>
<text top="882" left="59" width="46" height="8" font="24">CLASS IIa</text>
<text top="895" left="59" width="360" height="10" font="13">1. PCI to improve survival is reasonable as an alternative to CABG in</text>
<text top="912" left="74" width="211" height="10" font="13">selected stable patients with significant (</text>
<text top="908" left="286" width="133" height="16" font="13">ⱖ50% diameter stenosis)</text>
<text top="929" left="74" width="344" height="10" font="13">unprotected left main CAD with: 1) anatomic conditions associated</text>
<text top="945" left="74" width="344" height="10" font="13">with a low risk of PCI procedural complications and a high likelihood</text>
<text top="962" left="74" width="282" height="10" font="13">of good long-term outcome (e.g., a low SYNTAX score [</text>
<text top="959" left="356" width="62" height="16" font="13">ⱕ22], ostial</text>
<text top="979" left="74" width="344" height="10" font="13">or trunk left main CAD); <i>and </i>2) clinical characteristics that predict a</text>
<text top="996" left="74" width="344" height="10" font="13">significantly increased risk of adverse surgical outcomes (e.g.,</text>
<text top="1013" left="74" width="207" height="10" font="13">STS-predicted risk of operative mortality</text>
<text top="1010" left="285" width="133" height="16" font="13">ⱖ5%) <a href="e44.full.html#108">(949,953,955,958,</a></text>
<text top="1030" left="74" width="169" height="10" font="13"><a href="e44.full.html#108">963–979). </a><i>(Level of Evidence: B)</i></text>
<text top="1047" left="58" width="360" height="10" font="13">2. PCI to improve survival is reasonable in patients with UA/NSTEMI</text>
<text top="1063" left="74" width="344" height="10" font="13">when an unprotected left main coronary artery is the culprit lesion</text>
<text top="1080" left="74" width="344" height="10" font="13">and the patient is not a candidate for CABG <a href="e44.full.html#108">(949,968–971,976–</a></text>
<text top="1097" left="74" width="166" height="10" font="13"><a href="e44.full.html#108">979,981). </a><i>(Level of Evidence: B)</i></text>
<text top="424" left="446" width="360" height="10" font="13">3. PCI to improve survival is reasonable in patients with acute STEMI</text>
<text top="441" left="461" width="344" height="10" font="13">when an unprotected left main coronary artery is the culprit lesion,</text>
<text top="457" left="461" width="344" height="10" font="13">distal coronary flow is less than TIMI (Thrombolysis In Myocardial</text>
<text top="474" left="461" width="344" height="10" font="13">Infarction) grade 3, and PCI can be performed more rapidly and</text>
<text top="491" left="461" width="287" height="10" font="13">safely than CABG <a href="e44.full.html#108">(965,982,983). </a><i>(Level of Evidence: C)</i></text>
<text top="519" left="446" width="46" height="8" font="24">CLASS IIb</text>
<text top="531" left="446" width="360" height="10" font="13">1. PCI to improve survival may be reasonable as an alternative to</text>
<text top="548" left="461" width="260" height="10" font="13">CABG in selected stable patients with significant (</text>
<text top="545" left="722" width="84" height="16" font="13">ⱖ50% diameter</text>
<text top="565" left="461" width="344" height="10" font="13">stenosis) unprotected left main CAD with: a) anatomic conditions</text>
<text top="582" left="461" width="344" height="10" font="13">associated with a low to intermediate risk of PCI procedural com-</text>
<text top="599" left="461" width="344" height="10" font="13">plications and an intermediate to high likelihood of good long-term</text>
<text top="616" left="461" width="255" height="10" font="13">outcome (e.g., low–intermediate SYNTAX score of</text>
<text top="613" left="720" width="86" height="16" font="13">⬍33, bifurcation</text>
<text top="633" left="461" width="344" height="10" font="13">left main CAD); <i>and </i>b) clinical characteristics that predict an in-</text>
<text top="650" left="461" width="344" height="10" font="13">creased risk of adverse surgical outcomes (e.g., moderate–severe</text>
<text top="666" left="461" width="344" height="10" font="13">chronic obstructive pulmonary disease, disability from previous</text>
<text top="683" left="461" width="344" height="10" font="13">stroke, or previous cardiac surgery; STS-predicted risk of opera-</text>
<text top="700" left="461" width="71" height="10" font="13">tive mortality</text>
<text top="697" left="536" width="270" height="16" font="13">⬎2%) <a href="e44.full.html#108">(949,953,955,958,963–979,984). </a><i>(Level of</i></text>
<text top="717" left="462" width="66" height="10" font="25"><i>Evidence: B)</i></text>
<text top="745" left="446" width="74" height="8" font="24">CLASS III: Harm</text>
<text top="757" left="446" width="360" height="10" font="13">1. PCI to improve survival should not be performed in stable patients</text>
<text top="774" left="461" width="88" height="10" font="13">with significant (</text>
<text top="771" left="550" width="256" height="16" font="13">ⱖ50% diameter stenosis) unprotected left main</text>
<text top="791" left="461" width="344" height="10" font="13">CAD who have unfavorable anatomy for PCI and who are good</text>
<text top="808" left="461" width="344" height="10" font="13">candidates for CABG <a href="e44.full.html#87">(73,381,412,949,953,955,959–964). </a><i>(Level</i></text>
<text top="825" left="461" width="77" height="10" font="25"><i>of Evidence: B)</i></text>
<text top="846" left="446" width="260" height="16" font="26"><b>Non–Left Main CAD Revascularization</b></text>
<text top="876" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="888" left="446" width="360" height="10" font="13">1. CABG to improve survival is beneficial in patients with significant</text>
<text top="905" left="461" width="4" height="10" font="13">(</text>
<text top="902" left="465" width="340" height="16" font="13">ⱖ70% diameter) stenoses in 3 major coronary arteries (with or</text>
<text top="922" left="461" width="344" height="10" font="13">without involvement of the proximal LAD artery) or in the proximal</text>
<text top="939" left="461" width="344" height="10" font="13">LAD artery plus 1 other major coronary artery <a href="e44.full.html#94">(353,412,959,985–</a></text>
<text top="956" left="461" width="142" height="10" font="13"><a href="e44.full.html#94">987). </a><i>(Level of Evidence: B)</i></text>
<text top="973" left="446" width="360" height="10" font="13">2. CABG or PCI to improve survival is beneficial in survivors of sudden</text>
<text top="990" left="461" width="344" height="10" font="13">cardiac death with presumed ischemia-mediated ventricular tachy-</text>
<text top="1006" left="461" width="153" height="10" font="13">cardia caused by significant (</text>
<text top="1003" left="614" width="191" height="16" font="13">ⱖ70% diameter) stenosis in a major</text>
<text top="1023" left="461" width="344" height="10" font="13">coronary artery. <i>(CABG Level of Evidence: B </i><a href="e44.full.html#94">[350,1003,1004]; </a><i>PCI</i></text>
<text top="1040" left="461" width="146" height="10" font="25"><i>Level of Evidence: C </i><a href="e44.full.html#109">[1003]</a><i>)</i></text>
<text top="1068" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="1080" left="446" width="360" height="10" font="13">1. CABG to improve survival is reasonable in patients with significant</text>
<text top="1097" left="461" width="4" height="10" font="13">(</text>
<text top="1094" left="465" width="340" height="16" font="13">ⱖ70% diameter) stenoses in 2 major coronary arteries with severe</text>
<text top="105" left="59" width="739" height="13" font="13">Table 19. Revascularization to Improve Symptoms With Significant Anatomic (&gt;50% Left Main or &gt;70% Non–Left Main CAD) or</text>
<text top="121" left="58" width="304" height="13" font="13">Physiological (FFR &lt;0.80) Coronary Artery Stenoses</text>
<text top="147" left="246" width="73" height="9" font="6">Clinical Setting</text>
<text top="147" left="553" width="21" height="9" font="6">COR</text>
<text top="147" left="633" width="18" height="9" font="6">LOE</text>
<text top="147" left="707" width="53" height="9" font="6">References</text>
<text top="161" left="68" width="419" height="14" font="6">ⱖ1 significant stenoses amenable to revascularization and unacceptable angina despite</text>
<text top="178" left="80" width="29" height="9" font="6">GDMT</text>
<text top="164" left="515" width="44" height="9" font="6">1—CABG</text>
<text top="164" left="638" width="7" height="9" font="6">A</text>
<text top="164" left="671" width="4" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="164" left="675" width="97" height="9" font="7"><a href="e44.full.html#94">366,407,1012–1020</a></text>
<text top="164" left="772" width="4" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="181" left="515" width="33" height="9" font="6">1—PCI</text>
<text top="196" left="68" width="426" height="14" font="6">ⱖ1 significant stenoses and unacceptable angina in whom GDMT cannot be implemented</text>
<text top="213" left="80" width="383" height="9" font="6">because of medication contraindications, adverse effects, or patient preferences</text>
<text top="198" left="515" width="50" height="9" font="6">IIa—CABG</text>
<text top="198" left="638" width="7" height="9" font="6">C</text>
<text top="198" left="671" width="20" height="9" font="6">N/A</text>
<text top="216" left="515" width="39" height="9" font="6">IIa—PCI</text>
<text top="216" left="638" width="7" height="9" font="6">C</text>
<text top="216" left="671" width="20" height="9" font="6">N/A</text>
<text top="233" left="68" width="95" height="9" font="6">Previous CABG with</text>
<text top="230" left="166" width="325" height="14" font="6">ⱖ1 significant stenoses associated with ischemia and unacceptable</text>
<text top="247" left="80" width="102" height="9" font="6">angina despite GDMT</text>
<text top="233" left="515" width="39" height="9" font="6">IIa—PCI</text>
<text top="233" left="638" width="7" height="9" font="6">C</text>
<text top="233" left="671" width="4" height="9" font="6"><a href="e44.full.html#110">(</a></text>
<text top="233" left="675" width="55" height="9" font="7"><a href="e44.full.html#110">1021–1024</a></text>
<text top="233" left="730" width="4" height="9" font="6"><a href="e44.full.html#110">)</a></text>
<text top="250" left="515" width="50" height="9" font="6">IIb—CABG</text>
<text top="250" left="638" width="7" height="9" font="6">C</text>
<text top="250" left="671" width="4" height="9" font="6"><a href="e44.full.html#110">(</a></text>
<text top="250" left="675" width="25" height="9" font="7"><a href="e44.full.html#110">1025</a></text>
<text top="250" left="700" width="4" height="9" font="6"><a href="e44.full.html#110">)</a></text>
<text top="267" left="68" width="402" height="9" font="6">Complex 3-vessel CAD (e.g., SYNTAX score <b>&gt;</b>22) with or without involvement of the</text>
<text top="282" left="80" width="247" height="9" font="6">proximal LAD artery and a good candidate for CABG</text>
<text top="267" left="515" width="96" height="9" font="6">IIa—CABG preferred</text>
<text top="282" left="527" width="40" height="9" font="6">over PCI</text>
<text top="267" left="638" width="7" height="9" font="6">B</text>
<text top="267" left="671" width="4" height="9" font="6"><a href="e44.full.html#109">(</a></text>
<text top="267" left="675" width="63" height="9" font="7"><a href="e44.full.html#109">980,987–989</a></text>
<text top="267" left="738" width="4" height="9" font="6"><a href="e44.full.html#109">)</a></text>
<text top="299" left="68" width="420" height="9" font="6">Viable ischemic myocardium that is perfused by coronary arteries that are not amenable</text>
<text top="313" left="80" width="50" height="9" font="6">to grafting</text>
<text top="299" left="515" width="74" height="9" font="6">IIb—TMR as an</text>
<text top="313" left="527" width="79" height="9" font="6">adjunct to CABG</text>
<text top="299" left="638" width="7" height="9" font="6">B</text>
<text top="299" left="671" width="4" height="9" font="6"><a href="e44.full.html#107">(</a></text>
<text top="299" left="675" width="115" height="9" font="7"><a href="e44.full.html#107">923,927,929,1026,1027</a></text>
<text top="299" left="790" width="4" height="9" font="6"><a href="e44.full.html#107">)</a></text>
<text top="330" left="68" width="273" height="9" font="6">No anatomic or physiological criteria for revascularization</text>
<text top="330" left="515" width="79" height="9" font="6">III: Harm—CABG</text>
<text top="330" left="638" width="7" height="9" font="6">C</text>
<text top="330" left="671" width="20" height="9" font="6">N/A</text>
<text top="348" left="515" width="68" height="9" font="6">III: Harm—PCI</text>
<text top="348" left="638" width="7" height="9" font="6">C</text>
<text top="348" left="671" width="20" height="9" font="6">N/A</text>
<text top="385" left="59" width="747" height="7" font="17">CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, class of recommendation; FFR, fractional flow reserve; GDMT, guideline-directed medical therapy; LOE, level of evidence;</text>
<text top="397" left="59" width="747" height="7" font="17">N/A, not available; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and TMR, transmyocardial revascularization.</text>
<text top="52" left="59" width="25" height="10" font="12">e108</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1161" width="864">
<text top="105" left="75" width="344" height="10" font="13">or extensive myocardial ischemia (e.g., high-risk criteria on stress</text>
<text top="122" left="75" width="308" height="10" font="13">testing, abnormal intracoronary hemodynamic evaluation, or</text>
<text top="119" left="385" width="33" height="16" font="13">⬎20%</text>
<text top="139" left="75" width="344" height="10" font="13">perfusion defect by myocardial perfusion stress imaging) or target</text>
<text top="156" left="75" width="344" height="10" font="13">vessels supplying a large area of viable myocardium <a href="e44.full.html#93">(327,990–</a></text>
<text top="174" left="75" width="142" height="10" font="13"><a href="e44.full.html#93">992). </a><i>(Level of Evidence: B)</i></text>
<text top="191" left="59" width="360" height="10" font="13">2. CABG to improve survival is reasonable in patients with mild–</text>
<text top="208" left="75" width="344" height="10" font="13">moderate LV systolic dysfunction (EF 35% to 50%) and significant</text>
<text top="225" left="75" width="4" height="10" font="13">(</text>
<text top="222" left="78" width="340" height="16" font="13">ⱖ70% diameter stenosis) multivessel CAD or proximal LAD coro-</text>
<text top="242" left="75" width="344" height="10" font="13">nary artery stenosis, when viable myocardium is present in the</text>
<text top="259" left="75" width="344" height="10" font="13">region of intended revascularization <a href="e44.full.html#94">(365,412,999–1002). </a><i>(Level of</i></text>
<text top="277" left="75" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="294" left="59" width="360" height="10" font="13">3. CABG with a left internal mammary artery (LIMA) graft to improve</text>
<text top="311" left="75" width="257" height="10" font="13">survival is reasonable in patients with significant (</text>
<text top="308" left="332" width="87" height="16" font="13">ⱖ70% diameter)</text>
<text top="328" left="75" width="344" height="10" font="13">stenosis in the proximal LAD artery and evidence of extensive</text>
<text top="345" left="75" width="268" height="10" font="13">ischemia <a href="e44.full.html#95">(412,987,993,994). </a><i>(Level of Evidence: B)</i></text>
<text top="362" left="58" width="360" height="10" font="13">4. It is reasonable to choose CABG over PCI to improve survival in</text>
<text top="380" left="74" width="286" height="10" font="13">patients with complex 3-vessel CAD (e.g., SYNTAX score</text>
<text top="376" left="363" width="55" height="16" font="13">⬎22), with</text>
<text top="397" left="74" width="344" height="10" font="13">or without involvement of the proximal LAD artery who are good</text>
<text top="414" left="74" width="331" height="10" font="13">candidates for CABG <a href="e44.full.html#108">(964,980,987–989). </a><i>(Level of Evidence: B)</i></text>
<text top="431" left="58" width="360" height="10" font="13">5. CABG is probably recommended in preference to PCI to improve</text>
<text top="448" left="74" width="344" height="10" font="13">survival in patients with multivessel CAD and diabetes mellitus,</text>
<text top="465" left="74" width="344" height="10" font="13">particularly if a LIMA graft can be anastomosed to the LAD artery</text>
<text top="483" left="74" width="276" height="10" font="13"><a href="e44.full.html#109">(991,1005–1008,1008–1011). </a><i>(Level of Evidence: B)</i></text>
<text top="513" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="526" left="59" width="360" height="10" font="13">1. The usefulness of CABG to improve survival is uncertain in patients</text>
<text top="544" left="74" width="344" height="10" font="13">with significant (70%) diameter stenoses in 2 major coronary arter-</text>
<text top="561" left="74" width="344" height="10" font="13">ies not involving the proximal LAD artery and without extensive</text>
<text top="578" left="74" width="195" height="10" font="13">ischemia <a href="e44.full.html#109">(987). </a><i>(Level of Evidence: C)</i></text>
<text top="595" left="58" width="360" height="10" font="13">2. The usefulness of PCI to improve survival is uncertain in patients</text>
<text top="612" left="74" width="344" height="10" font="13">with 2- or 3-vessel CAD (with or without involvement of the proximal</text>
<text top="629" left="74" width="344" height="10" font="13">LAD artery) or 1-vessel proximal LAD disease <a href="e44.full.html#94">(366,959,985,987).</a></text>
<text top="647" left="74" width="111" height="10" font="25"><i>(Level of Evidence: B)</i></text>
<text top="664" left="58" width="360" height="10" font="13">3. CABG might be considered with the primary or sole intent of</text>
<text top="681" left="74" width="344" height="10" font="13">improving survival in patients with SIHD with severe LV systolic</text>
<text top="698" left="74" width="78" height="10" font="13">dysfunction (EF</text>
<text top="695" left="155" width="264" height="16" font="13">⬍35%) whether or not viable myocardium is present</text>
<text top="715" left="74" width="276" height="10" font="13"><a href="e44.full.html#94">(355,365,410,412,999–1002). </a><i>(Level of Evidence: B)</i></text>
<text top="732" left="58" width="360" height="10" font="13">4. The usefulness of CABG or PCI to improve survival is uncertain in</text>
<text top="749" left="74" width="344" height="10" font="13">patients with previous CABG and extensive anterior wall ischemia</text>
<text top="767" left="74" width="344" height="10" font="13">on noninvasive testing <a href="e44.full.html#110">(1021–1025,1029–1032). </a><i>(Level of Evi-</i></text>
<text top="784" left="74" width="48" height="10" font="25"><i>dence: B)</i></text>
<text top="815" left="59" width="74" height="8" font="24">CLASS III: Harm</text>
<text top="828" left="59" width="360" height="10" font="13">1. CABG or PCI should not be performed with the primary or sole intent</text>
<text top="845" left="74" width="344" height="10" font="13">to improve survival in patients with SIHD with 1 or more coronary</text>
<text top="862" left="74" width="344" height="10" font="13">stenoses that are not anatomically or functionally significant (e.g.,</text>
<text top="876" left="74" width="344" height="16" font="13">⬍70% diameter non–left main coronary artery stenosis, FFR ⬎0.80,</text>
<text top="896" left="74" width="344" height="10" font="13">no or only mild ischemia on noninvasive testing), involve only the</text>
<text top="913" left="74" width="344" height="10" font="13">left circumflex or right coronary artery, or subtend only a small area</text>
<text top="930" left="74" width="344" height="10" font="13">of viable myocardium <a href="e44.full.html#93">(306,327,412,985,990,995–998). </a><i>(Level of</i></text>
<text top="948" left="74" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="983" left="59" width="315" height="12" font="18">5.3. Revascularization to Improve Symptoms:</text>
<text top="1001" left="59" width="127" height="12" font="18">Recommendations</text>
<text top="1033" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="1046" left="59" width="360" height="10" font="13">1. CABG or PCI to improve symptoms is beneficial in patients with 1 or</text>
<text top="1063" left="74" width="92" height="10" font="13">more significant (</text>
<text top="1060" left="167" width="252" height="16" font="13">ⱖ70% diameter) coronary artery stenoses ame-</text>
<text top="1080" left="74" width="344" height="10" font="13">nable to revascularization and unacceptable angina despite GDMT</text>
<text top="1097" left="74" width="297" height="10" font="13"><a href="e44.full.html#94">(366,407,1012–1018,1020,1033). </a><i>(Level of Evidence: A)</i></text>
<text top="105" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="118" left="446" width="360" height="10" font="13">1. CABG or PCI to improve symptoms is reasonable in patients with 1</text>
<text top="135" left="461" width="104" height="10" font="13">or more significant (</text>
<text top="131" left="566" width="240" height="16" font="13">ⱖ70% diameter) coronary artery stenoses and</text>
<text top="152" left="461" width="344" height="10" font="13">unacceptable angina for whom GDMT cannot be implemented</text>
<text top="168" left="461" width="344" height="10" font="13">because of medication contraindications, adverse effects, or patient</text>
<text top="185" left="461" width="178" height="10" font="13">preferences. <i>(Level of Evidence: C)</i></text>
<text top="202" left="446" width="360" height="10" font="13">2. PCI to improve symptoms is reasonable in patients with previous</text>
<text top="219" left="461" width="166" height="10" font="13">CABG, 1 or more significant (</text>
<text top="216" left="628" width="178" height="16" font="13">ⱖ70% diameter) coronary artery</text>
<text top="236" left="461" width="344" height="10" font="13">stenoses associated with ischemia, and unacceptable angina de-</text>
<text top="253" left="461" width="278" height="10" font="13">spite GDMT <a href="e44.full.html#110">(1021,1023,1024). </a><i>(Level of Evidence: C)</i></text>
<text top="270" left="445" width="360" height="10" font="13">3. It is reasonable to choose CABG over PCI to improve symptoms in</text>
<text top="286" left="461" width="286" height="10" font="13">patients with complex 3-vessel CAD (e.g., SYNTAX score</text>
<text top="283" left="750" width="55" height="16" font="13">⬎22), with</text>
<text top="303" left="461" width="344" height="10" font="13">or without involvement of the proximal LAD artery, who are good</text>
<text top="320" left="461" width="344" height="10" font="13">candidates for CABG <a href="e44.full.html#108">(964,980,987–989). </a><i>(Level of Evidence: B)</i></text>
<text top="351" left="446" width="46" height="8" font="24">CLASS IIb</text>
<text top="363" left="446" width="360" height="10" font="13">1. CABG to improve symptoms might be reasonable for patients with</text>
<text top="380" left="461" width="206" height="10" font="13">previous CABG, 1 or more significant (</text>
<text top="377" left="667" width="138" height="16" font="13">ⱖ70% diameter) coronary</text>
<text top="397" left="461" width="344" height="10" font="13">artery stenoses not amenable to PCI, and unacceptable angina</text>
<text top="414" left="461" width="228" height="10" font="13">despite GDMT <a href="e44.full.html#110">(1025). </a><i>(Level of Evidence: C)</i></text>
<text top="431" left="445" width="360" height="10" font="13">2. TMR performed as an adjunct to CABG to improve symptoms may</text>
<text top="448" left="461" width="344" height="10" font="13">be reasonable in patients with viable ischemic myocardium that is</text>
<text top="465" left="461" width="344" height="10" font="13">perfused by arteries that are not amenable to grafting <a href="e44.full.html#107">(923,</a></text>
<text top="481" left="461" width="228" height="10" font="13"><a href="e44.full.html#107">927,929,1026,1027). </a><i>(Level of Evidence: B)</i></text>
<text top="512" left="446" width="74" height="8" font="24">CLASS III: Harm</text>
<text top="525" left="446" width="360" height="10" font="13">1. CABG or PCI to improve symptoms should not be performed in</text>
<text top="542" left="461" width="195" height="10" font="13">patients who do not meet anatomic (</text>
<text top="538" left="656" width="149" height="16" font="13">ⱖ50% diameter left main or</text>
<text top="555" left="461" width="344" height="16" font="13">ⱖ70% non–left main stenosis diameter) or physiological (e.g.,</text>
<text top="575" left="461" width="341" height="10" font="13">abnormal FFR) criteria for revascularization. <i>(Level of Evidence: C)</i></text>
<text top="604" left="446" width="252" height="12" font="18">5.4. CABG Versus Contemporaneous</text>
<text top="622" left="446" width="112" height="12" font="18">Medical Therapy</text>
<text top="644" left="446" width="360" height="16" font="4">In the 1970s and 1980s, 3 RCTs established the survival</text>
<text top="662" left="446" width="360" height="16" font="4">benefit of CABG compared with contemporaneous (al-</text>
<text top="680" left="446" width="360" height="16" font="4">though minimal by current standards) medical therapy</text>
<text top="698" left="446" width="360" height="16" font="4">without revascularization in certain subjects with stable</text>
<text top="716" left="446" width="321" height="16" font="4">angina: the Veterans Affairs Cooperative Study <a href="e44.full.html#110">(</a></text>
<text top="716" left="767" width="30" height="16" font="16"><a href="e44.full.html#110">1035</a></text>
<text top="716" left="797" width="9" height="16" font="4"><a href="e44.full.html#110">),</a></text>
<text top="734" left="446" width="246" height="16" font="4">European Coronary Surgery Study <a href="e44.full.html#109">(</a></text>
<text top="734" left="692" width="23" height="16" font="16"><a href="e44.full.html#109">986</a></text>
<text top="734" left="715" width="91" height="16" font="4"><a href="e44.full.html#109">), </a>and CASS</text>
<text top="752" left="446" width="5" height="16" font="4"><a href="e44.full.html#110">(</a></text>
<text top="752" left="450" width="30" height="16" font="16"><a href="e44.full.html#110">1036</a></text>
<text top="752" left="480" width="325" height="16" font="4"><a href="e44.full.html#110">). </a>Subsequently, a 1994 meta-analysis of 7 studies that</text>
<text top="770" left="446" width="360" height="16" font="4">randomized a total of 2,649 patients to medical therapy or</text>
<text top="788" left="446" width="54" height="16" font="4">CABG <a href="e44.full.html#95">(</a></text>
<text top="788" left="499" width="23" height="16" font="16"><a href="e44.full.html#95">412</a></text>
<text top="788" left="522" width="284" height="16" font="4"><a href="e44.full.html#95">) </a>showed that CABG offered a survival advan-</text>
<text top="806" left="446" width="360" height="16" font="4">tage over medical therapy for patients with left main or</text>
<text top="824" left="446" width="360" height="16" font="4">3-vessel CAD. The studies also established that CABG is</text>
<text top="842" left="446" width="360" height="16" font="4">more effective than medical therapy for relieving anginal</text>
<text top="860" left="446" width="360" height="16" font="4">symptoms. These studies have been replicated only once</text>
<text top="878" left="446" width="360" height="16" font="4">during the past decade. In MASS II (Medicine, Angio-</text>
<text top="896" left="446" width="360" height="16" font="4">plasty, or Surgery Study II), patients with multivessel CAD</text>
<text top="914" left="446" width="360" height="16" font="4">who were treated with CABG were less likely than those</text>
<text top="932" left="446" width="360" height="16" font="4">treated with medical therapy to have a subsequent MI, need</text>
<text top="950" left="446" width="360" height="16" font="4">additional revascularization, or experience cardiac death in</text>
<text top="968" left="446" width="209" height="16" font="4">the 10 years after randomization <a href="e44.full.html#110">(</a></text>
<text top="968" left="655" width="30" height="16" font="16"><a href="e44.full.html#110">1016</a></text>
<text top="968" left="685" width="9" height="16" font="4"><a href="e44.full.html#110">).</a></text>
<text top="986" left="461" width="345" height="16" font="4">Surgical techniques and medical therapy have improved</text>
<text top="1004" left="446" width="360" height="16" font="4">substantially during the intervening years. As a result, if</text>
<text top="1022" left="446" width="360" height="16" font="4">CABG were to be compared with GDMT in RCTs today,</text>
<text top="1040" left="446" width="360" height="16" font="4">the relative benefits for survival and angina relief observed</text>
<text top="1058" left="446" width="360" height="16" font="4">several decades ago might no longer be observed. Con-</text>
<text top="1076" left="446" width="360" height="16" font="4">versely, the concurrent administration of GDMT may</text>
<text top="1094" left="446" width="360" height="16" font="4">substantially improve long-term outcomes in patients</text>
<text top="52" left="781" width="25" height="10" font="12">e109</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">treated with CABG in comparison with those receiving</text>
<text top="122" left="59" width="360" height="16" font="4">medical therapy alone. In the BARI 2D (Bypass Angio-</text>
<text top="140" left="59" width="360" height="16" font="4">plasty Revascularization Investigation 2 Diabetes) trial of</text>
<text top="158" left="59" width="360" height="16" font="4">patients with diabetes mellitus, no significant difference in</text>
<text top="176" left="59" width="360" height="16" font="4">risk of mortality in the cohort of patients randomized to</text>
<text top="194" left="59" width="360" height="16" font="4">GDMT plus CABG or GDMT alone was observed,</text>
<text top="212" left="59" width="360" height="16" font="4">although the study was not powered for this endpoint,</text>
<text top="230" left="59" width="360" height="16" font="4">excluded patients with significant left main CAD, and</text>
<text top="248" left="59" width="360" height="16" font="4">included only a small percentage of patients with proximal</text>
<text top="266" left="59" width="184" height="16" font="4">LAD artery disease or LVEF</text>
<text top="263" left="248" width="49" height="20" font="4">⬍0.50 <a href="e44.full.html#95">(</a></text>
<text top="266" left="297" width="23" height="16" font="16"><a href="e44.full.html#95">408</a></text>
<text top="266" left="320" width="99" height="16" font="4"><a href="e44.full.html#95">). </a>The PCI and</text>
<text top="284" left="59" width="360" height="16" font="4">CABG guideline writing committees endorse the perfor-</text>
<text top="302" left="59" width="360" height="16" font="4">mance of the ISCHEMIA trial, which will provide con-</text>
<text top="320" left="59" width="360" height="16" font="4">temporary data on the optimal management strategy (med-</text>
<text top="338" left="59" width="360" height="16" font="4">ical therapy or revascularization with CABG or PCI) of</text>
<text top="356" left="59" width="360" height="16" font="4">patients with SIHD, including multivessel CAD, and mod-</text>
<text top="374" left="59" width="149" height="16" font="4">erate to severe ischemia.</text>
<text top="411" left="59" width="225" height="12" font="18">5.5. PCI Versus Medical Therapy</text>
<text top="434" left="59" width="360" height="16" font="4">Although contemporary interventional treatments have</text>
<text top="452" left="59" width="360" height="16" font="4">lowered the risk of restenosis compared with earlier tech-</text>
<text top="470" left="59" width="360" height="16" font="4">niques, meta-analyses have not shown that the introduction</text>
<text top="488" left="59" width="360" height="16" font="4">of bare metal stents (BMS) confers a survival advantage over</text>
<text top="506" left="59" width="130" height="16" font="4">balloon angioplasty <a href="e44.full.html#110">(</a></text>
<text top="506" left="189" width="68" height="16" font="16"><a href="e44.full.html#110">1037–1039</a></text>
<text top="506" left="256" width="162" height="16" font="4"><a href="e44.full.html#110">) </a>or that the use of DES</text>
<text top="524" left="59" width="248" height="16" font="4">confers a survival advantage over BMS <a href="e44.full.html#89">(</a></text>
<text top="524" left="306" width="56" height="16" font="16"><a href="e44.full.html#89">138,1040</a></text>
<text top="524" left="363" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="542" left="74" width="345" height="16" font="4">No study to date has demonstrated that PCI in patients</text>
<text top="560" left="59" width="253" height="16" font="4">with SIHD improves survival rates <a href="e44.full.html#89">(</a></text>
<text top="560" left="311" width="107" height="16" font="16"><a href="e44.full.html#89">138,366,408,959,</a></text>
<text top="578" left="59" width="125" height="16" font="16"><a href="e44.full.html#89">985,987,1041–1044</a></text>
<text top="578" left="184" width="175" height="16" font="4"><a href="e44.full.html#89">). </a>Neither COURAGE <a href="e44.full.html#94">(</a></text>
<text top="578" left="358" width="23" height="16" font="16"><a href="e44.full.html#94">366</a></text>
<text top="578" left="382" width="37" height="16" font="4"><a href="e44.full.html#94">) </a>nor</text>
<text top="596" left="59" width="72" height="16" font="4">BARI 2D <a href="e44.full.html#95">(</a></text>
<text top="596" left="130" width="23" height="16" font="16"><a href="e44.full.html#95">408</a></text>
<text top="596" left="153" width="266" height="16" font="4"><a href="e44.full.html#95">)</a>, which treated all patients with contem-</text>
<text top="614" left="59" width="360" height="16" font="4">porary optimal medical therapy, demonstrated any sur-</text>
<text top="632" left="59" width="360" height="16" font="4">vival advantage with PCI, although these trials were not</text>
<text top="650" left="59" width="360" height="16" font="4">specifically powered for this endpoint. Although 1 large</text>
<text top="668" left="59" width="360" height="16" font="4">analysis evaluating 17 RCTs of PCI versus medical</text>
<text top="686" left="59" width="360" height="16" font="4">therapy (including 5 trials of subjects with ACS) found a</text>
<text top="704" left="59" width="360" height="16" font="4">20% reduction in death with PCI compared with medical</text>
<text top="722" left="59" width="56" height="16" font="4">therapy <a href="e44.full.html#110">(</a></text>
<text top="722" left="115" width="31" height="16" font="16"><a href="e44.full.html#110">1043</a></text>
<text top="722" left="146" width="205" height="16" font="4"><a href="e44.full.html#110">), </a>2 other large analyses did not <a href="e44.full.html#89">(</a></text>
<text top="722" left="351" width="58" height="16" font="16"><a href="e44.full.html#89">138,1042</a></text>
<text top="722" left="410" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="740" left="59" width="360" height="16" font="4">An evaluation of 13 studies reporting the data from 5,442</text>
<text top="758" left="59" width="360" height="16" font="4">patients with nonacute CAD showed no advantage of</text>
<text top="776" left="59" width="360" height="16" font="4">PCI over medical therapy for the individual endpoints of</text>
<text top="794" left="59" width="360" height="16" font="4">all-cause death, cardiac death or MI, or nonfatal MI</text>
<text top="812" left="59" width="5" height="16" font="4"><a href="e44.full.html#110">(</a></text>
<text top="812" left="64" width="31" height="16" font="16"><a href="e44.full.html#110">1044</a></text>
<text top="812" left="95" width="324" height="16" font="4"><a href="e44.full.html#110">). </a>Evaluation of 61 trials of PCI conducted over</text>
<text top="830" left="59" width="360" height="16" font="4">several decades shows that despite improvements in PCI</text>
<text top="848" left="59" width="360" height="16" font="4">technology and pharmacotherapy, PCI has not been</text>
<text top="866" left="59" width="360" height="16" font="4">demonstrated to reduce the risk of death or MI in</text>
<text top="884" left="59" width="195" height="16" font="4">patients without recent ACS <a href="e44.full.html#89">(</a></text>
<text top="884" left="254" width="23" height="16" font="16"><a href="e44.full.html#89">138</a></text>
<text top="884" left="277" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="902" left="74" width="345" height="16" font="4">The findings from individual studies and systematic</text>
<text top="920" left="59" width="360" height="16" font="4">reviews of PCI versus medical therapy can be summarized as</text>
<text top="938" left="59" width="47" height="16" font="4">follows:</text>
<text top="965" left="74" width="259" height="20" font="4">• PCI reduces the incidence of angina <a href="e44.full.html#94">(</a></text>
<text top="968" left="332" width="86" height="16" font="16"><a href="e44.full.html#94">366,407,1016,</a></text>
<text top="986" left="90" width="98" height="16" font="16"><a href="e44.full.html#94">1020,1033,1045</a></text>
<text top="986" left="188" width="9" height="16" font="4"><a href="e44.full.html#94">).</a></text>
<text top="1001" left="74" width="345" height="20" font="4">• PCI has not been demonstrated to improve survival in</text>
<text top="1022" left="90" width="97" height="16" font="4">stable patients <a href="e44.full.html#89">(</a></text>
<text top="1022" left="187" width="90" height="16" font="16"><a href="e44.full.html#89">138,1041,1042</a></text>
<text top="1022" left="277" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="1037" left="74" width="319" height="20" font="4">• PCI may increase the short-term risk of MI <a href="e44.full.html#94">(</a></text>
<text top="1040" left="392" width="26" height="16" font="16"><a href="e44.full.html#94">366,</a></text>
<text top="1058" left="90" width="90" height="16" font="16"><a href="e44.full.html#94">397,1041,1045</a></text>
<text top="1058" left="181" width="9" height="16" font="4"><a href="e44.full.html#94">).</a></text>
<text top="1073" left="73" width="345" height="20" font="4">• PCI does not lower the long-term risk of MI</text>
<text top="1094" left="90" width="5" height="16" font="4"><a href="e44.full.html#89">(</a></text>
<text top="1094" left="95" width="169" height="16" font="16"><a href="e44.full.html#89">138,366,397,408,1041,1042</a></text>
<text top="1094" left="264" width="9" height="16" font="4"><a href="e44.full.html#89">).</a></text>
<text top="105" left="446" width="151" height="12" font="18">5.6. CABG Versus PCI</text>
<text top="128" left="446" width="360" height="16" font="4">The results of 26 RCTs comparing CABG and PCI have</text>
<text top="146" left="446" width="360" height="16" font="4">been published: Of these, 9 compared CABG with balloon</text>
<text top="164" left="446" width="89" height="16" font="4">angioplasty <a href="e44.full.html#86">(</a></text>
<text top="164" left="535" width="159" height="16" font="16"><a href="e44.full.html#86">30,368,1017,1046 –1059</a></text>
<text top="164" left="695" width="110" height="16" font="4"><a href="e44.full.html#86">), </a>14 compared</text>
<text top="182" left="446" width="214" height="16" font="4">CABG with BMS implantation <a href="e44.full.html#110">(</a></text>
<text top="182" left="660" width="137" height="16" font="16"><a href="e44.full.html#110">1022,1054,1060 –1076</a></text>
<text top="182" left="797" width="9" height="16" font="4"><a href="e44.full.html#110">),</a></text>
<text top="200" left="446" width="334" height="16" font="4">and 3 compared CABG with DES implantation <a href="e44.full.html#108">(</a></text>
<text top="200" left="779" width="26" height="16" font="16"><a href="e44.full.html#108">950,</a></text>
<text top="218" left="446" width="64" height="16" font="16"><a href="e44.full.html#108">1077,1078</a></text>
<text top="218" left="509" width="9" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="245" left="446" width="328" height="16" font="26"><b>5.6.1. CABG Versus Balloon Angioplasty or BMS</b></text>
<text top="270" left="446" width="360" height="16" font="4">A systematic review of the 22 RCTs comparing CABG</text>
<text top="288" left="446" width="360" height="16" font="4">with balloon angioplasty or BMS implantation concluded</text>
<text top="306" left="446" width="91" height="16" font="4">the following <a href="e44.full.html#111">(</a></text>
<text top="306" left="537" width="30" height="16" font="16"><a href="e44.full.html#111">1079</a></text>
<text top="306" left="567" width="9" height="16" font="4"><a href="e44.full.html#111">):</a></text>
<text top="336" left="446" width="360" height="16" font="4">1. Survival was similar for CABG and PCI (with balloon</text>
<text top="354" left="464" width="341" height="16" font="4">angioplasty or BMS) at 1 year and 5 years. Survival was</text>
<text top="372" left="464" width="341" height="16" font="4">similar for CABG and PCI in subjects with 1-vessel</text>
<text top="390" left="464" width="341" height="16" font="4">CAD (including those with disease of the proximal</text>
<text top="408" left="464" width="300" height="16" font="4">portion of the LAD artery) or multivessel CAD.</text>
<text top="426" left="446" width="360" height="16" font="4">2. Incidence of MI was similar at 5 years after randomiza-</text>
<text top="444" left="464" width="28" height="16" font="4">tion.</text>
<text top="462" left="446" width="360" height="16" font="4">3. Procedural stroke occurred more commonly with CABG</text>
<text top="480" left="464" width="215" height="16" font="4">than with PCI (1.2% versus 0.6%).</text>
<text top="498" left="446" width="360" height="16" font="4">4. Relief of angina was accomplished more effectively with</text>
<text top="516" left="464" width="341" height="16" font="4">CABG than with PCI 1 year after randomization and 5</text>
<text top="534" left="464" width="159" height="16" font="4">years after randomization.</text>
<text top="552" left="446" width="360" height="16" font="4">5. During the first year after randomization, repeat coro-</text>
<text top="570" left="464" width="341" height="16" font="4">nary revascularization was performed less often after</text>
<text top="588" left="464" width="341" height="16" font="4">CABG than after PCI (3.8% versus 26.5%). This was</text>
<text top="606" left="464" width="341" height="16" font="4">also demonstrated after 5 years of follow-up (9.8% versus</text>
<text top="624" left="464" width="341" height="16" font="4">46.1%). This difference was more pronounced with</text>
<text top="642" left="464" width="223" height="16" font="4">balloon angioplasty than with BMS.</text>
<text top="669" left="461" width="345" height="16" font="4">A collaborative analysis of data from 10 RCTs comparing</text>
<text top="687" left="446" width="360" height="16" font="4">CABG with balloon angioplasty (6 trials) or with BMS</text>
<text top="705" left="446" width="146" height="16" font="4">implantation (4 trials) <a href="e44.full.html#111">(</a></text>
<text top="705" left="591" width="30" height="16" font="16"><a href="e44.full.html#111">1080</a></text>
<text top="705" left="621" width="184" height="16" font="4"><a href="e44.full.html#111">) </a>permitted subgroup analyses</text>
<text top="723" left="446" width="360" height="16" font="4">of the data from the 7,812 patients. No difference was noted</text>
<text top="741" left="446" width="360" height="16" font="4">with regard to mortality rate 5.9 years after randomization</text>
<text top="759" left="446" width="360" height="16" font="4">or the composite endpoint of death or MI. Repeat revascu-</text>
<text top="777" left="446" width="360" height="16" font="4">larization and angina were noted more frequently in those</text>
<text top="795" left="446" width="360" height="16" font="4">treated with balloon angioplasty or BMS implantation</text>
<text top="813" left="446" width="5" height="16" font="4"><a href="e44.full.html#111">(</a></text>
<text top="813" left="450" width="30" height="16" font="16"><a href="e44.full.html#111">1080</a></text>
<text top="813" left="480" width="325" height="16" font="4"><a href="e44.full.html#111">). </a>The major new observation of this analysis was that</text>
<text top="831" left="446" width="360" height="16" font="4">CABG was associated with better outcomes in patients with</text>
<text top="849" left="446" width="178" height="16" font="4">diabetes mellitus and in those</text>
<text top="846" left="628" width="178" height="20" font="4">⬎65 years of age. Of interest,</text>
<text top="867" left="446" width="360" height="16" font="4">the relative outcomes of CABG and PCI were not influ-</text>
<text top="885" left="446" width="360" height="16" font="4">enced by other patient characteristics, including the number</text>
<text top="903" left="446" width="176" height="16" font="4">of diseased coronary arteries.</text>
<text top="921" left="461" width="345" height="16" font="4">The aforementioned meta-analysis and systematic review</text>
<text top="939" left="446" width="5" height="16" font="4"><a href="e44.full.html#111">(</a></text>
<text top="939" left="450" width="64" height="16" font="16"><a href="e44.full.html#111">1079,1080</a></text>
<text top="939" left="514" width="291" height="16" font="4"><a href="e44.full.html#111">) </a>comparing CABG and balloon angioplasty or</text>
<text top="957" left="446" width="296" height="16" font="4">BMS implantation were limited in several ways:</text>
<text top="986" left="446" width="360" height="16" font="4">1. Many trials did not report outcomes for other important</text>
<text top="1004" left="464" width="341" height="16" font="4">patient subsets. For example, the available data are</text>
<text top="1022" left="464" width="341" height="16" font="4">insufficient to determine if race, obesity, renal dysfunc-</text>
<text top="1040" left="464" width="341" height="16" font="4">tion, PAD, or previous coronary revascularization af-</text>
<text top="1058" left="464" width="329" height="16" font="4">fected the comparative outcomes of CABG and PCI.</text>
<text top="1076" left="446" width="360" height="16" font="4">2. Most of the patients enrolled in these trials were male,</text>
<text top="1094" left="464" width="341" height="16" font="4">and most had 1- or 2-vessel CAD and normal LV</text>
<text top="52" left="59" width="25" height="10" font="12">e110</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="77" width="135" height="16" font="4">systolic function (EF</text>
<text top="101" left="221" width="198" height="20" font="4">⬎50%)—subjects known to be</text>
<text top="123" left="77" width="341" height="16" font="4">unlikely to derive a survival benefit and less likely to</text>
<text top="142" left="77" width="243" height="16" font="4">experience complications after CABG <a href="e44.full.html#95">(</a></text>
<text top="142" left="321" width="23" height="16" font="16"><a href="e44.full.html#95">412</a></text>
<text top="142" left="343" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="160" left="58" width="360" height="16" font="4">3. The patients enrolled in these trials represented only a</text>
<text top="179" left="77" width="144" height="16" font="4">small fraction (generally</text>
<text top="175" left="225" width="194" height="20" font="4">⬍5% to 10%) of those who were</text>
<text top="197" left="77" width="341" height="16" font="4">screened. For example, most screened patients with</text>
<text top="216" left="77" width="341" height="16" font="4">1-vessel CAD and many with 3-vessel CAD were not</text>
<text top="234" left="77" width="184" height="16" font="4">considered for randomization.</text>
<text top="262" left="58" width="18" height="16" font="5"><i>See</i></text>
<text top="262" left="82" width="203" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplements 5 and 6</i></a></text>
<text top="262" left="290" width="129" height="16" font="5"><i>for additional data on</i></text>
<text top="280" left="58" width="112" height="16" font="5"><i>CABG versus PCI.</i></text>
<text top="308" left="58" width="172" height="16" font="26"><b>5.6.2. CABG Versus DES</b></text>
<text top="334" left="58" width="360" height="16" font="4">Although the results of 9 observational studies comparing</text>
<text top="353" left="58" width="360" height="16" font="4">CABG and DES implantation have been published</text>
<text top="371" left="58" width="5" height="16" font="4"><a href="e44.full.html#108">(</a></text>
<text top="371" left="63" width="94" height="16" font="16"><a href="e44.full.html#108">964,1081–1088</a></text>
<text top="371" left="157" width="261" height="16" font="4"><a href="e44.full.html#108">), </a>most of them had short (12 to 24</text>
<text top="390" left="58" width="360" height="16" font="4">months) follow-up periods. In a meta-analysis of 24,268</text>
<text top="408" left="58" width="360" height="16" font="4">patients with multivessel CAD treated with CABG or DES</text>
<text top="427" left="58" width="5" height="16" font="4"><a href="e44.full.html#111">(</a></text>
<text top="427" left="63" width="30" height="16" font="16"><a href="e44.full.html#111">1089</a></text>
<text top="427" left="93" width="325" height="16" font="4"><a href="e44.full.html#111">), </a>the incidences of death and MI were similar for the</text>
<text top="445" left="58" width="360" height="16" font="4">2 procedures, but the frequency with which repeat revascu-</text>
<text top="464" left="58" width="360" height="16" font="4">larization was performed was roughly 4 times higher after</text>
<text top="482" left="58" width="360" height="16" font="4">DES implantation. Only 1 large RCT comparing CABG</text>
<text top="501" left="58" width="360" height="16" font="4">and DES implantation has been published. The SYNTAX</text>
<text top="519" left="58" width="360" height="16" font="4">trial randomly assigned 1,800 patients (of a total of 4,337 who</text>
<text top="538" left="58" width="280" height="16" font="4">were screened) to receive DES or CABG <a href="e44.full.html#108">(</a></text>
<text top="538" left="338" width="72" height="16" font="16"><a href="e44.full.html#108">949,950,980</a></text>
<text top="538" left="410" width="8" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="556" left="58" width="360" height="16" font="4">MACE, a composite of death, stroke, MI, or repeat</text>
<text top="575" left="58" width="360" height="16" font="4">revascularization during the 3 years after randomization,</text>
<text top="594" left="58" width="360" height="16" font="4">occurred in 20.2% of CABG patients and 28.0% of those</text>
<text top="612" left="58" width="215" height="16" font="4">undergoing DES implantation (p</text>
<text top="609" left="273" width="145" height="20" font="4">⬍0.001). The rates of</text>
<text top="631" left="58" width="360" height="16" font="4">death and stroke were similar; however, MI (3.6% for</text>
<text top="649" left="58" width="360" height="16" font="4">CABG, 7.1% for DES) and repeat revascularization (10.7%</text>
<text top="668" left="58" width="360" height="16" font="4">for CABG, 19.7% for DES) were more likely to occur with</text>
<text top="686" left="58" width="123" height="16" font="4">DES implantation <a href="e44.full.html#109">(</a></text>
<text top="686" left="182" width="23" height="16" font="16"><a href="e44.full.html#109">980</a></text>
<text top="686" left="204" width="9" height="16" font="4"><a href="e44.full.html#109">).</a></text>
<text top="705" left="73" width="345" height="16" font="4">In SYNTAX, the extent of CAD was assessed by using</text>
<text top="723" left="58" width="360" height="16" font="4">the SYNTAX score, which is based on the location,</text>
<text top="742" left="58" width="360" height="16" font="4">severity, and extent of coronary stenoses, with a low score</text>
<text top="760" left="58" width="360" height="16" font="4">indicating less complicated anatomic CAD. In post hoc</text>
<text top="779" left="58" width="219" height="16" font="4">analyses, a low score was defined as</text>
<text top="776" left="282" width="136" height="20" font="4">ⱕ22; intermediate, 23</text>
<text top="798" left="58" width="96" height="16" font="4">to 32; and high,</text>
<text top="794" left="159" width="260" height="20" font="4">ⱖ33. The occurrence of MACE correlated</text>
<text top="816" left="58" width="360" height="16" font="4">with the SYNTAX score for DES patients but not for those</text>
<text top="835" left="58" width="360" height="16" font="4">undergoing CABG. At 12-month follow-up, the primary</text>
<text top="853" left="58" width="360" height="16" font="4">endpoint was similar for CABG and DES in those with a</text>
<text top="872" left="58" width="360" height="16" font="4">low SYNTAX score. In contrast, MACE occurred more</text>
<text top="890" left="58" width="360" height="16" font="4">often after DES implantation than after CABG in those</text>
<text top="909" left="58" width="294" height="16" font="4">with an intermediate or high SYNTAX score <a href="e44.full.html#108">(</a></text>
<text top="909" left="353" width="23" height="16" font="16"><a href="e44.full.html#108">950</a></text>
<text top="909" left="375" width="43" height="16" font="4"><a href="e44.full.html#108">). </a>At 3</text>
<text top="927" left="58" width="360" height="16" font="4">years of follow-up, the mortality rate was greater in subjects</text>
<text top="946" left="58" width="360" height="16" font="4">with 3-vessel CAD treated with PCI than in those treated</text>
<text top="964" left="58" width="360" height="16" font="4">with CABG (6.2% versus 2.9%). The differences in MACE</text>
<text top="983" left="58" width="360" height="16" font="4">between those treated with PCI or CABG increased with</text>
<text top="1001" left="58" width="193" height="16" font="4">an increasing SYNTAX score <a href="e44.full.html#38">(</a></text>
<text top="1001" left="251" width="59" height="16" font="16"><a href="e44.full.html#38">Figure 12</a></text>
<text top="1001" left="311" width="15" height="16" font="4"><a href="e44.full.html#38">) </a><a href="e44.full.html#109">(</a></text>
<text top="1001" left="325" width="23" height="16" font="16"><a href="e44.full.html#109">980</a></text>
<text top="1001" left="348" width="9" height="16" font="4"><a href="e44.full.html#109">).</a></text>
<text top="1020" left="73" width="345" height="16" font="4">Although the utility of using a SYNTAX score in</text>
<text top="1039" left="58" width="360" height="16" font="4">everyday clinical practice remains uncertain, it seems rea-</text>
<text top="1057" left="58" width="360" height="16" font="4">sonable to conclude from SYNTAX and other data that</text>
<text top="1076" left="58" width="360" height="16" font="4">outcomes of patients undergoing PCI or CABG in those</text>
<text top="1094" left="58" width="360" height="16" font="4">with relatively uncomplicated and lesser degrees of CAD are</text>
<text top="104" left="445" width="360" height="16" font="4">comparable, whereas in those with complex and diffuse</text>
<text top="122" left="445" width="249" height="16" font="4">CAD, CABG appears to be preferable <a href="e44.full.html#108">(</a></text>
<text top="122" left="694" width="49" height="16" font="16"><a href="e44.full.html#108">949,980</a></text>
<text top="122" left="743" width="9" height="16" font="4"><a href="e44.full.html#108">).</a></text>
<text top="149" left="445" width="18" height="16" font="5"><i>See</i></text>
<text top="149" left="471" width="213" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplements 6 and 7</i></a></text>
<text top="149" left="691" width="114" height="16" font="5"><i>for additional data</i></text>
<text top="167" left="445" width="173" height="16" font="5"><i>comparing CABG with DES.</i></text>
<text top="198" left="446" width="131" height="12" font="18">5.7. Left Main CAD</text>
<text top="224" left="446" width="324" height="16" font="26"><b>5.7.1. CABG or PCI Versus Medical Therapy for</b></text>
<text top="242" left="446" width="106" height="16" font="26"><b>Left Main CAD</b></text>
<text top="268" left="446" width="360" height="16" font="4">CABG confers a survival benefit over medical therapy in</text>
<text top="286" left="446" width="360" height="16" font="4">patients with left main CAD. Subgroup analyses from</text>
<text top="304" left="446" width="360" height="16" font="4">RCTs performed 3 decades ago included 91 patients with</text>
<text top="322" left="446" width="360" height="16" font="4">left main CAD in the Veterans Administration Cooperative</text>
<text top="340" left="446" width="44" height="16" font="4">Study <a href="e44.full.html#108">(</a></text>
<text top="340" left="490" width="23" height="16" font="16"><a href="e44.full.html#108">961</a></text>
<text top="340" left="512" width="293" height="16" font="4"><a href="e44.full.html#108">). </a>A meta-analysis of these trials demonstrated a</text>
<text top="358" left="446" width="360" height="16" font="4">66% reduction in RR of death with CABG, with the benefit</text>
<text top="376" left="446" width="152" height="16" font="4">extending to 10 years <a href="e44.full.html#95">(</a></text>
<text top="376" left="597" width="23" height="16" font="16"><a href="e44.full.html#95">412</a></text>
<text top="376" left="620" width="158" height="16" font="4"><a href="e44.full.html#95">). </a>The CASS Registry <a href="e44.full.html#95">(</a></text>
<text top="376" left="778" width="23" height="16" font="16"><a href="e44.full.html#95">381</a></text>
<text top="376" left="801" width="5" height="16" font="4"><a href="e44.full.html#95">)</a></text>
<text top="394" left="446" width="255" height="16" font="4">contained data from 1,484 patients with</text>
<text top="391" left="709" width="97" height="20" font="4">ⱖ50% diameter</text>
<text top="412" left="445" width="360" height="16" font="4">stenosis left main CAD initially treated surgically or nonsur-</text>
<text top="430" left="445" width="360" height="16" font="4">gically. Median survival duration was 13.3 years in the surgical</text>
<text top="448" left="445" width="360" height="16" font="4">group and 6.6 years in the medical group. The survival benefit</text>
<text top="466" left="445" width="360" height="16" font="4">of CABG over medical therapy appeared to extend to 53</text>
<text top="484" left="445" width="360" height="16" font="4">asymptomatic patients with left main CAD in the CASS</text>
<text top="502" left="445" width="59" height="16" font="4">Registry <a href="e44.full.html#108">(</a></text>
<text top="502" left="504" width="23" height="16" font="16"><a href="e44.full.html#108">962</a></text>
<text top="502" left="527" width="279" height="16" font="4"><a href="e44.full.html#108">). </a>Other therapies that subsequently have been</text>
<text top="520" left="445" width="360" height="16" font="4">shown to be associated with improved long-term outcome,</text>
<text top="538" left="445" width="360" height="16" font="4">such as the use of aspirin, statins, and internal mammary</text>
<text top="556" left="445" width="298" height="16" font="4">artery grafting, were not widely used in that era.</text>
<text top="574" left="460" width="345" height="16" font="4">RCTs and subgroup analyses that compare PCI with</text>
<text top="592" left="445" width="360" height="16" font="4">medical therapy in patients with “unprotected” left main</text>
<text top="610" left="445" width="116" height="16" font="4">CAD do not exist.</text>
<text top="637" left="445" width="320" height="16" font="26"><b>5.7.2. Studies Comparing PCI Versus CABG for</b></text>
<text top="655" left="445" width="106" height="16" font="26"><b>Left Main CAD</b></text>
<text top="680" left="445" width="360" height="16" font="4">Of all subjects undergoing coronary angiography, approxi-</text>
<text top="698" left="445" width="278" height="16" font="4">mately 4% are found to have left main CAD <a href="e44.full.html#112">(</a></text>
<text top="698" left="724" width="30" height="16" font="16"><a href="e44.full.html#112">1090</a></text>
<text top="698" left="754" width="9" height="16" font="4"><a href="e44.full.html#112">),</a></text>
<text top="695" left="767" width="39" height="20" font="4">⬎80%</text>
<text top="716" left="445" width="178" height="16" font="4">of whom have significant (</text>
<text top="713" left="623" width="183" height="20" font="4">ⱖ70% diameter) stenoses in</text>
<text top="734" left="445" width="204" height="16" font="4">other epicardial coronary arteries.</text>
<text top="752" left="460" width="345" height="16" font="4">Published cohort studies have found that major clinical</text>
<text top="770" left="445" width="360" height="16" font="4">outcomes are similar with PCI or CABG 1 year after</text>
<text top="788" left="445" width="360" height="16" font="4">revascularization and that mortality rates are similar at 1, 2,</text>
<text top="806" left="445" width="360" height="16" font="4">and 5 years of follow-up; however, the risk of needing</text>
<text top="824" left="445" width="360" height="16" font="4">target-vessel revascularization is significantly higher with</text>
<text top="842" left="445" width="166" height="16" font="4">stenting than with CABG.</text>
<text top="860" left="460" width="345" height="16" font="4">In the SYNTAX trial, 45% of screened patients with</text>
<text top="878" left="445" width="360" height="16" font="4">unprotected left main CAD had complex disease that</text>
<text top="896" left="445" width="360" height="16" font="4">prevented randomization; 89% of these underwent CABG</text>
<text top="914" left="445" width="5" height="16" font="4"><a href="e44.full.html#108">(</a></text>
<text top="914" left="450" width="49" height="16" font="16"><a href="e44.full.html#108">949,950</a></text>
<text top="914" left="499" width="306" height="16" font="4"><a href="e44.full.html#108">). </a>In addition, 705 of the 1,800 patients who were</text>
<text top="932" left="445" width="360" height="16" font="4">randomized had revascularization for unprotected left main</text>
<text top="950" left="445" width="360" height="16" font="4">CAD. The majority of patients with left main CAD and a</text>
<text top="968" left="445" width="360" height="16" font="4">low SYNTAX score had isolated left main CAD or left</text>
<text top="986" left="445" width="360" height="16" font="4">main CAD plus 1-vessel CAD; the majority of those with</text>
<text top="1004" left="445" width="360" height="16" font="4">an intermediate score had left main CAD plus 2-vessel</text>
<text top="1022" left="445" width="360" height="16" font="4">CAD; and most of those with a high SYNTAX score had</text>
<text top="1040" left="445" width="360" height="16" font="4">left main CAD plus 3-vessel CAD. At 1 year, rates of</text>
<text top="1058" left="445" width="360" height="16" font="4">all-cause death and MACE were similar for the 2 groups</text>
<text top="1076" left="445" width="5" height="16" font="4"><a href="e44.full.html#108">(</a></text>
<text top="1076" left="450" width="23" height="16" font="16"><a href="e44.full.html#108">949</a></text>
<text top="1076" left="473" width="333" height="16" font="4"><a href="e44.full.html#108">). </a>Repeat revascularization rates were higher in the PCI</text>
<text top="1094" left="445" width="360" height="16" font="4">group than the CABG group (11.8% versus 6.5%), but</text>
<text top="52" left="781" width="25" height="10" font="12">e111</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">stroke occurred more often in the CABG group (2.7%</text>
<text top="123" left="59" width="360" height="16" font="4">versus 0.3%). At 3 years of follow-up, the incidence of death</text>
<text top="141" left="59" width="360" height="16" font="4">in those undergoing left main CAD revascularization</text>
<text top="159" left="59" width="296" height="16" font="4">with low or intermediate SYNTAX scores (</text>
<text top="156" left="355" width="64" height="20" font="4">ⱕ32) was</text>
<text top="177" left="59" width="256" height="16" font="4">3.7% after PCI and 9.1% after CABG (p</text>
<text top="174" left="315" width="103" height="20" font="4">⫽0.03), whereas</text>
<text top="195" left="59" width="235" height="16" font="4">in those with a high SYNTAX score (</text>
<text top="192" left="294" width="124" height="20" font="4">ⱖ33), the incidence</text>
<text top="214" left="59" width="360" height="16" font="4">of death after 3 years was 13.4% after PCI and 7.6% after</text>
<text top="232" left="59" width="63" height="16" font="4">CABG (p</text>
<text top="229" left="122" width="55" height="20" font="4">⫽0.10) <a href="e44.full.html#108">(</a></text>
<text top="232" left="177" width="23" height="16" font="16"><a href="e44.full.html#108">949</a></text>
<text top="232" left="200" width="219" height="16" font="4"><a href="e44.full.html#108">). </a>Because the primary endpoint of</text>
<text top="250" left="59" width="360" height="16" font="4">SYNTAX was not met (i.e., noninferiority comparison of</text>
<text top="268" left="59" width="360" height="16" font="4">CABG and PCI), these subgroup analyses need to be</text>
<text top="287" left="59" width="171" height="16" font="4">considered in that context.</text>
<text top="305" left="74" width="345" height="16" font="4">In the LE MANS (Study of Unprotected Left Main</text>
<text top="323" left="59" width="246" height="16" font="4">Stenting Versus Bypass Surgery) trial <a href="e44.full.html#108">(</a></text>
<text top="323" left="304" width="23" height="16" font="16"><a href="e44.full.html#108">958</a></text>
<text top="323" left="327" width="92" height="16" font="4"><a href="e44.full.html#108">), </a>105 patients</text>
<text top="341" left="59" width="360" height="16" font="4">with left main CAD were randomized to receive PCI or</text>
<text top="359" left="59" width="360" height="16" font="4">CABG. Although a low proportion of patients treated with</text>
<text top="378" left="59" width="360" height="16" font="4">PCI received DES (35%) and a low proportion of patients</text>
<text top="396" left="59" width="360" height="16" font="4">treated with CABG received internal mammary grafts</text>
<text top="414" left="59" width="360" height="16" font="4">(72%), the outcomes at 30 days and 1 year were similar</text>
<text top="432" left="59" width="360" height="16" font="4">between the groups. In the PRECOMBAT (Premier of</text>
<text top="450" left="59" width="360" height="16" font="4">Randomized Comparison of Bypass Surgery versus Angio-</text>
<text top="469" left="59" width="360" height="16" font="4">plasty Using Sirolimus-Eluting Stent in Patients with Left</text>
<text top="487" left="59" width="360" height="16" font="4">Main Coronary Artery Disease) trial of 600 patients with</text>
<text top="505" left="59" width="360" height="16" font="4">left main disease, the composite endpoint of death, MI, or</text>
<text top="523" left="59" width="360" height="16" font="4">stroke at 2 years occurred in 4.4% of patients treated with</text>
<text top="541" left="59" width="360" height="16" font="4">PCI and 4.7% of patients treated with CABG, but</text>
<text top="560" left="59" width="360" height="16" font="4">ischemia-driven target-vessel revascularization was more</text>
<text top="578" left="59" width="360" height="16" font="4">often required in the patients treated with PCI (9.0% versus</text>
<text top="596" left="59" width="45" height="16" font="4">4.2%) <a href="e44.full.html#109">(</a></text>
<text top="596" left="103" width="23" height="16" font="16"><a href="e44.full.html#109">984</a></text>
<text top="596" left="126" width="9" height="16" font="4"><a href="e44.full.html#109">).</a></text>
<text top="614" left="74" width="345" height="16" font="4">The results from these 3 RCTs suggest (but do not</text>
<text top="633" left="59" width="360" height="16" font="4">definitively prove) that major clinical outcomes in <i>selected</i></text>
<text top="651" left="59" width="360" height="16" font="4">patients with left main CAD are similar with CABG and</text>
<text top="669" left="59" width="360" height="16" font="4">PCI at 1- to 2-year follow-up, but repeat revascularization</text>
<text top="687" left="59" width="360" height="16" font="4">rates are higher after PCI than after CABG. RCTs with</text>
<text top="705" left="59" width="140" height="16" font="4">extended follow-up of</text>
<text top="702" left="206" width="212" height="20" font="4">ⱖ5 years are required to provide</text>
<text top="724" left="59" width="360" height="16" font="4">definitive conclusions about the optimal treatment of left</text>
<text top="742" left="59" width="360" height="16" font="4">main CAD. In a meta-analysis of 8 cohort studies and 2</text>
<text top="760" left="59" width="48" height="16" font="4">RCTs <a href="e44.full.html#108">(</a></text>
<text top="760" left="107" width="23" height="16" font="16"><a href="e44.full.html#108">973</a></text>
<text top="760" left="129" width="289" height="16" font="4"><a href="e44.full.html#108">), </a>death, MI, and stroke occurred with similar</text>
<text top="778" left="59" width="360" height="16" font="4">frequency in the PCI- and CABG-treated patients at 1, 2,</text>
<text top="796" left="59" width="360" height="16" font="4">and 3 years of follow-up. Target-vessel revascularization was</text>
<text top="814" left="59" width="360" height="16" font="4">performed more often in the PCI group at 1 year (OR:</text>
<text top="833" left="59" width="310" height="16" font="4">4.36), 2 years (OR: 4.20), and 3 years (OR: 3.30).</text>
<text top="860" left="59" width="18" height="16" font="5"><i>See</i></text>
<text top="860" left="84" width="212" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplements 8 to 13</i></a></text>
<text top="860" left="304" width="115" height="16" font="5"><i>for additional data</i></text>
<text top="878" left="58" width="283" height="16" font="5"><i>comparing PCI with CABG for left main CAD.</i></text>
<text top="905" left="58" width="280" height="16" font="26"><b>5.7.3. Revascularization Considerations for</b></text>
<text top="923" left="58" width="106" height="16" font="26"><b>Left Main CAD</b></text>
<text top="949" left="58" width="360" height="16" font="4">Although CABG has been considered the “gold standard”</text>
<text top="967" left="58" width="360" height="16" font="4">for unprotected left main CAD revascularization, more</text>
<text top="985" left="58" width="360" height="16" font="4">recently PCI has emerged as a possible alternative mode of</text>
<text top="1004" left="58" width="360" height="16" font="4">revascularization in carefully selected patients. Lesion loca-</text>
<text top="1022" left="58" width="360" height="16" font="4">tion is an important determinant when PCI is considered</text>
<text top="1040" left="58" width="360" height="16" font="4">for unprotected left main CAD. Stenting of the left main</text>
<text top="1058" left="58" width="360" height="16" font="4">ostium or trunk is more straightforward than treating distal</text>
<text top="1076" left="58" width="360" height="16" font="4">bifurcation or trifurcation stenoses, which generally requires</text>
<text top="1094" left="58" width="321" height="16" font="4">a greater degree of operator experience and expertise <a href="e44.full.html#112">(</a></text>
<text top="1094" left="380" width="30" height="16" font="16"><a href="e44.full.html#112">1091</a></text>
<text top="1094" left="410" width="9" height="16" font="4"><a href="e44.full.html#112">).</a></text>
<text top="104" left="446" width="360" height="16" font="4">In addition, PCI of bifurcation disease is associated with</text>
<text top="123" left="446" width="360" height="16" font="4">higher restenosis rates than when disease is confined to the</text>
<text top="142" left="446" width="104" height="16" font="4">ostium or trunk <a href="e44.full.html#108">(</a></text>
<text top="142" left="549" width="56" height="16" font="16"><a href="e44.full.html#108">971,1092</a></text>
<text top="142" left="606" width="200" height="16" font="4"><a href="e44.full.html#108">). </a>Although lesion location influ-</text>
<text top="161" left="446" width="360" height="16" font="4">ences technical success and long-term outcomes after PCI,</text>
<text top="179" left="446" width="360" height="16" font="4">location exerts a negligible influence on the success of</text>
<text top="198" left="446" width="360" height="16" font="4">CABG. In subgroup analyses, patients with left main CAD</text>
<text top="217" left="446" width="133" height="16" font="4">and a SYNTAX score</text>
<text top="214" left="583" width="223" height="20" font="4">ⱖ33 with more complex or extensive</text>
<text top="236" left="445" width="360" height="16" font="4">CAD had a higher mortality rate with PCI than with</text>
<text top="254" left="445" width="54" height="16" font="4">CABG <a href="e44.full.html#108">(</a></text>
<text top="254" left="500" width="23" height="16" font="16"><a href="e44.full.html#108">949</a></text>
<text top="254" left="522" width="283" height="16" font="4"><a href="e44.full.html#108">). </a>Physicians can estimate operative risk for all</text>
<text top="273" left="445" width="360" height="16" font="4">CABG candidates by using a standard instrument, such as</text>
<text top="292" left="445" width="360" height="16" font="4">the risk calculator from the STS database. The above</text>
<text top="311" left="445" width="360" height="16" font="4">considerations are important factors when choosing among</text>
<text top="329" left="445" width="360" height="16" font="4">revascularization strategies for unprotected left main CAD</text>
<text top="348" left="445" width="360" height="16" font="4">and have been factored into revascularization recommenda-</text>
<text top="367" left="445" width="360" height="16" font="4">tions. Use of a Heart Team approach has been recom-</text>
<text top="386" left="445" width="360" height="16" font="4">mended in cases in which the choice of revascularization</text>
<text top="404" left="445" width="243" height="16" font="4">is not straightforward. As discussed in</text>
<text top="404" left="694" width="83" height="16" font="16"><a href="e44.full.html#70">Section 5.9.5</a></text>
<text top="404" left="777" width="29" height="16" font="4"><a href="e44.full.html#70">, </a>the</text>
<text top="423" left="445" width="360" height="16" font="4">ability of the patient to tolerate and comply with DAPT</text>
<text top="442" left="445" width="360" height="16" font="4">is also an important consideration in revascularization</text>
<text top="461" left="445" width="61" height="16" font="4">decisions.</text>
<text top="479" left="460" width="173" height="16" font="4">The 2005 PCI guideline <a href="e44.full.html#109">(</a></text>
<text top="479" left="633" width="23" height="16" font="16"><a href="e44.full.html#109">987</a></text>
<text top="479" left="656" width="150" height="16" font="4"><a href="e44.full.html#109">) </a>recommended routine</text>
<text top="498" left="445" width="360" height="16" font="4">angiographic follow-up 2 to 6 months after stenting for</text>
<text top="517" left="445" width="360" height="16" font="4">unprotected left main CAD. However, because angiography</text>
<text top="535" left="445" width="360" height="16" font="4">has limited ability to predict stent thrombosis and the</text>
<text top="554" left="445" width="360" height="16" font="4">results of SYNTAX suggest good intermediate-term results</text>
<text top="573" left="445" width="360" height="16" font="4">for PCI in subjects with left main CAD, this recommen-</text>
<text top="592" left="445" width="360" height="16" font="4">dation was removed in the 2009 STEMI/PCI focused</text>
<text top="610" left="445" width="51" height="16" font="4">update <a href="e44.full.html#85">(</a></text>
<text top="610" left="496" width="8" height="16" font="16"><a href="e44.full.html#85">3</a></text>
<text top="610" left="504" width="9" height="16" font="4"><a href="e44.full.html#85">).</a></text>
<text top="629" left="460" width="345" height="16" font="4">Experts have recommended immediate PCI for unpro-</text>
<text top="648" left="445" width="299" height="16" font="4">tected left main CAD in the setting of STEMI <a href="e44.full.html#109">(</a></text>
<text top="648" left="745" width="23" height="16" font="16"><a href="e44.full.html#109">983</a></text>
<text top="648" left="767" width="38" height="16" font="4"><a href="e44.full.html#109">). </a>The</text>
<text top="667" left="445" width="360" height="16" font="4">impetus for such a strategy is greatest when left main CAD</text>
<text top="685" left="445" width="360" height="16" font="4">is the site of the culprit lesion, antegrade coronary flow is</text>
<text top="704" left="445" width="360" height="16" font="4">diminished (e.g., TIMI flow grade 0, 1, or 2), the patient is</text>
<text top="723" left="445" width="360" height="16" font="4">hemodynamically unstable, and it is believed that PCI</text>
<text top="742" left="445" width="360" height="16" font="4">can be performed more quickly than CABG. When</text>
<text top="760" left="445" width="360" height="16" font="4">possible, the interventional cardiologist and cardiac sur-</text>
<text top="779" left="445" width="360" height="16" font="4">geon should decide together on the optimal form of</text>
<text top="798" left="445" width="360" height="16" font="4">revascularization for these subjects, although it is recog-</text>
<text top="817" left="445" width="360" height="16" font="4">nized that these patients are usually critically ill and</text>
<text top="835" left="445" width="360" height="16" font="4">therefore not amenable to a prolonged deliberation or</text>
<text top="854" left="445" width="205" height="16" font="4">discussion of treatment options.</text>
<text top="891" left="446" width="231" height="12" font="18">5.8. Proximal LAD Artery Disease</text>
<text top="915" left="446" width="105" height="16" font="4">A cohort study <a href="e44.full.html#109">(</a></text>
<text top="915" left="551" width="23" height="16" font="16"><a href="e44.full.html#109">985</a></text>
<text top="915" left="573" width="144" height="16" font="4"><a href="e44.full.html#109">) </a>and a meta-analysis <a href="e44.full.html#95">(</a></text>
<text top="915" left="717" width="23" height="16" font="16"><a href="e44.full.html#95">412</a></text>
<text top="915" left="740" width="66" height="16" font="4"><a href="e44.full.html#95">) </a>from the</text>
<text top="933" left="446" width="360" height="16" font="4">1990s suggested that CABG confers a survival advantage</text>
<text top="952" left="446" width="360" height="16" font="4">over contemporaneous medical therapy for patients with</text>
<text top="971" left="446" width="360" height="16" font="4">disease in the proximal segment of the LAD artery. Cohort</text>
<text top="990" left="446" width="127" height="16" font="4">studies and RCTs <a href="e44.full.html#95">(</a></text>
<text top="990" left="573" width="233" height="16" font="16"><a href="e44.full.html#95">412,1050,1062,1063,1065,1077,1093–</a></text>
<text top="1008" left="446" width="30" height="16" font="16"><a href="e44.full.html#95">1095</a></text>
<text top="1008" left="476" width="330" height="16" font="4"><a href="e44.full.html#95">) </a>as well as collaborative analyses and meta-analyses</text>
<text top="1027" left="446" width="5" height="16" font="4"><a href="e44.full.html#111">(</a></text>
<text top="1027" left="450" width="103" height="16" font="16"><a href="e44.full.html#111">1080,1096 –1098</a></text>
<text top="1027" left="554" width="252" height="16" font="4"><a href="e44.full.html#111">) </a>showed that PCI and CABG result in</text>
<text top="1046" left="446" width="233" height="16" font="4">similar survival rates in these patients.</text>
<text top="1076" left="446" width="18" height="16" font="5"><i>See</i></text>
<text top="1076" left="468" width="207" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplements 6 and 14</i></a></text>
<text top="1076" left="679" width="127" height="16" font="5"><i>for additional data on</i></text>
<text top="1094" left="446" width="171" height="16" font="5"><i>proximal LAD artery disease.</i></text>
<text top="52" left="59" width="25" height="10" font="12">e112</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1161" width="864">
<text top="105" left="59" width="301" height="12" font="18">5.9. Clinical Factors That May Influence the</text>
<text top="123" left="59" width="193" height="12" font="18">Choice of Revascularization</text>
<text top="150" left="59" width="268" height="16" font="26"><b>5.9.1. Completeness of Revascularization</b></text>
<text top="175" left="59" width="360" height="16" font="4">Most patients undergoing CABG receive complete or</text>
<text top="193" left="59" width="360" height="16" font="4">nearly complete revascularization, which seems to influence</text>
<text top="211" left="59" width="191" height="16" font="4">long-term prognosis positively <a href="e44.full.html#112">(</a></text>
<text top="211" left="249" width="30" height="16" font="16"><a href="e44.full.html#112">1099</a></text>
<text top="211" left="279" width="139" height="16" font="4"><a href="e44.full.html#112">). </a>In contrast, complete</text>
<text top="229" left="59" width="360" height="16" font="4">revascularization is accomplished less often in subjects</text>
<text top="247" left="59" width="134" height="16" font="4">receiving PCI (e.g., in</text>
<text top="244" left="197" width="222" height="20" font="4">⬍70% of patients), and the extent to</text>
<text top="265" left="59" width="360" height="16" font="4">which the absence of complete initial revascularization</text>
<text top="284" left="59" width="360" height="16" font="4">influences outcome is less clear. Rates of late survival and</text>
<text top="302" left="59" width="360" height="16" font="4">survival free of MI appear to be similar in patients with and</text>
<text top="320" left="59" width="360" height="16" font="4">without complete revascularization after PCI. Nevertheless,</text>
<text top="338" left="59" width="360" height="16" font="4">the need for subsequent CABG is usually higher in those</text>
<text top="356" left="59" width="360" height="16" font="4">whose initial revascularization procedure was incomplete</text>
<text top="374" left="59" width="360" height="16" font="4">(compared with those with complete revascularization) after</text>
<text top="392" left="59" width="36" height="16" font="4">PCI <a href="e44.full.html#112">(</a></text>
<text top="392" left="94" width="69" height="16" font="16"><a href="e44.full.html#112">1100 –1102</a></text>
<text top="392" left="164" width="9" height="16" font="4"><a href="e44.full.html#112">).</a></text>
<text top="419" left="59" width="201" height="16" font="26"><b>5.9.2. LV Systolic Dysfunction</b></text>
<text top="444" left="59" width="360" height="16" font="4">Several older studies and a meta-analysis of the data from</text>
<text top="463" left="59" width="360" height="16" font="4">these studies reported that patients with LV systolic dys-</text>
<text top="481" left="59" width="360" height="16" font="4">function (predominantly mild to moderate in severity) had</text>
<text top="499" left="59" width="360" height="16" font="4">better survival with CABG than with medical therapy alone</text>
<text top="517" left="59" width="5" height="16" font="4"><a href="e44.full.html#94">(</a></text>
<text top="517" left="63" width="114" height="16" font="16"><a href="e44.full.html#94">365,412,999 –1002</a></text>
<text top="517" left="178" width="241" height="16" font="4"><a href="e44.full.html#94">). </a>For patients with more severe LV</text>
<text top="535" left="59" width="360" height="16" font="4">systolic dysfunction, however, the evidence that CABG</text>
<text top="553" left="59" width="360" height="16" font="4">results in better survival compared with medical therapy is</text>
<text top="571" left="59" width="317" height="16" font="4">lacking. In the STICH trial of subjects with LVEF</text>
<text top="568" left="380" width="39" height="20" font="4">⬍35%</text>
<text top="589" left="59" width="360" height="16" font="4">with or without viability testing, CABG and GDMT</text>
<text top="607" left="59" width="360" height="16" font="4">resulted in similar rates of survival (death from any cause,</text>
<text top="625" left="59" width="360" height="16" font="4">the study’s primary outcome) after 5 years of follow-up. For</text>
<text top="643" left="59" width="360" height="16" font="4">several secondary outcomes at this time point, including</text>
<text top="661" left="59" width="360" height="16" font="4">1) death from any cause or hospitalization for heart failure,</text>
<text top="679" left="59" width="360" height="16" font="4">2) death from any cause or hospitalization for cardiovascular</text>
<text top="697" left="59" width="360" height="16" font="4">causes, 3) death from any cause or hospitalization for any</text>
<text top="715" left="59" width="360" height="16" font="4">cause, or 4) death from any cause or revascularization with</text>
<text top="733" left="59" width="360" height="16" font="4">PCI or CABG, CABG was superior to GDMT. Although</text>
<text top="751" left="59" width="360" height="16" font="4">the primary outcome (death from any cause) was similar in</text>
<text top="769" left="59" width="360" height="16" font="4">the 2 treatment groups after an average of 5 years of</text>
<text top="787" left="59" width="360" height="16" font="4">follow-up, the data suggest the possibility that outcomes</text>
<text top="805" left="59" width="360" height="16" font="4">would differ if the follow-up were longer in duration; as a</text>
<text top="823" left="59" width="360" height="16" font="4">result, the study is being continued to provide follow-up for</text>
<text top="841" left="59" width="97" height="16" font="4">up to 10 years <a href="e44.full.html#94">(</a></text>
<text top="841" left="156" width="49" height="16" font="16"><a href="e44.full.html#94">355,410</a></text>
<text top="841" left="205" width="9" height="16" font="4"><a href="e44.full.html#94">).</a></text>
<text top="860" left="74" width="345" height="16" font="4">Only very limited data comparing PCI with medical</text>
<text top="878" left="59" width="360" height="16" font="4">therapy in patients with LV systolic dysfunction are avail-</text>
<text top="896" left="59" width="35" height="16" font="4">able <a href="e44.full.html#109">(</a></text>
<text top="896" left="93" width="30" height="16" font="16"><a href="e44.full.html#109">1002</a></text>
<text top="896" left="123" width="295" height="16" font="4"><a href="e44.full.html#109">). </a>In several ways, these data are suboptimal, in</text>
<text top="914" left="59" width="360" height="16" font="4">that many studies compared CABG with balloon angio-</text>
<text top="932" left="59" width="360" height="16" font="4">plasty, many were retrospective, and many were based on</text>
<text top="950" left="59" width="360" height="16" font="4">cohort or registry data. Some of the studies demonstrated a</text>
<text top="968" left="59" width="360" height="16" font="4">similar survival rate in patients having CABG and PCI</text>
<text top="986" left="59" width="5" height="16" font="4"><a href="e44.full.html#109">(</a></text>
<text top="986" left="63" width="128" height="16" font="16"><a href="e44.full.html#109">988,1080,1103–1105</a></text>
<text top="986" left="191" width="228" height="16" font="4"><a href="e44.full.html#109">), </a>whereas others showed that those</text>
<text top="1004" left="59" width="265" height="16" font="4">undergoing CABG had better outcomes <a href="e44.full.html#108">(</a></text>
<text top="1004" left="324" width="23" height="16" font="16"><a href="e44.full.html#108">964</a></text>
<text top="1004" left="346" width="72" height="16" font="4"><a href="e44.full.html#108">). </a>The data</text>
<text top="1022" left="59" width="360" height="16" font="4">that exist at present on revascularization in patients with</text>
<text top="1040" left="59" width="360" height="16" font="4">CAD and LV systolic dysfunction are more robust for</text>
<text top="1058" left="59" width="360" height="16" font="4">CABG than for PCI, although data from contemporary</text>
<text top="1076" left="59" width="360" height="16" font="4">RCTs in this patient population are lacking. Therefore, the</text>
<text top="1094" left="59" width="360" height="16" font="4">choice of revascularization in patients with CAD and LV</text>
<text top="104" left="446" width="360" height="16" font="4">systolic dysfunction is best based on clinical variables (e.g.,</text>
<text top="122" left="446" width="360" height="16" font="4">coronary anatomy, presence of diabetes mellitus, presence of</text>
<text top="140" left="446" width="360" height="16" font="4">CKD), magnitude of LV systolic dysfunction, patient pref-</text>
<text top="158" left="446" width="360" height="16" font="4">erences, clinical judgment, and consultation between the</text>
<text top="176" left="446" width="313" height="16" font="4">interventional cardiologist and the cardiac surgeon.</text>
<text top="203" left="446" width="148" height="16" font="26"><b>5.9.3. Previous CABG</b></text>
<text top="229" left="446" width="360" height="16" font="4">In patients with recurrent angina after CABG, repeat</text>
<text top="247" left="446" width="360" height="16" font="4">revascularization is most likely to improve survival in sub-</text>
<text top="265" left="446" width="360" height="16" font="4">jects at highest risk, such as those with obstruction of the</text>
<text top="283" left="446" width="360" height="16" font="4">proximal LAD artery and extensive anterior ischemia</text>
<text top="301" left="446" width="5" height="16" font="4"><a href="e44.full.html#110">(</a></text>
<text top="301" left="450" width="141" height="16" font="16"><a href="e44.full.html#110">1021–1025,1029 –1032</a></text>
<text top="301" left="591" width="214" height="16" font="4"><a href="e44.full.html#110">). </a>Patients with ischemia in other</text>
<text top="319" left="446" width="360" height="16" font="4">locations and those with a patent LIMA to the LAD artery</text>
<text top="337" left="446" width="360" height="16" font="4">are unlikely to experience a survival benefit from repeat</text>
<text top="355" left="446" width="110" height="16" font="4">revascularization <a href="e44.full.html#110">(</a></text>
<text top="355" left="555" width="30" height="16" font="16"><a href="e44.full.html#110">1023</a></text>
<text top="355" left="585" width="9" height="16" font="4"><a href="e44.full.html#110">).</a></text>
<text top="373" left="461" width="345" height="16" font="4">Cohort studies comparing PCI and CABG among post-</text>
<text top="391" left="446" width="360" height="16" font="4">CABG patients report similar rates of mid- and long-term</text>
<text top="409" left="446" width="222" height="16" font="4">survival after the 2 procedures <a href="e44.full.html#110">(</a></text>
<text top="409" left="668" width="137" height="16" font="16"><a href="e44.full.html#110">1022,1024,1025,1029,</a></text>
<text top="427" left="446" width="98" height="16" font="16"><a href="e44.full.html#110">1031,1032,1106</a></text>
<text top="427" left="543" width="262" height="16" font="4"><a href="e44.full.html#110">). </a>In the patient with previous CABG who</text>
<text top="445" left="446" width="360" height="16" font="4">is referred for revascularization for medically refractory</text>
<text top="463" left="446" width="360" height="16" font="4">ischemia, factors that may support the choice of repeat</text>
<text top="481" left="446" width="360" height="16" font="4">CABG include vessels unsuitable for PCI, number of</text>
<text top="499" left="446" width="360" height="16" font="4">diseased bypass grafts, availability of the internal mammary</text>
<text top="517" left="446" width="360" height="16" font="4">artery for grafting chronically occluded coronary arteries,</text>
<text top="535" left="446" width="360" height="16" font="4">and good distal targets for bypass graft placement. Factors</text>
<text top="553" left="446" width="360" height="16" font="4">favoring PCI over CABG include limited areas of ischemia</text>
<text top="571" left="446" width="360" height="16" font="4">causing symptoms, suitable PCI targets, a patent graft to the</text>
<text top="589" left="446" width="360" height="16" font="4">LAD artery, poor CABG targets, and comorbid conditions.</text>
<text top="616" left="446" width="279" height="16" font="26"><b>5.9.4. Unstable Angina/Non–ST-Elevation</b></text>
<text top="634" left="446" width="141" height="16" font="26"><b>Myocardial Infarction</b></text>
<text top="660" left="446" width="360" height="16" font="4">The main difference between management of the patient</text>
<text top="678" left="446" width="360" height="16" font="4">with SIHD and the patient with UA/NSTEMI is that the</text>
<text top="696" left="446" width="360" height="16" font="4">impetus for revascularization is stronger in the setting of</text>
<text top="714" left="446" width="360" height="16" font="4">UA/NSTEMI, because myocardial ischemia occurring as</text>
<text top="732" left="446" width="360" height="16" font="4">part of an ACS is potentially life threatening, and associated</text>
<text top="750" left="446" width="360" height="16" font="4">anginal symptoms are more likely to be reduced with a</text>
<text top="768" left="446" width="322" height="16" font="4">revascularization procedure than with GDMT <a href="e44.full.html#112">(</a></text>
<text top="768" left="768" width="38" height="16" font="16"><a href="e44.full.html#112">1107–</a></text>
<text top="786" left="446" width="30" height="16" font="16"><a href="e44.full.html#112">1109</a></text>
<text top="786" left="476" width="329" height="16" font="4"><a href="e44.full.html#112">). </a>Thus, the indications for revascularization are</text>
<text top="804" left="446" width="360" height="16" font="4">strengthened by the acuity of presentation, the extent of</text>
<text top="822" left="446" width="360" height="16" font="4">ischemia, and the ability to achieve full revascularization.</text>
<text top="840" left="446" width="360" height="16" font="4">The choice of revascularization method is generally dictated</text>
<text top="858" left="446" width="360" height="16" font="4">by the same considerations used to decide on PCI or CABG</text>
<text top="876" left="446" width="149" height="16" font="4">for patients with SIHD.</text>
<text top="903" left="446" width="322" height="16" font="26"><b>5.9.5. DAPT Compliance and Stent Thrombosis:</b></text>
<text top="921" left="446" width="113" height="16" font="26"><b>Recommendation</b></text>
<text top="953" left="446" width="74" height="8" font="24">CLASS III: Harm</text>
<text top="966" left="446" width="360" height="10" font="13">1. PCI with coronary stenting (BMS or DES) should not be performed if</text>
<text top="983" left="461" width="344" height="10" font="13">the patient is not likely to be able to tolerate and comply with DAPT</text>
<text top="1000" left="461" width="344" height="10" font="13">for the appropriate duration of treatment based on the type of stent</text>
<text top="1017" left="461" width="243" height="10" font="13">implanted <a href="e44.full.html#112">(1110–1113). </a><i>(Level of Evidence: B)</i></text>
<text top="1040" left="446" width="360" height="16" font="4">The risk of stent thrombosis is increased dramatically in</text>
<text top="1058" left="446" width="360" height="16" font="4">patients who prematurely discontinue DAPT, and stent</text>
<text top="1076" left="446" width="360" height="16" font="4">thrombosis is associated with a mortality rate of 20% to 45%</text>
<text top="1094" left="446" width="5" height="16" font="4"><a href="e44.full.html#112">(</a></text>
<text top="1094" left="450" width="30" height="16" font="16"><a href="e44.full.html#112">1110</a></text>
<text top="1094" left="480" width="325" height="16" font="4"><a href="e44.full.html#112">). </a>Because the risk of stent thrombosis with BMS is</text>
<text top="52" left="781" width="25" height="10" font="12">e113</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="71" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">greatest in the first 14 to 30 days, this is the generally</text>
<text top="122" left="59" width="360" height="16" font="4">recommended minimum duration of DAPT therapy for</text>
<text top="140" left="59" width="360" height="16" font="4">these individuals. Consensus in clinical practice is to treat</text>
<text top="158" left="59" width="108" height="16" font="4">DES patients for</text>
<text top="155" left="172" width="246" height="20" font="4">ⱖ12 months with DAPT to avoid late</text>
<text top="176" left="59" width="197" height="16" font="4">(after 30 days) stent thrombosis <a href="e44.full.html#112">(</a></text>
<text top="176" left="256" width="64" height="16" font="16"><a href="e44.full.html#112">1110,1114</a></text>
<text top="176" left="320" width="99" height="16" font="4"><a href="e44.full.html#112">). </a>Therefore, the</text>
<text top="194" left="59" width="297" height="16" font="4">ability of the patient to tolerate and comply with</text>
<text top="191" left="360" width="58" height="20" font="4">ⱖ30 days</text>
<text top="212" left="59" width="216" height="16" font="4">of DAPT with BMS treatment and</text>
<text top="209" left="278" width="140" height="20" font="4">ⱖ12 months of DAPT</text>
<text top="230" left="59" width="360" height="16" font="4">with DES treatment is an important consideration in</text>
<text top="248" left="59" width="356" height="16" font="4">deciding whether to use PCI to treat patients with CAD.</text>
<text top="276" left="59" width="280" height="12" font="18">5.10. Transmyocardial Revascularization</text>
<text top="299" left="59" width="360" height="16" font="4">A single randomized multicenter comparison of TMR (with</text>
<text top="317" left="59" width="360" height="16" font="4">a holmium:YAG laser) plus CABG and CABG alone in</text>
<text top="335" left="59" width="360" height="16" font="4">patients in whom some myocardial segments were perfused</text>
<text top="353" left="59" width="325" height="16" font="4">by arteries considered not amenable to grafting <a href="e44.full.html#110">(</a></text>
<text top="353" left="384" width="30" height="16" font="16"><a href="e44.full.html#110">1026</a></text>
<text top="353" left="414" width="5" height="16" font="4"><a href="e44.full.html#110">)</a></text>
<text top="371" left="59" width="360" height="16" font="4">showed a significant reduction in perioperative mortality</text>
<text top="389" left="59" width="360" height="16" font="4">rate (1.5% versus 7.6%, respectively), and the survival</text>
<text top="407" left="59" width="360" height="16" font="4">benefit of the TMR–CABG combination was present after</text>
<text top="425" left="59" width="141" height="16" font="4">1 year of follow-up <a href="e44.full.html#110">(</a></text>
<text top="425" left="199" width="30" height="16" font="16"><a href="e44.full.html#110">1026</a></text>
<text top="425" left="229" width="190" height="16" font="4"><a href="e44.full.html#110">). </a>At the same time, a large</text>
<text top="443" left="59" width="360" height="16" font="4">retrospective analysis of data from the STS National Car-</text>
<text top="461" left="59" width="360" height="16" font="4">diac Database, as well as a study of 169 patients from the</text>
<text top="479" left="59" width="360" height="16" font="4">Washington Hospital Center who underwent combined</text>
<text top="497" left="59" width="360" height="16" font="4">TMR–CABG, showed no difference in adjusted mortality</text>
<text top="515" left="59" width="217" height="16" font="4">rate compared with CABG alone <a href="e44.full.html#110">(</a></text>
<text top="515" left="276" width="64" height="16" font="16"><a href="e44.full.html#110">1027,1115</a></text>
<text top="515" left="339" width="79" height="16" font="4"><a href="e44.full.html#110">). </a>In short, a</text>
<text top="533" left="59" width="360" height="16" font="4">TMR–CABG combination does not appear to improve</text>
<text top="551" left="59" width="360" height="16" font="4">survival compared with CABG alone. In selected patients,</text>
<text top="569" left="59" width="360" height="16" font="4">however, such a combination may be superior to CABG</text>
<text top="587" left="59" width="154" height="16" font="4">alone in relieving angina.</text>
<text top="614" left="59" width="283" height="12" font="18">5.11. Hybrid Coronary Revascularization:</text>
<text top="632" left="59" width="127" height="12" font="18">Recommendations</text>
<text top="658" left="59" width="46" height="8" font="24">CLASS IIa</text>
<text top="671" left="59" width="360" height="10" font="13">1. Hybrid coronary revascularization (defined as the planned combina-</text>
<text top="688" left="75" width="230" height="10" font="13">tion of LIMA-to-LAD artery grafting and PCI of</text>
<text top="685" left="308" width="111" height="16" font="13">ⱖ1 non-LAD coronary</text>
<text top="705" left="75" width="344" height="10" font="13">arteries) is reasonable in patients with 1 or more of the following</text>
<text top="722" left="75" width="187" height="10" font="13"><a href="e44.full.html#112">(1116–1122) </a><i>(Level of Evidence: B):</i></text>
<text top="738" left="74" width="345" height="10" font="13">a. Limitations to traditional CABG, such as heavily calcified proxi-</text>
<text top="755" left="90" width="328" height="10" font="13">mal aorta or poor target vessels for CABG (but amenable to PCI);</text>
<text top="772" left="74" width="177" height="10" font="13">b. Lack of suitable graft conduits;</text>
<text top="789" left="74" width="344" height="10" font="13">c. Unfavorable LAD artery for PCI (i.e., excessive vessel tortuosity or</text>
<text top="806" left="90" width="123" height="10" font="13">chronic total occlusion).</text>
<text top="831" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="843" left="59" width="360" height="10" font="13">1. Hybrid coronary revascularization (defined as the planned combina-</text>
<text top="860" left="74" width="230" height="10" font="13">tion of LIMA-to-LAD artery grafting and PCI of</text>
<text top="857" left="308" width="111" height="16" font="13">ⱖ1 non-LAD coronary</text>
<text top="877" left="74" width="344" height="10" font="13">arteries) may be reasonable as an alternative to multivessel PCI or</text>
<text top="894" left="74" width="344" height="10" font="13">CABG in an attempt to improve the overall risk–benefit ratio of the</text>
<text top="911" left="74" width="174" height="10" font="13">procedures. <i>(Level of Evidence: C)</i></text>
<text top="932" left="59" width="360" height="16" font="4">Hybrid coronary revascularization, defined as the planned</text>
<text top="950" left="59" width="360" height="16" font="4">combination of LIMA-to-LAD artery grafting and PCI of</text>
<text top="965" left="59" width="220" height="20" font="4">ⱖ1 non-LAD coronary arteries <a href="e44.full.html#112">(</a></text>
<text top="968" left="278" width="30" height="16" font="16"><a href="e44.full.html#112">1123</a></text>
<text top="968" left="308" width="111" height="16" font="4"><a href="e44.full.html#112">), </a>is intended to</text>
<text top="986" left="59" width="360" height="16" font="4">combine the advantages of CABG (i.e., durability of the</text>
<text top="1004" left="59" width="157" height="16" font="4">LIMA graft) and PCI <a href="e44.full.html#112">(</a></text>
<text top="1004" left="216" width="30" height="16" font="16"><a href="e44.full.html#112">1124</a></text>
<text top="1004" left="246" width="173" height="16" font="4"><a href="e44.full.html#112">). </a>Patients with multivessel</text>
<text top="1022" left="59" width="145" height="16" font="4">CAD (e.g., LAD and</text>
<text top="1019" left="212" width="207" height="20" font="4">ⱖ1 non-LAD stenoses) and an</text>
<text top="1040" left="59" width="360" height="16" font="4">indication for revascularization are potentially eligible for</text>
<text top="1058" left="59" width="360" height="16" font="4">this approach. Hybrid revascularization is ideal in subjects in</text>
<text top="1076" left="59" width="360" height="16" font="4">whom technical or anatomic limitations to CABG or PCI</text>
<text top="1094" left="59" width="360" height="16" font="4">alone may be present and for whom minimizing the</text>
<text top="104" left="446" width="360" height="16" font="4">invasiveness (and therefore the risk of morbidity and mor-</text>
<text top="122" left="446" width="287" height="16" font="4">tality) of surgical intervention is preferred <a href="e44.full.html#112">(</a></text>
<text top="122" left="732" width="30" height="16" font="16"><a href="e44.full.html#112">1118</a></text>
<text top="122" left="762" width="43" height="16" font="4"><a href="e44.full.html#112">) </a>(e.g.,</text>
<text top="140" left="446" width="360" height="16" font="4">patients with severe preexisting comorbidities, recent MI, a</text>
<text top="158" left="446" width="360" height="16" font="4">lack of suitable graft conduits, a heavily calcified ascending</text>
<text top="176" left="446" width="360" height="16" font="4">aorta, or a non-LAD coronary artery unsuitable for bypass</text>
<text top="194" left="446" width="360" height="16" font="4">but amenable to PCI, and situations in which PCI of the</text>
<text top="212" left="446" width="360" height="16" font="4">LAD artery is not feasible because of excessive tortuosity or</text>
<text top="230" left="446" width="152" height="16" font="4">chronic total occlusions).</text>
<text top="248" left="461" width="345" height="16" font="4">Hybrid coronary revascularization may be performed in a</text>
<text top="266" left="446" width="360" height="16" font="4">hybrid suite in one operative setting or as a staged procedure</text>
<text top="284" left="446" width="360" height="16" font="4">(i.e., PCI and CABG performed in 2 different operative</text>
<text top="302" left="446" width="360" height="16" font="4">suites, separated by hours to 2 days, but typically during the</text>
<text top="320" left="446" width="360" height="16" font="4">same hospital stay). Because most hospitals lack a hybrid</text>
<text top="338" left="446" width="360" height="16" font="4">operating room, staged procedures are usually performed.</text>
<text top="356" left="446" width="360" height="16" font="4">With the staged procedure, CABG before PCI is preferred,</text>
<text top="374" left="446" width="360" height="16" font="4">because this approach allows the interventional cardiologist</text>
<text top="392" left="446" width="360" height="16" font="4">to 1) verify the patency of the LIMA-to-LAD artery graft</text>
<text top="410" left="446" width="360" height="16" font="4">before attempting PCI of other vessels and 2) minimize the</text>
<text top="428" left="446" width="360" height="16" font="4">risk of perioperative bleeding that would occur if CABG</text>
<text top="446" left="446" width="360" height="16" font="4">were performed after PCI (i.e., while the patient is receiving</text>
<text top="464" left="446" width="360" height="16" font="4">DAPT). Because minimally invasive CABG may be associ-</text>
<text top="482" left="446" width="360" height="16" font="4">ated with lower graft patency rates compared with CABG</text>
<text top="500" left="446" width="360" height="16" font="4">performed through a midline sternotomy, it seems prudent to</text>
<text top="518" left="446" width="360" height="16" font="4">angiographically image all grafts performed through a mini-</text>
<text top="536" left="446" width="294" height="16" font="4">mally invasive approach to confirm graft patency <a href="e44.full.html#112">(</a></text>
<text top="536" left="739" width="29" height="16" font="16"><a href="e44.full.html#112">1118</a></text>
<text top="536" left="768" width="8" height="16" font="4"><a href="e44.full.html#112">).</a></text>
<text top="554" left="461" width="345" height="16" font="4">To date, no RCTs involving hybrid coronary revascular-</text>
<text top="572" left="446" width="360" height="16" font="4">ization have been published. Over the past 10 years, several</text>
<text top="590" left="446" width="360" height="16" font="4">small, retrospective series of hybrid revascularization using</text>
<text top="608" left="446" width="360" height="16" font="4">minimally invasive CABG and PCI have reported low</text>
<text top="626" left="446" width="360" height="16" font="4">mortality rates (0% to 2%) and event-free survival rates of</text>
<text top="644" left="446" width="360" height="16" font="4">83% to 92% at 6 to 12 months of follow-up. The few series</text>
<text top="662" left="446" width="360" height="16" font="4">that have compared the outcomes of hybrid coronary revas-</text>
<text top="680" left="446" width="360" height="16" font="4">cularization with standard CABG report similar outcomes</text>
<text top="698" left="446" width="163" height="16" font="4">at 30 days and 6 months <a href="e44.full.html#112">(</a></text>
<text top="698" left="608" width="69" height="16" font="16"><a href="e44.full.html#112">1116 –1122</a></text>
<text top="698" left="677" width="9" height="16" font="4"><a href="e44.full.html#112">).</a></text>
<text top="730" left="446" width="200" height="12" font="18">5.12. Special Considerations</text>
<text top="752" left="446" width="360" height="16" font="4">In addition to patients’ coronary anatomy and LV function</text>
<text top="770" left="446" width="360" height="16" font="4">and whether they have undergone prior revascularization,</text>
<text top="788" left="446" width="360" height="16" font="4">clinical features such as the existence of coexisting chronic</text>
<text top="806" left="446" width="360" height="16" font="4">conditions might influence decision making. However, the</text>
<text top="824" left="446" width="360" height="16" font="4">paucity of information about special subgroups represents</text>
<text top="842" left="446" width="360" height="16" font="4">one of the greatest challenges in developing evidence-based</text>
<text top="860" left="446" width="360" height="16" font="4">guidelines applicable to large populations. As is the case for</text>
<text top="878" left="446" width="360" height="16" font="4">many chronic conditions, studies specifically geared toward</text>
<text top="896" left="446" width="360" height="16" font="4">answering clinical questions about the management of</text>
<text top="914" left="446" width="360" height="16" font="4">SIHD in women, older adults, and individuals with diabetes</text>
<text top="932" left="446" width="360" height="16" font="4">mellitus or CKD are lacking. Moreover, clinicians are often</text>
<text top="950" left="446" width="360" height="16" font="4">guided by misconceptions and biases that serve to deprive</text>
<text top="968" left="446" width="360" height="16" font="4">patients of potentially beneficial therapies. ACCF/AHA</text>
<text top="986" left="446" width="360" height="16" font="4">guidelines for the management of patients with UA/NSTEMI</text>
<text top="1004" left="446" width="5" height="16" font="4"><a href="e44.full.html#85">(</a></text>
<text top="1004" left="450" width="25" height="16" font="16"><a href="e44.full.html#85">4,4a</a></text>
<text top="1004" left="476" width="330" height="16" font="4"><a href="e44.full.html#85">) </a>address special subgroups by recommending that</text>
<text top="1022" left="446" width="360" height="16" font="4">diagnostic, pharmacological and revascularization strategies</text>
<text top="1040" left="446" width="360" height="16" font="4">be congruent with those in men, the young, and those</text>
<text top="1058" left="446" width="360" height="16" font="4">without diabetes mellitus. This section echoes those man-</text>
<text top="1076" left="446" width="360" height="16" font="4">agement recommendations. Although this section will</text>
<text top="1094" left="446" width="360" height="16" font="4">briefly review some special considerations in diagnosis and</text>
<text top="52" left="59" width="25" height="10" font="12">e114</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="72" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">therapy in certain groups of patients, the general approach</text>
<text top="122" left="59" width="360" height="16" font="4">should be to apply the recommendations in this guideline</text>
<text top="141" left="59" width="166" height="16" font="4">consistently among groups.</text>
<text top="168" left="59" width="101" height="16" font="26"><b>5.12.1. Women</b></text>
<text top="193" left="59" width="360" height="16" font="4">Women generally have a lower incidence of SIHD than</text>
<text top="211" left="59" width="360" height="16" font="4">men until older age, but their outcomes after MI are worse</text>
<text top="229" left="59" width="5" height="16" font="4"><a href="e44.full.html#112">(</a></text>
<text top="229" left="63" width="30" height="16" font="16"><a href="e44.full.html#112">1125</a></text>
<text top="229" left="93" width="325" height="16" font="4"><a href="e44.full.html#112">). </a>Microvascular disease, typically with preserved LV</text>
<text top="247" left="59" width="360" height="16" font="4">function, is more common among women, particularly those</text>
<text top="265" left="59" width="360" height="16" font="4">who are younger, whereas obstructive epicardial CAD is less</text>
<text top="283" left="59" width="360" height="16" font="4">prevalent. Up to 50% of women with typical or atypical</text>
<text top="301" left="59" width="360" height="16" font="4">anginal symptoms undergoing cardiac catheterization are</text>
<text top="319" left="59" width="228" height="16" font="4">found not to have obstructive CAD <a href="e44.full.html#112">(</a></text>
<text top="319" left="287" width="64" height="16" font="16"><a href="e44.full.html#112">1126,1127</a></text>
<text top="319" left="351" width="68" height="16" font="4"><a href="e44.full.html#112">). </a>Contrary</text>
<text top="337" left="59" width="360" height="16" font="4">to earlier perceptions, the prognosis of women with chest</text>
<text top="355" left="59" width="360" height="16" font="4">pain and nonobstructive disease is not necessarily better</text>
<text top="373" left="59" width="5" height="16" font="4"><a href="e44.full.html#113">(</a></text>
<text top="373" left="63" width="64" height="16" font="16"><a href="e44.full.html#113">1128,1129</a></text>
<text top="373" left="127" width="291" height="16" font="4"><a href="e44.full.html#113">). </a>As women age, the prevalence of obstructive</text>
<text top="391" left="59" width="96" height="16" font="4">CAD increases.</text>
<text top="409" left="74" width="345" height="16" font="4">Stable angina is the most frequent initial manifestation of</text>
<text top="427" left="59" width="360" height="16" font="4">SIHD in women, as opposed to AMI and sudden death in</text>
<text top="445" left="59" width="37" height="16" font="4">men <a href="e44.full.html#86">(</a></text>
<text top="445" left="96" width="49" height="16" font="16"><a href="e44.full.html#86">35,1130</a></text>
<text top="445" left="144" width="274" height="16" font="4"><a href="e44.full.html#86">). </a>Atypical chest pain and angina-equivalent</text>
<text top="464" left="59" width="360" height="16" font="4">symptoms such as dyspnea are more common in women,</text>
<text top="482" left="59" width="360" height="16" font="4">although women still present with similar patterns, dura-</text>
<text top="500" left="59" width="360" height="16" font="4">tion, and frequency of symptoms. The lower prevalence of</text>
<text top="518" left="59" width="360" height="16" font="4">obstructive disease in conjunction with technical challenges</text>
<text top="536" left="59" width="360" height="16" font="4">makes the interpretation of ischemia on imaging studies</text>
<text top="554" left="59" width="360" height="16" font="4">somewhat more difficult. Accumulating evidence suggests</text>
<text top="572" left="59" width="360" height="16" font="4">that vascular reactivity related to abnormalities in microvas-</text>
<text top="590" left="59" width="360" height="16" font="4">cular and endothelial function and possibly plaque erosion</text>
<text top="608" left="59" width="360" height="16" font="4">or distal microembolization contribute to ischemia to a</text>
<text top="626" left="59" width="240" height="16" font="4">greater extent in women than in men <a href="e44.full.html#87">(</a></text>
<text top="626" left="299" width="15" height="16" font="16"><a href="e44.full.html#87">75</a></text>
<text top="626" left="314" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="644" left="74" width="345" height="16" font="4">On exercise testing, ST-segment changes are less accurate</text>
<text top="662" left="59" width="329" height="16" font="4">for the detection of CAD in women than in men <a href="e44.full.html#89">(</a></text>
<text top="662" left="387" width="23" height="16" font="16"><a href="e44.full.html#89">175</a></text>
<text top="662" left="410" width="9" height="16" font="4"><a href="e44.full.html#89">),</a></text>
<text top="680" left="59" width="360" height="16" font="4">although marked ST-segment changes (a visual interpreta-</text>
<text top="698" left="59" width="24" height="16" font="4">tion</text>
<text top="695" left="90" width="328" height="20" font="4">ⱖ1 mm of horizontal or downsloping ST-segment</text>
<text top="716" left="59" width="157" height="16" font="4">depression or elevation for</text>
<text top="713" left="219" width="199" height="20" font="4">ⱖ60 to 80 ms after the end of the</text>
<text top="734" left="58" width="360" height="16" font="4">QRS complex) remain diagnostic for all patients. Chal-</text>
<text top="752" left="58" width="360" height="16" font="4">lenges with exercise testing in women include their generally</text>
<text top="770" left="58" width="360" height="16" font="4">lower physical work capacity and the high prevalence of</text>
<text top="788" left="58" width="360" height="16" font="4">obesity, diabetes mellitus, frailty, and other comorbid con-</text>
<text top="806" left="58" width="173" height="16" font="4">ditions. Numerous reports <a href="e44.full.html#85">(</a></text>
<text top="806" left="232" width="109" height="16" font="16"><a href="e44.full.html#85">14,315,1131,1132</a></text>
<text top="806" left="341" width="78" height="16" font="4"><a href="e44.full.html#85">) </a>and an ex-</text>
<text top="824" left="58" width="160" height="16" font="4">pert consensus statement <a href="e44.full.html#89">(</a></text>
<text top="824" left="218" width="23" height="16" font="16"><a href="e44.full.html#89">175</a></text>
<text top="824" left="241" width="178" height="16" font="4"><a href="e44.full.html#89">) </a>have examined the diagnos-</text>
<text top="842" left="58" width="360" height="16" font="4">tic accuracy of the exercise ECG and various imaging</text>
<text top="860" left="58" width="360" height="16" font="4">modalities in large cohorts of women. Overall, most reports</text>
<text top="878" left="58" width="360" height="16" font="4">document an improvement in diagnostic accuracy with</text>
<text top="896" left="58" width="329" height="16" font="4">imaging when compared to a standard exercise ECG <a href="e44.full.html#89">(</a></text>
<text top="896" left="387" width="23" height="16" font="16"><a href="e44.full.html#89">175</a></text>
<text top="896" left="410" width="9" height="16" font="4"><a href="e44.full.html#89">),</a></text>
<text top="914" left="58" width="360" height="16" font="4">although that improvement does not necessarily translate</text>
<text top="932" left="58" width="224" height="16" font="4">into improved clinical outcomes <a href="e44.full.html#89">(</a></text>
<text top="932" left="283" width="23" height="16" font="16"><a href="e44.full.html#89">147</a></text>
<text top="932" left="305" width="113" height="16" font="4"><a href="e44.full.html#89">). </a>From a meta-</text>
<text top="950" left="58" width="360" height="16" font="4">analysis, the diagnostic sensitivity and specificity were 72%</text>
<text top="968" left="58" width="360" height="16" font="4">and 88% for women undergoing dobutamine stress echo-</text>
<text top="986" left="58" width="89" height="16" font="4">cardiography <a href="e44.full.html#89">(</a></text>
<text top="986" left="148" width="23" height="16" font="16"><a href="e44.full.html#89">149</a></text>
<text top="986" left="170" width="248" height="16" font="4"><a href="e44.full.html#89">). </a>From a small controlled clinical trial,</text>
<text top="1004" left="58" width="360" height="16" font="4">diagnostic specificity was improved considerably when using</text>
<text top="1022" left="58" width="360" height="16" font="4">gated Tc-99m myocardial perfusion SPECT over Tl-201</text>
<text top="1040" left="58" width="360" height="16" font="4">myocardial perfusion SPECT (92% versus 67%) because of</text>
<text top="1058" left="58" width="165" height="16" font="4">improved image quality <a href="e44.full.html#113">(</a></text>
<text top="1058" left="224" width="30" height="16" font="16"><a href="e44.full.html#113">1133</a></text>
<text top="1058" left="254" width="165" height="16" font="4"><a href="e44.full.html#113">). </a>Overall, sensitivity and</text>
<text top="1076" left="58" width="360" height="16" font="4">specificity of myocardial perfusion SPECT were reported as</text>
<text top="1094" left="58" width="173" height="16" font="4">88% and 96% for women <a href="e44.full.html#87">(</a></text>
<text top="1094" left="232" width="75" height="16" font="16"><a href="e44.full.html#87">86,175,1134</a></text>
<text top="1094" left="307" width="112" height="16" font="4"><a href="e44.full.html#87">). </a>For CMR, one</text>
<text top="104" left="445" width="360" height="16" font="4">study reported a diagnostic sensitivity and specificity of 92%</text>
<text top="122" left="445" width="360" height="16" font="4">and 80% with vasodilator stress magnetic resonance myo-</text>
<text top="140" left="445" width="111" height="16" font="4">cardial perfusion <a href="e44.full.html#92">(</a></text>
<text top="140" left="556" width="23" height="16" font="16"><a href="e44.full.html#92">281</a></text>
<text top="140" left="579" width="9" height="16" font="4"><a href="e44.full.html#92">).</a></text>
<text top="158" left="460" width="345" height="16" font="4">In part related to differing pathophysiology and clinical</text>
<text top="176" left="445" width="360" height="16" font="4">presentation, substantial differences in provision of clinical</text>
<text top="194" left="445" width="360" height="16" font="4">care have been observed between men and women with</text>
<text top="212" left="445" width="44" height="16" font="4">CAD <a href="e44.full.html#113">(</a></text>
<text top="212" left="489" width="30" height="16" font="16"><a href="e44.full.html#113">1135</a></text>
<text top="212" left="519" width="286" height="16" font="4"><a href="e44.full.html#113">). </a>Despite increasing recognition of the risks of</text>
<text top="230" left="445" width="360" height="16" font="4">worsening IHD and attendant complications in women, the</text>
<text top="249" left="445" width="360" height="16" font="4">frequency with which they are prescribed important risk-</text>
<text top="267" left="445" width="360" height="16" font="4">modifying therapies such as statins, aspirin, and beta block-</text>
<text top="285" left="445" width="360" height="16" font="4">ers after episodes of ACS remains significantly lower than</text>
<text top="303" left="445" width="79" height="16" font="4">among men <a href="e44.full.html#113">(</a></text>
<text top="303" left="525" width="64" height="16" font="16"><a href="e44.full.html#113">1136,1137</a></text>
<text top="303" left="589" width="217" height="16" font="4"><a href="e44.full.html#113">). </a>Among patients with documented</text>
<text top="321" left="445" width="360" height="16" font="4">SIHD, however, the differences between men and women</text>
<text top="339" left="445" width="360" height="16" font="4">appear to be much smaller with regard to prescription of</text>
<text top="357" left="445" width="100" height="16" font="4">these therapies <a href="e44.full.html#113">(</a></text>
<text top="357" left="546" width="30" height="16" font="16"><a href="e44.full.html#113">1138</a></text>
<text top="357" left="576" width="9" height="16" font="4"><a href="e44.full.html#113">).</a></text>
<text top="375" left="460" width="345" height="16" font="4">Data from COURAGE suggest that the benefits of</text>
<text top="393" left="445" width="360" height="16" font="4">GDMT alone in comparison with GDMT plus PCI were</text>
<text top="411" left="445" width="197" height="16" font="4">similar for men and women <a href="e44.full.html#94">(</a></text>
<text top="411" left="642" width="56" height="16" font="16"><a href="e44.full.html#94">366,1138</a></text>
<text top="411" left="698" width="107" height="16" font="4"><a href="e44.full.html#94">). </a>Moreover, the</text>
<text top="429" left="445" width="360" height="16" font="4">outcomes of revascularization appear to be less favorable</text>
<text top="447" left="445" width="166" height="16" font="4">among women than men <a href="e44.full.html#113">(</a></text>
<text top="447" left="612" width="69" height="16" font="16"><a href="e44.full.html#113">1139 –1142</a></text>
<text top="447" left="681" width="125" height="16" font="4"><a href="e44.full.html#113">), </a>although very few</text>
<text top="465" left="445" width="360" height="16" font="4">women were enrolled in COURAGE. In various risk</text>
<text top="483" left="445" width="360" height="16" font="4">models, the odds of in-hospital death after PCI have ranged</text>
<text top="501" left="445" width="322" height="16" font="4">from 25% to 80% higher for women than for men <a href="e44.full.html#113">(</a></text>
<text top="501" left="768" width="38" height="16" font="16"><a href="e44.full.html#113">1143–</a></text>
<text top="519" left="445" width="30" height="16" font="16"><a href="e44.full.html#113">1147</a></text>
<text top="519" left="475" width="330" height="16" font="4"><a href="e44.full.html#113">), </a>although this trend might have improved in recent</text>
<text top="537" left="445" width="360" height="16" font="4">years after the higher incidence of diabetes mellitus and</text>
<text top="555" left="445" width="291" height="16" font="4">hypertension in women is taken into account <a href="e44.full.html#113">(</a></text>
<text top="555" left="736" width="30" height="16" font="16"><a href="e44.full.html#113">1148</a></text>
<text top="555" left="766" width="39" height="16" font="4"><a href="e44.full.html#113">). </a>The</text>
<text top="573" left="445" width="360" height="16" font="4">risk of procedural complications also appears to be signifi-</text>
<text top="591" left="445" width="151" height="16" font="4">cantly higher in women <a href="e44.full.html#113">(</a></text>
<text top="591" left="597" width="30" height="16" font="16"><a href="e44.full.html#113">1149</a></text>
<text top="591" left="627" width="179" height="16" font="4"><a href="e44.full.html#113">). </a>Although fewer data on the</text>
<text top="609" left="445" width="360" height="16" font="4">experience of women after CABG are available, in the New</text>
<text top="627" left="445" width="360" height="16" font="4">York State registry, the odds of in-hospital death for women</text>
<text top="645" left="445" width="206" height="16" font="4">were 2-fold higher than for men <a href="e44.full.html#113">(</a></text>
<text top="645" left="652" width="64" height="16" font="16"><a href="e44.full.html#113">1149,1150</a></text>
<text top="645" left="716" width="90" height="16" font="4"><a href="e44.full.html#113">). </a>On the basis</text>
<text top="663" left="445" width="360" height="16" font="4">of these observations, the initial approach to therapy for</text>
<text top="681" left="445" width="360" height="16" font="4">women with SIHD should be to prescribe a full regimen of</text>
<text top="699" left="445" width="360" height="16" font="4">GDMT and to reserve consideration of revascularization for</text>
<text top="717" left="445" width="360" height="16" font="4">patients who do not obtain a satisfactory response or who</text>
<text top="735" left="445" width="360" height="16" font="4">experience unacceptable adverse effects. On the basis of the</text>
<text top="753" left="445" width="360" height="16" font="4">higher risk associated with PCI in women, it might be</text>
<text top="771" left="445" width="360" height="16" font="4">reasonable to adopt a more conservative approach in under-</text>
<text top="789" left="445" width="360" height="16" font="4">taking this procedure than in men, although the general</text>
<text top="807" left="445" width="360" height="16" font="4">principle of using revascularization in patients whose symp-</text>
<text top="825" left="445" width="360" height="16" font="4">toms are refractory to medical therapy and who are not</text>
<text top="843" left="445" width="309" height="16" font="4">satisfied with their current level of angina persists.</text>
<text top="870" left="445" width="135" height="16" font="26"><b>5.12.2. Older Adults</b></text>
<text top="896" left="445" width="193" height="16" font="4">In older adults, often defined as</text>
<text top="893" left="643" width="163" height="20" font="4">⬎75 years of age, coronary</text>
<text top="914" left="445" width="360" height="16" font="4">stenoses are likely to be more diffuse and more severe, with</text>
<text top="932" left="445" width="360" height="16" font="4">a higher prevalence of 3-vessel and left main disease. Several</text>
<text top="950" left="445" width="360" height="16" font="4">factors complicate the diagnosis and treatment of SIHD in</text>
<text top="968" left="445" width="360" height="16" font="4">this age group. Common coexisting conditions of the</text>
<text top="986" left="445" width="360" height="16" font="4">pulmonary, gastrointestinal, and musculoskeletal systems</text>
<text top="1004" left="445" width="360" height="16" font="4">can cause chest pain, making diagnosis more difficult, even</text>
<text top="1022" left="445" width="360" height="16" font="4">in patients with documented IHD. Physiological changes in</text>
<text top="1040" left="445" width="360" height="16" font="4">older adults, including alterations in cardiac output through</text>
<text top="1058" left="445" width="360" height="16" font="4">various mechanisms, muscle loss and deconditioning, neu-</text>
<text top="1076" left="445" width="360" height="16" font="4">ropathies, lung disease, and degenerative joint disease, make</text>
<text top="1094" left="445" width="360" height="16" font="4">stress testing more difficult. Thus, many elderly patients are</text>
<text top="52" left="781" width="25" height="10" font="12">e115</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="73" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">incapable of responding to graded increases in workload as</text>
<text top="123" left="59" width="295" height="16" font="4">required by standard exercise ECG protocols <a href="e44.full.html#88">(</a></text>
<text top="123" left="354" width="56" height="16" font="16"><a href="e44.full.html#88">118,1151</a></text>
<text top="123" left="410" width="9" height="16" font="4"><a href="e44.full.html#88">).</a></text>
<text top="141" left="59" width="360" height="16" font="4">For patients who are unable to exercise, pharmacological</text>
<text top="159" left="59" width="360" height="16" font="4">stress imaging is indicated. Although the majority of inves-</text>
<text top="178" left="59" width="360" height="16" font="4">tigations have focused on prognosis by markers of ischemia</text>
<text top="196" left="59" width="360" height="16" font="4">in the elderly, the results generally reveal a similar accuracy</text>
<text top="215" left="59" width="360" height="16" font="4">of testing when compared with younger individuals present-</text>
<text top="233" left="59" width="105" height="16" font="4">ing with SIHD <a href="e44.full.html#113">(</a></text>
<text top="233" left="164" width="67" height="16" font="16"><a href="e44.full.html#113">1152–1155</a></text>
<text top="233" left="231" width="9" height="16" font="4"><a href="e44.full.html#113">).</a></text>
<text top="251" left="74" width="345" height="16" font="4">Baseline ECG changes, arrhythmias, and LV hypertro-</text>
<text top="270" left="59" width="360" height="16" font="4">phy, which are more common in older adults who have</text>
<text top="288" left="59" width="360" height="16" font="4">accumulated cardiac comorbidities, also limit the value of</text>
<text top="306" left="59" width="87" height="16" font="4">stress testing <a href="e44.full.html#113">(</a></text>
<text top="306" left="145" width="64" height="16" font="16"><a href="e44.full.html#113">1156,1157</a></text>
<text top="306" left="209" width="209" height="16" font="4"><a href="e44.full.html#113">). </a>The higher prevalence of SIHD</text>
<text top="325" left="59" width="360" height="16" font="4">in older adults results in more tests that are falsely negative,</text>
<text top="343" left="59" width="360" height="16" font="4">and the prognostic value of the Duke treadmill score in</text>
<text top="361" left="59" width="189" height="16" font="4">older adults might be limited <a href="e44.full.html#113">(</a></text>
<text top="361" left="248" width="30" height="16" font="16"><a href="e44.full.html#113">1158</a></text>
<text top="361" left="278" width="9" height="16" font="4"><a href="e44.full.html#113">).</a></text>
<text top="380" left="74" width="345" height="16" font="4">Data based on RCTs to guide therapy in older adults are</text>
<text top="398" left="59" width="360" height="16" font="4">relatively sparse because of the common exclusion of older</text>
<text top="416" left="59" width="360" height="16" font="4">patients from early clinical trials. Several studies have shown</text>
<text top="435" left="59" width="360" height="16" font="4">less frequent use of evidence-based therapies in older adults,</text>
<text top="453" left="59" width="360" height="16" font="4">such as early invasive procedures, anticoagulants, beta</text>
<text top="471" left="59" width="325" height="16" font="4">blockers, and glycoprotein IIb/IIIa inhibitors <a href="e44.full.html#113">(</a></text>
<text top="471" left="383" width="35" height="16" font="16"><a href="e44.full.html#113">1156,</a></text>
<text top="490" left="59" width="64" height="16" font="16"><a href="e44.full.html#113">1159,1160</a></text>
<text top="490" left="122" width="296" height="16" font="4"><a href="e44.full.html#113">). </a>The findings are likely related to several factors.</text>
<text top="508" left="59" width="360" height="16" font="4">Pharmacotherapy is more difficult in older adults because of</text>
<text top="526" left="59" width="360" height="16" font="4">changes in drug bioavailability and elimination. Drug– drug</text>
<text top="545" left="59" width="360" height="16" font="4">interactions are more common because of polypharmacy. A</text>
<text top="563" left="59" width="360" height="16" font="4">more conservative approach to coronary angiography is</text>
<text top="581" left="59" width="360" height="16" font="4">often appropriate given the higher risk of contrast-induced</text>
<text top="600" left="59" width="180" height="16" font="4">nephropathy in older adults <a href="e44.full.html#113">(</a></text>
<text top="600" left="238" width="30" height="16" font="16"><a href="e44.full.html#113">1161</a></text>
<text top="600" left="268" width="150" height="16" font="4"><a href="e44.full.html#113">). </a>Moreover, the risks of</text>
<text top="618" left="59" width="360" height="16" font="4">morbidity and mortality associated with CABG are in-</text>
<text top="636" left="59" width="141" height="16" font="4">creased in older adults.</text>
<text top="655" left="74" width="345" height="16" font="4">Despite the complexities and concerns related to evalu-</text>
<text top="673" left="59" width="360" height="16" font="4">ating and treating elderly patients with SIHD, findings</text>
<text top="691" left="59" width="360" height="16" font="4">from the COURAGE trial indicated that initial medical</text>
<text top="710" left="59" width="360" height="16" font="4">therapy was not significantly less effective than medical</text>
<text top="728" left="59" width="360" height="16" font="4">therapy plus PCI in relieving angina (73% in the GDMT</text>
<text top="746" left="59" width="360" height="16" font="4">group at 60 months, versus 80% in the medical therapy–</text>
<text top="765" left="59" width="115" height="16" font="4">plus–PCI group) <a href="e44.full.html#113">(</a></text>
<text top="765" left="173" width="30" height="16" font="16"><a href="e44.full.html#113">1162</a></text>
<text top="765" left="203" width="215" height="16" font="4"><a href="e44.full.html#113">). </a>Although the mortality rate was</text>
<text top="783" left="59" width="170" height="16" font="4">50% higher among patients</text>
<text top="780" left="234" width="185" height="20" font="4">⬎65 years of age than among</text>
<text top="801" left="59" width="360" height="16" font="4">younger patients, there were no significant differences be-</text>
<text top="820" left="59" width="360" height="16" font="4">tween the 2 treatment groups in either patients younger or</text>
<text top="838" left="59" width="360" height="16" font="4">older than 65 years. Furthermore, although the incidence of</text>
<text top="856" left="59" width="360" height="16" font="4">MI and stroke was also higher in older patients, there were</text>
<text top="875" left="59" width="360" height="16" font="4">no significant differences between treatment groups. In the</text>
<text top="893" left="59" width="360" height="16" font="4">TIME (Trial of Invasive versus Medical Therapy in the</text>
<text top="911" left="59" width="164" height="16" font="4">Elderly) trial, 301 patients</text>
<text top="908" left="228" width="190" height="20" font="4">ⱖ75 years of age with chronic</text>
<text top="930" left="59" width="360" height="16" font="4">angina with CCS Class II or higher despite treatment with</text>
<text top="945" left="59" width="360" height="20" font="4">ⱖ2 antianginal drugs were randomized to GDMT or to an</text>
<text top="966" left="59" width="360" height="16" font="4">invasive strategy of coronary angiography followed by revas-</text>
<text top="985" left="59" width="269" height="16" font="4">cularization with PCI or CABG, if feasible <a href="e44.full.html#113">(</a></text>
<text top="985" left="327" width="30" height="16" font="16"><a href="e44.full.html#113">1163</a></text>
<text top="985" left="357" width="61" height="16" font="4"><a href="e44.full.html#113">). </a>Patients</text>
<text top="1003" left="59" width="360" height="16" font="4">who were assigned to the early revascularization group</text>
<text top="1021" left="59" width="360" height="16" font="4">experienced greater improvement in symptoms at 6 months.</text>
<text top="1040" left="59" width="360" height="16" font="4">This difference disappeared by 12 months, at which time</text>
<text top="1058" left="59" width="360" height="16" font="4">both groups had shown a 2-class improvement in their CCS</text>
<text top="1076" left="59" width="360" height="16" font="4">scores and similar results on other quality-of-life measures.</text>
<text top="1095" left="59" width="360" height="16" font="4">It should be noted that 45% of the group assigned to</text>
<text top="105" left="446" width="360" height="16" font="4">medical therapy ultimately underwent revascularization be-</text>
<text top="123" left="446" width="182" height="16" font="4">cause of refractory symptoms.</text>
<text top="141" left="461" width="345" height="16" font="4">Considerable evidence indicates that elderly patients have</text>
<text top="159" left="446" width="360" height="16" font="4">higher mortality following PCI and CABG than do</text>
<text top="177" left="446" width="360" height="16" font="4">younger patients, and the risk appears to rise monotonically</text>
<text top="195" left="446" width="33" height="16" font="4">when</text>
<text top="192" left="486" width="124" height="20" font="4">⬎65 years of age <a href="e44.full.html#113">(</a></text>
<text top="195" left="610" width="142" height="16" font="16"><a href="e44.full.html#113">1144 –1147,1164 –1166</a></text>
<text top="195" left="753" width="53" height="16" font="4"><a href="e44.full.html#113">). </a>Com-</text>
<text top="213" left="446" width="123" height="16" font="4">pared with patients</text>
<text top="210" left="576" width="229" height="20" font="4">ⱕ65 years of age, adjusted odds of</text>
<text top="231" left="446" width="360" height="16" font="4">short-term mortality after PCI among patients between the</text>
<text top="249" left="446" width="360" height="16" font="4">ages of 60 and 80 have ranged from 2.2 to 7.6 in various</text>
<text top="267" left="446" width="290" height="16" font="4">registries, and the odds of death among those</text>
<text top="264" left="742" width="64" height="20" font="4">ⱖ80 years</text>
<text top="285" left="446" width="145" height="16" font="4">have ranged from 2.7 to</text>
<text top="282" left="595" width="211" height="20" font="4">⬎13. Unfortunately, far fewer data</text>
<text top="303" left="446" width="360" height="16" font="4">are available on the outcomes of elderly patients undergoing</text>
<text top="321" left="446" width="360" height="16" font="4">CABG, and much of it could be outdated. On the basis of</text>
<text top="339" left="446" width="360" height="16" font="4">data from 16,120 patients entered into the New York State</text>
<text top="357" left="446" width="360" height="16" font="4">registry, the odds of in-hospital mortality rose 8% per year</text>
<text top="375" left="446" width="37" height="16" font="4">of age</text>
<text top="372" left="487" width="280" height="20" font="4">⬎60 years (OR: 1.08; 95% CI: 1.06 to 1.09) <a href="e44.full.html#113">(</a></text>
<text top="375" left="767" width="30" height="16" font="16"><a href="e44.full.html#113">1150</a></text>
<text top="375" left="797" width="9" height="16" font="4"><a href="e44.full.html#113">).</a></text>
<text top="393" left="446" width="360" height="16" font="4">On the other hand, in an analysis of 505,645 records from</text>
<text top="411" left="446" width="360" height="16" font="4">the registry maintained by the STS, age was not found to be</text>
<text top="429" left="446" width="163" height="16" font="4">a predictor of mortality <a href="e44.full.html#113">(</a></text>
<text top="429" left="608" width="30" height="16" font="16"><a href="e44.full.html#113">1167</a></text>
<text top="429" left="638" width="167" height="16" font="4"><a href="e44.full.html#113">). </a>In older studies, elderly</text>
<text top="447" left="446" width="360" height="16" font="4">patients were reported to have favorable results after CABG</text>
<text top="465" left="446" width="5" height="16" font="4"><a href="e44.full.html#114">(</a></text>
<text top="465" left="450" width="64" height="16" font="16"><a href="e44.full.html#114">1168,1169</a></text>
<text top="465" left="514" width="291" height="16" font="4"><a href="e44.full.html#114">), </a>and long-term survival rates for elderly pa-</text>
<text top="483" left="446" width="360" height="16" font="4">tients with SIHD treated medically versus surgically were</text>
<text top="501" left="446" width="51" height="16" font="4">similar <a href="e44.full.html#95">(</a></text>
<text top="501" left="496" width="23" height="16" font="16"><a href="e44.full.html#95">406</a></text>
<text top="501" left="519" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="519" left="461" width="345" height="16" font="4">Older adults constitute a growing proportion of patients</text>
<text top="537" left="446" width="360" height="16" font="4">with SIHD. On the basis of the available data, it is</text>
<text top="555" left="446" width="360" height="16" font="4">recommended that management by GDMT be the initial</text>
<text top="573" left="446" width="360" height="16" font="4">approach in most patients. Given concerns about higher</text>
<text top="592" left="446" width="233" height="16" font="4">mortality rate, particularly in patients</text>
<text top="588" left="684" width="121" height="20" font="4">⬎75 or 80 years of</text>
<text top="610" left="446" width="360" height="16" font="4">age, decisions to recommend revascularization should be</text>
<text top="628" left="446" width="360" height="16" font="4">undertaken only after careful consideration of patient pref-</text>
<text top="646" left="446" width="360" height="16" font="4">erences, functional capacity, quality-of-life and end-of-life</text>
<text top="664" left="446" width="256" height="16" font="4">issues, as well as therapeutic alternatives <a href="e44.full.html#85">(</a></text>
<text top="664" left="701" width="25" height="16" font="16"><a href="e44.full.html#85">4,4a</a></text>
<text top="664" left="727" width="9" height="16" font="4"><a href="e44.full.html#85">).</a></text>
<text top="691" left="446" width="165" height="16" font="26"><b>5.12.3. Diabetes Mellitus</b></text>
<text top="716" left="446" width="360" height="16" font="4">Type 1 and type 2 diabetes mellitus are associated with a</text>
<text top="734" left="446" width="360" height="16" font="4">greater risk of SIHD, and the effects of other risk factors</text>
<text top="752" left="446" width="269" height="16" font="4">such as hypercholesterolemia are magnified <a href="e44.full.html#114">(</a></text>
<text top="752" left="715" width="30" height="16" font="16"><a href="e44.full.html#114">1170</a></text>
<text top="752" left="745" width="61" height="16" font="4"><a href="e44.full.html#114">). </a>Cardio-</text>
<text top="770" left="446" width="360" height="16" font="4">vascular mortality rate is 3-fold higher in men with diabetes</text>
<text top="788" left="446" width="360" height="16" font="4">mellitus and between 2- and 5-fold higher in women with</text>
<text top="806" left="446" width="360" height="16" font="4">diabetes than in patients without diabetes mellitus</text>
<text top="824" left="446" width="5" height="16" font="4"><a href="e44.full.html#114">(</a></text>
<text top="824" left="450" width="64" height="16" font="16"><a href="e44.full.html#114">1171,1172</a></text>
<text top="824" left="514" width="291" height="16" font="4"><a href="e44.full.html#114">). </a>Sudden cardiac death occurs more frequently</text>
<text top="842" left="446" width="360" height="16" font="4">in patients with diabetes mellitus. Although direct evidence</text>
<text top="860" left="446" width="360" height="16" font="4">is lacking, asymptomatic ischemia could be more prevalent</text>
<text top="878" left="446" width="360" height="16" font="4">in patients with diabetes mellitus, possibly because of</text>
<text top="896" left="446" width="147" height="16" font="4">autonomic neuropathy <a href="e44.full.html#114">(</a></text>
<text top="896" left="592" width="30" height="16" font="16"><a href="e44.full.html#114">1173</a></text>
<text top="896" left="622" width="9" height="16" font="4"><a href="e44.full.html#114">).</a></text>
<text top="914" left="461" width="345" height="16" font="4">The risk of death in a patient with SIHD and diabetes</text>
<text top="932" left="446" width="360" height="16" font="4">mellitus has been equated to the risk of death in a patient</text>
<text top="950" left="446" width="215" height="16" font="4">with SIHD and a previous MI <a href="e44.full.html#114">(</a></text>
<text top="950" left="661" width="64" height="16" font="16"><a href="e44.full.html#114">1171,1174</a></text>
<text top="950" left="724" width="81" height="16" font="4"><a href="e44.full.html#114">). </a>Aggressive</text>
<text top="968" left="446" width="360" height="16" font="4">management of cardiovascular risk factors, including hyper-</text>
<text top="986" left="446" width="360" height="16" font="4">cholesterolemia, hypertension, smoking, low physical activ-</text>
<text top="1004" left="446" width="360" height="16" font="4">ity, and obesity, is essential, along with appropriate glycemic</text>
<text top="1022" left="446" width="47" height="16" font="4">control.</text>
<text top="1040" left="461" width="345" height="16" font="4">Among patients with IHD, the presence of concomitant</text>
<text top="1059" left="446" width="360" height="16" font="4">diabetes mellitus increases the risk of adverse events, irre-</text>
<text top="1077" left="446" width="360" height="16" font="4">spective of whether the patient is treated medically or with</text>
<text top="1095" left="446" width="360" height="16" font="4">revascularization. Two studies have suggested that survival</text>
<text top="52" left="59" width="25" height="10" font="12">e116</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="74" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">among patients with diabetes mellitus is more favorable</text>
<text top="122" left="59" width="360" height="16" font="4">after bypass surgery than with medical therapy, although</text>
<text top="140" left="59" width="360" height="16" font="4">these results are based on subgroup analyses from observa-</text>
<text top="158" left="59" width="78" height="16" font="4">tional data <a href="e44.full.html#109">(</a></text>
<text top="158" left="136" width="56" height="16" font="16"><a href="e44.full.html#109">991,1175</a></text>
<text top="158" left="193" width="226" height="16" font="4"><a href="e44.full.html#109">). </a>Of 2 studies comparing PCI and</text>
<text top="176" left="59" width="360" height="16" font="4">medical therapy in patients with diabetes mellitus, one</text>
<text top="194" left="59" width="151" height="16" font="4">reported longer survival <a href="e44.full.html#114">(</a></text>
<text top="194" left="209" width="30" height="16" font="16"><a href="e44.full.html#114">1175</a></text>
<text top="194" left="239" width="148" height="16" font="4"><a href="e44.full.html#114">), </a>but the other did not <a href="e44.full.html#109">(</a></text>
<text top="194" left="387" width="23" height="16" font="16"><a href="e44.full.html#109">991</a></text>
<text top="194" left="410" width="9" height="16" font="4"><a href="e44.full.html#109">).</a></text>
<text top="212" left="74" width="345" height="16" font="4">A subgroup analysis of data from the BARI trial sug-</text>
<text top="230" left="59" width="360" height="16" font="4">gested that patients with diabetes mellitus who underwent</text>
<text top="248" left="59" width="360" height="16" font="4">CABG with 1 arterial conduit had improved survival</text>
<text top="266" left="59" width="279" height="16" font="4">compared with those who underwent PCI <a href="e44.full.html#95">(</a></text>
<text top="266" left="338" width="23" height="16" font="16"><a href="e44.full.html#95">368</a></text>
<text top="266" left="360" width="58" height="16" font="4"><a href="e44.full.html#95">). </a>Several</text>
<text top="284" left="59" width="360" height="16" font="4">retrospective cohort studies have compared outcomes</text>
<text top="302" left="59" width="360" height="16" font="4">among patients with diabetes mellitus undergoing PCI</text>
<text top="320" left="59" width="360" height="16" font="4">versus CABG. Three observational studies have reported a</text>
<text top="338" left="59" width="360" height="16" font="4">survival advantage for CABG over PCI, whereas a fourth</text>
<text top="356" left="59" width="360" height="16" font="4">found no significant difference, and no studies located</text>
<text top="374" left="59" width="220" height="16" font="4">reported better outcomes after PCI.</text>
<text top="392" left="74" width="345" height="16" font="4">In the BARI 2D study, 2,368 patients with type 2</text>
<text top="410" left="59" width="360" height="16" font="4">diabetes mellitus and SIHD were initially selected as can-</text>
<text top="428" left="59" width="360" height="16" font="4">didates for either PCI or CABG on the basis of clinical and</text>
<text top="446" left="59" width="360" height="16" font="4">angiographic assessment and then were randomly assigned</text>
<text top="464" left="59" width="360" height="16" font="4">to undergo either prompt revascularization with intensive</text>
<text top="482" left="59" width="360" height="16" font="4">medical therapy or intensive medical therapy alone and to</text>
<text top="500" left="59" width="360" height="16" font="4">undergo either insulin-sensitization or insulin-provision</text>
<text top="518" left="59" width="54" height="16" font="4">therapy <a href="e44.full.html#95">(</a></text>
<text top="518" left="113" width="23" height="16" font="16"><a href="e44.full.html#95">408</a></text>
<text top="518" left="135" width="283" height="16" font="4"><a href="e44.full.html#95">). </a>The study was not designed to compare PCI</text>
<text top="536" left="59" width="360" height="16" font="4">with CABG. At 5 years, overall survival was similar between</text>
<text top="554" left="59" width="360" height="16" font="4">the revascularization and medical-therapy groups (88.3%</text>
<text top="572" left="59" width="360" height="16" font="4">versus 87.8%), as was the incidence of MACE (77.2%</text>
<text top="590" left="59" width="96" height="16" font="4">versus 75.9%) <a href="e44.full.html#95">(</a></text>
<text top="590" left="155" width="23" height="16" font="16"><a href="e44.full.html#95">409</a></text>
<text top="590" left="177" width="241" height="16" font="4"><a href="e44.full.html#95">). </a>Patients with the most severe CAD</text>
<text top="608" left="59" width="360" height="16" font="4">were assigned to the CABG stratum and those with the</text>
<text top="626" left="59" width="360" height="16" font="4">least severe CAD to the PCI stratum. In the PCI stratum,</text>
<text top="644" left="59" width="360" height="16" font="4">there was no significant difference in primary endpoints</text>
<text top="662" left="59" width="360" height="16" font="4">between the revascularization group and the medical-</text>
<text top="680" left="59" width="360" height="16" font="4">therapy group. In the 763 patients randomized to the</text>
<text top="698" left="59" width="360" height="16" font="4">CABG stratum, survival was similar but AMI less frequent</text>
<text top="716" left="59" width="360" height="16" font="4">among those assigned to revascularization plus intensive</text>
<text top="734" left="59" width="360" height="16" font="4">medical therapy compared with intensive medical therapy</text>
<text top="752" left="59" width="148" height="16" font="4">(10.0% versus 17.6%; p</text>
<text top="749" left="206" width="212" height="20" font="4">⫽0.003), and the composite end-</text>
<text top="770" left="59" width="360" height="16" font="4">points of all-cause death or MI (21.1% versus 29.2%;</text>
<text top="788" left="59" width="8" height="16" font="4">p</text>
<text top="785" left="66" width="352" height="20" font="4">⫽0.010) and cardiac death or MI (p⫽0.03) were also less</text>
<text top="806" left="59" width="360" height="16" font="4">frequent. Compared with those selected for PCI, patients in</text>
<text top="824" left="59" width="360" height="16" font="4">the CABG stratum had more 3-vessel disease (20% versus</text>
<text top="842" left="59" width="360" height="16" font="4">52%), more total occlusions (32% versus 61%), more prox-</text>
<text top="860" left="59" width="118" height="16" font="4">imal LAD stenoses</text>
<text top="857" left="181" width="237" height="20" font="4">⬎50% (10% versus 19%), and a signif-</text>
<text top="878" left="59" width="256" height="16" font="4">icantly higher myocardial jeopardy score <a href="e44.full.html#95">(</a></text>
<text top="878" left="315" width="23" height="16" font="16"><a href="e44.full.html#95">409</a></text>
<text top="878" left="337" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="896" left="74" width="345" height="16" font="4">One-year follow-up data from the SYNTAX study dem-</text>
<text top="914" left="59" width="360" height="16" font="4">onstrated a higher rate of repeat revascularization in patients</text>
<text top="932" left="59" width="360" height="16" font="4">with diabetes mellitus treated with PCI than in those</text>
<text top="950" left="59" width="360" height="16" font="4">treated with CABG, driven by a tendency for higher repeat</text>
<text top="968" left="59" width="360" height="16" font="4">revascularization rates in those with higher SYNTAX scores</text>
<text top="986" left="59" width="110" height="16" font="4">undergoing PCI <a href="e44.full.html#109">(</a></text>
<text top="986" left="168" width="30" height="16" font="16"><a href="e44.full.html#109">1006</a></text>
<text top="986" left="198" width="9" height="16" font="4"><a href="e44.full.html#109">).</a></text>
<text top="1004" left="74" width="345" height="16" font="4">A large meta-analysis that included the BARI trial but</text>
<text top="1022" left="59" width="360" height="16" font="4">not BARI 2D failed to identify any significant difference in</text>
<text top="1040" left="59" width="360" height="16" font="4">mortality rate after CABG versus PCI for patients with</text>
<text top="1058" left="59" width="116" height="16" font="4">diabetes mellitus <a href="e44.full.html#111">(</a></text>
<text top="1058" left="175" width="30" height="16" font="16"><a href="e44.full.html#111">1079</a></text>
<text top="1058" left="205" width="214" height="16" font="4"><a href="e44.full.html#111">). </a>In a more recent, collaborative</text>
<text top="1076" left="59" width="360" height="16" font="4">analysis that pooled patient-level data from 10 randomized</text>
<text top="1094" left="59" width="360" height="16" font="4">trials (again, not including BARI 2D), Hlatky and col-</text>
<text top="104" left="446" width="360" height="16" font="4">leagues found that of the 1,233 patients with diabetes</text>
<text top="122" left="446" width="360" height="16" font="4">mellitus, 23% of those assigned to CABG died, compared</text>
<text top="141" left="446" width="226" height="16" font="4">with 29% of those assigned to PCI <a href="e44.full.html#111">(</a></text>
<text top="141" left="671" width="30" height="16" font="16"><a href="e44.full.html#111">1080</a></text>
<text top="141" left="701" width="104" height="16" font="4"><a href="e44.full.html#111">). </a>By contrast, of</text>
<text top="159" left="446" width="360" height="16" font="4">the 6,561 patients without diabetes mellitus, 13% and 14%</text>
<text top="177" left="446" width="119" height="16" font="4">died, respectively (p</text>
<text top="173" left="564" width="241" height="20" font="4">⫽0.014 for interaction). The interaction</text>
<text top="195" left="446" width="360" height="16" font="4">between diabetes mellitus and treatment remained highly</text>
<text top="213" left="446" width="360" height="16" font="4">significant after adjustment for multiple patient character-</text>
<text top="231" left="446" width="360" height="16" font="4">istics and after exclusion of patients enrolled in the BARI</text>
<text top="249" left="446" width="53" height="16" font="4">2D trial.</text>
<text top="267" left="461" width="345" height="16" font="4">Some evidence indicates that the presence of diabetes</text>
<text top="285" left="446" width="360" height="16" font="4">mellitus adversely affects the outcomes of revascularization.</text>
<text top="303" left="446" width="360" height="16" font="4">An analysis of the 2009 data on 7,812 patients (1,233 with</text>
<text top="321" left="446" width="360" height="16" font="4">diabetes mellitus) in 10 RCTs demonstrated a worse long-</text>
<text top="339" left="446" width="360" height="16" font="4">term survival rate in patients with diabetes mellitus after</text>
<text top="357" left="446" width="360" height="16" font="4">balloon angioplasty or BMS implantation than after CABG</text>
<text top="375" left="446" width="5" height="16" font="4"><a href="e44.full.html#111">(</a></text>
<text top="375" left="450" width="30" height="16" font="16"><a href="e44.full.html#111">1080</a></text>
<text top="375" left="480" width="325" height="16" font="4"><a href="e44.full.html#111">). </a>Analyses from 3 registries found significantly ele-</text>
<text top="393" left="446" width="360" height="16" font="4">vated adjusted ORs for short-term mortality after PCI that</text>
<text top="411" left="446" width="360" height="16" font="4">ranged from 1.25 to 1.54 in relation to patients without</text>
<text top="429" left="446" width="117" height="16" font="4">diabetes mellitus <a href="e44.full.html#113">(</a></text>
<text top="429" left="563" width="98" height="16" font="16"><a href="e44.full.html#113">1144,1146,1165</a></text>
<text top="429" left="660" width="145" height="16" font="4"><a href="e44.full.html#113">). </a>Data from the STS</text>
<text top="447" left="446" width="360" height="16" font="4">registry indicated that patients with diabetes mellitus on oral</text>
<text top="465" left="446" width="360" height="16" font="4">therapy had an adjusted OR of 1.15 for death within 30 days</text>
<text top="483" left="446" width="360" height="16" font="4">(95% CI: 1.09 to 1.21), as well as significantly higher odds</text>
<text top="501" left="446" width="360" height="16" font="4">of stroke, renal failure, or sternal wound infection than those</text>
<text top="519" left="446" width="226" height="16" font="4">of patients without diabetes mellitus <a href="e44.full.html#113">(</a></text>
<text top="519" left="672" width="30" height="16" font="16"><a href="e44.full.html#113">1167</a></text>
<text top="519" left="702" width="104" height="16" font="4"><a href="e44.full.html#113">). </a>For patients on</text>
<text top="537" left="446" width="360" height="16" font="4">insulin, the adjusted OR for death within 30 days was 1.50</text>
<text top="555" left="446" width="360" height="16" font="4">(95% CI: 1.42 to 1.58), and the risks for other complications</text>
<text top="573" left="446" width="205" height="16" font="4">were also correspondingly higher.</text>
<text top="591" left="461" width="345" height="16" font="4">In summary, in subjects requiring revascularization for</text>
<text top="609" left="446" width="360" height="16" font="4">multivessel CAD, current evidence supports diabetes mel-</text>
<text top="627" left="446" width="360" height="16" font="4">litus as an important factor to consider when deciding on a</text>
<text top="645" left="446" width="360" height="16" font="4">revascularization strategy, particularly when complex or</text>
<text top="663" left="446" width="167" height="16" font="4">extensive CAD is present <a href="e44.full.html#75">(</a></text>
<text top="663" left="612" width="59" height="16" font="16"><a href="e44.full.html#75">Figure 14</a></text>
<text top="663" left="672" width="9" height="16" font="4"><a href="e44.full.html#75">).</a></text>
<text top="681" left="461" width="345" height="16" font="4">The basis of the currently available data, an intensive</text>
<text top="699" left="446" width="360" height="16" font="4">approach to reducing cardiovascular risk and symptoms in</text>
<text top="717" left="446" width="360" height="16" font="4">patients with diabetes mellitus by using GDMT should be</text>
<text top="735" left="446" width="360" height="16" font="4">the initial approach. For patients whose symptoms are</text>
<text top="753" left="446" width="360" height="16" font="4">inadequately managed or who experience intolerable adverse</text>
<text top="772" left="446" width="360" height="16" font="4">effects, revascularization should be considered. CABG</text>
<text top="790" left="446" width="360" height="16" font="4">might be associated with lower risk of mortality in patients</text>
<text top="808" left="446" width="360" height="16" font="4">with diabetes mellitus and multivessel disease than PCI, but</text>
<text top="826" left="446" width="360" height="16" font="4">this remains uncertain. The ongoing FREEDOM (Future</text>
<text top="844" left="446" width="360" height="16" font="4">Revascularization Evaluation in patients with Diabetes mel-</text>
<text top="862" left="446" width="360" height="16" font="4">litus: Optimal management of Multivessel disease) trial</text>
<text top="880" left="446" width="203" height="16" font="4">could help resolve this question <a href="e44.full.html#114">(</a></text>
<text top="880" left="649" width="30" height="16" font="16"><a href="e44.full.html#114">1177</a></text>
<text top="880" left="679" width="9" height="16" font="4"><a href="e44.full.html#114">).</a></text>
<text top="907" left="446" width="100" height="16" font="26"><b>5.12.4. Obesity</b></text>
<text top="932" left="446" width="360" height="16" font="4">Obese individuals frequently have reduced physical work</text>
<text top="950" left="446" width="360" height="16" font="4">capacity and exaggerated dyspnea on exertion. Furthermore,</text>
<text top="968" left="446" width="360" height="16" font="4">weight limits of exercise and imaging equipment preclude</text>
<text top="986" left="446" width="136" height="16" font="4">testing the very obese <a href="e44.full.html#114">(</a></text>
<text top="986" left="582" width="64" height="16" font="16"><a href="e44.full.html#114">1178,1179</a></text>
<text top="986" left="646" width="160" height="16" font="4"><a href="e44.full.html#114">). </a>Because of limitations in</text>
<text top="1004" left="446" width="360" height="16" font="4">exercise testing and challenges with imaging through in-</text>
<text top="1022" left="446" width="360" height="16" font="4">creased breast tissue or chest girth, reduced diagnostic</text>
<text top="1040" left="446" width="273" height="16" font="4">accuracy has been reported for obese patients <a href="e44.full.html#114">(</a></text>
<text top="1040" left="719" width="29" height="16" font="16"><a href="e44.full.html#114">1180</a></text>
<text top="1040" left="747" width="58" height="16" font="4"><a href="e44.full.html#114">). </a>Because</text>
<text top="1058" left="446" width="360" height="16" font="4">of breast tissue artifact, myocardial perfusion PET is more</text>
<text top="1076" left="446" width="360" height="16" font="4">accurate than myocardial perfusion SPECT for the obese</text>
<text top="1094" left="446" width="51" height="16" font="4">patient <a href="e44.full.html#90">(</a></text>
<text top="1094" left="497" width="72" height="16" font="16"><a href="e44.full.html#90">191,193,323</a></text>
<text top="1094" left="568" width="237" height="16" font="4"><a href="e44.full.html#90">), </a>although attenuation-correction algo-</text>
<text top="52" left="781" width="25" height="10" font="12">e117</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="75" position="absolute" top="0" left="0" height="1161" width="864">
<text top="376" left="59" width="360" height="16" font="4">rithms or prone imaging can help improve myocardial perfu-</text>
<text top="394" left="59" width="148" height="16" font="4">sion SPECT accuracy <a href="e44.full.html#90">(</a></text>
<text top="394" left="207" width="47" height="16" font="16"><a href="e44.full.html#90">187,188</a></text>
<text top="394" left="253" width="165" height="16" font="4"><a href="e44.full.html#90">). </a>Intravenous contrast en-</text>
<text top="412" left="59" width="360" height="16" font="4">hancement improves image quality in obese patients and</text>
<text top="430" left="59" width="360" height="16" font="4">results in improved diagnostic certainty for stress echocardiog-</text>
<text top="448" left="59" width="42" height="16" font="4">raphy <a href="e44.full.html#90">(</a></text>
<text top="448" left="100" width="22" height="16" font="16"><a href="e44.full.html#90">181</a></text>
<text top="448" left="122" width="8" height="16" font="4"><a href="e44.full.html#90">).</a></text>
<text top="475" left="59" width="207" height="16" font="26"><b>5.12.5. Chronic Kidney Disease</b></text>
<text top="500" left="59" width="360" height="16" font="4">CKD confers greater risk for developing SIHD, for its</text>
<text top="518" left="59" width="360" height="16" font="4">progression, and for poor outcomes after interventions for</text>
<text top="536" left="59" width="46" height="16" font="4">AMI <a href="e44.full.html#114">(</a></text>
<text top="536" left="104" width="68" height="16" font="16"><a href="e44.full.html#114">1181–1183</a></text>
<text top="536" left="172" width="247" height="16" font="4"><a href="e44.full.html#114">). </a>The mortality rate for patients on</text>
<text top="554" left="59" width="92" height="16" font="4">hemodialysis is</text>
<text top="551" left="156" width="263" height="20" font="4">⬎20% per year, and approximately 50% of</text>
<text top="572" left="59" width="360" height="16" font="4">deaths among these patients are due to a cardiovascular</text>
<text top="590" left="59" width="45" height="16" font="4">cause <a href="e44.full.html#86">(</a></text>
<text top="590" left="103" width="49" height="16" font="16"><a href="e44.full.html#86">27,1184</a></text>
<text top="590" left="152" width="266" height="16" font="4"><a href="e44.full.html#86">). </a>To avoid worsening underlying kidney</text>
<text top="608" left="59" width="360" height="16" font="4">disease, physicians should consider creatinine clearance in</text>
<text top="626" left="59" width="360" height="16" font="4">pharmacotherapy and should apply risk scores for predicting</text>
<text top="644" left="59" width="291" height="16" font="4">the likelihood of contrast-induced nephropathy <a href="e44.full.html#113">(</a></text>
<text top="644" left="350" width="64" height="16" font="16"><a href="e44.full.html#113">1161,1185</a></text>
<text top="644" left="414" width="5" height="16" font="4"><a href="e44.full.html#113">)</a></text>
<text top="662" left="59" width="360" height="16" font="4">in conjunction with the use of renal protective strategies</text>
<text top="680" left="59" width="360" height="16" font="4">such as isosmolar contrast agents during angiography</text>
<text top="698" left="59" width="5" height="16" font="4"><a href="e44.full.html#85">(</a></text>
<text top="698" left="63" width="37" height="16" font="16"><a href="e44.full.html#85">3,4,4a</a></text>
<text top="698" left="100" width="9" height="16" font="4"><a href="e44.full.html#85">).</a></text>
<text top="716" left="74" width="345" height="16" font="4">Unfortunately, studies evaluating the outcomes of revas-</text>
<text top="734" left="59" width="360" height="16" font="4">cularization in patients with renal disease have not applied a</text>
<text top="752" left="59" width="360" height="16" font="4">consistent definition of renal disease. Only one study iden-</text>
<text top="770" left="59" width="360" height="16" font="4">tified by the writing committee used the Kidney Disease</text>
<text top="788" left="59" width="360" height="16" font="4">Outcome Quality Definition of renal disease grades: Stage</text>
<text top="806" left="59" width="360" height="16" font="4">1, creatinine clearance of 90 to 120 mL/min; Stage 2, 60 to</text>
<text top="824" left="59" width="360" height="16" font="4">89 mL/min; Stage 3, 30 to 59 mL/min; Stage 4, 15 to 29</text>
<text top="842" left="59" width="142" height="16" font="4">mL/min; and Stage 5,</text>
<text top="839" left="207" width="211" height="20" font="4">⬍15 mL/min or ongoing dialysis</text>
<text top="860" left="59" width="5" height="16" font="4"><a href="e44.full.html#114">(</a></text>
<text top="860" left="63" width="30" height="16" font="16"><a href="e44.full.html#114">1186</a></text>
<text top="860" left="93" width="325" height="16" font="4"><a href="e44.full.html#114">). </a>Others studies simply described patients as receiving</text>
<text top="878" left="59" width="54" height="16" font="4">dialysis <a href="e44.full.html#114">(</a></text>
<text top="878" left="112" width="64" height="16" font="16"><a href="e44.full.html#114">1187,1188</a></text>
<text top="878" left="176" width="243" height="16" font="4"><a href="e44.full.html#114">) </a>or defined renal disease as any creati-</text>
<text top="896" left="59" width="89" height="16" font="4">nine clearance</text>
<text top="893" left="156" width="100" height="20" font="4">⬍60 mL/min <a href="e44.full.html#114">(</a></text>
<text top="896" left="256" width="64" height="16" font="16"><a href="e44.full.html#114">1189,1190</a></text>
<text top="896" left="319" width="99" height="16" font="4"><a href="e44.full.html#114">) </a>or any serum</text>
<text top="914" left="59" width="288" height="16" font="4">creatinine above approximately 2.3 mg/dL <a href="e44.full.html#114">(</a></text>
<text top="914" left="346" width="64" height="16" font="16"><a href="e44.full.html#114">1191,1192</a></text>
<text top="914" left="410" width="9" height="16" font="4"><a href="e44.full.html#114">).</a></text>
<text top="932" left="59" width="360" height="16" font="4">Ongoing studies are beginning to use the AKIN (Acute</text>
<text top="950" left="59" width="360" height="16" font="4">Kidney Injury Network) or RIFLE (Risk, Injury, Failure,</text>
<text top="968" left="59" width="360" height="16" font="4">Loss, and End-stage) criteria and should ensure more</text>
<text top="986" left="59" width="360" height="16" font="4">consistency in the study of periprocedural complications of</text>
<text top="1004" left="59" width="188" height="16" font="4">percutaneous revascularization.</text>
<text top="1022" left="74" width="345" height="16" font="4">Among patients who were enrolled in the COURAGE</text>
<text top="1040" left="59" width="360" height="16" font="4">trial, the presence of CKD was associated with odds of 1.48</text>
<text top="1058" left="59" width="360" height="16" font="4">for death, MI, or new heart failure relative to patients</text>
<text top="1076" left="59" width="151" height="16" font="4">without kidney disease <a href="e44.full.html#114">(</a></text>
<text top="1076" left="210" width="30" height="16" font="16"><a href="e44.full.html#114">1193</a></text>
<text top="1076" left="240" width="179" height="16" font="4"><a href="e44.full.html#114">). </a>Medical therapy, however,</text>
<text top="1094" left="59" width="360" height="16" font="4">was effective and associated with the same BP and lipid</text>
<text top="376" left="446" width="360" height="16" font="4">levels as in patients without CKD. Patients with CKD also</text>
<text top="394" left="446" width="360" height="16" font="4">experience significant and sustained improvement in angina</text>
<text top="412" left="446" width="360" height="16" font="4">with both PCI and GDMT, and there was no significant</text>
<text top="430" left="446" width="360" height="16" font="4">interaction between the presence of CKD and treatment</text>
<text top="448" left="446" width="360" height="16" font="4">assignment in survival rate, incidence of AMI, or improve-</text>
<text top="466" left="446" width="118" height="16" font="4">ment in symptoms.</text>
<text top="484" left="461" width="345" height="16" font="4">To date, randomized comparisons of coronary revascu-</text>
<text top="502" left="446" width="360" height="16" font="4">larization (with CABG or PCI) and medical therapy in</text>
<text top="520" left="446" width="360" height="16" font="4">patients with CKD have not been reported. Some, but not</text>
<text top="538" left="446" width="360" height="16" font="4">all, observational studies or subgroup analyses have demon-</text>
<text top="556" left="446" width="360" height="16" font="4">strated an improved survival rate with revascularization</text>
<text top="574" left="446" width="360" height="16" font="4">compared with medical therapy in patients with CKD and</text>
<text top="592" left="446" width="119" height="16" font="4">multivessel CAD <a href="e44.full.html#114">(</a></text>
<text top="592" left="565" width="98" height="16" font="16"><a href="e44.full.html#114">1191,1193,1194</a></text>
<text top="592" left="662" width="143" height="16" font="4"><a href="e44.full.html#114">), </a>despite the fact that</text>
<text top="610" left="446" width="360" height="16" font="4">the incidence of periprocedural complications (e.g., death,</text>
<text top="628" left="446" width="360" height="16" font="4">MI, stroke, infection, renal failure) is higher in patients with</text>
<text top="646" left="446" width="360" height="16" font="4">CKD than in those without renal dysfunction. In 2 cohort</text>
<text top="664" left="446" width="360" height="16" font="4">studies involving patients with a spectrum of kidney disease</text>
<text top="682" left="446" width="360" height="16" font="4">ranging from mild to severe, adjusted survival was superior</text>
<text top="700" left="446" width="360" height="16" font="4">for those who underwent bypass surgery compared with</text>
<text top="718" left="446" width="257" height="16" font="4">those who received only medical therapy <a href="e44.full.html#114">(</a></text>
<text top="718" left="703" width="64" height="16" font="16"><a href="e44.full.html#114">1191,1194</a></text>
<text top="718" left="766" width="39" height="16" font="4"><a href="e44.full.html#114">). </a>In 1</text>
<text top="736" left="446" width="360" height="16" font="4">study, survival after PCI was improved (compared with</text>
<text top="754" left="446" width="360" height="16" font="4">medical therapy) in patients with mild, moderate, or severe</text>
<text top="772" left="446" width="360" height="16" font="4">kidney disease but not in those with end-stage kidney</text>
<text top="790" left="446" width="360" height="16" font="4">disease. The other study yielded opposite results, with</text>
<text top="808" left="446" width="360" height="16" font="4">longer survival after PCI in patients with end-stage renal</text>
<text top="826" left="446" width="360" height="16" font="4">disease but <i>not </i>in those with mild, moderate, or severe</text>
<text top="844" left="446" width="91" height="16" font="4">kidney disease.</text>
<text top="862" left="461" width="345" height="16" font="4">Some studies have shown that CABG is associated with</text>
<text top="880" left="446" width="360" height="16" font="4">a greater survival benefit than PCI among patients with</text>
<text top="898" left="446" width="166" height="16" font="4">severe renal dysfunction <a href="e44.full.html#114">(</a></text>
<text top="898" left="612" width="101" height="16" font="16"><a href="e44.full.html#114">1187–1192,1194</a></text>
<text top="898" left="713" width="93" height="16" font="4"><a href="e44.full.html#114">). </a>Five studies</text>
<text top="916" left="446" width="360" height="16" font="4">have suggested that survival is prolonged among patients</text>
<text top="934" left="446" width="360" height="16" font="4">with CKD after CABG compared with after PCI</text>
<text top="952" left="446" width="5" height="16" font="4"><a href="e44.full.html#114">(</a></text>
<text top="952" left="450" width="165" height="16" font="16"><a href="e44.full.html#114">1187,1188,1191,1192,1194</a></text>
<text top="952" left="616" width="190" height="16" font="4"><a href="e44.full.html#114">), </a>whereas 3 other studies indi-</text>
<text top="970" left="446" width="360" height="16" font="4">cated that survival is similar after either of the 2 revascular-</text>
<text top="988" left="446" width="360" height="16" font="4">ization strategies, regardless of the severity of underlying</text>
<text top="1006" left="446" width="86" height="16" font="4">renal disease <a href="e44.full.html#114">(</a></text>
<text top="1006" left="532" width="98" height="16" font="16"><a href="e44.full.html#114">1189,1190,1192</a></text>
<text top="1006" left="629" width="9" height="16" font="4"><a href="e44.full.html#114">).</a></text>
<text top="1033" left="446" width="217" height="16" font="26"><b>5.12.6. HIV Infection and SIHD</b></text>
<text top="1058" left="446" width="360" height="16" font="4">HIV infection appears to be associated with an increased</text>
<text top="1076" left="446" width="360" height="16" font="4">risk of premature coronary and cerebrovascular atheroscle-</text>
<text top="1094" left="446" width="360" height="16" font="4">rosis, which is often accelerated, diffuse, and circumferen-</text>
<text top="269" left="59" width="665" height="11" font="13">Figure 14. One-Year Mortality Rates in Randomized Trials of Patients With Diabetes and Multivessel CAD, Comparing PCI</text>
<text top="285" left="59" width="196" height="10" font="13">(Experimental) With CABG (Control)</text>
<text top="317" left="59" width="26" height="8" font="11">An OR</text>
<text top="314" left="88" width="456" height="13" font="11">⬎1 suggests an advantage of CABG over PCI. ARTS1 indicates Arterial Revascularization Therapy Study I <a href="e44.full.html#110">(</a></text>
<text top="317" left="545" width="23" height="8" font="23"><a href="e44.full.html#110">1033</a></text>
<text top="317" left="568" width="234" height="8" font="11"><a href="e44.full.html#110">); </a>BARI I, Bypass Angioplasty Revascularization Investi-</text>
<text top="330" left="59" width="38" height="8" font="11">gation I <a href="e44.full.html#109">(</a></text>
<text top="330" left="97" width="23" height="8" font="23"><a href="e44.full.html#109">1005</a></text>
<text top="330" left="120" width="248" height="8" font="11"><a href="e44.full.html#109">); </a>CARDia, Coronary Artery Revascularization in Diabetes <a href="e44.full.html#114">(</a></text>
<text top="330" left="368" width="23" height="8" font="23"><a href="e44.full.html#114">1176</a></text>
<text top="330" left="391" width="393" height="8" font="11"><a href="e44.full.html#114">); </a>CI, confidence interval; DM, diabetes mellitus; MASS II, Medicine, Angioplasty, or Surgery</text>
<text top="344" left="59" width="38" height="8" font="11">Study II <a href="e44.full.html#109">(</a></text>
<text top="344" left="97" width="23" height="8" font="23"><a href="e44.full.html#109">1008</a></text>
<text top="344" left="120" width="569" height="8" font="11"><a href="e44.full.html#109">); </a>OR, odds ratio; SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and W, weighted <a href="e44.full.html#109">(</a></text>
<text top="344" left="689" width="23" height="8" font="23"><a href="e44.full.html#109">1006</a></text>
<text top="344" left="712" width="6" height="8" font="11"><a href="e44.full.html#109">).</a></text>
<text top="52" left="59" width="25" height="10" font="12">e118</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="76" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="180" height="16" font="4">tial, involving whole arteries <a href="e44.full.html#114">(</a></text>
<text top="104" left="238" width="64" height="16" font="16"><a href="e44.full.html#114">1195,1196</a></text>
<text top="104" left="302" width="117" height="16" font="4"><a href="e44.full.html#114">). </a>AMI is often the</text>
<text top="123" left="59" width="131" height="16" font="4">initial manifestation <a href="e44.full.html#114">(</a></text>
<text top="123" left="189" width="30" height="16" font="16"><a href="e44.full.html#114">1197</a></text>
<text top="123" left="219" width="199" height="16" font="4"><a href="e44.full.html#114">). </a>The etiology is likely multifac-</text>
<text top="141" left="59" width="360" height="16" font="4">torial and related to both the underlying infection and</text>
<text top="159" left="59" width="360" height="16" font="4">antiretroviral therapy. The former appears to promote</text>
<text top="177" left="59" width="360" height="16" font="4">proliferation of smooth muscle cells and elastin leading to</text>
<text top="195" left="59" width="360" height="16" font="4">luminal obstruction, although there is poor correlation</text>
<text top="213" left="59" width="360" height="16" font="4">between CD4 cell counts and severity of CAD. Of the</text>
<text top="231" left="59" width="360" height="16" font="4">therapeutic agents used to treat HIV infection, protease</text>
<text top="249" left="59" width="360" height="16" font="4">inhibitors in particular have been epidemiologically linked</text>
<text top="267" left="59" width="250" height="16" font="4">to dyslipidemia and insulin resistance <a href="e44.full.html#114">(</a></text>
<text top="267" left="308" width="69" height="16" font="16"><a href="e44.full.html#114">1198 –1200</a></text>
<text top="267" left="378" width="41" height="16" font="4"><a href="e44.full.html#114">). </a>The</text>
<text top="285" left="59" width="360" height="16" font="4">protease inhibitors amprenavir/fosamprenavir with or with-</text>
<text top="303" left="59" width="360" height="16" font="4">out ritonavir and lopinavir with ritonavir have the strongest</text>
<text top="321" left="59" width="360" height="16" font="4">association with risk of AMI, although saquinavir and</text>
<text top="339" left="59" width="360" height="16" font="4">nelfinavir do not appear to be associated with MI</text>
<text top="357" left="59" width="5" height="16" font="4"><a href="e44.full.html#114">(</a></text>
<text top="357" left="63" width="64" height="16" font="16"><a href="e44.full.html#114">1201,1202</a></text>
<text top="357" left="127" width="291" height="16" font="4"><a href="e44.full.html#114">). </a>The nucleoside reverse-transcriptase inhibitors</text>
<text top="375" left="59" width="360" height="16" font="4">didanosine and abacavir also are associated with risk of AMI</text>
<text top="393" left="59" width="5" height="16" font="4"><a href="e44.full.html#114">(</a></text>
<text top="393" left="64" width="30" height="16" font="16"><a href="e44.full.html#114">1202</a></text>
<text top="393" left="94" width="324" height="16" font="4"><a href="e44.full.html#114">). </a>Other agents, such as nonnucleoside reverse-</text>
<text top="411" left="59" width="360" height="16" font="4">transcriptase inhibitors (nevirapine and efavirenz), entry</text>
<text top="430" left="59" width="360" height="16" font="4">inhibitors, and integrase inhibitors, do not appear to be</text>
<text top="448" left="59" width="256" height="16" font="4">associated with an increased risk of IHD.</text>
<text top="466" left="74" width="345" height="16" font="4">Despite the increase in prevalence of IHD among pa-</text>
<text top="484" left="59" width="360" height="16" font="4">tients with HIV, the absolute increase in incidence of AMI</text>
<text top="502" left="59" width="360" height="16" font="4">is relatively low, and overall mortality does not appear to be</text>
<text top="520" left="59" width="69" height="16" font="4">increased <a href="e44.full.html#114">(</a></text>
<text top="520" left="127" width="64" height="16" font="16"><a href="e44.full.html#114">1198,1203</a></text>
<text top="520" left="191" width="227" height="16" font="4"><a href="e44.full.html#114">). </a>It is likely that this reflects the</text>
<text top="538" left="59" width="360" height="16" font="4">otherwise enormous benefit conferred by treatment with</text>
<text top="556" left="59" width="360" height="16" font="4">highly active antiretroviral therapy in the course of HIV</text>
<text top="574" left="59" width="360" height="16" font="4">infection. Nonetheless, patients receiving highly active an-</text>
<text top="592" left="59" width="360" height="16" font="4">tiretroviral therapy should be assessed for cardiovascular risk</text>
<text top="610" left="59" width="360" height="16" font="4">factors and monitored for signs and symptoms of IHD. It is</text>
<text top="628" left="59" width="360" height="16" font="4">prudent to recommend a healthy diet, regular physical</text>
<text top="646" left="59" width="360" height="16" font="4">activity, and avoidance of smoking. Patients with hypercho-</text>
<text top="664" left="59" width="360" height="16" font="4">lesterolemia should be managed in a fashion similar to other</text>
<text top="682" left="59" width="158" height="16" font="4">patients at risk for IHD <a href="e44.full.html#114">(</a></text>
<text top="682" left="217" width="30" height="16" font="16"><a href="e44.full.html#114">1204</a></text>
<text top="682" left="247" width="9" height="16" font="4"><a href="e44.full.html#114">).</a></text>
<text top="709" left="59" width="202" height="16" font="26"><b>5.12.7. Autoimmune Disorders</b></text>
<text top="735" left="59" width="360" height="16" font="4">Connective tissue disease represents a less well-studied issue</text>
<text top="753" left="59" width="360" height="16" font="4">in SIHD. In rheumatoid arthritis, findings from at least one</text>
<text top="771" left="59" width="360" height="16" font="4">study show increased inflammation in the coronary artery</text>
<text top="789" left="59" width="360" height="16" font="4">walls, with increased frequency of vulnerable plaques</text>
<text top="807" left="59" width="5" height="16" font="4"><a href="e44.full.html#114">(</a></text>
<text top="807" left="63" width="30" height="16" font="16"><a href="e44.full.html#114">1205</a></text>
<text top="807" left="93" width="325" height="16" font="4"><a href="e44.full.html#114">). </a>Accelerated atherosclerosis in systemic lupus ery-</text>
<text top="825" left="59" width="360" height="16" font="4">thematosis, due to impaired endothelial function and novel</text>
<text top="843" left="59" width="360" height="16" font="4">atherogenic and thrombotic risk factors, requires special</text>
<text top="861" left="59" width="360" height="16" font="4">attention inasmuch as the adjusted rate of SIHD in systemic</text>
<text top="879" left="59" width="139" height="16" font="4">lupus erythematosis is</text>
<text top="876" left="205" width="213" height="20" font="4">ⱖ50-fold higher than in patients</text>
<text top="897" left="59" width="78" height="16" font="4">without it <a href="e44.full.html#114">(</a></text>
<text top="897" left="137" width="64" height="16" font="16"><a href="e44.full.html#114">1206,1207</a></text>
<text top="897" left="201" width="218" height="16" font="4"><a href="e44.full.html#114">). </a>A younger population is more</text>
<text top="915" left="59" width="321" height="16" font="4">frequently affected in systemic lupus erythematosis <a href="e44.full.html#114">(</a></text>
<text top="915" left="380" width="30" height="16" font="16"><a href="e44.full.html#114">1208</a></text>
<text top="915" left="410" width="9" height="16" font="4"><a href="e44.full.html#114">),</a></text>
<text top="933" left="59" width="360" height="16" font="4">and coronary artery spasm is a frequent complication in</text>
<text top="951" left="59" width="159" height="16" font="4">connective tissue disease <a href="e44.full.html#115">(</a></text>
<text top="951" left="217" width="30" height="16" font="16"><a href="e44.full.html#115">1209</a></text>
<text top="951" left="247" width="9" height="16" font="4"><a href="e44.full.html#115">).</a></text>
<text top="978" left="59" width="198" height="16" font="26"><b>5.12.8. Socioeconomic Factors</b></text>
<text top="1004" left="59" width="360" height="16" font="4">Low socioeconomic status is highly associated with the risk</text>
<text top="1022" left="59" width="157" height="16" font="4">of cardiovascular disease <a href="e44.full.html#115">(</a></text>
<text top="1022" left="215" width="30" height="16" font="16"><a href="e44.full.html#115">1210</a></text>
<text top="1022" left="245" width="173" height="16" font="4"><a href="e44.full.html#115">). </a>Men 30 to 59 years of age</text>
<text top="1040" left="59" width="360" height="16" font="4">with low socioeconomic status are at 55% higher risk of</text>
<text top="1058" left="59" width="360" height="16" font="4">death due to IHD than are those of higher status (RR: 1.55;</text>
<text top="1076" left="59" width="220" height="16" font="4">95% CI: 1.51 to 1.60), and the risk is</text>
<text top="1073" left="282" width="137" height="20" font="4">⬎2-fold higher among</text>
<text top="1094" left="59" width="266" height="16" font="4">women (RR: 2.13; 95% CI: 1.98 to 2.29) <a href="e44.full.html#115">(</a></text>
<text top="1094" left="324" width="30" height="16" font="16"><a href="e44.full.html#115">1211</a></text>
<text top="1094" left="354" width="9" height="16" font="4"><a href="e44.full.html#115">).</a></text>
<text top="104" left="461" width="345" height="16" font="4">In addition to lower socioeconomic status being associ-</text>
<text top="123" left="446" width="360" height="16" font="4">ated with a higher prevalence of IHD, it has been amply</text>
<text top="141" left="446" width="360" height="16" font="4">demonstrated that patients of lower socioeconomic status</text>
<text top="160" left="446" width="360" height="16" font="4">and those who are members of an ethnic or racial minority</text>
<text top="179" left="446" width="360" height="16" font="4">(in particular African Americans and Hispanics) are less</text>
<text top="197" left="446" width="360" height="16" font="4">likely to receive a wide variety of diagnostic and therapeutic</text>
<text top="216" left="446" width="360" height="16" font="4">interventions. These disparities have been observed with</text>
<text top="235" left="446" width="360" height="16" font="4">regard to cardiac procedures as well as access to cardiologists</text>
<text top="253" left="446" width="5" height="16" font="4"><a href="e44.full.html#115">(</a></text>
<text top="253" left="450" width="30" height="16" font="16"><a href="e44.full.html#115">1212</a></text>
<text top="253" left="480" width="325" height="16" font="4"><a href="e44.full.html#115">). </a>Moreover, African Americans and Hispanics are</text>
<text top="272" left="446" width="360" height="16" font="4">10% to 40% less likely to receive outpatient secondary</text>
<text top="291" left="446" width="295" height="16" font="4">prevention therapies for cardiovascular disease <a href="e44.full.html#115">(</a></text>
<text top="291" left="740" width="30" height="16" font="16"><a href="e44.full.html#115">1213</a></text>
<text top="291" left="770" width="35" height="16" font="4"><a href="e44.full.html#115">). </a>Al-</text>
<text top="310" left="446" width="360" height="16" font="4">though lower rates of diagnostic and interventional services</text>
<text top="328" left="446" width="227" height="16" font="4">have not been adequately explained <a href="e44.full.html#115">(</a></text>
<text top="328" left="672" width="64" height="16" font="16"><a href="e44.full.html#115">1214,1215</a></text>
<text top="328" left="736" width="70" height="16" font="4"><a href="e44.full.html#115">), </a>it is clear</text>
<text top="347" left="446" width="360" height="16" font="4">that individuals of lower socioeconomic status and ethnic</text>
<text top="366" left="446" width="360" height="16" font="4">minorities typically have fewer healthcare resources, have</text>
<text top="384" left="446" width="360" height="16" font="4">worse general health and cardiac risk profiles, and are less</text>
<text top="403" left="446" width="360" height="16" font="4">knowledgeable about SIHD symptoms. Healthcare provid-</text>
<text top="422" left="446" width="360" height="16" font="4">ers and systems should strive to eliminate or ameliorate</text>
<text top="440" left="446" width="360" height="16" font="4">barriers to care for patients who have SIHD and are of low</text>
<text top="459" left="446" width="250" height="16" font="4">socioeconomic class or ethnic minorities.</text>
<text top="487" left="446" width="181" height="16" font="26"><b>5.12.9. Special Occupations</b></text>
<text top="513" left="446" width="360" height="16" font="4">Although not recommended for the general population,</text>
<text top="531" left="446" width="360" height="16" font="4">routine surveillance with functional testing is recommended</text>
<text top="550" left="446" width="360" height="16" font="4">in a few occupations in which the presence of even asymp-</text>
<text top="569" left="446" width="360" height="16" font="4">tomatic cardiac disease could endanger others, such as</text>
<text top="587" left="446" width="360" height="16" font="4">commercial pilots, police, firefighters, and bus drivers. The</text>
<text top="606" left="446" width="360" height="16" font="4">general parameters of test performance noted above apply in</text>
<text top="625" left="446" width="360" height="16" font="4">these circumstances, with the caveat that most of these</text>
<text top="643" left="446" width="360" height="16" font="4">individuals are at low risk and therefore could be more likely</text>
<text top="662" left="446" width="175" height="16" font="4">to have false positive results.</text>
<text top="700" left="446" width="281" height="14" font="15">6. Patient Follow-Up: Monitoring of</text>
<text top="720" left="446" width="280" height="14" font="15">Symptoms and Antianginal Therapy</text>
<text top="764" left="446" width="360" height="16" font="4">The goals of clinical follow-up of patients with SIHD are to</text>
<text top="782" left="446" width="360" height="16" font="4">maximize function and to minimize long-term mortality</text>
<text top="801" left="446" width="360" height="16" font="4">and morbidity. In this context, the primary goal of</text>
<text top="820" left="446" width="360" height="16" font="4">follow-up testing should be to reassess residual or new</text>
<text top="838" left="446" width="360" height="16" font="4">ischemic burden in the setting of persistent or worsening</text>
<text top="857" left="446" width="360" height="16" font="4">(but not unstable) symptoms. Thus, follow-up assessment</text>
<text top="876" left="446" width="360" height="16" font="4">and testing will vary according to the clinical status of the</text>
<text top="894" left="446" width="360" height="16" font="4">patient and with the evolution of evidence-based practice.</text>
<text top="913" left="446" width="360" height="16" font="4">Unnecessary testing should be avoided. For patients with</text>
<text top="932" left="446" width="360" height="16" font="4">SIHD who show no change in symptoms or functional</text>
<text top="950" left="446" width="326" height="16" font="4">capacity, periodic follow-up serves multiple purposes:</text>
<text top="979" left="461" width="345" height="20" font="4">• Ongoing reassessment of adherence to and effective-</text>
<text top="1001" left="477" width="328" height="16" font="4">ness of the therapeutic regimen, including clinical</text>
<text top="1020" left="477" width="328" height="16" font="4">response, occurrence of adverse effects, and treatment</text>
<text top="1038" left="477" width="328" height="16" font="4">goals, on the basis of evolving scientific evidence and</text>
<text top="1057" left="477" width="160" height="16" font="4">preferences of the patient.</text>
<text top="1073" left="461" width="345" height="20" font="4">• Evaluation of the effectiveness of interventions to</text>
<text top="1094" left="477" width="314" height="16" font="4">modify risk factors such as exertional hypertension.</text>
<text top="52" left="781" width="25" height="10" font="12">e119</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="77" position="absolute" top="0" left="0" height="1161" width="864">
<text top="101" left="74" width="345" height="20" font="4">• Assessment of the status of coexisting chronic medical</text>
<text top="122" left="89" width="330" height="16" font="4">conditions that could directly or indirectly affect the</text>
<text top="140" left="89" width="243" height="16" font="4">management of stable cardiac ischemia.</text>
<text top="166" left="74" width="345" height="16" font="4">Patients with SIHD who have accelerating symptoms or</text>
<text top="184" left="59" width="360" height="16" font="4">decreasing functional capacity require prompt reassessment.</text>
<text top="202" left="59" width="360" height="16" font="4">Patients with SIHD who develop new ACS should be</text>
<text top="220" left="59" width="360" height="16" font="4">evaluated and treated according to established guidelines</text>
<text top="238" left="59" width="5" height="16" font="4"><a href="e44.full.html#85">(</a></text>
<text top="238" left="63" width="67" height="16" font="16"><a href="e44.full.html#85">3,4,4a,9,10</a></text>
<text top="238" left="130" width="288" height="16" font="4"><a href="e44.full.html#85">). </a>Patients who have been treated for an ACS</text>
<text top="256" left="59" width="360" height="16" font="4">(i.e., AMI or UA) within the previous 6 months and who</text>
<text top="274" left="59" width="360" height="16" font="4">develop chest pain within 30 days of the AMI should be</text>
<text top="292" left="59" width="360" height="16" font="4">evaluated according to the STEMI or UA/NSTEMI guide-</text>
<text top="310" left="59" width="121" height="16" font="4">lines as warranted <a href="e44.full.html#85">(</a></text>
<text top="310" left="180" width="42" height="16" font="16"><a href="e44.full.html#85">2– 4,4a</a></text>
<text top="310" left="222" width="197" height="16" font="4"><a href="e44.full.html#85">). </a>Patients who have undergone</text>
<text top="328" left="59" width="360" height="16" font="4">revascularization with either PCI or CABG within 6</text>
<text top="346" left="59" width="360" height="16" font="4">months should be monitored according to the PCI and</text>
<text top="364" left="59" width="123" height="16" font="4">CABG guidelines <a href="e44.full.html#85">(</a></text>
<text top="364" left="182" width="26" height="16" font="16"><a href="e44.full.html#85">9,10</a></text>
<text top="364" left="208" width="211" height="16" font="4"><a href="e44.full.html#85">). </a>Patients with SIHD should be</text>
<text top="382" left="59" width="360" height="16" font="4">evaluated before elective or emergent surgery according to</text>
<text top="400" left="59" width="225" height="16" font="4">established perioperative guidelines <a href="e44.full.html#85">(</a></text>
<text top="400" left="283" width="55" height="16" font="16"><a href="e44.full.html#85">4,4a,9,10</a></text>
<text top="400" left="338" width="9" height="16" font="4"><a href="e44.full.html#85">).</a></text>
<text top="427" left="59" width="341" height="12" font="18">6.1. Clinical Evaluation, Echocardiography During</text>
<text top="445" left="59" width="325" height="12" font="18">Routine, Periodic Follow-Up: Recommendations</text>
<text top="473" left="59" width="37" height="8" font="24">CLASS I</text>
<text top="486" left="59" width="360" height="10" font="13">1. Patients with SIHD should receive periodic follow-up, at least annu-</text>
<text top="503" left="75" width="308" height="10" font="13">ally, that includes all of the following <i>(Level of Evidence: C)</i>:</text>
<text top="520" left="75" width="261" height="10" font="13">a. Assessment of symptoms and clinical function;</text>
<text top="537" left="75" width="344" height="10" font="13">b. Surveillance for complications of SIHD, including heart failure</text>
<text top="554" left="92" width="88" height="10" font="13">and arrhythmias;</text>
<text top="570" left="76" width="213" height="10" font="13">c. Monitoring of cardiac risk factors; and</text>
<text top="587" left="75" width="344" height="10" font="13">d. Assessment of the adequacy of and adherence to recommended</text>
<text top="604" left="92" width="199" height="10" font="13">lifestyle changes and medical therapy.</text>
<text top="629" left="59" width="360" height="10" font="13">2. Assessment of LVEF and segmental wall motion by echocardiogra-</text>
<text top="646" left="75" width="344" height="10" font="13">phy or radionuclide imaging is recommended in patients with new</text>
<text top="663" left="75" width="344" height="10" font="13">or worsening heart failure or evidence of intervening MI by history or</text>
<text top="680" left="75" width="138" height="10" font="13">ECG. <i>(Level of Evidence: C)</i></text>
<text top="707" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="720" left="59" width="360" height="10" font="13">1. Periodic screening for important comorbidities that are prevalent in</text>
<text top="736" left="74" width="344" height="10" font="13">patients with SIHD, including diabetes mellitus, depression, and</text>
<text top="753" left="74" width="252" height="10" font="13">CKD, might be reasonable. <i>(Level of Evidence: C)</i></text>
<text top="770" left="59" width="360" height="10" font="13">2. A resting 12-lead ECG at 1-year or longer intervals between studies</text>
<text top="787" left="74" width="344" height="10" font="13">in patients with stable symptoms might be reasonable. <i>(Level of</i></text>
<text top="804" left="74" width="63" height="10" font="25"><i>Evidence: C)</i></text>
<text top="831" left="59" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="843" left="59" width="360" height="10" font="13">1. Measurement of LV function with a technology such as echocardi-</text>
<text top="860" left="74" width="344" height="10" font="13">ography or radionuclide imaging is not recommended for routine</text>
<text top="877" left="74" width="344" height="10" font="13">periodic reassessment of patients who have not had a change in</text>
<text top="894" left="74" width="344" height="10" font="13">clinical status or who are at low risk of adverse cardiovascular</text>
<text top="911" left="74" width="183" height="10" font="13">events <a href="e44.full.html#88">(117). </a><i>(Level of Evidence: C)</i></text>
<text top="932" left="59" width="360" height="16" font="4">Standard risk-assessment tools that have been developed</text>
<text top="950" left="59" width="360" height="16" font="4">from clinical and laboratory evaluation of ambulatory pop-</text>
<text top="968" left="59" width="360" height="16" font="4">ulations with suspected CAD, as discussed in detail in</text>
<text top="986" left="59" width="61" height="16" font="16"><a href="e44.full.html#15">Section 2</a></text>
<text top="986" left="128" width="290" height="16" font="4">of this guideline, include patients who have</text>
<text top="1004" left="59" width="360" height="16" font="4">noncardiac causes of presenting symptoms. However, the</text>
<text top="1022" left="59" width="360" height="16" font="4">performance of these same tools in predicting short-term</text>
<text top="1040" left="59" width="360" height="16" font="4">and long-term risk for coronary mortality and coronary</text>
<text top="1058" left="59" width="360" height="16" font="4">events might vary in patients with known SIHD as com-</text>
<text top="1076" left="59" width="360" height="16" font="4">pared with patients without known disease who present</text>
<text top="1094" left="59" width="360" height="16" font="4">with chest pain syndromes that might or might not repre-</text>
<text top="104" left="446" width="360" height="16" font="4">sent angina. Although mortality and morbidity rates intui-</text>
<text top="123" left="446" width="360" height="16" font="4">tively might be considered to be higher in patients with</text>
<text top="141" left="446" width="360" height="16" font="4">documented as opposed to suspected CAD, evidence-based</text>
<text top="159" left="446" width="360" height="16" font="4">medical management, including adherence to appropriate</text>
<text top="178" left="446" width="360" height="16" font="4">lifestyle changes, and possibly appropriate revascularization</text>
<text top="196" left="446" width="360" height="16" font="4">in patients with ACS or patients identified as high risk with</text>
<text top="215" left="446" width="360" height="16" font="4">worsening clinical status or persistent symptoms despite</text>
<text top="233" left="446" width="360" height="16" font="4">GDMT, might explain the generally low mortality risk that</text>
<text top="251" left="446" width="360" height="16" font="4">has been found in several studies of patients with established</text>
<text top="270" left="446" width="47" height="16" font="4">SIHD <a href="e44.full.html#87">(</a></text>
<text top="270" left="492" width="117" height="16" font="16"><a href="e44.full.html#87">57,58,366,1216,1217</a></text>
<text top="270" left="609" width="197" height="16" font="4"><a href="e44.full.html#87">). </a>The incidence of adverse events</text>
<text top="288" left="446" width="360" height="16" font="4">during longitudinal follow-up of SIHD has declined and can be</text>
<text top="306" left="446" width="360" height="16" font="4">expected to vary with evolving medical management and with</text>
<text top="325" left="446" width="360" height="16" font="4">accruing information about the outcomes of revascularization</text>
<text top="343" left="446" width="5" height="16" font="4"><a href="e44.full.html#93">(</a></text>
<text top="343" left="450" width="141" height="16" font="16"><a href="e44.full.html#93">295,898,1163,1217–1219</a></text>
<text top="343" left="591" width="8" height="16" font="4"><a href="e44.full.html#93">).</a></text>
<text top="361" left="460" width="345" height="16" font="4">Although data on serial testing are limited, one approach</text>
<text top="380" left="445" width="360" height="16" font="4">to identifying candidates for follow-up testing is to apply</text>
<text top="398" left="445" width="360" height="16" font="4">prognostic scores for detection of patients with SIHD who</text>
<text top="416" left="445" width="360" height="16" font="4">are at high risk of MACE. The findings of studies that have</text>
<text top="435" left="445" width="360" height="16" font="4">examined the prognostic value of testing among patients</text>
<text top="453" left="445" width="360" height="16" font="4">with known stable CAD who are receiving contemporary</text>
<text top="471" left="445" width="59" height="16" font="4">GDMT <a href="e44.full.html#93">(</a></text>
<text top="471" left="505" width="96" height="16" font="16"><a href="e44.full.html#93">306,1220 –1223</a></text>
<text top="471" left="600" width="205" height="16" font="4"><a href="e44.full.html#93">) </a>could provide clues for identify-</text>
<text top="490" left="445" width="360" height="16" font="4">ing candidates and appropriate intervals for follow-up test-</text>
<text top="508" left="445" width="360" height="16" font="4">ing. In the TIBET (Total Ischemic Burden European Trial)</text>
<text top="526" left="445" width="360" height="16" font="4">study group, which comprised 682 patients with stable</text>
<text top="545" left="445" width="360" height="16" font="4">angina and positive exercise ECG tests, adverse outcome</text>
<text top="563" left="445" width="360" height="16" font="4">was predicted by time to ischemia during exercise, prior</text>
<text top="581" left="445" width="360" height="16" font="4">infarction or prior CABG, ECG evidence for LV hyper-</text>
<text top="600" left="445" width="336" height="16" font="4">trophy, and LV enlargement by echocardiography <a href="e44.full.html#87">(</a></text>
<text top="600" left="782" width="15" height="16" font="16"><a href="e44.full.html#87">58</a></text>
<text top="600" left="797" width="9" height="16" font="4"><a href="e44.full.html#87">).</a></text>
<text top="618" left="445" width="360" height="16" font="4">Easily available clinical characteristics have been the stron-</text>
<text top="636" left="445" width="360" height="16" font="4">gest predictors of risk during follow-up of patients with</text>
<text top="655" left="445" width="360" height="16" font="4">SIHD in other studies. The Euro Heart Survey found that</text>
<text top="673" left="445" width="360" height="16" font="4">a score based on the cumulative presence of comorbidity,</text>
<text top="691" left="445" width="360" height="16" font="4">diabetes mellitus, severity of angina, onset of recurrent</text>
<text top="710" left="445" width="61" height="16" font="4">symptoms</text>
<text top="707" left="516" width="289" height="20" font="4">⬍6 months previously, abnormal ventricular</text>
<text top="728" left="445" width="360" height="16" font="4">function, and resting ECG repolarization abnormalities was</text>
<text top="746" left="445" width="360" height="16" font="4">associated with an increase in the 1-year risk of death or</text>
<text top="765" left="445" width="360" height="16" font="4">nonfatal infarction that ranged nearly 100-fold (from 0.5%</text>
<text top="783" left="445" width="92" height="16" font="4">to 47%) among</text>
<text top="780" left="541" width="126" height="20" font="4">⬎3,000 outpatients <a href="e44.full.html#87">(</a></text>
<text top="783" left="667" width="15" height="16" font="16"><a href="e44.full.html#87">57</a></text>
<text top="783" left="682" width="124" height="16" font="4"><a href="e44.full.html#87">). </a>The ACTION (A</text>
<text top="801" left="445" width="360" height="16" font="4">Coronary Disease Trial Investigating Outcome with Nifed-</text>
<text top="820" left="445" width="360" height="16" font="4">ipine Gastrointestinal Therapeutic System) trial derived a</text>
<text top="838" left="445" width="360" height="16" font="4">clinical risk score that separated 5-year risk of death, MI, or</text>
<text top="856" left="445" width="174" height="16" font="4">stroke from 4% to 35% in</text>
<text top="853" left="627" width="178" height="20" font="4">⬎7,300 patients with stable</text>
<text top="875" left="445" width="360" height="16" font="4">angina on the basis of commonly available clinical variables.</text>
<text top="893" left="445" width="360" height="16" font="4">In order of decreasing importance, the variables included</text>
<text top="911" left="445" width="360" height="16" font="4">age, LVEF, smoking, white blood cell count, presence of</text>
<text top="930" left="445" width="360" height="16" font="4">diabetes mellitus, casual (any time of day without regard to</text>
<text top="948" left="445" width="360" height="16" font="4">time since the last meal) blood glucose concentration,</text>
<text top="966" left="445" width="360" height="16" font="4">creatinine, prior stroke, frequent angina, findings at coro-</text>
<text top="985" left="445" width="360" height="16" font="4">nary angiography, lipid-lowering treatment, QT interval on</text>
<text top="1003" left="445" width="360" height="16" font="4">the resting ECG, systolic hypertension, number of drugs</text>
<text top="1021" left="445" width="267" height="16" font="4">used for angina, prior infarction, and sex <a href="e44.full.html#115">(</a></text>
<text top="1021" left="713" width="30" height="16" font="16"><a href="e44.full.html#115">1216</a></text>
<text top="1021" left="743" width="63" height="16" font="4"><a href="e44.full.html#115">). </a>Because</text>
<text top="1040" left="445" width="360" height="16" font="4">the populations enrolled in these studies varied and the</text>
<text top="1058" left="445" width="360" height="16" font="4">results have not been independently validated, additional</text>
<text top="1076" left="445" width="360" height="16" font="4">prospective studies of patients with established SIHD are</text>
<text top="1095" left="445" width="360" height="16" font="4">required to establish appropriate follow-up evaluation strat-</text>
<text top="52" left="59" width="25" height="10" font="12">e120</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="78" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="16" font="4">egies and to establish efficient time intervals for evaluation</text>
<text top="122" left="59" width="114" height="16" font="4">in stable patients <a href="e44.full.html#93">(</a></text>
<text top="122" left="172" width="116" height="16" font="16"><a href="e44.full.html#93">307,320,1223,1224</a></text>
<text top="122" left="289" width="9" height="16" font="4"><a href="e44.full.html#93">).</a></text>
<text top="154" left="59" width="254" height="12" font="18">6.2. Follow-Up of Patients With SIHD</text>
<text top="176" left="59" width="360" height="16" font="4">Standard risk assessment tools that have been developed from</text>
<text top="194" left="59" width="360" height="16" font="4">clinical and laboratory evaluation of ambulatory populations</text>
<text top="212" left="59" width="263" height="16" font="4">with suspected CAD, as discussed in detail in</text>
<text top="212" left="325" width="54" height="16" font="16"><a href="e44.full.html#15">Section 2</a></text>
<text top="212" left="382" width="37" height="16" font="4">of this</text>
<text top="230" left="59" width="360" height="16" font="4">guideline, include patients who have noncardiac causes of</text>
<text top="248" left="59" width="360" height="16" font="4">presenting symptoms. Estimates of the likelihood of future</text>
<text top="266" left="59" width="259" height="16" font="4">cardiac events using the Framingham score <a href="e44.full.html#98">(</a></text>
<text top="266" left="317" width="54" height="16" font="16"><a href="e44.full.html#98">508,1225</a></text>
<text top="266" left="371" width="48" height="16" font="4"><a href="e44.full.html#98">), </a>which</text>
<text top="284" left="59" width="360" height="16" font="4">was derived from populations that included large numbers of</text>
<text top="302" left="59" width="360" height="16" font="4">low-risk individuals without disease in their low-risk subsets,</text>
<text top="320" left="59" width="360" height="16" font="4">are not generally useful when applied to patients with known</text>
<text top="338" left="59" width="360" height="16" font="4">SIHD. In fact, prediction of risk for coronary mortality and</text>
<text top="356" left="59" width="360" height="16" font="4">coronary events during short-term and long-term follow-up of</text>
<text top="374" left="59" width="360" height="16" font="4">patients with SIHD differs from risk stratification in less-</text>
<text top="392" left="59" width="360" height="16" font="4">ascertained populations with chest pain syndromes. Although</text>
<text top="410" left="59" width="360" height="16" font="4">mortality and morbidity rates intuitively might be considered</text>
<text top="428" left="59" width="360" height="16" font="4">to be higher in patients with documented as opposed to</text>
<text top="446" left="59" width="360" height="16" font="4">suspected IHD, several circumstances serve to confound this</text>
<text top="464" left="59" width="360" height="16" font="4">assumption. Patients at highest risk, for example, are often</text>
<text top="482" left="59" width="360" height="16" font="4">identified and aggressively treated during the course of ACS or</text>
<text top="500" left="59" width="360" height="16" font="4">during initial risk assessment of chest pain. After being treated,</text>
<text top="518" left="59" width="360" height="16" font="4">asymptomatic patients are typically at low risk for adverse</text>
<text top="536" left="59" width="360" height="16" font="4">events. Moreover, patients with recognized SIHD could be</text>
<text top="554" left="59" width="360" height="16" font="4">more likely to receive and adhere to effective therapies than are</text>
<text top="572" left="59" width="360" height="16" font="4">those whose disease has not been documented. Finally, patients</text>
<text top="590" left="59" width="360" height="16" font="4">who have been stable for long periods of time could be less</text>
<text top="608" left="59" width="360" height="16" font="4">prone to development of ACS than are newly ascertained</text>
<text top="626" left="59" width="360" height="16" font="4">patients with SIHD. Thus, evidence-based medical manage-</text>
<text top="644" left="59" width="360" height="16" font="4">ment, including adherence to appropriate lifestyle changes and</text>
<text top="662" left="59" width="360" height="16" font="4">possibly appropriate revascularization in patients with ACS or</text>
<text top="680" left="59" width="360" height="16" font="4">patients identified as high risk with worsening clinical status or</text>
<text top="698" left="59" width="360" height="16" font="4">persistent symptoms despite GDMT, could explain the gen-</text>
<text top="716" left="59" width="360" height="16" font="4">erally low mortality risk that has been found in several studies</text>
<text top="734" left="59" width="360" height="16" font="4">of patients with established but stable SIHD</text>
<text top="752" left="59" width="5" height="16" font="4"><a href="e44.full.html#87">(</a></text>
<text top="752" left="63" width="122" height="16" font="16"><a href="e44.full.html#87">57,58,366,1216,1217</a></text>
<text top="752" left="185" width="233" height="16" font="4"><a href="e44.full.html#87">). </a>Moreover, large trials conducted dur-</text>
<text top="770" left="59" width="360" height="16" font="4">ing the past decade have shown a declining mortality rate</text>
<text top="788" left="59" width="49" height="16" font="4">a m o n g</text>
<text top="788" left="129" width="60" height="16" font="4">p a t i e n t s</text>
<text top="788" left="212" width="33" height="16" font="4">w i t h</text>
<text top="788" left="267" width="84" height="16" font="4">e s t a b l i s h e d</text>
<text top="788" left="374" width="44" height="16" font="4">S I H D</text>
<text top="806" left="59" width="5" height="16" font="4"><a href="e44.full.html#93">(</a></text>
<text top="806" left="63" width="144" height="16" font="16"><a href="e44.full.html#93">295,898,1163,1217,1218</a></text>
<text top="806" left="207" width="212" height="16" font="4"><a href="e44.full.html#93">). </a>Accordingly, risk could change</text>
<text top="824" left="59" width="360" height="16" font="4">with advances in therapy and patient management, and these</text>
<text top="842" left="59" width="256" height="16" font="4">advances could alter risk-prediction models.</text>
<text top="860" left="74" width="345" height="16" font="4">A key component in following up patients with SIHD is</text>
<text top="878" left="59" width="360" height="16" font="4">to systematically and reproducibly monitor their symptoms</text>
<text top="896" left="59" width="360" height="16" font="4">and functional status. This should be done, at a minimum,</text>
<text top="914" left="59" width="360" height="16" font="4">yearly and ideally at each visit. Even though the CCS</text>
<text top="932" left="59" width="360" height="16" font="4">classification system is the most common metric with which</text>
<text top="950" left="59" width="360" height="16" font="4">to quantify patients’ symptoms and function, as noted</text>
<text top="968" left="59" width="360" height="16" font="4">previously, it is limited by being from the physician’s</text>
<text top="986" left="59" width="360" height="16" font="4">perspective rather than the patient’s. Moreover, it has</text>
<text top="1004" left="59" width="360" height="16" font="4">limitations in its reproducibility and interrater reliability. To</text>
<text top="1022" left="59" width="360" height="16" font="4">obtain a valid, reliable, reproducible, and sensitive assess-</text>
<text top="1040" left="59" width="360" height="16" font="4">ment of patients’ symptoms, function, and quality of life</text>
<text top="1058" left="59" width="360" height="16" font="4">from patients’ perspectives, the SAQ can be used</text>
<text top="1076" left="59" width="5" height="16" font="4"><a href="e44.full.html#96">(</a></text>
<text top="1076" left="63" width="56" height="16" font="16"><a href="e44.full.html#96">435,1226</a></text>
<text top="1076" left="120" width="299" height="16" font="4"><a href="e44.full.html#96">). </a>The SAQ is a 19-item, self-reported question-</text>
<text top="1094" left="59" width="360" height="16" font="4">naire that takes approximately 5 minutes for most patients</text>
<text top="104" left="446" width="360" height="16" font="4">to complete and explicitly quantifies patients’ angina fre-</text>
<text top="123" left="446" width="360" height="16" font="4">quency, recent changes in their angina, their physical</text>
<text top="141" left="446" width="360" height="16" font="4">limitations due to angina, their satisfaction with treatment,</text>
<text top="159" left="446" width="360" height="16" font="4">and their perceptions of how their angina limits their quality</text>
<text top="177" left="446" width="360" height="16" font="4">of life. Scores on the SAQ have been shown to be associated</text>
<text top="195" left="446" width="360" height="16" font="4">with subsequent survival. ACS admissions and costs</text>
<text top="213" left="446" width="5" height="16" font="4"><a href="e44.full.html#91">(</a></text>
<text top="213" left="450" width="83" height="16" font="16"><a href="e44.full.html#91">246,247,1227</a></text>
<text top="213" left="533" width="273" height="16" font="4"><a href="e44.full.html#91">) </a>can be integrated into prognostic models to</text>
<text top="231" left="446" width="360" height="16" font="4">identify patients warranting more aggressive treatment be-</text>
<text top="250" left="446" width="360" height="16" font="4">cause of an adverse prognosis. In the CADENCE (Coro-</text>
<text top="268" left="446" width="360" height="16" font="4">nary Artery Disease in General Practice) study, conducted</text>
<text top="286" left="446" width="321" height="16" font="4">in 207 primary care clinics throughout Australia <a href="e44.full.html#115">(</a></text>
<text top="286" left="767" width="30" height="16" font="16"><a href="e44.full.html#115">1228</a></text>
<text top="286" left="797" width="9" height="16" font="4"><a href="e44.full.html#115">),</a></text>
<text top="304" left="446" width="360" height="16" font="4">Beltrame and colleagues found wide variation in anginal</text>
<text top="322" left="446" width="360" height="16" font="4">symptoms according to the SAQ. Routine use of the SAQ</text>
<text top="340" left="446" width="360" height="16" font="4">has been endorsed as a performance measure of quality in</text>
<text top="359" left="446" width="49" height="16" font="4">SIHD <a href="e44.full.html#95">(</a></text>
<text top="359" left="494" width="49" height="16" font="16"><a href="e44.full.html#95">407,436</a></text>
<text top="359" left="543" width="9" height="16" font="4"><a href="e44.full.html#95">).</a></text>
<text top="386" left="446" width="280" height="16" font="26"><b>6.2.1. Focused Follow-Up Visit: Frequency</b></text>
<text top="411" left="446" width="360" height="16" font="4">Patients with SIHD should receive regular follow-up to</text>
<text top="429" left="446" width="360" height="16" font="4">monitor symptoms and progression or complications of</text>
<text top="448" left="446" width="360" height="16" font="4">disease. Regular visits with a healthcare provider are also</text>
<text top="466" left="446" width="360" height="16" font="4">necessary to evaluate patients’ adherence to and effectiveness</text>
<text top="484" left="446" width="360" height="16" font="4">of therapy as well as occurrence of any adverse effects.</text>
<text top="502" left="446" width="360" height="16" font="4">Although there are scant data on which to base a definitive</text>
<text top="520" left="446" width="360" height="16" font="4">recommendation, the writing committee recommends a</text>
<text top="538" left="446" width="360" height="16" font="4">clinical follow-up evaluation every 4 to 12 months. A more</text>
<text top="557" left="446" width="360" height="16" font="4">precise interval cannot be recommended because many</text>
<text top="575" left="446" width="360" height="16" font="4">factors influence the length of the follow-up period, includ-</text>
<text top="593" left="446" width="360" height="16" font="4">ing sharing of care by family physicians, internists, and</text>
<text top="611" left="446" width="360" height="16" font="4">cardiologists, which will vary with regional practice patterns,</text>
<text top="629" left="446" width="360" height="16" font="4">patient preference, and physician availability. During the first</text>
<text top="647" left="446" width="360" height="16" font="4">year of therapy, evaluations every 4 to 6 months are recom-</text>
<text top="665" left="446" width="360" height="16" font="4">mended. After the first year of therapy, evaluations every 6 to</text>
<text top="683" left="446" width="360" height="16" font="4">12 months are recommended if the patient is stable and reliable</text>
<text top="702" left="446" width="360" height="16" font="4">enough to call or make an appointment when symptoms or</text>
<text top="720" left="446" width="360" height="16" font="4">functional capacity become worse. Limited data from observa-</text>
<text top="738" left="446" width="360" height="16" font="4">tional studies indicate that outcomes might be better for</text>
<text top="756" left="446" width="360" height="16" font="4">patients who receive follow-up from a cardiologist</text>
<text top="774" left="446" width="5" height="16" font="4"><a href="e44.full.html#115">(</a></text>
<text top="774" left="450" width="61" height="16" font="16"><a href="e44.full.html#115">1229,1230</a></text>
<text top="774" left="511" width="294" height="16" font="4"><a href="e44.full.html#115">). </a>When patients are managed jointly by their</text>
<text top="792" left="446" width="360" height="16" font="4">primary care physician and cardiologist, effective communica-</text>
<text top="810" left="446" width="360" height="16" font="4">tion between physicians is essential. This ultimately will be</text>
<text top="829" left="446" width="360" height="16" font="4">facilitated by effective implementation of accessible electronic</text>
<text top="847" left="446" width="360" height="16" font="4">medical records. Periodic office visits can be supplemented by</text>
<text top="865" left="446" width="360" height="16" font="4">telephone, e-mail, or other types of contact between the patient</text>
<text top="883" left="446" width="145" height="16" font="4">and the healthcare team.</text>
<text top="910" left="446" width="346" height="16" font="26"><b>6.2.2. Focused Follow-Up Visit: Interval History and</b></text>
<text top="928" left="446" width="145" height="16" font="26"><b>Coexisting Conditions</b></text>
<text top="954" left="446" width="360" height="16" font="4">Although follow-up of patients with SIHD often is focused</text>
<text top="972" left="446" width="360" height="16" font="4">on periodic testing, the most crucial element is a careful</text>
<text top="990" left="446" width="296" height="16" font="4">interval history. Key elements of the history are:</text>
<text top="1019" left="461" width="276" height="20" font="4">• Changes in physical activity or symptoms;</text>
<text top="1037" left="461" width="345" height="20" font="4">• Response to therapy, adverse effects, and adherence to</text>
<text top="1058" left="477" width="138" height="16" font="4">recommendations; and</text>
<text top="1073" left="461" width="345" height="20" font="4">• Development of relevant, new chronic conditions or</text>
<text top="1094" left="477" width="188" height="16" font="4">changes in existing conditions.</text>
<text top="52" left="781" width="25" height="10" font="12">e121</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="79" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="74" width="345" height="16" font="4">Symptomatic change and decreasing functional capacity</text>
<text top="123" left="59" width="360" height="16" font="4">are important markers for increased risk in patients with</text>
<text top="141" left="59" width="360" height="16" font="4">SIHD, particularly with increasing age and additional co-</text>
<text top="159" left="59" width="360" height="16" font="4">morbidities. The evaluation of symptoms should be detailed</text>
<text top="177" left="59" width="360" height="16" font="4">and directed, as many patients are reluctant to volunteer</text>
<text top="195" left="59" width="360" height="16" font="4">such information. It should be noted whether patients have</text>
<text top="213" left="59" width="360" height="16" font="4">reduced their activity, perhaps in an effort to ameliorate</text>
<text top="231" left="59" width="360" height="16" font="4">anginal symptoms or as a symptom of ventricular dysfunc-</text>
<text top="249" left="59" width="360" height="16" font="4">tion. The adverse prognostic importance of frequent, typical</text>
<text top="267" left="59" width="360" height="16" font="4">angina in patients with SIHD is evident in both older and</text>
<text top="285" left="59" width="142" height="16" font="4">newer studies of risk <a href="e44.full.html#87">(</a></text>
<text top="285" left="200" width="135" height="16" font="16"><a href="e44.full.html#87">57,126,127,1231,1232</a></text>
<text top="285" left="335" width="83" height="16" font="4"><a href="e44.full.html#87">). </a>Motivation</text>
<text top="303" left="59" width="360" height="16" font="4">and compliance with risk-reduction measures should be</text>
<text top="321" left="59" width="360" height="16" font="4">carefully assessed. In particular, assistance with smoking</text>
<text top="339" left="59" width="360" height="16" font="4">cessation by means of a structured program might be</text>
<text top="357" left="59" width="360" height="16" font="4">necessary for some patients. Careful attention must be paid</text>
<text top="375" left="59" width="360" height="16" font="4">to concomitant conditions, such as hypertension, diabetes</text>
<text top="394" left="59" width="319" height="16" font="4">mellitus, dyslipidemia, heart failure, and depression.</text>
<text top="421" left="59" width="353" height="16" font="26"><b>6.2.3. Focused Follow-Up Visit: Physical Examination</b></text>
<text top="446" left="59" width="360" height="16" font="4">The physical examination should be directed according to the</text>
<text top="464" left="59" width="360" height="16" font="4">patient’s history. Every patient should have weight, BP, and</text>
<text top="482" left="59" width="360" height="16" font="4">heart rate measured. BMI and waist circumference can provide</text>
<text top="500" left="59" width="360" height="16" font="4">signs of additional risk. Signs of heart failure, such as elevated</text>
<text top="518" left="59" width="360" height="16" font="4">jugular venous pressure, hepatojugular reflux, pulmonary crack-</text>
<text top="536" left="59" width="360" height="16" font="4">les, new murmurs or gallops, or edema, should be sought. The</text>
<text top="554" left="59" width="360" height="16" font="4">vascular examination should identify any change in peripheral</text>
<text top="572" left="59" width="360" height="16" font="4">pulses or new bruits. Coexistence of SIHD with extracranial</text>
<text top="591" left="59" width="360" height="16" font="4">carotid disease makes palpation and auscultation of the carotid</text>
<text top="609" left="59" width="360" height="16" font="4">arteries particularly important, and examination of the abdo-</text>
<text top="627" left="59" width="360" height="16" font="4">men should include special attention to bruits or abnormally</text>
<text top="645" left="59" width="265" height="16" font="4">prominent pulsations of the abdominal aorta.</text>
<text top="672" left="59" width="360" height="16" font="26"><b>6.2.4. Focused Follow-Up Visit: Resting 12-Lead ECG</b></text>
<text top="697" left="59" width="360" height="16" font="4">An ECG is necessary when there is a change in anginal</text>
<text top="715" left="59" width="360" height="16" font="4">pattern, symptoms or findings suggestive of a dysrhythmia</text>
<text top="733" left="59" width="360" height="16" font="4">or conduction abnormality, and near or frank syncope. It is</text>
<text top="751" left="59" width="360" height="16" font="4">important to recognize that periodic recording of the</text>
<text top="769" left="59" width="360" height="16" font="4">standard 12-lead ECG has clinical value that is independent</text>
<text top="787" left="59" width="360" height="16" font="4">of diagnostic and prognostic content: It provides a baseline</text>
<text top="806" left="59" width="360" height="16" font="4">waveform against which tracings taken during symptoms</text>
<text top="824" left="59" width="360" height="16" font="4">reasonably can be compared. Because many patients with</text>
<text top="842" left="59" width="360" height="16" font="4">SIHD have resting repolarization abnormalities, absence of</text>
<text top="860" left="59" width="360" height="16" font="4">a timely tracing for comparison with a tracing taken during</text>
<text top="878" left="59" width="360" height="16" font="4">atypical symptoms can lead to overdiagnosis of acute isch-</text>
<text top="896" left="59" width="38" height="16" font="4">emia <a href="e44.full.html#115">(</a></text>
<text top="896" left="97" width="64" height="16" font="16"><a href="e44.full.html#115">1233,1234</a></text>
<text top="896" left="161" width="258" height="16" font="4"><a href="e44.full.html#115">). </a>Conversely, repolarization abnormalities</text>
<text top="914" left="59" width="360" height="16" font="4">during symptoms that might be new or significantly more</text>
<text top="932" left="59" width="360" height="16" font="4">marked can also be consistent with old disease and lead to</text>
<text top="950" left="59" width="360" height="16" font="4">underdiagnosis or undertreatment of unstable disease</text>
<text top="968" left="59" width="5" height="16" font="4"><a href="e44.full.html#115">(</a></text>
<text top="968" left="63" width="30" height="16" font="16"><a href="e44.full.html#115">1235</a></text>
<text top="968" left="93" width="325" height="16" font="4"><a href="e44.full.html#115">)</a>. New repolarization abnormalities during serial study</text>
<text top="986" left="59" width="360" height="16" font="4">have been shown to predict cardiovascular events during the</text>
<text top="1004" left="59" width="360" height="16" font="4">longitudinal study of hypertensive patients in the Framingham</text>
<text top="1022" left="59" width="89" height="16" font="4">Heart Study <a href="e44.full.html#93">(</a></text>
<text top="1022" left="147" width="22" height="16" font="16"><a href="e44.full.html#93">318</a></text>
<text top="1022" left="169" width="250" height="16" font="4"><a href="e44.full.html#93">). </a>A study of hypertensive patients that</text>
<text top="1040" left="59" width="360" height="16" font="4">included a subgroup with established SIHD also demonstrated</text>
<text top="1058" left="59" width="360" height="16" font="4">an increased risk of cardiovascular endpoints after the devel-</text>
<text top="1076" left="59" width="360" height="16" font="4">opment of new repolarization changes during serial evaluation</text>
<text top="1094" left="59" width="5" height="16" font="4"><a href="e44.full.html#93">(</a></text>
<text top="1094" left="63" width="54" height="16" font="16"><a href="e44.full.html#93">318,1236</a></text>
<text top="1094" left="117" width="301" height="16" font="4"><a href="e44.full.html#93">). </a>Although there are no prospective randomized</text>
<text top="104" left="446" width="360" height="16" font="4">data demonstrating that intervention based on routine, peri-</text>
<text top="122" left="446" width="360" height="16" font="4">odic evaluation of the ECG alone will alter outcomes in</text>
<text top="140" left="446" width="360" height="16" font="4">patients with SIHD, pending such evidence, the clinical value</text>
<text top="159" left="446" width="360" height="16" font="4">of a change in the resting ECG is widely accepted. In patients</text>
<text top="177" left="446" width="360" height="16" font="4">with established SIHD, a change in a periodically obtained</text>
<text top="195" left="446" width="360" height="16" font="4">ECG can be the only evidence of intercurrent silent infarction,</text>
<text top="213" left="446" width="360" height="16" font="4">inadequately treated hypertension, or complex arrhythmia that</text>
<text top="231" left="446" width="360" height="16" font="4">would modify treatment. The timing between routine record-</text>
<text top="249" left="446" width="360" height="16" font="4">ings of the 12-lead ECG that would be required and adequate</text>
<text top="267" left="446" width="360" height="16" font="4">to accomplish these purposes has not been established, but a</text>
<text top="285" left="446" width="360" height="16" font="4">consensus recommendation based on expert opinion and com-</text>
<text top="303" left="446" width="360" height="16" font="4">mon practice would be not greater than once yearly for stable</text>
<text top="322" left="446" width="360" height="16" font="4">patients with SIHD, as well as at the time of any clinical</text>
<text top="340" left="446" width="44" height="16" font="4">change.</text>
<text top="367" left="446" width="209" height="16" font="26"><b>6.2.5. Focused Follow-Up Visit:</b></text>
<text top="385" left="446" width="157" height="16" font="26"><b>Laboratory Examination</b></text>
<text top="410" left="446" width="360" height="16" font="4">Patients not known to have diabetes mellitus should have a</text>
<text top="429" left="446" width="360" height="16" font="4">fasting blood glucose measurement every 3 years to detect</text>
<text top="447" left="446" width="360" height="16" font="4">new-onset diabetes mellitus, and those with established</text>
<text top="465" left="446" width="360" height="16" font="4">diabetes mellitus should have glycosylated hemoglobin mea-</text>
<text top="483" left="446" width="360" height="16" font="4">sured at least annually to assess glycemic control. A lipid</text>
<text top="501" left="446" width="360" height="16" font="4">profile should be obtained as clinically warranted. Long-</text>
<text top="519" left="446" width="360" height="16" font="4">term studies (up to 7 years) demonstrate sustained benefit</text>
<text top="537" left="446" width="158" height="16" font="4">from continued therapy <a href="e44.full.html#86">(</a></text>
<text top="537" left="603" width="41" height="16" font="16"><a href="e44.full.html#86">18,318</a></text>
<text top="537" left="644" width="161" height="16" font="4"><a href="e44.full.html#86">). </a>Measurement of creati-</text>
<text top="555" left="446" width="360" height="16" font="4">nine kinase also could be appropriate at these times. In</text>
<text top="573" left="446" width="360" height="16" font="4">circumstances in which the patient is not concurrently</text>
<text top="591" left="446" width="360" height="16" font="4">followed up by a primary care physician, measurements of</text>
<text top="610" left="446" width="360" height="16" font="4">hemoglobin, thyroid function, serum electrolytes, and renal</text>
<text top="628" left="446" width="360" height="16" font="4">function should be obtained annually, or sooner when</text>
<text top="646" left="446" width="277" height="16" font="4">prompted by a change in symptoms or signs.</text>
<text top="683" left="446" width="277" height="12" font="18">6.3. Noninvasive Testing in Known SIHD</text>
<text top="705" left="446" width="360" height="16" font="4">For any patients with known SIHD who have recurrent but</text>
<text top="724" left="446" width="360" height="16" font="4">stable symptoms after having been symptom free for a</text>
<text top="742" left="446" width="360" height="16" font="4">period of time on GDMT or after revascularization and</text>
<text top="760" left="446" width="360" height="16" font="4">who do not fall into any of the categories listed in the</text>
<text top="778" left="446" width="360" height="16" font="4">previous paragraph, the concepts underlying the recommen-</text>
<text top="796" left="446" width="360" height="16" font="4">dations for “Noninvasive Testing for Diagnosis of SIHD”</text>
<text top="814" left="446" width="29" height="16" font="4">from</text>
<text top="814" left="478" width="67" height="16" font="16"><a href="e44.full.html#19">Section 2.2</a></text>
<text top="814" left="549" width="257" height="16" font="4">generally apply, with the modifications and</text>
<text top="832" left="446" width="231" height="16" font="4">special consideration discussed below.</text>
<text top="859" left="446" width="325" height="16" font="26"><b>6.3.1. Follow-Up Noninvasive Testing in Patients</b></text>
<text top="877" left="446" width="340" height="16" font="26"><b>With Known SIHD: New, Recurrent, or Worsening</b></text>
<text top="895" left="446" width="327" height="16" font="26"><b>Symptoms Not Consistent With Unstable Angina:</b></text>
<text top="914" left="446" width="119" height="16" font="26"><b>Recommendations</b></text>
<text top="939" left="446" width="21" height="16" font="4">See</text>
<text top="939" left="471" width="54" height="16" font="16"><a href="e44.full.html#80">Table 20</a></text>
<text top="939" left="529" width="276" height="16" font="4">for a summary of recommendations from this</text>
<text top="957" left="446" width="46" height="16" font="4">section.</text>
<text top="988" left="446" width="173" height="9" font="6">6.3.1.1. PATIENTS ABLE TO EXERCISE</text>
<text top="1017" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="1029" left="446" width="360" height="10" font="13">1. Standard exercise ECG testing is recommended in patients with</text>
<text top="1046" left="461" width="344" height="10" font="13">known SIHD who have new or worsening symptoms not consistent</text>
<text top="1063" left="461" width="344" height="10" font="13">with UA and who have a) at least moderate physical functioning and</text>
<text top="1080" left="461" width="344" height="10" font="13">no disabling comorbidity and b) an interpretable ECG <a href="e44.full.html#88">(114,145–</a></text>
<text top="1097" left="461" width="142" height="10" font="13"><a href="e44.full.html#88">147). </a><i>(Level of Evidence: B)</i></text>
<text top="52" left="59" width="25" height="10" font="12">e122</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1161" width="864">
<text top="755" left="59" width="360" height="10" font="13">2. Exercise with nuclear MPI or echocardiography is recommended in</text>
<text top="773" left="74" width="344" height="10" font="13">patients with known SIHD who have new or worsening symptoms</text>
<text top="790" left="74" width="344" height="10" font="13">not consistent with UA and who have a) at least moderate physical</text>
<text top="808" left="74" width="344" height="10" font="13">functioning or no disabling comorbidity but b) an <i>un</i>interpretable</text>
<text top="825" left="74" width="21" height="10" font="13">ECG</text>
<text top="825" left="113" width="306" height="10" font="13"><a href="e44.full.html#89">(172,276,278,284,306,313,314,320,324,327–329,1237–</a></text>
<text top="843" left="74" width="149" height="10" font="13"><a href="e44.full.html#89">1240). </a><i>(Level of Evidence: B)</i></text>
<text top="874" left="59" width="46" height="8" font="24">CLASS IIa</text>
<text top="887" left="59" width="360" height="10" font="13">1. Exercise with nuclear MPI or echocardiography is reasonable in pa-</text>
<text top="905" left="74" width="344" height="10" font="13">tients with known SIHD who have new or worsening symptoms not</text>
<text top="922" left="74" width="344" height="10" font="13">consistent with UA and who have a) at least moderate physical func-</text>
<text top="940" left="74" width="344" height="10" font="13">tioning and no disabling comorbidity, b) previously required imaging</text>
<text top="957" left="74" width="344" height="10" font="13">with exercise stress, or c) known multivessel disease or high risk for</text>
<text top="975" left="74" width="276" height="10" font="13">multivessel disease <a href="e44.full.html#115">(1241,1242). </a><i>(Level of Evidence: B)</i></text>
<text top="1013" left="59" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="1027" left="59" width="360" height="10" font="13">1. Pharmacological stress imaging with nuclear MPI, echocardiog-</text>
<text top="1044" left="74" width="344" height="10" font="13">raphy, or CMR is not recommended in patients with known SIHD</text>
<text top="1062" left="74" width="344" height="10" font="13">who have new or worsening symptoms not consistent with UA</text>
<text top="1079" left="74" width="344" height="10" font="13">and who are capable of at least moderate physical functioning or</text>
<text top="1097" left="74" width="318" height="10" font="13">have no disabling comorbidity <a href="e44.full.html#94">(333). </a><i>(Level of Evidence: C)</i></text>
<text top="759" left="446" width="186" height="9" font="6">6.3.1.2. PATIENTS UNABLE TO EXERCISE</text>
<text top="788" left="446" width="37" height="8" font="24">CLASS I</text>
<text top="801" left="446" width="360" height="10" font="13">1. Pharmacological stress imaging with nuclear MPI or echocardi-</text>
<text top="819" left="461" width="344" height="10" font="13">ography is recommended in patients with known SIHD who</text>
<text top="836" left="461" width="344" height="10" font="13">have new or worsening symptoms not consistent with UA and</text>
<text top="854" left="461" width="344" height="10" font="13">who are incapable of at least moderate physical functioning or</text>
<text top="871" left="461" width="344" height="10" font="13">have disabling comorbidity <a href="e44.full.html#89">(148–150,152–156). </a><i>(Level of Evi-</i></text>
<text top="889" left="461" width="50" height="10" font="25"><i>dence: B)</i></text>
<text top="926" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="940" left="446" width="360" height="10" font="13">1. Pharmacological stress imaging with CMR is reasonable in patients</text>
<text top="957" left="461" width="344" height="10" font="13">with known SIHD who have new or worsening symptoms not con-</text>
<text top="975" left="461" width="344" height="10" font="13">sistent with UA and who are incapable of at least moderate physical</text>
<text top="992" left="461" width="344" height="10" font="13">functioning or have disabling comorbidity <a href="e44.full.html#92">(280,281,283). </a><i>(Level of</i></text>
<text top="1010" left="461" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="1049" left="446" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="1062" left="446" width="360" height="10" font="13">1. Standard exercise ECG testing should not be performed in pa-</text>
<text top="1080" left="461" width="344" height="10" font="13">tients with known SIHD who have new or worsening symptoms</text>
<text top="1097" left="461" width="344" height="10" font="13">not consistent with UA and who a) are incapable of at least</text>
<text top="105" left="59" width="652" height="11" font="13">Table 20. Follow-Up Noninvasive Testing in Patients With Known SIHD: New, Recurrent, or Worsening Symptoms</text>
<text top="121" left="59" width="138" height="11" font="13">Not Consistent With UA</text>
<text top="182" left="130" width="21" height="9" font="6">Test</text>
<text top="147" left="241" width="40" height="9" font="6">Exercise</text>
<text top="159" left="246" width="31" height="9" font="6">Status</text>
<text top="147" left="340" width="20" height="9" font="6">ECG</text>
<text top="159" left="319" width="61" height="9" font="6">Interpretable</text>
<text top="182" left="424" width="21" height="9" font="6">COR</text>
<text top="182" left="481" width="18" height="9" font="6">LOE</text>
<text top="182" left="542" width="53" height="9" font="6">References</text>
<text top="182" left="656" width="121" height="9" font="6">Additional Considerations</text>
<text top="182" left="227" width="21" height="9" font="6">Able</text>
<text top="182" left="263" width="32" height="9" font="6">Unable</text>
<text top="182" left="318" width="17" height="9" font="6">Yes</text>
<text top="182" left="367" width="13" height="9" font="6">No</text>
<text top="199" left="68" width="117" height="9" font="6">Patients able to exercise*</text>
<text top="217" left="79" width="58" height="9" font="6">Exercise ECG</text>
<text top="217" left="234" width="6" height="9" font="6">X</text>
<text top="217" left="324" width="6" height="9" font="6">X</text>
<text top="217" left="403" width="3" height="9" font="6">I</text>
<text top="217" left="487" width="6" height="9" font="6">B</text>
<text top="217" left="514" width="3" height="9" font="6"><a href="e44.full.html#88">(</a></text>
<text top="217" left="517" width="63" height="9" font="7"><a href="e44.full.html#88">114,145–147</a></text>
<text top="217" left="580" width="3" height="9" font="6"><a href="e44.full.html#88">)</a></text>
<text top="234" left="79" width="128" height="9" font="6">Exercise with nuclear MPI or</text>
<text top="248" left="92" width="22" height="9" font="6">Echo</text>
<text top="234" left="234" width="6" height="9" font="6">X</text>
<text top="234" left="370" width="6" height="9" font="6">X</text>
<text top="234" left="403" width="3" height="9" font="6">I</text>
<text top="234" left="487" width="6" height="9" font="6">B</text>
<text top="234" left="514" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="234" left="517" width="105" height="9" font="7"><a href="e44.full.html#89">172,276,278,284,306,</a></text>
<text top="248" left="526" width="84" height="9" font="7"><a href="e44.full.html#89">313,314,320,324,</a></text>
<text top="262" left="526" width="99" height="9" font="7"><a href="e44.full.html#89">327–329,1237–1240</a></text>
<text top="262" left="625" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="280" left="79" width="128" height="9" font="6">Exercise with nuclear MPI or</text>
<text top="294" left="92" width="22" height="9" font="6">Echo</text>
<text top="280" left="234" width="6" height="9" font="6">X</text>
<text top="280" left="341" width="17" height="9" font="6">Any</text>
<text top="280" left="403" width="11" height="9" font="6">IIa</text>
<text top="280" left="487" width="6" height="9" font="6">B</text>
<text top="280" left="514" width="3" height="9" font="6"><a href="e44.full.html#115">(</a></text>
<text top="280" left="517" width="52" height="9" font="7"><a href="e44.full.html#115">1241,1242</a></text>
<text top="280" left="569" width="3" height="9" font="6"><a href="e44.full.html#115">)</a></text>
<text top="281" left="638" width="3" height="8" font="21">●</text>
<text top="280" left="645" width="135" height="9" font="6">Prior requirement for imaging</text>
<text top="294" left="645" width="59" height="9" font="6">with exercise</text>
<text top="310" left="638" width="3" height="8" font="21">●</text>
<text top="308" left="645" width="112" height="9" font="6">Known or at high risk for</text>
<text top="322" left="645" width="89" height="9" font="6">multivessel disease</text>
<text top="340" left="79" width="105" height="9" font="6">Pharmacological stress</text>
<text top="354" left="92" width="107" height="9" font="6">nuclear MPI/Echo/CMR</text>
<text top="340" left="234" width="6" height="9" font="6">X</text>
<text top="340" left="324" width="6" height="9" font="6">X</text>
<text top="340" left="403" width="62" height="9" font="6">III: No Benefit</text>
<text top="340" left="487" width="6" height="9" font="6">C</text>
<text top="340" left="514" width="3" height="9" font="6"><a href="e44.full.html#94">(</a></text>
<text top="340" left="517" width="18" height="9" font="7"><a href="e44.full.html#94">333</a></text>
<text top="340" left="535" width="3" height="9" font="6"><a href="e44.full.html#94">)</a></text>
<text top="371" left="68" width="123" height="9" font="6">Patients unable to exercise</text>
<text top="388" left="79" width="105" height="9" font="6">Pharmacological stress</text>
<text top="403" left="92" width="91" height="9" font="6">nuclear MPI or Echo</text>
<text top="388" left="276" width="6" height="9" font="6">X</text>
<text top="388" left="341" width="17" height="9" font="6">Any</text>
<text top="388" left="403" width="3" height="9" font="6">I</text>
<text top="388" left="487" width="6" height="9" font="6">B</text>
<text top="388" left="514" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="388" left="517" width="87" height="9" font="7"><a href="e44.full.html#89">148–150,152–156</a></text>
<text top="388" left="604" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="420" left="79" width="130" height="9" font="6">Pharmacological stress CMR</text>
<text top="420" left="276" width="6" height="9" font="6">X</text>
<text top="420" left="341" width="17" height="9" font="6">Any</text>
<text top="420" left="403" width="11" height="9" font="6">IIa</text>
<text top="420" left="487" width="6" height="9" font="6">B</text>
<text top="420" left="514" width="3" height="9" font="6"><a href="e44.full.html#92">(</a></text>
<text top="420" left="517" width="61" height="9" font="7"><a href="e44.full.html#92">280,281,283</a></text>
<text top="420" left="577" width="3" height="9" font="6"><a href="e44.full.html#92">)</a></text>
<text top="437" left="79" width="58" height="9" font="6">Exercise ECG</text>
<text top="437" left="276" width="6" height="9" font="6">X</text>
<text top="437" left="370" width="6" height="9" font="6">X</text>
<text top="437" left="403" width="62" height="9" font="6">III: No Benefit</text>
<text top="437" left="487" width="6" height="9" font="6">C</text>
<text top="437" left="514" width="18" height="9" font="6">N/A</text>
<text top="454" left="68" width="146" height="9" font="6">Irrespective of ability to exercise</text>
<text top="472" left="79" width="24" height="9" font="6">CCTA</text>
<text top="472" left="253" width="17" height="9" font="6">Any</text>
<text top="472" left="341" width="17" height="9" font="6">Any</text>
<text top="472" left="403" width="11" height="9" font="6">IIb</text>
<text top="472" left="487" width="6" height="9" font="6">B</text>
<text top="472" left="514" width="3" height="9" font="6"><a href="e44.full.html#115">(</a></text>
<text top="472" left="517" width="55" height="9" font="7"><a href="e44.full.html#115">1244–1248</a></text>
<text top="472" left="571" width="3" height="9" font="6"><a href="e44.full.html#115">)</a></text>
<text top="472" left="638" width="156" height="9" font="6">Patency of CABG or coronary stent</text>
<text top="483" left="650" width="80" height="14" font="6">ⱖ3 mm diameter</text>
<text top="503" left="79" width="24" height="9" font="6">CCTA</text>
<text top="503" left="253" width="17" height="9" font="6">Any</text>
<text top="503" left="341" width="17" height="9" font="6">Any</text>
<text top="503" left="403" width="11" height="9" font="6">IIb</text>
<text top="503" left="487" width="6" height="9" font="6">B</text>
<text top="503" left="514" width="3" height="9" font="6"><a href="e44.full.html#89">(</a></text>
<text top="503" left="517" width="67" height="9" font="7"><a href="e44.full.html#89">158,161,1244</a></text>
<text top="503" left="584" width="3" height="9" font="6"><a href="e44.full.html#89">)</a></text>
<text top="503" left="638" width="112" height="9" font="6">In the absence of known</text>
<text top="517" left="650" width="145" height="9" font="6">moderate or severe calcification</text>
<text top="532" left="650" width="133" height="9" font="6">and intent to assess coronary</text>
<text top="546" left="650" width="23" height="9" font="6">stent</text>
<text top="543" left="676" width="91" height="14" font="6">⬍3 mm in diameter</text>
<text top="563" left="79" width="24" height="9" font="6">CCTA</text>
<text top="606" left="253" width="17" height="9" font="6">Any</text>
<text top="606" left="341" width="17" height="9" font="6">Any</text>
<text top="563" left="403" width="62" height="9" font="6">III: No Benefit</text>
<text top="563" left="487" width="6" height="9" font="6">B</text>
<text top="563" left="514" width="3" height="9" font="6"><a href="e44.full.html#115">(</a></text>
<text top="563" left="517" width="55" height="9" font="7"><a href="e44.full.html#115">1244–1248</a></text>
<text top="563" left="571" width="3" height="9" font="6"><a href="e44.full.html#115">)</a></text>
<text top="563" left="638" width="153" height="9" font="6">Known moderate or severe native</text>
<text top="577" left="650" width="108" height="9" font="6">coronary calcification or</text>
<text top="592" left="650" width="134" height="9" font="6">assessment of coronary stent</text>
<text top="603" left="650" width="142" height="14" font="6">⬍3 mm in diameter in patients</text>
<text top="620" left="650" width="126" height="9" font="6">who have new or worsening</text>
<text top="634" left="650" width="136" height="9" font="6">symptoms not consistent with</text>
<text top="649" left="650" width="13" height="9" font="6">UA</text>
<text top="686" left="59" width="747" height="7" font="17">*Patients are candidates for exercise testing if they are capable of performing at least moderate physical functioning (i.e., moderate household, yard, or recreational work <i>and </i>most activities of daily</text>
<text top="698" left="59" width="456" height="7" font="17">living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicted maximum heart rate.</text>
<text top="710" left="67" width="739" height="7" font="17">CABG indicates coronary artery bypass graft surgery; CCTA, cardiac computed tomography angiography; CMR, cardiac magnetic resonance; COR, class of recommendation; ECG, electrocardiogram;</text>
<text top="722" left="59" width="634" height="7" font="17">Echo, echocardiography; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not available; SIHD, stable ischemic heart disease; and UA, unstable angina.</text>
<text top="52" left="781" width="25" height="10" font="12">e123</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1161" width="864">
<text top="105" left="75" width="344" height="10" font="13">moderate physical functioning or have disabling comorbidity or</text>
<text top="122" left="75" width="291" height="10" font="13">b) have an <i>un</i>interpretable ECG. <i>(Level of Evidence: C)</i></text>
<text top="151" left="59" width="220" height="9" font="6">6.3.1.3. IRRESPECTIVE OF ABILITY TO EXERCISE</text>
<text top="179" left="59" width="46" height="8" font="24">CLASS IIb</text>
<text top="192" left="59" width="360" height="10" font="13">1. CCTA for assessment of patency of CABG or of coronary stents 3</text>
<text top="209" left="74" width="344" height="10" font="13">mm or larger in diameter might be reasonable in patients with</text>
<text top="226" left="74" width="344" height="10" font="13">known SIHD who have new or worsening symptoms not consistent</text>
<text top="243" left="74" width="344" height="10" font="13">with UA, irrespective of ability to exercise <a href="e44.full.html#115">(1244–1248). </a><i>(Level of</i></text>
<text top="260" left="74" width="63" height="10" font="25"><i>Evidence: B)</i></text>
<text top="277" left="58" width="360" height="10" font="13">2. CCTA might be reasonable in patients with known SIHD who have</text>
<text top="294" left="74" width="344" height="10" font="13">new or worsening symptoms not consistent with UA, irrespective of</text>
<text top="311" left="74" width="344" height="10" font="13">ability to exercise, in the absence of known moderate or severe</text>
<text top="328" left="74" width="344" height="10" font="13">calcification or if the CCTA is intended to assess coronary stents less</text>
<text top="345" left="74" width="326" height="10" font="13">than 3 mm in diameter <a href="e44.full.html#89">(158,161,1244)</a><i>. (Level of Evidence: B)</i></text>
<text top="375" left="59" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="388" left="59" width="360" height="10" font="13">1. CCTA should not be performed for assessment of native coronary</text>
<text top="405" left="74" width="344" height="10" font="13">arteries with known moderate or severe calcification or with</text>
<text top="422" left="74" width="344" height="10" font="13">coronary stents less than 3 mm in diameter in patients with</text>
<text top="438" left="74" width="344" height="10" font="13">known SIHD who have new or worsening symptoms not consis-</text>
<text top="455" left="74" width="344" height="10" font="13">tent with UA, irrespective of ability to exercise <a href="e44.full.html#115">(1244–1248).</a></text>
<text top="473" left="74" width="116" height="10" font="25"><i>(Level of Evidence: B)</i></text>
<text top="493" left="59" width="18" height="16" font="5"><i>See</i></text>
<text top="493" left="82" width="159" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplement 1</i></a></text>
<text top="493" left="245" width="173" height="16" font="5"><i>for additional data on nonin-</i></text>
<text top="511" left="59" width="360" height="16" font="5"><i>vasive testing in known SIHD: recurrent or worsening</i></text>
<text top="529" left="59" width="58" height="16" font="5"><i>symptoms.</i></text>
<text top="553" left="74" width="345" height="16" font="4">Strategies for the selection and use of noninvasive testing</text>
<text top="571" left="59" width="360" height="16" font="4">in the evaluation of new or worsening symptoms in patients</text>
<text top="589" left="59" width="360" height="16" font="4">with documented SIHD are similar to those in suspected</text>
<text top="608" left="59" width="360" height="16" font="4">SIHD. As always, in patients with interpretable rest ECGs</text>
<text top="626" left="59" width="360" height="16" font="4">who are capable of exercise, treadmill exercise ECG testing</text>
<text top="644" left="59" width="360" height="16" font="4">remains the first choice. Whenever possible, initial and</text>
<text top="662" left="59" width="360" height="16" font="4">follow-up testing should be performed with the same stress</text>
<text top="680" left="59" width="360" height="16" font="4">and imaging techniques so that any interval change can be</text>
<text top="698" left="59" width="360" height="16" font="4">attributed more reliably to alterations in clinical status rather</text>
<text top="716" left="59" width="360" height="16" font="4">than mere differences in technique. Loss of the ability to</text>
<text top="734" left="59" width="360" height="16" font="4">exercise on follow-up testing, in and of itself, suggests</text>
<text top="752" left="59" width="360" height="16" font="4">deterioration in functional and clinical status. In general, the</text>
<text top="770" left="59" width="360" height="16" font="4">diagnostic accuracy of stress testing is similar in patients</text>
<text top="788" left="59" width="220" height="16" font="4">with and without known SIHD <a href="e44.full.html#25">(</a></text>
<text top="788" left="279" width="83" height="16" font="16"><a href="e44.full.html#25">Section 2.2.3</a></text>
<text top="788" left="362" width="57" height="16" font="4"><a href="e44.full.html#25">). </a>A few</text>
<text top="806" left="59" width="360" height="16" font="4">meta-analyses examining the effect of prior MI on diagnos-</text>
<text top="824" left="59" width="360" height="16" font="4">tic accuracy have found that the specificity of exercise ECG</text>
<text top="842" left="59" width="213" height="16" font="4">was higher in mixed populations <a href="e44.full.html#89">(</a></text>
<text top="842" left="272" width="23" height="16" font="16"><a href="e44.full.html#89">145</a></text>
<text top="842" left="294" width="124" height="16" font="4"><a href="e44.full.html#89">), </a>whereas the diag-</text>
<text top="860" left="59" width="360" height="16" font="4">nostic performance of exercise echocardiography was re-</text>
<text top="878" left="59" width="360" height="16" font="4">duced. In contrast, the specificity of exercise SPECT was</text>
<text top="896" left="59" width="360" height="16" font="4">increased because of the predictive value of total stress</text>
<text top="914" left="59" width="360" height="16" font="4">perfusion abnormalities, which includes both the risk of</text>
<text top="932" left="59" width="231" height="16" font="4">ischemia plus infarcted myocardium <a href="e44.full.html#87">(</a></text>
<text top="932" left="290" width="15" height="16" font="16"><a href="e44.full.html#87">91</a></text>
<text top="932" left="305" width="114" height="16" font="4"><a href="e44.full.html#87">). </a>Although CMR</text>
<text top="950" left="59" width="360" height="16" font="4">LGE imaging detects MI, current evidence indicates that</text>
<text top="968" left="59" width="360" height="16" font="4">assessment of myocardial ischemia provides incremental</text>
<text top="986" left="59" width="72" height="16" font="4">diagnostic <a href="e44.full.html#115">(</a></text>
<text top="986" left="130" width="30" height="16" font="16"><a href="e44.full.html#115">1249</a></text>
<text top="986" left="160" width="258" height="16" font="4"><a href="e44.full.html#115">) </a>and prognostic value above LGE detec-</text>
<text top="1004" left="59" width="115" height="16" font="4">tion of infarction <a href="e44.full.html#92">(</a></text>
<text top="1004" left="173" width="23" height="16" font="16"><a href="e44.full.html#92">284</a></text>
<text top="1004" left="196" width="222" height="16" font="4"><a href="e44.full.html#92">) </a>in patients with or without known</text>
<text top="1022" left="59" width="43" height="16" font="4">SIHD.</text>
<text top="1040" left="74" width="345" height="16" font="4">In contrast to stress testing, the diagnostic value of</text>
<text top="1058" left="59" width="360" height="16" font="4">CCTA differs in patients with and without known CAD.</text>
<text top="1076" left="59" width="360" height="16" font="4">Limitations of image quality relating to coronary calcifica-</text>
<text top="1094" left="59" width="360" height="16" font="4">tion, coronary stents, or vascular clips can reduce diagnostic</text>
<text top="104" left="446" width="360" height="16" font="4">accuracy, and revascularization also affects results. The large</text>
<text top="123" left="446" width="360" height="16" font="4">caliber of venous conduits facilitates the assessment of</text>
<text top="141" left="446" width="360" height="16" font="4">patients who have undergone CABG with CCTA and has</text>
<text top="159" left="446" width="360" height="16" font="4">sensitivities of 89% to 98% and specificities of 89% to 97%</text>
<text top="177" left="446" width="139" height="16" font="4">for the identification of</text>
<text top="174" left="587" width="218" height="20" font="4">⬎50% diameter stenoses in grafts on</text>
<text top="196" left="446" width="196" height="16" font="4">invasive coronary angiography <a href="e44.full.html#115">(</a></text>
<text top="196" left="642" width="69" height="16" font="16"><a href="e44.full.html#115">1244 –1246</a></text>
<text top="196" left="711" width="95" height="16" font="4"><a href="e44.full.html#115">). </a>The accurate</text>
<text top="214" left="446" width="360" height="16" font="4">evaluation of coronary stents with CCTA depends on the</text>
<text top="232" left="446" width="360" height="16" font="4">material and diameter of the stent, with image artifacts</text>
<text top="250" left="446" width="360" height="16" font="4">related to the stents’ metallic structure preventing assess-</text>
<text top="269" left="446" width="184" height="16" font="4">ment of 9% to 11% of stents <a href="e44.full.html#115">(</a></text>
<text top="269" left="630" width="64" height="16" font="16"><a href="e44.full.html#115">1247,1248</a></text>
<text top="269" left="694" width="112" height="16" font="4"><a href="e44.full.html#115">). </a>Typically, stents</text>
<text top="284" left="446" width="233" height="20" font="4">⬎3 mm in diameter can be assessed <a href="e44.full.html#115">(</a></text>
<text top="287" left="679" width="30" height="16" font="16"><a href="e44.full.html#115">1248</a></text>
<text top="287" left="709" width="97" height="16" font="4"><a href="e44.full.html#115">), </a>with sensitiv-</text>
<text top="305" left="446" width="120" height="16" font="4">ities for detecting a</text>
<text top="302" left="571" width="235" height="20" font="4">⬎50% diameter in-stent restenosis on</text>
<text top="324" left="446" width="360" height="16" font="4">invasive coronary angiography of 86% to 94% and specific-</text>
<text top="342" left="446" width="125" height="16" font="4">ities of 91% to 93%.</text>
<text top="369" left="446" width="296" height="16" font="26"><b>6.3.2. Noninvasive Testing in Known SIHD—</b></text>
<text top="387" left="446" width="350" height="16" font="26"><b>Asymptomatic (or Stable Symptoms): Recommendations</b></text>
<text top="413" left="446" width="21" height="16" font="4">See</text>
<text top="413" left="471" width="54" height="16" font="16"><a href="e44.full.html#82">Table 21</a></text>
<text top="413" left="529" width="276" height="16" font="4">for a summary of recommendations from this</text>
<text top="431" left="446" width="46" height="16" font="4">section.</text>
<text top="464" left="446" width="46" height="8" font="24">CLASS IIa</text>
<text top="477" left="446" width="360" height="10" font="13">1. Nuclear MPI, echocardiography, or CMR with either exercise or</text>
<text top="494" left="461" width="344" height="10" font="13">pharmacological stress can be useful for follow-up assessment at</text>
<text top="511" left="461" width="344" height="10" font="13">2-year or longer intervals in patients with SIHD with prior evidence of</text>
<text top="528" left="461" width="344" height="10" font="13">silent ischemia or who are at high risk for a recurrent cardiac event</text>
<text top="545" left="461" width="344" height="10" font="13">and a) are unable to exercise to an adequate workload, b) have an</text>
<text top="563" left="461" width="344" height="10" font="25"><i>un</i>interpretable ECG, or c) have a history of incomplete coronary</text>
<text top="580" left="461" width="263" height="10" font="13">revascularization <a href="e44.full.html#85">(10,12,15). </a><i>(Level of Evidence: C)</i></text>
<text top="610" left="446" width="46" height="8" font="24">CLASS IIb</text>
<text top="623" left="446" width="360" height="10" font="13">1. Standard exercise ECG testing performed at 1-year or longer inter-</text>
<text top="640" left="461" width="344" height="10" font="13">vals might be considered for follow-up assessment in patients with</text>
<text top="658" left="461" width="344" height="10" font="13">SIHD who have had prior evidence of silent ischemia or are at high</text>
<text top="675" left="461" width="344" height="10" font="13">risk for a recurrent cardiac event and are able to exercise to an</text>
<text top="692" left="461" width="344" height="10" font="13">adequate workload and have an interpretable ECG. (<i>Level of Evi-</i></text>
<text top="709" left="461" width="48" height="10" font="25"><i>dence: C)</i></text>
<text top="726" left="446" width="360" height="10" font="13">2. In patients who have no new or worsening symptoms or no prior</text>
<text top="743" left="461" width="344" height="10" font="13">evidence of silent ischemia and are not at high risk for a recurrent</text>
<text top="760" left="461" width="344" height="10" font="13">cardiac event, the usefulness of annual surveillance exercise ECG</text>
<text top="777" left="461" width="271" height="10" font="13">testing is not well established. <i>(Level of Evidence: C)</i></text>
<text top="808" left="446" width="99" height="8" font="24">CLASS III: No Benefit</text>
<text top="821" left="446" width="360" height="10" font="13">1. Nuclear MPI, echocardiography, or CMR, with either exercise or</text>
<text top="838" left="461" width="344" height="10" font="13">pharmacological stress or CCTA, is not recommended for follow-up</text>
<text top="855" left="461" width="344" height="10" font="13">assessment in patients with SIHD, if performed more frequently</text>
<text top="872" left="461" width="344" height="10" font="13">than at a) 5-year intervals after CABG or b) 2-year intervals after PCI</text>
<text top="890" left="461" width="172" height="10" font="13"><a href="e44.full.html#85">(10,12,15). </a><i>(Level of Evidence: C)</i></text>
<text top="914" left="446" width="18" height="16" font="5"><i>See</i></text>
<text top="914" left="468" width="156" height="16" font="33"><a href="http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2012.07.013"><i>Online Data Supplement 1</i></a></text>
<text top="914" left="628" width="177" height="16" font="5"><i>for additional data on noninva-</i></text>
<text top="932" left="446" width="360" height="16" font="5"><i>sive testing in known SIHD: asymptomatic (or stable symptoms).</i></text>
<text top="959" left="446" width="240" height="16" font="26"><b>6.3.3. Factors Influencing the Use of</b></text>
<text top="977" left="446" width="123" height="16" font="26"><b>Follow-Up Testing</b></text>
<text top="1003" left="446" width="360" height="16" font="4">The appropriateness of performing noninvasive testing in</text>
<text top="1021" left="446" width="360" height="16" font="4">patients who either are asymptomatic or have stable symp-</text>
<text top="1040" left="446" width="360" height="16" font="4">toms (i.e., routine surveillance testing) depends on factors</text>
<text top="1058" left="446" width="360" height="16" font="4">related to the likelihood of significant findings, such as the</text>
<text top="1076" left="446" width="360" height="16" font="4">patient’s risk for rapidly advancing disease, propensity to</text>
<text top="1094" left="446" width="360" height="16" font="4">have silent ischemia, and length of time since revasculariza-</text>
<text top="52" left="59" width="25" height="10" font="12">e124</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1161" width="864">
<text top="500" left="59" width="360" height="16" font="4">tion. The data supporting follow-up testing are sparse and</text>
<text top="518" left="59" width="360" height="16" font="4">insufficient to support routine, repeat testing in asymptom-</text>
<text top="536" left="59" width="360" height="16" font="4">atic individuals. However, evidence exists that persistent</text>
<text top="554" left="59" width="360" height="16" font="4">ischemia on testing is a prognostically poor finding. Explor-</text>
<text top="572" left="59" width="360" height="16" font="4">atory data from a small cohort of 314 patients with SIHD</text>
<text top="590" left="59" width="360" height="16" font="4">enrolled in the COURAGE trial nuclear substudy revealed</text>
<text top="608" left="59" width="360" height="16" font="4">that a reduction in the ischemic myocardium is associated</text>
<text top="626" left="59" width="360" height="16" font="4">with an (unadjusted) reduction in the incidence of death or</text>
<text top="644" left="59" width="98" height="16" font="4">MI combined <a href="e44.full.html#93">(</a></text>
<text top="644" left="156" width="23" height="16" font="16"><a href="e44.full.html#93">306</a></text>
<text top="644" left="179" width="240" height="16" font="4"><a href="e44.full.html#93">). </a>In the BARI 2D trial, at 1 year of</text>
<text top="662" left="59" width="360" height="16" font="4">follow-up, more extensive and severe stress myocardial</text>
<text top="680" left="59" width="360" height="16" font="4">perfusion SPECT abnormalities were associated with</text>
<text top="698" left="59" width="180" height="16" font="4">higher rates of death or MI <a href="e44.full.html#92">(</a></text>
<text top="698" left="239" width="23" height="16" font="16"><a href="e44.full.html#92">276</a></text>
<text top="698" left="261" width="9" height="16" font="4"><a href="e44.full.html#92">).</a></text>
<text top="716" left="74" width="345" height="16" font="4">There are, however, several circumstances in which a</text>
<text top="734" left="59" width="360" height="16" font="4">decision to perform follow-up testing is thought to be</text>
<text top="752" left="59" width="360" height="16" font="4">warranted in the absence of a change in clinical status,</text>
<text top="770" left="59" width="360" height="16" font="4">although data supporting this approach are limited. These</text>
<text top="788" left="59" width="360" height="16" font="4">circumstances include, but are not limited to, evaluation of</text>
<text top="806" left="59" width="360" height="16" font="4">incomplete revascularization, assessment of the adequacy of</text>
<text top="824" left="59" width="360" height="16" font="4">medical therapy by provocative exercise testing, a substantial</text>
<text top="842" left="59" width="360" height="16" font="4">change in risk profile, or the need to reevaluate coronary</text>
<text top="860" left="59" width="360" height="16" font="4">status in anticipation of major noncardiovascular surgery</text>
<text top="878" left="59" width="360" height="16" font="4">when the patient’s exercise capacity is limited or unknown</text>
<text top="896" left="59" width="360" height="16" font="4">(although revascularization in this circumstance has not</text>
<text top="914" left="59" width="360" height="16" font="4">been shown to reduce the risk of perioperative cardiovascu-</text>
<text top="932" left="59" width="360" height="16" font="4">lar complications), as detailed in the ACCF/AHA Periop-</text>
<text top="950" left="59" width="360" height="16" font="4">erative Cardiovascular Evaluation and Care for Noncardiac</text>
<text top="968" left="59" width="129" height="16" font="4">Surgery Guideline <a href="e44.full.html#115">(</a></text>
<text top="968" left="187" width="30" height="16" font="16"><a href="e44.full.html#115">1250</a></text>
<text top="968" left="217" width="201" height="16" font="4"><a href="e44.full.html#115">). </a>Care should be taken when</text>
<text top="986" left="59" width="360" height="16" font="4">interpreting paired testing results to incorporate not only</text>
<text top="1004" left="59" width="360" height="16" font="4">the change in the extent and severity of ischemia but also the</text>
<text top="1022" left="59" width="360" height="16" font="4">workload at onset and total exercise capacity achieved, as</text>
<text top="1040" left="59" width="360" height="16" font="4">these factors relate to the patient’s symptom burden and</text>
<text top="1058" left="59" width="360" height="16" font="4">functional correlates in daily life. Outside of such special</text>
<text top="1076" left="59" width="360" height="16" font="4">circumstances, routine periodic testing is not recommended</text>
<text top="1094" left="59" width="360" height="16" font="4">in patients who are at low risk for progression or had overt</text>
<text top="500" left="446" width="360" height="16" font="4">symptoms on initial presentation (i.e., those without known</text>
<text top="518" left="446" width="360" height="16" font="4">silent ischemia) or very early after revascularization. In</text>
<text top="537" left="446" width="360" height="16" font="4">addition to a lack of evidence for testing to detect ischemia,</text>
<text top="555" left="446" width="360" height="16" font="4">currently there is also little research to support exercise stress</text>
<text top="573" left="446" width="360" height="16" font="4">testing for risk assessment in asymptomatic patients with</text>
<text top="591" left="446" width="360" height="16" font="4">known CAD, except for cardiac rehabilitation and exercise</text>
<text top="609" left="446" width="139" height="16" font="4">prescription purposes <a href="e44.full.html#48">(</a></text>
<text top="609" left="585" width="91" height="16" font="16"><a href="e44.full.html#48">Section 4.4.1.4</a></text>
<text top="609" left="676" width="9" height="16" font="4"><a href="e44.full.html#48">).</a></text>
<text top="636" left="446" width="205" height="16" font="26"><b>6.3.4. Patient Risk and Testing</b></text>
<text top="661" left="446" width="360" height="16" font="4">By using clinical, noninvasive, and invasive data acquired</text>
<text top="679" left="446" width="360" height="16" font="4">during the initial evaluation and subsequently, recommen-</text>
<text top="697" left="446" width="360" height="16" font="4">dations about stress testing in patients with known SIHD</text>
<text top="715" left="446" width="360" height="16" font="4">can be formulated on the basis of the following consider-</text>
<text top="733" left="446" width="360" height="16" font="4">ations: In the absence of a change in clinical status, patients</text>
<text top="752" left="446" width="265" height="16" font="4">with a low projected annual mortality rate (</text>
<text top="748" left="710" width="95" height="20" font="4">⬍1%) are those</text>
<text top="770" left="446" width="360" height="16" font="4">with low-risk Duke treadmill scores, either without imaging</text>
<text top="788" left="446" width="360" height="16" font="4">or with negative imaging findings, whose 4-year cardiovas-</text>
<text top="806" left="446" width="360" height="16" font="4">cular survival rate approximates 99%. The low-risk category</text>
<text top="824" left="446" width="360" height="16" font="4">also includes patients with normal stress imaging who lack</text>
<text top="842" left="446" width="360" height="16" font="4">adverse prognostic characteristics, such as diabetes mellitus</text>
<text top="860" left="446" width="360" height="16" font="4">or prior MI. Younger women without diabetes mellitus or a</text>
<text top="878" left="446" width="360" height="16" font="4">prior MI who have normal stress nuclear MPI remain at</text>
<text top="896" left="446" width="242" height="16" font="4">very low risk for as long as 7 to 9 years <a href="e44.full.html#93">(</a></text>
<text top="896" left="687" width="23" height="16" font="16"><a href="e44.full.html#93">307</a></text>
<text top="896" left="710" width="96" height="16" font="4"><a href="e44.full.html#93">), </a>depending on</text>
<text top="914" left="446" width="360" height="16" font="4">specific clinical characteristics, and probably do not require</text>
<text top="932" left="446" width="360" height="16" font="4">repeat stress imaging during that period in the absence of</text>
<text top="950" left="446" width="161" height="16" font="4">changes in clinical status <a href="e44.full.html#93">(</a></text>
<text top="950" left="607" width="23" height="16" font="16"><a href="e44.full.html#93">307</a></text>
<text top="950" left="629" width="9" height="16" font="4"><a href="e44.full.html#93">).</a></text>
<text top="968" left="461" width="345" height="16" font="4">Data are more limited with regard to the value of serial</text>
<text top="986" left="446" width="360" height="16" font="4">testing strategies in patients at intermediate risk of cardiac</text>
<text top="1004" left="446" width="360" height="16" font="4">mortality (1% to 3% per year). Follow-up testing probably</text>
<text top="1022" left="446" width="360" height="16" font="4">should be performed only if decisions about a change in</text>
<text top="1040" left="446" width="360" height="16" font="4">pharmacological management, level of exercise, or revascu-</text>
<text top="1058" left="446" width="360" height="16" font="4">larization will be influenced directly by the test result or if</text>
<text top="1076" left="446" width="360" height="16" font="4">the patient has persistent symptoms despite adequate</text>
<text top="1094" left="446" width="360" height="16" font="4">GDMT. Thus, in the patient with known SIHD, the goal</text>
<text top="105" left="59" width="485" height="11" font="13">Table 21. Noninvasive Testing in Known SIHD: Asymptomatic (or Stable Symptoms)</text>
<text top="166" left="112" width="21" height="9" font="6">Test</text>
<text top="130" left="208" width="40" height="9" font="6">Exercise</text>
<text top="143" left="213" width="31" height="9" font="6">Status</text>
<text top="130" left="294" width="20" height="9" font="6">ECG</text>
<text top="143" left="273" width="61" height="9" font="6">Interpretable</text>
<text top="166" left="345" width="146" height="9" font="6">Pretest Probability of Ischemia</text>
<text top="166" left="520" width="21" height="9" font="6">COR</text>
<text top="166" left="569" width="76" height="9" font="6">LOE References</text>
<text top="166" left="668" width="121" height="9" font="6">Additional Considerations</text>
<text top="166" left="195" width="67" height="9" font="6">Able* Unable</text>
<text top="166" left="277" width="17" height="9" font="6">Yes</text>
<text top="166" left="316" width="13" height="9" font="6">No</text>
<text top="183" left="59" width="127" height="9" font="6">Exercise or pharmacological</text>
<text top="198" left="71" width="108" height="9" font="6">stress with nuclear MPI,</text>
<text top="212" left="71" width="73" height="9" font="6">Echo, or CMR at</text>
<text top="209" left="146" width="22" height="14" font="6">ⱖ2-y</text>
<text top="226" left="71" width="38" height="9" font="6">intervals</text>
<text top="183" left="243" width="6" height="9" font="6">X</text>
<text top="183" left="320" width="6" height="9" font="6">X</text>
<text top="183" left="344" width="148" height="9" font="6">Prior evidence of silent ischemia</text>
<text top="198" left="356" width="110" height="9" font="6">or high risk for recurrent</text>
<text top="212" left="356" width="128" height="9" font="6">cardiac event. Meets criteria</text>
<text top="226" left="356" width="84" height="9" font="6">listed in additional</text>
<text top="240" left="356" width="68" height="9" font="6">considerations.</text>
<text top="183" left="499" width="11" height="9" font="6">IIa</text>
<text top="183" left="575" width="6" height="9" font="6">C</text>
<text top="183" left="594" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="183" left="598" width="42" height="9" font="7"><a href="e44.full.html#85">10,12,15</a></text>
<text top="183" left="640" width="165" height="9" font="6"><a href="e44.full.html#85">) </a>a) Unable to exercise to adequate</text>
<text top="198" left="664" width="53" height="9" font="6">workload or</text>
<text top="212" left="651" width="116" height="9" font="6">b) <i>Un</i>interpretable ECG or</text>
<text top="226" left="651" width="108" height="9" font="6">c) History of incomplete</text>
<text top="240" left="663" width="118" height="9" font="6">coronary revascularization</text>
<text top="258" left="59" width="71" height="9" font="6">Exercise ECG at</text>
<text top="255" left="132" width="22" height="14" font="6">ⱖ1-y</text>
<text top="272" left="71" width="38" height="9" font="6">intervals</text>
<text top="258" left="205" width="6" height="9" font="6">X</text>
<text top="258" left="282" width="6" height="9" font="6">X</text>
<text top="258" left="410" width="17" height="9" font="6">Any</text>
<text top="258" left="499" width="11" height="9" font="6">IIb</text>
<text top="258" left="575" width="6" height="9" font="6">C</text>
<text top="258" left="594" width="18" height="9" font="6">N/A</text>
<text top="258" left="651" width="116" height="9" font="6">a) Prior evidence of silent</text>
<text top="272" left="664" width="57" height="9" font="6">ischemia OR</text>
<text top="286" left="651" width="124" height="9" font="6">b) At high risk for recurrent</text>
<text top="300" left="664" width="61" height="9" font="6">cardiac event</text>
<text top="318" left="59" width="58" height="9" font="6">Exercise ECG</text>
<text top="318" left="205" width="6" height="9" font="6">X</text>
<text top="318" left="282" width="6" height="9" font="6">X</text>
<text top="318" left="344" width="119" height="9" font="6">No prior evidence of silent</text>
<text top="332" left="356" width="132" height="9" font="6">ischemia and not at high risk</text>
<text top="346" left="356" width="119" height="9" font="6">of recurrent cardiac event.</text>
<text top="318" left="499" width="11" height="9" font="6">IIb</text>
<text top="318" left="575" width="6" height="9" font="6">C</text>
<text top="318" left="594" width="18" height="9" font="6">N/A</text>
<text top="318" left="651" width="105" height="9" font="6">For annual surveillance</text>
<text top="363" left="59" width="127" height="9" font="6">Exercise or pharmacological</text>
<text top="378" left="71" width="108" height="9" font="6">stress with nuclear MPI,</text>
<text top="392" left="71" width="99" height="9" font="6">Echo, or CMR or CCTA</text>
<text top="363" left="220" width="17" height="9" font="6">Any</text>
<text top="363" left="295" width="17" height="9" font="6">Any</text>
<text top="363" left="410" width="17" height="9" font="6">Any</text>
<text top="363" left="499" width="62" height="9" font="6">III: No Benefit</text>
<text top="363" left="575" width="6" height="9" font="6">C</text>
<text top="363" left="594" width="3" height="9" font="6"><a href="e44.full.html#85">(</a></text>
<text top="363" left="598" width="42" height="9" font="7"><a href="e44.full.html#85">10,12,15</a></text>
<text top="363" left="640" width="20" height="9" font="6"><a href="e44.full.html#85">) </a>a)</text>
<text top="361" left="664" width="131" height="14" font="6">⬍5-y intervals after CABG, or</text>
<text top="378" left="651" width="9" height="9" font="6">b)</text>
<text top="375" left="664" width="106" height="14" font="6">⬍2-y intervals after PCI</text>
<text top="429" left="59" width="747" height="7" font="17">*Patients are candidates for exercise testing if they are capable of performing at least moderate physical functioning (i.e., moderate household, yard, or recreational work <i>and </i>most activities of daily</text>
<text top="441" left="59" width="456" height="7" font="17">living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicted maximum heart rate.</text>
<text top="453" left="67" width="739" height="7" font="17">CABG indicates coronary artery bypass graft surgery; CCTA, cardiac computed tomography angiography; CMR, coronary magnetic resonance; COR, class of recommendation; CCTA, computed</text>
<text top="465" left="59" width="747" height="7" font="17">tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not available; PCI,</text>
<text top="477" left="59" width="297" height="7" font="17">percutaneous coronary intervention; and SIHD, stable ischemic heart disease.</text>
<text top="52" left="781" width="25" height="10" font="12">e125</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1161" width="864">
<text top="554" left="59" width="360" height="16" font="4">of repeat testing is the assessment of residual ischemic</text>
<text top="572" left="59" width="360" height="16" font="4">burden after optimization of GDMT or the consideration</text>
<text top="590" left="59" width="360" height="16" font="4">of revascularization as a result of failed optimal medical</text>
<text top="608" left="59" width="360" height="16" font="4">management. Furthermore, to be considered significant,</text>
<text top="626" left="59" width="360" height="16" font="4">findings should be outside the expected range of variability</text>
<text top="644" left="59" width="360" height="16" font="4">of test results, which is approximately 5% for stress nuclear</text>
<text top="662" left="59" width="40" height="16" font="4">MPI <a href="e44.full.html#93">(</a></text>
<text top="662" left="99" width="49" height="16" font="16"><a href="e44.full.html#93">306,366</a></text>
<text top="662" left="148" width="271" height="16" font="4"><a href="e44.full.html#93">), </a>such that patients move into a higher or</text>
<text top="680" left="59" width="119" height="16" font="4">lower risk category.</text>
<text top="698" left="74" width="345" height="16" font="4">Even for high-risk patients, the value of annual exercise</text>
<text top="716" left="59" width="360" height="16" font="4">testing (or serial exercise testing at alternative intervals) in</text>
<text top="734" left="59" width="360" height="16" font="4">the absence of a change in symptoms has not been studied</text>
<text top="752" left="59" width="360" height="16" font="4">adequately. Yearly exercise testing could be useful in pa-</text>
<text top="770" left="59" width="168" height="16" font="4">tients with SIHD who have</text>
<text top="767" left="231" width="188" height="20" font="4">⬎3% risk of mortality per year,</text>
<text top="788" left="59" width="360" height="16" font="4">because a marked decrease in exercise capacity or a marked</text>
<text top="806" left="59" width="360" height="16" font="4">increase in ischemic burden can warrant reevaluation of the</text>
<text top="824" left="59" width="360" height="16" font="4">medical regimen or interventional plan. Examples of such</text>
<text top="842" left="59" width="360" height="16" font="4">patients are those with a high-risk Duke treadmill score,</text>
<text top="860" left="59" width="129" height="16" font="4">patients with an EF</text>
<text top="857" left="194" width="224" height="20" font="4">⬍50% and significant CAD in ⬎1</text>
<text top="878" left="59" width="360" height="16" font="4">major vessel, patients with diabetes mellitus, and those with</text>
<text top="896" left="59" width="360" height="16" font="4">multivessel disease who have not undergone CABG. Some</text>
<text top="914" left="59" width="360" height="16" font="4">data also suggest that ischemic burden might be useful in</text>
<text top="932" left="59" width="360" height="16" font="4">targeting ischemia-guided revascularization. In a substudy</text>
<text top="950" left="59" width="360" height="16" font="4">of the COURAGE trial, the overall event-free survival rate</text>
<text top="968" left="59" width="177" height="16" font="4">was 86.6% in patients with</text>
<text top="965" left="243" width="176" height="20" font="4">ⱖ5% reduction in ischemic</text>
<text top="986" left="59" width="360" height="16" font="4">myocardium versus 75.3% in those without significant</text>
<text top="1004" left="59" width="360" height="16" font="4">reduction in ischemic burden after 6 to 18 months (unad-</text>
<text top="1022" left="59" width="47" height="16" font="4">justed p</text>
<text top="1019" left="105" width="167" height="20" font="4">⫽0.037; adjusted p⫽0.26) <a href="e44.full.html#93">(</a></text>
<text top="1022" left="272" width="23" height="16" font="16"><a href="e44.full.html#93">306</a></text>
<text top="1022" left="295" width="124" height="16" font="4"><a href="e44.full.html#93">). </a>Although this trial</text>
<text top="1040" left="59" width="360" height="16" font="4">substudy was not powered to examine differences in clinical</text>
<text top="1058" left="59" width="360" height="16" font="4">outcomes, the results are similar to the BARI 2D trial, in</text>
<text top="1076" left="59" width="360" height="16" font="4">which patients with high myocardial jeopardy scores ran-</text>
<text top="1094" left="59" width="360" height="16" font="4">domized to CABG had fewer cardiovascular events (AMI</text>
<text top="554" left="446" width="360" height="16" font="4">and composite endpoint of all-cause mortality or MI and</text>
<text top="573" left="446" width="360" height="16" font="4">cardiac death or MI) than those with high scores who</text>
<text top="592" left="446" width="191" height="16" font="4">received only medical therapy <a href="e44.full.html#92">(</a></text>
<text top="592" left="637" width="49" height="16" font="16"><a href="e44.full.html#92">276,409</a></text>
<text top="592" left="686" width="9" height="16" font="4"><a href="e44.full.html#92">).</a></text>
<text top="620" left="446" width="355" height="16" font="26"><b>6.3.5. Stability of Results After Normal Stress Testing</b></text>
<text top="638" left="446" width="205" height="16" font="26"><b>in Patients With Known SIHD</b></text>
<text top="664" left="446" width="360" height="16" font="4">The durability of information gained from a stress test</text>
<text top="683" left="446" width="360" height="16" font="4">over time varies widely according to the characteristics of</text>
<text top="702" left="446" width="360" height="16" font="4">the patients and the type of test performed. Among</text>
<text top="721" left="446" width="360" height="16" font="4">patients with several clinical risk factors and negative</text>
<text top="739" left="446" width="360" height="16" font="4">stress imaging studies, the relative hazard for cardiac</text>
<text top="758" left="446" width="360" height="16" font="4">death or MI can increase after a 2-year follow-up time</text>
<text top="777" left="446" width="360" height="16" font="4">period, whereas among other groups, the risk remains low</text>
<text top="795" left="446" width="360" height="16" font="4">through 2 years and can be safely assumed to remain low</text>
<text top="814" left="446" width="360" height="16" font="4">for an extended period of time. In 1 large single-site</text>
<text top="833" left="446" width="360" height="16" font="4">study, the factors associated with an earlier increase in</text>
<text top="852" left="446" width="360" height="16" font="4">risk included diabetes mellitus, male sex, increased age</text>
<text top="870" left="446" width="28" height="16" font="4">(i.e.,</text>
<text top="867" left="479" width="327" height="20" font="4">ⱖ70 years), a history of previous MI or revascular-</text>
<text top="889" left="446" width="360" height="16" font="4">ization, and having undergone a pharmacological stress</text>
<text top="908" left="446" width="216" height="16" font="4">test rather than an exercise test <a href="e44.full.html#93">(</a></text>
<text top="908" left="662" width="23" height="16" font="16"><a href="e44.full.html#93">327</a></text>
<text top="908" left="685" width="16" height="16" font="4"><a href="e44.full.html#93">) </a><a href="e44.full.html#83">(</a></text>
<text top="908" left="702" width="62" height="16" font="16"><a href="e44.full.html#83">Figure 15</a></text>
<text top="908" left="765" width="41" height="16" font="4"><a href="e44.full.html#83">). </a>The</text>
<text top="926" left="446" width="360" height="16" font="4">relationships were, however, complex and covarying.</text>
<text top="945" left="446" width="360" height="16" font="4">Importantly, among patients who were younger and</text>
<text top="964" left="446" width="360" height="16" font="4">female and did not have diabetes mellitus or a history of</text>
<text top="982" left="446" width="360" height="16" font="4">MI or revascularization, the annual risk of adverse</text>
<text top="1001" left="446" width="286" height="16" font="4">cardiovascular events was predicted to remain</text>
<text top="998" left="735" width="70" height="20" font="4">⬍1% for as</text>
<text top="1020" left="446" width="360" height="16" font="4">long as 9 years, on the basis of hard events observed</text>
<text top="1039" left="446" width="360" height="16" font="4">during the 2-year follow-up period. In contrast, in an</text>
<text top="1057" left="446" width="360" height="16" font="4">80-year-old man with a normal pharmacological stress</text>
<text top="1076" left="446" width="255" height="16" font="4">study, the risk of an adverse event rose to</text>
<text top="1073" left="704" width="101" height="20" font="4">⬎1% in ⬍1 year</text>
<text top="1095" left="446" width="285" height="16" font="4">after an index-negative perfusion evaluation.</text>
<text top="490" left="59" width="535" height="11" font="13">Figure 15. Incidence of Cardiac Death or Nonfatal MI During Follow-Up After a Normal Stress MPI</text>
<text top="522" left="59" width="223" height="8" font="11">Adapted with permission from Hachamovitch et al. <a href="e44.full.html#93">(</a></text>
<text top="522" left="281" width="18" height="8" font="23"><a href="e44.full.html#93">327</a></text>
<text top="522" left="299" width="309" height="8" font="11"><a href="e44.full.html#93">). </a>MI indicates myocardial infarction; MPI, myocardial perfusion imaging.</text>
<text top="52" left="59" width="25" height="10" font="12">e126</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="322" height="16" font="26"><b>6.3.6. Utility of Repeat Stress Testing in Patients</b></text>
<text top="123" left="59" width="125" height="16" font="26"><b>With Known CAD</b></text>
<text top="148" left="59" width="360" height="16" font="4">The interpretation of repeat testing should be based on a</text>
<text top="167" left="59" width="360" height="16" font="4">threshold change value that exceeds the expected variability</text>
<text top="185" left="59" width="360" height="16" font="4">in test results, even in patients at high risk for recurrent</text>
<text top="203" left="59" width="360" height="16" font="4">events, and especially in those with no interval clinical</text>
<text top="221" left="59" width="55" height="16" font="4">change <a href="e44.full.html#115">(</a></text>
<text top="221" left="114" width="30" height="16" font="16"><a href="e44.full.html#115">1244</a></text>
<text top="221" left="144" width="275" height="16" font="4"><a href="e44.full.html#115">). </a>Although the variability of exercise and</text>
<text top="240" left="59" width="295" height="16" font="4">stress testing results is not well established <a href="e44.full.html#93">(</a></text>
<text top="240" left="354" width="56" height="16" font="16"><a href="e44.full.html#93">306,1251</a></text>
<text top="240" left="410" width="9" height="16" font="4"><a href="e44.full.html#93">),</a></text>
<text top="258" left="59" width="360" height="16" font="4">factors such as differences in day-to-day operations in the</text>
<text top="276" left="59" width="360" height="16" font="4">same laboratory, interobserver variability, and differences</text>
<text top="294" left="59" width="360" height="16" font="4">between practices in different imaging laboratories are</text>
<text top="313" left="59" width="360" height="16" font="4">important contributory factors in observed differences in</text>
<text top="331" left="59" width="360" height="16" font="4">serial testing. A 5% change in the percent of ischemic</text>
<text top="349" left="59" width="360" height="16" font="4">myocardium (based on extent and severity) has been sug-</text>
<text top="367" left="59" width="360" height="16" font="4">gested by some investigators as a threshold that indicates</text>
<text top="386" left="59" width="360" height="16" font="4">clinically significant change for stress nuclear MPI</text>
<text top="404" left="59" width="5" height="16" font="4"><a href="e44.full.html#93">(</a></text>
<text top="404" left="63" width="56" height="16" font="16"><a href="e44.full.html#93">306,1251</a></text>
<text top="404" left="120" width="299" height="16" font="4"><a href="e44.full.html#93">). </a>The findings from different exercise or stress</text>
<text top="422" left="59" width="360" height="16" font="4">imaging modalities (echocardiography versus nuclear MPI)</text>
<text top="440" left="59" width="360" height="16" font="4">can be even more difficult to compare, such that clinicians</text>
<text top="458" left="59" width="360" height="16" font="4">should use the same imaging modality over time whenever</text>
<text top="477" left="59" width="360" height="16" font="4">possible. Despite these concerns, significant changes in risk</text>
<text top="495" left="59" width="360" height="16" font="4">category (such as shifting to a lower- or higher-risk patient</text>
<text top="513" left="59" width="360" height="16" font="4">subset) may be used to guide interpretability of interval</text>
<text top="531" left="59" width="167" height="16" font="4">change in repeat testing <a href="e44.full.html#93">(</a></text>
<text top="531" left="226" width="49" height="16" font="16"><a href="e44.full.html#93">306,333</a></text>
<text top="531" left="274" width="144" height="16" font="4"><a href="e44.full.html#93">), </a>and the presence of</text>
<text top="550" left="59" width="360" height="16" font="4">significant interval change can alter risk assessment. For</text>
<text top="568" left="59" width="360" height="16" font="4">example, in the ACME (Angioplasty Compared to Medi-</text>
<text top="586" left="59" width="360" height="16" font="4">cine) trial, patients whose exercise nuclear MPI normalized</text>
<text top="604" left="59" width="360" height="16" font="4">after 6 months of randomized treatment had an improved</text>
<text top="622" left="59" width="360" height="16" font="4">survival rate (92%) compared with those with persistent</text>
<text top="641" left="59" width="114" height="16" font="4">ischemia (82%, p</text>
<text top="637" left="173" width="58" height="20" font="4">⫽0.02) <a href="e44.full.html#94">(</a></text>
<text top="641" left="231" width="23" height="16" font="16"><a href="e44.full.html#94">333</a></text>
<text top="641" left="253" width="165" height="16" font="4"><a href="e44.full.html#94">). </a>The ongoing technical</text>
<text top="659" left="59" width="360" height="16" font="4">evolution within imaging modalities is, in part, aimed at</text>
<text top="677" left="59" width="360" height="16" font="4">minimizing intraobserver, interobserver, and intertest vari-</text>
<text top="695" left="59" width="41" height="16" font="4">ability.</text>
<text top="723" left="59" width="183" height="16" font="26"><b>6.3.7. Future Developments</b></text>
<text top="748" left="59" width="360" height="16" font="4">Numerous opportunities to improve the diagnosis and</text>
<text top="767" left="59" width="360" height="16" font="4">management of SIHD remain. Large registries have the</text>
<text top="785" left="59" width="360" height="16" font="4">potential to improve the diagnosis of IHD and to assess risk</text>
<text top="803" left="59" width="360" height="16" font="4">according to clinical information and results from noninva-</text>
<text top="821" left="59" width="360" height="16" font="4">sive testing. Risk-assessment strategies from older databases</text>
<text top="839" left="59" width="360" height="16" font="4">should be updated with modern information and statistical</text>
<text top="858" left="59" width="360" height="16" font="4">techniques. Technical development across all cardiac imag-</text>
<text top="876" left="59" width="360" height="16" font="4">ing modalities continues to evolve rapidly, often outpacing</text>
<text top="894" left="59" width="360" height="16" font="4">the ability to perform rigorous clinical validation and appli-</text>
<text top="912" left="59" width="360" height="16" font="4">cation. Current and anticipated technical developments of</text>
<text top="931" left="59" width="360" height="16" font="4">CT scanners and software are intended to improve the</text>
<text top="949" left="59" width="360" height="16" font="4">spatial and temporal resolution of cardiac CT images while</text>
<text top="967" left="59" width="360" height="16" font="4">reducing the radiation dose received from a typical exami-</text>
<text top="985" left="59" width="360" height="16" font="4">nation. They include wider detector arrays that allow higher</text>
<text top="1003" left="59" width="360" height="16" font="4">numbers of simultaneously acquired image slices, faster</text>
<text top="1022" left="59" width="360" height="16" font="4">x-ray tube rotation times, and the use of alternative image</text>
<text top="1040" left="59" width="360" height="16" font="4">reconstruction techniques that target image noise, all of</text>
<text top="1058" left="59" width="360" height="16" font="4">which could improve the diagnostic value of CCTA in</text>
<text top="1076" left="59" width="360" height="16" font="4">currently challenging scenarios, such as calcified coronary</text>
<text top="1095" left="59" width="360" height="16" font="4">arteries and coronary stents. The improvement also will</text>
<text top="105" left="446" width="360" height="16" font="4">foster the study and clinical use of newer applications of</text>
<text top="123" left="446" width="360" height="16" font="4">cardiac CT, such as coronary plaque characterization, late</text>
<text top="141" left="446" width="360" height="16" font="4">enhancement imaging for the detection of myocardial scar,</text>
<text top="159" left="446" width="272" height="16" font="4">and MPI to detect myocardial ischemia <a href="e44.full.html#116">(</a></text>
<text top="159" left="718" width="30" height="16" font="16"><a href="e44.full.html#116">1252</a></text>
<text top="159" left="748" width="58" height="16" font="4"><a href="e44.full.html#116">). </a>Efforts</text>
<text top="177" left="446" width="360" height="16" font="4">currently under way to obtain perfusion information from</text>
<text top="195" left="446" width="193" height="16" font="4">CCTA images are promising <a href="e44.full.html#90">(</a></text>
<text top="195" left="639" width="54" height="16" font="16"><a href="e44.full.html#90">196 –201</a></text>
<text top="195" left="693" width="112" height="16" font="4"><a href="e44.full.html#90">), </a>with one report</text>
<text top="213" left="446" width="217" height="16" font="4">also calculating FFR with CCTA <a href="e44.full.html#90">(</a></text>
<text top="213" left="662" width="23" height="16" font="16"><a href="e44.full.html#90">195</a></text>
<text top="213" left="685" width="121" height="16" font="4"><a href="e44.full.html#90">). </a>Moreover, plaque</text>
<text top="231" left="446" width="360" height="16" font="4">quantification software is in development and could further</text>
<text top="249" left="446" width="360" height="16" font="4">guide accurate detection of atherosclerotic disease burden</text>
<text top="267" left="446" width="5" height="16" font="4"><a href="e44.full.html#116">(</a></text>
<text top="267" left="450" width="30" height="16" font="16"><a href="e44.full.html#116">1253</a></text>
<text top="267" left="480" width="9" height="16" font="4"><a href="e44.full.html#116">).</a></text>
<text top="285" left="461" width="345" height="16" font="4">Several new developments in stress nuclear MPI have occurred,</text>
<text top="303" left="446" width="360" height="16" font="4">including new radioisotopes: 1) an F18 PET perfusion agent (in</text>
<text top="321" left="446" width="360" height="16" font="4">Phase III trials), which will allow exercise PET testing;</text>
<text top="339" left="446" width="12" height="16" font="4">2)</text>
<text top="336" left="460" width="16" height="10" font="11">123</text>
<text top="338" left="476" width="330" height="16" font="4">I-beta-methyl-iodophenylpentadecanoic acid SPECT, with</text>
<text top="356" left="446" width="360" height="16" font="4">the unique ability to document metabolic alterations representing</text>
<text top="374" left="446" width="325" height="16" font="4">prior ischemic episodes (i.e., ischemic memory); and 3)</text>
<text top="372" left="777" width="17" height="10" font="11">123</text>
<text top="374" left="794" width="12" height="16" font="4">I-</text>
<text top="392" left="445" width="360" height="16" font="4">labeled meta-iodobenzylguanidine SPECT, which could be</text>
<text top="410" left="445" width="360" height="16" font="4">helpful for assessment of arrhythmic risk in SIHD patients</text>
<text top="428" left="445" width="5" height="16" font="4"><a href="e44.full.html#116">(</a></text>
<text top="428" left="450" width="30" height="16" font="16"><a href="e44.full.html#116">1254</a></text>
<text top="428" left="480" width="325" height="16" font="4"><a href="e44.full.html#116">). </a>Several new SPECT cameras also have been intro-</text>
<text top="446" left="445" width="360" height="16" font="4">duced into the marketplace and offer the opportunity for</text>
<text top="464" left="445" width="360" height="16" font="4">improved image quality within a substantially shorter time</text>
<text top="482" left="445" width="241" height="16" font="4">period and with a lower radiation dose <a href="e44.full.html#116">(</a></text>
<text top="482" left="686" width="64" height="16" font="16"><a href="e44.full.html#116">1255,1256</a></text>
<text top="482" left="750" width="56" height="16" font="4"><a href="e44.full.html#116">). </a>Several</text>
<text top="500" left="445" width="360" height="16" font="4">studies have correlated atherosclerotic plaque characteristics</text>
<text top="518" left="445" width="360" height="16" font="4">with the extent of ischemic myocardium by stress nuclear</text>
<text top="536" left="445" width="39" height="16" font="4">MPI <a href="e44.full.html#90">(</a></text>
<text top="536" left="484" width="79" height="16" font="16"><a href="e44.full.html#90">202–206,215</a></text>
<text top="536" left="563" width="242" height="16" font="4"><a href="e44.full.html#90">). </a>Finally, the diagnostic and prognostic</text>
<text top="554" left="445" width="360" height="16" font="4">value of PET flow reserve data is currently under intense</text>
<text top="572" left="445" width="87" height="16" font="4">investigation <a href="e44.full.html#90">(</a></text>
<text top="572" left="532" width="56" height="16" font="16"><a href="e44.full.html#90">185,1257</a></text>
<text top="572" left="589" width="9" height="16" font="4"><a href="e44.full.html#90">).</a></text>
<text top="590" left="460" width="345" height="16" font="4">Echocardiography, being the most portable and widely</text>
<text top="608" left="445" width="360" height="16" font="4">available stress imaging technique, has developed novel</text>
<text top="626" left="445" width="360" height="16" font="4">methods that are promising in the assessment of SIHD</text>
<text top="644" left="445" width="360" height="16" font="4">patient. Speckle-tracking echocardiography provides a</text>
<text top="662" left="445" width="360" height="16" font="4">2-dimensional, angle-independent, real-time evaluation of</text>
<text top="680" left="445" width="360" height="16" font="4">myocardial strain and has been shown to detect myocardial</text>
<text top="698" left="445" width="287" height="16" font="4">ischemia incremental to wall motion analysis <a href="e44.full.html#116">(</a></text>
<text top="698" left="733" width="64" height="16" font="16"><a href="e44.full.html#116">1258,1259</a></text>
<text top="698" left="797" width="9" height="16" font="4"><a href="e44.full.html#116">).</a></text>
<text top="716" left="445" width="360" height="16" font="4">Recent reports of contrast echocardiography MPI during</text>
<text top="734" left="445" width="360" height="16" font="4">vasodilating stress indicate that it is a potentially robust and</text>
<text top="752" left="445" width="270" height="16" font="4">clinically viable tool in detection of CAD <a href="e44.full.html#116">(</a></text>
<text top="752" left="716" width="30" height="16" font="16"><a href="e44.full.html#116">1260</a></text>
<text top="752" left="746" width="60" height="16" font="4"><a href="e44.full.html#116">). </a>Finally,</text>
<text top="770" left="445" width="360" height="16" font="4">3-dimensional techniques can provide an improved assess-</text>
<text top="788" left="445" width="355" height="16" font="4">ment of cardiac size and function in patients with SIHD.</text>
<text top="806" left="460" width="345" height="16" font="4">Increasing recognition of the ability of CMR to accu-</text>
<text top="824" left="445" width="360" height="16" font="4">rately assess abnormal myocardial physiology of CAD by</text>
<text top="842" left="445" width="360" height="16" font="4">combined imaging of rest and stress ventricular function,</text>
<text top="860" left="445" width="360" height="16" font="4">perfusion, and myocardial viability is expected to increase its</text>
<text top="878" left="445" width="89" height="16" font="4">use in SIHD <a href="e44.full.html#89">(</a></text>
<text top="878" left="534" width="90" height="16" font="16"><a href="e44.full.html#89">172,1261,1262</a></text>
<text top="878" left="624" width="181" height="16" font="4"><a href="e44.full.html#89">). </a>With rapid data acquisition</text>
<text top="896" left="445" width="360" height="16" font="4">by parallel imaging, real-time cine, or sub-second single-</text>
<text top="914" left="445" width="360" height="16" font="4">shot imaging methods, a diagnostically adequate CMR can</text>
<text top="932" left="445" width="360" height="16" font="4">be obtained without the need for patient breath-holding or</text>
<text top="950" left="445" width="87" height="16" font="4">ECG gating <a href="e44.full.html#116">(</a></text>
<text top="950" left="532" width="30" height="16" font="16"><a href="e44.full.html#116">1263</a></text>
<text top="950" left="562" width="243" height="16" font="4"><a href="e44.full.html#116">). </a>A routine CMR assessment of CAD</text>
<text top="968" left="445" width="110" height="16" font="4">can be achieved in</text>
<text top="965" left="559" width="246" height="20" font="4">⬍30 minutes. These developments likely</text>
<text top="986" left="445" width="360" height="16" font="4">will improve diagnostic consistency and patient throughput</text>
<text top="1004" left="445" width="360" height="16" font="4">of CMR. CMR myocardial perfusion and LGE imaging for</text>
<text top="1022" left="445" width="360" height="16" font="4">ischemia and scar, respectively, have improved image quality</text>
<text top="1040" left="445" width="360" height="16" font="4">at 3.0T field strength compared to 1.5T and have been</text>
<text top="1058" left="445" width="360" height="16" font="4">shown to improve diagnostic accuracy in detecting CAD</text>
<text top="1076" left="445" width="5" height="16" font="4"><a href="e44.full.html#116">(</a></text>
<text top="1076" left="450" width="30" height="16" font="16"><a href="e44.full.html#116">1264</a></text>
<text top="1076" left="480" width="325" height="16" font="4"><a href="e44.full.html#116">). </a>Whole-heart 3-dimensional coronary magnetic res-</text>
<text top="1094" left="445" width="360" height="16" font="4">onance angiography with navigator respiratory-gating has</text>
<text top="52" left="781" width="25" height="10" font="12">e127</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="39" size="8" family="Times" color="#15549a"/>
<text top="104" left="59" width="360" height="16" font="4">shown promising pilot results and is being evaluated in</text>
<text top="122" left="59" width="87" height="16" font="4">clinical trials <a href="e44.full.html#116">(</a></text>
<text top="122" left="145" width="64" height="16" font="16"><a href="e44.full.html#116">1265,1266</a></text>
<text top="122" left="209" width="9" height="16" font="4"><a href="e44.full.html#116">).</a></text>
<text top="140" left="74" width="345" height="16" font="4">Further studies on lipid management are warranted to</text>
<text top="158" left="59" width="360" height="16" font="4">ascertain the optimal drug regimens for patients with</text>
<text top="176" left="59" width="360" height="16" font="4">SIHD. Questions remain as to the optimal dose of statins</text>
<text top="194" left="59" width="360" height="16" font="4">and the effectiveness of combining lipid-lowering medi-</text>
<text top="212" left="59" width="360" height="16" font="4">cations. In addition, studies that establish the effective-</text>
<text top="230" left="59" width="360" height="16" font="4">ness of CABG in comparison with contemporary</text>
<text top="248" left="59" width="360" height="16" font="4">GDMT are necessary, as are studies that better define the</text>
<text top="266" left="59" width="360" height="16" font="4">relative benefits of different revascularization techniques.</text>
<text top="284" left="59" width="5" height="16" font="4"><a href="e44.full.html#38">(</a></text>
<text top="284" left="64" width="62" height="16" font="16"><a href="e44.full.html#38">Figure 13</a></text>
<text top="284" left="126" width="9" height="16" font="4"><a href="e44.full.html#38">).</a></text>
<text top="321" left="59" width="165" height="14" font="15">Presidents and Staff</text>
<text top="364" left="59" width="254" height="16" font="5"><i>American College of Cardiology Foundation</i></text>
<text top="382" left="59" width="268" height="16" font="4">William A. Zoghbi, MD, FACC, <i>President</i></text>
<text top="400" left="59" width="349" height="16" font="4">Thomas E. Arend, Jr. Esq, CAE, <i>Interim Chief Staff Officer</i></text>
<text top="418" left="59" width="319" height="16" font="4">William J. Oetgen, MD, MBA, FACC, <i>Senior Vice</i></text>
<text top="436" left="70" width="177" height="16" font="5"><i>President, Science and Quality</i></text>
<text top="454" left="58" width="350" height="16" font="4">Charlene L. May, <i>Senior Director, Science and Clinical Policy</i></text>
<text top="472" left="58" width="360" height="16" font="4">Erin A. Barrett, MPS, <i>Senior Specialist, Science and Clinical</i></text>
<text top="490" left="70" width="34" height="16" font="5"><i>Policy</i></text>
<text top="508" left="58" width="360" height="16" font="5"><i>American College of Cardiology Foundation/American Heart</i></text>
<text top="526" left="70" width="62" height="16" font="5"><i>Association</i></text>
<text top="544" left="58" width="347" height="16" font="4">Lisa Bradfield, CAE, <i>Director, Science and Clinical Policy</i></text>
<text top="562" left="58" width="306" height="16" font="4">Maria Koinis, <i>Specialist, Science and Clinical Policy</i></text>
<text top="580" left="58" width="360" height="16" font="4">Sue Keller, BSN, MPH, <i>Senior Specialist, Evidence-Based</i></text>
<text top="598" left="70" width="53" height="16" font="5"><i>Medicine</i></text>
<text top="625" left="58" width="161" height="16" font="5"><i>American Heart Association</i></text>
<text top="643" left="58" width="281" height="16" font="4">Gordon F. Tomaselli, MD, FAHA, <i>President</i></text>
<text top="661" left="58" width="227" height="16" font="4">Nancy Brown, <i>Chief Executive Officer</i></text>
<text top="679" left="58" width="352" height="16" font="4">Rose Marie Robertson, MD, FAHA, <i>Chief Science Officer</i></text>
<text top="697" left="58" width="360" height="16" font="4">Gayle R. Whitman, PhD, RN, FAHA, FAAN, <i>Senior Vice</i></text>
<text top="715" left="70" width="219" height="16" font="5"><i>President, Office of Science Operations</i></text>
<text top="733" left="58" width="360" height="16" font="4">Judy L. Bezanson, DSN, RN, CNS-MS, FAHA, <i>Science</i></text>
<text top="751" left="70" width="294" height="16" font="5"><i>and Medicine Advisor, Office of Science Operations</i></text>
<text top="788" left="59" width="66" height="9" font="39">REFERENCES</text>
<text top="813" left="77" width="342" height="12" font="12">1. ACCF/AHA Task Force on Practice Guidelines. Methodology</text>
<text top="827" left="92" width="327" height="12" font="12">Manual and Policies From the ACCF/AHA Task Force on Practice</text>
<text top="840" left="92" width="166" height="12" font="12">Guidelines. 2012. Available at:</text>
<text top="840" left="266" width="153" height="12" font="37"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">http://assets.cardiosource.com/</a></text>
<text top="854" left="92" width="327" height="12" font="37"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf</a></text>
<text top="867" left="92" width="19" height="12" font="12">and</text>
<text top="867" left="119" width="299" height="12" font="37"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/sop/documents/downloadable/ucm_319826.pdf">http://my.americanheart.org/idc/groups/ahamah-public/</a></text>
<text top="881" left="92" width="271" height="12" font="37"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/sop/documents/downloadable/ucm_319826.pdf">@wcm/sop/documents/downloadable/ucm_319826.pdf</a></text>
<text top="881" left="363" width="56" height="12" font="12"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/sop/documents/downloadable/ucm_319826.pdf">. </a>Accessed</text>
<text top="894" left="92" width="72" height="12" font="12">May 16, 2012.</text>
<text top="908" left="76" width="342" height="12" font="12">2. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update</text>
<text top="921" left="92" width="327" height="12" font="12">of the ACC/AHA 2004 guidelines for the management of patients</text>
<text top="935" left="92" width="327" height="12" font="12">with ST-elevation myocardial infarction: a report of the American</text>
<text top="948" left="92" width="327" height="12" font="12">College of Cardiology/American Heart Association Task Force on</text>
<text top="962" left="92" width="285" height="12" font="12">Practice Guidelines. J Am Coll Cardiol. 2008;51:210 – 47.</text>
<text top="975" left="76" width="342" height="12" font="12">3. Kushner FG, Hand M, Smith SC Jr., et al. 2009 focused updates:</text>
<text top="989" left="92" width="327" height="12" font="12">ACC/AHA guidelines for the management of patients with ST-</text>
<text top="1002" left="92" width="327" height="12" font="12">elevation myocardial infarction (updating the 2004 guideline and</text>
<text top="1016" left="92" width="327" height="12" font="12">2007 focused update) and ACC/AHA/SCAI guidelines on percu-</text>
<text top="1029" left="92" width="327" height="12" font="12">taneous coronary intervention (updating the 2005 guideline and</text>
<text top="1043" left="92" width="327" height="12" font="12">2007 focused update): a report of the American College of Cardi-</text>
<text top="1056" left="92" width="327" height="12" font="12">ology Foundation/American Heart Association Task Force on</text>
<text top="1070" left="92" width="290" height="12" font="12">Practice Guidelines. J Am Coll Cardiol. 2009;54:2205– 41.</text>
<text top="1083" left="76" width="342" height="12" font="12">4. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA</text>
<text top="1097" left="92" width="327" height="12" font="12">focused update of the guideline for the management of patients with</text>
<text top="104" left="479" width="327" height="12" font="12">unstable angina/non–ST-elevation myocardial infarction (updating</text>
<text top="118" left="479" width="327" height="12" font="12">the 2007 guideline and replacing the 2011 focused update): a report</text>
<text top="132" left="479" width="327" height="12" font="12">of the American College of Cardiology Foundation/American</text>
<text top="145" left="479" width="327" height="12" font="12">Heart Association Task Force on Practice Guidelines. J Am Coll</text>
<text top="159" left="479" width="126" height="12" font="12">Cardiol. 2012;60:645– 81.</text>
<text top="172" left="464" width="342" height="12" font="12">4a.Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA</text>
<text top="186" left="478" width="328" height="12" font="12">focused update incorporated into the ACC/AHA 2007 guidelines</text>
<text top="200" left="478" width="328" height="12" font="12">for the management of patients with unstable angina/non–ST-</text>
<text top="213" left="478" width="328" height="12" font="12">elevation myocardial infarction: a report of the American College of</text>
<text top="227" left="478" width="328" height="12" font="12">Cardiology Foundation/American Heart Association Task Force on</text>
<text top="240" left="478" width="294" height="12" font="12">Practice Guidelines. J Am Coll Cardiol. 2011;57:e215–367.</text>
<text top="254" left="464" width="342" height="12" font="12">5. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA</text>
<text top="268" left="479" width="327" height="12" font="12">guideline for assessment of cardiovascular risk in asymptomatic</text>
<text top="281" left="479" width="327" height="12" font="12">adults: a report of the American College of Cardiology Foundation/</text>
<text top="295" left="479" width="327" height="12" font="12">American Heart Association Task Force on Practice Guidelines.</text>
<text top="308" left="479" width="187" height="12" font="12">J Am Coll Cardiol. 2010;56:e50 –103.</text>
<text top="322" left="464" width="342" height="12" font="12">6. Braunwald E, Mark D, Jones R, et al. Unstable Angina: Diagnosis</text>
<text top="336" left="479" width="327" height="12" font="12">and Management. Clinical Practice Guideline Number 10. Rock-</text>
<text top="349" left="479" width="327" height="12" font="12">ville, MD: Agency for Healthcare Policy and Research and the</text>
<text top="363" left="479" width="327" height="12" font="12">National Heart, Lung, and Blood Institue, Public Health Service,</text>
<text top="376" left="479" width="270" height="12" font="12">US Department of Health and Human Services: 1994.</text>
<text top="390" left="464" width="342" height="12" font="12">7. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002</text>
<text top="404" left="479" width="327" height="12" font="12">guideline update for the management of patients with chronic stable</text>
<text top="417" left="479" width="327" height="12" font="12">angina—summary article: a report of the American College of</text>
<text top="431" left="479" width="327" height="12" font="12">Cardiology/American Heart Association Task Force on practice</text>
<text top="444" left="479" width="327" height="12" font="12">guidelines (Committee on the Management of Patients With</text>
<text top="458" left="479" width="308" height="12" font="12">Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159 – 68.</text>
<text top="471" left="464" width="342" height="12" font="12">8. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF</text>
<text top="485" left="479" width="327" height="12" font="12">secondary prevention and risk reduction therapy for patients with</text>
<text top="499" left="479" width="327" height="12" font="12">coronary and other atherosclerotic vascular disease: 2011 update: a</text>
<text top="512" left="479" width="327" height="12" font="12">guideline from the American Heart Association and American</text>
<text top="526" left="479" width="327" height="12" font="12">College of Cardiology Foundation. J Am Coll Cardiol. 2011;58:</text>
<text top="539" left="479" width="46" height="12" font="12">2432– 46.</text>
<text top="553" left="464" width="342" height="12" font="12">9. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA</text>
<text top="567" left="479" width="327" height="12" font="12">guideline for coronary artery bypass graft surgery: a report of the</text>
<text top="580" left="479" width="327" height="12" font="12">American College of Cardiology Foundation/American Heart As-</text>
<text top="594" left="479" width="327" height="12" font="12">sociation Task Force on Practice Guidelines. J Am Coll Cardiol.</text>
<text top="607" left="479" width="92" height="12" font="12">2011;58:e123–210.</text>
<text top="621" left="458" width="348" height="12" font="12">10. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/</text>
<text top="635" left="479" width="327" height="12" font="12">SCAI guideline for percutaneous coronary intervention: a report of</text>
<text top="648" left="479" width="327" height="12" font="12">the American College of Cardiology Foundation/American Heart</text>
<text top="662" left="479" width="327" height="12" font="12">Association Task Force on Practice Guidelines and the Society for</text>
<text top="675" left="479" width="327" height="12" font="12">Cardiovascular Angiography and Interventions. J Am Coll Cardiol.</text>
<text top="689" left="479" width="88" height="12" font="12">2011;58:e44 –122.</text>
<text top="702" left="458" width="348" height="12" font="12">11. Patel MR, Spertus JA, Brindis RG, et al. ACCF proposed method</text>
<text top="716" left="479" width="327" height="12" font="12">for evaluating the appropriateness of cardiovascular imaging. J Am</text>
<text top="730" left="479" width="157" height="12" font="12">Coll Cardiol. 2005;46:1606 –13.</text>
<text top="743" left="458" width="348" height="12" font="12">12. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/</text>
<text top="757" left="479" width="327" height="12" font="12">AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for</text>
<text top="770" left="479" width="327" height="12" font="12">cardiac radionuclide imaging: a report of the American College of</text>
<text top="784" left="479" width="327" height="12" font="12">Cardiology Foundation Appropriate Use Criteria Task Force, the</text>
<text top="798" left="479" width="327" height="12" font="12">American Society of Nuclear Cardiology, the American College of</text>
<text top="811" left="479" width="327" height="12" font="12">Radiology, the American Heart Association, the American Society</text>
<text top="825" left="479" width="327" height="12" font="12">of Echocardiography, the Society of Cardiovascular Computed</text>
<text top="838" left="479" width="327" height="12" font="12">Tomography, the Society for Cardiovascular Magnetic Resonance,</text>
<text top="852" left="479" width="327" height="12" font="12">and the Society of Nuclear Medicine. J Am Coll Cardiol. 2009;53:</text>
<text top="865" left="479" width="45" height="12" font="12">2201–29.</text>
<text top="879" left="458" width="348" height="12" font="12">13. Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT/</text>
<text top="893" left="479" width="327" height="12" font="12">SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria</text>
<text top="906" left="479" width="327" height="12" font="12">for cardiac computed tomography and cardiac magnetic resonance</text>
<text top="920" left="479" width="327" height="12" font="12">imaging: a report of the American College of Cardiology Founda-</text>
<text top="933" left="479" width="327" height="12" font="12">tion Quality Strategic Directions Committee Appropriateness Cri-</text>
<text top="947" left="479" width="327" height="12" font="12">teria Working Group, American College of Radiology, Society of</text>
<text top="961" left="479" width="327" height="12" font="12">Cardiovascular Computed Tomography, Society for Cardiovascular</text>
<text top="974" left="479" width="327" height="12" font="12">Magnetic Resonance, American Society of Nuclear Cardiology,</text>
<text top="988" left="479" width="327" height="12" font="12">North American Society for Cardiac Imaging, Society for Cardio-</text>
<text top="1001" left="479" width="327" height="12" font="12">vascular Angiography and Interventions, and Society of Interven-</text>
<text top="1015" left="479" width="274" height="12" font="12">tional Radiology. J Am Coll Cardiol. 2006;48:1475–97.</text>
<text top="1028" left="458" width="348" height="12" font="12">14. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/</text>
<text top="1042" left="479" width="327" height="12" font="12">AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use</text>
<text top="1056" left="479" width="327" height="12" font="12">criteria for cardiac computed tomography: a report of the American</text>
<text top="1069" left="479" width="327" height="12" font="12">College of Cardiology Foundation Appropriate Use Criteria Task</text>
<text top="1083" left="479" width="327" height="12" font="12">Force, the Society of Cardiovascular Computed Tomography, the</text>
<text top="1096" left="479" width="327" height="12" font="12">American College of Radiology, the American Heart Association,</text>
<text top="52" left="59" width="25" height="10" font="12">e128</text>
<text top="52" left="113" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="92" width="327" height="12" font="12">the American Society of Echocardiography, the American Society</text>
<text top="118" left="92" width="327" height="12" font="12">of Nuclear Cardiology, the North American Society for</text>
<text top="132" left="92" width="327" height="12" font="12">Cardiovascular Imaging, the Society for Cardiovascular Angiogra-</text>
<text top="145" left="92" width="327" height="12" font="12">phy and Interventions, and the Society for Cardiovascular Magnetic</text>
<text top="159" left="92" width="247" height="12" font="12">Resonance. J Am Coll Cardiol. 2010;56:1864 –94.</text>
<text top="172" left="70" width="348" height="12" font="12">15. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/</text>
<text top="186" left="92" width="327" height="12" font="12">ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropri-</text>
<text top="200" left="92" width="327" height="12" font="12">ate use criteria for echocardiography: a report of the American</text>
<text top="213" left="92" width="327" height="12" font="12">College of Cardiology Foundation Appropriate Use Criteria Task</text>
<text top="227" left="92" width="327" height="12" font="12">Force, American Society of Echocardiography, American Heart</text>
<text top="240" left="92" width="327" height="12" font="12">Association, American Society of Nuclear Cardiology, Heart Failure</text>
<text top="254" left="92" width="327" height="12" font="12">Society of America, Heart Rhythm Society, Society for Cardiovas-</text>
<text top="268" left="92" width="327" height="12" font="12">cular Angiography and Interventions, Society of Critical Care</text>
<text top="281" left="92" width="327" height="12" font="12">Medicine, Society of Cardiovascular Computed Tomography, and</text>
<text top="295" left="92" width="327" height="12" font="12">Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol.</text>
<text top="308" left="92" width="90" height="12" font="12">2011;57:1126 – 66.</text>
<text top="322" left="70" width="348" height="12" font="12">16. Antman EM, Peterson ED. Tools for guiding clinical practice from</text>
<text top="336" left="92" width="327" height="12" font="12">the american heart association and the american college of cardiol-</text>
<text top="349" left="92" width="327" height="12" font="12">ogy: what are they and how should clinicians use them? Circulation.</text>
<text top="363" left="92" width="89" height="12" font="12">2009;119:1180 –5.</text>
<text top="376" left="70" width="348" height="12" font="12">17. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the</text>
<text top="390" left="92" width="327" height="12" font="12">Joint National Committee on Prevention, Detection, Evaluation,</text>
<text top="404" left="92" width="327" height="12" font="12">and Treatment of High Blood Pressure. Hypertension. 2003;42:</text>
<text top="417" left="92" width="46" height="12" font="12">1206 –52.</text>
<text top="431" left="70" width="348" height="12" font="12">18. Third Report of the National Cholesterol Education Program</text>
<text top="444" left="92" width="327" height="12" font="12">(NCEP) Expert Panel on Detection, Evaluation, and Treatment of</text>
<text top="458" left="92" width="327" height="12" font="12">High Blood Cholesterol in Adults (Adult Treatment Panel III) final</text>
<text top="471" left="92" width="199" height="12" font="12">report. Circulation. 2002;106:3143– 421.</text>
<text top="485" left="70" width="348" height="12" font="12">19. Fraker TD Jr., Fihn SD, Gibbons RJ, et al. 2007 chronic angina</text>
<text top="499" left="92" width="327" height="12" font="12">focused update of the ACC/AHA 2002 guidelines for the manage-</text>
<text top="512" left="92" width="327" height="12" font="12">ment of patients with chronic stable angina: a report of the</text>
<text top="526" left="92" width="327" height="12" font="12">American College of Cardiology/American Heart Association Task</text>
<text top="539" left="92" width="327" height="12" font="12">Force on Practice Guidelines Writing Group to Develop the</text>
<text top="553" left="92" width="327" height="12" font="12">Focused Update of the 2002 Guidelines for the Management of</text>
<text top="567" left="92" width="327" height="12" font="12">Patients with Chronic Stable Angina. J Am Coll Cardiol. 2007;50:</text>
<text top="580" left="92" width="46" height="12" font="12">2264 –74.</text>
<text top="594" left="70" width="348" height="12" font="12">20. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update</text>
<text top="607" left="92" width="327" height="12" font="12">incorporated into the ACC/AHA 2006 guidelines for the manage-</text>
<text top="621" left="92" width="327" height="12" font="12">ment of patients with valvular heart disease: a report of the</text>
<text top="635" left="92" width="327" height="12" font="12">American College of Cardiology/American Heart Association Task</text>
<text top="648" left="92" width="327" height="12" font="12">Force on Practice Guidelines (Writing Committee to Revise the</text>
<text top="662" left="92" width="327" height="12" font="12">1998 Guidelines for the Management of Patients with Valvular</text>
<text top="675" left="92" width="260" height="12" font="12">Heart Disease). J Am Coll Cardiol. 2008;52:e1–142.</text>
<text top="689" left="70" width="348" height="12" font="12">21. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update</text>
<text top="702" left="92" width="327" height="12" font="12">incorporated into the ACC/AHA 2005 guidelines for the diagnosis</text>
<text top="716" left="92" width="327" height="12" font="12">and management of heart failure in adults: a report of the American</text>
<text top="730" left="92" width="327" height="12" font="12">College of Cardiology Foundation/American Heart Association</text>
<text top="743" left="92" width="327" height="12" font="12">Task Force on Practice Guidelines: developed in collaboration with</text>
<text top="757" left="92" width="327" height="12" font="12">the International Society for Heart and Lung Transplantation. J Am</text>
<text top="770" left="92" width="150" height="12" font="12">Coll Cardiol. 2009;53:e1– e90.</text>
<text top="784" left="70" width="348" height="12" font="12">22. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA</text>
<text top="798" left="92" width="327" height="12" font="12">guidelines for the management of patients with ST-elevation</text>
<text top="811" left="92" width="327" height="12" font="12">myocardial infarction: a report of the American College of Cardi-</text>
<text top="825" left="92" width="327" height="12" font="12">ology/American Heart Association Task Force on Practice Guide-</text>
<text top="838" left="92" width="327" height="12" font="12">lines (Committee to Revise the 1999 Guidelines for the Manage-</text>
<text top="852" left="92" width="327" height="12" font="12">ment of patients with acute myocardial infarction). J Am Coll</text>
<text top="865" left="92" width="131" height="12" font="12">Cardiol. 2004;44:e1– e211.</text>
<text top="879" left="70" width="106" height="12" font="12">23. Deleted in proof.</text>
<text top="893" left="70" width="348" height="12" font="12">24. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent</text>
<text top="906" left="92" width="327" height="12" font="12">clinical trials for the National Cholesterol Education Program Adult</text>
<text top="920" left="92" width="308" height="12" font="12">Treatment Panel III guidelines. Circulation. 2004;110:227–39.</text>
<text top="933" left="70" width="348" height="12" font="12">25. Balady GJ, Ades PA, Bittner VA, et al. Referral, enrollment, and</text>
<text top="947" left="92" width="327" height="12" font="12">delivery of cardiac rehabilitation/secondary prevention programs at</text>
<text top="961" left="92" width="327" height="12" font="12">clinical centers and beyond: a presidential advisory from the Amer-</text>
<text top="974" left="92" width="276" height="12" font="12">ican Heart Association. Circulation. 2011;124:2951– 60.</text>
<text top="988" left="70" width="348" height="12" font="12">26. Mensah GA, Brown DW. An overview of cardiovascular disease</text>
<text top="1001" left="92" width="327" height="12" font="12">burden in the United States. Health Aff (Millwood). 2007;26:</text>
<text top="1015" left="92" width="36" height="12" font="12">38 – 48.</text>
<text top="1028" left="70" width="348" height="12" font="12">27. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and</text>
<text top="1042" left="92" width="327" height="12" font="12">stroke statistics—2010 update: a report from the American Heart</text>
<text top="1056" left="92" width="225" height="12" font="12">Association. Circulation. 2010;121:e46 – e215.</text>
<text top="1069" left="70" width="348" height="12" font="12">28. Ford ES, Capewell S. Coronary heart disease mortality among</text>
<text top="1083" left="92" width="327" height="12" font="12">young adults in the U.S. from 1980 through 2002: concealed</text>
<text top="1096" left="92" width="320" height="12" font="12">leveling of mortality rates. J Am Coll Cardiol. 2007;50:2128 –32.</text>
<text top="104" left="457" width="348" height="12" font="12">29. Murphy SL, Xu JQ, Kochanek KD. Deaths: Preliminary Data for</text>
<text top="118" left="479" width="239" height="12" font="12">2010. National Vital Statistics Reports. 2012;60.</text>
<text top="131" left="457" width="348" height="12" font="12">30. National Heart, Lung, and Blood Institute. 2006. Incidence and</text>
<text top="145" left="479" width="327" height="12" font="12">Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases.</text>
<text top="159" left="479" width="327" height="12" font="12">Bethesda, MD: National Institutes of Health. 2006. Available at:</text>
<text top="172" left="479" width="277" height="12" font="37"><a href="http://www.nhlbi.nih.gov/resources/docs/06_ip_chtbk.pdf">http://www.nhlbi.nih.gov/resources/docs/06_ip_chtbk.pdf.</a></text>
<text top="172" left="763" width="43" height="12" font="12">Accessed</text>
<text top="186" left="479" width="77" height="12" font="12">January 6, 2012.</text>
<text top="199" left="457" width="348" height="12" font="12">31. Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and</text>
<text top="213" left="479" width="327" height="12" font="12">quality of life after randomization to coronary angioplasty or</text>
<text top="227" left="479" width="327" height="12" font="12">coronary bypass surgery. Bypass Angioplasty Revascularization In-</text>
<text top="240" left="479" width="321" height="12" font="12">vestigation (BARI) Investigators. N Engl J Med. 1997;336:92–9.</text>
<text top="254" left="457" width="348" height="12" font="12">32. Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1 year after</text>
<text top="267" left="479" width="327" height="12" font="12">myocardial infarction: prevalence and associated findings. Arch</text>
<text top="281" left="479" width="154" height="12" font="12">Intern Med. 2008;168:1310 – 6.</text>
<text top="294" left="457" width="348" height="12" font="12">33. Hemingway H, McCallum A, Shipley M, et al. Incidence and</text>
<text top="308" left="479" width="327" height="12" font="12">prognostic implications of stable angina pectoris among women and</text>
<text top="322" left="479" width="163" height="12" font="12">men. JAMA. 2006;295:1404 –11.</text>
<text top="335" left="457" width="348" height="12" font="12">34. Elveback LR, Connolly DC. Coronary heart disease in residents of</text>
<text top="349" left="479" width="327" height="12" font="12">Rochester, Minnesota. V. Prognosis of patients with coronary heart</text>
<text top="362" left="479" width="327" height="12" font="12">disease based on initial manifestation. Mayo Clin Proc. 1985;60:</text>
<text top="376" left="479" width="39" height="12" font="12">305–11.</text>
<text top="390" left="457" width="348" height="12" font="12">35. Kannel WB, Feinleib M. Natural history of angina pectoris in the</text>
<text top="403" left="479" width="327" height="12" font="12">Framingham study. Prognosis and survival. Am J Cardiol. 1972;29:</text>
<text top="417" left="479" width="42" height="12" font="12">154 – 63.</text>
<text top="430" left="457" width="348" height="12" font="12">36. Rumsfeld JS, Magid DJ, Plomondon ME, et al. Health-related</text>
<text top="444" left="479" width="327" height="12" font="12">quality of life after percutaneous coronary intervention versus</text>
<text top="458" left="479" width="327" height="12" font="12">coronary bypass surgery in high-risk patients with medically refrac-</text>
<text top="471" left="479" width="254" height="12" font="12">tory ischemia. J Am Coll Cardiol. 2003;41:1732– 8.</text>
<text top="485" left="457" width="348" height="12" font="12">37. Rumsfeld JS, MaWhinney S, McCarthy M Jr., et al. Health-related</text>
<text top="498" left="479" width="327" height="12" font="12">quality of life as a predictor of mortality following coronary artery</text>
<text top="512" left="479" width="327" height="12" font="12">bypass graft surgery. Participants of the Department of Veterans</text>
<text top="526" left="479" width="327" height="12" font="12">Affairs Cooperative Study Group on Processes, Structures, and</text>
<text top="539" left="479" width="327" height="12" font="12">Outcomes of Care in Cardiac Surgery. JAMA. 1999;281:1298 –303.</text>
<text top="553" left="457" width="348" height="12" font="12">38. Wiest FC, Bryson CL, Burman M, et al. Suboptimal pharmaco-</text>
<text top="566" left="479" width="327" height="12" font="12">therapeutic management of chronic stable angina in the primary care</text>
<text top="580" left="479" width="190" height="12" font="12">setting. Am J Med. 2004;117:234 – 41.</text>
<text top="594" left="457" width="348" height="12" font="12">39. Medicare &amp; Medicaid Statistical Supplement. Centers for Medicare</text>
<text top="607" left="479" width="235" height="12" font="12">and Medicaid Services. 2006. Available at:</text>
<text top="607" left="722" width="84" height="12" font="37"><a href="http://www.cms.hhs.gov/MedicareMedicaidStatSupp/">http://www.cms.</a></text>
<text top="621" left="479" width="177" height="12" font="37"><a href="http://www.cms.hhs.gov/MedicareMedicaidStatSupp/">hhs.gov/MedicareMedicaidStatSupp/.</a></text>
<text top="621" left="659" width="143" height="12" font="12">Accessed September 12, 2008.</text>
<text top="634" left="457" width="348" height="12" font="12">40. Riley RF, Don CW, Powell W, et al. Trends in Coronary</text>
<text top="648" left="479" width="327" height="12" font="12">Revascularization in the United States from 2001–2009: recent</text>
<text top="661" left="479" width="327" height="12" font="12">declines in percutaneous coronary intervention volumes. Circ Car-</text>
<text top="675" left="479" width="193" height="12" font="12">diovasc Qual Outcomes. 2011;4:193–7.</text>
<text top="689" left="457" width="348" height="12" font="12">41. Schappert SM, Burt CW. Ambulatory care visits to physician</text>
<text top="702" left="479" width="327" height="12" font="12">offices, hospital outpatient departments, and emergency depart-</text>
<text top="716" left="479" width="324" height="12" font="12">ments: United States, 2001– 02. Vital Health Stat 13. 2006;1– 66.</text>
<text top="729" left="457" width="348" height="12" font="12">42. Javitz HS, Ward MM, Watson JB, et al. Cost of illness of chronic</text>
<text top="743" left="479" width="240" height="12" font="12">angina. Am J Manag Care. 2004;10:S358 –S369.</text>
<text top="757" left="457" width="348" height="12" font="12">43. Shaw LJ, Merz CNB, Pepine CJ, et al. The economic burden of</text>
<text top="770" left="479" width="327" height="12" font="12">angina in women with suspected ischemic heart disease: results from</text>
<text top="784" left="479" width="327" height="12" font="12">the National Institutes of Health—National Heart, Lung, and</text>
<text top="797" left="479" width="327" height="12" font="12">Blood Institute—sponsored Women’s Ischemia Syndrome Evalua-</text>
<text top="811" left="479" width="183" height="12" font="12">tion. Circulation. 2006;114:894 –904.</text>
<text top="824" left="457" width="348" height="12" font="12">44. Frosch DL, Kaplan RM. Shared decision making in clinical</text>
<text top="838" left="479" width="327" height="12" font="12">medicine: past research and future directions. Am J Prev Med.</text>
<text top="852" left="479" width="81" height="12" font="12">1999;17:285–94.</text>
<text top="865" left="457" width="348" height="12" font="12">45. Kasper JF, Mulley AG Jr., Wennberg JE. Developing shared</text>
<text top="879" left="479" width="327" height="12" font="12">decision-making programs to improve the quality of health care.</text>
<text top="892" left="479" width="189" height="12" font="12">QRB Qual Rev Bull. 1992;18:183–90.</text>
<text top="906" left="457" width="348" height="12" font="12">46. Krumholz HM. Informed consent to promote patient-centered</text>
<text top="920" left="479" width="156" height="12" font="12">care. JAMA. 2010;303:1190 –1.</text>
<text top="933" left="457" width="348" height="12" font="12">47. Fox K, Garcia MAA, Ardissino D, et al. Guidelines on the</text>
<text top="947" left="479" width="327" height="12" font="12">management of stable angina pectoris: executive summary: the Task</text>
<text top="960" left="479" width="327" height="12" font="12">Force on the Management of Stable Angina Pectoris of the</text>
<text top="974" left="479" width="319" height="12" font="12">European Society of Cardiology. Eur Heart J. 2006;27:1341– 81.</text>
<text top="987" left="457" width="348" height="12" font="12">48. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002</text>
<text top="1001" left="479" width="327" height="12" font="12">guideline update for exercise testing: summary article. A report of</text>
<text top="1015" left="479" width="327" height="12" font="12">the American College of Cardiology/American Heart Association</text>
<text top="1028" left="479" width="327" height="12" font="12">Task Force on Practice Guidelines (Committee to Update the 1997</text>
<text top="1042" left="479" width="322" height="12" font="12">Exercise Testing Guidelines). J Am Coll Cardiol. 2002;40:1531–40.</text>
<text top="1055" left="457" width="348" height="12" font="12">49. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial</text>
<text top="1069" left="479" width="240" height="12" font="12">revascularization. Eur Heart J. 2010;31:2501–55.</text>
<text top="1083" left="457" width="348" height="12" font="12">50. Braunwald E. Unstable angina. A classification. Circulation. 1989;</text>
<text top="1096" left="479" width="51" height="12" font="12">80:410 – 4.</text>
<text top="52" left="781" width="25" height="10" font="12">e129</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="71" width="348" height="12" font="12">51. Critchfield TS, Kollins SH. Temporal discounting: basic research</text>
<text top="118" left="92" width="327" height="12" font="12">and the analysis of socially important behavior. J Appl Behav Anal.</text>
<text top="132" left="92" width="81" height="12" font="12">2001;34:101–22.</text>
<text top="146" left="71" width="348" height="12" font="12">52. Diamond GA, Forrester JS. Analysis of probability as an aid in the</text>
<text top="160" left="92" width="327" height="12" font="12">clinical diagnosis of coronary-artery disease. N Engl J Med. 1979;</text>
<text top="174" left="92" width="63" height="12" font="12">300:1350 – 8.</text>
<text top="188" left="71" width="106" height="12" font="12">53. Deleted in proof.</text>
<text top="202" left="71" width="348" height="12" font="12">54. Pepine CJ, Balaban RS, Bonow RO, et al. Women’s Ischemic</text>
<text top="216" left="92" width="327" height="12" font="12">Syndrome Evaluation: current status and future research directions:</text>
<text top="230" left="92" width="327" height="12" font="12">report of the National Heart, Lung and Blood Institute workshop:</text>
<text top="244" left="92" width="327" height="12" font="12">October 2– 4, 2002: Section 1: diagnosis of stable ischemia and</text>
<text top="258" left="92" width="271" height="12" font="12">ischemic heart disease. Circulation. 2004;109:e44 – e46.</text>
<text top="272" left="71" width="348" height="12" font="12">55. Califf RM, Armstrong PW, Carver JR, et al. 27th Bethesda</text>
<text top="286" left="92" width="327" height="12" font="12">Conference: matching the intensity of risk factor management with</text>
<text top="300" left="92" width="327" height="12" font="12">the hazard for coronary disease events. Task Force 5. Stratification</text>
<text top="314" left="92" width="327" height="12" font="12">of patients into high, medium and low risk subgroups for purposes</text>
<text top="328" left="92" width="323" height="12" font="12">of risk factor management. J Am Coll Cardiol. 1996;27:1007–19.</text>
<text top="342" left="71" width="348" height="12" font="12">56. Chatterjee K. Recognition and management of patients with stable</text>
<text top="356" left="92" width="327" height="12" font="12">angina pectoris. In: Goldman L, Braunwald E, editors. Primary</text>
<text top="370" left="92" width="271" height="12" font="12">Cardiology. Philadelphia: WB Saunders; 1998:234 –56.</text>
<text top="384" left="71" width="348" height="12" font="12">57. Daly CA, De Stavola B, Sendon JLL, et al. Predicting prognosis in</text>
<text top="398" left="92" width="327" height="12" font="12">stable angina—results from the Euro heart survey of stable angina:</text>
<text top="412" left="92" width="270" height="12" font="12">prospective observational study. BMJ. 2006;332:262–7.</text>
<text top="426" left="71" width="348" height="12" font="12">58. Daly C, Norrie J, Murdoch DL, et al. The value of routine</text>
<text top="440" left="92" width="327" height="12" font="12">non-invasive tests to predict clinical outcome in stable angina. Eur</text>
<text top="454" left="92" width="126" height="12" font="12">Heart J. 2003;24:532– 40.</text>
<text top="468" left="71" width="348" height="12" font="12">59. Hammermeister KE, DeRouen TA, Dodge HT. Variables predic-</text>
<text top="482" left="92" width="327" height="12" font="12">tive of survival in patients with coronary disease. Selection by</text>
<text top="496" left="92" width="327" height="12" font="12">univariate and multivariate analyses from the clinical, electrocardio-</text>
<text top="510" left="92" width="327" height="12" font="12">graphic, exercise, arteriographic, and quantitative angiographic eval-</text>
<text top="524" left="92" width="185" height="12" font="12">uations. Circulation. 1979;59:421–30.</text>
<text top="538" left="71" width="348" height="12" font="12">60. Block WJ Jr., Crumpacker EL, Dry TJ, et al. Prognosis of angina</text>
<text top="552" left="92" width="327" height="12" font="12">pectoris; observations in 6,882 cases. J Am Med Assoc. 1952;150:</text>
<text top="566" left="92" width="42" height="12" font="12">259 – 64.</text>
<text top="580" left="71" width="348" height="12" font="12">61. Prospective randomised study of coronary artery bypass surgery in</text>
<text top="594" left="92" width="327" height="12" font="12">stable angina pectoris. Second interim report by the European</text>
<text top="608" left="92" width="271" height="12" font="12">Coronary Surgery Study Group. Lancet. 1980;2:491–5.</text>
<text top="622" left="71" width="348" height="12" font="12">62. Frank CW, Weinblatt E, Shapiro S. Angina pectoris in men.</text>
<text top="636" left="92" width="327" height="12" font="12">Prognostic significance of selected medical factors. Circulation.</text>
<text top="650" left="92" width="83" height="12" font="12">1973;47:509 –17.</text>
<text top="664" left="71" width="348" height="12" font="12">63. Murphy ML, Hultgren HN, Detre K, et al. Treatment of chronic</text>
<text top="678" left="92" width="327" height="12" font="12">stable angina. A preliminary report of survival data of the random-</text>
<text top="692" left="92" width="327" height="12" font="12">ized Veterans Administration cooperative study. N Engl J Med.</text>
<text top="706" left="92" width="81" height="12" font="12">1977;297:621–7.</text>
<text top="720" left="71" width="348" height="12" font="12">64. Proudfit WJ, Bruschke AV, MacMillan JP, et al. Fifteen year</text>
<text top="734" left="92" width="327" height="12" font="12">survival study of patients with obstructive coronary artery disease.</text>
<text top="747" left="92" width="144" height="12" font="12">Circulation. 1983;68:986 –97.</text>
<text top="761" left="71" width="348" height="12" font="12">65. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular</text>
<text top="775" left="92" width="327" height="12" font="12">premature complexes in prognosis of angina. Circulation. 1980;61:</text>
<text top="789" left="92" width="46" height="12" font="12">1172– 82.</text>
<text top="803" left="71" width="348" height="12" font="12">66. Detre K, Peduzzi P, Murphy M, et al. Effect of bypass surgery on</text>
<text top="817" left="92" width="327" height="12" font="12">survival in patients in low- and high-risk subgroups delineated by</text>
<text top="831" left="92" width="325" height="12" font="12">the use of simple clinical variables. Circulation. 1981;63:1329 –38.</text>
<text top="845" left="71" width="348" height="12" font="12">67. Knochel JP, Beisel WR, Herndon EG Jr., et al. The renal,</text>
<text top="859" left="92" width="327" height="12" font="12">cardiovascular, hematologic and serum electrolyte abnormalities of</text>
<text top="873" left="92" width="210" height="12" font="12">heat stroke. Am J Med. 1961;30:299 –309.</text>
<text top="887" left="71" width="348" height="12" font="12">68. Hollander JE. The management of cocaine-associated myocardial</text>
<text top="901" left="92" width="221" height="12" font="12">ischemia. N Engl J Med. 1995;333:1267–72.</text>
<text top="915" left="71" width="348" height="12" font="12">69. McCord J, Jneid H, Hollander JE, et al. Management of cocaine-</text>
<text top="929" left="92" width="327" height="12" font="12">associated chest pain and myocardial infarction: a scientific state-</text>
<text top="943" left="92" width="327" height="12" font="12">ment from the American Heart Association Acute Cardiac Care</text>
<text top="957" left="92" width="327" height="12" font="12">Committee of the Council on Clinical Cardiology. Circulation.</text>
<text top="971" left="92" width="99" height="12" font="12">2008;117:1897–907.</text>
<text top="985" left="71" width="348" height="12" font="12">70. Pryor DB, Shaw L, Harrell FE Jr., et al. Estimating the likelihood</text>
<text top="999" left="92" width="308" height="12" font="12">of severe coronary artery disease. Am J Med. 1991;90:553– 62.</text>
<text top="1013" left="71" width="348" height="12" font="12">71. Pryor DB, Shaw L, McCants CB, et al. Value of the history and</text>
<text top="1027" left="92" width="327" height="12" font="12">physical in identifying patients at increased risk for coronary artery</text>
<text top="1041" left="92" width="212" height="12" font="12">disease. Ann Intern Med. 1993;118:81–90.</text>
<text top="1055" left="71" width="348" height="12" font="12">72. Sox HC Jr., Hickam DH, Marton KI, et al. Using the patient’s</text>
<text top="1069" left="92" width="327" height="12" font="12">history to estimate the probability of coronary artery disease: a</text>
<text top="1083" left="92" width="327" height="12" font="12">comparison of primary care and referral practices. Am J Med.</text>
<text top="1097" left="92" width="69" height="12" font="12">1990;89:7–14.</text>
<text top="105" left="458" width="348" height="12" font="12">73. Chaitman BR, Bourassa MG, Davis K, et al. Angiographic preva-</text>
<text top="118" left="479" width="327" height="12" font="12">lence of high-risk coronary artery disease in patient subsets (CASS).</text>
<text top="132" left="479" width="138" height="12" font="12">Circulation. 1981;64:360 –7.</text>
<text top="146" left="458" width="348" height="12" font="12">74. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the</text>
<text top="160" left="479" width="327" height="12" font="12">NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation</text>
<text top="173" left="479" width="327" height="12" font="12">(WISE) Study: Part I: gender differences in traditional and novel</text>
<text top="187" left="479" width="327" height="12" font="12">risk factors, symptom evaluation, and gender-optimized diagnostic</text>
<text top="201" left="479" width="235" height="12" font="12">strategies. J Am Coll Cardiol. 2006;47:S4 –S20.</text>
<text top="215" left="458" width="348" height="12" font="12">75. Shaw LJ, Bugiardini R, Merz CNB. Women and ischemic heart</text>
<text top="229" left="479" width="327" height="12" font="12">disease: evolving knowledge. J Am Coll Cardiol. 2009;54:1561–75.</text>
<text top="242" left="458" width="348" height="12" font="12">76. Shaw LJ, Berman DS. Functional versus anatomic imaging in</text>
<text top="256" left="479" width="327" height="12" font="12">patients with suspected coronary artery disease. Cardiol Clin.</text>
<text top="270" left="479" width="89" height="12" font="12">2009;27:597– 604.</text>
<text top="284" left="458" width="348" height="12" font="12">77. Raff GL, Gallagher MJ, O’Neill WW, et al. Diagnostic accuracy of</text>
<text top="298" left="479" width="327" height="12" font="12">noninvasive coronary angiography using 64-slice spiral computed</text>
<text top="311" left="479" width="240" height="12" font="12">tomography. J Am Coll Cardiol. 2005;46:552–7.</text>
<text top="325" left="458" width="348" height="12" font="12">78. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging.</text>
<text top="339" left="479" width="180" height="12" font="12">Med Decis Making. 1991;11:88 –94.</text>
<text top="353" left="458" width="348" height="12" font="12">79. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation</text>
<text top="367" left="479" width="327" height="12" font="12">of novel markers of cardiovascular risk: a scientific statement from</text>
<text top="380" left="479" width="323" height="12" font="12">the American Heart Association. Circulation. 2009;119:2408 –16.</text>
<text top="394" left="458" width="348" height="12" font="12">80. Rozanski A, Diamond GA, Berman D, et al. The declining</text>
<text top="408" left="479" width="327" height="12" font="12">specificity of exercise radionuclide ventriculography. N Engl J Med.</text>
<text top="422" left="479" width="89" height="12" font="12">1983;309:518 –22.</text>
<text top="435" left="458" width="348" height="12" font="12">81. Douglas PS. Is noninvasive testing for coronary artery disease</text>
<text top="449" left="479" width="198" height="12" font="12">accurate? Circulation. 1997;95:299 –302.</text>
<text top="463" left="458" width="348" height="12" font="12">82. Kaul S. Technical, economic, interpretative, and outcomes issues</text>
<text top="477" left="479" width="327" height="12" font="12">regarding utilization of cardiac imaging techniques in patients with</text>
<text top="491" left="479" width="327" height="12" font="12">known or suspected coronary artery disease. Am J Cardiol. 1995;</text>
<text top="504" left="479" width="68" height="12" font="12">75:18D–24D.</text>
<text top="518" left="458" width="348" height="12" font="12">83. Diamond GA. Reverend Bayes’ silent majority. An alternative factor</text>
<text top="532" left="479" width="327" height="12" font="12">affecting sensitivity and specificity of exercise electrocardiography.</text>
<text top="546" left="479" width="163" height="12" font="12">Am J Cardiol. 1986;57:1175– 80.</text>
<text top="560" left="458" width="348" height="12" font="12">84. Roger VL, Pellikka PA, Bell MR, et al. Sex and test verification</text>
<text top="573" left="479" width="327" height="12" font="12">bias. Impact on the diagnostic value of exercise echocardiography.</text>
<text top="587" left="479" width="143" height="12" font="12">Circulation. 1997;95:405–10.</text>
<text top="601" left="458" width="348" height="12" font="12">85. Cecil MP, Kosinski AS, Jones MT, et al. The importance of</text>
<text top="615" left="479" width="327" height="12" font="12">work-up (verification) bias correction in assessing the accuracy of</text>
<text top="628" left="479" width="327" height="12" font="12">SPECT thallium-201 testing for the diagnosis of coronary artery</text>
<text top="642" left="479" width="215" height="12" font="12">disease. J Clin Epidemiol. 1996;49:735– 42.</text>
<text top="656" left="458" width="348" height="12" font="12">86. Miller TD, Hodge DO, Christian TF, et al. Effects of adjustment</text>
<text top="670" left="479" width="327" height="12" font="12">for referral bias on the sensitivity and specificity of single photon</text>
<text top="684" left="479" width="327" height="12" font="12">emission computed tomography for the diagnosis of coronary artery</text>
<text top="697" left="479" width="184" height="12" font="12">disease. Am J Med. 2002;112:290 –7.</text>
<text top="711" left="458" width="348" height="12" font="12">87. Diamond GA, Forrester JS, Hirsch M, et al. Application of</text>
<text top="725" left="479" width="327" height="12" font="12">conditional probability analysis to the clinical diagnosis of coronary</text>
<text top="739" left="479" width="230" height="12" font="12">artery disease. J Clin Invest. 1980;65:1210 –21.</text>
<text top="752" left="458" width="348" height="12" font="12">88. Goldman L, Cook EF, Mitchell N, et al. Incremental value of the</text>
<text top="766" left="479" width="327" height="12" font="12">exercise test for diagnosing the presence or absence of coronary</text>
<text top="780" left="479" width="215" height="12" font="12">artery disease. Circulation. 1982;66:945–53.</text>
<text top="794" left="458" width="348" height="12" font="12">89. Melin JA, Wijns W, Vanbutsele RJ, et al. Alternative diagnostic</text>
<text top="808" left="479" width="327" height="12" font="12">strategies for coronary artery disease in women: demonstration of</text>
<text top="821" left="479" width="327" height="12" font="12">the usefulness and efficiency of probability analysis. Circulation.</text>
<text top="835" left="479" width="83" height="12" font="12">1985;71:535– 42.</text>
<text top="849" left="458" width="348" height="12" font="12">90. Diamond GA, Kaul S. Low diagnostic yield of elective coronary</text>
<text top="863" left="479" width="221" height="12" font="12">angiography. N Engl J Med. 2010;363:93–5.</text>
<text top="876" left="458" width="348" height="12" font="12">91. Fleischmann KE, Hunink MG, Kuntz KM, et al. Exercise echo-</text>
<text top="890" left="479" width="327" height="12" font="12">cardiography or exercise SPECT imaging? A meta-analysis of</text>
<text top="904" left="479" width="269" height="12" font="12">diagnostic test performance. JAMA. 1998;280:913–20.</text>
<text top="918" left="458" width="348" height="12" font="12">92. Cheng VY, Berman DS, Rozanski A, et al. Performance of the</text>
<text top="932" left="479" width="327" height="12" font="12">Traditional Age, Sex, and Angina Typicality-Based Approach for</text>
<text top="945" left="479" width="327" height="12" font="12">Estimating Pretest Probability of Angiographically Significant Cor-</text>
<text top="959" left="479" width="327" height="12" font="12">onary Artery Disease in Patients Undergoing Coronary Computed</text>
<text top="973" left="479" width="327" height="12" font="12">Tomographic Angiography: results from the Multinational Coro-</text>
<text top="987" left="479" width="327" height="12" font="12">nary CT Angiography Evaluation for Clinical Outcomes: An</text>
<text top="1000" left="479" width="327" height="12" font="12">International Multicenter Registry (CONFIRM). Circulation.</text>
<text top="1014" left="479" width="93" height="12" font="12">2011;124:2423–32.</text>
<text top="1028" left="458" width="348" height="12" font="12">93. Berrington de Gonzalez A, Mahesh M, Kim K-P, et al. Projected</text>
<text top="1042" left="479" width="327" height="12" font="12">cancer risks from computed tomographic scans performed in the</text>
<text top="1056" left="479" width="295" height="12" font="12">United States in 2007. Arch Intern Med. 2009;169:2071–7.</text>
<text top="1069" left="458" width="348" height="12" font="12">94. Gerber TC, Gibbons RJ. Weighing the risks and benefits of cardiac</text>
<text top="1083" left="479" width="327" height="12" font="12">imaging with ionizing radiation. J Am Coll Cardiol Cardiovasc</text>
<text top="1097" left="479" width="124" height="12" font="12">Imaging. 2010;3:528 –35.</text>
<text top="52" left="59" width="25" height="10" font="12">e130</text>
<text top="52" left="113" width="48" height="10" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="71" width="348" height="12" font="12">95. Berrington de Gonzalez A, Kim K-P, Smith-Bindman R, et al.</text>
<text top="118" left="92" width="327" height="12" font="12">Myocardial perfusion scans: projected population cancer risks from</text>
<text top="132" left="92" width="327" height="12" font="12">current levels of use in the United States. Circulation. 2010;122:</text>
<text top="146" left="92" width="45" height="12" font="12">2403–10.</text>
<text top="160" left="71" width="348" height="12" font="12">96. Halliburton SS, Abbara S, Chen MY, et al. SCCT guidelines on</text>
<text top="173" left="92" width="327" height="12" font="12">radiation dose and dose-optimization strategies in cardiovascular</text>
<text top="187" left="92" width="264" height="12" font="12">CT. J Cardiovasc Comput Tomogr. 2011;5:198 –224.</text>
<text top="201" left="71" width="348" height="12" font="12">97. Cerqueira MD, Allman KC, Ficaro EP, et al. Recommendations for</text>
<text top="215" left="92" width="327" height="12" font="12">reducing radiation exposure in myocardial perfusion imaging. J Nucl</text>
<text top="228" left="92" width="126" height="12" font="12">Cardiol. 2010;17:709 –18.</text>
<text top="242" left="71" width="348" height="12" font="12">98. Gerber TC, Carr JJ, Arai AE, et al. Ionizing radiation in cardiac</text>
<text top="256" left="92" width="327" height="12" font="12">imaging: a science advisory from the American Heart Association</text>
<text top="270" left="92" width="327" height="12" font="12">Committee on Cardiac Imaging of the Council on Clinical Cardi-</text>
<text top="284" left="92" width="327" height="12" font="12">ology and Committee on Cardiovascular Imaging and Intervention</text>
<text top="297" left="92" width="327" height="12" font="12">of the Council on Cardiovascular Radiology and Intervention.</text>
<text top="311" left="92" width="158" height="12" font="12">Circulation. 2009;119:1056 – 65.</text>
<text top="325" left="71" width="348" height="12" font="12">99. Sharir T, Slomka PJ, Hayes SW, et al. Multicenter trial of</text>
<text top="339" left="92" width="327" height="12" font="12">high-speed versus conventional single-photon emission computed</text>
<text top="353" left="92" width="327" height="12" font="12">tomography imaging: quantitative results of myocardial perfusion</text>
<text top="366" left="92" width="327" height="12" font="12">and left ventricular function. J Am Coll Cardiol. 2010;55:1965–74.</text>
<text top="380" left="65" width="354" height="12" font="12">100. Berman DS, Kang X, Tamarappoo B, et al. Stress thallium-201/rest</text>
<text top="394" left="92" width="327" height="12" font="12">technetium-99m sequential dual isotope high-speed myocardial</text>
<text top="408" left="92" width="327" height="12" font="12">perfusion imaging. J Am Coll Cardiol Cardiovasc Imaging. 2009;</text>
<text top="422" left="92" width="50" height="12" font="12">2:273– 82.</text>
<text top="435" left="65" width="354" height="12" font="12">101. Bonow RO. High-speed myocardial perfusion imaging: dawn of a</text>
<text top="449" left="92" width="327" height="12" font="12">new era in nuclear cardiology? J Am Coll Cardiol Cardiovasc</text>
<text top="463" left="92" width="120" height="12" font="12">Imaging. 2008;1:164 – 6.</text>
<text top="477" left="65" width="354" height="12" font="12">102. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer</text>
<text top="490" left="92" width="327" height="12" font="12">associated with radiation exposure from 64-slice computed tomog-</text>
<text top="504" left="92" width="271" height="12" font="12">raphy coronary angiography. JAMA. 2007;298:317–23.</text>
<text top="518" left="65" width="354" height="12" font="12">103. Paridon SM, Alpert BS, Boas SR, et al. Clinical stress testing in the</text>
<text top="532" left="92" width="327" height="12" font="12">pediatric age group: a statement from the American Heart Associ-</text>
<text top="546" left="92" width="327" height="12" font="12">ation Council on Cardiovascular Disease in the Young, Committee</text>
<text top="559" left="92" width="327" height="12" font="12">on Atherosclerosis, Hypertension, and Obesity in Youth. Circula-</text>
<text top="573" left="92" width="120" height="12" font="12">tion. 2006;113:1905–20.</text>
<text top="587" left="65" width="354" height="12" font="12">104. Myers J, Arena R, Franklin B, et al. Recommendations for clinical</text>
<text top="601" left="92" width="327" height="12" font="12">exercise laboratories: a scientific statement from the american heart</text>
<text top="615" left="92" width="217" height="12" font="12">association. Circulation. 2009;119:3144 – 61.</text>
<text top="628" left="65" width="354" height="12" font="12">105. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for</text>
<text top="642" left="92" width="327" height="12" font="12">testing and training: a statement for healthcare professionals from the</text>
<text top="656" left="92" width="296" height="12" font="12">American Heart Association. Circulation. 2001;104:1694–740.</text>
<text top="670" left="65" width="354" height="12" font="12">106. Christian TF, Miller TD, Bailey KR, et al. Exercise tomographic</text>
<text top="683" left="92" width="327" height="12" font="12">thallium-201 imaging in patients with severe coronary artery disease</text>
<text top="697" left="92" width="327" height="12" font="12">and normal electrocardiograms. Ann Intern Med. 1994;121:825–32.</text>
<text top="711" left="65" width="354" height="12" font="12">107. Gibbons RJ, Zinsmeister AR, Miller TD, et al. Supine exercise</text>
<text top="725" left="92" width="327" height="12" font="12">electrocardiography compared with exercise radionuclide angiogra-</text>
<text top="739" left="92" width="327" height="12" font="12">phy in noninvasive identification of severe coronary artery disease.</text>
<text top="752" left="92" width="171" height="12" font="12">Ann Intern Med. 1990;112:743–9.</text>
<text top="766" left="65" width="354" height="12" font="12">108. Hachamovitch R, Hayes SW, Friedman JD, et al. Stress myocardial</text>
<text top="780" left="92" width="327" height="12" font="12">perfusion single-photon emission computed tomography is clinically</text>
<text top="794" left="92" width="327" height="12" font="12">effective and cost effective in risk stratification of patients with a</text>
<text top="807" left="92" width="327" height="12" font="12">high likelihood of coronary artery disease (CAD) but no known</text>
<text top="821" left="92" width="212" height="12" font="12">CAD. J Am Coll Cardiol. 2004;43:200 – 8.</text>
<text top="835" left="65" width="354" height="12" font="12">109. Ladenheim ML, Kotler TS, Pollock BH, et al. Incremental prog-</text>
<text top="849" left="92" width="327" height="12" font="12">nostic power of clinical history, exercise electrocardiography and</text>
<text top="863" left="92" width="327" height="12" font="12">myocardial perfusion scintigraphy in suspected coronary artery</text>
<text top="876" left="92" width="191" height="12" font="12">disease. Am J Cardiol. 1987;59:270 –7.</text>
<text top="890" left="65" width="354" height="12" font="12">110. Mattera JA, Arain SA, Sinusas AJ, et al. Exercise testing with</text>
<text top="904" left="92" width="327" height="12" font="12">myocardial perfusion imaging in patients with normal baseline</text>
<text top="918" left="92" width="327" height="12" font="12">electrocardiograms: cost savings with a stepwise diagnostic strategy.</text>
<text top="931" left="92" width="162" height="12" font="12">J Nucl Cardiol. 1998;5:498 –506.</text>
<text top="945" left="65" width="354" height="12" font="12">111. Metz LD, Beattie M, Hom R, et al. The prognostic value of normal</text>
<text top="959" left="92" width="327" height="12" font="12">exercise myocardial perfusion imaging and exercise echocardiogra-</text>
<text top="973" left="92" width="287" height="12" font="12">phy: a meta-analysis. J Am Coll Cardiol. 2007;49:227–37.</text>
<text top="987" left="65" width="354" height="12" font="12">112. Mowatt G, Vale L, Brazzelli M, et al. Systematic review of the</text>
<text top="1000" left="92" width="327" height="12" font="12">effectiveness and cost-effectiveness, and economic evaluation, of</text>
<text top="1014" left="92" width="327" height="12" font="12">myocardial perfusion scintigraphy for the diagnosis and manage-</text>
<text top="1028" left="92" width="327" height="12" font="12">ment of angina and myocardial infarction. Health Technol Assess.</text>
<text top="1042" left="92" width="73" height="12" font="12">2004;8:iii–207.</text>
<text top="1055" left="65" width="354" height="12" font="12">113. Nallamothu N, Ghods M, Heo J, et al. Comparison of thallium-201</text>
<text top="1069" left="92" width="327" height="12" font="12">single-photon emission computed tomography and electrocardio-</text>
<text top="1083" left="92" width="327" height="12" font="12">graphic response during exercise in patients with normal rest</text>
<text top="1097" left="92" width="317" height="12" font="12">electrocardiographic results. J Am Coll Cardiol. 1995;25:830 – 6.</text>
<text top="104" left="452" width="354" height="12" font="12">114. Sabharwal NK, Stoykova B, Taneja AK, et al. A randomized trial of</text>
<text top="118" left="479" width="327" height="12" font="12">exercise treadmill ECG versus stress SPECT myocardial perfusion</text>
<text top="132" left="479" width="327" height="12" font="12">imaging as an initial diagnostic strategy in stable patients with chest</text>
<text top="146" left="479" width="327" height="12" font="12">pain and suspected CAD: cost analysis. J Nucl Cardiol. 2007;14:</text>
<text top="160" left="479" width="42" height="12" font="12">174 – 86.</text>
<text top="174" left="452" width="354" height="12" font="12">115. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial</text>
<text top="188" left="479" width="257" height="12" font="12">perfusion SPECT. J Nucl Cardiol. 2004;11:171– 85.</text>
<text top="202" left="452" width="354" height="12" font="12">116. Simari RD, Miller TD, Zinsmeister AR, et al. Capabilities of</text>
<text top="216" left="479" width="327" height="12" font="12">supine exercise electrocardiography versus exercise radionuclide</text>
<text top="230" left="479" width="327" height="12" font="12">angiography in predicting coronary events. Am J Cardiol. 1991;67:</text>
<text top="244" left="479" width="33" height="12" font="12">573–7.</text>
<text top="258" left="452" width="354" height="12" font="12">117. Hachamovitch R, Berman DS, Kiat H, et al. Value of stress</text>
<text top="272" left="479" width="327" height="12" font="12">myocardial perfusion single photon emission computed tomography</text>
<text top="286" left="479" width="327" height="12" font="12">in patients with normal resting electrocardiograms: an evaluation of</text>
<text top="300" left="479" width="327" height="12" font="12">incremental prognostic value and cost-effectiveness. Circulation.</text>
<text top="314" left="479" width="81" height="12" font="12">2002;105:823–9.</text>
<text top="328" left="452" width="354" height="12" font="12">118. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a</text>
<text top="342" left="479" width="327" height="12" font="12">nomogram for exercise capacity in women. N Engl J Med. 2005;</text>
<text top="356" left="479" width="62" height="12" font="12">353:468 –75.</text>
<text top="370" left="452" width="354" height="12" font="12">119. Myers J, Prakash M, Froelicher V, et al. Exercise capacity and</text>
<text top="384" left="479" width="327" height="12" font="12">mortality among men referred for exercise testing. N Engl J Med.</text>
<text top="398" left="479" width="95" height="12" font="12">2002;346:793– 801.</text>
<text top="412" left="452" width="354" height="12" font="12">120. Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart</text>
<text top="426" left="479" width="245" height="12" font="12">rate revisited. J Am Coll Cardiol. 2001;37:153– 6.</text>
<text top="440" left="452" width="354" height="12" font="12">121. Pinkstaff S, Peberdy MA, Kontos MC, et al. Quantifying exertion</text>
<text top="454" left="479" width="327" height="12" font="12">level during exercise stress testing using percentage of age-predicted</text>
<text top="468" left="479" width="327" height="12" font="12">maximal heart rate, rate pressure product, and perceived exertion.</text>
<text top="482" left="479" width="180" height="12" font="12">Mayo Clin Proc. 2010;85:1095–100.</text>
<text top="496" left="452" width="354" height="12" font="12">122. Gulati M, Shaw LJ, Thisted RA, et al. Heart rate response to</text>
<text top="510" left="479" width="327" height="12" font="12">exercise stress testing in asymptomatic women: the St. James women</text>
<text top="524" left="479" width="237" height="12" font="12">take heart project. Circulation. 2010;122:130 –7.</text>
<text top="538" left="452" width="354" height="12" font="12">123. Carnethon MR, Gulati M, Greenland P. Prevalence and cardiovas-</text>
<text top="552" left="479" width="327" height="12" font="12">cular disease correlates of low cardiorespiratory fitness in adolescents</text>
<text top="566" left="479" width="187" height="12" font="12">and adults. JAMA. 2005;294:2981– 8.</text>
<text top="580" left="452" width="354" height="12" font="12">124. Gupta S, Rohatgi A, Ayers CR, et al. Cardiorespiratory fitness and</text>
<text top="594" left="479" width="327" height="12" font="12">classification of risk of cardiovascular disease mortality. Circulation.</text>
<text top="608" left="479" width="95" height="12" font="12">2011;123:1377– 83.</text>
<text top="622" left="452" width="354" height="12" font="12">125. Lauer MS. How will exercise capacity gain enough respect? Circu-</text>
<text top="636" left="479" width="125" height="12" font="12">lation. 2011;123:1364 – 6.</text>
<text top="650" left="452" width="354" height="12" font="12">126. Mark DB, Hlatky MA, Harrell FE Jr., et al. Exercise treadmill score</text>
<text top="664" left="479" width="327" height="12" font="12">for predicting prognosis in coronary artery disease. Ann Intern Med.</text>
<text top="678" left="479" width="95" height="12" font="12">1987;106:793– 800.</text>
<text top="692" left="452" width="354" height="12" font="12">127. Mark DB, Shaw L, Harrell FE Jr., et al. Prognostic value of a</text>
<text top="706" left="479" width="327" height="12" font="12">treadmill exercise score in outpatients with suspected coronary artery</text>
<text top="720" left="479" width="208" height="12" font="12">disease. N Engl J Med. 1991;325:849 –53.</text>
<text top="734" left="452" width="354" height="12" font="12">128. Cheezum MK, Hulten EA, Taylor AJ, et al. Cardiac CT angiogra-</text>
<text top="748" left="479" width="327" height="12" font="12">phy compared with myocardial perfusion stress testing on downstream</text>
<text top="762" left="479" width="311" height="12" font="12">resource utilization. J Cardiovasc Comput Tomogr. 2011;5:101–9.</text>
<text top="775" left="452" width="354" height="12" font="12">129. Min JK, Shaw LJ, Berman DS, et al. Costs and clinical outcomes in</text>
<text top="789" left="479" width="327" height="12" font="12">individuals without known coronary artery disease undergoing</text>
<text top="803" left="479" width="327" height="12" font="12">coronary computed tomographic angiography from an analysis of</text>
<text top="817" left="479" width="327" height="12" font="12">Medicare category III transaction codes. Am J Cardiol. 2008;102:</text>
<text top="831" left="479" width="34" height="12" font="12">672– 8.</text>
<text top="845" left="452" width="354" height="12" font="12">130. Min JK, Kang N, Shaw LJ, et al. Costs and clinical outcomes after</text>
<text top="859" left="479" width="327" height="12" font="12">coronary multidetector CT angiography in patients without known</text>
<text top="873" left="479" width="327" height="12" font="12">coronary artery disease: comparison to myocardial perfusion</text>
<text top="887" left="479" width="184" height="12" font="12">SPECT. Radiology. 2008;249:62–70.</text>
<text top="901" left="452" width="354" height="12" font="12">131. Fazel R, Shaw LJ. Radiation exposure from radionuclide myocardial</text>
<text top="915" left="479" width="327" height="12" font="12">perfusion imaging: concerns and solutions. J Nucl Cardiol. 2011;</text>
<text top="929" left="479" width="48" height="12" font="12">18:562–5.</text>
<text top="943" left="452" width="354" height="12" font="12">132. Garber AM, Solomon NA. Cost-effectiveness of alternative test</text>
<text top="957" left="479" width="327" height="12" font="12">strategies for the diagnosis of coronary artery disease. Ann Intern</text>
<text top="971" left="479" width="119" height="12" font="12">Med. 1999;130:719 –28.</text>
<text top="985" left="452" width="354" height="12" font="12">133. Kuntz KM, Fleischmann KE, Hunink MG, et al. Cost-effectiveness</text>
<text top="999" left="479" width="327" height="12" font="12">of diagnostic strategies for patients with chest pain. Ann Intern</text>
<text top="1013" left="479" width="119" height="12" font="12">Med. 1999;130:709 –18.</text>
<text top="1027" left="452" width="354" height="12" font="12">134. Lorenzoni R, Cortigiani L, Magnani M, et al. Cost-effectiveness</text>
<text top="1041" left="479" width="327" height="12" font="12">analysis of noninvasive strategies to evaluate patients with chest</text>
<text top="1055" left="479" width="239" height="12" font="12">pain. J Am Soc Echocardiogr. 2003;16:1287–91.</text>
<text top="1069" left="452" width="354" height="12" font="12">135. Marwick TH, Shaw L, Case C, et al. Clinical and economic impact</text>
<text top="1083" left="479" width="327" height="12" font="12">of exercise electrocardiography and exercise echocardiography in</text>
<text top="1097" left="479" width="237" height="12" font="12">clinical practice. Eur Heart J. 2003;24:1153– 63.</text>
<text top="52" left="781" width="25" height="10" font="12">e131</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">136. Otero HJ, Rybicki FJ, Greenberg D, et al. Cost-effective diagnostic</text>
<text top="118" left="92" width="327" height="12" font="12">cardiovascular imaging: when does it provide good value for the</text>
<text top="132" left="92" width="253" height="12" font="12">money? Int J Cardiovasc Imaging. 2010;26:605–12.</text>
<text top="146" left="65" width="354" height="12" font="12">137. Shaw LJ, Marwick TH, Berman DS, et al. Incremental cost-</text>
<text top="160" left="92" width="327" height="12" font="12">effectiveness of exercise echocardiography vs. SPECT imaging for</text>
<text top="173" left="92" width="327" height="12" font="12">the evaluation of stable chest pain. Eur Heart J. 2006;27:2448 –58.</text>
<text top="187" left="65" width="354" height="12" font="12">138. Trikalinos TA, Siebert U, Lau J. Decision-analytic modeling to</text>
<text top="201" left="92" width="327" height="12" font="12">evaluate benefits and harms of medical tests: uses and limitations.</text>
<text top="215" left="92" width="191" height="12" font="12">Med Decis Making. 2009;29:e22– e29.</text>
<text top="228" left="65" width="354" height="12" font="12">139. Halpern EJ, Fischman D, Savage MP, et al. Decision analytic model</text>
<text top="242" left="92" width="327" height="12" font="12">for evaluation of suspected coronary disease with stress testing and</text>
<text top="256" left="92" width="284" height="12" font="12">coronary CT angiography. Acad Radiol. 2010;17:577– 86.</text>
<text top="270" left="65" width="354" height="12" font="12">140. Min JK, Gilmore A, Budoff MJ, et al. Cost-effectiveness of coronary</text>
<text top="284" left="92" width="327" height="12" font="12">CT angiography versus myocardial perfusion SPECT for evaluation</text>
<text top="297" left="92" width="327" height="12" font="12">of patients with chest pain and no known coronary artery disease.</text>
<text top="311" left="92" width="139" height="12" font="12">Radiology. 2010;254:801– 8.</text>
<text top="325" left="65" width="354" height="12" font="12">141. Hachamovitch R, Nutter B, Hlatky M, et al. Patient Management</text>
<text top="339" left="92" width="327" height="12" font="12">After Noninvasive Cardiac Imaging Results From SPARC (Study</text>
<text top="353" left="92" width="327" height="12" font="12">of Myocardial Perfusion and Coronary Anatomy Imaging Roles in</text>
<text top="366" left="92" width="313" height="12" font="12">Coronary Artery Disease). J Am Coll Cardiol. 2012;59:462–74.</text>
<text top="380" left="65" width="354" height="12" font="12">142. Shreibati JB, Baker LC, Hlatky MA. Association of coronary CT</text>
<text top="394" left="92" width="327" height="12" font="12">angiography or stress testing with subsequent utilization and spend-</text>
<text top="408" left="92" width="307" height="12" font="12">ing among Medicare beneficiaries. JAMA. 2011;306:2128 –36.</text>
<text top="422" left="65" width="354" height="12" font="12">143. Ladapo JA, Jaffer FA, Hoffmann U, et al. Clinical outcomes and</text>
<text top="435" left="92" width="327" height="12" font="12">cost-effectiveness of coronary computed tomography angiography in</text>
<text top="449" left="92" width="327" height="12" font="12">the evaluation of patients with chest pain. J Am Coll Cardiol.</text>
<text top="463" left="92" width="89" height="12" font="12">2009;54:2409 –22.</text>
<text top="477" left="65" width="354" height="12" font="12">144. Bruder O, Schneider S, Nothnagel D, et al. EuroCMR (European</text>
<text top="490" left="92" width="327" height="12" font="12">Cardiovascular Magnetic Resonance) registry: results of the German</text>
<text top="504" left="92" width="248" height="12" font="12">pilot phase. J Am Coll Cardiol. 2009;54:1457– 66.</text>
<text top="518" left="65" width="354" height="12" font="12">145. Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST</text>
<text top="532" left="92" width="327" height="12" font="12">depression in the diagnosis of coronary artery disease. A meta-</text>
<text top="546" left="92" width="181" height="12" font="12">analysis. Circulation. 1989;80:87–98.</text>
<text top="559" left="65" width="354" height="12" font="12">146. Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing</text>
<text top="573" left="92" width="327" height="12" font="12">to detect coronary artery disease in women. Am J Cardiol. 1999;83:</text>
<text top="587" left="92" width="36" height="12" font="12">660 – 6.</text>
<text top="601" left="65" width="354" height="12" font="12">147. Shaw LJ, Mieres JH, Hendel RH, et al. Comparative Effectiveness</text>
<text top="615" left="92" width="327" height="12" font="12">of exercise electrocardiography with or without myocardial perfusion</text>
<text top="628" left="92" width="327" height="12" font="12">single photon emission computed tomography in women with</text>
<text top="642" left="92" width="327" height="12" font="12">suspected coronary artery disease: results from the What Is the</text>
<text top="656" left="92" width="327" height="12" font="12">Optimal Method for Ischemia Evaluation in Women (WOMEN)</text>
<text top="670" left="92" width="184" height="12" font="12">trial. Circulation. 2011;124:1239 – 49.</text>
<text top="683" left="65" width="354" height="12" font="12">148. Biagini E, Shaw LJ, Poldermans D, et al. Accuracy of non-invasive</text>
<text top="697" left="92" width="327" height="12" font="12">techniques for diagnosis of coronary artery disease and prediction of</text>
<text top="711" left="92" width="327" height="12" font="12">cardiac events in patients with left bundle branch block: a meta-</text>
<text top="725" left="92" width="288" height="12" font="12">analysis. Eur J Nucl Med Mol Imaging. 2006;33:1442–51.</text>
<text top="739" left="65" width="354" height="12" font="12">149. Geleijnse ML, Krenning BJ, Soliman OI, et al. Dobutamine stress</text>
<text top="752" left="92" width="327" height="12" font="12">echocardiography for the detection of coronary artery disease in</text>
<text top="766" left="92" width="193" height="12" font="12">women. Am J Cardiol. 2007;99:714 –7.</text>
<text top="780" left="65" width="354" height="12" font="12">150. Imran MB, Palinkas A, Picano E. Head-to-head comparison of</text>
<text top="794" left="92" width="327" height="12" font="12">dipyridamole echocardiography and stress perfusion scintigraphy for</text>
<text top="807" left="92" width="327" height="12" font="12">the detection of coronary artery disease: a meta-analysis. Compar-</text>
<text top="821" left="92" width="327" height="12" font="12">ison between stress echo and scintigraphy. Int J Cardiovasc Imaging.</text>
<text top="835" left="92" width="71" height="12" font="12">2003;19:23– 8.</text>
<text top="849" left="65" width="354" height="12" font="12">151. Mahajan N, Polavaram L, Vankayala H, et al. Diagnostic accuracy</text>
<text top="863" left="92" width="327" height="12" font="12">of myocardial perfusion imaging and stress echocardiography for the</text>
<text top="876" left="92" width="327" height="12" font="12">diagnosis of left main and triple vessel coronary artery disease: a</text>
<text top="890" left="92" width="254" height="12" font="12">comparative meta-analysis. Heart. 2010;96:956 – 66.</text>
<text top="904" left="65" width="354" height="12" font="12">152. Marcassa C, Bax JJ, Bengel F, et al. Clinical value, cost-</text>
<text top="918" left="92" width="327" height="12" font="12">effectiveness, and safety of myocardial perfusion scintigraphy: a</text>
<text top="931" left="92" width="246" height="12" font="12">position statement. Eur Heart J. 2008;29:557– 63.</text>
<text top="945" left="65" width="354" height="12" font="12">153. Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic</text>
<text top="959" left="92" width="327" height="12" font="12">performance of stress cardiac magnetic resonance imaging in the</text>
<text top="973" left="92" width="327" height="12" font="12">detection of coronary artery disease: a meta-analysis. J Am Coll</text>
<text top="987" left="92" width="131" height="12" font="12">Cardiol. 2007;50:1343–53.</text>
<text top="1000" left="65" width="354" height="12" font="12">154. Picano E, Molinaro S, Pasanisi E. The diagnostic accuracy of</text>
<text top="1014" left="92" width="327" height="12" font="12">pharmacological stress echocardiography for the assessment of</text>
<text top="1028" left="92" width="327" height="12" font="12">coronary artery disease: a meta-analysis. Cardiovasc Ultrasound.</text>
<text top="1042" left="92" width="327" height="12" font="12">2008;60:30. Published online 2008 June 19, doi:10.1186/1476-</text>
<text top="1055" left="92" width="55" height="12" font="12">7120-6-30.</text>
<text top="1069" left="65" width="354" height="12" font="12">155. Underwood SR, Shaw LJ, Anagnostopoulos C, et al. Myocardial</text>
<text top="1083" left="92" width="327" height="12" font="12">perfusion scintigraphy and cost effectiveness of diagnosis and manage-</text>
<text top="1097" left="92" width="307" height="12" font="12">ment of coronary heart disease. Heart. 2004;90 Suppl 5:v34–v36.</text>
<text top="104" left="452" width="354" height="12" font="12">156. Underwood SR, Anagnostopoulos C, Cerqueira M, et al. Myocar-</text>
<text top="118" left="479" width="327" height="12" font="12">dial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol</text>
<text top="132" left="479" width="129" height="12" font="12">Imaging. 2004;31:261–91.</text>
<text top="145" left="452" width="354" height="12" font="12">157. Hamon M, Fau G, Nee G, et al. Meta-analysis of the diagnostic</text>
<text top="159" left="479" width="327" height="12" font="12">performance of stress perfusion cardiovascular magnetic resonance</text>
<text top="172" left="479" width="327" height="12" font="12">for detection of coronary artery disease. J Cardiovasc Magn Reson.</text>
<text top="186" left="479" width="57" height="12" font="12">2010;12:29.</text>
<text top="200" left="452" width="354" height="12" font="12">158. Schuetz GM, Zacharopoulou NM, Schlattmann P, et al. Meta-</text>
<text top="213" left="479" width="327" height="12" font="12">analysis: noninvasive coronary angiography using computed tomog-</text>
<text top="227" left="479" width="327" height="12" font="12">raphy versus magnetic resonance imaging. Ann Intern Med. 2010;</text>
<text top="240" left="479" width="60" height="12" font="12">152:167–77.</text>
<text top="254" left="452" width="354" height="12" font="12">159. Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of</text>
<text top="268" left="479" width="327" height="12" font="12">64-multidetector row coronary computed tomographic angiography</text>
<text top="281" left="479" width="327" height="12" font="12">for evaluation of coronary artery stenosis in individuals without</text>
<text top="295" left="479" width="327" height="12" font="12">known coronary artery disease: results from the prospective multi-</text>
<text top="308" left="479" width="327" height="12" font="12">center ACCURACY (Assessment by Coronary Computed Tomo-</text>
<text top="322" left="479" width="327" height="12" font="12">graphic Angiography of Individuals Undergoing Invasive Coronary</text>
<text top="336" left="479" width="285" height="12" font="12">Angiography) trial. J Am Coll Cardiol. 2008;52:1724 –32.</text>
<text top="349" left="452" width="354" height="12" font="12">160. Hamon M, Biondi-Zoccai GG, Malagutti P, et al. Diagnostic</text>
<text top="363" left="479" width="327" height="12" font="12">performance of multislice spiral computed tomography of coronary</text>
<text top="376" left="479" width="327" height="12" font="12">arteries as compared with conventional invasive coronary angiogra-</text>
<text top="390" left="479" width="300" height="12" font="12">phy: a meta-analysis. J Am Coll Cardiol. 2006;48:1896 –910.</text>
<text top="404" left="452" width="354" height="12" font="12">161. Janne d’Othee B, Siebert U, Cury R, et al. A systematic review on</text>
<text top="417" left="479" width="327" height="12" font="12">diagnostic accuracy of CT-based detection of significant coronary</text>
<text top="431" left="479" width="225" height="12" font="12">artery disease. Eur J Radiol. 2008;65:449 – 61.</text>
<text top="444" left="452" width="354" height="12" font="12">162. Meijboom WB, Meijs MF, Schuijf JD, et al. Diagnostic accuracy</text>
<text top="458" left="479" width="327" height="12" font="12">of 64-slice computed tomography coronary angiography: a pro-</text>
<text top="472" left="479" width="327" height="12" font="12">spective, multicenter, multivendor study. J Am Coll Cardiol.</text>
<text top="485" left="479" width="92" height="12" font="12">2008;52:2135– 44.</text>
<text top="499" left="452" width="354" height="12" font="12">163. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance</text>
<text top="512" left="479" width="327" height="12" font="12">of coronary angiography by 64-row CT. N Engl J Med. 2008;359:</text>
<text top="526" left="479" width="39" height="12" font="12">232–36.</text>
<text top="540" left="452" width="354" height="12" font="12">164. Schuijf JD, Bax JJ, Shaw LJ, et al. Meta-analysis of comparative</text>
<text top="553" left="479" width="327" height="12" font="12">diagnostic performance of magnetic resonance imaging and mul-</text>
<text top="567" left="479" width="327" height="12" font="12">tislice computed tomography for noninvasive coronary angiography.</text>
<text top="580" left="479" width="155" height="12" font="12">Am Heart J. 2006;151:404 –11.</text>
<text top="594" left="452" width="354" height="12" font="12">165. Stein PD, Beemath A, Kayali F, et al. Multidetector computed</text>
<text top="607" left="479" width="327" height="12" font="12">tomography for the diagnosis of coronary artery disease: a systematic</text>
<text top="621" left="479" width="186" height="12" font="12">review. Am J Med. 2006;119:203–16.</text>
<text top="635" left="452" width="354" height="12" font="12">166. Sun Z, Jiang W. Diagnostic value of multislice computed tomog-</text>
<text top="648" left="479" width="327" height="12" font="12">raphy angiography in coronary artery disease: a meta-analysis. Eur J</text>
<text top="662" left="479" width="123" height="12" font="12">Radiol. 2006;60:279 – 86.</text>
<text top="675" left="452" width="354" height="12" font="12">167. Underwood SR, Godman B, Salyani S, et al. Economics of</text>
<text top="689" left="479" width="327" height="12" font="12">myocardial perfusion imaging in Europe—the EMPIRE Study. Eur</text>
<text top="703" left="479" width="126" height="12" font="12">Heart J. 1999;20:157– 66.</text>
<text top="716" left="452" width="354" height="12" font="12">168. Nucifora G, Schuijf JD, van Werkhoven JM, et al. Relationship</text>
<text top="730" left="479" width="327" height="12" font="12">between obstructive coronary artery disease and abnormal stress</text>
<text top="743" left="479" width="327" height="12" font="12">testing in patients with paroxysmal or persistent atrial fibrillation.</text>
<text top="757" left="479" width="214" height="12" font="12">Int J Cardiovasc Imaging. 2011;27:777– 85.</text>
<text top="770" left="452" width="354" height="12" font="12">169. Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular</text>
<text top="784" left="479" width="327" height="12" font="12">magnetic resonance and single-photon emission computed tomog-</text>
<text top="798" left="479" width="327" height="12" font="12">raphy for diagnosis of coronary heart disease (CE-MARC): a</text>
<text top="811" left="479" width="213" height="12" font="12">prospective trial. Lancet. 2012;379:453– 60.</text>
<text top="825" left="452" width="354" height="12" font="12">170. Hundley WG, Hamilton CA, Thomas MS, et al. Utility of fast cine</text>
<text top="838" left="479" width="327" height="12" font="12">magnetic resonance imaging and display for the detection of</text>
<text top="852" left="479" width="327" height="12" font="12">myocardial ischemia in patients not well suited for second harmonic</text>
<text top="866" left="479" width="283" height="12" font="12">stress echocardiography. Circulation. 1999;100:1697–702.</text>
<text top="879" left="452" width="354" height="12" font="12">171. Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis</text>
<text top="893" left="479" width="327" height="12" font="12">of ischemia-induced wall motion abnormalities with the use of</text>
<text top="906" left="479" width="327" height="12" font="12">high-dose dobutamine stress MRI: comparison with dobutamine</text>
<text top="920" left="479" width="265" height="12" font="12">stress echocardiography. Circulation. 1999;99:763–70.</text>
<text top="933" left="452" width="354" height="12" font="12">172. Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT:</text>
<text top="947" left="479" width="327" height="12" font="12">comparison of perfusion-cardiac magnetic resonance with single-</text>
<text top="961" left="479" width="327" height="12" font="12">photon emission computed tomography for the detection of coro-</text>
<text top="974" left="479" width="327" height="12" font="12">nary artery disease in a multicentre, multivendor, randomized trial.</text>
<text top="988" left="479" width="142" height="12" font="12">Eur Heart J. 2008;29:480 –9.</text>
<text top="1001" left="452" width="354" height="12" font="12">173. de Azevedo CF, Hadlich MS, Bezerra SG, et al. Prognostic value of</text>
<text top="1015" left="479" width="327" height="12" font="12">CT angiography in patients with inconclusive functional stress tests.</text>
<text top="1029" left="479" width="278" height="12" font="12">J Am Coll Cardiol Cardiovasc Imaging. 2011;4:740 –51.</text>
<text top="1042" left="452" width="354" height="12" font="12">174. Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic</text>
<text top="1056" left="479" width="327" height="12" font="12">value of absence of coronary artery calcification. J Am Coll Cardiol</text>
<text top="1069" left="479" width="181" height="12" font="12">Cardiovasc Imaging. 2009;2:675– 88.</text>
<text top="1083" left="452" width="354" height="12" font="12">175. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the</text>
<text top="1096" left="479" width="327" height="12" font="12">clinical evaluation of women with suspected coronary artery disease:</text>
<text top="52" left="59" width="25" height="10" font="12">e132</text>
<text top="52" left="113" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="92" width="327" height="12" font="12">Consensus statement from the Cardiac Imaging Committee,</text>
<text top="118" left="92" width="327" height="12" font="12">Council on Clinical Cardiology, and the Cardiovascular Imaging</text>
<text top="132" left="92" width="327" height="12" font="12">and Intervention Committee, Council on Cardiovascular Radiology</text>
<text top="145" left="92" width="327" height="12" font="12">and Intervention, American Heart Association. Circulation.</text>
<text top="159" left="92" width="87" height="12" font="12">2005;111:682–96.</text>
<text top="172" left="64" width="354" height="12" font="12">176. Nieman K, Galema TW, Neefjes LA, et al. Comparison of the value</text>
<text top="186" left="92" width="327" height="12" font="12">of coronary calcium detection to computed tomographic angiogra-</text>
<text top="200" left="92" width="327" height="12" font="12">phy and exercise testing in patients with chest pain. Am J Cardiol.</text>
<text top="213" left="92" width="101" height="12" font="12">2009;104:1499 –504.</text>
<text top="227" left="64" width="354" height="12" font="12">177. Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill</text>
<text top="240" left="92" width="280" height="12" font="12">testing in women. J Am Coll Cardiol. 1998;32:1657– 64.</text>
<text top="254" left="64" width="354" height="12" font="12">178. Daugherty SL, Magid DJ, Kikla JR, et al. Gender differences in the</text>
<text top="268" left="92" width="327" height="12" font="12">prognostic value of exercise treadmill test characteristics. Am</text>
<text top="281" left="92" width="132" height="12" font="12">Heart J. 2011;161:908 –14.</text>
<text top="295" left="64" width="354" height="12" font="12">179. Ovrehus KA, Jensen JK, Mickley HF, et al. Comparison of</text>
<text top="308" left="92" width="327" height="12" font="12">usefulness of exercise testing versus coronary computed tomographic</text>
<text top="322" left="92" width="327" height="12" font="12">angiography for evaluation of patients suspected of having coronary</text>
<text top="336" left="92" width="227" height="12" font="12">artery disease. Am J Cardiol. 2010;105:773–9.</text>
<text top="349" left="64" width="354" height="12" font="12">180. Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic</text>
<text top="363" left="92" width="327" height="12" font="12">treadmill score in identifying diagnostic coronary disease subgroups.</text>
<text top="376" left="92" width="149" height="12" font="12">Circulation. 1998;98:1622–30.</text>
<text top="390" left="64" width="354" height="12" font="12">181. Mulvagh SL, DeMaria AN, Feinstein SB, et al. Contrast echocar-</text>
<text top="404" left="92" width="327" height="12" font="12">diography: current and future applications. J Am Soc Echocardiogr.</text>
<text top="417" left="92" width="83" height="12" font="12">2000;13:331– 42.</text>
<text top="431" left="64" width="354" height="12" font="12">182. Abdelmoneim SS, Bernier M, Dhoble A, et al. Assessment of</text>
<text top="444" left="92" width="327" height="12" font="12">myocardial perfusion during adenosine stress using real time three-</text>
<text top="458" left="92" width="327" height="12" font="12">dimensional and two-dimensional myocardial contrast echocardiog-</text>
<text top="471" left="92" width="327" height="12" font="12">raphy: comparison with single-photon emission computed tomog-</text>
<text top="485" left="92" width="204" height="12" font="12">raphy. Echocardiography. 2010;27:421–9.</text>
<text top="499" left="64" width="354" height="12" font="12">183. Berman D, Hachamovitch R, Shaw L, et al. Nuclear Cardiology. In:</text>
<text top="512" left="92" width="327" height="12" font="12">Fuster V, Alexander RW, O’Rourke RA, et al., eds. Hurst’s The</text>
<text top="526" left="92" width="327" height="12" font="12">Heart, 11th edition. New York: The McGraw-Hill Companies,</text>
<text top="539" left="92" width="127" height="12" font="12">Inc.; 2004: 563–98; 2004.</text>
<text top="553" left="64" width="354" height="12" font="12">184. Fukushima K, Javadi MS, Higuchi T, et al. Prediction of short-term</text>
<text top="567" left="92" width="327" height="12" font="12">cardiovascular events using quantification of global myocardial flow</text>
<text top="580" left="92" width="327" height="12" font="12">reserve in patients referred for clinical 82Rb PET perfusion imag-</text>
<text top="594" left="92" width="171" height="12" font="12">ing. J Nucl Med. 2011;52:726 –32.</text>
<text top="607" left="64" width="354" height="12" font="12">185. El Fakhri G, Kardan A, Sitek A, et al. Reproducibility and</text>
<text top="621" left="92" width="327" height="12" font="12">accuracy of quantitative myocardial blood flow assessment with</text>
<text top="635" left="92" width="327" height="12" font="12">(82)Rb PET: comparison with (13)N-ammonia PET. J Nucl</text>
<text top="648" left="92" width="122" height="12" font="12">Med. 2009;50:1062–71.</text>
<text top="662" left="64" width="354" height="12" font="12">186. Yoshinaga K, Katoh C, Manabe O, et al. Incremental Diagnostic Value</text>
<text top="675" left="92" width="327" height="12" font="12">of Regional Myocardial Blood Flow Quantification Over Relative</text>
<text top="689" left="92" width="327" height="12" font="12">Perfusion Imaging With Generator-Produced Rubidium-82 PET.</text>
<text top="702" left="92" width="119" height="12" font="12">Circ J. 2011;75:2628–34.</text>
<text top="716" left="64" width="354" height="12" font="12">187. Duvall WL, Sweeny J, Croft LB, et al. SPECT myocardial</text>
<text top="730" left="92" width="327" height="12" font="12">perfusion imaging in morbidly obese patients: image quality, hemo-</text>
<text top="743" left="92" width="327" height="12" font="12">dynamic response to pharmacologic stress, and diagnostic and</text>
<text top="757" left="92" width="241" height="12" font="12">prognostic value. J Nucl Cardiol. 2006;13:202–9.</text>
<text top="770" left="64" width="354" height="12" font="12">188. Berman DS, Kang X, Nishina H, et al. Diagnostic accuracy of gated</text>
<text top="784" left="92" width="327" height="12" font="12">Tc-99m sestamibi stress myocardial perfusion SPECT with com-</text>
<text top="798" left="92" width="327" height="12" font="12">bined supine and prone acquisitions to detect coronary artery disease</text>
<text top="811" left="92" width="327" height="12" font="12">in obese and nonobese patients. J Nucl Cardiol. 2006;13:191–201.</text>
<text top="825" left="64" width="354" height="12" font="12">189. Slomka PJ, Nishina H, Abidov A, et al. Combined quantitative</text>
<text top="838" left="92" width="327" height="12" font="12">supine-prone myocardial perfusion SPECT improves detection of</text>
<text top="852" left="92" width="327" height="12" font="12">coronary artery disease and normalcy rates in women. J Nucl</text>
<text top="865" left="92" width="120" height="12" font="12">Cardiol. 2007;14:44 –52.</text>
<text top="879" left="64" width="354" height="12" font="12">190. Pazhenkottil AP, Ghadri J-R, Nkoulou RN, et al. Improved</text>
<text top="893" left="92" width="327" height="12" font="12">outcome prediction by SPECT myocardial perfusion imaging after</text>
<text top="906" left="92" width="290" height="12" font="12">CT attenuation correction. J Nucl Med. 2011;52:196 –200.</text>
<text top="920" left="64" width="354" height="12" font="12">191. Sampson UK, Dorbala S, Limaye A, et al. Diagnostic accuracy of</text>
<text top="933" left="92" width="327" height="12" font="12">rubidium-82 myocardial perfusion imaging with hybrid positron</text>
<text top="947" left="92" width="327" height="12" font="12">emission tomography/computed tomography in the detection of</text>
<text top="961" left="92" width="300" height="12" font="12">coronary artery disease. J Am Coll Cardiol. 2007;49:1052– 8.</text>
<text top="974" left="64" width="354" height="12" font="12">192. Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic</text>
<text top="988" left="92" width="327" height="12" font="12">performance of positron emission tomography in the detection of</text>
<text top="1001" left="92" width="327" height="12" font="12">coronary artery disease: a meta-analysis. Acad Radiol. 2008;15:</text>
<text top="1015" left="92" width="42" height="12" font="12">444 –51.</text>
<text top="1028" left="64" width="354" height="12" font="12">193. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of</text>
<text top="1042" left="92" width="327" height="12" font="12">rest/stress ECG-gated Rb-82 myocardial perfusion PET: compar-</text>
<text top="1056" left="92" width="327" height="12" font="12">ison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol.</text>
<text top="1069" left="92" width="77" height="12" font="12">2006;13:24 –33.</text>
<text top="1083" left="64" width="354" height="12" font="12">194. Pilz G, Eierle S, Heer T, et al. Negative predictive value of normal</text>
<text top="1096" left="92" width="327" height="12" font="12">adenosine-stress cardiac MRI in the assessment of coronary artery</text>
<text top="104" left="479" width="327" height="12" font="12">disease and correlation with semiquantitative perfusion analysis. J</text>
<text top="118" left="479" width="196" height="12" font="12">Magn Reson Imaging. 2010;32:615–21.</text>
<text top="132" left="451" width="354" height="12" font="12">195. Koo B-K, Erglis A, Doh J-H, et al. Diagnosis of ischemia-causing</text>
<text top="146" left="479" width="327" height="12" font="12">coronary stenoses by noninvasive fractional flow reserve computed</text>
<text top="159" left="479" width="327" height="12" font="12">from coronary computed tomographic angiograms. Results from the</text>
<text top="173" left="479" width="327" height="12" font="12">prospective multicenter DISCOVER-FLOW (Diagnosis of</text>
<text top="187" left="479" width="327" height="12" font="12">Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional</text>
<text top="201" left="479" width="294" height="12" font="12">Flow Reserve) study. J Am Coll Cardiol. 2011;58:1989 –97.</text>
<text top="214" left="451" width="354" height="12" font="12">196. George RT, Arbab-Zadeh A, Cerci RJ, et al. Diagnostic perfor-</text>
<text top="228" left="479" width="327" height="12" font="12">mance of combined noninvasive coronary angiography and myocar-</text>
<text top="242" left="479" width="327" height="12" font="12">dial perfusion imaging using 320-MDCT: the CT angiography and</text>
<text top="256" left="479" width="327" height="12" font="12">perfusion methods of the CORE320 multicenter multinational</text>
<text top="270" left="479" width="293" height="12" font="12">diagnostic study. AJR Am J Roentgenol. 2011;197:829 –37.</text>
<text top="283" left="451" width="354" height="12" font="12">197. Valdiviezo C, Ambrose M, Mehra V, et al. Quantitative and</text>
<text top="297" left="479" width="327" height="12" font="12">qualitative analysis and interpretation of CT perfusion imaging.</text>
<text top="311" left="479" width="172" height="12" font="12">J Nucl Cardiol. 2010;17:1091–100.</text>
<text top="325" left="451" width="354" height="12" font="12">198. Feuchtner G, Goetti R, Plass A, et al. Adenosine stress high-pitch</text>
<text top="339" left="479" width="327" height="12" font="12">128-slice dual-source myocardial computed tomography perfusion</text>
<text top="352" left="479" width="327" height="12" font="12">for imaging of reversible myocardial ischemia: comparison with</text>
<text top="366" left="479" width="327" height="12" font="12">magnetic resonance imaging. Circ Cardiovasc Imaging. 2011;4:</text>
<text top="380" left="479" width="34" height="12" font="12">540 –9.</text>
<text top="394" left="451" width="354" height="12" font="12">199. Cury RC, Magalhaes TA, Borges AC, et al. Dipyridamole stress</text>
<text top="407" left="479" width="327" height="12" font="12">and rest myocardial perfusion by 64-detector row computed tomog-</text>
<text top="421" left="479" width="327" height="12" font="12">raphy in patients with suspected coronary artery disease. Am J</text>
<text top="435" left="479" width="126" height="12" font="12">Cardiol. 2010;106:310 –5.</text>
<text top="449" left="451" width="354" height="12" font="12">200. Rocha-Filho JA, Blankstein R, Shturman LD, et al. Incremental</text>
<text top="463" left="479" width="327" height="12" font="12">value of adenosine-induced stress myocardial perfusion imaging</text>
<text top="476" left="479" width="327" height="12" font="12">with dual-source CT at cardiac CT angiography. Radiology. 2010;</text>
<text top="490" left="479" width="56" height="12" font="12">254:410 –9.</text>
<text top="504" left="451" width="354" height="12" font="12">201. Blankstein R, Shturman LD, Rogers IS, et al. Adenosine-induced</text>
<text top="518" left="479" width="327" height="12" font="12">stress myocardial perfusion imaging using dual-source cardiac com-</text>
<text top="532" left="479" width="285" height="12" font="12">puted tomography. J Am Coll Cardiol. 2009;54:1072– 84.</text>
<text top="545" left="451" width="354" height="12" font="12">202. van Werkhoven JM, Schuijf JD, Gaemperli O, et al. Prognostic</text>
<text top="559" left="479" width="327" height="12" font="12">value of multislice computed tomography and gated single-photon</text>
<text top="573" left="479" width="327" height="12" font="12">emission computed tomography in patients with suspected coronary</text>
<text top="587" left="479" width="252" height="12" font="12">artery disease. J Am Coll Cardiol. 2009;53:623–32.</text>
<text top="601" left="451" width="354" height="12" font="12">203. Hachamovitch R, Di Carli MF. Nuclear cardiology will remain the</text>
<text top="614" left="479" width="327" height="12" font="12">“gatekeeper” over CT angiography. J Nucl Cardiol. 2007;14:</text>
<text top="628" left="479" width="42" height="12" font="12">634 – 44.</text>
<text top="642" left="451" width="354" height="12" font="12">204. Di Carli MF, Dorbala S, Curillova Z, et al. Relationship between</text>
<text top="656" left="479" width="327" height="12" font="12">CT coronary angiography and stress perfusion imaging in patients</text>
<text top="669" left="479" width="327" height="12" font="12">with suspected ischemic heart disease assessed by integrated</text>
<text top="683" left="479" width="266" height="12" font="12">PET-CT imaging. J Nucl Cardiol. 2007;14:799 – 809.</text>
<text top="697" left="451" width="354" height="12" font="12">205. Pazhenkottil AP, Husmann L, Kaufmann PA. Cardiac hybrid</text>
<text top="711" left="479" width="327" height="12" font="12">imaging with high-speed single-photon emission computed tomog-</text>
<text top="725" left="479" width="327" height="12" font="12">raphy/CT camera to detect ischaemia and coronary artery obstruc-</text>
<text top="738" left="479" width="131" height="12" font="12">tion. Heart. 2010;96:2050.</text>
<text top="752" left="451" width="354" height="12" font="12">206. Pazhenkottil AP, Nkoulou RN, Ghadri J-R, et al. Prognostic value</text>
<text top="766" left="479" width="327" height="12" font="12">of cardiac hybrid imaging integrating single-photon emission com-</text>
<text top="780" left="479" width="327" height="12" font="12">puted tomography with coronary computed tomography angiogra-</text>
<text top="793" left="479" width="178" height="12" font="12">phy. Eur Heart J. 2011;32:1465–71.</text>
<text top="807" left="451" width="354" height="12" font="12">207. van Velzen JE, Schuijf JD, van Werkhoven JM, et al. Predictive</text>
<text top="821" left="479" width="327" height="12" font="12">value of multislice computed tomography variables of atherosclerosis</text>
<text top="835" left="479" width="327" height="12" font="12">for ischemia on stress-rest single-photon emission computed to-</text>
<text top="848" left="479" width="262" height="12" font="12">mography. Circ Cardiovasc Imaging. 2010;3:718 –26.</text>
<text top="862" left="451" width="354" height="12" font="12">208. Min JK, Shaw LJ, Berman DS. The present state of coronary</text>
<text top="876" left="479" width="327" height="12" font="12">computed tomography angiography a process in evolution. J Am</text>
<text top="890" left="479" width="151" height="12" font="12">Coll Cardiol. 2010;55:957– 65.</text>
<text top="904" left="451" width="354" height="12" font="12">209. Mark DB, Berman DS, Budoff MJ, et al. ACCF/ACR/AHA/</text>
<text top="917" left="479" width="327" height="12" font="12">NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on</text>
<text top="931" left="479" width="327" height="12" font="12">coronary computed tomographic angiography: a report of the</text>
<text top="945" left="479" width="327" height="12" font="12">American College of Cardiology Foundation Task Force on Expert</text>
<text top="959" left="479" width="305" height="12" font="12">Consensus Documents. J Am Coll Cardiol. 2010;55:2663–99.</text>
<text top="972" left="451" width="354" height="12" font="12">210. Pundziute G, Schuijf JD, Jukema JW, et al. Gender influence on the</text>
<text top="986" left="479" width="327" height="12" font="12">diagnostic accuracy of 64-slice multislice computed tomography</text>
<text top="1000" left="479" width="327" height="12" font="12">coronary angiography for detection of obstructive coronary artery</text>
<text top="1014" left="479" width="152" height="12" font="12">disease. Heart. 2008;94:48 –52.</text>
<text top="1028" left="451" width="354" height="12" font="12">211. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic</text>
<text top="1041" left="479" width="327" height="12" font="12">angiography characteristics of atherosclerotic plaques subsequently</text>
<text top="1055" left="479" width="327" height="12" font="12">resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:</text>
<text top="1069" left="479" width="34" height="12" font="12">49 –57.</text>
<text top="1083" left="451" width="354" height="12" font="12">212. Shaw LJ, Min JK, Narula J, et al. Sex differences in mortality</text>
<text top="1096" left="479" width="327" height="12" font="12">associated with computed tomographic angiographic measurements</text>
<text top="52" left="781" width="25" height="10" font="12">e133</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="92" width="327" height="12" font="12">of obstructive and nonobstructive coronary artery disease: an</text>
<text top="118" left="92" width="308" height="12" font="12">exploratory analysis. Circ Cardiovasc Imaging. 2010;3:473– 81.</text>
<text top="132" left="64" width="354" height="12" font="12">213. Motoyama S, Kondo T, Sarai M, et al. Multislice computed</text>
<text top="146" left="92" width="327" height="12" font="12">tomographic characteristics of coronary lesions in acute coronary</text>
<text top="160" left="92" width="240" height="12" font="12">syndromes. J Am Coll Cardiol. 2007;50:319 –26.</text>
<text top="173" left="64" width="354" height="12" font="12">214. Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and Severity of</text>
<text top="187" left="92" width="327" height="12" font="12">Coronary Artery Disease and Adverse Events Among Symptomatic</text>
<text top="201" left="92" width="327" height="12" font="12">Patients With Coronary Artery Calcification Scores of Zero Un-</text>
<text top="215" left="92" width="327" height="12" font="12">dergoing Coronary Computed Tomography Angiography: Results</text>
<text top="228" left="92" width="327" height="12" font="12">From the CONFIRM (Coronary CT Angiography Evaluation for</text>
<text top="242" left="92" width="327" height="12" font="12">Clinical Outcomes: An International Multicenter) Registry. J Am</text>
<text top="256" left="92" width="138" height="12" font="12">Coll Cardiol. 2011;58:2540.</text>
<text top="270" left="64" width="354" height="12" font="12">215. Shmilovich H, Cheng VY, Tamarappoo BK, et al. Vulnerable</text>
<text top="284" left="92" width="327" height="12" font="12">plaque features on coronary CT angiography as markers of inducible</text>
<text top="297" left="92" width="327" height="12" font="12">regional myocardial hypoperfusion from severe coronary artery</text>
<text top="311" left="92" width="215" height="12" font="12">stenoses. Atherosclerosis. 2011;219:588 –95.</text>
<text top="325" left="64" width="354" height="12" font="12">216. Lin FY, Shaw LJ, Dunning AM, et al. Mortality risk in symptom-</text>
<text top="339" left="92" width="327" height="12" font="12">atic patients with nonobstructive coronary artery disease: a prospec-</text>
<text top="353" left="92" width="327" height="12" font="12">tive 2-center study of 2,583 patients undergoing 64-detector row</text>
<text top="366" left="92" width="327" height="12" font="12">coronary computed tomographic angiography. J Am Coll Cardiol.</text>
<text top="380" left="92" width="77" height="12" font="12">2011;58:510 –9.</text>
<text top="394" left="64" width="354" height="12" font="12">217. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of</text>
<text top="408" left="92" width="327" height="12" font="12">coronary artery calcium using ultrafast computed tomography. J Am</text>
<text top="422" left="92" width="150" height="12" font="12">Coll Cardiol. 1990;15:827–32.</text>
<text top="435" left="64" width="354" height="12" font="12">218. O’Rourke RA, Brundage BH, Froelicher VF, et al. American</text>
<text top="449" left="92" width="327" height="12" font="12">College of Cardiology/American Heart Association expert consen-</text>
<text top="463" left="92" width="327" height="12" font="12">sus document on electron-beam computed tomography for the</text>
<text top="477" left="92" width="327" height="12" font="12">diagnosis and prognosis of coronary artery disease. J Am Coll</text>
<text top="490" left="92" width="128" height="12" font="12">Cardiol. 2000;32:326 – 40.</text>
<text top="504" left="64" width="354" height="12" font="12">219. Akram K, O’Donnell RE, King S, et al. Influence of symptomatic</text>
<text top="518" left="92" width="327" height="12" font="12">status on the prevalence of obstructive coronary artery disease in</text>
<text top="532" left="92" width="326" height="12" font="12">patients with zero calcium score. Atherosclerosis. 2009;203:533–7.</text>
<text top="546" left="64" width="354" height="12" font="12">220. Cademartiri F, Maffei E, Palumbo A, et al. Diagnostic accuracy of</text>
<text top="559" left="92" width="327" height="12" font="12">computed tomography coronary angiography in patients with a zero</text>
<text top="573" left="92" width="203" height="12" font="12">calcium score. Eur Radiol. 2010;20:81–7.</text>
<text top="587" left="64" width="354" height="12" font="12">221. Haberl R, Tittus J, Bohme E, et al. Multislice spiral computed</text>
<text top="601" left="92" width="327" height="12" font="12">tomographic angiography of coronary arteries in patients with</text>
<text top="615" left="92" width="327" height="12" font="12">suspected coronary artery disease: an effective filter before catheter</text>
<text top="628" left="92" width="221" height="12" font="12">angiography? Am Heart J. 2005;149:1112–9.</text>
<text top="642" left="64" width="354" height="12" font="12">222. Henneman MM, Schuijf JD, Pundziute G, et al. Noninvasive</text>
<text top="656" left="92" width="327" height="12" font="12">evaluation with multislice computed tomography in suspected acute</text>
<text top="670" left="92" width="327" height="12" font="12">coronary syndrome: plaque morphology on multislice computed</text>
<text top="683" left="92" width="327" height="12" font="12">tomography versus coronary calcium score. J Am Coll Cardiol.</text>
<text top="697" left="92" width="83" height="12" font="12">2008;52:216 –22.</text>
<text top="711" left="64" width="354" height="12" font="12">223. Rubinshtein R, Gaspar T, Halon DA, et al. Prevalence and extent</text>
<text top="725" left="92" width="327" height="12" font="12">of obstructive coronary artery disease in patients with zero or low</text>
<text top="739" left="92" width="327" height="12" font="12">calcium score undergoing 64-slice cardiac multidetector computed</text>
<text top="752" left="92" width="327" height="12" font="12">tomography for evaluation of a chest pain syndrome. Am J Cardiol.</text>
<text top="766" left="92" width="75" height="12" font="12">2007;99:472–5.</text>
<text top="780" left="64" width="354" height="12" font="12">224. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for</text>
<text top="794" left="92" width="327" height="12" font="12">cardiovascular magnetic resonance (CMR): Consensus Panel report.</text>
<text top="807" left="92" width="156" height="12" font="12">Eur Heart J. 2004;25:1940 – 65.</text>
<text top="821" left="64" width="354" height="12" font="12">225. Kim WY, Danias PG, Stuber M, et al. Coronary magnetic reso-</text>
<text top="835" left="92" width="327" height="12" font="12">nance angiography for the detection of coronary stenoses. N Engl</text>
<text top="849" left="92" width="125" height="12" font="12">J Med. 2001;345:1863–9.</text>
<text top="863" left="64" width="354" height="12" font="12">226. Danias PG, Roussakis A, Ioannidis JP. Diagnostic performance of</text>
<text top="876" left="92" width="327" height="12" font="12">coronary magnetic resonance angiography as compared against</text>
<text top="890" left="92" width="327" height="12" font="12">conventional X-ray angiography: a meta-analysis. J Am Coll Car-</text>
<text top="904" left="92" width="113" height="12" font="12">diol. 2004;44:1867–76.</text>
<text top="918" left="64" width="354" height="12" font="12">227. Sakuma H. Coronary CT versus MR angiography: the role of MR</text>
<text top="931" left="92" width="205" height="12" font="12">angiography. Radiology. 2011;258:340 –9.</text>
<text top="945" left="64" width="354" height="12" font="12">228. Hamdan A, Asbach P, Wellnhofer E, et al. A prospective study for</text>
<text top="959" left="92" width="327" height="12" font="12">comparison of MR and CT imaging for detection of coronary artery</text>
<text top="973" left="92" width="317" height="12" font="12">stenosis. J Am Coll Cardiol Cardiovasc Imaging. 2011;4:50 – 61.</text>
<text top="987" left="64" width="354" height="12" font="12">229. Buckley BS, Simpson CR, McLernon DJ, et al. Five year prognosis</text>
<text top="1000" left="92" width="327" height="12" font="12">in patients with angina identified in primary care: incident cohort</text>
<text top="1014" left="92" width="145" height="12" font="12">study. BMJ. 2009;339:b3058.</text>
<text top="1028" left="64" width="354" height="12" font="12">230. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and</text>
<text top="1042" left="92" width="327" height="12" font="12">mortality following acute coronary syndromes. JAMA. 2007;298:</text>
<text top="1055" left="92" width="39" height="12" font="12">765–75.</text>
<text top="1069" left="64" width="354" height="12" font="12">231. Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk</text>
<text top="1083" left="92" width="327" height="12" font="12">factor for recurrent cardiovascular disease and mortality. Am J</text>
<text top="1097" left="92" width="152" height="12" font="12">Kidney Dis. 2004;44:198 –206.</text>
<text top="104" left="451" width="354" height="12" font="12">232. Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic importance of</text>
<text top="118" left="479" width="327" height="12" font="12">comorbidity for mortality in patients with stable coronary artery</text>
<text top="132" left="479" width="224" height="12" font="12">disease. J Am Coll Cardiol. 2004;43:576 – 82.</text>
<text top="146" left="451" width="354" height="12" font="12">233. Hlatky MA. Comorbidity and outcome in patients with coronary</text>
<text top="160" left="479" width="248" height="12" font="12">artery disease. J Am Coll Cardiol. 2004;43:583– 4.</text>
<text top="173" left="451" width="354" height="12" font="12">234. Chirinos JA, Veerani A, Zambrano JP, et al. Evaluation of comor-</text>
<text top="187" left="479" width="327" height="12" font="12">bidity scores to predict all-cause mortality in patients with estab-</text>
<text top="201" left="479" width="308" height="12" font="12">lished coronary artery disease. Int J Cardiol. 2007;117:97–102.</text>
<text top="215" left="451" width="354" height="12" font="12">235. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological</text>
<text top="229" left="479" width="327" height="12" font="12">factors on the pathogenesis of cardiovascular disease and implica-</text>
<text top="242" left="479" width="244" height="12" font="12">tions for therapy. Circulation. 1999;99:2192–217.</text>
<text top="256" left="451" width="354" height="12" font="12">236. Denollet J, Pedersen SS, Vrints CJ, et al. Usefulness of type D</text>
<text top="270" left="479" width="327" height="12" font="12">personality in predicting five-year cardiac events above and beyond</text>
<text top="284" left="479" width="327" height="12" font="12">concurrent symptoms of stress in patients with coronary heart</text>
<text top="297" left="479" width="191" height="12" font="12">disease. Am J Cardiol. 2006;97:970 –3.</text>
<text top="311" left="451" width="354" height="12" font="12">237. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating</text>
<text top="325" left="479" width="327" height="12" font="12">depression and low perceived social support on clinical events after</text>
<text top="339" left="479" width="327" height="12" font="12">myocardial infarction: the Enhancing Recovery in Coronary Heart</text>
<text top="353" left="479" width="327" height="12" font="12">Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;</text>
<text top="366" left="479" width="68" height="12" font="12">289:3106 –16.</text>
<text top="380" left="451" width="354" height="12" font="12">238. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treat-</text>
<text top="394" left="479" width="327" height="12" font="12">ment of major depression in patients with acute MI or unstable</text>
<text top="408" left="479" width="161" height="12" font="12">angina. JAMA. 2002;288:701–9.</text>
<text top="422" left="451" width="354" height="12" font="12">239. Ruo B, Rumsfeld JS, Hlatky MA, et al. Depressive symptoms and</text>
<text top="435" left="479" width="327" height="12" font="12">health-related quality of life: the Heart and Soul Study. JAMA.</text>
<text top="449" left="479" width="87" height="12" font="12">2003;290:215–21.</text>
<text top="463" left="451" width="354" height="12" font="12">240. Rumsfeld JS, Magid DJ, Plomondon ME, et al. History of</text>
<text top="477" left="479" width="327" height="12" font="12">depression, angina, and quality of life after acute coronary syn-</text>
<text top="491" left="479" width="190" height="12" font="12">dromes. Am Heart J. 2003;145:493–9.</text>
<text top="504" left="451" width="354" height="12" font="12">241. Rumsfeld JS, Jones PG, Whooley MA, et al. Depression predicts</text>
<text top="518" left="479" width="327" height="12" font="12">mortality and hospitalization in patients with myocardial infarction</text>
<text top="532" left="479" width="291" height="12" font="12">complicated by heart failure. Am Heart J. 2005;150:961–7.</text>
<text top="546" left="451" width="354" height="12" font="12">242. Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call</text>
<text top="559" left="479" width="224" height="12" font="12">for recognition. Circulation. 2005;111:250 –3.</text>
<text top="573" left="451" width="354" height="12" font="12">243. Rutledge T, Reis SE, Olson M, et al. Social networks are associated</text>
<text top="587" left="479" width="327" height="12" font="12">with lower mortality rates among women with suspected coronary</text>
<text top="601" left="479" width="327" height="12" font="12">disease: the National Heart, Lung, and Blood Institute-Sponsored</text>
<text top="615" left="479" width="327" height="12" font="12">Women’s Ischemia Syndrome Evaluation study. Psychosom Med.</text>
<text top="628" left="479" width="77" height="12" font="12">2004;66:882– 8.</text>
<text top="642" left="451" width="354" height="12" font="12">244. Horne BD, Muhlestein JB, Lappe DL, et al. Less affluent area of</text>
<text top="656" left="479" width="327" height="12" font="12">residence and lesser-insured status predict an increased risk of death</text>
<text top="670" left="479" width="327" height="12" font="12">or myocardial infarction after angiographic diagnosis of coronary</text>
<text top="683" left="479" width="205" height="12" font="12">disease. Ann Epidemiol. 2004;14:143–50.</text>
<text top="697" left="451" width="354" height="12" font="12">245. Rosengren A, Hawken S, Ounpuu S, et al. Association of psycho-</text>
<text top="711" left="479" width="327" height="12" font="12">social risk factors with risk of acute myocardial infarction in 11119</text>
<text top="725" left="479" width="327" height="12" font="12">cases and 13648 controls from 52 countries (the INTERHEART</text>
<text top="739" left="479" width="261" height="12" font="12">study): case-control study. Lancet. 2004;364:953– 62.</text>
<text top="752" left="451" width="354" height="12" font="12">246. Spertus JA, Jones P, McDonell M, et al. Health status predicts</text>
<text top="766" left="479" width="327" height="12" font="12">long-term outcome in outpatients with coronary disease. Circula-</text>
<text top="780" left="479" width="102" height="12" font="12">tion. 2002;106:43–9.</text>
<text top="794" left="451" width="354" height="12" font="12">247. Mozaffarian D, Bryson CL, Spertus JA, et al. Anginal symptoms</text>
<text top="807" left="479" width="327" height="12" font="12">consistently predict total mortality among outpatients with coronary</text>
<text top="821" left="479" width="231" height="12" font="12">artery disease. Am Heart J. 2003;146:1015–22.</text>
<text top="835" left="451" width="354" height="12" font="12">248. Lauer MS, Pothier CE, Magid DJ, et al. An externally validated</text>
<text top="849" left="479" width="327" height="12" font="12">model for predicting long-term survival after exercise treadmill</text>
<text top="863" left="479" width="327" height="12" font="12">testing in patients with suspected coronary artery disease and a</text>
<text top="876" left="479" width="304" height="12" font="12">normal electrocardiogram. Ann Intern Med. 2007;147:821– 8.</text>
<text top="890" left="451" width="354" height="12" font="12">249. Hubbard BL, Gibbons RJ, Lapeyre AC, III, et al. Identification of</text>
<text top="904" left="479" width="327" height="12" font="12">severe coronary artery disease using simple clinical parameters. Arch</text>
<text top="918" left="479" width="153" height="12" font="12">Intern Med. 1992;152:309 –12.</text>
<text top="931" left="451" width="354" height="12" font="12">250. Ho K-T, Miller TD, Hodge DO, et al. Use of a simple clinical score</text>
<text top="945" left="479" width="327" height="12" font="12">to predict prognosis of patients with normal or mildly abnormal</text>
<text top="959" left="479" width="327" height="12" font="12">resting electrocardiographic findings undergoing evaluation for cor-</text>
<text top="973" left="479" width="271" height="12" font="12">onary artery disease. Mayo Clin Proc. 2002;77:515–21.</text>
<text top="987" left="451" width="354" height="12" font="12">251. Miller TD, Roger VL, Hodge DO, et al. A simple clinical score</text>
<text top="1000" left="479" width="327" height="12" font="12">accurately predicts outcome in a community-based population</text>
<text top="1014" left="479" width="278" height="12" font="12">undergoing stress testing. Am J Med. 2005;118:866 –72.</text>
<text top="1028" left="451" width="354" height="12" font="12">252. Diamond GA, Kaul S. COURAGE under fire: on the management</text>
<text top="1042" left="479" width="313" height="12" font="12">of stable coronary disease. J Am Coll Cardiol. 2007;50:1604 –9.</text>
<text top="1055" left="451" width="354" height="12" font="12">253. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk</text>
<text top="1069" left="479" width="327" height="12" font="12">factor for coronary heart disease: a systematic review and meta-</text>
<text top="1083" left="479" width="327" height="12" font="12">analyses for the U.S. Preventive Services Task Force. Ann Intern</text>
<text top="1097" left="479" width="117" height="12" font="12">Med. 2009;151:483–95.</text>
<text top="52" left="58" width="25" height="10" font="12">e134</text>
<text top="52" left="112" width="48" height="10" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">254. Oremus M, Raina PS, Santaguida P, et al. A systematic review of</text>
<text top="118" left="92" width="327" height="12" font="12">BNP as a predictor of prognosis in persons with coronary artery</text>
<text top="132" left="92" width="193" height="12" font="12">disease. Clin Biochem. 2008;41:260 –5.</text>
<text top="146" left="65" width="354" height="12" font="12">255. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP</text>
<text top="160" left="92" width="327" height="12" font="12">measurement for the prediction of coronary heart disease events:</text>
<text top="173" left="92" width="327" height="12" font="12">new data and systematic review of 31 prospective cohorts. Int J</text>
<text top="187" left="92" width="139" height="12" font="12">Epidemiol. 2009;38:217–31.</text>
<text top="201" left="65" width="354" height="12" font="12">256. Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive</text>
<text top="215" left="92" width="327" height="12" font="12">protein have combined utility for long-term prediction of cardio-</text>
<text top="228" left="92" width="327" height="12" font="12">vascular mortality after coronary angiography. J Am Coll Cardiol.</text>
<text top="242" left="92" width="81" height="12" font="12">2010;55:1102–9.</text>
<text top="256" left="65" width="354" height="12" font="12">257. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and man-</text>
<text top="270" left="92" width="327" height="12" font="12">agement of the metabolic syndrome: an American Heart Associa-</text>
<text top="284" left="92" width="327" height="12" font="12">tion/National Heart, Lung, and Blood Institute Scientific State-</text>
<text top="297" left="92" width="187" height="12" font="12">ment. Circulation. 2005;112:2735–52.</text>
<text top="311" left="65" width="354" height="12" font="12">258. O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-</text>
<text top="325" left="92" width="327" height="12" font="12">associated phospholipase A2 and its association with cardiovascular</text>
<text top="339" left="92" width="327" height="12" font="12">outcomes in patients with acute coronary syndromes in the PROVE</text>
<text top="353" left="92" width="327" height="12" font="12">IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection</text>
<text top="366" left="92" width="327" height="12" font="12">Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation.</text>
<text top="380" left="92" width="93" height="12" font="12">2006;113:1745–52.</text>
<text top="394" left="65" width="354" height="12" font="12">259. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of</text>
<text top="408" left="92" width="327" height="12" font="12">coronary heart disease and mortality in 70-year-old men: a</text>
<text top="422" left="92" width="309" height="12" font="12">community-based cohort study. Circulation. 2006;113:1071– 8.</text>
<text top="435" left="65" width="354" height="12" font="12">260. Mock MB, Ringqvist I, Fisher LD, et al. Survival of medically</text>
<text top="449" left="92" width="327" height="12" font="12">treated patients in the coronary artery surgery study (CASS)</text>
<text top="463" left="92" width="181" height="12" font="12">registry. Circulation. 1982;66:562– 8.</text>
<text top="477" left="65" width="354" height="12" font="12">261. Vitarelli A, Tiukinhoy S, Di Luzio S, et al. The role of echocardi-</text>
<text top="490" left="92" width="327" height="12" font="12">ography in the diagnosis and management of heart failure. Heart</text>
<text top="504" left="92" width="117" height="12" font="12">Fail Rev. 2003;8:181–9.</text>
<text top="518" left="65" width="354" height="12" font="12">262. Levy D, Garrison RJ, Savage DD, et al. Left ventricular mass and</text>
<text top="532" left="92" width="327" height="12" font="12">incidence of coronary heart disease in an elderly cohort. The</text>
<text top="546" left="92" width="305" height="12" font="12">Framingham Heart Study. Ann Intern Med. 1989;110:101–7.</text>
<text top="559" left="65" width="354" height="12" font="12">263. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of</text>
<text top="573" left="92" width="327" height="12" font="12">echocardiographically determined left ventricular mass in the Fra-</text>
<text top="587" left="92" width="286" height="12" font="12">mingham Heart Study. N Engl J Med. 1990;322:1561– 6.</text>
<text top="601" left="65" width="354" height="12" font="12">264. Nagao T, Chikamori T, Hida S, et al. Quantitative gated single-</text>
<text top="615" left="92" width="327" height="12" font="12">photon emission computed tomography with (99m)Tc sestamibi</text>
<text top="628" left="92" width="327" height="12" font="12">predicts major cardiac events in elderly patients with known or</text>
<text top="642" left="92" width="327" height="12" font="12">suspected coronary artery disease: the QGS-Prognostic Value in the</text>
<text top="656" left="92" width="268" height="12" font="12">Elderly (Q-PROVE) Study. Circ J. 2007;71:1029 –34.</text>
<text top="670" left="65" width="354" height="12" font="12">265. Leischik R, Dworrak B, Littwitz H, et al. Prognostic significance of</text>
<text top="683" left="92" width="327" height="12" font="12">exercise stress echocardiography in 3329 outpatients (5-year longi-</text>
<text top="697" left="92" width="238" height="12" font="12">tudinal study). Int J Cardiol. 2007;119:297–305.</text>
<text top="711" left="65" width="354" height="12" font="12">266. Johansen A, Hoilund-Carlsen PF, Vach W, et al. Prognostic value</text>
<text top="725" left="92" width="327" height="12" font="12">of myocardial perfusion imaging in patients with known or sus-</text>
<text top="739" left="92" width="327" height="12" font="12">pected stable angina pectoris: evaluation in a setting in which</text>
<text top="752" left="92" width="327" height="12" font="12">myocardial perfusion imaging did not influence the choice of</text>
<text top="766" left="92" width="282" height="12" font="12">treatment. Clin Physiol Funct Imaging. 2006;26:288 –95.</text>
<text top="780" left="65" width="354" height="12" font="12">267. Badran HM, Elnoamany MF, Seteha M. Tissue velocity imaging</text>
<text top="794" left="92" width="327" height="12" font="12">with dobutamine stress echocardiography—a quantitative technique</text>
<text top="807" left="92" width="327" height="12" font="12">for identification of coronary artery disease in patients with left</text>
<text top="821" left="92" width="314" height="12" font="12">bundle branch block. J Am Soc Echocardiogr. 2007;20:820 –31.</text>
<text top="835" left="65" width="354" height="12" font="12">268. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular</text>
<text top="849" left="92" width="327" height="12" font="12">magnetic resonance predicts reversible myocardial dysfunction and</text>
<text top="863" left="92" width="327" height="12" font="12">remodeling in patients with heart failure undergoing beta-blocker</text>
<text top="876" left="92" width="198" height="12" font="12">therapy. Circulation. 2003;108:1945–53.</text>
<text top="890" left="65" width="354" height="12" font="12">269. Epstein FH. MRI of left ventricular function. J Nucl Cardiol.</text>
<text top="904" left="92" width="84" height="12" font="12">2007;14:729 – 44.</text>
<text top="918" left="65" width="354" height="12" font="12">270. Wagdy HM, Hodge D, Christian TF, et al. Prognostic value of</text>
<text top="931" left="92" width="327" height="12" font="12">vasodilator myocardial perfusion imaging in patients with left</text>
<text top="945" left="92" width="257" height="12" font="12">bundle-branch block. Circulation. 1998;97:1563–70.</text>
<text top="959" left="65" width="354" height="12" font="12">271. Bouzas-Mosquera A, Peteiro J, Alvarez-Garcia N, et al. Prediction</text>
<text top="973" left="92" width="327" height="12" font="12">of mortality and major cardiac events by exercise echocardiography</text>
<text top="987" left="92" width="327" height="12" font="12">in patients with normal exercise electrocardiographic testing. J Am</text>
<text top="1000" left="92" width="156" height="12" font="12">Coll Cardiol. 2009;53:1981–90.</text>
<text top="1014" left="65" width="354" height="12" font="12">272. Navare SM, Mather JF, Shaw LJ, et al. Comparison of risk</text>
<text top="1028" left="92" width="327" height="12" font="12">stratification with pharmacologic and exercise stress myocardial perfu-</text>
<text top="1042" left="92" width="299" height="12" font="12">sion imaging: a meta-analysis. J Nucl Cardiol. 2004;11:551–61.</text>
<text top="1055" left="64" width="354" height="12" font="12">273. Gebker R, Jahnke C, Manka R, et al. The role of dobutamine stress</text>
<text top="1069" left="92" width="327" height="12" font="12">cardiovascular magnetic resonance in the clinical management of</text>
<text top="1083" left="92" width="327" height="12" font="12">patients with suspected and known coronary artery disease. J Car-</text>
<text top="1097" left="92" width="166" height="12" font="12">diovasc Magn Reson. 2011;13:46.</text>
<text top="104" left="452" width="354" height="12" font="12">274. Peteiro J, Bouzas-Mosquera A, Broullon FJ, et al. Prognostic value</text>
<text top="118" left="479" width="327" height="12" font="12">of peak and post-exercise treadmill exercise echocardiography in</text>
<text top="132" left="479" width="327" height="12" font="12">patients with known or suspected coronary artery disease. Eur</text>
<text top="146" left="479" width="125" height="12" font="12">Heart J. 2010;31:187–95.</text>
<text top="160" left="452" width="354" height="12" font="12">275. Yao SS, Wever-Pinzon O, Zhang X, et al. Prognostic value of stress</text>
<text top="174" left="479" width="327" height="12" font="12">echocardiogram in patients with angiographically significant coro-</text>
<text top="188" left="479" width="254" height="12" font="12">nary artery disease. Am J Cardiol. 2012;109:153– 8.</text>
<text top="202" left="452" width="354" height="12" font="12">276. Shaw L, Cerqueira M, Brooks M, et al. Impact of left ventricular</text>
<text top="216" left="479" width="327" height="12" font="12">function and the extent of ischemia and scar by stress myocaridal</text>
<text top="230" left="479" width="327" height="12" font="12">perfusion imaging on prognosis and therapeutic risk reduction in</text>
<text top="244" left="479" width="327" height="12" font="12">diabetic patients with coronary artery disease: results from the</text>
<text top="258" left="479" width="327" height="12" font="12">Bypass Angioplasty Revascuarization Investigation 2 Diabetes</text>
<text top="272" left="479" width="199" height="12" font="12">(BARI 2D) Trial. J Nucl Cardiol. 2012.</text>
<text top="286" left="452" width="354" height="12" font="12">277. Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of</text>
<text top="300" left="479" width="327" height="12" font="12">ischaemia and scar on the therapeutic benefit derived from</text>
<text top="314" left="479" width="327" height="12" font="12">myocardial revascularization vs. medical therapy among patients</text>
<text top="328" left="479" width="327" height="12" font="12">undergoing stress-rest myocardial perfusion scintigraphy. Eur</text>
<text top="342" left="479" width="136" height="12" font="12">Heart J. 2011;32:1012–24.</text>
<text top="356" left="452" width="354" height="12" font="12">278. Doesch C, Seeger A, Doering J, et al. Risk stratification by</text>
<text top="370" left="479" width="327" height="12" font="12">adenosine stress cardiac magnetic resonance in patients with coro-</text>
<text top="384" left="479" width="327" height="12" font="12">nary artery stenoses of intermediate angiographic severity. J Am Coll</text>
<text top="398" left="479" width="222" height="12" font="12">Cardiol Cardiovasc Imaging. 2009;2:424 –33.</text>
<text top="412" left="452" width="354" height="12" font="12">279. Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac</text>
<text top="426" left="479" width="327" height="12" font="12">magnetic resonance stress tests: adenosine stress perfusion and</text>
<text top="440" left="479" width="327" height="12" font="12">dobutamine stress wall motion imaging. Circulation. 2007;115:</text>
<text top="454" left="479" width="46" height="12" font="12">1769 –76.</text>
<text top="468" left="452" width="354" height="12" font="12">280. Bingham SE, Hachamovitch R. Incremental prognostic significance</text>
<text top="482" left="479" width="327" height="12" font="12">of combined cardiac magnetic resonance imaging, adenosine stress</text>
<text top="496" left="479" width="327" height="12" font="12">perfusion, delayed enhancement, and left ventricular function over</text>
<text top="510" left="479" width="327" height="12" font="12">preimaging information for the prediction of adverse events. Circu-</text>
<text top="524" left="479" width="129" height="12" font="12">lation. 2011;123:1509 –18.</text>
<text top="538" left="452" width="354" height="12" font="12">281. Coelho-Filho OR, Seabra LF, Mongeon F-P. Stress Myocardial</text>
<text top="552" left="479" width="327" height="12" font="12">Perfusion Imaging by CMR Provides Strong Prognostic Value to</text>
<text top="566" left="479" width="327" height="12" font="12">Cardiac Events Regardless of Patient’s Sex. J Am Coll Cardiol</text>
<text top="580" left="479" width="183" height="12" font="12">Cardiovasc Imaging. 2011;4:850 – 61.</text>
<text top="594" left="452" width="354" height="12" font="12">282. Kelle S, Chiribiri A, Vierecke J, et al. Long-term prognostic value of</text>
<text top="608" left="479" width="327" height="12" font="12">dobutamine stress CMR. J Am Coll Cardiol Cardiovasc Imaging.</text>
<text top="622" left="479" width="75" height="12" font="12">2011;4:161–72.</text>
<text top="636" left="452" width="354" height="12" font="12">283. Korosoglou G, Elhmidi Y, Steen H, et al. Prognostic value of</text>
<text top="650" left="479" width="327" height="12" font="12">high-dose dobutamine stress magnetic resonance imaging in 1,493</text>
<text top="664" left="479" width="327" height="12" font="12">consecutive patients: assessment of myocardial wall motion and</text>
<text top="678" left="479" width="239" height="12" font="12">perfusion. J Am Coll Cardiol. 2010;56:1225–34.</text>
<text top="692" left="452" width="354" height="12" font="12">284. Steel K, Broderick R, Gandla V, et al. Complementary prognostic</text>
<text top="706" left="479" width="327" height="12" font="12">values of stress myocardial perfusion and late gadolinium enhance-</text>
<text top="720" left="479" width="327" height="12" font="12">ment imaging by cardiac magnetic resonance in patients with known</text>
<text top="734" left="479" width="327" height="12" font="12">or suspected coronary artery disease. Circulation. 2009;120:1390 –</text>
<text top="748" left="479" width="21" height="12" font="12">400.</text>
<text top="762" left="452" width="354" height="12" font="12">285. Chow BJW, Wells GA, Chen L, et al. Prognostic value of 64-slice</text>
<text top="775" left="479" width="327" height="12" font="12">cardiac computed tomography severity of coronary artery disease,</text>
<text top="789" left="479" width="327" height="12" font="12">coronary atherosclerosis, and left ventricular ejection fraction. J Am</text>
<text top="803" left="479" width="156" height="12" font="12">Coll Cardiol. 2010;55:1017–28.</text>
<text top="817" left="452" width="354" height="12" font="12">286. Min JK, Dunning A, Lin FY, et al. Age- and Sex-Related</text>
<text top="831" left="479" width="327" height="12" font="12">Differences in All-Cause Mortality Risk Based on Coronary Com-</text>
<text top="845" left="479" width="327" height="12" font="12">puted Tomography Angiography Findings Results From the Inter-</text>
<text top="859" left="479" width="327" height="12" font="12">national Multicenter CONFIRM (Coronary CT Angiography</text>
<text top="873" left="479" width="327" height="12" font="12">Evaluation for Clinical Outcomes: An International Multicenter</text>
<text top="887" left="479" width="327" height="12" font="12">Registry) of 23,854 Patients Without Known Coronary Artery</text>
<text top="901" left="479" width="227" height="12" font="12">Disease. J Am Coll Cardiol. 2011;58:849 – 60.</text>
<text top="915" left="452" width="354" height="12" font="12">287. America YGCJ, Bax JJ, Boersma E, et al. Prognostic value of gated</text>
<text top="929" left="479" width="327" height="12" font="12">SPECT in patients with left bundle branch block. J Nucl Cardiol.</text>
<text top="943" left="479" width="77" height="12" font="12">2007;14:75– 81.</text>
<text top="957" left="452" width="354" height="12" font="12">288. Gil VM, Almeida M, Ventosa A, et al. Prognosis in patients with</text>
<text top="971" left="479" width="327" height="12" font="12">left bundle branch block and normal dipyridamole thallium-201</text>
<text top="985" left="479" width="216" height="12" font="12">scintigraphy. J Nucl Cardiol. 1998;5:414 –7.</text>
<text top="999" left="452" width="354" height="12" font="12">289. Nallamothu N, Bagheri B, Acio ER, et al. Prognostic value of stress</text>
<text top="1013" left="479" width="327" height="12" font="12">myocardial perfusion single photon emission computed tomography</text>
<text top="1027" left="479" width="327" height="12" font="12">imaging in patients with left ventricular bundle branch block. J Nucl</text>
<text top="1041" left="479" width="119" height="12" font="12">Cardiol. 1997;4:487–93.</text>
<text top="1055" left="452" width="354" height="12" font="12">290. Nigam A, Humen DP. Prognostic value of myocardial perfusion</text>
<text top="1069" left="479" width="327" height="12" font="12">imaging with exercise and/or dipyridamole hyperemia in patients</text>
<text top="1083" left="479" width="327" height="12" font="12">with preexisting left bundle branch block. J Nucl Med. 1998;39:</text>
<text top="1097" left="479" width="43" height="12" font="12">579 – 81.</text>
<text top="52" left="781" width="25" height="10" font="12">e135</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">291. Pilz G, Jeske A, Klos M, et al. Prognostic value of normal</text>
<text top="118" left="92" width="327" height="12" font="12">adenosine-stress cardiac magnetic resonance imaging. Am J Cardiol.</text>
<text top="132" left="92" width="95" height="12" font="12">2008;101:1408 –12.</text>
<text top="146" left="65" width="354" height="12" font="12">292. Tandogan I, Yetkin E, Yanik A, et al. Comparison of thallium-201</text>
<text top="160" left="92" width="327" height="12" font="12">exercise SPECT and dobutamine stress echocardiography for diag-</text>
<text top="174" left="92" width="327" height="12" font="12">nosis of coronary artery disease in patients with left bundle branch</text>
<text top="188" left="92" width="248" height="12" font="12">block. Int J Cardiovasc Imaging. 2001;17:339 – 45.</text>
<text top="202" left="65" width="354" height="12" font="12">293. Hacker M, Jakobs T, Hack N, et al. Combined use of 64-slice</text>
<text top="216" left="92" width="327" height="12" font="12">computed tomography angiography and gated myocardial perfusion</text>
<text top="230" left="92" width="327" height="12" font="12">SPECT for the detection of functionally relevant coronary artery</text>
<text top="244" left="92" width="327" height="12" font="12">stenoses. First results in a clinical setting concerning patients with</text>
<text top="258" left="92" width="232" height="12" font="12">stable angina. Nuklearmedizin. 2007;46:29 –35.</text>
<text top="272" left="65" width="354" height="12" font="12">294. Yao SS, Bangalore S, Chaudhry FA. Prognostic implications of</text>
<text top="286" left="92" width="327" height="12" font="12">stress echocardiography and impact on patient outcomes: an effec-</text>
<text top="300" left="92" width="327" height="12" font="12">tive gatekeeper for coronary angiography and revascularization.</text>
<text top="314" left="92" width="199" height="12" font="12">J Am Soc Echocardiogr. 2010;23:832–9.</text>
<text top="328" left="65" width="354" height="12" font="12">295. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-</text>
<text top="342" left="92" width="327" height="12" font="12">converting-enzyme inhibition in stable coronary artery disease.</text>
<text top="356" left="92" width="175" height="12" font="12">N Engl J Med. 2004;351:2058 – 68.</text>
<text top="370" left="65" width="354" height="12" font="12">296. Fox KM. Efficacy of perindopril in reduction of cardiovascular</text>
<text top="384" left="92" width="327" height="12" font="12">events among patients with stable coronary artery disease: ran-</text>
<text top="398" left="92" width="327" height="12" font="12">domised, double-blind, placebo-controlled, multicentre trial (the</text>
<text top="412" left="92" width="215" height="12" font="12">EUROPA study). Lancet. 2003;362:782– 8.</text>
<text top="426" left="65" width="354" height="12" font="12">297. Garg R, Yusuf S. Overview of randomized trials of angiotensin-</text>
<text top="440" left="92" width="327" height="12" font="12">converting enzyme inhibitors on mortality and morbidity in patients</text>
<text top="454" left="92" width="327" height="12" font="12">with heart failure. Collaborative Group on ACE Inhibitor Trials.</text>
<text top="468" left="92" width="131" height="12" font="12">JAMA. 1995;273:1450 – 6.</text>
<text top="482" left="65" width="354" height="12" font="12">298. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of</text>
<text top="496" left="92" width="327" height="12" font="12">monotherapy and combination therapy with inhibitors of the renin</text>
<text top="510" left="92" width="327" height="12" font="12">angiotensin system on proteinuria in renal disease. Ann Intern Med.</text>
<text top="524" left="92" width="84" height="12" font="12">2008;148:30 – 48.</text>
<text top="538" left="65" width="354" height="12" font="12">299. McCully RB, Roger VL, Mahoney DW, et al. Outcome after</text>
<text top="552" left="92" width="327" height="12" font="12">abnormal exercise echocardiography for patients with good exercise</text>
<text top="566" left="92" width="327" height="12" font="12">capacity: prognostic importance of the extent and severity of</text>
<text top="580" left="92" width="327" height="12" font="12">exercise-related left ventricular dysfunction. J Am Coll Cardiol.</text>
<text top="594" left="92" width="87" height="12" font="12">2002;39:1345–52.</text>
<text top="608" left="65" width="354" height="12" font="12">300. Shaw LJ, Hendel R, Borges-Neto S, et al. Prognostic value of</text>
<text top="622" left="92" width="327" height="12" font="12">normal exercise and adenosine (99m)Tc-tetrofosmin SPECT im-</text>
<text top="636" left="92" width="327" height="12" font="12">aging: results from the multicenter registry of 4,728 patients. J Nucl</text>
<text top="650" left="92" width="107" height="12" font="12">Med. 2003;44:134 –9.</text>
<text top="664" left="65" width="354" height="12" font="12">301. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-</text>
<text top="678" left="92" width="327" height="12" font="12">converting-enzyme inhibitor, ramipril, on cardiovascular events in</text>
<text top="692" left="92" width="327" height="12" font="12">high-risk patients. The Heart Outcomes Prevention Evaluation</text>
<text top="706" left="92" width="267" height="12" font="12">Study Investigators. N Engl J Med. 2000;342:145–53.</text>
<text top="720" left="65" width="354" height="12" font="12">302. Weiner DA, Ryan TJ, McCabe CH, et al. Prognostic importance of</text>
<text top="734" left="92" width="327" height="12" font="12">a clinical profile and exercise test in medically treated patients with</text>
<text top="747" left="92" width="286" height="12" font="12">coronary artery disease. J Am Coll Cardiol. 1984;3:772–9.</text>
<text top="761" left="65" width="354" height="12" font="12">303. Cole CR, Blackstone EH, Pashkow FJ, et al. Heart-rate recovery</text>
<text top="775" left="92" width="327" height="12" font="12">immediately after exercise as a predictor of mortality. N Engl J Med.</text>
<text top="789" left="92" width="87" height="12" font="12">1999;341:1351–7.</text>
<text top="803" left="65" width="354" height="12" font="12">304. McCully RB, Roger VL, Mahoney DW, et al. Outcome after</text>
<text top="817" left="92" width="327" height="12" font="12">normal exercise echocardiography and predictors of subsequent</text>
<text top="831" left="92" width="327" height="12" font="12">cardiac events: follow-up of 1,325 patients. J Am Coll Cardiol.</text>
<text top="845" left="92" width="77" height="12" font="12">1998;31:144 –9.</text>
<text top="859" left="65" width="354" height="12" font="12">305. Hachamovitch R, Rozanski A, Hayes SW, et al. Predicting thera-</text>
<text top="873" left="92" width="327" height="12" font="12">peutic benefit from myocardial revascularization procedures: are</text>
<text top="887" left="92" width="327" height="12" font="12">measurements of both resting left ventricular ejection fraction and</text>
<text top="901" left="92" width="327" height="12" font="12">stress-induced myocardial ischemia necessary? J Nucl Cardiol.</text>
<text top="915" left="92" width="83" height="12" font="12">2006;13:768 –78.</text>
<text top="929" left="65" width="354" height="12" font="12">306. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy</text>
<text top="943" left="92" width="327" height="12" font="12">with or without percutaneous coronary intervention to reduce</text>
<text top="957" left="92" width="327" height="12" font="12">ischemic burden: results from the Clinical Outcomes Utilizing</text>
<text top="971" left="92" width="327" height="12" font="12">Revascularization and Aggressive Drug Evaluation (COURAGE)</text>
<text top="985" left="92" width="266" height="12" font="12">trial nuclear substudy. Circulation. 2008;117:1283–91.</text>
<text top="999" left="65" width="354" height="12" font="12">307. Hachamovitch R, Hayes S, Friedman JD, et al. Determinants of risk</text>
<text top="1013" left="92" width="327" height="12" font="12">and its temporal variation in patients with normal stress myocardial</text>
<text top="1027" left="92" width="327" height="12" font="12">perfusion scans: what is the warranty period of a normal scan? J Am</text>
<text top="1041" left="92" width="159" height="12" font="12">Coll Cardiol. 2003;41:1329 – 40.</text>
<text top="1055" left="65" width="354" height="12" font="12">308. Chaowalit N, McCully RB, Callahan MJ, et al. Outcomes after</text>
<text top="1069" left="92" width="327" height="12" font="12">normal dobutamine stress echocardiography and predictors of ad-</text>
<text top="1083" left="92" width="327" height="12" font="12">verse events: long-term follow-up of 3014 patients. Eur Heart J.</text>
<text top="1097" left="92" width="90" height="12" font="12">2006;27:3039 – 44.</text>
<text top="105" left="452" width="354" height="12" font="12">309. Elhendy A, Mahoney DW, Khandheria BK, et al. Prognostic</text>
<text top="118" left="479" width="327" height="12" font="12">significance of the location of wall motion abnormalities during</text>
<text top="132" left="479" width="314" height="12" font="12">exercise echocardiography. J Am Coll Cardiol. 2002;40:1623–9.</text>
<text top="146" left="452" width="354" height="12" font="12">310. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prog-</text>
<text top="160" left="479" width="327" height="12" font="12">nostic value of myocardial perfusion single photon emission com-</text>
<text top="173" left="479" width="327" height="12" font="12">puted tomography for the prediction of cardiac death: differential</text>
<text top="187" left="479" width="327" height="12" font="12">stratification for risk of cardiac death and myocardial infarction.</text>
<text top="201" left="479" width="144" height="12" font="12">Circulation. 1998;97:535– 43.</text>
<text top="215" left="452" width="354" height="12" font="12">311. Marwick TH, Case C, Vasey C, et al. Prediction of mortality by</text>
<text top="229" left="479" width="327" height="12" font="12">exercise echocardiography: a strategy for combination with the duke</text>
<text top="242" left="479" width="235" height="12" font="12">treadmill score. Circulation. 2001;103:2566 –71.</text>
<text top="256" left="452" width="354" height="12" font="12">312. Marwick TH, Case C, Sawada S, et al. Prediction of mortality using</text>
<text top="270" left="479" width="327" height="12" font="12">dobutamine echocardiography. J Am Coll Cardiol. 2001;37:</text>
<text top="284" left="479" width="42" height="12" font="12">754 – 60.</text>
<text top="298" left="452" width="354" height="12" font="12">313. Shaw LJ, Hachamovitch R, Heller GV, et al. Noninvasive strategies</text>
<text top="311" left="479" width="327" height="12" font="12">for the estimation of cardiac risk in stable chest pain patients. The</text>
<text top="325" left="479" width="327" height="12" font="12">Economics of Noninvasive Diagnosis (END) Study Group. Am J</text>
<text top="339" left="479" width="107" height="12" font="12">Cardiol. 2000;86:1–7.</text>
<text top="353" left="452" width="354" height="12" font="12">314. Shaw LJ, Hendel RC, Cerquiera M, et al. Ethnic differences in the</text>
<text top="367" left="479" width="327" height="12" font="12">prognostic value of stress technetium-99m tetrofosmin gated single-</text>
<text top="380" left="479" width="327" height="12" font="12">photon emission computed tomography myocardial perfusion im-</text>
<text top="394" left="479" width="227" height="12" font="12">aging. J Am Coll Cardiol. 2005;45:1494 –504.</text>
<text top="408" left="452" width="354" height="12" font="12">315. Shaw LJ, Vasey C, Sawada S, et al. Impact of gender on risk</text>
<text top="422" left="479" width="327" height="12" font="12">stratification by exercise and dobutamine stress echocardiography:</text>
<text top="435" left="479" width="327" height="12" font="12">long-term mortality in 4234 women and 6898 men. Eur Heart J.</text>
<text top="449" left="479" width="81" height="12" font="12">2005;26:447–56.</text>
<text top="463" left="452" width="354" height="12" font="12">316. Gibbons RJ, Hodge DO, Berman DS, et al. Long-term outcome of</text>
<text top="477" left="479" width="327" height="12" font="12">patients with intermediate-risk exercise electrocardiograms who do</text>
<text top="491" left="479" width="327" height="12" font="12">not have myocardial perfusion defects on radionuclide imaging.</text>
<text top="504" left="479" width="150" height="12" font="12">Circulation. 1999;100:2140 –5.</text>
<text top="518" left="452" width="354" height="12" font="12">317. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial</text>
<text top="532" left="479" width="327" height="12" font="12">perfusion SPECT in patients without known coronary artery</text>
<text top="546" left="479" width="327" height="12" font="12">disease: incremental prognostic value and use in risk stratification.</text>
<text top="560" left="479" width="143" height="12" font="12">Circulation. 1996;93:905–14.</text>
<text top="573" left="452" width="354" height="12" font="12">318. Levy D, Salomon M, D’Agostino RB, et al. Prognostic implications</text>
<text top="587" left="479" width="327" height="12" font="12">of baseline electrocardiographic features and their serial changes in</text>
<text top="601" left="479" width="327" height="12" font="12">subjects with left ventricular hypertrophy. Circulation. 1994;90:</text>
<text top="615" left="479" width="46" height="12" font="12">1786 –93.</text>
<text top="628" left="452" width="354" height="12" font="12">319. Poornima IG, Miller TD, Christian TF, et al. Utility of myocardial</text>
<text top="642" left="479" width="327" height="12" font="12">perfusion imaging in patients with low-risk treadmill scores. J Am</text>
<text top="656" left="479" width="145" height="12" font="12">Coll Cardiol. 2004;43:194 –9.</text>
<text top="670" left="452" width="354" height="12" font="12">320. Hachamovitch R, Hayes SW, Friedman JD, et al. A prognostic</text>
<text top="684" left="479" width="327" height="12" font="12">score for prediction of cardiac mortality risk after adenosine stress</text>
<text top="697" left="479" width="327" height="12" font="12">myocardial perfusion scintigraphy. J Am Coll Cardiol. 2005;45:</text>
<text top="711" left="479" width="33" height="12" font="12">722–9.</text>
<text top="725" left="452" width="354" height="12" font="12">321. America YG, Bax JJ, Boersma E, et al. The additive prognostic</text>
<text top="739" left="479" width="327" height="12" font="12">value of perfusion and functional data assessed by quantitative gated</text>
<text top="752" left="479" width="249" height="12" font="12">SPECT in women. J Nucl Cardiol. 2009;16:10 –9.</text>
<text top="766" left="452" width="354" height="12" font="12">322. Sharir T, Kang X, Germano G, et al. Prognostic value of poststress</text>
<text top="780" left="479" width="327" height="12" font="12">left ventricular volume and ejection fraction by gated myocardial</text>
<text top="794" left="479" width="327" height="12" font="12">perfusion SPECT in women and men: gender-related differences in</text>
<text top="808" left="479" width="311" height="12" font="12">normal limits and outcomes. J Nucl Cardiol. 2006;13:495–506.</text>
<text top="821" left="452" width="354" height="12" font="12">323. Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic</text>
<text top="835" left="479" width="327" height="12" font="12">value of myocardial perfusion imaging using rubidium-82 positron</text>
<text top="849" left="479" width="301" height="12" font="12">emission tomography? J Am Coll Cardiol. 2006;48:1029 –39.</text>
<text top="863" left="452" width="354" height="12" font="12">324. Yao SS, Qureshi E, Sherrid MV, et al. Practical applications in</text>
<text top="876" left="479" width="327" height="12" font="12">stress echocardiography: risk stratification and prognosis in patients</text>
<text top="890" left="479" width="327" height="12" font="12">with known or suspected ischemic heart disease. J Am Coll Cardiol.</text>
<text top="904" left="479" width="89" height="12" font="12">2003;42:1084 –90.</text>
<text top="918" left="452" width="354" height="12" font="12">325. Lertsburapa K, Ahlberg AW, Bateman TM, et al. Independent and</text>
<text top="932" left="479" width="327" height="12" font="12">incremental prognostic value of left ventricular ejection fraction</text>
<text top="945" left="479" width="327" height="12" font="12">determined by stress gated rubidium 82 PET imaging in patients</text>
<text top="959" left="479" width="327" height="12" font="12">with known or suspected coronary artery disease. J Nucl Cardiol.</text>
<text top="973" left="479" width="81" height="12" font="12">2008;15:745–53.</text>
<text top="987" left="452" width="354" height="12" font="12">326. Hachamovitch R. Risk assessment of patients with known or</text>
<text top="1000" left="479" width="327" height="12" font="12">suspected CAD using stress myocardial perfusion SPECT. Part I:</text>
<text top="1014" left="479" width="327" height="12" font="12">The ongoing evolution of clinical evidence. Rev Cardiovasc Med.</text>
<text top="1028" left="479" width="75" height="12" font="12">2000;1:91–102.</text>
<text top="1042" left="452" width="354" height="12" font="12">327. Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of</text>
<text top="1056" left="479" width="327" height="12" font="12">the short-term survival benefit associated with revascularization</text>
<text top="1069" left="479" width="327" height="12" font="12">compared with medical therapy in patients with no prior coronary</text>
<text top="1083" left="479" width="327" height="12" font="12">artery disease undergoing stress myocardial perfusion single photon</text>
<text top="1097" left="479" width="314" height="12" font="12">emission computed tomography. Circulation. 2003;107:2900 –7.</text>
<text top="52" left="59" width="25" height="10" font="12">e136</text>
<text top="52" left="113" width="48" height="10" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">328. Gehi AK, Ali S, Na B, et al. Inducible ischemia and the risk of</text>
<text top="118" left="92" width="327" height="12" font="12">recurrent cardiovascular events in outpatients with stable coronary</text>
<text top="132" left="92" width="327" height="12" font="12">heart disease: the heart and soul study. Arch Intern Med. 2008;168:</text>
<text top="145" left="92" width="40" height="12" font="12">1423– 8.</text>
<text top="159" left="65" width="354" height="12" font="12">329. Bodi V, Sanchis J, Lopez-Lereu MP, et al. Prognostic value of</text>
<text top="172" left="92" width="327" height="12" font="12">dipyridamole stress cardiovascular magnetic resonance imaging in</text>
<text top="186" left="92" width="327" height="12" font="12">patients with known or suspected coronary artery disease. J Am Coll</text>
<text top="200" left="92" width="126" height="12" font="12">Cardiol. 2007;50:1174 –9.</text>
<text top="213" left="65" width="354" height="12" font="12">330. Bangalore S, Yao SS, Chaudhry FA. Usefulness of stress echocar-</text>
<text top="227" left="92" width="327" height="12" font="12">diography for risk stratification and prognosis of patients with left</text>
<text top="240" left="92" width="285" height="12" font="12">ventricular hypertrophy. Am J Cardiol. 2007;100:536 – 43.</text>
<text top="254" left="65" width="354" height="12" font="12">331. Sharir T, Germano G, Kavanagh PB, et al. Incremental prognostic</text>
<text top="268" left="92" width="327" height="12" font="12">value of post-stress left ventricular ejection fraction and volume by</text>
<text top="281" left="92" width="327" height="12" font="12">gated myocardial perfusion single photon emission computed to-</text>
<text top="295" left="92" width="212" height="12" font="12">mography. Circulation. 1999;100:1035– 42.</text>
<text top="308" left="65" width="354" height="12" font="12">332. Abidov A, Bax JJ, Hayes SW, et al. Transient ischemic dilation ratio</text>
<text top="322" left="92" width="327" height="12" font="12">of the left ventricle is a significant predictor of future cardiac events</text>
<text top="336" left="92" width="327" height="12" font="12">in patients with otherwise normal myocardial perfusion SPECT.</text>
<text top="349" left="92" width="188" height="12" font="12">J Am Coll Cardiol. 2003;42:1818 –25.</text>
<text top="363" left="65" width="354" height="12" font="12">333. Parisi AF, Hartigan PM, Folland ED. Evaluation of exercise</text>
<text top="376" left="92" width="327" height="12" font="12">thallium scintigraphy versus exercise electrocardiography in predict-</text>
<text top="390" left="92" width="327" height="12" font="12">ing survival outcomes and morbid cardiac events in patients with</text>
<text top="404" left="92" width="327" height="12" font="12">single- and double-vessel disease. Findings from the Angioplasty</text>
<text top="417" left="92" width="327" height="12" font="12">Compared to Medicine (ACME) Study. J Am Coll Cardiol.</text>
<text top="431" left="92" width="90" height="12" font="12">1997;30:1256 – 63.</text>
<text top="444" left="65" width="354" height="12" font="12">334. Poldermans D, Fioretti PM, Boersma E, et al. Long-term prog-</text>
<text top="458" left="92" width="327" height="12" font="12">nostic value of dobutamine-atropine stress echocardiography in</text>
<text top="471" left="92" width="327" height="12" font="12">1737 patients with known or suspected coronary artery disease: A</text>
<text top="485" left="92" width="268" height="12" font="12">single-center experience. Circulation. 1999;99:757– 62.</text>
<text top="499" left="65" width="354" height="12" font="12">335. Kamalesh M, Matorin R, Sawada S. Prognostic value of a negative</text>
<text top="512" left="92" width="327" height="12" font="12">stress echocardiographic study in diabetic patients. Am Heart J.</text>
<text top="526" left="92" width="83" height="12" font="12">2002;143:163– 8.</text>
<text top="539" left="65" width="354" height="12" font="12">336. Bjork Ingul C, Rozis E, Slordahl SA, et al. Incremental value of</text>
<text top="553" left="92" width="327" height="12" font="12">strain rate imaging to wall motion analysis for prediction of outcome</text>
<text top="567" left="92" width="327" height="12" font="12">in patients undergoing dobutamine stress echocardiography. Circu-</text>
<text top="580" left="92" width="122" height="12" font="12">lation. 2007;115:1252–9.</text>
<text top="594" left="65" width="354" height="12" font="12">337. Poldermans D, Rambaldi R, Fioretti PM, et al. Prognostic value of</text>
<text top="607" left="92" width="327" height="12" font="12">dobutamine-atropine stress echocardiography for peri-operative and</text>
<text top="621" left="92" width="327" height="12" font="12">late cardiac events in patients scheduled for vascular surgery. Eur</text>
<text top="635" left="92" width="185" height="12" font="12">Heart J. 1997;18 Suppl D:D86 –D96.</text>
<text top="648" left="65" width="354" height="12" font="12">338. Shaw LJ, Eagle KA, Gersh BJ, et al. Meta-analysis of intravenous</text>
<text top="662" left="92" width="327" height="12" font="12">dipyridamole-thallium-201 imaging (1985 to 1994) and dobut-</text>
<text top="675" left="92" width="327" height="12" font="12">amine echocardiography (1991 to 1994) for risk stratification before</text>
<text top="689" left="92" width="264" height="12" font="12">vascular surgery. J Am Coll Cardiol. 1996;27:787–98.</text>
<text top="702" left="65" width="354" height="12" font="12">339. Hachamovitch R, Berman DS, Kiat H, et al. Incremental prognostic</text>
<text top="716" left="92" width="327" height="12" font="12">value of adenosine stress myocardial perfusion single-photon emis-</text>
<text top="730" left="92" width="327" height="12" font="12">sion computed tomography and impact on subsequent management</text>
<text top="743" left="92" width="327" height="12" font="12">in patients with or suspected of having myocardial ischemia. Am J</text>
<text top="757" left="92" width="126" height="12" font="12">Cardiol. 1997;80:426 –33.</text>
<text top="770" left="65" width="354" height="12" font="12">340. Lima RS, De Lorenzo A, Pantoja MR, et al. Incremental prognostic</text>
<text top="784" left="92" width="327" height="12" font="12">value of myocardial perfusion 99m-technetium-sestamibi SPECT</text>
<text top="798" left="92" width="225" height="12" font="12">in the elderly. Int J Cardiol. 2004;93:137– 43.</text>
<text top="811" left="65" width="354" height="12" font="12">341. Schinkel AF, Elhendy A, Biagini E, et al. Prognostic stratification</text>
<text top="825" left="92" width="327" height="12" font="12">using dobutamine stress 99mTc-tetrofosmin myocardial perfusion</text>
<text top="838" left="92" width="327" height="12" font="12">SPECT in elderly patients unable to perform exercise testing. J Nucl</text>
<text top="852" left="92" width="101" height="12" font="12">Med. 2005;46:12– 8.</text>
<text top="865" left="65" width="354" height="12" font="12">342. Rozanski A, Gransar H, Hayes SW, et al. Comparison of long-term</text>
<text top="879" left="92" width="327" height="12" font="12">mortality risk following normal exercise vs adenosine myocardial</text>
<text top="893" left="92" width="269" height="12" font="12">perfusion SPECT. J Nucl Cardiol. 2010;17:999 –1008.</text>
<text top="906" left="65" width="354" height="12" font="12">343. Wallace EL, Morgan TM, Walsh TF, et al. Dobutamine cardiac</text>
<text top="920" left="92" width="327" height="12" font="12">magnetic resonance results predict cardiac prognosis in women with</text>
<text top="933" left="92" width="327" height="12" font="12">known or suspected ischemic heart disease. J Am Coll Cardiol</text>
<text top="947" left="92" width="187" height="12" font="12">Cardiovasc Imaging. 2009;2:299 –307.</text>
<text top="961" left="65" width="354" height="12" font="12">344. Cortigiani L, Picano E, Vigna C, et al. Prognostic value of</text>
<text top="974" left="92" width="327" height="12" font="12">pharmacologic stress echocardiography in patients with left bundle</text>
<text top="988" left="92" width="212" height="12" font="12">branch block. Am J Med. 2001;110:361–9.</text>
<text top="1001" left="65" width="354" height="12" font="12">345. Min JK, Shaw LJ, Devereux RB, et al. Prognostic value of</text>
<text top="1015" left="92" width="327" height="12" font="12">multidetector coronary computed tomographic angiography for</text>
<text top="1028" left="92" width="327" height="12" font="12">prediction of all-cause mortality. J Am Coll Cardiol. 2007;50:</text>
<text top="1042" left="92" width="45" height="12" font="12">1161–70.</text>
<text top="1056" left="65" width="354" height="12" font="12">346. Small GR, Yam Y, Chen L, et al. Prognostic assessment of coronary</text>
<text top="1069" left="92" width="327" height="12" font="12">artery bypass patients with 64-slice computed tomography angiog-</text>
<text top="1083" left="92" width="327" height="12" font="12">raphy anatomical information is incremental to clinical risk predic-</text>
<text top="1096" left="92" width="214" height="12" font="12">tion. J Am Coll Cardiol. 2011;58:2389 –95.</text>
<text top="104" left="452" width="354" height="12" font="12">347. Chow BJ, Ahmed O, Small G, et al. Prognostic value of CT</text>
<text top="118" left="479" width="327" height="12" font="12">angiography in coronary bypass patients. J Am Coll Cardiol Car-</text>
<text top="131" left="479" width="169" height="12" font="12">diovasc Imaging. 2011;4:496 –502.</text>
<text top="145" left="452" width="354" height="12" font="12">348. Hachamovitch R, Johnson JR, Hlatky MA, et al. The study of</text>
<text top="159" left="479" width="327" height="12" font="12">myocardial perfusion and coronary anatomy imaging roles in CAD</text>
<text top="172" left="479" width="327" height="12" font="12">(SPARC): design, rationale, and baseline patient characteristics of a</text>
<text top="186" left="479" width="327" height="12" font="12">prospective, multicenter observational registry comparing PET,</text>
<text top="199" left="479" width="327" height="12" font="12">SPECT, and CTA for resource utilization and clinical outcomes.</text>
<text top="213" left="479" width="162" height="12" font="12">J Nucl Cardiol. 2009;16:935– 48.</text>
<text top="227" left="452" width="354" height="12" font="12">349. Survivors of out-of-hospital cardiac arrest with apparently normal</text>
<text top="240" left="479" width="327" height="12" font="12">heart. Need for definition and standardized clinical evaluation.</text>
<text top="254" left="479" width="327" height="12" font="12">Consensus statement of the Joint Steering Committees of the</text>
<text top="267" left="479" width="327" height="12" font="12">Unexplained Cardiac Arrest Registry of Europe and of the Idio-</text>
<text top="281" left="479" width="327" height="12" font="12">pathic Ventricular Fibrillation Registry of the United States. Cir-</text>
<text top="294" left="479" width="127" height="12" font="12">culation. 1997;95:265–72.</text>
<text top="308" left="452" width="354" height="12" font="12">350. Every NR, Fahrenbruch CE, Hallstrom AP, et al. Influence of</text>
<text top="322" left="479" width="327" height="12" font="12">coronary bypass surgery on subsequent outcome of patients resus-</text>
<text top="335" left="479" width="327" height="12" font="12">citated from out of hospital cardiac arrest. J Am Coll Cardiol.</text>
<text top="349" left="479" width="81" height="12" font="12">1992;19:1435–9.</text>
<text top="362" left="452" width="354" height="12" font="12">351. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary</text>
<text top="376" left="479" width="327" height="12" font="12">angiography in survivors of out-of-hospital cardiac arrest. N Engl</text>
<text top="390" left="479" width="133" height="12" font="12">J Med. 1997;336:1629 –33.</text>
<text top="403" left="452" width="354" height="12" font="12">352. Califf RM, Harrell FE Jr., Lee KL, et al. The evolution of medical</text>
<text top="417" left="479" width="327" height="12" font="12">and surgical therapy for coronary artery disease. A 15-year perspec-</text>
<text top="430" left="479" width="160" height="12" font="12">tive. JAMA. 1989;261:2077– 86.</text>
<text top="444" left="452" width="354" height="12" font="12">353. Myers WO, Schaff HV, Gersh BJ, et al. Improved survival of</text>
<text top="458" left="479" width="327" height="12" font="12">surgically treated patients with triple vessel coronary artery disease</text>
<text top="471" left="479" width="327" height="12" font="12">and severe angina pectoris. A report from the Coronary Artery</text>
<text top="485" left="479" width="327" height="12" font="12">Surgery Study (CASS) registry. J Thorac Cardiovasc Surg. 1989;97:</text>
<text top="498" left="479" width="39" height="12" font="12">487–95.</text>
<text top="512" left="452" width="354" height="12" font="12">354. Myers WO, Gersh BJ, Fisher LD, et al. Medical versus early</text>
<text top="526" left="479" width="327" height="12" font="12">surgical therapy in patients with triple-vessel disease and mild</text>
<text top="539" left="479" width="327" height="12" font="12">angina pectoris: a CASS registry study of survival. Ann Thorac</text>
<text top="553" left="479" width="112" height="12" font="12">Surg. 1987;44:471– 86.</text>
<text top="566" left="452" width="354" height="12" font="12">355. Bonow RO, Maurer G, Lee KL, et al. Myocardial Viability and</text>
<text top="580" left="479" width="327" height="12" font="12">Survival in Ischemic Left Ventricular Dysfunction. N Engl J Med.</text>
<text top="594" left="479" width="93" height="12" font="12">2011;364:1617–25.</text>
<text top="607" left="452" width="354" height="12" font="12">356. Brunelli C, Cristofani R, L’Abbate A. Long-term survival in</text>
<text top="621" left="479" width="327" height="12" font="12">medically treated patients with ischaemic heart disease and prog-</text>
<text top="634" left="479" width="327" height="12" font="12">nostic importance of clinical and electrocardiographic data (the</text>
<text top="648" left="479" width="327" height="12" font="12">Italian CNR Multicentre Prospective Study OD1). Eur Heart J.</text>
<text top="661" left="479" width="87" height="12" font="12">1989;10:292–303.</text>
<text top="675" left="452" width="354" height="12" font="12">357. Chuah SC, Pellikka PA, Roger VL, et al. Role of dobutamine stress</text>
<text top="689" left="479" width="327" height="12" font="12">echocardiography in predicting outcome in 860 patients with known</text>
<text top="702" left="479" width="327" height="12" font="12">or suspected coronary artery disease. Circulation. 1998;97:1474 – 80.</text>
<text top="716" left="452" width="354" height="12" font="12">358. Harris PJ, Harrell FE Jr., Lee KL, et al. Survival in medically treated</text>
<text top="729" left="479" width="270" height="12" font="12">coronary artery disease. Circulation. 1979;60:1259 – 69.</text>
<text top="743" left="452" width="354" height="12" font="12">359. Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity</text>
<text top="757" left="479" width="327" height="12" font="12">of myocardial hypoperfusion as predictors of prognosis in patients</text>
<text top="770" left="479" width="327" height="12" font="12">with suspected coronary artery disease. J Am Coll Cardiol. 1986;7:</text>
<text top="784" left="479" width="40" height="12" font="12">464 –71.</text>
<text top="797" left="452" width="354" height="12" font="12">360. Marwick TH, Mehta R, Arheart K, et al. Use of exercise echocar-</text>
<text top="811" left="479" width="327" height="12" font="12">diography for prognostic evaluation of patients with known or</text>
<text top="824" left="479" width="327" height="12" font="12">suspected coronary artery disease. J Am Coll Cardiol. 1997;30:83–</text>
<text top="838" left="479" width="15" height="12" font="12">90.</text>
<text top="852" left="452" width="354" height="12" font="12">361. Morrow K, Morris CK, Froelicher VF, et al. Prediction of cardio-</text>
<text top="865" left="479" width="327" height="12" font="12">vascular death in men undergoing noninvasive evaluation for coro-</text>
<text top="879" left="479" width="275" height="12" font="12">nary artery disease. Ann Intern Med. 1993;118:689 –95.</text>
<text top="892" left="452" width="354" height="12" font="12">362. Stratmann HG, Williams GA, Wittry MD, et al. Exercise</text>
<text top="906" left="479" width="327" height="12" font="12">technetium-99m sestamibi tomography for cardiac risk stratification</text>
<text top="920" left="479" width="312" height="12" font="12">of patients with stable chest pain. Circulation. 1994;89:615–22.</text>
<text top="933" left="452" width="354" height="12" font="12">363. Miller TD, Christian TF, Taliercio CP, et al. Impaired left</text>
<text top="947" left="479" width="327" height="12" font="12">ventricular function, one- or two-vessel coronary artery disease, and</text>
<text top="960" left="479" width="327" height="12" font="12">severe ischemia: outcome with medical therapy versus revasculariza-</text>
<text top="974" left="479" width="196" height="12" font="12">tion. Mayo Clin Proc. 1994;69:626 –31.</text>
<text top="987" left="452" width="354" height="12" font="12">364. Emond M, Mock MB, Davis KB, et al. Long-term survival of</text>
<text top="1001" left="479" width="327" height="12" font="12">medically treated patients in the Coronary Artery Surgery Study</text>
<text top="1015" left="479" width="239" height="12" font="12">(CASS) Registry. Circulation. 1994;90:2645–57.</text>
<text top="1028" left="452" width="354" height="12" font="12">365. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery</text>
<text top="1042" left="479" width="327" height="12" font="12">surgery in patients with poor left ventricular function (CASS).</text>
<text top="1055" left="479" width="143" height="12" font="12">Circulation. 1983;68:785–95.</text>
<text top="1069" left="452" width="354" height="12" font="12">366. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy</text>
<text top="1083" left="479" width="327" height="12" font="12">with or without PCI for stable coronary disease. N Engl J Med.</text>
<text top="1096" left="479" width="93" height="12" font="12">2007;356:1503–16.</text>
<text top="52" left="781" width="25" height="10" font="12">e137</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">367. Coronary artery surgery study (CASS): a randomized trial of</text>
<text top="118" left="92" width="327" height="12" font="12">coronary artery bypass surgery. Quality of life in patients randomly</text>
<text top="132" left="92" width="293" height="12" font="12">assigned to treatment groups. Circulation. 1983;68:951– 60.</text>
<text top="145" left="65" width="354" height="12" font="12">368. Comparison of coronary bypass surgery with angioplasty in</text>
<text top="159" left="92" width="327" height="12" font="12">patients with multivessel disease. The Bypass Angioplasty Re-</text>
<text top="172" left="92" width="327" height="12" font="12">vascularization Investigation (BARI) Investigators. N Engl</text>
<text top="186" left="92" width="131" height="12" font="12">J Med. 1996;335:217–25.</text>
<text top="200" left="65" width="354" height="12" font="12">369. Leape LL, Park RE, Bashore TM, et al. Effect of variability in</text>
<text top="213" left="92" width="327" height="12" font="12">the interpretation of coronary angiograms on the appropriateness</text>
<text top="227" left="92" width="327" height="12" font="12">of use of coronary revascularization procedures. Am Heart J.</text>
<text top="240" left="92" width="92" height="12" font="12">2000;139:106 –13.</text>
<text top="254" left="65" width="354" height="12" font="12">370. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angio-</text>
<text top="268" left="92" width="327" height="12" font="12">graphic progression of coronary artery disease and the development</text>
<text top="281" left="92" width="302" height="12" font="12">of myocardial infarction. J Am Coll Cardiol. 1988;12:56 – 62.</text>
<text top="295" left="65" width="354" height="12" font="12">371. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary</text>
<text top="308" left="92" width="327" height="12" font="12">angiography predict the site of a subsequent myocardial infarction in</text>
<text top="322" left="92" width="327" height="12" font="12">patients with mild-to-moderate coronary artery disease? Circula-</text>
<text top="336" left="92" width="115" height="12" font="12">tion. 1988;78:1157– 66.</text>
<text top="349" left="65" width="354" height="12" font="12">372. Braunwald E. Epilogue: what do clinicians expect from imagers?</text>
<text top="363" left="92" width="204" height="12" font="12">J Am Coll Cardiol. 2006;47:C101–C103.</text>
<text top="376" left="65" width="354" height="12" font="12">373. Eleven-year survival in the Veterans Administration randomized</text>
<text top="390" left="92" width="327" height="12" font="12">trial of coronary bypass surgery for stable angina. The Veterans</text>
<text top="404" left="92" width="327" height="12" font="12">Administration Coronary Artery Bypass Surgery Cooperative Study</text>
<text top="417" left="92" width="206" height="12" font="12">Group. N Engl J Med. 1984;311:1333–9.</text>
<text top="431" left="65" width="354" height="12" font="12">374. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of</text>
<text top="444" left="92" width="327" height="12" font="12">angiographic indices of coronary artery disease from the Coronary</text>
<text top="458" left="92" width="314" height="12" font="12">Artery Surgery Study (CASS). J Clin Invest. 1983;71:1854 – 66.</text>
<text top="471" left="65" width="354" height="12" font="12">375. Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up</text>
<text top="485" left="92" width="327" height="12" font="12">of survival and myocardial infarction in the randomized Coronary</text>
<text top="499" left="92" width="263" height="12" font="12">Artery Surgery Study. Circulation. 1990;82:1629 – 46.</text>
<text top="512" left="65" width="354" height="12" font="12">376. Gersh BJ, Califf RM, Loop FD, et al. Coronary bypass surgery in</text>
<text top="526" left="92" width="258" height="12" font="12">chronic stable angina. Circulation. 1989;79:I46 –I59.</text>
<text top="539" left="65" width="354" height="12" font="12">377. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of</text>
<text top="553" left="92" width="327" height="12" font="12">therapy for coronary artery disease. Initial results from the era of</text>
<text top="567" left="92" width="256" height="12" font="12">coronary angioplasty. Circulation. 1994;89:2015–25.</text>
<text top="580" left="65" width="354" height="12" font="12">378. Califf RM, Phillips HR, III, Hindman MC, et al. Prognostic</text>
<text top="594" left="92" width="327" height="12" font="12">value of a coronary artery jeopardy score. J Am Coll Cardiol.</text>
<text top="607" left="92" width="86" height="12" font="12">1985;5:1055– 63.</text>
<text top="621" left="65" width="354" height="12" font="12">379. Nakagomi A, Celermajer DS, Lumley T, et al. Angiographic</text>
<text top="635" left="92" width="327" height="12" font="12">severity of coronary narrowing is a surrogate marker for the extent of</text>
<text top="648" left="92" width="274" height="12" font="12">coronary atherosclerosis. Am J Cardiol. 1996;78:516 –9.</text>
<text top="662" left="65" width="354" height="12" font="12">380. Campeau L, Corbara F, Crochet D, et al. Left main coronary artery</text>
<text top="675" left="92" width="327" height="12" font="12">stenosis: the influence of aortocoronary bypass surgery on survival.</text>
<text top="689" left="92" width="143" height="12" font="12">Circulation. 1978;57:1111–5.</text>
<text top="702" left="65" width="354" height="12" font="12">381. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical</text>
<text top="716" left="92" width="327" height="12" font="12">and medical group survival in patients with left main coronary artery</text>
<text top="730" left="92" width="325" height="12" font="12">disease. Long-term CASS experience. Circulation. 1995;91:2325–34.</text>
<text top="743" left="65" width="354" height="12" font="12">382. Conley MJ, Ely RL, Kisslo J, et al. The prognostic spectrum of left</text>
<text top="757" left="92" width="216" height="12" font="12">main stenosis. Circulation. 1978;57:947–52.</text>
<text top="770" left="65" width="354" height="12" font="12">383. Cameron A, Kemp HG Jr., Fisher LD, et al. Left main coronary</text>
<text top="784" left="92" width="327" height="12" font="12">artery stenosis: angiographic determination. Circulation. 1983;68:</text>
<text top="798" left="92" width="34" height="12" font="12">484 –9.</text>
<text top="811" left="65" width="354" height="12" font="12">384. Isner JM, Kishel J, Kent KM, et al. Accuracy of angiographic</text>
<text top="825" left="92" width="327" height="12" font="12">determination of left main coronary arterial narrowing. Angio-</text>
<text top="838" left="92" width="327" height="12" font="12">graphic— histologic correlative analysis in 28 patients. Circulation.</text>
<text top="852" left="92" width="90" height="12" font="12">1981;63:1056 – 64.</text>
<text top="865" left="65" width="354" height="12" font="12">385. Topol EJ, Nissen SE. Our preoccupation with coronary luminology.</text>
<text top="879" left="92" width="327" height="12" font="12">The dissociation between clinical and angiographic findings in</text>
<text top="893" left="92" width="265" height="12" font="12">ischemic heart disease. Circulation. 1995;92:2333– 42.</text>
<text top="906" left="65" width="354" height="12" font="12">386. West JN, Bennett MR, Pentecost BL. Association of transient</text>
<text top="920" left="92" width="327" height="12" font="12">abnormal Q-waves during exercise testing with a stenosis of the</text>
<text top="933" left="92" width="327" height="12" font="12">main stem of the left coronary artery. Int J Cardiol. 1991;31:102– 4.</text>
<text top="947" left="65" width="354" height="12" font="12">387. Gibbons RJ, Fyke FE, III, Brown ML, et al. Comparison of exercise</text>
<text top="961" left="92" width="327" height="12" font="12">performance in left main and three-vessel coronary artery disease.</text>
<text top="974" left="92" width="208" height="12" font="12">Cathet Cardiovasc Diagn. 1991;22:14 –20.</text>
<text top="988" left="65" width="354" height="12" font="12">388. Janosi A, Vertes A. Exercise testing and left main coronary artery</text>
<text top="1001" left="92" width="327" height="12" font="12">stenosis. Can patients with left main disease be identified? Chest.</text>
<text top="1015" left="92" width="81" height="12" font="12">1991;100:227–9.</text>
<text top="1028" left="65" width="354" height="12" font="12">389. Morris SN, Phillips JF, Jordan JW, et al. Incidence and significance</text>
<text top="1042" left="92" width="327" height="12" font="12">of decreases in systolic blood pressure during graded treadmill</text>
<text top="1056" left="92" width="231" height="12" font="12">exercise testing. Am J Cardiol. 1978;41:221– 6.</text>
<text top="1069" left="65" width="354" height="12" font="12">390. Plotnick GD, Greene HL, Carliner NH, et al. Clinical indicators of</text>
<text top="1083" left="92" width="327" height="12" font="12">left main coronary artery disease in unstable angina. Ann Intern</text>
<text top="1096" left="92" width="113" height="12" font="12">Med. 1979;91:149 –53.</text>
<text top="104" left="452" width="354" height="12" font="12">391. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S.</text>
<text top="118" left="479" width="327" height="12" font="12">deaths from coronary disease, 1980 –2000. N Engl J Med. 2007;</text>
<text top="132" left="479" width="68" height="12" font="12">356:2388 –98.</text>
<text top="146" left="452" width="354" height="12" font="12">392. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially</text>
<text top="160" left="479" width="327" height="12" font="12">modifiable risk factors associated with myocardial infarction in 52</text>
<text top="174" left="479" width="327" height="12" font="12">countries (the INTERHEART study): case-control study. Lancet.</text>
<text top="188" left="479" width="87" height="12" font="12">2004;364:937–52.</text>
<text top="202" left="452" width="354" height="12" font="12">393. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus</text>
<text top="216" left="479" width="327" height="12" font="12">aspirin alone for the prevention of atherothrombotic events. N Engl</text>
<text top="230" left="479" width="133" height="12" font="12">J Med. 2006;354:1706 –17.</text>
<text top="244" left="452" width="354" height="12" font="12">394. Randomised trial of cholesterol lowering in 4444 patients with</text>
<text top="258" left="479" width="327" height="12" font="12">coronary heart disease: the Scandinavian Simvastatin Survival Study</text>
<text top="272" left="479" width="155" height="12" font="12">(4S). Lancet. 1994;344:1383–9.</text>
<text top="286" left="452" width="354" height="12" font="12">395. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on</text>
<text top="300" left="479" width="327" height="12" font="12">coronary events after myocardial infarction in patients with average</text>
<text top="314" left="479" width="327" height="12" font="12">cholesterol levels. Cholesterol and Recurrent Events Trial investi-</text>
<text top="328" left="479" width="203" height="12" font="12">gators. N Engl J Med. 1996;335:1001–9.</text>
<text top="342" left="452" width="354" height="12" font="12">396. Prevention of cardiovascular events and death with pravastatin in</text>
<text top="356" left="479" width="327" height="12" font="12">patients with coronary heart disease and a broad range of initial</text>
<text top="370" left="479" width="327" height="12" font="12">cholesterol levels. The Intervention with Pravastatin in Ischaemic</text>
<text top="384" left="479" width="327" height="12" font="12">Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349 –57.</text>
<text top="398" left="452" width="354" height="12" font="12">397. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering</text>
<text top="412" left="479" width="327" height="12" font="12">therapy compared with angioplasty in stable coronary artery disease.</text>
<text top="426" left="479" width="327" height="12" font="12">Atorvastatin versus Revascularization Treatment Investigators.</text>
<text top="440" left="479" width="157" height="12" font="12">N Engl J Med. 1999;341:70 – 6.</text>
<text top="454" left="452" width="354" height="12" font="12">398. MRC-BHF Heart Protection Study of cholesterol lowering with</text>
<text top="468" left="479" width="327" height="12" font="12">simvastatin in 20,536 high-risk individuals: a randomised placebo-</text>
<text top="482" left="479" width="195" height="12" font="12">controlled trial. Lancet. 2002;360:7–22.</text>
<text top="496" left="452" width="354" height="12" font="12">399. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels</text>
<text top="510" left="479" width="327" height="12" font="12">and outcomes after statin therapy. N Engl J Med. 2005;352:20 – 8.</text>
<text top="524" left="452" width="354" height="12" font="12">400. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering</text>
<text top="538" left="479" width="327" height="12" font="12">with atorvastatin in patients with stable coronary disease. N Engl</text>
<text top="552" left="479" width="131" height="12" font="12">J Med. 2005;352:1425–35.</text>
<text top="565" left="452" width="354" height="12" font="12">401. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of</text>
<text top="579" left="479" width="327" height="12" font="12">statin therapy in adults with coronary heart disease. Arch Intern</text>
<text top="593" left="479" width="123" height="12" font="12">Med. 2004;164:1427–36.</text>
<text top="607" left="452" width="354" height="12" font="12">402. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on</text>
<text top="621" left="479" width="327" height="12" font="12">mortality among high-risk and low-risk patients after myocardial</text>
<text top="635" left="479" width="222" height="12" font="12">infarction. N Engl J Med. 1998;339:489 –97.</text>
<text top="649" left="452" width="354" height="12" font="12">403. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug</text>
<text top="663" left="479" width="327" height="12" font="12">therapy of mild to moderate hypertension and decreased risk of</text>
<text top="677" left="479" width="298" height="12" font="12">coronary heart disease. Arch Intern Med. 1993;153:578 – 81.</text>
<text top="691" left="452" width="354" height="12" font="12">404. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new</text>
<text top="705" left="479" width="297" height="12" font="12">mechanisms and clinical targets. Nat Med. 2002;8:1257– 62.</text>
<text top="719" left="452" width="354" height="12" font="12">405. Coronary angioplasty versus medical therapy for angina: the second</text>
<text top="733" left="479" width="327" height="12" font="12">Randomised Intervention Treatment of Angina (RITA-2) trial.</text>
<text top="747" left="479" width="255" height="12" font="12">RITA-2 trial participants. Lancet. 1997;350:461– 8.</text>
<text top="761" left="452" width="354" height="12" font="12">406. Pfisterer M. Long-term outcome in elderly patients with chronic</text>
<text top="775" left="479" width="327" height="12" font="12">angina managed invasively versus by optimized medical therapy:</text>
<text top="789" left="479" width="327" height="12" font="12">four-year follow-up of the randomized Trial of Invasive versus</text>
<text top="803" left="479" width="327" height="12" font="12">Medical therapy in Elderly patients (TIME). Circulation. 2004;110:</text>
<text top="817" left="479" width="40" height="12" font="12">1213– 8.</text>
<text top="831" left="452" width="354" height="12" font="12">407. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality</text>
<text top="845" left="479" width="327" height="12" font="12">of life in patients with stable coronary disease. N Engl J Med.</text>
<text top="859" left="479" width="89" height="12" font="12">2008;359:677– 87.</text>
<text top="873" left="452" width="354" height="12" font="12">408. Frye RL, August P, Brooks MM, et al. A randomized trial of</text>
<text top="887" left="479" width="327" height="12" font="12">therapies for type 2 diabetes and coronary artery disease. N Engl</text>
<text top="901" left="479" width="131" height="12" font="12">J Med. 2009;360:2503–15.</text>
<text top="915" left="452" width="354" height="12" font="12">409. Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angio-</text>
<text top="929" left="479" width="327" height="12" font="12">plasty Revascularization Investigation 2 Diabetes randomized trial of</text>
<text top="943" left="479" width="327" height="12" font="12">different treatment strategies in type 2 diabetes mellitus with stable</text>
<text top="957" left="479" width="327" height="12" font="12">ischemic heart disease: impact of treatment strategy on cardiac mortal-</text>
<text top="971" left="479" width="292" height="12" font="12">ity and myocardial infarction. Circulation. 2009;120:2529–40.</text>
<text top="985" left="452" width="354" height="12" font="12">410. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass</text>
<text top="999" left="479" width="327" height="12" font="12">surgery in patients with left ventricular dysfunction. N Engl J Med.</text>
<text top="1013" left="479" width="93" height="12" font="12">2011;364:1607–16.</text>
<text top="1027" left="452" width="354" height="12" font="12">411. Pittman MA, Margolin FS. Community health. Crossing the</text>
<text top="1041" left="479" width="285" height="12" font="12">quality chasm: steps you can take. Trustee. 2001;54:30 –2.</text>
<text top="1055" left="452" width="354" height="12" font="12">412. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass</text>
<text top="1069" left="479" width="327" height="12" font="12">graft surgery on survival: overview of 10-year results from ran-</text>
<text top="1083" left="479" width="327" height="12" font="12">domised trials by the Coronary Artery Bypass Graft Surgery</text>
<text top="1097" left="479" width="245" height="12" font="12">Trialists Collaboration. Lancet. 1994;344:563–70.</text>
<text top="52" left="59" width="25" height="10" font="12">e138</text>
<text top="52" left="113" width="48" height="10" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="96" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">413. Nikolsky E, Gruberg L, Patil CV, et al. Percutaneous coronary</text>
<text top="118" left="92" width="327" height="12" font="12">interventions in diabetic patients: is complete revascularization</text>
<text top="132" left="92" width="228" height="12" font="12">important? J Invasive Cardiol. 2004;16:102– 6.</text>
<text top="145" left="65" width="354" height="12" font="12">414. Osswald BR, Tochtermann U, Schweiger P, et al. Does the</text>
<text top="159" left="92" width="327" height="12" font="12">completeness of revascularization contribute to an improved early</text>
<text top="172" left="92" width="327" height="12" font="12">survival in patients up to 70 years of age? Thorac Cardiovasc Surg.</text>
<text top="186" left="92" width="75" height="12" font="12">2001;49:373–7.</text>
<text top="200" left="65" width="354" height="12" font="12">415. Kleisli T, Cheng W, Jacobs MJ, et al. In the current era, complete</text>
<text top="213" left="92" width="327" height="12" font="12">revascularization improves survival after coronary artery bypass</text>
<text top="227" left="92" width="269" height="12" font="12">surgery. J Thorac Cardiovasc Surg. 2005;129:1283–91.</text>
<text top="240" left="65" width="354" height="12" font="12">416. Kozower BD, Moon MR, Barner HB, et al. Impact of complete</text>
<text top="254" left="92" width="327" height="12" font="12">revascularization on long-term survival after coronary artery bypass</text>
<text top="268" left="92" width="300" height="12" font="12">grafting in octogenarians. Ann Thorac Surg. 2005;80:112– 6.</text>
<text top="281" left="65" width="354" height="12" font="12">417. McLellan CS, Ghali WA, Labinaz M, et al. Association between</text>
<text top="295" left="92" width="327" height="12" font="12">completeness of percutaneous coronary revascularization and post-</text>
<text top="308" left="92" width="255" height="12" font="12">procedure outcomes. Am Heart J. 2005;150:800 – 6.</text>
<text top="322" left="65" width="354" height="12" font="12">418. Wenaweser P, Surmely JF, Windecker S, et al. Prognostic value of</text>
<text top="336" left="92" width="327" height="12" font="12">early exercise testing after coronary stent implantation. Am J</text>
<text top="349" left="92" width="131" height="12" font="12">Cardiol. 2008;101:807–11.</text>
<text top="363" left="65" width="354" height="12" font="12">419. Martuscelli E, Clementi F, Gallagher MM, et al. Revascularization</text>
<text top="376" left="92" width="327" height="12" font="12">strategy in patients with multivessel disease and a major vessel</text>
<text top="390" left="92" width="327" height="12" font="12">chronically occluded; data from the CABRI trial. Eur J Cardiotho-</text>
<text top="404" left="92" width="114" height="12" font="12">rac Surg. 2008;33:4 – 8.</text>
<text top="417" left="65" width="354" height="12" font="12">420. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of</text>
<text top="431" left="92" width="327" height="12" font="12">trials comparing beta-blockers, calcium antagonists, and nitrates for</text>
<text top="444" left="92" width="204" height="12" font="12">stable angina. JAMA. 1999;281:1927–36.</text>
<text top="458" left="65" width="354" height="12" font="12">421. Moss AJ, Zareba W, Schwarz KQ, et al. Ranolazine shortens</text>
<text top="471" left="92" width="327" height="12" font="12">repolarization in patients with sustained inward sodium current due</text>
<text top="485" left="92" width="327" height="12" font="12">to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;</text>
<text top="499" left="92" width="62" height="12" font="12">19:1289 –93.</text>
<text top="512" left="65" width="354" height="12" font="12">422. Holmes DR Jr., Gersh BJ, Whitlow P, et al. Percutaneous coronary</text>
<text top="526" left="92" width="327" height="12" font="12">intervention for chronic stable angina: a reassessment. J Am Coll</text>
<text top="539" left="92" width="140" height="12" font="12">Cardiol Intv. 2008;1:34 – 43.</text>
<text top="553" left="65" width="354" height="12" font="12">423. Chan PS, Patel MR, Klein LW, et al. Appropriateness of percuta-</text>
<text top="567" left="92" width="267" height="12" font="12">neous coronary intervention. JAMA. 2011;306:53– 61.</text>
<text top="580" left="65" width="354" height="12" font="12">424. Poses RM, Krueger JI, Sloman S, et al. Physicians’ judgments of</text>
<text top="594" left="92" width="327" height="12" font="12">survival after medical management and mortality risk reduction due</text>
<text top="607" left="92" width="327" height="12" font="12">to revascularization procedures for patients with coronary artery</text>
<text top="621" left="92" width="163" height="12" font="12">disease. Chest. 2002;122:122–33.</text>
<text top="635" left="65" width="354" height="12" font="12">425. Holmboe ES, Fiellin DA, Cusanelli E, et al. Perceptions of benefit</text>
<text top="648" left="92" width="327" height="12" font="12">and risk of patients undergoing first-time elective percutaneous</text>
<text top="662" left="92" width="306" height="12" font="12">coronary revascularization. J Gen Intern Med. 2000;15:632–7.</text>
<text top="675" left="65" width="354" height="12" font="12">426. Lin GA, Dudley RA, Redberg RF. Cardiologists’ use of percuta-</text>
<text top="689" left="92" width="327" height="12" font="12">neous coronary interventions for stable coronary artery disease. Arch</text>
<text top="702" left="92" width="153" height="12" font="12">Intern Med. 2007;167:1604 –9.</text>
<text top="716" left="65" width="354" height="12" font="12">427. Ko DT, Wang Y, Alter DA, et al. Regional variation in cardiac</text>
<text top="730" left="92" width="327" height="12" font="12">catheterization appropriateness and baseline risk after acute myo-</text>
<text top="743" left="92" width="272" height="12" font="12">cardial infarction. J Am Coll Cardiol. 2008;51:716 –23.</text>
<text top="757" left="65" width="354" height="12" font="12">428. Fisher E, Goodman D, Skinner J, et al. Health care spending, quality,</text>
<text top="770" left="92" width="327" height="12" font="12">and outcomes: more isn’t always better: a topic brief by the Dartmouth</text>
<text top="784" left="92" width="172" height="12" font="12">Atlas of Health Care Project.</text>
<text top="784" left="272" width="146" height="12" font="37"><a href="http://www.dartmouthatlas.org/downloads/reports/Spending_Brief_022709.pdf">http://www.dartmouthatlas.</a></text>
<text top="798" left="92" width="244" height="12" font="37"><a href="http://www.dartmouthatlas.org/downloads/reports/Spending_Brief_022709.pdf">org/downloads/reports/Spending_Brief_022709.pdf.</a></text>
<text top="798" left="343" width="76" height="12" font="12">2009. Accessed</text>
<text top="811" left="92" width="77" height="12" font="12">January 6, 2012.</text>
<text top="825" left="64" width="354" height="12" font="12">429. Charatan F. Dozens of patients allege unnecessary heart surgery.</text>
<text top="838" left="92" width="106" height="12" font="12">BMJ. 2003;326:1055.</text>
<text top="852" left="64" width="354" height="12" font="12">430. Fred HL. Dishonesty in medicine revisited. Tex Heart Inst J.</text>
<text top="865" left="92" width="71" height="12" font="12">2008;35:6 –15.</text>
<text top="879" left="64" width="354" height="12" font="12">431. Nallamothu BK, Rogers MA, Chernew ME, et al. Opening of</text>
<text top="893" left="92" width="327" height="12" font="12">specialty cardiac hospitals and use of coronary revascularization in</text>
<text top="906" left="92" width="237" height="12" font="12">medicare beneficiaries. JAMA. 2007;297:962– 8.</text>
<text top="920" left="64" width="354" height="12" font="12">432. Campeau L. Letter: Grading of angina pectoris. Circulation. 1976;</text>
<text top="933" left="92" width="48" height="12" font="12">54:522–3.</text>
<text top="947" left="64" width="354" height="12" font="12">433. The Criteria Committee of the New York Heart Association I.</text>
<text top="961" left="92" width="327" height="12" font="12">Diseases of the heart and blood vessels: nomenclature and critera for</text>
<text top="974" left="92" width="232" height="12" font="12">diagnosis. 6th ed. Boston: Little, Brown; 1964.</text>
<text top="988" left="64" width="354" height="12" font="12">434. Spertus JA, Eagle KA, Krumholz HM, et al. American College of</text>
<text top="1001" left="92" width="327" height="12" font="12">Cardiology and American Heart Association methodology for the</text>
<text top="1015" left="92" width="327" height="12" font="12">selection and creation of performance measures for quantifying the</text>
<text top="1028" left="92" width="327" height="12" font="12">quality of cardiovascular care. J Am Coll Cardiol. 2005;45:1147–56.</text>
<text top="1042" left="64" width="354" height="12" font="12">435. Spertus JA, Winder JA, Dewhurst TA, et al. Monitoring the quality</text>
<text top="1056" left="92" width="327" height="12" font="12">of life in patients with coronary artery disease. Am J Cardiol.</text>
<text top="1069" left="92" width="84" height="12" font="12">1994;74:1240 – 4.</text>
<text top="1083" left="64" width="354" height="12" font="12">436. Drozda J Jr., Messer JV, Spertus J, et al. ACCF/AHA/AMA-PCPI</text>
<text top="1096" left="92" width="327" height="12" font="12">2011 performance measures for adults with coronary artery disease</text>
<text top="104" left="479" width="327" height="12" font="12">and hypertension: a report of the American College of Cardiology</text>
<text top="118" left="479" width="327" height="12" font="12">Foundation/American Heart Association Task Force on</text>
<text top="132" left="479" width="327" height="12" font="12">Performance Measures and the American Medical Association-</text>
<text top="146" left="479" width="327" height="12" font="12">Physician Consortium for Performance Improvement. J Am Coll</text>
<text top="159" left="479" width="126" height="12" font="12">Cardiol. 2011;58:316 –36.</text>
<text top="173" left="452" width="354" height="12" font="12">437. McGillion M, Watt-Watson J, LeFort S, et al. Positive shifts in the</text>
<text top="187" left="479" width="327" height="12" font="12">perceived meaning of cardiac pain following a psychoeducation</text>
<text top="201" left="479" width="327" height="12" font="12">program for chronic stable angina. Can J Nurs Res. 2007;39:48 – 65.</text>
<text top="214" left="452" width="354" height="12" font="12">438. Muszbek N, Brixner D, Benedict A, et al. The economic conse-</text>
<text top="228" left="479" width="327" height="12" font="12">quences of noncompliance in cardiovascular disease and related</text>
<text top="242" left="479" width="319" height="12" font="12">conditions: a literature review. Int J Clin Pract. 2008;62:338 –51.</text>
<text top="256" left="452" width="354" height="12" font="12">439. Rao SV, Schulman KA, Curtis LH, et al. Socioeconomic status and</text>
<text top="270" left="479" width="327" height="12" font="12">outcome following acute myocardial infarction in elderly patients.</text>
<text top="283" left="479" width="187" height="12" font="12">Arch Intern Med. 2004;164:1128 –33.</text>
<text top="297" left="452" width="354" height="12" font="12">440. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guide-</text>
<text top="311" left="479" width="327" height="12" font="12">lines for the prevention of cardiovascular disease in women—2011</text>
<text top="325" left="479" width="327" height="12" font="12">update: a guideline from the American Heart Association. Circu-</text>
<text top="339" left="479" width="129" height="12" font="12">lation. 2011;123:1243– 62.</text>
<text top="352" left="452" width="354" height="12" font="12">441. Joint Commission. The Joint Commission announces the 2008</text>
<text top="366" left="479" width="327" height="12" font="12">National Patient Safety Goals and Requirements. Jt Comm Per-</text>
<text top="380" left="479" width="120" height="12" font="12">spect. 2007;27:1,9 –1,22.</text>
<text top="394" left="452" width="354" height="12" font="12">442. Miller NH, Taylor C. Lifestyle Management for Patients with</text>
<text top="407" left="479" width="327" height="12" font="12">Coronary Heart Disease. (Current Issues in Cardiac Rehabilitation,</text>
<text top="421" left="479" width="327" height="12" font="12">Monograph No. 2.). 1st ed. Champaign, IL: Human Kinetics;</text>
<text top="435" left="479" width="27" height="12" font="12">1995.</text>
<text top="449" left="452" width="354" height="12" font="12">443. DeBusk RF, Miller NH, Superko HR, et al. A case-management</text>
<text top="463" left="479" width="327" height="12" font="12">system for coronary risk factor modification after acute myocardial</text>
<text top="476" left="479" width="225" height="12" font="12">infarction. Ann Intern Med. 1994;120:721–9.</text>
<text top="490" left="452" width="354" height="12" font="12">444. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive</text>
<text top="504" left="479" width="327" height="12" font="12">multiple risk factor reduction on coronary atherosclerosis and</text>
<text top="518" left="479" width="327" height="12" font="12">clinical cardiac events in men and women with coronary artery</text>
<text top="532" left="479" width="327" height="12" font="12">disease. The Stanford Coronary Risk Intervention Project (SCRIP).</text>
<text top="545" left="479" width="143" height="12" font="12">Circulation. 1994;89:975–90.</text>
<text top="559" left="452" width="354" height="12" font="12">445. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle</text>
<text top="573" left="479" width="327" height="12" font="12">recommendations revision 2006: a scientific statement from the</text>
<text top="587" left="479" width="327" height="12" font="12">American Heart Association Nutrition Committee. Circulation.</text>
<text top="601" left="479" width="81" height="12" font="12">2006;114:82–96.</text>
<text top="614" left="452" width="354" height="12" font="12">446. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical</text>
<text top="628" left="479" width="327" height="12" font="12">activity in the prevention and treatment of atherosclerotic car-</text>
<text top="642" left="479" width="327" height="12" font="12">diovascular disease: a statement from the Council on Clinical</text>
<text top="656" left="479" width="327" height="12" font="12">Cardiology (Subcommittee on Exercise, Rehabilitation, and</text>
<text top="669" left="479" width="327" height="12" font="12">Prevention) and the Council on Nutrition, Physical Activity, and</text>
<text top="683" left="479" width="327" height="12" font="12">Metabolism (Subcommittee on Physical Activity). Circulation.</text>
<text top="697" left="479" width="98" height="12" font="12">2003;107:3109 –16.</text>
<text top="711" left="452" width="354" height="12" font="12">447. Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute</text>
<text top="725" left="479" width="327" height="12" font="12">cardiovascular events placing the risks into perspective: a scientific</text>
<text top="738" left="479" width="327" height="12" font="12">statement from the American Heart Association Council on Nutri-</text>
<text top="752" left="479" width="327" height="12" font="12">tion, Physical Activity, and Metabolism and the Council on Clinical</text>
<text top="766" left="479" width="219" height="12" font="12">Cardiology. Circulation. 2007;115:2358 – 68.</text>
<text top="780" left="452" width="354" height="12" font="12">448. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to</text>
<text top="793" left="479" width="327" height="12" font="12">promote physical activity and dietary lifestyle changes for cardiovas-</text>
<text top="807" left="479" width="327" height="12" font="12">cular risk factor reduction in adults: a scientific statement from the</text>
<text top="821" left="479" width="299" height="12" font="12">American Heart Association. Circulation. 2010;122:406 – 41.</text>
<text top="835" left="452" width="354" height="12" font="12">449. National Institutes of Health, National Heart Lung and Blood</text>
<text top="848" left="479" width="327" height="12" font="12">Institute. Clinical guidelines on the identification, evaluation, and</text>
<text top="862" left="479" width="327" height="12" font="12">treatment of overweight and obesity in adults: the evidence report.</text>
<text top="876" left="479" width="291" height="12" font="37"><a href="http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf">http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf.</a></text>
<text top="876" left="778" width="28" height="12" font="12">1998.</text>
<text top="890" left="479" width="128" height="12" font="12">Accessed January 6, 2012.</text>
<text top="904" left="452" width="354" height="12" font="12">450. Oka R, Kobayashi J, Yagi K, et al. Reassessment of the cutoff values</text>
<text top="917" left="479" width="327" height="12" font="12">of waist circumference and visceral fat area for identifying Japanese</text>
<text top="931" left="479" width="327" height="12" font="12">subjects at risk for the metabolic syndrome. Diabetes Res Clin Pract.</text>
<text top="945" left="479" width="84" height="12" font="12">2008;79:474 – 81.</text>
<text top="959" left="452" width="354" height="12" font="12">451. Tan CE, Ma S, Wai D, et al. Can we apply the National</text>
<text top="972" left="479" width="327" height="12" font="12">Cholesterol Education Program Adult Treatment Panel definition</text>
<text top="986" left="479" width="327" height="12" font="12">of the metabolic syndrome to Asians? Diabetes Care. 2004;27:</text>
<text top="1000" left="479" width="40" height="12" font="12">1182– 6.</text>
<text top="1014" left="452" width="354" height="12" font="12">452. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of</text>
<text top="1028" left="479" width="327" height="12" font="12">cardiovascular diseases in people with diabetes mellitus: a scientific</text>
<text top="1041" left="479" width="327" height="12" font="12">statement from the American Heart Association and the American</text>
<text top="1055" left="479" width="260" height="12" font="12">Diabetes Association. Circulation. 2007;115:114 –26.</text>
<text top="1069" left="452" width="354" height="12" font="12">453. Bosworth HB, Olsen MK, Dudley T, et al. The Take Control of</text>
<text top="1083" left="479" width="327" height="12" font="12">Your Blood pressure (TCYB) study: study design and methodology.</text>
<text top="1096" left="479" width="188" height="12" font="12">Contemp Clin Trials. 2007;28:33– 47.</text>
<text top="52" left="781" width="25" height="10" font="12">e139</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="97" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">454. The 2004 United States Surgeon General’s Report: The Health</text>
<text top="118" left="92" width="327" height="12" font="12">Consequences of Smoking. N S W Public Health Bull. 2004;15:</text>
<text top="132" left="92" width="21" height="12" font="12">107.</text>
<text top="146" left="65" width="354" height="12" font="12">455. Critchley JA, Capewell S. Mortality risk reduction associated with</text>
<text top="160" left="92" width="327" height="12" font="12">smoking cessation in patients with coronary heart disease: a system-</text>
<text top="173" left="92" width="182" height="12" font="12">atic review. JAMA. 2003;290:86 –97.</text>
<text top="187" left="65" width="354" height="12" font="12">456. Standards of medical care in diabetes—2011. Diabetes Care.</text>
<text top="201" left="92" width="130" height="12" font="12">2011;34 Suppl 1:S11–S61.</text>
<text top="215" left="65" width="354" height="12" font="12">457. Appel LJ, Champagne CM, Harsha DW, et al. Effects of compre-</text>
<text top="228" left="92" width="327" height="12" font="12">hensive lifestyle modification on blood pressure control: main results</text>
<text top="242" left="92" width="292" height="12" font="12">of the PREMIER clinical trial. JAMA. 2003;289:2083–93.</text>
<text top="256" left="65" width="354" height="12" font="12">458. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of</text>
<text top="270" left="92" width="327" height="12" font="12">more intensive lowering of LDL cholesterol: a meta-analysis of data</text>
<text top="284" left="92" width="327" height="12" font="12">from 170,000 participants in 26 randomised trials. Lancet. 2010;</text>
<text top="297" left="92" width="69" height="12" font="12">376:1670 – 81.</text>
<text top="311" left="65" width="354" height="12" font="12">459. Frattaroli J, Weidner G, Merritt-Worden TA, et al. Angina pectoris</text>
<text top="325" left="92" width="327" height="12" font="12">and atherosclerotic risk factors in the multisite cardiac lifestyle</text>
<text top="339" left="92" width="268" height="12" font="12">intervention program. Am J Cardiol. 2008;101:911– 8.</text>
<text top="353" left="65" width="354" height="12" font="12">460. Carney RM, Freedland KE, Eisen SA, et al. Major depression and</text>
<text top="366" left="92" width="327" height="12" font="12">medication adherence in elderly patients with coronary artery</text>
<text top="380" left="92" width="199" height="12" font="12">disease. Health Psychol. 1995;14:88 –90.</text>
<text top="394" left="65" width="354" height="12" font="12">461. Rees K, Bennett P, West R, et al. Psychological interventions for</text>
<text top="408" left="92" width="327" height="12" font="12">coronary heart disease. Cochrane Database Syst Rev. 2004;</text>
<text top="422" left="92" width="58" height="12" font="12">CD002902.</text>
<text top="435" left="65" width="354" height="12" font="12">462. Ziegelstein RC, Fauerbach JA, Stevens SS, et al. Patients with</text>
<text top="449" left="92" width="327" height="12" font="12">depression are less likely to follow recommendations to reduce</text>
<text top="463" left="92" width="327" height="12" font="12">cardiac risk during recovery from a myocardial infarction. Arch</text>
<text top="477" left="92" width="159" height="12" font="12">Intern Med. 2000;160:1818 –23.</text>
<text top="490" left="65" width="354" height="12" font="12">463. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of</text>
<text top="504" left="92" width="327" height="12" font="12">citalopram and interpersonal psychotherapy on depression in pa-</text>
<text top="518" left="92" width="327" height="12" font="12">tients with coronary artery disease: the Canadian Cardiac Random-</text>
<text top="532" left="92" width="327" height="12" font="12">ized Evaluation of Antidepressant and Psychotherapy Efficacy</text>
<text top="546" left="92" width="217" height="12" font="12">(CREATE) trial. JAMA. 2007;297:367–79.</text>
<text top="559" left="65" width="354" height="12" font="12">464. McManus D, Pipkin SS, Whooley MA. Screening for depression in</text>
<text top="573" left="92" width="327" height="12" font="12">patients with coronary heart disease (data from the Heart and Soul</text>
<text top="587" left="92" width="203" height="12" font="12">Study). Am J Cardiol. 2005;96:1076 – 81.</text>
<text top="601" left="65" width="112" height="12" font="12">465. Deleted in proof.</text>
<text top="615" left="65" width="112" height="12" font="12">466. Deleted in proof.</text>
<text top="628" left="65" width="354" height="12" font="12">467. Whooley MA. Depression and cardiovascular disease: healing the</text>
<text top="642" left="92" width="218" height="12" font="12">broken-hearted. JAMA. 2006;295:2874 – 81.</text>
<text top="656" left="65" width="354" height="12" font="12">468. Lichtman JH, Bigger JT Jr., Blumenthal JA, et al. Depression and</text>
<text top="670" left="92" width="327" height="12" font="12">Coronary Heart Disease. Recommendations for Screening, Referral,</text>
<text top="683" left="92" width="327" height="12" font="12">and Treatment. A Science Advisory From the American Heart</text>
<text top="697" left="92" width="327" height="12" font="12">Association Prevention Committee of the Council on Cardiovascu-</text>
<text top="711" left="92" width="327" height="12" font="12">lar Nursing, Council on Clinical Cardiology, Council on Epidemi-</text>
<text top="725" left="92" width="327" height="12" font="12">ology and Prevention, and Interdisciplinary Council on Quality of</text>
<text top="739" left="92" width="310" height="12" font="12">Care and Outcomes Research. Circulation. 2008;118:1768 –75.</text>
<text top="752" left="65" width="354" height="12" font="12">469. Patient education. American Academy of Family Physicians. Am</text>
<text top="766" left="92" width="162" height="12" font="12">Fam Physician. 2000;62:1712– 4.</text>
<text top="780" left="65" width="354" height="12" font="12">470. Tobacco Use and Dependence Guideline Panel. Treating Tobacco</text>
<text top="794" left="92" width="327" height="12" font="12">Use and Dependence: 2008 Update. Rockville (MD): US Depart-</text>
<text top="807" left="92" width="290" height="12" font="12">ment of Health and Human Services. 2008. Available at:</text>
<text top="807" left="387" width="32" height="12" font="37"><a href="http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat2.chapter.28163">http://</a></text>
<text top="821" left="92" width="206" height="12" font="37"><a href="http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat2.chapter.28163">www.ncbi.nlm.nih.gov/books/bv.fcgi?rid</a></text>
<text top="819" left="298" width="120" height="16" font="37"><a href="http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat2.chapter.28163">⫽hstat2.chapter.28163.</a></text>
<text top="835" left="92" width="128" height="12" font="12">Accessed January 6, 2012.</text>
<text top="849" left="65" width="354" height="12" font="12">471. Smith PM, Taylor CB. Implementing an Inpatient Smoking</text>
<text top="863" left="92" width="307" height="12" font="12">Cessation Program. Lawrence Erlbaum Associates, Inc.: 2006.</text>
<text top="876" left="65" width="354" height="12" font="12">472. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2</text>
<text top="890" left="92" width="327" height="12" font="12">diabetes mellitus by changes in lifestyle among subjects with</text>
<text top="904" left="92" width="309" height="12" font="12">impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.</text>
<text top="918" left="65" width="354" height="12" font="12">473. Kok G, van den Borne B, Mullen PD. Effectiveness of health</text>
<text top="931" left="92" width="327" height="12" font="12">education and health promotion: meta-analyses of effect studies and</text>
<text top="945" left="92" width="327" height="12" font="12">determinants of effectiveness. Patient Educ Couns. 1997;30:19 –27.</text>
<text top="959" left="65" width="354" height="12" font="12">474. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to</text>
<text top="973" left="92" width="327" height="12" font="12">improve control of blood pressure in patients with hypertension.</text>
<text top="987" left="92" width="243" height="12" font="12">Cochrane Database Syst Rev. 2010;3:CD005182.</text>
<text top="1000" left="65" width="354" height="12" font="12">475. American Heart Association. AHA Choose to Move. American</text>
<text top="1014" left="92" width="191" height="12" font="12">Heart Association. 2008. Available at:</text>
<text top="1014" left="288" width="131" height="12" font="37"><a href="http://www.choosetomove.org">http://www.choosetomove.</a></text>
<text top="1028" left="92" width="19" height="12" font="37"><a href="http://www.choosetomove.org">org.</a></text>
<text top="1028" left="114" width="119" height="12" font="12">Accessed June 24, 2008.</text>
<text top="1042" left="65" width="354" height="12" font="12">476. Miller W, Rollnick S. Motivational Interviewing: Preparing People</text>
<text top="1055" left="92" width="238" height="12" font="12">for Change. 2nd ed. New York: Guilford; 2002.</text>
<text top="1069" left="65" width="354" height="12" font="12">477. Bandura A, Cervone D. Self-evaluative and self-efficacy mecha-</text>
<text top="1083" left="92" width="327" height="12" font="12">nisms governing the motivational effects of goal systems. J Pers Soc</text>
<text top="1097" left="92" width="122" height="12" font="12">Psych. 1983;45:1017–28.</text>
<text top="104" left="452" width="354" height="12" font="12">478. Prochaska J, Norcross J, DiClemente C. Changing for Good: A</text>
<text top="118" left="479" width="327" height="12" font="12">Revolutionary Six Stage Program for Overcoming Bad Habits and</text>
<text top="132" left="479" width="327" height="12" font="12">Moving Your Life Positively Forward. New York: Avon Books,</text>
<text top="145" left="479" width="53" height="12" font="12">Inc.; 1984.</text>
<text top="159" left="452" width="354" height="12" font="12">479. Coleman K, Austin BT, Brach C, et al. Evidence on the Chronic</text>
<text top="172" left="479" width="327" height="12" font="12">Care Model in the new millennium. Health Aff (Millwood).</text>
<text top="186" left="479" width="77" height="12" font="12">2009;28:75– 85.</text>
<text top="200" left="452" width="354" height="12" font="12">480. Dorr DA, Wilcox AB, Brunker CP, et al. The effect of technology-</text>
<text top="213" left="479" width="327" height="12" font="12">supported, multidisease care management on the mortality and</text>
<text top="227" left="479" width="317" height="12" font="12">hospitalization of seniors. J Am Geriatr Soc. 2008;56:2195–202.</text>
<text top="240" left="452" width="354" height="12" font="12">481. Reid RJ, Fishman PA, Yu O, et al. Patient-centered medical home</text>
<text top="254" left="479" width="327" height="12" font="12">demonstration: a prospective, quasi-experimental, before and after</text>
<text top="268" left="479" width="242" height="12" font="12">evaluation. Am J Manag Care. 2009;15:e71– e87.</text>
<text top="281" left="452" width="354" height="12" font="12">482. Bohlen JG, Held JP, Sanderson MO, et al. Heart rate, rate-pressure</text>
<text top="295" left="479" width="327" height="12" font="12">product, and oxygen uptake during four sexual activities. Arch</text>
<text top="308" left="479" width="153" height="12" font="12">Intern Med. 1984;144:1745– 8.</text>
<text top="322" left="452" width="354" height="12" font="12">483. Moller J, Ahlbom A, Hulting J, et al. Sexual activity as a trigger of</text>
<text top="336" left="479" width="327" height="12" font="12">myocardial infarction. A case-crossover analysis in the Stockholm</text>
<text top="349" left="479" width="327" height="12" font="12">Heart Epidemiology Programme (SHEEP). Heart. 2001;86:</text>
<text top="363" left="479" width="39" height="12" font="12">387–90.</text>
<text top="376" left="452" width="354" height="12" font="12">484. Muller JE. Triggering of cardiac events by sexual activity: findings</text>
<text top="390" left="479" width="312" height="12" font="12">from a case-crossover analysis. Am J Cardiol. 2000;86:14F– 8F.</text>
<text top="404" left="452" width="354" height="12" font="12">485. Ebrahim S, May M, Ben Shlomo Y, et al. Sexual intercourse and</text>
<text top="417" left="479" width="327" height="12" font="12">risk of ischaemic stroke and coronary heart disease: the Caerphilly</text>
<text top="431" left="479" width="282" height="12" font="12">study. J Epidemiol Community Health. 2002;56:99 –102.</text>
<text top="444" left="452" width="354" height="12" font="12">486. Dahabreh IJ, Paulus JK. Association of episodic physical and sexual</text>
<text top="458" left="479" width="327" height="12" font="12">activity with triggering of acute cardiac events: systematic review and</text>
<text top="472" left="479" width="206" height="12" font="12">meta-analysis. JAMA. 2011;305:1225–33.</text>
<text top="485" left="452" width="354" height="12" font="12">487. Cheitlin MD. Sexual activity and cardiac risk. Am J Cardiol.</text>
<text top="499" left="479" width="94" height="12" font="12">2005;96:24M– 8M.</text>
<text top="512" left="452" width="354" height="12" font="12">488. Grimm RH Jr., Grandits GA, Prineas RJ, et al. Long-term effects</text>
<text top="526" left="479" width="327" height="12" font="12">on sexual function of five antihypertensive drugs and nutritional</text>
<text top="540" left="479" width="327" height="12" font="12">hygienic treatment in hypertensive men and women. Treatment</text>
<text top="553" left="479" width="327" height="12" font="12">of Mild Hypertension Study (TOMHS). Hypertension. 1997;29:</text>
<text top="567" left="479" width="29" height="12" font="12">8 –14.</text>
<text top="580" left="452" width="354" height="12" font="12">489. Dusing R. Sexual dysfunction in male patients with hypertension:</text>
<text top="594" left="479" width="297" height="12" font="12">influence of antihypertensive drugs. Drugs. 2005;65:773– 86.</text>
<text top="607" left="452" width="354" height="12" font="12">490. Franzen D, Metha A, Seifert N, et al. Effects of beta-blockers on</text>
<text top="621" left="479" width="327" height="12" font="12">sexual performance in men with coronary heart disease. A prospec-</text>
<text top="635" left="479" width="327" height="12" font="12">tive, randomized and double blinded study. Int J Impot Res.</text>
<text top="648" left="479" width="83" height="12" font="12">2001;13:348 –51.</text>
<text top="662" left="452" width="354" height="12" font="12">491. Baumhakel M, Schlimmer N, Kratz M, et al. Cardiovascular risk,</text>
<text top="675" left="479" width="327" height="12" font="12">drugs and erectile function—a systematic analysis. Int J Clin Pract.</text>
<text top="689" left="479" width="83" height="12" font="12">2011;65:289 –98.</text>
<text top="703" left="452" width="354" height="12" font="12">492. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and</text>
<text top="716" left="479" width="327" height="12" font="12">symptoms of depression, fatigue, and sexual dysfunction. JAMA.</text>
<text top="730" left="479" width="81" height="12" font="12">2002;288:351–7.</text>
<text top="743" left="452" width="354" height="12" font="12">493. Padma-nathan H, Eardley I, Kloner RA, et al. A 4-year update on</text>
<text top="757" left="479" width="314" height="12" font="12">the safety of sildenafil citrate (Viagra). Urology. 2002;60:67–90.</text>
<text top="770" left="452" width="354" height="12" font="12">494. Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety</text>
<text top="784" left="479" width="327" height="12" font="12">and tolerability of tadalafil in the treatment of erectile dysfunction.</text>
<text top="798" left="479" width="136" height="12" font="12">Eur Urol. 2004;45:339 – 44.</text>
<text top="811" left="452" width="354" height="12" font="12">495. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the</text>
<text top="825" left="479" width="327" height="12" font="12">phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, dox-</text>
<text top="838" left="479" width="327" height="12" font="12">azosin and tamsulosin in healthy normotensive men. J Urol. 2004;</text>
<text top="852" left="479" width="68" height="12" font="12">172:1935– 40.</text>
<text top="866" left="452" width="354" height="12" font="12">496. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on</text>
<text top="879" left="479" width="327" height="12" font="12">blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr.</text>
<text top="893" left="479" width="78" height="12" font="12">1992;56:320 – 8.</text>
<text top="906" left="452" width="354" height="12" font="12">497. Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing</text>
<text top="920" left="479" width="327" height="12" font="12">dietary saturated fatty acids on plasma lipids and lipoproteins in</text>
<text top="933" left="479" width="327" height="12" font="12">healthy subjects: the DELTA Study, protocol 1. Arterioscler</text>
<text top="947" left="479" width="174" height="12" font="12">Thromb Vasc Biol. 1998;18:441–9.</text>
<text top="961" left="452" width="354" height="12" font="12">498. Schaefer EJ, Lamon-Fava S, Ausman LM, et al. Individual vari-</text>
<text top="974" left="479" width="327" height="12" font="12">ability in lipoprotein cholesterol response to National Cholesterol</text>
<text top="988" left="479" width="327" height="12" font="12">Education Program Step 2 diets. Am J Clin Nutr. 1997;65:823–30.</text>
<text top="1001" left="452" width="354" height="12" font="12">499. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, et al. Efficacy of a</text>
<text top="1015" left="479" width="327" height="12" font="12">National Cholesterol Education Program Step 2 diet in normolipi-</text>
<text top="1029" left="479" width="327" height="12" font="12">demic and hypercholesterolemic middle-aged and elderly men and</text>
<text top="1042" left="479" width="292" height="12" font="12">women. Arterioscler Thromb Vasc Biol. 1995;15:1079 – 85.</text>
<text top="1056" left="452" width="354" height="12" font="12">500. Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National</text>
<text top="1069" left="479" width="327" height="12" font="12">Cholesterol Education Program’s Step I and Step II dietary inter-</text>
<text top="1083" left="479" width="327" height="12" font="12">vention programs on cardiovascular disease risk factors: a meta-</text>
<text top="1096" left="479" width="213" height="12" font="12">analysis. Am J Clin Nutr. 1999;69:632– 46.</text>
<text top="52" left="59" width="25" height="10" font="12">e140</text>
<text top="52" left="113" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="98" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">501. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorva-</text>
<text top="118" left="92" width="327" height="12" font="12">statin vs usual-dose simvastatin for secondary prevention after</text>
<text top="132" left="92" width="327" height="12" font="12">myocardial infarction: the IDEAL study: a randomized controlled</text>
<text top="145" left="92" width="162" height="12" font="12">trial. JAMA. 2005;294:2437– 45.</text>
<text top="159" left="65" width="354" height="12" font="12">502. The Lipid Research Clinics Coronary Primary Prevention Trial</text>
<text top="172" left="92" width="327" height="12" font="12">results. I. Reduction in incidence of coronary heart disease. JAMA.</text>
<text top="186" left="92" width="89" height="12" font="12">1984;251:351– 64.</text>
<text top="200" left="65" width="112" height="12" font="12">503. Deleted in proof.</text>
<text top="213" left="65" width="354" height="12" font="12">504. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in</text>
<text top="227" left="92" width="327" height="12" font="12">Coronary Drug Project patients: long-term benefit with niacin.</text>
<text top="240" left="92" width="180" height="12" font="12">J Am Coll Cardiol. 1986;8:1245–55.</text>
<text top="254" left="65" width="354" height="12" font="12">505. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin,</text>
<text top="268" left="92" width="327" height="12" font="12">antioxidant vitamins, or the combination for the prevention of</text>
<text top="281" left="92" width="259" height="12" font="12">coronary disease. N Engl J Med. 2001;345:1583–92.</text>
<text top="295" left="65" width="354" height="12" font="12">506. The Lipid Research Clinics Coronary Primary Prevention Trial</text>
<text top="308" left="92" width="327" height="12" font="12">results. II. The relationship of reduction in incidence of coronary</text>
<text top="322" left="92" width="312" height="12" font="12">heart disease to cholesterol lowering. JAMA. 1984;251:365–74.</text>
<text top="336" left="65" width="354" height="12" font="12">507. Stamler J, Wentworth D, Neaton JD. Is relationship between serum</text>
<text top="349" left="92" width="327" height="12" font="12">cholesterol and risk of premature death from coronary heart disease</text>
<text top="363" left="92" width="327" height="12" font="12">continuous and graded? Findings in 356,222 primary screenees of</text>
<text top="376" left="92" width="327" height="12" font="12">the Multiple Risk Factor Intervention Trial (MRFIT). JAMA.</text>
<text top="390" left="92" width="89" height="12" font="12">1986;256:2823– 8.</text>
<text top="404" left="65" width="354" height="12" font="12">508. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of</text>
<text top="417" left="92" width="327" height="12" font="12">coronary heart disease using risk factor categories. Circulation.</text>
<text top="431" left="92" width="92" height="12" font="12">1998;97:1837– 47.</text>
<text top="444" left="65" width="354" height="12" font="12">509. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from</text>
<text top="458" left="92" width="327" height="12" font="12">cardiovascular disease in relation to cholesterol level among men</text>
<text top="471" left="92" width="327" height="12" font="12">with and without preexisting cardiovascular disease. N Engl J Med.</text>
<text top="485" left="92" width="89" height="12" font="12">1990;322:1700 –7.</text>
<text top="499" left="65" width="354" height="12" font="12">510. Rossouw JE, Lewis B, Rifkind BM. The value of lowering choles-</text>
<text top="512" left="92" width="327" height="12" font="12">terol after myocardial infarction. N Engl J Med. 1990;323:1112–9.</text>
<text top="526" left="65" width="354" height="12" font="12">511. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a</text>
<text top="539" left="92" width="327" height="12" font="12">prognostic factor after myocardial infarction: the Framingham</text>
<text top="553" left="92" width="212" height="12" font="12">Study. Ann Intern Med. 1991;115:687–93.</text>
<text top="567" left="65" width="354" height="12" font="12">512. Chen JT, Wesley R, Shamburek RD, et al. Meta-analysis of natural</text>
<text top="580" left="92" width="327" height="12" font="12">therapies for hyperlipidemia: plant sterols and stanols versus poli-</text>
<text top="594" left="92" width="217" height="12" font="12">cosanol. Pharmacotherapy. 2005;25:171– 83.</text>
<text top="607" left="65" width="354" height="12" font="12">513. Goldberg AC Ostlund RE Jr., Bateman JH, et al. Effect of plant</text>
<text top="621" left="92" width="327" height="12" font="12">stanol tablets on low-density lipoprotein cholesterol lowering in</text>
<text top="635" left="92" width="273" height="12" font="12">patients on statin drugs. Am J Cardiol. 2006;97:376 –9.</text>
<text top="648" left="65" width="354" height="12" font="12">514. Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant stanol esters</text>
<text top="662" left="92" width="327" height="12" font="12">affect serum cholesterol concentrations of hypercholesterolemic men</text>
<text top="675" left="92" width="327" height="12" font="12">and women in a dose-dependent manner. J Nutr. 2000;130:767–76.</text>
<text top="689" left="65" width="354" height="12" font="12">515. Nguyen TT, Dale LC, von Bergmann K, et al. Cholesterol-</text>
<text top="702" left="92" width="327" height="12" font="12">lowering effect of stanol ester in a US population of mildly</text>
<text top="716" left="92" width="327" height="12" font="12">hypercholesterolemic men and women: a randomized controlled</text>
<text top="730" left="92" width="208" height="12" font="12">trial. Mayo Clin Proc. 1999;74:1198 –206.</text>
<text top="743" left="65" width="354" height="12" font="12">516. Durstine JL, Grandjean PW, Cox CA, et al. Lipids, lipoproteins,</text>
<text top="757" left="92" width="262" height="12" font="12">and exercise. J Cardiopulm Rehabil. 2002;22:385–98.</text>
<text top="770" left="65" width="354" height="12" font="12">517. Durstine JL, Grandjean PW, Davis PG, et al. Blood lipid and</text>
<text top="784" left="92" width="327" height="12" font="12">lipoprotein adaptations to exercise: a quantitative analysis. Sports</text>
<text top="798" left="92" width="119" height="12" font="12">Med. 2001;31:1033– 62.</text>
<text top="811" left="65" width="354" height="12" font="12">518. Leon AS, Sanchez OA. Response of blood lipids to exercise training</text>
<text top="825" left="92" width="327" height="12" font="12">alone or combined with dietary intervention. Med Sci Sports Exerc.</text>
<text top="838" left="92" width="100" height="12" font="12">2001;33:S502–S515.</text>
<text top="852" left="65" width="354" height="12" font="12">519. Major outcomes in moderately hypercholesterolemic, hypertensive</text>
<text top="865" left="92" width="327" height="12" font="12">patients randomized to pravastatin vs usual care: The Antihyper-</text>
<text top="879" left="92" width="327" height="12" font="12">tensive and Lipid-Lowering Treatment to Prevent Heart Attack</text>
<text top="893" left="92" width="272" height="12" font="12">Trial (ALLHAT-LLT). JAMA. 2002;288:2998 –3007.</text>
<text top="906" left="65" width="354" height="12" font="12">520. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus</text>
<text top="920" left="92" width="327" height="12" font="12">moderate lipid lowering with statins after acute coronary syndromes.</text>
<text top="933" left="92" width="178" height="12" font="12">N Engl J Med. 2004;350:1495–504.</text>
<text top="947" left="65" width="354" height="12" font="12">521. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and</text>
<text top="961" left="92" width="327" height="12" font="12">stroke events with atorvastatin in hypertensive patients who have</text>
<text top="974" left="92" width="327" height="12" font="12">average or lower-than-average cholesterol concentrations, in the</text>
<text top="988" left="92" width="327" height="12" font="12">Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering</text>
<text top="1001" left="92" width="327" height="12" font="12">Arm (ASCOT-LLA): a multicentre randomised controlled trial.</text>
<text top="1015" left="92" width="135" height="12" font="12">Lancet. 2003;361:1149 –58.</text>
<text top="1028" left="65" width="354" height="12" font="12">522. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly</text>
<text top="1042" left="92" width="327" height="12" font="12">individuals at risk of vascular disease (PROSPER): a randomised</text>
<text top="1056" left="92" width="213" height="12" font="12">controlled trial. Lancet. 2002;360:1623–30.</text>
<text top="1069" left="65" width="354" height="12" font="12">523. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipopro-</text>
<text top="1083" left="92" width="327" height="12" font="12">tein cholesterol level as a predictor of cardiovascular disease mor-</text>
<text top="1096" left="92" width="211" height="12" font="12">tality. Arch Intern Med. 2001;161:1413–9.</text>
<text top="104" left="452" width="354" height="12" font="12">524. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the</text>
<text top="118" left="479" width="327" height="12" font="12">secondary prevention of coronary heart disease in men with low</text>
<text top="132" left="479" width="327" height="12" font="12">levels of high-density lipoprotein cholesterol. Veterans Affairs</text>
<text top="146" left="479" width="327" height="12" font="12">High-Density Lipoprotein Cholesterol Intervention Trial Study</text>
<text top="159" left="479" width="202" height="12" font="12">Group. N Engl J Med. 1999;341:410 – 8.</text>
<text top="173" left="452" width="354" height="12" font="12">525. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery</text>
<text top="187" left="479" width="327" height="12" font="12">disease as a result of intensive lipid-lowering therapy in men with</text>
<text top="201" left="479" width="327" height="12" font="12">high levels of apolipoprotein B. N Engl J Med. 1990;323:1289 –98.</text>
<text top="214" left="452" width="354" height="12" font="12">526. Whelton SP, He J, Whelton PK, et al. Meta-analysis of observa-</text>
<text top="228" left="479" width="327" height="12" font="12">tional studies on fish intake and coronary heart disease. Am J</text>
<text top="242" left="479" width="132" height="12" font="12">Cardiol. 2004;93:1119 –23.</text>
<text top="256" left="452" width="354" height="12" font="12">527. Dietary supplementation with n-3 polyunsaturated fatty acids and</text>
<text top="270" left="479" width="327" height="12" font="12">vitamin E after myocardial infarction: results of the GISSI-</text>
<text top="283" left="479" width="327" height="12" font="12">Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza</text>
<text top="297" left="479" width="245" height="12" font="12">nell’Infarto miocardico. Lancet. 1999;354:447–55.</text>
<text top="311" left="452" width="354" height="12" font="12">528. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3</text>
<text top="325" left="479" width="327" height="12" font="12">polyunsaturated fatty acid concentrate administered for one year</text>
<text top="339" left="479" width="327" height="12" font="12">decreased triglycerides in simvastatin treated patients with coronary</text>
<text top="352" left="479" width="327" height="12" font="12">heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:</text>
<text top="366" left="479" width="36" height="12" font="12">544 – 8.</text>
<text top="380" left="452" width="354" height="12" font="12">529. Effects of weight loss and sodium reduction intervention on blood</text>
<text top="394" left="479" width="327" height="12" font="12">pressure and hypertension incidence in overweight people with</text>
<text top="407" left="479" width="327" height="12" font="12">high-normal blood pressure. The Trials of Hypertension Preven-</text>
<text top="421" left="479" width="327" height="12" font="12">tion, phase II. The Trials of Hypertension Prevention Collaborative</text>
<text top="435" left="479" width="268" height="12" font="12">Research Group. Arch Intern Med. 1997;157:657– 67.</text>
<text top="449" left="452" width="354" height="12" font="12">530. Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss inter-</text>
<text top="463" left="479" width="327" height="12" font="12">vention in phase 1 of the Trials of Hypertension Prevention. The</text>
<text top="476" left="479" width="327" height="12" font="12">TOHP Collaborative Research Group. Arch Intern Med. 1993;153:</text>
<text top="490" left="479" width="40" height="12" font="12">849 –58.</text>
<text top="504" left="452" width="354" height="12" font="12">531. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and</text>
<text top="518" left="479" width="327" height="12" font="12">weight loss in the treatment of hypertension in older persons: a</text>
<text top="532" left="479" width="327" height="12" font="12">randomized controlled trial of nonpharmacologic interventions in</text>
<text top="545" left="479" width="327" height="12" font="12">the elderly (TONE). TONE Collaborative Research Group.</text>
<text top="559" left="479" width="131" height="12" font="12">JAMA. 1998;279:839 – 46.</text>
<text top="573" left="452" width="354" height="12" font="12">532. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the</text>
<text top="587" left="479" width="327" height="12" font="12">effects of dietary patterns on blood pressure. DASH Collaborative</text>
<text top="601" left="479" width="259" height="12" font="12">Research Group. N Engl J Med. 1997;336:1117–24.</text>
<text top="614" left="452" width="354" height="12" font="12">533. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood</text>
<text top="628" left="479" width="327" height="12" font="12">pressure of reduced dietary sodium and the Dietary Approaches to</text>
<text top="642" left="479" width="327" height="12" font="12">Stop Hypertension (DASH) diet. DASH-Sodium Collaborative</text>
<text top="656" left="479" width="240" height="12" font="12">Research Group. N Engl J Med. 2001;344:3-10.</text>
<text top="669" left="452" width="354" height="12" font="12">534. MacGregor GA, Markandu ND, Sagnella GA, et al. Double-blind</text>
<text top="683" left="479" width="327" height="12" font="12">study of three sodium intakes and long-term effects of sodium</text>
<text top="697" left="479" width="297" height="12" font="12">restriction in essential hypertension. Lancet. 1989;2:1244 –7.</text>
<text top="711" left="452" width="354" height="12" font="12">535. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on</text>
<text top="725" left="479" width="327" height="12" font="12">blood pressure: a meta-analysis of randomized, controlled trials.</text>
<text top="738" left="479" width="183" height="12" font="12">Ann Intern Med. 2002;136:493–503.</text>
<text top="752" left="452" width="354" height="12" font="12">536. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on</text>
<text top="766" left="479" width="327" height="12" font="12">blood pressure: a meta-analysis of randomized controlled trials.</text>
<text top="780" left="479" width="154" height="12" font="12">Hypertension. 2001;38:1112–7.</text>
<text top="793" left="452" width="354" height="12" font="12">537. Appel LJ, Frohlich ED, Hall JE, et al. The importance of</text>
<text top="807" left="479" width="327" height="12" font="12">population-wide sodium reduction as a means to prevent cardiovas-</text>
<text top="821" left="479" width="327" height="12" font="12">cular disease and stroke: a call to action from the American Heart</text>
<text top="835" left="479" width="221" height="12" font="12">Association. Circulation. 2011;123:1138 – 43.</text>
<text top="848" left="452" width="354" height="12" font="12">538. Medical Research Council trial of treatment of hypertension in</text>
<text top="862" left="479" width="327" height="12" font="12">older adults: principal results. MRC Working Party. BMJ. 1992;</text>
<text top="876" left="479" width="60" height="12" font="12">304:405–12.</text>
<text top="890" left="452" width="354" height="12" font="12">539. Prevention of stroke by antihypertensive drug treatment in older</text>
<text top="904" left="479" width="327" height="12" font="12">persons with isolated systolic hypertension. Final results of the</text>
<text top="917" left="479" width="327" height="12" font="12">Systolic Hypertension in the Elderly Program (SHEP). SHEP</text>
<text top="931" left="479" width="285" height="12" font="12">Cooperative Research Group. JAMA. 1991;265:3255– 64.</text>
<text top="945" left="452" width="354" height="12" font="12">540. MRC trial of treatment of mild hypertension: principal results.</text>
<text top="959" left="479" width="327" height="12" font="12">Medical Research Council Working Party. Br Med J (Clin Res Ed).</text>
<text top="972" left="479" width="87" height="12" font="12">1985;291:97–104.</text>
<text top="986" left="452" width="354" height="12" font="12">541. Effect of stepped care treatment on the incidence of myocardial</text>
<text top="1000" left="479" width="327" height="12" font="12">infarction and angina pectoris. 5-year findings of the hypertension</text>
<text top="1014" left="479" width="327" height="12" font="12">detection and follow-up program. Hypertension. 1984;6:I198 –</text>
<text top="1028" left="479" width="26" height="12" font="12">I206.</text>
<text top="1041" left="452" width="354" height="12" font="12">542. The effect of treatment on mortality in “mild” hypertension: results</text>
<text top="1055" left="479" width="327" height="12" font="12">of the hypertension detection and follow-up program. N Engl</text>
<text top="1069" left="479" width="128" height="12" font="12">J Med. 1982;307:976 – 80.</text>
<text top="1083" left="452" width="354" height="12" font="12">543. Five-year findings of the hypertension detection and follow-up pro-</text>
<text top="1096" left="479" width="327" height="12" font="12">gram. I. Reduction in mortality of persons with high blood pressure,</text>
<text top="52" left="781" width="25" height="10" font="12">e141</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="99" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="92" width="327" height="12" font="12">including mild hypertension. Hypertension Detection and Follow-up</text>
<text top="118" left="92" width="270" height="12" font="12">Program Cooperative Group. JAMA. 1979;242:2562–71.</text>
<text top="132" left="64" width="354" height="12" font="12">544. Major outcomes in high-risk hypertensive patients randomized</text>
<text top="146" left="92" width="327" height="12" font="12">to angiotensin-converting enzyme inhibitor or calcium channel</text>
<text top="160" left="92" width="327" height="12" font="12">blocker vs diuretic: The Antihypertensive and Lipid-Lowering</text>
<text top="174" left="92" width="327" height="12" font="12">Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA.</text>
<text top="188" left="92" width="97" height="12" font="12">2002;288:2981–97.</text>
<text top="202" left="64" width="354" height="12" font="12">545. Turnbull F. Effects of different blood-pressure-lowering regimens</text>
<text top="216" left="92" width="327" height="12" font="12">on major cardiovascular events: results of prospectively-designed</text>
<text top="230" left="92" width="289" height="12" font="12">overviews of randomised trials. Lancet. 2003;362:1527–35.</text>
<text top="244" left="64" width="354" height="12" font="12">546. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of</text>
<text top="258" left="92" width="327" height="12" font="12">usual blood pressure to vascular mortality: a meta-analysis of</text>
<text top="272" left="92" width="327" height="12" font="12">individual data for one million adults in 61 prospective studies.</text>
<text top="286" left="92" width="134" height="12" font="12">Lancet. 2002;360:1903–13.</text>
<text top="300" left="64" width="354" height="12" font="12">547. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke</text>
<text top="314" left="92" width="327" height="12" font="12">and coronary heart disease. In: Swales JD, editor. Textbook of</text>
<text top="328" left="92" width="266" height="12" font="12">Hypertension. Blackwell Scientific Publications; 1994.</text>
<text top="342" left="64" width="354" height="12" font="12">548. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on</text>
<text top="356" left="92" width="327" height="12" font="12">blood pressure: a meta-analysis of randomized controlled trials.</text>
<text top="370" left="92" width="157" height="12" font="12">Hypertension. 2003;42:878 – 84.</text>
<text top="384" left="64" width="354" height="12" font="12">549. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss</text>
<text top="398" left="92" width="327" height="12" font="12">and changes in blood pressure: results of the Trials of Hypertension</text>
<text top="412" left="92" width="272" height="12" font="12">Prevention, phase II. Ann Intern Med. 2001;134:1–11.</text>
<text top="426" left="64" width="354" height="12" font="12">550. He FJ, MacGregor GA. Effect of modest salt reduction on blood</text>
<text top="440" left="92" width="327" height="12" font="12">pressure: a meta-analysis of randomized trials. Implications for</text>
<text top="454" left="92" width="247" height="12" font="12">public health. J Hum Hypertens. 2002;16:761–70.</text>
<text top="468" left="64" width="354" height="12" font="12">551. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyper-</text>
<text top="482" left="92" width="327" height="12" font="12">tension in patients 80 years of age or older. N Engl J Med.</text>
<text top="496" left="92" width="97" height="12" font="12">2008;358:1887–98.</text>
<text top="510" left="64" width="354" height="12" font="12">552. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind</text>
<text top="524" left="92" width="327" height="12" font="12">comparison of placebo and active treatment for older patients with</text>
<text top="538" left="92" width="327" height="12" font="12">isolated systolic hypertension. The Systolic Hypertension in Europe</text>
<text top="552" left="92" width="281" height="12" font="12">(Syst-Eur) Trial Investigators. Lancet. 1997;350:757– 64.</text>
<text top="566" left="64" width="354" height="12" font="12">553. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hyper-</text>
<text top="580" left="92" width="327" height="12" font="12">tension in the prevention and management of ischemic heart</text>
<text top="594" left="92" width="327" height="12" font="12">disease: a scientific statement from the American Heart Association</text>
<text top="608" left="92" width="327" height="12" font="12">Council for High Blood Pressure Research and the Councils on</text>
<text top="622" left="92" width="327" height="12" font="12">Clinical Cardiology and Epidemiology and Prevention. Circulation.</text>
<text top="636" left="92" width="95" height="12" font="12">2007;115:2761– 88.</text>
<text top="650" left="64" width="354" height="12" font="12">554. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can</text>
<text top="664" left="92" width="327" height="12" font="12">aggressively lowering blood pressure in hypertensive patients with</text>
<text top="678" left="92" width="327" height="12" font="12">coronary artery disease be dangerous? Ann Intern Med. 2006;144:</text>
<text top="692" left="92" width="40" height="12" font="12">884 –93.</text>
<text top="706" left="64" width="354" height="12" font="12">555. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination</text>
<text top="720" left="92" width="327" height="12" font="12">lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:</text>
<text top="734" left="92" width="45" height="12" font="12">1563–74.</text>
<text top="747" left="64" width="354" height="12" font="12">556. Appel LJ, Wright JT Jr., Greene T, et al. Intensive blood-pressure</text>
<text top="761" left="92" width="327" height="12" font="12">control in hypertensive chronic kidney disease. N Engl J Med.</text>
<text top="775" left="92" width="89" height="12" font="12">2010;363:918 –29.</text>
<text top="789" left="64" width="354" height="12" font="12">557. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes</text>
<text top="803" left="92" width="327" height="12" font="12">associated with various antihypertensive therapies used as first-line</text>
<text top="817" left="92" width="299" height="12" font="12">agents: a network meta-analysis. JAMA. 2003;289:2534 – 44.</text>
<text top="831" left="64" width="354" height="12" font="12">558. Randomised placebo-controlled trial of effect of ramipril on decline</text>
<text top="845" left="92" width="327" height="12" font="12">in glomerular filtration rate and risk of terminal renal failure in</text>
<text top="859" left="92" width="327" height="12" font="12">proteinuric, non-diabetic nephropathy. The GISEN Group</text>
<text top="873" left="92" width="327" height="12" font="12">(Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet.</text>
<text top="887" left="92" width="95" height="12" font="12">1997;349:1857– 63.</text>
<text top="901" left="64" width="354" height="12" font="12">559. Effect of ramipril on mortality and morbidity of survivors of acute</text>
<text top="915" left="92" width="327" height="12" font="12">myocardial infarction with clinical evidence of heart failure. The</text>
<text top="929" left="92" width="327" height="12" font="12">Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.</text>
<text top="943" left="92" width="123" height="12" font="12">Lancet. 1993;342:821– 8.</text>
<text top="957" left="64" width="354" height="12" font="12">560. Effect of enalapril on survival in patients with reduced left ventric-</text>
<text top="971" left="92" width="327" height="12" font="12">ular ejection fractions and congestive heart failure. The SOLVD</text>
<text top="985" left="92" width="241" height="12" font="12">Investigators. N Engl J Med. 1991;325:293–302.</text>
<text top="999" left="64" width="354" height="12" font="12">561. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the</text>
<text top="1013" left="92" width="327" height="12" font="12">angiotensin-converting-enzyme inhibitor trandolapril in patients</text>
<text top="1027" left="92" width="327" height="12" font="12">with left ventricular dysfunction after myocardial infarction. Tran-</text>
<text top="1041" left="92" width="327" height="12" font="12">dolapril Cardiac Evaluation (TRACE) Study Group. N Engl</text>
<text top="1055" left="92" width="128" height="12" font="12">J Med. 1995;333:1670 – 6.</text>
<text top="1069" left="64" width="354" height="12" font="12">562. Wright JT Jr., Agodoa L, Contreras G, et al. Successful blood</text>
<text top="1083" left="92" width="327" height="12" font="12">pressure control in the African American Study of Kidney Disease</text>
<text top="1097" left="92" width="284" height="12" font="12">and Hypertension. Arch Intern Med. 2002;162:1636 – 43.</text>
<text top="105" left="451" width="354" height="12" font="12">563. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on</text>
<text top="118" left="479" width="327" height="12" font="12">renal and cardiovascular outcomes in patients with type 2 diabetes</text>
<text top="132" left="479" width="250" height="12" font="12">and nephropathy. N Engl J Med. 2001;345:861–9.</text>
<text top="146" left="451" width="354" height="12" font="12">564. Cohn JN, Tognoni G. A randomized trial of the angiotensin-</text>
<text top="160" left="479" width="327" height="12" font="12">receptor blocker valsartan in chronic heart failure. N Engl J Med.</text>
<text top="173" left="479" width="93" height="12" font="12">2001;345:1667–75.</text>
<text top="187" left="451" width="354" height="12" font="12">565. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective</text>
<text top="201" left="479" width="327" height="12" font="12">effect of the angiotensin-receptor antagonist irbesartan in pa-</text>
<text top="215" left="479" width="327" height="12" font="12">tients with nephropathy due to type 2 diabetes. N Engl J Med.</text>
<text top="229" left="479" width="92" height="12" font="12">2001;345:851– 60.</text>
<text top="242" left="451" width="354" height="12" font="12">566. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in</text>
<text top="256" left="479" width="327" height="12" font="12">patients at high risk for vascular events. N Engl J Med. 2008;358:</text>
<text top="270" left="479" width="45" height="12" font="12">1547–59.</text>
<text top="284" left="451" width="354" height="12" font="12">567. A randomized trial of beta-blockade in heart failure. The Cardiac</text>
<text top="298" left="479" width="327" height="12" font="12">Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and</text>
<text top="311" left="479" width="216" height="12" font="12">Committees. Circulation. 1994;90:1765–73.</text>
<text top="325" left="451" width="354" height="12" font="12">568. A randomized trial of propranolol in patients with acute myocardial</text>
<text top="339" left="479" width="287" height="12" font="12">infarction. I. Mortality results. JAMA. 1982;247:1707–14.</text>
<text top="353" left="451" width="354" height="12" font="12">569. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction</text>
<text top="367" left="479" width="327" height="12" font="12">in patients with left-ventricular dysfunction: the CAPRICORN ran-</text>
<text top="380" left="479" width="195" height="12" font="12">domised trial. Lancet. 2001;357:1385–90.</text>
<text top="394" left="451" width="354" height="12" font="12">570. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on</text>
<text top="408" left="479" width="327" height="12" font="12">survival in severe chronic heart failure. N Engl J Med. 2001;344:</text>
<text top="422" left="479" width="40" height="12" font="12">1651– 8.</text>
<text top="435" left="451" width="354" height="12" font="12">571. Tepper D. Frontiers in congestive heart failure: Effect of Metoprolol</text>
<text top="449" left="479" width="327" height="12" font="12">CR/XL in chronic heart failure: Metoprolol CR/XL Randomised</text>
<text top="463" left="479" width="327" height="12" font="12">Intervention Trial in Congestive Heart Failure (MERIT-HF).</text>
<text top="477" left="479" width="173" height="12" font="12">Congest Heart Fail. 1999;5:184 –5.</text>
<text top="491" left="451" width="354" height="12" font="12">572. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective</text>
<text top="504" left="479" width="327" height="12" font="12">aldosterone blocker, in patients with left ventricular dysfunction</text>
<text top="518" left="479" width="310" height="12" font="12">after myocardial infarction. N Engl J Med. 2003;348:1309 –21.</text>
<text top="532" left="451" width="354" height="12" font="12">573. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on</text>
<text top="546" left="479" width="327" height="12" font="12">morbidity and mortality in patients with severe heart failure.</text>
<text top="560" left="479" width="327" height="12" font="12">Randomized Aldactone Evaluation Study Investigators. N Engl</text>
<text top="573" left="479" width="127" height="12" font="12">J Med. 1999;341:709 –17.</text>
<text top="587" left="451" width="354" height="12" font="12">574. The effect of intensive treatment of diabetes on the development</text>
<text top="601" left="479" width="327" height="12" font="12">and progression of long-term complications in insulin-dependent</text>
<text top="615" left="479" width="327" height="12" font="12">diabetes mellitus. The Diabetes Control and Complications Trial</text>
<text top="628" left="479" width="254" height="12" font="12">Research Group. N Engl J Med. 1993;329:977– 86.</text>
<text top="642" left="451" width="354" height="12" font="12">575. Intensive blood-glucose control with sulphonylureas or insulin</text>
<text top="656" left="479" width="327" height="12" font="12">compared with conventional treatment and risk of complications in</text>
<text top="670" left="479" width="327" height="12" font="12">patients with type 2 diabetes (UKPDS 33). UK Prospective Diabe-</text>
<text top="684" left="479" width="269" height="12" font="12">tes Study (UKPDS) Group. Lancet. 1998;352:837–53.</text>
<text top="697" left="451" width="354" height="12" font="12">576. Patel A, MacMahon S, Chalmers J, et al. Intensive Blood Glucose</text>
<text top="711" left="479" width="327" height="12" font="12">Control and Vascular Outcomes in Patients with Type 2 Diabetes.</text>
<text top="725" left="479" width="174" height="12" font="12">N Engl J Med. 2008;358:2560 –72.</text>
<text top="739" left="451" width="354" height="12" font="12">577. Dluhy RG, McMahon GT. Intensive Glycemic Control in the</text>
<text top="752" left="479" width="327" height="12" font="12">ACCORD and ADVANCE Trials. N Engl J Med. 2008;358:</text>
<text top="766" left="479" width="40" height="12" font="12">2630 –3.</text>
<text top="780" left="451" width="354" height="12" font="12">578. Duckworth W, Abraira C, Moritz T, et al. Glucose Control and</text>
<text top="794" left="479" width="327" height="12" font="12">Vascular Complications in Veterans with Type 2 Diabetes. N Engl</text>
<text top="808" left="479" width="127" height="12" font="12">J Med. 2009;360:129 –39.</text>
<text top="821" left="451" width="354" height="12" font="12">579. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes</text>
<text top="835" left="479" width="327" height="12" font="12">treatment and cardiovascular disease in patients with type 1 diabetes.</text>
<text top="849" left="479" width="172" height="12" font="12">N Engl J Med. 2005;353:2643–53.</text>
<text top="863" left="451" width="354" height="12" font="12">580. Effect of intensive blood-glucose control with metformin on com-</text>
<text top="876" left="479" width="327" height="12" font="12">plications in overweight patients with type 2 diabetes (UKPDS 34).</text>
<text top="890" left="479" width="327" height="12" font="12">UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;</text>
<text top="904" left="479" width="63" height="12" font="12">352:854 – 65.</text>
<text top="918" left="451" width="354" height="12" font="12">581. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary pre-</text>
<text top="932" left="479" width="327" height="12" font="12">vention of macrovascular events in patients with type 2 diabetes in</text>
<text top="945" left="479" width="327" height="12" font="12">the PROactive Study (PROspective pioglitAzone Clinical Trial In</text>
<text top="959" left="479" width="327" height="12" font="12">macroVascular Events): a randomised controlled trial. Lancet.</text>
<text top="973" left="479" width="96" height="12" font="12">2005;366:1279 – 89.</text>
<text top="987" left="451" width="354" height="12" font="12">582. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic</text>
<text top="1000" left="479" width="327" height="12" font="12">control and the prevention of cardiovascular events: implications of</text>
<text top="1014" left="479" width="327" height="12" font="12">the ACCORD, ADVANCE, and VA diabetes trials: a position</text>
<text top="1028" left="479" width="327" height="12" font="12">statement of the American Diabetes Association and a scientific</text>
<text top="1042" left="479" width="327" height="12" font="12">statement of the American College of Cardiology Foundation and</text>
<text top="1056" left="479" width="309" height="12" font="12">the American Heart Association. Circulation. 2009;119:351–7.</text>
<text top="1069" left="451" width="354" height="12" font="12">583. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review:</text>
<text top="1083" left="479" width="327" height="12" font="12">glucose control and cardiovascular disease in type 2 diabetes. Ann</text>
<text top="1097" left="479" width="160" height="12" font="12">Intern Med. 2009;151:394 – 403.</text>
<text top="52" left="58" width="25" height="10" font="12">e142</text>
<text top="52" left="112" width="48" height="10" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="100" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="40" size="10" family="Times" color="#00007f"/>
<text top="104" left="65" width="354" height="12" font="12">584. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials</text>
<text top="118" left="92" width="327" height="12" font="12">of oral diabetes medications: a systematic review. Arch Intern Med.</text>
<text top="132" left="92" width="96" height="12" font="12">2008;168:2070 – 80.</text>
<text top="146" left="65" width="354" height="12" font="12">585. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose</text>
<text top="160" left="92" width="327" height="12" font="12">control and macrovascular outcomes in type 2 diabetes. Diabetolo-</text>
<text top="173" left="92" width="110" height="12" font="12">gia. 2009;52:2288 –98.</text>
<text top="187" left="65" width="354" height="12" font="12">586. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control</text>
<text top="201" left="92" width="327" height="12" font="12">of glucose on cardiovascular outcomes and death in patients with</text>
<text top="215" left="92" width="327" height="12" font="12">diabetes mellitus: a meta-analysis of randomised controlled trials.</text>
<text top="228" left="92" width="134" height="12" font="12">Lancet. 2009;373:1765–72.</text>
<text top="242" left="65" width="354" height="12" font="12">587. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of</text>
<text top="256" left="92" width="327" height="12" font="12">HbA(1c) in people with type 2 diabetes: a retrospective cohort</text>
<text top="270" left="92" width="154" height="12" font="12">study. Lancet. 2010;375:481–9.</text>
<text top="284" left="65" width="354" height="12" font="12">588. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of</text>
<text top="297" left="92" width="327" height="12" font="12">intensive glucose control in type 2 diabetes. N Engl J Med.</text>
<text top="311" left="92" width="95" height="12" font="12">2008;359:1577– 89.</text>
<text top="325" left="65" width="354" height="12" font="12">589. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of</text>
<text top="339" left="92" width="327" height="12" font="12">thiazolidinediones: systematic review and meta-analysis of observa-</text>
<text top="353" left="92" width="178" height="12" font="12">tional studies. BMJ. 2011;342:1309.</text>
<text top="366" left="65" width="354" height="12" font="12">590. Woodcock J. Center for Drug Evaluation and Research. Decision on</text>
<text top="380" left="92" width="327" height="12" font="12">continued marketing of rosiglitazone (Avandia, Avandamet,</text>
<text top="394" left="92" width="327" height="12" font="12">Avandaryl) [Report NDA 021071]. 2010. Available at:</text>
<text top="408" left="92" width="327" height="12" font="37"><a href="http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf">http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrug</a></text>
<text top="422" left="92" width="300" height="12" font="37"><a href="http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf">SafetyInformationforPatientsandProviders/UCM226959.pdf.</a></text>
<text top="422" left="400" width="19" height="12" font="12">Ac-</text>
<text top="435" left="92" width="115" height="12" font="12">cessed January 15, 2011.</text>
<text top="449" left="65" width="354" height="12" font="12">591. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and</text>
<text top="463" left="92" width="327" height="12" font="12">determinants of coronary artery disease in juvenile-onset, insulin-</text>
<text top="477" left="92" width="294" height="12" font="12">dependent diabetes mellitus. Am J Cardiol. 1987;59:750 –5.</text>
<text top="490" left="65" width="354" height="12" font="12">592. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart</text>
<text top="504" left="92" width="327" height="12" font="12">disease in a cohort of 23,000 patients with insulin-treated diabetes.</text>
<text top="518" left="92" width="146" height="12" font="12">Diabetologia. 2003;46:760 –5.</text>
<text top="532" left="65" width="354" height="12" font="12">593. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease</text>
<text top="546" left="92" width="245" height="12" font="12">mortality in US adults. JAMA. 1999;281:1291–7.</text>
<text top="559" left="65" width="354" height="12" font="12">594. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The</text>
<text top="573" left="92" width="229" height="12" font="12">Framingham study. JAMA. 1979;241:2035– 8.</text>
<text top="587" left="65" width="354" height="12" font="12">595. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of</text>
<text top="601" left="92" width="327" height="12" font="12">maturity-onset diabetes mellitus and risk of coronary heart disease</text>
<text top="615" left="92" width="291" height="12" font="12">and stroke in women. Arch Intern Med. 1991;151:1141–7.</text>
<text top="628" left="65" width="354" height="12" font="12">596. Getz GS. Report on the workshop on diabetes and mechanisms of</text>
<text top="642" left="92" width="327" height="12" font="12">atherogenesis. September 17th and 18th, 1992, Bethesda, Mary-</text>
<text top="656" left="92" width="220" height="12" font="12">land. Arterioscler Thromb. 1993;13:459 – 64.</text>
<text top="670" left="65" width="354" height="12" font="12">597. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic</text>
<text top="683" left="92" width="327" height="12" font="12">follow-up of factors associated with progression of coronary artery</text>
<text top="697" left="92" width="327" height="12" font="12">disease in the Coronary Artery Surgery Study (CASS). CASS</text>
<text top="711" left="92" width="327" height="12" font="12">Participating Investigators and Staff. J Am Coll Cardiol. 1993;22:</text>
<text top="725" left="92" width="45" height="12" font="12">1141–54.</text>
<text top="739" left="65" width="354" height="12" font="12">598. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term</text>
<text top="752" left="92" width="327" height="12" font="12">intensified insulin treatment on the development of microvascular</text>
<text top="766" left="92" width="327" height="12" font="12">complications of diabetes mellitus. N Engl J Med. 1993;329:304 –9.</text>
<text top="780" left="65" width="354" height="12" font="12">599. McCormack J, Greenhalgh T. Seeing what you want to see in</text>
<text top="794" left="92" width="327" height="12" font="12">randomised controlled trials: versions and perversions of UKPDS</text>
<text top="807" left="92" width="327" height="12" font="12">data. United Kingdom prospective diabetes study. BMJ. 2000;320:</text>
<text top="821" left="92" width="40" height="12" font="12">1720 –3.</text>
<text top="835" left="65" width="354" height="12" font="12">600. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive</text>
<text top="849" left="92" width="327" height="12" font="12">glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:</text>
<text top="863" left="92" width="47" height="12" font="12">2545–59.</text>
<text top="876" left="65" width="354" height="12" font="12">601. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and</text>
<text top="890" left="92" width="327" height="12" font="12">cardiovascular disease in patients with type 2 diabetes. N Engl</text>
<text top="904" left="92" width="125" height="12" font="12">J Med. 2003;348:383–93.</text>
<text top="918" left="65" width="354" height="12" font="12">602. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilita-</text>
<text top="931" left="92" width="327" height="12" font="12">tion for patients with coronary heart disease: systematic review and</text>
<text top="945" left="92" width="327" height="12" font="12">meta-analysis of randomized controlled trials. Am J Med. 2004;116:</text>
<text top="959" left="92" width="39" height="12" font="12">682–92.</text>
<text top="973" left="65" width="354" height="12" font="12">603. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public</text>
<text top="987" left="92" width="327" height="12" font="12">health: updated recommendation for adults from the American</text>
<text top="1000" left="92" width="327" height="12" font="12">College of Sports Medicine and the American Heart Association.</text>
<text top="1014" left="92" width="155" height="12" font="12">Circulation. 2007;116:1081–93.</text>
<text top="1028" left="65" width="354" height="12" font="12">604. US Department of Health and Human Services. 2008 Physical</text>
<text top="1042" left="92" width="295" height="12" font="12">Activity Guidelines for Americans. Washington, DC: 2008.</text>
<text top="1055" left="65" width="354" height="12" font="12">605. Ken-Dror G, Lerman Y, Segev S, et al. [Development of a Hebrew</text>
<text top="1069" left="92" width="327" height="12" font="12">questionnaire to be used in epidemiological studies to assess physical</text>
<text top="1083" left="92" width="327" height="12" font="12">fitness—validation against sub maximal stress test and predicted</text>
<text top="1097" left="92" width="222" height="12" font="12">VO2max]. Harefuah. 2004;143:566 –72, 623.</text>
<text top="104" left="452" width="354" height="12" font="12">606. Cardinal BJ. Predicting cardiorespiratory fitness without exercise</text>
<text top="118" left="479" width="327" height="12" font="12">testing in epidemiologic studies: a concurrent validity study. J</text>
<text top="132" left="479" width="121" height="12" font="12">Epidemiol. 1996;6:31–5.</text>
<text top="146" left="452" width="354" height="12" font="12">607. Nowak Z, Plewa M, Skowron M, et al. Paffenbarger Physical</text>
<text top="160" left="479" width="327" height="12" font="12">Activity Questionnaire as an additional tool in clinical assessment of</text>
<text top="174" left="479" width="327" height="12" font="12">patients with coronary artery disease treated with angioplasty.</text>
<text top="188" left="479" width="133" height="12" font="12">Kardiol Pol. 2010;68:32–9.</text>
<text top="202" left="452" width="354" height="12" font="12">608. Jurca R, Jackson AS, LaMonte MJ, et al. Assessing cardiorespiratory</text>
<text top="216" left="479" width="327" height="12" font="12">fitness without performing exercise testing. Am J Prev Med.</text>
<text top="230" left="479" width="81" height="12" font="12">2005;29:185–93.</text>
<text top="244" left="452" width="354" height="12" font="12">609. Taylor RS, Dalal H, Jolly K, et al. Home-based versus centre-based</text>
<text top="258" left="479" width="327" height="12" font="12">cardiac rehabilitation. Cochrane Database of Systematic Reviews</text>
<text top="272" left="479" width="221" height="12" font="12">CD007130. 2010. Accessed January 6, 2012.</text>
<text top="286" left="452" width="354" height="12" font="12">610. Clark AM, Haykowsky M, Kryworuchko J, et al. A meta-analysis of</text>
<text top="300" left="479" width="327" height="12" font="12">randomized control trials of home-based secondary prevention</text>
<text top="314" left="479" width="327" height="12" font="12">programs for coronary artery disease. Eur J Cardiovasc Prev Rehabil.</text>
<text top="328" left="479" width="81" height="12" font="12">2010;17:261–70.</text>
<text top="342" left="452" width="354" height="12" font="12">611. McCartney N, McKelvie RS, Haslam DR, et al. Usefulness of</text>
<text top="356" left="479" width="327" height="12" font="12">weightlifting training in improving strength and maximal power</text>
<text top="370" left="479" width="326" height="12" font="12">output in coronary artery disease. Am J Cardiol. 1991;67:939 – 45.</text>
<text top="384" left="452" width="354" height="12" font="12">612. Beniamini Y, Rubenstein JJ, Faigenbaum AD, et al. High-intensity</text>
<text top="398" left="479" width="327" height="12" font="12">strength training of patients enrolled in an outpatient cardiac</text>
<text top="412" left="479" width="302" height="12" font="12">rehabilitation program. J Cardiopulm Rehabil. 1999;19:8 –17.</text>
<text top="426" left="452" width="354" height="12" font="12">613. Centers for Disease Control and Prevention. 2008 Physical Activity</text>
<text top="440" left="479" width="57" height="12" font="12">Guidelines.</text>
<text top="440" left="544" width="37" height="12" font="40"><a href="http://cdc.gov">cdc.gov</a></text>
<text top="440" left="581" width="114" height="12" font="12"><a href="http://cdc.gov">. </a>2008. Available at:</text>
<text top="440" left="703" width="103" height="12" font="37"><a href="http://www.cdc.gov/physicalactivity/everyone/guidelines/">http://www.cdc.gov/</a></text>
<text top="454" left="479" width="179" height="12" font="37"><a href="http://www.cdc.gov/physicalactivity/everyone/guidelines/">physicalactivity/everyone/guidelines/.</a></text>
<text top="454" left="662" width="120" height="12" font="12">Accessed May 20, 2010.</text>
<text top="468" left="452" width="354" height="12" font="12">614. Thomas RJ, King M, Lui K, et al. AACVPR/ACCF/AHA 2010</text>
<text top="482" left="479" width="327" height="12" font="12">update: performance measures on cardiac rehabilitation for referral</text>
<text top="496" left="479" width="327" height="12" font="12">to cardiac rehabilitation/secondary prevention services: a report of</text>
<text top="510" left="479" width="327" height="12" font="12">the American Association of Cardiovascular and Pulmonary Reha-</text>
<text top="524" left="479" width="327" height="12" font="12">bilitation and the American College of Cardiology Foundation/</text>
<text top="538" left="479" width="327" height="12" font="12">American Heart Association Task Force on Performance Measures</text>
<text top="552" left="479" width="327" height="12" font="12">(Writing Committee to Develop Clinical Performance Measures for</text>
<text top="566" left="479" width="311" height="12" font="12">Cardiac Rehabilitation). J Am Coll Cardiol. 2010;56:1159 – 67.</text>
<text top="580" left="452" width="354" height="12" font="12">615. Froelicher V, Jensen D, Genter F, et al. A randomized trial of</text>
<text top="594" left="479" width="327" height="12" font="12">exercise training in patients with coronary heart disease. JAMA.</text>
<text top="608" left="479" width="87" height="12" font="12">1984;252:1291–7.</text>
<text top="622" left="452" width="354" height="12" font="12">616. Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of</text>
<text top="636" left="479" width="327" height="12" font="12">leisure time physical activity in patients with coronary artery disease:</text>
<text top="650" left="479" width="327" height="12" font="12">effects on cardiorespiratory fitness and progression of coronary</text>
<text top="664" left="479" width="295" height="12" font="12">atherosclerotic lesions. J Am Coll Cardiol. 1993;22:468 –77.</text>
<text top="678" left="452" width="354" height="12" font="12">617. May GA, Nagle FJ. Changes in rate-pressure product with physical</text>
<text top="692" left="479" width="327" height="12" font="12">training of individuals with coronary artery disease. Phys Ther.</text>
<text top="706" left="479" width="83" height="12" font="12">1984;64:1361– 6.</text>
<text top="720" left="452" width="354" height="12" font="12">618. Oldridge NB, McCartney N, Hicks A, et al. Improvement in</text>
<text top="734" left="479" width="327" height="12" font="12">maximal isokinetic cycle ergometry with cardiac rehabilitation. Med</text>
<text top="748" left="479" width="171" height="12" font="12">Sci Sports Exerc. 1989;21:308 –12.</text>
<text top="762" left="452" width="354" height="12" font="12">619. Ornish D, Scherwitz LW, Doody RS, et al. Effects of stress</text>
<text top="775" left="479" width="327" height="12" font="12">management training and dietary changes in treating ischemic heart</text>
<text top="789" left="479" width="158" height="12" font="12">disease. JAMA. 1983;249:54 –9.</text>
<text top="803" left="452" width="354" height="12" font="12">620. Sebrechts CP, Klein JL, Ahnve S, et al. Myocardial perfusion</text>
<text top="817" left="479" width="327" height="12" font="12">changes following 1 year of exercise training assessed by thallium-</text>
<text top="831" left="479" width="327" height="12" font="12">201 circumferential count profiles. Am Heart J. 1986;112:1217–26.</text>
<text top="845" left="452" width="354" height="12" font="12">621. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise</text>
<text top="859" left="479" width="327" height="12" font="12">and low-fat diet. Effects on progression of coronary artery disease.</text>
<text top="873" left="479" width="131" height="12" font="12">Circulation. 1992;86:1–11.</text>
<text top="887" left="452" width="354" height="12" font="12">622. Todd IC, Ballantyne D. Effect of exercise training on the total</text>
<text top="901" left="479" width="327" height="12" font="12">ischaemic burden: an assessment by 24 hour ambulatory electrocar-</text>
<text top="915" left="479" width="254" height="12" font="12">diographic monitoring. Br Heart J. 1992;68:560 – 6.</text>
<text top="929" left="452" width="354" height="12" font="12">623. Rauramaa R, Li G, Vaisanen SB. Dose-response and coagulation</text>
<text top="943" left="479" width="327" height="12" font="12">and hemostatic factors. Med Sci Sports Exerc. 2001;33:S516 –S520.</text>
<text top="957" left="452" width="354" height="12" font="12">624. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein</text>
<text top="971" left="479" width="327" height="12" font="12">through cardiac rehabilitation and exercise training. J Am Coll</text>
<text top="985" left="479" width="134" height="12" font="12">Cardiol. 2004;43:1056 – 61.</text>
<text top="999" left="452" width="354" height="12" font="12">625. Blumenthal JA, Sherwood A, Babyak MA, et al. Effects of exercise</text>
<text top="1013" left="479" width="327" height="12" font="12">and stress management training on markers of cardiovascular risk in</text>
<text top="1027" left="479" width="327" height="12" font="12">patients with ischemic heart disease: a randomized controlled trial.</text>
<text top="1041" left="479" width="135" height="12" font="12">JAMA. 2005;293:1626 –34.</text>
<text top="1055" left="452" width="354" height="12" font="12">626. Hambrecht R, Adams V, Erbs S, et al. Regular physical activity</text>
<text top="1069" left="479" width="327" height="12" font="12">improves endothelial function in patients with coronary artery</text>
<text top="1083" left="479" width="327" height="12" font="12">disease by increasing phosphorylation of endothelial nitric oxide</text>
<text top="1097" left="479" width="198" height="12" font="12">synthase. Circulation. 2003;107:3152– 8.</text>
<text top="52" left="781" width="25" height="10" font="12">e143</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="101" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">627. Hosokawa S, Hiasa Y, Takahashi T, et al. Effect of regular exercise</text>
<text top="118" left="92" width="327" height="12" font="12">on coronary endothelial function in patients with recent myocardial</text>
<text top="132" left="92" width="167" height="12" font="12">infarction. Circ J. 2003;67:221– 4.</text>
<text top="145" left="65" width="354" height="12" font="12">628. Goldsmith RL, Bloomfield DM, Rosenwinkel ET. Exercise and</text>
<text top="159" left="92" width="280" height="12" font="12">autonomic function. Coron Artery Dis. 2000;11:129 –35.</text>
<text top="172" left="65" width="354" height="12" font="12">629. Malfatto G, Blengino S, Annoni L, et al. Original articles primary</text>
<text top="186" left="92" width="327" height="12" font="12">coronary angioplasty and subsequent cardiovascular rehabilitation</text>
<text top="200" left="92" width="327" height="12" font="12">are linked to a favorable sympathovagal balance after a first anterior</text>
<text top="213" left="92" width="238" height="12" font="12">myocardial infarction. Ital Heart J. 2005;6:21–7.</text>
<text top="227" left="65" width="354" height="12" font="12">630. Digenio AG, Sim JG, Dowdeswell RJ, et al. Exercise-related</text>
<text top="240" left="92" width="327" height="12" font="12">cardiac arrest in cardiac rehabilitation. The Johannesburg experi-</text>
<text top="254" left="92" width="181" height="12" font="12">ence. S Afr Med J. 1991;79:188 –91.</text>
<text top="268" left="65" width="354" height="12" font="12">631. Franklin BA, Bonzheim K, Gordon S, et al. Safety of medically</text>
<text top="281" left="92" width="327" height="12" font="12">supervised outpatient cardiac rehabilitation exercise therapy: a 16-</text>
<text top="295" left="92" width="196" height="12" font="12">year follow-up. Chest. 1998;114:902– 6.</text>
<text top="308" left="65" width="354" height="12" font="12">632. Van Camp SP, Peterson RA. Cardiovascular complications of</text>
<text top="322" left="92" width="327" height="12" font="12">outpatient cardiac rehabilitation programs. JAMA. 1986;256:</text>
<text top="336" left="92" width="40" height="12" font="12">1160 –3.</text>
<text top="349" left="65" width="354" height="12" font="12">633. Vongvanich P, Paul-Labrador MJ, Merz CN. Safety of medically</text>
<text top="363" left="92" width="327" height="12" font="12">supervised exercise in a cardiac rehabilitation center. Am J Cardiol.</text>
<text top="376" left="92" width="81" height="12" font="12">1996;77:1383–5.</text>
<text top="390" left="65" width="354" height="12" font="12">634. Rehabilitation after cardiovascular diseases, with special emphasis</text>
<text top="404" left="92" width="327" height="12" font="12">on developing countries. Report of a WHO Expert Committee.</text>
<text top="417" left="92" width="266" height="12" font="12">World Health Organ Tech Rep Ser. 1993;831:1–122.</text>
<text top="431" left="65" width="354" height="12" font="12">635. Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of</text>
<text top="444" left="92" width="327" height="12" font="12">overweight with increased risk of coronary heart disease partly</text>
<text top="458" left="92" width="327" height="12" font="12">independent of blood pressure and cholesterol levels: a meta-analysis</text>
<text top="471" left="92" width="327" height="12" font="12">of 21 cohort studies including more than 300 000 persons. Arch</text>
<text top="485" left="92" width="154" height="12" font="12">Intern Med. 2007;167:1720 – 8.</text>
<text top="499" left="65" width="354" height="12" font="12">636. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity</text>
<text top="512" left="92" width="327" height="12" font="12">with specific focus on cardiovascular disease: a statement for</text>
<text top="526" left="92" width="327" height="12" font="12">professionals from the American Heart Association Council on</text>
<text top="539" left="92" width="327" height="12" font="12">Nutrition, Physical Activity, and Metabolism. Circulation. 2004;</text>
<text top="553" left="92" width="68" height="12" font="12">110:2952– 67.</text>
<text top="567" left="65" width="354" height="12" font="12">637. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and</text>
<text top="580" left="92" width="327" height="12" font="12">mortality in a prospective cohort of U.S. adults. N Engl J Med.</text>
<text top="594" left="92" width="99" height="12" font="12">1999;341:1097–105.</text>
<text top="607" left="65" width="354" height="12" font="12">638. Jensen MK, Chiuve SE, Rimm EB, et al. Obesity, behavioral</text>
<text top="621" left="92" width="327" height="12" font="12">lifestyle factors, and risk of acute coronary events. Circulation.</text>
<text top="635" left="92" width="87" height="12" font="12">2008;117:3062–9.</text>
<text top="648" left="65" width="354" height="12" font="12">639. Arnlov J, Ingelsson E, Sundstrom J, et al. Impact of body mass index</text>
<text top="662" left="92" width="327" height="12" font="12">and the metabolic syndrome on the risk of cardiovascular disease and</text>
<text top="675" left="92" width="283" height="12" font="12">death in middle-aged men. Circulation. 2010;121:230 – 6.</text>
<text top="689" left="65" width="354" height="12" font="12">640. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular</text>
<text top="702" left="92" width="327" height="12" font="12">disease: risk factor, paradox, and impact of weight loss. J Am Coll</text>
<text top="716" left="92" width="131" height="12" font="12">Cardiol. 2009;53:1925–32.</text>
<text top="730" left="65" width="354" height="12" font="12">641. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity</text>
<text top="743" left="92" width="327" height="12" font="12">on the short-term and long-term outcomes after percutaneous</text>
<text top="757" left="92" width="327" height="12" font="12">coronary intervention: the obesity paradox? J Am Coll Cardiol.</text>
<text top="770" left="92" width="84" height="12" font="12">2002;39:578 – 84.</text>
<text top="784" left="65" width="354" height="12" font="12">642. Jacobs EJ, Newton CC, Wang Y, et al. Waist circumference and</text>
<text top="798" left="92" width="327" height="12" font="12">all-cause mortality in a large US cohort. Arch Intern Med. 2010;</text>
<text top="811" left="92" width="72" height="12" font="12">170:1293–301.</text>
<text top="825" left="65" width="354" height="12" font="12">643. Hsieh SD, Yoshinaga H. Abdominal fat distribution and coronary</text>
<text top="838" left="92" width="327" height="12" font="12">heart disease risk factors in men-waist/height ratio as a simple and</text>
<text top="852" left="92" width="320" height="12" font="12">useful predictor. Int J Obes Relat Metab Disord. 1995;19:585–9.</text>
<text top="865" left="65" width="354" height="12" font="12">644. Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat</text>
<text top="879" left="92" width="327" height="12" font="12">distribution as predictors of coronary heart disease among middle-</text>
<text top="893" left="92" width="306" height="12" font="12">aged and older US men. Am J Epidemiol. 1995;141:1117–27.</text>
<text top="906" left="65" width="354" height="12" font="12">645. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac</text>
<text top="920" left="92" width="327" height="12" font="12">and vascular outcomes in extremely obese women. JAMA.</text>
<text top="933" left="92" width="87" height="12" font="12">2006;296:79 – 86.</text>
<text top="947" left="65" width="354" height="12" font="12">646. Pi-Sunyer FX. The obesity epidemic: pathophysiology and conse-</text>
<text top="961" left="92" width="287" height="12" font="12">quences of obesity. Obes Res. 2002;10 Suppl 2:97S–104S.</text>
<text top="974" left="65" width="354" height="12" font="12">647. Romero-Corral A, Montori VM, Somers VK, et al. Association of</text>
<text top="988" left="92" width="327" height="12" font="12">bodyweight with total mortality and with cardiovascular events in</text>
<text top="1001" left="92" width="327" height="12" font="12">coronary artery disease: a systematic review of cohort studies.</text>
<text top="1015" left="92" width="129" height="12" font="12">Lancet. 2006;368:666 –78.</text>
<text top="1028" left="65" width="354" height="12" font="12">648. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric</text>
<text top="1042" left="92" width="327" height="12" font="12">surgery on mortality in Swedish obese subjects. N Engl J Med.</text>
<text top="1056" left="92" width="87" height="12" font="12">2007;357:741–52.</text>
<text top="1069" left="65" width="354" height="12" font="12">649. Lopez-Jimenez F, Bhatia S, Collazo-Clavell ML, et al. Safety and</text>
<text top="1083" left="92" width="327" height="12" font="12">efficacy of bariatric surgery in patients with coronary artery disease.</text>
<text top="1096" left="92" width="176" height="12" font="12">Mayo Clin Proc. 2005;80:1157– 62.</text>
<text top="104" left="452" width="354" height="12" font="12">650. Critchley J, Capewell S. Smoking cessation for the secondary</text>
<text top="118" left="479" width="327" height="12" font="12">prevention of coronary heart disease. Cochrane Database Syst Rev.</text>
<text top="131" left="479" width="85" height="12" font="12">2003;CD003041.</text>
<text top="145" left="452" width="354" height="12" font="12">651. Rigotti NA. Helping smokers with cardiac disease to abstain from</text>
<text top="159" left="479" width="286" height="12" font="12">tobacco after a stay in hospital. CMAJ. 2009;180:1283– 4.</text>
<text top="172" left="452" width="354" height="12" font="12">652. Smith PM, Burgess E. Smoking cessation initiated during hospital</text>
<text top="186" left="479" width="327" height="12" font="12">stay for patients with coronary artery disease: a randomized con-</text>
<text top="199" left="479" width="202" height="12" font="12">trolled trial. CMAJ. 2009;180:1297–303.</text>
<text top="213" left="452" width="354" height="12" font="12">653. Doll R, Peto R. Mortality in relation to smoking: 20 years’</text>
<text top="227" left="479" width="321" height="12" font="12">observations on male British doctors. Br Med J. 1976;2:1525–36.</text>
<text top="240" left="452" width="354" height="12" font="12">654. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute</text>
<text top="254" left="479" width="327" height="12" font="12">excess risks of coronary heart disease among women who smoke</text>
<text top="267" left="479" width="219" height="12" font="12">cigarettes. N Engl J Med. 1987;317:1303–9.</text>
<text top="281" left="452" width="354" height="12" font="12">655. Kannel WB, D’Agostino RB, Belanger AJ. Fibrinogen, cigarette</text>
<text top="294" left="479" width="327" height="12" font="12">smoking, and risk of cardiovascular disease: insights from the</text>
<text top="308" left="479" width="262" height="12" font="12">Framingham Study. Am Heart J. 1987;113:1006 –10.</text>
<text top="322" left="452" width="354" height="12" font="12">656. Davis JW, Hartman CR, Lewis HD Jr., et al. Cigarette smoking—</text>
<text top="335" left="479" width="327" height="12" font="12">induced enhancement of platelet function: lack of prevention by</text>
<text top="349" left="479" width="327" height="12" font="12">aspirin in men with coronary artery disease. J Lab Clin Med.</text>
<text top="362" left="479" width="90" height="12" font="12">1985;105:479 – 83.</text>
<text top="376" left="452" width="354" height="12" font="12">657. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smok-</text>
<text top="390" left="479" width="327" height="12" font="12">ing impairs endothelium-dependent coronary arterial vasodilator</text>
<text top="403" left="479" width="204" height="12" font="12">function. Circulation. 1995;92:1094 –100.</text>
<text top="417" left="452" width="354" height="12" font="12">658. Taylor AE, Johnson DC, Kazemi H. Environmental tobacco smoke</text>
<text top="430" left="479" width="327" height="12" font="12">and cardiovascular disease. A position paper from the Council on</text>
<text top="444" left="479" width="327" height="12" font="12">Cardiopulmonary and Critical Care, American Heart Association.</text>
<text top="458" left="479" width="150" height="12" font="12">Circulation. 1992;86:699 –702.</text>
<text top="471" left="452" width="354" height="12" font="12">659. Winniford MD, Jansen DE, Reynolds GA, et al. Cigarette</text>
<text top="485" left="479" width="327" height="12" font="12">smoking-induced coronary vasoconstriction in atherosclerotic coro-</text>
<text top="498" left="479" width="327" height="12" font="12">nary artery disease and prevention by calcium antagonists and</text>
<text top="512" left="479" width="218" height="12" font="12">nitroglycerin. Am J Cardiol. 1987;59:203–7.</text>
<text top="526" left="452" width="354" height="12" font="12">660. Dobson AJ, Alexander HM, Heller RF, et al. How soon after</text>
<text top="539" left="479" width="327" height="12" font="12">quitting smoking does risk of heart attack decline? J Clin Epidemiol.</text>
<text top="553" left="479" width="87" height="12" font="12">1991;44:1247–53.</text>
<text top="566" left="452" width="354" height="12" font="12">661. Gordon T, Kannel WB, McGee D, et al. Death and coronary</text>
<text top="580" left="479" width="327" height="12" font="12">attacks in men after giving up cigarette smoking. A report from the</text>
<text top="594" left="479" width="216" height="12" font="12">Framingham study. Lancet. 1974;2:1345– 8.</text>
<text top="607" left="452" width="354" height="12" font="12">662. Gorin SS, Heck JE. Meta-analysis of the efficacy of tobacco</text>
<text top="621" left="479" width="327" height="12" font="12">counseling by health care providers. Cancer Epidemiol Biomarkers</text>
<text top="634" left="479" width="116" height="12" font="12">Prev. 2004;13:2012–22.</text>
<text top="648" left="452" width="354" height="12" font="12">663. Hughes JR. Motivating and helping smokers to stop smoking.</text>
<text top="661" left="479" width="179" height="12" font="12">J Gen Intern Med. 2003;18:1053–7.</text>
<text top="675" left="452" width="354" height="12" font="12">664. Lancaster T, Stead LF. Individual behavioural counselling for</text>
<text top="689" left="479" width="327" height="12" font="12">smoking cessation. Cochrane Database Syst Rev. 2005;CD001292.</text>
<text top="702" left="452" width="354" height="12" font="12">665. Stead LF, Lancaster T. Group behaviour therapy programmes for</text>
<text top="716" left="479" width="327" height="12" font="12">smoking cessation. Cochrane Database Syst Rev. 2005;CD001007.</text>
<text top="729" left="452" width="354" height="12" font="12">666. Stead LF, Lancaster T, Perera R. Telephone counselling for</text>
<text top="743" left="479" width="327" height="12" font="12">smoking cessation. Cochrane Database Syst Rev. 2003;CD002850.</text>
<text top="757" left="452" width="354" height="12" font="12">667. Ussher M. Exercise interventions for smoking cessation. Cochrane</text>
<text top="770" left="479" width="183" height="12" font="12">Database Syst Rev. 2005;CD002295.</text>
<text top="784" left="452" width="354" height="12" font="12">668. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy</text>
<text top="797" left="479" width="327" height="12" font="12">for smoking cessation. Cochrane Database Syst Rev. 2004;</text>
<text top="811" left="479" width="58" height="12" font="12">CD000146.</text>
<text top="824" left="452" width="354" height="12" font="12">669. Hughes J, Stead L, Lancaster T. Antidepressants for smoking</text>
<text top="838" left="479" width="284" height="12" font="12">cessation. Cochrane Database Syst Rev. 2004;CD000031.</text>
<text top="852" left="452" width="354" height="12" font="12">670. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an</text>
<text top="865" left="479" width="327" height="12" font="12">alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs</text>
<text top="879" left="479" width="327" height="12" font="12">sustained-release bupropion and placebo for smoking cessation: a</text>
<text top="892" left="479" width="262" height="12" font="12">randomized controlled trial. JAMA. 2006;296:47–55.</text>
<text top="906" left="452" width="354" height="12" font="12">671. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an</text>
<text top="920" left="479" width="327" height="12" font="12">alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs</text>
<text top="933" left="479" width="327" height="12" font="12">placebo or sustained-release bupropion for smoking cessation: a</text>
<text top="947" left="479" width="258" height="12" font="12">randomized controlled trial. JAMA. 2006;296:5– 63.</text>
<text top="960" left="452" width="354" height="12" font="12">672. US Food and Drug Administration. Information for Healthcare</text>
<text top="974" left="479" width="327" height="12" font="12">Professionals. Varenicline (marketed as Chantix). Center for Drug</text>
<text top="987" left="479" width="224" height="12" font="12">Evaluation and Research. 2008. Available at:</text>
<text top="987" left="707" width="99" height="12" font="37"><a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124818.htm">http://www.fda.gov/</a></text>
<text top="1001" left="479" width="328" height="12" font="37"><a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124818.htm">Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand</a></text>
<text top="1015" left="479" width="127" height="12" font="37"><a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124818.htm">Providers/ucm124818.htm.</a></text>
<text top="1015" left="609" width="126" height="12" font="12">Accessed October 9, 2008.</text>
<text top="1028" left="452" width="354" height="12" font="12">673. US Food and Drug Administration. Public Health Advisory.</text>
<text top="1042" left="479" width="327" height="12" font="12">Important Information on Chantix (varenicline). Center for Drug</text>
<text top="1055" left="479" width="224" height="12" font="12">Evaluation and Research. 2008. Available at:</text>
<text top="1055" left="707" width="99" height="12" font="37"><a href="http://www.fda.gov/cder/drug/advisory/varenicline.htm">http://www.fda.gov/</a></text>
<text top="1069" left="479" width="172" height="12" font="37"><a href="http://www.fda.gov/cder/drug/advisory/varenicline.htm">cder/drug/advisory/varenicline.htm.</a></text>
<text top="1069" left="655" width="132" height="12" font="12">Accessed October 9, 2008.</text>
<text top="1083" left="452" width="354" height="12" font="12">674. Honig A, Kuyper AM, Schene AH, et al. Treatment of post-</text>
<text top="1096" left="479" width="327" height="12" font="12">myocardial infarction depressive disorder: a randomized, placebo-</text>
<text top="52" left="59" width="25" height="10" font="12">e144</text>
<text top="52" left="113" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="102" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="92" width="327" height="12" font="12">controlled trial with mirtazapine. Psychosom Med. 2007;69:</text>
<text top="118" left="92" width="40" height="12" font="12">606 –13.</text>
<text top="132" left="64" width="354" height="12" font="12">675. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk</text>
<text top="145" left="92" width="327" height="12" font="12">factor for noncompliance with medical treatment: meta-analysis of</text>
<text top="159" left="92" width="327" height="12" font="12">the effects of anxiety and depression on patient adherence. Arch</text>
<text top="172" left="92" width="152" height="12" font="12">Intern Med. 2000;160:2101–7.</text>
<text top="186" left="64" width="354" height="12" font="12">676. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antide-</text>
<text top="200" left="92" width="327" height="12" font="12">pressant medication on morbidity and mortality in depressed pa-</text>
<text top="213" left="92" width="327" height="12" font="12">tients after myocardial infarction. Arch Gen Psychiatry. 2005;62:</text>
<text top="227" left="92" width="34" height="12" font="12">792– 8.</text>
<text top="240" left="64" width="354" height="12" font="12">677. Murray CJ, Lopez AD. Global mortality, disability, and the</text>
<text top="254" left="92" width="327" height="12" font="12">contribution of risk factors: Global Burden of Disease Study.</text>
<text top="268" left="92" width="136" height="12" font="12">Lancet. 1997;349:1436 – 42.</text>
<text top="281" left="64" width="354" height="12" font="12">678. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic</text>
<text top="295" left="92" width="327" height="12" font="12">diseases, and decrements in health: results from the World Health</text>
<text top="308" left="92" width="167" height="12" font="12">Surveys. Lancet. 2007;370:851– 8.</text>
<text top="322" left="64" width="354" height="12" font="12">679. Carney RM, Rich MW, Tevelde A, et al. Major depressive disorder</text>
<text top="336" left="92" width="287" height="12" font="12">in coronary artery disease. Am J Cardiol. 1987;60:1273–5.</text>
<text top="349" left="64" width="354" height="12" font="12">680. Frasure-Smith N, Lesperance F, Talajic M. Depression following</text>
<text top="363" left="92" width="327" height="12" font="12">myocardial infarction. Impact on –month survival. JAMA. 1993;</text>
<text top="376" left="92" width="68" height="12" font="12">270:1819 –25.</text>
<text top="390" left="64" width="354" height="12" font="12">681. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary</text>
<text top="404" left="92" width="312" height="12" font="12">artery disease and depression. Biol Psychiatry. 2003;54:227– 40.</text>
<text top="417" left="64" width="354" height="12" font="12">682. Schleifer SJ, ari-Hinson MM, Coyle DA, et al. The nature and</text>
<text top="431" left="92" width="327" height="12" font="12">course of depression following myocardial infarction. Arch Intern</text>
<text top="444" left="92" width="117" height="12" font="12">Med. 1989;149:1785–9.</text>
<text top="458" left="64" width="354" height="12" font="12">683. Spertus JA, McDonell M, Woodman CL, et al. Association between</text>
<text top="471" left="92" width="327" height="12" font="12">depression and worse disease-specific functional status in outpatients</text>
<text top="485" left="92" width="283" height="12" font="12">with coronary artery disease. Am Heart J. 2000;140:105–10.</text>
<text top="499" left="64" width="354" height="12" font="12">684. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic</text>
<text top="512" left="92" width="327" height="12" font="12">and prognostic factor in coronary heart disease: a meta-analysis of</text>
<text top="526" left="92" width="327" height="12" font="12">6362 events among 146 538 participants in 54 observational studies.</text>
<text top="539" left="92" width="153" height="12" font="12">Eur Heart J. 2006;27:2763–74.</text>
<text top="553" left="64" width="354" height="12" font="12">685. Bonnet F, Irving K, Terra JL, et al. Anxiety and depression are</text>
<text top="567" left="92" width="327" height="12" font="12">associated with unhealthy lifestyle in patients at risk of cardiovas-</text>
<text top="580" left="92" width="238" height="12" font="12">cular disease. Atherosclerosis. 2005;178:339 – 44.</text>
<text top="594" left="64" width="354" height="12" font="12">686. Caulin-Glaser T, Maciejewski PK, Snow R, et al. Depressive</text>
<text top="607" left="92" width="327" height="12" font="12">symptoms and sex affect completion rates and clinical outcomes in</text>
<text top="621" left="92" width="254" height="12" font="12">cardiac rehabilitation. Prev Cardiol. 2007;10:15–21.</text>
<text top="635" left="64" width="354" height="12" font="12">687. Gehi A, Haas D, Pipkin S, et al. Depression and medication</text>
<text top="648" left="92" width="327" height="12" font="12">adherence in outpatients with coronary heart disease: findings from</text>
<text top="662" left="92" width="322" height="12" font="12">the Heart and Soul Study. Arch Intern Med. 2005;165:2508 –13.</text>
<text top="675" left="64" width="354" height="12" font="12">688. Kronish IM, Rieckmann N, Halm EA, et al. Persistent depression</text>
<text top="689" left="92" width="327" height="12" font="12">affects adherence to secondary prevention behaviors after acute</text>
<text top="702" left="92" width="292" height="12" font="12">coronary syndromes. J Gen Intern Med. 2006;21:1178 – 83.</text>
<text top="716" left="64" width="354" height="12" font="12">689. McKellar JD, Humphreys K, Piette JD. Depression increases</text>
<text top="730" left="92" width="327" height="12" font="12">diabetes symptoms by complicating patients’ self-care adherence.</text>
<text top="743" left="92" width="160" height="12" font="12">Diabetes Educ. 2004;30:485–92.</text>
<text top="757" left="64" width="354" height="12" font="12">690. Rieckmann N, Kronish IM, Haas D, et al. Persistent depressive</text>
<text top="770" left="92" width="327" height="12" font="12">symptoms lower aspirin adherence after acute coronary syndromes.</text>
<text top="784" left="92" width="147" height="12" font="12">Am Heart J. 2006;152:922–7.</text>
<text top="798" left="64" width="354" height="12" font="12">691. Rieckmann N, Gerin W, Kronish IM, et al. Course of depressive</text>
<text top="811" left="92" width="327" height="12" font="12">symptoms and medication adherence after acute coronary syn-</text>
<text top="825" left="92" width="327" height="12" font="12">dromes: an electronic medication monitoring study. J Am Coll</text>
<text top="838" left="92" width="132" height="12" font="12">Cardiol. 2006;48:2218 –22.</text>
<text top="852" left="64" width="354" height="12" font="12">692. Laghrissi-Thode F, Wagner WR, Pollock BG, et al. Elevated</text>
<text top="865" left="92" width="327" height="12" font="12">platelet factor 4 and beta-thromboglobulin plasma levels in de-</text>
<text top="879" left="92" width="327" height="12" font="12">pressed patients with ischemic heart disease. Biol Psychiatry. 1997;</text>
<text top="893" left="92" width="50" height="12" font="12">42:290 –5.</text>
<text top="906" left="64" width="354" height="12" font="12">693. Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated</text>
<text top="920" left="92" width="327" height="12" font="12">platelet reactivity in major depression. Am J Psychiatry. 1996;153:</text>
<text top="933" left="92" width="39" height="12" font="12">1313–7.</text>
<text top="947" left="64" width="354" height="12" font="12">694. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of</text>
<text top="961" left="92" width="327" height="12" font="12">platelet activation in depressed patients with ischemic heart disease</text>
<text top="974" left="92" width="327" height="12" font="12">after paroxetine or nortriptyline treatment. J Clin Psychopharmacol.</text>
<text top="988" left="92" width="83" height="12" font="12">2000;20:137– 40.</text>
<text top="1001" left="64" width="354" height="12" font="12">695. Shimbo D, Child J, Davidson K, et al. Exaggerated serotonin-</text>
<text top="1015" left="92" width="327" height="12" font="12">mediated platelet reactivity as a possible link in depression and acute</text>
<text top="1028" left="92" width="254" height="12" font="12">coronary syndromes. Am J Cardiol. 2002;89:331–3.</text>
<text top="1042" left="64" width="354" height="12" font="12">696. Sherwood A, Hinderliter AL, Watkins LL, et al. Impaired endo-</text>
<text top="1056" left="92" width="327" height="12" font="12">thelial function in coronary heart disease patients with depressive</text>
<text top="1069" left="92" width="263" height="12" font="12">symptomatology. J Am Coll Cardiol. 2005;46:656 –9.</text>
<text top="1083" left="64" width="354" height="12" font="12">697. Agelink MW, Boz C, Ullrich H, et al. Relationship between major</text>
<text top="1096" left="92" width="327" height="12" font="12">depression and heart rate variability. Clinical consequences and</text>
<text top="104" left="479" width="327" height="12" font="12">implications for antidepressive treatment. Psychiatry Res.</text>
<text top="118" left="479" width="90" height="12" font="12">2002;113:139 – 49.</text>
<text top="131" left="451" width="354" height="12" font="12">698. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate</text>
<text top="145" left="479" width="327" height="12" font="12">variability, and acute myocardial infarction. Circulation. 2001;104:</text>
<text top="159" left="479" width="42" height="12" font="12">2024 – 8.</text>
<text top="172" left="451" width="354" height="12" font="12">699. Gorman JM, Sloan RP. Heart rate variability in depressive and</text>
<text top="186" left="479" width="237" height="12" font="12">anxiety disorders. Am Heart J. 2000;140:77– 83.</text>
<text top="199" left="451" width="354" height="12" font="12">700. Kop WJ, Gottdiener JS, Tangen CM, et al. Inflammation and</text>
<text top="213" left="479" width="145" height="12" font="12">coagulation factors in persons</text>
<text top="210" left="627" width="179" height="16" font="12">⬎ 65 years of age with symptoms of</text>
<text top="227" left="479" width="327" height="12" font="12">depression but without evidence of myocardial ischemia. Am J</text>
<text top="240" left="479" width="126" height="12" font="12">Cardiol. 2002;89:419 –24.</text>
<text top="254" left="451" width="354" height="12" font="12">701. Whooley MA, Avins AL, Miranda J, et al. Case-finding instru-</text>
<text top="267" left="479" width="327" height="12" font="12">ments for depression. Two questions are as good as many. J Gen</text>
<text top="281" left="479" width="148" height="12" font="12">Intern Med. 1997;12:439 – 45.</text>
<text top="294" left="451" width="354" height="12" font="12">702. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief</text>
<text top="308" left="479" width="307" height="12" font="12">depression severity measure. J Gen Intern Med. 2001;16:606–13.</text>
<text top="322" left="451" width="354" height="12" font="12">703. Di Castelnuovo A., Rotondo S, Iacoviello L, et al. Meta-analysis of</text>
<text top="335" left="479" width="327" height="12" font="12">wine and beer consumption in relation to vascular risk. Circulation.</text>
<text top="349" left="479" width="96" height="12" font="12">2002;105:2836 – 44.</text>
<text top="362" left="451" width="354" height="12" font="12">704. Mukamal KJ, Maclure M, Muller JE, et al. Prior alcohol consump-</text>
<text top="376" left="479" width="327" height="12" font="12">tion and mortality following acute myocardial infarction. JAMA.</text>
<text top="390" left="479" width="93" height="12" font="12">2001;285:1965–70.</text>
<text top="403" left="451" width="354" height="12" font="12">705. Muntwyler J, Hennekens CH, Buring JE, et al. Mortality and light</text>
<text top="417" left="479" width="327" height="12" font="12">to moderate alcohol consumption after myocardial infarction. Lan-</text>
<text top="430" left="479" width="108" height="12" font="12">cet. 1998;352:1882–5.</text>
<text top="444" left="451" width="354" height="12" font="12">706. Greenfield JR, Samaras K, Hayward CS, et al. Beneficial postpran-</text>
<text top="458" left="479" width="327" height="12" font="12">dial effect of a small amount of alcohol on diabetes and cardiovas-</text>
<text top="471" left="479" width="327" height="12" font="12">cular risk factors: modification by insulin resistance. J Clin Endo-</text>
<text top="485" left="479" width="152" height="12" font="12">crinol Metab. 2005;90:661–72.</text>
<text top="498" left="451" width="354" height="12" font="12">707. Mukamal KJ, Mackey RH, Kuller LH, et al. Alcohol consumption</text>
<text top="512" left="479" width="327" height="12" font="12">and lipoprotein subclasses in older adults. J Clin Endocrinol Metab.</text>
<text top="526" left="479" width="90" height="12" font="12">2007;92:2559 – 66.</text>
<text top="539" left="451" width="354" height="12" font="12">708. Davies MJ, Baer DJ, Judd JT, et al. Effects of moderate alcohol</text>
<text top="553" left="479" width="327" height="12" font="12">intake on fasting insulin and glucose concentrations and insulin</text>
<text top="566" left="479" width="327" height="12" font="12">sensitivity in postmenopausal women: a randomized controlled trial.</text>
<text top="580" left="479" width="137" height="12" font="12">JAMA. 2002;287:2559 – 62.</text>
<text top="594" left="451" width="354" height="12" font="12">709. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and</text>
<text top="607" left="479" width="327" height="12" font="12">plasma concentration of C-reactive protein. Circulation. 2003;107:</text>
<text top="621" left="479" width="33" height="12" font="12">443–7.</text>
<text top="634" left="451" width="354" height="12" font="12">710. Sierksma A, van der Gaag MS, Kluft C, et al. Moderate alcohol</text>
<text top="648" left="479" width="327" height="12" font="12">consumption reduces plasma C-reactive protein and fibrinogen</text>
<text top="661" left="479" width="327" height="12" font="12">levels; a randomized, diet-controlled intervention study. Eur J Clin</text>
<text top="675" left="479" width="115" height="12" font="12">Nutr. 2002;56:1130 – 6.</text>
<text top="689" left="451" width="354" height="12" font="12">711. Naimi TS, Brown DW, Brewer RD, et al. Cardiovascular risk</text>
<text top="702" left="479" width="327" height="12" font="12">factors and confounders among nondrinking and moderate-drinking</text>
<text top="716" left="479" width="230" height="12" font="12">U.S. adults. Am J Prev Med. 2005;28:369 –73.</text>
<text top="729" left="451" width="354" height="12" font="12">712. Pope CA, III, Burnett RT, Thurston GD, et al. Cardiovascular</text>
<text top="743" left="479" width="327" height="12" font="12">mortality and long-term exposure to particulate air pollution:</text>
<text top="757" left="479" width="327" height="12" font="12">epidemiological evidence of general pathophysiological pathways of</text>
<text top="770" left="479" width="177" height="12" font="12">disease. Circulation. 2004;109:71–7.</text>
<text top="784" left="451" width="354" height="12" font="12">713. Pope CA, III, Muhlestein JB, May HT, et al. Ischemic heart disease</text>
<text top="797" left="479" width="327" height="12" font="12">events triggered by short-term exposure to fine particulate air</text>
<text top="811" left="479" width="201" height="12" font="12">pollution. Circulation. 2006;114:2443– 8.</text>
<text top="824" left="451" width="354" height="12" font="12">714. Pope CA, III.Mortality effects of longer term exposures to fine</text>
<text top="838" left="479" width="327" height="12" font="12">particulate air pollution: review of recent epidemiological evidence.</text>
<text top="852" left="479" width="186" height="12" font="12">Inhal Toxicol. 2007;19 Suppl 1:33– 8.</text>
<text top="865" left="451" width="354" height="12" font="12">715. Brook RD, Rajagopalan S, Pope CA, III, et al. Particulate matter air</text>
<text top="879" left="479" width="327" height="12" font="12">pollution and cardiovascular disease: An update to the scientific</text>
<text top="892" left="479" width="327" height="12" font="12">statement from the American Heart Association. Circulation. 2010;</text>
<text top="906" left="479" width="66" height="12" font="12">121:2331–78.</text>
<text top="920" left="451" width="354" height="12" font="12">716. Collaborative meta-analysis of randomised trials of antiplatelet</text>
<text top="933" left="479" width="327" height="12" font="12">therapy for prevention of death, myocardial infarction, and stroke in</text>
<text top="947" left="479" width="206" height="12" font="12">high risk patients. BMJ. 2002;324:71– 86.</text>
<text top="960" left="451" width="354" height="12" font="12">717. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial</text>
<text top="974" left="479" width="327" height="12" font="12">of aspirin in primary prevention of myocardial infarction in patients</text>
<text top="987" left="479" width="327" height="12" font="12">with stable chronic angina pectoris. The Swedish Angina Pectoris</text>
<text top="1001" left="479" width="287" height="12" font="12">Aspirin Trial (SAPAT) Group. Lancet. 1992;340:1421–5.</text>
<text top="1015" left="451" width="354" height="12" font="12">718. A randomised, blinded, trial of clopidogrel versus aspirin in patients</text>
<text top="1028" left="479" width="327" height="12" font="12">at risk of ischaemic events (CAPRIE). CAPRIE Steering Commit-</text>
<text top="1042" left="479" width="156" height="12" font="12">tee. Lancet. 1996;348:1329 –39.</text>
<text top="1055" left="451" width="354" height="12" font="12">719. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior</text>
<text top="1069" left="479" width="327" height="12" font="12">myocardial infarction, stroke, or symptomatic peripheral arterial</text>
<text top="1083" left="479" width="327" height="12" font="12">disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:</text>
<text top="1096" left="479" width="40" height="12" font="12">1982– 8.</text>
<text top="52" left="781" width="25" height="10" font="12">e145</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="103" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">720. Hirsh J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active</text>
<text top="118" left="92" width="327" height="12" font="12">drugs. The relationship among dose, effectiveness, and side effects.</text>
<text top="132" left="92" width="136" height="12" font="12">Chest. 1995;108:247S–57S.</text>
<text top="145" left="65" width="354" height="12" font="12">721. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with</text>
<text top="159" left="92" width="327" height="12" font="12">ticlopidine in unstable angina. A controlled multicenter clinical trial.</text>
<text top="172" left="92" width="327" height="12" font="12">The Studio della Ticlopidina nell’Angina Instabile Group. Circu-</text>
<text top="186" left="92" width="110" height="12" font="12">lation. 1990;82:17–26.</text>
<text top="200" left="65" width="354" height="12" font="12">722. The Persantine-aspirin reinfarction study. The Persantine-aspirin</text>
<text top="213" left="92" width="327" height="12" font="12">Reinfarction Study (PARIS) research group. Circulation. 1980;62:</text>
<text top="227" left="92" width="50" height="12" font="12">V85–V88.</text>
<text top="240" left="65" width="354" height="12" font="12">723. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when</text>
<text top="254" left="92" width="327" height="12" font="12">used alone or in combination with clopidogrel in patients with acute</text>
<text top="268" left="92" width="327" height="12" font="12">coronary syndromes: observations from the Clopidogrel in Unstable</text>
<text top="281" left="92" width="327" height="12" font="12">angina to prevent Recurrent Events (CURE) study. Circulation.</text>
<text top="295" left="92" width="87" height="12" font="12">2003;108:1682–7.</text>
<text top="308" left="65" width="354" height="12" font="12">724. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition</text>
<text top="322" left="92" width="327" height="12" font="12">to aspirin in patients with acute coronary syndromes without</text>
<text top="336" left="92" width="288" height="12" font="12">ST-segment elevation. N Engl J Med. 2001;345:494 –502.</text>
<text top="349" left="65" width="354" height="12" font="12">725. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained</text>
<text top="363" left="92" width="327" height="12" font="12">dual oral antiplatelet therapy following percutaneous coronary in-</text>
<text top="376" left="92" width="327" height="12" font="12">tervention: a randomized controlled trial. JAMA. 2002;288:</text>
<text top="390" left="92" width="45" height="12" font="12">2411–20.</text>
<text top="404" left="65" width="354" height="12" font="12">726. Helton TJ, Bavry AA, Kumbhani DJ, et al. Incremental effect of</text>
<text top="417" left="92" width="327" height="12" font="12">clopidogrel on important outcomes in patients with cardiovascular</text>
<text top="431" left="92" width="327" height="12" font="12">disease: a meta-analysis of randomized trials. Am J Cardiovasc</text>
<text top="444" left="92" width="114" height="12" font="12">Drugs. 2007;7:289 –97.</text>
<text top="458" left="65" width="354" height="12" font="12">727. Sirois C, Poirier P, Moisan J, et al. The benefit of aspirin therapy in</text>
<text top="471" left="92" width="327" height="12" font="12">type 2 diabetes: what is the evidence? Int J Cardiol. 2008;129:172–9.</text>
<text top="485" left="65" width="354" height="12" font="12">728. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of</text>
<text top="499" left="92" width="327" height="12" font="12">cytochrome P450 2C19 genotype with the antiplatelet effect and</text>
<text top="512" left="92" width="320" height="12" font="12">clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849 –57.</text>
<text top="526" left="65" width="354" height="12" font="12">729. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19</text>
<text top="539" left="92" width="327" height="12" font="12">polymorphism in young patients treated with clopidogrel after</text>
<text top="553" left="92" width="317" height="12" font="12">myocardial infarction: a cohort study. Lancet. 2009;373:309 –17.</text>
<text top="567" left="65" width="354" height="12" font="12">730. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 poly-</text>
<text top="580" left="92" width="327" height="12" font="12">morphisms and response to clopidogrel. N Engl J Med. 2009;360:</text>
<text top="594" left="92" width="42" height="12" font="12">354 – 62.</text>
<text top="607" left="65" width="354" height="12" font="12">731. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants</text>
<text top="621" left="92" width="327" height="12" font="12">of response to clopidogrel and cardiovascular events. N Engl J Med.</text>
<text top="635" left="92" width="87" height="12" font="12">2009;360:363–75.</text>
<text top="648" left="65" width="354" height="12" font="12">732. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and</text>
<text top="662" left="92" width="327" height="12" font="12">cardiovascular outcomes after percutaneous coronary intervention: a</text>
<text top="675" left="92" width="327" height="12" font="12">time-dependent analysis of the Gauging Responsiveness with a</text>
<text top="689" left="92" width="327" height="12" font="12">VerifyNow P2Y12 assay: Impact on Thrombosis and Safety</text>
<text top="702" left="92" width="251" height="12" font="12">(GRAVITAS) trial. Circulation. 2011;124:1132–7.</text>
<text top="716" left="65" width="354" height="12" font="12">733. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype</text>
<text top="730" left="92" width="327" height="12" font="12">on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:</text>
<text top="743" left="92" width="48" height="12" font="12">1704 –14.</text>
<text top="757" left="65" width="354" height="12" font="12">734. Gilard M, Arnaud B, Le GG, et al. Influence of omeprazol on the</text>
<text top="770" left="92" width="327" height="12" font="12">antiplatelet action of clopidogrel associated to aspirin. J Thromb</text>
<text top="784" left="92" width="128" height="12" font="12">Haemost. 2006;4:2508 –9.</text>
<text top="798" left="65" width="354" height="12" font="12">735. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on</text>
<text top="811" left="92" width="327" height="12" font="12">the antiplatelet action of clopidogrel associated with aspirin: the</text>
<text top="825" left="92" width="327" height="12" font="12">randomized, double-blind OCLA (Omeprazole CLopidogrel As-</text>
<text top="838" left="92" width="247" height="12" font="12">pirin) study. J Am Coll Cardiol. 2008;51:256 – 60.</text>
<text top="852" left="65" width="354" height="12" font="12">736. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of</text>
<text top="865" left="92" width="327" height="12" font="12">the drug interaction between proton pump inhibitors and clopi-</text>
<text top="879" left="92" width="161" height="12" font="12">dogrel. CMAJ. 2009;180:713– 8.</text>
<text top="893" left="65" width="354" height="12" font="12">737. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes</text>
<text top="906" left="92" width="327" height="12" font="12">associated with concomitant use of clopidogrel and proton pump</text>
<text top="920" left="92" width="327" height="12" font="12">inhibitors following acute coronary syndrome. JAMA. 2009;301:</text>
<text top="933" left="92" width="40" height="12" font="12">937– 44.</text>
<text top="947" left="65" width="354" height="12" font="12">738. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacody-</text>
<text top="961" left="92" width="327" height="12" font="12">namic effect and clinical efficacy of clopidogrel and prasugrel with or</text>
<text top="974" left="92" width="327" height="12" font="12">without a proton-pump inhibitor: an analysis of two randomised</text>
<text top="988" left="92" width="160" height="12" font="12">trials. Lancet. 2009;374:989 –97.</text>
<text top="1001" left="65" width="354" height="12" font="12">739. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or</text>
<text top="1015" left="92" width="327" height="12" font="12">without omeprazole in coronary artery disease. N Engl J Med.</text>
<text top="1028" left="92" width="95" height="12" font="12">2010;363:1909 –17.</text>
<text top="1042" left="65" width="354" height="12" font="12">740. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibi-</text>
<text top="1056" left="92" width="327" height="12" font="12">tory effects of the proton pump-inhibiting drugs omeprazole,</text>
<text top="1069" left="92" width="327" height="12" font="12">esomeprazole, lansoprazole, pantoprazole, and rabeprazole on hu-</text>
<text top="1083" left="92" width="327" height="12" font="12">man cytochrome P450 activities. Drug Metab Dispos. 2004;32:</text>
<text top="1096" left="92" width="33" height="12" font="12">821–7.</text>
<text top="104" left="452" width="354" height="12" font="12">741. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole</text>
<text top="118" left="479" width="327" height="12" font="12">and esomeprazole on platelet inhibition by clopidogrel. Am Heart J.</text>
<text top="131" left="479" width="83" height="12" font="12">2009;157:148 –5.</text>
<text top="145" left="452" width="354" height="12" font="12">742. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and</text>
<text top="159" left="479" width="327" height="12" font="12">pantoprazole influence on a high 15–mg clopidogrel maintenance</text>
<text top="172" left="479" width="327" height="12" font="12">dose the PACA (Proton Pump Inhibitors And Clopidogrel Asso-</text>
<text top="186" left="479" width="327" height="12" font="12">ciation) prospective randomized study. J Am Coll Cardiol. 2009;54:</text>
<text top="199" left="479" width="46" height="12" font="12">1149 –53.</text>
<text top="213" left="452" width="354" height="12" font="12">743. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a</text>
<text top="227" left="479" width="327" height="12" font="12">clopidogrel-statin interaction in the CHARISMA trial. J Am Coll</text>
<text top="240" left="479" width="119" height="12" font="12">Cardiol. 2007;50:291–5.</text>
<text top="254" left="452" width="354" height="12" font="12">744. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of</text>
<text top="267" left="479" width="327" height="12" font="12">platelet inhibition after a 60 –mg loading dose of clopidogrel in a</text>
<text top="281" left="479" width="327" height="12" font="12">large, unselected cohort of candidates for percutaneous coronary</text>
<text top="294" left="479" width="218" height="12" font="12">intervention. Circulation. 2005;111:2560 – 4.</text>
<text top="308" left="452" width="354" height="12" font="12">745. von Beckerath N., Taubert D, Pogatsa-Murray G, et al. Absorption,</text>
<text top="322" left="479" width="327" height="12" font="12">metabolization, and antiplatelet effects of 30 –, 60 –, and 90 –mg</text>
<text top="335" left="479" width="327" height="12" font="12">loading doses of clopidogrel: results of the ISAR-CHOICE (Intra-</text>
<text top="349" left="479" width="327" height="12" font="12">coronary Stenting and Antithrombotic Regimen: Choose Between 3</text>
<text top="362" left="479" width="327" height="12" font="12">High Oral Doses for Immediate Clopidogrel Effect) Trial. Circu-</text>
<text top="376" left="479" width="129" height="12" font="12">lation. 2005;112:2946 –50.</text>
<text top="390" left="452" width="354" height="12" font="12">746. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus</text>
<text top="403" left="479" width="327" height="12" font="12">clopidogrel in patients with acute coronary syndromes. N Engl</text>
<text top="417" left="479" width="131" height="12" font="12">J Med. 2007;357:2001–15.</text>
<text top="430" left="452" width="354" height="12" font="12">747. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopi-</text>
<text top="444" left="479" width="327" height="12" font="12">dogrel in patients with acute coronary syndromes. N Engl J Med.</text>
<text top="458" left="479" width="93" height="12" font="12">2009;361:1045–57.</text>
<text top="471" left="452" width="354" height="12" font="12">748. Jagathesan R, Rosen SD, Foale RA, et al. Effects of long-term oral</text>
<text top="485" left="479" width="327" height="12" font="12">dipyridamole treatment on coronary microcirculatory function in</text>
<text top="498" left="479" width="327" height="12" font="12">patients with chronic stable angina: A substudy of the persantine in</text>
<text top="512" left="479" width="327" height="12" font="12">stable angina (PISA) study. J Cardiovasc Pharmacol. 2006;48:</text>
<text top="526" left="479" width="36" height="12" font="12">110 – 6.</text>
<text top="539" left="452" width="354" height="12" font="12">749. Tsuya T, Okada M, Horie H, et al. Effect of dipyridamole at the</text>
<text top="553" left="479" width="327" height="12" font="12">usual oral dose on exercise-induced myocardial ischemia in stable</text>
<text top="566" left="479" width="232" height="12" font="12">angina pectoris. Am J Cardiol. 1990;66:275– 8.</text>
<text top="580" left="452" width="354" height="12" font="12">750. Byzova TV, Plow EF. Networking in the hemostatic system.</text>
<text top="594" left="479" width="327" height="12" font="12">Integrin alphaiibbeta3 binds prothrombin and influences its activa-</text>
<text top="607" left="479" width="190" height="12" font="12">tion. J Biol Chem. 1997;272:27183– 8.</text>
<text top="621" left="452" width="322" height="12" font="12">751. Dahlback B. Blood coagulation. Lancet. 2000;355:1627–32.</text>
<text top="634" left="452" width="354" height="12" font="12">752. Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and</text>
<text top="648" left="479" width="327" height="12" font="12">cardiovascular prognosis in patients with stable angina pectoris</text>
<text top="661" left="479" width="327" height="12" font="12">treated with verapamil or metoprolol. Results from the Angina</text>
<text top="675" left="479" width="300" height="12" font="12">Prognosis study in Stockholm. Circulation. 1997;95:2380 – 6.</text>
<text top="689" left="452" width="354" height="12" font="12">753. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary</text>
<text top="702" left="479" width="254" height="12" font="12">artery disease. J Am Coll Cardiol. 2003;41:62S–9S.</text>
<text top="716" left="452" width="354" height="12" font="12">754. Boekholdt SM, Bijsterveld NR, Moons AH, et al. Genetic variation</text>
<text top="729" left="479" width="327" height="12" font="12">in coagulation and fibrinolytic proteins and their relation with acute</text>
<text top="743" left="479" width="327" height="12" font="12">myocardial infarction: a systematic review. Circulation. 2001;104:</text>
<text top="757" left="479" width="40" height="12" font="12">3063– 8.</text>
<text top="770" left="452" width="354" height="12" font="12">755. Martini CH, Doggen CJ, Cavallini C, et al. No effect of polymor-</text>
<text top="784" left="479" width="327" height="12" font="12">phisms in prothrombotic genes on the risk of myocardial infarction</text>
<text top="797" left="479" width="327" height="12" font="12">in young adults without cardiovascular risk factors. J Thromb</text>
<text top="811" left="479" width="120" height="12" font="12">Haemost. 2005;3:177–9.</text>
<text top="824" left="452" width="354" height="12" font="12">756. No evidence of association between prothrombotic gene polymor-</text>
<text top="838" left="479" width="327" height="12" font="12">phisms and the development of acute myocardial infarction at a</text>
<text top="852" left="479" width="212" height="12" font="12">young age. Circulation. 2003;107:1117–22.</text>
<text top="865" left="452" width="354" height="12" font="12">757. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy</text>
<text top="879" left="479" width="327" height="12" font="12">improve clinical outcomes of acute myocardial infarction after</text>
<text top="892" left="479" width="327" height="12" font="12">successful primary angioplasty? J Am Coll Cardiol. 2004;43:1773–9.</text>
<text top="906" left="452" width="354" height="12" font="12">758. de Peuter OR, Lussana F, Peters RJ, et al. A systematic review of</text>
<text top="920" left="479" width="327" height="12" font="12">selective and non-selective beta blockers for prevention of vascular</text>
<text top="933" left="479" width="327" height="12" font="12">events in patients with acute coronary syndrome or heart failure.</text>
<text top="947" left="479" width="150" height="12" font="12">Neth J Med. 2009;67:284 –94.</text>
<text top="960" left="452" width="354" height="12" font="12">759. Freemantle N, Cleland J, Young P, et al. beta Blockade after</text>
<text top="974" left="479" width="327" height="12" font="12">myocardial infarction: systematic review and meta regression anal-</text>
<text top="987" left="479" width="143" height="12" font="12">ysis. BMJ. 1999;318:1730 –7.</text>
<text top="1001" left="452" width="354" height="12" font="12">760. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on</text>
<text top="1015" left="479" width="327" height="12" font="12">morbidity and mortality in patients with chronic heart failure. U.S.</text>
<text top="1028" left="479" width="327" height="12" font="12">Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:</text>
<text top="1042" left="479" width="46" height="12" font="12">1349 –55.</text>
<text top="1055" left="452" width="354" height="12" font="12">761. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the</text>
<text top="1069" left="479" width="327" height="12" font="12">treatment of chronic heart failure: a meta-analysis on individual data</text>
<text top="1083" left="479" width="327" height="12" font="12">of two placebo-controlled studies—CIBIS and CIBIS II. Cardiac</text>
<text top="1096" left="479" width="300" height="12" font="12">Insufficiency Bisoprolol Study. Am Heart J. 2002;143:301–7.</text>
<text top="52" left="59" width="25" height="10" font="12">e146</text>
<text top="52" left="113" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="104" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">762. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of</text>
<text top="118" left="92" width="327" height="12" font="12">carvedilol and metoprolol on clinical outcomes in patients with</text>
<text top="132" left="92" width="327" height="12" font="12">chronic heart failure in the Carvedilol Or Metoprolol European</text>
<text top="145" left="92" width="327" height="12" font="12">Trial (COMET): randomised controlled trial. Lancet. 2003;362:</text>
<text top="159" left="92" width="27" height="12" font="12">7–13.</text>
<text top="172" left="65" width="354" height="12" font="12">763. Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A compar-</text>
<text top="186" left="92" width="327" height="12" font="12">ative analysis of the results from 4 trials of beta-blocker therapy for</text>
<text top="200" left="92" width="327" height="12" font="12">heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.</text>
<text top="213" left="92" width="140" height="12" font="12">J Card Fail. 2003;9:354 – 63.</text>
<text top="227" left="65" width="354" height="12" font="12">764. Goldstein S. Beta-blocking drugs and coronary heart disease.</text>
<text top="240" left="92" width="247" height="12" font="12">Cardiovasc Drugs Ther. 1997;11 Suppl 1:219 –25.</text>
<text top="254" left="65" width="354" height="12" font="12">765. Frishman WH, Heiman M, Soberman J, et al. Comparison of</text>
<text top="268" left="92" width="327" height="12" font="12">celiprolol and propranolol in stable angina pectoris. Celiprolol</text>
<text top="281" left="92" width="327" height="12" font="12">International Angina Study Group. Am J Cardiol. 1991;67:665–70.</text>
<text top="295" left="65" width="354" height="12" font="12">766. Narahara KA. Double-blind comparison of once daily betaxolol</text>
<text top="308" left="92" width="327" height="12" font="12">versus propranolol four times daily in stable angina pectoris. Betax-</text>
<text top="322" left="92" width="284" height="12" font="12">olol Investigators Group. Am J Cardiol. 1990;65:577– 82.</text>
<text top="336" left="65" width="354" height="12" font="12">767. Kardas P. Compliance, clinical outcome, and quality of life of</text>
<text top="349" left="92" width="327" height="12" font="12">patients with stable angina pectoris receiving once-daily betaxolol</text>
<text top="363" left="92" width="327" height="12" font="12">versus twice daily metoprolol: a randomized controlled trial. Vasc</text>
<text top="376" left="92" width="181" height="12" font="12">Health Risk Manag. 2007;3:235– 42.</text>
<text top="390" left="65" width="354" height="12" font="12">768. Ryden L. Efficacy of epanolol versus metoprolol in angina pectoris:</text>
<text top="404" left="92" width="327" height="12" font="12">report from a Swedish multicentre study of exercise tolerance.</text>
<text top="417" left="92" width="148" height="12" font="12">J Intern Med. 1992;231:7–11.</text>
<text top="431" left="65" width="354" height="12" font="12">769. Boberg J, Larsen FF, Pehrsson SK. The effects of beta blockade with</text>
<text top="444" left="92" width="327" height="12" font="12">(epanolol) and without (atenolol) intrinsic sympathomimetic activity</text>
<text top="458" left="92" width="327" height="12" font="12">in stable angina pectoris. The Visacor Study Group. Clin Cardiol.</text>
<text top="471" left="92" width="75" height="12" font="12">1992;15:591–5.</text>
<text top="485" left="65" width="354" height="12" font="12">770. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, et al.</text>
<text top="499" left="92" width="327" height="12" font="12">Carvedilol versus verapamil in chronic stable angina: a multicentre</text>
<text top="512" left="92" width="222" height="12" font="12">trial. Eur J Clin Pharmacol. 1997;52:95–100.</text>
<text top="526" left="65" width="354" height="12" font="12">771. Raftery EB. The preventative effects of vasodilating beta-blockers in</text>
<text top="539" left="92" width="294" height="12" font="12">cardiovascular disease. Eur Heart J. 1996;17 Suppl B:30 – 8.</text>
<text top="553" left="65" width="354" height="12" font="12">772. Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during</text>
<text top="567" left="92" width="327" height="12" font="12">exercise as a predictor of sudden death. N Engl J Med. 2005;352:</text>
<text top="580" left="92" width="40" height="12" font="12">1951– 8.</text>
<text top="594" left="65" width="354" height="12" font="12">773. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic</text>
<text top="607" left="92" width="327" height="12" font="12">value of resting heart rate in patients with suspected or proven</text>
<text top="621" left="92" width="265" height="12" font="12">coronary artery disease. Eur Heart J. 2005;26:967–74.</text>
<text top="635" left="65" width="354" height="12" font="12">774. Maqbool A, Hall AS, Ball SG, et al. Common polymorphisms of</text>
<text top="648" left="92" width="327" height="12" font="12">beta–adrenoceptor: identification and rapid screening assay. Lancet.</text>
<text top="662" left="92" width="69" height="12" font="12">1999;353:897.</text>
<text top="675" left="65" width="354" height="12" font="12">775. Borjesson M, Magnusson Y, Hjalmarson A, et al. A novel poly-</text>
<text top="689" left="92" width="327" height="12" font="12">morphism in the gene coding for the beta(1)-adrenergic receptor</text>
<text top="702" left="92" width="327" height="12" font="12">associated with survival in patients with heart failure. Eur Heart J.</text>
<text top="716" left="92" width="83" height="12" font="12">2000;21:1853– 8.</text>
<text top="730" left="65" width="354" height="12" font="12">776. Mason DA, Moore JD, Green SA, et al. A gain-of-function</text>
<text top="743" left="92" width="327" height="12" font="12">polymorphism in a G-protein coupling domain of the human</text>
<text top="757" left="92" width="292" height="12" font="12">beta–adrenergic receptor. J Biol Chem. 1999;274:12670 – 4.</text>
<text top="770" left="65" width="354" height="12" font="12">777. Nieminen T, Lehtimaki T, Laiho J, et al. Effects of polymorphisms</text>
<text top="784" left="92" width="327" height="12" font="12">in beta–adrenoceptor and alpha-subunit of G protein on heart rate</text>
<text top="798" left="92" width="327" height="12" font="12">and blood pressure during exercise test. The Finnish Cardiovascular</text>
<text top="811" left="92" width="201" height="12" font="12">Study. J Appl Physiol. 2006;100:507–11.</text>
<text top="825" left="65" width="354" height="12" font="12">778. Xie HG, Dishy V, Sofowora G, et al. Arg389Gly beta –adrenocep-</text>
<text top="838" left="92" width="327" height="12" font="12">tor polymorphism varies in frequency among different ethnic groups</text>
<text top="852" left="92" width="327" height="12" font="12">but does not alter response in vivo. Pharmacogenetics. 2001;11:</text>
<text top="865" left="92" width="33" height="12" font="12">191–7.</text>
<text top="879" left="65" width="354" height="12" font="12">779. Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of</text>
<text top="893" left="92" width="327" height="12" font="12">beta–adrenergic receptor is associated with the cardiovascular re-</text>
<text top="906" left="92" width="298" height="12" font="12">sponse to metoprolol. Clin Pharmacol Ther. 2003;74:372–9.</text>
<text top="920" left="65" width="354" height="12" font="12">780. Sofowora GG, Dishy V, Muszkat M, et al. A common beta–</text>
<text top="933" left="92" width="327" height="12" font="12">adrenergic receptor polymorphism (Arg389Gly) affects blood</text>
<text top="947" left="92" width="327" height="12" font="12">pressure response to beta-blockade. Clin Pharmacol Ther. 2003;</text>
<text top="961" left="92" width="58" height="12" font="12">73:366 –71.</text>
<text top="974" left="65" width="354" height="12" font="12">781. Defoor J, Martens K, Zielinska D, et al. The CAREGENE study:</text>
<text top="988" left="92" width="327" height="12" font="12">polymorphisms of the beta–adrenoceptor gene and aerobic power in</text>
<text top="1001" left="92" width="266" height="12" font="12">coronary artery disease. Eur Heart J. 2006;27:808 –16.</text>
<text top="1015" left="65" width="354" height="12" font="12">782. Johnson JA, Zineh I, Puckett BJ, et al. Beta –adrenergic receptor</text>
<text top="1028" left="92" width="327" height="12" font="12">polymorphisms and antihypertensive response to metoprolol. Clin</text>
<text top="1042" left="92" width="163" height="12" font="12">Pharmacol Ther. 2003;74:44 –52.</text>
<text top="1056" left="65" width="354" height="12" font="12">783. Liu J, Liu ZQ, Yu BN, et al. beta–Adrenergic receptor polymor-</text>
<text top="1069" left="92" width="327" height="12" font="12">phisms influence the response to metoprolol monotherapy in pa-</text>
<text top="1083" left="92" width="327" height="12" font="12">tients with essential hypertension. Clin Pharmacol Ther. 2006;80:</text>
<text top="1096" left="92" width="33" height="12" font="12">23–32.</text>
<text top="104" left="452" width="354" height="12" font="12">784. Karlsson J, Lind L, Hallberg P, et al. Beta–adrenergic receptor</text>
<text top="118" left="479" width="327" height="12" font="12">gene polymorphisms and response to beta–adrenergic receptor</text>
<text top="131" left="479" width="327" height="12" font="12">blockade in patients with essential hypertension. Clin Cardiol.</text>
<text top="145" left="479" width="84" height="12" font="12">2004;27:347–50.</text>
<text top="159" left="452" width="354" height="12" font="12">785. O’Shaughnessy KM, Fu B, Dickerson C, et al. The gain-of-</text>
<text top="172" left="479" width="327" height="12" font="12">function G389R variant of the beta–adrenoceptor does not influence</text>
<text top="186" left="479" width="327" height="12" font="12">blood pressure or heart rate response to beta-blockade in hyperten-</text>
<text top="199" left="479" width="229" height="12" font="12">sive subjects. Clin Sci (Lond). 2000;99:233– 8.</text>
<text top="213" left="452" width="354" height="12" font="12">786. Rehnqvist N, Hjemdahl P, Billing E, et al. Treatment of stable</text>
<text top="227" left="479" width="327" height="12" font="12">angina pectoris with calcium antagonists and beta-blockers. The</text>
<text top="240" left="479" width="327" height="12" font="12">APSIS study. Angina Prognosis Study in Stockholm. Cardiologia.</text>
<text top="254" left="479" width="63" height="12" font="12">1995;40:301.</text>
<text top="267" left="452" width="354" height="12" font="12">787. von Arnim T. Medical treatment to reduce total ischemic burden:</text>
<text top="281" left="479" width="327" height="12" font="12">total ischemic burden bisoprolol study (TIBBS), a multicenter trial</text>
<text top="294" left="479" width="327" height="12" font="12">comparing bisoprolol and nifedipine. The TIBBS Investigators.</text>
<text top="308" left="479" width="176" height="12" font="12">J Am Coll Cardiol. 1995;25:231– 8.</text>
<text top="322" left="452" width="354" height="12" font="12">788. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy</text>
<text top="335" left="479" width="327" height="12" font="12">with metoprolol and nifedipine versus monotherapy in patients with</text>
<text top="349" left="479" width="327" height="12" font="12">stable angina pectoris. Results of the International Multicenter</text>
<text top="362" left="479" width="327" height="12" font="12">Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1996;27:</text>
<text top="376" left="479" width="34" height="12" font="12">311– 6.</text>
<text top="390" left="452" width="354" height="12" font="12">789. Emanuelsson H, Egstrup K, Nikus K, et al. Antianginal efficacy of</text>
<text top="403" left="479" width="327" height="12" font="12">the combination of felodipine-metoprolol 10/100 mg compared</text>
<text top="417" left="479" width="327" height="12" font="12">with each drug alone in patients with stable effort-induced angina</text>
<text top="430" left="479" width="327" height="12" font="12">pectoris: a multicenter parallel group study. The TRAFFIC Study</text>
<text top="444" left="479" width="195" height="12" font="12">Group. Am Heart J. 1999;137:854 – 62.</text>
<text top="458" left="452" width="354" height="12" font="12">790. Waysbort J, Meshulam N, Brunner D. Isosorbide—mononitrate</text>
<text top="471" left="479" width="327" height="12" font="12">and atenolol in the treatment of stable exertional angina. Cardiol-</text>
<text top="485" left="479" width="143" height="12" font="12">ogy. 1991;79 Suppl 2:19 –26.</text>
<text top="498" left="452" width="354" height="12" font="12">791. Krepp HP. Evaluation of the antianginal and anti-ischemic efficacy</text>
<text top="512" left="479" width="327" height="12" font="12">of slow-release isosorbide—mononitrate capsules, bupranolol and</text>
<text top="526" left="479" width="327" height="12" font="12">their combination, in patients with chronic stable angina pectoris.</text>
<text top="539" left="479" width="175" height="12" font="12">Cardiology. 1991;79 Suppl 2:14 – 8.</text>
<text top="553" left="452" width="354" height="12" font="12">792. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan</text>
<text top="566" left="479" width="327" height="12" font="12">in patients with chronic heart failure and reduced left-ventricular</text>
<text top="580" left="479" width="327" height="12" font="12">systolic function taking angiotensin-converting-enzyme inhibitors:</text>
<text top="594" left="479" width="263" height="12" font="12">the CHARM-Added trial. Lancet. 2003;362:767–71.</text>
<text top="607" left="452" width="354" height="12" font="12">793. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive</text>
<text top="621" left="479" width="327" height="12" font="12">agents on cardiovascular events in patients with coronary disease and</text>
<text top="634" left="479" width="327" height="12" font="12">normal blood pressure: the CAMELOT study: a randomized</text>
<text top="648" left="479" width="213" height="12" font="12">controlled trial. JAMA. 2004;292:2217–25.</text>
<text top="661" left="452" width="354" height="12" font="12">794. Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihyper-</text>
<text top="675" left="479" width="327" height="12" font="12">tensive Long-Term Use Evaluation (VALUE) trial: outcomes in</text>
<text top="689" left="479" width="314" height="12" font="12">patients receiving monotherapy. Hypertension. 2006;48:385–91.</text>
<text top="702" left="452" width="354" height="12" font="12">795. Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting</text>
<text top="716" left="479" width="327" height="12" font="12">enzyme inhibitors in patients with coronary artery disease and</text>
<text top="729" left="479" width="327" height="12" font="12">absence of heart failure or left ventricular systolic dysfunction: an</text>
<text top="743" left="479" width="327" height="12" font="12">overview of long-term randomized controlled trials. Arch Intern</text>
<text top="757" left="479" width="117" height="12" font="12">Med. 2006;166:787–96.</text>
<text top="770" left="452" width="354" height="12" font="12">796. Al-Mallah MH, Tleyjeh IM, bdel-Latif AA, et al. Angiotensin-</text>
<text top="784" left="479" width="327" height="12" font="12">converting enzyme inhibitors in coronary artery disease and pre-</text>
<text top="797" left="479" width="327" height="12" font="12">served left ventricular systolic function: a systematic review and</text>
<text top="811" left="479" width="327" height="12" font="12">meta-analysis of randomized controlled trials. J Am Coll Cardiol.</text>
<text top="824" left="479" width="90" height="12" font="12">2006;47:1576 – 83.</text>
<text top="838" left="452" width="354" height="12" font="12">797. Pitt B, O’Neill B, Feldman R, et al. The QUinapril Ischemic Event</text>
<text top="852" left="479" width="327" height="12" font="12">Trial (QUIET): evaluation of chronic ACE inhibitor therapy in</text>
<text top="865" left="479" width="327" height="12" font="12">patients with ischemic heart disease and preserved left ventricular</text>
<text top="879" left="479" width="212" height="12" font="12">function. Am J Cardiol. 2001;87:1058 – 63.</text>
<text top="892" left="452" width="354" height="12" font="12">798. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-</text>
<text top="906" left="479" width="327" height="12" font="12">converting enzyme inhibitors in cardiac and vascular protection.</text>
<text top="920" left="479" width="152" height="12" font="12">Circulation. 1994;90:2056 – 69.</text>
<text top="933" left="452" width="354" height="12" font="12">799. Prasad A, Husain S, Quyyumi AA. Abnormal flow-mediated</text>
<text top="947" left="479" width="327" height="12" font="12">epicardial vasomotion in human coronary arteries is improved by</text>
<text top="960" left="479" width="327" height="12" font="12">angiotensin-converting enzyme inhibition: a potential role of bra-</text>
<text top="974" left="479" width="233" height="12" font="12">dykinin. J Am Coll Cardiol. 1999;33:796 – 804.</text>
<text top="987" left="452" width="354" height="12" font="12">800. Tummala PE, Chen XL, Sundell CL, et al. Angiotensin II induces</text>
<text top="1001" left="479" width="327" height="12" font="12">vascular cell adhesion molecule-1 expression in rat vasculature: A</text>
<text top="1015" left="479" width="327" height="12" font="12">potential link between the renin-angiotensin system and atheroscle-</text>
<text top="1028" left="479" width="178" height="12" font="12">rosis. Circulation. 1999;100:1223–9.</text>
<text top="1042" left="452" width="354" height="12" font="12">801. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on</text>
<text top="1055" left="479" width="327" height="12" font="12">mortality and morbidity in patients with left ventricular dysfunction</text>
<text top="1069" left="479" width="327" height="12" font="12">after myocardial infarction. Results of the survival and ventricular</text>
<text top="1083" left="479" width="327" height="12" font="12">enlargement trial. The SAVE Investigators. N Engl J Med. 1992;</text>
<text top="1096" left="479" width="62" height="12" font="12">327:669 –77.</text>
<text top="52" left="781" width="25" height="10" font="12">e147</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="105" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">802. Effects of ramipril on cardiovascular and microvascular outcomes in</text>
<text top="118" left="92" width="327" height="12" font="12">people with diabetes mellitus: results of the HOPE study and</text>
<text top="132" left="92" width="327" height="12" font="12">MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation</text>
<text top="146" left="92" width="222" height="12" font="12">Study Investigators. Lancet. 2000;355:253–9.</text>
<text top="160" left="65" width="354" height="12" font="12">803. Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-</text>
<text top="173" left="92" width="327" height="12" font="12">converting enzyme inhibition in low-risk patients early after coro-</text>
<text top="187" left="92" width="278" height="12" font="12">nary artery bypass surgery. Circulation. 2008;117:24 –31.</text>
<text top="201" left="65" width="354" height="12" font="12">804. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and</text>
<text top="215" left="92" width="327" height="12" font="12">independent effects of agents that inhibit the renin-angiotensin</text>
<text top="228" left="92" width="181" height="12" font="12">system. J Hypertens. 2007;25:951– 8.</text>
<text top="242" left="65" width="354" height="12" font="12">805. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardio-</text>
<text top="256" left="92" width="327" height="12" font="12">graphic left ventricular hypertrophy by losartan versus atenolol: The</text>
<text top="270" left="92" width="327" height="12" font="12">Losartan Intervention for Endpoint reduction in Hypertension</text>
<text top="284" left="92" width="225" height="12" font="12">(LIFE) Study. Circulation. 2003;108:684 –90.</text>
<text top="297" left="65" width="354" height="12" font="12">806. H5N1 avian influenza: first steps towards development of a human</text>
<text top="311" left="92" width="230" height="12" font="12">vaccine. Wkly Epidemiol Rec. 2005;80:277– 8.</text>
<text top="325" left="65" width="354" height="12" font="12">807. Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as</text>
<text top="339" left="92" width="327" height="12" font="12">secondary prevention for cardiovascular disease: a science advisory</text>
<text top="353" left="92" width="327" height="12" font="12">from the American Heart Association/American College of Cardi-</text>
<text top="366" left="92" width="227" height="12" font="12">ology. J Am Coll Cardiol. 2006;48:1498 –502.</text>
<text top="380" left="65" width="354" height="12" font="12">808. de Diego C, Vila-Corcoles A, Ochoa O, et al. Effects of annual</text>
<text top="394" left="92" width="327" height="12" font="12">influenza vaccination on winter mortality in elderly people with</text>
<text top="408" left="92" width="257" height="12" font="12">chronic heart disease. Eur Heart J. 2008;30:209 –16.</text>
<text top="422" left="65" width="354" height="12" font="12">809. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity</text>
<text top="435" left="92" width="327" height="12" font="12">of a high dosage trivalent influenza vaccine among elderly subjects.</text>
<text top="449" left="92" width="135" height="12" font="12">Vaccine. 2007;25:7656 – 63.</text>
<text top="463" left="65" width="354" height="12" font="12">810. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of</text>
<text top="477" left="92" width="327" height="12" font="12">influenza vaccine and effect on antibody responses in elderly persons.</text>
<text top="490" left="92" width="180" height="12" font="12">Arch Intern Med. 2006;166:1121–7.</text>
<text top="504" left="65" width="354" height="12" font="12">811. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus</text>
<text top="518" left="92" width="327" height="12" font="12">progestin for secondary prevention of coronary heart disease in</text>
<text top="532" left="92" width="327" height="12" font="12">postmenopausal women. Heart and Estrogen/progestin Replace-</text>
<text top="546" left="92" width="321" height="12" font="12">ment Study (HERS) Research Group. JAMA. 1998;280:605–13.</text>
<text top="559" left="65" width="354" height="12" font="12">812. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated</text>
<text top="573" left="92" width="327" height="12" font="12">equine estrogen in postmenopausal women with hysterectomy: the</text>
<text top="587" left="92" width="327" height="12" font="12">Women’s Health Initiative randomized controlled trial. JAMA.</text>
<text top="601" left="92" width="93" height="12" font="12">2004;291:1701–12.</text>
<text top="615" left="65" width="354" height="12" font="12">813. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and</text>
<text top="628" left="92" width="327" height="12" font="12">the risk of coronary heart disease. N Engl J Med. 2003;349:523–34.</text>
<text top="642" left="65" width="354" height="12" font="12">814. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits</text>
<text top="656" left="92" width="327" height="12" font="12">of estrogen plus progestin in healthy postmenopausal women:</text>
<text top="670" left="92" width="327" height="12" font="12">principal results From the Women’s Health Initiative randomized</text>
<text top="683" left="92" width="207" height="12" font="12">controlled trial. JAMA. 2002;288:321–33.</text>
<text top="697" left="65" width="354" height="12" font="12">815. de Gaetano G. Low-dose aspirin and vitamin E in people at</text>
<text top="711" left="92" width="327" height="12" font="12">cardiovascular risk: a randomised trial in general practice. Collab-</text>
<text top="725" left="92" width="327" height="12" font="12">orative Group of the Primary Prevention Project. Lancet. 2001;357:</text>
<text top="739" left="92" width="34" height="12" font="12">89 –95.</text>
<text top="752" left="65" width="354" height="12" font="12">816. Stephens NG, Parsons A, Schofield PM, et al. Randomised con-</text>
<text top="766" left="92" width="327" height="12" font="12">trolled trial of vitamin E in patients with coronary disease: Cam-</text>
<text top="780" left="92" width="327" height="12" font="12">bridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:</text>
<text top="794" left="92" width="34" height="12" font="12">781– 6.</text>
<text top="807" left="65" width="354" height="12" font="12">817. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation</text>
<text top="821" left="92" width="327" height="12" font="12">and cardiovascular events in high-risk patients. The Heart Out-</text>
<text top="835" left="92" width="327" height="12" font="12">comes Prevention Evaluation Study Investigators. N Engl J Med.</text>
<text top="849" left="92" width="90" height="12" font="12">2000;342:154 – 60.</text>
<text top="863" left="65" width="354" height="12" font="12">818. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in random-</text>
<text top="876" left="92" width="327" height="12" font="12">ized trials of antioxidant supplements for primary and secondary</text>
<text top="890" left="92" width="327" height="12" font="12">prevention: systematic review and meta-analysis. JAMA. 2007;297:</text>
<text top="904" left="92" width="39" height="12" font="12">842–57.</text>
<text top="918" left="65" width="354" height="12" font="12">819. Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid</text>
<text top="931" left="92" width="327" height="12" font="12">supplementation on risk of cardiovascular diseases: a meta-analysis</text>
<text top="945" left="92" width="289" height="12" font="12">of randomized controlled trials. JAMA. 2006;296:2720 – 6.</text>
<text top="959" left="65" width="354" height="12" font="12">820. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering</text>
<text top="973" left="92" width="327" height="12" font="12">and cardiovascular events after acute myocardial infarction. N Engl</text>
<text top="987" left="92" width="134" height="12" font="12">J Med. 2006;354:1578 – 88.</text>
<text top="1000" left="65" width="354" height="12" font="12">821. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with</text>
<text top="1014" left="92" width="327" height="12" font="12">folic acid and B vitamins in vascular disease. N Engl J Med.</text>
<text top="1028" left="92" width="93" height="12" font="12">2006;354:1567–77.</text>
<text top="1042" left="65" width="354" height="12" font="12">822. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocys-</text>
<text top="1055" left="92" width="327" height="12" font="12">teine in patients with ischemic stroke to prevent recurrent stroke,</text>
<text top="1069" left="92" width="327" height="12" font="12">myocardial infarction, and death: the Vitamin Intervention for</text>
<text top="1083" left="92" width="327" height="12" font="12">Stroke Prevention (VISP) randomized controlled trial. JAMA.</text>
<text top="1097" left="92" width="87" height="12" font="12">2004;291:565–75.</text>
<text top="104" left="452" width="354" height="12" font="12">823. Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of</text>
<text top="118" left="479" width="327" height="12" font="12">intermittent claudication—a double-blind, placebo-controlled</text>
<text top="132" left="479" width="186" height="12" font="12">study. J Intern Med. 1992;231:261–7.</text>
<text top="145" left="452" width="354" height="12" font="12">824. van Rij AM, Solomon C, Packer SG, et al. Chelation therapy for</text>
<text top="159" left="479" width="327" height="12" font="12">intermittent claudication. A double-blind, randomized, controlled</text>
<text top="172" left="479" width="171" height="12" font="12">trial. Circulation. 1994;90:1194 –9.</text>
<text top="186" left="452" width="354" height="12" font="12">825. Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic</text>
<text top="200" left="479" width="327" height="12" font="12">findings in EDTA chelation therapy on peripheral arteriosclerosis.</text>
<text top="213" left="479" width="141" height="12" font="12">Am J Surg. 1991;162:122–5.</text>
<text top="227" left="452" width="354" height="12" font="12">826. Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy</text>
<text top="240" left="479" width="327" height="12" font="12">for ischemic heart disease: a randomized controlled trial. JAMA.</text>
<text top="254" left="479" width="83" height="12" font="12">2002;287:481– 6.</text>
<text top="268" left="452" width="354" height="12" font="12">827. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent</text>
<text top="281" left="479" width="327" height="12" font="12">disease and prolong life in postmenopausal women. Ann Intern</text>
<text top="295" left="479" width="125" height="12" font="12">Med. 1992;117:1016 –37.</text>
<text top="308" left="452" width="354" height="12" font="12">828. Stampfer MJ, Colditz GA. Estrogen replacement therapy and</text>
<text top="322" left="479" width="327" height="12" font="12">coronary heart disease: a quantitative assessment of the epidemio-</text>
<text top="336" left="479" width="208" height="12" font="12">logic evidence. Prev Med. 1991;20:47– 63.</text>
<text top="349" left="452" width="354" height="12" font="12">829. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal</text>
<text top="363" left="479" width="327" height="12" font="12">estrogen therapy and cardiovascular disease. Ten-year follow-up</text>
<text top="376" left="479" width="319" height="12" font="12">from the nurses’ health study. N Engl J Med. 1991;325:756 – 62.</text>
<text top="390" left="452" width="354" height="12" font="12">830. Effects of estrogen or estrogen/progestin regimens on heart disease</text>
<text top="404" left="479" width="327" height="12" font="12">risk factors in postmenopausal women. The Postmenopausal Estro-</text>
<text top="417" left="479" width="327" height="12" font="12">gen/Progestin Interventions (PEPI) Trial. The Writing Group for</text>
<text top="431" left="479" width="217" height="12" font="12">the PEPI Trial. JAMA. 1995;273:199 –208.</text>
<text top="444" left="452" width="354" height="12" font="12">831. Hong MK, Romm PA, Reagan K, et al. Effects of estrogen</text>
<text top="458" left="479" width="327" height="12" font="12">replacement therapy on serum lipid values and angiographically</text>
<text top="472" left="479" width="327" height="12" font="12">defined coronary artery disease in postmenopausal women. Am J</text>
<text top="485" left="479" width="122" height="12" font="12">Cardiol. 1992;69:176 – 8.</text>
<text top="499" left="452" width="354" height="12" font="12">832. Koh KK. Effects of estrogen on the vascular wall: vasomotor</text>
<text top="512" left="479" width="303" height="12" font="12">function and inflammation. Cardiovasc Res. 2002;55:714 –26.</text>
<text top="526" left="452" width="354" height="12" font="12">833. Manolio TA, Furberg CD, Shemanski L, et al. Associations of</text>
<text top="540" left="479" width="327" height="12" font="12">postmenopausal estrogen use with cardiovascular disease and its risk</text>
<text top="553" left="479" width="327" height="12" font="12">factors in older women. The CHS Collaborative Research Group.</text>
<text top="567" left="479" width="149" height="12" font="12">Circulation. 1993;88:2163–71.</text>
<text top="580" left="452" width="354" height="12" font="12">834. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease</text>
<text top="594" left="479" width="327" height="12" font="12">outcomes during 6.8 years of hormone therapy: Heart and Estrogen/</text>
<text top="607" left="479" width="327" height="12" font="12">progestin Replacement Study follow-up (HERS II). JAMA. 2002;</text>
<text top="621" left="479" width="56" height="12" font="12">288:49 –57.</text>
<text top="635" left="452" width="354" height="12" font="12">835. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone</text>
<text top="648" left="479" width="327" height="12" font="12">replacement therapy and antioxidant vitamin supplements on cor-</text>
<text top="662" left="479" width="327" height="12" font="12">onary atherosclerosis in postmenopausal women: a randomized</text>
<text top="675" left="479" width="214" height="12" font="12">controlled trial. JAMA. 2002;288:2432– 40.</text>
<text top="689" left="452" width="354" height="12" font="12">836. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption</text>
<text top="703" left="479" width="327" height="12" font="12">and the risk of coronary heart disease in men. N Engl J Med.</text>
<text top="716" left="479" width="90" height="12" font="12">1993;328:1450 – 6.</text>
<text top="730" left="452" width="354" height="12" font="12">837. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E</text>
<text top="743" left="479" width="327" height="12" font="12">consumption and the risk of coronary disease in women. N Engl</text>
<text top="757" left="479" width="127" height="12" font="12">J Med. 1993;328:1444 –9.</text>
<text top="770" left="452" width="354" height="12" font="12">838. Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant</text>
<text top="784" left="479" width="327" height="12" font="12">vitamins for the prevention of cardiovascular disease: meta-analysis</text>
<text top="798" left="479" width="238" height="12" font="12">of randomised trials. Lancet. 2003;361:2017–23.</text>
<text top="811" left="452" width="354" height="12" font="12">839. Homocysteine and risk of ischemic heart disease and stroke: a</text>
<text top="825" left="479" width="206" height="12" font="12">meta-analysis. JAMA. 2002;288:2015–22.</text>
<text top="838" left="452" width="354" height="12" font="12">840. Arnesen E, Refsum H, Bonaa KH, et al. Serum total homocysteine</text>
<text top="852" left="479" width="298" height="12" font="12">and coronary heart disease. Int J Epidemiol. 1995;24:704 –9.</text>
<text top="866" left="452" width="354" height="12" font="12">841. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine</text>
<text top="879" left="479" width="327" height="12" font="12">levels and mortality in patients with coronary artery disease. N Engl</text>
<text top="893" left="479" width="122" height="12" font="12">J Med. 1997;337:230 – 6.</text>
<text top="906" left="452" width="354" height="12" font="12">842. Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic</text>
<text top="920" left="479" width="327" height="12" font="12">cardiovascular disease. Cochrane Database Syst Rev. 2002;</text>
<text top="933" left="479" width="58" height="12" font="12">CD002785.</text>
<text top="947" left="452" width="354" height="12" font="12">843. Abrams J. Clinical practice. Chronic stable angina. N Engl J Med.</text>
<text top="961" left="479" width="95" height="12" font="12">2005;352:2524 –33.</text>
<text top="974" left="452" width="354" height="12" font="12">844. Wight LJ, VandenBurg MJ, Potter CE, et al. A large scale</text>
<text top="988" left="479" width="327" height="12" font="12">comparative study in general practice with nitroglycerin spray and</text>
<text top="1001" left="479" width="327" height="12" font="12">tablet formulations in elderly patients with angina pectoris. Eur</text>
<text top="1015" left="479" width="168" height="12" font="12">J Clin Pharmacol. 1992;42:341–2.</text>
<text top="1029" left="452" width="354" height="12" font="12">845. VandenBurg MJ, Wight LJ, Griffiths GK, et al. Sublingual nitro-</text>
<text top="1042" left="479" width="327" height="12" font="12">glycerin or spray in the treatment of angina. Br J Clin Pract.</text>
<text top="1056" left="479" width="77" height="12" font="12">1986;40:524 –7.</text>
<text top="1069" left="452" width="354" height="12" font="12">846. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of</text>
<text top="1083" left="479" width="327" height="12" font="12">ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol.</text>
<text top="1096" left="479" width="77" height="12" font="12">2005;95:311– 6.</text>
<text top="52" left="59" width="25" height="10" font="12">e148</text>
<text top="52" left="113" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="106" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">847. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine</text>
<text top="118" left="92" width="327" height="12" font="12">with atenolol, amlodipine, or diltiazem on exercise tolerance and</text>
<text top="132" left="92" width="327" height="12" font="12">angina frequency in patients with severe chronic angina: a random-</text>
<text top="145" left="92" width="232" height="12" font="12">ized controlled trial. JAMA. 2004;291:309 –16.</text>
<text top="159" left="65" width="354" height="12" font="12">848. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of</text>
<text top="172" left="92" width="327" height="12" font="12">ranolazine when added to treatment with amlodipine: the ERICA</text>
<text top="186" left="92" width="327" height="12" font="12">(Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol.</text>
<text top="200" left="92" width="83" height="12" font="12">2006;48:566 –75.</text>
<text top="213" left="65" width="354" height="12" font="12">849. Ishikawa K, Nakai S, Takenaka T, et al. Short-acting nifedipine and</text>
<text top="227" left="92" width="327" height="12" font="12">diltiazem do not reduce the incidence of cardiac events in patients</text>
<text top="240" left="92" width="327" height="12" font="12">with healed myocardial infarction. Secondary Prevention Group.</text>
<text top="254" left="92" width="150" height="12" font="12">Circulation. 1997;95:2368 –73.</text>
<text top="268" left="65" width="354" height="12" font="12">850. The effect of diltiazem on mortality and reinfarction after myocar-</text>
<text top="281" left="92" width="327" height="12" font="12">dial infarction. The Multicenter Diltiazem Postinfarction Trial</text>
<text top="295" left="92" width="253" height="12" font="12">Research Group. N Engl J Med. 1988;319:385–92.</text>
<text top="308" left="65" width="354" height="12" font="12">851. Effect of verapamil on mortality and major events after acute</text>
<text top="322" left="92" width="327" height="12" font="12">myocardial infarction (the Danish Verapamil Infarction Trial II—</text>
<text top="336" left="92" width="222" height="12" font="12">DAVIT II). Am J Cardiol. 1990;66:779 – 85.</text>
<text top="349" left="65" width="354" height="12" font="12">852. Frishman WH, Sica DA. Calcium Channel Blockers. In: Frishman</text>
<text top="363" left="92" width="327" height="12" font="12">WH, Sonnenblick EH, Sica DA, editors. Cardiovascular Pharma-</text>
<text top="376" left="92" width="233" height="12" font="12">coherapeutics. New York: McGraw-Hill; 2003.</text>
<text top="390" left="65" width="354" height="12" font="12">853. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl</text>
<text top="404" left="92" width="131" height="12" font="12">J Med. 1999;341:1447–57.</text>
<text top="417" left="65" width="354" height="12" font="12">854. Ezekowitz MD, Hossack K, Mehta JL, et al. Amlodipine in chronic</text>
<text top="431" left="92" width="327" height="12" font="12">stable angina: results of a multicenter double-blind crossover trial.</text>
<text top="444" left="92" width="153" height="12" font="12">Am Heart J. 1995;129:527–35.</text>
<text top="458" left="65" width="354" height="12" font="12">855. Boman K, Saetre H, Karlsson LG, et al. Antianginal effect of</text>
<text top="471" left="92" width="327" height="12" font="12">conventional and controlled release diltiazem in stable angina</text>
<text top="485" left="92" width="235" height="12" font="12">pectoris. Eur J Clin Pharmacol. 1995;49:27–30.</text>
<text top="499" left="65" width="354" height="12" font="12">856. Brogden RN, Benfield P. Verapamil: a review of its pharmacological</text>
<text top="512" left="92" width="327" height="12" font="12">properties and therapeutic use in coronary artery disease. Drugs.</text>
<text top="526" left="92" width="89" height="12" font="12">1996;51:792– 819.</text>
<text top="539" left="65" width="354" height="12" font="12">857. Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for</text>
<text top="553" left="92" width="327" height="12" font="12">coronary-artery spasm. Experience in 127 patients. N Engl J Med.</text>
<text top="567" left="92" width="95" height="12" font="12">1980;302:1269 –73.</text>
<text top="580" left="65" width="354" height="12" font="12">858. Pepine CJ, Feldman RL, Whittle J, et al. Effect of diltiazem in</text>
<text top="594" left="92" width="327" height="12" font="12">patients with variant angina: a randomized double-blind trial. Am</text>
<text top="607" left="92" width="132" height="12" font="12">Heart J. 1981;101:719 –25.</text>
<text top="621" left="65" width="354" height="12" font="12">859. Johnson SM, Mauritson DR, Willerson JT, et al. Verapamil</text>
<text top="635" left="92" width="327" height="12" font="12">administration in variant angina pectoris. Efficacy shown by ecg</text>
<text top="648" left="92" width="197" height="12" font="12">monitoring. JAMA. 1981;245:1849 –51.</text>
<text top="662" left="65" width="354" height="12" font="12">860. Alderman MH, Cohen H, Roque R, et al. Effect of long-acting and</text>
<text top="675" left="92" width="327" height="12" font="12">short-acting calcium antagonists on cardiovascular outcomes in</text>
<text top="689" left="92" width="234" height="12" font="12">hypertensive patients. Lancet. 1997;349:594 – 8.</text>
<text top="702" left="65" width="354" height="12" font="12">861. Parmley WW, Nesto RW, Singh BN, et al. Attenuation of the</text>
<text top="716" left="92" width="327" height="12" font="12">circadian patterns of myocardial ischemia with nifedipine GITS in</text>
<text top="730" left="92" width="327" height="12" font="12">patients with chronic stable angina. N-CAP Study Group. J Am</text>
<text top="743" left="92" width="151" height="12" font="12">Coll Cardiol. 1992;19:1380 –9.</text>
<text top="757" left="65" width="354" height="12" font="12">862. Tatti P, Pahor M, Byington RP, et al. Outcome results of the</text>
<text top="770" left="92" width="327" height="12" font="12">Fosinopril Versus Amlodipine Cardiovascular Events Randomized</text>
<text top="784" left="92" width="327" height="12" font="12">Trial (FACET) in patients with hypertension and NIDDM. Dia-</text>
<text top="798" left="92" width="147" height="12" font="12">betes Care. 1998;21:597– 603.</text>
<text top="811" left="65" width="354" height="12" font="12">863. Gori T, Di Stolfo G, Sicuro S, et al. Nitroglycerin protects the</text>
<text top="825" left="92" width="327" height="12" font="12">endothelium from ischaemia and reperfusion: human mechanistic</text>
<text top="838" left="92" width="230" height="12" font="12">insight. Br J Clin Pharmacol. 2007;64:145–50.</text>
<text top="852" left="65" width="354" height="12" font="12">864. Dawn B, Bolli R. Role of nitric oxide in myocardial precondition-</text>
<text top="865" left="92" width="209" height="12" font="12">ing. Ann N Y Acad Sci. 2002;962:18 – 41.</text>
<text top="879" left="65" width="354" height="12" font="12">865. Jneid H, Chandra M, Alshaher M, et al. Delayed preconditioning-</text>
<text top="893" left="92" width="327" height="12" font="12">mimetic actions of nitroglycerin in patients undergoing exercise</text>
<text top="906" left="92" width="231" height="12" font="12">tolerance tests. Circulation. 2005;111:2565–71.</text>
<text top="920" left="65" width="354" height="12" font="12">866. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris.</text>
<text top="933" left="92" width="168" height="12" font="12">N Engl J Med. 1998;338:520 –31.</text>
<text top="947" left="65" width="354" height="12" font="12">867. Bottcher M, Madsen MM, Randsbaek F, et al. Effect of oral</text>
<text top="961" left="92" width="327" height="12" font="12">nitroglycerin and cold stress on myocardial perfusion in areas</text>
<text top="974" left="92" width="327" height="12" font="12">subtended by stenosed and nonstenosed coronary arteries. Am J</text>
<text top="988" left="92" width="132" height="12" font="12">Cardiol. 2002;89:1019 –24.</text>
<text top="1001" left="65" width="354" height="12" font="12">868. Munzel T, Mulsch A, Kleschyov A. Mechanisms underlying</text>
<text top="1015" left="92" width="327" height="12" font="12">nitroglycerin-induced superoxide production in platelets: some in-</text>
<text top="1028" left="92" width="256" height="12" font="12">sight, more questions. Circulation. 2002;106:170 –2.</text>
<text top="1042" left="65" width="354" height="12" font="12">869. Lacoste LL, Theroux P, Lidon RM, et al. Antithrombotic proper-</text>
<text top="1056" left="92" width="327" height="12" font="12">ties of transdermal nitroglycerin in stable angina pectoris. Am J</text>
<text top="1069" left="92" width="134" height="12" font="12">Cardiol. 1994;73:1058 – 62.</text>
<text top="1083" left="65" width="354" height="12" font="12">870. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of</text>
<text top="1096" left="92" width="219" height="12" font="12">nitrate tolerance. Circ Res. 2005;97:618 –28.</text>
<text top="104" left="452" width="354" height="12" font="12">871. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller</text>
<text top="118" left="479" width="242" height="12" font="12">than we thought? Circulation. 2002;106:2404 – 8.</text>
<text top="132" left="452" width="354" height="12" font="12">872. Azevedo ER, Schofield AM, Kelly S, et al. Nitroglycerin withdrawal</text>
<text top="146" left="479" width="327" height="12" font="12">increases endothelium-dependent vasomotor response to acetylcho-</text>
<text top="159" left="479" width="199" height="12" font="12">line. J Am Coll Cardiol. 2001;37:505–9.</text>
<text top="173" left="452" width="354" height="12" font="12">873. Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin</text>
<text top="187" left="479" width="327" height="12" font="12">treatment is associated with supersensitivity to vasoconstrictors in</text>
<text top="201" left="479" width="327" height="12" font="12">men with stable coronary artery disease: prevention by concomitant</text>
<text top="214" left="479" width="296" height="12" font="12">treatment with captopril. J Am Coll Cardiol. 1998;31:83– 8.</text>
<text top="228" left="452" width="354" height="12" font="12">874. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide</text>
<text top="242" left="479" width="327" height="12" font="12">dinitrate and hydralazine in blacks with heart failure. N Engl J Med.</text>
<text top="256" left="479" width="95" height="12" font="12">2004;351:2049 –57.</text>
<text top="270" left="452" width="354" height="12" font="12">875. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to</text>
<text top="283" left="479" width="327" height="12" font="12">hemodynamic effects of nitrates with concomitant use of hydralazine</text>
<text top="297" left="479" width="327" height="12" font="12">in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:</text>
<text top="311" left="479" width="46" height="12" font="12">1575– 80.</text>
<text top="325" left="452" width="354" height="12" font="12">876. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin</text>
<text top="339" left="479" width="327" height="12" font="12">therapy in the treatment of chronic stable angina. J Am Coll</text>
<text top="352" left="479" width="126" height="12" font="12">Cardiol. 1989;13:786 –95.</text>
<text top="366" left="452" width="354" height="12" font="12">877. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of</text>
<text top="380" left="479" width="327" height="12" font="12">extended-release isosorbide mononitrate for stable effort angina</text>
<text top="394" left="479" width="207" height="12" font="12">pectoris. Am J Cardiol. 1993;72:1249 –56.</text>
<text top="407" left="452" width="354" height="12" font="12">878. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent</text>
<text top="421" left="479" width="327" height="12" font="12">transdermal nitroglycerin therapy in angina pectoris. Clinically</text>
<text top="435" left="479" width="327" height="12" font="12">effective without tolerance or rebound. Minitran Efficacy Study</text>
<text top="449" left="479" width="190" height="12" font="12">Group. Circulation. 1995;91:1368 –74.</text>
<text top="463" left="452" width="354" height="12" font="12">879. Abrams J. Glyceryl trinitrate (nitroglycerin) and the organic nitrates.</text>
<text top="476" left="479" width="327" height="12" font="12">Choosing the method of administration. Drugs. 1987;34:391– 403.</text>
<text top="490" left="452" width="354" height="12" font="12">880. Iafrate RP Jr., Yost RL, Curry SH, et al. Effect of dose and</text>
<text top="504" left="479" width="327" height="12" font="12">ointment application technique on nitroglycerin plasma concentra-</text>
<text top="518" left="479" width="199" height="12" font="12">tions. Pharmacotherapy. 1983;3:118 –24.</text>
<text top="532" left="452" width="354" height="12" font="12">881. Moe G, Armstrong PW. Influence of skin site on bioavailability of</text>
<text top="545" left="479" width="327" height="12" font="12">nitroglycerin ointment in congestive heart failure. Am J Med.</text>
<text top="559" left="479" width="81" height="12" font="12">1986;81:765–70.</text>
<text top="573" left="452" width="354" height="12" font="12">882. Silber S. Nitrates: why and how should they be used today? Current</text>
<text top="587" left="479" width="327" height="12" font="12">status of the clinical usefulness of nitroglycerin, isosorbide dinitrate</text>
<text top="601" left="479" width="327" height="12" font="12">and isosorbide—mononitrate. Eur J Clin Pharmacol. 1990;38 Suppl</text>
<text top="614" left="479" width="55" height="12" font="12">1:S35–S51.</text>
<text top="628" left="452" width="229" height="12" font="12">883. CV Therapeutics. Ranexa Package Insert.</text>
<text top="628" left="684" width="122" height="12" font="40"><a href="http://www.cvt.com/pdf/RanexaPI.pdf">http://www.cvt.com/pdf/</a></text>
<text top="642" left="479" width="70" height="12" font="40"><a href="http://www.cvt.com/pdf/RanexaPI.pdf">RanexaPI.pdf</a></text>
<text top="642" left="549" width="118" height="12" font="12"><a href="http://www.cvt.com/pdf/RanexaPI.pdf">. </a>2007. Available at:</text>
<text top="642" left="676" width="130" height="12" font="37"><a href="http://www.cvt.com/pdf/RanexaPI.pdf">http://www.cvt.com/pdf/</a></text>
<text top="656" left="479" width="69" height="12" font="37"><a href="http://www.cvt.com/pdf/RanexaPI.pdf">RanexaPI.pdf.</a></text>
<text top="656" left="552" width="116" height="12" font="12">Accessed July 15, 2008.</text>
<text top="669" left="452" width="354" height="12" font="12">884. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects</text>
<text top="683" left="479" width="327" height="12" font="12">and long-term survival during ranolazine monotherapy in patients</text>
<text top="697" left="479" width="326" height="12" font="12">with chronic severe angina. J Am Coll Cardiol. 2004;43:1375– 82.</text>
<text top="711" left="452" width="354" height="12" font="12">885. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of</text>
<text top="725" left="479" width="327" height="12" font="12">ranolazine on recurrent cardiovascular events in patients with non-ST-</text>
<text top="738" left="479" width="327" height="12" font="12">elevation acute coronary syndromes: the MERLIN-TIMI 36 random-</text>
<text top="752" left="479" width="177" height="12" font="12">ized trial. JAMA. 2007;297:1775–83.</text>
<text top="766" left="452" width="354" height="12" font="12">886. Vardeny O, Sweitzer NK, Detry MA, et al. Decreased immune</text>
<text top="780" left="479" width="327" height="12" font="12">responses to influenza vaccination in patients with heart failure.</text>
<text top="793" left="479" width="145" height="12" font="12">J Card Fail. 2009;15:368 –73.</text>
<text top="807" left="452" width="354" height="12" font="12">887. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on</text>
<text top="821" left="479" width="327" height="12" font="12">disease-specific health status and quality of life among patients with</text>
<text top="835" left="479" width="327" height="12" font="12">acute coronary syndromes: results from the MERLIN-TIMI 36</text>
<text top="848" left="479" width="327" height="12" font="12">randomized trial. Circ Cardiovasc Qual Outcomes. 2008;1:107–15.</text>
<text top="862" left="452" width="354" height="12" font="12">888. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the</text>
<text top="876" left="479" width="327" height="12" font="12">glycometabolic effects of ranolazine in patients with and without</text>
<text top="890" left="479" width="327" height="12" font="12">diabetes mellitus in the MERLIN-TIMI 36 randomized controlled</text>
<text top="904" left="479" width="175" height="12" font="12">trial. Circulation. 2009;119:2032–9.</text>
<text top="917" left="452" width="354" height="12" font="12">889. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on</text>
<text top="931" left="479" width="327" height="12" font="12">exercise tolerance and HbA1c in patients with chronic angina and</text>
<text top="945" left="479" width="182" height="12" font="12">diabetes. Eur Heart J. 2006;27:42– 8.</text>
<text top="959" left="452" width="354" height="12" font="12">890. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an</text>
<text top="972" left="479" width="327" height="12" font="12">antianginal agent with novel electrophysiological properties, on the</text>
<text top="986" left="479" width="327" height="12" font="12">incidence of arrhythmias in patients with non ST-segment elevation</text>
<text top="1000" left="479" width="327" height="12" font="12">acute coronary syndrome: results from the Metabolic Efficiency</text>
<text top="1014" left="479" width="327" height="12" font="12">With Ranolazine for Less Ischemia in Non ST-Elevation Acute</text>
<text top="1028" left="479" width="327" height="12" font="12">Coronary Syndrome Thrombolysis in Myocardial Infarction 36</text>
<text top="1041" left="479" width="327" height="12" font="12">(MERLIN-TIMI 36) randomized controlled trial. Circulation.</text>
<text top="1055" left="479" width="93" height="12" font="12">2007;116:1647–52.</text>
<text top="1069" left="452" width="354" height="12" font="12">891. Mega JL, Hochman JS, Scirica BM, et al. Clinical features and</text>
<text top="1083" left="479" width="327" height="12" font="12">outcomes of women with unstable ischemic heart disease: observations</text>
<text top="1096" left="479" width="327" height="12" font="12">from metabolic efficiency with ranolazine for less ischemia in non-ST-</text>
<text top="52" left="781" width="25" height="10" font="12">e149</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="107" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="92" width="327" height="12" font="12">elevation acute coronary syndromes-thrombolysis in myocardial</text>
<text top="118" left="92" width="324" height="12" font="12">infarction 36 (MERLIN-TIMI 36). Circulation. 2010;121:1809–17.</text>
<text top="132" left="64" width="354" height="12" font="12">892. Jerling M, Abdallah H. Effect of renal impairment on multiple-dose</text>
<text top="146" left="92" width="327" height="12" font="12">pharmacokinetics of extended-release ranolazine. Clin Pharmacol</text>
<text top="160" left="92" width="114" height="12" font="12">Ther. 2005;78:288 –97.</text>
<text top="174" left="64" width="354" height="12" font="12">893. Markham A, Plosker GL, Goa KL. Nicorandil. An updated review</text>
<text top="188" left="92" width="327" height="12" font="12">of its use in ischaemic heart disease with emphasis on its cardio-</text>
<text top="202" left="92" width="206" height="12" font="12">protective effects. Drugs. 2000;60:955–74.</text>
<text top="216" left="64" width="354" height="12" font="12">894. Nicorandil study ivestigators. Nicorandil for angina—an update.</text>
<text top="230" left="92" width="157" height="12" font="12">Drug Ther Bull. 2003;41:86 – 8.</text>
<text top="244" left="64" width="354" height="12" font="12">895. Treese N, Erbel R, Meyer J. Acute hemodynamic effects of</text>
<text top="258" left="92" width="327" height="12" font="12">nicorandil in coronary artery disease. J Cardiovasc Pharmacol.</text>
<text top="272" left="92" width="130" height="12" font="12">1992;20 Suppl 3:S52–S56.</text>
<text top="286" left="64" width="354" height="12" font="12">896. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in</text>
<text top="300" left="92" width="327" height="12" font="12">comparison with isosorbide—mononitrate and isosorbide dinitrate:</text>
<text top="314" left="92" width="327" height="12" font="12">results from two multicenter, double-blind, randomized studies with</text>
<text top="328" left="92" width="327" height="12" font="12">stable coronary heart disease patients. J Cardiovasc Pharmacol.</text>
<text top="342" left="92" width="132" height="12" font="12">1992;20 Suppl 3:S74 –S81.</text>
<text top="356" left="64" width="354" height="12" font="12">897. Di Somma S., Liguori V, Petitto M, et al. A double-blind</text>
<text top="370" left="92" width="327" height="12" font="12">comparison of nicorandil and metoprolol in stable effort angina</text>
<text top="384" left="92" width="243" height="12" font="12">pectoris. Cardiovasc Drugs Ther. 1993;7:119 –23.</text>
<text top="398" left="64" width="354" height="12" font="12">898. Effect of nicorandil on coronary events in patients with stable</text>
<text top="412" left="92" width="327" height="12" font="12">angina: the Impact Of Nicorandil in Angina (IONA) randomised</text>
<text top="426" left="92" width="161" height="12" font="12">trial. Lancet. 2002;359:1269 –75.</text>
<text top="440" left="64" width="354" height="12" font="12">899. Rajaratnam R, Brieger DB, Hawkins R, et al. Attenuation of</text>
<text top="454" left="92" width="327" height="12" font="12">anti-ischemic efficacy during chronic therapy with nicorandil in</text>
<text top="468" left="92" width="327" height="12" font="12">patients with stable angina pectoris. Am J Cardiol. 1999;83:</text>
<text top="482" left="92" width="66" height="12" font="12">1120 – 4, A9.</text>
<text top="496" left="64" width="354" height="12" font="12">900. DiFrancesco D, Camm JA. Heart rate lowering by specific and</text>
<text top="510" left="92" width="327" height="12" font="12">selective I(f) current inhibition with ivabradine: a new therapeutic</text>
<text top="524" left="92" width="308" height="12" font="12">perspective in cardiovascular disease. Drugs. 2004;64:1757– 65.</text>
<text top="538" left="64" width="354" height="12" font="12">901. Joannides R, Moore N, Iacob M, et al. Comparative effects of</text>
<text top="552" left="92" width="327" height="12" font="12">ivabradine, a selective heart rate-lowering agent, and propranolol on</text>
<text top="566" left="92" width="327" height="12" font="12">systemic and cardiac haemodynamics at rest and during exercise.</text>
<text top="580" left="92" width="190" height="12" font="12">Br J Clin Pharmacol. 2006;61:127–37.</text>
<text top="594" left="64" width="354" height="12" font="12">902. Manz M, Reuter M, Lauck G, et al. A single intravenous dose of</text>
<text top="608" left="92" width="327" height="12" font="12">ivabradine, a novel I(f) inhibitor, lowers heart rate but does not</text>
<text top="622" left="92" width="327" height="12" font="12">depress left ventricular function in patients with left ventricular</text>
<text top="636" left="92" width="213" height="12" font="12">dysfunction. Cardiology. 2003;100:149 –55.</text>
<text top="650" left="64" width="354" height="12" font="12">903. Camm AJ, Lau CP. Electrophysiological effects of a single intrave-</text>
<text top="664" left="92" width="327" height="12" font="12">nous administration of ivabradine (S 16257) in adult patients with</text>
<text top="678" left="92" width="298" height="12" font="12">normal baseline electrophysiology. Drugs R D. 2003;4:83–9.</text>
<text top="692" left="64" width="354" height="12" font="12">904. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects</text>
<text top="706" left="92" width="327" height="12" font="12">of ivabradine, an I(f) inhibitor, in stable angina: a randomized,</text>
<text top="720" left="92" width="327" height="12" font="12">double-blind, multicentered, placebo-controlled trial. Circulation.</text>
<text top="734" left="92" width="87" height="12" font="12">2003;107:817–23.</text>
<text top="747" left="64" width="354" height="12" font="12">905. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new</text>
<text top="761" left="92" width="327" height="12" font="12">selective I(f) inhibitor, compared with atenolol in patients with</text>
<text top="775" left="92" width="265" height="12" font="12">chronic stable angina. Eur Heart J. 2005;26:2529 –36.</text>
<text top="789" left="64" width="354" height="12" font="12">906. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable</text>
<text top="803" left="92" width="327" height="12" font="12">coronary artery disease and left-ventricular systolic dysfunction</text>
<text top="817" left="92" width="327" height="12" font="12">(BEAUTIFUL): a randomised, double-blind, placebo-controlled</text>
<text top="831" left="92" width="154" height="12" font="12">trial. Lancet. 2008;372:807–16.</text>
<text top="845" left="64" width="354" height="12" font="12">907. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug</text>
<text top="859" left="92" width="327" height="12" font="12">trimetazidine shifts cardiac energy metabolism from fatty acid</text>
<text top="873" left="92" width="327" height="12" font="12">oxidation to glucose oxidation by inhibiting mitochondrial long-</text>
<text top="887" left="92" width="317" height="12" font="12">chain – ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580 – 8.</text>
<text top="901" left="64" width="354" height="12" font="12">908. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in</text>
<text top="915" left="92" width="327" height="12" font="12">stable angina: a meta-analysis of randomized, double-blind, con-</text>
<text top="929" left="92" width="236" height="12" font="12">trolled trials. Coron Artery Dis. 2003;14:171–9.</text>
<text top="943" left="64" width="354" height="12" font="12">909. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina.</text>
<text top="957" left="92" width="234" height="12" font="12">Cochrane Database Syst Rev. 2005;CD003614.</text>
<text top="971" left="64" width="354" height="12" font="12">910. Arora RR, Chou TM, Jain D, et al. The multicenter study of</text>
<text top="985" left="92" width="327" height="12" font="12">enhanced external counterpulsation (MUST-EECP): effect of</text>
<text top="999" left="92" width="327" height="12" font="12">EECP on exercise-induced myocardial ischemia and anginal epi-</text>
<text top="1013" left="92" width="221" height="12" font="12">sodes. J Am Coll Cardiol. 1999;33:1833– 40.</text>
<text top="1027" left="64" width="354" height="12" font="12">911. Mannheimer C, Eliasson T, Augustinsson LE, et al. Electrical</text>
<text top="1041" left="92" width="327" height="12" font="12">stimulation versus coronary artery bypass surgery in severe angina</text>
<text top="1055" left="92" width="282" height="12" font="12">pectoris: the ESBY study. Circulation. 1998;97:1157– 63.</text>
<text top="1069" left="64" width="354" height="12" font="12">912. Hautvast RW, DeJongste MJ, Staal MJ, et al. Spinal cord stimu-</text>
<text top="1083" left="92" width="327" height="12" font="12">lation in chronic intractable angina pectoris: a randomized, con-</text>
<text top="1097" left="92" width="267" height="12" font="12">trolled efficacy study. Am Heart J. 1998;136:1114 –20.</text>
<text top="105" left="451" width="354" height="12" font="12">913. van der Sloot JA, Huikeshoven M, Tukkie R, et al. Transmyocardial</text>
<text top="118" left="479" width="327" height="12" font="12">revascularization using an XeCl excimer laser: results of a random-</text>
<text top="132" left="479" width="227" height="12" font="12">ized trial. Ann Thorac Surg. 2004;78:875– 81.</text>
<text top="145" left="451" width="354" height="12" font="12">914. Guleserian KJ, Maniar HS, Camillo CJ, et al. Quality of life and</text>
<text top="159" left="479" width="327" height="12" font="12">survival after transmyocardial laser revascularization with the hol-</text>
<text top="173" left="479" width="267" height="12" font="12">mium:YAG laser. Ann Thorac Surg. 2003;75:1842–7.</text>
<text top="186" left="451" width="354" height="12" font="12">915. Myers J, Oesterle SN, Jones J, et al. Do transmyocardial and</text>
<text top="200" left="479" width="327" height="12" font="12">percutaneous laser revascularization induce silent ischemia? An</text>
<text top="213" left="479" width="305" height="12" font="12">assessment by exercise testing. Am Heart J. 2002;143:1052–7.</text>
<text top="227" left="451" width="354" height="12" font="12">916. Ballegaard S, Pedersen F, Pietersen A, et al. Effects of acupuncture</text>
<text top="240" left="479" width="327" height="12" font="12">in moderate, stable angina pectoris: a controlled study. J Intern</text>
<text top="254" left="479" width="111" height="12" font="12">Med. 1990;227:25–30.</text>
<text top="268" left="451" width="354" height="12" font="12">917. Ballegaard S, Jensen G, Pedersen F, et al. Acupuncture in severe,</text>
<text top="281" left="479" width="327" height="12" font="12">stable angina pectoris: a randomized trial. Acta Med Scand. 1986;</text>
<text top="295" left="479" width="60" height="12" font="12">220:307–13.</text>
<text top="308" left="451" width="354" height="12" font="12">918. Spertus JA, Jones PG, Coen M, et al. Transmyocardial CO(2) laser</text>
<text top="322" left="479" width="327" height="12" font="12">revascularization improves symptoms, function, and quality of life:</text>
<text top="336" left="479" width="327" height="12" font="12">1–month results from a randomized controlled trial. Am J Med.</text>
<text top="349" left="479" width="83" height="12" font="12">2001;111:341– 8.</text>
<text top="363" left="451" width="354" height="12" font="12">919. Bridges CR, Horvath KA, Nugent WC, et al. The Society of</text>
<text top="376" left="479" width="327" height="12" font="12">Thoracic Surgeons practice guideline series: transmyocardial laser</text>
<text top="390" left="479" width="276" height="12" font="12">revascularization. Ann Thorac Surg. 2004;77:1494 –502.</text>
<text top="404" left="451" width="354" height="12" font="12">920. Vineberg AM. Development of an anastomosis between the coro-</text>
<text top="417" left="479" width="327" height="12" font="12">nary vessels and a transplanted internal mammary artery. Can Med</text>
<text top="431" left="479" width="119" height="12" font="12">Assoc J. 1946;55:117–9.</text>
<text top="444" left="451" width="354" height="12" font="12">921. Stone GW, Teirstein PS, Rubenstein R, et al. A prospective,</text>
<text top="458" left="479" width="327" height="12" font="12">multicenter, randomized trial of percutaneous transmyocardial laser</text>
<text top="472" left="479" width="327" height="12" font="12">revascularization in patients with nonrecanalizable chronic total</text>
<text top="485" left="479" width="237" height="12" font="12">occlusions. J Am Coll Cardiol. 2002;39:1581–7.</text>
<text top="499" left="451" width="354" height="12" font="12">922. Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocar-</text>
<text top="512" left="479" width="327" height="12" font="12">dial laser revascularisation for severe angina: the PACIFIC ran-</text>
<text top="526" left="479" width="327" height="12" font="12">domised trial. Potential Class Improvement From Intramyocardial</text>
<text top="540" left="479" width="186" height="12" font="12">Channels. Lancet. 2000;356:1705–10.</text>
<text top="553" left="451" width="354" height="12" font="12">923. Aaberge L, Nordstrand K, Dragsund M, et al. Transmyocardial</text>
<text top="567" left="479" width="327" height="12" font="12">revascularization with CO2 laser in patients with refractory angina</text>
<text top="580" left="479" width="327" height="12" font="12">pectoris. Clinical results from the Norwegian randomized trial.</text>
<text top="594" left="479" width="182" height="12" font="12">J Am Coll Cardiol. 2000;35:1170 –7.</text>
<text top="608" left="451" width="354" height="12" font="12">924. Frazier OH, March RJ, Horvath KA. Transmyocardial revascular-</text>
<text top="621" left="479" width="327" height="12" font="12">ization with a carbon dioxide laser in patients with end-stage</text>
<text top="635" left="479" width="286" height="12" font="12">coronary artery disease. N Engl J Med. 1999;341:1021– 8.</text>
<text top="648" left="451" width="354" height="12" font="12">925. Jones JW, Schmidt SE, Richman BW, et al. Holmium:YAG laser</text>
<text top="662" left="479" width="327" height="12" font="12">transmyocardial revascularization relieves angina and improves func-</text>
<text top="675" left="479" width="256" height="12" font="12">tional status. Ann Thorac Surg. 1999;67:1596 – 601.</text>
<text top="689" left="451" width="354" height="12" font="12">926. Galinanes M, Loubani M, Sensky PR, et al. Efficacy of transmyo-</text>
<text top="703" left="479" width="327" height="12" font="12">cardial laser revascularization and thoracic sympathectomy for the</text>
<text top="716" left="479" width="325" height="12" font="12">treatment of refractory angina. Ann Thorac Surg. 2004;78:122– 8.</text>
<text top="730" left="451" width="354" height="12" font="12">927. Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser</text>
<text top="743" left="479" width="327" height="12" font="12">revascularisation compared with continued medical therapy for</text>
<text top="757" left="479" width="327" height="12" font="12">treatment of refractory angina pectoris: a prospective randomised</text>
<text top="771" left="479" width="327" height="12" font="12">trial. ATLANTIC Investigators. Angina Treatments-Lasers and</text>
<text top="784" left="479" width="301" height="12" font="12">Normal Therapies in Comparison. Lancet. 1999;354:885–90.</text>
<text top="798" left="451" width="354" height="12" font="12">928. Allen KB, Dowling RD, Fudge TL, et al. Comparison of trans-</text>
<text top="811" left="479" width="327" height="12" font="12">myocardial revascularization with medical therapy in patients with</text>
<text top="825" left="479" width="263" height="12" font="12">refractory angina. N Engl J Med. 1999;341:1029 –36.</text>
<text top="838" left="451" width="354" height="12" font="12">929. Schofield PM, Sharples LD, Caine N, et al. Transmyocardial laser</text>
<text top="852" left="479" width="327" height="12" font="12">revascularisation in patients with refractory angina: a randomised</text>
<text top="866" left="479" width="208" height="12" font="12">controlled trial. Lancet. 1999;353:519 –24.</text>
<text top="879" left="451" width="354" height="12" font="12">930. Dowling RD, Petracek MR, Selinger SL, et al. Transmyocardial</text>
<text top="893" left="479" width="327" height="12" font="12">revascularization in patients with refractory, unstable angina. Cir-</text>
<text top="906" left="479" width="139" height="12" font="12">culation. 1998;98:II73–II75.</text>
<text top="920" left="451" width="354" height="12" font="12">931. Allen KB, Dowling RD, Angell WW, et al. Transmyocardial</text>
<text top="934" left="479" width="327" height="12" font="12">revascularization: 5-year follow-up of a prospective, randomized</text>
<text top="947" left="479" width="269" height="12" font="12">multicenter trial. Ann Thorac Surg. 2004;77:1228 –34.</text>
<text top="961" left="451" width="354" height="12" font="12">932. Liao L, Sarria-Santamera A, Matchar DB, et al. Meta-analysis of</text>
<text top="974" left="479" width="327" height="12" font="12">survival and relief of angina pectoris after transmyocardial revascu-</text>
<text top="988" left="479" width="208" height="12" font="12">larization. Am J Cardiol. 2005;95:1243–5.</text>
<text top="1001" left="451" width="354" height="12" font="12">933. Mukherjee D, Bhatt DL, Roe MT, et al. Direct myocardial</text>
<text top="1015" left="479" width="327" height="12" font="12">revascularization and angiogenesis— how many patients might be</text>
<text top="1029" left="479" width="229" height="12" font="12">eligible? Am J Cardiol. 1999;84:598 – 600, A8.</text>
<text top="1042" left="451" width="354" height="12" font="12">934. Bernstein SJ, Brorsson B, Aberg T, et al. Appropriateness of referral</text>
<text top="1056" left="479" width="327" height="12" font="12">of coronary angiography patients in Sweden. SECOR/SBU Project</text>
<text top="1069" left="479" width="151" height="12" font="12">Group. Heart. 1999;81:470 –7.</text>
<text top="1083" left="451" width="354" height="12" font="12">935. Brorsson B, Bernstein SJ, Brook RH, et al. Quality of life of patients</text>
<text top="1097" left="479" width="327" height="12" font="12">with chronic stable angina before and four years after coronary</text>
<text top="52" left="58" width="25" height="10" font="12">e150</text>
<text top="52" left="112" width="48" height="10" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="108" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="92" width="327" height="12" font="12">revascularisation compared with a normal population. Heart.</text>
<text top="118" left="92" width="77" height="12" font="12">2002;87:140 –5.</text>
<text top="132" left="64" width="354" height="12" font="12">936. Akhtar M, Wu GF, Du ZM, et al. Effect of external counterpul-</text>
<text top="145" left="92" width="327" height="12" font="12">sation on plasma nitric oxide and endothelin-1 levels. Am J Cardiol.</text>
<text top="159" left="92" width="77" height="12" font="12">2006;98:28 –30.</text>
<text top="172" left="64" width="354" height="12" font="12">937. Shechter M, Matetzky S, Feinberg MS, et al. External counterpul-</text>
<text top="186" left="92" width="327" height="12" font="12">sation therapy improves endothelial function in patients with</text>
<text top="200" left="92" width="313" height="12" font="12">refractory angina pectoris. J Am Coll Cardiol. 2003;42:2090 –5.</text>
<text top="213" left="64" width="354" height="12" font="12">938. Urano H, Ikeda H, Ueno T, et al. Enhanced external counter-</text>
<text top="227" left="92" width="327" height="12" font="12">pulsation improves exercise tolerance, reduces exercise-induced</text>
<text top="240" left="92" width="327" height="12" font="12">myocardial ischemia and improves left ventricular diastolic filling</text>
<text top="254" left="92" width="327" height="12" font="12">in patients with coronary artery disease. J Am Coll Cardiol.</text>
<text top="268" left="92" width="72" height="12" font="12">2001;37:93–9.</text>
<text top="281" left="64" width="354" height="12" font="12">939. Shah SA, Shapiro RJ, Mehta R, et al. Impact of enhanced external</text>
<text top="295" left="92" width="327" height="12" font="12">counterpulsation on Canadian Cardiovascular Society angina class</text>
<text top="308" left="92" width="327" height="12" font="12">in patients with chronic stable angina: a meta-analysis. Pharmaco-</text>
<text top="322" left="92" width="127" height="12" font="12">therapy. 2010;30:639 – 45.</text>
<text top="336" left="64" width="354" height="12" font="12">940. Stys TP, Lawson WE, Hui JC, et al. Effects of enhanced external</text>
<text top="349" left="92" width="327" height="12" font="12">counterpulsation on stress radionuclide coronary perfusion and</text>
<text top="363" left="92" width="327" height="12" font="12">exercise capacity in chronic stable angina pectoris. Am J Cardiol.</text>
<text top="376" left="92" width="77" height="12" font="12">2002;89:822– 4.</text>
<text top="390" left="64" width="354" height="12" font="12">941. Barsness G, Feldman AM, Holmes DR Jr., et al. The International</text>
<text top="404" left="92" width="327" height="12" font="12">EECP Patient Registry (IEPR): design, methods, baseline charac-</text>
<text top="417" left="92" width="284" height="12" font="12">teristics, and acute results. Clin Cardiol. 2001;24:435– 42.</text>
<text top="431" left="64" width="354" height="12" font="12">942. Amin F, Al Hajeri A, Civelek B, et al. Enhanced external counter-</text>
<text top="444" left="92" width="327" height="12" font="12">pulsation for chronic angina pectoris. Cochrane Database Syst Rev.</text>
<text top="458" left="92" width="85" height="12" font="12">2010;CD007219.</text>
<text top="471" left="64" width="354" height="12" font="12">943. De Jongste MJ, Haaksma J, Hautvast RW, et al. Effects of spinal</text>
<text top="485" left="92" width="327" height="12" font="12">cord stimulation on myocardial ischaemia during daily life in</text>
<text top="499" left="92" width="327" height="12" font="12">patients with severe coronary artery disease. A prospective ambula-</text>
<text top="512" left="92" width="293" height="12" font="12">tory electrocardiographic study. Br Heart J. 1994;71:413– 8.</text>
<text top="526" left="64" width="354" height="12" font="12">944. De Landsheere C, Mannheimer C, Habets A, et al. Effect of spinal</text>
<text top="539" left="92" width="327" height="12" font="12">cord stimulation on regional myocardial perfusion assessed by</text>
<text top="553" left="92" width="311" height="12" font="12">positron emission tomography. Am J Cardiol. 1992;69:1143–9.</text>
<text top="567" left="64" width="354" height="12" font="12">945. Hautvast RW, Blanksma PK, DeJongste MJ, et al. Effect of spinal</text>
<text top="580" left="92" width="327" height="12" font="12">cord stimulation on myocardial blood flow assessed by positron</text>
<text top="594" left="92" width="327" height="12" font="12">emission tomography in patients with refractory angina pectoris.</text>
<text top="607" left="92" width="149" height="12" font="12">Am J Cardiol. 1996;77:462–7.</text>
<text top="621" left="64" width="354" height="12" font="12">946. Di Pede F., Lanza GA, Zuin G, et al. Immediate and long-term</text>
<text top="635" left="92" width="327" height="12" font="12">clinical outcome after spinal cord stimulation for refractory stable</text>
<text top="648" left="92" width="230" height="12" font="12">angina pectoris. Am J Cardiol. 2003;91:951–5.</text>
<text top="662" left="64" width="354" height="12" font="12">947. Lapenna E, Rapati D, Cardano P, et al. Spinal cord stimulation for</text>
<text top="675" left="92" width="327" height="12" font="12">patients with refractory angina and previous coronary surgery. Ann</text>
<text top="689" left="92" width="153" height="12" font="12">Thorac Surg. 2006;82:1704 – 8.</text>
<text top="702" left="64" width="354" height="12" font="12">948. Richter A, Herlitz J, Hjalmarson A. Effect of acupuncture in</text>
<text top="716" left="92" width="291" height="12" font="12">patients with angina pectoris. Eur Heart J. 1991;12:175– 8.</text>
<text top="730" left="64" width="354" height="12" font="12">949. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in</text>
<text top="743" left="92" width="327" height="12" font="12">patients with de novo left main disease treated with either percuta-</text>
<text top="757" left="92" width="327" height="12" font="12">neous coronary intervention using paclitaxel-eluting stents or coro-</text>
<text top="770" left="92" width="327" height="12" font="12">nary artery bypass graft treatment in the Synergy Between Percuta-</text>
<text top="784" left="92" width="327" height="12" font="12">neous Coronary Intervention with TAXUS and Cardiac Surgery</text>
<text top="798" left="92" width="243" height="12" font="12">(SYNTAX) trial. Circulation. 2010;121:2645–53.</text>
<text top="811" left="64" width="354" height="12" font="12">950. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous</text>
<text top="825" left="92" width="327" height="12" font="12">coronary intervention versus coronary-artery bypass grafting for</text>
<text top="838" left="92" width="317" height="12" font="12">severe coronary artery disease. N Engl J Med. 2009;360:961–72.</text>
<text top="852" left="64" width="354" height="12" font="12">951. Feit F, Brooks MM, Sopko G, et al. Long-term clinical outcome in</text>
<text top="865" left="92" width="327" height="12" font="12">the Bypass Angioplasty Revascularization Investigation Registry:</text>
<text top="879" left="92" width="327" height="12" font="12">comparison with the randomized trial. BARI Investigators. Circu-</text>
<text top="893" left="92" width="135" height="12" font="12">lation. 2000;101:2795– 802.</text>
<text top="906" left="64" width="354" height="12" font="12">952. King SB, III, Barnhart HX, Kosinski AS, et al. Angioplasty or</text>
<text top="920" left="92" width="327" height="12" font="12">surgery for multivessel coronary artery disease: comparison of</text>
<text top="933" left="92" width="327" height="12" font="12">eligible registry and randomized patients in the EAST trial and</text>
<text top="947" left="92" width="327" height="12" font="12">influence of treatment selection on outcomes. Emory Angioplasty</text>
<text top="961" left="92" width="326" height="12" font="12">versus Surgery Trial Investigators. Am J Cardiol. 1997;79:1453–9.</text>
<text top="974" left="64" width="354" height="12" font="12">953. Chakravarty T, Buch MH, Naik H, et al. Predictive accuracy of</text>
<text top="988" left="92" width="327" height="12" font="12">SYNTAX score for predicting long-term outcomes of unprotected</text>
<text top="1001" left="92" width="327" height="12" font="12">left main coronary artery revascularization. Am J Cardiol. 2011;107:</text>
<text top="1015" left="92" width="36" height="12" font="12">360 – 6.</text>
<text top="1028" left="64" width="354" height="12" font="12">954. Grover FL, Shroyer AL, Hammermeister K, et al. A decade’s</text>
<text top="1042" left="92" width="327" height="12" font="12">experience with quality improvement in cardiac surgery using the</text>
<text top="1056" left="92" width="327" height="12" font="12">Veterans Affairs and Society of Thoracic Surgeons national data-</text>
<text top="1069" left="92" width="176" height="12" font="12">bases. Ann Surg. 2001;234:464 –72.</text>
<text top="1083" left="64" width="354" height="12" font="12">955. Kim YH, Park DW, Kim WJ, et al. Validation of SYNTAX</text>
<text top="1096" left="92" width="327" height="12" font="12">(Synergy between PCI with Taxus and Cardiac Surgery) score for</text>
<text top="104" left="479" width="327" height="12" font="12">prediction of outcomes after unprotected left main coronary</text>
<text top="118" left="479" width="285" height="12" font="12">revascularization. J Am Coll Cardiol Intv. 2010;3:612–23.</text>
<text top="131" left="451" width="354" height="12" font="12">956. Shahian DM, O’Brien SM, Filardo G, et al. The Society of</text>
<text top="145" left="479" width="327" height="12" font="12">Thoracic Surgeons 2008 cardiac surgery risk models: part — cor-</text>
<text top="159" left="479" width="327" height="12" font="12">onary artery bypass grafting surgery. Ann Thorac Surg. 2009;88:</text>
<text top="172" left="479" width="35" height="12" font="12">S2–22.</text>
<text top="186" left="451" width="354" height="12" font="12">957. Shahian DM, O’Brien SM, Normand SL, et al. Association of</text>
<text top="199" left="479" width="327" height="12" font="12">hospital coronary artery bypass volume with processes of care,</text>
<text top="213" left="479" width="327" height="12" font="12">mortality, morbidity, and the Society of Thoracic Surgeons com-</text>
<text top="227" left="479" width="323" height="12" font="12">posite quality score. J Thorac Cardiovasc Surg. 2010;139:273– 82.</text>
<text top="240" left="451" width="354" height="12" font="12">958. Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes</text>
<text top="254" left="479" width="327" height="12" font="12">of unprotected left main stenting in comparison with surgical</text>
<text top="267" left="479" width="270" height="12" font="12">revascularization. J Am Coll Cardiol. 2008;51:538 – 45.</text>
<text top="281" left="451" width="354" height="12" font="12">959. Dzavik V, Ghali WA, Norris C, et al. Long-term survival in 11,661</text>
<text top="294" left="479" width="327" height="12" font="12">patients with multivessel coronary artery disease in the era of</text>
<text top="308" left="479" width="327" height="12" font="12">stenting: a report from the Alberta Provincial Project for Outcome</text>
<text top="322" left="479" width="327" height="12" font="12">Assessment in Coronary Heart Disease (APPROACH) Investiga-</text>
<text top="335" left="479" width="180" height="12" font="12">tors. Am Heart J. 2001;142:119 –26.</text>
<text top="349" left="451" width="354" height="12" font="12">960. Takaro T, Hultgren HN, Lipton MJ, et al. The VA cooperative</text>
<text top="362" left="479" width="327" height="12" font="12">randomized study of surgery for coronary arterial occlusive disease</text>
<text top="376" left="479" width="327" height="12" font="12">II. Subgroup with significant left main lesions. Circulation. 1976;</text>
<text top="390" left="479" width="87" height="12" font="12">54:III107–III117.</text>
<text top="403" left="451" width="354" height="12" font="12">961. Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of</text>
<text top="417" left="479" width="327" height="12" font="12">patients with left main coronary artery disease. Veterans Adminis-</text>
<text top="430" left="479" width="327" height="12" font="12">tration Cooperative Study of Surgery for Coronary Arterial Occlu-</text>
<text top="444" left="479" width="204" height="12" font="12">sive Disease. Circulation. 1982;66:14 –22.</text>
<text top="458" left="451" width="354" height="12" font="12">962. Taylor HA, Deumite NJ, Chaitman BR, et al. Asymptomatic left</text>
<text top="471" left="479" width="327" height="12" font="12">main coronary artery disease in the Coronary Artery Surgery Study</text>
<text top="485" left="479" width="229" height="12" font="12">(CASS) registry. Circulation. 1989;79:1171–9.</text>
<text top="498" left="451" width="354" height="12" font="12">963. Capodanno D, Caggegi A, Miano M, et al. Global Risk Classifi-</text>
<text top="512" left="479" width="327" height="12" font="12">cation and Clinical SYNTAX (Synergy between Percutaneous</text>
<text top="526" left="479" width="327" height="12" font="12">Coronary Intervention with TAXUS and Cardiac Surgery) Score in</text>
<text top="539" left="479" width="327" height="12" font="12">Patients Undergoing Percutaneous or Surgical Left Main Revascu-</text>
<text top="553" left="479" width="251" height="12" font="12">larization. J Am Coll Cardiol Intv. 2011;4:287–97.</text>
<text top="566" left="451" width="354" height="12" font="12">964. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs.</text>
<text top="580" left="479" width="327" height="12" font="12">coronary-artery bypass grafting in multivessel coronary disease.</text>
<text top="594" left="479" width="168" height="12" font="12">N Engl J Med. 2008;358:331– 41.</text>
<text top="607" left="451" width="354" height="12" font="12">965. Ellis SG, Tamai H, Nobuyoshi M, et al. Contemporary percutane-</text>
<text top="621" left="479" width="327" height="12" font="12">ous treatment of unprotected left main coronary stenoses: initial</text>
<text top="634" left="479" width="327" height="12" font="12">results from a multicenter registry analysis 199 –1996. Circulation.</text>
<text top="648" left="479" width="87" height="12" font="12">1997;96:3867–72.</text>
<text top="661" left="451" width="354" height="12" font="12">966. Biondi-Zoccai GG, Lotrionte M, Moretti C, et al. A collaborative</text>
<text top="675" left="479" width="327" height="12" font="12">systematic review and meta-analysis on 1278 patients undergoing</text>
<text top="689" left="479" width="327" height="12" font="12">percutaneous drug-eluting stenting for unprotected left main coro-</text>
<text top="702" left="479" width="253" height="12" font="12">nary artery disease. Am Heart J. 2008;155:274 – 83.</text>
<text top="716" left="451" width="354" height="12" font="12">967. Boudriot E, Thiele H, Walther T, et al. Randomized comparison of</text>
<text top="729" left="479" width="327" height="12" font="12">percutaneous coronary intervention with sirolimus-eluting stents</text>
<text top="743" left="479" width="327" height="12" font="12">versus coronary artery bypass grafting in unprotected left main stem</text>
<text top="757" left="479" width="228" height="12" font="12">stenosis. J Am Coll Cardiol. 2011;57:538 – 45.</text>
<text top="770" left="451" width="354" height="12" font="12">968. Brener SJ, Galla JM, Bryant R, III, et al. Comparison of percuta-</text>
<text top="784" left="479" width="327" height="12" font="12">neous versus surgical revascularization of severe unprotected left</text>
<text top="797" left="479" width="327" height="12" font="12">main coronary stenosis in matched patients. Am J Cardiol. 2008;</text>
<text top="811" left="479" width="62" height="12" font="12">101:169 –72.</text>
<text top="824" left="451" width="354" height="12" font="12">969. Chieffo A, Magni V, Latib A, et al. 5-year outcomes following</text>
<text top="838" left="479" width="327" height="12" font="12">percutaneous coronary intervention with drug-eluting stent implan-</text>
<text top="852" left="479" width="327" height="12" font="12">tation versus coronary artery bypass graft for unprotected left main</text>
<text top="865" left="479" width="327" height="12" font="12">coronary artery lesions the milan experience. J Am Coll Cardiol</text>
<text top="879" left="479" width="109" height="12" font="12">Intv. 2010;3:595– 601.</text>
<text top="892" left="451" width="354" height="12" font="12">970. Chieffo A, Morici N, Maisano F, et al. Percutaneous treatment with</text>
<text top="906" left="479" width="327" height="12" font="12">drug-eluting stent implantation versus bypass surgery for unpro-</text>
<text top="920" left="479" width="327" height="12" font="12">tected left main stenosis: a single-center experience. Circulation.</text>
<text top="933" left="479" width="87" height="12" font="12">2006;113:2542–7.</text>
<text top="947" left="451" width="354" height="12" font="12">971. Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery</text>
<text top="960" left="479" width="327" height="12" font="12">bypass surgery with percutaneous coronary intervention with drug-</text>
<text top="974" left="479" width="327" height="12" font="12">eluting stents for unprotected left main coronary artery disease.</text>
<text top="987" left="479" width="182" height="12" font="12">J Am Coll Cardiol. 2006;47:864 –70.</text>
<text top="1001" left="451" width="354" height="12" font="12">972. Makikallio TH, Niemela M, Kervinen K, et al. Coronary angio-</text>
<text top="1015" left="479" width="327" height="12" font="12">plasty in drug eluting stent era for the treatment of unprotected left</text>
<text top="1028" left="479" width="327" height="12" font="12">main stenosis compared to coronary artery bypass grafting. Ann</text>
<text top="1042" left="479" width="113" height="12" font="12">Med. 2008;40:437– 43.</text>
<text top="1055" left="451" width="354" height="12" font="12">973. Naik H, White AJ, Chakravarty T, et al. A meta-analysis of 3,773</text>
<text top="1069" left="479" width="327" height="12" font="12">patients treated with percutaneous coronary intervention or surgery</text>
<text top="1083" left="479" width="327" height="12" font="12">for unprotected left main coronary artery stenosis. J Am Coll</text>
<text top="1096" left="479" width="146" height="12" font="12">Cardiol Intv. 2009;2:739 – 47.</text>
<text top="52" left="781" width="25" height="10" font="12">e151</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="109" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="65" width="354" height="12" font="12">974. Palmerini T, Marzocchi A, Marrozzini C, et al. Comparison</text>
<text top="118" left="92" width="327" height="12" font="12">between coronary angioplasty and coronary artery bypass surgery for</text>
<text top="132" left="92" width="327" height="12" font="12">the treatment of unprotected left main coronary artery stenosis (the</text>
<text top="146" left="92" width="240" height="12" font="12">Bologna Registry). Am J Cardiol. 2006;98:54 –9.</text>
<text top="160" left="65" width="354" height="12" font="12">975. Park DW, Seung KB, Kim YH, et al. Long-term safety and efficacy</text>
<text top="174" left="92" width="327" height="12" font="12">of stenting versus coronary artery bypass grafting for unprotected left</text>
<text top="188" left="92" width="327" height="12" font="12">main coronary artery disease: 5-year results from the MAIN-</text>
<text top="202" left="92" width="327" height="12" font="12">COMPARE (Revascularization for Unprotected Left Main Coro-</text>
<text top="216" left="92" width="327" height="12" font="12">nary Artery Stenosis: Comparison of Percutaneous Coronary An-</text>
<text top="230" left="92" width="327" height="12" font="12">gioplasty Versus Surgical Revascularization) registry. J Am Coll</text>
<text top="244" left="92" width="125" height="12" font="12">Cardiol. 2010;56:117–24.</text>
<text top="258" left="65" width="354" height="12" font="12">976. Rodes-Cabau J, Deblois J, Bertrand OF, et al. Nonrandomized</text>
<text top="272" left="92" width="327" height="12" font="12">comparison of coronary artery bypass surgery and percutaneous</text>
<text top="286" left="92" width="327" height="12" font="12">coronary intervention for the treatment of unprotected left main</text>
<text top="300" left="92" width="327" height="12" font="12">coronary artery disease in octogenarians. Circulation. 2008;118:</text>
<text top="314" left="92" width="48" height="12" font="12">2374 – 81.</text>
<text top="328" left="65" width="354" height="12" font="12">977. Sanmartin M, Baz JA, Claro R, et al. Comparison of drug-eluting</text>
<text top="342" left="92" width="327" height="12" font="12">stents versus surgery for unprotected left main coronary artery</text>
<text top="356" left="92" width="197" height="12" font="12">disease. Am J Cardiol. 2007;100:970 –3.</text>
<text top="370" left="65" width="354" height="12" font="12">978. Seung KB, Park DW, Kim YH, et al. Stents versus coronary-artery</text>
<text top="384" left="92" width="327" height="12" font="12">bypass grafting for left main coronary artery disease. N Engl J Med.</text>
<text top="398" left="92" width="93" height="12" font="12">2008;358:1781–92.</text>
<text top="412" left="65" width="354" height="12" font="12">979. White A, Kedia G, Mirocha J, et al. Comparison of coronary artery</text>
<text top="426" left="92" width="327" height="12" font="12">bypass surgery and percutaneous drug-eluting stent implantation for</text>
<text top="440" left="92" width="327" height="12" font="12">treatment of left main coronary artery stenosis. J Am Coll Cardiol</text>
<text top="454" left="92" width="137" height="12" font="12">Card Inter. 2008;1:236 – 45.</text>
<text top="468" left="65" width="354" height="12" font="12">980. Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of</text>
<text top="482" left="92" width="327" height="12" font="12">coronary bypass surgery with drug-eluting stenting for the treatment</text>
<text top="496" left="92" width="327" height="12" font="12">of left main and/or three-vessel disease: 3-year follow-up of the</text>
<text top="510" left="92" width="233" height="12" font="12">SYNTAX trial. Eur Heart J. 2011;32:2125–34.</text>
<text top="524" left="65" width="354" height="12" font="12">981. Montalescot G, Brieger D, Eagle KA, et al. Unprotected left main</text>
<text top="538" left="92" width="327" height="12" font="12">revascularization in patients with acute coronary syndromes. Eur</text>
<text top="552" left="92" width="132" height="12" font="12">Heart J. 2009;30:2308 –17.</text>
<text top="566" left="65" width="354" height="12" font="12">982. Lee MS, Tseng CH, Barker CM, et al. Outcome after surgery and</text>
<text top="580" left="92" width="327" height="12" font="12">percutaneous intervention for cardiogenic shock and left main</text>
<text top="594" left="92" width="211" height="12" font="12">disease. Ann Thorac Surg. 2008;86:29 –34.</text>
<text top="608" left="65" width="354" height="12" font="12">983. Lee MS, Bokhoor P, Park SJ, et al. Unprotected left main coronary</text>
<text top="622" left="92" width="327" height="12" font="12">disease and ST-segment elevation myocardial infarction: a contem-</text>
<text top="636" left="92" width="327" height="12" font="12">porary review and argument for percutaneous coronary intervention.</text>
<text top="650" left="92" width="192" height="12" font="12">J Am Coll Cardiol Intv. 2010;3:791–5.</text>
<text top="664" left="65" width="354" height="12" font="12">984. Park SJ, Kim YH, Park DW, et al. Randomized Trial of Stents</text>
<text top="678" left="92" width="327" height="12" font="12">versus Bypass Surgery for Left Main Coronary Artery Disease.</text>
<text top="692" left="92" width="174" height="12" font="12">N Engl J Med. 2011;364:1718 –27.</text>
<text top="706" left="65" width="354" height="12" font="12">985. Jones RH, Kesler K, Phillips HR III, et al. Long-term survival</text>
<text top="720" left="92" width="327" height="12" font="12">benefits of coronary artery bypass grafting and percutaneous translu-</text>
<text top="734" left="92" width="327" height="12" font="12">minal angioplasty in patients with coronary artery disease. J Thorac</text>
<text top="747" left="92" width="180" height="12" font="12">Cardiovasc Surg. 1996;111:1013–25.</text>
<text top="761" left="65" width="354" height="12" font="12">986. Varnauskas E. Twelve-year follow-up of survival in the randomized</text>
<text top="775" left="92" width="327" height="12" font="12">European Coronary Surgery Study. N Engl J Med. 1988;319:332–7.</text>
<text top="789" left="65" width="354" height="12" font="12">987. Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or</text>
<text top="803" left="92" width="327" height="12" font="12">percutaneous coronary intervention provides differential longevity</text>
<text top="817" left="92" width="218" height="12" font="12">benefit. Ann Thorac Surg. 2006;82:1420 – 8.</text>
<text top="831" left="65" width="354" height="12" font="12">988. Brener SJ, Lytle BW, Casserly IP, et al. Propensity analysis of</text>
<text top="845" left="92" width="327" height="12" font="12">long-term survival after surgical or percutaneous revascularization in</text>
<text top="859" left="92" width="327" height="12" font="12">patients with multivessel coronary artery disease and high-risk</text>
<text top="873" left="92" width="195" height="12" font="12">features. Circulation. 2004;109:2290 –5.</text>
<text top="887" left="65" width="354" height="12" font="12">989. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of</text>
<text top="901" left="92" width="327" height="12" font="12">coronary-artery bypass grafting versus stent implantation. N Engl</text>
<text top="915" left="92" width="134" height="12" font="12">J Med. 2005;352:2174 – 83.</text>
<text top="929" left="65" width="354" height="12" font="12">990. Di Carli MF, Maddahi J, Rokhsar S, et al. Long-term survival of</text>
<text top="943" left="92" width="327" height="12" font="12">patients with coronary artery disease and left ventricular dysfunc-</text>
<text top="957" left="92" width="327" height="12" font="12">tion: implications for the role of myocardial viability assessment in</text>
<text top="971" left="92" width="327" height="12" font="12">management decisions. J Thorac Cardiovasc Surg. 1998;116:997–</text>
<text top="985" left="92" width="27" height="12" font="12">1004.</text>
<text top="999" left="65" width="354" height="12" font="12">991. Sorajja P, Chareonthaitawee P, Rajagopalan N, et al. Improved</text>
<text top="1013" left="92" width="327" height="12" font="12">survival in asymptomatic diabetic patients with high-risk SPECT</text>
<text top="1027" left="92" width="327" height="12" font="12">imaging treated with coronary artery bypass grafting. Circulation.</text>
<text top="1041" left="92" width="102" height="12" font="12">2005;112:I311–I316.</text>
<text top="1055" left="65" width="354" height="12" font="12">992. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac</text>
<text top="1069" left="92" width="327" height="12" font="12">Ischemia Pilot (ACIP) study two-year follow-up: outcomes of</text>
<text top="1083" left="92" width="327" height="12" font="12">patients randomized to initial strategies of medical therapy versus</text>
<text top="1097" left="92" width="238" height="12" font="12">revascularization. Circulation. 1997;95:2037– 43.</text>
<text top="105" left="452" width="354" height="12" font="12">993. Cameron A, Davis KB, Green G, et al. Coronary bypass surgery</text>
<text top="118" left="479" width="327" height="12" font="12">with internal-thoracic-artery grafts— effects on survival over a 15-</text>
<text top="132" left="479" width="223" height="12" font="12">year period. N Engl J Med. 1996;334:216 –9.</text>
<text top="146" left="452" width="354" height="12" font="12">994. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the</text>
<text top="160" left="479" width="327" height="12" font="12">internal-mammary-artery graft on 10-year survival and other cardiac</text>
<text top="173" left="479" width="187" height="12" font="12">events. N Engl J Med. 1986;314:1– 6.</text>
<text top="187" left="452" width="354" height="12" font="12">995. Cashin WL, Sanmarco ME, Nessim SA, et al. Accelerated pro-</text>
<text top="201" left="479" width="327" height="12" font="12">gression of atherosclerosis in coronary vessels with minimal lesions</text>
<text top="215" left="479" width="233" height="12" font="12">that are bypassed. N Engl J Med. 1984;824 – 8.</text>
<text top="229" left="452" width="354" height="12" font="12">996. Pijls NH, de BB, Peels K, et al. Measurement of fractional flow</text>
<text top="242" left="479" width="327" height="12" font="12">reserve to assess the functional severity of coronary-artery stenoses.</text>
<text top="256" left="479" width="168" height="12" font="12">N Engl J Med. 1996;334:1703– 8.</text>
<text top="270" left="452" width="354" height="12" font="12">997. Tonino PA, de BB, Pijls NH, et al. Fractional flow reserve versus</text>
<text top="284" left="479" width="327" height="12" font="12">angiography for guiding percutaneous coronary intervention.</text>
<text top="298" left="479" width="166" height="12" font="12">N Engl J Med. 2009;360:213–24.</text>
<text top="311" left="452" width="354" height="12" font="12">998. Sawada S, Bapat A, Vaz D, et al. Incremental value of myocardial</text>
<text top="325" left="479" width="327" height="12" font="12">viability for prediction of long-term prognosis in surgically revascu-</text>
<text top="339" left="479" width="327" height="12" font="12">larized patients with left ventricular dysfunction. J Am Coll Cardiol.</text>
<text top="353" left="479" width="95" height="12" font="12">2003;42:2099 –105.</text>
<text top="367" left="452" width="354" height="12" font="12">999. O’Connor CM, Velazquez EJ, Gardner LH, et al. Comparison of</text>
<text top="380" left="479" width="327" height="12" font="12">coronary artery bypass grafting versus medical therapy on long-term</text>
<text top="394" left="479" width="327" height="12" font="12">outcome in patients with ischemic cardiomyopathy (a 25-year</text>
<text top="408" left="479" width="327" height="12" font="12">experience from the Duke Cardiovascular Disease Databank). Am J</text>
<text top="422" left="479" width="119" height="12" font="12">Cardiol. 2002;90:101–7.</text>
<text top="435" left="446" width="360" height="12" font="12">1000. Phillips HR, O’Connor CM, Rogers J. Revascularization for heart</text>
<text top="449" left="479" width="185" height="12" font="12">failure. Am Heart J. 2007;153:65–73.</text>
<text top="463" left="446" width="360" height="12" font="12">1001. Tarakji KG, Brunken R, McCarthy PM, et al. Myocardial viability</text>
<text top="477" left="479" width="327" height="12" font="12">testing and the effect of early intervention in patients with advanced</text>
<text top="491" left="479" width="321" height="12" font="12">left ventricular systolic dysfunction. Circulation. 2006;113:230 –7.</text>
<text top="504" left="446" width="360" height="12" font="12">1002. Tsuyuki RT, Shrive FM, Galbraith PD, et al. Revascularization in</text>
<text top="518" left="479" width="256" height="12" font="12">patients with heart failure. CMAJ. 2006;175:361–5.</text>
<text top="532" left="446" width="360" height="12" font="12">1003. Borger van der Burg AE, Bax JJ, Boersma E, et al. Impact of</text>
<text top="546" left="479" width="327" height="12" font="12">percutaneous coronary intervention or coronary artery bypass graft-</text>
<text top="560" left="479" width="327" height="12" font="12">ing on outcome after nonfatal cardiac arrest outside the hospital.</text>
<text top="573" left="479" width="149" height="12" font="12">Am J Cardiol. 2003;91:785–9.</text>
<text top="587" left="446" width="360" height="12" font="12">1004. Kaiser GA, Ghahramani A, Bolooki H, et al. Role of coronary</text>
<text top="601" left="479" width="327" height="12" font="12">artery surgery in patients surviving unexpected cardiac arrest. Sur-</text>
<text top="615" left="479" width="110" height="12" font="12">gery. 1975;78:749 –54.</text>
<text top="628" left="446" width="360" height="12" font="12">1005. The BARI Investigators. Influence of diabetes on 5-year mortality</text>
<text top="642" left="479" width="327" height="12" font="12">and morbidity in a randomized trial comparing CABG and PTCA</text>
<text top="656" left="479" width="327" height="12" font="12">in patients with multivessel disease: the Bypass Angioplasty Revas-</text>
<text top="670" left="479" width="315" height="12" font="12">cularization Investigation (BARI). Circulation. 1997;96:1761–9.</text>
<text top="684" left="446" width="360" height="12" font="12">1006. Banning AP, Westaby S, Morice MC, et al. Diabetic and nondia-</text>
<text top="697" left="479" width="327" height="12" font="12">betic patients with left main and/or 3-vessel coronary artery disease:</text>
<text top="711" left="479" width="327" height="12" font="12">comparison of outcomes with cardiac surgery and paclitaxel-eluting</text>
<text top="725" left="479" width="221" height="12" font="12">stents. J Am Coll Cardiol. 2010;55:1067–75.</text>
<text top="739" left="446" width="360" height="12" font="12">1007. Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of</text>
<text top="752" left="479" width="327" height="12" font="12">randomized controlled trials comparing coronary artery bypass graft</text>
<text top="766" left="479" width="327" height="12" font="12">with percutaneous transluminal coronary angioplasty: one- to eight-</text>
<text top="780" left="479" width="269" height="12" font="12">year outcomes. J Am Coll Cardiol. 2003;41:1293–304.</text>
<text top="794" left="446" width="360" height="12" font="12">1008. Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the</text>
<text top="808" left="479" width="327" height="12" font="12">Medicine, Angioplasty, or Surgery Study (MASS II): a randomized</text>
<text top="821" left="479" width="327" height="12" font="12">controlled clinical trial of 3 therapeutic strategies for multivessel</text>
<text top="835" left="479" width="267" height="12" font="12">coronary artery disease. Circulation. 2007;115:1082–9.</text>
<text top="849" left="446" width="360" height="12" font="12">1009. Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term</text>
<text top="863" left="479" width="327" height="12" font="12">survival of patients with multivessel coronary disease after CABG or</text>
<text top="876" left="479" width="327" height="12" font="12">PCI: analysis of BARI-like patients in northern New England.</text>
<text top="890" left="479" width="164" height="12" font="12">Circulation. 2005;112:I371–I376.</text>
<text top="904" left="446" width="360" height="12" font="12">1010. Niles NW, McGrath PD, Malenka D, et al. Survival of patients</text>
<text top="918" left="479" width="327" height="12" font="12">with diabetes and multivessel coronary artery disease after surgical or</text>
<text top="932" left="479" width="327" height="12" font="12">percutaneous coronary revascularization: results of a large regional</text>
<text top="945" left="479" width="327" height="12" font="12">prospective study. Northern New England Cardiovascular Disease</text>
<text top="959" left="479" width="259" height="12" font="12">Study Group. J Am Coll Cardiol. 2001;37:1008 –15.</text>
<text top="973" left="446" width="360" height="12" font="12">1011. Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary</text>
<text top="987" left="479" width="327" height="12" font="12">bypass surgery versus coronary angioplasty in diabetic patients with</text>
<text top="1000" left="479" width="327" height="12" font="12">multivessel coronary artery disease. J Am Coll Cardiol. 1998;31:</text>
<text top="1014" left="479" width="28" height="12" font="12">10 –9.</text>
<text top="1028" left="446" width="360" height="12" font="12">1012. Benzer W, Hofer S, Oldridge NB. Health-related quality of life in</text>
<text top="1042" left="479" width="327" height="12" font="12">patients with coronary artery disease after different treatments for</text>
<text top="1056" left="479" width="279" height="12" font="12">angina in routine clinical practice. Herz. 2003;28:421– 8.</text>
<text top="1069" left="446" width="360" height="12" font="12">1013. Bonaros N, Schachner T, Ohlinger A, et al. Assessment of health-</text>
<text top="1083" left="479" width="327" height="12" font="12">related quality of life after coronary revascularization. Heart Surg</text>
<text top="1097" left="479" width="139" height="12" font="12">Forum. 2005;8:E380 –E385.</text>
<text top="52" left="59" width="25" height="10" font="12">e152</text>
<text top="52" left="113" width="48" height="10" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="110" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="12" font="12">1014. Bucher HC, Hengstler P, Schindler C, et al. Percutaneous translu-</text>
<text top="118" left="92" width="327" height="12" font="12">minal coronary angioplasty versus medical treatment for non-acute</text>
<text top="132" left="92" width="327" height="12" font="12">coronary heart disease: meta-analysis of randomised controlled</text>
<text top="145" left="92" width="137" height="12" font="12">trials. BMJ. 2000;321:73–7.</text>
<text top="159" left="59" width="360" height="12" font="12">1015. Favarato ME, Hueb W, Boden WE, et al. Quality of life in patients</text>
<text top="172" left="92" width="327" height="12" font="12">with symptomatic multivessel coronary artery disease: a comparative</text>
<text top="186" left="92" width="327" height="12" font="12">post hoc analyses of medical, angioplasty or surgical strategies-</text>
<text top="200" left="92" width="236" height="12" font="12">MASS II trial. Int J Cardiol. 2007;116:364 –70.</text>
<text top="213" left="59" width="360" height="12" font="12">1016. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of</text>
<text top="227" left="92" width="327" height="12" font="12">the Medicine, Angioplasty, or Surgery Study (MASS II): a random-</text>
<text top="240" left="92" width="327" height="12" font="12">ized controlled clinical trial of 3 therapeutic strategies for multivessel</text>
<text top="254" left="92" width="268" height="12" font="12">coronary artery disease. Circulation. 2010;122:949 –57.</text>
<text top="268" left="59" width="360" height="12" font="12">1017. Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employ-</text>
<text top="281" left="92" width="327" height="12" font="12">ment status, and anginal symptoms after coronary angioplasty or</text>
<text top="295" left="92" width="327" height="12" font="12">bypass surgery. 3-year follow-up in the Randomized Intervention</text>
<text top="308" left="92" width="327" height="12" font="12">Treatment of Angina (RITA) Trial. Circulation. 1996;94:135– 42.</text>
<text top="322" left="59" width="360" height="12" font="12">1018. Pocock SJ, Henderson RA, Clayton T, et al. Quality of life after</text>
<text top="336" left="92" width="327" height="12" font="12">coronary angioplasty or continued medical treatment for angina:</text>
<text top="349" left="92" width="327" height="12" font="12">three-year follow-up in the RITA-2 trial. Randomized Intervention</text>
<text top="363" left="92" width="293" height="12" font="12">Treatment of Angina. J Am Coll Cardiol. 2000;35:907–14.</text>
<text top="376" left="59" width="360" height="12" font="12">1019. Trial of invasive versus medical therapy in elderly patients with</text>
<text top="390" left="92" width="327" height="12" font="12">chronic symptomatic coronary-artery disease (TIME): a randomised</text>
<text top="404" left="92" width="148" height="12" font="12">trial. Lancet. 2001;358:951–7.</text>
<text top="417" left="59" width="360" height="12" font="12">1020. Wijeysundera HC, Nallamothu BK, Krumholz HM, et al. Meta-</text>
<text top="431" left="92" width="327" height="12" font="12">analysis: effects of percutaneous coronary intervention versus med-</text>
<text top="444" left="92" width="317" height="12" font="12">ical therapy on angina relief. Ann Intern Med. 2010;152:370 –9.</text>
<text top="458" left="59" width="360" height="12" font="12">1021. Gurfinkel EP, Perez de la Hoz R, Brito VM, et al. Invasive vs</text>
<text top="471" left="92" width="327" height="12" font="12">non-invasive treatment in acute coronary syndromes and prior</text>
<text top="485" left="92" width="228" height="12" font="12">bypass surgery. Int J Cardiol. 2007;119:65–72.</text>
<text top="499" left="59" width="360" height="12" font="12">1022. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary</text>
<text top="512" left="92" width="327" height="12" font="12">intervention versus coronary artery bypass graft surgery for patients</text>
<text top="526" left="92" width="327" height="12" font="12">with medically refractory myocardial ischemia and risk factors for</text>
<text top="539" left="92" width="327" height="12" font="12">adverse outcomes with bypass: a multicenter, randomized trial.</text>
<text top="553" left="92" width="327" height="12" font="12">Investigators of the Department of Veterans Affairs Cooperative</text>
<text top="567" left="92" width="327" height="12" font="12">Study #385, the Angina With Extremely Serious Operative Mor-</text>
<text top="580" left="92" width="327" height="12" font="12">tality Evaluation (AWESOME). J Am Coll Cardiol. 2001;38:</text>
<text top="594" left="92" width="33" height="12" font="12">143–9.</text>
<text top="607" left="59" width="360" height="12" font="12">1023. Subramanian S, Sabik JF, Houghtaling PL, et al. Decision-making</text>
<text top="621" left="92" width="327" height="12" font="12">for patients with patent left internal thoracic artery grafts to left</text>
<text top="635" left="92" width="279" height="12" font="12">anterior descending. Ann Thorac Surg. 2009;87:1392– 8.</text>
<text top="648" left="59" width="360" height="12" font="12">1024. Pfautsch P, Frantz E, Ellmer A, et al. [Long-term outcome of</text>
<text top="662" left="92" width="327" height="12" font="12">therapy of recurrent myocardial ischemia after surgical revascular-</text>
<text top="675" left="92" width="183" height="12" font="12">ization]. Z Kardiol. 1999;88:489 –97.</text>
<text top="689" left="59" width="360" height="12" font="12">1025. Weintraub WS, Jones EL, Morris DC, et al. Outcome of reopera-</text>
<text top="702" left="92" width="327" height="12" font="12">tive coronary bypass surgery versus coronary angioplasty after</text>
<text top="716" left="92" width="265" height="12" font="12">previous bypass surgery. Circulation. 1997;95:868 –77.</text>
<text top="730" left="59" width="360" height="12" font="12">1026. Allen KB, Dowling RD, DelRossi AJ, et al. Transmyocardial laser</text>
<text top="743" left="92" width="327" height="12" font="12">revascularization combined with coronary artery bypass grafting: a</text>
<text top="757" left="92" width="327" height="12" font="12">multicenter, blinded, prospective, randomized, controlled trial.</text>
<text top="770" left="92" width="216" height="12" font="12">J Thorac Cardiovasc Surg. 2000;119:540 –9.</text>
<text top="784" left="59" width="360" height="12" font="12">1027. Stamou SC, Boyce SW, Cooke RH, et al. One-year outcome after</text>
<text top="798" left="92" width="327" height="12" font="12">combined coronary artery bypass grafting and transmyocardial laser</text>
<text top="811" left="92" width="327" height="12" font="12">revascularization for refractory angina pectoris. Am J Cardiol.</text>
<text top="825" left="92" width="83" height="12" font="12">2002;89:1365– 8.</text>
<text top="838" left="59" width="118" height="12" font="12">1028. Deleted in proof.</text>
<text top="852" left="59" width="360" height="12" font="12">1029. Brener SJ, Lytle BW, Casserly IP, et al. Predictors of revascular-</text>
<text top="865" left="92" width="327" height="12" font="12">ization method and long-term outcome of percutaneous coronary</text>
<text top="879" left="92" width="327" height="12" font="12">intervention or repeat coronary bypass surgery in patients with</text>
<text top="893" left="92" width="327" height="12" font="12">multivessel coronary disease and previous coronary bypass surgery.</text>
<text top="906" left="92" width="142" height="12" font="12">Eur Heart J. 2006;27:413– 8.</text>
<text top="920" left="59" width="360" height="12" font="12">1030. Lytle BW, Loop FD, Taylor PC, et al. The effect of coronary</text>
<text top="933" left="92" width="327" height="12" font="12">reoperation on the survival of patients with stenoses in saphenous</text>
<text top="947" left="92" width="327" height="12" font="12">vein bypass grafts to coronary arteries. J Thorac Cardiovasc Surg.</text>
<text top="961" left="92" width="87" height="12" font="12">1993;105:605–12.</text>
<text top="974" left="59" width="360" height="12" font="12">1031. Sergeant P, Blackstone E, Meyns B, et al. First cardiological or</text>
<text top="988" left="92" width="327" height="12" font="12">cardiosurgical reintervention for ischemic heart disease after primary</text>
<text top="1001" left="92" width="327" height="12" font="12">coronary artery bypass grafting. Eur J Cardiothorac Surg. 1998;14:</text>
<text top="1015" left="92" width="34" height="12" font="12">480 –7.</text>
<text top="1028" left="59" width="360" height="12" font="12">1032. Stephan WJ, O’Keefe JH Jr., Piehler JM, et al. Coronary angio-</text>
<text top="1042" left="92" width="327" height="12" font="12">plasty versus repeat coronary artery bypass grafting for patients with</text>
<text top="1056" left="92" width="304" height="12" font="12">previous bypass surgery. J Am Coll Cardiol. 1996;28:1140 – 6.</text>
<text top="1069" left="59" width="360" height="12" font="12">1033. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic</text>
<text top="1083" left="92" width="327" height="12" font="12">impact of diabetes mellitus on percutaneous and surgical treatment</text>
<text top="1096" left="92" width="327" height="12" font="12">of multivessel coronary disease patients: insights from the Arterial</text>
<text top="104" left="479" width="327" height="12" font="12">Revascularization Therapy Study (ARTS) trial. Circulation.</text>
<text top="118" left="479" width="83" height="12" font="12">2001;104:533– 8.</text>
<text top="131" left="446" width="118" height="12" font="12">1034. Deleted in proof.</text>
<text top="145" left="446" width="360" height="12" font="12">1035. The Veterans Administration Coronary Artery Bypass Surgery</text>
<text top="159" left="479" width="327" height="12" font="12">Cooperative Study Group. Eighteen-year follow-up in the Veterans</text>
<text top="172" left="479" width="327" height="12" font="12">Affairs Cooperative Study of Coronary Artery Bypass Surgery for</text>
<text top="186" left="479" width="214" height="12" font="12">stable angina. Circulation. 1992;86:121–30.</text>
<text top="199" left="446" width="360" height="12" font="12">1036. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of</text>
<text top="213" left="479" width="327" height="12" font="12">coronary artery bypass surgery. Survival of patients with a low</text>
<text top="227" left="479" width="258" height="12" font="12">ejection fraction. N Engl J Med. 1985;312:1665–71.</text>
<text top="240" left="446" width="360" height="12" font="12">1037. Al Suwaidi J, Holmes DR Jr., Salam AM, et al. Impact of coronary</text>
<text top="254" left="479" width="327" height="12" font="12">artery stents on mortality and nonfatal myocardial infarction: meta-</text>
<text top="267" left="479" width="327" height="12" font="12">analysis of randomized trials comparing a strategy of routine</text>
<text top="281" left="479" width="327" height="12" font="12">stenting with that of balloon angioplasty. Am Heart J. 2004;147:</text>
<text top="294" left="479" width="39" height="12" font="12">815–22.</text>
<text top="308" left="446" width="360" height="12" font="12">1038. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents.</text>
<text top="322" left="479" width="327" height="12" font="12">A hierarchical bayesian meta-analysis. Ann Intern Med. 2003;138:</text>
<text top="335" left="479" width="40" height="12" font="12">777– 86.</text>
<text top="349" left="446" width="360" height="12" font="12">1039. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous</text>
<text top="362" left="479" width="327" height="12" font="12">coronary interventions for non-acute coronary artery disease: a</text>
<text top="376" left="479" width="327" height="12" font="12">quantitative 20-year synopsis and a network meta-analysis. Lancet.</text>
<text top="390" left="479" width="83" height="12" font="12">2009;373:911– 8.</text>
<text top="403" left="446" width="360" height="12" font="12">1040. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing</text>
<text top="417" left="479" width="327" height="12" font="12">sirolimus-eluting stents with bare-metal stents. N Engl J Med.</text>
<text top="430" left="479" width="89" height="12" font="12">2007;356:1030 –9.</text>
<text top="444" left="446" width="360" height="12" font="12">1041. Cecil WT, Kasteridis P, Barnes JW Jr., et al. A meta-analysis</text>
<text top="458" left="479" width="327" height="12" font="12">update: percutaneous coronary interventions. Am J Manag Care.</text>
<text top="471" left="479" width="77" height="12" font="12">2008;14:521– 8.</text>
<text top="485" left="446" width="360" height="12" font="12">1042. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention</text>
<text top="498" left="479" width="327" height="12" font="12">versus conservative therapy in nonacute coronary artery disease: a</text>
<text top="512" left="479" width="229" height="12" font="12">meta-analysis. Circulation. 2005;111:2906 –12.</text>
<text top="526" left="446" width="360" height="12" font="12">1043. Schomig A, Mehilli J, de WA, et al. A meta-analysis of 17</text>
<text top="539" left="479" width="327" height="12" font="12">randomized trials of a percutaneous coronary intervention-based</text>
<text top="553" left="479" width="327" height="12" font="12">strategy in patients with stable coronary artery disease. J Am Coll</text>
<text top="566" left="479" width="132" height="12" font="12">Cardiol. 2008;52:894 –904.</text>
<text top="580" left="446" width="360" height="12" font="12">1044. Katritsis DG, Ioannidis JP. PCI for stable coronary disease. N Engl</text>
<text top="594" left="479" width="121" height="12" font="12">J Med. 2007;357:414 –5.</text>
<text top="607" left="446" width="360" height="12" font="12">1045. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous</text>
<text top="621" left="479" width="327" height="12" font="12">coronary angioplasty compared with exercise training in patients</text>
<text top="634" left="479" width="327" height="12" font="12">with stable coronary artery disease: a randomized trial. Circulation.</text>
<text top="648" left="479" width="89" height="12" font="12">2004;109:1371– 8.</text>
<text top="661" left="446" width="360" height="12" font="12">1046. Coronary angioplasty versus coronary artery bypass surgery: the</text>
<text top="675" left="479" width="327" height="12" font="12">Randomized Intervention Treatment of Angina (RITA) trial. Lan-</text>
<text top="689" left="479" width="109" height="12" font="12">cet. 1993;341:573– 80.</text>
<text top="702" left="446" width="360" height="12" font="12">1047. First-year results of CABRI (Coronary Angioplasty versus Bypass</text>
<text top="716" left="479" width="327" height="12" font="12">Revascularisation Investigation). CABRI Trial Participants. Lancet.</text>
<text top="729" left="479" width="96" height="12" font="12">1995;346:1179 – 84.</text>
<text top="743" left="446" width="360" height="12" font="12">1048. Five-year clinical and functional outcome comparing bypass surgery</text>
<text top="757" left="479" width="327" height="12" font="12">and angioplasty in patients with multivessel coronary disease. A</text>
<text top="770" left="479" width="327" height="12" font="12">multicenter randomized trial. Writing Group for the Bypass An-</text>
<text top="784" left="479" width="327" height="12" font="12">gioplasty Revascularization Investigation (BARI) Investigators.</text>
<text top="797" left="479" width="128" height="12" font="12">JAMA. 1997;277:715–21.</text>
<text top="811" left="446" width="360" height="12" font="12">1049. Carrie D, Elbaz M, Puel J, et al. Five-year outcome after coronary</text>
<text top="824" left="479" width="327" height="12" font="12">angioplasty versus bypass surgery in multivessel coronary artery</text>
<text top="838" left="479" width="327" height="12" font="12">disease: results from the French Monocentric Study. Circulation.</text>
<text top="852" left="479" width="65" height="12" font="12">1997;96:II-6.</text>
<text top="865" left="446" width="360" height="12" font="12">1050. Goy JJ, Eeckhout E, Burnand B, et al. Coronary angioplasty versus</text>
<text top="879" left="479" width="327" height="12" font="12">left internal mammary artery grafting for isolated proximal left</text>
<text top="892" left="479" width="310" height="12" font="12">anterior descending artery stenosis. Lancet. 1994;343:1449 –53.</text>
<text top="906" left="446" width="360" height="12" font="12">1051. Goy JJ, Eeckhout E, Moret C, et al. Five-year outcome in patients</text>
<text top="920" left="479" width="327" height="12" font="12">with isolated proximal left anterior descending coronary artery</text>
<text top="933" left="479" width="327" height="12" font="12">stenosis treated by angioplasty or left internal mammary artery</text>
<text top="947" left="479" width="285" height="12" font="12">grafting. A prospective trial. Circulation. 1999;99:3255–9.</text>
<text top="960" left="446" width="360" height="12" font="12">1052. Hamm CW, Reimers J, Ischinger T, et al. A randomized study of</text>
<text top="974" left="479" width="327" height="12" font="12">coronary angioplasty compared with bypass surgery in patients with</text>
<text top="987" left="479" width="327" height="12" font="12">symptomatic multivessel coronary disease. German Angioplasty</text>
<text top="1001" left="479" width="327" height="12" font="12">Bypass Surgery Investigation (GABI). N Engl J Med. 1994;331:</text>
<text top="1015" left="479" width="46" height="12" font="12">1037– 43.</text>
<text top="1028" left="446" width="360" height="12" font="12">1053. Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of</text>
<text top="1042" left="479" width="327" height="12" font="12">RITA-1 trial: clinical and cost comparisons of coronary angioplasty</text>
<text top="1055" left="479" width="327" height="12" font="12">and coronary-artery bypass grafting. Randomised Intervention</text>
<text top="1069" left="479" width="247" height="12" font="12">Treatment of Angina. Lancet. 1998;352:1419 –25.</text>
<text top="1083" left="446" width="360" height="12" font="12">1054. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or</text>
<text top="1096" left="479" width="327" height="12" font="12">surgery study (MASS-II): a randomized, controlled clinical trial of</text>
<text top="52" left="781" width="25" height="10" font="12">e153</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="111" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="92" width="327" height="12" font="12">three therapeutic strategies for multivessel coronary artery disease:</text>
<text top="118" left="92" width="270" height="12" font="12">one-year results. J Am Coll Cardiol. 2004;43:1743–51.</text>
<text top="132" left="58" width="360" height="12" font="12">1055. King SB, III, Lembo NJ, Weintraub WS, et al. A randomized trial</text>
<text top="145" left="92" width="327" height="12" font="12">comparing coronary angioplasty with coronary bypass surgery.</text>
<text top="159" left="92" width="327" height="12" font="12">Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med.</text>
<text top="172" left="92" width="95" height="12" font="12">1994;331:1044 –50.</text>
<text top="186" left="58" width="360" height="12" font="12">1056. King SB, III, Kosinski AS, Guyton RA, et al. Eight-year mortality</text>
<text top="200" left="92" width="327" height="12" font="12">in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll</text>
<text top="213" left="92" width="132" height="12" font="12">Cardiol. 2000;35:1116 –21.</text>
<text top="227" left="58" width="360" height="12" font="12">1057. Rodriguez A, Boullon F, Perez-Balino N, et al. Argentine random-</text>
<text top="240" left="92" width="327" height="12" font="12">ized trial of percutaneous transluminal coronary angioplasty versus</text>
<text top="254" left="92" width="327" height="12" font="12">coronary artery bypass surgery in multivessel disease (ERACI):</text>
<text top="268" left="92" width="327" height="12" font="12">in-hospital results and 1-year follow-up. ERACI Group. J Am Coll</text>
<text top="281" left="92" width="126" height="12" font="12">Cardiol. 1993;22:1060 –7.</text>
<text top="295" left="58" width="360" height="12" font="12">1058. Rodriguez A, Mele E, Peyregne E, et al. Three-year follow-up of</text>
<text top="308" left="92" width="327" height="12" font="12">the Argentine Randomized Trial of Percutaneous Transluminal</text>
<text top="322" left="92" width="327" height="12" font="12">Coronary Angioplasty Versus Coronary Artery Bypass Surgery in</text>
<text top="336" left="92" width="327" height="12" font="12">Multivessel Disease (ERACI). J Am Coll Cardiol. 1996;27:</text>
<text top="349" left="92" width="48" height="12" font="12">1178 – 84.</text>
<text top="363" left="58" width="360" height="12" font="12">1059. Wahrborg P. Quality of life after coronary angioplasty or bypass</text>
<text top="376" left="92" width="327" height="12" font="12">surgery. 1-year follow-up in the Coronary Angioplasty versus</text>
<text top="390" left="92" width="327" height="12" font="12">Bypass Revascularization investigation (CABRI) trial. Eur Heart J.</text>
<text top="404" left="92" width="77" height="12" font="12">1999;20:653– 8.</text>
<text top="417" left="58" width="360" height="12" font="12">1060. Coronary artery bypass surgery versus percutaneous coronary inter-</text>
<text top="431" left="92" width="327" height="12" font="12">vention with stent implantation in patients with multivessel coro-</text>
<text top="444" left="92" width="327" height="12" font="12">nary artery disease (the Stent or Surgery trial): a randomised</text>
<text top="458" left="92" width="207" height="12" font="12">controlled trial. Lancet. 2002;360:965–70.</text>
<text top="471" left="58" width="360" height="12" font="12">1061. Cisowski M, Drzewiecki J, Drzewiecka-Gerber A, et al. Primary</text>
<text top="485" left="92" width="327" height="12" font="12">stenting versus MIDCAB: preliminary report-comparision of two</text>
<text top="499" left="92" width="327" height="12" font="12">methods of revascularization in single left anterior descending</text>
<text top="512" left="92" width="327" height="12" font="12">coronary artery stenosis. Ann Thorac Surg. 2002;74:S1334 –S1339.</text>
<text top="526" left="58" width="360" height="12" font="12">1062. Cisowski M, Drzewiecka-Gerber A, Ulczok R, et al. Primary direct</text>
<text top="539" left="92" width="327" height="12" font="12">stenting versus endoscopic atraumatic coronary artery bypass surgery</text>
<text top="553" left="92" width="327" height="12" font="12">in patients with proximal stenosis of the left anterior descending</text>
<text top="567" left="92" width="327" height="12" font="12">coronary artery—a prospective, randomised study. Kardiol Pol.</text>
<text top="580" left="92" width="83" height="12" font="12">2004;61:253– 61.</text>
<text top="594" left="58" width="360" height="12" font="12">1063. Diegeler A, Thiele H, Falk V, et al. Comparison of stenting with</text>
<text top="607" left="92" width="327" height="12" font="12">minimally invasive bypass surgery for stenosis of the left anterior</text>
<text top="621" left="92" width="300" height="12" font="12">descending coronary artery. N Engl J Med. 2002;347:561– 6.</text>
<text top="635" left="58" width="360" height="12" font="12">1064. Drenth DJ, Veeger NJ, Winter JB, et al. A prospective randomized</text>
<text top="648" left="92" width="327" height="12" font="12">trial comparing stenting with off-pump coronary surgery for high-</text>
<text top="662" left="92" width="327" height="12" font="12">grade stenosis in the proximal left anterior descending coronary</text>
<text top="675" left="92" width="327" height="12" font="12">artery: three-year follow-up. J Am Coll Cardiol. 2002;40:1955– 60.</text>
<text top="689" left="58" width="360" height="12" font="12">1065. Drenth DJ, Veeger NJ, Middel B, et al. Comparison of late (four</text>
<text top="702" left="92" width="327" height="12" font="12">years) functional health status between percutaneous transluminal</text>
<text top="716" left="92" width="327" height="12" font="12">angioplasty intervention and off-pump left internal mammary artery</text>
<text top="730" left="92" width="327" height="12" font="12">bypass grafting for isolated high-grade narrowing of the proximal</text>
<text top="743" left="92" width="327" height="12" font="12">left anterior descending coronary artery. Am J Cardiol. 2004;94:</text>
<text top="757" left="92" width="40" height="12" font="12">1414 –7.</text>
<text top="770" left="58" width="360" height="12" font="12">1066. Eefting F, Nathoe H, van DD, et al. Randomized comparison</text>
<text top="784" left="92" width="327" height="12" font="12">between stenting and off-pump bypass surgery in patients referred</text>
<text top="798" left="92" width="231" height="12" font="12">for angioplasty. Circulation. 2003;108:2870 – 6.</text>
<text top="811" left="58" width="360" height="12" font="12">1067. Goy JJ, Kaufmann U, Goy-Eggenberger D, et al. A prospective</text>
<text top="825" left="92" width="327" height="12" font="12">randomized trial comparing stenting to internal mammary artery</text>
<text top="838" left="92" width="327" height="12" font="12">grafting for proximal, isolated de novo left anterior coronary artery</text>
<text top="852" left="92" width="327" height="12" font="12">stenosis: the SIMA trial. Stenting vs Internal Mammary Artery.</text>
<text top="865" left="92" width="176" height="12" font="12">Mayo Clin Proc. 2000;75:1116 –23.</text>
<text top="879" left="58" width="360" height="12" font="12">1068. Kim JW, Lim DS, Sun K, et al. Stenting or MIDCAB using</text>
<text top="893" left="92" width="327" height="12" font="12">ministernotomy for revascularization of proximal left anterior de-</text>
<text top="906" left="92" width="235" height="12" font="12">scending artery? Int J Cardiol. 2005;99:437– 41.</text>
<text top="920" left="58" width="360" height="12" font="12">1069. Pohl T, Giehrl W, Reichart B, et al. Retroinfusion-supported</text>
<text top="933" left="92" width="327" height="12" font="12">stenting in high-risk patients for percutaneous intervention and</text>
<text top="947" left="92" width="327" height="12" font="12">bypass surgery: results of the prospective randomized myoprotect I</text>
<text top="961" left="92" width="254" height="12" font="12">study. Catheter Cardiovasc Interv. 2004;62:323–30.</text>
<text top="974" left="58" width="360" height="12" font="12">1070. Reeves BC, Angelini GD, Bryan AJ, et al. A multi-centre ran-</text>
<text top="988" left="92" width="327" height="12" font="12">domised controlled trial of minimally invasive direct coronary bypass</text>
<text top="1001" left="92" width="327" height="12" font="12">grafting versus percutaneous transluminal coronary angioplasty with</text>
<text top="1015" left="92" width="327" height="12" font="12">stenting for proximal stenosis of the left anterior descending</text>
<text top="1028" left="92" width="265" height="12" font="12">coronary artery. Health Technol Assess. 2004;8:1– 43.</text>
<text top="1042" left="58" width="360" height="12" font="12">1071. Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized</text>
<text top="1056" left="92" width="327" height="12" font="12">Study: Coronary Angioplasty with Stenting versus Coronary Bypass</text>
<text top="1069" left="92" width="327" height="12" font="12">Surgery in patients with Multiple-Vessel Disease (ERACI II):</text>
<text top="1083" left="92" width="327" height="12" font="12">30-day and one-year follow-up results. ERACI II Investigators.</text>
<text top="1096" left="92" width="170" height="12" font="12">J Am Coll Cardiol. 2001;37:51– 8.</text>
<text top="104" left="445" width="360" height="12" font="12">1072. Rodriguez AE, Baldi J, Fernandez Pereira C, et al. Five-year</text>
<text top="118" left="479" width="327" height="12" font="12">follow-up of the Argentine randomized trial of coronary angioplasty</text>
<text top="132" left="479" width="327" height="12" font="12">with stenting versus coronary bypass surgery in patients with</text>
<text top="146" left="479" width="327" height="12" font="12">multiple vessel disease (ERACI II). J Am Coll Cardiol. 2005;46:</text>
<text top="159" left="479" width="34" height="12" font="12">582– 8.</text>
<text top="173" left="445" width="360" height="12" font="12">1073. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-</text>
<text top="187" left="479" width="327" height="12" font="12">artery bypass surgery and stenting for the treatment of multivessel</text>
<text top="201" left="479" width="213" height="12" font="12">disease. N Engl J Med. 2001;344:1117–24.</text>
<text top="214" left="445" width="360" height="12" font="12">1074. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year</text>
<text top="228" left="479" width="327" height="12" font="12">outcomes after coronary stenting versus bypass surgery for the</text>
<text top="242" left="479" width="327" height="12" font="12">treatment of multivessel disease: the final analysis of the Arterial</text>
<text top="256" left="479" width="327" height="12" font="12">Revascularization Therapies Study (ARTS) randomized trial. J Am</text>
<text top="270" left="479" width="151" height="12" font="12">Coll Cardiol. 2005;46:575– 81.</text>
<text top="283" left="445" width="360" height="12" font="12">1075. Stroupe KT, Morrison DA, Hlatky MA, et al. Cost-effectiveness of</text>
<text top="297" left="479" width="327" height="12" font="12">coronary artery bypass grafts versus percutaneous coronary interven-</text>
<text top="311" left="479" width="327" height="12" font="12">tion for revascularization of high-risk patients. Circulation. 2006;</text>
<text top="325" left="479" width="60" height="12" font="12">114:1251–7.</text>
<text top="339" left="445" width="360" height="12" font="12">1076. Thiele H, Oettel S, Jacobs S, et al. Comparison of bare-metal</text>
<text top="352" left="479" width="327" height="12" font="12">stenting with minimally invasive bypass surgery for stenosis of the</text>
<text top="366" left="479" width="327" height="12" font="12">left anterior descending coronary artery: a 5-year follow-up. Circu-</text>
<text top="380" left="479" width="128" height="12" font="12">lation. 2005;112:3445–50.</text>
<text top="394" left="445" width="360" height="12" font="12">1077. Hong SJ, Lim DS, Seo HS, et al. Percutaneous coronary interven-</text>
<text top="407" left="479" width="327" height="12" font="12">tion with drug-eluting stent implantation vs. minimally invasive</text>
<text top="421" left="479" width="327" height="12" font="12">direct coronary artery bypass (MIDCAB) in patients with left</text>
<text top="435" left="479" width="327" height="12" font="12">anterior descending coronary artery stenosis. Catheter Cardiovasc</text>
<text top="449" left="479" width="113" height="12" font="12">Interv. 2005;64:75– 81.</text>
<text top="463" left="445" width="360" height="12" font="12">1078. Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized</text>
<text top="476" left="479" width="327" height="12" font="12">comparison of minimally invasive direct coronary artery bypass</text>
<text top="490" left="479" width="327" height="12" font="12">surgery versus sirolimus-eluting stenting in isolated proximal left</text>
<text top="504" left="479" width="327" height="12" font="12">anterior descending coronary artery stenosis. J Am Coll Cardiol.</text>
<text top="518" left="479" width="89" height="12" font="12">2009;53:2324 –31.</text>
<text top="532" left="445" width="360" height="12" font="12">1079. Bravata DM, Gienger AL, McDonald KM, et al. Systematic review:</text>
<text top="545" left="479" width="327" height="12" font="12">the comparative effectiveness of percutaneous coronary interventions</text>
<text top="559" left="479" width="327" height="12" font="12">and coronary artery bypass graft surgery. Ann Intern Med. 2007;</text>
<text top="573" left="479" width="60" height="12" font="12">147:703–16.</text>
<text top="587" left="445" width="360" height="12" font="12">1080. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery</text>
<text top="601" left="479" width="327" height="12" font="12">bypass surgery compared with percutaneous coronary interventions</text>
<text top="614" left="479" width="327" height="12" font="12">for multivessel disease: a collaborative analysis of individual patient</text>
<text top="628" left="479" width="291" height="12" font="12">data from ten randomised trials. Lancet. 2009;373:1190 –7.</text>
<text top="642" left="445" width="360" height="12" font="12">1081. Briguori C, Condorelli G, Airoldi F, et al. Comparison of coronary</text>
<text top="656" left="479" width="327" height="12" font="12">drug-eluting stents versus coronary artery bypass grafting in patients</text>
<text top="669" left="479" width="272" height="12" font="12">with diabetes mellitus. Am J Cardiol. 2007;99:779 – 84.</text>
<text top="683" left="445" width="360" height="12" font="12">1082. Javaid A, Steinberg DH, Buch AN, et al. Outcomes of coronary</text>
<text top="697" left="479" width="327" height="12" font="12">artery bypass grafting versus percutaneous coronary intervention</text>
<text top="711" left="479" width="327" height="12" font="12">with drug-eluting stents for patients with multivessel coronary artery</text>
<text top="725" left="479" width="206" height="12" font="12">disease. Circulation. 2007;116:I200 –I206.</text>
<text top="738" left="445" width="360" height="12" font="12">1083. Lee MS, Jamal F, Kedia G, et al. Comparison of bypass surgery with</text>
<text top="752" left="479" width="327" height="12" font="12">drug-eluting stents for diabetic patients with multivessel disease. Int</text>
<text top="766" left="479" width="136" height="12" font="12">J Cardiol. 2007;123:34 – 42.</text>
<text top="780" left="445" width="360" height="12" font="12">1084. Park DW, Yun SC, Lee SW, et al. Long-term mortality after</text>
<text top="793" left="479" width="327" height="12" font="12">percutaneous coronary intervention with drug-eluting stent implan-</text>
<text top="807" left="479" width="327" height="12" font="12">tation versus coronary artery bypass surgery for the treatment of</text>
<text top="821" left="479" width="327" height="12" font="12">multivessel coronary artery disease. Circulation. 2008;117:2079 – 86.</text>
<text top="835" left="445" width="360" height="12" font="12">1085. Tarantini G, Ramondo A, Napodano M, et al. PCI versus CABG</text>
<text top="848" left="479" width="327" height="12" font="12">for multivessel coronary disease in diabetics. Catheter Cardiovasc</text>
<text top="862" left="479" width="108" height="12" font="12">Interv. 2009;73:50 – 8.</text>
<text top="876" left="445" width="360" height="12" font="12">1086. Varani E, Balducelli M, Vecchi G, et al. Comparison of multiple</text>
<text top="890" left="479" width="327" height="12" font="12">drug-eluting stent percutaneous coronary intervention and surgical</text>
<text top="904" left="479" width="327" height="12" font="12">revascularization in patients with multivessel coronary artery disease:</text>
<text top="917" left="479" width="327" height="12" font="12">one-year clinical results and total treatment costs. J Invasive Cardiol.</text>
<text top="931" left="479" width="83" height="12" font="12">2007;19:469 –75.</text>
<text top="945" left="445" width="360" height="12" font="12">1087. Yang JH, Gwon HC, Cho SJ, et al. Comparison of coronary artery</text>
<text top="959" left="479" width="327" height="12" font="12">bypass grafting with drug-eluting stent implantation for the treat-</text>
<text top="972" left="479" width="327" height="12" font="12">ment of multivessel coronary artery disease. Ann Thorac Surg.</text>
<text top="986" left="479" width="75" height="12" font="12">2008;85:65–70.</text>
<text top="1000" left="445" width="360" height="12" font="12">1088. Yang ZK, Shen WF, Zhang RY, et al. Coronary artery bypass</text>
<text top="1014" left="479" width="327" height="12" font="12">surgery versus percutaneous coronary intervention with drug-eluting</text>
<text top="1028" left="479" width="327" height="12" font="12">stent implantation in patients with multivessel coronary disease.</text>
<text top="1041" left="479" width="157" height="12" font="12">J Interv Cardiol. 2007;20:10 – 6.</text>
<text top="1055" left="445" width="360" height="12" font="12">1089. Benedetto U, Melina G, Angeloni E, et al. Coronary artery bypass</text>
<text top="1069" left="479" width="327" height="12" font="12">grafting versus drug-eluting stents in multivessel coronary disease. A</text>
<text top="1083" left="479" width="327" height="12" font="12">meta-analysis on 24,268 patients. Eur J Cardiothorac Surg. 2009;</text>
<text top="1096" left="479" width="48" height="12" font="12">36:611–5.</text>
<text top="52" left="58" width="25" height="10" font="12">e154</text>
<text top="52" left="112" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="112" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="12" font="12">1090. Ragosta M, Dee S, Sarembock IJ, et al. Prevalence of unfavorable</text>
<text top="118" left="92" width="327" height="12" font="12">angiographic characteristics for percutaneous intervention in pa-</text>
<text top="132" left="92" width="327" height="12" font="12">tients with unprotected left main coronary artery disease. Catheter</text>
<text top="146" left="92" width="176" height="12" font="12">Cardiovasc Interv. 2006;68:357– 62.</text>
<text top="160" left="59" width="360" height="12" font="12">1091. Chieffo A, Park SJ, Valgimigli M, et al. Favorable long-term</text>
<text top="173" left="92" width="327" height="12" font="12">outcome after drug-eluting stent implantation in nonbifurcation</text>
<text top="187" left="92" width="327" height="12" font="12">lesions that involve unprotected left main coronary artery: a multi-</text>
<text top="201" left="92" width="228" height="12" font="12">center registry. Circulation. 2007;116:158 – 62.</text>
<text top="215" left="59" width="360" height="12" font="12">1092. Tamburino C, Capranzano P, Capodanno D, et al. Plaque distri-</text>
<text top="228" left="92" width="327" height="12" font="12">bution patterns in distal left main coronary artery to predict</text>
<text top="242" left="92" width="327" height="12" font="12">outcomes after stent implantation. J Am Coll Cardiol Intv. 2010;</text>
<text top="256" left="92" width="50" height="12" font="12">3:624 –31.</text>
<text top="270" left="59" width="360" height="12" font="12">1093. Ben-Gal Y, Mohr R, Braunstein R, et al. Revascularization of left</text>
<text top="284" left="92" width="327" height="12" font="12">anterior descending artery with drug-eluting stents: comparison</text>
<text top="297" left="92" width="327" height="12" font="12">with minimally invasive direct coronary artery bypass surgery. Ann</text>
<text top="311" left="92" width="156" height="12" font="12">Thorac Surg. 2006;82:2067–71.</text>
<text top="325" left="59" width="360" height="12" font="12">1094. Fraund S, Herrmann G, Witzke A, et al. Midterm follow-up after</text>
<text top="339" left="92" width="327" height="12" font="12">minimally invasive direct coronary artery bypass grafting versus</text>
<text top="353" left="92" width="327" height="12" font="12">percutaneous coronary intervention techniques. Ann Thorac Surg.</text>
<text top="366" left="92" width="87" height="12" font="12">2005;79:1225–31.</text>
<text top="380" left="59" width="360" height="12" font="12">1095. Goy JJ, Kaufmann U, Hurni M, et al. 10-year follow-up of a</text>
<text top="394" left="92" width="327" height="12" font="12">prospective randomized trial comparing bare-metal stenting with</text>
<text top="408" left="92" width="327" height="12" font="12">internal mammary artery grafting for proximal, isolated de novo left</text>
<text top="422" left="92" width="327" height="12" font="12">anterior coronary artery stenosis the SIMA (Stenting versus Internal</text>
<text top="435" left="92" width="327" height="12" font="12">Mammary Artery grafting) trial. J Am Coll Cardiol. 2008;52:815–7.</text>
<text top="449" left="59" width="360" height="12" font="12">1096. Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally</text>
<text top="463" left="92" width="327" height="12" font="12">invasive internal thoracic artery bypass versus percutaneous revascu-</text>
<text top="477" left="92" width="327" height="12" font="12">larisation for isolated lesions of the left anterior descending artery.</text>
<text top="490" left="92" width="100" height="12" font="12">BMJ. 2007;334:617.</text>
<text top="504" left="59" width="360" height="12" font="12">1097. Jaffery Z, Kowalski M, Weaver WD, et al. A meta-analysis of</text>
<text top="518" left="92" width="327" height="12" font="12">randomized control trials comparing minimally invasive direct</text>
<text top="532" left="92" width="327" height="12" font="12">coronary bypass grafting versus percutaneous coronary intervention</text>
<text top="546" left="92" width="327" height="12" font="12">for stenosis of the proximal left anterior descending artery. Eur</text>
<text top="559" left="92" width="181" height="12" font="12">J Cardiothorac Surg. 2007;31:691–7.</text>
<text top="573" left="59" width="360" height="12" font="12">1098. Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the</text>
<text top="587" left="92" width="327" height="12" font="12">proximal left anterior descending artery comparing the effectiveness</text>
<text top="601" left="92" width="327" height="12" font="12">of percutaneous coronary interventions and coronary artery bypass</text>
<text top="615" left="92" width="240" height="12" font="12">surgery. J Am Coll Cardiol Intv. 2008;1:483–91.</text>
<text top="628" left="59" width="360" height="12" font="12">1099. Jones EL, Craver JM, Guyton RA, et al. Importance of complete</text>
<text top="642" left="92" width="327" height="12" font="12">revascularization in performance of the coronary bypass operation.</text>
<text top="656" left="92" width="143" height="12" font="12">Am J Cardiol. 1983;51:7–12.</text>
<text top="670" left="59" width="360" height="12" font="12">1100. Bell MR, Bailey KR, Reeder GS, et al. Percutaneous transluminal</text>
<text top="683" left="92" width="327" height="12" font="12">angioplasty in patients with multivessel coronary disease: how</text>
<text top="697" left="92" width="327" height="12" font="12">important is complete revascularization for cardiac event-free sur-</text>
<text top="711" left="92" width="212" height="12" font="12">vival? J Am Coll Cardiol. 1990;16:553– 62.</text>
<text top="725" left="59" width="360" height="12" font="12">1101. Bourassa MG, Yeh W, Holubkov R, et al. Long-term outcome of</text>
<text top="739" left="92" width="327" height="12" font="12">patients with incomplete vs complete revascularization after multi-</text>
<text top="752" left="92" width="327" height="12" font="12">vessel PTCA. A report from the NHLBI PTCA Registry. Eur</text>
<text top="766" left="92" width="125" height="12" font="12">Heart J. 1998;19:103–11.</text>
<text top="780" left="59" width="360" height="12" font="12">1102. Faxon DP, Ghalilli K, Jacobs AK, et al. The degree of revascular-</text>
<text top="794" left="92" width="327" height="12" font="12">ization and outcome after multivessel coronary angioplasty. Am</text>
<text top="807" left="92" width="126" height="12" font="12">Heart J. 1992;123:854 –9.</text>
<text top="821" left="59" width="360" height="12" font="12">1103. Berger PB, Velianou JL, Aslanidou Vlachos H, et al. Survival</text>
<text top="835" left="92" width="327" height="12" font="12">following coronary angioplasty versus coronary artery bypass surgery</text>
<text top="849" left="92" width="327" height="12" font="12">in anatomic subsets in which coronary artery bypass surgery im-</text>
<text top="863" left="92" width="327" height="12" font="12">proves survival compared with medical therapy. Results from the</text>
<text top="876" left="92" width="327" height="12" font="12">Bypass Angioplasty Revascularization Investigation (BARI). J Am</text>
<text top="890" left="92" width="151" height="12" font="12">Coll Cardiol. 2001;38:1440 –9.</text>
<text top="904" left="59" width="360" height="12" font="12">1104. Gioia G, Matthai W, Gillin K, et al. Revascularization in severe left</text>
<text top="918" left="92" width="327" height="12" font="12">ventricular dysfunction: outcome comparison of drug-eluting stent</text>
<text top="931" left="92" width="327" height="12" font="12">implantation versus coronary artery by-pass grafting. Catheter</text>
<text top="945" left="92" width="170" height="12" font="12">Cardiovasc Interv. 2007;70:26 –33.</text>
<text top="959" left="59" width="360" height="12" font="12">1105. O’Keefe JH Jr., Allan JJ, McCallister BD, et al. Angioplasty versus</text>
<text top="973" left="92" width="327" height="12" font="12">bypass surgery for multivessel coronary artery disease with left</text>
<text top="987" left="92" width="134" height="12" font="12">ventricular ejection fraction</text>
<text top="984" left="230" width="188" height="16" font="12">⬍ or ⫽ 40%. Am J Cardiol. 1993;71:</text>
<text top="1000" left="92" width="45" height="12" font="12">897–901.</text>
<text top="1014" left="58" width="360" height="12" font="12">1106. Cole JH, Jones EL, Craver JM, et al. Outcomes of repeat revascu-</text>
<text top="1028" left="92" width="327" height="12" font="12">larization in diabetic patients with prior coronary surgery. J Am Coll</text>
<text top="1042" left="92" width="132" height="12" font="12">Cardiol. 2002;40:1968 –75.</text>
<text top="1055" left="58" width="360" height="12" font="12">1107. Choudhry NK, Singh JM, Barolet A, et al. How should patients</text>
<text top="1069" left="92" width="327" height="12" font="12">with unstable angina and non-ST-segment elevation myocardial</text>
<text top="1083" left="92" width="327" height="12" font="12">infarction be managed? A meta-analysis of randomized trials. Am J</text>
<text top="1097" left="92" width="117" height="12" font="12">Med. 2005;118:465–74.</text>
<text top="104" left="445" width="360" height="12" font="12">1108. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional</text>
<text top="118" left="479" width="327" height="12" font="12">versus conservative treatment for patients with unstable angina or</text>
<text top="132" left="479" width="327" height="12" font="12">non-ST-elevation myocardial infarction: the British Heart Founda-</text>
<text top="146" left="479" width="327" height="12" font="12">tion RITA 3 randomised trial. Randomized Intervention Trial of</text>
<text top="160" left="479" width="214" height="12" font="12">unstable Angina. Lancet. 2002;360:743–51.</text>
<text top="173" left="445" width="360" height="12" font="12">1109. Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a</text>
<text top="187" left="479" width="327" height="12" font="12">routine versus selective invasive strategy in patients with non-ST-</text>
<text top="201" left="479" width="327" height="12" font="12">segment elevation acute coronary syndrome a meta-analysis of</text>
<text top="215" left="479" width="305" height="12" font="12">individual patient data. J Am Coll Cardiol. 2010;55:2435– 45.</text>
<text top="229" left="445" width="360" height="12" font="12">1110. Grines CL, Bonow RO, Casey DE Jr., et al. Prevention of</text>
<text top="242" left="479" width="327" height="12" font="12">premature discontinuation of dual antiplatelet therapy in patients</text>
<text top="256" left="479" width="327" height="12" font="12">with coronary artery stents: a science advisory from the American</text>
<text top="270" left="479" width="327" height="12" font="12">Heart Association, American College of Cardiology, Society for</text>
<text top="284" left="479" width="327" height="12" font="12">Cardiovascular Angiography and Interventions, American College</text>
<text top="297" left="479" width="327" height="12" font="12">of Surgeons, and American Dental Association, with representation</text>
<text top="311" left="479" width="327" height="12" font="12">from the American College of Physicians. Circulation. 2007;115:</text>
<text top="325" left="479" width="34" height="12" font="12">813– 8.</text>
<text top="339" left="445" width="360" height="12" font="12">1111. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing</text>
<text top="353" left="479" width="327" height="12" font="12">three antithrombotic-drug regimens after coronary-artery stenting.</text>
<text top="366" left="479" width="327" height="12" font="12">Stent Anticoagulation Restenosis Study Investigators. N Engl</text>
<text top="380" left="479" width="131" height="12" font="12">J Med. 1998;339:1665–71.</text>
<text top="394" left="445" width="360" height="12" font="12">1112. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in</text>
<text top="408" left="479" width="327" height="12" font="12">randomized clinical trials of drug-eluting stents. N Engl J Med.</text>
<text top="422" left="479" width="89" height="12" font="12">2007;356:1020 –9.</text>
<text top="435" left="445" width="360" height="12" font="12">1113. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in</text>
<text top="449" left="479" width="327" height="12" font="12">drug-eluting coronary stents after discontinuation of antiplatelet</text>
<text top="463" left="479" width="178" height="12" font="12">therapy. Lancet. 2004;364:1519 –21.</text>
<text top="477" left="445" width="360" height="12" font="12">1114. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and</text>
<text top="491" left="479" width="327" height="12" font="12">long-term clinical outcomes after drug-eluting stent implantation.</text>
<text top="504" left="479" width="131" height="12" font="12">JAMA. 2007;297:159 – 68.</text>
<text top="518" left="445" width="360" height="12" font="12">1115. Peterson ED, Kaul P, Kaczmarek RG, et al. From controlled trials</text>
<text top="532" left="479" width="327" height="12" font="12">to clinical practice: monitoring transmyocardial revascularization use</text>
<text top="546" left="479" width="257" height="12" font="12">and outcomes. J Am Coll Cardiol. 2003;42:1611– 6.</text>
<text top="559" left="445" width="360" height="12" font="12">1116. Bonatti J, Schachner T, Bonaros N, et al. Simultaneous hybrid</text>
<text top="573" left="479" width="327" height="12" font="12">coronary revascularization using totally endoscopic left internal</text>
<text top="587" left="479" width="327" height="12" font="12">mammary artery bypass grafting and placement of rapamycin eluting</text>
<text top="601" left="479" width="327" height="12" font="12">stents in the same interventional session. The COMBINATION</text>
<text top="615" left="479" width="195" height="12" font="12">pilot study. Cardiology. 2008;110:92–5.</text>
<text top="628" left="445" width="360" height="12" font="12">1117. Gilard M, Bezon E, Cornily JC, et al. Same-day combined</text>
<text top="642" left="479" width="327" height="12" font="12">percutaneous coronary intervention and coronary artery surgery.</text>
<text top="656" left="479" width="142" height="12" font="12">Cardiology. 2007;108:363–7.</text>
<text top="670" left="445" width="360" height="12" font="12">1118. Holzhey DM, Jacobs S, Mochalski M, et al. Minimally invasive</text>
<text top="683" left="479" width="327" height="12" font="12">hybrid coronary artery revascularization. Ann Thorac Surg. 2008;</text>
<text top="697" left="479" width="63" height="12" font="12">86:1856 – 60.</text>
<text top="711" left="445" width="360" height="12" font="12">1119. Kon ZN, Brown EN, Tran R, et al. Simultaneous hybrid coronary</text>
<text top="725" left="479" width="327" height="12" font="12">revascularization reduces postoperative morbidity compared with</text>
<text top="739" left="479" width="327" height="12" font="12">results from conventional off-pump coronary artery bypass. J Thorac</text>
<text top="752" left="479" width="174" height="12" font="12">Cardiovasc Surg. 2008;135:367–75.</text>
<text top="766" left="445" width="360" height="12" font="12">1120. Reicher B, Poston RS, Mehra MR, et al. Simultaneous “hybrid”</text>
<text top="780" left="479" width="327" height="12" font="12">percutaneous coronary intervention and minimally invasive surgical</text>
<text top="794" left="479" width="327" height="12" font="12">bypass grafting: feasibility, safety, and clinical outcomes. Am</text>
<text top="807" left="479" width="125" height="12" font="12">Heart J. 2008;155:661–7.</text>
<text top="821" left="445" width="360" height="12" font="12">1121. Vassiliades TA Jr., Douglas JS, Morris DC, et al. Integrated</text>
<text top="835" left="479" width="327" height="12" font="12">coronary revascularization with drug-eluting stents: immediate and</text>
<text top="849" left="479" width="327" height="12" font="12">seven-month outcome. J Thorac Cardiovasc Surg. 2006;131:</text>
<text top="863" left="479" width="42" height="12" font="12">956 – 62.</text>
<text top="876" left="445" width="360" height="12" font="12">1122. Zhao DX, Leacche M, Balaguer JM, et al. Routine intraoperative</text>
<text top="890" left="479" width="327" height="12" font="12">completion angiography after coronary artery bypass grafting and</text>
<text top="904" left="479" width="327" height="12" font="12">–stop hybrid revascularization results from a fully integrated hybrid</text>
<text top="918" left="479" width="327" height="12" font="12">catheterization laboratory/operating room. J Am Coll Cardiol.</text>
<text top="931" left="479" width="83" height="12" font="12">2009;53:232– 41.</text>
<text top="945" left="445" width="360" height="12" font="12">1123. Angelini GD, Wilde P, Salerno TA, et al. Integrated left small</text>
<text top="959" left="479" width="327" height="12" font="12">thoracotomy and angioplasty for multivessel coronary artery revas-</text>
<text top="973" left="479" width="185" height="12" font="12">cularisation. Lancet. 1996;347:757– 8.</text>
<text top="987" left="445" width="360" height="12" font="12">1124. Simoons ML. Myocardial revascularization— bypass surgery or</text>
<text top="1000" left="479" width="223" height="12" font="12">angioplasty? N Engl J Med. 1996;335:275–7.</text>
<text top="1014" left="445" width="360" height="12" font="12">1125. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences</text>
<text top="1028" left="479" width="327" height="12" font="12">in early mortality after myocardial infarction. National Registry</text>
<text top="1042" left="479" width="327" height="12" font="12">of Myocardial Infarction 2 Participants. N Engl J Med. 1999;</text>
<text top="1055" left="479" width="62" height="12" font="12">341:217–25.</text>
<text top="1069" left="445" width="360" height="12" font="12">1126. Merz NB, Johnson BD, Kelsey PSF, et al. Diagnostic, prognostic,</text>
<text top="1083" left="479" width="327" height="12" font="12">and cost assessment of coronary artery disease in women. Am J</text>
<text top="1097" left="479" width="147" height="12" font="12">Manag Care. 2001;7:959 – 65.</text>
<text top="52" left="781" width="25" height="10" font="12">e155</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="113" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="12" font="12">1127. Sharaf BL, Pepine CJ, Kerensky RA, et al. Detailed angiographic</text>
<text top="118" left="92" width="327" height="12" font="12">analysis of women with suspected ischemic chest pain (pilot phase</text>
<text top="132" left="92" width="327" height="12" font="12">data from the NHLBI-sponsored Women’s Ischemia Syndrome</text>
<text top="145" left="92" width="327" height="12" font="12">Evaluation [WISE] Study Angiographic Core Laboratory). Am J</text>
<text top="159" left="92" width="126" height="12" font="12">Cardiol. 2001;87:937– 41.</text>
<text top="172" left="59" width="360" height="12" font="12">1128. Bugiardini R, Bairey Merz CN. Angina with “normal” coronary</text>
<text top="186" left="92" width="288" height="12" font="12">arteries: a changing philosophy. JAMA. 2005;293:477– 84.</text>
<text top="200" left="59" width="360" height="12" font="12">1129. Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardio-</text>
<text top="213" left="92" width="327" height="12" font="12">vascular outcomes in women with nonobstructive coronary artery</text>
<text top="227" left="92" width="327" height="12" font="12">disease: a report from the Women’s Ischemia Syndrome Evaluation</text>
<text top="240" left="92" width="327" height="12" font="12">Study and the St James Women Take Heart Project. Arch Intern</text>
<text top="254" left="92" width="117" height="12" font="12">Med. 2009;169:843–50.</text>
<text top="268" left="59" width="360" height="12" font="12">1130. Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in</text>
<text top="281" left="92" width="327" height="12" font="12">women: clinical, investigative, and prognostic features. BMJ. 1994;</text>
<text top="295" left="92" width="56" height="12" font="12">308:883– 6.</text>
<text top="308" left="59" width="360" height="12" font="12">1131. Kwong RY, Farzaneh-Far A. Measuring myocardial scar by CMR.</text>
<text top="322" left="92" width="278" height="12" font="12">J Am Coll Cardiol Cardiovasc Imaging. 2011;4:157– 60.</text>
<text top="336" left="59" width="360" height="12" font="12">1132. Lerakis S, Janik M, McLean DS, et al. Adenosine stress magnetic</text>
<text top="349" left="92" width="327" height="12" font="12">resonance imaging in women with low risk chest pain: the Emory</text>
<text top="363" left="92" width="279" height="12" font="12">University experience. Am J Med Sci. 2010;339:216 –20.</text>
<text top="376" left="59" width="360" height="12" font="12">1133. Taillefer R, DePuey EG, Udelson JE, et al. Comparative diagnostic</text>
<text top="390" left="92" width="327" height="12" font="12">accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfu-</text>
<text top="404" left="92" width="327" height="12" font="12">sion and ECG-gated SPECT) in detecting coronary artery disease</text>
<text top="417" left="92" width="232" height="12" font="12">in women. J Am Coll Cardiol. 1997;29:69 –77.</text>
<text top="431" left="59" width="360" height="12" font="12">1134. Santana-Boado C, Candell-Riera J, Castell-Conesa J, et al. Diag-</text>
<text top="444" left="92" width="327" height="12" font="12">nostic accuracy of technetium-99m-MIBI myocardial SPECT in</text>
<text top="458" left="92" width="230" height="12" font="12">women and men. J Nucl Med. 1998;39:751–5.</text>
<text top="471" left="59" width="360" height="12" font="12">1135. Philpott S, Boynton PM, Feder G, et al. Gender differences in</text>
<text top="485" left="92" width="327" height="12" font="12">descriptions of angina symptoms and health problems immediately</text>
<text top="499" left="92" width="327" height="12" font="12">prior to angiography: the ACRE study. Appropriateness of Coro-</text>
<text top="512" left="92" width="302" height="12" font="12">nary Revascularisation study. Soc Sci Med. 2001;52:1565–75.</text>
<text top="526" left="59" width="360" height="12" font="12">1136. Daly C, Clemens F, Lopez Sendon JL, et al. Gender differences in</text>
<text top="539" left="92" width="327" height="12" font="12">the management and clinical outcome of stable angina. Circulation.</text>
<text top="553" left="92" width="84" height="12" font="12">2006;113:490 – 8.</text>
<text top="567" left="59" width="360" height="12" font="12">1137. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in</text>
<text top="580" left="92" width="327" height="12" font="12">the diagnosis and treatment of non-ST-segment elevation acute</text>
<text top="594" left="92" width="327" height="12" font="12">coronary syndromes: large-scale observations from the CRUSADE</text>
<text top="607" left="92" width="327" height="12" font="12">(Can Rapid Risk Stratification of Unstable Angina Patients Sup-</text>
<text top="621" left="92" width="327" height="12" font="12">press Adverse Outcomes With Early Implementation of the Amer-</text>
<text top="635" left="92" width="327" height="12" font="12">ican College of Cardiology/American Heart Association Guide-</text>
<text top="648" left="92" width="327" height="12" font="12">lines) National Quality Improvement Initiative. J Am Coll Cardiol.</text>
<text top="662" left="92" width="75" height="12" font="12">2005;45:832–7.</text>
<text top="675" left="59" width="360" height="12" font="12">1138. Dey S, Flather MD, Devlin G, et al. Sex-related differences in the</text>
<text top="689" left="92" width="327" height="12" font="12">presentation, treatment and outcomes among patients with acute</text>
<text top="702" left="92" width="327" height="12" font="12">coronary syndromes: the Global Registry of Acute Coronary Events.</text>
<text top="716" left="92" width="107" height="12" font="12">Heart. 2009;95:20 – 6.</text>
<text top="730" left="59" width="360" height="12" font="12">1139. Jacobs AK, Johnston JM, Haviland A, et al. Improved outcomes for</text>
<text top="743" left="92" width="327" height="12" font="12">women undergoing contemporary percutaneous coronary interven-</text>
<text top="757" left="92" width="327" height="12" font="12">tion: a report from the National Heart, Lung, and Blood Institute</text>
<text top="770" left="92" width="279" height="12" font="12">Dynamic registry. J Am Coll Cardiol. 2002;39:1608 –14.</text>
<text top="784" left="59" width="360" height="12" font="12">1140. Holubkov R, Laskey WK, Haviland A, et al. Angina 1 year after</text>
<text top="798" left="92" width="327" height="12" font="12">percutaneous coronary intervention: a report from the NHLBI</text>
<text top="811" left="92" width="250" height="12" font="12">Dynamic Registry. Am Heart J. 2002;144:826 –33.</text>
<text top="825" left="59" width="360" height="12" font="12">1141. Vaccarino V, Abramson JL, Veledar E, et al. Sex differences in</text>
<text top="838" left="92" width="327" height="12" font="12">hospital mortality after coronary artery bypass surgery: evidence</text>
<text top="852" left="92" width="327" height="12" font="12">for a higher mortality in younger women. Circulation. 2002;105:</text>
<text top="865" left="92" width="50" height="12" font="12">1176 – 81.</text>
<text top="879" left="59" width="360" height="12" font="12">1142. Edwards FH, Carey JS, Grover FL, et al. Impact of gender on</text>
<text top="893" left="92" width="327" height="12" font="12">coronary bypass operative mortality. Ann Thorac Surg. 1998;66:</text>
<text top="906" left="92" width="40" height="12" font="12">125–31.</text>
<text top="920" left="59" width="360" height="12" font="12">1143. Shaw RE, Anderson HV, Brindis RG, et al. Development of a risk</text>
<text top="933" left="92" width="327" height="12" font="12">adjustment mortality model using the American College of</text>
<text top="947" left="92" width="327" height="12" font="12">Cardiology-National Cardiovascular Data Registry (ACC-NCDR)</text>
<text top="961" left="92" width="308" height="12" font="12">experience: 1998 –2000. J Am Coll Cardiol. 2002;39:1104 –12.</text>
<text top="974" left="59" width="360" height="12" font="12">1144. Singh M, Rihal CS, Lennon RJ, et al. Prediction of complications</text>
<text top="988" left="92" width="327" height="12" font="12">following nonemergency percutaneous coronary interventions. Am J</text>
<text top="1001" left="92" width="125" height="12" font="12">Cardiol. 2005;96:907–12.</text>
<text top="1015" left="59" width="360" height="12" font="12">1145. Shaw RE, Anderson HV, Brindis RG, et al. Updated risk adjust-</text>
<text top="1028" left="92" width="327" height="12" font="12">ment mortality model using the complete 1.1 dataset from the</text>
<text top="1042" left="92" width="327" height="12" font="12">American College of Cardiology National Cardiovascular Data</text>
<text top="1056" left="92" width="306" height="12" font="12">Registry (ACC-NCDR). J Invasive Cardiol. 2003;15:578 – 80.</text>
<text top="1069" left="59" width="360" height="12" font="12">1146. Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside</text>
<text top="1083" left="92" width="327" height="12" font="12">additive tool for prediction of in-hospital mortality after percutane-</text>
<text top="1096" left="92" width="281" height="12" font="12">ous coronary interventions. Circulation. 2001;104:263– 8.</text>
<text top="104" left="446" width="360" height="12" font="12">1147. Wu C, Hannan EL, Walford G, et al. A risk score to predict</text>
<text top="118" left="479" width="327" height="12" font="12">in-hospital mortality for percutaneous coronary interventions. J Am</text>
<text top="132" left="479" width="153" height="12" font="12">Coll Cardiol. 2006;47:654 – 60.</text>
<text top="146" left="446" width="360" height="12" font="12">1148. Singh M, Rihal CS, Gersh BJ, et al. Mortality differences</text>
<text top="159" left="479" width="327" height="12" font="12">between men and women after percutaneous coronary interven-</text>
<text top="173" left="479" width="327" height="12" font="12">tions. A 25-year, single-center experience. J Am Coll Cardiol.</text>
<text top="187" left="479" width="91" height="12" font="12">2008;51:2313–20.</text>
<text top="201" left="446" width="360" height="12" font="12">1149. Singh M, Lennon RJ, Holmes DR Jr., et al. Correlates of procedural</text>
<text top="214" left="479" width="327" height="12" font="12">complications and a simple integer risk score for percutaneous</text>
<text top="228" left="479" width="292" height="12" font="12">coronary intervention. J Am Coll Cardiol. 2002;40:387–93.</text>
<text top="242" left="446" width="360" height="12" font="12">1150. Hannan EL, Wu C, Bennett EV, et al. Risk stratification of</text>
<text top="256" left="479" width="327" height="12" font="12">in-hospital mortality for coronary artery bypass graft surgery. J Am</text>
<text top="270" left="479" width="145" height="12" font="12">Coll Cardiol. 2006;47:661– 8.</text>
<text top="283" left="446" width="360" height="12" font="12">1151. Katzel LI, Sorkin JD, Goldberg AP. Exercise-induced silent myo-</text>
<text top="297" left="479" width="327" height="12" font="12">cardial ischemia and future cardiac events in healthy, sedentary,</text>
<text top="311" left="479" width="313" height="12" font="12">middle-aged and older men. J Am Geriatr Soc. 1999;47:923–9.</text>
<text top="325" left="446" width="360" height="12" font="12">1152. Innocenti F, Totti A, Baroncini C, et al. Prognostic value of</text>
<text top="339" left="479" width="327" height="12" font="12">dobutamine stress echocardiography in octogenarians. Int J Cardio-</text>
<text top="352" left="479" width="146" height="12" font="12">vasc Imaging. 2011;27:65–74.</text>
<text top="366" left="446" width="360" height="12" font="12">1153. Perrone-Filardi P, Costanzo P, Dellegrottaglie S, et al. Prognostic</text>
<text top="380" left="479" width="327" height="12" font="12">role of myocardial single photon emission computed tomography in</text>
<text top="394" left="479" width="214" height="12" font="12">the elderly. J Nucl Cardiol. 2010;17:310 –5.</text>
<text top="407" left="446" width="360" height="12" font="12">1154. Bouzas-Mosquera A, Peteiro J, Broullon FJ, et al. Value of exercise</text>
<text top="421" left="479" width="327" height="12" font="12">echocardiography for predicting mortality in elderly patients. Eur</text>
<text top="435" left="479" width="157" height="12" font="12">J Clin Invest. 2010;40:1122–30.</text>
<text top="449" left="446" width="360" height="12" font="12">1155. Bernheim AM, Kittipovanonth M, Takahashi PY, et al. Does the</text>
<text top="463" left="479" width="327" height="12" font="12">prognostic value of dobutamine stress echocardiography differ</text>
<text top="476" left="479" width="291" height="12" font="12">among different age groups? Am Heart J. 2011;161:740 –5.</text>
<text top="490" left="446" width="360" height="12" font="12">1156. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive</text>
<text top="504" left="479" width="327" height="12" font="12">management strategies for high-risk patients with non-ST-segment</text>
<text top="518" left="479" width="327" height="12" font="12">elevation acute coronary syndromes: results from the CRUSADE</text>
<text top="532" left="479" width="302" height="12" font="12">Quality Improvement Initiative. JAMA. 2004;292:2096 –104.</text>
<text top="545" left="446" width="360" height="12" font="12">1157. Karlson BW, Herlitz J, Pettersson P, et al. One-year prognosis in</text>
<text top="559" left="479" width="327" height="12" font="12">patients hospitalized with a history of unstable angina pectoris. Clin</text>
<text top="573" left="479" width="132" height="12" font="12">Cardiol. 1993;16:397– 402.</text>
<text top="587" left="446" width="360" height="12" font="12">1158. Kwok JM, Miller TD, Hodge DO, et al. Prognostic value of the</text>
<text top="601" left="479" width="327" height="12" font="12">Duke treadmill score in the elderly. J Am Coll Cardiol. 2002;39:</text>
<text top="614" left="479" width="46" height="12" font="12">1475– 81.</text>
<text top="628" left="446" width="360" height="12" font="12">1159. Avezum A, Makdisse M, Spencer F, et al. Impact of age on</text>
<text top="642" left="479" width="327" height="12" font="12">management and outcome of acute coronary syndrome: observations</text>
<text top="656" left="479" width="327" height="12" font="12">from the Global Registry of Acute Coronary Events (GRACE). Am</text>
<text top="669" left="479" width="125" height="12" font="12">Heart J. 2005;149:67–73.</text>
<text top="683" left="446" width="360" height="12" font="12">1160. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison</text>
<text top="697" left="479" width="327" height="12" font="12">of early invasive and conservative strategies in patients with unstable</text>
<text top="711" left="479" width="327" height="12" font="12">coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor</text>
<text top="725" left="479" width="224" height="12" font="12">tirofiban. N Engl J Med. 2001;344:1879 – 87.</text>
<text top="738" left="446" width="360" height="12" font="12">1161. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for</text>
<text top="752" left="479" width="327" height="12" font="12">prediction of contrast-induced nephropathy after percutaneous cor-</text>
<text top="766" left="479" width="327" height="12" font="12">onary intervention: development and initial validation. J Am Coll</text>
<text top="780" left="479" width="125" height="12" font="12">Cardiol. 2004;44:1393–9.</text>
<text top="793" left="446" width="360" height="12" font="12">1162. Maron DJ, Spertus JA, Mancini GB, et al. Impact of an initial</text>
<text top="807" left="479" width="327" height="12" font="12">strategy of medical therapy without percutaneous coronary interven-</text>
<text top="821" left="479" width="327" height="12" font="12">tion in high-risk patients from the Clinical Outcomes Utilizing</text>
<text top="835" left="479" width="327" height="12" font="12">Revascularization and Aggressive DruG Evaluation (COURAGE)</text>
<text top="848" left="479" width="195" height="12" font="12">trial. Am J Cardiol. 2009;104:1055– 62.</text>
<text top="862" left="446" width="360" height="12" font="12">1163. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients</text>
<text top="876" left="479" width="327" height="12" font="12">with chronic symptomatic coronary artery disease with an invasive vs</text>
<text top="890" left="479" width="327" height="12" font="12">optimized medical treatment strategy: one-year results of the ran-</text>
<text top="904" left="479" width="243" height="12" font="12">domized TIME trial. JAMA. 2003;289:1117–23.</text>
<text top="917" left="446" width="360" height="12" font="12">1164. Resnic FS, Ohno-Machado L, Selwyn A, et al. Simplified risk score</text>
<text top="931" left="479" width="327" height="12" font="12">models accurately predict the risk of major in-hospital complications</text>
<text top="945" left="479" width="327" height="12" font="12">following percutaneous coronary intervention. Am J Cardiol. 2001;</text>
<text top="959" left="479" width="36" height="12" font="12">88:5–9.</text>
<text top="972" left="446" width="360" height="12" font="12">1165. Qureshi MA, Safian RD, Grines CL, et al. Simplified scoring</text>
<text top="986" left="479" width="327" height="12" font="12">system for predicting mortality after percutaneous coronary inter-</text>
<text top="1000" left="479" width="225" height="12" font="12">vention. J Am Coll Cardiol. 2003;42:1890 –5.</text>
<text top="1014" left="446" width="360" height="12" font="12">1166. Feldman DN, Gade CL, Slotwiner AJ, et al. Comparison of</text>
<text top="1028" left="479" width="327" height="12" font="12">outcomes of percutaneous coronary interventions in patients of three</text>
<text top="1041" left="479" width="62" height="12" font="12">age groups (</text>
<text top="1039" left="540" width="265" height="16" font="12">⬍60, 60 to 80, and ⬎80 years) (from the New York</text>
<text top="1055" left="479" width="298" height="12" font="12">State Angioplasty Registry). Am J Cardiol. 2006;98:1334 –9.</text>
<text top="1069" left="445" width="360" height="12" font="12">1167. Shroyer AL, Coombs LP, Peterson ED, et al. The Society of</text>
<text top="1083" left="479" width="327" height="12" font="12">Thoracic Surgeons: 30-day operative mortality and morbidity risk</text>
<text top="1096" left="479" width="226" height="12" font="12">models. Ann Thorac Surg. 2003;75:1856 – 64.</text>
<text top="52" left="58" width="25" height="10" font="12">e156</text>
<text top="52" left="112" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="114" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="12" font="12">1168. Freeman WK, Schaff HV, O’Brien PC, et al. Cardiac surgery in the</text>
<text top="118" left="92" width="327" height="12" font="12">octogenarian: perioperative outcome and clinical follow-up. J Am</text>
<text top="132" left="92" width="145" height="12" font="12">Coll Cardiol. 1991;18:29 –35.</text>
<text top="145" left="59" width="360" height="12" font="12">1169. Peterson ED, Jollis JG, Bebchuk JD, et al. Changes in mortality</text>
<text top="159" left="92" width="327" height="12" font="12">after myocardial revascularization in the elderly. The national</text>
<text top="172" left="92" width="286" height="12" font="12">Medicare experience. Ann Intern Med. 1994;121:919 –27.</text>
<text top="186" left="59" width="360" height="12" font="12">1170. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors,</text>
<text top="200" left="92" width="327" height="12" font="12">and 12-yr cardiovascular mortality for men screened in the Multiple</text>
<text top="213" left="92" width="317" height="12" font="12">Risk Factor Intervention Trial. Diabetes Care. 1993;16:434 – 44.</text>
<text top="227" left="59" width="360" height="12" font="12">1171. Haffner SM. Coronary heart disease in patients with diabetes.</text>
<text top="240" left="92" width="168" height="12" font="12">N Engl J Med. 2000;342:1040 –2.</text>
<text top="254" left="59" width="360" height="12" font="12">1172. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and</text>
<text top="268" left="92" width="321" height="12" font="12">cardiovascular disease: an update. Hypertension. 2001;37:1053–9.</text>
<text top="281" left="59" width="360" height="12" font="12">1173. Blendea MC, McFarlane SI, Isenovic ER, et al. Heart disease in</text>
<text top="295" left="92" width="238" height="12" font="12">diabetic patients. Curr Diab Rep. 2003;3:223–9.</text>
<text top="308" left="59" width="360" height="12" font="12">1174. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary</text>
<text top="322" left="92" width="327" height="12" font="12">heart disease in subjects with type 2 diabetes and in nondiabetic</text>
<text top="336" left="92" width="327" height="12" font="12">subjects with and without prior myocardial infarction. N Engl</text>
<text top="349" left="92" width="127" height="12" font="12">J Med. 1998;339:229 –34.</text>
<text top="363" left="59" width="360" height="12" font="12">1175. Hueb W, Gersh BJ, Costa F, et al. Impact of diabetes on five-year</text>
<text top="376" left="92" width="327" height="12" font="12">outcomes of patients with multivessel coronary artery disease. Ann</text>
<text top="390" left="92" width="138" height="12" font="12">Thorac Surg. 2007;83:93–9.</text>
<text top="404" left="59" width="360" height="12" font="12">1176. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of</text>
<text top="417" left="92" width="327" height="12" font="12">percutaneous coronary intervention with coronary artery bypass</text>
<text top="431" left="92" width="327" height="12" font="12">grafting in diabetic patients. 1-year results of the CARDia (Coro-</text>
<text top="444" left="92" width="327" height="12" font="12">nary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol.</text>
<text top="458" left="92" width="83" height="12" font="12">2010;55:432– 40.</text>
<text top="471" left="59" width="360" height="12" font="12">1177. Farkouh ME, Dangas G, Leon MB, et al. Design of the Future</text>
<text top="485" left="92" width="327" height="12" font="12">REvascularization Evaluation in patients with Diabetes mellitus:</text>
<text top="499" left="92" width="327" height="12" font="12">Optimal management of Multivessel disease (FREEDOM) Trial.</text>
<text top="512" left="92" width="153" height="12" font="12">Am Heart J. 2008;155:215–23.</text>
<text top="526" left="59" width="360" height="12" font="12">1178. Goel K, Thomas RJ, Squires RW, et al. Combined effect of</text>
<text top="539" left="92" width="327" height="12" font="12">cardiorespiratory fitness and adiposity on mortality in patients with</text>
<text top="553" left="92" width="266" height="12" font="12">coronary artery disease. Am Heart J. 2011;161:590 –7.</text>
<text top="567" left="59" width="360" height="12" font="12">1179. Goyal D, Logie IM, Nadar SK, et al. Generalized obesity but not</text>
<text top="580" left="92" width="327" height="12" font="12">that characterized by raised waist-hip ratio is associated with</text>
<text top="594" left="92" width="327" height="12" font="12">increased perceived breathlessness during treadmill exercise testing.</text>
<text top="607" left="92" width="160" height="12" font="12">Cardiovasc Ther. 2009;27:10 – 6.</text>
<text top="621" left="59" width="360" height="12" font="12">1180. McNulty PH, Ettinger SM, Field JM, et al. Cardiac catheterization</text>
<text top="635" left="92" width="327" height="12" font="12">in morbidly obese patients. Catheter Cardiovasc Interv. 2002;56:</text>
<text top="648" left="92" width="34" height="12" font="12">174 –7.</text>
<text top="662" left="59" width="360" height="12" font="12">1181. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between</text>
<text top="675" left="92" width="327" height="12" font="12">renal dysfunction and cardiovascular outcomes after myocardial</text>
<text top="689" left="92" width="226" height="12" font="12">infarction. N Engl J Med. 2004;351:1285–95.</text>
<text top="702" left="59" width="360" height="12" font="12">1182. Brosius FC, III, Hostetter TH, Kelepouris E, et al. Detection of</text>
<text top="716" left="92" width="327" height="12" font="12">chronic kidney disease in patients with or at increased risk of</text>
<text top="730" left="92" width="327" height="12" font="12">cardiovascular disease: a science advisory from the American Heart</text>
<text top="743" left="92" width="327" height="12" font="12">Association Kidney And Cardiovascular Disease Council; the</text>
<text top="757" left="92" width="327" height="12" font="12">Councils on High Blood Pressure Research, Cardiovascular Disease</text>
<text top="770" left="92" width="327" height="12" font="12">in the Young, and Epidemiology and Prevention; and the Quality of</text>
<text top="784" left="92" width="327" height="12" font="12">Care and Outcomes Research Interdisciplinary Working Group:</text>
<text top="798" left="92" width="327" height="12" font="12">developed in collaboration with the National Kidney Foundation.</text>
<text top="811" left="92" width="149" height="12" font="12">Circulation. 2006;114:1083–7.</text>
<text top="825" left="59" width="360" height="12" font="12">1183. Matzkies FK, Reinecke H, Regetmeier A, et al. Long-term out-</text>
<text top="838" left="92" width="327" height="12" font="12">come after percutaneous transluminal coronary angioplasty in pa-</text>
<text top="852" left="92" width="327" height="12" font="12">tients with chronic renal failure with and without diabetic nephrop-</text>
<text top="865" left="92" width="151" height="12" font="12">athy. Nephron. 2001;89:10 – 4.</text>
<text top="879" left="59" width="360" height="12" font="12">1184. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a</text>
<text top="893" left="92" width="327" height="12" font="12">risk factor for development of cardiovascular disease: a statement</text>
<text top="906" left="92" width="327" height="12" font="12">from the American Heart Association Councils on Kidney in</text>
<text top="920" left="92" width="327" height="12" font="12">Cardiovascular Disease, High Blood Pressure Research, Clinical</text>
<text top="933" left="92" width="327" height="12" font="12">Cardiology, and Epidemiology and Prevention. Circulation. 2003;</text>
<text top="947" left="92" width="69" height="12" font="12">108:2154 – 69.</text>
<text top="961" left="59" width="360" height="12" font="12">1185. Gurm HS, Dixon SR, Smith DE, et al. Renal function-based</text>
<text top="974" left="92" width="327" height="12" font="12">contrast dosing to define safe limits of radiographic contrast media</text>
<text top="988" left="92" width="327" height="12" font="12">in patients undergoing percutaneous coronary interventions. J Am</text>
<text top="1001" left="92" width="150" height="12" font="12">Coll Cardiol. 2011;58:907–14.</text>
<text top="1015" left="59" width="360" height="12" font="12">1186. K/DOQI clinical practice guidelines for chronic kidney disease:</text>
<text top="1028" left="92" width="327" height="12" font="12">evaluation, classification, and stratification. Am J Kidney Dis.</text>
<text top="1042" left="92" width="82" height="12" font="12">2002;39:S1–266.</text>
<text top="1056" left="59" width="360" height="12" font="12">1187. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis</text>
<text top="1069" left="92" width="327" height="12" font="12">patients in the United States after coronary angioplasty, coronary</text>
<text top="1083" left="92" width="327" height="12" font="12">artery stenting, and coronary artery bypass surgery and impact of</text>
<text top="1096" left="92" width="201" height="12" font="12">diabetes. Circulation. 2002;106:2207–11.</text>
<text top="104" left="446" width="360" height="12" font="12">1188. Koyanagi T, Nishida H, Kitamura M, et al. Comparison of clinical</text>
<text top="118" left="479" width="327" height="12" font="12">outcomes of coronary artery bypass grafting and percutaneous</text>
<text top="131" left="479" width="327" height="12" font="12">transluminal coronary angioplasty in renal dialysis patients. Ann</text>
<text top="145" left="479" width="151" height="12" font="12">Thorac Surg. 1996;61:1793– 6.</text>
<text top="159" left="446" width="360" height="12" font="12">1189. Bae KS, Park HC, Kang BS, et al. Percutaneous coronary interven-</text>
<text top="172" left="479" width="327" height="12" font="12">tion versus coronary artery bypass grafting in patients with coronary</text>
<text top="186" left="479" width="327" height="12" font="12">artery disease and diabetic nephropathy: a single center experience.</text>
<text top="199" left="479" width="196" height="12" font="12">Korean J Intern Med. 2007;22:139 – 46.</text>
<text top="213" left="446" width="360" height="12" font="12">1190. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic</text>
<text top="227" left="479" width="327" height="12" font="12">kidney disease with clinical outcomes after coronary revasculariza-</text>
<text top="240" left="479" width="327" height="12" font="12">tion: the Arterial Revascularization Therapies Study (ARTS). Am</text>
<text top="254" left="479" width="125" height="12" font="12">Heart J. 2005;149:512–9.</text>
<text top="267" left="446" width="360" height="12" font="12">1191. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after</text>
<text top="281" left="479" width="327" height="12" font="12">coronary revascularization among patients with kidney disease.</text>
<text top="294" left="479" width="150" height="12" font="12">Circulation. 2004;110:1890 –5.</text>
<text top="308" left="446" width="360" height="12" font="12">1192. Szczech LA, Reddan DN, Owen WF, et al. Differential survival</text>
<text top="322" left="479" width="327" height="12" font="12">after coronary revascularization procedures among patients with</text>
<text top="335" left="479" width="229" height="12" font="12">renal insufficiency. Kidney Int. 2001;60:292–9.</text>
<text top="349" left="446" width="360" height="12" font="12">1193. Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal medical</text>
<text top="362" left="479" width="327" height="12" font="12">therapy with or without percutaneous coronary intervention for</text>
<text top="376" left="479" width="327" height="12" font="12">patients with stable coronary artery disease and chronic kidney</text>
<text top="390" left="479" width="208" height="12" font="12">disease. Am J Cardiol. 2009;104:1647–53.</text>
<text top="403" left="446" width="360" height="12" font="12">1194. Reddan DN, Szczech LA, Tuttle RH, et al. Chronic kidney</text>
<text top="417" left="479" width="327" height="12" font="12">disease, mortality, and treatment strategies among patients with</text>
<text top="430" left="479" width="327" height="12" font="12">clinically significant coronary artery disease. J Am Soc Nephrol.</text>
<text top="444" left="479" width="92" height="12" font="12">2003;14:2373– 80.</text>
<text top="458" left="446" width="360" height="12" font="12">1195. Tabib A, Leroux C, Mornex JF, et al. Accelerated coronary athero-</text>
<text top="471" left="479" width="327" height="12" font="12">sclerosis and arteriosclerosis in young human-immunodeficiency-virus-</text>
<text top="485" left="479" width="240" height="12" font="12">positive patients. Coron Artery Dis. 2000;11:41–6.</text>
<text top="498" left="446" width="360" height="12" font="12">1196. Mehta NJ, Khan IA. HIV-associated coronary artery disease.</text>
<text top="512" left="479" width="140" height="12" font="12">Angiology. 2003;54:269 –75.</text>
<text top="526" left="446" width="360" height="12" font="12">1197. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction</text>
<text top="539" left="479" width="327" height="12" font="12">in human immunodeficiency virus-infected patients. Arch Intern</text>
<text top="553" left="479" width="119" height="12" font="12">Med. 2003;163:457– 60.</text>
<text top="566" left="446" width="360" height="12" font="12">1198. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral</text>
<text top="580" left="479" width="327" height="12" font="12">drugs and the risk of myocardial infarction. N Engl J Med.</text>
<text top="594" left="479" width="93" height="12" font="12">2007;356:1723–35.</text>
<text top="607" left="446" width="360" height="12" font="12">1199. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and</text>
<text top="621" left="479" width="307" height="12" font="12">HAART on serum lipids in men. JAMA. 2003;289:2978 – 82.</text>
<text top="634" left="446" width="360" height="12" font="12">1200. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation</text>
<text top="648" left="479" width="327" height="12" font="12">and management of dyslipidemia in human immunodeficiency virus</text>
<text top="661" left="479" width="327" height="12" font="12">(HIV)-infected adults receiving antiretroviral therapy: recommen-</text>
<text top="675" left="479" width="327" height="12" font="12">dations of the HIV Medical Association of the Infectious Disease</text>
<text top="689" left="479" width="327" height="12" font="12">Society of America and the Adult AIDS Clinical Trials Group. Clin</text>
<text top="702" left="479" width="138" height="12" font="12">Infect Dis. 2003;37:613–27.</text>
<text top="716" left="446" width="360" height="12" font="12">1201. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual</text>
<text top="729" left="479" width="327" height="12" font="12">antiretroviral drugs on the risk of myocardial infarction in human</text>
<text top="743" left="479" width="327" height="12" font="12">immunodeficiency virus-infected patients: a case-control study</text>
<text top="757" left="479" width="327" height="12" font="12">nested within the French Hospital Database on HIV ANRS cohort</text>
<text top="770" left="479" width="219" height="12" font="12">CO4. Arch Intern Med. 2010;170:1228 –38.</text>
<text top="784" left="446" width="360" height="12" font="12">1202. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction</text>
<text top="797" left="479" width="327" height="12" font="12">in patients with HIV infection exposed to specific individual</text>
<text top="811" left="479" width="327" height="12" font="12">antiretroviral drugs from the 3 major drug classes: the data collection</text>
<text top="824" left="479" width="327" height="12" font="12">on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis.</text>
<text top="838" left="479" width="89" height="12" font="12">2010;201:318 –30.</text>
<text top="852" left="446" width="360" height="12" font="12">1203. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebro-</text>
<text top="865" left="479" width="327" height="12" font="12">vascular events in patients treated for human immunodeficiency</text>
<text top="879" left="479" width="243" height="12" font="12">virus infection. N Engl J Med. 2003;348:702–10.</text>
<text top="892" left="446" width="360" height="12" font="12">1204. Khunnawat C, Mukerji S, Havlichek D Jr., et al. Cardiovascular</text>
<text top="906" left="479" width="327" height="12" font="12">manifestations in human immunodeficiency virus-infected patients.</text>
<text top="920" left="479" width="163" height="12" font="12">Am J Cardiol. 2008;102:635– 42.</text>
<text top="933" left="446" width="360" height="12" font="12">1205. Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in</text>
<text top="947" left="479" width="327" height="12" font="12">atherosclerotic coronary heart disease between subjects with and</text>
<text top="960" left="479" width="298" height="12" font="12">without rheumatoid arthritis. J Rheumatol. 2007;34:937– 42.</text>
<text top="974" left="446" width="360" height="12" font="12">1206. Lee AB, Godfrey T, Rowley KG, et al. Traditional risk factor</text>
<text top="987" left="479" width="327" height="12" font="12">assessment does not capture the extent of cardiovascular risk in</text>
<text top="1001" left="479" width="305" height="12" font="12">systemic lupus erythematosus. Intern Med J. 2006;36:237– 43.</text>
<text top="1015" left="446" width="360" height="12" font="12">1207. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates</text>
<text top="1028" left="479" width="327" height="12" font="12">of myocardial infarction and angina in women with systemic lupus</text>
<text top="1042" left="479" width="327" height="12" font="12">erythematosus: comparison with the Framingham Study. Am J</text>
<text top="1055" left="479" width="147" height="12" font="12">Epidemiol. 1997;145:408 –15.</text>
<text top="1069" left="446" width="360" height="12" font="12">1208. Homcy CJ, Liberthson RR, Fallon JT, et al. Ischemic heart disease</text>
<text top="1083" left="479" width="327" height="12" font="12">in systemic lupus erythematosus in the young patient: report of six</text>
<text top="1096" left="479" width="189" height="12" font="12">cases. Am J Cardiol. 1982;49:478 – 84.</text>
<text top="52" left="781" width="25" height="10" font="12">e157</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="115" position="absolute" top="0" left="0" height="1161" width="864">
<text top="104" left="59" width="360" height="12" font="12">1209. Soejima H, Miyamoto S, Kojima S, et al. Coronary spastic angina</text>
<text top="118" left="92" width="325" height="12" font="12">in patients with connective tissue disease. Circ J. 2004;68:367–70.</text>
<text top="132" left="59" width="360" height="12" font="12">1210. Clark AM, DesMeules M, Luo W, et al. Socioeconomic status and</text>
<text top="145" left="92" width="327" height="12" font="12">cardiovascular disease: risks and implications for care. Nat Rev</text>
<text top="159" left="92" width="119" height="12" font="12">Cardiol. 2009;6:712–22.</text>
<text top="172" left="59" width="360" height="12" font="12">1211. Avendano M, Kunst AE, Huisman M, et al. Socioeconomic status</text>
<text top="186" left="92" width="327" height="12" font="12">and ischaemic heart disease mortality in 10 western European</text>
<text top="200" left="92" width="261" height="12" font="12">populations during the 1990s. Heart. 2006;92:461–7.</text>
<text top="213" left="59" width="360" height="12" font="12">1212. Alter DA, Iron K, Austin PC, et al. Socioeconomic status, service</text>
<text top="227" left="92" width="327" height="12" font="12">patterns, and perceptions of care among survivors of acute myocar-</text>
<text top="240" left="92" width="259" height="12" font="12">dial infarction in Canada. JAMA. 2004;291:1100 –7.</text>
<text top="254" left="59" width="360" height="12" font="12">1213. Davis AM, Vinci LM, Okwuosa TM, et al. Cardiovascular health</text>
<text top="268" left="92" width="327" height="12" font="12">disparities: a systematic review of health care interventions. Med</text>
<text top="281" left="92" width="169" height="12" font="12">Care Res Rev. 2007;64:29S–100S.</text>
<text top="295" left="59" width="360" height="12" font="12">1214. Cromwell J, McCall NT, Burton J, et al. Race/ethnic disparities in</text>
<text top="308" left="92" width="327" height="12" font="12">utilization of lifesaving technologies by Medicare ischemic heart</text>
<text top="322" left="92" width="238" height="12" font="12">disease beneficiaries. Med Care. 2005;43:330 –7.</text>
<text top="336" left="59" width="360" height="12" font="12">1215. Peterson ED, Shaw LK, Delong ER, et al. Racial variation in the</text>
<text top="349" left="92" width="327" height="12" font="12">use of coronary-revascularization procedures. Are the differences</text>
<text top="363" left="92" width="274" height="12" font="12">real? Do they matter? N Engl J Med. 1997;336:480 – 6.</text>
<text top="376" left="59" width="360" height="12" font="12">1216. Clayton TC, Lubsen J, Pocock SJ, et al. Risk score for predicting</text>
<text top="390" left="92" width="327" height="12" font="12">death, myocardial infarction, and stroke in patients with stable</text>
<text top="404" left="92" width="327" height="12" font="12">angina, based on a large randomised trial cohort of patients. BMJ.</text>
<text top="417" left="92" width="69" height="12" font="12">2005;331:869.</text>
<text top="431" left="59" width="360" height="12" font="12">1217. Poole-Wilson PA, Voko Z, Kirwan BA, et al. Clinical course of</text>
<text top="444" left="92" width="327" height="12" font="12">isolated stable angina due to coronary heart disease. Eur Heart J.</text>
<text top="458" left="92" width="89" height="12" font="12">2007;28:1928 –35.</text>
<text top="471" left="59" width="360" height="12" font="12">1218. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome</text>
<text top="485" left="92" width="327" height="12" font="12">in the RITA-2 trial: coronary angioplasty versus medical therapy.</text>
<text top="499" left="92" width="186" height="12" font="12">J Am Coll Cardiol. 2003;42:1161–70.</text>
<text top="512" left="59" width="360" height="12" font="12">1219. Wijeysundera HC, Machado M, Farahati F, et al. Association of</text>
<text top="526" left="92" width="327" height="12" font="12">temporal trends in risk factors and treatment uptake with coronary</text>
<text top="539" left="92" width="307" height="12" font="12">heart disease mortality, 1994 –2005. JAMA. 2010;303:1841–7.</text>
<text top="553" left="59" width="360" height="12" font="12">1220. Gimelli A, Rossi G, Landi P, et al. Stress/Rest Myocardial</text>
<text top="567" left="92" width="327" height="12" font="12">Perfusion Abnormalities by Gated SPECT: Still the Best Predictor</text>
<text top="580" left="92" width="327" height="12" font="12">of Cardiac Events in Stable Ischemic Heart Disease. J Nucl Med.</text>
<text top="594" left="92" width="83" height="12" font="12">2009;50:546 –53.</text>
<text top="607" left="59" width="360" height="12" font="12">1221. Hashimoto A, Nakata T, Wakabayashi T, et al. Incremental</text>
<text top="621" left="92" width="327" height="12" font="12">prognostic value of stress/rest gated perfusion SPECT in patients</text>
<text top="635" left="92" width="327" height="12" font="12">with coronary artery disease—subanalysis of the J-ACCESS study.</text>
<text top="648" left="92" width="125" height="12" font="12">Circ J. 2009;73:2288 –93.</text>
<text top="662" left="59" width="360" height="12" font="12">1222. Nakata T, Hashimoto A, Wakabayashi T, et al. Prediction of</text>
<text top="675" left="92" width="327" height="12" font="12">new-onset refractory congestive heart failure using gated myocardial</text>
<text top="689" left="92" width="327" height="12" font="12">perfusion SPECT imaging in patients with known or suspected</text>
<text top="702" left="92" width="327" height="12" font="12">coronary artery disease subanalysis of the J-ACCESS database.</text>
<text top="716" left="92" width="290" height="12" font="12">J Am Coll Cardiol Cardiovasc Imaging. 2009;2:1393– 400.</text>
<text top="730" left="59" width="360" height="12" font="12">1223. Shaw LJ, Hendel RC, Heller GV, et al. Prognostic estimation of</text>
<text top="743" left="92" width="327" height="12" font="12">coronary artery disease risk with resting perfusion abnormalities and</text>
<text top="757" left="92" width="327" height="12" font="12">stress ischemia on myocardial perfusion SPECT. J Nucl Cardiol.</text>
<text top="770" left="92" width="81" height="12" font="12">2008;15:762–73.</text>
<text top="784" left="59" width="360" height="12" font="12">1224. Kang X, Shaw LJ, Hayes SW, et al. Impact of body mass index on</text>
<text top="798" left="92" width="327" height="12" font="12">cardiac mortality in patients with known or suspected coronary</text>
<text top="811" left="92" width="327" height="12" font="12">artery disease undergoing myocardial perfusion single-photon emis-</text>
<text top="825" left="92" width="327" height="12" font="12">sion computed tomography. J Am Coll Cardiol. 2006;47:1418 –26.</text>
<text top="838" left="59" width="360" height="12" font="12">1225. D’Agostino RB, Sr., Grundy S, Sullivan LM, et al. Validation of the</text>
<text top="852" left="92" width="327" height="12" font="12">Framingham coronary heart disease prediction scores: results of a</text>
<text top="865" left="92" width="306" height="12" font="12">multiple ethnic groups investigation. JAMA. 2001;286:180 –7.</text>
<text top="879" left="59" width="360" height="12" font="12">1226. Spertus JA, Winder JA, Dewhurst TA, et al. Development and</text>
<text top="893" left="92" width="327" height="12" font="12">evaluation of the Seattle Angina Questionnaire: a new functional</text>
<text top="906" left="92" width="327" height="12" font="12">status measure for coronary artery disease. J Am Coll Cardiol.</text>
<text top="920" left="92" width="83" height="12" font="12">1995;25:333– 41.</text>
<text top="933" left="59" width="360" height="12" font="12">1227. Arnold SV, Morrow DA, Lei Y, et al. Economic impact of angina</text>
<text top="947" left="92" width="327" height="12" font="12">after an acute coronary syndrome: insights from the MERLIN-</text>
<text top="961" left="92" width="319" height="12" font="12">TIMI 36 trial. Circ Cardiovasc Qual Outcomes. 2009;2:344 –53.</text>
<text top="974" left="59" width="360" height="12" font="12">1228. Beltrame JF, Weekes AJ, Morgan C, et al. The prevalence of</text>
<text top="988" left="92" width="327" height="12" font="12">weekly angina among patients with chronic stable angina in</text>
<text top="1001" left="92" width="327" height="12" font="12">primary care practices: The Coronary Artery Disease in General</text>
<text top="1015" left="92" width="318" height="12" font="12">Practice (CADENCE) Study. Arch Intern Med. 2009;169:1491–9.</text>
<text top="1028" left="59" width="360" height="12" font="12">1229. Guadagnoli E, Normand SL, DiSalvo TG, et al. Effects of treat-</text>
<text top="1042" left="92" width="327" height="12" font="12">ment recommendations and specialist intervention on care provided</text>
<text top="1056" left="92" width="327" height="12" font="12">by primary care physicians to patients with myocardial infarction or</text>
<text top="1069" left="92" width="208" height="12" font="12">heart failure. Am J Med. 2004;117:371–9.</text>
<text top="1083" left="59" width="360" height="12" font="12">1230. Ho PM, Luther SA, Masoudi FA, et al. Inpatient and follow-up</text>
<text top="1096" left="92" width="327" height="12" font="12">cardiology care and mortality for acute coronary syndrome</text>
<text top="104" left="479" width="327" height="12" font="12">patients in the Veterans Health Administration. Am Heart J.</text>
<text top="118" left="479" width="92" height="12" font="12">2007;154:489 –94.</text>
<text top="131" left="446" width="360" height="12" font="12">1231. Christopher JR, Pothier CE, Blackstone EH, et al. Prognostic</text>
<text top="145" left="479" width="327" height="12" font="12">importance of presenting symptoms in patients undergoing exercise</text>
<text top="159" left="479" width="327" height="12" font="12">testing for evaluation of known or suspected coronary disease. Am J</text>
<text top="172" left="479" width="113" height="12" font="12">Med. 2004;117:380 –9.</text>
<text top="186" left="446" width="360" height="12" font="12">1232. Morise AP, Jalisi F. Evaluation of pretest and exercise test scores to</text>
<text top="199" left="479" width="327" height="12" font="12">assess all-cause mortality in unselected patients presenting for</text>
<text top="213" left="479" width="327" height="12" font="12">exercise testing with symptoms of suspected coronary artery disease.</text>
<text top="227" left="479" width="180" height="12" font="12">J Am Coll Cardiol. 2003;42:842–50.</text>
<text top="240" left="446" width="360" height="12" font="12">1233. Larson DM, Menssen KM, Sharkey SW, et al. “False-positive”</text>
<text top="254" left="479" width="327" height="12" font="12">cardiac catheterization laboratory activation among patients with</text>
<text top="267" left="479" width="327" height="12" font="12">suspected ST-segment elevation myocardial infarction. JAMA.</text>
<text top="281" left="479" width="96" height="12" font="12">2007;298:2754 – 60.</text>
<text top="294" left="446" width="360" height="12" font="12">1234. Lee TH, Cook EF, Weisberg MC, et al. Impact of the availability</text>
<text top="308" left="479" width="327" height="12" font="12">of a prior electrocardiogram on the triage of the patient with acute</text>
<text top="322" left="479" width="225" height="12" font="12">chest pain. J Gen Intern Med. 1990;5:381– 8.</text>
<text top="335" left="446" width="360" height="12" font="12">1235. Fesmire FM, Percy RF, Wears RL. Diagnostic and prognostic</text>
<text top="349" left="479" width="327" height="12" font="12">importance of comparing the initial to the previous electrocardio-</text>
<text top="362" left="479" width="327" height="12" font="12">gram in patients admitted for suspected acute myocardial infarction.</text>
<text top="376" left="479" width="148" height="12" font="12">South Med J. 1991;84:841– 6.</text>
<text top="390" left="446" width="360" height="12" font="12">1236. Okin PM, Oikarinen L, Viitasalo M, et al. Prognostic value of</text>
<text top="403" left="479" width="327" height="12" font="12">changes in the electrocardiographic strain pattern during antihyper-</text>
<text top="417" left="479" width="327" height="12" font="12">tensive treatment: the Losartan Intervention for End-Point Reduc-</text>
<text top="430" left="479" width="327" height="12" font="12">tion in Hypertension Study (LIFE). Circulation. 2009;119:</text>
<text top="444" left="479" width="45" height="12" font="12">1883–91.</text>
<text top="458" left="446" width="360" height="12" font="12">1237. Sawada SG, Safadi A, Gaitonde RS, et al. Stress-induced wall</text>
<text top="471" left="479" width="327" height="12" font="12">motion abnormalities with low-dose dobutamine infusion indicate</text>
<text top="485" left="479" width="327" height="12" font="12">the presence of severe disease and vulnerable myocardium. Echo-</text>
<text top="498" left="479" width="154" height="12" font="12">cardiography. 2007;24:739 – 44.</text>
<text top="512" left="446" width="360" height="12" font="12">1238. Lauer MS, Lytle B, Pashkow F, et al. Prediction of death and</text>
<text top="526" left="479" width="327" height="12" font="12">myocardial infarction by screening with exercise-thallium testing</text>
<text top="539" left="479" width="313" height="12" font="12">after coronary-artery-bypass grafting. Lancet. 1998;351:615–22.</text>
<text top="553" left="446" width="360" height="12" font="12">1239. Calnon DA, McGrath PD, Doss AL, et al. Prognostic value of</text>
<text top="566" left="479" width="327" height="12" font="12">dobutamine stress technetium-99m-sestamibi single-photon emis-</text>
<text top="580" left="479" width="327" height="12" font="12">sion computed tomography myocardial perfusion imaging: stratifi-</text>
<text top="594" left="479" width="327" height="12" font="12">cation of a high-risk population. J Am Coll Cardiol. 2001;38:</text>
<text top="607" left="479" width="39" height="12" font="12">1511–7.</text>
<text top="621" left="446" width="360" height="12" font="12">1240. Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of</text>
<text top="634" left="479" width="327" height="12" font="12">prognostic testing in patients with known or suspected ischemic</text>
<text top="648" left="479" width="327" height="12" font="12">heart disease: a basis for optimal utilization of exercise technetium-</text>
<text top="661" left="479" width="327" height="12" font="12">99m sestamibi myocardial perfusion single-photon emission com-</text>
<text top="675" left="479" width="280" height="12" font="12">puted tomography. J Am Coll Cardiol. 1995;26:639 – 47.</text>
<text top="689" left="446" width="360" height="12" font="12">1241. Chatziioannou SN, Moore WH, Ford PV, et al. Prognostic value of</text>
<text top="702" left="479" width="327" height="12" font="12">myocardial perfusion imaging in patients with high exercise toler-</text>
<text top="716" left="479" width="172" height="12" font="12">ance. Circulation. 1999;99:867–72.</text>
<text top="729" left="446" width="360" height="12" font="12">1242. Peteiro J, Monserrrat L, Pineiro M, et al. Comparison of exercise</text>
<text top="743" left="479" width="327" height="12" font="12">echocardiography and the Duke treadmill score for risk stratification</text>
<text top="757" left="479" width="327" height="12" font="12">in patients with known or suspected coronary artery disease and</text>
<text top="770" left="479" width="327" height="12" font="12">normal resting electrocardiogram. Am Heart J. 2006;151:1324 –10.</text>
<text top="784" left="446" width="118" height="12" font="12">1243. Deleted in proof.</text>
<text top="797" left="446" width="360" height="12" font="12">1244. Mowatt G, Cook JA, Hillis GS, et al. 64-Slice computed</text>
<text top="811" left="479" width="327" height="12" font="12">tomography angiography in the diagnosis and assessment of</text>
<text top="824" left="479" width="327" height="12" font="12">coronary artery disease: systematic review and meta-analysis.</text>
<text top="838" left="479" width="129" height="12" font="12">Heart. 2008;94:1386 –93.</text>
<text top="852" left="446" width="360" height="12" font="12">1245. Jones CM, Athanasiou T, Dunne N, et al. Multi-detector computed</text>
<text top="865" left="479" width="327" height="12" font="12">tomography in coronary artery bypass graft assessment: a meta-</text>
<text top="879" left="479" width="215" height="12" font="12">analysis. Ann Thorac Surg. 2007;83:341– 8.</text>
<text top="892" left="446" width="360" height="12" font="12">1246. Hamon M, Lepage O, Malagutti P, et al. Diagnostic performance</text>
<text top="906" left="479" width="327" height="12" font="12">of 1– and 6 –section spiral CT for coronary artery bypass graft</text>
<text top="920" left="479" width="278" height="12" font="12">assessment: meta-analysis. Radiology. 2008;247:679 – 86.</text>
<text top="933" left="446" width="360" height="12" font="12">1247. Carrabba N, Schuijf JD, de Graaf FR, et al. Diagnostic accuracy of</text>
<text top="947" left="479" width="327" height="12" font="12">64-slice computed tomography coronary angiography for the detec-</text>
<text top="960" left="479" width="327" height="12" font="12">tion of in-stent restenosis: a meta-analysis. J Nucl Cardiol. 2010;</text>
<text top="974" left="479" width="51" height="12" font="12">17:470 – 8.</text>
<text top="987" left="446" width="360" height="12" font="12">1248. Sun Z, Almutairi AM. Diagnostic accuracy of 64-multislice CT</text>
<text top="1001" left="479" width="327" height="12" font="12">angiography in the assessment of coronary in-stent restenosis: a</text>
<text top="1015" left="479" width="224" height="12" font="12">meta-analysis. Eur J Radiol. 2010;73:266 –73.</text>
<text top="1028" left="446" width="360" height="12" font="12">1249. Klem I, Heitner JF, Shah DJ, et al. Improved detection of coronary</text>
<text top="1042" left="479" width="327" height="12" font="12">artery disease by stress perfusion cardiovascular magnetic resonance</text>
<text top="1055" left="479" width="327" height="12" font="12">with the use of delayed enhancement infarction imaging. J Am Coll</text>
<text top="1069" left="479" width="128" height="12" font="12">Cardiol. 2006;47:1630 – 8.</text>
<text top="1083" left="446" width="360" height="12" font="12">1250. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA</text>
<text top="1096" left="479" width="327" height="12" font="12">focused update on perioperative beta blockade incorporated into the</text>
<text top="52" left="59" width="25" height="10" font="12">e158</text>
<text top="52" left="113" width="48" height="11" font="12">Fihn et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="116" position="absolute" top="0" left="0" height="1161" width="864">
	<fontspec id="41" size="10" family="Times" color="#231f20"/>
	<fontspec id="42" size="15" family="Times" color="#005d59"/>
	<fontspec id="43" size="7" family="Times" color="#231f20"/>
	<fontspec id="44" size="2" family="Times" color="#231f20"/>
<text top="104" left="92" width="327" height="12" font="12">ACC/AHA 2007 guidelines on perioperative cardiovascular</text>
<text top="118" left="92" width="327" height="12" font="12">evaluation and care for noncardiac surgery. J Am Coll Cardiol.</text>
<text top="131" left="92" width="93" height="12" font="12">2009;54:e13– e118.</text>
<text top="145" left="58" width="360" height="12" font="12">1251. Slomka PJ, Nishina H, Berman DS, et al. Automated quantification</text>
<text top="158" left="92" width="327" height="12" font="12">of myocardial perfusion SPECT using simplified normal limits.</text>
<text top="172" left="92" width="156" height="12" font="12">J Nucl Cardiol. 2005;12:66 –77.</text>
<text top="185" left="58" width="360" height="12" font="12">1252. van der Bijl N, Geleijns J, Joemai R, et al. Recent developments in</text>
<text top="199" left="92" width="212" height="12" font="12">cardiac CT. Imaging Med. 2011;2:167–92.</text>
<text top="212" left="58" width="360" height="12" font="12">1253. Dey D, Schepis T, Marwan M, et al. Automated three-dimensional</text>
<text top="226" left="92" width="327" height="12" font="12">quantification of noncalcified coronary plaque from coronary CT</text>
<text top="239" left="92" width="327" height="12" font="12">angiography: comparison with intravascular US. Radiology. 2010;</text>
<text top="253" left="92" width="62" height="12" font="12">257:516 –22.</text>
<text top="266" left="58" width="360" height="12" font="12">1254. Tamaki N, Yoshinaga K. Novel iodinated tracers, MIBG and</text>
<text top="280" left="92" width="321" height="12" font="12">BMIPP, for nuclear cardiology. J Nucl Cardiol. 2011;18:135– 43.</text>
<text top="293" left="58" width="360" height="12" font="12">1255. Sharir T, Ben-Haim S, Merzon K, et al. High-speed myocardial</text>
<text top="307" left="92" width="327" height="12" font="12">perfusion imaging initial clinical comparison with conventional dual</text>
<text top="320" left="92" width="327" height="12" font="12">detector anger camera imaging. J Am Coll Cardiol Cardiovasc</text>
<text top="334" left="92" width="126" height="12" font="12">Imaging. 2008;1:156 – 63.</text>
<text top="347" left="58" width="360" height="12" font="12">1256. Fiechter M, Ghadri JR, Wolfrum M, et al. Downstream resource</text>
<text top="361" left="92" width="327" height="12" font="12">utilization following hybrid cardiac imaging with an integrated</text>
<text top="374" left="92" width="327" height="12" font="12">cadmium-zinc-telluride/64-slice CT device. Eur J Nucl Med Mol</text>
<text top="388" left="92" width="126" height="12" font="12">Imaging. 2011;39:430 – 6.</text>
<text top="401" left="58" width="360" height="12" font="12">1257. Murthy VL, Naya M, Foster CR, et al. Improved cardiac risk</text>
<text top="415" left="92" width="327" height="12" font="12">assessment with noninvasive measures of coronary flow reserve.</text>
<text top="428" left="92" width="155" height="12" font="12">Circulation. 2011;124:2215–24.</text>
<text top="442" left="58" width="360" height="12" font="12">1258. Winter R, Jussila R, Nowak J, et al. Speckle tracking echocardiog-</text>
<text top="455" left="92" width="327" height="12" font="12">raphy is a sensitive tool for the detection of myocardial ischemia: a</text>
<text top="469" left="92" width="327" height="12" font="12">pilot study from the catheterization laboratory during percutaneous</text>
<text top="482" left="92" width="320" height="12" font="12">coronary intervention. J Am Soc Echocardiogr. 2007;20:974 – 81.</text>
<text top="496" left="58" width="360" height="12" font="12">1259. Ng AC, Sitges M, Pham PN, et al. Incremental value of – dimen-</text>
<text top="509" left="92" width="327" height="12" font="12">sional speckle tracking strain imaging to wall motion analysis for</text>
<text top="523" left="92" width="327" height="12" font="12">detection of coronary artery disease in patients undergoing dobut-</text>
<text top="536" left="92" width="311" height="12" font="12">amine stress echocardiography. Am Heart J. 2009;158:836 – 44.</text>
<text top="104" left="445" width="360" height="12" font="12">1260. Porter TR, Adolphson M, High RR, et al. Rapid detection of</text>
<text top="119" left="479" width="327" height="12" font="12">coronary artery stenoses with real-time perfusion echocardiogra-</text>
<text top="133" left="479" width="327" height="12" font="12">phy during regadenoson stress. Circ Cardiovasc Imaging. 2011;</text>
<text top="147" left="479" width="51" height="12" font="12">4:628 –35.</text>
<text top="161" left="445" width="360" height="12" font="12">1261. Ingkanisorn WP, Kwong RY, Bohme NS, et al. Prognosis of</text>
<text top="175" left="479" width="327" height="12" font="12">negative adenosine stress magnetic resonance in patients presenting</text>
<text top="189" left="479" width="327" height="12" font="12">to an emergency department with chest pain. J Am Coll Cardiol.</text>
<text top="203" left="479" width="87" height="12" font="12">2006;47:1427–32.</text>
<text top="218" left="445" width="360" height="12" font="12">1262. Kwong RY, Schussheim AE, Rekhraj S, et al. Detecting acute</text>
<text top="232" left="479" width="327" height="12" font="12">coronary syndrome in the emergency department with cardiac</text>
<text top="246" left="479" width="289" height="12" font="12">magnetic resonance imaging. Circulation. 2003;107:531–7.</text>
<text top="260" left="445" width="360" height="12" font="12">1263. Sievers B, Elliott MD, Hurwitz LM, et al. Rapid detection of</text>
<text top="274" left="479" width="327" height="12" font="12">myocardial infarction by subsecond, free-breathing delayed</text>
<text top="288" left="479" width="327" height="12" font="12">contrast-enhancement cardiovascular magnetic resonance. Circula-</text>
<text top="303" left="479" width="116" height="12" font="12">tion. 2007;115:236 – 44.</text>
<text top="317" left="445" width="360" height="12" font="12">1264. Cheng AS, Pegg TJ, Karamitsos TD, et al. Cardiovascular magnetic</text>
<text top="331" left="479" width="327" height="12" font="12">resonance perfusion imaging at –tesla for the detection of coronary</text>
<text top="345" left="479" width="327" height="12" font="12">artery disease: a comparison with 1.–tesla. J Am Coll Cardiol.</text>
<text top="359" left="479" width="83" height="12" font="12">2007;49:2440 –9.</text>
<text top="373" left="445" width="360" height="12" font="12">1265. Nagata M, Kato S, Kitagawa K, et al. Diagnostic accuracy of 1.–T</text>
<text top="387" left="479" width="327" height="12" font="12">unenhanced whole-heart coronary MR angiography performed with</text>
<text top="402" left="479" width="327" height="12" font="12">3– channel cardiac coils: initial single-center experience. Radiology.</text>
<text top="416" left="479" width="89" height="12" font="12">2011;259:384 –92.</text>
<text top="430" left="445" width="360" height="12" font="12">1266. Sakuma H, Ichikawa Y, Chino S, et al. Detection of coronary artery</text>
<text top="444" left="479" width="327" height="12" font="12">stenosis with whole-heart coronary magnetic resonance angiogra-</text>
<text top="458" left="479" width="213" height="12" font="12">phy. J Am Coll Cardiol. 2006;48:1946 –50.</text>
<text top="494" left="446" width="331" height="13" font="41"><b>Key Words: </b>cardiovascular diagnostic techniques y coronary artery</text>
<text top="508" left="446" width="348" height="13" font="12">disease y coronary stenosis y minimally invasive surgical procedures y</text>
<text top="522" left="446" width="347" height="13" font="12">myocardial ischemia y myocardial revascularization y prognosis y risk</text>
<text top="536" left="446" width="115" height="13" font="12">factors y stable angina.</text>
<text top="572" left="59" width="605" height="14" font="42"><b>APPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT):</b></text>
<text top="592" left="59" width="701" height="14" font="42"><b>2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF</b></text>
<text top="612" left="59" width="343" height="14" font="42"><b>PATIENTS WITH STABLE ISCHEMIC HEART DISEASE</b></text>
<text top="661" left="66" width="44" height="8" font="11">Committee</text>
<text top="673" left="72" width="33" height="8" font="11">Member</text>
<text top="673" left="157" width="50" height="8" font="11">Employment</text>
<text top="673" left="266" width="44" height="8" font="11">Consultant</text>
<text top="673" left="348" width="72" height="8" font="11">Speaker’s Bureau</text>
<text top="650" left="451" width="47" height="8" font="11">Ownership/</text>
<text top="661" left="449" width="52" height="8" font="11">Partnership/</text>
<text top="673" left="457" width="35" height="8" font="11">Principal</text>
<text top="673" left="532" width="76" height="8" font="11">Personal Research</text>
<text top="639" left="639" width="51" height="8" font="11">Institutional,</text>
<text top="650" left="629" width="71" height="8" font="11">Organizational, or</text>
<text top="661" left="634" width="61" height="8" font="11">Other Financial</text>
<text top="673" left="650" width="29" height="8" font="11">Benefit</text>
<text top="661" left="715" width="26" height="8" font="11">Expert</text>
<text top="673" left="712" width="33" height="8" font="11">Witness</text>
<text top="650" left="767" width="26" height="8" font="11">Voting</text>
<text top="661" left="756" width="49" height="8" font="11">Recusals by</text>
<text top="673" left="763" width="35" height="8" font="11">Section*</text>
<text top="688" left="58" width="43" height="8" font="11">Stephan D.</text>
<text top="700" left="70" width="45" height="8" font="11">Fihn <i>(Chair)</i></text>
<text top="688" left="128" width="62" height="8" font="11">Veterans Health</text>
<text top="700" left="140" width="66" height="8" font="11">Administration—</text>
<text top="711" left="140" width="68" height="8" font="11">Director, Office of</text>
<text top="722" left="140" width="89" height="8" font="11">Analytics and Business</text>
<text top="733" left="140" width="47" height="8" font="11">Intelligence;</text>
<text top="745" left="128" width="105" height="8" font="11">University of Washington—</text>
<text top="756" left="140" width="84" height="8" font="11">Professor of Medicine</text>
<text top="767" left="140" width="90" height="8" font="11">and of Health Services;</text>
<text top="778" left="140" width="65" height="8" font="11">Head, Division of</text>
<text top="790" left="140" width="63" height="8" font="11">General Internal</text>
<text top="801" left="140" width="35" height="8" font="11">Medicine</text>
<text top="688" left="245" width="20" height="8" font="11">None</text>
<text top="688" left="341" width="20" height="8" font="11">None</text>
<text top="688" left="437" width="20" height="8" font="11">None</text>
<text top="688" left="522" width="20" height="8" font="11">None</text>
<text top="688" left="628" width="20" height="8" font="11">None</text>
<text top="688" left="711" width="20" height="8" font="11">None</text>
<text top="688" left="755" width="20" height="8" font="11">None</text>
<text top="811" left="59" width="34" height="8" font="11">Julius M.</text>
<text top="823" left="71" width="47" height="8" font="11">Gardin <i>(Vice</i></text>
<text top="834" left="71" width="23" height="8" font="43"><i>Chair)</i></text>
<text top="811" left="128" width="87" height="8" font="11">Hackensack University</text>
<text top="823" left="140" width="67" height="8" font="11">Medical Center—</text>
<text top="834" left="140" width="54" height="8" font="11">Professor and</text>
<text top="845" left="140" width="89" height="8" font="11">Chairman, Department</text>
<text top="856" left="140" width="78" height="8" font="11">of Internal Medicine</text>
<text top="813" left="245" width="3" height="6" font="44">●</text>
<text top="811" left="251" width="23" height="8" font="11">Arena</text>
<text top="823" left="251" width="65" height="8" font="11">Pharmaceuticals</text>
<text top="834" left="251" width="77" height="8" font="11">(Expired Dec. 2008)</text>
<text top="847" left="245" width="3" height="6" font="44">●</text>
<text top="845" left="251" width="48" height="8" font="11">AstraZeneca</text>
<text top="856" left="251" width="77" height="8" font="11">(Expired Dec. 2009)</text>
<text top="869" left="245" width="3" height="6" font="44">●</text>
<text top="868" left="251" width="79" height="8" font="11">Bristol-Myers Squibb</text>
<text top="879" left="251" width="77" height="8" font="11">(Expired Dec. 2009)</text>
<text top="892" left="245" width="3" height="6" font="44">●</text>
<text top="890" left="251" width="62" height="8" font="11">CV Therapeutics</text>
<text top="901" left="251" width="77" height="8" font="11">(Expired Dec. 2007)</text>
<text top="914" left="245" width="3" height="6" font="44">●</text>
<text top="913" left="251" width="75" height="8" font="11">Pfizer (Expired Dec.</text>
<text top="924" left="251" width="24" height="8" font="11">2009)</text>
<text top="937" left="245" width="3" height="6" font="44">●</text>
<text top="935" left="251" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="946" left="251" width="58" height="8" font="11">(Expired 2009)</text>
<text top="959" left="245" width="3" height="6" font="44">●</text>
<text top="958" left="251" width="62" height="8" font="11">Takeda (Expired</text>
<text top="969" left="251" width="44" height="8" font="11">Dec. 2007)</text>
<text top="813" left="341" width="3" height="6" font="44">●</text>
<text top="811" left="347" width="79" height="8" font="11">Bristol-Myers Squibb</text>
<text top="823" left="347" width="77" height="8" font="11">(Expired Dec. 2009)</text>
<text top="836" left="341" width="3" height="6" font="44">●</text>
<text top="834" left="347" width="62" height="8" font="11">CV Therapeutics</text>
<text top="845" left="347" width="77" height="8" font="11">(Expired Dec. 2007)</text>
<text top="858" left="341" width="3" height="6" font="44">●</text>
<text top="856" left="347" width="75" height="8" font="11">Pfizer (Expired Dec.</text>
<text top="868" left="347" width="24" height="8" font="11">2009)</text>
<text top="881" left="341" width="3" height="6" font="44">●</text>
<text top="879" left="347" width="62" height="8" font="11">Takeda (Expired</text>
<text top="890" left="347" width="44" height="8" font="11">Dec. 2007)</text>
<text top="811" left="437" width="20" height="8" font="11">None</text>
<text top="813" left="522" width="3" height="6" font="44">●</text>
<text top="811" left="529" width="77" height="8" font="11">Merck (Expired Dec.</text>
<text top="823" left="529" width="24" height="8" font="11">2009)</text>
<text top="811" left="628" width="20" height="8" font="11">None</text>
<text top="811" left="711" width="20" height="8" font="11">None</text>
<text top="811" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="823" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="834" left="755" width="28" height="8" font="11">4.4.1.3</text>
<text top="845" left="755" width="28" height="8" font="11">4.4.1.5</text>
<text top="856" left="755" width="28" height="8" font="11">4.4.2.1</text>
<text top="868" left="755" width="28" height="8" font="11">4.4.2.2</text>
<text top="879" left="755" width="28" height="8" font="11">4.4.2.3</text>
<text top="890" left="755" width="28" height="8" font="11">4.4.3.1</text>
<text top="901" left="755" width="20" height="8" font="11">4.4.4</text>
<text top="979" left="58" width="35" height="8" font="11">Jonathan</text>
<text top="991" left="70" width="30" height="8" font="11">Abrams</text>
<text top="979" left="128" width="99" height="8" font="11">University of New Mexico,</text>
<text top="991" left="140" width="61" height="8" font="11">Office of CME—</text>
<text top="1002" left="140" width="84" height="8" font="11">Professor of Medicine</text>
<text top="1013" left="140" width="46" height="8" font="11">(Cardiology)</text>
<text top="979" left="245" width="20" height="8" font="11">None</text>
<text top="979" left="341" width="20" height="8" font="11">None</text>
<text top="979" left="437" width="20" height="8" font="11">None</text>
<text top="979" left="522" width="20" height="8" font="11">None</text>
<text top="979" left="628" width="20" height="8" font="11">None</text>
<text top="979" left="711" width="20" height="8" font="11">None</text>
<text top="979" left="755" width="20" height="8" font="11">None</text>
<text top="1024" left="58" width="58" height="8" font="11">Kathleen Berra</text>
<text top="1024" left="128" width="77" height="8" font="11">Stanford Prevention</text>
<text top="1035" left="140" width="36" height="8" font="11">Research</text>
<text top="1046" left="140" width="82" height="8" font="11">Center—Clinical Trial</text>
<text top="1057" left="140" width="31" height="8" font="11">Director</text>
<text top="1025" left="245" width="3" height="6" font="44">●</text>
<text top="1024" left="251" width="42" height="8" font="11">Boehringer</text>
<text top="1035" left="251" width="38" height="8" font="11">Ingelheim</text>
<text top="1048" left="245" width="3" height="6" font="44">●</text>
<text top="1046" left="251" width="62" height="8" font="11">CV Therapeutics</text>
<text top="1059" left="245" width="3" height="6" font="44">●</text>
<text top="1057" left="251" width="61" height="8" font="11">Gilead Sciences</text>
<text top="1070" left="245" width="3" height="6" font="44">●</text>
<text top="1069" left="251" width="37" height="8" font="11">Novartis‡</text>
<text top="1082" left="245" width="3" height="6" font="44">●</text>
<text top="1080" left="251" width="22" height="8" font="11">Pfizer</text>
<text top="1025" left="341" width="3" height="6" font="44">●</text>
<text top="1024" left="347" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="1024" left="437" width="20" height="8" font="11">None</text>
<text top="1025" left="522" width="3" height="6" font="44">●</text>
<text top="1024" left="529" width="80" height="8" font="11">Kai Pharmaceuticals</text>
<text top="1025" left="628" width="3" height="6" font="44">●</text>
<text top="1024" left="635" width="54" height="8" font="11">PCNA—Board</text>
<text top="1035" left="635" width="38" height="8" font="11">Member‡</text>
<text top="1024" left="711" width="20" height="8" font="11">None</text>
<text top="1024" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="1035" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="1046" left="755" width="28" height="8" font="11">4.4.2.1</text>
<text top="1057" left="755" width="28" height="8" font="11">4.4.2.2</text>
<text top="1069" left="755" width="28" height="8" font="11">4.4.2.3</text>
<text top="1080" left="755" width="28" height="8" font="11">4.4.3.1</text>
<text top="52" left="781" width="25" height="10" font="12">e159</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="117" position="absolute" top="0" left="0" height="1161" width="864">
<text top="135" left="66" width="44" height="8" font="11">Committee</text>
<text top="146" left="72" width="33" height="8" font="11">Member</text>
<text top="146" left="157" width="50" height="8" font="11">Employment</text>
<text top="146" left="266" width="44" height="8" font="11">Consultant</text>
<text top="146" left="348" width="72" height="8" font="11">Speaker’s Bureau</text>
<text top="124" left="451" width="47" height="8" font="11">Ownership/</text>
<text top="135" left="449" width="52" height="8" font="11">Partnership/</text>
<text top="146" left="457" width="35" height="8" font="11">Principal</text>
<text top="146" left="532" width="76" height="8" font="11">Personal Research</text>
<text top="112" left="639" width="51" height="8" font="11">Institutional,</text>
<text top="124" left="629" width="71" height="8" font="11">Organizational, or</text>
<text top="135" left="634" width="61" height="8" font="11">Other Financial</text>
<text top="146" left="650" width="29" height="8" font="11">Benefit</text>
<text top="135" left="715" width="26" height="8" font="11">Expert</text>
<text top="146" left="712" width="33" height="8" font="11">Witness</text>
<text top="124" left="767" width="26" height="8" font="11">Voting</text>
<text top="135" left="756" width="49" height="8" font="11">Recusals by</text>
<text top="146" left="763" width="35" height="8" font="11">Section*</text>
<text top="162" left="58" width="35" height="8" font="11">James C.</text>
<text top="173" left="70" width="48" height="8" font="11">Blankenship</text>
<text top="162" left="128" width="106" height="8" font="11">Geisinger Medical Center—</text>
<text top="173" left="140" width="76" height="8" font="11">Director Cardiology;</text>
<text top="184" left="140" width="62" height="8" font="11">Director Cardiac</text>
<text top="196" left="140" width="59" height="8" font="11">Catheterization</text>
<text top="207" left="140" width="41" height="8" font="11">Laboratory</text>
<text top="162" left="245" width="20" height="8" font="11">None</text>
<text top="164" left="341" width="3" height="6" font="44">●</text>
<text top="162" left="347" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="162" left="437" width="20" height="8" font="11">None</text>
<text top="164" left="522" width="3" height="6" font="44">●</text>
<text top="162" left="529" width="35" height="8" font="11">Abiomed</text>
<text top="175" left="522" width="3" height="6" font="44">●</text>
<text top="173" left="529" width="48" height="8" font="11">AstraZeneca</text>
<text top="186" left="522" width="3" height="6" font="44">●</text>
<text top="184" left="529" width="65" height="8" font="11">Boston Scientific</text>
<text top="197" left="522" width="3" height="6" font="44">●</text>
<text top="196" left="529" width="74" height="8" font="11">Conor Medsystems</text>
<text top="209" left="522" width="3" height="6" font="44">●</text>
<text top="207" left="529" width="76" height="8" font="11">Kai Pharmaceutical</text>
<text top="220" left="522" width="3" height="6" font="44">●</text>
<text top="218" left="529" width="32" height="8" font="11">Novartis</text>
<text top="231" left="522" width="3" height="6" font="44">●</text>
<text top="229" left="529" width="63" height="8" font="11">Schering-Plough</text>
<text top="242" left="522" width="3" height="6" font="44">●</text>
<text top="241" left="529" width="56" height="8" font="11">The Medicines</text>
<text top="252" left="529" width="36" height="8" font="11">Company</text>
<text top="162" left="628" width="20" height="8" font="11">None</text>
<text top="162" left="711" width="20" height="8" font="11">None</text>
<text top="162" left="755" width="28" height="8" font="11">4.4.2.1</text>
<text top="262" left="58" width="48" height="8" font="11">Apostolos P.</text>
<text top="274" left="70" width="24" height="8" font="11">Dallas</text>
<text top="262" left="128" width="106" height="8" font="11">Carilion Roanoke Memorial</text>
<text top="274" left="140" width="81" height="8" font="11">Hospital—Director of</text>
<text top="285" left="140" width="74" height="8" font="11">Continuing Medical</text>
<text top="296" left="140" width="38" height="8" font="11">Education</text>
<text top="262" left="245" width="20" height="8" font="11">None</text>
<text top="262" left="341" width="20" height="8" font="11">None</text>
<text top="264" left="437" width="3" height="6" font="44">●</text>
<text top="262" left="443" width="69" height="8" font="11">GlaxoSmithKline†</text>
<text top="275" left="437" width="3" height="6" font="44">●</text>
<text top="274" left="443" width="41" height="8" font="11">Johnson &amp;</text>
<text top="285" left="443" width="37" height="8" font="11">Johnson†</text>
<text top="298" left="437" width="3" height="6" font="44">●</text>
<text top="296" left="443" width="37" height="8" font="11">Novartis†</text>
<text top="309" left="437" width="3" height="6" font="44">●</text>
<text top="307" left="443" width="60" height="8" font="11">Sanofi-aventis†</text>
<text top="262" left="522" width="20" height="8" font="11">None</text>
<text top="262" left="628" width="20" height="8" font="11">None</text>
<text top="262" left="711" width="20" height="8" font="11">None</text>
<text top="262" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="274" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="285" left="755" width="28" height="8" font="11">4.4.1.3</text>
<text top="296" left="755" width="28" height="8" font="11">4.4.1.6</text>
<text top="307" left="755" width="28" height="8" font="11">4.4.2.1</text>
<text top="319" left="755" width="28" height="8" font="11">4.4.2.2</text>
<text top="330" left="755" width="28" height="8" font="11">4.4.2.3</text>
<text top="341" left="755" width="28" height="8" font="11">4.4.3.1</text>
<text top="352" left="58" width="40" height="8" font="11">Pamela S.</text>
<text top="363" left="70" width="31" height="8" font="11">Douglas</text>
<text top="352" left="128" width="93" height="8" font="11">Duke University Medical</text>
<text top="363" left="140" width="84" height="8" font="11">Center—Ursula Geller</text>
<text top="374" left="140" width="86" height="8" font="11">Professor of Research</text>
<text top="385" left="140" width="67" height="8" font="11">in Cardiovascular</text>
<text top="397" left="140" width="35" height="8" font="11">Diseases</text>
<text top="352" left="245" width="20" height="8" font="11">None</text>
<text top="352" left="341" width="20" height="8" font="11">None</text>
<text top="352" left="437" width="20" height="8" font="11">None</text>
<text top="353" left="522" width="3" height="6" font="44">●</text>
<text top="352" left="529" width="37" height="8" font="11">Novartis‡</text>
<text top="352" left="628" width="20" height="8" font="11">None</text>
<text top="352" left="711" width="20" height="8" font="11">None</text>
<text top="352" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="363" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="374" left="755" width="28" height="8" font="11">4.4.1.3</text>
<text top="385" left="755" width="28" height="8" font="11">4.4.2.3</text>
<text top="407" left="58" width="40" height="8" font="11">JoAnne M.</text>
<text top="418" left="70" width="23" height="8" font="11">Foody</text>
<text top="407" left="128" width="101" height="8" font="11">Harvard Medical School—</text>
<text top="418" left="140" width="79" height="8" font="11">Associate Professor;</text>
<text top="430" left="128" width="93" height="8" font="11">Brigham and Women’s/</text>
<text top="441" left="140" width="72" height="8" font="11">Faulkner Hospitals</text>
<text top="409" left="245" width="3" height="6" font="44">●</text>
<text top="407" left="251" width="26" height="8" font="11">Abbott</text>
<text top="420" left="245" width="3" height="6" font="44">●</text>
<text top="418" left="251" width="28" height="8" font="11">Amarin</text>
<text top="431" left="245" width="3" height="6" font="44">●</text>
<text top="430" left="251" width="25" height="8" font="11">Gilead</text>
<text top="443" left="245" width="3" height="6" font="44">●</text>
<text top="441" left="251" width="24" height="8" font="11">Merck</text>
<text top="454" left="245" width="3" height="6" font="44">●</text>
<text top="452" left="251" width="32" height="8" font="11">Novartis</text>
<text top="465" left="245" width="3" height="6" font="44">●</text>
<text top="463" left="251" width="22" height="8" font="11">Pfizer</text>
<text top="476" left="245" width="3" height="6" font="44">●</text>
<text top="475" left="251" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="407" left="341" width="20" height="8" font="11">None</text>
<text top="407" left="437" width="20" height="8" font="11">None</text>
<text top="407" left="522" width="20" height="8" font="11">None</text>
<text top="407" left="628" width="20" height="8" font="11">None</text>
<text top="407" left="711" width="20" height="8" font="11">None</text>
<text top="407" left="755" width="28" height="8" font="11">2.2.2.2</text>
<text top="418" left="755" width="28" height="8" font="11">2.2.3.3</text>
<text top="430" left="755" width="28" height="8" font="11">3.2.2.6</text>
<text top="441" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="452" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="463" left="755" width="28" height="8" font="11">4.4.1.3</text>
<text top="475" left="755" width="35" height="8" font="11">4.4.3.1.4</text>
<text top="485" left="58" width="41" height="8" font="11">Thomas C.</text>
<text top="496" left="70" width="26" height="8" font="11">Gerber</text>
<text top="485" left="128" width="94" height="8" font="11">Mayo Clinic—Radiology,</text>
<text top="496" left="140" width="84" height="8" font="11">Professor of Medicine</text>
<text top="485" left="245" width="20" height="8" font="11">None</text>
<text top="485" left="341" width="20" height="8" font="11">None</text>
<text top="485" left="437" width="20" height="8" font="11">None</text>
<text top="485" left="522" width="20" height="8" font="11">None</text>
<text top="485" left="628" width="20" height="8" font="11">None</text>
<text top="485" left="711" width="20" height="8" font="11">None</text>
<text top="485" left="755" width="20" height="8" font="11">None</text>
<text top="507" left="58" width="27" height="8" font="11">Alan L.</text>
<text top="518" left="70" width="40" height="8" font="11">Hinderliter</text>
<text top="507" left="128" width="71" height="8" font="11">University of North</text>
<text top="518" left="140" width="77" height="8" font="11">Carolina: Division of</text>
<text top="529" left="140" width="87" height="8" font="11">Cardiology—Associate</text>
<text top="541" left="140" width="37" height="8" font="11">Professor</text>
<text top="507" left="245" width="20" height="8" font="11">None</text>
<text top="507" left="341" width="20" height="8" font="11">None</text>
<text top="507" left="437" width="20" height="8" font="11">None</text>
<text top="507" left="522" width="20" height="8" font="11">None</text>
<text top="507" left="628" width="20" height="8" font="11">None</text>
<text top="507" left="711" width="20" height="8" font="11">None</text>
<text top="507" left="755" width="20" height="8" font="11">None</text>
<text top="551" left="59" width="42" height="8" font="11">Spencer B.</text>
<text top="562" left="71" width="27" height="8" font="11">King III</text>
<text top="551" left="128" width="96" height="8" font="11">Saint Joseph’s Heart and</text>
<text top="562" left="140" width="76" height="8" font="11">Vascular Institute—</text>
<text top="574" left="140" width="39" height="8" font="11">President;</text>
<text top="585" left="128" width="83" height="8" font="11">Saint Joseph’s Health</text>
<text top="596" left="140" width="74" height="8" font="11">System—Executive</text>
<text top="607" left="140" width="72" height="8" font="11">Director Academic</text>
<text top="619" left="140" width="25" height="8" font="11">Affairs</text>
<text top="553" left="245" width="3" height="6" font="44">●</text>
<text top="551" left="251" width="72" height="8" font="11">Medtronic (Expired</text>
<text top="562" left="251" width="50" height="8" font="11">June 2007)†</text>
<text top="551" left="341" width="20" height="8" font="11">None</text>
<text top="551" left="437" width="20" height="8" font="11">None</text>
<text top="551" left="522" width="20" height="8" font="11">None</text>
<text top="553" left="628" width="3" height="6" font="44">●</text>
<text top="551" left="635" width="56" height="8" font="11">Merck (DSMB)</text>
<text top="564" left="628" width="3" height="6" font="44">●</text>
<text top="562" left="635" width="24" height="8" font="11">Wyeth</text>
<text top="574" left="635" width="65" height="8" font="11">Pharmaceuticals</text>
<text top="585" left="635" width="29" height="8" font="11">(DSMB)</text>
<text top="551" left="711" width="20" height="8" font="11">None</text>
<text top="551" left="755" width="28" height="8" font="11">4.4.2.1</text>
<text top="562" left="755" width="28" height="8" font="11">4.4.2.2</text>
<text top="574" left="755" width="28" height="8" font="11">4.4.2.3</text>
<text top="585" left="755" width="28" height="8" font="11">4.4.3.1</text>
<text top="629" left="59" width="28" height="8" font="11">Paul D.</text>
<text top="640" left="70" width="31" height="8" font="11">Kligfield</text>
<text top="629" left="128" width="97" height="8" font="11">Cornell Medical Center—</text>
<text top="640" left="140" width="84" height="8" font="11">Professor of Medicine</text>
<text top="631" left="245" width="3" height="6" font="44">●</text>
<text top="629" left="251" width="62" height="8" font="11">Cardiac Science</text>
<text top="642" left="245" width="3" height="6" font="44">●</text>
<text top="640" left="251" width="55" height="8" font="11">GE Healthcare</text>
<text top="653" left="245" width="3" height="6" font="44">●</text>
<text top="652" left="251" width="52" height="8" font="11">MDS Pharma</text>
<text top="663" left="251" width="37" height="8" font="11">Services†</text>
<text top="676" left="245" width="3" height="6" font="44">●</text>
<text top="674" left="251" width="76" height="8" font="11">Mortara Instrument</text>
<text top="687" left="245" width="3" height="6" font="44">●</text>
<text top="685" left="251" width="59" height="8" font="11">Philips Medical</text>
<text top="697" left="251" width="33" height="8" font="11">Systems</text>
<text top="629" left="341" width="20" height="8" font="11">None</text>
<text top="629" left="437" width="20" height="8" font="11">None</text>
<text top="629" left="522" width="20" height="8" font="11">None</text>
<text top="629" left="628" width="20" height="8" font="11">None</text>
<text top="629" left="711" width="20" height="8" font="11">None</text>
<text top="629" left="755" width="20" height="8" font="11">2.2.1</text>
<text top="640" left="755" width="28" height="8" font="11">2.2.4.2</text>
<text top="652" left="755" width="28" height="8" font="11">2.2.4.3</text>
<text top="663" left="755" width="20" height="8" font="11">3.2.2</text>
<text top="674" left="755" width="13" height="8" font="11">6.1</text>
<text top="707" left="58" width="38" height="8" font="11">Harlan M.</text>
<text top="718" left="70" width="37" height="8" font="11">Krumholz</text>
<text top="707" left="128" width="95" height="8" font="11">Yale University School of</text>
<text top="718" left="140" width="80" height="8" font="11">Medicine—Harold H.</text>
<text top="730" left="140" width="84" height="8" font="11">Hines, Jr. Professor of</text>
<text top="741" left="140" width="52" height="8" font="11">Medicine and</text>
<text top="752" left="140" width="69" height="8" font="11">Epidemiology and</text>
<text top="763" left="140" width="52" height="8" font="11">Public Health</text>
<text top="707" left="245" width="20" height="8" font="11">None</text>
<text top="707" left="341" width="20" height="8" font="11">None</text>
<text top="707" left="437" width="20" height="8" font="11">None</text>
<text top="707" left="522" width="20" height="8" font="11">None</text>
<text top="707" left="628" width="20" height="8" font="11">None</text>
<text top="707" left="711" width="20" height="8" font="11">None</text>
<text top="707" left="755" width="20" height="8" font="11">None</text>
<text top="774" left="58" width="54" height="8" font="11">Raymond Y.K.</text>
<text top="785" left="70" width="26" height="8" font="11">Kwong</text>
<text top="774" left="128" width="81" height="8" font="11">Brigham &amp; Women’s</text>
<text top="785" left="140" width="71" height="8" font="11">Hospital Medicine,</text>
<text top="796" left="140" width="57" height="8" font="11">Cardiovascular</text>
<text top="808" left="140" width="86" height="8" font="11">Division—Instructor of</text>
<text top="819" left="140" width="35" height="8" font="11">Medicine</text>
<text top="774" left="245" width="20" height="8" font="11">None</text>
<text top="774" left="341" width="20" height="8" font="11">None</text>
<text top="774" left="437" width="20" height="8" font="11">None</text>
<text top="774" left="522" width="20" height="8" font="11">None</text>
<text top="774" left="628" width="20" height="8" font="11">None</text>
<text top="774" left="711" width="20" height="8" font="11">None</text>
<text top="774" left="755" width="20" height="8" font="11">None</text>
<text top="829" left="59" width="56" height="8" font="11">Michael J. Lim</text>
<text top="829" left="128" width="82" height="8" font="11">St. Louis University—</text>
<text top="841" left="140" width="87" height="8" font="11">Associate Professor of</text>
<text top="852" left="140" width="80" height="8" font="11">Medicine; Division of</text>
<text top="863" left="140" width="73" height="8" font="11">Cardiology, Interim</text>
<text top="874" left="140" width="94" height="8" font="11">Director; J. Gerard Mudd</text>
<text top="886" left="140" width="90" height="8" font="11">Cardiac Catheterization</text>
<text top="897" left="140" width="77" height="8" font="11">Laboratory, Director</text>
<text top="831" left="245" width="3" height="6" font="44">●</text>
<text top="829" left="251" width="79" height="8" font="11">Bristol-Myers Squibb</text>
<text top="842" left="245" width="3" height="6" font="44">●</text>
<text top="841" left="251" width="24" height="8" font="11">Cordis</text>
<text top="854" left="245" width="3" height="6" font="44">●</text>
<text top="852" left="251" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="865" left="245" width="3" height="6" font="44">●</text>
<text top="863" left="251" width="63" height="8" font="11">Schering-Plough</text>
<text top="829" left="341" width="20" height="8" font="11">None</text>
<text top="829" left="437" width="20" height="8" font="11">None</text>
<text top="829" left="522" width="20" height="8" font="11">None</text>
<text top="829" left="628" width="20" height="8" font="11">None</text>
<text top="829" left="711" width="20" height="8" font="11">None</text>
<text top="829" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="841" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="852" left="755" width="28" height="8" font="11">4.4.1.3</text>
<text top="863" left="755" width="35" height="8" font="11">4.4.2.1.1</text>
<text top="874" left="755" width="28" height="8" font="11">4.4.2.3</text>
<text top="907" left="58" width="28" height="8" font="11">Jane A.</text>
<text top="919" left="70" width="46" height="8" font="11">Linderbaum</text>
<text top="907" left="128" width="89" height="8" font="11">Mayo Clinic—Assistant</text>
<text top="919" left="140" width="84" height="8" font="11">Professor of Medicine</text>
<text top="907" left="245" width="20" height="8" font="11">None</text>
<text top="907" left="341" width="20" height="8" font="11">None</text>
<text top="907" left="437" width="20" height="8" font="11">None</text>
<text top="907" left="522" width="20" height="8" font="11">None</text>
<text top="907" left="628" width="20" height="8" font="11">None</text>
<text top="907" left="711" width="20" height="8" font="11">None</text>
<text top="907" left="755" width="20" height="8" font="11">None</text>
<text top="929" left="58" width="38" height="8" font="11">Michael J.</text>
<text top="940" left="70" width="21" height="8" font="11">Mack</text>
<text top="929" left="128" width="99" height="8" font="11">The Heart Hospital Baylor</text>
<text top="940" left="140" width="62" height="8" font="11">Plano—Director</text>
<text top="929" left="245" width="20" height="8" font="11">None</text>
<text top="929" left="341" width="20" height="8" font="11">None</text>
<text top="929" left="437" width="20" height="8" font="11">None</text>
<text top="929" left="522" width="20" height="8" font="11">None</text>
<text top="929" left="628" width="20" height="8" font="11">None</text>
<text top="929" left="711" width="20" height="8" font="11">None</text>
<text top="929" left="755" width="20" height="8" font="11">None</text>
<text top="951" left="59" width="30" height="8" font="11">Mark A.</text>
<text top="962" left="71" width="29" height="8" font="11">Munger</text>
<text top="951" left="128" width="99" height="8" font="11">University of Utah College</text>
<text top="962" left="140" width="58" height="8" font="11">of Pharmacy—</text>
<text top="973" left="140" width="37" height="8" font="11">Professor</text>
<text top="985" left="140" width="86" height="8" font="11">Pharmacotherapy and</text>
<text top="996" left="140" width="70" height="8" font="11">Internal Medicine;</text>
<text top="1007" left="140" width="62" height="8" font="11">Associate Dean,</text>
<text top="1018" left="140" width="66" height="8" font="11">Academic Affairs</text>
<text top="951" left="245" width="20" height="8" font="11">None</text>
<text top="953" left="341" width="3" height="6" font="44">●</text>
<text top="951" left="347" width="25" height="8" font="11">Gilead</text>
<text top="951" left="437" width="20" height="8" font="11">None</text>
<text top="953" left="522" width="3" height="6" font="44">●</text>
<text top="951" left="529" width="37" height="8" font="11">Novartis†</text>
<text top="951" left="628" width="20" height="8" font="11">None</text>
<text top="951" left="711" width="20" height="8" font="11">None</text>
<text top="951" left="755" width="28" height="8" font="11">4.4.3.1</text>
<text top="1029" left="58" width="39" height="8" font="11">Richard L.</text>
<text top="1040" left="70" width="26" height="8" font="11">Prager</text>
<text top="1029" left="128" width="85" height="8" font="11">University of Michigan</text>
<text top="1040" left="140" width="81" height="8" font="11">Hospitals and Health</text>
<text top="1051" left="140" width="85" height="8" font="11">Centers—Professor of</text>
<text top="1063" left="140" width="73" height="8" font="11">Surgery, Section of</text>
<text top="1074" left="140" width="61" height="8" font="11">Cardiac Surgery</text>
<text top="1029" left="245" width="20" height="8" font="11">None</text>
<text top="1029" left="341" width="20" height="8" font="11">None</text>
<text top="1029" left="437" width="20" height="8" font="11">None</text>
<text top="1029" left="522" width="20" height="8" font="11">None</text>
<text top="1029" left="628" width="20" height="8" font="11">None</text>
<text top="1029" left="711" width="20" height="8" font="11">None</text>
<text top="1029" left="755" width="20" height="8" font="11">None</text>
<text top="52" left="59" width="25" height="10" font="12">e160</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="118" position="absolute" top="0" left="0" height="1161" width="864">
<text top="135" left="66" width="44" height="8" font="11">Committee</text>
<text top="146" left="72" width="33" height="8" font="11">Member</text>
<text top="146" left="157" width="50" height="8" font="11">Employment</text>
<text top="146" left="266" width="44" height="8" font="11">Consultant</text>
<text top="146" left="348" width="72" height="8" font="11">Speaker’s Bureau</text>
<text top="124" left="451" width="47" height="8" font="11">Ownership/</text>
<text top="135" left="449" width="52" height="8" font="11">Partnership/</text>
<text top="146" left="457" width="35" height="8" font="11">Principal</text>
<text top="146" left="532" width="76" height="8" font="11">Personal Research</text>
<text top="112" left="639" width="51" height="8" font="11">Institutional,</text>
<text top="124" left="629" width="71" height="8" font="11">Organizational, or</text>
<text top="135" left="634" width="61" height="8" font="11">Other Financial</text>
<text top="146" left="650" width="29" height="8" font="11">Benefit</text>
<text top="135" left="715" width="26" height="8" font="11">Expert</text>
<text top="146" left="712" width="33" height="8" font="11">Witness</text>
<text top="124" left="767" width="26" height="8" font="11">Voting</text>
<text top="135" left="756" width="49" height="8" font="11">Recusals by</text>
<text top="146" left="763" width="35" height="8" font="11">Section*</text>
<text top="162" left="58" width="36" height="8" font="11">Joseph F.</text>
<text top="173" left="70" width="22" height="8" font="11">Sabik</text>
<text top="162" left="128" width="61" height="8" font="11">Cleveland Clinic</text>
<text top="173" left="140" width="89" height="8" font="11">Foundation—Professor</text>
<text top="184" left="140" width="40" height="8" font="11">of Surgery</text>
<text top="164" left="245" width="3" height="6" font="44">●</text>
<text top="162" left="251" width="39" height="8" font="11">Medtronic</text>
<text top="175" left="245" width="3" height="6" font="44">●</text>
<text top="173" left="251" width="51" height="8" font="11">Novo Nordisk</text>
<text top="162" left="341" width="20" height="8" font="11">None</text>
<text top="162" left="437" width="20" height="8" font="11">None</text>
<text top="162" left="522" width="20" height="8" font="11">None</text>
<text top="162" left="628" width="20" height="8" font="11">None</text>
<text top="162" left="711" width="20" height="8" font="11">None</text>
<text top="162" left="755" width="28" height="8" font="11">4.4.1.3</text>
<text top="195" left="58" width="57" height="8" font="11">Leslee J. Shaw</text>
<text top="195" left="128" width="103" height="8" font="11">Emory University School of</text>
<text top="206" left="140" width="91" height="8" font="11">Medicine—Professor of</text>
<text top="217" left="140" width="35" height="8" font="11">Medicine</text>
<text top="195" left="245" width="20" height="8" font="11">None</text>
<text top="195" left="341" width="20" height="8" font="11">None</text>
<text top="195" left="437" width="20" height="8" font="11">None</text>
<text top="197" left="522" width="3" height="6" font="44">●</text>
<text top="195" left="529" width="79" height="8" font="11">Bracco Diagnostics†</text>
<text top="195" left="628" width="20" height="8" font="11">None</text>
<text top="195" left="711" width="20" height="8" font="11">None</text>
<text top="195" left="755" width="30" height="8" font="11">3.2.2.6.</text>
<text top="228" left="59" width="38" height="8" font="11">Joanna D.</text>
<text top="239" left="71" width="34" height="8" font="11">Sikkema</text>
<text top="228" left="128" width="103" height="8" font="11">University of Miami School</text>
<text top="239" left="140" width="40" height="8" font="11">of Nursing</text>
<text top="228" left="245" width="20" height="8" font="11">None</text>
<text top="230" left="341" width="3" height="6" font="44">●</text>
<text top="228" left="347" width="48" height="8" font="11">AstraZeneca</text>
<text top="228" left="437" width="20" height="8" font="11">None</text>
<text top="228" left="522" width="20" height="8" font="11">None</text>
<text top="228" left="628" width="20" height="8" font="11">None</text>
<text top="228" left="711" width="20" height="8" font="11">None</text>
<text top="228" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="239" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="250" left="58" width="31" height="8" font="11">Craig R.</text>
<text top="261" left="70" width="34" height="8" font="11">Smith, Jr</text>
<text top="250" left="128" width="86" height="8" font="11">Columbia University—</text>
<text top="261" left="140" width="89" height="8" font="11">Chairman, Department</text>
<text top="272" left="140" width="40" height="8" font="11">of Surgery</text>
<text top="250" left="245" width="20" height="8" font="11">None</text>
<text top="250" left="341" width="20" height="8" font="11">None</text>
<text top="250" left="437" width="20" height="8" font="11">None</text>
<text top="250" left="522" width="20" height="8" font="11">None</text>
<text top="250" left="628" width="20" height="8" font="11">None</text>
<text top="250" left="711" width="20" height="8" font="11">None</text>
<text top="250" left="755" width="20" height="8" font="11">None</text>
<text top="283" left="59" width="36" height="8" font="11">Sidney C.</text>
<text top="294" left="71" width="34" height="8" font="11">Smith, Jr</text>
<text top="283" left="128" width="98" height="8" font="11">Center for Cardiovascular</text>
<text top="294" left="140" width="94" height="8" font="11">Science and Medicine—</text>
<text top="305" left="140" width="87" height="8" font="11">Professor of Medicine;</text>
<text top="316" left="140" width="31" height="8" font="11">Director</text>
<text top="284" left="245" width="3" height="6" font="44">●</text>
<text top="283" left="251" width="78" height="8" font="11">Eli Lilly (Expired July</text>
<text top="294" left="251" width="24" height="8" font="11">2007)</text>
<text top="307" left="245" width="3" height="6" font="44">●</text>
<text top="305" left="251" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="316" left="251" width="54" height="8" font="11">(Expired Sept.</text>
<text top="328" left="251" width="24" height="8" font="11">2009)</text>
<text top="284" left="341" width="3" height="6" font="44">●</text>
<text top="283" left="347" width="48" height="8" font="11">AstraZeneca</text>
<text top="294" left="347" width="77" height="8" font="11">(Expired Nov. 2009)</text>
<text top="307" left="341" width="3" height="6" font="44">●</text>
<text top="305" left="347" width="73" height="8" font="11">Bayer (Expired Oct.</text>
<text top="316" left="347" width="24" height="8" font="11">2009)</text>
<text top="329" left="341" width="3" height="6" font="44">●</text>
<text top="328" left="347" width="79" height="8" font="11">Fornier (Expired May</text>
<text top="339" left="347" width="24" height="8" font="11">2009)</text>
<text top="352" left="341" width="3" height="6" font="44">●</text>
<text top="350" left="347" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="361" left="347" width="77" height="8" font="11">(Expired Nov. 2009)</text>
<text top="283" left="437" width="20" height="8" font="11">None</text>
<text top="284" left="522" width="3" height="6" font="44">●</text>
<text top="283" left="529" width="64" height="8" font="11">GlaxoSmithKline</text>
<text top="294" left="529" width="90" height="8" font="11">(DSMB) (Expired March</text>
<text top="305" left="529" width="24" height="8" font="11">2009)</text>
<text top="283" left="628" width="20" height="8" font="11">None</text>
<text top="283" left="711" width="20" height="8" font="11">None</text>
<text top="283" left="755" width="28" height="8" font="11">4.4.2.1</text>
<text top="372" left="58" width="28" height="8" font="11">John A.</text>
<text top="383" left="70" width="30" height="8" font="11">Spertus</text>
<text top="372" left="128" width="105" height="8" font="11">MidAmerica Heart Institute</text>
<text top="383" left="140" width="91" height="8" font="11">of St. Luke’s Hospital—</text>
<text top="394" left="140" width="75" height="8" font="11">Director, Outcomes</text>
<text top="406" left="140" width="89" height="8" font="11">Research; University of</text>
<text top="417" left="140" width="82" height="8" font="11">Missouri–Kansas City</text>
<text top="374" left="245" width="3" height="6" font="44">●</text>
<text top="372" left="251" width="25" height="8" font="11">Gilead</text>
<text top="372" left="341" width="20" height="8" font="11">None</text>
<text top="372" left="437" width="20" height="8" font="11">None</text>
<text top="374" left="522" width="3" height="6" font="44">●</text>
<text top="372" left="529" width="81" height="8" font="11">BMS/sanofi-aventis†</text>
<text top="385" left="522" width="3" height="6" font="44">●</text>
<text top="383" left="529" width="29" height="8" font="11">Cordis†</text>
<text top="396" left="522" width="3" height="6" font="44">●</text>
<text top="394" left="529" width="32" height="8" font="11">Eli Lilly†</text>
<text top="407" left="522" width="3" height="6" font="44">●</text>
<text top="406" left="529" width="80" height="8" font="11">Johnson &amp; Johnson†</text>
<text top="419" left="522" width="3" height="6" font="44">●</text>
<text top="417" left="529" width="77" height="8" font="11">Roche Diagnostics‡</text>
<text top="372" left="628" width="20" height="8" font="11">None</text>
<text top="372" left="711" width="20" height="8" font="11">None</text>
<text top="372" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="383" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="394" left="755" width="28" height="8" font="11">4.4.1.3</text>
<text top="406" left="755" width="28" height="8" font="11">4.4.3.1</text>
<text top="417" left="755" width="20" height="8" font="11">6.3.1</text>
<text top="427" left="58" width="38" height="8" font="11">Sankey V.</text>
<text top="439" left="70" width="34" height="8" font="11">Williams</text>
<text top="427" left="128" width="97" height="8" font="11">Hospital of the University</text>
<text top="439" left="140" width="70" height="8" font="11">of Pennsylvania—</text>
<text top="450" left="140" width="93" height="8" font="11">Solomon Katz Professor</text>
<text top="461" left="140" width="80" height="8" font="11">of General Medicine,</text>
<text top="472" left="140" width="73" height="8" font="11">Division of General</text>
<text top="484" left="140" width="67" height="8" font="11">Internal Medicine</text>
<text top="427" left="245" width="20" height="8" font="11">None</text>
<text top="427" left="341" width="20" height="8" font="11">None</text>
<text top="429" left="437" width="3" height="6" font="44">●</text>
<text top="427" left="443" width="41" height="8" font="11">Johnson &amp;</text>
<text top="439" left="443" width="32" height="8" font="11">Johnson</text>
<text top="452" left="437" width="3" height="6" font="44">●</text>
<text top="450" left="443" width="24" height="8" font="11">Merck</text>
<text top="427" left="522" width="20" height="8" font="11">None</text>
<text top="427" left="628" width="20" height="8" font="11">None</text>
<text top="427" left="711" width="20" height="8" font="11">None</text>
<text top="427" left="755" width="28" height="8" font="11">4.4.1.1</text>
<text top="439" left="755" width="28" height="8" font="11">4.4.1.2</text>
<text top="450" left="755" width="28" height="8" font="11">4.4.1.3</text>
<text top="461" left="755" width="28" height="8" font="11">4.4.1.5</text>
<text top="472" left="755" width="28" height="8" font="11">4.4.1.6</text>
<text top="484" left="755" width="28" height="8" font="11">4.4.2.1</text>
<text top="495" left="755" width="28" height="8" font="11">4.4.2.2</text>
<text top="506" left="755" width="28" height="8" font="11">4.4.2.3</text>
<text top="542" left="59" width="747" height="7" font="17">This table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and</text>
<text top="554" left="59" width="747" height="7" font="17">updated in conjunction with all meetings and conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at</text>
<text top="566" left="59" width="479" height="7" font="17">the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of</text>
<text top="564" left="540" width="265" height="11" font="17">ⱖ5% of the–Solomon Katz Professor of General Medicine voting stock</text>
<text top="578" left="59" width="178" height="7" font="17">or share of the business entity, or ownership of</text>
<text top="576" left="240" width="566" height="11" font="17">ⱖ$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross</text>
<text top="590" left="59" width="738" height="7" font="17">income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.</text>
<text top="602" left="67" width="739" height="7" font="17">*Writing committee members are required to recuse from voting on sections to which their specific relationships with industry and other entities could apply. Section numbers apply to the full-text</text>
<text top="614" left="59" width="39" height="7" font="17">guideline <a href="e44.full.html#85">(</a></text>
<text top="614" left="98" width="5" height="7" font="22"><a href="e44.full.html#85">2</a></text>
<text top="614" left="103" width="185" height="7" font="17"><a href="e44.full.html#85">). </a>†Significant relationship. ‡No financial benefit.</text>
<text top="626" left="67" width="739" height="7" font="17">The current guideline was developed during the transition in RWI policy and occurred over an extended period of time. In the interest of transparency, we provide full information on RWI existing over</text>
<text top="638" left="59" width="353" height="7" font="17">the entire period of guideline development, including delineation of relationships that expired</text>
<text top="636" left="415" width="181" height="11" font="17">⬎24 months before the guideline was finalized.</text>
<text top="650" left="67" width="421" height="7" font="17">CV indicates cardiovascular; DSMB, data safety and monitoring board; and SAQ, Seattle Angina Questionnaire.</text>
<text top="683" left="59" width="619" height="14" font="42"><b>APPENDIX 2. REVIEWER RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT):</b></text>
<text top="703" left="59" width="701" height="14" font="42"><b>2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF</b></text>
<text top="723" left="59" width="343" height="14" font="42"><b>PATIENTS WITH STABLE ISCHEMIC HEART DISEASE</b></text>
<text top="784" left="72" width="37" height="8" font="11">Reviewer</text>
<text top="784" left="157" width="62" height="8" font="11">Representation</text>
<text top="784" left="273" width="44" height="8" font="11">Consultant</text>
<text top="784" left="386" width="33" height="8" font="11">Speaker</text>
<text top="761" left="472" width="47" height="8" font="11">Ownership/</text>
<text top="772" left="470" width="52" height="8" font="11">Partnership/</text>
<text top="784" left="478" width="35" height="8" font="11">Principal</text>
<text top="784" left="563" width="38" height="8" font="11">Research</text>
<text top="750" left="652" width="51" height="8" font="11">Institutional,</text>
<text top="761" left="643" width="71" height="8" font="11">Organizational, or</text>
<text top="772" left="648" width="61" height="8" font="11">Other Financial</text>
<text top="784" left="664" width="29" height="8" font="11">Benefit</text>
<text top="784" left="737" width="62" height="8" font="11">Expert Witness</text>
<text top="799" left="58" width="62" height="8" font="11">Ralph G. Brindis</text>
<text top="799" left="138" width="94" height="8" font="11">Official Reviewer—ACCF</text>
<text top="811" left="150" width="68" height="8" font="11">Board of Trustees</text>
<text top="799" left="253" width="20" height="8" font="11">None</text>
<text top="799" left="352" width="20" height="8" font="11">None</text>
<text top="799" left="485" width="20" height="8" font="11">None</text>
<text top="799" left="538" width="20" height="8" font="11">None</text>
<text top="799" left="642" width="20" height="8" font="11">None</text>
<text top="799" left="730" width="20" height="8" font="11">None</text>
<text top="822" left="58" width="42" height="8" font="11">Timothy D.</text>
<text top="833" left="70" width="22" height="8" font="11">Henry</text>
<text top="822" left="138" width="91" height="8" font="11">Official Reviewer—AHA</text>
<text top="824" left="253" width="3" height="6" font="44">●</text>
<text top="822" left="259" width="62" height="8" font="11">CV Therapeutics</text>
<text top="835" left="253" width="3" height="6" font="44">●</text>
<text top="833" left="259" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="822" left="352" width="20" height="8" font="11">None</text>
<text top="822" left="485" width="20" height="8" font="11">None</text>
<text top="824" left="538" width="3" height="6" font="44">●</text>
<text top="822" left="544" width="30" height="8" font="11">Baxter*</text>
<text top="835" left="538" width="3" height="6" font="44">●</text>
<text top="833" left="544" width="67" height="8" font="11">CV Therapeutics*</text>
<text top="822" left="642" width="20" height="8" font="11">None</text>
<text top="822" left="730" width="20" height="8" font="11">None</text>
<text top="844" left="59" width="33" height="8" font="11">Judith S.</text>
<text top="856" left="70" width="37" height="8" font="11">Hochman</text>
<text top="844" left="138" width="99" height="8" font="11">Official Reviewer—ACCF/</text>
<text top="856" left="150" width="73" height="8" font="11">AHA Task Force on</text>
<text top="867" left="150" width="75" height="8" font="11">Practice Guidelines</text>
<text top="846" left="253" width="3" height="6" font="44">●</text>
<text top="844" left="259" width="27" height="8" font="11">Eli Lilly</text>
<text top="857" left="253" width="3" height="6" font="44">●</text>
<text top="856" left="259" width="64" height="8" font="11">GlaxoSmithKline</text>
<text top="844" left="352" width="20" height="8" font="11">None</text>
<text top="844" left="485" width="20" height="8" font="11">None</text>
<text top="846" left="538" width="3" height="6" font="44">●</text>
<text top="844" left="544" width="75" height="8" font="11">Johnson &amp; Johnson</text>
<text top="857" left="538" width="3" height="6" font="44">●</text>
<text top="856" left="544" width="24" height="8" font="11">Merck</text>
<text top="878" left="59" width="61" height="8" font="11">Robert H. Jones</text>
<text top="878" left="138" width="89" height="8" font="11">Official Reviewer—STS</text>
<text top="878" left="253" width="20" height="8" font="11">None</text>
<text top="878" left="352" width="20" height="8" font="11">None</text>
<text top="878" left="485" width="20" height="8" font="11">None</text>
<text top="878" left="538" width="20" height="8" font="11">None</text>
<text top="878" left="642" width="20" height="8" font="11">None</text>
<text top="878" left="730" width="20" height="8" font="11">None</text>
<text top="889" left="59" width="52" height="8" font="11">Janet B. Long</text>
<text top="889" left="138" width="96" height="8" font="11">Official Reviewer—PCNA</text>
<text top="889" left="253" width="20" height="8" font="11">None</text>
<text top="891" left="352" width="3" height="6" font="44">●</text>
<text top="889" left="358" width="48" height="8" font="11">AstraZeneca</text>
<text top="889" left="485" width="20" height="8" font="11">None</text>
<text top="889" left="538" width="20" height="8" font="11">None</text>
<text top="889" left="642" width="20" height="8" font="11">None</text>
<text top="889" left="730" width="20" height="8" font="11">None</text>
<text top="901" left="59" width="56" height="8" font="11">Bruce W. Lytle</text>
<text top="901" left="138" width="94" height="8" font="11">Official Reviewer—AATS</text>
<text top="901" left="253" width="20" height="8" font="11">None</text>
<text top="901" left="352" width="20" height="8" font="11">None</text>
<text top="901" left="485" width="20" height="8" font="11">None</text>
<text top="901" left="538" width="20" height="8" font="11">None</text>
<text top="901" left="642" width="20" height="8" font="11">None</text>
<text top="901" left="730" width="20" height="8" font="11">None</text>
<text top="912" left="59" width="46" height="8" font="11">Douglass A.</text>
<text top="923" left="71" width="34" height="8" font="11">Morrison</text>
<text top="912" left="138" width="92" height="8" font="11">Official Reviewer—SCAI</text>
<text top="912" left="253" width="20" height="8" font="11">None</text>
<text top="912" left="352" width="20" height="8" font="11">None</text>
<text top="912" left="485" width="20" height="8" font="11">None</text>
<text top="912" left="538" width="20" height="8" font="11">None</text>
<text top="912" left="642" width="20" height="8" font="11">None</text>
<text top="912" left="730" width="20" height="8" font="11">None</text>
<text top="934" left="58" width="40" height="8" font="11">E. Magnus</text>
<text top="946" left="70" width="28" height="8" font="11">Ohman</text>
<text top="934" left="138" width="91" height="8" font="11">Official Reviewer—AHA</text>
<text top="936" left="253" width="3" height="6" font="44">●</text>
<text top="934" left="259" width="35" height="8" font="11">Abiomed</text>
<text top="947" left="253" width="3" height="6" font="44">●</text>
<text top="946" left="259" width="41" height="8" font="11">Datascope</text>
<text top="959" left="253" width="3" height="6" font="44">●</text>
<text top="957" left="259" width="32" height="8" font="11">Inovise*</text>
<text top="970" left="253" width="3" height="6" font="44">●</text>
<text top="968" left="259" width="45" height="8" font="11">Liposcience</text>
<text top="981" left="253" width="3" height="6" font="44">●</text>
<text top="979" left="259" width="56" height="8" font="11">The Medicines</text>
<text top="991" left="259" width="36" height="8" font="11">Company</text>
<text top="1004" left="253" width="3" height="6" font="44">●</text>
<text top="1002" left="259" width="38" height="8" font="11">Response</text>
<text top="1013" left="259" width="43" height="8" font="11">Biomedical</text>
<text top="936" left="352" width="3" height="6" font="44">●</text>
<text top="934" left="358" width="67" height="8" font="11">CV Therapeutics*</text>
<text top="947" left="352" width="3" height="6" font="44">●</text>
<text top="946" left="358" width="56" height="8" font="11">The Medicines</text>
<text top="957" left="358" width="41" height="8" font="11">Company*</text>
<text top="934" left="479" width="32" height="8" font="11">Inovise*</text>
<text top="936" left="538" width="3" height="6" font="44">●</text>
<text top="934" left="544" width="50" height="8" font="11">Bristol-Myers</text>
<text top="946" left="544" width="32" height="8" font="11">Squibb*</text>
<text top="959" left="538" width="3" height="6" font="44">●</text>
<text top="957" left="544" width="62" height="8" font="11">Daiichi-Sankyo*</text>
<text top="970" left="538" width="3" height="6" font="44">●</text>
<text top="968" left="544" width="32" height="8" font="11">Eli Lilly*</text>
<text top="981" left="538" width="3" height="6" font="44">●</text>
<text top="979" left="544" width="56" height="8" font="11">The Medicines</text>
<text top="991" left="544" width="41" height="8" font="11">Company*</text>
<text top="1004" left="538" width="3" height="6" font="44">●</text>
<text top="1002" left="544" width="43" height="8" font="11">Millennium</text>
<text top="1013" left="544" width="70" height="8" font="11">Pharmaceuticals*</text>
<text top="1026" left="538" width="3" height="6" font="44">●</text>
<text top="1024" left="544" width="59" height="8" font="11">Sanofi-aventis*</text>
<text top="1037" left="538" width="3" height="6" font="44">●</text>
<text top="1036" left="544" width="67" height="8" font="11">Schering-Plough*</text>
<text top="934" left="642" width="20" height="8" font="11">None</text>
<text top="934" left="730" width="20" height="8" font="11">None</text>
<text top="1047" left="59" width="42" height="8" font="11">Douglas K.</text>
<text top="1058" left="70" width="26" height="8" font="11">Owens</text>
<text top="1047" left="138" width="90" height="8" font="11">Official Reviewer—ACP</text>
<text top="1049" left="253" width="3" height="6" font="44">●</text>
<text top="1047" left="259" width="60" height="8" font="11">GE Healthcare*</text>
<text top="1047" left="352" width="20" height="8" font="11">None</text>
<text top="1047" left="485" width="20" height="8" font="11">None</text>
<text top="1047" left="538" width="20" height="8" font="11">None</text>
<text top="1047" left="642" width="20" height="8" font="11">None</text>
<text top="1047" left="730" width="20" height="8" font="11">None</text>
<text top="1069" left="58" width="45" height="8" font="11">Paul Poirier</text>
<text top="1069" left="138" width="94" height="8" font="11">Official Reviewer—ACCF</text>
<text top="1081" left="150" width="75" height="8" font="11">Board of Governors</text>
<text top="1069" left="253" width="20" height="8" font="11">None</text>
<text top="1069" left="352" width="20" height="8" font="11">None</text>
<text top="1069" left="485" width="20" height="8" font="11">None</text>
<text top="1069" left="538" width="20" height="8" font="11">None</text>
<text top="1069" left="642" width="20" height="8" font="11">None</text>
<text top="1069" left="730" width="20" height="8" font="11">None</text>
<text top="52" left="781" width="25" height="10" font="12">e161</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="119" position="absolute" top="0" left="0" height="1161" width="864">
<text top="146" left="72" width="37" height="8" font="11">Reviewer</text>
<text top="146" left="157" width="62" height="8" font="11">Representation</text>
<text top="146" left="273" width="44" height="8" font="11">Consultant</text>
<text top="146" left="386" width="33" height="8" font="11">Speaker</text>
<text top="124" left="472" width="47" height="8" font="11">Ownership/</text>
<text top="135" left="470" width="52" height="8" font="11">Partnership/</text>
<text top="146" left="478" width="35" height="8" font="11">Principal</text>
<text top="146" left="563" width="38" height="8" font="11">Research</text>
<text top="112" left="652" width="51" height="8" font="11">Institutional,</text>
<text top="124" left="643" width="71" height="8" font="11">Organizational, or</text>
<text top="135" left="648" width="61" height="8" font="11">Other Financial</text>
<text top="146" left="664" width="29" height="8" font="11">Benefit</text>
<text top="146" left="737" width="62" height="8" font="11">Expert Witness</text>
<text top="162" left="58" width="53" height="8" font="11">Amir Qaseem</text>
<text top="162" left="138" width="90" height="8" font="11">Official Reviewer—ACP</text>
<text top="162" left="253" width="20" height="8" font="11">None</text>
<text top="162" left="352" width="20" height="8" font="11">None</text>
<text top="162" left="485" width="20" height="8" font="11">None</text>
<text top="162" left="538" width="20" height="8" font="11">None</text>
<text top="162" left="642" width="20" height="8" font="11">None</text>
<text top="162" left="730" width="20" height="8" font="11">None</text>
<text top="173" left="58" width="52" height="8" font="11">Joyce L. Ross</text>
<text top="173" left="138" width="96" height="8" font="11">Official Reviewer—PCNA</text>
<text top="175" left="253" width="3" height="6" font="44">●</text>
<text top="173" left="259" width="64" height="8" font="11">Kaneka America</text>
<text top="175" left="352" width="3" height="6" font="44">●</text>
<text top="173" left="358" width="26" height="8" font="11">Abbott</text>
<text top="186" left="352" width="3" height="6" font="44">●</text>
<text top="184" left="358" width="53" height="8" font="11">AstraZeneca*</text>
<text top="197" left="352" width="3" height="6" font="44">●</text>
<text top="196" left="358" width="79" height="8" font="11">Bristol-Myers Squibb</text>
<text top="209" left="352" width="3" height="6" font="44">●</text>
<text top="207" left="358" width="29" height="8" font="11">Oscient</text>
<text top="220" left="352" width="3" height="6" font="44">●</text>
<text top="218" left="358" width="22" height="8" font="11">Pfizer</text>
<text top="231" left="352" width="3" height="6" font="44">●</text>
<text top="229" left="358" width="57" height="8" font="11">Sanofi–aventis</text>
<text top="173" left="485" width="20" height="8" font="11">None</text>
<text top="173" left="538" width="20" height="8" font="11">None</text>
<text top="173" left="642" width="20" height="8" font="11">None</text>
<text top="173" left="730" width="20" height="8" font="11">None</text>
<text top="241" left="59" width="41" height="8" font="11">Timothy A.</text>
<text top="252" left="71" width="32" height="8" font="11">Sanborn</text>
<text top="241" left="138" width="92" height="8" font="11">Official Reviewer—SCAI</text>
<text top="241" left="253" width="20" height="8" font="11">None</text>
<text top="242" left="352" width="3" height="6" font="44">●</text>
<text top="241" left="358" width="95" height="8" font="11">The Medicines Company</text>
<text top="254" left="352" width="3" height="6" font="44">●</text>
<text top="252" left="358" width="24" height="8" font="11">Merck</text>
<text top="241" left="485" width="20" height="8" font="11">None</text>
<text top="242" left="538" width="3" height="6" font="44">●</text>
<text top="241" left="544" width="63" height="8" font="11">St. Jude Medical</text>
<text top="252" left="544" width="29" height="8" font="11">(DSMB)</text>
<text top="241" left="642" width="20" height="8" font="11">None</text>
<text top="241" left="730" width="20" height="8" font="11">None</text>
<text top="263" left="59" width="35" height="8" font="11">Jeffrey L.</text>
<text top="274" left="70" width="37" height="8" font="11">Anderson</text>
<text top="263" left="138" width="77" height="8" font="11">Content Reviewer—</text>
<text top="274" left="150" width="86" height="8" font="11">ACCF/AHA Task Force</text>
<text top="286" left="150" width="87" height="8" font="11">on Practice Guidelines</text>
<text top="265" left="253" width="3" height="6" font="44">●</text>
<text top="263" left="259" width="78" height="8" font="11">BMS/sanofi–aventis</text>
<text top="276" left="253" width="3" height="6" font="44">●</text>
<text top="274" left="259" width="57" height="8" font="11">Daiichi-Sankyo</text>
<text top="287" left="253" width="3" height="6" font="44">●</text>
<text top="286" left="259" width="27" height="8" font="11">Eli Lilly</text>
<text top="263" left="352" width="20" height="8" font="11">None</text>
<text top="263" left="485" width="20" height="8" font="11">None</text>
<text top="263" left="538" width="20" height="8" font="11">None</text>
<text top="263" left="642" width="20" height="8" font="11">None</text>
<text top="263" left="730" width="20" height="8" font="11">None</text>
<text top="297" left="58" width="39" height="8" font="11">William E.</text>
<text top="308" left="70" width="25" height="8" font="11">Boden</text>
<text top="297" left="138" width="68" height="8" font="11">Content Reviewer</text>
<text top="299" left="253" width="3" height="6" font="44">●</text>
<text top="297" left="259" width="26" height="8" font="11">Abbott</text>
<text top="310" left="253" width="3" height="6" font="44">●</text>
<text top="308" left="259" width="67" height="8" font="11">CV Therapeutics/</text>
<text top="319" left="259" width="29" height="8" font="11">Gilead*</text>
<text top="332" left="253" width="3" height="6" font="44">●</text>
<text top="331" left="259" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="344" left="253" width="3" height="6" font="44">●</text>
<text top="342" left="259" width="63" height="8" font="11">Schering-Plough</text>
<text top="299" left="352" width="3" height="6" font="44">●</text>
<text top="297" left="358" width="69" height="8" font="11">Medicure Pharma</text>
<text top="297" left="485" width="20" height="8" font="11">None</text>
<text top="297" left="538" width="20" height="8" font="11">None</text>
<text top="297" left="642" width="20" height="8" font="11">None</text>
<text top="297" left="730" width="20" height="8" font="11">None</text>
<text top="353" left="58" width="62" height="8" font="11">Matthew Budoff</text>
<text top="353" left="138" width="98" height="8" font="11">Content Reviewer—ACCF</text>
<text top="364" left="150" width="62" height="8" font="11">Imaging Council</text>
<text top="353" left="253" width="20" height="8" font="11">None</text>
<text top="353" left="352" width="20" height="8" font="11">None</text>
<text top="353" left="485" width="20" height="8" font="11">None</text>
<text top="353" left="538" width="20" height="8" font="11">None</text>
<text top="353" left="642" width="20" height="8" font="11">None</text>
<text top="353" left="730" width="20" height="8" font="11">None</text>
<text top="376" left="58" width="50" height="8" font="11">Kim A. Eagle</text>
<text top="376" left="138" width="68" height="8" font="11">Content Reviewer</text>
<text top="376" left="253" width="20" height="8" font="11">None</text>
<text top="376" left="352" width="20" height="8" font="11">None</text>
<text top="376" left="485" width="20" height="8" font="11">None</text>
<text top="376" left="538" width="20" height="8" font="11">None</text>
<text top="376" left="642" width="20" height="8" font="11">None</text>
<text top="376" left="730" width="20" height="8" font="11">None</text>
<text top="387" left="58" width="56" height="8" font="11">Gordon A. Ewy</text>
<text top="387" left="138" width="68" height="8" font="11">Content Reviewer</text>
<text top="387" left="253" width="20" height="8" font="11">None</text>
<text top="387" left="352" width="20" height="8" font="11">None</text>
<text top="387" left="485" width="20" height="8" font="11">None</text>
<text top="387" left="538" width="20" height="8" font="11">None</text>
<text top="387" left="642" width="20" height="8" font="11">None</text>
<text top="387" left="730" width="20" height="8" font="11">None</text>
<text top="398" left="58" width="50" height="8" font="11">Victor Ferrari</text>
<text top="398" left="138" width="98" height="8" font="11">Content Reviewer—ACCF</text>
<text top="409" left="150" width="62" height="8" font="11">Imaging Council</text>
<text top="398" left="253" width="20" height="8" font="11">None</text>
<text top="398" left="352" width="20" height="8" font="11">None</text>
<text top="398" left="485" width="20" height="8" font="11">None</text>
<text top="398" left="538" width="20" height="8" font="11">None</text>
<text top="398" left="642" width="20" height="8" font="11">None</text>
<text top="398" left="730" width="20" height="8" font="11">None</text>
<text top="421" left="58" width="45" height="8" font="11">Raymond J.</text>
<text top="432" left="70" width="31" height="8" font="11">Gibbons</text>
<text top="421" left="138" width="68" height="8" font="11">Content Reviewer</text>
<text top="422" left="253" width="3" height="6" font="44">●</text>
<text top="421" left="259" width="57" height="8" font="11">Cardiovascular</text>
<text top="432" left="259" width="59" height="8" font="11">Clinical Studies</text>
<text top="445" left="253" width="3" height="6" font="44">●</text>
<text top="443" left="259" width="68" height="8" font="11">Lantheus Medical</text>
<text top="454" left="259" width="31" height="8" font="11">Imaging</text>
<text top="467" left="253" width="3" height="6" font="44">●</text>
<text top="466" left="259" width="39" height="8" font="11">Medscape</text>
<text top="479" left="253" width="3" height="6" font="44">●</text>
<text top="477" left="259" width="67" height="8" font="11">Molecular Insight</text>
<text top="490" left="253" width="3" height="6" font="44">●</text>
<text top="488" left="259" width="27" height="8" font="11">TherOx</text>
<text top="421" left="352" width="20" height="8" font="11">None</text>
<text top="421" left="485" width="20" height="8" font="11">None</text>
<text top="422" left="538" width="3" height="6" font="44">●</text>
<text top="421" left="544" width="45" height="8" font="11">Velomedix*</text>
<text top="421" left="642" width="20" height="8" font="11">None</text>
<text top="421" left="730" width="20" height="8" font="11">None</text>
<text top="499" left="59" width="49" height="8" font="11">Linda Gillam</text>
<text top="499" left="138" width="98" height="8" font="11">Content Reviewer—ACCF</text>
<text top="511" left="150" width="62" height="8" font="11">Imaging Council</text>
<text top="501" left="253" width="3" height="6" font="44">●</text>
<text top="499" left="259" width="61" height="8" font="11">Abbott Vascular</text>
<text top="512" left="253" width="3" height="6" font="44">●</text>
<text top="511" left="259" width="33" height="8" font="11">Edwards</text>
<text top="522" left="259" width="47" height="8" font="11">Lifesciences</text>
<text top="499" left="352" width="20" height="8" font="11">None</text>
<text top="499" left="485" width="20" height="8" font="11">None</text>
<text top="499" left="538" width="20" height="8" font="11">None</text>
<text top="501" left="642" width="3" height="6" font="44">●</text>
<text top="499" left="648" width="34" height="8" font="11">Core Lab</text>
<text top="511" left="648" width="32" height="8" font="11">Services</text>
<text top="499" left="730" width="20" height="8" font="11">None</text>
<text top="533" left="59" width="36" height="8" font="11">Robert A.</text>
<text top="544" left="71" width="27" height="8" font="11">Guyton</text>
<text top="533" left="138" width="77" height="8" font="11">Content Reviewer—</text>
<text top="544" left="150" width="86" height="8" font="11">ACCF/AHA Task Force</text>
<text top="556" left="150" width="87" height="8" font="11">on Practice Guidelines</text>
<text top="533" left="253" width="20" height="8" font="11">None</text>
<text top="533" left="352" width="20" height="8" font="11">None</text>
<text top="533" left="485" width="20" height="8" font="11">None</text>
<text top="535" left="538" width="3" height="6" font="44">●</text>
<text top="533" left="544" width="33" height="8" font="11">Edwards</text>
<text top="544" left="544" width="47" height="8" font="11">Lifesciences</text>
<text top="533" left="642" width="20" height="8" font="11">None</text>
<text top="533" left="730" width="20" height="8" font="11">None</text>
<text top="567" left="59" width="52" height="8" font="11">L. David Hillis</text>
<text top="567" left="138" width="68" height="8" font="11">Content Reviewer</text>
<text top="567" left="253" width="20" height="8" font="11">None</text>
<text top="567" left="352" width="20" height="8" font="11">None</text>
<text top="567" left="485" width="20" height="8" font="11">None</text>
<text top="567" left="538" width="20" height="8" font="11">None</text>
<text top="567" left="642" width="20" height="8" font="11">None</text>
<text top="567" left="730" width="20" height="8" font="11">None</text>
<text top="578" left="58" width="32" height="8" font="11">David R.</text>
<text top="589" left="70" width="29" height="8" font="11">Holmes</text>
<text top="578" left="138" width="98" height="8" font="11">Content Reviewer—ACCF</text>
<text top="589" left="150" width="53" height="8" font="11">Interventional</text>
<text top="601" left="150" width="66" height="8" font="11">Scientific Council</text>
<text top="578" left="253" width="20" height="8" font="11">None</text>
<text top="578" left="352" width="20" height="8" font="11">None</text>
<text top="578" left="485" width="20" height="8" font="11">None</text>
<text top="578" left="538" width="20" height="8" font="11">None</text>
<text top="578" left="642" width="20" height="8" font="11">None</text>
<text top="578" left="730" width="20" height="8" font="11">None</text>
<text top="612" left="58" width="40" height="8" font="11">Hani Jneid</text>
<text top="612" left="138" width="94" height="8" font="11">Content Reviewer—AHA</text>
<text top="623" left="150" width="71" height="8" font="11">Council on Clinical</text>
<text top="634" left="150" width="40" height="8" font="11">Cardiology</text>
<text top="612" left="253" width="20" height="8" font="11">None</text>
<text top="612" left="352" width="20" height="8" font="11">None</text>
<text top="612" left="485" width="20" height="8" font="11">None</text>
<text top="612" left="538" width="20" height="8" font="11">None</text>
<text top="612" left="642" width="20" height="8" font="11">None</text>
<text top="612" left="730" width="20" height="8" font="11">None</text>
<text top="646" left="58" width="46" height="8" font="11">Sanjay Kaul</text>
<text top="646" left="138" width="68" height="8" font="11">Content Reviewer</text>
<text top="646" left="253" width="20" height="8" font="11">None</text>
<text top="646" left="352" width="20" height="8" font="11">None</text>
<text top="646" left="485" width="20" height="8" font="11">None</text>
<text top="646" left="538" width="20" height="8" font="11">None</text>
<text top="646" left="642" width="20" height="8" font="11">None</text>
<text top="646" left="730" width="20" height="8" font="11">None</text>
<text top="657" left="58" width="40" height="8" font="11">Howard C.</text>
<text top="668" left="70" width="23" height="8" font="11">Lewin</text>
<text top="657" left="138" width="98" height="8" font="11">Content Reviewer—ACCF</text>
<text top="668" left="150" width="62" height="8" font="11">Imaging Council</text>
<text top="657" left="253" width="20" height="8" font="11">None</text>
<text top="657" left="352" width="20" height="8" font="11">None</text>
<text top="659" left="469" width="3" height="6" font="44">●</text>
<text top="657" left="475" width="32" height="8" font="11">Positron</text>
<text top="668" left="475" width="31" height="8" font="11">Imaging</text>
<text top="679" left="475" width="33" height="8" font="11">Partners</text>
<text top="657" left="538" width="20" height="8" font="11">None</text>
<text top="657" left="642" width="20" height="8" font="11">None</text>
<text top="657" left="730" width="20" height="8" font="11">None</text>
<text top="691" left="58" width="54" height="8" font="11">Todd D. Miller</text>
<text top="691" left="138" width="94" height="8" font="11">Content Reviewer—AHA</text>
<text top="702" left="150" width="71" height="8" font="11">Council on Clinical</text>
<text top="713" left="150" width="40" height="8" font="11">Cardiology</text>
<text top="692" left="253" width="3" height="6" font="44">●</text>
<text top="691" left="259" width="56" height="8" font="11">The Medicines</text>
<text top="702" left="259" width="36" height="8" font="11">Company</text>
<text top="715" left="253" width="3" height="6" font="44">●</text>
<text top="713" left="259" width="27" height="8" font="11">TherOx</text>
<text top="691" left="352" width="20" height="8" font="11">None</text>
<text top="691" left="485" width="20" height="8" font="11">None</text>
<text top="692" left="538" width="3" height="6" font="44">●</text>
<text top="691" left="544" width="80" height="8" font="11">Kai Pharmaceuticals</text>
<text top="704" left="538" width="3" height="6" font="44">●</text>
<text top="702" left="544" width="17" height="8" font="11">King</text>
<text top="713" left="544" width="65" height="8" font="11">Pharmaceuticals</text>
<text top="726" left="538" width="3" height="6" font="44">●</text>
<text top="724" left="544" width="68" height="8" font="11">Lantheus Medical</text>
<text top="736" left="544" width="31" height="8" font="11">Imaging</text>
<text top="749" left="538" width="3" height="6" font="44">●</text>
<text top="747" left="544" width="67" height="8" font="11">Molecular Insight</text>
<text top="758" left="544" width="65" height="8" font="11">Pharmaceuticals</text>
<text top="691" left="642" width="20" height="8" font="11">None</text>
<text top="691" left="730" width="20" height="8" font="11">None</text>
<text top="769" left="59" width="62" height="8" font="11">L. Kristin Newby</text>
<text top="769" left="138" width="94" height="8" font="11">Content Reviewer—AHA</text>
<text top="781" left="150" width="71" height="8" font="11">Council on Clinical</text>
<text top="792" left="150" width="40" height="8" font="11">Cardiology</text>
<text top="771" left="253" width="3" height="6" font="44">●</text>
<text top="769" left="259" width="25" height="8" font="11">Adolor</text>
<text top="782" left="253" width="3" height="6" font="44">●</text>
<text top="781" left="259" width="44" height="8" font="11">Biovascular</text>
<text top="794" left="253" width="3" height="6" font="44">●</text>
<text top="792" left="259" width="62" height="8" font="11">CV Therapeutics</text>
<text top="805" left="253" width="3" height="6" font="44">●</text>
<text top="803" left="259" width="70" height="8" font="11">Inverness Medical</text>
<text top="816" left="253" width="3" height="6" font="44">●</text>
<text top="814" left="259" width="75" height="8" font="11">Johnson &amp; Johnson</text>
<text top="827" left="253" width="3" height="6" font="44">●</text>
<text top="826" left="259" width="32" height="8" font="11">Novartis</text>
<text top="839" left="253" width="3" height="6" font="44">●</text>
<text top="837" left="259" width="72" height="8" font="11">Roche Diagnostics</text>
<text top="771" left="352" width="3" height="6" font="44">●</text>
<text top="769" left="358" width="57" height="8" font="11">Daiichi-Sankyo</text>
<text top="769" left="485" width="20" height="8" font="11">None</text>
<text top="771" left="538" width="3" height="6" font="44">●</text>
<text top="769" left="544" width="48" height="8" font="11">AstraZeneca</text>
<text top="782" left="538" width="3" height="6" font="44">●</text>
<text top="781" left="544" width="49" height="8" font="11">BG Medicine</text>
<text top="794" left="538" width="3" height="6" font="44">●</text>
<text top="792" left="544" width="41" height="8" font="11">Carvio Dx*</text>
<text top="805" left="538" width="3" height="6" font="44">●</text>
<text top="803" left="544" width="69" height="8" font="11">GlaxoSmithKline*</text>
<text top="816" left="538" width="3" height="6" font="44">●</text>
<text top="814" left="544" width="41" height="8" font="11">Medicare*</text>
<text top="827" left="538" width="3" height="6" font="44">●</text>
<text top="826" left="544" width="43" height="8" font="11">Millennium</text>
<text top="837" left="544" width="65" height="8" font="11">Pharmaceuticals</text>
<text top="850" left="538" width="3" height="6" font="44">●</text>
<text top="848" left="544" width="67" height="8" font="11">Schering-Plough*</text>
<text top="769" left="642" width="20" height="8" font="11">None</text>
<text top="769" left="730" width="20" height="8" font="11">None</text>
<text top="859" left="59" width="57" height="8" font="11">Elizabeth Ross</text>
<text top="859" left="138" width="68" height="8" font="11">Content Reviewer</text>
<text top="859" left="253" width="20" height="8" font="11">None</text>
<text top="859" left="352" width="20" height="8" font="11">None</text>
<text top="859" left="485" width="20" height="8" font="11">None</text>
<text top="859" left="538" width="20" height="8" font="11">None</text>
<text top="859" left="642" width="20" height="8" font="11">None</text>
<text top="859" left="730" width="20" height="8" font="11">None</text>
<text top="871" left="58" width="39" height="8" font="11">William S.</text>
<text top="882" left="70" width="40" height="8" font="11">Weintraub</text>
<text top="871" left="138" width="68" height="8" font="11">Content Reviewer</text>
<text top="872" left="253" width="3" height="6" font="44">●</text>
<text top="871" left="259" width="53" height="8" font="11">AstraZeneca*</text>
<text top="884" left="253" width="3" height="6" font="44">●</text>
<text top="882" left="259" width="27" height="8" font="11">Bayer*</text>
<text top="895" left="253" width="3" height="6" font="44">●</text>
<text top="893" left="259" width="50" height="8" font="11">Bristol-Myers</text>
<text top="904" left="259" width="27" height="8" font="11">Squibb</text>
<text top="917" left="253" width="3" height="6" font="44">●</text>
<text top="916" left="259" width="37" height="8" font="11">Cardionet</text>
<text top="929" left="253" width="3" height="6" font="44">●</text>
<text top="927" left="259" width="27" height="8" font="11">Eli Lilly</text>
<text top="940" left="253" width="3" height="6" font="44">●</text>
<text top="938" left="259" width="27" height="8" font="11">Pfizer*</text>
<text top="951" left="253" width="3" height="6" font="44">●</text>
<text top="949" left="259" width="54" height="8" font="11">Sanofi-aventis</text>
<text top="962" left="253" width="3" height="6" font="44">●</text>
<text top="961" left="259" width="33" height="8" font="11">Shionogi</text>
<text top="871" left="352" width="20" height="8" font="11">None</text>
<text top="871" left="485" width="20" height="8" font="11">None</text>
<text top="872" left="538" width="3" height="6" font="44">●</text>
<text top="871" left="544" width="31" height="8" font="11">Abbott*</text>
<text top="884" left="538" width="3" height="6" font="44">●</text>
<text top="882" left="544" width="53" height="8" font="11">AstraZeneca*</text>
<text top="895" left="538" width="3" height="6" font="44">●</text>
<text top="893" left="544" width="50" height="8" font="11">Bristol-Myers</text>
<text top="904" left="544" width="32" height="8" font="11">Squibb*</text>
<text top="917" left="538" width="3" height="6" font="44">●</text>
<text top="916" left="544" width="32" height="8" font="11">Otsuka*</text>
<text top="929" left="538" width="3" height="6" font="44">●</text>
<text top="927" left="544" width="59" height="8" font="11">Sanofi-aventis*</text>
<text top="871" left="642" width="20" height="8" font="11">None</text>
<text top="872" left="730" width="3" height="6" font="44">●</text>
<text top="871" left="736" width="69" height="8" font="11">2004; Defendant;</text>
<text top="882" left="736" width="35" height="8" font="11">Aprotinin</text>
<text top="895" left="730" width="3" height="6" font="44">●</text>
<text top="893" left="736" width="69" height="8" font="11">2008; Defendant;</text>
<text top="904" left="736" width="42" height="8" font="11">Quetiapine</text>
<text top="917" left="730" width="3" height="6" font="44">●</text>
<text top="916" left="736" width="69" height="8" font="11">2008; Defendant;</text>
<text top="927" left="736" width="33" height="8" font="11">Celebrex</text>
<text top="998" left="59" width="747" height="7" font="17">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect relationships with industry at the time</text>
<text top="1010" left="59" width="435" height="7" font="17">of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of</text>
<text top="1008" left="495" width="310" height="11" font="17">ⱖ5% of the voting stock or share of the business entity, or ownership of &gt;$10,000</text>
<text top="1023" left="59" width="747" height="7" font="17">of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered</text>
<text top="1036" left="59" width="540" height="7" font="17">to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted.</text>
<text top="1050" left="67" width="94" height="7" font="17">*Significant relationship.</text>
<text top="1063" left="67" width="739" height="7" font="17">AATS indicates American Association for Thoracic Surgery; ACCF, American College of Cardiology Foundation; ACP, American College of Physicans; AHA, American Heart Association; NIH, National</text>
<text top="1076" left="59" width="677" height="7" font="17">Institutes of Health; PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society for Cardiovascular Interventions and Angiography; and STS, Society of Thoracic Surgeons.</text>
<text top="52" left="59" width="25" height="10" font="12">e162</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<page number="120" position="absolute" top="0" left="0" height="1161" width="864">
<text top="108" left="59" width="175" height="9" font="39">APPENDIX 3. ABBREVIATIONS LIST</text>
<text top="137" left="77" width="33" height="16" font="4">ACE</text>
<text top="134" left="114" width="208" height="20" font="4">⫽ angiotensin-converting enzyme</text>
<text top="161" left="77" width="31" height="16" font="4">ACS</text>
<text top="157" left="112" width="170" height="20" font="4">⫽ acute coronary syndrome</text>
<text top="184" left="77" width="31" height="16" font="4">AMI</text>
<text top="181" left="113" width="183" height="20" font="4">⫽ acute myocardial infarction</text>
<text top="207" left="77" width="32" height="16" font="4">ARB</text>
<text top="204" left="113" width="191" height="20" font="4">⫽ angiotensin-receptor blocker</text>
<text top="230" left="77" width="22" height="16" font="4">AV</text>
<text top="227" left="103" width="109" height="20" font="4">⫽ atrioventricular</text>
<text top="254" left="77" width="30" height="16" font="4">BMI</text>
<text top="250" left="112" width="119" height="20" font="4">⫽ body mass index</text>
<text top="277" left="77" width="33" height="16" font="4">BMS</text>
<text top="274" left="114" width="117" height="20" font="4">⫽ bare-metal stent</text>
<text top="300" left="77" width="19" height="16" font="4">BP</text>
<text top="297" left="101" width="106" height="20" font="4">⫽ blood pressure</text>
<text top="323" left="77" width="45" height="16" font="4">CABG</text>
<text top="320" left="126" width="186" height="20" font="4">⫽ coronary artery bypass graft</text>
<text top="347" left="77" width="34" height="16" font="4">CAC</text>
<text top="343" left="115" width="160" height="20" font="4">⫽ coronary artery calcium</text>
<text top="370" left="77" width="35" height="16" font="4">CAD</text>
<text top="367" left="116" width="156" height="20" font="4">⫽ coronary artery disease</text>
<text top="393" left="77" width="31" height="16" font="4">CCS</text>
<text top="390" left="112" width="219" height="20" font="4">⫽ Canadian Cardiovascular Society</text>
<text top="416" left="77" width="44" height="16" font="4">CCTA</text>
<text top="413" left="126" width="260" height="20" font="4">⫽ coronary/cardiac computed tomography</text>
<text top="435" left="95" width="74" height="16" font="4">angiography</text>
<text top="458" left="77" width="34" height="16" font="4">CKD</text>
<text top="455" left="116" width="154" height="20" font="4">⫽ chronic kidney disease</text>
<text top="482" left="77" width="36" height="16" font="4">CMR</text>
<text top="478" left="118" width="184" height="20" font="4">⫽ cardiac magnetic resonance</text>
<text top="505" left="77" width="22" height="16" font="4">CT</text>
<text top="502" left="103" width="155" height="20" font="4">⫽ computed tomography</text>
<text top="528" left="77" width="43" height="16" font="4">DAPT</text>
<text top="525" left="124" width="165" height="20" font="4">⫽ dual antiplatelet therapy</text>
<text top="551" left="77" width="31" height="16" font="4">DES</text>
<text top="548" left="112" width="127" height="20" font="4">⫽ drug-eluting stent</text>
<text top="575" left="77" width="34" height="16" font="4">ECG</text>
<text top="571" left="115" width="126" height="20" font="4">⫽ electrocardiogram</text>
<text top="598" left="77" width="44" height="16" font="4">EDTA</text>
<text top="595" left="126" width="217" height="20" font="4">⫽ ethylene diamine tetraacetic acid</text>
<text top="621" left="77" width="41" height="16" font="4">EECP</text>
<text top="618" left="122" width="233" height="20" font="4">⫽ enhanced external counterpulsation</text>
<text top="644" left="77" width="19" height="16" font="4">EF</text>
<text top="641" left="101" width="116" height="20" font="4">⫽ ejection fraction</text>
<text top="668" left="77" width="32" height="16" font="4">FDA</text>
<text top="664" left="114" width="244" height="20" font="4">⫽ U.S. Food and Drug Administration</text>
<text top="691" left="77" width="28" height="16" font="4">FFR</text>
<text top="688" left="110" width="151" height="20" font="4">⫽ fractional flow reserve</text>
<text top="714" left="77" width="50" height="16" font="4">GDMT</text>
<text top="711" left="131" width="229" height="20" font="4">⫽ guideline-directed medical therapy</text>
<text top="737" left="77" width="45" height="16" font="4">HbA1c</text>
<text top="734" left="127" width="119" height="20" font="4">⫽ hemoglobin A1c</text>
<text top="109" left="464" width="35" height="16" font="4">HDL</text>
<text top="106" left="503" width="165" height="20" font="4">⫽ high-density lipoprotein</text>
<text top="132" left="464" width="29" height="16" font="4">HIV</text>
<text top="129" left="497" width="209" height="20" font="4">⫽ human immunodeficiency virus</text>
<text top="155" left="464" width="31" height="16" font="4">IHD</text>
<text top="152" left="499" width="152" height="20" font="4">⫽ ischemic heart disease</text>
<text top="178" left="464" width="33" height="16" font="4">LAD</text>
<text top="175" left="502" width="162" height="20" font="4">⫽ left anterior descending</text>
<text top="201" left="464" width="40" height="16" font="4">LBBB</text>
<text top="198" left="508" width="168" height="20" font="4">⫽ left bundle-branch block</text>
<text top="224" left="464" width="32" height="16" font="4">LDL</text>
<text top="220" left="501" width="159" height="20" font="4">⫽ low-density lipoprotein</text>
<text top="247" left="464" width="33" height="16" font="4">LGE</text>
<text top="243" left="501" width="198" height="20" font="4">⫽ late gadolinium enhancement</text>
<text top="269" left="464" width="41" height="16" font="4">LIMA</text>
<text top="266" left="510" width="194" height="20" font="4">⫽ left internal mammary artery</text>
<text top="292" left="464" width="21" height="16" font="4">LV</text>
<text top="289" left="489" width="106" height="20" font="4">⫽ left ventricular</text>
<text top="315" left="464" width="40" height="16" font="4">LVEF</text>
<text top="312" left="508" width="209" height="20" font="4">⫽ left ventricular ejection fraction</text>
<text top="338" left="464" width="47" height="16" font="4">MACE</text>
<text top="335" left="516" width="185" height="20" font="4">⫽ major adverse cardiac event</text>
<text top="361" left="464" width="36" height="16" font="4">MET</text>
<text top="358" left="504" width="143" height="20" font="4">⫽ metabolic equivalent</text>
<text top="384" left="464" width="20" height="16" font="4">MI</text>
<text top="381" left="489" width="147" height="20" font="4">⫽ myocardial infarction</text>
<text top="407" left="464" width="29" height="16" font="4">MPI</text>
<text top="403" left="498" width="199" height="20" font="4">⫽ myocardial perfusion imaging</text>
<text top="430" left="464" width="61" height="16" font="4">NSTEMI</text>
<text top="426" left="530" width="261" height="20" font="4">⫽ non–ST-elevation myocardial infarction</text>
<text top="452" left="464" width="32" height="16" font="4">PAD</text>
<text top="449" left="501" width="164" height="20" font="4">⫽ peripheral artery disease</text>
<text top="475" left="464" width="26" height="16" font="4">PCI</text>
<text top="472" left="494" width="232" height="20" font="4">⫽ percutaneous coronary intervention</text>
<text top="498" left="464" width="30" height="16" font="4">PET</text>
<text top="495" left="498" width="203" height="20" font="4">⫽ positron emission tomography</text>
<text top="521" left="464" width="34" height="16" font="4">PHQ</text>
<text top="518" left="503" width="199" height="20" font="4">⫽ Patient Health Questionnaire</text>
<text top="544" left="464" width="32" height="16" font="4">RCT</text>
<text top="541" left="501" width="184" height="20" font="4">⫽ randomized controlled trial</text>
<text top="566" left="464" width="32" height="16" font="4">SAQ</text>
<text top="563" left="500" width="199" height="20" font="4">⫽ Seattle Angina Questionnaire</text>
<text top="589" left="464" width="39" height="16" font="4">SIHD</text>
<text top="586" left="507" width="192" height="20" font="4">⫽ stable ischemic heart disease</text>
<text top="611" left="464" width="49" height="16" font="4">SPECT</text>
<text top="608" left="518" width="225" height="20" font="4">⫽ single-photon emission computed</text>
<text top="629" left="482" width="73" height="16" font="4">tomography</text>
<text top="652" left="464" width="49" height="16" font="4">STEMI</text>
<text top="649" left="518" width="230" height="20" font="4">⫽ ST-elevation myocardial infarction</text>
<text top="674" left="464" width="36" height="16" font="4">TMR</text>
<text top="671" left="504" width="218" height="20" font="4">⫽ transmyocardial revascularization</text>
<text top="697" left="464" width="22" height="16" font="4">UA</text>
<text top="694" left="491" width="112" height="20" font="4">⫽ unstable angina</text>
<text top="719" left="464" width="89" height="16" font="4">UA/NSTEMI</text>
<text top="716" left="557" width="227" height="20" font="4">⫽ unstable angina/non–ST-elevation</text>
<text top="737" left="482" width="129" height="16" font="4">myocardial infarction</text>
<text top="52" left="781" width="25" height="10" font="12">e163</text>
<text top="53" left="59" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="52" left="703" width="21" height="10" font="12">Fihn</text>
<text top="52" left="727" width="24" height="10" font="12">et al.</text>
<text top="68" left="59" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
<text top="67" left="555" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
</page>
<page number="121" position="absolute" top="0" left="0" height="1161" width="864">
<text top="664" left="59" width="734" height="11" font="13">Appendix 4. Nomogram for Estimating 2-Year CAD Event-Free Survival (i.e., Freedom From CAD Death or Nonfatal MI) by Using</text>
<text top="680" left="59" width="485" height="11" font="13">Percent Ischemic Myocardium in Intermediate-Likelihood Patients by Post-Stress LV</text>
<text top="712" left="59" width="729" height="8" font="11">CAD indicates coronary artery disease, LVEF, left ventricular ejection fraction; MI, myocardial infarction; and SPECT, single-photon emission computed tomography. Repro-</text>
<text top="726" left="59" width="177" height="8" font="11">duced with permission from Shaw et al. <a href="e44.full.html#92">(</a></text>
<text top="726" left="235" width="18" height="8" font="23"><a href="e44.full.html#92">276</a></text>
<text top="726" left="253" width="6" height="8" font="11"><a href="e44.full.html#92">).</a></text>
<text top="52" left="59" width="25" height="10" font="12">e164</text>
<text top="52" left="113" width="21" height="10" font="12">Fihn</text>
<text top="52" left="136" width="24" height="10" font="12">et al.</text>
<text top="53" left="692" width="113" height="10" font="12">JACC Vol. 60, No. 24, 2012</text>
<text top="67" left="113" width="196" height="10" font="12">Stable Ischemic Heart Disease: Full Text</text>
<text top="68" left="677" width="129" height="10" font="12">December 18, 2012:e44 – e164</text>
</page>
<outline>
<item page="1">2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With ...</item>
<outline>
<item page="4">Preamble</item>
<item page="6">1. Introduction</item>
<outline>
<item page="6">1.1. Methodology and Evidence Overview</item>
<item page="7">1.2. Organization of the Writing Committee</item>
<item page="7">1.3. Document Review and Approval</item>
<item page="7">1.4. Scope of the Guideline</item>
<item page="9">1.5. General Approach and Overlap With Other Guidelines or Statements</item>
<item page="10">1.6. Magnitude of the Problem</item>
<item page="11">1.7. Organization of the Guideline</item>
<item page="13">1.8. Vital Importance of Involvement by an Informed Patient: Recommendation</item>
</outline>
<item page="15">2. Diagnosis of SIHD</item>
<outline>
<item page="15">2.1. Clinical Evaluation of Patients With Chest Pain</item>
<outline>
<item page="15">2.1.1. Clinical Evaluation in the Initial Diagnosis of SIHD in Patients With Chest Pain: Recomme ...</item>
<item page="15">2.1.2. History</item>
<item page="17">2.1.3. Physical Examination</item>
<item page="17">2.1.4. Electrocardiography</item>
<outline>
<item page="17">2.1.4.1. Resting Electrocardiography to Assess Risk: Recommendation</item>
</outline>
<item page="17">2.1.5. Differential Diagnosis</item>
<item page="18">2.1.6. Developing the Probability Estimate</item>
</outline>
<item page="19">2.2. Noninvasive Testing for Diagnosis of IHD</item>
<outline>
<item page="19">2.2.1. Approach to the Selection of Diagnostic Tests to Diagnose SIHD</item>
<outline>
<item page="20">2.2.1.1. Assessing Diagnostic Test Characteristics</item>
<item page="21">2.2.1.2. Safety and Other Considerations Potentially Affecting Test Selection</item>
<item page="22">2.2.1.3. Exercise Versus Pharmacological Testing</item>
<item page="22">2.2.1.4. Concomitant Diagnosis of SIHD and Assessment of Risk</item>
<item page="22">2.2.1.5. Cost-Effectiveness</item>
</outline>
<item page="23">2.2.2. Stress Testing and Advanced Imaging for Initial Diagnosis in Patients With Suspected SIHD ...</item>
<outline>
<item page="23">2.2.2.1. Able to Exercise</item>
<item page="23">2.2.2.2. Unable to Exercise</item>
<item page="24">2.2.2.3. Other</item>
</outline>
<item page="25">2.2.3. Diagnostic Accuracy of Nonimaging and Imaging Stress Testing for the Initial Diagnosis of ...</item>
<outline>
<item page="25">2.2.3.1. Exercise ECG</item>
<item page="25">2.2.3.2. Exercise and Pharmacological Stress Echocardiography</item>
<item page="25">2.2.3.3. Exercise and Pharmacological Stress Nuclear Myocardial Perfusion SPECT and Myocardial P ...</item>
<item page="26">2.2.3.4. Pharmacological Stress CMR Wall Motion/Perfusion</item>
<item page="26">2.2.3.5. Hybrid Imaging</item>
</outline>
<item page="26">2.2.4. Diagnostic Accuracy of Anatomic Testing for the Initial Diagnosis of SIHD</item>
<outline>
<item page="26">2.2.4.1. Coronary CT Angiography</item>
<item page="27">2.2.4.2. CAC Scoring</item>
<item page="27">2.2.4.3. CMR Angiography</item>
</outline>
</outline>
</outline>
<item page="27">3. Risk Assessment</item>
<outline>
<item page="27">3.1. Clinical Assessment</item>
<outline>
<item page="27">3.1.1. Prognosis of IHD for Death or Nonfatal MI: General Considerations</item>
<item page="28">3.1.2. Risk Assessment Using Clinical Parameters</item>
</outline>
<item page="29">3.2. Advanced Testing: Resting and Stress Noninvasive Testing</item>
<outline>
<item page="29">3.2.1. Resting Imaging to Assess Cardiac Structure and Function: Recommendations</item>
<item page="31">3.2.2. Stress Testing and Advanced Imaging in Patients With Known SIHD Who Require Noninvasive T ...</item>
<outline>
<item page="31">3.2.2.1. Risk Assessment in Patients Able to Exercise</item>
<item page="31">3.2.2.2. Risk Assessment in Patients Unable to Exercise</item>
<item page="31">3.2.2.3. Risk Assessment Regardless of Patients` Ability to Exercise</item>
<item page="32">3.2.2.4. Exercise ECG</item>
<item page="33">3.2.2.5. Exercise Echocardiography and Exercise Nuclear MPI</item>
<item page="34">3.2.2.6. Dobutamine Stress Echocardiography and Pharmacological Stress Nuclear MPI</item>
<item page="34">3.2.2.7. Pharmacological Stress CMR Imaging</item>
<item page="34">3.2.2.8. Special Patient Group: Risk Assessment in Patients Who Have an Uninterpretable ECG Beca ...</item>
</outline>
<item page="35">3.2.3. Prognostic Accuracy of Anatomic Testing to Assess Risk in Patients With Known CAD</item>
<outline>
<item page="35">3.2.3.1. Coronary CT Angiography</item>
</outline>
</outline>
<item page="35">3.3. Coronary Angiography</item>
<outline>
<item page="35">3.3.1. Coronary Angiography as an Initial Testing Strategy to Assess Risk: Recommendations</item>
<item page="35">3.3.2. Coronary Angiography to Assess Risk After Initial Workup With Noninvasive Testing: Recomm ...</item>
</outline>
</outline>
<item page="37">4. Treatment</item>
<outline>
<item page="37">4.1. Definition of Successful Treatment</item>
<item page="39">4.2. General Approach to Therapy</item>
<outline>
<item page="40">4.2.1. Factors That Should Not Influence Treatment Decisions</item>
<item page="41">4.2.2. Assessing Patients` Quality of Life</item>
</outline>
<item page="41">4.3. Patient Education: Recommendations</item>
<item page="43">4.4. Guideline-Directed Medical Therapy</item>
<outline>
<item page="43">4.4.1. Risk Factor Modification: Recommendations</item>
<outline>
<item page="43">4.4.1.1. Lipid Management</item>
<item page="45">4.4.1.2. Blood Pressure Management</item>
<item page="46">4.4.1.3. Diabetes Management</item>
<item page="48">4.4.1.4. Physical Activity</item>
<item page="49">4.4.1.5. Weight Management</item>
<item page="49">4.4.1.6. Smoking Cessation Counseling</item>
<item page="50">4.4.1.7. Management of Psychological Factors</item>
<item page="51">4.4.1.8. Alcohol Consumption</item>
<item page="51">4.4.1.9. Avoiding Exposure to Air Pollution</item>
</outline>
<item page="52">4.4.2. Additional Medical Therapy to Prevent MI and Death: Recommendations</item>
<outline>
<item page="52">4.4.2.1. Antiplatelet Therapy</item>
<outline>
<item page="52">4.4.2.1.1. Antiplatelet Agents</item>
<item page="53">4.4.2.1.2. Oral Anticoagulant Therapy</item>
</outline>
<item page="53">4.4.2.2. Beta-Blocker Therapy</item>
<item page="54">4.4.2.3. Renin-Angiotensin-Aldosterone Blocker Therapy</item>
<item page="55">4.4.2.4. Influenza Vaccination</item>
<item page="56">4.4.2.5. Additional Therapy to Reduce Risk of MI and Death</item>
<outline>
<item page="56">4.4.2.5.1. Hormone Replacement Therapy</item>
<item page="56">4.4.2.5.2. Vitamin C, Vitamin E, and Beta-Carotene</item>
<item page="56">4.4.2.5.3. Folate and Vitamins B6 and B12</item>
<item page="57">4.4.2.5.4. Chelation Therapy</item>
<item page="57">4.4.2.5.5. Garlic, Coenzyme Q10, Selenium, and Chromium</item>
</outline>
</outline>
<item page="57">4.4.3. Medical Therapy for Relief of Symptoms</item>
<outline>
<item page="57">4.4.3.1. Use of Anti-ischemic Medications: Recommendations</item>
<outline>
<item page="57">4.4.3.1.1. Beta Blockers</item>
<item page="58">4.4.3.1.2. Calcium Channel Blockers</item>
<item page="58">4.4.3.1.3. Nitrates</item>
<item page="60">4.4.3.1.4. Ranolazine</item>
<item page="60">4.4.3.1.5. Antianginal Agents Not Currently Available in the United States</item>
<outline>
<item page="60">4.4.3.1.5.1. Nicorandil</item>
<item page="61">4.4.3.1.5.2. Ivabradine</item>
<item page="61">4.4.3.1.5.3. Trimetazidine</item>
</outline>
</outline>
</outline>
<item page="61">4.4.4. Alternative Therapies for Relief of Symptoms in Patients With Refractory Angina: Recommen ...</item>
<outline>
<item page="61">4.4.4.1. Enhanced External Counterpulsation</item>
<item page="62">4.4.4.2. Spinal Cord Stimulation</item>
<item page="62">4.4.4.3. Acupuncture</item>
</outline>
</outline>
</outline>
<item page="63">5. CAD Revascularization</item>
<outline>
<item page="63">5.1. Heart Team Approach to Revascularization Decisions: Recommendations</item>
<item page="65">5.2. Revascularization to Improve Survival: Recommendations</item>
<item page="66">5.3. Revascularization to Improve Symptoms: Recommendations</item>
<item page="66">5.4. CABG Versus Contemporaneous Medical Therapy</item>
<item page="67">5.5. PCI Versus Medical Therapy</item>
<item page="67">5.6. CABG Versus PCI</item>
<outline>
<item page="67">5.6.1. CABG Versus Balloon Angioplasty or BMS</item>
<item page="68">5.6.2. CABG Versus DES</item>
</outline>
<item page="68">5.7. Left Main CAD</item>
<outline>
<item page="68">5.7.1. CABG or PCI Versus Medical Therapy for Left Main CAD</item>
<item page="68">5.7.2. Studies Comparing PCI Versus CABG for Left Main CAD</item>
<item page="69">5.7.3. Revascularization Considerations for Left Main CAD</item>
</outline>
<item page="69">5.8. Proximal LAD Artery Disease</item>
<item page="70">5.9. Clinical Factors That May Influence the Choice of Revascularization</item>
<outline>
<item page="70">5.9.1. Completeness of Revascularization</item>
<item page="70">5.9.2. LV Systolic Dysfunction</item>
<item page="70">5.9.3. Previous CABG</item>
<item page="70">5.9.4. Unstable Angina/Non–ST-Elevation Myocardial Infarction</item>
<item page="70">5.9.5. DAPT Compliance and Stent Thrombosis: Recommendation</item>
</outline>
<item page="71">5.10. Transmyocardial Revascularization</item>
<item page="71">5.11. Hybrid Coronary Revascularization: Recommendations</item>
<item page="71">5.12. Special Considerations</item>
<outline>
<item page="72">5.12.1. Women</item>
<item page="72">5.12.2. Older Adults</item>
<item page="73">5.12.3. Diabetes Mellitus</item>
<item page="74">5.12.4. Obesity</item>
<item page="75">5.12.5. Chronic Kidney Disease</item>
<item page="75">5.12.6. HIV Infection and SIHD</item>
<item page="76">5.12.7. Autoimmune Disorders</item>
<item page="76">5.12.8. Socioeconomic Factors</item>
<item page="76">5.12.9. Special Occupations</item>
</outline>
</outline>
<item page="76">6. Patient Follow-Up: Monitoring of Symptoms and Antianginal Therapy</item>
<outline>
<item page="77">6.1. Clinical Evaluation, Echocardiography During Routine, Periodic Follow-Up: Recommendations</item>
<item page="78">6.2. Follow-Up of Patients With SIHD</item>
<outline>
<item page="78">6.2.1. Focused Follow-Up Visit: Frequency</item>
<item page="78">6.2.2. Focused Follow-Up Visit: Interval History and Coexisting Conditions</item>
<item page="79">6.2.3. Focused Follow-Up Visit: Physical Examination</item>
<item page="79">6.2.4. Focused Follow-Up Visit: Resting 12-Lead ECG</item>
<item page="79">6.2.5. Focused Follow-Up Visit: Laboratory Examination</item>
</outline>
<item page="79">6.3. Noninvasive Testing in Known SIHD</item>
<outline>
<item page="79">6.3.1. Follow-Up Noninvasive Testing in Patients With Known SIHD: New, Recurrent, or Worsening S ...</item>
<outline>
<item page="79">6.3.1.1. Patients Able to Exercise</item>
<item page="80">6.3.1.2. Patients Unable to Exercise</item>
<item page="81">6.3.1.3. Irrespective of Ability to Exercise</item>
</outline>
<item page="81">6.3.2. Noninvasive Testing in Known SIHD—Asymptomatic (or Stable Symptoms): Recommendations</item>
<item page="81">6.3.3. Factors Influencing the Use of Follow-Up Testing</item>
<item page="82">6.3.4. Patient Risk and Testing</item>
<item page="83">6.3.5. Stability of Results After Normal Stress Testing in Patients With Known SIHD</item>
<item page="84">6.3.6. Utility of Repeat Stress Testing in Patients With Known CAD</item>
<item page="84">6.3.7. Future Developments</item>
</outline>
</outline>
<item page="85">Presidents and Staff</item>
<item page="85">References</item>
<item page="116">APPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT): 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH STABLE ISCHEMIC HEART DISEASE</item>
<item page="118">Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant): 2012 ACCF/AHA/AC ...</item>
<item page="120">Appendix 3. Abbreviations List</item>
</outline>
</outline>
</pdf2xml>
